10-K

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

0000950170-23-004645.txt : 20230227 0000950170-23-004645.hdr.sgml : 20230227 20230227160750 ACCESSION NUMBER: 0000950170-23-004645 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 93 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230227 DATE AS OF CHANGE: 20230227 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Revolution Medicines, Inc. CENTRAL INDEX KEY: 0001628171 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 472029180 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39219 FILM NUMBER: 23674819 BUSINESS ADDRESS: STREET 1: 700 SAGINAW DR CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 415-766-3638 MAIL ADDRESS: STREET 1: 700 SAGINAW DR CITY: REDWOOD CITY STATE: CA ZIP: 94063 10-K 1 rvmd-20221231.htm 10-K 10-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

(Mark One)


☒	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2022


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO

Commission File Number 001-39219

Revolution Medicines, Inc.

(Exact name of Registrant as specified in its Charter)


Delaware		47-2029180
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)
700 Saginaw Drive Redwood City, CA		94063
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (650) 481-6801

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading
Symbol(s)

Name of each exchange on which registered

Common Stock $0.0001 Par Value per Share

RVMD

The Nasdaq Stock Market LLC 
(Nasdaq Global Select Market)

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐

Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐No ☒

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the Registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the Registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the Registrant’s executive oﬃcers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The aggregate market value of the common stock held by non-affiliates of the Registrant as of June 30, 2022 (the last business day of the Registrant’s most recently completed second fiscal quarter) was approximately $1,231 million, based on the closing price of the Registrant’s common stock, as reported by the Nasdaq Global Select Market on June 30, 2022 of $19.49 per share.

The number of shares of the Registrant’s Common Stock outstanding on the Nasdaq Global Select Market as of February 23, 2023 was 90,491,696.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the Registrant’s definitive Proxy Statement relating to the Registrant’s 2023 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. The proxy statement will be filed with the Securities and Exchange Commission within 120 days of the Registrant’s fiscal year ended December 31, 2022.

Table of Contents


		Page
PART I		4
Item 1.	Business	4
Item 1A.	Risk Factors	30
Item 1B.	Unresolved Staff Comments	75
Item 2.	Properties	76
Item 3.	Legal Proceedings	76
Item 4.	Mine Safety Disclosures	76

PART II		77
Item 5.	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	77
Item 6.	[Reserved.]	78
Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	79
Item 7A.	Quantitative and Qualitative Disclosures About Market Risk	91
Item 8.	Financial Statements and Supplementary Data	93
Item 9.	Changes in and Disagreements With Accountants on Accounting and Financial Disclosure	121
Item 9A.	Controls and Procedures	121
Item 9B.	Other Information	121
Item 9C.	Disclosure Regarding Foreign Jurisdictions that Prevent Inspections	121

PART III		122
Item 10.	Directors, Executive Officers and Corporate Governance	122
Item 11.	Executive Compensation	122
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	122
Item 13.	Certain Relationships and Related Transactions, and Director Independence	122
Item 14.	Principal Accounting Fees and Services	122

PART IV		123
Item 15.	Exhibits, Financial Statement Schedules	123
Item 16.	Form 10-K Summary	126
	Signatures	127

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Annual Report on Form 10-K contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond our control and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would,” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:

•

the scope, progress, results and costs of developing our product candidates or any other future product candidates, and conducting preclinical studies and clinical trials;

•

the scope, progress, results and costs related to the research and development of our pipeline;

•

the timing of and costs involved in obtaining and maintaining regulatory approval for any of current or future product candidates, and any related restrictions, limitations and/or warnings in the label of an approved product candidate;

•

our expectations regarding the potential market size and size of the potential patient populations for our product candidates and any future product candidates, if approved for commercial use;

•

our ability to maintain and establish new collaborations, licensing or other arrangements and the financial terms of any such agreements;

•

our commercialization, marketing and manufacturing capabilities and expectations;

•

the rate and degree of market acceptance of our product candidates, as well as the pricing and reimbursement of our product candidates, if approved;

•

the implementation of our business model and strategic plans for our business, product candidates and technology, including additional indications for which we may pursue;

•

the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates, including the projected term of patent protection;

•

estimates of our expenses, future revenue, capital requirements, our needs for additional financing and our ability to obtain additional capital;

•

developments and projections relating to our competitors and our industry, including competing therapies and procedures;

•

regulatory and legal developments in the United States and foreign countries;

•

the performance of our third-party suppliers and manufacturers;

•

our ability to attract and retain key scientific or management personnel;

•

our expectations regarding our ability to obtain, maintain, enforce and defend our intellectual property protection for our product candidates; and

•

other risks and uncertainties, including those listed under the caption “Risk Factors.”

We have based these forward-looking statements largely on management’s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and management’s beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. These forward-looking statements speak only as of the date of this Annual Report on Form 10-K and are subject to a number of risks, uncertainties and assumptions described in the section titled “Risk Factors” and elsewhere in this Annual Report on Form 10-K. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein until after we distribute this Annual Report on Form 10-K, whether as a result of any new information, future events or otherwise.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report on Form 10-K, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements.

Investors and others should note that we may announce material business and financial information to our investors using our investor relations website (https://ir.revmed.com), Securities and Exchange Commission (SEC) filings, webcasts, press releases and conference calls. We use these mediums, including our website, to communicate with our members and public about our company, our products and other issues. It is possible that the information that we make available may be deemed to be material information. We therefore encourage investors and others interested in our company to review the information that we make available on our website.

Summary of Material Risks Associated with Our Business

The principal risks and uncertainties affecting our business include the following:

•

We are a clinical-stage precision oncology company with a limited operating history and no products approved for commercial sale. We have incurred significant losses since inception. We expect to incur losses for at least the next several years and may never achieve or maintain profitability, which, together with our limited operating history, makes it difficult to assess our future viability.

•

We have never generated revenue from product sales and may never be profitable.

•

We will require substantial additional financing to achieve our goals, which may not be available on acceptable terms, or at all. A failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts.

•

We are early in our development efforts. Our business is dependent on the successful development of our current and future product candidates. If we are unable to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop, or experience significant delays in doing so, our business will be materially harmed.

•

Preclinical development is uncertain. Our preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize our product candidates on a timely basis or at all, which would have an adverse effect on our business.

•

Historically, direct inhibition of any RAS protein has been challenging due to a lack of tractable, or “druggable,” binding pockets. Given this approach is unproven, it may not be successful.

•

The results of preclinical studies and early-stage clinical trials may not be predictive of future results.

•

If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise be adversely affected.

•

We are a party to a collaboration agreement with Sanofi, which has been terminated effective as of June 2023. Until the effectiveness of this termination, we are dependent on our collaboration with Sanofi for the development of RMC-4630 and must successfully manage the transition of all rights, obligations and activities under the agreement from Sanofi to us.

•

We are currently developing, and may in the future develop, our product candidates in combination with
other therapies, which exposes us to additional risks.

•

We face significant competition, and if our competitors develop and market products that are more effective, safer or less expensive than the product candidates we develop, our commercial opportunities will be negatively impacted.

•

If we and our collaborators are unable to obtain and maintain sufficient patent and other intellectual property protection for our product candidates and technology, our competitors could develop and commercialize products and technology similar or identical to ours, and we may not be able to compete effectively in our market or successfully commercialize any product candidates we may develop.

•

The COVID-19 pandemic, or other epidemic and pandemic diseases or governmental or other actions taken in response to them, could significantly disrupt our business.

The summary risk factors described above should be read together with the text of the full risk factors below in the section entitled “Risk Factors” and the other information set forth in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes, as well as in other documents that we file with the SEC. The risks summarized above or described in full below are not the only risks that we face. Additional risks and uncertainties not precisely known to us or that we currently deem to be immaterial may also materially and adversely affect our business, competitive position, financial condition, results of operations, cash flows and growth prospects.

PART I

Item 1. Business.

Overview

We are a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers. We possess sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Our understanding of genetic drivers and adaptive resistance mechanisms in cancer, coupled with robust drug discovery and medicinal chemistry capabilities, has guided us to establish a deep pipeline targeting critical signaling nodes within the RAS pathway and associated pathways. This cohesive approach underpins our clinical strategy of exploring mechanism-based dosing paradigms and in-pathway combinations to optimize treatment for cancer patients.

Our research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which we refer to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which we refer to as RAS Companion Inhibitors. Our RAS Companion Inhibitors (e.g., SHP2, mTORC1 and SOS1 inhibitors) are designed primarily for combination treatment strategies involving one or more therapeutic agents, which may include our RAS(ON) Inhibitors. Our long-term goal is to combine our RAS(ON) Inhibitors with selected RAS Companion Inhibitors or other therapies on behalf of patients based on molecular tumor features.

RAS(ON) Inhibitors

Our RAS(ON) Inhibitors are based on our proprietary tri-complex technology platform, which enables a highly differentiated approach to inhibiting the active, GTP-bound form of RAS, which we refer to as RAS(ON). We are developing a portfolio of compounds that we believe are the first and only RAS(ON) Inhibitors to use this mechanism of action. We believe that direct inhibitors of RAS(ON) will suppress cell growth and survival and be less susceptible to adaptive resistance mechanisms recognized for RAS(OFF) Inhibitors. We plan to evaluate our RAS(ON) Inhibitors alone and in combination with other drugs and investigational drug candidates, particularly in-pathway agents.

We currently consider three development-stage candidates as the first wave of RAS(ON) Inhibitors that we are advancing:

RMC-6236

RMC-6236, our RASMULTI(ON) Inhibitor, is designed as a first-in-class, potent, oral, RAS-selective tri-complex inhibitor of multiple RAS(ON) variants including cancer drivers at all three of the major mutation hotspot positions, G12, G13, and Q61. RMC-6236 inhibits all three major RAS isoforms, suppressing the mutant cancer driver and cooperating wild-type RAS proteins.

A monotherapy dose-escalation study of RMC-6236 is ongoing and, based on early observations from this study, we believe that RMC-6236 is orally bioavailable and has achieved dose-dependent exposures in patients that are consistent with our preclinical projections. The compound has been generally well-tolerated, including at dose levels at which we have observed clear signals of anti-tumor activity, as reflected in the interim clinical data reported below. We continue in dose escalation and we currently expect to provide additional evidence of first-in-class single agent activity for this compound in mid-2023.

RMC-6291

A monotherapy dose-escalation study of RMC-6291 is ongoing and, based on early observations from this study, we believe that RMC-6291 is orally bioavailable in patients, that it is exhibiting pharmacokinetics consistent with our expectations based on preclinical experiments and that we are dosing the compound in a pharmacologically active range with acceptable safety and tolerability. We currently expect to provide preliminary evidence of a superior profile for this compound in the second half of 2023.

RMC-9805

covalently inactivate KRASG12D irreversibly. We currently expect to announce dosing of the first patient in a monotherapy dose-escalation study of this compound in mid-2023.

Additional RAS(ON) Inhibitors

Beyond this first wave of RAS(ON) Inhibitors, we have other RAS(ON) Inhibitor compounds currently in our research and development pipeline, including our development candidate RMC-8839, which is designed as a first-in-class, potent, oral and selective, covalent tri-complex inhibitor of KRASG13C(ON) and RMC-0708, which is designed as a first-in-class, potent, oral and selective, non-covalent tri-complex inhibitor of KRASQ61H(ON). RMC-8839 is designed to exhibit picomolar potency for suppressing RAS pathway signaling and growth of KRASG13C-bearing cancer cells and is engineered to covalently inactivate KRASG13C for irreversible inhibition. RMC-0708 is designed to exhibit picomolar potency for suppressing RAS pathway signaling and growth of KRASQ61H-bearing cancer cells and is engineered for selective inhibition of KRASQ61H over other RAS isoforms via non-covalent binding interactions. We are pursuing pipeline expansion programs focused on KRASG12R, KRASG12V, KRASG13D, RASQ61X and other targets.

RAS Companion Inhibitors

RMC-4630

Our RAS Companion Inhibitor RMC-4630 is designed as a potent and selective inhibitor of SHP2, a central node in the RAS signaling pathway. RMC-4630 is being evaluated in a Phase 1/2 clinical program. In 2018, we entered into a collaborative research, development and commercialization agreement with Aventis, Inc. (an affiliate of Sanofi) (the Sanofi Agreement) with respect to SHP2 inhibitors, including RMC-4630. The Sanofi Agreement has been terminated effective as of June 2023, and following the effectiveness of termination, we will regain all global rights granted under the Sanofi Agreement (except as necessary to permit Sanofi to perform any surviving obligations under the Sanofi Agreement), including decision-making regarding research and development, and rights to all commercial proceeds, from RMC-4630.

Our highest priority hypothesis regarding RMC-4630 is that it can deliver additional clinical benefit to patients with RAS-addicted tumors treated with a RAS inhibitor. Below is a list of the clinical studies of RMC-4630 in combination with RAS inhibitors:

•

an Amgen-sponsored Phase 1b study of RMC-4630 in combination with Amgen’s KRASG12C(OFF) inhibitor, sotorasib (LUMAKRAS(R));

•

RMC-4630-03, a Phase 2 study of RMC-4630 in combination with sotorasib that we are sponsoring under a clinical trial collaboration and supply agreement with Amgen; and

•

a Sanofi-sponsored Phase 1/2 study of RMC-4630 in combination with Mirati Therapeutics’ KRASG12C(OFF) inhibitor, adagrasib (KRAZATI(R)).

Amgen is currently evaluating RMC-4630 in a Phase 1b study in combination with Amgen’s KRASG12C(OFF) agent sotorasib in Amgen’s CodeBreaK 101c study. In August 2022, Amgen reported results from this study at the 2022 World Conference on Lung Cancer.

As a complement to the CodeBreaK 101c study, we are sponsoring RMC-4630-03, which is an additional global Phase 2 study of RMC-4630 in combination with sotorasib for patients with non-small cell lung cancer (NSCLC) carrying a KRASG12C mutation who have failed prior standard therapy and who have not previously been treated with a RAS inhibitor. We are sponsoring the RMC-4630-03 study under our global partnership with Sanofi and conducting the trial in collaboration with Amgen, which is supplying sotorasib globally under a clinical collaboration and supply agreement. We currently plan to provide topline data from this study in the second half of 2023.

Sanofi has sponsored a combination study under the Sanofi Agreement and under a clinical trial collaboration and supply agreement between Sanofi and Mirati to evaluate RMC-4630 (also known as SAR442720) in combination with Mirati’s KRASG12C(OFF) inhibitor, adagrasib. We expect that this study will be wound down in connection with the termination of the Sanofi Agreement.

There are also several clinical studies of RMC-4630 that do not involve combinations with RAS inhibitors:

•

RMC-4630-01, a Phase 1 study of RMC-4630 as monotherapy;

•

a Sanofi-sponsored Phase 1/2 study of RMC-4630 in combination with the PD-1 inhibitor pembrolizumab (Keytruda®), which we expect will be wound down in connection with the termination of the Sanofi Agreement; and

•

a combination of RMC-4630 with an ERK inhibitor in patients with pancreatic cancer as part of an investigator-sponsored study by Netherlands Cancer Institute.

RMC-5552

We have reported initial findings from the ongoing dose escalation portion of the RMC-5552-001 study and currently expect to provide additional evidence of single agent activity for this compound in 2023.

We have agreed to supply RMC-5552 to the Regents of the University of California on behalf of its San Francisco campus (UCSF) for an investigator-initiated Phase 1/1b trial by UCSF of RMC-5552 in patients with recurrent glioblastoma.

RMC-5845

Our RAS Companion Inhibitor RMC-5845 targets SOS1, a protein that plays a key role in converting RAS(OFF) to RAS(ON) in cells. RMC-5845 is intended for select combination therapies for certain genetically-defined tumors. This compound is ready for preparation of an IND based on our preclinical development. We continue to evaluate whether to advance RMC-5845 into clinical development in the context of other assets in our portfolio.

RMC-6236

Our RASMULTI(ON) Inhibitor, RMC-6236, is designed to inhibit essentially all RAS(ON) proteins, including normal or wild-type RAS proteins that may help augment oncogenic signaling to tumor cells that have a mutant RAS as a primary driver. Given this broad activity of RMC-6236, we believe it may also be useful as a RAS Companion Inhibitor and we may evaluate the potential benefit from combining RMC-6236 with a RAS inhibitor, including with a RAS(ON) mutant-selective inhibitor such as RMC-6291.

Our strategy

Our goal is to develop and commercialize novel targeted therapies to outsmart RAS-addicted cancers for the benefit of patients. RAS proteins drive 30% of human cancers (Prior et al, Cancer Research 2020), and are largely unserved by targeted therapeutics. The KRASG12C mutation has been clinically validated as a therapeutic target, and the evidence is strong that numerous other oncogenic mutations in the RAS family of proteins are likewise compelling cancer targets. Our collection of RAS(ON) Inhibitors, designed to have best-in-class preclinical profiles and/or first-in-class potential, is tailored to target RAS cancer mutations that together comprise the vast majority of RAS-addicted cancers.

Data from the ongoing development of first-generation KRASG12C inhibitors have clearly demonstrated that selective targeting of RAS cancer drivers is often insufficient to confer deep and durable clinical benefit, as RAS cancers are also supported and maintained by other cellular proteins we call RAS cooperating targets and pathways. We believe it is important to match our treatment strategies to this biological cooperativity by developing RAS(ON) Inhibitors to suppress the primary RAS drivers and RAS Companion Inhibitors to suppress the cooperating proteins. We expect drugs of these two types may be combined to form the optimal therapeutic regimens capable of delivering maximal clinical benefit. To develop these optimal therapies for RAS cancers, we plan to pursue the following strategies:

RAS(ON) Inhibitors

•

Establish tri-complex inhibition of RAS(ON) as a first-in-class therapeutic modality. There are dozens of RAS variants that have been implicated as molecular drivers of cancer. We are developing a portfolio of small molecules designed to target multiple oncogenic forms of RAS(ON) that are derived from our proprietary tri-complex technology platform. We believe that targeted inhibition of oncogenic RAS(ON) variants represents a highly differentiated approach for treating the large population of patients with diverse RAS mutations, including non-small cell lung cancer, or NSCLC, colorectal, pancreatic and other cancers.

We have advanced our first two RAS(ON) development candidates into clinical development: RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants and RMC-6291, a mutant-selective inhibitor of KRASG12C(ON). We are also conducting IND-enabling studies of RMC-9805, our inhibitor targeting KRASG12D(ON). We may evaluate our RAS(ON) development candidates both as monotherapies and/or in combination with other drugs and investigational new drugs, particularly our RAS Companion Inhibitors and standard of care therapies, including immunotherapies.

•

Deploy our innovation engine against additional RAS targets. In parallel with the IND-enabling development of our RAS(ON) development candidates, we are focusing on optimization of mutant-selective tri-complex inhibitors of additional targets, including KRASG12R, KRASG12V, KRASG13D and RASQ61X. Discovery and development of mutant-selective inhibitors of these targets may help to maximize clinical benefit for some patients with cancers bearing these RAS variants.

RAS Companion Inhibitors

•

Establish our proprietary SHP2 inhibitor, RMC-4630, as the backbone of targeted therapy combinations for the treatment of RAS-dependent tumors. We are evaluating RMC-4630 as both a monotherapy and as a backbone of combination therapies designed to maximize clinical benefit by combating drug resistance pathways that depend on SHP2. In the future, we may leverage our complementary pipeline of RAS(ON) and RAS Companion Inhibitors by evaluating RMC-4630 in combination with certain RAS(ON) inhibitors, which could include RMC-6291 or RMC-9805.

•

Demonstrate clinical utility of our RAS Companion Inhibitors targeting mTORC1/4EBP1 (RMC-5552) through precision oncology. We are investigating RMC-5552 as a monotherapy in patients with cancers harboring genotypes linked to hyperactivated mTORC1 signaling in a Phase 1 study (RMC-5552-001), and plan to test RMC-5552 as a combination partner for RAS inhibitors in patients with cancers harboring RAS mutations with a co-occurring mutation in the mTOR signaling pathway.

•

Explore the clinical utility of RMC-6236 as a RAS Companion Inhibitor. Given this broad activity of RMC-6236, we believe it may also be useful as a RAS Companion Inhibitor and we may evaluate the potential benefit from combining RMC-6236 with a RAS inhibitor, including with a RAS(ON) mutant-selective inhibitor such as RMC-6291.

Corporate

•

Maximize the global value of our programs through synergistic and value-creating transactions. We have the organizational capabilities and resources to enable us to continue to complete value-creating transactions. In the future, we may enter into transactions where we believe there is an opportunity to accelerate the development and commercialization of our product candidates while allowing us to retain meaningful rights in major markets. We may also seek to acquire or in-license product candidates or technologies opportunistically that are synergistic with our drug discovery and development efforts.

•

Maintain our culture of tireless commitment to patients. As we grow our business, we will continue to apply transformative science in the development of novel targeted therapies for patients suffering from cancers with limited therapeutic options. To accomplish this, we intend to continue building our team of qualified individuals who share our commitment to collaboration and scientific rigor in the development of novel therapies to outsmart cancer and improve the lives of patients.

Our opportunity: multiple large unmet needs in RAS-addicted cancers

RAS mutant epidemiology in the United States

Variants in RAS proteins account for approximately 30% of all human cancers in the United States, many of which are fatal. Diverse oncogenic RAS variants in three different RAS isoforms (KRAS, NRAS and HRAS) drive distinct human cancers. Figure 1 below summarizes the estimated new RAS-addicted cancers diagnosed each year in the U.S. organized into convenience groups based on tumor genetics. Based on these data, we believe there are an estimated 230,000 new cancers diagnosed per year that could potentially be addressed by RAS inhibitors in the U.S. alone.

Figure 1.

(1)

HRASX = all HRAS mutants; NRASQ61X X = H, K, L, R, P; RASWT = NF1LOF, RASWTamp, BRAFclass3 and PTPN11MUT; KRASX X = G12A, G12R, G12S and A146T; KRASQ61X X = H, K, L; RASG12C includes KRASG12C and NRASG12C.

(2)

Calculated using tumor mutation frequencies from Foundation Medicine Insights August 2020 and scaled to estimated patient numbers using cancer incidence from ACS Cancer Facts and Figures 2020. Includes 12 major types: non-small cell lung cancer, colorectal, pancreatic adenocarcinoma, renal, gastroesophageal, head and neck squamous cell, ovarian and biliary cancers, acute myeloid leukemia, and advanced melanoma, bladder and uterine/endometrial cancers causing mortality.

(3)

Estimated worldwide annual incidence of RAS-mutated cancers is 3.4 million per year. Prior et al., Cancer Research 2020.

Our innovation engine

We have built an innovation engine that enables us to discover and develop novel targeted therapies for elusive high-value frontier cancer targets with particular focus on a cohesive set of disease targets within notorious growth and survival pathways. This engine is centered around our proprietary tri-complex platform and is bolstered by three complementary pillars:

•

Deep chemical biology and cancer pharmacology know-how, including assays and proprietary tool compounds, to define the critical vulnerabilities of “frontier” RAS and mTOR pathway targets and associated signaling circuits in cancer cells;

•

Sophisticated structure-based drug discovery capabilities, including proven access to complex chemical space, to create drug candidates tailored to unconventional binding sites on elusive cancer targets; and

•

Astute precision medicine approach, embracing patient selection and innovative single agent and combination drug regimens, to translate our preclinical insights into clinical benefit for patients with RAS-addicted cancers.

Our Tri-complex platform

Our proprietary tri-complex technology enables us to discover small molecule inhibitors of targets lacking intrinsic drug binding sites by inducing new druggable pockets. This occurs through small molecule-driven formation of a high affinity ternary complex (tri-complex) between the target protein, the small molecule, and a widely expressed cytosolic protein called a chaperone (e.g., FKPB12 or cyclophilin A). This platform technology is the foundation of our RAS(ON) Inhibitor programs. In this context, the inhibitory effect of tri-complex formation on the RAS(ON) target is mediated by steric occlusion of the site where RAS(ON) binds its downstream effector molecules, such as RAF, which are required for propagating the oncogenic signal. Thus, tri-complex formation with RAS(ON) targets disrupts RAS effector binding and terminates oncogenic signaling. Our RAS(ON) tri-complex inhibitors, which are inspired by natural products, are “Beyond Rule of 5” compounds.

Pipeline

Our pipeline is summarized below:

RAS(ON) Inhibitors

Overview

Our RAS(ON) Inhibitors are based on our proprietary tri-complex technology platform, which enables a highly differentiated approach to inhibiting the active, GTP-bound form of RAS, or RAS(ON). We are developing a portfolio of compounds that we believe are the first and only RAS(ON) Inhibitors to use this mechanism of action. Our portfolio of RAS(ON) inhibitors includes three compounds that we consider as the first wave of RAS(ON) Inhibitors that we are advancing: RMC-6236 (RASMULTI), RMC-6291 (KRASG12C) and RMC-9805 (KRASG12D). Beyond this first wave of RAS(ON) Inhibitors, we have other RAS(ON) Inhibitor compounds currently in our research and development pipeline, including our development candidates RMC-8839 (KRASG13C) and RMC-0708 (KRASQ61H).

We believe that direct inhibitors of RAS(ON) will suppress cell growth and survival and be less susceptible to adaptive resistance mechanisms recognized for RAS(OFF) inhibitors. We plan to evaluate our RAS(ON) Inhibitors alone and in combination with other drugs and investigational drug candidates, particularly in-pathway agents. We believe tailored RAS(ON) inhibitors will be useful to serve the diverse landscape of RAS-driven cancers optimally. We believe that in some cases, patients may experience maximal clinical benefit from the broad activity of our RASMULTI(ON) inhibitor, RMC-6236, if approved. In others, treatment with a mutant-selective RAS(ON) inhibitor like RMC-6291 (KRASG12C), RMC-9805 (KRASG12D), RMC-8839 (KRASG13C) or RMC-0708 (KRASQ61H) may be optimal. Consistent with this thesis, we are pursuing additional RAS mutant-selective inhibitors for RAS variants KRASG12R, KRASG12V, KRASG13D and RASQ61X. This strategy is a component of our broader mission to develop the best therapeutic regimens for patients with RAS mutant cancer by combining the optimal RAS(ON) Inhibitor with the optimal RAS Companion Inhibitor.

RMC-6236

RMC-6236, our RASMULTI(ON) inhibitor development candidate, designed as a first-in-class, potent, oral, RAS-selective tri-complex inhibitor of multiple RAS(ON) variants including cancer drivers at all three of the major mutation hotspot positions, G12, G13, and Q61. RMC-6236 inhibits all three major RAS isoforms, suppressing the mutant cancer driver and cooperating wild-type RAS proteins. RMC-6236 is being evaluated in an ongoing monotherapy dose-escalation Phase 1/1b clinical study in certain patients with KRASG12X tumors, focused on NSCLC, pancreatic and colorectal cancers.

In a series of in vivo tumor xenograft studies, RMC-6236 was highly active against lung, pancreatic and colorectal cancers bearing KRASG12X driver mutations (KRASG12D, KRASG12V, KRASG12R or KRASG12C; Figure 2). Across cancer types, RMC-6236 drove deep tumor regressions, including complete responses, and established preclinical response rates supporting advancement into clinical development.

Figure 2. RMC-6236 was highly active in vivo across cancer models with KRASG12X drivers.

In vivo characterization of the effect of RMC-6236 on the growth of KRASG12X cancers. RMC-6236 was dosed at 25 mg/kg po qd. n=1-10/group. NSCLC = non-small cell lung cancer; PDAC = pancreatic ductal adenocarcinoma; CRC = colorectal cancer. Responses assigned according to mRECIST (modified from Gao et al. Nat Med. 2015). ORR = objective response rate; DCR = disease control rate. RVMD preclinical research as of 06/01/22.

We believe the preclinical results for RMC-6236 show that this product candidate has the potential to treat patients whose cancers harbor a range of RAS variants, including KRASG12X mutations. While first-generation KRASG12C inhibitors have provided strong clinical validation of RAS as a cancer driver, patients with cancers bearing KRASG12D, KRASG12V, or KRASG12R mutations continue to lack targeted therapy options. In total, KRASG12X mutations are found in 137,000 new patients per year in the U.S., indicating major unmet medical need in the cancer types for which RMC-6236 has demonstrated strong preclinical activity.

In the ongoing RMC-6236-001 Phase 1/1b trial, 36 patients treated across five dose cohorts ranging from 10 mg daily to 120 mg daily were evaluable for initial safety and tolerability as of a data cut-off date of February 17, 2023. All of these patients have been previously treated with standard of care and/or other regimens, with an overall median of three prior treatments. Across the study as of the data cut-off date, we have observed that RMC-6236 is orally bioavailable and exhibited dose-dependent exposures in patients that are consistent with our preclinical projections. We continue in dose escalation, as we have not yet reached a maximum-tolerated dose or defined a recommended phase 2 dose.

The most common adverse events we have observed are consistent with on-target, RAS pathway toxicities (Table 1).

Table 1. RMC-6236-001: Treatment-related adverse events occurring in ≥ 10% of all patients.

Electronic Data Capture (EDC) data as of 02/17/2023. CMQ = Customized MedDRA Query.

* Consists of dermatitis acneiform, dermatitis psoriasiform, palmar-plantar erythrodysesthesia syndrome, rash maculo-papular and rash pustular.

As of the data cut-off, one related grade 4 adverse event of bowel perforation (also considered a serious adverse event) was reported in a patient receiving 80 mg daily. The likely cause of the perforation was considered to be shrinkage of metastatic KRASG12V pancreatic cancer at the site of full-thickness bowel infiltration by the tumor.

Consistent with study eligibility criteria, patients with a range of tumor types in which KRASG12X mutations are common have been enrolled, including major epithelial cancers such as NSCLC, pancreatic, colorectal, and others including ovarian, appendiceal and bile duct cancers. The KRAS mutations in those tumors cover the range of KRASG12 mutations: G12D, G12V, G12A, G12S and G12R, with G12D being the most heavily represented as of the data cut-off date. At the 10 mg and 20 mg dose levels, radiographic imaging showed either stable disease with some tumor reduction, or disease progression, as the best responses. The waterfall plot of tumor volumes below includes the nine pancreatic cancer patients and three NSCLC patients treated at 40 mg daily or higher doses and that are efficacy evaluable (Figure 3).

Figure 3. RMC-6236-001: Change in tumor burden from efficacy-evaluable patients with KRASG12X NSCLC or pancreatic cancer treated at ≥ 40 mg daily (n=12).

EDC data as of 02/17/2023; efficacy evaluable patients defined as those in this data set with at least one post baseline response assessment or who have died or have experienced clinical progression prior to the first post baseline scan (n=12). Cycle time is 21 days. SD = stable disease, PR = partial response. NSCLC = non-small cell lung cancer; PDAC = pancreatic ductal adenocarcinoma. *PR unconfirmed as of 02/17/2023.

All 12 of these patients exhibited stable disease or better as their best response. All 12 patients remained on treatment from approximately 1.5 to 4.5 months as of the data cut-off date. 10 of 12 patients had shown some degree of tumor volume reduction by RECIST.

One patient, a 76 year-old with metastatic pancreatic cancer harboring KRASG12D, also achieved a PR that was unconfirmed as of the data cut-off date, with a 70% tumor reduction by response evaluation criteria in solid tumors, or RECIST. At baseline this patient had three distinct lesions – one in the right lung and two in the left lung. These lesions are identified on the upper row of the three computerized tomography (CT) images below (Figure 4). All three lesions underwent significant reduction over 12 weeks of therapy. At six weeks the target lesions were reduced in size by 17% by RECIST. On the 12-week scans shown in the second row below, target lesion 1 was too small to measure, target lesion 2 was considerably reduced and the single non-target lesion was barely detectable. RECIST quantifies response by measuring only the unidimensional longest axis for each target lesion and does not consider density or three-dimensional volume. As the first target lesion was assigned a measurement of 5 mm for purposes of the RECIST calculation, this patient achieved a 70% tumor reduction and a PR by RECIST even though volumetrically the reduction in tumor burden appears to be greater than 70%. As of the data cut-off date, this patient continued on treatment at the 80 mg daily dose level and the PR was unconfirmed pending a confirmatory follow-up scan.

Figure 4. CT scans showing three lesions in the lungs of a KRASG12D pancreatic cancer patient at baseline and at cycle 5, day 1 of treatment with RMC-6236.

Images courtesy of RMC-6236-001 trial site with additional annotation by Revolution Medicines (red arrows and target lesion measurements at top right of each scan).

*Per EDC, target lesion #1 on C5D1 was too small to measure; 5 mm used to calculate the percentage reduction in sum of longest diameters of target lesions by RECIST. RLL = right lower lobe; LLL = left lower lobe.

RMC-6291

RMC-6291 is designed as a first-in-class, potent, oral and selective tri-complex inhibitor of KRASG12C(ON). It is designed to exhibit subnanomolar potency for suppressing RAS pathway signaling and growth of KRASG12C-bearing cancer cells and is engineered to be highly selective for KRASG12C over wild type RAS and other cellular targets. RMC-6291 is designed to be differentiated from first-generation KRASG12C(OFF) inhibitors, which sequester the KRASG12C(OFF) form, by its potential mechanism of directly inhibiting the KRASG12C(ON) form. We believe direct inhibition of the ON form offers important biological advantages, including more rapid termination of RAS signaling and more robust inhibition in the face of known resistance mechanisms. RMC-6291 is being evaluated in an ongoing monotherapy dose-escalation Phase 1/1b clinical study, where our goal is to pursue best-in-class activity against KRASG12C tumors, focused on NSCLC, pancreatic and colorectal cancers. Based on early observations from this study, we believe that RMC-6291 is orally bioavailable in patients, that it is exhibiting pharmacokinetics consistent with our expectations based on

preclinical experiments and that we are dosing the compound at a pharmacologically active range with acceptable safety and tolerability.

While KRASG12C(OFF) inhibitors have validated the target and changed the treatment landscape for patients with cancers bearing KRASG12C, significant unmet medical need remains. In NSCLC, KRASG12C(OFF) inhibitor single agent response rates are less than 50%, and the vast majority of patients are expected to progress on therapy within a year. We believe RMC-6291 has the potential to improve on the KRASG12C(OFF) inhibitor class. In a series of in vivo tumor xenograft studies, RMC-6291 outperformed adagrasib, a representative KRASG12C(OFF) inhibitor, across 25 models of KRASG12C NSCLC (Figure 5). Within this set of experiments, we observed examples of RMC-6291 driving increased rate, depth and/or duration of response (Figure 6).

Figure 5. RMC-6291 drove superior outcomes in a mouse clinical trial with KRASG12C NSCLC models.

In vivo characterization of the effect of RMC-6291 on the growth of KRASG12C NSCLC models. RMC-6291 (blue) and adagrasib (gray) were administered at approximately molar equivalent doses (RMC-6291 is roughly twice the molecular weight of adagrasib). RMC-6291 was dosed at 200 mg/kg po qd. Adagrasib was dosed at 100 mg/kg po qd. n=3-10/group. NSCLC = non-small cell lung cancer. Responses assigned according to mRECIST (modified from Gao et al. Nat Med. 2015). ORR = objective response rate; DCR = disease control rate. RVMD preclinical research as of 11/20/22.

Figure 6. RMC-6291 drove increased rate, depth, and duration of response in a mouse clinical trial with KRASG12C NSCLC models.

In vivo characterization of the effect of RMC-6291 on the growth of KRASG12C NSCLC models. RMC-6291 and adagrasib were administered at approximately molar equivalent doses (RMC-6291 is roughly twice the molecular weight of adagrasib). RMC-6291 was dosed at 200 mg/kg po qd. Adagrasib was dosed at 100 mg/kg po qd. PDX Models: (a) LUN055; (b) LXFA-983; (c) CTG-0828 N=3-10/group. NSCLC = non-small cell lung cancer. RVMD preclinical research as of 07/28/21.

RMC-9805

RMC-9805 is designed as a first-in-class, potent, oral and selective tri-complex inhibitor of KRASG12D(ON). It is designed to exhibit low nanomolar potency for suppressing RAS pathway signaling and growth of KRASG12D-bearing cancer cells and is engineered to covalently inactivate KRASG12D for irreversible inhibition. To our knowledge, RMC-9805 is the first ever drug candidate that covalently modified an aspartic acid residue in preclinical studies. RMC-9805 is in the IND-enabling stage of preclinical development, and is part of the first wave of RAS(ON) Inhibitors we are advancing.

In a series of in vivo tumor xenograft studies, RMC-9805 was highly active against lung, pancreatic and colorectal cancers bearing the KRASG12D driver mutation (Figure 7). Across cancer types, RMC-9805 drove deep tumor regressions, including complete responses, and established preclinical response rates, which we believe support advancement into clinical development.

Figure 7. RMC-9805 was highly active in vivo across KRASG12D cancer models.

In vivo characterization of the effect of RMC-9805 on the growth of KRASG12D cancers. RMC-9805 was dosed at 100 mg/kg po qd. N=2-8/group. NSCLC = non-small cell lung cancer; PDAC = pancreatic ductal adenocarcinoma; CRC = colorectal cancer. Responses assigned according to mRECIST (modified from Gao et al. Nat Med. 2015). ORR = objective response rate; DCR = disease control rate. RVMD preclinical research as of 11/02/22.

In the initial clinical development of RMC-9805, we plan to pursue best-in-class activity against KRASG12D tumors, focused on NSCLC, pancreatic and colorectal cancers.

RMC-8839

RMC-8839 is designed as a first-in-class, potent, oral and selective tri-complex inhibitor of KRASG13C(ON). It is designed to exhibit picomolar potency for suppressing RAS pathway signaling and growth of KRASG13C-bearing cancer cells and is engineered to covalently inactivate KRASG13C for irreversible inhibition. We believe RMC-8839 is ready for preparation of an IND based on our preclinical development, however we have deferred active development of this compound.

RMC-0708

RMC-0708 is designed as a first-in-class, potent, oral and selective tri-complex inhibitor of KRASQ61H(ON). It is designed to exhibit picomolar potency for suppressing RAS pathway signaling and growth of KRASQ61H-bearing cancer cells and is engineered for selective inhibition of KRASQ61H over other RAS isoforms via non-covalent binding interactions. RMC-0708 is in the IND-enabling stage of preclinical development.

RAS Companion Inhibitors

Overview

Our RAS Companion Inhibitors are designed to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Each of our RAS Companion Inhibitors, when administered in combination with a RAS inhibitor, may provide deeper and more durable

suppression of RAS cancer signaling, helping to maximize clinical benefit for patients with RAS cancers. RMC-4630, our most advanced RAS Companion Inhibitor, is designed to be a potent and selective inhibitor of SHP2 and to suppress resistance to RAS inhibition through inhibition of cooperating RAS pathway signaling. RMC-5552 is designed to be a potent and selective inhibitor of mTORC1/4EBP1 and to suppress resistance to RAS inhibition through inhibition of cooperating mTORC1 pathway signaling. RMC-5845, our investigational SOS1 inhibitor, is designed to suppress resistance to RAS inhibition through inhibition of cooperating RAS pathway signaling. RMC-5552 is under clinical evaluation in a Phase 1 dose escalation program.

RMC-4630

Our RAS Companion Inhibitor RMC-4630 is designed as a potent and selective inhibitor of SHP2, a central node in the RAS signaling pathway. RMC-4630 is being evaluated in a multi-cohort Phase 1/2 clinical program. In 2018, we entered into the Sanofi Agreement with respect to SHP2 inhibitors, including RMC-4630. In December 2022, the Sanofi Agreement was terminated effective as of June 2023 and following the effectiveness of termination, we will regain all global rights granted under the Sanofi Agreement (except as necessary to permit Sanofi to perform any surviving obligations under the Sanofi Agreement), including decision-making regarding research and development, and the rights to all commercial proceeds, from RMC-4630.

In our monotherapy dose escalation study (RMC-4630-01), we have observed that RMC-4630 was a clinically active SHP2 inhibitor, with broad anti-tumor effects, including a confirmed partial response in a patient with NSCLC bearing a KRASG12C mutation and a complete response in a patient with uterine cancer bearing an NF1LOFmutation. The anti-tumor activity of RMC-4630 observed in this study was enabled by a unique intermittent dosing paradigm (200 mg D1D2 weekly) designed to maximize dose intensity without compromising safety and tolerability. Accordingly, and consistent with the highly selective profile of RMC 4630, all dose-limiting toxicities observed in the RMC-4630-01 study have been linked to on-target SHP2 inhibition. We continue to evaluate RMC-4630 monotherapy at the RP2DS in an expansion cohort of the RMC-4630-01 study, consisting of patients with gynecologic tumors harboring NF1LOF mutations, in addition to a small safety/tolerability cohort representing a broader set of histotypes and RAS pathway genotypes.

•

an Amgen-sponsored Phase 1b study of RMC-4630 in combination with Amgen’s KRASG12C(OFF) inhibitor, sotorasib (LUMAKRAS(R));

•

RMC-4630-03, a Phase 2 study of RMC-4630 in combination with sotorasib that we are sponsoring under a clinical trial collaboration and supply agreement with Amgen; and

•

a Sanofi-sponsored Phase 1/2 study of RMC-4630 in combination with Mirati Therapeutics’ KRASG12C(OFF) inhibitor, adagrasib (KRAZATI(R)).

Amgen is currently evaluating RMC-4630 in an active Phase 1b study in combination with Amgen’s KRASG12C(OFF) agent sotorasib in Amgen’s CodeBreaK 101c study. In August 2022, Amgen reported results from this study at the 2022 World Conference on Lung Cancer.

As a complement to the CodeBreaK 101c study, we are sponsoring RMC-4630-03, which is an additional global Phase 2 study of RMC-4630 in combination with sotorasib for patients with NSCLC carrying a KRASG12C mutation who have failed prior standard therapy and who have not previously been treated with a RAS inhibitor. We are sponsoring the RMC-4630-03 study under our global partnership with Sanofi and conducting the trial in collaboration with Amgen, which is supplying sotorasib globally under a clinical collaboration and supply agreement.

Sanofi sponsored a combination study under the Sanofi Agreement and under a clinical trial collaboration and supply agreement between Sanofi and Mirati to evaluate RMC-4630 (also known as SAR442720) in combination with Mirati’s KRASG12C(OFF) inhibitor, adagrasib. We expect that this study will be wound down in connection with the termination of the Sanofi Agreement.

There are also several clinical studies of RMC-4630 that do not involve combinations with RAS inhibitors:

•

RMC-4630-01, a Phase 1 study of RMC-4630 as monotherapy;

•

a Sanofi-sponsored Phase 1/2 study of RMC-4630 in combination with the PD-1 inhibitor pembrolizumab (Keytruda®) which we expect will be wound down in connection with the termination of the Sanofi Agreement; and

•

a combination of RMC-4630 with an ERK inhibitor in patients as part of an investigator-sponsored study by Netherlands Cancer Institute.

RMC-5552

Our RAS Companion Inhibitor RMC-5552 is designed as a selective inhibitor of hyperactivated mTORC1 signaling in tumors. We are evaluating RMC-5552 first as a monotherapy in a Phase 1 study (RMC-5552-001), and plan to evaluate RMC-5552 in combination with RAS inhibitors for patients with cancers harboring a RAS mutation and co-occurring mutations in the mTOR signaling pathway.

mTORC1 is a critical regulator of metabolism, growth and proliferation within cells, including cancer cells. The abnormal activation of mTORC1, and subsequent inactivation of the tumor suppressor 4EBP1, is a mechanism that is frequently harnessed by cancer cells to gain a growth and proliferation advantage over normal cells. RMC-5552 is designed to selectively and deeply inhibit mTORC1, thereby preventing phosphorylation and inactivation of 4EBP1, a downstream protein in the mTOR signaling pathway that normally suppresses expression of certain oncogenes such as C-MYC. RMC-5552 has been shown to have combinatorial activity with KRASG12C inhibitors in preclinical models of KRASG12C lung and colon cancer, suggesting that RMC-5552 may be a meaningful and rational addition to our portfolio of RAS Companion Inhibitors.

In interim data from our ongoing clinical trial with a December 19, 2022 data cut-off date, we have observed preliminary evidence of clinical activity at tolerable doses, including a confirmed partial response in a patient with head and neck cancer bearing an mTOR pathway mutation and a disease control rate of 71% in efficacy-evaluable patients treated at majority doses of 6 mg or 8 mg IV weekly (Figure 8).

Figure 8. Best Tumor Change in Efficacy Evaluable Patients Treated at 6 mg or 8 mg IV Weekly.

(1) n = 28 efficacy evaluable subjects. *Patient received one dose of 12 mg, followed by weekly doses of 6 mg, had complete loss of oncogenic PTEN variant by ctDNA and has been on RMC-5552 for >12 months. #Patient received one dose of 10 mg, followed by weekly doses of 6 mg. Both patients were on RMC-5552 for >24 weeks. 6 mg weekly was well tolerated. Further enrollment at doses above 6 mg is ongoing to define the recommended Phase 2 dose and schedule. Data as of 12/19/2022. PD = progressive disease, SD = stable disease, PR = partial response, DCR=disease control rate. mo = months.

RMC-5845

RMC-5845 targets SOS1, a protein that plays a key role in converting RAS(OFF) to RAS(ON) in cells. RMC-5845 is intended for select combination therapies for certain genetically-defined tumors. This compound is ready for preparation of an IND based on our preclinical development. We continue evaluating whether to advance RMC-5845 into clinical development in the context of other assets in our portfolio.

Commercial plan

We intend to retain significant development and commercialization rights to our product candidates and, if marketing approval is obtained, to commercialize our product candidates on our own, or potentially with a partner, in the United States and other regions. We currently have no sales, marketing or commercial product distribution capabilities. We intend to build the necessary infrastructure and capabilities over time for the United States, and potentially other regions, in connection with the advancement of our product candidates. Clinical data, the size of the addressable patient population, the size of the commercial infrastructure and manufacturing needs, and the status of our pipeline, may all influence or alter our commercialization plans.

Our most advanced product candidate, RMC-4630, is the subject of a global collaboration with Sanofi, which has been terminated effective as of June 2023. The terms of this collaboration give Sanofi certain rights with respect to SHP2-related commercialization decisions and to economics from commercial activities, as well as commercial manufacturing obligations, however all of these rights and obligations will revert to us upon effectiveness of termination of the collaboration agreement.

Collaboration agreement with Sanofi

In June 2018, we entered into the Sanofi Agreement with Aventis, Inc. (an affiliate of Sanofi) to research and develop SHP2 inhibitors, including RMC-4630, for any indications. The Sanofi Agreement was assigned to Genzyme Corporation, a Sanofi affiliate, in December 2018. For the purposes of this discussion, we refer to Genzyme Corporation as Sanofi. In December 2022, the Sanofi Agreement was terminated effective as of June 2023, and all rights and obligations described below will terminate and revert to us upon effectiveness of this termination, except as necessary to permit Sanofi to perform any surviving obligations under the Sanofi Agreement.

Pursuant to the Sanofi Agreement, we granted Sanofi a worldwide, exclusive, sublicensable (subject to our consent in certain circumstances) license under certain of our patents and know-how to research, develop, manufacture, use, sell, offer for sale, import and otherwise commercialize SHP2 inhibitors, including RMC-4630, for any and all uses, subject to our exercise of rights and performance of obligations under the Sanofi Agreement. Such intellectual property exclusively licensed to Sanofi includes our interest under any of our solely-owned or jointly-owned inventions arising out of activities undertaken pursuant to the development of SHP2 inhibitor product candidates under the Sanofi Agreement.

We are responsible for the manufacture of SHP2 inhibitors for Phase 1 and non-registrational Phase 2 clinical trials pursuant to an approved development plan, while Sanofi is responsible for manufacturing SHP2 inhibitors for all other clinical trials and commercial supply. Sanofi has the sole right and responsibility to perform all regulatory activities under the Sanofi Agreement, except with respect to certain trials conducted by us or otherwise conducted under our IND, including our current clinical trials evaluating RMC-4630.

Unless otherwise delegated to us by the joint commercialization committee, during the term of the Sanofi Agreement, Sanofi also has the sole right and responsibility for all aspects of the commercialization of SHP2 inhibitors in the world for any and all uses, at its expense, subject to our right to elect to co-promote SHP2 inhibitors in the United States. Sanofi agrees to provide us, and we agree to provide Sanofi, with research, development and commercialization updates through the joint committees.

During the term of the Sanofi Agreement, we may not, alone or with any affiliate or third party, conduct certain research activities with respect to, or develop or commercialize, any product that contains a SHP2 inhibitor outside of the Sanofi Agreement.

Pursuant to the Sanofi Agreement, we received an upfront payment of $50 million from Sanofi in July 2018. The Sanofi Agreement includes obligations for Sanofi to make certain milestone payments and royalty payments, all of which will expire upon effectiveness of termination of the Sanofi Agreement.

During the term of the Sanofi Agreement, Sanofi has the sole and exclusive right to file, prosecute and maintain any patents licensed to it pursuant to the Sanofi Agreement, as well as to enforce infringement of or defend claims against such patents that relate to SHP2 inhibitor products.

Upon effectiveness of the termination of the Sanofi Agreement, the licenses granted to Sanofi thereunder shall become fully paid-up, royalty-free, perpetual and irrevocable and all rights and obligations of Sanofi under the Sanofi Agreement will revert to us.

Through December 31, 2022, we have received an aggregate of $176.9 million from Sanofi, including the upfront payment and research and development expense reimbursements.

Manufacturing

We rely on and will continue to rely on our contract manufacturing organizations, or CMOs, for both drug substance and drug product. Currently, all of our manufacturing is outsourced to well-established third-party manufacturers. We have entered into contracts with CMOs for production of drug substance and drug product for our clinical trials and IND-enabling development studies, and plan to enter into additional contracts with these or other manufacturers for additional supply.

Our outsourced approach to manufacturing relies on CMOs to first develop manufacturing processes that are compliant with current Good Manufacturing Practice, or cGMP, then produce material for preclinical and clinical studies. Our agreements with CMOs may obligate them to develop and qualify upstream and downstream processes, develop drug product process, validate (and in some cases develop) suitable analytical methods for test and release as well as stability testing, produce drug substance for preclinical testing, produce cGMP-compliant drug substance, or produce cGMP-compliant drug product. We conduct audits of CMOs prior to initiation of activities under these agreements and monitor operations to ensure compliance with the mutually agreed process descriptions and to cGMP regulations.

Competition

The biotechnology and pharmaceutical industries, and the oncology sector, are characterized by rapid evolution of technologies, fierce competition and strong defense of intellectual property rights. While we believe that our discovery programs, technology, knowledge, experience, and scientific resources provide us with competitive advantages, we face competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions, among others.

Any product candidates that we successfully develop and commercialize will compete with currently approved therapies and new therapies that may become available in the future. Key product features that would affect our ability to effectively compete with other therapeutics include the efficacy, safety and convenience of our products and the ease of use and effectiveness of any complementary diagnostics and/or companion diagnostics.

There are a number of companies developing or marketing treatments for cancer, including many major pharmaceutical and biotechnology companies. These treatments consist of small molecule drug products, biologics, cell-based therapies and traditional chemotherapy. Smaller and other early-stage companies may also prove to be significant competitors. In addition, academic research departments and public and private research institutions may be conducting research on compounds that could prove to be competitive.

There are several programs in clinical development targeting KRASG12C, including programs directed at KRASG12C (OFF) being conducted by Amgen Inc., Betta Pharmaceuticals Co., Ltd., Boehringer Ingelheim, D3 BIO, Inc., Eli Lilly, Genhouse Bio Co. Ltd., HUYA Bioscience, InnoCare Pharma Ltd., Innovent Biologics, Inc., InventisBio, Jacobio Pharmaceuticals Co. Ltd., Merck, Sharpe & Dohme LLC, Mirati Therapeutics, Inc., Novartis AG, Roche, Shanghai YingLi Pharmaceutical, Suzhou Genhouse Bio and Suzhou Zelgen Biopharmaceuticals. There are also several clinical programs directed at KRASG12D, including those being conducted by Astellas Pharma Inc., Jiangsu Hengrui Pharmaceuticals Company Ltd. and Mirati Therapeutics, Inc. Other clinical programs directed at mutant RAS are being conducted, including those by Alaunos Therapeutics, Inc., Elicio Therapeutics, Gritstone bio, Inc., Moderna, Inc., Silenseed Ltd. and Targovax ASA. The above list includes corporate competitors that we are currently aware of and that are currently conducting clinical trials or marketing in geographies where we currently anticipate conducting clinical trials for our product candidates. However, companies operating in other geographies and smaller and other early-stage companies may also prove to be significant competitors. In addition, academic research departments and public and private research institutions may be conducting research on compounds that could prove to be competitive.

The availability of coverage and reimbursement from government and other third-party payors will also significantly affect the pricing and competitiveness of our products. Our competitors also may obtain FDA, or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.

Many of the companies against which we may compete have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.

Intellectual property

Our success depends in part on our ability and the ability of our collaborators to obtain and maintain proprietary protection for our technology, programs, and know-how related to our business, defend and enforce our intellectual property rights, in particular, our patent rights, preserve the confidentiality of our trade secrets, and operate without infringing valid and enforceable intellectual property rights of others. We endeavor to establish, maintain and enforce intellectual property rights that protect our business interests.

The term of individual patents depends upon the legal term of patents in the countries in which they are obtained. In most countries in which we file, including the United States, the patent term is generally 20 years from the earliest date of filing a non-provisional patent application, assuming the patent has not been terminally disclaimed over a commonly-owned patent or a patent naming a common inventor, or over a patent not commonly owned but that was disqualified as prior art as the result of activities undertaken within the scope of a joint research agreement. In the United States, the term of a patent may also be eligible for patent term adjustment for delays within the United States Patent and Trademark Office, or USPTO. In addition, for patents that cover an FDA-approved drug, the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, may permit a patent term extension of up to five years beyond the expiration of the patent. While the length of such patent term extension is related to the length of time the drug is under regulatory review, patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent per approved drug may be extended and only those claims covering the approved drug product, a method for using it or a method for manufacturing it may be extended. Similar provisions are available in Europe and certain other foreign jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our products receive FDA approval, we expect to apply for patent term extensions on patents covering those products. We plan to seek any available patent term extension to any issued patents we may be granted in any jurisdiction where such extensions are available; however, there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and if granted, the length of such extensions.

We also rely on trade secrets, know-how, and confidential information relating to our programs to develop and maintain our proprietary position, and seek to protect and maintain the confidentiality of such items to protect aspects of our business that are not amenable to, or that we do not presently consider appropriate for, patent protection. Our trade secrets include, for example, certain program specific syntheses, manufacturing schema, formulations, biomarkers, patient selection strategies, and certain aspects of our proprietary tri-complex technology platform. It is our policy to require our employees, consultants, contractors, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements prior to the commencement of employment or consulting relationships with us, and for employees, contractors and consultants to enter into invention assignment agreements with us. These agreements generally provide that all confidential information developed or made known to the individual during the course of the individual’s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. Where applicable, the agreements provide that all inventions to which the individual contributed as an inventor shall be assigned to us, and as such, will become our property. There can be no assurance, however, that these agreements will be self-executing or otherwise provide meaningful protection or adequate remedies for our trade secrets or other proprietary information, including in the event of unauthorized use or disclosure of such information. We also seek to preserve the integrity and confidentiality of our trade secrets and confidential information by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in the measures we take to protect and preserve our trade secrets, such measures can be breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. For more information regarding the risks related to intellectual property, please see “Risk factors—Risks related to intellectual property.”

Our program-specific patent portfolio

Our patent portfolio is directed to small molecules, platform methodologies, and related technology. We seek patent protection for product candidates, development programs, and related alternatives by filing and prosecuting patent applications in the United States and other countries, as appropriate.

We own and co-own patents and patent applications related to our SHP2 development program. Our patent portfolio related to this program consists of ownership or co-ownership rights to several patent families that include filings covering compositions of matter or methods of using our development candidate, RMC-4630, alone or in combination with certain other therapeutic agents. The single co-owned patent family is co-owned with The University of California, San Francisco, or UCSF. The issued patents have, and any

patents issuing from these patent applications would have, nominal expiration dates ranging from 2037 to 2041, without accounting for any applicable patent term adjustments or extensions.

We own or exclusively license patents and patent applications related to our mTORC1 development program. Our patent portfolio related to this program consists of ownership or the exclusive license of rights to several patent families that include filings covering compositions of matter or methods of using our development candidate, RMC-5552, alone or in combination with certain other therapeutic agents. The single exclusively licensed patent family is licensed from UCSF. The issued patents have, and any patents issuing from these patent applications would have, nominal expiration dates ranging from 2035 to 2042, without accounting for any applicable patent term adjustments or extensions.

We own patent applications related to our SOS1 development program. Our patent portfolio related to this program consists of ownership of several patent families that include filings covering compositions of matter or methods of using our development candidate, RMC-5845, alone or in combination with certain other therapeutic agents. The issued patents have, and any patents issuing from these patent applications would have, nominal expiration dates ranging from 2040 to 2042, without accounting for any applicable patent term adjustments or extensions.

We own patents and patent applications related to our RAS tri-complex inhibitors and related platform technology. Our patent portfolio related to this program consists of ownership rights to several patent families that include filings covering compositions of matter or methods of using our development candidates alone or in combination with certain other therapeutic agents, or aspects pertaining to our tri-complex approach to RAS inhibition. The issued patents have, and any patents issuing from these patent applications would have, nominal expiration dates ranging from 2031 (for patents originating from the Warp Drive Bio portfolio) to 2042 (for patents originating from the Company’s portfolio), without accounting for any applicable patent term adjustments or extensions.

Government regulation

The FDA and other regulatory authorities at federal, state, and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, marketing and promotion, distribution, post-approval monitoring and reporting, sampling, and import and export of products, such as those we are developing. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources.

U.S. drug regulation

In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. FDA approval is required before any new unapproved drug can be marketed in the United States. Drugs are also subject to other federal, state and local statutes and regulations. Failure to comply with applicable FDA or other requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA clinical holds, refusal to approve pending applications, withdrawal of an approval, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution.

The process required by the FDA before product candidates may be marketed in the United States generally involves the following:

•

completion of extensive preclinical laboratory tests and animal studies, where all supporting safety and toxicity studies are performed in accordance with applicable regulations, including the FDA’s Good Laboratory Practice, or GLP, regulations;

•

manufacture of clinical drug supply in accordance with FDA’s current Good Manufacturing Practice, or cGMP, regulations, when required;

•

submission to the FDA of an investigational new drug application, or IND, which must become effective before human clinical studies may begin and must be updated annually or when significant changes are made;

•

approval by an independent institutional review board, or IRB, representing each clinical site before a clinical study may be initiated;

•

performance of adequate and well-controlled human clinical trials in accordance with good clinical practice, or GCP, regulations to establish the safety and efficacy of the product candidate for each proposed indication;

•

preparation of and submission to the FDA of an NDA after completion of all pivotal trials;

•

a determination by the FDA within 60 days of its receipt of an NDA to file the application for review;

•

satisfactory completion of an FDA advisory committee review, if applicable;

•

satisfactory completion of an FDA pre-approval inspection of the manufacturing facility(ies) where the product is manufactured to assess compliance with cGMP regulations, and of selected clinical investigation sites to assess compliance with GCP;

•

payment of users fees for FDA review of the NDA; and

•

FDA review and approval of an NDA to permit commercial marketing of the product for its particular labeled uses in the United States.

Preclinical and clinical studies

The preclinical and clinical testing and approval process can take many years and the actual time required to obtain approval, if any, may vary substantially based upon the type, complexity and novelty of the product or condition being treated.

Preclinical tests include laboratory (in vitro) evaluation of product chemistry, formulation and toxicity, as well as animal (in vivo) studies to assess the characteristics and potential safety and efficacy of the product. The conduct of preclinical tests that provide safety and toxicological information must comply with federal regulations and requirements, including GLP. The results of preclinical testing are submitted to the FDA as part of an IND along with other information, including information about product chemistry, manufacturing and controls (CMC) and any available human data or literature to support use of the product in humans. An IND is a request for authorization from the FDA to administer an investigational product to humans and must become effective before clinical trials may begin. Long-term preclinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted.

The central focus of an IND submission is on the general investigational plan and the protocol(s) for human studies. An IND must become effective before human clinical trials may begin. An IND will automatically become effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to the proposed clinical studies. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before clinical studies can begin.

For each successive clinical trial conducted with the investigational drug, a separate, new protocol submission to an existing IND must be made, along with any subsequent changes to the investigational plan. Sponsors are also subject to ongoing reporting requirements, including submission of IND safety reports for any serious adverse experiences associated with use of the investigational drug or findings from preclinical studies suggesting a significant risk for human subjects, as well as IND annual reports on the progress of the investigations conducted under the IND.

Clinical studies involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for participation in each clinical study. Clinical studies are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the efficacy criteria to be evaluated. A protocol for each clinical study and any subsequent protocol amendments must be submitted to the FDA as part of the IND. Additionally, approval must also be obtained from each clinical study site’s IRB before a study may be initiated at the site, and the IRB must monitor the study until completed. Sponsors of clinical trials generally must register and report ongoing clinical studies and clinical study results to public registries, including the website maintained by the U.S. National Institutes of Health, ClinicalTrials.gov.

Human clinical trials are typically divided into three or four phases. Although the phases are usually conducted sequentially, they may overlap or be combined.

•

Phase 1. The drug is initially introduced into healthy human subjects or into patients with the target disease or condition. These studies are designed to evaluate the safety, dosage tolerance, metabolism and pharmacologic actions of the drug in humans, the side effects associated with increasing doses, and if possible, to gain early evidence on effectiveness. In the case of some products for severe or life-threatening diseases, such as cancer, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.

•

Phase 2. The drug is administered to a limited patient population to evaluate tolerance and optimal dose, identify possible adverse side effects and safety risks, and preliminarily evaluate efficacy. Multiple Phase 2 trials may be conducted to obtain additional data prior to beginning Phase 3 trials.

•

Phase 3. The drug is administered to an expanded patient population, generally at geographically dispersed clinical study sites to generate enough data to statistically evaluate dosage, clinical effectiveness and safety, to establish the overall benefit-risk relationship of the investigational product and to provide an adequate basis for product approval.

•

Phase 4. In some cases, the FDA may condition approval of an NDA for a product candidate on the sponsor’s agreement to conduct additional clinical studies after approval. In other cases, a sponsor may voluntarily conduct additional clinical studies after approval to gain more information about the drug. Such post-approval studies are typically referred to as Phase 4 clinical studies.

The FDA, the IRB, other regulatory authorities or the clinical study sponsor may suspend or terminate a clinical study at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. The sponsor may also suspend or terminate a clinical study based on evolving business objectives and/or competitive climate.

Concurrent with clinical trials, companies may complete additional in vivo studies and develop additional information about the characteristics of the product candidate. Companies must also finalize a process for manufacturing the product in commercially applicable quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product and, among other things, must use validated methods for testing the product against specifications to confirm its identity, strength, quality and purity. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product does not undergo unacceptable deterioration over its shelf life.

U.S. review and approval process

Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of preclinical studies and other non-clinical studies and clinical trials, together with detailed information relating to the product’s chemistry, manufacture, controls, and proposed labeling, among other things, are submitted to the FDA in the form of an NDA requesting approval to market the product for one or more indications. The submission of an NDA requires payment of a substantial application user fee to the FDA, unless a waiver or exemption applies.

An NDA must include all relevant data available from pertinent preclinical and clinical studies, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product’s chemistry, manufacturing, controls and proposed labeling, among other things. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of a use of a product, or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and effectiveness of the investigational product to the satisfaction of the FDA.

The FDA reviews all submitted NDAs before it accepts them for filing. The FDA has 60 days from its receipt of an NDA to determine whether the application will be accepted for filing based on the agency’s threshold determination that it is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an application for filing. In this event, the application must be resubmitted with the additional information and is subject to payment of additional user fees. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. Under applicable Prescription Drug User Fee Act, or PDUFA, performance goals, the FDA endeavors to review applications subject to standard review within ten to twelve months, and to review applications subject to priority review within six to eight months, depending on whether the drug is a new molecular entity.

The FDA may refer applications for novel drug products or drug products which present difficult questions of safety or efficacy to an advisory committee for review, evaluation and recommendation as to whether the application should be approved and under what conditions.

Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, the FDA will typically inspect one or more clinical sites to assure that relevant study data was obtained in compliance with GCP requirements. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.

After the FDA evaluates the NDA and conducts inspections of manufacturing facilities, it may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A complete response letter indicates that the review cycle of the application is complete and the application will not be approved in its present form. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information, including additional clinical trials or other significant and time-consuming requirements related to the clinical trials, in order for the FDA to reconsider the application. Even with submission of this additional information, the FDA may ultimately decide that an application does not satisfy the regulatory criteria for approval.

If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, as a condition of NDA approval, the FDA may require a Risk Evaluation and Mitigation Strategy, or REMS, program to help ensure that the benefits of the drug outweigh its risks. If the FDA determines a REMS program is necessary during review of the application, the drug sponsor must agree to the REMS plan at the time of approval. A REMS program may be required to include various elements, such as a medication guide or patient package insert, a communication plan to educate healthcare providers of the drug’s risks, or other elements to assure safe use, such as limitations on who may prescribe or dispense the drug, dispensing only under certain circumstances, special monitoring and the use of patient registries. In addition, all REMS programs must include a timetable to periodically assess the strategy following implementation. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications.

Further, product approval may require substantial post-approval testing and surveillance to monitor the drug’s safety and efficacy, and the FDA has the authority to prevent or limit further marketing of a product based on the results of these post-marketing programs. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial marketing. Moreover, changes to the conditions established in an approved application, including changes in indications, labeling or manufacturing processes or facilities may require submission and FDA approval of a new NDA or NDA supplement before the changes can be implemented. An NDA supplement for a new indication typically requires clinical data similar to that supporting the original approval, and the FDA uses similar procedures in reviewing supplements as it does in reviewing original applications. In addition, new government requirements, including those resulting from new legislation, may be established, or the FDA’s policies may change, which could impact the timeline for regulatory approval or otherwise impact ongoing development programs.

Expedited development and review programs

The FDA offers a number of expedited development and review programs for qualifying product candidates, and we may seek one or more of these programs for our current or future products.

New drug products may be eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a fast track product has opportunities for frequent interactions with the review team during product development and, once an NDA is submitted, the product may be eligible for priority review. A fast track product may also be eligible for rolling review, where the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.

A product intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy designation to expedite its development and review. A product can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product, including involvement of senior managers.

After an NDA is submitted for a product, including a product with a fast track designation and/or breakthrough therapy designation, the NDA may be eligible for priority review. A product is eligible for priority review if it has the potential to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition compared to marketed products. Depending on whether a drug contains a new molecular entity, priority review designation means the FDA’s goal is to take an action on the marketing application within six to eight months of the 60-day filing date, compared with ten to twelve months under standard review.

Additionally, products studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled post-marketing clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. The FDA may withdraw approval of a drug or an indication approved under accelerated approval if, for example, sponsor fails to conduct the confirmatory trial in a timely manner, or if the confirmatory trial fails to verify the predicted clinical benefit of the product. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.

Fast track designation, breakthrough therapy designation, priority review and accelerated approval do not change the scientific or medical standards for approval or the quality of evidence necessary to support approval, though they may expedite the development or review process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or the time period for FDA review or approval may not be shortened.

Orphan drug designation

We intend to pursue orphan drug designation for one or more of our product candidates with respect to certain oncology indications, as appropriate, with the potential to obtain orphan drug exclusivity for our products, if approved.

Under the Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States for which there is no reasonable expectation that the cost of developing and making available in the United States a drug for this type of disease or condition will be recovered from sales in the United States for that drug. Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process.

If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusive approval (or exclusivity), which means that the FDA may not approve any other applications, including a full NDA, to market the same drug for the same disease or condition for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition. Orphan product exclusivity also could block the approval of one of our products for seven years if a competitor obtains approval of the same drug as defined by the FDA or if our product candidate is determined to be contained within the competitor’s product for the same disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the application user fee.

A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.

Pediatric information and pediatric exclusivity

Under the Pediatric Research Equity Act, or PREA, certain NDAs and certain supplements to an NDA must contain data to assess the safety and efficacy of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of pediatric data or full or partial waivers. The Food and Drug Administration Safety and Innovation Act, or FDASIA, amended the FDCA to require that a sponsor who is planning to submit a marketing application for a drug that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial Pediatric Study Plan, or iPSP, within 60 days of an end-of-Phase 2 meeting or, if there is no such meeting, as early as practicable before the initiation of a Phase 3 or Phase 2/3 study. The iPSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement on the iPSP. A sponsor can submit amendments to an agreed-upon iPSP at any time if changes to the pediatric plan need to be considered based on data collected from preclinical studies, early phase clinical trials and/or other clinical development programs.

A drug product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued “Written Request” for such a study.

Post-approval requirements

Once an NDA is approved, a product will be subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to drug listing and registration, recordkeeping, periodic reporting, product sampling and distribution, adverse event reporting and advertising, marketing and promotion. Drugs may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. While physicians may prescribe for off-label uses, manufacturers may only

promote for the approved indications and in accordance with the provisions of the approved label. However, companies may share truthful and not misleading information that is otherwise consistent with a product’s FDA approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.

After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which FDA assesses an annual program fee for each product identified in an approved NDA. In addition, quality-control, drug manufacture, packaging and labeling procedures must continue to conform to cGMPs after approval. Drug manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies. Registration with the FDA subjects entities to periodic unannounced and announced inspections by the FDA and these state agencies, during which the agency inspects manufacturing facilities to assess compliance with cGMP requirements and other laws. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance. The FDA may withdraw approval of a product if compliance with regulatory requirements is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:

•

restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls;

•

fines, warning or untitled letters or holds on clinical studies;

•

refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;

•

product seizure or detention, or refusal of the FDA to permit the import or export of products;

•

mandated modifications of promotional materials and labeling and the issuance of corrective information;

•

the issuance of safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product; or

•

injunctions or the imposition of civil or criminal penalties.

We also must comply with the FDA’s advertising and promotion requirements, such as those related to direct-to-consumer advertising, the prohibition on promoting products for uses or in patient populations that are not described in the product’s approved labeling, known as “off-label use,” industry-sponsored scientific and educational activities, and promotional activities involving the internet.

The FDA may also require post-approval studies and clinical trials if the FDA finds that scientific data, including information regarding related drugs, deem it appropriate. The purpose of such studies would be to assess a known serious risk or signals of serious risk related to the drug or to identify an unexpected serious risk when available data indicate the potential for a serious risk. The FDA may also require a labeling change if it becomes aware of new safety information that it believes should be included in the labeling of a drug.

Failure to comply with the applicable regulatory requirements at any time during the product development process, approval process or after approval may subject an applicant or manufacturer to, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical hold, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment, restitution, disgorgement of profits, or civil or criminal penalties.

International regulation

In addition to regulations in the United States, we could become subject to a variety of foreign regulations regarding development, approval, commercial sales and distribution of our products if we seek to market our product candidates in other jurisdictions. Whether or not we obtain FDA approval for a product, we must obtain the necessary approvals by the comparable regulatory authorities of foreign countries before we can commence clinical trials or marketing of the product in those countries. The approval process varies from country to country and can involve additional product testing and additional review periods, and the time may be

longer or shorter than that required to obtain FDA approval. The requirements governing, among other things, the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may negatively impact the regulatory process in others. If we fail to comply with applicable foreign regulatory requirements, we may be subject to fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.

Other healthcare laws

Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation, U.S. federal and state anti-kickback, fraud and abuse, false claims, consumer fraud, pricing reporting, and transparency laws and regulations as well as similar foreign laws in jurisdictions outside the U.S.

For example, the federal Anti-Kickback Statute prohibits, among other things, individuals or entities from knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, overtly or covertly, in cash or in kind to induce or in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. A person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation.

The federal civil and criminal false claims laws, including the civil False Claims Act, prohibit, among other things, any individual or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act.

The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal civil and criminal statutes that prohibit, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate it in order to have committed a violation.

The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program, with specific exceptions, to report annually to CMS information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician practitioners (physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiology assistants and certified nurse midwives) and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by physicians and their immediate family members.

Similar state and local laws and regulations may also restrict business practices in the pharmaceutical industry, such as state anti-kickback and false claims laws, which may apply to business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, or by patients themselves; state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information or which require tracking gifts and other remuneration and items of value provided to physicians, other healthcare providers and entities; and state and local laws that require the registration of pharmaceutical sales representatives.

Violation of any of such laws or any other governmental regulations that apply may result in penalties, including, without limitation, civil and criminal penalties, damages, fines, additional reporting obligations, the curtailment or restructuring of operations, exclusion from participation in governmental healthcare programs and individual imprisonment.

Data privacy and security

Pharmaceutical companies may be subject to numerous federal, state and foreign laws, regulations that govern the collection, use, disclosure and protection of health-related and other personal information. In the United States, numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws and consumer protection laws and regulations govern the collection, use, disclosure, and protection of health-related and other personal information. In addition, certain foreign laws govern the privacy and security of personal data, including health-related data. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing.

Coverage and reimbursement

Sales of any pharmaceutical product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Significant uncertainty exists as to the coverage and reimbursement status of any newly approved product. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. One third-party payor’s decision to cover a particular product does not ensure that other payors will also provide coverage for the product. As a result, the coverage determination process can require manufacturers to provide scientific and clinical support for the use of a product to each payor separately and can be a time-consuming process, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.

In addition, third-party payors are increasingly reducing reimbursements for pharmaceutical products and services. The U.S. government and state legislatures have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Third-party payors are increasingly challenging the prices charged, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical products, in addition to questioning their safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product.

In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Pharmaceutical products may face competition from lower-priced products in foreign countries that have placed price controls on pharmaceutical products and may also compete with imported foreign products. Furthermore, there is no assurance that a product will be considered medically reasonable and necessary for a specific indication, will be considered cost-effective by third-party payors, that an adequate level of reimbursement will be established even if coverage is available or that the third-party payors’ reimbursement policies will not adversely affect the ability for manufacturers to sell products profitably.

Healthcare reform

In the United States and certain foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system. In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, was signed into law, which substantially changed the way healthcare is financed by both governmental and private insurers in the United States. The ACA contains a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement adjustments and fraud and abuse changes. Additionally, the ACA increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1%; required collection of rebates for drugs paid by Medicaid managed care organizations; imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell certain “branded prescription drugs” to specified federal government programs; expanded eligibility criteria for Medicaid programs; created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare and Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.

Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. In June 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court’s decision, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the

ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA.

Other legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers, which will remain in effect through 2032, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022 absent additional congressional action. Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted legislation designed, among other things, to bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for pharmaceutical products. On August 16, 2022, the Inflation Reduction Act of 2022, or the IRA was signed into law. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023), and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the Department of Health and Human Services to implement many of these provisions through guidance, as opposed to regulation, for the initial years. For that and other reasons, it is currently unclear how the IRA will be effectuated.

Individual states in the United States have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures and, in some cases, mechanisms to encourage importation from other countries and bulk purchasing. Furthermore, there has been increased interest by third party payors and governmental authorities in reference pricing systems and publication of discounts and list prices.

We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare product candidates and services, which could result in reduced demand for our product candidates once approved or additional pricing pressures.

Employees and human capital resources

As of December 31, 2022, we had 246 full-time employees, including 105 employees who have M.D. or Ph.D. degrees. Within our workforce, as of December 31, 2022, 202 employees were engaged in research and development. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.

Our human capital resources objectives include meeting hiring goals, deepening our oncology and public company expertise, integrating new employees, and retaining, incentivizing and developing our existing employees. We provide competitive compensation and benefit programs, including competitive salaries, incentive programs, equity awards, and employee stock purchase plan, healthcare and insurance benefits. The principal purposes of our equity incentive programs are to attract, retain and motivate selected employees, consultants and directors through the granting of stock-based compensation awards and to align the interests of these individuals with those of our stockholders. We regularly review our compensation practices to support our employees, including evaluating innovative health and wellness programs to continue to respond to employee needs.

We are committed to creating an environment where diverse perspectives are encouraged and supported. This commitment is memorialized as one of our corporate core values (Inclusiveness and Fairness) and is brought to life for every employee during our cultural integration sessions for new hires and through an informal network of cultural champions that we foster. As of December 31, 2022, females represented 56% of our full-time employees and 207 of our employees as of this date self-identified their race, of which 57% self-identified as an “underrepresented minority,” as this term is defined by Nasdaq rules.

We are equally committed to the development of our employees and one of our corporate core values (Exceptional Together) captures this commitment. We offer our employees career-specific training and resources and support development opportunities through company-sponsored programs, including learning, mentoring, and coaching opportunities. We host regular company-wide sessions where our employees discuss ideas related to corporate initiatives and scientific breakthroughs and recognize each other’s contributions. In addition, we conduct an anonymous all-employee engagement survey at least annually, and take the results of this survey into account in management of our employees and business.

The health and safety of our employees is a top priority. We continue to monitor and adjust our comprehensive plan related to the COVID-19 pandemic, which includes COVID-19 policies, safety protocols and employee communications.

Corporate Information

We were founded in October 2014 as a Delaware corporation. Our principal executive offices are located at 700 Saginaw Drive, Redwood City, California 94063, and our telephone number is (650) 481-6801.

Our website address is www.revmed.com. We make available on or through our website certain reports and amendments to those reports that we file with or furnish to the SEC in accordance with the Securities Exchange Act of 1934, as amended, or the Exchange Act. These include our annual reports on Form 10-K, our quarterly reports on Form 10-Q, and our current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act. We make this information available on or through our website free of charge as soon as reasonably practicable after we electronically file the information with, or furnish it to, the SEC. References to our website address do not constitute incorporation by reference of the information contained on the website, and the information contained on the website is not part of this document or any other document that we file with or furnish to the SEC. The SEC maintains a site on the worldwide web that contains reports, proxy and information statements and other information regarding our filings at www.sec.gov.

Item 1A. Risk Factors.

Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Annual Report on Form 10-K, including our financial statements and the related notes and the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below or other risks we face could materially and adversely affect our business, competitive position, financial condition, results of operations, cash flows and growth prospects. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations and the market price of our common stock.

Risks related to our limited operating history, financial position and need for additional capital

Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We are a clinical-stage precision oncology company, and we have only a limited operating history upon which you can evaluate our business and prospects. We currently have no products approved for commercial sale, have not generated any revenue from sales of products and have incurred losses in each year since our inception in October 2014. In addition, we have limited experience as a company and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical industry.

Since inception, we have incurred significant net losses. Our net losses were $248.7 million, $187.1 million and $108.2 million, for the years ended December 31, 2022, 2021 and 2020, respectively. As of December 31, 2022, we had an accumulated deficit of $701.3 million. We have funded our operations to date primarily with proceeds from the sale of common stock and preferred stock and upfront payments and research and development cost reimbursement received under our collaboration agreement with Genzyme Corporation, an affiliate of Sanofi (the Sanofi Agreement). The Sanofi Agreement has been terminated effective as of June 2023, and Sanofi will have no further reimbursement obligations post this termination. To date, we have devoted substantially all of our resources to organizing and staffing our company, business planning, raising capital, acquiring and discovering development programs, securing intellectual property rights and conducting discovery, research and development activities for our programs. We have not yet demonstrated our ability to successfully complete any clinical trials, including pivotal clinical trials, obtain marketing approvals, manufacture a commercial-scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Our product candidates will require substantial additional development time and resources before we will be able to apply for or receive regulatory approvals and, if approved, begin generating revenue from product sales. We expect to continue to incur significant expenses and operating losses for the foreseeable future.

We have never generated revenue from product sales and may never be profitable.

Our ability to generate revenue from product sales and achieve profitability depends on our ability, alone or with our collaboration partners, to successfully complete the development of, and obtain the regulatory approvals necessary to commercialize, our development programs. We do not anticipate generating revenue from product sales for the next several years, if ever. Our ability to generate future revenue from product sales depends heavily on our, and any potential future collaborators’, success in:

•

completing clinical and preclinical development of product candidates and programs and identifying and developing new product candidates;

•

seeking and obtaining marketing approvals for any product candidates that we develop;

•

launching and commercializing product candidates for which we obtain marketing approval by establishing a sales force, marketing, medical affairs and distribution infrastructure or, alternatively, collaborating with a commercialization partner;

•

achieving adequate coverage and reimbursement by third-party payors for product candidates that we develop;

•

establishing and maintaining supply and manufacturing relationships with third parties that can provide adequate, in both amount and quality, products and services to support clinical development and the market demand for product candidates that we develop, if approved;

•

obtaining market acceptance of product candidates that we develop as viable treatment options;

•

addressing any competing technological and market developments;

•

negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter and performing our obligations in such collaborations;

•

maintaining, protecting, enforcing and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how;

•

defending against third-party interference, infringement or other intellectual property-related claims, if any; and

•

attracting, hiring and retaining qualified personnel.

Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate, including prior to a potential launch of any approved product candidate. Our expenses could increase beyond expectations if we are required by the U.S. Food and Drug Administration (the FDA), the European Medicines Agency (the EMA) or other regulatory agencies to perform clinical trials or studies in addition to those that we currently anticipate. Even if we are able to generate revenue from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations.

Our operations have consumed substantial amounts of cash since inception. Since our inception, we have invested a significant portion of our efforts and financial resources in research and development activities for our initial preclinical and clinical product candidates.

Preclinical studies and clinical trials and additional research and development activities will require substantial funds to complete. As of December 31, 2022, we had cash, cash equivalents and marketable securities of $644.9 million. In February 2020, we raised $250.7 million upon the completion of our initial public offering (IPO), net of underwriting discounts and commissions and offering expenses. In July 2020, we raised $167.8 million upon the completion of an underwritten public offering, net of underwriting discounts and commissions and offering expenses. In February 2021, we raised $281.1 million upon the completion of an underwritten public offering, net of underwriting discounts and commissions and offering expenses. In July 2022, we raised $248.1 million upon the completion of an underwritten public offering, net of underwriting discounts and commissions and offering expenses. As of December 31, 2022, we have completed sales totaling $61.7 million in gross proceeds pursuant to our at-the-market equity offering program with Cowen and Company, LLC (Cowen). After deducting commissions and expenses of $1.7 million, net proceeds to us were $60.0 million. We expect to continue to spend substantial amounts to continue the preclinical and clinical development of our current and future programs and to prepare for their potential commercialization. If we are able to gain marketing approval for product candidates that we develop, we will require significant additional amounts of cash in order to launch and commercialize our product candidates to the extent that their launch and commercialization are not the responsibility of another collaborator that we may contract with in the future. In addition, other unanticipated costs may arise. Because the design and outcome of our current, planned and potential future clinical trials is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of any product candidate we develop.

The timing and amount of our future funding requirements depends on many factors, including:

•

the scope, progress, results and costs of researching and developing our product candidates and programs, and of conducting preclinical studies and clinical trials;

•

the timing of, and the costs involved in, obtaining marketing approvals for product candidates we develop if clinical trials are successful;

•

the successful wind-up of our collaboration with Sanofi, which has been terminated effective as of June 2023, including the continued reimbursement by Sanofi of our research and development costs for our SHP2 program in accordance with the Sanofi Agreement prior to the effectiveness of termination;

•

the cost of commercialization activities for any product candidates we develop, whether alone or in collaboration, including marketing, sales and distribution costs if any product candidate we develop is approved for sale;

•

the cost of manufacturing our current and future product candidates for clinical trials in preparation for marketing approval and in preparation for commercialization;

•

our ability to establish and maintain strategic licenses or other arrangements and the financial terms of such agreements;

•

the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs and the outcome of such litigation;

•

the timing, receipt and amount of sales of, profit share or royalties on, our future products, if any;

•

the emergence of competing cancer therapies or other adverse market developments; and

•

any plans to acquire or in-license other programs or technologies.

We do not have any committed external source of funds or other support for our development efforts. We expect to finance our cash needs through a combination of public or private equity offerings, debt financings, credit or loan facilities, collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.

Our ability to raise additional funds will depend on financial, economic and other factors, many of which are beyond our control.

Additional funds may not be available when we need them, on terms that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis, we may be required to:

•

delay, limit, reduce or terminate preclinical studies, clinical trials or other research and development activities or eliminate one or more of our development programs altogether; or

•

delay, limit, reduce or terminate our efforts to establish manufacturing and sales and marketing capabilities or other activities that may be necessary to commercialize any future approved products, or reduce our flexibility in developing or maintaining our sales and marketing strategy.

Our operating results may fluctuate significantly, which will make our future results difficult to predict and could cause our results to fall below expectations.

Our quarterly and annual operating results may fluctuate significantly, which will make it difficult for us to predict our future results. These fluctuations may occur due to a variety of factors, many of which are outside of our control and may be difficult to predict, including:

•

the timing and cost of, and level of investment in, research, development and commercialization activities, which may change from time to time;

•

the timing and status of enrollment for our clinical trials;

•

the timing of regulatory approvals, if any, in the United States and internationally;

•

the timing of expanding our operational, financial and management systems and personnel, including personnel to support our clinical development, quality control, manufacturing and commercialization efforts and our operations as a public company;

•

the cost of manufacturing, as well as building out our supply chain, which may vary depending on the quantity of productions, and the terms of any agreements we enter into with third-party suppliers;

•

timing and amount of any milestone, royalty or other payments due under any current or future collaboration or license agreement, including the Sanofi Agreement prior to effectiveness of termination;

•

coverage and reimbursement policies with respect to any future approved products, and potential future drugs that compete with our products;

•

the timing and cost to establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any products for which we may obtain marketing approval and intend to commercialize on our own or jointly with a collaborator;

•

expenditures that we may incur to acquire, develop or commercialize additional products and technologies;

•

the level of demand for any future approved products, which may vary significantly over time;

•

future accounting pronouncements or changes in our accounting policies; and

•

the timing and success or failure of preclinical studies and clinical trials for our product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or collaboration partners.

The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance.

This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or operating guidance we may provide.

Risks related to product development and regulatory process

We are early in our development efforts. Only certain of our product candidates are being evaluated in clinical trials whereas our other programs are in the preclinical stage. We have invested substantially all of our efforts and financial resources in the identification of targets and preclinical development of small molecules to treat cancer. The success of our business, including our ability to finance our company and generate revenue from products in the future, which we do not expect will occur for several years, if ever, will depend heavily on the successful development and eventual commercialization of the product candidates we develop, which may never occur. Our current product candidates, and any future product candidates we develop, will require additional preclinical and clinical development, management of clinical, preclinical and manufacturing activities, marketing approval in the United States and other markets, demonstrating effectiveness to pricing and reimbursement authorities, obtaining sufficient manufacturing supply for both clinical development and commercial production, building of a commercial organization, and substantial investment and significant marketing efforts before we generate any revenues from product sales.

We have not previously submitted a new drug application (NDA) to the FDA or similar approval filings to a comparable foreign regulatory authority, for any product candidate. An NDA or other relevant regulatory filing must include extensive preclinical and clinical data and supporting information to establish that the product candidate is safe and effective for each desired indication. The NDA or other relevant regulatory filing must also include significant information regarding the chemistry, manufacturing and controls for the product. We cannot be certain that our current or future product candidates will be successful in clinical trials or receive regulatory approval. Further, even if they are successful in clinical trials, our product candidates or any future product candidates may not receive regulatory approval. If we do not receive regulatory approvals for current or future product candidates, we may not be able to continue our operations. Even if we successfully obtain regulatory approval to market a product candidate, our revenue will depend, in part, upon the size of the markets in the territories for which we gain regulatory approval and have commercial rights, as well as the availability of competitive products, whether there is sufficient third-party reimbursement and adoption by physicians.

We plan to seek regulatory approval to commercialize our product candidates both in the United States and in select foreign countries. While the scope of regulatory approval generally is similar in other countries, in order to obtain separate regulatory approval in other countries we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy. Other countries also have their own regulations governing, among other things, clinical trials and commercial sales, as well as pricing and distribution of drugs, and we may be required to expend significant resources to obtain regulatory approval and to comply with ongoing regulations in these jurisdictions.

The success of our current and future product candidates will depend on several factors, including the following:

•

successful completion of clinical trials and preclinical studies;

•

sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;

•

acceptance of investigational new drug applications (INDs) for our planned clinical trials or future clinical trials;

•

successful enrollment and completion of clinical trials, particularly where competitors may also be recruiting patients;

•

data from our clinical programs that supports an acceptable risk-benefit profile of our product candidates in the intended populations;

•

receipt and maintenance of marketing approvals from applicable regulatory authorities;

•

establishing agreements with third-party manufacturers for clinical supply for our clinical trials and commercial manufacturing, if one of our product candidates is approved;

•

entry into collaborations to further the development of our product candidates;

•

obtaining and maintaining our portfolio of intellectual property rights, including patents, trade secrets and know-how;

•

enforcing and defending intellectual property rights and claims;

•

obtaining and maintaining regulatory exclusivity for our product candidates;

•

successfully launching commercial sales of our product candidates, if approved;

•

acceptance of the product candidate’s benefits and uses, if approved, by patients, the medical community and third-party payors;

•

the prevalence, duration and severity of potential side effects or other safety issues experienced with our product candidates following approval;

•

effectively competing with other therapies; and

•

obtaining and maintaining healthcare coverage and adequate reimbursement from third-party payors.

If we are not successful with respect to one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize the product candidates we develop, which would materially harm our business. If we do not receive marketing approvals for any product candidate we develop, we may not be able to continue our operations.

In order to obtain approval from the FDA or comparable foreign authorities to market a new small molecule product, we must demonstrate proof of safety and efficacy in humans. To meet these requirements, we will have to conduct adequate and well-controlled clinical trials. Before we can commence clinical trials for a product candidate, we must complete extensive preclinical studies that support our planned INDs in the United States. We cannot be certain of the timely completion or outcome of our preclinical studies and cannot predict if the FDA or foreign authorities will accept our proposed clinical programs or if the outcome of our preclinical studies will ultimately support further development of our programs. As a result, we cannot be sure that we will be able to submit INDs or similar applications on the timelines we expect, if at all, and we cannot be sure that submission of INDs or similar applications will result in the FDA or other regulatory authorities allowing additional clinical trials to begin.

Conducting preclinical testing is a lengthy, time-consuming and expensive process. The length of time may vary substantially according to the type, complexity and novelty of the program, and often can be several years or more per program. Delays associated with programs for which we are directly conducting preclinical studies may cause us to incur additional operating expenses. Moreover, we may be affected by delays or decisions to discontinue development associated with the studies of certain programs that are the responsibility of our current or potential future partners over which we have no control. The commencement and rate of completion of preclinical studies and clinical trials for a product candidate may be delayed by many factors, including, for example:

•

inability to generate sufficient preclinical or other in vivo or in vitro data to support the initiation of clinical studies;

•

delays in reaching a consensus with regulatory agencies on study design and obtaining regulatory authorization to commence clinical trials;

•

obtaining sufficient quantities of starting materials, intermediate materials and our product candidates for use in preclinical studies and clinical trials from third-party suppliers on a timely basis; and

•

delays due to the COVID-19 pandemic, including the implementation of remote work policies, or reduced workforce resulting from illness, or delays at our third-party contract research organizations (CROs) throughout the world, due to similar restrictions imposed by governments or reduced workforce resulting from illness.

Moreover, even if clinical trials do begin for our preclinical programs, our development efforts may not be successful, and clinical trials that we conduct or that third parties conduct on our behalf may not demonstrate sufficient safety or efficacy to obtain the requisite regulatory approvals for any product candidates we develop. Even if we obtain positive results from preclinical studies or initial clinical trials, we may not achieve the same success in future trials.

Some of our programs focus on the discovery and development of “Beyond Rule of 5” small molecules. Such molecules can be associated with longer development timelines and greater costs compared to traditional small molecule drugs. Our “Beyond Rule of 5” product candidates may take longer to develop and/or manufacture relative to traditional small molecules, and we may not be able to formulate “Beyond Rule of 5” candidates for certain routes of administration.

We enlist various technologies and capabilities that give us chemical access to challenging sites on target proteins that generally are not accessible using conventional small molecule drug discovery approaches. For each target, we consider the specific structural,

physico-chemical, functional and dynamic properties of the target and deploy the approach or approaches that appear most likely to yield viable development candidates. The “Rule of 5” is a set of criteria used in pharmaceutical drug development to determine whether chemical compounds have certain physico-chemical properties that make them likely to be orally active drugs in humans. In some instances, the compounds we discover and develop are traditional small molecules (i.e., less than 500 daltons) with properties that generally satisfy conventional pharmaceutical “Rule of 5” criteria, while in other cases, they are larger (i.e., more than 500 daltons) “Beyond Rule of 5” (BRo5) compounds that do not satisfy these criteria. For example, our mTORC1 program and our RAS(ON) Inhibitors each include pursuit of BRo5 compounds.

BRo5 compounds have been successfully pursued by many pharmaceutical companies. Examples of BRo5 compounds include natural products and semi-synthetic derivatives, peptidomimetics, macrocycles and degraders. However, larger molecular weight small molecules often cannot be formulated into orally absorbed drugs and also often face solubility, potency, bioavailability and stability challenges, among others. In addition, many of the commonly used predictive and other drug development tools are designed specifically for traditional Rule of 5 small molecule drugs rather than BRo5 molecules, contributing to the difficulty and uncertainty of development of BRo5 compounds.

Due to their size and complexity, drug development of our BRo5 compounds may be slower and/or more expensive than drug development of traditional “Rule of 5” compounds, resulting in program delays, increased costs or failure to obtain regulatory approval in a commercially reasonable timeframe, if at all. Our competitors developing traditional small molecules in areas where we are developing BRo5 compounds could obtain regulatory approval and reach the market before we do. Even if we succeed in generating an approved drug from a BRo5 compound, it may be less convenient to administer, have higher grade and/or more frequent side effects or be more costly to manufacture and formulate than competing products on the market. The discovery and development of BRo5 small molecules may pose risks to us such as:

•

BRo5 small molecules may present difficult synthetic chemistry and manufacturing challenges, including with any scale-up of our product candidates in sufficient quality and quantity;

•

BRo5 small molecules may be challenging to purify, including with any scale-up of our product candidates in sufficient quality and quantity;

•

BRo5 small molecules may present solubility challenges;

•

BRo5 small molecules may present oral absorption challenges due to low passive permeability, and may not achieve acceptable oral bioavailability for development and may result in poor pharmaceutical properties for formulation development;

•

BRo5 small molecules may present cell permeability challenges, especially with regards to lipophilicity, hydrogen bond donor and rotatable bond count, and high topological polar surface area;

•

BRo5 small molecules may have a propensity to be substrates for efflux proteins such as the adenosine triphosphate (ATP) binding cassette (ABC) transporter protein family, including multidrug resistance protein 1. Cancer cells may overexpress these transporter proteins causing an increase in expulsion of BRo5 small molecules from the cell. For example, as the site of action of our RAS(ON) Inhibitors is inside the cell, expulsion by these transporter proteins may decrease the effective concentration in the cell sufficiently to reduce target inhibition and thereby render a RAS-dependent tumor less susceptible to the inhibitory activity of a BRo5 small molecule, such as our product candidates;

•

BRo5 small molecules may present central nervous system (CNS) penetration challenges due to low passive permeability and/or interaction with efflux transporters at the blood-brain barrier and this could limit sensitivity of CNS tumors to BRo5 small molecules;

•

BRo5 small molecules may present formulation vehicle challenges for administration, such as intravenous and subcutaneous administration, due to aspects such as solubility and hydrophobicity;

•

BRo5 small molecules may present stability and shelf-life limitations due to the incorporation of labile functionality in their scaffolds, including for example in the development of RMC-5552 which currently requires a cold chain storage of zero degrees Celsius; and

•

BRo5 small molecules may present off-target toxicities due to physico-chemical properties such as lipophilicity, which is the ability to dissolve fats, oils and lipids, the presence of off-target pharmacophores in the molecule that can interact with other cellular proteins, or other characteristics that have not been fully characterized within a novel chemical scaffold or platform.

These and other risks related to our research and development of BRo5 small molecules may result in delays in development, an increase in development costs and/or the failure to develop any BRo5 small molecule to approval. As a result, our competitors may develop products more rapidly and cost effectively than we do if they are able to target the same indications as our product candidates

using conventional small molecules. In particular, competitors may develop and commercialize a product that competes with a RAS(ON) Inhibitor product candidate we may develop.

The regulatory approval processes of the FDA, the EMA and comparable foreign authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.

The time required to obtain approval by the FDA, the EMA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate’s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that none of our current or future product candidates will ever obtain regulatory approval.

Our current and future product candidates could fail to receive regulatory approval for many reasons, including the following:

•

the FDA, the EMA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;

•

we may be unable to demonstrate to the satisfaction of the FDA, the EMA or comparable foreign regulatory authorities that a product candidate is safe or effective for its proposed indication or indications;

•

the results of clinical trials may not meet the level of statistical significance required by the FDA, the EMA or comparable foreign regulatory authorities for approval;

•

we may be unable to demonstrate that a product candidate’s clinical and other benefits outweigh its safety risks;

•

the FDA, the EMA or comparable foreign regulatory authorities may disagree with our interpretation of data from clinical trials or preclinical studies;

•

the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA to the FDA or other submission or to obtain regulatory approval in the United States, the European Union or elsewhere;

•

the FDA, the EMA or comparable foreign regulatory authorities may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and

•

the approval policies or regulations of the FDA, the EMA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.

This lengthy approval process as well as the unpredictability of clinical trial results may result in our failing to obtain regulatory approval to market any product candidate we develop. The FDA, the EMA and other comparable foreign authorities have substantial discretion in the approval process, and determining when or whether regulatory approval will be obtained for any product candidate that we develop. Even if we believe the data collected from future clinical trials of our product candidates are promising, this data may not be sufficient to support approval by the FDA, the EMA or any other regulatory authority.

In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we may desire to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the prospects for our product candidates.

Further, we have not previously submitted an NDA to the FDA, or a Marketing Authorization Application (MAA) to the EMA. We cannot be certain that any of our programs will be successful in clinical trials or receive regulatory approval. Further, product candidates we develop may not receive regulatory approval even if they are successful in clinical trials. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations.

Clinical product development involves a lengthy and expensive process, with uncertain outcomes. We may experience delays in completing, or ultimately be unable to complete, the development and commercialization of our current and future product candidates.

To obtain the requisite regulatory approvals to commercialize any of our product candidates, we must demonstrate through extensive preclinical studies and clinical trials that our products are safe or effective in humans. Clinical testing is expensive and can take many

years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process and our future clinical trial results may not be successful.

We may experience delays in completing our clinical trials or preclinical studies and initiating or completing additional clinical trials. We may also experience numerous unforeseen events during our clinical trials that could delay or prevent our ability to receive marketing approval or commercialize the product candidates we develop, including:

•

actions by regulators, Institutional Review Boards (IRBs) or ethics committees, which may cause us or our investigators to not commence or conduct a clinical trial at a prospective trial site or at all sites and cause us to pause or stop an in-process clinical trial;

•

delays in reaching, or failing to reach, agreement on acceptable terms with prospective trial sites and prospective contract research organizations (CROs);

•

the number of patients required for clinical trials being larger than we anticipate;

•

difficulty enrolling a sufficient number of patients for our clinical trials or enrollment in these clinical trials being slower than we anticipate, including in both cases because appropriate patients must have the relevant mutations in the signaling pathways our therapies are designed to target;

•

participants dropping out of these clinical trials or failing to return for post-treatment follow-up at a higher rate than we anticipate;

•

patients not complying with our clinical trial protocols, particularly with respect to intermittent dosing, which we are evaluating for our product candidates;

•

our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that we add new clinical trial sites or investigators;

•

the supply or quality of materials for product candidates we develop or other materials necessary to conduct clinical trials may be insufficient or inadequate; and

•

our collaborators may delay the development process by waiting to take action or focusing on other priorities.

We could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs or ethics committees of the institutions in which any such trial is being conducted, by the Data Safety Monitoring Board for such trial or by the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of marketing approval of our product candidates.

If we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Clinical trial delays could also allow our competitors to bring products to market before we do or shorten any periods during which we have the exclusive right to commercialize our product candidates and impair our ability to commercialize our product candidates.

Our clinical trial sites may be affected by the COVID-19 pandemic due to prioritization of hospital resources toward the COVID-19 pandemic, travel or quarantine restrictions imposed by governments, and the inability to access sites for initiation and patient monitoring and enrollment. As a result, patient screening, new patient enrollment, monitoring and data collection may be affected or delayed. We are aware that several clinical sites involved in our clinical studies temporarily stopped or delayed enrolling new patients, with exemptions if appropriate, and it is possible that these or other clinical sites may be similarly affected in the future.

These developments may delay our clinical trial timelines. Our clinical trials currently permit patients to receive COVID-19 vaccines while they are on study. The potential impact of our candidates on the safety and efficacy of COVID-19 vaccines, and the potential impact of COVID-19 vaccines on the safety and efficacy of our candidates is unknown at this time, but it is possible that adverse impacts will negatively affect our clinical trials.

experience disruptions, such as temporary closures or suspension of services, we would likely experience delays in advancing these trials.

Many of the factors described above that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates or result in the development of our product candidates being stopped early.

Historically, direct inhibition of any RAS protein has been challenging due to a lack of tractable, or “druggable,” binding pockets. Given this approach is unproven, it may not be successful.

Historically, direct inhibition of any RAS protein has been challenging due to a lack of tractable, or “druggable,” binding pockets. Our tri-complex technology has enabled us to design potent, cell-active inhibitors of multiple mutant RAS(ON) proteins. We cannot be certain that our approach will lead to the development of approvable or marketable products, alone or in combination with other therapies.

The results of preclinical studies and early-stage clinical trials may not be predictive of future results.

The results of preclinical studies may not be predictive of the results of clinical trials, and the results of any early-stage clinical trials we commence may not be predictive of the results of the later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy despite having progressed through preclinical studies and initial clinical trials. For example, historically, targeted therapies have been susceptible to resistance mutations in cancer cells that facilitate escape from anti-tumor response. Should such resistance mutations arise in patients being treated with our product candidates, the clinical benefit associated with those candidates may be compromised.

There can be no assurance that any of our current or future clinical trials will ultimately be successful or support further clinical development of any of our product candidates. There is a high failure rate for drugs proceeding through clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies. Even if our clinical trials are completed, the results may not be sufficient to obtain regulatory approval of any products.

Interim, “topline” and preliminary data from our clinical trials may differ materially from the final data.

From time to time, we may disclose interim data from our clinical trials. For example, we have reported interim Phase 1 single agent clinical data for RMC-6236, RMC-5552 and RMC-4630. In each case, this interim data included a limited number of patients and time of exposure to the study drug. Interim data from clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more data on existing patients become available. Our clinical trial program is ongoing, and the final results may be materially different from those reflected in any interim data we report.

From time to time, we may also publicly disclose preliminary or “topline” data from our clinical trials, which are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same clinical trials, or different conclusions or considerations may qualify such topline results once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available.

Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and the value of our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is typically a summary of extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product, product candidate or our business. If the topline data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed.

If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise be adversely affected.

The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The enrollment of patients depends on many factors, including:

•

the patient eligibility criteria defined in the protocol;

•

our ability to enroll a sufficient number of patients with mutations in the signaling pathways our therapies are designed to target;

•

the size of the patient population required for analysis of the trial’s primary endpoints;

•

the proximity of patients to study sites;

•

the design of the trial;

•

our ability to recruit clinical trial investigators with the appropriate competencies and experience;

•

clinicians’ and patients’ perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new products that may be approved for the indications we are investigating;

•

our ability to obtain and maintain patient consents for participation in our clinical trials and, where appropriate, biopsies for future patient enrichment efforts;

•

the risk that patients enrolled in clinical trials will not remain on the trial through the completion of evaluation; and

•

the ability of our clinical trial investigators to enroll patients in cases of outbreak of disease, including COVID-19, or other natural disasters.

In addition, our clinical trials will compete with approved therapies, including sotorasib and adagrasib, as well as other clinical trials for product candidates that are in the same therapeutic areas (and that seek to evaluate patients with cancer cells having the same mutations, particularly with patients having KRASG12C or KRASG12D mutations as our current and potential future product candidates. This competition and competition with approved therapies will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to pursue a treatment regime using an approved therapy or enroll in a trial conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such sites. Moreover, because our current and potential future product candidates may represent a departure from more commonly used methods for cancer treatment, potential patients and their doctors may be inclined to use conventional therapies, such as chemotherapy, rather than enroll patients in our ongoing or any future clinical trials.

The clinical trial sites for our clinical studies may be affected by the COVID-19 outbreak due to prioritization of hospital resources toward the COVID-19 outbreak, travel or quarantine restrictions imposed by governments, and the inability to access sites for initiation and patient monitoring and enrollment. As a result, patient screening, new patient enrollment, monitoring and data collection may be affected or delayed. We are aware that several clinical sites involved in our clinical studies temporarily stopped or delayed enrolling new patients, with exemptions if appropriate, and it is possible that these or other clinical sites may be similarly affected in the future. These developments may delay our clinical trial timelines. Some of our third-party manufacturers which we use for the supply of materials for product candidates or other materials necessary to manufacture product to conduct clinical trials and CROs that we may utilize may be impacted by COVID-19, and should they experience disruptions, such as temporary closures or suspension of services, we would likely experience delays in advancing these trials.

In addition, the ongoing armed conflict between Russia and Ukraine or related actions may affect European clinical sites for our clinical studies. See the risk factor entitled “The ongoing armed conflict between Russia and Ukraine and resulting actions could adversely affect our business, financial condition and results of operations” for a further description of risks related to this conflict.

Delays in patient enrollment may result in increased costs or may affect the timing or outcome of clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of the product candidates we develop.

Our current or future product candidates may cause undesirable side effects or have other properties when used alone or in combination with other approved products or investigational new drugs that could delay or halt their clinical development, prevent their marketing approval, limit their commercial potential or result in significant negative consequences.

Undesirable or clinically unmanageable side effects could occur and cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of marketing approval by the FDA or comparable foreign regulatory authorities. Results of our trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics.

For example, the safety data we released for RMC-6236-001 and that we released in 2020 for both our RMC-4630-01 and RMC-4630-02 trials all included both serious adverse events (SAEs) and other adverse events (AEs), including the grade 4 adverse event of bowel perforation (also considered a serious adverse event) reported for RMC-6236-001.

Although our current and future product candidates will undergo safety testing to the extent possible and, where applicable, under such conditions discussed with regulatory authorities, not all adverse effects of drugs can be predicted or anticipated. Unforeseen side effects could arise either during clinical development or, if such side effects are more rare, after our products have been approved by regulatory authorities and the approved product has been marketed, resulting in the exposure of additional patients. So far, we have not demonstrated that our product candidates are safe in humans, and we cannot predict if ongoing or future clinical trials will do so.

Furthermore, certain of our product candidates are currently being, and may in the future be, co-administered with approved or experimental therapies. These combinations may have additional side effects, including those that could lead us to discontinue the studies. The uncertainty resulting from the use of our product candidates in combination with other therapies may make it difficult to accurately predict side effects in future clinical trials.

If any of our product candidates receives marketing approval and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:

•

regulatory authorities may withdraw their approval of the product;

•

we may be required to recall a product or change the way such product is administered to patients;

•

additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof;

•

regulatory authorities may require the addition of labeling statements, such as a “black box” warning or a contraindication;

•

we may be required to implement a Risk Evaluation and Mitigation Strategy (REMS) or create a Medication Guide outlining the risks of such side effects for distribution to patients;

•

we could be sued and held liable for harm caused to patients;

•

the product may become less competitive; and

•

our reputation may suffer.

Any of the foregoing events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved. In addition, if one or more of our product candidates prove to be unsafe, our entire technology platform and pipeline could be affected.

Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us or any of our existing or potential future collaboration partners from obtaining approvals for the commercialization of any product candidate we develop.

Any current or future product candidate we may develop and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, and distribution, are subject to comprehensive regulation by the FDA and other regulatory authorities in the United States and by comparable authorities in other countries. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate in a given jurisdiction. We have not received approval to market any product candidates from regulatory authorities in any jurisdiction and it is possible that none of our current or future product candidates will ever obtain regulatory approval. We have no experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party CROs or regulatory consultants to assist us in this process. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the product candidate’s safety and efficacy. Securing regulatory approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Any product candidates we develop may not be effective, may be only moderately effective, or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use.

The process of obtaining marketing approvals, both in the United States and abroad, is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type,

complexity, and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. The FDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit, or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.

If we experience delays in obtaining approval or if we fail to obtain approval of any current or future product candidates we may develop, the commercial prospects for those product candidates may be harmed.

Obtaining and maintaining marketing approval of our current and future product candidates in one jurisdiction does not mean that we will be successful in obtaining marketing approval of our current and future product candidates in other jurisdictions.

Obtaining and maintaining marketing approval of our current and future product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain marketing approval in any other jurisdiction, while a failure or delay in obtaining marketing approval in one jurisdiction may have a negative effect on the marketing approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials as clinical studies conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we may charge for our products is also subject to approval.

We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign marketing approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.

Adverse events in the field of oncology or the biopharmaceutical industry could damage public perception of our current or future product candidates and negatively affect our business.

The commercial success of our products will depend in part on public acceptance of the use of targeted cancer therapies. While a number of targeted cancer therapies have received regulatory approval and are being commercialized, our approach to targeting cancer cells carrying tumor causing mutations, including oncogenic RAS(ON) pathway mutations, is novel and unproven. Adverse events in clinical trials of our product candidates, or post-marketing activities, or in clinical trials of others developing similar products or that are related to approved targeted therapies, particularly those targeting oncogenic RAS pathway mutations, including sotorasib, and adagrasib and the resulting publicity, as well as any other adverse events in the field of oncology that may occur in the future, could result in a decrease in demand for any product that we may develop. If public perception is influenced by claims that the use of cancer therapies is unsafe, whether related to our therapies or those of our competitors, our products may not be accepted by the general public or the medical community.

Future adverse events in oncology or the biopharmaceutical industry could also result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approvals of our products. Any increased scrutiny could delay or increase the costs of obtaining marketing approval for the product candidates we develop.

Even if we receive marketing approval of a product candidate, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products, if approved.

Any marketing approvals that we receive for any current or future product candidate may be subject to limitations on the approved indicated uses for which the product may be marketed or the conditions of approval, or contain requirements for potentially costly post-market testing and surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require REMS as a condition of approval of any product candidate, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves a product candidate, the manufacturing processes,

labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import and export and record keeping for the product candidate will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with current Good Manufacturing Practice (cGMP) and Good Clinical Practice (GCP) for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with any approved candidate, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:

•

restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or product recalls;

•

fines, untitled and warning letters, or holds on clinical trials;

•

refusal by the FDA to approve pending applications or supplements to approved applications we filed or suspension or revocation of license approvals;

•

product seizure or detention, or refusal to permit the import or export of the product; and

•

injunctions or the imposition of civil or criminal penalties.

The FDA’s and other regulatory authorities’ policies may change, and additional government regulations may be enacted that could prevent, limit or delay marketing approval of a product. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained.

Even if a current or future product candidate receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.

If any current or future product candidate we develop receives marketing approval, whether as a single agent or in combination with other therapies, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors, and others in the medical community to be a viable product. For example, current approved immunotherapies, and other cancer treatments like chemotherapy and radiation therapy, are well established in the medical community, and doctors may continue to rely on these therapies. The degree of market acceptance of any product candidate, if approved for commercial sale, will depend on a number of factors, including:

•

efficacy and potential advantages compared to alternative treatments;

•

the ability to offer our products, if approved, for sale at competitive prices;

•

convenience and ease of administration compared to alternative treatments;

•

the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;

•

the strength of marketing and distribution support;

•

the ability to obtain sufficient third-party coverage and adequate reimbursement, including with respect to the use of the approved product as a combination therapy;

•

adoption of a companion diagnostic and/or complementary diagnostic (if any); and

•

the prevalence and severity of any side effects.

The market opportunities for any current or future product candidate we develop, if and when approved, may be limited to those patients who are ineligible for established therapies or for whom prior therapies have failed, and may be small.

Cancer therapies are sometimes characterized as first-line, second-line or third-line, and the FDA often approves new therapies initially only for third-line use. When cancer is detected early enough, first-line therapy, usually chemotherapy, hormone therapy, surgery, radiation therapy or a combination of these, is sometimes adequate to cure the cancer or prolong life without a cure. Second- and third-line therapies are administered to patients when prior therapy is not effective. We expect to initially seek approval of any product candidates we develop as a therapy for patients who have received one or more prior treatments. Subsequently, for those products that prove to be sufficiently beneficial, if any, we would expect to seek approval potentially as a first-line therapy, but there is no guarantee that product candidates we develop, even if approved, would be approved for first-line therapy, and, prior to any such approvals, we may have to conduct additional clinical trials.

The number of patients who have the cancers we are targeting, including those with the necessary mutations, may turn out to be lower than expected. Additionally, the potentially addressable patient population for our current programs or future product candidates may be limited, if and when approved. Even if we obtain significant market share for any product candidate, if and when approved, if the potential target populations are small, we may never achieve commercial success without obtaining marketing approval for additional indications, including to be used as first- or second-line therapy.

We are currently developing, and may in the future develop, our product candidates in combination with other therapies, which exposes us to additional risks.

The development of RMC-4630 has included combinations with Amgen’s KRASG12C(OFF) inhibitor sotorasib, Mirati’s KRASG12C(OFF) inhibitor adagrasib and Merck’s PD-1 inhibitor pembrolizumab, and we may in the future, develop our product candidates in combination with one or more approved cancer therapies. Even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or similar regulatory authorities outside of the United States could revoke approval of the therapy used in combination with our product candidate or that safety, efficacy, manufacturing or supply issues could arise with these existing therapies. Combination therapies are commonly used for the treatment of cancer, and we would be subject to similar risks if we develop any of our product candidates for use in combination with other drugs or for indications other than cancer. This could result in our own products being removed from the market or being less successful commercially.

We or our collaborators may also evaluate our current or future product candidates in combination with one or more other cancer therapies that have not yet been approved for marketing by the FDA or similar regulatory authorities outside of the United States or with approved cancer therapies at an unapproved dose and/or schedule, and/or with approved cancer therapies in unapproved indications. For example, we have agreed to provide RMC-4630 to the Netherlands Cancer Institute to support their evaluation of RMC-4630 in combination with Eli Lilly’s ERK inhibitor LY3214996. We will not be able to market and sell any product candidate we develop in combination with any such cancer therapies, outside existing approved labels that do not ultimately obtain marketing approval.

If the FDA or similar regulatory authorities outside of the United States do not approve the drugs we choose to evaluate in combination with or any product candidate we develop or revoke their approval of, or if safety, efficacy, manufacturing, or supply issues arise with, these drugs, we may be unable to obtain approval of or market or any product candidate we develop.

In addition, prior to the effectiveness of the termination of the Sanofi Agreement in June 2023, Sanofi primarily controls the research and development activities of our SHP2 inhibitors, including RMC-4630, pursuant to the terms of the Sanofi Agreement, and may disagree with us regarding which other therapies should be evaluated in combination with RMC-4630. As a result of any such disagreement, our completion of a trial in combination with our preferred combination product candidate may be delayed or prevented.

The life sciences industry is highly competitive. We are currently developing therapies that will compete, if approved, with other products and therapies that currently exist or are being developed. Products we may develop in the future are also likely to face competition from other products and therapies, some of which we may not currently be aware of. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, universities and other research institutions. Many of our competitors have significantly greater financial, manufacturing, marketing, product development, technical and human resources than we do. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining marketing approvals, recruiting patients and manufacturing pharmaceutical products. These companies also have significantly greater research and marketing capabilities than we do and may also have products that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. As a result of all of these factors, our competitors may succeed in obtaining patent protection and/or marketing approval or discovering, developing and commercializing products in our field before we do.

There are a number of companies developing or marketing treatments for cancer, including many major pharmaceutical and biotechnology companies. These treatments consist of small molecule drug products, biologics, cell-based therapies and traditional chemotherapy. Smaller and other early stage companies may also prove to be significant competitors. In addition, academic research

departments and public and private research institutions may be conducting research on compounds that could prove to be competitive.

There are several programs in clinical development targeting SHP2, including those being conducted by Betta Pharmaceuticals Co., Ltd., Erasca, Inc., Etern BioPharma (Shanghai) Co. Ltd., Genhouse Bio Co. Ltd., HUYA Bioscience, InnoCare Pharma Ltd., Jacobio Pharmaceuticals Co. Ltd. (licensed to AbbVie Inc.), Nanjing Sanhome Pharmaceutical, Navire Pharma, Inc., a BridgeBio company (licensed to Bristol-Myers Squibb Company, Inc.), Novartis AG, Pfizer, Inc., and Relay Therapeutics Inc. (licensed to Roche). There are several programs in clinical development targeting KRASG12C, including programs directed at KRASG12C (OFF) being conducted by Amgen Inc., Betta Pharmaceuticals Co., Ltd., Boehringer Ingelheim, D3 BIO, Inc., Eli Lilly, Genhouse Bio Co. Ltd., HUYA Bioscience, InnoCare Pharma Ltd., Innovent Biologics, Inc., InventisBio, Jacobio Pharmaceuticals Co. Ltd., Merck, Sharpe & Dohme LLC, Mirati Therapeutics, Inc., Novartis AG, Roche, Shanghai YingLi Pharmaceutical, Suzhou Genhouse Bio and Suzhou Zelgen Biopharmaceuticals. There are also several clinical programs directed at KRASG12D, including those being conducted by Astellas Pharma Inc., Jiangsu Hengrui Pharmaceuticals Company Ltd. and Mirati Therapeutics, Inc. Other clinical programs directed at mutant RAS are being conducted, including those by Alaunos Therapeutics, Inc., Elicio Therapeutics, Gritstone bio, Inc., Moderna, Inc., Silenseed Ltd. and Targovax ASA. The above list includes corporate competitors that we are currently aware of and that are currently conducting clinical trials or marketing in geographies where we currently anticipate conducting clinical trials for our product candidates. However, companies operating in other geographies and smaller and other early-stage companies may also prove to be significant competitors. In addition, academic research departments and public and private research institutions may be conducting research on compounds that could prove to be competitive.

Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe effects, are more convenient, have a broader label, are marketed more effectively, are reimbursed or are less expensive than any products that we may develop. Our competitors also may obtain FDA, EMA or other marketing approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Even if the product candidates we develop achieve marketing approval, they may be priced at a significant premium over competitive products if any have been approved by then, resulting in reduced competitiveness.

Third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. In addition, the biopharmaceutical industry is characterized by rapid technological change. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render our product candidates obsolete, less competitive or not economical.

Even if we are able to commercialize any product candidates, such products may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business.

The regulations that govern marketing approvals, pricing and reimbursement for new products vary widely from country to country. Some countries require approval of the sale price of a product before it can be marketed. In many countries, the pricing review period begins after marketing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product candidate in a particular country, but then be subject to price regulations that delay our commercial launch of the product candidate, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the product candidate in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval.

Our ability to commercialize any product candidates, whether as a single agent or combination therapy, successfully also will depend in part on the extent to which coverage and reimbursement for these product candidates and related treatments will be available from government authorities, private health insurers and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels.

It is difficult to predict at this time what government authorities and third-party payors will decide with respect to coverage and reimbursement for our programs.

There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, as the process is time-consuming and costly, and coverage may be more limited than the purposes for which the drug is approved by the FDA or comparable foreign regulatory authorities. Additionally, no uniform policy requirement for coverage and reimbursement for drug products exists among third-party payors in the United States, which may result in coverage and reimbursement for drug products that can differ significantly from payor to payor. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if

applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies.

A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular products and requiring substitutions of generic products and/or biosimilars. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for drugs. We cannot be sure that coverage will be available for any product candidate that we commercialize and, if coverage is available, the level of reimbursement. These third-party payors are also examining the cost-effectiveness of drugs in addition to their safety and efficacy. Reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval.

We may fail to select or capitalize on the most scientifically, clinically and commercially promising or profitable mutant RAS(ON) targets.

We have limited technical, managerial and financial resources to determine which of our RAS(ON) Inhibitors should be advanced into further preclinical development, initial clinical trials, later-stage clinical development and potential commercialization. From our RAS(ON) Inhibitors, we have selected RMC-6236, our inhibitor of multiple RAS variants, which we refer to as RASMULTI(ON), RMC-6291, our inhibitor targeting KRASG12C(ON) and RMC-9805, our inhibitor targeting KRASG12D(ON) as the first candidates for clinical evaluation. In selecting these or other development candidates, we may make incorrect determinations. Our decisions to allocate our research and development, management and financial resources toward particular development candidates or therapeutic areas may not lead to the development of viable commercial products and may divert resources from better opportunities. Similarly, our decisions to delay or terminate development programs may also be incorrect and could cause us to miss valuable opportunities.

We may not be successful in our efforts to identify or discover other product candidates and may fail to capitalize on programs or product candidates that may present a greater commercial opportunity or for which there is a greater likelihood of success.

The success of our business depends upon our ability to identify, develop and commercialize product candidates. Research programs to identify new product candidates require substantial technical, financial and human resources, and we may fail to identify potential product candidates for numerous reasons.

Additionally, because we have limited resources, we may forego or delay pursuit of opportunities with certain programs or product candidates or for indications that later prove to have greater commercial potential. However, the advancement of this product candidate may ultimately prove to be unsuccessful or less successful than another program in our pipeline that we might have chosen to pursue on a less aggressive basis. Our estimates regarding the potential market for our product candidates could be inaccurate, and our spending on current and future research and development programs may not yield any commercially viable products. If we do not accurately evaluate the commercial potential for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. For example, we licensed worldwide development and commercialization rights with respect to RMC-4630 to Sanofi and under the terms of the Sanofi Agreement, which has been terminated effective as of June 2023, we receive only milestone payments, an equal share of profits and losses in the United States and royalties on annual net sales of each product outside the United States. Alternatively, we may allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a partnering arrangement.

If any of these events occur, we may be forced to abandon or delay our development efforts with respect to a particular product candidate or fail to develop a potentially successful product candidate.

We may need to use existing commercial diagnostic tests or develop, or enter into a collaboration or partnership to develop, novel complementary diagnostics and/or novel companion diagnostics for some of our current or future product candidates. If we or our future partners are unable to successfully develop these companion diagnostics or complementary diagnostics, or experience significant delays in doing so, we may not realize the full commercial potential of our future product candidates.

As one of the key elements of our product development strategy, we seek to identify cancer patient populations that may derive meaningful benefit from our current or future product candidates. Because predictive biomarkers may be used to identify the right patients for our programs and our current or future product candidates, we believe that our success may depend, in part, on our ability

to use existing diagnostic tests from third parties or develop novel complementary diagnostics and/or novel companion diagnostics in collaboration with partners.

In the event that novel tests will need to be developed, we have little experience in the development of diagnostics. As such, we expect to rely on future partners in developing appropriate diagnostics to pair with our current or future product candidates. We may be unsuccessful in entering into collaborations for the development of companion diagnostics for our programs and our current or future product candidates.

Complementary diagnostics and/or companion diagnostics are subject to regulation by the FDA and similar regulatory authorities outside the United States as medical devices and require separate regulatory approval or clearance prior to commercialization. If we, our partners, or any third parties that we engage to assist us, are unable to successfully develop complementary diagnostics and/or companion diagnostics for our product candidates and any future product candidates, or experience delays in doing so:

•

the development of our product candidates and any other future product candidates may be adversely affected if we are unable to appropriately select patients for enrollment in our clinical trials; and

•

we may not realize the full commercial potential of our product candidates and any other future product candidates that receive marketing approval if, among other reasons, we are unable to appropriately identify, or it takes us longer to identify, patients who are likely to benefit from therapy with our products, if approved.

We may seek and fail to obtain fast track or breakthrough therapy designations for our current or future product candidates. If we are successful, these programs may not lead to a faster development or regulatory review process, and they do not guarantee we will receive approval for any product candidate. We may also seek to obtain accelerated approval for one or more of our product candidates but the FDA or foreign regulators may disagree that we have met the requirements for such approval.

If a product is intended for the treatment of a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address an unmet medical need for this condition, the product sponsor may apply for fast track designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, the FDA may reach a different conclusion and not grant it. Even if we do receive fast track designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may rescind the fast track designation if it believes that the designation is no longer supported by data from our clinical development program.

We may also seek breakthrough therapy designation for any product candidate that we develop. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Like fast track designation, breakthrough therapy designation is within the discretion of the FDA. Accordingly, even if we believe a product candidate we develop meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of breakthrough therapy designation for a product candidate may not result in a faster development process, review or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if a product candidate we develop qualifies as a breakthrough therapy, the FDA may later decide that the drug no longer meets the conditions for qualification and rescind the designation.

Drugs designated as fast track products or breakthrough therapies by the FDA are also eligible for accelerated approval if the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled post-marketing clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. In addition, the FDA requires pre-approval of promotional materials for accelerated approval products, once approved.

We cannot guarantee that the FDA will agree any of our product candidates has met the criteria to receive accelerated approval, which would require us to conduct additional clinical testing prior to seeking FDA approval. Even if any of our product candidates received approval through this pathway, the product may fail required post-approval confirmatory clinical trials, and we may be required to remove the product from the market or amend the product label in a way that adversely impacts its marketing.

Jurisdictions where we may seek to pursue product candidates outside of the United States have processes similar to the breakthrough designation and fast track processes described above, and to the extent we desire to enter these markets, we will face similar risks and challenges as those described in the United States.

We may seek orphan drug designation for product candidates we develop, and we may be unsuccessful or may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.

As part of our business strategy, we may seek orphan drug designation for product candidates we develop. Regulatory authorities in some jurisdictions, including the United States, may designate drugs for relatively small patient populations as orphan drugs or, in Europe, orphan medicinal products. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers.

Similarly, in Europe, the European Commission grants orphan medicinal product designation after receiving the opinion of the EMA Committee for Orphan Medicinal Products on an orphan medicinal product designation application. Orphan medicinal product designation is intended to promote the development of drugs that are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions affecting not more than 5 in 10,000 persons in Europe and for which no satisfactory method of diagnosis, prevention, or treatment has been authorized (or the product would be a significant benefit to those affected). Additionally, designation is granted for drugs intended for the diagnosis, prevention, or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely that sales of the drug in Europe would be sufficient to justify the necessary investment in developing the drug. In Europe, Orphan Drug Designation entitles a party to a number of incentives, such as protocol assistance and scientific advice specifically for designated orphan medicines, and potential fee reductions depending on the status of the sponsor.

Generally, if a drug with an orphan drug designation subsequently receives the first marketing approval for the disease or condition for which it has such designation, the drug is entitled to a period of marketing exclusivity, which precludes the EMA or the FDA from approving another marketing application for the same drug for the same disease or condition for that time period, except in limited circumstances. The applicable period is seven years in the United States and ten years in Europe. The European exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable such that market exclusivity is no longer justified.

We may be unsuccessful in obtaining orphan drug designation for our product candidates. In addition, even if we obtain orphan drug exclusivity for a product candidate, that exclusivity may not effectively protect the product candidate from competition because different therapies can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same disease or condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In addition, a designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. Moreover, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. While we may seek orphan drug designation for applicable indications for our current and any future product candidates, we may never receive such designations. Even if we do receive such designations, there is no guarantee that we will enjoy the benefits of those designations.

If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of any approved products.

We face an inherent risk of product liability as a result of the clinical testing of product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if any product candidate we develop causes or is perceived to cause injury or is found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of any approved products. Even successful defense would require significant financial and management resources.

Regardless of the merits or eventual outcome, liability claims may result in:

•

decreased demand for any approved product;

•

injury to our reputation;

•

withdrawal of clinical trial participants;

•

initiation of investigations by regulators;

•

costs to defend the related litigation;

•

a diversion of management’s time and our resources;

•

substantial monetary awards to trial participants or patients;

•

product recalls, withdrawals or labeling, marketing or promotional restrictions;

•

exhaustion of any available insurance and our capital resources and potential increase in our insurance premiums and/or retention amounts; and

•

the inability to commercialize any product candidate.

Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with collaboration partners.

Insurance coverage is increasingly expensive. We may not be able to maintain insurance at a reasonable cost or in an amount adequate to satisfy any liability that may arise, if at all. Our insurance policy contains various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any current or future collaborator entitle us to indemnification against losses, such indemnification is limited and may not be available or adequate should any claim arise.

The ongoing armed conflict between Russia and Ukraine and resulting actions could adversely affect our business, financial condition and results of operations.

In February 2022, Russian military forces launched a military action in Ukraine, and sustained conflict and disruption in the region is likely. The length, impact, scope and outcome of this ongoing military conflict is highly unpredictable and could lead to significant market and other disruptions, including significant volatility in commodity prices and supply of energy resources, instability in financial markets, supply chain interruptions, political and social instability, trade disputes or trade barriers, changes in consumer or purchaser preferences, as well as an increase in cyberattacks and espionage.

Russia’s recognition of two separatist republics in the Donetsk and Luhansk regions of Ukraine and subsequent military action against Ukraine have led to substantial expansion of sanction programs imposed by the United States, the European Union, the United Kingdom, Canada, Switzerland, Japan, and other countries against Russia, Belarus, the Crimea Region of Ukraine, the so-called Donetsk People’s Republic, and the so-called Luhansk People’s Republic, including, among others:

•

blocking sanctions against some of the largest state-owned and private Russian financial institutions (and their subsequent removal from the Society for Worldwide Interbank Financial Telecommunication payment system) and certain Russian businesses, some of which have significant financial and trade ties to the European Union;

•

blocking sanctions against Russian and Belarusian individuals, including the Russian President, other politicians and those with government connections or involved in Russian military activities; and

•

blocking of Russia’s foreign currency reserves as well as expansion of sectoral sanctions and export and trade restrictions, limitations on investments and access to capital markets, and bans on various Russian imports.

In retaliation against new international sanctions and as part of measures to stabilize and support the volatile Russian financial and currency markets, the Russian authorities also imposed significant currency control measures aimed at restricting the outflow of foreign currency and capital from Russia, imposed various restrictions on transacting with non-Russian parties, banned exports of various products, and imposed other economic and financial restrictions. The situation is rapidly evolving, and additional sanctions by Russia on the one hand, and by the other countries on the other hand, could adversely affect the global economy and financial markets and could adversely affect our business, financial condition, and results of operations. In addition, it is possible that the conflict could expand beyond its current scope and involve additional countries and regions.

We are actively monitoring the situation in Ukraine and Russia and assessing its impact on our business, including our current and planned clinical operations, and our business partners and customers. Although we have not experienced material interruptions in our infrastructure, supplies, technology systems, or networks needed to support our operations, this conflict may limit our ability to include European sites as clinical trial locations in the future, and we may have to delay, reduce the scope of or suspend one or more of our clinical trials.

We cannot predict the progress or outcome of the military conflict in Ukraine, whether it will expand or its impacts in Ukraine, Russia, Europe, the United States or the rest of the world. The extent and duration of the military action, sanctions, and resulting market disruptions could be significant and could potentially have substantial impact on the global economy and our business for an unknown period of time. Any such disruption may also magnify the impact of other risks described in Item 1A.

Healthcare legislative reform measures may significantly impact our business and results of operations.

In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the Affordable Care Act (the ACA) was passed, which substantially changes the way healthcare is financed by both governmental and private insurers, and significantly impacts the U.S. pharmaceutical industry. The ACA, among other things, increases the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid managed care organizations, establishes annual fees and taxes on manufacturers of certain branded prescription drugs, and creates a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer’s outpatient drugs to be covered under Medicare Part D.

Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. In June 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court’s decision, President Biden issued an executive order initiating a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare.

Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In March 2021, the American Rescue Plan Act of 2021 was signed into law, which eliminates the statutory cap on the Medicaid drug rebate, currently set at 100% of a drug’s AMP, beginning January 1, 2024. Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. Most recently, in August 2022, the Inflation Reduction Act of 2022 (IRA) was signed into law. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the Department of Health and Human Services to implement many of these provisions through guidance, as opposed to regulation, for the initial years. For that and other reasons, it is currently unclear how the IRA will be effectuated, and the impact of the IRA on our business and the pharmaceutical industry cannot yet be fully determined. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for any product candidate we develop or complementary diagnostics or companion diagnostics or additional pricing pressures.

Additionally, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs.

In addition, FDA regulations and guidance may be revised or reinterpreted by the FDA in ways that may significantly affect our business. Any new regulations or guidance, or revisions or reinterpretations of existing regulations or guidance, may impose additional costs or lengthen FDA review times for our product candidates. We cannot determine how changes in regulations, statutes, policies, or interpretations when and if issued, enacted or adopted, may affect our business in the future.

Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.

The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result.

Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA and other government employees and stop critical activities. If a prolonged government shutdown occurs or FDA experiences other delays, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a negative impact on our business.

Separately, in response to the COVID-19 pandemic, the FDA announced its intention to postpone most inspections of foreign and domestic manufacturing facilities and products at various points. Even though the FDA has since resumed standard inspection operations of domestic facilities where feasible, the FDA has continued to monitor and implement changes to its inspectional activities to ensure the safety of its employees and those of the firms it regulates as it adapts to the evolving COVID-19 pandemic, and any resurgence of the virus, including as a result of the emergence of new variants may lead to further inspectional delays. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic and may experience delays in their regulatory activities. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting business as usual or conducting inspections, reviews or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material effect on our business.

We are subject to stringent privacy laws, information security policies and contractual obligations governing the use, processing and transfer of personal information.

The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal information, such as information that we may collect in connection with clinical trials in the United States and abroad. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulations, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a negative impact on our business.

As our operations and business grow, we may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. In the United States, HIPAA imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information. We may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA. Depending on the facts and circumstances, we could be subject to significant penalties if we violate HIPAA.

Further, various states have implemented certain data privacy and security laws and regulations that impose restrictive requirements regulating the use and disclosure of health-related and other personal information. California enacted the California Consumer Privacy Act (CCPA), which creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal data. The CCPA went into effect on January 1, 2020, and became enforceable by the California Attorney General on July 1, 2020. Further, the California Privacy Rights Act (CPRA) was approved by California voters in the November 3, 2020 election and generally went into effect on January 1, 2023. The CPRA significantly amends the CCPA and imposes additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. The CPRA also creates a new state agency that will be vested with authority to implement and enforce the CCPA and the CPRA. Additional compliance investment and potential business process changes may be required. Similar laws have passed in Virginia, Colorado, Utah and Connecticut, and have been proposed in other states and at the federal level, reflecting a trend toward more stringent privacy legislation in the United States. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging. In the event that we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.

State laws and regulations are not necessarily preempted by federal laws and regulations, such as HIPAA, particularly if a state affords greater protection to individuals than federal law. Where state laws are more protective, we have to comply with the stricter provisions. In addition to fines and penalties imposed upon violators, some of these state laws also afford private rights of action to individuals who believe their personal information has been misused. The interplay of federal and state laws may be subject to varying interpretations by courts and government agencies, creating complex compliance issues for us and data we receive, use and share,

potentially exposing us to additional expense, adverse publicity and liability. Legal requirements relating to the collection, storage, handling, and transfer of personal information and personal data continue to evolve and may result in increased public scrutiny and escalating levels of enforcement, sanctions and increased costs of compliance.

The collection and use of personal data in the EU and the European Economic Area (EEA), are governed by the GDPR. The GDPR imposes stringent requirements for controllers and processors of personal data. The GDPR applies extraterritorially, and we may be subject to the GDPR because of our data processing activities that involve the personal data of individuals located in the EEA, such as in connection with any EEA clinical trials. GDPR regulations may impose additional responsibility and liability in relation to the personal data that we process and we may be required to put in place additional mechanisms to ensure compliance with the new data protection rules. This may be onerous and may interrupt or delay our development activities. If we or our vendors fail to comply with the GDPR and the applicable national data protection laws of the EU or EEA member states, or if regulators assert we have failed to comply with these laws, it may lead to regulatory enforcement actions, which can result in monetary penalties of up to €20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties. The GDPR also imposes strict rules on the transfer of personal data out of the EU and the EEA to the United States and other third countries. In July 2020, the Court of Justice of the European Union (CJEU) limited how organizations could lawfully transfer personal data from the EU/EEA to the United States by invalidating the Privacy Shield for purposes of international transfers and imposing further restrictions on the use of standard contractual clauses (SCCs). In March 2022, the United States and EU announced a new regulatory regime intended to replace the invalidated regulations; however, this new EU-U.S. Data Privacy Framework has not been implemented beyond an executive order signed by President Biden in October 2022 on Enhancing Safeguards for United States Signals Intelligence Activities. European court and regulatory decisions subsequent to the July 2020 CJEU decision have taken a restrictive approach to international data transfers. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the SCCs cannot be used, and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services and the geographical location or segregation of our relevant systems and operations. Further, we must comply with both the GDPR and the UK GDPR, which together with the UK Data Protection Act 2018, retains the GDPR in United Kingdom national law. The UK GDPR mirrors the fines under the GDPR, i.e. fines up to the greater of £17.5 million or 4% of global turnover. We may incur liabilities, expenses, costs and other operational losses under the GDPR and privacy laws of the applicable EU and EEA Member States and the United Kingdom in connection with any measures we take to comply with them. As we continue to expand into other foreign countries and jurisdictions, we may also be subject to additional laws and regulations that may affect how we conduct business.

Compliance with U.S. and international data protection laws and regulations could cause us to incur substantial costs or require us to change our business practices and compliance procedures in a manner adverse to our business. Penalties for violations of these laws vary and may be significant. Moreover, complying with these various laws could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. In addition, we rely on third-party vendors to collect, process and store data on our behalf and we cannot guarantee that such vendors are in compliance with all applicable data protection laws and regulations. Our or our vendors’ failure to comply with U.S. and international data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation and adverse publicity. Claims that we have violated individuals’ privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend and could result in adverse publicity.

Our business and operations, or those of our CROs or third parties, may suffer in the event of computer system failures, cyberattacks or deficiencies in our cybersecurity, which could materially affect our results.

We receive, generate and store significant and increasing volumes of sensitive information, such as health information, insurance information and other potentially personally identifiable information. We face a number of risks relative to protecting the computer systems we rely on and this critical information, including loss of access risk, inappropriate use or disclosure, inappropriate modification and the risk of our being unable to adequately monitor, audit and modify our controls over our critical information. This risk extends to the computer systems and information of any collaboration partners, medical institutions, clinical investigators, CROs, contract laboratories, or other third parties involved in our business.

Despite the implementation of security measures, our information technology systems, as well as those of CROs or other third parties with which we have relationships, are vulnerable to attack and damage from computer viruses and malware (e.g., ransomware), unauthorized access, natural and manmade disasters, terrorism, war and telecommunication and electrical failures, malfeasance by external or internal parties, and human error (e.g., social engineering, phishing). Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. Furthermore, because the technologies used to obtain unauthorized access to, or to sabotage or disrupt, systems change frequently and often are not recognized until launched against a

target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. We may not be able to anticipate all types of security threats, and even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence. As a result of the COVID-19 pandemic, we may also face increased cybersecurity risks due to our reliance on internet technology and the number of our and our service providers’ employees who are (and may continue to be) working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. The White House, SEC and other regulators have also increased their focus on companies’ cybersecurity vulnerabilities and risks.

We, our CROs and certain of our other service providers are from time to time, subject to cyberattacks and security incidents. While we have not to our knowledge experienced any significant system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our or our critical third parties’ operations, it could result in delays and/or material disruptions of our research and development programs, our operations and ultimately, our financial results. For example, the loss of trial data from completed, ongoing or planned trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties for the manufacture of our product candidates and to conduct clinical trials, and similar events relating to their computer systems could also adversely impact our business. Further, due to the current political uncertainty involving Russia and Ukraine, there is an increased likelihood that the tensions could result in cyberattacks or cybersecurity incidents that could either directly or indirectly impact our or our critical third parties’ operations. To the extent that any disruption or security breach were to result in a loss of or damage to data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability due to delays in the development and commercialization of our product candidates or other business activities and/or due to reputational harm, litigation, regulatory investigations and enforcement, fines and penalties, or increased costs of compliance and system remediation.

Our existing general liability and cyber liability insurance policies may not cover, or may cover only a portion of, any potential claims related to security breaches to which we are exposed or may not be adequate to indemnify us for all or any portion of liabilities that may be imposed. We also cannot be certain that our existing insurance coverage will continue to be available on acceptable terms or in amounts sufficient to cover the potentially significant losses that may result from a security incident or breach or that the insurer will not deny coverage of any future claim. If the information technology systems of our CROs or other service providers become subject to disruptions or security breaches, we may have insufficient recourse against such third parties and we may have to expend significant resources to mitigate the impact of such an event, and to develop and implement protections to prevent future events of this nature from occurring.

Risks related to reliance on third parties

In June 2018, we entered into a collaborative research, development and commercialization agreement with Sanofi (the Sanofi Agreement), focused on researching, developing and commercializing SHP2 inhibitors as cancer therapies and potentially other indications. In December 2022, Sanofi terminated the Sanofi Agreement for convenience, effective as of June 2023. Prior to the effectiveness of this termination, Sanofi will continue to exert control over our SHP2 inhibitor-related research and development activities pursuant to the terms of the Sanofi Agreement, and our lack of control over these activities, including with respect to RMC-4630, could result in delays or other difficulties in the development and commercialization of product candidates, which may prevent completion of intended NDA filings in a timely fashion, if at all. Any dispute with Sanofi, including with respect to the termination of the Sanofi Agreement and the transition of the activities thereunder, may result in the delay or termination of the research, development or commercialization of RMC-4630 or other SHP2 inhibitor product candidates, and may result in costly litigation that diverts management attention and resources away from our day-to-day activities. For example, we plan to evaluate RMC-4630 in combination with other therapies (which may include product candidates from our pipeline), and Sanofi may disagree with us regarding which other therapies should be evaluated in combination with RMC-4630. As a result of this disagreement, our completion of a trial in combination with our preferred combination product candidate may be delayed or prevented.

In connection with the termination of the Sanofi Agreement, we must transition all rights, obligations and activities occurring as part of the collaboration (including those conducted by third parties on behalf of Sanofi) to us, which is a complex and challenging process. Our inability to successfully manage this transition, or to do so on a timely basis, may adversely impact our SHP2 development efforts.

In addition, following the effectiveness of the termination of the Sanofi Agreement, we will no longer receive any research and development funding, milestone payments, profit share payments, royalty payments and other benefits under that agreement. Termination of the Sanofi Agreement may require us to seek additional funding in order to avoid delaying, reducing the scope of, or

suspending, one or more of our research and development programs or clinical trials. In addition, Sanofi’s decision to terminate the Sanofi Agreement may negatively impact public perception of RMC-4630, or all of the SHP2 program covered by the Sanofi Agreement. For more information regarding the Sanofi Agreement, see “Business—Collaboration agreement with Sanofi.”

We may depend on collaborations with other third parties for the development and commercialization of our product candidates in the future. If our collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.

In the future, we may form or seek other strategic alliances, joint ventures, or collaborations, or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to product candidates we develop.

Collaborations involving our current and future product candidates, including our collaborations with Sanofi and Amgen, may pose the following risks to us:

•

collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations and may have incentives that are different than ours;

•

collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial, abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;

•

collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates;

•

a collaborator with marketing, manufacturing and distribution rights to one or more products may not commit sufficient resources to or otherwise not perform satisfactorily in carrying out these activities;

•

collaborators may not properly prosecute, maintain, enforce or defend our intellectual property rights or may use our proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation, or other intellectual property proceedings;

•

collaborators may own or co-own intellectual property covering products that result from our collaboration with them, and in such cases, we may not have the exclusive right to develop, license or commercialize this intellectual property;

•

disputes may arise with respect to ownership of any intellectual property developed pursuant to our collaborations;

•

disputes may arise between a collaborator and us that cause the delay or termination of the research, development or commercialization of the product candidate, or that result in costly litigation or arbitration that diverts management attention and resources; and

•

if a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program under such collaboration could be delayed, diminished or terminated, including if the partner in such a business combination has products that compete with ours.

As a result, if we enter into additional collaboration agreements and strategic partnerships or license our intellectual property, products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction. Any delays in entering into new collaborations or strategic partnership agreements related to any product candidate we develop could delay the development and commercialization of our product candidates, which would harm our business prospects, financial condition, and results of operations.

We may seek to establish additional collaborations, and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans.

The advancement of our product candidates and development programs and the potential commercialization of our current and future product candidates will require substantial additional cash to fund expenses. For some of our programs, we may decide to collaborate with additional pharmaceutical and biotechnology companies with respect to development and potential commercialization. Any of these relationships may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business.

We face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Whether we reach a definitive agreement for other collaborations will depend, among other things, upon our assessment of the collaborator’s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator’s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the progress of our clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. Further, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for future product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view them as having the requisite potential to demonstrate safety and efficacy.

We may also be restricted under existing collaboration agreements from entering into future agreements on certain terms with potential collaborators. For example, under the Sanofi Agreement, we granted worldwide exclusive rights under our intellectual property to Sanofi for SHP2 inhibitors, and during the term of the agreement, which has been terminated effective as of June 2023, we are restricted from granting similar rights to other parties. This exclusivity could limit our ability to enter into collaborations with future collaborators.

In addition, business combinations among large pharmaceutical companies have in the past and may in the future result in a reduced number of potential future collaborators.

We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.

If conflicts arise between us and our collaborators or strategic partners, these parties may act in a manner adverse to us and could limit our ability to implement our strategies.

If conflicts arise between our corporate or academic collaborators or strategic partners and us, the other party may act in a manner adverse to us and could limit our ability to implement our strategies. Sanofi, Amgen or future collaborators or strategic partners may develop, either alone or with others, products in related fields that are competitive with the products or potential products that are the subject of these collaborations. Competing products, either developed by the collaborators or strategic partners or to which the collaborators or strategic partners have rights, may result in the withdrawal of partner support for our product candidates. Our current or future collaborators or strategic partners may preclude us from entering into collaborations with their competitors, fail to obtain timely regulatory approvals, terminate their agreements with us prematurely, or fail to devote sufficient resources to the development and commercialization of products. Any of these developments could harm our product development efforts.

We rely on third parties to conduct the clinical trials for the product candidates we develop. If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain marketing approval for or commercialize our product candidates.

We do not have the ability to independently conduct clinical trials. We and any collaboration partners who may conduct clinical trials involving our product candidates rely on medical institutions, clinical investigators, CROs, contract laboratories, and other third parties to conduct or otherwise support these clinical trials, all of which we refer to herein as our clinical trials. We and our collaborators rely heavily on these parties for execution of clinical trials and control only certain aspects of their activities. In addition, we have limited control over the activities of our collaborators who may conduct clinical trials involving our product candidates. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. For any violations of laws and regulations during the conduct of our clinical trials, we could be subject to untitled and warning letters or enforcement action that may include civil penalties or criminal prosecution.

We, our collaborators and the other third parties involved in our clinical trials are required to comply with regulations and requirements, including GCP, for conducting, monitoring, recording and reporting the results of clinical trials to ensure that the data and results are scientifically credible and accurate, and that the trial patients are adequately informed of the potential risks of

participating in clinical trials and their rights are protected. These regulations are enforced by the FDA, the Competent Authorities of the Member States of the EEA and comparable foreign regulatory authorities for any drugs in clinical development. The FDA enforces GCP requirements through periodic inspections of clinical trial sponsors, principal investigators and trial sites. If we, our collaborators or other third parties fail to comply with applicable GCP, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. Upon inspection, the FDA may determine that any of our current or future clinical trials do not comply with GCP. In addition, our clinical trials must be conducted with product candidates produced under cGMP regulations. Our failure or the failure of third parties to comply with these regulations may require us to repeat clinical trials, which would delay the marketing approval process and could also subject us to enforcement action. We also are required to register certain ongoing clinical trials and provide certain information, including information relating to the trial’s protocol, on a government-sponsored database, ClinicalTrials.gov, within specific timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.

We have participated and in the future may participate in clinical collaborations where a partner is responsible for conduct of a clinical trial involving our product candidates. These collaborators may be commercial entities, such as Amgen’s Phase 1b trial evaluating the combination of RMC-4630 and the KRASG12C(OFF) inhibitor sotorasib in Amgen’s CodeBreaK 101c study, Sanofi’s Phase 1/2 trial evaluating the combination of RMC-4630 and Merck’s PD-1 inhibitor pembrolizumab and the Phase 1/2 study of RMC-4630 in combination with Mirati Therapeutics’ KRASG12C(OFF) inhibitor, adagrasib, or investigator-sponsored or initiated studies that use our product candidates, such as the Netherlands Cancer Institute's study of the combination of RMC-4630 with Eli Lilly’s investigational ERK inhibitor (LY3214996) and UCSF’s Phase 1/1b trial of RMC-5552. Although we intend to design the clinical trials for our product candidates, or be involved in the design when other parties sponsor the trials, because these collaborators will have primary responsibility for the conduct of these trials, many important aspects of our clinical development for these trials, including their conduct and timing, is outside of our direct control.

Our reliance on third parties to conduct future clinical trials will also result in less direct control over the management of data developed through clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with third parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Third parties may:

•

have staffing difficulties;

•

fail to comply with contractual obligations;

•

experience regulatory compliance issues;

•

have incentives that are different than ours;

•

undergo changes in priorities or become financially distressed; or

•

form relationships with other entities, some of which may be our competitors.

These factors may materially adversely affect the willingness or ability of third parties to conduct our clinical trials and may subject us to unexpected cost increases that are beyond our control. If the CROs or other third parties involved in our clinical trials do not perform these trials in a satisfactory manner, breach their obligations to us or our collaborators or fail to comply with regulatory requirements, the development, marketing approval and commercialization of our product candidates may be delayed, we may not be able to obtain marketing approval and commercialize our product candidates, or our development program may be materially and irreversibly harmed. If we are unable to rely on clinical data collected by third parties involved in our clinical trials, we could be required to repeat, extend the duration of, or increase the size of our clinical trials and this could significantly delay commercialization and require significantly greater expenditures.

If any of our relationships with our CROs or other third parties involved in our clinical trials terminate, we may not be able to enter into arrangements with alternative CROs or other third parties on commercially reasonable terms, or at all. If CROs or other third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain are compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, any clinical trials such CROs or other third parties are associated with may be extended, delayed or terminated, and we may not be able to obtain marketing approval for or successfully commercialize our product candidates.

we may utilize may be impacted by COVID-19, and should they experience disruptions, such as temporary closures or suspension of services, we would likely experience delays in advancing these trials.

We rely on third parties to manufacture preclinical and clinical drug supplies, and we intend to rely on third parties to produce commercial supplies of any approved product, which increases the risk that we will not have sufficient quantities of these product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.

We do not own or operate manufacturing facilities for the production of preclinical, clinical or commercial supplies of the product candidates that we are developing or evaluating in our development programs. We have limited personnel with experience in drug manufacturing and lack the resources and the capabilities to manufacture any of our product candidates on a preclinical, clinical or commercial scale. We rely on third parties for supply of our preclinical and clinical drug supplies (including key starting and intermediate materials), and our strategy is to outsource all manufacturing of our product candidates and products to third parties.

In order to conduct clinical trials of product candidates, we will need to have them manufactured in potentially large quantities. Our third-party manufacturers may be unable to successfully increase the manufacturing capacity for any of our clinical drug supplies (including key starting and intermediate materials) in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities and at any other time. For example, ongoing data on the stability of our product candidates may shorten the expiry of our product candidates and lead to clinical trial material supply shortages, and potentially clinical trial delays. If these third-party manufacturers are unable to successfully scale up the manufacture of our product candidates in sufficient quality and quantity, the development, testing and clinical trials of that product candidate may be delayed or infeasible, and regulatory approval or commercial launch of that product candidate may be delayed or not obtained.

Our use of new third-party manufacturers increases the risk of delays in production or insufficient supplies of our product candidates (and the key starting and intermediate materials for such product candidates) as we transfer our manufacturing technology to these manufacturers and as they gain experience manufacturing our product candidates (and the key starting and intermediate materials for such product candidates).

Even after a third-party manufacturer has gained significant experience in manufacturing our product candidates (or the key starting and intermediate materials for such product candidates) or even if we believe we have succeeded in optimizing the manufacturing process, there can be no assurance that such manufacturer will produce sufficient quantities of our product candidates (or the key starting and intermediate materials for such product candidates) in a timely manner or continuously over time, or at all.

We may be delayed if we need to change the manufacturing process used by a third party. Further, if we change an approved manufacturing process, then we may be delayed if the FDA or a comparable foreign authority needs to review the new manufacturing process before it may be used.

We do not currently have any agreements with third-party manufacturers for long-term commercial supply. In the future, we may be unable to enter into agreements with third-party manufacturers for commercial supplies of any product candidate that we develop, or may be unable to do so on acceptable terms. Even if we are able to establish and maintain arrangements with third-party manufacturers, reliance on third-party manufacturers entails risks, including:

•

reliance on the third party for regulatory compliance and quality assurance;

•

the possible breach of the manufacturing agreement by the third party;

•

the possible misappropriation of our proprietary information, including our trade secrets and know-how; and

•

the possible termination or non-renewal of the agreement by the third party at a time that is costly or inconvenient for us.

Third-party manufacturers may not be able to comply with cGMP requirements or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable requirements could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and/or criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates.

Our future product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP requirements particularly for the development of monoclonal antibodies, and that might be capable of manufacturing for us.

If the third parties that we engage to supply any materials or manufacture product for our preclinical tests and clinical trials should cease to continue to do so for any reason, we likely would experience delays in advancing these tests and trials while we identify and

qualify replacement suppliers or manufacturers and we may be unable to obtain replacement supplies on terms that are favorable to us. In addition, if we are not able to obtain adequate supplies of our product candidates or the substances used to manufacture them, it will be more difficult for us to develop our product candidates and compete effectively.

Some of our third-party manufacturers which we use for the supply of materials for product candidates or other materials necessary to manufacture product to conduct clinical trials are located in may be affected by COVID-19, and should they experience disruptions, such as temporary closures or suspension of services, we would likely experience delays in advancing these trials.

Our current and anticipated future dependence upon others for the manufacture of our product candidates (or the key starting and intermediate materials for such product candidates) may adversely affect our future profit margins and our ability to develop product candidates and commercialize any products that receive marketing approval on a timely and competitive basis.

Our future relationships with customers and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable anti-kickback, fraud and abuse, false claims, transparency, health information privacy and security and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings.

Healthcare providers, physicians and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act (FCA), which may constrain the business or financial arrangements and relationships through which we sell, market and distribute any products for which we obtain marketing approval. The applicable federal, state and foreign healthcare laws and regulations that may affect our ability to operate include:

•

the federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under the Medicare and Medicaid programs or other federal healthcare programs. A person or entity can be found guilty of violating the statute without actual knowledge of the statute or specific intent to violate it. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution;

•

the federal civil and criminal false claims laws, including the FCA, and civil monetary penalty laws, which prohibit any person or entity from, among other things, knowingly presenting, or causing to be presented, a false, fictitious or fraudulent claim for payment to, or approval by, the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA;

•

the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which created federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty of violating HIPAA without actual knowledge of the statutes or specific intent to violate them;

•

the Physician Payments Sunshine Act, created under the ACA, and its implementing regulations, which requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program (with certain exceptions) to report annually to CMS information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician practitioners (physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiologist assistants and certified nurse midwives), and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;

•

federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and

•

analogous or related foreign, state or local laws and regulations, including anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; and state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures.

Because of the breadth of the laws described above and the narrowness of the statutory exceptions and regulatory safe harbors available under them, it is possible that some of our business activities could be subject to challenge under one or more of these laws.

The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Ensuring that our business arrangements with third parties comply with applicable healthcare laws, as well as responding to investigations by government authorities, can be time- and resource-consuming and can divert management’s attention from the business.

If our operations are found to be in violation of any of the laws described above or any other government regulations that apply to us, we may be subject to penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from participation in federal and state funded healthcare programs, contractual damages and the curtailment or restricting of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, any of which could harm our ability to operate our business and our financial results. Further, if the physicians or other providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. In addition, the approval and commercialization of any product candidate we develop outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.

Risks related to intellectual property

Our success depends in significant part on our ability and the ability of our collaborators to obtain, maintain, enforce and defend patents and other intellectual property rights with respect to our product candidates and technology and to operate our business without infringing, misappropriating, or otherwise violating the intellectual property rights of others. If we and our collaborators are unable to obtain and maintain sufficient intellectual property protection for our product candidates or the product candidates that we may identify, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors and other third parties could develop and commercialize product candidates similar or identical to ours, and our ability (and the ability of our collaborators) to successfully commercialize the product candidates that we (and our collaborators) may pursue may be impaired. Our patent coverage with respect to our clinical and preclinical programs is limited, and we can provide no assurance that any of our current or future patent applications will result in issued patents or that any issued patents will provide us with any competitive advantage. Failure to obtain such issued patents could negatively impact our ability to develop or commercialize any of our product candidates or technology.

We seek to protect our proprietary positions by, among other things, filing patent applications in the United States and abroad related to our current product candidates and the product candidates that we may identify. Obtaining, maintaining, defending and enforcing pharmaceutical patents is costly, time consuming and complex, and we may not be able to file and prosecute all necessary or desirable patent applications, or maintain, enforce and license any patents that may issue from such patent applications, at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. We may not have the right to control the preparation, filing, prosecution and maintenance of patent applications, or to maintain the rights to patents licensed to or from third parties.

Although we enter into confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. Further, we may not be aware of all third-party intellectual property rights

potentially relating to our product candidates. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or, in some cases, not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions.

The patent position of pharmaceutical companies generally is highly uncertain, involves complex legal, technological and factual questions and has, in recent years, been the subject of much debate and litigation throughout the world. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States, or vice versa. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. The subject matter claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Therefore, our pending and future patent applications may not result in patents being issued in relevant jurisdictions that protect our product candidates, in whole or in part, or which effectively prevent others from commercializing competitive product candidates, and even if our patent applications issue as patents in relevant jurisdictions, they may not issue in a form that will provide us with any meaningful protection for our product candidates or technology, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Additionally, our competitors may be able to circumvent our patents by developing similar or alternative product candidates or technologies in a non-infringing manner.

The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. We may be subject to a third-party preissuance submission of prior art to the United States Patent and Trademark Office (the USPTO) or become involved in opposition, derivation, revocation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others, or other proceedings in the USPTO or applicable foreign offices that challenge priority of invention or other features of patentability. An adverse determination in any such submission, proceeding or litigation could result in loss of exclusivity or freedom to operate, patent claims being narrowed, invalidated or held unenforceable, in whole or in part, or limits of the scope or duration of the patent protection of our product candidates, all of which could limit our ability to stop others from using or commercializing similar or identical product candidates or technology to compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates, or could negatively impact our ability to raise funds necessary to continue our research programs or clinical trials. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us.

In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products or technology similar or identical to ours for a meaningful amount of time, or at all. Moreover, some of our owned or licensed patents and patent applications are, and may in the future be, co-owned with third parties. If we are unable to obtain exclusive licenses to any such co-owners’ interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could harm our competitive position, business, financial condition, results of operations and prospects.

We have entered into licensing agreements with third parties. If we or a third party fail to comply with the obligations in the agreements under which we license intellectual property rights to or from third parties, or these agreements are terminated, or we otherwise experience disruptions to business relationships with our licensors or licensees, competitive position, business, financial condition, results of operations and prospects could be harmed.

In addition to patent and other intellectual property rights we own or co-own, we have licensed, and may in the future license, patent and other intellectual property rights to and from other parties. Licenses may not provide us with exclusive rights to use the applicable intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our products and technology in the future. As a result, we may not be able to prevent competitors from developing and commercializing competitive products or technologies.

In addition, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications or to maintain, defend and enforce the patents that we license to or from third parties, and we may have to rely on our partners to fulfill these responsibilities. For example, in June 2018, we entered into the Sanofi Agreement, wherein we exclusively licensed the worldwide rights in our SHP2 inhibitor program, including RMC-4630, to Sanofi. The Sanofi Agreement has been terminated effective as of June 2023. Although we have review and comment rights regarding patent prosecution decisions while the agreement remains in effect, Sanofi retains ultimate decision-making control, as well as the sole and exclusive right to enforce infringement of or defend claims against patents that relate to SHP2 inhibitor products licensed to it pursuant to the Sanofi Agreement. Consequently,

any such licensed patents and applications may not be prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent with the best interests of our business. In connection with the termination of the Sanofi Agreement, we will regain all decision-making and operational rights with respect to patents and applications solely owned by us, except as necessary to permit Sanofi to perform any surviving obligations under the Sanofi Agreement. The failure to successfully manage the transition from Sanofi to us of these patent rights and patent rights of patents and applications jointly owned with Sanofi or solely owned by Sanofi may negatively impact our ability to effectively manage our patent portfolio.

If our current or future licensors, licensees or collaborators fail to prepare, file, prosecute, maintain, enforce, and defend licensed patents and other intellectual property rights, such rights may be reduced or eliminated, and our right to develop and commercialize any of our product candidates or technology that are the subject of such licensed rights could be adversely affected. In addition, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor’s rights.

If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties, the licensor may have the right to terminate the license. If these agreements are terminated, the underlying patents fail to provide the intended exclusivity or we otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business or be prevented from developing and commercializing our product candidates, and competitors could have the freedom to seek regulatory approval of, and to market, products identical to ours. Termination of these agreements or reduction or elimination of our rights under these agreements may also result in our having to negotiate new or reinstated agreements with less favorable terms, cause us to lose our rights under these agreements, including our rights to important intellectual property or technology, or impede, delay or prohibit the further development or commercialization of one or more product candidates that rely on such agreements. It is possible that we may be unable to obtain any additional licenses at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant time and resources to redesign our product candidates or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis.

In addition, the research resulting in certain of our owned and in-licensed patent rights and technology was funded in part by the U.S. federal or state governments. As a result, the government may have certain rights, including march-in rights, to such patent rights and technology. When new technologies are developed with government funding, the government generally obtains certain rights in any resulting patents, including a non-exclusive license authorizing the government to use the invention for noncommercial purposes. These rights may permit the government to disclose our confidential information to third parties or allow third parties to use our licensed technology. The government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in the United States. Any of the foregoing could harm our competitive position, business, financial condition, results of operations and prospects.

Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues and certain provisions in intellectual property license agreements may be susceptible to multiple interpretations. Disputes may arise between us and our licensing partners regarding intellectual property subject to a license agreement, including:

•

the scope of rights granted under the license agreement and other interpretation-related issues;

•

whether and the extent to which technology and processes of one party infringe on intellectual property of the other party that are not subject to the licensing agreement;

•

rights to sublicense patent and other rights to third parties;

•

any diligence obligations with respect to the use of the licensed technology in relation to development and commercialization of our product candidates, and what activities satisfy those diligence obligations;

•

the ownership of inventions and know-how resulting from the joint creation or use of intellectual property;

•

rights to transfer or assign the license; and

•

the effects of termination.

The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could harm our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.

In addition, if our licensors or licensees fail to abide by the terms of the license, if the licensors or licensees fail to prevent infringement by third parties or if the licensed patents or other rights are found to be invalid or unenforceable, our business, competitive position, financial condition, results of operations and prospects could be materially harmed.

If we are unable to obtain licenses from third parties on commercially reasonable terms or at all, our business could be harmed.

It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our products, in which case we would be required to obtain a license from these third parties. The licensing of third-party intellectual property rights is a competitive area, and more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. More established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to license needed technology, or if we are forced to license this technology on unfavorable terms, our business could be materially harmed. If we are unable to obtain a necessary license, we may be unable to develop or commercialize the affected product candidates, and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties or other forms of compensation. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us.

We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might subject us to infringement claims or adversely affect our ability to develop and market our product candidates.

We cannot guarantee that any of our or our licensors’ patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending patent application in the United States and abroad that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. For example, U.S. patent applications filed before November 29, 2000 and certain U.S. patent applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Patent applications in the United States and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with the earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our product candidates could have been filed by third parties without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our product candidates or the use of our product candidates. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent’s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our product candidates. We may incorrectly determine that our product candidates are not covered by a third-party patent or may incorrectly predict whether a third party’s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our product candidates.

If we fail to identify and correctly interpret relevant patents, we may be subject to infringement claims. We cannot guarantee that we will be able to successfully settle or otherwise resolve any infringement claims. If we fail in any of these disputes, in addition to being forced to pay damages, which may be significant, we may be temporarily or permanently prohibited from commercializing any of our product candidates that are held to be infringing. We might, if possible, also be forced to redesign product candidates so that we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.

Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.

Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product candidate, we may be open to competition from competitive medications, including generic medications. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing product candidates similar or identical to ours for a meaningful amount of time, or at all.

Depending upon the timing, duration and conditions of any FDA marketing approval of our product candidates, one or more of our owned or licensed U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term

Restoration Act of 1984, referred to as the Hatch-Waxman Amendments, and similar legislation in the European Union and certain other countries. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, we may not receive an extension if we fail to exercise due diligence during the testing phase or regulatory review process, fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. Only one patent per approved product can be extended, the extension cannot extend the total patent term beyond 14 years from approval and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for the applicable product candidate will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced. Further, if this occurs, our competitors may take advantage of our investment in development and trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case.

Also, there are detailed rules and requirements regarding the patents that may be submitted to the FDA for listing in the Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book). We may be unable to obtain patents covering our product candidates that contain one or more claims that satisfy the requirements for listing in the Orange Book. Even if we submit a patent for listing in the Orange Book, the FDA may decline to list the patent, or a manufacturer of generic drugs may challenge the listing. If one of our product candidates is approved and a patent covering that product candidate is not listed in the Orange Book, a manufacturer of generic drugs would not have to provide advance notice to us of any abbreviated new drug application filed with the FDA to obtain permission to sell a generic version of such product candidate.

We may not be able to protect our intellectual property rights throughout the world.

Filing, prosecuting, maintaining, defending and enforcing patents on our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws and enforcement practices of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. The current conflict between Russia and Ukraine may also make it difficult or impossible to continue to prosecute patent applications or maintain patents in those countries or other affected territories. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may export otherwise infringing products to territories where we have patent protection, but enforcement rights are not as strong as those in the United States. These products may compete with our product candidates and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.

Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of some countries do not favor the enforcement or protection of patents, trade secrets and other intellectual property, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful.

Many foreign countries, including some European Union countries, India, Japan and China, have compulsory licensing laws under which a patent owner may be compelled under specified circumstances to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In those countries, we may have limited remedies if patents are infringed or if we are compelled to grant a license to a third party, which could materially diminish the value of the applicable patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.

Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.

Obtaining and enforcing patents in the pharmaceutical industry is inherently uncertain, due in part to ongoing changes in the patent laws. For example, in the United States, depending on decisions by Congress, the federal courts, and the USPTO, the laws and regulations governing patents, and interpretation thereof, could change in unpredictable ways that could weaken our and our licensors’ or collaborators’ ability to obtain new patents or to enforce existing or future patents. For example, the U.S. Supreme Court has ruled

on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Therefore, there is increased uncertainty with regard to our and our licensors’ or collaborators’ ability to obtain patents in the future, as well as uncertainty with respect to the value of patents once obtained.

Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our and our licensors’ or collaborators’ patent applications and the enforcement or defense of our or our licensors’ or collaborators’ issued patents. For example, assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith America Invents Act (the Leahy-Smith Act) enacted in September 2011, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications are prosecuted and may also affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to challenge the validity of a patent by USPTO-administered post-grant proceedings, including post-grant review, inter partes review and derivation proceedings. The USPTO has developed regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, particularly the first inventor-to-file provisions. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our or our licensors’ patent applications and the enforcement or defense of our or our licensors’ issued patents. Similarly, statutory or judicial changes to the patent laws of other countries may increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents.

In 2012, the European Patent Package (the EU Patent Package) regulations were passed with the goal of providing a single pan-European Unitary Patent and a new European Unified Patent Court (the UPC), for litigation involving European patents. Implementation of the EU Patent Package is planned for June 2023. Under the UPC, all European patents, including those issued prior to ratification of the European Patent Package, will by default automatically fall under the jurisdiction of the UPC. The UPC will provide our competitors with a new forum to centrally revoke our European patents, and allow for the possibility of a competitor to obtain pan-European injunctions. It will be several years before we will understand the scope of patent rights that will be recognized and the strength of patent remedies that will be provided by the UPC. As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Under the EU Patent Package, we will have the right to opt our patents out of the UPC over the first seven years of the court’s existence, but doing so may preclude us from realizing the benefits, if any, of the new unified court.

Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated if we fail to comply with these requirements.

Periodic maintenance fees, renewal fees, annuity fees, and various other fees are required to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of a patent. In certain circumstances, we rely on our licensors and collaborators to pay these fees. The USPTO and various foreign patent agencies also require compliance with a number of procedural, documentary, fee payment and other similar requirements during the patent application and prosecution process. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official communications within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. While an inadvertent lapse can in some cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which non-compliance can result in irrevocable abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If we or our licensors or collaborators fail to maintain the patents and patent applications covering our product candidates, our competitors might be able to enter the market with similar or identical products or technology, which would harm our business, financial condition, results of operations and prospects.

We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful, and issued patents covering our technology and product candidates could be found invalid or unenforceable if challenged.

Competitors and other third parties may infringe or otherwise violate our issued patents or other intellectual property or the patents or other intellectual property of our licensors. In addition, our patents or the patents of our licensors may become involved in inventorship or priority disputes. Our pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. To counter infringement or other unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. Our ability to enforce patent rights also depends on our ability to detect infringement. It may be difficult to detect infringers who do not advertise the components or methods that are used in connection with their products and services. Moreover, it may be difficult or impossible to obtain evidence of

infringement in a competitor’s or potential competitor’s product or service. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents or that our patents are invalid or unenforceable. In a patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole or in part, construe the patent’s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology. An adverse result in any litigation proceeding could put one or more of our owned or licensed patents at risk of being invalidated, held unenforceable or interpreted narrowly. We may find it impractical or undesirable to enforce our intellectual property against some third parties.

If we were to initiate legal proceedings against a third party to enforce a patent directed to our product candidates, or one of our future product candidates, the defendant could counterclaim that our patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement or insufficient written description. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Third parties may also raise similar claims before the USPTO or an equivalent foreign body, even outside the context of litigation. Potential proceedings include re-examination, post-grant review, inter partes review, interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in the revocation of, cancellation of, or amendment to our patents in such a way that they no longer cover our technology or any product candidates that we may develop. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on the applicable product candidates or technology covered by the patent rendered invalid or unenforceable.

Interference proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be materially harmed if the prevailing party does not offer us a license on commercially reasonable terms.

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.

Some of our competitors are larger than we are and have substantially greater resources. They are, therefore, likely to be able to sustain the costs of complex patent litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon, misappropriating or otherwise violating our intellectual property. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims could result in substantial costs and diversion of management resources, which could harm our business. In addition, the uncertainties associated with litigation could compromise our ability to raise the funds necessary to continue our clinical trials, continue our internal research programs, or in-license needed technology or other product candidates. There could also be public announcements of the results of the hearing, motions, or other interim proceedings or developments. If securities analysts or investors perceive those results to be negative, it could cause the price of shares of our common stock to decline.

Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could negatively impact the success of our business.

Our commercial success depends upon our ability to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property and other proprietary rights of third parties. There is considerable intellectual property litigation in the pharmaceutical industry.

We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our product candidates and their manufacture and our other technology, including re-examination, interference, post-grant review, inter partes review or derivation proceedings before the USPTO or an equivalent foreign body. Numerous U.S. and foreign issued patents and pending patent applications owned by third parties exist in the fields in which we are developing our product candidates. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit.

Even if we believe third-party intellectual property claims are without merit, there is no assurance that a court would find in our favor on questions of infringement, validity, enforceability or priority. A court of competent jurisdiction could hold that third-party patents asserted against us are valid, enforceable and infringed, which could materially and adversely affect our ability to commercialize any

product candidates we may develop and any other product candidates or technologies covered by the asserted third-party patents. In order to successfully challenge the validity of a U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of a U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. If we are found to infringe, misappropriate or otherwise violate a third party’s intellectual property rights, and we are unsuccessful in demonstrating that these rights are invalid or unenforceable, we could be required to obtain a license from such a third party in order to continue developing and marketing our products and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the infringing technology or product. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, pay royalties and other fees, redesign our infringing product candidate or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.

We may be subject to claims by third parties asserting that we or our employees have infringed upon, misappropriated or otherwise violated their intellectual property rights, or claiming ownership of what we regard as our own intellectual property.

Many of our employees were previously employed at other biotechnology or pharmaceutical companies and our consultants and advisors may work for other biotechnology or pharmaceutical companies in addition to us. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of any of these individuals’ former or concurrent employers or clients. We may also be subject to claims that patents and applications we have filed to protect inventions of our employees, consultants and advisors, even those related to one or more of our product candidates, are rightfully owned by their former or concurrent employer. Litigation may be necessary to defend against these claims.

If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in prosecuting or defending against these claims, litigation could result in substantial costs, delay development of our product candidates and be a distraction to management.

We may be subject to claims challenging the inventorship of our patents and other intellectual property.

We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patents, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we or our licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. While it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning this intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may not be self-executing or may be breached, and litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors’ ownership of our owned or in-licensed patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.

Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.

Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. As noted above, some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace, including compromising our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary

technology from third parties, or enter into development collaborations that would help us commercialize our product candidates, if approved.

If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.

We rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology and other proprietary information (including unpatented know-how associated with Warp Drive Bio) and to maintain our competitive position. Trade secrets and know-how can be difficult to protect. We seek to protect these trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. We cannot guarantee that we have entered into these agreements with each party that may have or has had access to our trade secrets or proprietary technology and processes. Despite our efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Unauthorized parties may also attempt to copy or reverse engineer certain aspects of our products that we consider proprietary. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary information will be effective.

We also seek to preserve the integrity and confidentiality of our confidential proprietary information by maintaining physical security of our premises and physical and electronic security of our information technology systems, but it is possible that these security measures could be breached. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to, or independently developed by, a competitor or other third party, our competitive position would be materially and adversely harmed.

If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.

Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential collaborators or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources.

Intellectual property rights do not necessarily address all potential threats.

The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:

•

others may be able to make products that are similar to any product candidates we may develop or utilize similar technology but that are not covered by the claims of our patents or the patents that we license or may own in the future;

•

we, or our current or future licensors, might not have been the first to make the inventions covered by an issued patent or pending patent application that we license or may own in the future;

•

we, or our current or future licensors might not have been the first to file patent applications covering certain of our or their inventions;

•

others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights;

•

it is possible that our pending owned or licensed patent applications or those that we may own or license in the future will not lead to issued patents;

•

issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors;

•

our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;

•

we may not develop additional proprietary technologies that are patentable;

•

the patents of others may harm our business; and

•

we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.

Risks related to employee matters and managing our growth

We are highly dependent on our key personnel, and if we are not successful in attracting, motivating and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.

We are highly dependent on members of our executive team. The loss of the services of any of them may adversely impact the achievement of our objectives. Any of our executive officers could leave our employment at any time, as all of our employees are “at-will” employees. We currently do not have “key person” insurance on any of our employees. The loss of the services of one or more of our key personnel might impede the achievement of our research, development and commercialization objectives.

Recruiting and retaining qualified employees, consultants and advisors for our business, including scientific and technical personnel, is critical to our success. Competition for skilled personnel is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies and academic institutions for skilled individuals. In addition, failure to succeed in preclinical studies, clinical trials or applications for marketing approval may make it more challenging to recruit and retain qualified personnel. The inability to recruit, or the loss of services of certain executives, key employees, consultants or advisors, may impede the progress of our research, development and commercialization objectives.

We currently have no sales organization. If we are unable to establish sales capabilities on our own or through third parties, we may not be able to market and sell any products effectively, if approved, or generate product revenue.

We currently do not have a marketing or sales organization. In order to commercialize any product, if approved, in the United States and foreign jurisdictions, we must build our marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. In advance of any of our product candidates receiving regulatory approval, we expect to establish a sales organization with technical expertise and supporting distribution capabilities to commercialize each such product candidate, which will be expensive and time-consuming. We have no prior experience in the marketing, sale and distribution of pharmaceutical products, and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain, and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel, and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may choose to collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter into such arrangements on acceptable terms or at all, we may not be able to successfully commercialize our product candidates.

We will need to grow the size of our organization, and we may experience difficulties in managing this growth.

As of December 31, 2022, we had 246 full-time employees, including 202 employees engaged in research and development. As our development and commercialization plans and strategies develop, and as we operate as a public company, we expect to need additional managerial, research and development, operational, sales, marketing, financial and other personnel. Future growth would impose significant added responsibilities on members of management, including:

•

identifying, recruiting, integrating, maintaining and motivating additional employees;

•

managing our internal development efforts effectively, including the clinical and FDA review process for any product candidate we develop, while complying with our contractual obligations to contractors and other third parties; and

•

improving our operational, financial and management controls, reporting systems and procedures.

Our future financial performance and our ability to advance development of and, if approved, commercialize any product candidate we develop will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.

We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services, including substantially all aspects of marketing approval, clinical management and manufacturing. We cannot assure you that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain marketing approval of any current or future product candidates or otherwise advance our business. We cannot assure you that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all.

If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize any product candidates we develop and, accordingly, may not achieve our research, development and commercialization goals.

We have in the past engaged and may in the future engage in strategic transactions; these transactions could affect our liquidity, dilute our existing stockholders, increase our expenses and present significant challenges in focus and energy to our management or prove not to be successful.

From time to time, we may consider strategic transactions, such as acquisitions of companies, asset purchases and out-licensing or in-licensing of intellectual property, products or technologies. For example, in October 2018, we acquired all of the outstanding shares of Warp Drive Bio, which became our direct wholly-owned subsidiary.

Additional potential transactions that we may consider in the future include a variety of business arrangements, including spin-offs, strategic partnerships, joint ventures, restructurings, divestitures, business combinations and investments. Any future transactions could result in potentially dilutive issuances of our equity securities, including our common stock, or the incurrence of debt, contingent liabilities, amortization expenses or acquired in-process research and development expenses, any of which could affect our financial condition, liquidity and results of operations. Future acquisitions may also require us to obtain additional financing, which may not be available on favorable terms or at all. These transactions may never be successful and may require significant time and attention of management. In addition, the integration of any business that we may acquire in the future may disrupt our existing business and may be a complex, risky and costly endeavor for which we may never realize the full benefits of the acquisition.

If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could negatively impact our business.

We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.

Although we maintain workers’ compensation insurance to cover us for costs and expenses, we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.

We or the third parties upon whom we depend may be adversely affected by earthquakes, outbreak of disease, or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.

Our corporate headquarters and other facilities are located in the San Francisco Bay Area, which in the past has experienced both severe earthquakes and wildfires. We do not carry earthquake insurance. Earthquakes, wildfires or other natural disasters could severely disrupt our operations, and negatively impact our business.

If a natural disaster, power outage, outbreak of disease, or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our enterprise financial systems or manufacturing resource planning and enterprise quality systems, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. As an example, our operations have been impacted as a result of the COVID-19 pandemic, as described in the risk factor entitled “The COVID-19 pandemic, or other epidemic and pandemic diseases or governmental or other actions taken in response to them, could significantly disrupt our business.” The disaster recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could negatively impact our business.

Furthermore, integral third parties used in our activities and in our supply chain are similarly vulnerable to natural disasters, outbreak of disease, or other sudden, unforeseen and severe adverse events. If such an event were to affect our activities or our supply chain, it could negatively impact our business.

Our employees, independent contractors, vendors, principal investigators, CROs and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.

We are exposed to the risk that our employees, independent contractors, vendors, principal investigators, CROs and consultants may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless or negligent conduct or disclosure of unauthorized activities to us that violate the regulations of the FDA or comparable foreign regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities; healthcare fraud and abuse laws and regulations in the United States and abroad; or laws that require the reporting of financial information or data accurately. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve the improper use of information obtained in the course of clinical trials or creating fraudulent data in our preclinical studies or clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Additionally, we are subject to the risk that a person could allege fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, and curtailment of our operations.

Risks related to our common stock

The price of our common stock is volatile and fluctuates substantially, which could result in substantial losses for investors.

Our stock price is highly volatile. The stock market in general, and the market for biopharmaceutical companies in particular, have experienced extreme volatility that has often been unrelated to the operating performance of particular companies.

The market price for our common stock may be influenced by many factors, including:

•

our research and development efforts and our ability to discover and develop product candidates;

•

results of our clinical trials and preclinical studies or those of our competitors;

•

the success of competitive products or technologies;

•

regulatory or legal developments in the United States and other countries;

•

developments or disputes concerning patent applications, issued patents or other proprietary rights;

•

the recruitment or departure of key personnel;

•

the level of expenses related to our product candidates or clinical development programs;

•

the results of our efforts to discover, develop, acquire or in-license product candidates or companion diagnostics;

•

actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;

•

variations in our financial results or those of companies that are perceived to be similar to us;

•

changes in the structure of healthcare payment systems;

•

market conditions in the pharmaceutical and biotechnology sectors; and

•

general economic, industry and market conditions.

An active and liquid market for our common stock may not be sustained.

Our common stock is currently listed on the Nasdaq Global Select Market under the symbol “RVMD”. The price for our common stock may vary and an active and liquid market in our common stock may not be sustained. The lack of an active market may impair the value of your shares, your ability to sell your shares at the time you wish to sell them and the prices that you may obtain for your shares. An inactive market may also impair our ability to raise capital by selling our common stock and our ability to acquire other companies, products or technologies by using our common stock as consideration.

We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.

We do not currently intend to pay any cash dividends on our common stock for the foreseeable future. We currently intend to invest our future earnings, if any, to fund our growth. Therefore, stockholders are not likely to receive any dividends on their common stock for the foreseeable future. Since we do not intend to pay dividends, stockholders’ ability to receive a return on their investment will depend on any future appreciation in the market value of our common stock. There is no guarantee that our common stock will appreciate or even maintain the price at which our holders have purchased it.

Our executive officers, directors and their affiliates have significant influence over our company, which will limit your ability to influence corporate matters and could delay or prevent a change in corporate control.

As of December 31, 2022, our executive officers, directors and their affiliates beneficially owned, in the aggregate, approximately 8.4% of our outstanding common stock. As a result, these stockholders, if they act together, may be able to influence our management and affairs and the outcome of matters submitted to our stockholders for approval, including the election of directors and any sale, merger, consolidation or sale of all or substantially all of our assets. In addition, this concentration of ownership might adversely affect the market price of our common stock by:

•

delaying, deferring or preventing a change of control of us;

•

impeding a merger, consolidation, takeover or other business combination involving us; or

•

discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us.

Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.

If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the market price of our common stock could decline.

As of December 31, 2022, 17.8 million shares of common stock that are either subject to outstanding options or restricted stock units reserved for future issuance under our equity incentive plans are eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, lock-up agreements and Rule 144 and Rule 701 under the Securities Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline.

In addition, as of December 31, 2022, holders of approximately 2.1 million shares of our common stock are entitled to rights with respect to the registration of their shares under the Securities Act. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares purchased by affiliates. Any sales of securities by these stockholders could impact the market price of our common stock.

Our ability to utilize our net operating loss carryforwards and certain other tax attributes has been limited by “ownership changes” and may be further limited.

Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the Code), and corresponding provisions of state law, if a corporation undergoes an “ownership change” (generally defined as a greater than 50 percentage point change (by value) in its equity ownership over a rolling three-year period), the corporation’s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes (such as research and development tax credits) to offset its post-change income or taxes may be limited. We have experienced ownership changes in the past, and we may experience ownership changes in the future as a result of our public offerings or other changes in our stock ownership (some of which are not in our control). Use of our federal and state net operating loss carryforwards have been limited as a result of ownership changes and could be further limited if we experience additional ownership changes.

Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management.

Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent changes in control or changes in our management without the consent of our board of directors. These provisions include the following:

•

a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of our board of directors;

•

no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;

•

the exclusive right of our board of directors to appoint a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;

•

the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror;

•

the ability of our board of directors to alter our amended and restated bylaws without obtaining stockholder approval;

•

the required approval of at least 66 2/3% of the shares entitled to vote at an election of directors to adopt, amend or repeal our amended and restated bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors;

•

a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;

•

the requirement that a special meeting of stockholders may be called only by our chief executive officer or president or by the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and

•

advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders’ meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror’s own slate of directors or otherwise attempting to obtain control of us.

We are also subject to the anti-takeover provisions contained in Section 203 of the Delaware General Corporation Law. Under Section 203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of directors has approved the transaction.

Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.

Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law.

In addition, as permitted by Section 145 of the Delaware General Corporation Law, our amended and restated bylaws and our indemnification agreements that we have entered into with our directors and officers provide that:

•

we will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person’s conduct was unlawful;

•

we may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law;

•

we are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification;

•

we are not obligated pursuant to our amended and restated bylaws to indemnify a person with respect to proceedings initiated by that person against us or our other indemnitees, except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification;

•

the rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons; and

•

we may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents.

Our amended and restated certificate of incorporation and amended and restated bylaws provide for an exclusive forum in the Court of Chancery of the State of Delaware for certain disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.

Our amended and restated certificate of incorporation and amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for any state law derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, any action to interpret, apply, enforce, or determine the validity of our amended and restated certificate of incorporation or our amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine; provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. Our amended and restated bylaws also provide that the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause or causes of action under the Securities Act. Such provision is intended to benefit and may be enforced by us, our officers and directors, the underwriters to any offering giving rise to such a compliant and any other professional or entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering. Nothing in our amended and restated certificate of incorporation or amended and restated bylaws precludes stockholders that assert claims under the Exchange Act from bringing such claims in state or federal court, subject to applicable law.

We believe these provisions may benefit us by providing increased consistency in the application of Delaware law and federal securities laws by chancellors and judges, as applicable, particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. This choice of forum provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims, although our stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies’ certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive-forum provisions, and there can be no assurance that such provisions will be enforced by a court in those other jurisdictions. If a court were to find the choice of forum provision in our amended and restated certificate of incorporation or amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business, financial condition, results of operations and prospects.

Risks related to the COVID-19 pandemic

The COVID-19 pandemic, or other epidemic and pandemic diseases or governmental or other actions taken in response to them, could significantly disrupt our business.

Outbreaks of epidemic, pandemic or contagious diseases, such as the recent SARS-CoV-2 virus, or coronavirus, which causes COVID-19 or, historically, the Ebola virus, Middle East Respiratory Syndrome, Severe Acute Respiratory Syndrome or the H1N1 virus, could significantly disrupt our business. These outbreaks pose the risk that we or our employees, contractors, suppliers, and other partners may be prevented from conducting business activities for an indefinite period of time due to spread of the disease within these groups, or due to restrictions that may be requested or mandated by governmental authorities. Business disruptions could include disruptions or restrictions on our ability to travel, as well as temporary closures of all or part of our facilities and the facilities of our partners, clinical trial sites, service providers, suppliers or contract manufacturers. As the COVID-19 pandemic evolves and spreads, both across the United States and through the world, we continue to actively monitor the impact that COVID-19 is having and may have on our business. The pandemic and the measures taken by governmental authorities could disrupt and delay our ongoing clinical trials, our preclinical activities, the manufacture or shipment of both drug substance and finished drug product for our product candidates for preclinical testing and clinical trials and otherwise significantly disrupt our business.

As a result of the COVID-19 pandemic, the state of California, where our corporate offices are located, and many counties where our offices are located or our employees reside, previously issued and may in the future issue orders for all residents to remain at home, except as needed for essential activities, and have placed restrictions on the scope and conduct of business activities. We have taken steps to ensure the safety of our patients and employees, while working to ensure the sustainability of our business operations as this unprecedented situation continues to evolve. As a result, we have implemented policies that require or permit many of our employees to work remotely. Some of these policies may continue for an indefinite period and may become more restrictive in response to developments related to the pandemic and the associated governmental responses. We continue to evaluate the impact of COVID-19 on the healthcare system and work with healthcare providers supporting our clinical studies to mitigate risk to patients while taking into account regulatory, institutional, and government guidance and policies.

The clinical trial sites for our clinical studies may be affected by the COVID-19 outbreak due to prioritization of hospital resources toward the COVID-19 outbreak, travel, quarantine or other restrictions imposed by governments, and the inability to access sites for initiation and patient monitoring and enrollment. As a result, patient screening, new patient enrollment, monitoring and data collection may be affected or delayed. We are aware that several clinical sites involved in our clinical studies temporarily stopped or delayed enrolling new patients, with exemptions if appropriate, and it is possible that these or other clinical sites may be similarly affected in the future. These developments may delay our clinical trial timelines. Our clinical trials currently permit patients to receive COVID-19 vaccines while they are on study. The potential impact of our candidates on the safety and efficacy of COVID-19 vaccines, and the potential impact of COVID-19 vaccines on the safety and efficacy of our candidates is unknown at this time, but it is possible that adverse impacts will negatively affect our clinical trials.

Although we are currently not aware of any material impacts on our supply chain of our current or potential product candidates as a result of the COVID-19 pandemic, some of our third-party manufacturers which we use for the supply of materials for product candidates or other materials necessary to manufacture product to conduct preclinical tests and clinical trials and CROs that we may utilize may be impacted by COVID-19, and should they experience continued disruptions, such as temporary closures or suspension of services, we would likely experience delays in advancing clinical trials. Furthermore, the spread of the virus may affect the operations of key governmental agencies, such as the FDA, which may delay the development of our product candidates. The spread of an infectious disease, including COVID-19, may also result in the inability of our suppliers to deliver components or raw materials on a timely basis or at all. Such events may result in a period of business disruption, and in reduced operations, or doctors and medical providers may be unwilling to participate in our clinical trials.

In addition, a significant outbreak of epidemic, pandemic or contagious diseases in the human population, such as the global COVID-19 pandemic, could result in a widespread health crisis and adversely affect the economies and financial markets of many countries, resulting in an economic downturn that could affect demand for our current or future products.

While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, a continuing widespread pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could negatively impact the price of our common stock.

General risk factors

Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies.

To date, we have primarily financed our operations through the sale of preferred stock and common stock and upfront payments and research and development cost reimbursement received in connection with our collaboration with Sanofi. We will be required to seek additional funding in the future and may do so through a combination of public or private equity offerings, debt financings, credit or loan facilities, collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements. If we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish certain valuable rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. If we raise additional funds by issuing equity securities, our stockholders may suffer dilution and the terms of any financing may adversely affect the rights of our stockholders. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. Debt financing, if available, is likely to involve restrictive covenants limiting our flexibility in conducting future business activities, and, in the event of insolvency, debt holders would be repaid before holders of our equity securities would receive any distribution of our corporate assets. Attempting to secure additional financing may also divert our management from our day-to-day activities, which may adversely affect our ability to develop our product candidates.

We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations.

Among other matters, U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, which are collectively referred to as Trade Laws, prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We also expect our non-U.S. activities to increase in time. We plan to engage third parties for clinical trials and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals and we can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities.

We incur significantly increased costs as a result of operating as a public company, and our management devotes substantial time to new compliance initiatives. We may fail to comply with the rules that apply to public companies, including Section 404 of the Sarbanes-Oxley Act of 2002, which could result in sanctions or other penalties that would harm our business.

We incur significant legal, accounting and other expenses as a public company, including costs resulting from public company reporting obligations under the Securities Exchange Act of 1934, as amended (the Exchange Act), and regulations regarding corporate governance practices. The listing requirements of the Nasdaq Global Select Market and the rules of the Securities and Exchange Commission (SEC) require that we satisfy certain corporate governance requirements relating to director independence, filing annual and interim reports, stockholder meetings, approvals and voting, soliciting proxies, conflicts of interest and a code of conduct. Our management and other personnel devote a substantial amount of time to ensure that we comply with all of these requirements. Moreover, the reporting requirements, rules and regulations will increase our legal and financial compliance costs and make some activities more time-consuming and costly. Any changes we make to comply with these obligations may not be sufficient to allow us to satisfy our obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors or board committees or to serve as executive officers, or to obtain certain types of insurance, including directors’ and officers’ insurance, on acceptable terms. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.

As a public company, we are subject to Section 404 of the Sarbanes-Oxley Act of 2002 (Section 404) and the related rules of the SEC, which generally require our management and independent registered public accounting firm to report on the effectiveness of our internal control over financial reporting.

In order to provide the reports required by these rules we must conduct reviews and testing of our internal controls. During the course of our review and testing, we may identify deficiencies and be unable to remediate them before we must provide the required reports.

Furthermore, if we have a material weakness in our internal controls over financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated. We or our independent registered public accounting firm may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which could harm our operating results, cause investors to lose confidence in our reported financial information and cause the trading price of our stock to fall. In addition, as a public company we are required to file accurate and timely quarterly and annual reports with the SEC under the Exchange Act. In order to report our results of operations and financial statements on an accurate and timely basis, we will depend on third party vendors to provide timely and accurate notice of their costs to us. Any failure to report our financial results on an accurate and timely basis could result in sanctions, lawsuits, delisting of our shares from the Nasdaq Global Select Market or other adverse consequences.

If we sell shares of our common stock in future financings, stockholders may experience immediate dilution and, as a result, our stock price may decline.

We have issued in the past, and may from time to time issue, additional shares of common stock at a discount from the current trading price of our common stock. As a result, our stockholders would experience immediate dilution upon the purchase of any shares of our common stock sold at such discount. In addition, as opportunities present themselves, we may enter into financing or similar arrangements in the future, including the issuance of debt securities, preferred stock or common stock. For example, on November 10, 2021, we entered into a sales agreement with Cowen to sell shares of common stock, from time to time, with aggregate gross sales proceeds of up to $250.0 million, through an at-the-market equity offering program under which Cowen acts as our sales agent. As of December 31, 2022, we have completed sales totaling $61.7 million in gross proceeds pursuant to this program. After deducting commissions and expenses of $1.7 million, net proceeds to us were $60.0 million. If we issue common stock or securities convertible into common stock, our common stockholders would experience additional dilution and, as a result, our stock price may decline.

If securities analysts do not continue to publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.

The trading market for our common stock relies, in part, on the research and reports that industry or financial analysts publish about us or our business. If few analysts publish research or reports about us, the trading price of our stock would likely decrease. If one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which, in turn, could cause our stock price to decline.

If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.

Pursuant to Section 404 of Sarbanes-Oxley, our management is required to report upon the effectiveness of our internal control over financial reporting and our independent registered public accounting firm is required to attest to the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation.

There may be material weaknesses in our internal control over financial reporting in the future. Any failure to implement and maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness in our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.

Item 1B. Unresolved Staff Comments.

None.

Item 2. Properties.

Our corporate headquarters is located in Redwood City, California, where we lease and occupy approximately 102,000 square feet of office and laboratory space. The term of our Redwood City lease expires in November 2033, with an option to extend the term through November 2043.

We also lease approximately 22,000 square feet of office and laboratory space in Cambridge, Massachusetts. The current term of our Cambridge lease expires in February 2023, with an option to extend the term through February 2028, subject to certain conditions. We have subleased this office and laboratory space to Casma Therapeutics, Inc. The current term of this sublease expires in February 2023.

We believe our existing facilities are sufficient for our needs for the foreseeable future. To meet the future needs of our business, we may lease additional or alternate space, and we believe suitable additional or alternative space will be available in the future on commercially reasonable terms.

Item 3. Legal Proceedings.

From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management resources and other factors.

Item 4. Mine Safety Disclosures.

Not applicable.

PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

Market price of common stock

Our common stock has been listed on the Nasdaq Global Select Market under the symbol “RVMD” since February 13, 2020. Prior to that date, there was no public trading market for our common stock.

On February 23, 2022, there were 45 holders of record of our common stock. We believe the actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.

Dividend policy

We have never declared or paid cash dividends on our common stock. We intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors our board of directors might deem relevant.

Stock performance graph

This graph is not “soliciting material” or deemed “filed” with the SEC for purposes of Section 18 of the Exchange Act, or otherwise subject to liabilities under that Section, and shall not be deemed incorporated by reference into any filing of Revolution Medicines, Inc. under the Securities Act of 1933, as amended, or the Securities Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.

The following graph compares the cumulative total return to stockholder return on our common stock relative to the cumulative total returns of the NASDAQ Composite Index and the NASDAQ Biotechnology Index. An investment of $100 is assumed to have been made in our common stock and each index on February 13, 2020 (the first day of trading of our common stock) and its relative performance is tracked through December 31, 2022. Pursuant to applicable Securities and Exchange Commission rules, all values assume reinvestment of the full amount of all dividends, however no dividends have been declared on our common stock to date. The stockholder returns shown on the graph below are based on historical results and are not necessarily indicative of future performance, and we do not make or endorse any predictions as to future stockholder returns.

Recent sales of unregistered securities

None.

Issuer Purchases of Equity Securities

The following table summarizes repurchases of our common stock during the three months ended December 31, 2022:


Period	Total Number of Shares Purchased		Average Price Paid Per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs		Maximum Number of Shares that May Yet be Repurchased Under the Plans or Programs
October 1, 2022 to October 31, 2022		—	$	—		—		—
November 1, 2022 to November 30, 2022		272		4.47		—		—
December 1, 2022 to December 31, 2022		—		—		—		—
Total		272	$	4.47		—		—

All of the shares repurchased, as reflected in the table above, were repurchases of unvested shares of our common stock that had been issued upon early exercise of stock options. Upon termination of employment of a person holding unvested shares, we are entitled to repurchase the unvested shares.

Item 6. [Reserved.]

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the consolidated financial statements and the related notes included elsewhere in this Annual Report on Form 10-K. In addition to historical financial information, this discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties. As a result of many factors, including those factors set forth in the “Risk Factors” section of this Annual Report on Form 10-K, our actual results could differ materially from the results described or implied by the forward-looking statements contained in the following discussion and analysis.

Overview

RAS (ON) Inhibitors

We currently consider three development-stage candidates as the first wave of RAS(ON) Inhibitors that we are advancing:

RMC-6236

A monotherapy dose-escalation study of RMC-6236 is ongoing and, based on early observations from this study, we believe that RMC-6236 is orally bioavailable and has achieved dose-dependent exposures in patients that are consistent with our preclinical projections. The compound has been generally well-tolerated, including at dose levels at which we have observed clear signals of anti-tumor activity. We continue in dose escalation and we currently expect to provide additional evidence of first-in-class single agent activity for this compound in mid-2023.

RMC-6291

RMC-9805

RMC-9805 is designed as a first-in-class, potent, oral and selective, tri-complex inhibitor of KRASG12D(ON). It is designed to exhibit low nanomolar potency for suppressing RAS pathway signaling and growth of KRASG12D-bearing cancer cells and is engineered to covalently inactivate KRASG12D irreversibly. We currently expect to announce dosing of the first patient in a monotherapy dose-escalation study of this compound in mid-2023.

Additional RAS(ON) Inhibitors

RAS Companion Inhibitors

RMC-4630

•

an Amgen-sponsored Phase 1b study of RMC-4630 in combination with Amgen’s KRASG12C(OFF) inhibitor, sotorasib (LUMAKRAS(R));

•

RMC-4630-03, a Phase 2 study of RMC-4630 in combination with sotorasib that we are sponsoring under a clinical trial collaboration and supply agreement with Amgen; and

•

a Sanofi-sponsored Phase 1/2 study of RMC-4630 in combination with Mirati Therapeutics’ KRASG12C(OFF) inhibitor, adagrasib (KRAZATI(R)).

There are also several clinical studies of RMC-4630 that do not involve combinations with RAS inhibitors:

•

RMC-4630-01, a Phase 1 study of RMC-4630 as monotherapy;

•

a combination of RMC-4630 with an ERK inhibitor in patients with pancreatic cancer as part of an investigator-sponsored study by Netherlands Cancer Institute.

RMC-5552

RMC-5845

RMC-6236

Collaboration agreement with Sanofi

Under the Sanofi Agreement, we have primary responsibility for early clinical development of RMC-4630 pursuant to an approved development plan. Sanofi is responsible to reimburse us for all internal and external costs and expenses to perform our activities under approved development plans, except for costs and expenses related to studies designated in the Sanofi Agreement as RevMed Studies, for which we will bear all costs and expenses, and for the RMC-4630-03 study, for which we have agreed that Sanofi will reimburse us for 50% of the costs and expenses. Unreimbursed costs borne by us for any RevMed Studies and for our 50% share of the RMC-4630-03 collaboration study are subject to future reimbursement by Sanofi through a buy-in payment pursuant to the terms of the Sanofi Agreement if they use data from a RevMed Study or the RMC-4630-03 study in support of a marketing approval application. There currently are no active RevMed Studies.

Through December 31, 2022, we have received an aggregate of $176.9 million from Sanofi, including the upfront payment and research and development expense reimbursements.

Financial Operations Overview

Collaboration revenue

Collaboration revenue consists of revenue under the Sanofi Agreement for our SHP2 program. We received a $50.0 million upfront payment from Sanofi in July 2018 and receive reimbursement for research and development services. The Sanofi Agreement is expected to terminate in June 2023.

For further information on our revenue recognition policies, see “Note 2. Summary of significant accounting policies” in the “Notes to Consolidated Financial Statements” contained in Part II, Item 8 of this Annual Report on Form 10-K.

Research and development expenses

We substantially rely on third parties to conduct our preclinical studies, clinical trials and manufacturing. We estimate research and development expenses based on estimates of services performed, and rely on third party contractors and vendors to provide us with timely and accurate estimates of expenses of services performed to assist us in these estimates. Research and development expenses consist primarily of costs incurred for the development of our product candidates and costs associated with identifying compounds through our discovery platform, which include:

•

expenses incurred under agreements with third-party contract organizations, investigative clinical trial sites that conduct research and development activities on our behalf and consultants;

•

costs related to production of clinical and preclinical materials, including fees paid to contract manufacturers;

•

laboratory and vendor expenses related to the execution of discovery programs, preclinical and clinical trials;

•

employee-related expenses, which include salaries, benefits and stock-based compensation; and

•

facilities and other expenses, which include allocated expenses for rent and maintenance of facilities, depreciation and amortization expense, information technology and other supplies.

We expense all research and development costs in the periods in which they are incurred. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors, collaborators and third-party service providers. Nonrefundable advance payments for goods or services to be received in future periods for use in research and development activities are deferred and recorded as prepaid assets. The prepaid amounts are then expensed as the related goods are delivered or as services are performed.

Up to the termination date of the Sanofi Agreement, Sanofi is responsible to reimburse us for all internal and external costs and expenses to perform our activities under approved development plans, except for 50% of the RMC-4630-03 study. These reimbursements from Sanofi are recorded as collaboration revenue.

We expect our research and development expenses to increase for the foreseeable future as we continue to invest in discovering and developing product candidates and advancing product candidates into later stages of development, which may include conducting larger clinical trials. The process of conducting the necessary research and development and clinical trials to seek regulatory approval for product candidates is costly and time-consuming, and the successful development of our product candidates is highly uncertain. As a result, we are unable to determine the duration and completion costs of our research and development projects or clinical trials or if and to what extent we will generate revenue from the commercialization and sale of any of our product candidates.

General and administrative expenses

General and administrative expenses consist primarily of personnel-related costs, consultants and professional services expenses, including legal, audit, accounting and human resources services, insurance, allocated facilities and information technology costs, and other general operating expenses not otherwise classified as research and development expenses. Personnel-related costs consist of salaries, benefits and stock-based compensation. Facilities costs consist of rent, utilities and maintenance of facilities. We expect our general and administrative expenses to increase for the foreseeable future due to anticipated increases in headcount and as a result of operating as a public company, including expenses related to compliance with the rules and regulations of the Securities and Exchange Commission, the Nasdaq Global Select Market, investor relations activities and other administrative and professional services.

Interest income

Interest income primarily consists of interest earned on and accretion of our cash equivalents and marketable securities.

Interest expense

Interest expense primarily consists of interest related to our finance lease and interest on other outstanding obligations.

Benefit from income taxes

Benefit from income taxes relates to net changes in the deferred tax liability associated with our Warp Drive acquisition resulting from changes in the effective state tax rate and changes in our valuation allowance.

Results of operations

Comparison of the years ended December 31, 2022 and 2021


	Years Ended December 31,
	2022			2021			Increase/ (decrease)
	(in thousands)
Revenue:
Collaboration revenue	$	35,380		$	29,390		$	5,990
Total revenue		35,380			29,390			5,990
Operating expenses:
Research and development		253,073			186,948			66,125
General and administrative		40,586			30,450			10,136
Total operating expenses		293,659			217,398			76,261
Loss from operations		(258,279	)		(188,008	)		(70,271	)
Other income (expense), net:
Interest income		9,154			929			8,225
Interest expense		—			(12	)		12
Total other income, net		9,154			917			8,237
Loss before income taxes		(249,125	)		(187,091	)		(62,034	)
Benefit from income taxes		420			—			420
Net loss	$	(248,705	)	$	(187,091	)	$	(61,614	)

Collaboration revenue

Collaboration revenue consists of revenue under the Sanofi Agreement, which is expected to terminate in 2023. As a result of the expected termination of the agreement and development plan adjustments during the year, we revised our estimate of the accounting transaction price and increased our percentage of completion under the agreements with Sanofi, which resulted in total cumulative catch-up adjustments that increased collaboration revenue by $3.0 million for the year ended December 31, 2022.

In August 2021, we entered into a Letter Agreement with Sanofi to include RMC-4630-03 under the development plan for RMC-4630 and decided to no longer enroll new patients in RMC-4630-02. As a result of these development plan adjustments, we revised the estimate of the accounting transaction price and decreased our estimated percentage of completion under the agreements with Sanofi, and resulted in a cumulative catch-up adjustment that reduced collaboration revenue by $8.5 million for the year ended December 31, 2021.

Collaboration revenue increased by $6.0 million, or 20%, during the year ended December 31, 2022 compared to the same period in 2021. The increase was due to the cumulative catch-up adjustments resulting from the Sanofi Agreement termination and development plan adjustments, partially offset by lower reimbursable SHP2 program research and development costs under the Sanofi Agreement for the year ended December 31, 2022.

Research and development expenses

Research and development expenses increased by $66.1 million, or 35%, during the year ended December 31, 2022 compared to the same period in 2021. The increase in research and development expenses during the year ended December 31, 2022 was primarily due to a $16.1 million increase in third-party costs for our preclinical research portfolio, primarily driven by higher chemistry contract research organization, material sourcing and manufacturing costs; a $16.1 million increase in salaries and other employee-related expenses due to increased headcount to support our research and development programs; a $14.8 million increase in RMC-6236 costs, which commenced clinical trials in the second quarter of 2022; a $10.2 million increase in facilities and other allocated expenses as a result of higher rent, utilities and information technology expenses associated with increased headcount; a $6.3 million increase in stock-based compensation; and a $5.2 million increase in RMC-6291 costs, which commenced clinical trials in the third quarter of 2022.

General and administrative expenses

General and administrative expenses increased by $10.1 million, or 33%, during the year ended December 31, 2022 compared to the same period in 2021. The increase in general and administrative expenses during the year ended December 31, 2022 was primarily due to an increase of $4.2 million in stock-based compensation expense; an increase of $3.9 million in salaries and other employee-related expenses due to increased headcount; a $0.7 million increase in facilities and other allocated expenses as a result of higher rent, utilities and information technology expenses associated with increased headcount; and a $0.8 million increase in legal and accounting fees.

Interest income

Interest income increased by $8.2 million for the year ended December 31, 2022, compared to the same period in 2021 due to a larger cash, cash equivalents and marketable securities balance and higher interest rates.

Interest expense

Interest expense was zero for the year ended December 31, 2022 and less than $0.1 million for the year ended December 31, 2021.

Benefit from income taxes

Benefit from income taxes was $0.4 million for the year ended December 31, 2022 and zero for the year ended December 31, 2021 and related to net changes in the valuation allowance resulting from the Warp Drive acquisition.

Comparison of the years ended December 31, 2021 and 2020


	Years Ended December 31,
	2021			2020			Increase/ (decrease)
	(in thousands)
Revenue:
Collaboration revenue	$	29,390		$	42,983		$	(13,593	)
Total revenue		29,390			42,983			(13,593	)
Operating expenses:
Research and development		186,948			132,252			54,696
General and administrative		30,450			21,428			9,022
Total operating expenses		217,398			153,680			63,718
Loss from operations		(188,008	)		(110,697	)		(77,311	)
Other income (expense), net:
Interest income		929			2,238			(1,309	)
Interest expense		(12	)		(71	)		59
Total interest income (expense), net		917			2,167			(1,250	)
Loss before income taxes		(187,091	)		(108,530	)		(78,561	)
Benefit from income taxes		—			371			(371	)
Net loss	$	(187,091	)	$	(108,159	)	$	(78,932	)

Collaboration revenue

In August 2021, we entered into a Letter Agreement with Sanofi to include RMC-4630-03 under the development plan for RMC-4630 and ceased enrollment of new patients in RMC-4630-02. As a result of these development plan adjustments, we revised our estimate of the accounting transaction price and our percentage of completion under the agreements with Sanofi, which resulted in a cumulative catch-up adjustment that reduced collaboration revenue by $8.5 million for the year ended December 31, 2021.

Collaboration revenue decreased by $13.6 million, or 32%, during the year ended December 31, 2021 compared to the same period in 2020. The decreases in collaboration revenue during the year ended December 31, 2021 was primarily due to the cumulative catch-up adjustment and lower reimbursed manufacturing costs.

Research and development expenses

Research and development expenses increased by $54.7 million, or 41%, during the year ended December 31, 2021 compared to the same period in 2020. The increase in research and development expenses during the year ended December 31, 2021 was primarily

due to a $34.5 million increase in third-party costs for our preclinical research portfolio, primarily driven by higher chemistry contract research organization, material sourcing and manufacturing costs; a $9.2 million increase in salaries and other employee-related expenses due to increased headcount to support our research and development programs, a $7.0 million increase in stock-based compensation, and a $5.4 million increase in facilities and other allocated expenses as a result of higher rent, utilities and information technology expenses associated with increased headcount.

General and administrative expenses

General and administrative expenses increased by $9.0 million, or 42%, during the year ended December 31, 2021 compared to the same period in 2020. The increase in general and administrative expenses during the year ended December 31, 2021 was primarily due to an increase of $4.8 million in stock-based compensation expense; an increase of $2.3 million in salaries and other employee-related expenses due to increased headcount; and an increase of $0.8 million in insurance.

Interest income

Interest income decreased by $1.3 million for the year ended December 31, 2021, compared to the same period in 2020 due to lower interest rates.

Interest expense

Interest expense was less than $0.1 million for both years ended December 31, 2021 and 2020.

Benefit from income taxes

Benefit from income taxes was zero for the year ended December 31, 2021 and $0.4 million for the year ended December 31, 2020 and related to net changes in the valuation allowance resulting from the Warp Drive acquisition.

Liquidity and capital resources

In February 2020, we closed our IPO and issued 16,100,000 shares of our common stock at a price to the public of $17.00 per share for net proceeds of approximately $250.7 million, after deducting underwriting discounts and commissions of $19.2 million and expenses of $3.8 million.

In July 2020, we issued 6,900,000 shares of our common stock in an underwritten public offering at a price to the public of $26.00 per share for net proceeds of $167.8 million, after deducting underwriting discounts and commissions of $10.8 million and offering expenses of $0.8 million.

In February 2021, we issued 6,666,666 shares of our common stock in an underwritten public offering at a price to the public of $45.00 per share for net proceeds of $281.1 million, after deducting underwriting discounts and commissions of $18.0 million and offering expenses of $0.9 million.

In November 2021, we entered into a sales agreement with Cowen and Company, LLC (Cowen) to sell shares of our common stock, from time to time, with aggregate gross proceeds of up to $250 million, through an at-the-market equity offering program (ATM) under which Cowen agreed to act as our sales agent. In 2021, we sold an aggregate of 339,302 shares of common stock under the ATM resulting in gross proceeds to us of $10.4 million. After deducting commissions and expenses of $0.3 million, net proceeds to us were $10.1 million.

In July 2022, we issued 13,225,000 shares of our common stock in an underwritten public offering at a price to the public of $20.00 per share, for net proceeds of $248.1 million, after deducting underwriting discounts and commissions of $15.9 million and estimated offering expenses of $0.5 million.

During the year ended December 31, 2022, we sold an aggregate of 2,385,846 shares of common stock under the ATM resulting in gross proceeds of $51.3 million. After deducting commissions and expenses of $1.4 million, our net proceeds under the ATM were $49.9 million.

Our operations have been financed primarily by our public offerings of common stock, net proceeds of $230.6 million from the issuance of our preferred stock and $176.9 million received under the Sanofi Agreement for upfront payments and for research and development cost reimbursement.

As of December 31, 2022, we had $644.9 million in cash, cash equivalents and marketable securities.

As of December 31, 2022, we had an accumulated deficit of $701.3 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures related to our product candidates and our preclinical research portfolio, and to a lesser extent, general and administrative expenditures. We expect our expenses to continue to increase in connection with our ongoing activities, particularly as we continue to advance our product candidates and preclinical research portfolio.

We believe that our existing cash, cash equivalents and marketable securities will enable us to fund our planned operations for at least 12 months following the date of this report.

The timing and amount of our future funding requirements depends on many factors, including:

•

the scope, progress, results and costs of researching and developing our product candidates and programs, and of conducting preclinical studies and clinical trials;

•

the timing of, and the costs involved in, obtaining marketing approvals for product candidates we develop if clinical trials are successful;

•

the cost of manufacturing our current and future product candidates for clinical trials in preparation for marketing approval and in preparation for commercialization;

•

our ability to establish and maintain strategic licenses or other arrangements and the financial terms of such agreements;

•

the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs and the outcome of such litigation;

•

the timing, receipt and amount of sales of, profit share or royalties on, our future products, if any;

•

the emergence of competing cancer therapies or other adverse market developments; and

•

any plans to acquire or in-license other programs or technologies.

We expect to need to obtain substantial additional funding in the future to continue the preclinical and clinical development of our current and future programs and to prepare for their potential commercialization. If we need to raise additional capital to fund our operations, funding may not be available to us on acceptable terms, or at all. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of or suspend one or more of our clinical trials, research and development programs or commercialization efforts. We may seek to raise any necessary additional capital through a combination of public or private equity offerings, debt financings and collaborations or licensing arrangements. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders’ rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, and if the debt is convertible into our common stock, the ownership interest of our stockholders may be diluted. If we are unable to raise capital, we may need to delay, reduce or terminate planned activities to reduce costs. Doing so will likely harm our ability to execute our business plans.

Cash flows

The following table summarizes our consolidated cash flows for the periods indicated:


	Year Ended December 31,
	2022			2021			2020
	(in thousands)
Net cash provided by (used in):
Operating activities	$	(224,401	)	$	(147,180	)	$	(100,064	)
Investing activities		(24,116	)		(142,117	)		(234,233	)
Financing activities		301,432			294,179			422,776
Net change in cash and cash equivalents	$	52,915		$	4,882		$	88,479

Cash used in operating activities

During the year ended December 31, 2022, cash used in operating activities of $224.4 million was attributable to a net loss of $248.7 million partially offset by $37.8 million in non-cash charges and by a net change of $13.5 million in our operating assets and liabilities. The non-cash charges primarily consisted of stock-based compensation expense of $31.2 million, depreciation and amortization of $5.0 million, amortization of operating lease right-of-use asset of $4.6 million offset by net amortization of premium on marketable securities of $3.1 million. The change in operating assets and liabilities was primarily due to a $3.8 million increase in prepaid expenses and other current assets primarily resulting from the timing of prepayments made for research and development activities, a $14.5 million decrease in deferred revenue associated with the Sanofi Agreement, a $2.4 million decrease in operating lease liability, offset by a $7.3 million increase in accounts payable, $1.5 million increase in accrued expenses and other current liabilities and a $1.3 million decrease in accounts receivable.

During the year ended December 31, 2021, cash used in operating activities of $147.2 million was attributable to a net loss of $187.1 million partially offset by $31.2 million in non-cash charges and by net change of $8.7 million in our operating assets and liabilities. The non-cash charges primarily consisted of stock-based compensation expense of $20.7 million, depreciation and amortization of $4.2 million, net amortization of premium on marketable securities of $3.0 million and amortization of operating lease right-of-use asset of $3.2 million. The change in operating assets and liabilities was primarily due to an $11.0 million increase in accrued expenses and accounts payable partially offset by a $1.7 million decrease in deferred revenue associated with the Sanofi Agreement and a $1.5 million decrease in operating lease liability.

During the year ended December 31, 2020, cash used in operating activities of $100.1 million was attributable to a net loss of $108.2 million and a net change of $8.3 million in our operating assets and liabilities, partially offset by $16.4 million in non-cash charges. The non-cash charges primarily consisted of stock-based compensation expense of $8.9 million, depreciation and amortization of $3.7 million, net amortization of premium on marketable securities of $0.1 million and amortization of operating lease right-of-use asset of $2.9 million. The change in operating assets and liabilities was primarily due to an $11.3 million decrease in deferred revenue associated with the Sanofi Agreement partially offset by a $4.9 million increase in accrued expenses and other current assets.

Cash used in investing activities

During the year ended December 31, 2022, cash used in investing activities of $24.1 million was primarily comprised of purchases of marketable securities of $612.8 million and purchases of property and equipment of $10.8 million, offset by cash provided by maturities of marketable securities of $599.5 million.

During the year ended December 31, 2021, cash used in investing activities of $142.1 million was primarily comprised of purchases of marketable securities of $671.3 million and purchases of property and equipment of $6.5 million, offset by cash provided by maturities of marketable securities of $526.8 million and sale of marketable securities of $9.0 million.

During the year ended December 31, 2020, cash used in investing activities of $234.2 million was primarily comprised of purchases of marketable securities of $544.1 million and purchases of property and equipment of $2.9 million, partially offset by cash provided by maturities of marketable securities of $309.8 million and sale of marketable securities of $3.0 million.

Cash provided by financing activities

During the year ended December 31, 2022, cash provided by financing activities of $301.4 million was comprised of $248.1 million in net proceeds from the July 2022 underwritten public offering, $49.9 million in net proceeds from the issuance of common stock under the ATM, $1.9 million in proceeds from the issuance of common stock under the employee stock purchase plan and $1.5 million in proceeds from the issuance of common stock upon the exercise of stock options.

During the year ended December 31, 2021, cash provided by financing activities of $294.2 million was comprised of $281.1 million in net proceeds from the issuance of common stock related from the February 2021 underwritten public offering, $10.1 million in net proceeds from the issuance of common stock under the ATM, $1.9 million in proceeds from the issuance of common stock under the employee stock purchase plan and $ 1.5 million in proceeds from the issuance of common stock upon the exercise of stock options.

During the year ended December 31, 2020, cash provided by financing activities of $422.8 million was comprised of $420.1 million in net proceeds from the issuance of common stock related to our IPO in February 2020 and our underwritten public offering in July 2020, $1.9 million in proceeds from the issuance of common stock upon the exercise of stock options and $0.8 million in proceeds from the issuance of common stock under the employee stock purchase plan.

Contractual obligations and commitments

We have contractual obligations related to office and laboratory space leases in Redwood City, California and Cambridge, Massachusetts, described in “Note 7. Commitments and contingencies” in the “Notes to Consolidated Financial Statements” contained in Part II, Item 8 of this Annual Report on Form 10-K.

We enter into agreements in the ordinary course of business with contract research organizations for clinical trials, contract manufacturing organizations to provide clinical trial materials and with vendors for preclinical studies and other services and products for operating purposes which are generally cancelable at any time by us upon 30 to 90 days prior written notice.

Indemnification agreements

We enter into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, we indemnify, hold harmless and agree to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The maximum potential amount of future payments we could be required to make under these arrangements is not determinable. We have never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, we believe the fair value of these agreements is minimal.

Critical accounting policies, significant judgments and use of estimate

Our management’s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with United States generally accepted accounting principles (U.S. GAAP). The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management’s judgments and estimates.

Revenue recognition

We recognize revenue is accordance with Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (ASC 606). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which such entity expects to receive in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under arrangements, we perform the following steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies the performance obligation. At contract inception, once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract and determine those that are performance obligations and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

We enter into collaboration agreements under which we may obtain upfront license fees, research and development funding, and development, regulatory and commercial milestone payments and royalty payments. Our performance obligations under these arrangements may include licenses of intellectual property, sales and distribution rights, research and development services, delivery of manufactured product and/or participation on joint steering committees.

Licenses of intellectual property: If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from upfront license fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring proportional performance for purposes of recognizing revenue from non-refundable, upfront fees. We evaluate the measure of proportional performance each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.

Research, development and regulatory milestone payments: At the inception of each arrangement that includes research, development, or regulatory milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price. We use the most likely amount method for research, development and regulatory milestone payments. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.

Sales-based milestones and royalties: For arrangements that include sales-based milestone or royalty payments based on the level of sales, and in which the license is deemed to be the predominant item to which the sales-based milestone or royalties relate to, we recognize revenue in the period in which the sales-based milestone is achieved and in the period in which the sales associated with the royalty occur. To date, we have not recognized any sales-based milestone or royalty revenue resulting from our collaboration arrangements.

The transaction price for each collaboration agreement is determined based on the amount of consideration we expect to be entitled for satisfying all performance obligations within the agreement. Significant judgment may be required in determining the amount of variable consideration to be included in the transaction price. We use the most likely amount method to determine variable consideration and will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.

Revenue is recognized based on actual costs incurred as a percentage of total estimated costs to be incurred over the performance obligation as we fulfill our performance obligations. A cost-based input method of revenue recognition requires management to make estimates of costs to complete our performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to fulfill our performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated.

Accrued research and development expenses

We record accrued expenses for estimated preclinical studies and clinical trial expenses. Estimates are based on the services performed pursuant to contracts with research institutions and contract research organizations and clinical manufacturing organizations that conduct and manage preclinical studies and clinical trials on our behalf based on actual time and expenses incurred by them. Further, we accrue expenses related to clinical trials based on the level of patient enrollment and activity according to the related agreement. We monitor patient enrollment levels and related activity to the extent reasonably possible and make judgments and estimates in determining the accrued balance in each reporting period. If we underestimate or overestimate the level of services performed or the costs of these services, our actual expenses could differ from our estimates. To date, we have not experienced significant changes in our estimates of preclinical studies and clinical trial accruals.

Stock-based compensation

We maintain an equity incentive plan as a long-term incentive for employees, consultants and members of our board of directors. The plan allows for the issuance of non-statutory options, or NSOs, incentive stock options, or ISOs, restricted stock unit awards, or RSUs to employees and NSOs and RSUs to nonemployees.

Stock-based compensation is measured using estimated grant date fair value and recognized as compensation expense over the service period in which the awards are expected to vest. The grant date fair value of an RSU award is based on our stock price on the date of grant. For options, we estimate the grant date fair value, and the resulting stock-based compensation, using the Black-Scholes option-pricing model, and we use the straight-line method for expense attribution. The Black-Scholes model requires us to make assumptions and judgments about the variables used in the calculations, including the expected term (weighted-average period of time that the options granted are expected to be outstanding), the expected volatility of our common stock, the related risk-free interest rate and the expected dividend. We have elected to recognize forfeitures of stock-based awards as they occur.

The Black-Scholes option-pricing model requires the use of highly subjective assumptions to determine the fair value of stock-based awards. These assumptions include:

•

Expected Term—The expected term is calculated using the simplified method, which is available where there is insufficient historical data about exercise patterns and post-vesting employment termination behavior. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting-tranche for awards with graded vesting. The mid-point between the vesting date and the maximum contractual expiration date is used as the expected term under this method.

•

Expected Volatility—Given that we do not have sufficient trading history for our common stock, the expected volatility was estimated based on the average volatility of the Company and comparable publicly traded biotechnology companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on their similar size, stage in the life cycle or area of specialty.

•

Risk-Free Interest Rate—The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the option.

•

Expected Dividend—We have never paid dividends on our common stock and have no plans to pay dividends on our common stock. Therefore, we used an expected dividend yield of zero.

Recent accounting pronouncements

For a description of the expected impact of recent accounting pronouncements, see “Note 2. Summary of significant accounting policies” in the “Notes to Consolidated Financial Statements” contained in Part II, Item 8 of this Annual Report on Form 10-K.

Item 7A. Quantitative and Qualitative Disclosures About Market Risk.

Interest rate risk

We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities. The primary objective of our investment activities is to preserve capital to fund our operations. We also seek to maximize income from our investments without assuming significant risk. To achieve our objectives, we maintain a portfolio of investments in a variety of securities of high credit quality and short-term duration, invested in compliance with our policy.

We held cash, cash equivalents and marketable securities of $644.9 million and $577.1 million as of December 31, 2022 and December 31, 2021, respectively, which consisted of bank deposits, money market funds, U.S. government debt securities, U.S. government agency bonds, commercial paper and corporate bonds. Such interest-earning instruments carry a degree of interest rate risk; however, historical fluctuations in interest income have not been significant for us. Due to the short-term maturities of our cash equivalents and marketable securities, an immediate one percent change in interest rates would not have a material effect on the fair value of our cash equivalents and marketable securities.

Foreign currency risk

Our expenses are generally denominated in U.S. dollars. However, we have entered into a limited number of contracts with vendors for research and development services with payments denominated in foreign currencies, including the Euro, British Pound and Chinese Yuan. We are subject to foreign currency transaction gains or losses on our contracts denominated in foreign currencies. To date, foreign currency transaction gains and losses have not been material to our consolidated financial statements, and we have not had a formal hedging program with respect to foreign currency. A 10% increase or decrease in current exchange rates would not have a material effect on our financial results.

Item 8. Financial Statements and Supplementary Data.

REVOLUTION MEDICINES, INC.

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS


	Page
Report of Independent Registered Public Accounting Firm (PCAOB ID: 238)	94
Consolidated Balance Sheets	96
Consolidated Statements of Operations	97
Consolidated Statements of Comprehensive Loss	98
Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)	99
Consolidated Statements of Cash Flows	100
Notes to Consolidated Financial Statements	101

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders of Revolution Medicines, Inc.

Opinions on the Financial Statements and Internal Control over Financial Reporting

We have audited the accompanying consolidated balance sheets of Revolution Medicines, Inc. and its subsidiary (the “Company”) as of December 31, 2022 and 2021, and the related consolidated statements of operations, of comprehensive loss, of redeemable convertible preferred stock and stockholders’ equity (deficit) and of cash flows for each of the three years in the period ended December 31, 2022, including the related notes (collectively referred to as the “consolidated financial statements”). We also have audited the Company’s internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.

Basis for Opinions

The Company’s management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management’s Annual Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company’s consolidated financial statements and on the Company’s internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.

Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

Definition and Limitations of Internal Control over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Critical Audit Matters

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

Revenue Recognition - Actual Costs Incurred under the Collaboration Agreement with Sanofi

As described in Note 8 to the consolidated financial statements the Company’s consolidated revenue was $35.4 million for the year ended December 31, 2022. Revenue is recognized under the collaboration agreement with Sanofi based on actual costs incurred as a percentage of total estimated costs to be incurred over the performance obligation as the Company completes its performance obligation. A cost-based input method of revenue recognition requires management to make estimates of costs to fulfill their performance obligation. A percentage of the actual costs incurred under approved research and development plans are reimbursed by Sanofi under the collaboration agreement. The research and development plans are determined by a joint research and development committee, over which Sanofi has final decision-making, subject to certain exceptions.

The principal considerations for our determination that performing procedures relating to revenue recognition – actual costs incurred under the collaboration agreement with Sanofi is a critical audit matter are a high degree of auditor effort in performing procedures and evaluating audit evidence related to the Company’s revenue recognition and determination of actual costs incurred subject to approved development plans related to the collaboration agreement with Sanofi. Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to the revenue recognition process, including controls over the inputs and assumptions used to estimate the total effort required to complete the performance obligation. These procedures also included, among others, (i) testing management’s process for recognizing revenue under the collaboration agreement with Sanofi, (ii) testing the mathematical accuracy of the cost-based input method; (iii) evaluating the terms of the master service agreement; (iv) testing the accuracy and existence of actual costs used in the cost-based input method; and (v) testing the accuracy, existence and classification of costs that are reimbursable by the collaborative partner under the approved research and development plans.

/s/ PricewaterhouseCoopers LLP

San Jose, California

February 27, 2023

We have served as the Company’s auditor since 2017.

REVOLUTION MEDICINES, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)


	December 31,			December 31,
	2022			2021
Assets
Current assets:
Cash and cash equivalents	$	161,412		$	108,497
Marketable securities		483,531			468,557
Accounts receivable		4,673			5,929
Prepaid expenses and other current assets		10,569			6,790
Total current assets		660,185			589,773
Property and equipment, net		18,659			11,544
Operating lease right-of-use asset		55,077			59,692
Intangible assets, net		58,807			59,876
Goodwill		14,608			14,608
Restricted cash		1,737			1,737
Other noncurrent assets		2,857			758
Total assets	$	811,930		$	737,988
Liabilities and stockholders' equity
Current liabilities:
Accounts payable	$	21,306		$	14,057
Accrued expenses and other current liabilities		29,446			27,721
Operating lease liability, current		6,773			6,214
Deferred revenue, current		4,459			12,358
Total current liabilities		61,984			60,350
Deferred revenue, noncurrent		—			6,573
Deferred tax liability		7,025			7,444
Operating lease liability, noncurrent		57,432			60,419
Other noncurrent liabilities		301			634
Total liabilities		126,742			135,420
Commitments and contingencies (Note 7)
Stockholders' equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at December 31, 2022 and December 31, 2021, respectively; zero shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively		—			—
Common stock, $0.0001 par value; 300,000,000 shares authorized at December 31, 2022 and December 31, 2021, respectively; 90,411,912 and 74,142,619 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively		9			8
Additional paid-in capital		1,388,300			1,055,572
Accumulated other comprehensive loss		(1,780	)		(376	)
Accumulated deficit		(701,341	)		(452,636	)
Total stockholders' equity		685,188			602,568
Total liabilities and stockholders' equity	$	811,930		$	737,988

The accompanying notes are an integral part of these Consolidated Financial Statements.

REVOLUTION MEDICINES, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except share and per share data)


	Year Ended December 31,
	2022			2021			2020
Revenue:
Collaboration revenue	$	35,380		$	29,390		$	42,983
Total revenue		35,380			29,390			42,983
Operating expenses:
Research and development		253,073			186,948			132,252
General and administrative		40,586			30,450			21,428
Total operating expenses		293,659			217,398			153,680
Loss from operations		(258,279	)		(188,008	)		(110,697	)
Other income (expense), net:
Interest income		9,154			929			2,238
Interest expense		—			(12	)		(71	)
Total other income, net		9,154			917			2,167
Loss before income taxes		(249,125	)		(187,091	)		(108,530	)
Benefit from income taxes		420			—			371
Net loss	$	(248,705	)	$	(187,091	)	$	(108,159	)
Redeemable convertible preferred stock dividends – undeclared and cumulative		—			—			(2,219	)
Net loss attributable to common stockholders	$	(248,705	)	$	(187,091	)	$	(110,378	)
Net loss per share attributable to common stockholders, basic and diluted	$	(3.08	)	$	(2.57	)	$	(2.01	)
Weighted-average common shares used to compute net loss per share, basic and diluted		80,626,525			72,806,079			54,874,119

The accompanying notes are an integral part of these Consolidated Financial Statements.

REVOLUTION MEDICINES, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(in thousands)


	Year Ended December 31,
	2022			2021			2020
Net loss	$	(248,705	)	$	(187,091	)	$	(108,159	)
Other comprehensive income (loss):
Unrealized gain (loss) on investments, net		(1,404	)		(492	)		42
Total comprehensive loss	$	(250,109	)	$	(187,583	)	$	(108,117	)

The accompanying notes are an integral part of these Consolidated Financial Statements.

REVOLUTION MEDICINES, INC.

CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)

(in thousands, except share and per share data)


														Accumulated
	Redeemable Convertible											Additional		Other						Total
	Preferred Stock						Common Stock					Paid-in		Comprehensive			Accumulated			Stockholders'
	Shares			Amount			Shares			Amount		Capital		Income/ (Loss)			Deficit			Equity/(Deficit)
Balance at December 31, 2019		39,600,423		$	305,109			3,292,124		$	—	$	4,738	$	74		$	(157,386	)	$	(152,574	)
Conversion of redeemable convertible preferred stock into common stock		(39,600,423	)		(305,109	)		39,600,423			4		305,105		—			—			305,109
Issuance of common stock from initial public offering, net of offering costs of $23,003		—			—			16,100,000			2		250,695	$	—		$	—			250,697
Issuance of common stock from follow-on offering, net of offering costs of $11,633		—			—			6,900,000			1		167,766	$	—		$	—			167,767
Issuance of common stock pursuant to stock option exercises		—			—			694,441			—		1,877		—			—			1,877
Issuance of common stock related to employee stock purchase plan		—			—			29,237			—		832		—			—			832
Issuance of common stock related to vesting of restricted stock units		—			—			1,681			—		—		—			—			—
Vesting of early exercised stock options		—			—			—			—		199		—			—			199
Repurchases of early exercised stock		—			—			(18,158	)		—		—		—			—			—
Stock-based compensation expense		—			—			—			—		8,886		—			—			8,886
Net unrealized gain on marketable securities		—			—			—			—		—		42			—			42
Net loss		—			—			—			—		—		—			(108,159	)		(108,159	)
Balance at December 31, 2020		—			—			66,599,748		$	7	$	740,098	$	116		$	(265,545	)	$	474,676
Issuance of common stock pursuant to stock option exercises		—			—			388,695			—		1,487		—			—			1,487
Issuance of common stock related to employee stock purchase plan		—			—			75,991			—		1,875		—			—			1,875
Issuance of common stock related to vesting of restricted stock units		—			—			78,010			—		—		—			—			—
Vesting of early exercised stock options		—			—			—			—		148		—			—			148
Repurchases of early exercised stock		—			—			(5,793	)		—		—		—			—			—
Issuance of common stock from follow-on offering, net of offering costs of $18,855		—			—			6,666,666			1		281,144		—			—			281,145
Issuance of common stock from at-the-market offering		—			—			339,302			—		10,096		—			—			10,096
Stock-based compensation expense		—			—			—			—		20,724		—			—			20,724
Net unrealized loss on marketable securities		—			—			—			—		—		(492	)		—			(492	)
Net loss		—			—			—			—		—		—			(187,091	)		(187,091	)
Balance at December 31, 2021		—			—			74,142,619		$	8	$	1,055,572	$	(376	)	$	(452,636	)	$	602,568
Issuance of common stock pursuant to stock option exercises		—			—			249,544			—		1,481		—			—			1,481
Issuance of common stock upon follow-on offering, net of offering costs of $16,374		—			—			13,225,000			1		248,125		—			—			248,126
Issuance of common stock related to vesting of restricted stock units		—			—			278,848			—		—		—			—			—
Issuance of common stock related to employee stock purchase plan		—			—			130,327			—		1,864		—			—			1,864
Issuance of common stock from at-the-market offering		—			—			2,385,846			—		49,919		—			—			49,919
Repurchases of early exercised stock		—			—			(272	)		—		—		—			—			—
Vesting of early exercised stock options		—			—			—			—		143		—			—			143
Stock-based compensation expense		—			—			—			—		31,196		—						31,196
Net unrealized loss on marketable securities		—			—			—			—		—		(1,404	)		—			(1,404	)
Net loss		—			—			—			—		—		—			(248,705	)		(248,705	)
Balance at December 31, 2022		—		$	—			90,411,912		$	9	$	1,388,300	$	(1,780	)	$	(701,341	)	$	685,188

The accompanying notes are an integral part of these Consolidated Financial Statements.

REVOLUTION MEDICINES, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)


	Year Ended December 31,
	2022			2021			2020
Cash flows from operating activities
Net loss	$	(248,705	)	$	(187,091	)	$	(108,159	)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on disposal of fixed assets	19				119			—
Amortization of intangible assets		1,069			1,069			1,068
Stock-based compensation expense		31,196			20,724			8,886
Depreciation and amortization		3,972			3,083			2,611
Net amortization of premium (discount) on marketable securities		(3,078	)		3,012			968
Amortization of operating lease right-of-use asset		4,615			3,180			2,866
Changes in operating assets and liabilities:
Accounts receivable		1,256			464			2,344
Prepaid expenses and other current assets		(3,779	)		198			(1,924	)
Accounts payable		7,288			2,239			305
Accrued expenses and other current liabilities		1,502			8,720			4,855
Deferred revenue		(14,472	)		(1,661	)		(11,259	)
Operating lease liability		(2,428	)		(1,468	)		(2,565	)
Deferred tax liability		(419	)		—			(375	)
Other noncurrent assets		(2,247	)		81			139
Other noncurrent liabilities		(190	)		151			176
Net cash used in operating activities		(224,401	)		(147,180	)		(100,064	)
Cash flows from investing activities
Purchases of marketable securities		(612,769	)		(671,335	)		(544,133	)
Maturities of marketable securities		599,469			526,754			309,828
Sales of marketable securities		—			8,992			3,005
Purchases of property and equipment		(10,816	)		(6,528	)		(2,933	)
Net cash used in investing activities		(24,116	)		(142,117	)		(234,233	)
Cash flows from financing activities
Proceeds from issuance of common stock, net of issuance costs		248,126			281,145			420,067
Proceeds from issuance of common stock from at-the-market offering		49,919			10,096			—
Proceeds from issuance of common stock under equity incentive plans		1,481			1,487			1,877
Proceeds from issuance of common stock related to employee stock purchase plan		1,864			1,875			832
Payments of deferred offering costs		42			(424	)		—
Net cash provided by financing activities		301,432			294,179			422,776
Net increase in cash, cash equivalents and restricted cash		52,915			4,882			88,479
Cash, cash equivalents and restricted cash - beginning of year		110,234			105,352			16,873
Cash, cash equivalents and restricted cash - end of year	$	163,149		$	110,234		$	105,352
Reconciliation of cash, cash equivalents and restricted cash to consolidated balance sheets
Cash and cash equivalents		161,412			108,497			104,268
Restricted cash		1,737			1,737			1,084
Cash, cash equivalents and restricted cash - end of period	$	163,149		$	110,234		$	105,352
Supplemental disclosure of non-cash investing and financing activities
Vesting of early exercised options and restricted stock	$	143		$	149		$	199
Purchases of property and equipment in accounts payable and accrued expenses and other current liabilities		1,419			1,129			1,813
Advance payments for property and equipment		82			—			—
Right-of-use assets obtained in exchange for operating lease liabilities		—			35,437			21,188
Unpaid deferred offering costs		2			110			—

The accompanying notes are an integral part of these Consolidated Financial Statements.

100

REVOLUTION MEDICINES, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Organization

Revolution Medicines, Inc. (the Company) is a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers. The Company was founded in October 2014 and is headquartered in Redwood City, California.

Liquidity

The Company has incurred net operating losses in each year since inception. As of December 31, 2022, the Company had an accumulated deficit of $701.3 million. Management believes that its existing cash, cash equivalents and marketable securities will enable the Company to fund its planned operations for at least 12 months following the issuance date of these consolidated financial statements. The Company has been able to fund its operations through the issuance and sale of common stock and redeemable convertible preferred stock in addition to upfront payments and research and development cost reimbursement received under the Company’s collaboration agreement with Genzyme Corporation, an affiliate of Sanofi. Future capital requirements will depend on many factors, including the timing and extent of spending on research and development. There can be no assurance that, in the event the Company requires additional financing, such financing will be available at terms acceptable to the Company, if at all. Failure to generate sufficient cash flows from operations, raise additional capital and reduce discretionary spending should additional capital not become available could have a material adverse effect on the Company’s ability to achieve its business objectives.

Public offerings

In February 2021, the Company issued and sold 6,666,666 shares of its common stock in an underwritten public offering at a price of $45.00 per share (including the exercise in full by the underwriters of their option to purchase an additional 869,565 shares of its common stock) for net proceeds of $281.1 million, after deducting underwriting discounts and commissions of $18.0 million and expenses of $0.9 million.

In November 2021, the Company entered into a sales agreement with Cowen and Company, LLC (Cowen) to sell shares of its common stock, from time to time, with aggregate gross proceeds of up to $250 million, through an at-the-market equity offering program (ATM). During the year ended December 31, 2021, the Company sold an aggregate of 339,302 shares of common stock under the ATM resulting in gross proceeds of $10.4 million. After deducting commissions and expenses of $0.3 million, net proceeds to the Company for the year ended December 31, 2021 were $10.1 million. During the year ended December 31, 2022, the Company sold an aggregate of 2,385,846 shares of common stock under the ATM resulting in gross proceeds of $51.3 million. After deducting commissions and expenses of $1.4 million, net proceeds to the Company for the year ended December 31, 2022 were $49.9 million.

In July 2022, the Company issued and sold 13,225,000 shares of its common stock in an underwritten public offering (including the exercise in full by the underwriters of their option to purchase an additional 1,725,000 shares of the Company’s common stock) at a price to the public of $20.00 per share, for net proceeds of $248.1 million, after deducting underwriting discounts and commissions of $15.9 million and expenses of $0.5 million.

Summary of significant accounting policies

Basis of presentation

The consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (GAAP) and applicable rules of the Securities and Exchange Commission (SEC) regarding financial reporting and, in the opinion of management, include all normal and recurring adjustments which are necessary to state fairly the Company’s financial position and results of operations for the reported periods. The consolidated financial statements for the years ended December 31, 2022, 2021 and 2020 include the accounts of the Company and its wholly owned subsidiary, Warp Drive Bio, Inc. (Warp Drive). All intercompany balances and transactions have been eliminated in consolidation. The functional and reporting currency of the Company and its subsidiary is the U.S. dollar.

101

Reverse stock split

On February 7, 2020, the Company amended and restated its amended and restated certificate of incorporation to effect a 1-for-4.8661 reverse stock split of the Company’s common stock and redeemable convertible preferred stock. The par value and authorized shares of the common stock and redeemable convertible preferred stock were not adjusted as a result of the reverse stock split. All issued and outstanding common stock, options to purchase common stock and per share amounts contained in the financial statements have been retroactively adjusted to give effect to the reverse stock split for all periods presented.

Use of estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, clinical accruals, valuation of in-process research and development and developed technologies, income taxes, useful lives of property and equipment and intangible assets, impairment of goodwill and intangibles, the incremental borrowing rate for determining operating lease assets and liabilities, and stock-based compensation. The extent to which the COVID-19 pandemic may directly or indirectly impact the Company’s business, financial condition and results of operations is highly uncertain and subject to change. The Company considered the potential impact of the COVID-19 pandemic on its estimates and assumptions and there was not a material impact to the Company’s consolidated financial statements as of and for the twelve months ended December 31, 2022. Actual results could materially differ from the Company’s estimates, and there may be changes to the estimates in future periods.

Cash and cash equivalents

The Company considers all highly liquid investments purchased with original maturities of three months or less at the date of purchase to be cash equivalents. As of December 31, 2022 and 2021, cash equivalents consist of amounts invested in money market funds, commercial paper and corporate bonds with original maturities of three months or less at the date of purchase.

Marketable securities

Investments in marketable securities primarily consist of U.S. government debt securities, U.S. government agency bonds, commercial paper, Canadian government securities and corporate bonds. The Company has classified its marketable securities as available-for-sale and may sell these securities prior to their stated maturities. The Company views these marketable securities as available to support current operations and classifies marketable securities with maturities beyond 12 months as current assets. The Company’s investments in marketable securities are carried at estimated fair value, which is derived from independent pricing sources based on quoted prices in active markets for similar securities. Unrealized gains and losses are reported as a component of accumulated other comprehensive loss. The amortized cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the consolidated statements of operations. Realized gains and losses are included in interest income on the consolidated statements of operations.

The Company periodically evaluates its investments to assess whether those with unrealized loss positions are other than temporarily impaired. The Company considers various factors in determining whether to recognize an impairment charge. If the Company determines that the decline in an investment’s fair value is other-than-temporary, the difference is recognized as an impairment loss in the consolidated statements of operations. As of December 31, 2022, no other-than-temporary-impairment has been recorded.

Restricted cash

As of December 31, 2022 and 2021, the Company had $1.7 million and $1.7 million, respectively, of noncurrent restricted cash related to Company issued letters of credit in connection with leases. These amounts are held in separate bank accounts to support letter of credit agreements for the leases.

Concentration of credit risk and other risks and uncertainties

Financial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents and marketable securities. The Company’s cash is held by two financial institutions in the United States, which management believes to be of high credit quality. The Company invests in money market funds, U.S. government debt securities, U.S. government agency bonds, commercial paper and corporate bonds. The Company has not experienced any losses on its deposits of cash and cash equivalents.

102

The Company is subject to credit risk as its receivable and collaboration revenue are entirely related to its collaboration agreement with Sanofi. For more information, see Note 8, “Sanofi collaboration agreement.”

The Company’s clinical trial sites may be affected by the COVID-19 outbreak due to prioritization of hospital resources toward the COVID-19 outbreak, travel or quarantine restrictions imposed by governments, and the inability to access sites for initiation and patient monitoring and enrollment. As a result, patient screening, new patient enrollment, monitoring and data collection may be affected or delayed. The Company is aware that several clinical sites involved in its clinical studies temporarily stopped or delayed enrolling new patients, with exemptions if appropriate, and it is possible that these or other clinical sites may be similarly affected in the future. These developments may delay the Company’s clinical trial timelines. Some of the Company’s third-party manufacturers which it uses for the supply of materials for product candidates or other materials necessary to manufacture product to conduct preclinical tests and clinical trials and contract research organizations may be impacted by COVID-19, and should they experience disruptions, such as temporary closures or suspension of services, the Company would likely experience delays in advancing clinical trials.

Fair value measurement

The carrying amounts of the Company’s certain financial instruments, including cash equivalents, accounts payable and accrued expenses and other current liabilities approximate fair value due to their relatively short maturities and market interest rates, if applicable. For more information, refer to Note 4 regarding the fair value of the Company’s available-for-sale securities.

Assets and liabilities recorded at fair value on a recurring basis in the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:

Level 1—Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;

Level 2—Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active; and

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Property and equipment, net

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed on a straight-line basis over the estimated useful lives of the related assets, which is generally three to five years. Leasehold improvements are amortized using the straight-line method over the shorter of the assets’ estimated useful lives or the remaining term of the lease. Maintenance and repairs are charged to operations as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is reflected in the consolidated statement of operations.

Useful lives of property and equipment are as follows:


Property and equipment		Estimated useful life
Laboratory equipment		4-5 years
Leasehold improvements		Lesser of estimated useful life or remaining lease term
Computer equipment and software		3 years
Furniture and fixtures		5 years

103

Leases

The Company determines if an arrangement is, or contains, a lease at inception and then classifies the lease as operating or financing based on the underlying terms and conditions of the contract. Leases with terms greater than one year are initially recognized on the balance sheet as right-of-use assets and lease liabilities based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the rate incurred to borrow, on a collateralized basis, an amount equal to the lease payments over a similar term and in a similar economic environment of the applicable country or region. Variable lease payments are excluded from the right-of-use assets and operating lease liabilities and are recognized in the period in which the obligation for those payments is incurred. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets.

Impairment of long-lived assets

Long-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Recoverability is measured by comparison of the carrying amounts of the asset group to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable, and the carrying amount exceeds the projected discounted future cash flows arising from these assets. There were no impairments of long-lived assets for any of the periods presented.

Acquired intangible assets

Indefinite-lived intangible assets represent the estimated fair value assigned to in-process research and development (IPR&D) acquired in a business combination. The Company reviews indefinite-lived intangible assets for impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying value of the assets might not be recoverable. If the carrying value of an indefinite-lived intangible asset exceeds its fair value, then it is written down to its adjusted fair value. As of December 31, 2022, there have been no such impairments. For IPR&D, if a product candidate derived from the indefinite-lived intangible asset is developed and commercialized, the useful life will be determined, and the carrying value will be amortized prospectively over that estimated useful life. Alternatively, if a product candidate is abandoned, the carrying value of the intangible asset will be charged to research and development expenses in the consolidated statements of operations.

Finite-lived intangible assets acquired in a business combination are recognized separately from goodwill and are initially recognized at their fair value at the acquisition date and are carried at cost less accumulated amortization and impairment. Amortization is computed using the straight-line method over the estimated useful lives of the respective finite-lived intangible assets and is included in research and development expenses in the consolidated statement of operations. Intangible assets are reviewed for impairment at least annually or more frequently if indicators of potential impairment exist. As of December 31, 2022, no such impairment has been recorded.

Goodwill

Goodwill represents the excess of the purchase price over the estimated fair value of the net tangible and intangible assets acquired in a business combination. The Company reviews goodwill for impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying value of goodwill may not be recoverable. Goodwill is tested for impairment at the reporting unit level by first assessing the qualitative factors to determine whether it is more likely than not that the fair value of the Company’s single reporting unit is less than its carrying amount. Qualitative indicators assessed include consideration of macroeconomic, industry and market conditions, the Company’s overall financial performance and personnel or strategy changes. Based on the qualitative assessment, if it is determined that it is more likely than not that its fair value is less than its carrying amount, the fair value of the Company’s single reporting unit is compared to its carrying value. Any excess of the goodwill carrying amount over the fair value is recognized as an impairment loss, and the carrying value of goodwill is written down to fair value. As of December 31, 2022, no goodwill impairment has been identified.

104

Redeemable convertible preferred stock

The Company records all shares of redeemable convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. The redeemable convertible preferred stock is recorded outside of permanent equity because while it is not mandatorily redeemable, in the event of certain events considered not solely within the Company’s control, such as a merger, acquisition or sale of all or substantially all of the Company’s assets (each, a deemed liquidation event), the redeemable convertible preferred stock would have become redeemable at the option of the holders of at least a majority of the then outstanding such shares. The Company did not adjust the carrying values of the redeemable convertible preferred stock to the liquidation preferences of such shares because it was uncertain whether or when a deemed liquidation event would occur that would obligate the Company to pay the liquidation preferences to holders of shares of redeemable convertible preferred stock.

Revenue recognition

The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

The Company enters into collaboration agreements under which it may obtain upfront license fees, research and development funding, and development, regulatory and commercial milestone payments and royalty payments. The Company’s performance obligations under these arrangements may include licenses of intellectual property, sales and distribution rights, research and development services, delivery of manufactured product and/or participation on joint steering committees.

Licenses of intellectual property: If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from upfront license fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring proportional performance for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of proportional performance each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.

Research, development and regulatory milestone payments: At the inception of each arrangement that includes research, development, or regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. The Company uses the most likely amount method for research, development and regulatory milestone payments. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.

105

Sales-based milestones and royalties: For arrangements that include sales-based milestone or royalty payments based on the level of sales, and in which the license is deemed to be the predominant item to which the sales-based milestone or royalties relate to, the Company recognizes revenue in the period in which the sales-based milestone is achieved and in the period in which the sales associated with the royalty occur. To date, the Company has not recognized any sales-based milestone or royalty revenue resulting from its collaboration arrangements.

Deferred revenue represents amounts received by the Company for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. The current portion of deferred revenue represents the amount to be recognized within one year from the balance sheet date based on the estimated performance period of the underlying performance obligation. The noncurrent portion of deferred revenue represents amounts to be recognized after one year through the end of the performance period of the performance obligation.

Research and development expenditures

Research and development expenses consist of costs incurred for the Company’s own and for collaborative research and development activities. Research and development costs are expensed as incurred. Research and development costs consist of salaries and benefits, including associated stock-based compensation, and laboratory supplies and facility costs, as well as fees paid to other entities that conduct certain research and development activities on the Company’s behalf. The Company estimates preclinical studies and clinical trial expenses based on the services performed pursuant to contracts with research institutions, contract research organizations and clinical manufacturing organizations that conduct and manage preclinical studies and clinical trials on the Company’s behalf based on actual time and expenses incurred by them. Further, the Company accrues expenses related to clinical trials based on the level of patient activity according to the related agreement. The Company monitors patient enrollment levels and related activity to the extent reasonably possible and adjusts estimates accordingly.

Stock-based compensation

The Company measures its stock-based awards granted to employees and directors based on the estimated fair values of the awards and recognizes the compensation on a straight-line basis over the requisite service period. The fair value of options issued under the employee stock purchase plan is calculated using the Black-Scholes option-pricing model. Restricted stock units are valued based on the closing price of the Company’s common stock on the date of grant.

Comprehensive loss

For the years ended December 31, 2022, 2021 and 2020, other comprehensive loss includes net unrealized gains or losses on marketable securities.

Income taxes

Income taxes are accounted for under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Management makes an assessment of the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company’s historical operating performance and the recorded cumulative net losses in prior fiscal periods, the net deferred tax assets have been fully offset by a valuation allowance.

The Company recognizes uncertain income tax positions at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Changes in recognition or measurement are reflected in the period in which judgment occurs. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of interest expense.

106

Net loss per share attributable to common stockholders

Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock, stock options, common stock subject to repurchase related to unvested restricted stock awards and early exercise of stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities as the redeemable convertible preferred stock is considered a participating security because it participates in dividends with common stock. The Company also considers the shares issued upon the early exercise of stock options subject to repurchase to be participating securities because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. The holders of all series of redeemable convertible preferred stock and the holders of early exercised shares subject to repurchase do not have a contractual obligation to share in the Company’s losses. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for all periods presented, diluted net loss per share is the same as basic net loss per share for those periods.

Deferred offering costs

The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders’ deficit (equity) as a reduction of additional paid-in capital generated as a result of the equity financing. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations. As of December 31, 2022 and 2021, $0.6 million and $0.5 million of deferred offering costs, respectively, were capitalized in other noncurrent assets on the consolidated balance sheets.

Segment reporting

The Company has one operating and reportable segment. The Company’s chief operating decision maker, its Chief Executive Officer, manages the Company’s operations on a consolidated basis for the purposes of allocating resources and evaluating financial performance. All of the Company’s long-lived assets are located in the United States.

401(k) retirement plans

The Company maintains a 401(k) retirement plan for its employees. The Company is responsible for administrative costs of the 401(k) plan. The Company may, at its discretion, make matching or profit-sharing contributions to the 401(k) plan. For the years ended December 31, 2022, 2021 and 2020, the Company made $1.3 million, $0.9 million and $0.2 million matching contributions, respectively, under the plan.

Recent accounting pronouncements

From time to time, new accounting pronouncements are issued by the FASB, under its ASC or other standard setting bodies, and adopted by the Company as of the specified effective date, unless otherwise discussed below.

Recently adopted accounting pronouncements

In October 2020, the FASB issued ASU 2020-08, Codification Improvements to Subtopic 310-20, Receivables-Nonrefundable Fees and Other Costs (ASU 2020-08). ASU 2020-08 clarifies that an entity should reevaluate whether a callable debt security is within the scope of ASC paragraph 310-20-35-33 for each reporting period. The guidance is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021. Early application is not permitted. All entities should apply ASU 2020-08 on a prospective basis as of the beginning of the period of adoption for existing or newly purchased callable debt securities. The Company adopted the standard for the fiscal year beginning on January 1, 2022 and concluded that adoption of the standard did not have a material impact on its consolidated financial statements.

In October 2020, FASB issued ASU 2020-10, Codification Improvements (ASU 2020-10). ASU 2020-10 updates various codification topics by clarifying or improving disclosure requirements to align with the SEC’s regulations. The amendments are effective for the Company for fiscal years beginning after December 15, 2021, including interim period within those fiscal years. Early

107

adoption is permitted. Adoption shall be applied retrospectively. The Company adopted the standard for the fiscal year beginning on January 1, 2022 and concluded that adoption of the standard did not have a material impact on its consolidated financial statements.

Fair value measurements

The following table presents information about the Company’s financial assets that are measured at fair value and indicates the fair value hierarchy of the valuation:


	December 31, 2022
	Total		Level 1		Level 2		Level 3
	(in thousands)
Assets:
Money market funds(1)	$	48,522	$	48,522	$	—	$	—
Commercial paper(1, 2)		313,928		—		313,928		—
U.S. and Canadian government and agency securities(2)		251,830		—		251,830		—
Corporate bonds(1, 2)		31,405		—		31,405		—
Total	$	645,685	$	48,522	$	597,163	$	—


	December 31, 2021
	Total		Level 1		Level 2		Level 3
	(in thousands)
Assets:
Money market funds(1)	$	57,134	$	57,134	$	—	$	—
Commercial paper(1, 2)		291,369		—		291,369		—
U.S. and Canadian government and agency securities(2)		87,745		—		87,745		—
Corporate bonds(2)		141,698		—		141,698		—
Total	$	577,946	$	57,134	$	520,812	$	—

(1)

Included in cash and cash equivalents on the consolidated balance sheets.

(2)

Included in marketable securities on the consolidated balance sheets.

Money market funds are measured at fair value on a recurring basis using quoted prices. U.S. and Canadian government debt securities, government agency bonds, commercial paper and corporate bonds are measured at fair value, which is derived from independent pricing sources based on quoted prices in active markets for similar securities.

There were no transfers between Levels 1, 2 or 3 for any of the periods presented.

Available-for-sale securities

The following tables summarize the estimated value of the Company’s available-for-sale marketable securities and cash equivalents and the gross unrealized gains and losses:


	December 31, 2022
			Gross		Gross
	Amortized		unrealized		unrealized				Estimated
	cost		gain		loss				fair value
	(in thousands)
Marketable securities:
Commercial paper	$	216,765	$	—	$	(328	)		$	216,437
U.S. and Canadian government and agency securities		236,916		43		(1,270	)			235,689
Corporate bonds		31,599		—		(194	)			31,405
Total marketable securities		485,280		43		(1,792	)			483,531
Cash equivalents:
Money market funds		48,522		—		—				48,522
Commercial paper		97,526		—		(35	)			97,491
Corporate bonds		16,137		4		—				16,141
Total cash equivalents		162,185		4		(35	)	—		162,154
Total available-for-sale investments	$	647,465	$	47	$	(1,827	)		$	645,685

108


	December 31, 2021
			Gross		Gross
	Amortized		unrealized		unrealized			Estimated
	cost		gain		loss			fair value
	(in thousands)
Marketable securities:
Commercial paper	$	239,176	$	1	$	(63	)	$	239,114
U.S. and Canadian government and agency securities		87,926		—		(181	)		87,745
Corporate bonds		141,829		—		(131	)		141,698
Total marketable securities		468,931		1		(375	)		468,557
Cash equivalents:
Money market funds		57,134		—		—			57,134
Commercial paper		52,257		—		(2	)		52,255
Total cash equivalents		109,391		—		(2	)		109,389
Total available-for-sale investments	$	578,322	$	1	$	(377	)	$	577,946

The amortized cost and estimated fair value of the Company’s available-for-sale marketable securities and cash equivalents by contractual maturity are summarized below as of December 31, 2022:


	December 31, 2022
			Gross			Gross
	Amortized		unrealized			unrealized			Estimated
	cost		gain			loss			fair value
	(in thousands)
Mature in one year or less	$	618,025	$	48		$	(1,752	)	$	616,321
Mature after one year through two years		29,440		(1	)		(75	)		29,364
Total marketable securities	$	647,465	$	47		$	(1,827	)	$	645,685

Balance sheet components

Property and equipment, net

Property and equipment, net consists of the following:


	December 31,
	2022			2021
	(in thousands)
Laboratory equipment	$	17,163		$	12,727
Leasehold improvements		11,404			7,245
Computer equipment and software		3,965			2,186
Furniture and fixtures		616			69
Construction in progress		—			129
		33,148			22,356
Less: accumulated depreciation and amortization		(14,489	)		(10,812	)
Property and equipment, net	$	18,659		$	11,544

109

Depreciation and amortization expense for property and equipment amounted to $4.0 million, $3.1 million and $2.6 million for the years ended December 31, 2022, 2021 and 2020, respectively.

Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consist of the following:


	December 31,
	2022		2021
	(in thousands)
Accrued compensation	$	13,281	$	9,852
Accrued research and development		15,161		17,018
Accrued professional services		499		540
Other		505		311
Total accrued expenses and other current liabilities	$	29,446	$	27,721

Intangible assets and goodwill

Intangible assets, net

Intangible assets, net consist of the following as of December 31, 2022:


	Gross value		Accumulated amortization			Net book value		Weighted- average remaining useful life
	(in thousands)							(in years)
In-process research and development — RAS Programs	$	55,800	$	—		$	55,800	n/a
Developed technology — tri-complex platform		7,480		(4,473	)		3,007		2.9
Total	$	63,280	$	(4,473	)	$	58,807

Amortization expense for the years ended December 31, 2022, 2021 and 2020 were $1.1 million, $1.1 million and $1.1 million, respectively.

As of December 31, 2022, future amortization expense is as follows:


	Amount
	(in thousands)
2023	$	1,069
2024		1,068
2025		870
Total	$	3,007

Intangible assets, net consist of the following as of December 31, 2021:


	Gross value		Accumulated amortization			Net book value		Weighted- average remaining useful life
	(in thousands)							(in years)
In-process research and development — RAS Programs	$	55,800	$	—		$	55,800	n/a
Developed technology — tri-complex platform		7,480		(3,404	)		4,076		3.9
Total	$	63,280	$	(3,404	)	$	59,876

110

Goodwill

Goodwill consists of the following:


	Amount
	(in thousands)
Balance at December 31, 2021	$	14,608
Adjustment		—
Balance at December 31, 2022	$	14,608

No impairment has been recognized as of December 31, 2022. Goodwill is not deductible for income tax purposes.

Commitments and contingencies

Leases

In January 2015, as amended in September 2016, the Company entered into an operating lease for approximately 42,000 square feet of office and laboratory space located at 700 Saginaw Drive, Redwood City, California (the 700 Building), with a term through April 2023. In April 2020, the Company amended the lease to lease an additional 19,000 square feet of office, laboratory and research and development space located at 300 Saginaw Drive, Redwood City, California (the 300 Building), and to extend the lease term through December 2030. In November 2021, the Company amended the lease to lease an additional 41,000 square feet of office, laboratory and research and development space located at 800 Saginaw Drive, Redwood City, California (the 800 Building), and to extend the lease term through November 2033. The Company has the option to extend the lease for an additional ten years after November 30, 2033.

The Company maintains letters of credit for the benefit of the landlord which is disclosed as restricted cash in the consolidated balance sheets. Restricted cash related to letters of credit due to the landlord was $1.5 million and $1.5 million as of December 31, 2022 and December 31, 2021, respectively.

Through December 31, 2022, the landlord had provided the Company with $3.4 million in tenant improvement allowances for the 700 Building, and $4.6 million for the 300 building, which were recognized as lease incentives. The lease incentives are being amortized as an offset to rent expense over the lease term in the consolidated statements of operations.

Upon the execution of the lease in April 2020, which was deemed to be a lease modification, the Company re-evaluated the assumptions used during the adoption of ASC 842 for the lease. The Company determined the amendment consists of two separate contracts under ASC 842. One contract is related to a new right-of-use asset for the 300 Building, which is being accounted for as an operating lease, and the other is related to the modification of the original lease term for the 700 Building. As a result, the Company recorded a right-of-use asset of $6.4 million and a lease liability of $9.0 million for the 300 Building and an increase of $14.8 million to the right-of-use asset and lease liability for the 700 Building upon execution of the lease amendment. The Company is recognizing rent expense for both buildings on a straight-line basis through the remaining extended term of the lease.

Upon the execution of the lease amendment in November 2021, which was deemed to be a lease modification, the Company re-evaluated the assumptions used during the lease amendment in April 2020. The Company determined the amendment consists of two separate contracts under ASC 842. One contract is related to a new right-of-use asset for the 800 Building, which is being accounted for as an operating lease, and the other is related to the modification of the lease term, as amended in April 2020, for the 700 Building and 300 Building. As a result, the Company recorded a right-of-use asset and a lease liability of $26.8 million for the 800 Building and an aggregate increase of $8.6 million to the right-of-use assets and lease liabilities for the 700 Building and 300 Building upon execution of the lease amendment. The Company is recognizing rent expense for the buildings on a straight-line basis through the remaining extended term of the lease.

As part of the Warp Drive acquisition in October 2018, the Company assumed an operating lease for approximately 22,000 square feet of office and laboratory space located in Cambridge, Massachusetts (Cambridge Lease), which expires in February 2023, with an option to extend the term through February 2028, subject to certain conditions. In March 2019, the Company fully subleased the Cambridge Lease to Casma Therapeutics, Inc. (Casma), a related party, on financial terms substantially the same as the original lease. The sublease term with Casma is through the remainder of the Cambridge Lease term. The sublease by Casma and related sublease payments by Casma to the Company are fully guaranteed by Third Rock Ventures, LLC, a related party. In conjunction with the Cambridge Lease, the Company issued a letter of credit for $0.2 million, which is included in restricted cash on the consolidated balance sheets as of December 31, 2022 and 2021.

111

The balance sheet classification of the Company’s operating lease liabilities was as follows:


	December 31,
	2022
	(in thousands)
Operating lease liabilities:
Operating lease liability – current	$	6,773
Operating lease liability – noncurrent		57,432
Total operating lease liabilities	$	64,205

For the years ended December 31, 2022 and 2021, operating lease cost was $6.4 million and $3.4 million, respectively, net of sublease income of $2.5 million and $2.1 million, respectively. The operating cash flows for operating leases were $2.4 million and $1.5 million year ended December 31, 2022 and 2021, respectively. Short-term lease costs were immaterial for the years ended December 31, 2022 and 2021.

As of December 31, 2022, the maturities of the Company’s operating lease liabilities were as follows (in thousands):




2023	$	6,961
2024		7,100
2025		7,349
2026		7,606
2027		7,872
Thereafter		52,550
Total undiscounted lease payments	$	89,438
Less: Imputed interest		(25,233	)
Less: Tenant improvement allowance		—
Total operating lease liabilities	$	64,205

The amounts reflected in the table above include the Company’s lease payments for the Cambridge lease, but do not reflect any offset for the sublease payments the Company is entitled to receive from Casma.

Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company uses its incremental borrowing rate. The weighted-average discount rate used to determine the operating lease liability was 6.1%. As of December 31, 2022 and 2021, the weighted-average remaining lease term is 10.9 years and 11.6 years, respectively.

Legal matters

From time to time, the Company may be involved in litigation related to claims that arise in the ordinary course of its business activities. The Company accrues for these matters when it is probable that losses will be incurred and these losses can be reasonably estimated. As of December 31, 2022 and 2021, the Company does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company’s financial position, results of operations or cash flows.

Indemnification

The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these arrangements is not determinable. The Company has not incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the Company believes the fair value of these agreements is minimal.

112

Other

The Company enters into agreements in the ordinary course of business with contract research organizations for clinical trials, contract manufacturing organizations to provide clinical trial materials and with vendors for preclinical studies and other services and products for operating purposes which are generally cancelable at any time by us upon 30 to 90 days prior written notice.

Sanofi collaboration agreement

In June 2018, the Company entered into a collaborative research, development and commercialization agreement (the Sanofi Agreement) with Aventis, Inc. (an affiliate of Sanofi) to research and develop SHP2 inhibitors, including RMC-4630, for any indications. The Sanofi Agreement was assigned to Genzyme Corporation, a Sanofi affiliate, in December 2018. For the purposes of this discussion, we refer to Genzyme Corporation as Sanofi. Pursuant to the Sanofi Agreement, the Company granted Sanofi a worldwide, exclusive, sublicensable (subject to the Company’s consent in certain circumstances) license under certain of the Company’s patents and know-how to research, develop, manufacture, use, sell, offer for sale, import and otherwise commercialize SHP2 inhibitors, including RMC-4630, for any and all uses, subject to the Company’s exercise of rights and performance of obligations under the Sanofi Agreement. In December 2022, the Company received notice of Sanofi’s decision to terminate for convenience under the Sanofi Agreement, with a termination date in June 2023. Upon effectiveness of the termination of the Sanofi Agreement (the termination date), the licenses granted to Sanofi thereunder shall become fully paid-up, royalty-free, perpetual and irrevocable and all rights and obligations of Sanofi under the Sanofi Agreement will revert to the Company.

In October 2018, the Company acquired Warp Drive in exchange for issuance of shares of the Company’s Series B redeemable convertible preferred stock and payment of cash. Sanofi was a stockholder of Warp Drive and received the Company’s Series B redeemable convertible preferred stock during the transaction and accordingly became an investor and related party of the Company. As a result of the Company’s underwritten offering of common stock in February 2021, Sanofi’s ownership percentage in the Company decreased and Sanofi is no longer considered a related party.

Under the Sanofi Agreement, the Company received a non-refundable, upfront cash payment of $50 million in July 2018.

Prior to the termination date, the Company has primary responsibility for early clinical development of RMC-4630 and is responsible for the manufacture of SHP2 inhibitors for Phase 1 and non-registrational Phase 2 clinical trials pursuant to an approved development plan. In August 2021, the Company entered into a letter agreement with Sanofi (the Letter Agreement) to include an additional clinical study, RMC-4630-03, as part of the Company’s responsibilities under the development plan. Sanofi is responsible to reimburse the Company all internal and external costs and expenses to perform the Company’s activities under approved development plans up to the termination date, except for the RMC-4630-03 study, for which Sanofi will reimburse the Company for 50% of the costs and expenses up to the termination date.

In addition to the ongoing development plan, the Company was also primarily responsible for performing preclinical research on SHP2 inhibitors pursuant to a research plan through 2021. Sanofi was responsible to reimburse the Company for all internal and external costs and expenses incurred to perform activities under approved research plan for 2021.

The Company identified the following promises in the agreement (1) the license related to SHP2 inhibitors, (2) the performance of research and development services for Phase 1 clinical studies and Phase 2 clinical trials that are non-registrational clinical trials and (3) the performance of manufacturing services for the non-registrational clinical trials. The Company determined that the license is not distinct from the services within the context of the agreement because the research, development and manufacturing significantly increase the utility of the intellectual property. The intellectual property (IP) related to SHP2 inhibitors, which is proprietary to the Company, is the foundation for the research and development activities. The manufacturing services are a necessary and integral part of the research and development services as they could only be conducted utilizing the outcomes of these services. Given the research and development services under the Sanofi Agreement are expected to involve significant further development of the initial IP, the Company has concluded that the research, development and manufacturing services are not distinct from the license, and thus the license, research and development services and manufacturing services are combined into a single performance obligation.

For revenue recognition purposes, the Company determined that the duration of the contract begins on the effective date of the Sanofi Agreement in July 2018 and ends on the termination date in June 2023.

113

The Company determined that the transaction price of the Sanofi Agreement was $186.9 million as of December 31, 2022. In order to determine the transaction price, the Company evaluated all the payments to be received during the duration of the contract. The Company determined that the $50.0 million upfront payment and $136.9 million of estimated variable consideration for expense reimbursements from Sanofi for agreed upon research and development services as of December 31, 2022 constituted consideration to be included in the transaction price, which is to be allocated to the combined performance obligation. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.

The license, research, development and manufacturing services are combined as one performance obligation that will be performed over the duration of the contract, which is from the effective date of the Sanofi Agreement through the termination date. The Company concluded that it would utilize a cost-based input method to measure proportional performance and to calculate the corresponding amount of revenue to recognize. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to estimated costs to fulfill the combined performance obligation. These costs consist primarily of internal full-time equivalent efforts and third-party costs. As noted above, a percentage of the actual costs incurred under approved research and development plans are reimbursed by Sanofi under the collaboration agreement. The research and development plans are determined by a joint research and development committee, over which Sanofi has final decision-making subject to certain exceptions. Revenue is recognized under the collaboration agreement with Sanofi, based on actual costs incurred as a percentage of total estimated costs to be incurred over the performance obligation as the Company completes its performance obligation. The cumulative effect of revisions to estimated costs to complete the Company’s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated.

Pursuant to the termination noticed provided by Sanofi in December 2022, effective as of the termination date, Sanofi will have no further reimbursement obligations post termination. As a result of the termination and development plan adjustments during the year, the Company updated the accounting transaction price for the estimated consideration to be received and updated the estimated costs to fulfill the performance obligation, which increased the Company’s percentage of completion under the agreement with Sanofi, and resulted in total cumulative catch-up adjustments that increased collaboration revenue by $3.0 million for the year ended December 31, 2022.

As a result of entering into the Letter Agreement for the RMC-4630-03 study in August 2021, the Company updated the transaction price for the estimated consideration to be received, and updated the estimated costs to fulfill the performance obligation, which decreased the estimated percentage of completion to date and resulted in a cumulative catch-up adjustment that reduced collaboration revenue by $8.5 million for the year ended December 31, 2021.

During the years ended December 31, 2022, 2021 and 2020, the Company recognized $35.4 million, $29.4 million and $43.0 million of collaboration revenue associated with this agreement, respectively.

As of December 31, 2022 and 2021, $4.5 million and $12.4 million of deferred revenue is classified as current and zero and $6.6 million is classified as noncurrent, respectively.

114

Redeemable convertible preferred stock

Upon the closing of the Company’s initial public offering in February 2020, all shares of redeemable convertible preferred stock then outstanding converted into 39,600,423 shares of common stock. There were no shares of redeemable convertible preferred stock outstanding as of December 31, 2022 and 2021.

10.

Common stock

As of December 31, 2022 and 2021, the Company’s certificate of incorporation authorized the Company to issue 300,000,000 shares of common stock, at a par value of $0.0001 per share. Each share of common stock is entitled to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to prior rights of the redeemable convertible preferred stockholders. As of December 31, 2022, no dividends have been declared to date.

The Company has reserved shares of common stock for future issuance as follows:


	December 31,		December 31,
	2022		2021
Outstanding options to purchase common stock		8,164,375		6,050,938
Unvested restricted stock units of common stock		1,175,032		423,621
Available for future issuance under the 2020 Incentive Award Plan		6,726,307		6,403,548
Available for issuance under the 2020 Employee Stock Purchase Plan		1,700,887		1,089,728
Total		17,766,601		13,967,835

11.

Stock-based compensation

2020 Incentive Award Plan

In February 2020, the Company adopted the 2020 Equity Incentive Plan (the 2020 Plan). The 2020 Plan became effective on February 11, 2020. The 2020 Plan provides for a variety of stock-based compensation awards, including stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance bonus awards, performance stock unit awards, dividend equivalents, or other stock or cash based awards. Under the 2020 Plan, the Company generally grants stock-based awards with service-based vesting conditions only. Options and restricted stock unit awards granted typically vest over a four-year period, but may be granted with different vesting terms.

Following the effectiveness of the 2020 Plan, the Company will not make any further grants under the 2014 Equity Incentive Plan (the 2014 Plan). However, the 2014 Plan will continue to govern the terms and conditions of the outstanding awards granted under it. Shares of common stock subject to awards granted under the 2014 Plan that are forfeited or lapse unexercised and which following the effective date of the 2020 Plan were not issued under the 2014 Plan are available for issuance under the 2020 Plan.

2020 Employee Stock Purchase Plan

In February 2020, the Company adopted the 2020 Employee Stock Purchase Plan (the ESPP). Under the ESPP, employees have the ability to purchase shares of the Company’s common stock through payroll deductions at a discount during a series of offering periods of 24 months, each comprised of four six-month purchase periods. The purchase price will be the lower of 85% of the closing

115

trading price per share of the Company’s common stock on the first day of an offering period in which an employee is enrolled or 85% of the closing trading price per share on the purchase date, which will occur on the last trading day of each purchase period.

As of December 31, 2022, there have been 235,555 shares of common stock purchased under the ESPP. As of December 31, 2022, a total of 1,700,887 shares of common stock were available for future issuance under the ESPP. As of December 31, 2022, there was $3.2 million of unrecognized compensation cost related to the ESPP.

Stock options

The following summarizes option activity under both the 2020 Plan and the 2014 Plan:


	Number of Shares underlying options			Weighted- average exercise price		Weighted- average remaining contractual term		Aggregate intrinsic value
						(in years)		(in thousands)
Balance, December 31, 2021		6,050,938		$	14.88		7.74	$	83,953
Options granted		2,758,710			19.37
Options exercised		(249,544	)		6.12
Options cancelled		(395,729	)		26.78
Balance, December 31, 2022		8,164,375		$	16.09		7.53	$	85,181
Options vested and expected to vest as of December 31, 2022		8,164,375		$	16.09		7.53	$	85,181
Options vested and exercisable as of December 31, 2022		4,555,124		$	11.43		6.65	$	66,783

The aggregate intrinsic values of options outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the options and the estimated fair value of the Company’s common stock by the Board of Directors. The intrinsic value of the options exercised for the years December 31, 2022, 2021 and 2020 was $3.8 million, $13.1 million and $21.7 million, respectively.

During the years ended December 31, 2022, 2021 and 2020, the weighted-average grant-date fair value of options granted was $12.33, $25.13 and $15.59 per share, respectively. As of December 31, 2022, there was $48.8 million of unrecognized stock-based compensation expense related to unvested stock options that is expected to be recognized over a weighted-average period of 2.57 years.

The fair value of employee and director stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:


	Year Ended December 31,
	2022	2021	2020
Expected term (years)	6	6	6
Expected volatility	70-73%	70-75%	74-80%
Risk-free interest rate	1.5%-4.2%	0.5%-1.3%	0.2%-1.5%
Dividend yield	0%	0%	0%

Non-employee stock option awards were measured at fair value at each reporting period using a Black-Scholes option-pricing model with the following assumptions:


	Year Ended December 31,
	2022	2021	2020
Expected term (years)	6	6	6-10
Expected volatility	70-71%	70-75%	74-80%
Risk-free interest rate	1.6%-3.4%	0.9%-1.3%	1.2%-1.5%
Dividend yield	0%	0%	0%

116

The Black-Scholes model assumptions that determine the fair value of stock-based awards include:

Expected term—The expected term is calculated using the simplified method, which is available where there is insufficient historical data about exercise patterns and post-vesting employment termination behavior. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting-tranche for awards with graded vesting. The mid-point between the vesting date and the maximum contractual expiration date is used as the expected term under this method.

Expected volatility—Given the Company does not have sufficient trading history for its common stock, the expected volatility was estimated based on the average volatility of the Company and comparable publicly traded biotechnology companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on their similar size, stage in the life cycle or area of specialty.

Risk-free interest rate—The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.

Expected dividend—The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.

Restricted stock units

Restricted stock units (RSUs) have been granted to employees and directors. The fair value of an RSU award is based on the Company’s stock price on the date of grant. The shares underlying the RSU awards are not issued until the RSUs vest. Upon vesting, each RSU converts into one share of the Company’s common stock. The Company has granted RSUs pursuant to the 2020 plan.

Activity under the 2020 Plan with respect to the Company’s RSUs during the year ended December 31, 2022 was as follows:


	Number of Shares			Weighted- average grant date fair value per share		Weighted- average remaining contractual term		Aggregate intrinsic value
						(in years)		(in thousands)
Balance, December 31, 2021		423,621		$	37.16		3.16	$	10,663
Restricted stock units granted		1,142,366			19.43
Restricted stock units vested		(278,848	)		28.23
Restricted stock units forfeited		(112,107	)		24.58
Balance, December 31, 2022		1,175,032		$	23.25		1.62		27,989
Expected to vest as of December 31, 2022		1,175,032		$	23.25		1.62		27,989

The number of RSUs vested includes shares of common stock that the Company withheld to satisfy the minimum statutory tax withholding requirements. As of December 31, 2022, there was $25.8 million of total unrecognized compensation cost related to RSUs that is expected to be recognized over a weighted average period of 3.07 years.

The total fair value of RSUs vested for the years ended December 31, 2022, 2021 and 2020 was $7.9 million, $3.1 million and $0.1 million, respectively.

Stock-based compensation expense

Total stock-based compensation expense related to stock options, RSUs and the ESPP by function was as follows:


	Year Ended December 31,
	2022		2021		2020
	(in thousands)
Research and development	$	18,113	$	11,847	$	4,848
General and administrative		13,083		8,877		4,038
Total	$	31,196	$	20,724	$	8,886

Stock-based compensation related to options and RSUs granted to non-employees was $0.5 million, $0.7 million and $0.8 million for the years ended December 31, 2022, 2021 and 2020, respectively.

117

12.

Income taxes

The Company recorded an income tax benefit of 0.4 million and zero for the years ended December 31, 2022 and 2021, respectively, which reflects state tax rates applied to the indefinite lived intangibles recorded as part of the Company’s acquisition of Warp Drive Bio in 2018. The Company has incurred net pre-tax losses in the United States only for all periods presented. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the carrying amounts of existing assets and liabilities in the financial statements and their respective tax bases using tax rates expected to be in effect during the years in which the basis differences reverse.

The benefit from income taxes differs from the amount expected by applying the federal statutory rate to the loss before taxes as follows:


	Year Ended December 31,
	2022			2021
Federal statutory income tax rate		21.0	%		21.0	%
State income tax rate, net of federal benefit		9.4	%		8.9	%
Research tax credits		3.2	%		2.2	%
Change in valuation allowance		-32.4	%		-31.4	%
Non-deductible permanent expenses		-1.0	%		-0.5	%
Other		0.0	%		-0.2	%
Benefit from income taxes		0.2	%		0.0	%

Deferred income tax reflects the tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The categories that give rise to significant components of the deferred tax assets are as follows (in thousands):


	December 31,
	2022			2021
	(in thousands)
Deferred tax assets:
Net operating loss carryforwards	$	132,080		$	123,991
Accruals and reserves		5,494			9,164
Research and development credits		22,558			14,449
Lease liability		18,998			19,979
Stock-based compensation		7,063			3,829
Capitalized research expenses		64,149			—
Other		42			33
Gross deferred tax assets		250,384			171,445
Less: valuation allowance		(224,125	)		(143,474	)
Total deferred tax assets		26,259			27,971
Deferred tax liabilities:
Fixed assets and finite-lived intangible assets		(9,961	)		(10,073	)
Indefinite-lived intangible assets		(7,025	)		(7,444	)
Lease asset		—			—
Right-of-use asset		(16,298	)		(17,898	)
Gross deferred tax liabilities		(33,284	)		(35,415	)
Net deferred tax liability	$	(7,025	)	$	(7,444	)

The realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Due to the lack of earnings history, the net deferred tax assets have been offset by a valuation allowance excluding certain indefinite lived intangibles. The valuation allowance increased by $80.7 million and $58.8 million during the years ended December 31, 2022 and 2021, respectively. The Company had federal and state net operating loss carryforwards of $448.3 million and $445.5 million, respectively, as of December 31, 2022. The federal net operating loss carryforwards, if not utilized, will expire beginning in 2035, with the exception of $354.7 million in federal net operating loss carryforwards, which can be carried forward indefinitely. State net operating loss carryforwards, if not utilized, will expire beginning in 2035. Under the Tax Cuts and Jobs Act (the TCJA), federal net operating losses arising after December 31, 2017 do not expire and cannot be carried back. However, the TCJA limits the amount of federal net operating losses that can be used annually to 80% of taxable income for periods beginning after December 31, 2017. Existing federal net operating losses arising in years ending on or before December 31, 2017 are not affected by these provisions.

118

The Company also had federal and state research and development credit carryforwards of $20.6 million and $11.6 million, respectively, as of December 31, 2022. The federal credits will expire starting in 2034 if not utilized and the state research credits will expire beginning in 2031, with the exception of $10.7 million in California research credits, which can be carried forward indefinitely. Federal, California, Massachusetts and New Jersey tax laws impose significant restrictions on the utilization of net operating loss carryforwards in the event of a change in ownership of the Company, as defined by Internal Revenue Code Section 382 (Section 382). The Company performed a study in which it determined that it had experienced changes in ownership in 2014, 2018, and 2020 as defined by Section 382. No federal or state net operating losses are expected to expire unutilized as a result of the limitation, with the exception of $5.5 million in California net operating losses. The Company's deferred tax assets have been reduced by the amount of net operating loss carryforwards expected to expire due to the limitation. In addition, in the future the Company may experience ownership changes, which may limit the utilization of net operating loss carryforwards or other tax attributes.

The TCJA amended Internal Revenue Code Section 174 requiring capitalization of specified research and experimental expenditures paid or incurred in tax years beginning after December 31, 2021 and amortizing over a period of 5 or 15 years. This resulted in a deferred tax asset for capitalized research expenses in 2022. Also on August 16, 2022, the United States enacted the Inflation Reduction Act (the IRA), which contains among other things, numerous income tax provisions. At this time, the Company does not anticipate the IRA to have a material impact on its financial statements.

A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:


	December 31,
	2022			2021
	(in thousands)
Beginning balance	$	5,143		$	3,593
Changes related to tax positions taken in the prior year		(7	)		(21	)
Changes related to tax positions taken in the current year		2,466			1,571
Ending balance	$	7,602		$	5,143

The Company has unrecognized tax benefits of $7.1 million and $4.7 million as of December 31, 2022 and 2021, which would affect the effective tax rate if recognized; however, recognition would be in the form of a deferred tax attribute which would likely be offset by a valuation allowance. The Company does not anticipate any significant changes to unrecognized tax benefits over the next 12 months. The Company has recognized no interest or penalties related to uncertain tax positions for the periods presented.

Income tax returns are filed in the United States. The years 2010 through 2022 remain open to examination by the domestic taxing jurisdictions to which the Company is subject. Net operating losses generated on a tax return basis by the Company for 2010 through 2022 remain open to examination by the domestic taxing jurisdictions.

13.

Net loss per share attributable to common stockholders

The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders:


	Years Ended December 31,
	2022			2021			2020
	(in thousands, except share and per share data)
Numerator:
Net loss	$	(248,705	)	$	(187,091	)	$	(108,159	)
Redeemable convertible preferred stock dividends-undeclared and cumulative		—			—			(2,219	)
Net loss attributable to common stockholders	$	(248,705	)	$	(187,091	)	$	(110,378	)
Denominator:
Weighted-average shares outstanding		80,636,570			72,866,022			55,109,929
Less: Weighted-average unvested restricted shares and shares subject to repurchase		(10,045	)		(59,943	)		(235,810	)
Weighted-average shares used to compute net loss per share attributable to common stockholders, basic and diluted		80,626,525			72,806,079			54,874,119
Net loss per share attributable to common stockholders, basic and diluted	$	(3.08	)	$	(2.57	)	$	(2.01	)

119

The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect:


	As of December 31,
	2022		2021		2020
Options to purchase common stock		8,164,375		6,050,938		5,118,979
Options early exercised subject to future vesting		6,918		30,378		130,793
Unvested restricted stock units of common stock		1,175,032		423,621		85,639
Expected shares to be purchased under ESPP		378,429		176,131		91,210
Total		9,724,754		6,681,068		5,426,621

120

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

None.

Item 9A. Controls and Procedures.

Our management, with the participation of our President and Chief Executive Officer and our Chief Financial Officer, our principal executive officer and principal financial officer, respectively, have evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of December 31, 2022. Based on the evaluation, our President and Chief Executive Officer and our Chief Financial Officer have concluded that, as of December 31, 2022, our disclosure controls and procedures were effective.

Management’s annual report on internal control over financial reporting

Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Management has assessed the effectiveness of our internal control over financial reporting based on the framework set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework (2013 framework). Based on our evaluation, management has concluded that our internal control over financial reporting was effective at the reasonable assurance level as of December 31, 2022.

The effectiveness of our internal control over financial reporting as of December 31, 2022 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which appears herein.

Changes in internal control over financial reporting

There were no changes in our internal controls over financial reporting during the three months ended December 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Inherent limitation on the effectiveness over financial reporting

The effectiveness of any system of internal control over financial reporting, including ours, is subject to inherent limitations, including the exercise of judgment in designing, implementing, operating, and evaluating the controls and procedures, and the inability to eliminate misconduct completely. Accordingly, any system of internal control over financial reporting, including ours, no matter how well designed and operated, can only provide reasonable, not absolute assurances. In addition, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. We intend to continue to monitor and upgrade our internal controls as necessary or appropriate for our business, but cannot assure you that such improvements will be sufficient to provide us with effective internal control over financial reporting.

Item 9B. Other Information.

None.

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.

None.

121

PART III

Item 10. Directors, Executive Officers and Corporate Governance.

Information required by this item will be contained in our definitive proxy statement to be filed with the SEC on Schedule 14A within 120 days after December 31, 2022, and is incorporated herein by reference.

Code of Business Conduct and Ethics

We have adopted a Code of Business Conduct and Ethics that applies to our officers, directors and employees, which is available on our website at https://ir.revmed.com/. The Code of Business Conduct and Ethics contains general guidelines for conducting the business of our company consistent with the highest standards of business ethics and is intended to qualify as a “code of ethics” within the meaning of Section 406 of the Sarbanes-Oxley Act of 2002 and Item 406 of Regulation S-K. In addition, we intend to promptly disclose (1) the nature of any amendment to our Code of Business Conduct and Ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions and (2) the nature of any waiver, including an implicit waiver, from a provision of our code of ethics that is granted to one of these specified officers, the name of such person who is granted the waiver and the date of the waiver on our website in the future.

Item 11. Executive Compensation.

Information required by this item will be contained in our definitive proxy statement to be filed with the SEC on Schedule 14A to be filed within 120 days after December 31, 2022, and is incorporated herein by reference.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

Item 13. Certain Relationships and Related Transactions, and Director Independence.

Item 14. Principal Accounting Fees and Services.

122

PART IV

Item 15. Exhibits, Financial Statement Schedules.

(a)

The following documents are filed as part of this Annual Report on Form 10-K:

Financial Statements:

The following financial statements and schedules of the Registrant are contained in Part II, Item 8, “Financial Statements and Supplementary Data” of this Annual Report on Form 10-K:


	Page
Report of Independent Registered Public Accounting Firm	94
Consolidated Balance Sheets	96
Consolidated Statements of Operations	97
Consolidated Statements of Comprehensive Loss	98
Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)	99
Consolidated Statements of Cash Flows	100
Notes to Consolidated Financial Statements	101

Financial Statement Schedules

No financial statement schedules are provided because the information called for is not required or is shown either in the financial statements or notes thereto.

(b)

Exhibits

The exhibits listed in the following “Exhibit Index” are filed, furnished or incorporated by reference as part of this Annual Report.

123

Exhibit Index

Incorporated by reference

Filed
herewith

Exhibit
number

Exhibit description

Form

Date

Number

3.1

Amended and Restated Certificate of Incorporation.

8-K

2/18/2020

3.1

3.2

Amended and Restated Bylaws.

8-K

3/8/2021

3.1

4.1

Reference is made to Exhibits 3.1 through 3.2.

4.2

Form of Common Stock Certificate.

S-1

1/17/2020

4.2

4.3

Description of Common Stock.

10-K

02/28/2022

4.3

10.1A†

Collaborative Research, Development and Commercialization Agreement, dated as of June 8, 2018, by and between Revolution Medicines, Inc. and Aventis, Inc., as amended.

S-1

1/17/2020

10.1

10.1B†

Letter Agreement and Amendment, dated as of August 5, 2021 by and between Revolution Medicines, Inc. and Genzyme Corporation.

10-Q

8/11/2021

10.2

10.2

Amended and Restated Investors’ Rights Agreement, dated as of June 5, 2019, by and among Revolution Medicines, Inc. and the investors listed therein.

S-1

1/17/2020

10.2

10.3A

Lease between HCP LS Redwood City, LLC and Revolution Medicines, Inc., dated as of January 15, 2015.

S-1

1/17/2020

10.3A

124

Incorporated by reference

Filed
herewith

Exhibit
number

Exhibit description

Form

Date

Number

10.3B

First Amendment to Lease by and between HCP LS Redwood City, LLC and Revolution Medicines, Inc., dated as of September 16, 2016.

S-1

1/17/2020

10.3B

10.3C

Sublease between OncoMed Pharmaceuticals, Inc. and Revolution Medicines, Inc., dated as of January 16, 2019.

S-1

1/17/2020

10.3C

10.3D

Second Amendment to Lease by and between HCP LS Redwood City, LLC and Revolution Medicines, Inc., dated as of April 17, 2020.

10-Q

5/14/2020

10.4

10.3E

Third Amendment to Lease by and between HCP LS Redwood City, LLC and Revolution Medicines, Inc., dated as of November 1, 2021.

10-Q

11/10/2021

10.1

10.4(a)#

2014 Equity Incentive Plan, as amended.

S-1

1/17/2020

10.6(a)

10.4(b)#

Form of Amended and Restated Early Exercise Stock Option Grant Notice and Amended and Restated Stock Option Agreement under 2014 Equity Incentive Plan, as amended.

S-1

1/17/2020

10.6(b)

10.5(a)#

2020 Incentive Award Plan.

S-1/A

2/3/2020

10.7(a)

10.5(b)#

Form of Stock Option Grant Notice and Stock Option Agreement under the 2020 Incentive Award Plan.

S-1/A

2/3/2020

10.7(b)

10.5(c)#

Form of Restricted Stock Award Agreement under the 2020 Incentive Award Plan.

S-1/A

2/3/2020

10.7(c)

10.5(d)#

Form of Restricted Stock Unit Award Grant Notice under the 2020 Incentive Award Plan.

S-1/A

2/3/2020

10.7(d)

10.6#

2020 Employee Stock Purchase Plan.

S-1/A

2/3/2020

10.8

10.7A#

Employment Agreement by and between Revolution Medicines, Inc. and Mark A. Goldsmith, M.D., Ph.D.

S-1

1/17/2020

10.9

10.7B#

First Amendment to Employment Agreement dated June 10, 2022 by and between Revolution Medicines, Inc. and Mark Goldsmith, M.D., Ph.D.

8-K

06/10/2022

10.1

10.8#

Employment Agreement by and between Revolution Medicines, Inc. and Steve Kelsey, M.D., FRCP, FRCPath.

S-1

1/17/2020

10.10

10.9#

Employment Agreement by and between Revolution Medicines, Inc. and Margaret Horn, J.D.

S-1

1/17/2020

10.11

10.10#

Non-Employee Director Compensation Program.

10-Q

05/09/2022

10.1

125

Incorporated by reference

Filed
herewith

Exhibit
number

Exhibit description

Form

Date

Number

10.11#

Form of Indemnification Agreement for directors and officers.

S-1/A

2/3/2020

10.13

10.12#

Employment Agreement by and between Revolution Medicines, Inc.
and Jack Anders.

10-Q

05/09/2022

10.2

10.13#

Employment Agreement by and between Revolution Medicines, Inc.
and Xiaolin Wang Sc.D.

10-Q

05/09/2022

10.3

21.1

Subsidiary of Registrant.

S-1

1/17/2020

21.1

23.1

Consent of Independent Registered Public Accounting Firm.

X

24.1

Power of Attorney (included on signature page to this Form 10-K).

X

31.1

Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

X

31.2

Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

X

32.1*

Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

X

32.2*

Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

X

101.INS

Inline XBRL Instance Document.

X

101.SCH

Inline XBRL Taxonomy Extension Schema Document.

X

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document.

X

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document.

X

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document.

X

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document.

X

104

The cover page from Revolution Medicines, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2022, formatted in Inline XBRL and contained in Exhibit 101.

X

† Portions of the exhibit, marked by brackets, have been omitted because the omitted information (i) is not material and (ii) is the type of information that Revolution Medicines, Inc. treats as private or confidential.

# Indicates management contract or compensatory plan.

* The certifications attached as Exhibits 32.1 and 32.2 that accompany this Annual Report on Form 10-K, are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Revolution Medicines, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing.

Item 16. Form 10-K Summary.

None.

126

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.


	Revolution Medicines, Inc.

Date: February 27, 2023	By:	/s/ Mark A. Goldsmith
		Mark A. Goldsmith, M.D., Ph.D.
		President and Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Mark A. Goldsmith, M.D., Ph.D., Margaret A. Horn and Jack Anders, and each of them acting individually, as his or her true and lawful attorneys-in-fact and agents, each with full power of substitution, for him in any and all capacities, to sign any and all amendments to this annual report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.


Name	Title	Date

/s/ Mark A. Goldsmith	President, Chief Executive Officer and Director	February 27, 2023
Mark A. Goldsmith, M.D., Ph.D.	(Principal Executive Officer)

/s/ Jack Anders	Chief Financial Officer	February 27, 2023
Jack Anders	(Principal Financial and Accounting Officer)

/s/ Elizabeth McKee Anderson	Director	February 27, 2023
Elizabeth McKee Anderson

/s/ Flavia Borellini	Director	February 27, 2023
Flavia Borellini, Ph.D.

/s/ Alexis Borisy	Director	February 27, 2023
Alexis Borisy

/s/ Sushil Patel	Director	February 27, 2023
Sushil Patel, Ph.D.

/s/ Lorence Kim	Director	February 27, 2023
Lorence Kim, M.D.

/s/ Eric Schmidt	Director	February 27, 2023
Eric Schmidt. Ph.D.

/s/ Thilo Schroeder	Director	February 27, 2023
Thilo Schroeder, Ph.D.

/s/ Barbara Weber	Director	February 27, 2023
Barbara Weber, M.D.

127

EX-23 2 rvmd-ex23_1.htm EX-23.1 EX-23

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-263098, No.333-253791, No. 333-236493) and Form S-3 (No. 333-253790) of Revolution Medicines, Inc. of our report dated February 27, 2023 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.

/s/ PricewaterhouseCoopers LLP
San Jose, California
February 27, 2023

EX-31 3 rvmd-ex31_1.htm EX-31.1 EX-31

Exhibit 31.1

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Mark A. Goldsmith, certify that:

I have reviewed this Annual Report on Form 10-K of Revolution Medicines, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: February 27, 2023	By:	/s/ Mark A. Goldsmith
		Mark A. Goldsmith, M.D., Ph.D.
		President and Chief Executive Officer (Principal Executive Officer)

EX-31 4 rvmd-ex31_2.htm EX-31.2 EX-31

Exhibit 31.2

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Jack Anders, certify that:

I have reviewed this Annual Report on Form 10-K of Revolution Medicines, Inc.;

(a)

(b)

(c)

(d)

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: February 27, 2023	By:	/s/ Jack Anders
		Jack Anders
		Chief Financial Officer (Principal Financial and Accounting Officer)

EX-32 5 rvmd-ex32_1.htm EX-32.1 EX-32

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Revolution Medicines, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.


Date: February 27, 2023	By:	/s/ Mark A. Goldsmith
		Mark A. Goldsmith, M.D., Ph.D.
		President and Chief Executive Officer (Principal Executive Officer)

EX-32 6 rvmd-ex32_2.htm EX-32.2 EX-32

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.


Date: February 27, 2023	By:	/s/ Jack Anders
		Jack Anders
		Chief Financial Officer (Principal Financial and Accounting Officer)

GRAPHIC 7 img27442415_0.jpg GRAPHIC begin 644 img27442415_0.jpg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end GRAPHIC 8 img27442415_1.jpg GRAPHIC begin 644 img27442415_1.jpg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end GRAPHIC 9 img27442415_2.jpg GRAPHIC begin 644 img27442415_2.jpg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end GRAPHIC 10 img27442415_3.jpg GRAPHIC begin 644 img27442415_3.jpg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�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end GRAPHIC 11 img27442415_4.jpg GRAPHIC begin 644 img27442415_4.jpg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img27442415_5.jpg GRAPHIC begin 644 img27442415_5.jpg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�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ⅅ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end GRAPHIC 13 img27442415_6.jpg GRAPHIC begin 644 img27442415_6.jpg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�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end GRAPHIC 14 img27442415_7.jpg GRAPHIC begin 644 img27442415_7.jpg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
'M-TPL'-I:QP%AW*J!G]*\>_MKX\ M_P#0!L_RA_\ CE>SZ6UX^DV;ZBBI?- AN$7HLFT;@/QS5K2-EY?@K(E_%]_X M[ENBBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 5X+\5M]5X;\3;S7M$^*NG:YX<\,W]U>(=$>: M!))(6SF-BH)4Y]#Q5=">I;HHHI#"BBN1^)>H:]IW@F\;PW9SW6I2E84$$;.\ M8;[S@#G('3T)!H XOQ)\7;J+XHZ1X8T,0M9F_BL[Z=TW;W:1594.>-H."?4^ MW.KX\\8^(T\::7X,\(_9(]3NX3<37-R-RQ)\V!C!QPI)X/48KQ>^NKK1;_P) M;+X.U.PGTV[$^RX0B349C)$S;H*YSUYVXJI%;/ MK7CWXK7NGL);<:1<6^Z/D,Y"X (]?*<4VXU>P?\ 95AM5N(OM'FBW,6X;@XN M=^,>NWYOH: /H2RNHKZQM[R$YBGB65">ZL,C]#4]>?W?@:X\3>!_#%DVMZAI M,ME91!S:,5+GRU!#<]L5Y?\ %#P5J/@'PU;:K:^,=5>'[^YUOX_>(F6[G;3]*LU@6$2'R_-.T$EM@F-?E![L> /SK.\(6MS#HJW%Y+))<71\T M[V)PIZ#VXY_&@#H***Y[Q7K4FG6B6=GEM0NSY<*KU7/&[^@]_I0!T-%9NA:; M)I>EQP33/-.?FD=V+98]AGL.E:5 !1110 4444 %%.=?\3_'71I9I;RST:\BF>TLC*RQR M0K%,%=DS@DLI.2.PQP!7H'Q:\+>(O%V@6FF:%+ L1GWW<VOQDT*W9=(C\0Q6)2R6(8MUA"2C!'KMW_ *4 =?K"ZM\2?BUJ MWAR#Q!>Z5I6C6X(%H2"\OR@DX(S\S'KV7C&2:J>'?B-K.F_"GQ6MY>->H S4MMK6G_#SXZ^)IO$$[6EEJ=N)K>X,;,K$[6Q M\H)ZAQ]17-:)X>O==^$_C_6K>WD/]IWB3VZ;1BO?]0\2Z%I+1)J6M:=9 M/*F^-;JZ2(LOJ Q&17SUXK\4V'CKX>^"O">BR-/K'FP1S0;"/+9(S'R<8P2< M\'H.<5[CK_P\\+^*9;:;7-,^URVT(AC?SY8\+UQA& ZT 7(/&GA6ZN(K>W\2 MZ--/*X2..._B9G8G ;))/&*W*^?_'/@GP[X.^(?P[_ +!T_P"Q_:M57SOW MTDF[;+!M^^QQC02(V#@X8$@\@BL3Q_="S^'OB M*BBB@ HHHH **** M"BBB@ HHHH J76JZ=8W5M:W=_:V]Q=,5MXIIE1YCQP@)RQY'3U%6Z\?N WBW M]HN!$<-9>&K3<^.096'3ZY=?^^#7L% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<7\3/'$?@CP MWYL11M3O"8;)'8!=_=V)XVKD$Y]AWH T%\\%G&KM$I&06RP XYQUQS7D?@Y=&\ M-?&32))/$5E>F73WDOM0^UJ\;W3[]PWYQG[H]3U[UU_P^BCO?CAX]N;E5>6, MF%=XS\F[&/IA5% 'I.F^,="U7PLWB2WOD&F(C/+*XP8MOW@PZ@CT^F,Y%D0&\MI9GV6\MU$J1S-G "D,2">V0/3KQ7BMO+):?"+QM80$BU M76844 \8W?\ V"UV'Q-L[>P^%/@"ZM45;BV>V6%U&#AH=Q_-E4_6@#Z HKBO M&?B'QCH^H6\7AOPNFKV[Q;I96EV[&R>.H[8-QT444 %%%% !1110 4444 %%%% !117%>+_&U MQH'BGPUH-C:Q7-SJ\Y23>Q'DQ@J"V!UZM_WR: .UHHHH **** "BN6^(7BUO M!7@^YUJ.!)YD=(XHG8@,S,!R1[9/X5M:)=W-_H5A>7D*P7,]O'++$I)$;,H) M7GTSB@"_1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %>9^._$7Q)TSQ"+?PKX>M[[3?)5O.DB+'>2@+>;A?Q(KWC3)+N72K22_1([QX4:=(SE5<@;@#D\9SW- M?/GBGQ7\0OB'HY\.)X%N;2.XD0O(UO*,;2"/FVM8X9'SGO#5UTHB02^:(/ M,/DALY^YTQGMT]L5WU% !7C_ .T=_P D]T__ +"L?_HJ6O8*\?\ VCO^2>Z? M_P!A6/\ ]%2T >P4444 %%%% #7=8T9W8*J@DD] *\E^!,'VRR\2>)I ?-U; M4W.3_=7+?SD;\J[+XE:D=)^&^OW:MM86;Q*P[,_R _FPJI\)=).C?##1(&&) M)H?M+?\ ;0EQ^C ?A0!RFL*_B']I#2+,'=;:'8FXD7^ZQ!(/YO%^5>P5Y!\) MC)KOC_QQXID^:.2Z%I;OZHI/'X*L=>OT %>9_'/6GTWX?/I]N"UUJTZ6D:KU MQG/^*#)XJ^/GA[0U&^ST.'[?<#TGY?\ MH0KL54*H50 !P .U3,,GLH/;\?Y"NNH KWU[#IUC-=W# M;8HEW,?Z#WKE_#%E/JNH2^)-07YY"5M8R/N)TS_3\SWJ'4I&\6^(ETJ!C_9M MFV^Y=3]]O3^GYFNTCC6*-8T4*B@!5'0 4 .HHHH **@N[RWL;9[BZF6*).K, M:Y"74M6\72M;:2&L]-SMDNG&&?V'^ _$B@#0U?Q8(;O^SM(@^W:@3C:O*(>^ M<=?\\U5.F>+M43_3-4BL(SUC@'S#\1_\56]H^AV6B6WE6L?SG[\K5^,^N/\/>6FE6,%T^=TT5NB. MV>N6 S6A110!X_\ %_\ Y*'\,?\ L*G_ -&V]>P5X_\ %_\ Y*'\,?\ L*G_ M -&V]>P4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !114%[=PV%C<7EPVV&WB:61O15&2?R% '%^'OB3:ZY M\1M;\*>4D9L,B"7?DS%.) 1V()X]@:[NOE?2M'U&T\%Q_%*P$G]JP:S)<3 $ MX>W) 8$>F[<#[,?2OIC0M8M?$&AV>K63%K:[B$J9ZC/4'W!R#[B@#0HHHH X M#XUW1M?A-K.TX:7RHQ^,J9_3-;W@.V-G\/\ P] 1AETZ#K:E;Z-H]YJ=T<06D+S28ZX4$G'OQ5RO+OCGJMQ#X1M/#]BN^^UR[ M2UC0=2H()Q]6V#_@5 $7P+TV23P_J?BF\4F]UR]DF9CW16./_'B_Z5ZM6?H> ME0Z'H-AI4 'E6END(P.NT 9_'K^-:% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8?B/P=H'BU;== M=T];P6Q8Q!I'7;NQG[I'H*W** /)#\#](C^(-KJ=M96:>'HH,/9F:7S#,,X8 M>WW?XNW2G^(/ 'BS3O'5]XI\$:C90R:E%Y=U!>9PIX^9>"#]T'U!SU!Q7K%% M 'EVB_""&S^%^H>%K^]$E[J+^?-=1@E4E!!3;G!*C:,YP3D],UAV/PM\::I< MZ#IOBG5=.?0="=3"EMDO,%QM!RH[ +D]!GK7MM% !7C_ ,7_ /DH7PQ_["I_ M]&V]>P5X_P#%_P#Y*%\,?^PJ?_1MO0![!1110 4444 %%%% !1110 4444 % M>0:)_VC]0O=V^W\/V(AC(Z>81@C\"\GXK7K]>1? F(7EMXH\0'E]1U9QN M/4A?F_G(: /7:*** "BBB@#R;XV ZI+X1\,KR=2U56=1_<7"G/M^\S^%>L 8 M&*\GN2=<_:3M(/O1:'I;2%>P=QC/UQ*OY5ZS0 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% '(?$&[\9VFEVK>"[*&ZN MS-B=9-O";3R-S =<5YY_;7QY_P"@#9_E#_\ '*]RKR'XB^(/%VK>.+;P/X.N M5LIOLWVFYNBVT@'_ &L$J ,=!DDBEL[=Q]/0R_[:^//_ $ ;/\H?_CE>SZ6U MX^DV;ZBBI?- AN$7HLFT;@/QS7@NI67Q5^&%LOB"Z\1#6=.B=?M,,ES),,$X MY$@R!D@94YYKWK2]0BU;2;/48,B*Z@29 >P901_.K^SH2]RW1114C"BBB@ H MHHH **** "O'_P!H[_DGNG_]A6/_ -%2U[!7C_[1W_)/=/\ ^PK'_P"BI: / M8**** "BBB@#R?X^W4[^$M,T2UYGU748X0O]X#)Q_P!]%*[;Q'?)X2\ 7]U M0O\ 9]@1#G^\J[4_7%<%XUD;6_CSX,T11NBT]&OW] W+<_\ ?I?^^JM_'K4) MX_!-KHMH-USJ][';A!U90=W_ *$$'XT :'P1TEM+^&%@\BE9;YY+ML]]QPI_ M%54UZ)532["/2])LM/B_U=K D*X]%4 ?RJW0 CNL:,[L%51DDG KR'X,QR: M[KGBOQM<$M_:-X;>V)ZB-><$M)\I MQ[A=Q_"KOPWT$>&_A]H^GD8E\@339'/F/\[#\",+L6GA>].<-(HB7WW'!_3-;M P,#I7'2$Z_X]2,,&M-*7O8*\?^+_ /R4/X8_ M]A4_^C;>O8* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ KA?C%JJZ3\+M9??MDN8Q:H/[Q<@$?]\[C^%=U7 MD/QH5=M]/^&NE:)/"&B>Q"W$ M;#AC(-T@/XLU-=6^'.H22-#O:[TJ23^.,\D#ZCGCC*O7L*@*H M '0"O+_C-X>NGTRR\8:.&75]!D$X*_Q0@Y;/J!U^F[UH ]1HK(\+^(+7Q3 MX:L-9M.(KJ(,4SDHW1E/N""/PK7H \B^.4GVB7P=I/7[7JZ-CUVX7_VI7KM> M0?$J/^T/C#\/;'KY4[W./HRM_P"TZ]?H **** "BBB@ HHHH **** "O'G!\ M9?M$(H??I_ABVW$=5,Q_KN8?]^Z]3UK58-#T2]U6Y_U%I \S@=2%&<#W/2O. M?@7I<@\+W_B6[4_;MJ4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 5X_P#%_P#Y*%\,?^PJ?_1MO7L%>/\ Q?\ ^2A?#'_L*G_T M;;T >P4444 %%%% !1110 4444 %%%% &1XKU Z3X1UG4%.&MK*:5?\ >"$C M]<5QWP*LOLOPJT^0C!N99IC_ -]E1^BBKWQCO!9?"K7'SAI(TA4>N^15/Z$U ML^!+$:;X!T"T P4L(2P_VB@+?J30!T--+J'"%@&/09Y-.KYU^*'BC4-)^-=O MJMC')+%H%K";E$/ C=OF!]-PE5?Q% 'T515>QO8-1T^VOK5Q);W$2RQL/XE8 M9!_(UF>,-7.@^#M8U1#B2VM)'C/^WM.W]<4 >=_"(2:WXV\;^*I/FCGO/LMN M_P#L*22Z;/?4R?!/7O#DK7' M@?QC=6ASG[/N/#(TFQF=?M$LEM)", M YR6D/(! .%&>*]ZTC3H](T:QTV)BT=I D"D]PJ@9_2O$[GXJ>//A_ORY'YJM>W:7?QZKI-GJ$2,D=U DRJW4!E! /YU2^'0E_$ MKENBBBD,**** "BBB@ HHHH *\?_ &CO^2>Z?_V%8_\ T5+7L%>/_M'?\D]T M_P#["L?_ **EH ]@HHHH ***AN[J*RLI[N=ML,$;2.WHJC)/Y"@#R?P7(NO_ M !X\9:P!NBT^%+",_P!TY"G'XQ/^=)XM9_$7Q\\*Z*HW6^DPM?R_[+\L,_BD M?_?56/@):M)X3U/6YE_TC5=1DE9O51@#_P >+_G5?X8L_B'XI>-_%#C,2RBP MMW[%5../PC0_C0!Z_1110!X]\4RGB?XB>#O!>"\33_;;Q.QC&>/^^5D_,5[" M!@8KQ_X<%O%GQ4\6>,'3-M;L-/LGZC X)'OM53_VTKV"@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH *R?$>M#0M*-WL$CEU1$)QN)Z_H#6M7'^)"-3\ M6:/I &Z.-OM$P[$>A_!3^= &CI'B[3=480LQM;K.TPS<'/H#T/\ /VK.11J7 MQ*D?.4T^W 'IN(_^S/Y5M:OX>TS6(R;R !P/]F:5;1S1(TI>Y5N"H';\L_I7H"(J(J M* %48 '84 .HHHH *X[2]NL>/=0OL;HK%/(C/HW(/_L_YUTFK7PTW2;J\.,Q M1E@#W/8?GBLCP19-:^'4FD'[VZO8*\? M^+__ "4/X8_]A4_^C;>O8* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ KR"&,>(_P!I2>;=N@\/Z>%'IO8= M/K^];_OFO7F8(I9B H&23T KR+X'0G4G\5>+)8_X#0! MZ]3)8DFB>*5 \;J596&00>H-/HH \8\#RM\-OB1J/@>]8II.I,;O2I9'X!Y^ M3)[D#;]4']ZO9ZYCQGX"T/QS91P:M"XEA!\BYA;;)%G&<=B.!P0:X Z1\3?A MR2VD78\5:)&O%K<9\^-1V7OQT&"?]V@"[K#"\_:6T",NR>,OCOJNMR6,UEY6EA/L\WWHF'E*0>!WW=AQ7N] !1110 4444 %% M%% !114%Y=P6%E/=W4JQ6\$;222-T50,DG\* /+_ (T:Q/>6FG>!=)*OJFN3 M('&?]7"&SD^@+#KZ*U>E:/ID.C:+8Z9;@>3:0)"G&,A0!G]*\K^%EK/XP\7: MS\1=2B&V5VM=,1A_JXQP2/3C"Y[DO7L- !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !7C_P 7_P#DH7PQ_P"PJ?\ T;;U[!7C_P 7_P#DH7PQ_P"PJ?\ MT;;T >P4444 %%%% !1110 4444 %%%% 'D?[04LLG@_2]+@/[V_U.- /4!6 MX_[Z*UZQ;PK;VT4"?I^;8#^2"@"C\&=4NM._M;P%JNX M7^B3,82W\<#-U'L"01[.M3?'O5)+3X>C3H 6FU2[CMPJ]2 =YQ^*J/QJA\5; M:7PAXOT3XBV$4C)#(+74HX_XXCP"?P)7GN$IGCB]A\4?%SP#HULPFMHQ_:C, MO*NI^=<_A%_X]0!ZMHVGKI6AV&G)C;:VT< Q_LJ%_I5ZBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .=\<:_?>&? M"EUJFFZ>;^[C9%CMP&.XLP7HO)QFO)5LOC3X[YNKD>'K!_X0?LYQ]%S)^!(K MWRDWJ'";AN/.,\TDNX[]CQ_0_P!GO0+:3[3K^H7>KW!.YQN,4;'WP2Q_[ZKU MRVMH;.UAM;>-8X(4$<:+T50, #\*EHJK]";=0HHHI#"BBB@ HHHH **** "O M'_VCO^2>Z?\ ]A6/_P!%2U[!7C_[1W_)/=/_ .PK'_Z*EH ]@HHHH *XOXM: MD-+^%VO2[L-+;_9U]_,8(?T8UVE>1_'LRWVB^'_#\#$2ZGJB( .^ 5Q^;K^5 M &UH+#P+\#;>Y EM-*-U@_\]74OC_OIL5%\#M*?3?AE9S2J1+?S27;YZG)V MJ?Q55/XU1^.E\]A\/;;1+)"9=3NHK2.->I5?FP/Q51^->D:/IZ:5HMCIT>-E MI;QP+CT50O\ 2@"[7+?$;7SX:\ :OJ4HM U76=*T:"UA\.3S( 6$N\C?N.=^&I9['QK*VH636KZ@',:L,;26W8' MY$?E7HU.)9+B"PT>!L27LX!_W01U]LD'\*ZF")+>".&,82-0JCV P*Y*UVZQ\ M0[BXSNATV+RU]-_(_F6_*NQH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH \?^+_\ R4/X8_\ 85/_ *-MZ]@KQ_XO_P#)0_AC_P!A M4_\ HVWKV"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH Y3XEZJ=&^&^O7BOL?[*T2,.H:3Y 1^+56^$^CG1 M/AEHENPQ)+#]I?ZR$N/R! _"N9^.\DU]I/A_PU:OMFUC4TC^H7C\MSJ?PKU6 MW@CM;:*WB&V.) BCT &!0!+1110 4444 0"SM5O6O%MX1=,@C:8(-Y4'(4MU MQGM4]%% !1110 4444 %%>4?%7Q=K\.NZ/X5\'EFUJ8F[E\LC(102$.>,'#$ MY[ >M=#\/OB-8^-K-X)(_L6M6ORW=B^0RD'!9<\D9_$=#V) .VKR?XRZQ=WX MTOP'HTB_VEK-I99&Z*H&2: M\G^%%E<>*_$VL_$;4T'^E2-;:UT#0[+2;) MMO:1"-.,9QU)]R@7VCW@/D7<1C8CJOHP]P<$?2O#O@AH>H0?$76AJY=Y]#M M?L"[^=F7^7'MM5L>QKZ#IB0Q1R/(D:*\F"[!0"V.!D]Z 'T444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\]?%/ MQ%:^#OC5IFO6\4MU>06R^?;RJ!&4(9?D?.0V">V ?7I7T+7FOQ(^)1\*:E:: M+I.C?VMKERF]8=I8(O..%&YB<'@8Z4F[--#2NFCG/^&D]$_Z .H?]_$KV+2[ MY-4TFSU"-&1+J!)E1NJAE!P?SKQ*U^,/BC0[V ^-?!2V6GS.%^T16LD.S/\ MOE@Q'ID&O=()HKBWBF@8/%(@=&7H5(R"/PJK:7)ZDE%%%(84444 %%%% !11 M10 5X_\ M'?\D]T__L*Q_P#HJ6O8*\?_ &CO^2>Z?_V%8_\ T5+0![!1110 M5Y#XSD;6?CYX,T91NCL(GO7]%8[F_P#:2_G7KU>1^%736?V@_%FHK\T>G6B6 M:'^ZWR _JC_G0 SQB[^(OCMX2T)!N@TI#J$WH&^\,_\ ?"?]]5Z_7D/PT=_$ M/Q6\;^)V&8HY%L+=^Q53CC\(T/\ P*O7J "O'_AZ?^$N^+7BGQ>Z9M+3&GV3 M'D<<$C\%S_VTKN/B)KY\,^ =7U..3RYT@,<#9Y$C_*I'T)S^%9_PB\/GP[\- M]+AE7%Q=*;N;ZR<@'W"[1^% '<4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% '(>-F:^FTO18WPUU.&?'91QG]2?PIME&E]\1+AU'[K3K<1)['&,? MJWY4VS>/4O']_?.@;D'_P!GJ7P)&9;;4-4Y_\ VE_*NPKC_!H:]U/6M7;D33^7&?8<_P BM=A0!#=6 MT=Y:36TPS'*A1A[$8KF?!%R\,%YHT^?/L9F SW4D]/QS^8KK*X[5(1WY['^7UIWB/7 MYHITT?21YNIS\97_ )9 ]S[_ ,NM7O#V@0Z':')\V[EYFF/5CZ#VH ?H&A0Z M%8^2A\R:0[II3U=O\*UJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** /'_B__P E#^&/_85/_HVWKV"O'_B__P E#^&/_85/_HVW MKV"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ KF/&WCG2? VD&\U"3?/)D6]JA^>9O0>@]6Z#ZX!H>/_ (C6/@NV M2VAC-]K=R,6MA%\S,3P"P'('IW/0=R,'P3\.;ZZU@>,?'4@O==DPT%LW,=H, MY7CID=AT'N>: *W@[PGX@\6^);;QUXT=X&A._3-+7A85/1F!Z=CCJ3@GIBO7 M:** "BBB@ HHHH **** "BBB@ JIJFI6VCZ5=ZE>2!+:UB:61O8#/YU;KR+X MOW]UXBU?1OAUI3?O]2D6>]=3_JX5.1G\BW_ 1ZT 'P>TRYUS4M8^(FK0[;O5 M96CM%)SY<(.#CV^4*#Z)[UJ_$#X;2:Q>)XF\,3_V=XHM?G25#M%Q@8VMV!QQ MGOT/'3OM-TZVTC3+73K*,1VUM$L42#LH&!5J@#YVU_X@ZUX^TFP\!"PDT_Q# M>78M]2#*0JHN"2.X!^\1Z*>H->]Z-I-KH6C6>EV2!+:UB6)!CJ .I]SU/N:C M;0-);7UUTV$/]J+"8!WOTZ]<9'P5X_\7_\ DH7PQ_[" MI_\ 1MO0![!1110 4444 %%%% !1110 4'I16-XNOSI7@W6[]3A[>QFD3_>" M''ZXH \\^ \0NM-\2Z\?OZCJS\^JJ-P/YR-7KE><_ VR-I\*M-\:^*7 M.Y;W43#"WHJEFQ],.@_"O7Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ/QYJV5Y=\2?BC%X;U:+PW9Z#_;=_<1AY(&Y0 YP M-H!+$XSBDW9IK?\ X TKIIG%_$+XOZ1XX\,R>&= TK4+B\OI(U4S1*-I# _* M Q);C'XU[CX:L)M*\+Z3I]P>:!))(6SF-BH)4Y]#Q5I6B[$MW:N6Z M***D84444 %%%% !1110 5X_^T=_R3W3_P#L*Q_^BI:]@KQ_]H[_ ))[I_\ MV%8__14M 'L%%%% "$@ DD #N:\-^&6HC3/!7CSQRV#+/\ Q?8>)?%?A/P+&[8N[K[5=JO41#(!_P"^1*?P%>O( MBQQJB*%51@ = *\@\ M_PEWQA\4^*V3=:V &GV;'IQP67\%)_P"VE>PT %%% M% !1110 4444 %%%% !1110 4444 %%%% !69KNLPZ'IKW4N&?[L4>?OMV%: M$TT<$+RRN$C12S,>@ KC=-A?Q7KAUFZ5AIMJQ6UB?HQ'&"V!!6SMSP/KV_F: -3P99FS\+V@ M88:4&4_\"/'Z8K?ID,200I#&,(BA5'H ,"GT %8GBK1VUG1)((5W7",)(1D# MYAVS]":VZ* ,'PWX>31H&FG;SM0GYFF/)YYP/;/?O6]110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%-5U8G:P.#@X/2@!U%(SJ@RQ 'J32T M %%-#J6*A@2.HSTIU 'C_P 7_P#DH?PQ_P"PJ?\ T;;U[!7C_P 7_P#DH?PQ M_P"PJ?\ T;;U[!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !7 ?$3XC)X52+2=)A^W^)+S"VMH@W;,\!G Y^@[_3FCXC? M$3_A%UAT?1X#?>);X!;6U1=VS/ =A_(=\>E1_#OX77]?F_M#Q/>Y>>X M<[O)SU5#ZXX)_ <=0"/X>_#9M$G?Q'XDE_M'Q1=$O)/(=XM\_P *'UQP2/H. M.OH]%% !1110 4444 %%%8WB?Q1I7A'19=4U:?RX4X5!R\K=E4=R?TZG H V M:*\2T^;XN^.XWUS3-3L_#^EW#9M;6= 6,?\ >SY;$Y]3C/88Q5\>"?BW)_K? MB!;)_N0__8"@#UZBO//"W@_QOI>OP7VM^-6U*S0-YEIY6 Y*D#GV)!Z=J]#H M J:IJ5MH^E76I7CA+:UB:61O91G\Z\O^#^F7.MW^L?$/5H=MYJTK):*3GRX M<<>WRA1[)[TWXO7UUXBUC1OAUI;?OM2D6>^=3_JX5.1G\BW_ $>M>IZ=I]M MI6FVVGV40BMK:)8HD'90,"@"U1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !7C_ ,7_ /DH7PQ_["I_]&V]>P5X_P#%_P#Y*%\,?^PJ M?_1MO0![!1110 4444 %%%% !1110 5P?QEO18_"G6VW8:5(X5'KND4'],UW ME>1_M O+<>%='TB _O;_ %2- /7"L,?FRT =[X'L1IO@30;0#!CL(=P_VB@+ M?J33_&6JMH?@O6=31MLEO9R/&?\ ;VD+^N*V88E@@CA082-0JCV Q7F?QZU4 MV'PVELTR9-1N8K8 =< [S_Z!C\: +GP1TQM-^%NFEUVR7;27+#_>8A3_ -\A M:]#JAH>GC2= T[3@ !:VL<&!_LJ!_2K] !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M44$@#).!0 45A:EXOTC36,;7'GS?\\X/G/Y]!^=97]H^*M=7%A9)IMN3_KIO MO$>V1_(?C0!V5%[M=2FT'69"UTA+03,?\ 6KUZ]_;\1VKK* "BBB@ MHHHH **** "BBB@ HHHH **** "O!_BIXDM/!OQ9T?7-+C-UK MO+N[0K\CQ M'(7#=0YYZ ]!]#[Q7@7Q,\3Z?X+^-.FZY#:RW-W':!;N%U 0HVX!D;.0^,]L M<#GDTOM1_KHQ_9?]=46_^&@M4_Z)_>?^!;?_ !FO9]+O6U'2;.^:!H&N($E, M3'E"R@[3],XKQW_AI/1/^@#J'_?Q*]BTN^35-)L]0C1D2Z@294;JH90<'\ZK MH3U+=%%%(85C>*[S5[#PQ?7&@V)O=45,6\/'+$@9.2,@9)QWQ6S6;K^N67AO M0KO5]0DV6MK'O8]R>@4>Y) 'N: /$=>O_B9X&T#3/%6J>)Q<27,Z)/I4MNH" ME@6V<#&<*0<8QVKI_&_B/Q'JWQ#TGP1X;U,:2\]J;F[NO+#LO#';SZ!>V,EA MS7&Z5XQ\-^,/$T?B;QUKL-O#9RDZ;HJQR,L.#D/(0N&/ ^N!G ^6M[7KZT\- M_M%:;K.IW"6^G7^G86YDX13M9<$]N0O_ 'T* +_@SQWK.F7'C#0_$]VNH7?A M^![J.X"A#+&@)(./^ X[_-7)CQ+\1X?!$7Q(D\11/:MN.,?BAK&E'[1:2Z9-:02)TE=@NW'KGROU'K69-XNT>;]FV'P^ ME[$=6\T0FT!_><7'F9QZ;<<^O% 'TAIMZFI:7:7\0Q'*O!WAW3->%RK:;:1H!#)L(;RU5L\'^[7DO MQ?\ A;X=\$>$[74M(-Y]HEODMV\Z8,-I21CQ@?_0,?C6#JEFU_P#%OP)X21,VOA^Q2YE Z*RJ,9_[]Q_] M]5H_%G9JOCGP%X?/S++?FXF3_84K_3?3?A>S^(?B9XV\5.,Q"86%L_8HI[?\ M!2,_C0!Z]7"_%GQ<_A3P7,;1V&J7[?9;,)RP9NK#Z#./#?!5EIA'^E,//NF]96 W?E M@+]%KK*** "BBB@ HHHH **** "BBB@ HHHH **** "BBN8\3Z[+"RZ1I@,F MI7/R@+_RR4]SZ''Y=: *6LW,WB?6O[!L7*V4)S>3#H<'[H_SU^E)JMQ)=W$? MA705\J-%VW,J\B-.X_Q]2<>M1SN/"^FPZ'I0\[6+OEW7D@G^+_#\S[]!H&BP MZ!IA5F5IV^>XG/\ $?J>PH YO3-(M8?'J6MJ@$.G6X9CW=R.I/K\_P"E=[7( M>"5-W<:OJ['/VFY*I]!S_P"S#\JZ^@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH Y/XB:/XCU[PL^F^&KZ"RNII )I9I&3]U M@Y52H)!)V_AFO)+WPA;?#GXC^#K3PMJM[+J=[.JW]N\@.Z+J_$OQF_@GPH][:P&>_G<0VJ;2RAR"=S8[ _4X'>O)?AOXXT'3-8BN- M0TS6M0\3ZK,D5QJ4\:X4N0-J_-P@X[9('88 -;4M'3XJ_&37-&U6^O8](T: MW"P0P.!B3Y03R",Y+'.,\ =JS?#WC?5M$^$WC+3S>RR7NAW"VMK<,Q+HDC^6 M,$_W=K$>G'I6E=:S!\+OC3KVJ:S;W?\ 96L6X>">*/<"_P I([#J''KT[&LC MP_X.U37/A+XUU-+.9;K6KE;FU@*G>Z12&3@=\[G ]<4 4-5\.R_#;PSX4\>: M9J-Z^J7DD3WJR2?)+YB&0J>,XP"#DG/6O?M8\:>'/#\D$>KZM;V ZWXE'Q&\)>$/ ^E6=U_:UO)$EV'CPL7EQF,L3ZUQ MX'U72+2]D@C$<;SQABJ^E 'D7Q"\5:%XF^(?PY_L74X+W[/JH\WRB3LW2P8S M]=I_*O>*\*^(OAG1/#OQ#^'']C:7;6/GZJ/-\A N_;+!C/TR?SKW6@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YCQWXTLO _A MN;4[G;).V4M;?.#-)C@>P[D]A[XK,/^$YUV%DT2RD*:19.6X\9 M^)\S>(M4^<"0G444 %%%% !574=0M-)TZXO[Z=(+6W M0R2R/T515EF5%+,0J@9))P *\1U6\N_C3XN.AZ;+)#X.TR4->W29!NG'0+V/ MM[98]A0!/9_%+QYK"W6M:'X,2_\ #HG:. AB)V"]\9.?P4@'C)Q5ZU^/.E6Y M6'Q'H&L:+<'J)(=ZC\3M;_QVO4K&QMM-L8+*S@2"V@01Q1H,!5' %23V\%U" MT-Q#'-$PPR2*&4_4&@#A+OXS>"(-"GU.WU>.Y:,?+:HK+,[=@%8 _CT%.HBMFOS:;I#?<1#T9AZ< X/+=^, ]XWPU\%MJ$-\/#>GI<0N M)$,<>Q0P[E1A3^(KJJ $ &!T%+110 4R65(87EE8)&BEF8] !U-/KSOXT>( M9-$\ 3VUJW^G:HXLH57[Q#??P/\ =R/JPH POA)$?%/B_P 3^/YT?%S.;2RW M_P ,0QG\=HC'_?5>PU@>"O#R^%O!NEZ-A?,MX0)2O0R'YG/_ 'T36_0 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 5A^+?%FF^#-!DU?5&D\E6$:)&N7D M<]% ]>"?P-;E9/B'3-#U+32VOVUK-96I\\FY V1D _-D], F@#A_#_QFL=4U MZTTC5=#U'19KX@6"ZD4JUY*&5OE!_A MRB_@#W. [X<@2?&[Q])+S.K;$)Z[-_\ ]9: .ZTKXAZ!JW@F;Q7'<-%I]NK? M:%D WQ,,?(0#]XY&,= I+7'FQO:" CKCR M,_S"T >^UX_\7_\ DH7PQ_["I_\ 1MO77>,+WQ_:W]NOA#2])N[4Q9F:]8A@ M^3P,.O&,5Y/XLN_&UU\0OA__ ,)CIVF6>W54^R_86)WYEAW[LNW3Y<=.IH ^ MBJ*** "BBB@ HHHH **** "O)/B6XU#XK?#W2!R8[IKQU]0&4C_T6U>M,P52 MS$ 9))Z5XSX8D;XA_&JX\76R%=&T.$V=M*1Q.Y##(_[[=O8;?6@#V>O(OB@ MZ:Q\3? ?AO[P%R;V=/5 01^B25Z[7D6EHFN_M)ZK=D[X]%TY88V]'8 $?^1) M!^% 'KM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 5QOB6236M>M/#UO*RQ?ZV[* M'D+Z?E^I%=5>W<=A9374QQ'$A<_AVKF_!=I+-'=:Y=J/M%\Y*GT3/;VS^@% M&QIOAW2])VFUM$$@'^M;YG_,]/PK4HHH P?%&@G5[-9K8[+^V.^"0'!)'.W/ M^>:L^'M0N=2TB*>[MY(9QE7#KMW$=P/0_P"-:M% !1110 4444 %%%% !111 M0 4444 %%%% !7F/CWXE:EX4\1C3;7P=-JT7D+)]I5F R2?EX1NF/6O3J\V\ M//BY:_$+P M^/#VE>'+IKR:9&B=R'9"#GY N3D]/H37T)X?BO8/#FF0ZBQ:^2UB6X).29 H MW?KFK7PMON2_B5C1HHHJ1A5/4M*L-9LVL]2LX;NV8@M%,@921R.#5RB@#F/^ M%<^"_P#H5])_\!4_PK2UKPSHOB*R2SU?3;>[@C.461>4_P!TCD?A6K10!GZ/ MH>F:!8+9:38P6=L#GRX4QD^I]3[FLU? ?A5-=_MI="LAJ._S/.$?\?\ >QTW M=\XSGFNBHH *\?\ VCO^2>Z?_P!A6/\ ]%2U[!7C_P"T=_R3W3_^PK'_ .BI M: /8**** /!_&FJ&'XU:GJX89\-Z"\J ]/-92$'_ 'U.OY5VGP2TA]*^&-@\ MJD2WSO=OGJ=QPI_%54_C7B'B/4+K6-9\7M;#?/K6LQ:;!_MQH[''YI!^=?5. MFV4>FZ5:6,7^KMH4A3Z*H _E0!R7Q5\7?$CX(NKB"0KJ%U_HUF%Z[V'+#_= M&3]<>M3_ R$_\ "'>"+.PD'^FR_P"D79(Y\U@,C\!A?PKB5;_A9/QOR'\S M0O"O(&,K)<9_^*7\H_>O9J "BBB@ HHHH **** "HY+B&%D665$,C;4#,!N/ MH/6I*X6>W'C3Q/-&[.-,L%,8>-L;G/V3_(CZ58M/&]L)_LNKVLVG7 '/F*2OY]?T_&@#JJ*CAFBN(5EAD62- MQE64Y!%24 %%%9FNZU!H>G-75KT?:=8NVVY8YVLW.W],G'7&*N^&]$N'N&UW5_GO MY^41A_JE^G8X_(5B^.-2>3Q'86=NHE>V(<1GH9&(P"/H!^= &EIL%MX:M9-9 MUV<'4KK+$'EA_LJ/7U[#ITJ);?5O&;B2X+V&C9!6,'YY1_GUX^M7=+\*/)=# M4M>E^V7IY$9Y2/VQT/\ *NJ P,"@"M86%MIMHEK:1".).@'<^I/7'QD\:CP[IDSIX3TJ0/?W49(^T./X5/?D$#\6YXKV2&*RTC3 MXH(_)M;.W01HN0JHH& .?:OG_P"&W@SQ[J_A*WDT_P 3#0-$F=GB2&']\_." MYP%)SC@EN@[#%=7Q M-I"2G^$WD?'U.<#\:T[36-+O\?8]2L[G/3R9U?/Y&N2A^#G@&&W\D>'HG'=G MFD9C^.[(_"LC4/@#X'O,FWAOK'/_ #[W)./^_@:@#TF\O[/3X#->W<%M$/XY MI B_F:X36/C9X(TB1HEU)]0F'&RQB,F?HQPI_ UE67[/_AB*Z6;4K[5-31.$ MAGG"J!Z$J ?R(KN]%\&>&O#Q#:3HEE:R 8$J1 R?]]G+?K0!Y7J_B;QE\5(5 MT'0_#M[HNCW3A;K4KH$;H>XZ ?@I)/3(!->M>&O#FG>%-!MM(TR+9!"O)/WI M&[NQ[D_YXK7K#\7^)K3PAX9O-9O""L*?NX\X,LA^Z@^I_(9/:@#6CO+::YFM MHKB)YX,>;&K@M'D9&X=1D<\U-7SWH?@7QT-+7XA:9J+IXFO96N9;&4@)/ V" M%.>YQG:>Q&,$5Z7X'^)>G^*Y#I=Y$VF>(8,K<:?."K;AUV9Z_3J/UH [FBBB M@ HHHH *\;U/;XZ^/UEIVTR:;X9A,\O]TS9!_P#0C&,?[!KU'Q#K-OX>\/7^ MKW+ 16D+2$'^(@<+]2<#\:X+X(:-
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
("""='OF^]C/E-[GV_E]*[@$, 000>A%5-3TV#5=/EL[A< MHXZ]U/8CWKF- UE]$EGT/6I0AM5+03-P'C'./RZ?EVH Z35]5M]&TZ2[N#\J M\*HZNW8"L'PQI5Q=7LGB/4QMNK@9AC7@(A&,D?3I[55T^WE\8:P-5O(V72[= ML6T+?QGU/K[_ )>M=O0!!=W45E9RW,[!8XE+,?I7(>"-/>ZN+OQ#/_ !?_ .2A_#'_ +"I_P#1MO7L%>/_ M !?_ .2A_#'_ +"I_P#1MO7L% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%<+\2?B G@[3XK.PC^U>(+_\ =V5HHW'). Y'IG@#N>/4@ R? MB=XVNH[B/P3X8C6Z\0ZD/+< BWC8 M:::9=0UN[ R%.WL#]W"YP/=.I)KN_"OAV'X;>%-3\7^)I#F2< ^IQV J+X,Z)=7%OJ/CC5PQU/796=-W\$&>,>Q(X]E6@#U&UMX[2T MAMH5VQ0HL:#.<*!@?I4M%% !1110 4444 %>*:R?^%J?%N#182K^'O#C>;=R M+QYLV>5##GJ-O_ 7.>E=C\5?&3^$?"C"R+'5]0;[-8H@RV\]7 ]@?S*U9^&G M@Y?!?A""SEPVH3GS[R3N9&[9[A1Q^9[T =B.*X?XA_#73_'=I'*96M=5MEQ: MW()*CG.UEZ$$]^O\J[BB@#R;PE\1-4T36X?!WCZV%KJ1(CL[]%Q#,V\8>$H MVNRPU:Q/V:^1QAMXZ-C_ &A^H([4 =Q117*_$#QG;>!_"\VI2@273_NK2#/, MDIZ?@.I]A[B@#A_B]J3^*=6TSX=:./.O+F=)[YUP1;Q#GGT.#N^@']ZO6[.T MAL+&"SMU*PP1K%&I.<*HP!GZ"N ^%/@RZT6PN/$.O;I?$6L'SKAY%^:)3R$] MCW(X[#^&O1J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ KQ_P"+_P#R4+X8_P#85/\ Z-MZ]@KQ_P"+_P#R4+X8_P#85/\ MZ-MZ /8**** "BBB@ HHHH *\3UIV^+GQ-CT"!M_A?0)/-OG4D">7D;<]^05 M'MO(/2NW^*OBE?"G@*_ND<"\N5^RVH(SEW!&<>R[C^%2?"_PLWA+P%I]A-G[ M5(/M%R#VD?!*_@,+^% '7QQI%&L<:A44!551@ #L*YGX@>+X/!7A&[U5RAN< M>7:Q-_RTE/0?0*::TGQ9^*L>LH&7PSX /*J??DD^['T% M>AT44 %%%% !1110 4444 %%%% !3#+&LJQ%U$C E4)Y('7 J'4+^#3;&6[N M7VQ1C)]_0#W-F3Z\P_$UA>#=/F$,^M7G_ M !]7[;\#@!,Y''OU^F* .BLK2*PLH;6!=L42A5%3T44 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4A(4$D@ =2:6O"/B7I%_XQ^,&F>%K_59- M/TB6U$D'=9&&XM@9 +DC'/3^:UNDNH^C;Z'N?VB#_GM'_P!]"I U#_OVE>Q:78II>DV>GQNSI:P)"KMU8*H&3^55I8G6Y;HHHI#"BBB@ M HHHH **** "O'_VCO\ DGNG_P#85C_]%2U[!7C_ .T=_P D]T__ +"L?_HJ M6@#V"O$OVD[_ ,KPSHVGAL>?>--CU")C_P!J"O;:^)?$OQ4T#PS _P#R MSCB_W'EDY/\ WR%- 'JGPKTI/#?PMTI;AEC+P&\F=N -^7Y^BD#\*YKX+02Z MUJ/B?QO=9+ZI>-#;[NJQ*<_ERJ_\ K9^,.LQ>&OA==VT'R27BK86ZKZ,/F_\ M<#?I72>!M 3PQX)TG20NV2&!3-[R-\S_ /CQ- '0T444 %%%% !1110 5ROC M>\N2,?0'UH MRO#6G2WWC"*2\+/+&/M4^X=&/*C\RI_,5ZG7*>![>62UO-6N5Q-?3%QD?PC/ M3VR3^5=70 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110!X_\7_^2A_#'_L*G_T;;U[!7C_Q M?_Y*'\,?^PJ?_1MO7L% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M5RGCCX@:/X%T\2WSF:\E'^CV41'F2GI^"^Y_#)XH /'WCJP\#:$;RXQ->392 MTM0?FF?_ .)&1D_U(KF?AOX%OQJ$OC;Q=F;Q%>_-'$XQ]D0]!CLV.,?PCCUJ MIX)\&ZOXE\2GQUXY@*W6?^)=IKCY;9>S%3T([ \YR3SBNO\ B'XUM_ _AB6^ M8"2]E_=6=OGF20]#CT'4_EW% '$?$VYD\<>.-(^'6GR2"!7%WJLD9^X@&0I^ M@.>>,LE>OVUO%:6L5M @CAB01QH.BJ!@ ?A7"?"OP=<:!I$VL:R'D\1:NWGW MLDOWD!.0GMUR??CL*] H **** "BBB@ KFO&WC?2_ VB-J&H/OE?*V]LIP\[ M^@] ,\GM^0+/'/CK2_ NBF]OF\RXDRMM:*(=; M7QSX[7S-0?#6.GLN$M5_A)7U[@=NI^;H '@?P;K'B3Q!'X\\;[A><-IVG]%M ME_A8CL>X'7N>>GKE%% !1110 5XOXJ1_AA\4;7Q=;HXT'6V^SZFB_=CE/.__ M -F_!QWKVBL?Q3X=M/%?AN]T:]4>7<1X5^\;CE6'N#@T :,]Y;VUC)>S3(EK M'&97E)^4(!DMGTQS7C?A>UF^+/C^3Q?J,3#P[I,ABTNWD7'FN#G>1WP<$^^T MCZ39Z%I%KI> MGQ"*TMHQ'&GL.Y/P5X_\7_\ MDH7PQ_["I_\ 1MO0![!1110 4444 %%%87C+Q'%X4\):CK4@4M;Q$Q(QX>0\ M(OXL1^% 'F^L$_$+XX6>D*5DT;PTOVBY'57GR/E/KSM7'^R]>RUYO\%_##CJU^I.J:U(;R=V^\5/* _@2W_ S72>.O&%IX)\+W.K7.UY0-EM"3@S2GHO MT[GV!H XOXK^([W4KVT^'GAUPVJZJ0+MQG$$!Y.2.F1DG_9!]17H'A;PW8^$ M_#MIH]@F(H%^9SUD<\LQ]R?\.U<9\)O"%WI]K<^*]?W2>(-9)ED+]8HB7!'EIW!_K^7.: $E9_ M&NO>2A8:+9-EV!XF?_/Z?6NV1%C0(BA548 P *JZ7IMOI.GQ6=LN$0-C]ALCYET1T9O M3^GXGTKLU4*H50 , #M6'X5T8Z1I*^<#]KG/FSECDY/;\/YYK=H **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH BN+JWLXO-N9XH(\@;Y7 M"C)]S7E?Q)^'3^,/$4%])XTCTR*&)?)M)!N"-D_.O[P8)XY [=:[+QUX)L_' MFAQZ7>W4]LDV&-*;ZVN[N_U*)[>UCM5$3I@J@P M":5K_ '_H.]CB?^%17O\ T57_ ,>;_P"/5[II-JUEHUC:ML MN% W=3UZUY/_ ,,W^%O^@MK'_?<7_P 17K6FV,6EZ7::?"S-%:PI"AZ?_ -A6/_T5+7L% M>/\ [1W_ "3W3_\ L*Q_^BI: /8*^>/""GQG^T?JNL-\UOISRNOH0@$,?]&_ M"O<_$NK#0?#.IZL<'[):R3 'NP4D#\3@5Y)^SMI7V?P_K/B*Y;#74XB#N>BQ MC\;,?%GQK\,>&%3S+/2Q_:%V.HS]X!AZ?*@_P"VE=CXDNI] M8UFW\.V$CH,B2[E3^!>N/Z_4BO//AYJAENO%_P 0[HAI-0NC:6"MU*KSCZ > M6/\ @!KTGPY:0Z#IC:CJT\<5W>MOD>5@",\A?KSD_P#UJ (5\,:]8MG3O$4C M+V2X4D#\\C]*#>^-+!L36%K?1CJT1P3^H_E771R)-&LD;JZ,,JRG((^M.H Q M-!\11ZTT\$D#6MY <20.H^G7V M^E4[OQ'=>)O*TS0T>,RH#V7)/,DA'S.?4_X5HT M>?:_%XETW2WN[W75Y8(L<"[=Q/;( [9/X5+I?@2X&GQM+JUS;F10[P1#:%)' M0\\G\*NZQ_Q._&-CI YM[,?:9_<\8!_3_OJNOH XE;_6_"3"+4E;4-,'"W"# MYT^O^!_.JEI8#QSJ%_J%S(R6T8\FU4'E3U!(_7WS[5I^++R;4+NW\.6!_?7! M#7# _<3KS_/\O6FW7@^33F6\\.W+V]S&N&B=LK+CZ]S[\?2@"3PWJ]Q:W;>' M]7.+N'B&0])5[<]^.G^(KK*X"ZNX?%$8M+I?[.\06I_=;LJ&;K@'W].W;/-; M_AG7VU2)[.]7RM2MOEFC;@MCC[?T^IKF/"WA^76HH7ND,>EP-N6/IY[]R?4=L^G'J: MELM.G\;:]+J=V'CTV-MJ \%E'11_,GWKT2**.")8HD5$0855& !0 J(L:!$4 M*JC & !3J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** /'_ (O_ /)0_AC_ -A4_P#H MVWKV"O'_ (O_ /)0_AC_ -A4_P#HVWKV"@ HHHH **** "BBB@ HHHH ***X MKQW\2M*\%1+;8-]K,V!;Z?"P- ':YK UGQMX8T!F35-=L;> M5>L1E!D'_ !EOTKS:R^'?C/QT/[4\:>);S389SD:38DJ(U[ \[5/U#'U.>*U MV^&7PS\#6)U35K:)HH^/.U&4R!CZ!/NL?8*30!T>E_%#P3K#A+3Q'9!RN?2OG#7KC2OB+OMO!/PT$K*VS^TV3[,B_ M@A52?3O$,FBM!>>*(K9FPWV.)'DBS[G(Y_X": .X\7?%RVBF30_ M!:+KNO7)*1_9_P!Y%%[DCANYX.!C)([R^"/A>=/U$^)?%ER-6\23'S"\GS1V MY]%'0D>N !T '4\?H>@?$#X4G-GX;TG7;(Y\V6R3%R5]-V _X;6%=CH/QN\* MZI,UKJ;3Z)?(=K0WZ;5![_..!_P+;0!Z'>WEOIUE/>7%4#)) MKQWPA97/Q3\=/XXU:%ET+3G,6D6LJ\,P/WSV.#R>OS8&?EH\<:Q-\3/%=KX" M\.W2MI:8N-6O8CN3:,$*&'! X^K$>AKU[2]-M-'TNVTZPA$-K;1B.*,=@/YG MW[T 6Z*** "BBB@ KG?&GC+3?!/A^75+]MS?=@MPV&F?LH_J>PJ_X@U_3_#& MB7.K:G,(K:!/?&P,NI38>PLG&$M4_A.WUQT';J/7*** M"BBB@ HHHH **** *L6G64&H7%_%:PI=W"JLTRH \@7[H)[XS5JBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O' M_B__ ,E"^&/_ &%3_P"C;>O8*\?^+_\ R4+X8_\ 85/_ *-MZ /8**** "BB MB@ KQOXDR'QQ\1]"\ P;VM+=Q>ZH4/1<<*?0[3^21 MF;:1;6[-AIY,<*!UQTR>PKPGP%X,^(/B9]2UR'5'T2'5FWS7SH1-."2?W>/F M"\]BH/'7' ![_K/BCP]X5MD_M74[2Q0+B.-V^8@?W4')'T%>6:*DGQA^(AU^ MYCD_X1/1'V64,B_+<2]W M<<+$9"G))'K@/\ 3?,\JSMKJ[D/38F M?SY_2JOV/5/%^HQMJ5I+8:7!AO(?(:0_D#_A0 EC;W'C/4AJ-]&T>D0-_H\! M/^L/J?7W_+UKM@ H 4 < "FQQI#$L<:!$0 *JC I] "$ @@C(/:J=II-A8 MW,UQ:VL<,DV-Y08SC^7X5=HH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BL_4M;T[2$W7ETD;8R$ZL?H!S7.GQ!KFO$)H6GFWM MV.#=W'\QV_+- &IKWB>#22+6!/M.H2<1P)S@GIN_PZFJ6D>&KBYO%U?7Y//O M,AHX<_)%Z<=,^W3ZU>T'PU;Z.#<2L;B_DYDN'Y.3UQGI_6MV@ HHHH **** M"BBB@ HK%U?Q1IFC!DFF\RX'_+"+YFS[^GXU=TJ^DU'3X[J6UDM6?/[J3J.> M/S% %VBBB@ HHHH **** "BBB@ HHHH **** "N:\7>/?#_@F&)]9NRDDV?* M@B0O(X'4X'0>YP*Z6O$?&-SHNB?'6VU+Q? LFDS::$M)9H3)%'(#W&#TY['& MX&D]TOZV'T;.^LOB9X;O/![>*6FN+?2TG\AWE@8LK9 Y"YXY'-=;%*DT22QL M'C=0RL.A!Z&OF+_A,=!M_@WKGAZ.=9M1O]3E-O;1H>$,BD-TP!@<=Z^B?"MM M<67A#1K6[!%Q#90I*#U#! "*I:IOT_%:_<3L[>OX/0UZ***0PHHHH **** " MBBB@ KQ_]H[_ ))[I_\ V%8__14M>P5X_P#M'?\ )/=/_P"PK'_Z*EH T?CU MK/\ 9GPUFM5/[S4;B.W&.H4'>Q_),?C6+J\T?P__ &Q\P1WM]:")5SAC) M/\S_ )*S<^PJI\9\>)OB)X1\'J3L=Q+/CLKL%/XA48_C7/\ CB[D\=?%73=$ MLH_,@@# M\QX'/ '%>B6O@F.>0W.NW8Y0_T_,?C2P>,+G3I$M_$.G26KDX$\:Y0_P"? M8FNOJ.:&*XB,4T:21MU5U!!_ T ]8'B3Q5:Z%$8EQ->L/EB!X7W;T M'\ZY,Z[JOAI;C0(=MQ*KA;:53N*J>V.YZ<=N>M:_ASP85E&I:U^^N6.]8G.[ M:?5O4^U &9H-SKMA/LM+TE4=F]3CCGG'KQ7K%17-M!>6[ MP7$22Q.,,K#(- '!KX_U.^D6#3M)1IR.A+2?C@8XI]SX?\5>(-AU.ZAMX,@F M -T_ 9!/U-=I8Z=9Z; (;.WCA0=E')^IZG\:M4 06=I#86<5K;KMBB4*HJ>B MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH \?\ B_\ \E#^&/\ V%3_ .C;>O8* M\?\ B_\ \E#^&/\ V%3_ .C;>O8* "BBB@ HHHH ***1F"J68@ #))[4 +4< M\\-K;R3W$J10QJ7>21@JJHZDD]!7'^)_BEX4\,V#3R:G!>W&2L=K92K+(S>A MP<+]3C\3Q7%1>'?&'Q9N$O/%3RZ%X;5MT.EQ'$LR]B^?PY8?11G- %K7OBO= M^(KT>'OAQ;/?ZC)D27[)B*W7."PW=>QW'CD=2<5T'@7X86/A65M5U*=M5\0S M9::^G);:3UV9Y'^\>3[#BI]0U7P1\)=%\L1V]CO4,EM;J#/<%1@''4]/O,<> MIKB\>/?B[W?PQX4DP1U\^Y3]"0?P7G^+% '1>+/BY9:=>_V'X8M6U[7Y"42& MV^:.)A_>(ZX[@>AR169HOPKU+Q)J*:_\2+YK^ZX:+3(WQ#!_LG'!^B\>I;-= MWX3\#Z!X+LOL^CV01V'[RXD^:63_ 'F_H,#VKHJ (X+>&U@2"WBCBAC&U(XU M"JH] !P*DHHH *QM>\)Z#XF@,.LZ5;78(P'=,.OT$? VB>" M+:Z@T:!T%S)YDC2OO8X& N?0BF^LUO19-=0"Z*[Q 9!O*^NWKC@\^U6*\?T_X&6NJ MVDE_XRU2^O=?NF\R:XMYMHB/95RO./ICH !RJ_"KQEH,ID\+?$&\2,?4_]\4 >O.ZQHSNP55&22< "O-?$7QGT2PNUTOP];R^(=6D)5(;+)3= M[N <_P# 0?PK(;X;^.?&-RJ>.O%"IIL1Q]CTSY1-[GY0!]2"?85Z-X;\'Z#X M2L_L^C:=#; C#R8W2/\ [SGD_P J /-[3P+XO^(&IV6J?$*>"VTRWD,L6C0# MK_O$'CMU).,CYO8*\?\ B_\ \E"^&/\ V%3_ M .C;>@#V"BBB@ KSWQQ\4+;P_#_!%Y?1G_39A]GM #SYK X/X#+?A7FS:?#\*?A?%I^H%4(H50 H& !VKD?AMX.3P7X0M[%\-?3?O[R3NTK=1GN ,#\,]ZZ^@ MHHK+N/$>CVS,LNI6P93@A7#$'Z"@#4HKF;CQYH4&=DTLY](XC_[-BJO_ L& MS $C:=?+;GCS=H_QQ^M '845B6GB[0[P#9?QQL?X9Y_P * )O$/B1-(5;:V3[1J,W$4*C.">A(_IWJIHOA4;GU'7 M MY?S\-_V)8XD&%51@"@#"TSP9IME()[G=?774R3\C/KC_'-=$ % M '0"EHH **** "BBB@ HHHH *YGQ3K4T)CTC3WL?Y=* +.A^% MK#1XT8^>=QDY[XSTK=HHH **** "BBB@ HHHH **** "BBB@ HHHH * M\5^)_C">V\=1^&[GPS%XCTUK)9Q8K$3+YA+#<' 8K@#L*]JKRCQEIWBSPY\1 M1XQ\-:0FL175D+2XM\_,A!R".^.!R,]#GM4O=7_K1C6SM_6IS&F:EX TCP+? M^,M$\(1V^L:?.L!M;R224PSL0%/S$\#I_M/B&]COGEB.8X=F["' M'"]>K$&NR\+:EXA\=_%72-3U'P[/I$&A6LLWT445)04444 %%%% !113=Z;]FY=^,[<\XH =7C_[ M1W_)/=/_ .PK'_Z*EKV"O'_VCO\ DGNG_P#85C_]%2T <%XB\2V[?%KQ5XB< MEDTN%K2U /\ RTP(C^?[W\Q6M\(M.UFVDNM?MM.CO-1NQN=IO^6:,>,)XO]=X;+_]&+]1ZKEA_P"@UUE%8#.0_P"%@V43;;K3[Z$^Z#^I%6X?'6@R M_>N7B/H\3?T!KHR 1@@$>]5Y-.L9O];96[_[T2G^E '/W?CBR\T6^EP3:C<, M.%B4@?RS^E5O[-\4:^N=0O%TVV)_U,/WB/?!_F?PKJ[:RM;-2MK;0P \D1(% MS^53T 8VD>%]+T9Q);PEY\?ZZ4[F_#L/PK9HHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HJK!J5AV\MQ%_K(HY59D^H! MR*M4 >/_ !?_ .2A_#'_ +"I_P#1MO7L%>/_ !?_ .2A_#'_ +"I_P#1MO7L M&: "BC-5=1U.RTBPEOM1NHK6UB&7EE8*H_SZ4 6JX?QI\4M$$3+8J'U+6)& M"II]HX\>:E;^%O!MTFF178Q<:E>N(6 (Y5.!ZGD^W2II/@OK.GMGP[\0=9LD'2*9F8'ZE64?^.U[!2, MRHI9B%4#)). * /./"7P9T'P_>#4M2EEUK5,[O.O!E5;N0ISSG)RZY_F>3@X4]: /7I)$BC9Y'5$49+,< "N6U+XF>"])+ M"Z\26&Y>JPR><1^"9-<;:? FUO427Q3XEUC5KGJP\_"9[_>W,?KD5U.D_"?P M/HQ#0>'[:9Q_'=YG/Y.2!^ H YNX_:&\%P7!BCBU6X0=)8K=0I_[Z<']*. M7_C/Q'\5KR31? T/_%_ M_DH7PQ_["I_]&V] 'L%%%>:?$_XK:=X.LI]-LI!($\4_%7R^#I'AH-DLWR-< Y)/; 8#CTC/K5?P99:]XT\6R>++ M?%Y8Z)+Y5E'<,2))",DJ#W&0W4'E?2N5\!>!M>\=V_V:U5K71Q+OO;V0_P"N MD_NCN3C''0=3U KWCPY"? %S#X>G"#2I.;:8# 5N^?J>ON<]Z ->S\;6PG^R MZM;3:=<@];=UK&GVE@+V:[B%N?NN&SN]ACK^%2WEA::C"8KN MWCF0]G7./H>U8,'@31X;X3XEDB7E;>1LH#_,_0T 9[7>L^,6,=F&T_23PTS? M?D^G^ X]36S9^#M#LT4?8EF<#EYB6)_#I^E;JJJ*%50% P !@"EH K0Z?96_ M^HM+>+_H^-+"RN_LMO'+?3#.X6XR%]L]_PK,:YUCQDQCM ^GZ1_%,WWY?8?X#C MU)KIM)T2QT6W\JSAVD_>D;EF^IH PQXNU.3F#PQ?..Q;*C_T&FMXQU"R_>:I MH%S!;G_EHAW8^N0!^HKKZ0@$8(R#0!E:=XDTG4]JVUY'YC?\LW^5OR/7\*UJ MQ-1$:-J1+26@BD_YZ0?(?TX/XBL672/$'AU&N-+U"2^MD.3:S#)V^W_ -;% M ':T5E:'K]IKMKYD#;95_P!9"Q^9#_4>]:M !1169J/B#2]*;;>7D:/_ '!E MF_(DER2!^1Q_.@#KZC-Q"I(,J CJ"PXKS'5)_ M$5_J2:9_:/GW3??@M#M2/V8C X[]<>M;]M\.M/\ LB"[N+AKD\N\3 #/L"#0 M!U;7]HOWKJ ?605B:CXTTFR;RX)&O)R<".W&[GZ]/RS6-/\ #2$_\>^I2)[2 M1!OY$5'I<[^"[H6NJZ?%Y#MB._B3)/U/7\.OUH O%_%FO%@JII%HW=O]81_/ M/_?-7M/\%:9:R">[WWUQU9YSD$_[O^.:W[>YANX$GMY4EB<95T.0:EH 155% M"J % P .U(]:31-(DN,@S-\D*G MNQ_H.M5O">BMIFGM<70S?79\R9CU&>0/UY]S0!3A\<103+!K%A[*67Z M],_D#7166IV6HIOL[J*8#KL;)'U'45--;PW,9CGBCE0]5=0P_(USMYX&TN9S M-:&:QGZAH6X!^A_IB@#IJ*X_[%XPTE/]%O8-2B7HDPPY_$__ !5.3QI+9ND> MM:1]MUGMIDEB;HR'(J:@ J&ZN8;.UDN9W"1 M1KN9CV%2LP12S$ 9)/:N(N99O&VJFSMF9-&MF!EE'_+5AV']/S]* )-&M9O M%&L?V[?QE;*$[;.!AP<'[WY_K]*[2HX88[>%(8D"1HH554< "I* "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ KQ_P"(?C+QG)X]M_!G@Q8X;EH!-).R MH2,?$W1/'=Q\0=.UKPGHL;-8P )>I(BO)DG=&X9P"OX= MSS2>ZOL-;,J?V+\>?^@]9_G#_P#&Z]GTM;Q-)LTU%U>^6!!<.O1I-HW$?CFO M&/[:^//_ $ ;/\H?_CE>SZ6UX^DV;ZBBI?- AN$7HLFT;@/QS5=">I;HHHI# M"BBB@ HHHH R?%.IOHOA35]4BQYEI9RS)D9^94)'ZXKYS/A1K7X10_$E-2OA MXD^TBR6_A72I?#VE:7JVFV.H"PMHX4^TVZRA2J!21N!QG%>5?'KP[H>A^!["Z MTG1=.L+@ZG&AEM;5(F*F*4XRH!QD#CV%-6OJ!P'P^\,VFK>797NO6FEVL\@% MP//43W!QD1A>R@=VXR>,U[)XG\$>&;KPW'X5T8VMKJ\,1O;!%D'FR%>"Q/4A MNF3[>E1ZU\"_#-^KMILMUILQ^[M;S8Q]5;G_ ,>%>=7_ (=UWX.^(],UOSX[ MRU+F/=%E0Z_Q1L#TR,D=>1GM7UF']EB%"&!KN,HZJ#5KM=VG9M^?IL8.Z^)' ML'PV\9?\)1H7V>]8)K-C^YO(FX8D^.??-=58ZK8:FURMC=PW!M9FMYQ& MV?+D7JI]",UY)X@ND\->(=-^)6@9FT74U5-2BB'9OXB.@.1_WTO/WJ]FK1GT_E:WC\GMY6-(/HR"W\ M0:1=:*^LP:C;R:;&KL]RK@HH7.XD^V#2W.NZ59Z*NLW%_!%IK(DBW3/A"KXV MG/HG.3GZTLEE:2V@M)+6%[8 *(6C!0 M =!MZ<8'Y5YI9%>ZK8:<]HEY=Q0-=RB"W#MCS9#T4>IHFU6PMM3M=-FNX8[V MZ5V@@9L/(%&6P.^!4\UM;W!B,T$4ABW#?.J$X#$>F:+35;"_NKNVM+N&:> MS<1W$:-DQ,1D!AVJ<6UNMTUR((A<,H1I0@WE1T!/7'M1%;00R2R101QO*VZ1 ME0 N<8R3W.* *EKKNE7NFSZC;7\$MG 7$LZOE4V?>R?;%-F\0:1;Z$NMS:C; MII;(KBZ9\(58@*<^Y(%6X[*UAMW@BMH4AR%D]I MUH%"B Q@H .@V],# H COM6T_3$MGO;R&W6YF6"$R-@22-]U1ZDX-$^JV%MJ M5IIT]W%'>78".41N)$WH&VL.C#/0CUH>V@D MN(KB2"-IHLB.1D!9,]<'J,T 0#5; ZN=)%W#_: A^T&VW?/Y>=N['IGBBUU6 MPO;R\L[6[BEN+-E2XC1LM$6&0&],BI_LT'VK[5Y$?V@IY?F[!OVYSMSUQGG% M$=M;PRRRQ01)),09'5 "Y P"3WX]: *UGK.F:A:W%U9WT$\%M(\4TB."L;)] MX$]L5&/$&DG0O[<&H6_]E^7YGVK?\FW.,Y^O%7(K6W@C>.&WBC21BSJB !B> MI('4GO31868L?L(M(!:;=GD>6/+V^FWICVH @O-:TRPL8+V[OH(;6=D2*9G& MUR_W0#WS3[K5;"QN[2TNKN&&XO&*6\;MAI6 R0H[\5--:6UQ$D4UO%)&A#*C MH"%(Z$ ],=J62V@FEBEE@C>2$DQNR E"1@D'MQ0! VJV":M'I37<0OY(C.EN M6^=D!P6QZ9H@U6PNM2NM.@NX9+RT"&X@5LM$&&5W#MDK''4^],6PLTL39+:0"T*E3 (QY9!ZC;C&#DT 5[O7-+L=,BU*ZO[ M>&REV>7.[@(V_&W!]\BI+S5;#3[BTM[N[BAFO)/*MT=L&5\9P/4U-+9VLUNM MO+;0R0KC;&R J,=,#IQ@8I9;6WGDBDF@BD>%M\;.@)1L8R,]#0!!)JMA%JL6 MEO=PK?S1F6.W+?.R#@D#THBU6PGU2XTR*[B>^MT626 -\Z*W0D>]3M;0-TF,%PL;9,<@ZJ?0U%;Z_I-WI$FK6^H6\FGQ!V>Y5QL4)G<2?;!JY#;06 M[2-##'&97WR%$ WMZG'4\=:;'8VD5JUK':P);L�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end GRAPHIC 15 img27442415_8.jpg GRAPHIC begin 644 img27442415_8.jpg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img27442415_9.jpg GRAPHIC begin 644 img27442415_9.jpg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img27442415_10.jpg GRAPHIC begin 644 img27442415_10.jpg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rvmd-20221231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Address, City or Town Entity Address, City or Town Repurchases of early exercised stock Stock Repurchased During Period, Value Deferred tax liabilities: Deferred Tax Liabilities, Net [Abstract] Summary of Benefit from Income Taxes to Amount Computed by Applying Federal Statutory Rate to Loss Before Taxes Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Exercise price of early exercised shares Exercise Price Of Early Exercised Shares Of Common Stock Exercise price of early exercised shares of common stock. Net loss attributable to common stockholders Net Income (Loss) Available to Common Stockholders, Basic Years remain open to examination Income Tax Examination, Year under Examination Fair Value Disclosures [Abstract] Earnings Per Share [Abstract] Level 1 Fair Value, Inputs, Level 1 [Member] Federal Domestic Tax Authority [Member] Stock Issued During Period, Value, New Issues Issuance of common stock from offering, net of offering costs Research and Development Expenditures Research and Development Expense, Policy [Policy Text Block] Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Weighted-average remaining contractual term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms In-process Research and Development - KRASG12D Program In Process Research And Development Related To K R A S G12 D Program [Member] In-process research and development related to KRASG12D program. Intangible assets, Gross value Intangible Assets, Gross (Excluding Goodwill) Intangible Assets, Gross (Excluding Goodwill), Total Convertible notes payable Convertible Notes Payable Convertible Notes Payable, Total Amendment Flag Amendment Flag RSU vested, fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Purchases of property and equipment in accounts payable and accrued expenses and other current liabilities Capital Expenditures Incurred but Not yet Paid Developed technology - tri-complex platform, Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Balance at December 31, 2022 Balance at December 31, 2021 Goodwill Goodwill Goodwill Goodwill, Total Operating lease right-of-use asset Operating Lease, Right-of-Use Asset Redeemable convertible preferred stock, shares issued Issuance of redeemable convertible preferred stock, net of issuance costs, shares Temporary Equity Stock Issued During Period Shares New Issues Temporary equity, stock issued during period, shares, new issues. Disposal Group Name Disposal Group Name [Axis] Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration Net operating loss carryforwards which can be carried forward indefinitely Less: Imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Net Loss per Share Attributable to Common Stockholders Earnings Per Share, Policy [Policy Text Block] Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Statement [Table] Statement [Table] Operating lease liability, noncurrent Operating lease liability – noncurrent Operating Lease, Liability, Noncurrent Unrecognized tax benefits that would affect effective tax rate if recognized Unrecognized Tax Benefits that Would Impact Effective Tax Rate Capitalized research expenses Deferred Tax Assets Tax Credit Capitalized Research Expenses Deferred Tax Assets Tax Credit Capitalized Research Expenses Change in accounting principle, accounting standards update, immaterial effect Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false] Operating cash flows for operating leases Operating Lease, Payments Deferred rent derecognized Deferred Rent Derecognized Deferred rent derecognized. Issuance of common stock related to employee stock purchase plan, shares Stock Issued During Period, Shares, Employee Stock Purchase Plans Number of operating segment Number of Operating Segments Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding, Ending Balance Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Business Acquisition Business Acquisition [Axis] Common stock reserved for future issuance, Total Common Stock, Capital Shares Reserved for Future Issuance Auditor Firm ID Schedule of Useful Lives of Property and Equipment Property And Equipment Estimated Useful Lives Table [Text Block] Property and equipment estimated useful lives. Weighted-average grant date fair value per share, Beginning balance Weighted-average grant date fair value per share, Ending balance Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Weighted-average grant date fair value per share, Restricted stock units vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Adjustment Goodwill, Translation and Purchase Accounting Adjustments Total lease liabilities Lease Liabilities Lease liabilities. Acquisition of Warp Drive Business Combination Disclosure [Text Block] Income Tax Authority Income Tax Authority [Domain] Accounting Standards Update 2019-12 [Member] ASU 2019-12 Product and Service Product and Service [Axis] Dividends paid Payments of Dividends Payments of Dividends, Total Issuance of common stock pursuant to early exercised stock options, shares Stock Issued During Period Shares Stock Options Early Exercised Stock issued during period shares stock options early exercised. Concentration of Credit Risk and Other Risks and Uncertainties Concentration Of Credit Risk And Other Risks And Uncertainties Policy [Text Block] Concentration of credit risk and other risks and uncertainties. Restricted Cash Restricted Cash [Member] Restricted cash. Cumulative Effect, Period of Adoption, Adjustment [Member] Cumulative Effect Period of Adoption Adjustment Useful life of intangible assets Developed technology - tri-complex platform, Weighted-average remaining useful life Finite-Lived Intangible Asset, Useful Life Acquired Intangible Assets Intangible Assets Acquired From Business Combination Policy Policy [Text Block] Intangible assets acquired from business combination policy, Operating lease, weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Total liabilities and stockholders' equity Liabilities and Equity Lease asset Deferred Tax Liabilities, Leasing Arrangements Tenant improvement allowance Payments for (Proceeds from) Tenant Allowance Maximum development and regulatory milestone payments to be received Maximum Development And Regulatory Milestone Payments To Be Received Maximum development and regulatory milestone payments to be received. Plan Name Plan Name [Domain] Other Other Liabilities, Current Other Liabilities, Current, Total Denominator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Change in accounting principle, accounting standards update, adopted Change in Accounting Principle, Accounting Standards Update, Adopted [true false] Discount Rates Measurement Input, Discount Rate [Member] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Income Statement [Abstract] Reverse stock split, description Stockholders' Equity, Reverse Stock Split Organization Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Proceeds from issuance of common stock under equity incentive plans Proceeds from Stock Plans Debt Securities, Available-for-Sale [Abstract] Developed Technology - Tri-complex Platform Developed Technology Tri Complex Platform [Member] Developed technology - tri-complex platform. Finance Lease, Liability, Current Accrued expenses and other current liabilities Sale of Stock Sale of Stock [Domain] Total current liabilities Liabilities, Current Issuance of common stock related to employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Non-deductible permanent expenses Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent, Total 2025 Lessee, Operating Lease, Liability, to be Paid, Year Three Business Acquisition, Acquiree Business Acquisition, Acquiree [Domain] Fair Value, Recurring Fair Value, Recurring [Member] Interest expense Interest Expense Interest Expense, Total Income Taxes Income Tax, Policy [Policy Text Block] Name of Property Name of Property [Axis] Increase (Decrease) in Contract with Customer, Liability Deferred revenue Gingko Bioworks Gingko Bioworks [Member] Gingko Bioworks. Purchase price rate Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate Preferred Stock, Shares Authorized Preferred stock, shares authorized Other Noncurrent Assets Other Noncurrent Assets [Member] Net deferred tax liability Deferred Tax Liabilities, Net Deferred Tax Liabilities, Net, Total Accrued Expenses And Other Current Liabilities [Abstract] Accrued expenses and other current liabilities. Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Proceeds from issuance of common stock gross. Proceeds From Issuance Of Common Stock Gross Proceeds from issuance of common stock gross Cumulative Effect, Period of Adoption [Axis] Operating lease, weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Commercial Paper Commercial Paper, Not Included with Cash and Cash Equivalents [Member] Entity Small Business Entity Small Business Number of reportable segment Number of Reportable Segments Cash, cash equivalents and restricted cash - end of period Cash, cash equivalents and restricted cash - end of year Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance Net loss of acquiree since acquisition date Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Issuance of common stock related to vesting of restricted stock units, shares Stock Issued During Period Shares Vesting Of Restricted Stock Stock issued during period shares vesting of restricted stock. Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Summary of significant accounting policies. Schedule of Intangible Assets, Net Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Business acquisition, other consideration Business Combination, Consideration Transferred, Other Series C Preferred Stock Series C Preferred Stock [Member] Total current assets Assets, Current Property Plant And Equipment [Line Items] Property, Plant and Equipment [Line Items] Indefinite-lived Intangible Assets Indefinite-Lived Intangible Assets [Axis] Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs Proceeds from Issuance of Redeemable Convertible Preferred Stock Indefinite-Lived Intangible Assets (Excluding Goodwill) Indefinite-lived Intangible Assets (Excluding Goodwill), Total Indefinite-lived Intangible Assets (Excluding Goodwill), Beginning Balance Indefinite-lived Intangible Assets (Excluding Goodwill), Ending Balance In-process research and development - RAS Programs Eight hundred saginaw drive redwood city, california. Eight Hundred Saginaw Drive Redwood City, California [Member] The 800 Building Weighted-average shares used to compute net loss per share attributable to common stockholders, basic Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Basic, Total Total financing lease liabilities Finance Lease, Liability City Area Code City Area Code Aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Accrued research and development Accrued Research And Development Expense Current Accrued research and development expense current. Accounts Receivable, before Allowance for Credit Loss, Current Account receivable Number of Shares underlying options, Options cancelled Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Share-Based Payment Arrangement [Abstract] Payments of deferred offering costs Payments Of Deferred Offering Costs Payments of deferred offering costs. Total liabilities Liabilities Document Period End Date Document Period End Date Stock issuance expenses Payments of Stock Issuance Costs U.S. and Canadian Government And Agency Securities US and Canadian Government Agencies Debt Securities [Member] US and Canadian government agencies debt securities. Redeemable convertible preferred stock dividends - undeclared and cumulative Redeemable Convertible Preferred Stock Dividends Undeclared And Cumulative Redeemable convertible preferred stock dividends - undeclared and cumulative. Schedule Of Common Stock Reserved For Future Issuance Table [Text Block] Schedule of common stock reserved for future issuance table text block. Schedule of Common Stock for Future Issuance Restricted Stock Awards Restricted Stock [Member] Construction in Progress Construction in Progress [Member] Stock-based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Weighted-average grant-date fair value of options granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Lessee, operating lease option to extend lease term Lessee, Operating Lease, Renewal Term Amortized Cost Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Contract with Customer, Liability, Noncurrent Deferred revenue, noncurrent Statistical Measurement Statistical Measurement [Axis] Effective Income Tax Rate Reconciliation, Percent [Abstract] At the market equity offering. At The Market Equity Offering [Member] At The Market Equity Offering Fair value, transfers between Levels 1, 2 or 3, amount Fair Value Level1 Level2 Level3 Transfers Amount Fair value level1 level2 level 3 transfers amount. Total assets Assets Revenue of acquiree since acquisition date Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual ASC 842 ASU 2016-02 Accounting Standards Update 2016-02 [Member] Summary of balance sheet classification of operating lease liabilities. Summary Of Balance Sheet Classification Of Operating Lease Liabilities [Table Text Block] Summary of Balance Sheet Classification of Operating Lease Liabilities Conversion of shares Conversion of redeemable convertible preferred stock into common stock, shares Stock Issued During Period, Shares, Conversion of Convertible Securities State and Local Net California State State and Local Jurisdiction [Member] Net loss per share attributable to common stockholders, diluted Earnings Per Share, Diluted Earnings Per Share, Diluted, Total Unpaid deferred offering costs Unpaid Deferred Offering Costs Unpaid deferred offering costs. Schedule of Outstanding Potentially Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Dividends declared Dividends Dividends, Total Entity Address, Postal Zip Code Entity Address, Postal Zip Code Advance payments for property and equipment Advance Payments For Property And Equipment Advance Payments For Property And Equipment Intangible assets, measurement input Intangible Assets Measurement Input Intangible assets measurement input. Document Fiscal Period Focus Document Fiscal Period Focus Restricted cash Restricted Cash Restricted Cash, Total Upfront cash payment received Upfront Cash Payment Received Upfront cash payment received. Accounts receivable Accounts receivable Increase (Decrease) in Accounts Receivable Estimated variable consideration for expense reimbursements upon research and development services Estimated Variable Consideration For Expense Reimbursements Upon Research And Development Services Estimated variable consideration for expense reimbursements upon research and development services. Deferred offering costs Deferred Offering Costs Less: valuation allowance Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Valuation Allowance, Total Preferred stock, $0.0001 par value; 10,000,000 shares authorized at December 31, 2022 and December 31, 2021, respectively; zero shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively Preferred Stock, Value, Issued, Total Preferred Stock, Value, Issued, Beginning Balance Preferred Stock, Value, Issued, Ending Balance Preferred Stock, Value, Issued Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total Percentage of reimbursement of internal and external research costs and expenses under research plan Percentage Of Reimbursement Of Internal And External Research Costs And Expenses Under Research Plan Percentage of reimbursement of internal and external research costs and expenses under research plan. Interest income Investment Income, Interest Total operating lease liabilities Total operating lease liabilities Operating lease liability Operating Lease, Liability Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Statement of Financial Position [Abstract] Impairment of intangible assets, indefinite-lived Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill) Follow-on Offering Follow On Offering [Member] Follow-on offering. Securities Act File Number Entity File Number Maximum milestone payments receivable upon achievement of certain marketing approval milestones Maximum Milestone Payments Receivable Upon Achievement Of Certain Marketing Approval Milestones Maximum milestone payments receivable upon achievement of certain marketing approval milestones. Statement of Cash Flows [Abstract] Balance Sheet Related Disclosures [Abstract] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Sublease income Sublease Income Valuation Approach and Technique Valuation Approach and Technique [Domain] Geographical Geographical [Domain] Statistical Measurement Statistical Measurement [Domain] Statement of Stockholders' Equity [Abstract] Sale of Stock Sale of Stock [Axis] Net operating loss carryforwards expiration beginning year Net Operating Loss Carryforwards Expiration Starting Year Net operating loss carryforwards expiration starting year. Auditor Location Class of Stock Class of Stock [Domain] Stockholders' Equity Note [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Outstanding Options to Purchase Common Stock Outstanding Options To Purchase Common Stock [Member] Outstanding options to purchase common stock. Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Weighted-average remaining contractual term, Options vested and exercisable Proceeds from issuance of common stock, net of issuance costs Net proceeds from issuance Gross cash proceeds from issuance of common stock Issuance of redeemable convertible preferred stock, net of issuance costs, value Temporary Equity, Stock Issued During Period, Value, New Issues Redeemable convertible preferred stock tranche liability Redeemable Convertible Preferred Stock Tranche Liability Redeemable convertible preferred stock tranche liability. Research and development credit carryforwards Research and development credits Deferred Tax Assets, Tax Credit Carryforwards, Research Deferred tax liability Deferred Income Tax Liabilities, Net Deferred Income Tax Liabilities, Net, Total Schedule of Property and Equipment, Net Property, Plant and Equipment [Table Text Block] Schedule of Redeemable Convertible Preferred Stock Temporary Equity [Table Text Block] Accounting Standards Update [Extensible Enumeration] Pension and Other Postretirement Plans, Pensions, Policy [Policy Text Block] 401(k) Retirement Plans Preferred Stock, Par or Stated Value Per Share Preferred stock, par or stated value per share Contract with Customer, Liability, Current Deferred revenue, current Gross Unrealized Gain Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Lessee Lease Description [Line Items] Lessee, Lease, Description [Line Items] Transaction costs Business Acquisition, Transaction Costs Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] Credit Facility Credit Facility [Domain] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Weighted-average shares used to compute net loss per share attributable to common stockholders, diluted Weighted Average Number of Shares Outstanding, Diluted Weighted Average Number of Shares Outstanding, Diluted, Total Cash Equivalents Cash Equivalents [Member] Finite-Lived Intangible Assets, Major Class Name Finite-Lived Intangible Assets, Major Class Name [Domain] Credit Facility Credit Facility [Axis] Unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Corporate Bonds Corporate Debt Securities [Member] Net loss Business Acquisition, Pro Forma Net Income (Loss) Holdback Provision Associated with Warp Drive’s Agreement with Roche Holdback Provision Associated With Warp Drive Agreement With Roche [Member] Holdback provision associated with Warp Drive agreement with Roche. General and Administrative Expense [Member] General and Administrative Expenses General and Administrative Unrecognized stock-based compensation expense related to unvested stock options Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Commercial Paper Commercial Paper [Member] Current Fiscal Year End Date Current Fiscal Year End Date Financial Instruments Financial Instruments [Domain] Cash, cash equivalents and restricted cash - beginning of year Cash, cash equivalents and restricted cash - end of year Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total Repurchases of early exercised stock, shares Stock Repurchased During Period, Shares Underwritten Public Offering Underwritten Public Offering [Member] Underwritten public offering. Other noncurrent assets Other Assets, Noncurrent Other Assets, Noncurrent, Total Entity Address, Address Line One Entity Address, Address Line One Document Annual Report Document Annual Report Available for Future Issuance under the 2020 Incentive Award Plan Available For Future Issuance Under The Two Zero Two Zero Incentive Award Plan [Member] Available for future issuance under the two zero two zero incentive award plan. Finite-Lived Intangible Assets by Major Class Finite-Lived Intangible Assets by Major Class [Axis] Issuance of common stock related to vesting of restricted stock units Stock Issued During Period Value Vesting Of Restricted Stock Stock issued during period value vesting of restricted stock. Available-for-sale securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Restricted cash Restricted Cash, Noncurrent Benefit from income taxes Benefit from income taxes Income Tax Expense (Benefit) Income Tax Expense (Benefit), Total Series C Series C Redeemable Convertible Preferred Stock Series C Redeemable Convertible Preferred Stock [Member] Series C redeemable convertible preferred stock. Increase in operating lease liability Operating lease liability Increase (Decrease) in Operating Lease Liability Less: Weighted-average unvested restricted shares and shares subject to repurchase Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation Mature after One Year through Two Years Mature After One Year Through Two Years [Member] Mature after one year through two years. Income Taxes Income Tax Disclosure [Text Block] Preferred Stock, Shares Issued, Total Preferred Stock, Shares Issued Preferred stock, shares issued Balance Sheet Location Balance Sheet Location [Domain] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Payments to Acquire Property, Plant, and Equipment, Total Income Tax Disclosure [Abstract] Change in accounting principle, accounting standards update, adoption date Change in Accounting Principle, Accounting Standards Update, Adoption Date Option to Purchase Common Stock Options To Purchase Common Stock [Member] Options to purchase common stock. Stock Issued During Period, Shares, New Issues Shares issued Issuance of common stock from offering, net of offering costs, shares Accruals and reserves Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total Redeemable Convertible Preferred Stock Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block] Other Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Goodwill and Intangible Assets Disclosure [Abstract] Three Hundred Saginaw Drive Redwood City California [Member] 300 Saginaw Drive, Redwood City, California. The 300 Building Developed Technology - Genome Mining Platform Developed Technology Genome Mining Platform [Member] Developed technology - genome mining platform. Stock-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Maturities of marketable securities Proceeds From Maturity Of Marketable Securities Proceeds from maturity of marketable securities. Auditor Name Equity [Abstract] Area of space leased Area Of Office Space Leased Area of office space leased. Transaction price Transaction Price Transaction price. Reverse Stock Split Reverse Stock Split Policy Policy [Text Block] Reverse stock split policy. Weighted-average exercise price, Options cancelled Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Other noncurrent liabilities Increase (Decrease) in Other Noncurrent Liabilities Loss from operations Operating Income (Loss) Lessee, operating lease, option to extend Lessee, Operating Lease, Option to Extend Employee And Director Employee And Director [Member] Employee and director. Additional paid-in capital Additional Paid in Capital, Common Stock Additional Paid in Capital, Common Stock, Beginning Balance Additional Paid in Capital, Common Stock, Ending Balance Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Redeemable convertible preferred stock, beginning balance Redeemable convertible preferred stock, ending balance Temporary Equity, Carrying Amount, Attributable to Parent Redeemable convertible preferred stock, $0.0001 par value; zero shares authorized at December 31, 2021 and 2020, respectively; zero and 39,600,423 shares issued and outstanding at December 31, 2021 and 2020, respectively; aggregate liquidation preference of zero at December 31, 2021 and 2020, respectively Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Seven hundred and three hundred saginaw drive redwood city california. Seven Hundred and Three Hundred Saginaw Drive Redwood City California [Member] The 700 Building and 300 Building Percentage of other internal and external costs and expenses incurred under research and development plans Percentage Of Other Internal And External Costs And Expenses Incurred Under Research And Development Plans Percentage of other internal and external costs and expenses incurred under research and development plans. In-process research and development - RAS programs Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets Accrued professional services Accrued Professional Fees, Current Common stock, voting rights Common Stock, Voting Rights Entity Filer Category Entity Filer Category Severance costs Severance Costs Purchases of marketable securities Payments to Acquire Marketable Securities Payments to Acquire Marketable Securities, Total Series A Series A Redeemable Convertible Preferred Stock Series A Redeemable Convertible Preferred Stock [Member] Series A redeemable convertible preferred stock. Change in Accounting Principle, Accounting Standards Update, Early Adoption [true false] Change in accounting principle, accounting standards update, early adoption Total operating expenses Operating Expenses Deferred rent, noncurrent Deferred Rent Credit, Noncurrent Entity Current Reporting Status Entity Current Reporting Status Options Early Exercised Subject to Future Vesting Options Early Exercised Subject To Future Vesting [Member] Options early exercised subject to future vesting member. Less: Tenant improvement allowance Lessee Operating Lease Liability Tenant Improvement Allowance Lessee operating lease liability tenant improvement allowance. Income Taxes [Line Items] Income Taxes [Line Items] Income taxes. Asset Class Asset Class [Domain] ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Aggregate intrinsic value, Options vested and exercisable Series B Series B Redeemable Convertible Preferred Stock Series B Redeemable Convertible Preferred Stock [Member] Series B redeemable convertible preferred stock. Common Stock Stockholders' Equity Note Disclosure [Text Block] Collaboration Agreement [Abstract] Collaboration agreement. Business Combinations [Abstract] Developed technology - tri-complex platform, Net book value Finite-Lived Intangible Assets, Net Finite-Lived Intangible Assets, Net, Beginning Balance Finite-Lived Intangible Assets, Net, Ending Balance Beginning balance Ending balance Stockholders' Equity Attributable to Parent Total stockholders' equity Income Approach Valuation, Income Approach [Member] Accumulated Other Comprehensive Income AOCI Attributable to Parent [Member] Asset Class Asset Class [Axis] Documents Incorporated by Reference [Text Block] Documents Incorporated by Reference Entity Tax Identification Number Entity Tax Identification Number Income Statement Location Income Statement Location [Axis] Number of Shares, Restricted stock units forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Common stock, $0.0001 par value; 300,000,000 shares authorized at December 31, 2022 and December 31, 2021, respectively; 90,411,912 and 74,142,619 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively Common Stock, Value, Issued Common Stock, Value, Issued, Total Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Ending Balance Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Retained Earnings (Accumulated Deficit), Total Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Ending Balance Adjustment to accumulated deficit Cumulative Effect, Period of Adoption [Domain] Equity Components Equity Components [Axis] Acquisition-related costs Business Combination, Acquisition Related Costs Accounting Standards Update Accounting Standards Update [Domain] Accounting Standards Update 2016-13 [Member] ASU 2016-13 Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] 2020 Plan and 2014 Plan Two Thousand Twenty And Two Thousand Fourteen Equity Incentive Plan [Member] Two thousand twenty and two thousand fourteen equity incentive plan. Entity Emerging Growth Company Entity Emerging Growth Company Schedule Of Business Acquisitions By Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Operating expenses: Operating Expenses [Abstract] Number of Shares underlying options, Options vested and exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Restricted Cash Restricted Cash Policy [Text Block] Restricted cash. Revenue Recognition Revenue [Policy Text Block] Schedule Of Stock By Class [Table] Schedule of Stock by Class [Table] Letter Of Credit Letter of Credit [Member] At-the-market equity offering program. At-the-market Equity Offering Program [Member] ATM Expected term (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Collaboration revenue recognized Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer Issuance of common stock pursuant to early exercised stock options Stock Issued During Period Value Stock Options Early Exercised Stock issued during period value stock options early exercised. 2014 Equity Incentive Plan Two Thousand Fourteen Equity Incentive Plan [Member] Two thousand fourteen equity incentive plan. Debt Securities Available For Sale [Table] Debt Securities, Available-for-Sale [Table] Entity Voluntary Filers Entity Voluntary Filers Expected volatility, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Depreciation and amortization expense Depreciation, Depletion and Amortization, Nonproduction Depreciation, Depletion and Amortization, Nonproduction, Total Document Transition Report Document Transition Report Vesting of early exercised stock options and restricted stock Adjustments To Additional Paid In Capital Vesting Of Early Exercise Of Stock Option And Restricted Stock Adjustments to additional paid in capital vesting of early exercise of stock option and restricted stock. Assets, Fair Value Disclosure, Total Assets fair value Assets, Fair Value Disclosure Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Alternative [Abstract] Weighted-average grant date fair value per share, Restricted stock units granted Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Total other income, net Nonoperating Income (Expense) Depreciation and amortization Depreciation, Depletion and Amortization Depreciation, Depletion and Amortization, Total Impairments of long-lived assets Impairment, Long-Lived Asset, Held-for-Use Impairment, Long-Lived Asset, Held-for-Use, Total Sanofi Collaboration Agreement Collaborative Arrangement Disclosure [Text Block] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Weighted-average exercise price, Options exercised Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Deferred tax liability Increase (Decrease) in Deferred Income Taxes Marketable Securities Marketable Securities, Policy [Policy Text Block] In-process Research and Development - KRASG12C Program In Process Research And Development Related To K R A S G12 C Program [Member] In-process research and development related to KRASG12C program. Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding The 700 Building Seven Hundred Saginaw Drive Redwood City California [Member] 700 Saginaw Drive, Redwood City, California. Net loss Net loss Net Income (Loss) Attributable to Parent Operating lease liability, current Operating lease liability – current Operating Lease, Liability, Current Shares subject to repurchase Shares Of Common Stock Subject To Repurchase Shares of common stock subject to repurchase. Retirement plan name description Defined Contribution Plan, Description Additional Paid-In Capital Additional Paid-in Capital [Member] Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards Deferred Tax Assets, Operating Loss Carryforwards, Total Entity Registrant Name Entity Registrant Name Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Cash and Cash Equivalents, at Carrying Value, Total Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Ending Balance Net Loss Per Share Attributable to Common Stockholders Earnings Per Share [Text Block] Summary of Fair Value of Stock Option Awards Estimated at Date of Grant Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Redeemable convertible preferred stock, issued price per share Shares issued price per share Temporary Equity, Redemption Price Per Share Class of Stock Class of Stock [Axis] U.s. Government And Agency Securities US Government Agencies Debt Securities [Member] Lessee Lease Description [Table] Lessee, Lease, Description [Table] Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Share-based Payment Arrangement, Noncash Expense, Total Statement of Comprehensive Income [Abstract] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Ending Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Weighted-average remaining contractual term, Options vested and expected to vest Award Type Award Type [Domain] Statement [Line Items] Statement [Line Items] Income Taxes [Table] Income Taxes [Table] Income taxes. Temporary Equity By Class Of Stock [Table] Temporary Equity, by Class of Stock [Table] Weighted-average exercise price, Options vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price 2020 Employee Stock Purchase Plan Two Thousand Twenty Employee Stock Purchase Plan [Member] Two thousand twenty employee stock purchase plan. Title of 12(b) Security Title of 12(b) Security Developed technology - tri-complex platform, Gross value Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Gross, Total Accounts payable Increase (Decrease) in Accounts Payable Increase (Decrease) in Accounts Payable, Total Common Stock Common Stock [Member] Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Equity Component Equity Component [Domain] Fair Value Measurement Fair Value Measurement, Policy [Policy Text Block] Total revenue Revenue from Contract with Customer, Excluding Assessed Tax Revenue from Contract with Customer, Excluding Assessed Tax, Total Revenue Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Entity Address, State or Province Entity Address, State or Province 2026 Lessee, Operating Lease, Liability, to be Paid, Year Four Geographical Geographical [Axis] Mature in One Year or Less Mature In One Year Or Less [Member] Mature in one year or less. Net increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Document Type Document Type Summary of Proforma Financial Information of Acquisition Business Acquisition, Pro Forma Information [Table Text Block] Research and development credit carryforwards which can be carried forward indefinitely Deferred Tax Assets Tax Credit Carryforwards Research Not Subject To Expiration Deferred tax assets tax credit carryforwards research not subject to expiration. Research and development credit carryforwards expiration starting year Research And Development Tax Credit Carryforwards Expiration Starting Year Research and development credit carryforwards expiration starting year. U.S. Government and Agency Securities US Government Corporations and Agencies Securities [Member] Increase in operating lease right-of-use asset Increase Decrease In Operating Lease Right Of Use Asset Increase (decrease) in operating lease right-of-use asset. Laboratory Equipment Laboratory Equipment [Member] Laboratory equipment. Entity Shell Company Entity Shell Company Fixed assets and finite-lived intangible assets Deferred Tax Liabilities Fixed Assets And Finite Lived Intangible Assets Deferred tax liabilities fixed assets and finite-lived intangible assets. Stock-based compensation expense Share-Based Payment Arrangement, Expense Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Right-of-use asset Deferred Tax Liabilities Right Of Use Asset Deferred tax liabilities, right-of-use asset. Security Exchange Name Security Exchange Name Contingently returnable consideration asset Contingently returnable consideration asset Business Combination Contingently Returnable Consideration Asset Business combination, contingently returnable consideration asset. Class Of Stock [Line Items] Class of Stock [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Weighted-average remaining contractual term, Expected to vest Share Based Compensation Arrangement By Share Based Payment Awards Equity Instruments Other Than Options Expected To Vest Weighted Average Remaining Contractual Term Share based compensation arrangement by share based payment awards equity instruments other than options expected to vest weighted average remaining contractual term. Two thousand twenty equity incentive plan. Two Thousand Twenty Equity Incentive Plans [Member] 2020 Equity Incentive Plan Unrecognized stock-based compensation expense, weighted-average period of recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Weighted-average remaining contractual term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Cash consideration Cash Payments to Acquire Businesses, Gross Commitments and Contingencies Disclosure [Abstract] Operating lease cost Operating Lease, Cost Sanofi Agreement Sanofi Agreement [Member] Sanofi agreement. Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Proceeds from issuance of common stock under employee stock purchase plan Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan Proceeds from issuance of common stock under employee stock purchase plan. Schedule of Maturities of Operating Lease Liabilities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Reconciliation of Gross Unrecognized Tax Benefits Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Redwood City Lease Redwood City California [Member] Redwood City, California. Lease liability Deferred Tax Assets Lease Liability Deferred tax assets, lease liability. Revenue Business Acquisition, Pro Forma Revenue Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Summary of RSUs Activity Under the Plan Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Summary of Option Activity Under the Plan Share-Based Payment Arrangement, Option, Activity [Table Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Common stock, shares, outstanding Common Stock, Shares, Outstanding Common Stock, Shares, Outstanding, Beginning Balance Common Stock, Shares, Outstanding, Ending Balance Business Acquisition [Line Items] Business Acquisition [Line Items] Net amortization of premium (discount) on marketable securities Accretion (Amortization) of Discounts and Premiums, Investments Underwriter's Option to Purchase Additional Shares Over-Allotment Option [Member] Research tax credits Research tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Level 2 Fair Value, Inputs, Level 2 [Member] Estimated Fair Value Estimated Fair Value Debt Securities, Available-for-Sale Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Schedule of Future Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Aggregate gross proceeds through equity issuance maximum potential amount. Aggregate Gross Proceeds Through Equity Issuance Maximum Potential Amount Aggregate gross proceeds through equity issuance maximum potential amount Changes related to tax positions taken in current year Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Commitments and Contingencies Commitments and contingencies (Note 7) Common stock, shares, issued Common Stock, Shares, Issued Common Stock, Shares, Issued, Total Tax cut and jobs act net operating loss deduction limitation percentage Tax Cuts And Jobs Act Of2017 Net Operating Losses Limitation Percentage Tax cuts and jobs act of 2017 net operating losses limitation percentage. Minimum Minimum [Member] Expected Shares To Be Purchased Under ESPP Expected Shares To Be Purchased Under E S P P [Member] Expected shares to be purchased under ESPP. Commissions and expenses. Commissions And Expenses Commissions and expenses Risk-free interest rate, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Leases Lessee, Leases [Policy Text Block] Weighted-average exercise price, Options vested and exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Accounting Standards Update Accounting Standards Update [Axis] Weighted-average shares outstanding Weighted Average Number Of Shares Issued Basic And Diluted Weighted average number of shares issued basic and diluted. Debt Instrument [Axis] Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity: State income tax rate, net of federal benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Unvested Restricted Stock Units Of Common Stock Unvested Restricted Stock Units Of Common Stock [Member] Unvested restricted stock units of common stock. Revenue: Revenues [Abstract] Weighted-average grant date fair value per share, Restricted stock units forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Amortization of intangible assets Amortization of Intangible Assets Amortization of Intangible Assets, Total Amortization expenses Award Type Award Type [Axis] Unrecognized compensation cost related to ESPP Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total Total consideration Business acquisition, total consideration Business Combination, Consideration Transferred Gross deferred tax assets Deferred Tax Assets, Gross Lessee operating lease expiration month and year Lessee Operating Lease Expiration Month And Year Lessee operating lease expiration month and year. Impairment of Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Options exercised Intrinsic value of the options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Vesting of early exercised stock options Adjustments To Additional Paid In Capital Vesting Of Early Exercise Of Stock Options Adjustments to additional paid in capital vesting of early exercise of stock options. Maximum milestone payments receivable upon achievement of specified development milestones Maximum Milestone Payments Receivable Upon Achievement Of Specified Development Milestones Maximum milestone payments receivable upon achievement of specified development milestones. Aggregate intrinsic value, Expected to vest Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Expected To Vest Share based compensation arrangement by share based payment award equity instruments other than options aggregate intrinsic value expected to vest. Summary Of Balance Sheet Classification Of Lease Liabilities Table [Text Block] Summary of balance sheet classification of lease liabilities. Summary of Balance Sheet Classification of Operating Lease Liabilities Other income (expense), net: Nonoperating Income (Expense) [Abstract] Research and development Research and Development Expense Research and Development Expense, Total Total undiscounted lease payments Lessee, Operating Lease, Liability, to be Paid Changes related to tax positions taken in the prior year Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions New Jersey NEW JERSEY Entity Central Index Key Entity Central Index Key Increase in valuation allowance Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Schedule of Accrued Expenses and Other Current Liabilities Schedule Of Accrued Expenses And Other Current Liabilities Table [Text Block] Schedule of accrued expenses and other current liabilities. Numerator: Net Income (Loss) Attributable to Parent [Abstract] Accounting Policies [Abstract] Accrued expenses and other current liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Investments, Debt and Equity Securities [Abstract] Schedule Of Available For Sale Securities [Line Items] Debt Securities, Available-for-Sale [Line Items] Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance Schedule Of Property Plant And Equipment [Table] Property, Plant and Equipment [Table] Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Measurement Frequency Measurement Frequency [Axis] Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration Net operating loss carryforwards subject to expire Consultant. Consultant [Member] Consultant Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Redeemable Convertible Preferred Stock Redeemable Convertible Preferred Stock [Member] Number of voting rights per common share Number Of Voting Rights Per Common Share Number of voting rights per common share. Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Aggregate intrinsic value, Options vested and expected to vest General and administrative General and Administrative Expense General and Administrative Expense, Total Measurement Input Type Measurement Input Type [Domain] Organization, Consolidation and Presentation of Financial Statements [Abstract] Weighted-average exercise price, Beginning balance Weighted-average exercise price, Ending balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Research and Development Research and Development Expense [Member] Risk-free interest rate, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Redeemable convertible preferred stock tranche obligation Redeemable Convertible Preferred Stock Tranche Obligation Redeemable convertible preferred stock tranche obligation. Right-of-use assets obtained in exchange for operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Weighted-average grant date fair value per share, Expected to vest Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expected To Vest Weighted Average Grant Date Fair Value Share based compensation arrangement by share based payment award equity instruments other than options expected to vest weighted average grant date fair value. Letter Agreement for the RMC Letter Agreement for RMC [Member] Letter agreement for RMC Member. Adjustments to reconcile net loss to net cash (used in) provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Accumulated Deficit Retained Earnings [Member] Vesting of early exercised options and restricted stock Vesting Of Early Exercised Options And Restricted Stock Vesting of early exercised options and restricted stock. Collaboration revenue member. Collaboration Revenue Member Collaboration Revenue Business acquisition, shares issued Business Acquisition, Equity Interest Issued or Issuable, Number of Shares In-process research and development - RAS Programs, Weighted-average remaining useful life Intangible Asset, Useful Life Intangible asset, useful life. Money Market Funds Money Market Funds [Member] Measurement Input Type Measurement Input Type [Axis] Benefit from income taxes Effective Income Tax Rate Reconciliation, Percent Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Loss on disposal of fixed assets Gain (Loss) on Disposition of Property Plant Equipment Gain (Loss) on Disposition of Property Plant Equipment, Total Series B redeemable convertible preferred stock Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Property and equipment, gross Property, Plant and Equipment, Gross Property, Plant and Equipment, Gross, Total Property, Plant and Equipment, Gross, Beginning Balance Property, Plant and Equipment, Gross, Ending Balance Entity Interactive Data Current Entity Interactive Data Current Entity Public Float Entity Public Float Financial Asset, Period Past Due Financial Asset, Aging [Domain] Number of Shares underlying options, Options vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Letter of credit Letters of Credit Outstanding, Amount Temporary Equity [Line Items] Temporary Equity [Line Items] Supplemental disclosure of non-cash investing and financing activities Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Net operating losses, limitations on use Operating Loss Carryforwards, Limitations on Use Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Summary of significant accounting policies. 2020 Equity Incentive Plan Two Thousand Twenty Equity Incentive Plan [Member] Two thousand twenty equity incentive plan. 2023 Lessee, Operating Lease, Liability, to be Paid, Year One Number of Shares, Expected to vest Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expected To Vest Outstanding Number Share based compensation arrangement by share based payment award equity instruments other than options expected to vest outstanding number. Leasehold Improvements Leasehold Improvements [Member] Stock issuance cost Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Shares outstanding Temporary equity, shares outstanding Redeemable convertible preferred stock, beginning balance, shares Redeemable convertible preferred stock, ending balance, shares Temporary Equity, Shares Outstanding Accounting Standards Update 2018-15 [Member] ASU 2018-15 Local Phone Number Local Phone Number Federal statutory income tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Beginning balance Ending balance Unrecognized Tax Benefits Schedule of Financial Assets Measured at Fair Value Fair Value, Assets Measured on Recurring Basis [Table Text Block] Summary of Fair Values of Assets Acquired and Liabilities Assumed at Acquisition Date Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Award vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Summary of Quarterly Financial Data (Unaudited) Quarterly Financial Information [Table Text Block] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Initial Public Offering IPO [Member] Number of Shares underlying options, Options granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Other noncurrent liabilities Other Liabilities, Noncurrent Other Liabilities, Noncurrent, Total Reverse stock split Stockholders' Equity Note, Stock Split, Conversion Ratio Redeemable Convertible Preferred Stock Redeemable Convertible Preferred Stock [Text Block] Redeemable convertible preferred stock. Warp Drive Warp Drive Warp Drive Bio Inc [Member] Warp Drive Bio, Inc. Income Statement Location Income Statement Location [Domain] Number of Shares, Beginning balance Number of Shares, Ending balance Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Percentage of future milestones payments receivable Percentage Of Maximum Milestone Payments Receivable Percentage of maximum milestone payments receivable. Beginning balance, shares Ending balance, shares Shares, Outstanding Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Prepaid Expense and Other Assets, Total Available for issuance under the 2020 Employee Stock Purchase Plan Available For Future Issuance Under The Two Zero Two Zero Employee Stock Purchase Plan [Member] Available for future issuance under the two zero two zero employee stock purchase plan. Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Selected Quarterly Financial Data (Unaudited) Quarterly Financial Information [Text Block] Reduction in Collaboration Revenue Reduction in Collaboration Revenue Reduction in collaboration revenue Number of Shares underlying options, Beginning balance Number of Shares underlying options, Ending balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share Price Share Price Marketable securities Marketable Securities, Current Marketable Securities, Current, Total Debt Instrument, Name [Domain] Document Fiscal Year Focus Document Fiscal Year Focus Intangible assets, Net book value Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Summary of Purchase Price Consideration For Acquisition Schedule of Business Acquisitions, by Acquisition [Table Text Block] 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two Net loss per share attributable to common stockholders, basic Earnings Per Share, Basic Earnings Per Share, Basic, Total Assets Assets [Abstract] Underwriting discounts and commissions Payments for Underwriting Expense Reconciliation of cash, cash equivalents and restricted cash to consolidated balance sheets Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Expected volatility, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Common stock, price per share Stock issued, price per share Shares Issued, Price Per Share Marketable securities. Marketable Securities [Member] Marketable Securities Financial Instrument Financial Instrument [Axis] Long-Lived Tangible Asset Long-Lived Tangible Asset [Axis] Liabilities, redeemable convertible preferred stock and stockholders' equity (deficit) Liabilities and Equity [Abstract] Accrued compensation Accrued Employee Benefits, Current Impairment of intangible assets, finite-lived Impairment of Intangible Assets, Finite-Lived Property and Equipment, Net Property, Plant and Equipment, Policy [Policy Text Block] Income Tax Authority Income Tax Authority [Axis] Valuation Approach and Technique Valuation Approach and Technique [Axis] Total deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Temporary Equity Disclosure [Abstract] Current assets: Assets, Current [Abstract] Common stock, dividends declared Dividends, Common Stock Dividends, Common Stock, Total 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Four Massachusetts Cambridge, Massachusetts MASSACHUSETTS 2023 Finite-Lived Intangible Asset, Expected Amortization, Year Two Summary of Categories that Give Rise to Significant Components of Deferred Tax Assets Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of Goodwill Schedule of Goodwill [Table Text Block] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Summary of Amortized Cost and Estimated Fair Value of Available-for-sale Securities and Cash Equivalents by Contractual Maturity Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block] Total accrued expenses and other current liabilities Accrued expenses and other current liabilities Accrued Expenses And Other Current Liabilities Accrued expenses and other current liabilities. Retirement plan, matching contributions Defined Contribution Plan, Employer Discretionary Contribution Amount Measurement Frequency Measurement Frequency [Domain] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Selected Quarterly Financial Information [Abstract] Computer Equipment and Software Computer Equipment And Software [Member] Computer equipment and software. Cover [Abstract] Interest or penalties related to uncertain tax positions Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total Product and Service Product and Service [Domain] 2027 Lessee, Operating Lease, Liability, to be Paid, Year Five Number of Shares, Restricted stock units vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Goodwill impairment Goodwill, Impairment Loss Current liabilities: Liabilities, Current [Abstract] Disposal Group Name Disposal Group Name [Domain] Maximum Maximum [Member] Unrealized gain (loss) on investments, net Net unrealized gains on marketable securities Net unrealized gains (loss) on marketable securities Summary of Total Stock-Based Compensation Expense Related to Stock Options, RSUs and Employee Stock Purchase Plan Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Other-than-temporary impairment Other-than-temporary Impairment Loss, Debt Securities, Available-for-Sale, Recognized in Earnings Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Furniture and Fixtures Furniture and Fixtures [Member] Indefinite-lived intangible assets Deferred Tax Liabilities Indefinite Lived Intangible Assets Deferred tax liabilities indefinite-lived intangible assets. Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Number of Shares underlying options, Options exercised Issuance of common stock pursuant to stock option exercises, shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Intangible Assets and Goodwill Goodwill and Intangible Assets Disclosure [Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Use of Estimates Use of Estimates, Policy [Policy Text Block] Proceeds from issuance of common stock from at-the-market offering Proceeds From Issuance Of Common Stock From At The Market Offering Proceeds from issuance of common stock from at the market offering. Gross deferred tax liabilities Deferred Tax Liabilities, Gross Deferred Tax Liabilities, Gross, Total Financial Asset, Period Past Due Financial Asset, Aging [Axis] Issuance of common stock pursuant to stock option exercises Stock Issued During Period, Value, Stock Options Exercised Segment Reporting Segment Reporting, Policy [Policy Text Block] Property and equipment, estimated useful lives Estimated useful life Property, Plant and Equipment, Useful Life Sales of marketable securities Proceeds From Sale Of Marketable Securities Proceeds from sale of marketable securities. Deferred tax assets: Deferred Tax Assets, Net [Abstract] 2024 Finite-Lived Intangible Asset, Expected Amortization, Year Three Common stock, shares authorized Common Stock, Shares Authorized Trading Symbol Trading Symbol Summary of Estimated Value of Available-for-sale Securities and Cash Equivalents and Gross Unrealized Gains and Losses Debt Securities, Available-for-Sale [Table Text Block] Title of Individual Title of Individual [Domain] Other Deferred Tax Assets, Other Amortization of operating lease right-of-use asset Operating Lease, Right-of-Use Asset, Amortization Expense Redeemable Convertible Preferred Stock Liability Redeemable Convertible Preferred Stock Liability Policy Policy [Text Block] Redeemable convertible preferred stock liability policy. Balance Sheet Location Balance Sheet Location [Axis] Total comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Deferred Offering Costs Deferred Charges, Policy [Policy Text Block] Accounts payable Accounts Payable, Current Accounts Payable, Current, Total Gross Unrealized Loss Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Name of Property Name of Property [Domain] Plan Name Plan Name [Axis] Title of Individual Title of Individual [Axis] Long-Lived Tangible Asset Long-Lived Tangible Asset [Domain] Common stock, par or stated value per share Common Stock, Par or Stated Value Per Share Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Net operating losses expected to expire unutilized as a result of the limitation Net Operating Loss Carryforwards Expected To Expiration Unutilized Due To Limitations On Use Net operating loss carryforwards expected to expiration unutilized due to limitations on use. In-process Research and Development - RAS Programs In Process Research And Development Related To R A S Programs [Member] In-process research and development related to RAS programs. Conversion of redeemable convertible preferred stock into common stock Stock Issued During Period, Value, Conversion of Convertible Securities Comprehensive Loss Comprehensive Income, Policy [Policy Text Block] Number of Shares, Restricted stock units granted Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Shares purchases Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award Finance Lease, Liability, Current, Statement of Financial Position [Extensible List] Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Estimated useful life, description Property, Plant and Equipment, Estimated Useful Lives Stock voting rights description Stock Voting Rights Description Stock voting rights description. Weighted-average exercise price, Options granted Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Potentially dilutive shares Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Indefinite-lived Intangible Assets, Major Class Name Indefinite-Lived Intangible Assets, Major Class Name [Domain] Other noncurrent assets Increase (Decrease) in Other Noncurrent Assets EX-101.DEF 19 rvmd-20221231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.PRE 20 rvmd-20221231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.CAL 21 rvmd-20221231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.SCH 22 rvmd-20221231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 100020 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100030 - Disclosure - Intangible Assets and Goodwill - Schedule of Intangibles Assets, Net (Details) 2 link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 100060 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 100070 - Statement - CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) link:presentationLink link:calculationLink link:definitionLink 100080 - Statement - CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100090 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 100100 - Disclosure - Organization link:presentationLink link:calculationLink link:definitionLink 100110 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 100120 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 100130 - Disclosure - Available-for-sale Securities link:presentationLink link:calculationLink link:definitionLink 100140 - Disclosure - Balance Sheet Components link:presentationLink link:calculationLink link:definitionLink 100150 - Disclosure - Acquisition of Warp Drive link:presentationLink link:calculationLink link:definitionLink 100160 - Disclosure - Intangible Assets and Goodwill link:presentationLink link:calculationLink link:definitionLink 100170 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 100180 - Disclosure - Sanofi Collaboration Agreement link:presentationLink link:calculationLink link:definitionLink 100190 - Disclosure - Redeemable Convertible Preferred Stock link:presentationLink link:calculationLink link:definitionLink 100200 - Disclosure - Common Stock link:presentationLink link:calculationLink link:definitionLink 100210 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 100220 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 100230 - Disclosure - Net Loss Per Share Attributable to Common Stockholders link:presentationLink link:calculationLink link:definitionLink 100240 - Disclosure - Selected Quarterly Financial Data (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100250 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 100260 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 100270 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 100280 - Disclosure - Available-for-sale Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 100290 - Disclosure - Balance Sheet Components (Tables) link:presentationLink link:calculationLink link:definitionLink 100300 - Disclosure - Acquisition of Warp Drive (Tables) link:presentationLink link:calculationLink link:definitionLink 100310 - Disclosure - Intangible Assets and Goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 100320 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 100330 - Disclosure - Redeemable Convertible Preferred Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 100340 - Disclosure - Common Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 100350 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 100360 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 100370 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables) link:presentationLink link:calculationLink link:definitionLink 100380 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables) link:presentationLink link:calculationLink link:definitionLink 100390 - Disclosure - Organization - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100400 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100410 - Disclosure - Summary of Significant Accounting Policies - Schedule of Useful Lives of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 100420 - Disclosure - Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 100430 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100440 - Disclosure - Available-for-sale Securities - Summary of Estimated Value of Available-for-sale Securities and Cash Equivalents and Gross Unrealized Gains and Losses (Details) link:presentationLink link:calculationLink link:definitionLink 100450 - Disclosure - Available-for-sale Securities - Summary of Amortized Cost and Estimated Fair Value of Available-for-sale Securities and Cash Equivalents by Contractual Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 100460 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 100470 - Disclosure - Balance Sheet Components - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100480 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 100490 - Disclosure - Acquisition of Warp Drive - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100500 - Disclosure - Acquisition of Warp Drive - Summary of Purchase Price Consideration For Acquisition (Details) link:presentationLink link:calculationLink link:definitionLink 100510 - Disclosure - Acquisition of Warp Drive - Summary of Fair Values of Assets Acquired and Liabilities Assumed at Acquisition Date (Details) link:presentationLink link:calculationLink link:definitionLink 100520 - Disclosure - Acquisition of Warp Drive - Summary of Proforma Financial Information of Acquisition (Details) link:presentationLink link:calculationLink link:definitionLink 100530 - Disclosure - Intangible Assets and Goodwill - Schedule of Intangibles Assets, Net (Details) link:presentationLink link:calculationLink link:definitionLink 100540 - Disclosure - Intangible Assets and Goodwill - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100550 - Disclosure - Intangible Assets and Goodwill - Schedule of Future Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 100560 - Disclosure - Intangible Assets and Goodwill - Schedule of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 100570 - Disclosure - Commitment and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100580 - Disclosure - Commitments and Contingencies - Summary of Balance Sheet Classification of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 100590 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 100600 - Disclosure - Sanofi Collaboration Agreement - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100610 - Disclosure - Redeemable Convertible Preferred Stock - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100620 - Disclosure - Common Stock - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100630 - Disclosure - Common Stock - Schedule of Common Stock for Future Issuance (Details) link:presentationLink link:calculationLink link:definitionLink 100640 - Disclosure - Stock-Based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100650 - Disclosure - Stock-Based Compensation - Summary of Option Activity Under the Plan (Details) link:presentationLink link:calculationLink link:definitionLink 100660 - Disclosure - Summary of Fair Value of Stock Option Awards Estimated at Date of Grant (Details) link:presentationLink link:calculationLink link:definitionLink 100670 - Disclosure - Stock-Based Compensation - Summary of RSUs Activity Under the Plan (Details) link:presentationLink link:calculationLink link:definitionLink 100680 - Disclosure - Stock-Based Compensation - Summary of Total Stock-Based Compensation Expense Related to Stock Options, RSUs and Employee Stock Purchase Plan (Details) link:presentationLink link:calculationLink link:definitionLink 100690 - Disclosure - Income Taxes - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100700 - Disclosure - Income Taxes - Summary of Benefit from Income Taxes to Amount Computed by Applying Federal Statutory Rate to Loss Before Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 100710 - Disclosure - Income Taxes - Summary of Categories that Give Rise to Significant Components of Deferred Tax Assets (Details) link:presentationLink link:calculationLink link:definitionLink 100720 - Disclosure - Income Taxes - Reconciliation of Gross Unrecognized Tax Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 100730 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details) link:presentationLink link:calculationLink link:definitionLink 100740 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Outstanding Potentially Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink XML 23 R1.htm IDEA: XBRL DOCUMENT v3.22.4

Document and Entity Information - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2022

Feb. 23, 2023

Jun. 30, 2022

Cover [Abstract]

Document Type 10-K

Amendment Flag false

Document Period End Date Dec. 31, 2022

Document Fiscal Year Focus 2022

Document Fiscal Period Focus FY

Entity Registrant Name Revolution Medicines, Inc.

Entity Central Index Key 0001628171

Entity Interactive Data Current Yes

Current Fiscal Year End Date --12-31

Entity Well-known Seasoned Issuer Yes

Entity Current Reporting Status Yes

Entity Voluntary Filers No

Entity Filer Category Large Accelerated Filer

Entity Emerging Growth Company false

Entity Common Stock, Shares Outstanding 90,491,696

Entity Shell Company false

Entity Small Business false

Title of 12(b) Security Common Stock $0.0001 Par Value per Share

Trading Symbol RVMD

Security Exchange Name NASDAQ

Entity File Number 001-39219

Entity Incorporation, State or Country Code DE

Entity Tax Identification Number 47-2029180

Entity Address, Address Line One 700 Saginaw Drive

Entity Address, City or Town Redwood City

Entity Address, State or Province CA

Entity Address, Postal Zip Code 94063

City Area Code 650

Local Phone Number 481-6801

ICFR Auditor Attestation Flag true

Document Annual Report true

Document Transition Report false

Entity Public Float $ 1,231

Documents Incorporated by Reference
Portions of the Registrant’s definitive Proxy Statement relating to the Registrant’s 2023 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. The proxy statement will be filed with the Securities and Exchange Commission within 120 days of the Registrant’s fiscal year ended December 31, 2022.

Auditor Name PricewaterhouseCoopers LLP

Auditor Location San Jose, California

Auditor Firm ID 238

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
PCAOB issued Audit Firm Identifier
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 10-K
-Number 249
-Section 310

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 20-F
-Number 249
-Section 220
-Subsection f

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 40-F
-Number 249
-Section 240
-Subsection f
+ Details

Name: dei_AuditorFirmId

Namespace Prefix: dei_

Data Type: dei:nonemptySequenceNumberItemType

Balance Type: na

Period Type: duration

X

- References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 10-K
-Number 249
-Section 310

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 20-F
-Number 249
-Section 220
-Subsection f

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 40-F
-Number 249
-Section 240
-Subsection f
+ Details

Name: dei_AuditorLocation

Namespace Prefix: dei_

Data Type: dei:internationalNameItemType

Balance Type: na

Period Type: duration

X

- References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 10-K
-Number 249
-Section 310

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 20-F
-Number 249
-Section 220
-Subsection f

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 40-F
-Number 249
-Section 240
-Subsection f
+ Details

Name: dei_AuditorName

Namespace Prefix: dei_

Data Type: dei:internationalNameItemType

Balance Type: na

Period Type: duration

X

- Definition
Area code of city
+ References
No definition available.
+ Details

Name: dei_CityAreaCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Cover page.
+ References
No definition available.
+ Details

Name: dei_CoverAbstract

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true only for a form used as an annual report.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 10-K
-Number 249
-Section 310

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 20-F
-Number 249
-Section 220
-Subsection f

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 40-F
-Number 249
-Section 240
-Subsection f
+ Details

Name: dei_DocumentAnnualReport

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true only for a form used as a transition report.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Forms 10-K, 10-Q, 20-F
-Number 240
-Section 13
-Subsection a-1
+ Details

Name: dei_DocumentTransitionReport

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
Documents incorporated by reference.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-23
+ Details

Name: dei_DocumentsIncorporatedByReferenceTextBlock

Namespace Prefix: dei_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details

Name: dei_EntityAddressAddressLine1

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the City or Town
+ References
No definition available.
+ Details

Name: dei_EntityAddressCityOrTown

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details

Name: dei_EntityAddressPostalZipCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the state or province.
+ References
No definition available.
+ Details

Name: dei_EntityAddressStateOrProvince

Namespace Prefix: dei_

Data Type: dei:stateOrProvinceItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details

Name: dei_EntityFileNumber

Namespace Prefix: dei_

Data Type: dei:fileNumberItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details

Name: dei_EntityIncorporationStateCountryCode

Namespace Prefix: dei_

Data Type: dei:edgarStateCountryItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-T
-Number 232
-Section 405
+ Details

Name: dei_EntityInteractiveDataCurrent

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.
+ References
No definition available.
+ Details

Name: dei_EntityPublicFloat

Namespace Prefix: dei_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityShellCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a Smaller Reporting Company (SRC).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityTaxIdentificationNumber

Namespace Prefix: dei_

Data Type: dei:employerIdItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
+ References
No definition available.
+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 405
+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 10-K
-Number 249
-Section 310

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 20-F
-Number 249
-Section 220
-Subsection f

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 40-F
-Number 249
-Section 240
-Subsection f
+ Details

Name: dei_IcfrAuditorAttestationFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Local phone number for entity.
+ References
No definition available.
+ Details

Name: dei_LocalPhoneNumber

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details

Name: dei_Security12bTitle

Namespace Prefix: dei_

Data Type: dei:securityTitleItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details

Name: dei_SecurityExchangeName

Namespace Prefix: dei_

Data Type: dei:edgarExchangeCodeItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: dei:tradingSymbolItemType

Balance Type: na

Period Type: duration

XML 24 R2.htm IDEA: XBRL DOCUMENT v3.22.4

CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands

Dec. 31, 2022

Dec. 31, 2021

Current assets:

Cash and cash equivalents $ 161,412 $ 108,497

Marketable securities 483,531 468,557

Account receivable 4,673 5,929

Prepaid expenses and other current assets 10,569 6,790

Total current assets 660,185 589,773

Property and equipment, net 18,659 11,544

Operating lease right-of-use asset 55,077 59,692

Intangible assets, net 58,807 59,876

Goodwill 14,608 14,608

Restricted cash 1,737 1,737

Other noncurrent assets 2,857 758

Total assets 811,930 737,988

Current liabilities:

Accounts payable 21,306 14,057

Accrued expenses and other current liabilities 29,446 27,721

Operating lease liability, current 6,773 6,214

Deferred revenue, current 4,459 12,358

Total current liabilities 61,984 60,350

Deferred revenue, noncurrent 0 6,573

Deferred tax liability 7,025 7,444

Operating lease liability, noncurrent 57,432 60,419

Other noncurrent liabilities 301 634

Total liabilities 126,742 135,420

Commitments and contingencies (Note 7)

Stockholders' equity:

Preferred stock, $0.0001 par value; 10,000,000 shares authorized at December 31, 2022 and December 31, 2021, respectively; zero shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively 0 0

Common stock, $0.0001 par value; 300,000,000 shares authorized at December 31, 2022 and December 31, 2021, respectively; 90,411,912 and 74,142,619 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively 9 8

Additional paid-in capital 1,388,300 1,055,572

Accumulated other comprehensive loss (1,780) (376)

Accumulated deficit (701,341) (452,636)

Total stockholders' equity 685,188 602,568

Total liabilities and stockholders' equity $ 811,930 $ 737,988

X

- Definition
Accrued expenses and other current liabilities.
+ References
No definition available.
+ Details

Name: rvmd_AccruedExpensesAndOtherCurrentLiabilities

Namespace Prefix: rvmd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3)(a)(1))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsReceivableGrossCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(4))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(3))
-URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(18))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(9))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318
+ Details

Name: us-gaap_DeferredIncomeTaxLiabilitiesNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10)(1))
-URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 55
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(15))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph ((a)(1),(b))
-URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274
+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765

Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of investment in marketable security, classified as current.
+ References
No definition available.
+ Details

Name: us-gaap_MarketableSecuritiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's right to use underlying asset under operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of noncurrent assets classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.24)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(9))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 360
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 210
-Section 45
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580
+ Details

Name: us-gaap_RestrictedCashNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 25 R3.htm IDEA: XBRL DOCUMENT v3.22.4

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares

Dec. 31, 2022

Dec. 31, 2021

Statement of Financial Position [Abstract]

Preferred stock, par or stated value per share $ 0.0001 $ 0.0001

Preferred stock, shares authorized 10,000,000 10,000,000

Preferred stock, shares issued 0 0

Preferred stock, shares outstanding 0 0

Common stock, par or stated value per share $ 0.0001 $ 0.0001

Common stock, shares authorized 300,000,000 300,000,000

Common stock, shares, issued 90,411,912 74,142,619

Common stock, shares, outstanding 90,411,912 74,142,619

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 26 R4.htm IDEA: XBRL DOCUMENT v3.22.4

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
12 Months Ended

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Revenue:

Total revenue $ 35,380,000 $ 29,390,000 $ 42,983,000

Operating expenses:

Research and development 253,073,000 186,948,000 132,252,000

General and administrative 40,586,000 30,450,000 21,428,000

Total operating expenses 293,659,000 217,398,000 153,680,000

Loss from operations (258,279,000) (188,008,000) (110,697,000)

Other income (expense), net:

Interest income 9,154,000 929,000 2,238,000

Interest expense 0 (12,000) (71,000)

Total other income, net 9,154,000 917,000 2,167,000

Loss before income taxes (249,125,000) (187,091,000) (108,530,000)

Benefit from income taxes 420,000 0 371,000

Net loss (248,705,000) (187,091,000) (108,159,000)

Redeemable convertible preferred stock dividends - undeclared and cumulative 0 0 (2,219,000)

Net loss attributable to common stockholders $ (248,705,000) $ (187,091,000) $ (110,378,000)

Net loss per share attributable to common stockholders, basic $ (3.08) $ (2.57) $ (2.01)

Net loss per share attributable to common stockholders, diluted $ (3.08) $ (2.57) $ (2.01)

Weighted-average shares used to compute net loss per share attributable to common stockholders, basic 80,626,525 72,806,079 54,874,119

Weighted-average shares used to compute net loss per share attributable to common stockholders, diluted 80,626,525 72,806,079 54,874,119

Collaboration Revenue

Revenue:

Total revenue $ 35,380,000 $ 29,390,000 $ 42,983,000

X

- Definition
Redeemable convertible preferred stock dividends - undeclared and cumulative.
+ References
No definition available.
+ Details

Name: rvmd_RedeemableConvertiblePreferredStockDividendsUndeclaredAndCumulative

Namespace Prefix: rvmd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (210.5-03(11))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7(b))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599
+ Details

Name: us-gaap_InvestmentIncomeInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7)
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227
+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 912
-SubTopic 730
-Section 25
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856
+ Details

Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_ProductOrServiceAxis=rvmd_CollaborationRevenueMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 27 R5.htm IDEA: XBRL DOCUMENT v3.22.4

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Statement of Comprehensive Income [Abstract]

Net loss $ (248,705) $ (187,091) $ (108,159)

Other comprehensive income (loss):

Unrealized gain (loss) on investments, net (1,404) (492) 42

Total comprehensive loss $ (250,109) $ (187,583) $ (108,117)

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(22))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(24))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(26))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 28 R6.htm IDEA: XBRL DOCUMENT v3.22.4

CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
$ in Thousands

Total

Initial Public Offering

Follow-on Offering

At The Market Equity Offering

Common Stock

Common Stock

Initial Public Offering

Common Stock

Follow-on Offering

Common Stock

At The Market Equity Offering

Additional Paid-In Capital

Additional Paid-In Capital

Initial Public Offering

Additional Paid-In Capital

Follow-on Offering

Additional Paid-In Capital

At The Market Equity Offering

Accumulated Other Comprehensive Income

Accumulated Deficit

Redeemable Convertible Preferred Stock

Beginning balance at Dec. 31, 2019 $ (152,574) $ 4,738 $ 74 $ (157,386)

Redeemable convertible preferred stock, beginning balance, shares at Dec. 31, 2019 39,600,423

Redeemable convertible preferred stock, beginning balance at Dec. 31, 2019 $ 305,109

Beginning balance, shares at Dec. 31, 2019 3,292,124

Conversion of redeemable convertible preferred stock into common stock 305,109 $ 4 305,105 $ (305,109)

Conversion of redeemable convertible preferred stock into common stock, shares 39,600,423 (39,600,423)

Issuance of common stock from offering, net of offering costs $ 250,697 $ 167,767 $ 2 $ 1 $ 250,695 $ 167,766

Issuance of common stock from offering, net of offering costs, shares 16,100,000 6,900,000

Issuance of common stock pursuant to stock option exercises 1,877 1,877

Issuance of common stock pursuant to stock option exercises, shares 694,441

Issuance of common stock related to employee stock purchase plan 832 832

Issuance of common stock related to employee stock purchase plan, shares 29,237

Issuance of common stock related to vesting of restricted stock units, shares 1,681

Vesting of early exercised stock options 199 199

Repurchases of early exercised stock, shares (18,158)

Stock-based compensation expense 8,886 8,886

Net unrealized gains (loss) on marketable securities 42 42

Net loss (108,159) (108,159)

Ending balance at Dec. 31, 2020 474,676 $ 7 740,098 116 (265,545)

Ending balance, shares at Dec. 31, 2020 66,599,748

Issuance of common stock from offering, net of offering costs 281,145 $ 10,096 $ 1 281,144 $ 10,096

Issuance of common stock from offering, net of offering costs, shares 6,666,666 339,302

Issuance of common stock pursuant to stock option exercises 1,487 1,487

Issuance of common stock pursuant to stock option exercises, shares 388,695

Issuance of common stock related to employee stock purchase plan 1,875 1,875

Issuance of common stock related to employee stock purchase plan, shares 75,991

Issuance of common stock related to vesting of restricted stock units, shares 78,010

Vesting of early exercised stock options 148 148

Repurchases of early exercised stock, shares (5,793)

Stock-based compensation expense 20,724 20,724

Net unrealized gains (loss) on marketable securities (492) (492)

Net loss (187,091) (187,091)

Ending balance at Dec. 31, 2021 $ 602,568 $ 8 1,055,572 (376) (452,636)

Redeemable convertible preferred stock, ending balance, shares at Dec. 31, 2021 0

Ending balance, shares at Dec. 31, 2021 74,142,619

Issuance of common stock from offering, net of offering costs $ 49,919 $ 248,126 $ 1 $ 248,125 $ 49,919

Issuance of common stock from offering, net of offering costs, shares 13,225,000 2,385,846

Issuance of common stock pursuant to stock option exercises 1,481 1,481

Issuance of common stock pursuant to stock option exercises, shares 249,544

Issuance of common stock related to employee stock purchase plan 1,864 1,864

Issuance of common stock related to employee stock purchase plan, shares 130,327

Issuance of common stock related to vesting of restricted stock units, shares 278,848

Vesting of early exercised stock options 143 143

Repurchases of early exercised stock, shares (272)

Stock-based compensation expense 31,196

Net unrealized gains (loss) on marketable securities (1,404) (1,404)

Net loss (248,705) (248,705)

Ending balance at Dec. 31, 2022 $ 685,188 $ 9 $ 1,388,300 $ (1,780) $ (701,341)

Redeemable convertible preferred stock, ending balance, shares at Dec. 31, 2022 0

Ending balance, shares at Dec. 31, 2022 90,411,912

X

- Definition
Adjustments to additional paid in capital vesting of early exercise of stock options.
+ References
No definition available.
+ Details

Name: rvmd_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExerciseOfStockOptions

Namespace Prefix: rvmd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Stock issued during period shares vesting of restricted stock.
+ References
No definition available.
+ Details

Name: rvmd_StockIssuedDuringPeriodSharesVestingOfRestrictedStock

Namespace Prefix: rvmd_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 12
-URI https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 35
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued during the period as a result of the conversion of convertible securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-30)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued during the period as a result of an employee stock purchase plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The gross value of stock issued during the period upon the conversion of convertible securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued as a result of the exercise of stock options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockRepurchasedDuringPeriodShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
+ Details

Name: us-gaap_TemporaryEquityCarryingAmountAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27)(b))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_TemporaryEquitySharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 29 R7.htm IDEA: XBRL DOCUMENT v3.22.4

CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Initial Public Offering

Stock issuance cost $ 23,003

Follow-on Offering

Stock issuance cost $ 16,374 $ 18,855 $ 11,633

X

- Definition
Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=rvmd_FollowOnOfferingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 30 R8.htm IDEA: XBRL DOCUMENT v3.22.4

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Cash flows from operating activities

Net loss $ (248,705) $ (187,091) $ (108,159)

Adjustments to reconcile net loss to net cash (used in) provided by operating activities:

Loss on disposal of fixed assets 19 119 0

Amortization of intangible assets 1,069 1,069 1,068

Stock-based compensation expense 31,196 20,724 8,886

Depreciation and amortization 3,972 3,083 2,611

Net amortization of premium (discount) on marketable securities (3,078) 3,012 968

Amortization of operating lease right-of-use asset 4,615 3,180 2,866

Changes in operating assets and liabilities:

Accounts receivable 1,256 464 2,344

Prepaid expenses and other current assets (3,779) 198 (1,924)

Accounts payable 7,288 2,239 305

Accrued expenses and other current liabilities 1,502 8,720 4,855

Deferred revenue (14,472) (1,661) (11,259)

Operating lease liability (2,428) (1,468) (2,565)

Deferred tax liability (419) 0 (375)

Other noncurrent assets (2,247) 81 139

Other noncurrent liabilities (190) 151 176

Net cash used in operating activities (224,401) (147,180) (100,064)

Cash flows from investing activities

Purchases of marketable securities (612,769) (671,335) (544,133)

Maturities of marketable securities 599,469 526,754 309,828

Sales of marketable securities 0 8,992 3,005

Purchases of property and equipment (10,816) (6,528) (2,933)

Net cash used in investing activities (24,116) (142,117) (234,233)

Cash flows from financing activities

Proceeds from issuance of common stock, net of issuance costs 248,126 281,145 420,067

Proceeds from issuance of common stock from at-the-market offering 49,919 10,096 0

Proceeds from issuance of common stock under equity incentive plans 1,481 1,487 1,877

Proceeds from issuance of common stock under employee stock purchase plan 1,864 1,875 832

Payments of deferred offering costs 42 (424) 0

Net cash provided by financing activities 301,432 294,179 422,776

Net increase in cash, cash equivalents and restricted cash 52,915 4,882 88,479

Cash, cash equivalents and restricted cash - beginning of year 110,234 105,352 16,873

Cash, cash equivalents and restricted cash - end of year 163,149 110,234 105,352

Reconciliation of cash, cash equivalents and restricted cash to consolidated balance sheets

Cash and cash equivalents 161,412 108,497 104,268

Restricted cash 1,737 1,737 1,084

Cash, cash equivalents and restricted cash - end of year 163,149 110,234 105,352

Supplemental disclosure of non-cash investing and financing activities

Vesting of early exercised options and restricted stock 143 149 199

Purchases of property and equipment in accounts payable and accrued expenses and other current liabilities 1,419 1,129 1,813

Advance payments for property and equipment 82 0 0

Right-of-use assets obtained in exchange for operating lease liabilities 0 35,437 21,188

Unpaid deferred offering costs $ 2 $ 110 $ 0

X

- Definition
Advance Payments For Property And Equipment
+ References
No definition available.
+ Details

Name: rvmd_AdvancePaymentsForPropertyAndEquipment

Namespace Prefix: rvmd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Payments of deferred offering costs.
+ References
No definition available.
+ Details

Name: rvmd_PaymentsOfDeferredOfferingCosts

Namespace Prefix: rvmd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Proceeds from issuance of common stock from at the market offering.
+ References
No definition available.
+ Details

Name: rvmd_ProceedsFromIssuanceOfCommonStockFromAtTheMarketOffering

Namespace Prefix: rvmd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Proceeds from issuance of common stock under employee stock purchase plan.
+ References
No definition available.
+ Details

Name: rvmd_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan

Namespace Prefix: rvmd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Proceeds from maturity of marketable securities.
+ References
No definition available.
+ Details

Name: rvmd_ProceedsFromMaturityOfMarketableSecurities

Namespace Prefix: rvmd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Proceeds from sale of marketable securities.
+ References
No definition available.
+ Details

Name: rvmd_ProceedsFromSaleOfMarketableSecurities

Namespace Prefix: rvmd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Unpaid deferred offering costs.
+ References
No definition available.
+ Details

Name: rvmd_UnpaidDeferredOfferingCosts

Namespace Prefix: rvmd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Vesting of early exercised options and restricted stock.
+ References
No definition available.
+ Details

Name: rvmd_VestingOfEarlyExercisedOptionsAndRestrictedStock

Namespace Prefix: rvmd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585
+ Details

Name: us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Future cash outflow to pay for purchases of fixed assets that have occurred.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586
+ Details

Name: us-gaap_CapitalExpendituresIncurredButNotYetPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585
+ Details

Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase (decrease) in accrued expenses, and obligations classified as other.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 912
-SubTopic 310
-Section 45
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406
+ Details

Name: us-gaap_IncreaseDecreaseInContractWithCustomerLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInDeferredIncomeTaxes

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in obligation for operating lease.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(1)
-URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) in noncurrent assets classified as other.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInOtherNoncurrentAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase (decrease) in noncurrent operating liabilities classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) in prepaid expenses, and assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of amortization expense for right-of-use asset from operating lease.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash outflow for purchase of marketable security.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 11
-URI https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562
+ Details

Name: us-gaap_PaymentsToAcquireMarketableSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from the stock plan during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromStockPlans

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 23: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 31: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(1)(a))
-URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(2))
-URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910
+ Details

Name: us-gaap_RestrictedCash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase in right-of-use asset obtained in exchange for operating lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(2)
-URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980
+ Details

Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 31 R9.htm IDEA: XBRL DOCUMENT v3.22.4

Organization
12 Months Ended

Dec. 31, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization

1.
Organization
Revolution Medicines, Inc. (the Company) is a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers. The Company was founded in October 2014 and is headquartered in Redwood City, California.
Liquidity
The Company has incurred net operating losses in each year since inception. As of December 31, 2022, the Company had an accumulated deficit of $701.3 million. Management believes that its existing cash, cash equivalents and marketable securities will enable the Company to fund its planned operations for at least 12 months following the issuance date of these consolidated financial statements. The Company has been able to fund its operations through the issuance and sale of common stock and redeemable convertible preferred stock in addition to upfront payments and research and development cost reimbursement received under the Company’s collaboration agreement with Genzyme Corporation, an affiliate of Sanofi. Future capital requirements will depend on many factors, including the timing and extent of spending on research and development. There can be no assurance that, in the event the Company requires additional financing, such financing will be available at terms acceptable to the Company, if at all. Failure to generate sufficient cash flows from operations, raise additional capital and reduce discretionary spending should additional capital not become available could have a material adverse effect on the Company’s ability to achieve its business objectives.
Public offerings
In February 2021, the Company issued and sold 6,666,666 shares of its common stock in an underwritten public offering at a price of $45.00 per share (including the exercise in full by the underwriters of their option to purchase an additional 869,565 shares of its common stock) for net proceeds of $281.1 million, after deducting underwriting discounts and commissions of $18.0 million and expenses of $0.9 million.
In November 2021, the Company entered into a sales agreement with Cowen and Company, LLC (Cowen) to sell shares of its common stock, from time to time, with aggregate gross proceeds of up to $250 million, through an at-the-market equity offering program (ATM). During the year ended December 31, 2021, the Company sold an aggregate of 339,302 shares of common stock under the ATM resulting in gross proceeds of $10.4 million. After deducting commissions and expenses of $0.3 million, net proceeds to the Company for the year ended December 31, 2021 were $10.1 million. During the year ended December 31, 2022, the Company sold an aggregate of 2,385,846 shares of common stock under the ATM resulting in gross proceeds of $51.3 million. After deducting commissions and expenses of $1.4 million, net proceeds to the Company for the year ended December 31, 2022 were $49.9 million.
In July 2022, the Company issued and sold 13,225,000 shares of its common stock in an underwritten public offering (including the exercise in full by the underwriters of their option to purchase an additional 1,725,000 shares of the Company’s common stock) at a price to the public of $20.00 per share, for net proceeds of $248.1 million, after deducting underwriting discounts and commissions of $15.9 million and expenses of $0.5 million.

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-URI https://asc.fasb.org/topic&trid=2122149

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-URI https://asc.fasb.org/topic&trid=2197479
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R10.htm IDEA: XBRL DOCUMENT v3.22.4

Summary of Significant Accounting Policies
12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

Summary of Significant Accounting Policies
2.
Summary of significant accounting policies
Basis of presentation
The consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (GAAP) and applicable rules of the Securities and Exchange Commission (SEC) regarding financial reporting and, in the opinion of management, include all normal and recurring adjustments which are necessary to state fairly the Company’s financial position and results of operations for the reported periods. The consolidated financial statements for the years ended December 31, 2022, 2021 and 2020 include the accounts of the Company and its wholly owned subsidiary, Warp Drive Bio, Inc. (Warp Drive). All intercompany balances and transactions have been eliminated in consolidation. The functional and reporting currency of the Company and its subsidiary is the U.S. dollar.
Reverse stock split
On February 7, 2020, the Company amended and restated its amended and restated certificate of incorporation to effect a 1-for-4.8661 reverse stock split of the Company’s common stock and redeemable convertible preferred stock. The par value and authorized shares of the common stock and redeemable convertible preferred stock were not adjusted as a result of the reverse stock split. All issued and outstanding common stock, options to purchase common stock and per share amounts contained in the financial statements have been retroactively adjusted to give effect to the reverse stock split for all periods presented.
Use of estimates
The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, clinical accruals, valuation of in-process research and development and developed technologies, income taxes, useful lives of property and equipment and intangible assets, impairment of goodwill and intangibles, the incremental borrowing rate for determining operating lease assets and liabilities, and stock-based compensation. The extent to which the COVID-19 pandemic may directly or indirectly impact the Company’s business, financial condition and results of operations is highly uncertain and subject to change. The Company considered the potential impact of the COVID-19 pandemic on its estimates and assumptions and there was not a material impact to the Company’s consolidated financial statements as of and for the twelve months ended December 31, 2022. Actual results could materially differ from the Company’s estimates, and there may be changes to the estimates in future periods.
Cash and cash equivalents
The Company considers all highly liquid investments purchased with original maturities of three months or less at the date of purchase to be cash equivalents. As of December 31, 2022 and 2021, cash equivalents consist of amounts invested in money market funds, commercial paper and corporate bonds with original maturities of three months or less at the date of purchase.
Marketable securities
Investments in marketable securities primarily consist of U.S. government debt securities, U.S. government agency bonds, commercial paper, Canadian government securities and corporate bonds. The Company has classified its marketable securities as available-for-sale and may sell these securities prior to their stated maturities. The Company views these marketable securities as available to support current operations and classifies marketable securities with maturities beyond 12 months as current assets. The Company’s investments in marketable securities are carried at estimated fair value, which is derived from independent pricing sources based on quoted prices in active markets for similar securities. Unrealized gains and losses are reported as a component of accumulated other comprehensive loss. The amortized cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the consolidated statements of operations. Realized gains and losses are included in interest income on the consolidated statements of operations.
The Company periodically evaluates its investments to assess whether those with unrealized loss positions are other than temporarily impaired. The Company considers various factors in determining whether to recognize an impairment charge. If the Company determines that the decline in an investment’s fair value is other-than-temporary, the difference is recognized as an impairment loss in the consolidated statements of operations. As of December 31, 2022, no other-than-temporary-impairment has been recorded.
Restricted cash
As of December 31, 2022 and 2021, the Company had $1.7 million and $1.7 million, respectively, of noncurrent restricted cash related to Company issued letters of credit in connection with leases. These amounts are held in separate bank accounts to support letter of credit agreements for the leases.
Concentration of credit risk and other risks and uncertainties
Financial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents and marketable securities. The Company’s cash is held by two financial institutions in the United States, which management believes to be of high credit quality. The Company invests in money market funds, U.S. government debt securities, U.S. government agency bonds, commercial paper and corporate bonds. The Company has not experienced any losses on its deposits of cash and cash equivalents.
The Company is subject to credit risk as its receivable and collaboration revenue are entirely related to its collaboration agreement with Sanofi. For more information, see Note 8, “Sanofi collaboration agreement.”
The Company’s clinical trial sites may be affected by the COVID-19 outbreak due to prioritization of hospital resources toward the COVID-19 outbreak, travel or quarantine restrictions imposed by governments, and the inability to access sites for initiation and patient monitoring and enrollment. As a result, patient screening, new patient enrollment, monitoring and data collection may be affected or delayed. The Company is aware that several clinical sites involved in its clinical studies temporarily stopped or delayed enrolling new patients, with exemptions if appropriate, and it is possible that these or other clinical sites may be similarly affected in the future. These developments may delay the Company’s clinical trial timelines. Some of the Company’s third-party manufacturers which it uses for the supply of materials for product candidates or other materials necessary to manufacture product to conduct preclinical tests and clinical trials and contract research organizations may be impacted by COVID-19, and should they experience disruptions, such as temporary closures or suspension of services, the Company would likely experience delays in advancing clinical trials.
Fair value measurement
The carrying amounts of the Company’s certain financial instruments, including cash equivalents, accounts payable and accrued expenses and other current liabilities approximate fair value due to their relatively short maturities and market interest rates, if applicable. For more information, refer to Note 4 regarding the fair value of the Company’s available-for-sale securities.
Assets and liabilities recorded at fair value on a recurring basis in the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:
Level 1—Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;
Level 2—Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active; and
Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
Property and equipment, net
Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed on a straight-line basis over the estimated useful lives of the related assets, which is generally three to five years. Leasehold improvements are amortized using the straight-line method over the shorter of the assets’ estimated useful lives or the remaining term of the lease. Maintenance and repairs are charged to operations as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is reflected in the consolidated statement of operations.
Useful lives of property and equipment are as follows:

Property and equipment

Estimated useful life

Laboratory equipment

4-5 years

Leasehold improvements

Lesser of estimated useful life or remaining lease term

Computer equipment and software

3 years

Furniture and fixtures

5 years

Leases
The Company determines if an arrangement is, or contains, a lease at inception and then classifies the lease as operating or financing based on the underlying terms and conditions of the contract. Leases with terms greater than one year are initially recognized on the balance sheet as right-of-use assets and lease liabilities based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the rate incurred to borrow, on a collateralized basis, an amount equal to the lease payments over a similar term and in a similar economic environment of the applicable country or region. Variable lease payments are excluded from the right-of-use assets and operating lease liabilities and are recognized in the period in which the obligation for those payments is incurred. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets.
Impairment of long-lived assets
Long-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Recoverability is measured by comparison of the carrying amounts of the asset group to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable, and the carrying amount exceeds the projected discounted future cash flows arising from these assets. There were no impairments of long-lived assets for any of the periods presented.
Acquired intangible assets
Indefinite-lived intangible assets represent the estimated fair value assigned to in-process research and development (IPR&D) acquired in a business combination. The Company reviews indefinite-lived intangible assets for impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying value of the assets might not be recoverable. If the carrying value of an indefinite-lived intangible asset exceeds its fair value, then it is written down to its adjusted fair value. As of December 31, 2022, there have been no such impairments. For IPR&D, if a product candidate derived from the indefinite-lived intangible asset is developed and commercialized, the useful life will be determined, and the carrying value will be amortized prospectively over that estimated useful life. Alternatively, if a product candidate is abandoned, the carrying value of the intangible asset will be charged to research and development expenses in the consolidated statements of operations.
Finite-lived intangible assets acquired in a business combination are recognized separately from goodwill and are initially recognized at their fair value at the acquisition date and are carried at cost less accumulated amortization and impairment. Amortization is computed using the straight-line method over the estimated useful lives of the respective finite-lived intangible assets and is included in research and development expenses in the consolidated statement of operations. Intangible assets are reviewed for impairment at least annually or more frequently if indicators of potential impairment exist. As of December 31, 2022, no such impairment has been recorded.
Goodwill
Goodwill represents the excess of the purchase price over the estimated fair value of the net tangible and intangible assets acquired in a business combination. The Company reviews goodwill for impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying value of goodwill may not be recoverable. Goodwill is tested for impairment at the reporting unit level by first assessing the qualitative factors to determine whether it is more likely than not that the fair value of the Company’s single reporting unit is less than its carrying amount. Qualitative indicators assessed include consideration of macroeconomic, industry and market conditions, the Company’s overall financial performance and personnel or strategy changes. Based on the qualitative assessment, if it is determined that it is more likely than not that its fair value is less than its carrying amount, the fair value of the Company’s single reporting unit is compared to its carrying value. Any excess of the goodwill carrying amount over the fair value is recognized as an impairment loss, and the carrying value of goodwill is written down to fair value. As of December 31, 2022, no goodwill impairment has been identified.
Redeemable convertible preferred stock
The Company records all shares of redeemable convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. The redeemable convertible preferred stock is recorded outside of permanent equity because while it is not mandatorily redeemable, in the event of certain events considered not solely within the Company’s control, such as a merger, acquisition or sale of all or substantially all of the Company’s assets (each, a deemed liquidation event), the redeemable convertible preferred stock would have become redeemable at the option of the holders of at least a majority of the then outstanding such shares. The Company did not adjust the carrying values of the redeemable convertible preferred stock to the liquidation preferences of such shares because it was uncertain whether or when a deemed liquidation event would occur that would obligate the Company to pay the liquidation preferences to holders of shares of redeemable convertible preferred stock.
Revenue recognition
The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.
The Company enters into collaboration agreements under which it may obtain upfront license fees, research and development funding, and development, regulatory and commercial milestone payments and royalty payments. The Company’s performance obligations under these arrangements may include licenses of intellectual property, sales and distribution rights, research and development services, delivery of manufactured product and/or participation on joint steering committees.
Licenses of intellectual property: If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from upfront license fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring proportional performance for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of proportional performance each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.
Research, development and regulatory milestone payments: At the inception of each arrangement that includes research, development, or regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. The Company uses the most likely amount method for research, development and regulatory milestone payments. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.
Sales-based milestones and royalties: For arrangements that include sales-based milestone or royalty payments based on the level of sales, and in which the license is deemed to be the predominant item to which the sales-based milestone or royalties relate to, the Company recognizes revenue in the period in which the sales-based milestone is achieved and in the period in which the sales associated with the royalty occur. To date, the Company has not recognized any sales-based milestone or royalty revenue resulting from its collaboration arrangements.
Deferred revenue represents amounts received by the Company for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. The current portion of deferred revenue represents the amount to be recognized within one year from the balance sheet date based on the estimated performance period of the underlying performance obligation. The noncurrent portion of deferred revenue represents amounts to be recognized after one year through the end of the performance period of the performance obligation.
Research and development expenditures
Research and development expenses consist of costs incurred for the Company’s own and for collaborative research and development activities. Research and development costs are expensed as incurred. Research and development costs consist of salaries and benefits, including associated stock-based compensation, and laboratory supplies and facility costs, as well as fees paid to other entities that conduct certain research and development activities on the Company’s behalf. The Company estimates preclinical studies and clinical trial expenses based on the services performed pursuant to contracts with research institutions, contract research organizations and clinical manufacturing organizations that conduct and manage preclinical studies and clinical trials on the Company’s behalf based on actual time and expenses incurred by them. Further, the Company accrues expenses related to clinical trials based on the level of patient activity according to the related agreement. The Company monitors patient enrollment levels and related activity to the extent reasonably possible and adjusts estimates accordingly.
Stock-based compensation
The Company measures its stock-based awards granted to employees and directors based on the estimated fair values of the awards and recognizes the compensation on a straight-line basis over the requisite service period. The fair value of options issued under the employee stock purchase plan is calculated using the Black-Scholes option-pricing model. Restricted stock units are valued based on the closing price of the Company’s common stock on the date of grant.
Comprehensive loss
For the years ended December 31, 2022, 2021 and 2020, other comprehensive loss includes net unrealized gains or losses on marketable securities.
Income taxes
Income taxes are accounted for under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Management makes an assessment of the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company’s historical operating performance and the recorded cumulative net losses in prior fiscal periods, the net deferred tax assets have been fully offset by a valuation allowance.
The Company recognizes uncertain income tax positions at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Changes in recognition or measurement are reflected in the period in which judgment occurs. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of interest expense.
Net loss per share attributable to common stockholders
Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock, stock options, common stock subject to repurchase related to unvested restricted stock awards and early exercise of stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities as the redeemable convertible preferred stock is considered a participating security because it participates in dividends with common stock. The Company also considers the shares issued upon the early exercise of stock options subject to repurchase to be participating securities because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. The holders of all series of redeemable convertible preferred stock and the holders of early exercised shares subject to repurchase do not have a contractual obligation to share in the Company’s losses. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for all periods presented, diluted net loss per share is the same as basic net loss per share for those periods.
Deferred offering costs
The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders’ deficit (equity) as a reduction of additional paid-in capital generated as a result of the equity financing. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations. As of December 31, 2022 and 2021, $0.6 million and $0.5 million of deferred offering costs, respectively, were capitalized in other noncurrent assets on the consolidated balance sheets.
Segment reporting
The Company has one operating and reportable segment. The Company’s chief operating decision maker, its Chief Executive Officer, manages the Company’s operations on a consolidated basis for the purposes of allocating resources and evaluating financial performance. All of the Company’s long-lived assets are located in the United States.
401(k) retirement plans
The Company maintains a 401(k) retirement plan for its employees. The Company is responsible for administrative costs of the 401(k) plan. The Company may, at its discretion, make matching or profit-sharing contributions to the 401(k) plan. For the years ended December 31, 2022, 2021 and 2020, the Company made $1.3 million, $0.9 million and $0.2 million matching contributions, respectively, under the plan.
Recent accounting pronouncements
From time to time, new accounting pronouncements are issued by the FASB, under its ASC or other standard setting bodies, and adopted by the Company as of the specified effective date, unless otherwise discussed below.
Recently adopted accounting pronouncements
In October 2020, the FASB issued ASU 2020-08, Codification Improvements to Subtopic 310-20, Receivables-Nonrefundable Fees and Other Costs (ASU 2020-08). ASU 2020-08 clarifies that an entity should reevaluate whether a callable debt security is within the scope of ASC paragraph 310-20-35-33 for each reporting period. The guidance is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021. Early application is not permitted. All entities should apply ASU 2020-08 on a prospective basis as of the beginning of the period of adoption for existing or newly purchased callable debt securities. The Company adopted the standard for the fiscal year beginning on January 1, 2022 and concluded that adoption of the standard did not have a material impact on its consolidated financial statements.
In October 2020, FASB issued ASU 2020-10, Codification Improvements (ASU 2020-10). ASU 2020-10 updates various codification topics by clarifying or improving disclosure requirements to align with the SEC’s regulations. The amendments are effective for the Company for fiscal years beginning after December 15, 2021, including interim period within those fiscal years. Early
adoption is permitted. Adoption shall be applied retrospectively. The Company adopted the standard for the fiscal year beginning on January 1, 2022 and concluded that adoption of the standard did not have a material impact on its consolidated financial statements.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI https://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R11.htm IDEA: XBRL DOCUMENT v3.22.4

Fair Value Measurements
12 Months Ended

Dec. 31, 2022

Fair Value Disclosures [Abstract]

Fair Value Measurements
3.
Fair value measurements
The following table presents information about the Company’s financial assets that are measured at fair value and indicates the fair value hierarchy of the valuation:

December 31, 2022

Total

Level 1

Level 2

Level 3

(in thousands)

Assets:

Money market funds(1)

$

48,522

$

48,522

$

—

$

—

Commercial paper(1, 2)

313,928

—

313,928

—

U.S. and Canadian government and agency securities(2)

251,830

—

251,830

—

Corporate bonds(1, 2)

31,405

—

31,405

—

Total

$

645,685

$

48,522

$

597,163

$

—

December 31, 2021

Total

Level 1

Level 2

Level 3

(in thousands)

Assets:

Money market funds(1)

$

57,134

$

57,134

$

—

$

—

Commercial paper(1, 2)

291,369

—

291,369

—

U.S. and Canadian government and agency securities(2)

87,745

—

87,745

—

Corporate bonds(2)

141,698

—

141,698

—

Total

$

577,946

$

57,134

$

520,812

$

—

(1)
Included in cash and cash equivalents on the consolidated balance sheets.
(2)
Included in marketable securities on the consolidated balance sheets.
Money market funds are measured at fair value on a recurring basis using quoted prices. U.S. and Canadian government debt securities, government agency bonds, commercial paper and corporate bonds are measured at fair value, which is derived from independent pricing sources based on quoted prices in active markets for similar securities.
There were no transfers between Levels 1, 2 or 3 for any of the periods presented.

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R12.htm IDEA: XBRL DOCUMENT v3.22.4

Available-for-sale Securities
12 Months Ended

Dec. 31, 2022

Investments, Debt and Equity Securities [Abstract]

Available-for-sale securities
4.
Available-for-sale securities
The following tables summarize the estimated value of the Company’s available-for-sale marketable securities and cash equivalents and the gross unrealized gains and losses:

December 31, 2022

Gross

Gross

Amortized

unrealized

unrealized

Estimated

cost

gain

loss

fair value

(in thousands)

Marketable securities:

Commercial paper

$

216,765

$

—

$

(328

)

$

216,437

U.S. and Canadian government and agency securities

236,916

43

(1,270

)

235,689

Corporate bonds

31,599

—

(194

)

31,405

Total marketable securities

485,280

43

(1,792

)

483,531

Cash equivalents:

Money market funds

48,522

—

—

48,522

Commercial paper

97,526

—

(35

)

97,491

Corporate bonds

16,137

4

—

16,141

Total cash equivalents

162,185

4

(35

)

—

162,154

Total available-for-sale investments

$

647,465

$

47

$

(1,827

)

$

645,685

December 31, 2021

Gross

Gross

Amortized

unrealized

unrealized

Estimated

cost

gain

loss

fair value

(in thousands)

Marketable securities:

Commercial paper

$

239,176

$

1

$

(63

)

$

239,114

U.S. and Canadian government and agency securities

87,926

—

(181

)

87,745

Corporate bonds

141,829

—

(131

)

141,698

Total marketable securities

468,931

1

(375

)

468,557

Cash equivalents:

Money market funds

57,134

—

—

57,134

Commercial paper

52,257

—

(2

)

52,255

Total cash equivalents

109,391

—

(2

)

109,389

Total available-for-sale investments

$

578,322

$

1

$

(377

)

$

577,946

The amortized cost and estimated fair value of the Company’s available-for-sale marketable securities and cash equivalents by contractual maturity are summarized below as of December 31, 2022:

December 31, 2022

Gross

Gross

Amortized

unrealized

unrealized

Estimated

cost

gain

loss

fair value

(in thousands)

Mature in one year or less

$

618,025

$

48

$

(1,752

)

$

616,321

Mature after one year through two years

29,440

(1

)

(75

)

29,364

Total marketable securities

$

647,465

$

47

$

(1,827

)

$

645,685

X

- References
No definition available.
+ Details

Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for investments in certain debt and equity securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-URI https://asc.fasb.org/subtopic&trid=2209399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 320
-URI https://asc.fasb.org/subtopic&trid=2324412

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-URI https://asc.fasb.org/topic&trid=2196928

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 320
-URI https://asc.fasb.org/subtopic&trid=2176304

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher SEC
-Name Regulation S-K (SK)
-Number 229
-Section 1403
-Paragraph (b)
+ Details

Name: us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R13.htm IDEA: XBRL DOCUMENT v3.22.4

Balance Sheet Components
12 Months Ended

Dec. 31, 2022

Balance Sheet Related Disclosures [Abstract]

Balance Sheet Components
5.
Balance sheet components
Property and equipment, net
Property and equipment, net consists of the following:

December 31,

2022

2021

(in thousands)

Laboratory equipment

$

17,163

$

12,727

Leasehold improvements

11,404

7,245

Computer equipment and software

3,965

2,186

Furniture and fixtures

616

69

Construction in progress

—

129

33,148

22,356

Less: accumulated depreciation and amortization

(14,489

)

(10,812

)

Property and equipment, net

$

18,659

$

11,544

Depreciation and amortization expense for property and equipment amounted to $4.0 million, $3.1 million and $2.6 million for the years ended December 31, 2022, 2021 and 2020, respectively.
Accrued expenses and other current liabilities
Accrued expenses and other current liabilities consist of the following:

December 31,

2022

2021

(in thousands)

Accrued compensation

$

13,281

$

9,852

Accrued research and development

15,161

17,018

Accrued professional services

499

540

Other

505

311

Total accrued expenses and other current liabilities

$

29,446

$

27,721

X

- References
No definition available.
+ Details

Name: us-gaap_BalanceSheetRelatedDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-URI https://asc.fasb.org/topic&trid=2122208
+ Details

Name: us-gaap_SupplementalBalanceSheetDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R14.htm IDEA: XBRL DOCUMENT v3.22.4

Intangible Assets and Goodwill
12 Months Ended

Dec. 31, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets and Goodwill
6.
Intangible assets and goodwill
Intangible assets, net
Intangible assets, net consist of the following as of December 31, 2022:

Gross value

Accumulated
amortization

Net book
value

Weighted-
average
remaining
useful life

(in thousands)

(in years)

In-process research and development — RAS
 Programs

$

55,800

$

—

$

55,800

n/a

Developed technology — tri-complex platform

7,480

(4,473

)

3,007

2.9

Total

$

63,280

$

(4,473

)

$

58,807

Amortization expense for the years ended December 31, 2022, 2021 and 2020 were $1.1 million, $1.1 million and $1.1 million, respectively.

As of December 31, 2022, future amortization expense is as follows:

Amount

(in thousands)

2023

$

1,069

2024

1,068

2025

870

Total

$

3,007

Intangible assets, net consist of the following as of December 31, 2021:

Gross value

Accumulated
amortization

Net book
value

Weighted-
average
remaining
useful life

(in thousands)

(in years)

In-process research and development — RAS
 Programs

$

55,800

$

—

$

55,800

n/a

Developed technology — tri-complex platform

7,480

(3,404

)

4,076

3.9

Total

$

63,280

$

(3,404

)

$

59,876

Goodwill
Goodwill consists of the following:

Amount

(in thousands)

Balance at December 31, 2021

$

14,608

Adjustment

—

Balance at December 31, 2022

$

14,608

No impairment has been recognized as of December 31, 2022. Goodwill is not deductible for income tax purposes.

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for goodwill and intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-URI https://asc.fasb.org/topic&trid=2144416
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R15.htm IDEA: XBRL DOCUMENT v3.22.4

Commitments and Contingencies
12 Months Ended

Dec. 31, 2022

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies
7.
Commitments and contingencies
Leases
In January 2015, as amended in September 2016, the Company entered into an operating lease for approximately 42,000 square feet of office and laboratory space located at 700 Saginaw Drive, Redwood City, California (the 700 Building), with a term through April 2023. In April 2020, the Company amended the lease to lease an additional 19,000 square feet of office, laboratory and research and development space located at 300 Saginaw Drive, Redwood City, California (the 300 Building), and to extend the lease term through December 2030. In November 2021, the Company amended the lease to lease an additional 41,000 square feet of office, laboratory and research and development space located at 800 Saginaw Drive, Redwood City, California (the 800 Building), and to extend the lease term through November 2033. The Company has the option to extend the lease for an additional ten years after November 30, 2033.
The Company maintains letters of credit for the benefit of the landlord which is disclosed as restricted cash in the consolidated balance sheets. Restricted cash related to letters of credit due to the landlord was $1.5 million and $1.5 million as of December 31, 2022 and December 31, 2021, respectively.
Through December 31, 2022, the landlord had provided the Company with $3.4 million in tenant improvement allowances for the 700 Building, and $4.6 million for the 300 building, which were recognized as lease incentives. The lease incentives are being amortized as an offset to rent expense over the lease term in the consolidated statements of operations.
Upon the execution of the lease in April 2020, which was deemed to be a lease modification, the Company re-evaluated the assumptions used during the adoption of ASC 842 for the lease. The Company determined the amendment consists of two separate contracts under ASC 842. One contract is related to a new right-of-use asset for the 300 Building, which is being accounted for as an operating lease, and the other is related to the modification of the original lease term for the 700 Building. As a result, the Company recorded a right-of-use asset of $6.4 million and a lease liability of $9.0 million for the 300 Building and an increase of $14.8 million to the right-of-use asset and lease liability for the 700 Building upon execution of the lease amendment. The Company is recognizing rent expense for both buildings on a straight-line basis through the remaining extended term of the lease.
Upon the execution of the lease amendment in November 2021, which was deemed to be a lease modification, the Company re-evaluated the assumptions used during the lease amendment in April 2020. The Company determined the amendment consists of two separate contracts under ASC 842. One contract is related to a new right-of-use asset for the 800 Building, which is being accounted for as an operating lease, and the other is related to the modification of the lease term, as amended in April 2020, for the 700 Building and 300 Building. As a result, the Company recorded a right-of-use asset and a lease liability of $26.8 million for the 800 Building and an aggregate increase of $8.6 million to the right-of-use assets and lease liabilities for the 700 Building and 300 Building upon execution of the lease amendment. The Company is recognizing rent expense for the buildings on a straight-line basis through the remaining extended term of the lease.
As part of the Warp Drive acquisition in October 2018, the Company assumed an operating lease for approximately 22,000 square feet of office and laboratory space located in Cambridge, Massachusetts (Cambridge Lease), which expires in February 2023, with an option to extend the term through February 2028, subject to certain conditions. In March 2019, the Company fully subleased the Cambridge Lease to Casma Therapeutics, Inc. (Casma), a related party, on financial terms substantially the same as the original lease. The sublease term with Casma is through the remainder of the Cambridge Lease term. The sublease by Casma and related sublease payments by Casma to the Company are fully guaranteed by Third Rock Ventures, LLC, a related party. In conjunction with the Cambridge Lease, the Company issued a letter of credit for $0.2 million, which is included in restricted cash on the consolidated balance sheets as of December 31, 2022 and 2021.
The balance sheet classification of the Company’s operating lease liabilities was as follows:

December 31,

2022

(in thousands)

Operating lease liabilities:

Operating lease liability – current

$

6,773

Operating lease liability – noncurrent

57,432

Total operating lease liabilities

$

64,205

For the years ended December 31, 2022 and 2021, operating lease cost was $6.4 million and $3.4 million, respectively, net of sublease income of $2.5 million and $2.1 million, respectively. The operating cash flows for operating leases were $2.4 million and $1.5 million year ended December 31, 2022 and 2021, respectively. Short-term lease costs were immaterial for the years ended December 31, 2022 and 2021.
As of December 31, 2022, the maturities of the Company’s operating lease liabilities were as follows (in thousands):

2023

$

6,961

2024

7,100

2025

7,349

2026

7,606

2027

7,872

Thereafter

52,550

Total undiscounted lease payments

$

89,438

Less: Imputed interest

(25,233

)

Less: Tenant improvement allowance

—

Total operating lease liabilities

$

64,205

The amounts reflected in the table above include the Company’s lease payments for the Cambridge lease, but do not reflect any offset for the sublease payments the Company is entitled to receive from Casma.
Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company uses its incremental borrowing rate. The weighted-average discount rate used to determine the operating lease liability was 6.1%. As of December 31, 2022 and 2021, the weighted-average remaining lease term is 10.9 years and 11.6 years, respectively.
Legal matters
From time to time, the Company may be involved in litigation related to claims that arise in the ordinary course of its business activities. The Company accrues for these matters when it is probable that losses will be incurred and these losses can be reasonably estimated. As of December 31, 2022 and 2021, the Company does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company’s financial position, results of operations or cash flows.
Indemnification
The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these arrangements is not determinable. The Company has not incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the Company believes the fair value of these agreements is minimal.
Other
The Company enters into agreements in the ordinary course of business with contract research organizations for clinical trials, contract manufacturing organizations to provide clinical trial materials and with vendors for preclinical studies and other services and products for operating purposes which are generally cancelable at any time by us upon 30 to 90 days prior written notice.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI https://asc.fasb.org/topic&trid=2144648

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 440
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI https://asc.fasb.org/topic&trid=2127136

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R16.htm IDEA: XBRL DOCUMENT v3.22.4

Sanofi Collaboration Agreement
12 Months Ended

Dec. 31, 2022

Collaboration Agreement [Abstract]

Sanofi Collaboration Agreement
8.
Sanofi collaboration agreement
In June 2018, the Company entered into a collaborative research, development and commercialization agreement (the Sanofi Agreement) with Aventis, Inc. (an affiliate of Sanofi) to research and develop SHP2 inhibitors, including RMC-4630, for any indications. The Sanofi Agreement was assigned to Genzyme Corporation, a Sanofi affiliate, in December 2018. For the purposes of this discussion, we refer to Genzyme Corporation as Sanofi. Pursuant to the Sanofi Agreement, the Company granted Sanofi a worldwide, exclusive, sublicensable (subject to the Company’s consent in certain circumstances) license under certain of the Company’s patents and know-how to research, develop, manufacture, use, sell, offer for sale, import and otherwise commercialize SHP2 inhibitors, including RMC-4630, for any and all uses, subject to the Company’s exercise of rights and performance of obligations under the Sanofi Agreement. In December 2022, the Company received notice of Sanofi’s decision to terminate for convenience under the Sanofi Agreement, with a termination date in June 2023. Upon effectiveness of the termination of the Sanofi Agreement (the termination date), the licenses granted to Sanofi thereunder shall become fully paid-up, royalty-free, perpetual and irrevocable and all rights and obligations of Sanofi under the Sanofi Agreement will revert to the Company.
In October 2018, the Company acquired Warp Drive in exchange for issuance of shares of the Company’s Series B redeemable convertible preferred stock and payment of cash. Sanofi was a stockholder of Warp Drive and received the Company’s Series B redeemable convertible preferred stock during the transaction and accordingly became an investor and related party of the Company. As a result of the Company’s underwritten offering of common stock in February 2021, Sanofi’s ownership percentage in the Company decreased and Sanofi is no longer considered a related party.
Under the Sanofi Agreement, the Company received a non-refundable, upfront cash payment of $50 million in July 2018.
Prior to the termination date, the Company has primary responsibility for early clinical development of RMC-4630 and is responsible for the manufacture of SHP2 inhibitors for Phase 1 and non-registrational Phase 2 clinical trials pursuant to an approved development plan. In August 2021, the Company entered into a letter agreement with Sanofi (the Letter Agreement) to include an additional clinical study, RMC-4630-03, as part of the Company’s responsibilities under the development plan. Sanofi is responsible to reimburse the Company all internal and external costs and expenses to perform the Company’s activities under approved development plans up to the termination date, except for the RMC-4630-03 study, for which Sanofi will reimburse the Company for 50% of the costs and expenses up to the termination date.
In addition to the ongoing development plan, the Company was also primarily responsible for performing preclinical research on SHP2 inhibitors pursuant to a research plan through 2021. Sanofi was responsible to reimburse the Company for all internal and external costs and expenses incurred to perform activities under approved research plan for 2021.
The Company identified the following promises in the agreement (1) the license related to SHP2 inhibitors, (2) the performance of research and development services for Phase 1 clinical studies and Phase 2 clinical trials that are non-registrational clinical trials and (3) the performance of manufacturing services for the non-registrational clinical trials. The Company determined that the license is not distinct from the services within the context of the agreement because the research, development and manufacturing significantly increase the utility of the intellectual property. The intellectual property (IP) related to SHP2 inhibitors, which is proprietary to the Company, is the foundation for the research and development activities. The manufacturing services are a necessary and integral part of the research and development services as they could only be conducted utilizing the outcomes of these services. Given the research and development services under the Sanofi Agreement are expected to involve significant further development of the initial IP, the Company has concluded that the research, development and manufacturing services are not distinct from the license, and thus the license, research and development services and manufacturing services are combined into a single performance obligation.
For revenue recognition purposes, the Company determined that the duration of the contract begins on the effective date of the Sanofi Agreement in July 2018 and ends on the termination date in June 2023.
The Company determined that the transaction price of the Sanofi Agreement was $186.9 million as of December 31, 2022. In order to determine the transaction price, the Company evaluated all the payments to be received during the duration of the contract. The Company determined that the $50.0 million upfront payment and $136.9 million of estimated variable consideration for expense reimbursements from Sanofi for agreed upon research and development services as of December 31, 2022 constituted consideration to be included in the transaction price, which is to be allocated to the combined performance obligation. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.
The license, research, development and manufacturing services are combined as one performance obligation that will be performed over the duration of the contract, which is from the effective date of the Sanofi Agreement through the termination date. The Company concluded that it would utilize a cost-based input method to measure proportional performance and to calculate the corresponding amount of revenue to recognize. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to estimated costs to fulfill the combined performance obligation. These costs consist primarily of internal full-time equivalent efforts and third-party costs. As noted above, a percentage of the actual costs incurred under approved research and development plans are reimbursed by Sanofi under the collaboration agreement. The research and development plans are determined by a joint research and development committee, over which Sanofi has final decision-making subject to certain exceptions. Revenue is recognized under the collaboration agreement with Sanofi, based on actual costs incurred as a percentage of total estimated costs to be incurred over the performance obligation as the Company completes its performance obligation. The cumulative effect of revisions to estimated costs to complete the Company’s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated.
Pursuant to the termination noticed provided by Sanofi in December 2022, effective as of the termination date, Sanofi will have no further reimbursement obligations post termination. As a result of the termination and development plan adjustments during the year, the Company updated the accounting transaction price for the estimated consideration to be received and updated the estimated costs to fulfill the performance obligation, which increased the Company’s percentage of completion under the agreement with Sanofi, and resulted in total cumulative catch-up adjustments that increased collaboration revenue by $3.0 million for the year ended December 31, 2022.
As a result of entering into the Letter Agreement for the RMC-4630-03 study in August 2021, the Company updated the transaction price for the estimated consideration to be received, and updated the estimated costs to fulfill the performance obligation, which decreased the estimated percentage of completion to date and resulted in a cumulative catch-up adjustment that reduced collaboration revenue by $8.5 million for the year ended December 31, 2021.
During the years ended December 31, 2022, 2021 and 2020, the Company recognized $35.4 million, $29.4 million and $43.0 million of collaboration revenue associated with this agreement, respectively.
As of December 31, 2022 and 2021, $4.5 million and $12.4 million of deferred revenue is classified as current and zero and $6.6 million is classified as noncurrent, respectively.

X

- Definition
Collaboration agreement.
+ References
No definition available.
+ Details

Name: rvmd_CollaborationAgreementAbstract

Namespace Prefix: rvmd_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 808
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 808
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 808
-URI https://asc.fasb.org/topic&trid=5833765
+ Details

Name: us-gaap_CollaborativeArrangementDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R17.htm IDEA: XBRL DOCUMENT v3.22.4

Redeemable Convertible Preferred Stock
12 Months Ended

Dec. 31, 2022

Temporary Equity Disclosure [Abstract]

Redeemable Convertible Preferred Stock
9.
Redeemable convertible preferred stock
Upon the closing of the Company’s initial public offering in February 2020, all shares of redeemable convertible preferred stock then outstanding converted into 39,600,423 shares of common stock. There were no shares of redeemable convertible preferred stock outstanding as of December 31, 2022 and 2021.

X

- Definition
Redeemable convertible preferred stock.
+ References
No definition available.
+ Details

Name: rvmd_RedeemableConvertiblePreferredStockTextBlock

Namespace Prefix: rvmd_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TemporaryEquityDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 40 R18.htm IDEA: XBRL DOCUMENT v3.22.4

Common Stock
12 Months Ended

Dec. 31, 2022

Stockholders' Equity Note [Abstract]

Common Stock
10.
Common stock
As of December 31, 2022 and 2021, the Company’s certificate of incorporation authorized the Company to issue 300,000,000 shares of common stock, at a par value of $0.0001 per share. Each share of common stock is entitled to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to prior rights of the redeemable convertible preferred stockholders. As of December 31, 2022, no dividends have been declared to date.
The Company has reserved shares of common stock for future issuance as follows:

December 31,

December 31,

2022

2021

Outstanding options to purchase common stock

8,164,375

6,050,938

Unvested restricted stock units of common stock

1,175,032

423,621

Available for future issuance under the 2020 Incentive Award Plan

6,726,307

6,403,548

Available for issuance under the 2020 Employee Stock Purchase Plan

1,700,887

1,089,728

Total

17,766,601

13,967,835

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R19.htm IDEA: XBRL DOCUMENT v3.22.4

Stock-Based Compensation
12 Months Ended

Dec. 31, 2022

Share-Based Payment Arrangement [Abstract]

Stock-Based Compensation
11.
Stock-based compensation
2020 Incentive Award Plan
In February 2020, the Company adopted the 2020 Equity Incentive Plan (the 2020 Plan). The 2020 Plan became effective on February 11, 2020. The 2020 Plan provides for a variety of stock-based compensation awards, including stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance bonus awards, performance stock unit awards, dividend equivalents, or other stock or cash based awards. Under the 2020 Plan, the Company generally grants stock-based awards with service-based vesting conditions only. Options and restricted stock unit awards granted typically vest over a four-year period, but may be granted with different vesting terms.
Following the effectiveness of the 2020 Plan, the Company will not make any further grants under the 2014 Equity Incentive Plan (the 2014 Plan). However, the 2014 Plan will continue to govern the terms and conditions of the outstanding awards granted under it. Shares of common stock subject to awards granted under the 2014 Plan that are forfeited or lapse unexercised and which following the effective date of the 2020 Plan were not issued under the 2014 Plan are available for issuance under the 2020 Plan.
2020 Employee Stock Purchase Plan
In February 2020, the Company adopted the 2020 Employee Stock Purchase Plan (the ESPP). Under the ESPP, employees have the ability to purchase shares of the Company’s common stock through payroll deductions at a discount during a series of offering periods of 24 months, each comprised of four six-month purchase periods. The purchase price will be the lower of 85% of the closing
trading price per share of the Company’s common stock on the first day of an offering period in which an employee is enrolled or 85% of the closing trading price per share on the purchase date, which will occur on the last trading day of each purchase period.
As of December 31, 2022, there have been 235,555 shares of common stock purchased under the ESPP. As of December 31, 2022, a total of 1,700,887 shares of common stock were available for future issuance under the ESPP. As of December 31, 2022, there was $3.2 million of unrecognized compensation cost related to the ESPP.
Stock options
The following summarizes option activity under both the 2020 Plan and the 2014 Plan:

Number of
Shares
underlying
options

Weighted-
average
exercise price

Weighted-
average
remaining
contractual
term

Aggregate
intrinsic
value

(in years)

(in thousands)

Balance, December 31, 2021

6,050,938

$

14.88

7.74

$

83,953

Options granted

2,758,710

19.37

Options exercised

(249,544

)

6.12

Options cancelled

(395,729

)

26.78

Balance, December 31, 2022

8,164,375

$

16.09

7.53

$

85,181

Options vested and expected to vest as of December 31, 2022

8,164,375

$

16.09

7.53

$

85,181

Options vested and exercisable as of December 31, 2022

4,555,124

$

11.43

6.65

$

66,783

The aggregate intrinsic values of options outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the options and the estimated fair value of the Company’s common stock by the Board of Directors. The intrinsic value of the options exercised for the years December 31, 2022, 2021 and 2020 was $3.8 million, $13.1 million and $21.7 million, respectively.
During the years ended December 31, 2022, 2021 and 2020, the weighted-average grant-date fair value of options granted was $12.33, $25.13 and $15.59 per share, respectively. As of December 31, 2022, there was $48.8 million of unrecognized stock-based compensation expense related to unvested stock options that is expected to be recognized over a weighted-average period of 2.57 years.
The fair value of employee and director stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:

Year Ended December 31,

2022

2021

2020

Expected term (years)

6

6

6

Expected volatility

70-73%

70-75%

74-80%

Risk-free interest rate

1.5%-4.2%

0.5%-1.3%

0.2%-1.5%

Dividend yield

0%

0%

0%

Non-employee stock option awards were measured at fair value at each reporting period using a Black-Scholes option-pricing model with the following assumptions:

Year Ended December 31,

2022

2021

2020

Expected term (years)

6

6

6-10

Expected volatility

70-71%

70-75%

74-80%

Risk-free interest rate

1.6%-3.4%

0.9%-1.3%

1.2%-1.5%

Dividend yield

0%

0%

0%

The Black-Scholes model assumptions that determine the fair value of stock-based awards include:
Expected term—The expected term is calculated using the simplified method, which is available where there is insufficient historical data about exercise patterns and post-vesting employment termination behavior. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting-tranche for awards with graded vesting. The mid-point between the vesting date and the maximum contractual expiration date is used as the expected term under this method.
Expected volatility—Given the Company does not have sufficient trading history for its common stock, the expected volatility was estimated based on the average volatility of the Company and comparable publicly traded biotechnology companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on their similar size, stage in the life cycle or area of specialty.
Risk-free interest rate—The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.
Expected dividend—The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.
Restricted stock units
Restricted stock units (RSUs) have been granted to employees and directors. The fair value of an RSU award is based on the Company’s stock price on the date of grant. The shares underlying the RSU awards are not issued until the RSUs vest. Upon vesting, each RSU converts into one share of the Company’s common stock. The Company has granted RSUs pursuant to the 2020 plan.
Activity under the 2020 Plan with respect to the Company’s RSUs during the year ended December 31, 2022 was as follows:

Number of
Shares

Weighted-
average
grant date fair value per share

Weighted-
average
remaining contractual term

Aggregate intrinsic value

(in years)

(in thousands)

Balance, December 31, 2021

423,621

$

37.16

3.16

$

10,663

Restricted stock units granted

1,142,366

19.43

Restricted stock units vested

(278,848

)

28.23

Restricted stock units forfeited

(112,107

)

24.58

Balance, December 31, 2022

1,175,032

$

23.25

1.62

27,989

Expected to vest as of December 31, 2022

1,175,032

$

23.25

1.62

27,989

The number of RSUs vested includes shares of common stock that the Company withheld to satisfy the minimum statutory tax withholding requirements. As of December 31, 2022, there was $25.8 million of total unrecognized compensation cost related to RSUs that is expected to be recognized over a weighted average period of 3.07 years.
The total fair value of RSUs vested for the years ended December 31, 2022, 2021 and 2020 was $7.9 million, $3.1 million and $0.1 million, respectively.
Stock-based compensation expense
Total stock-based compensation expense related to stock options, RSUs and the ESPP by function was as follows:

Year Ended December 31,

2022

2021

2020

(in thousands)

Research and development

$

18,113

$

11,847

$

4,848

General and administrative

13,083

8,877

4,038

Total

$

31,196

$

20,724

$

8,886

Stock-based compensation related to options and RSUs granted to non-employees was $0.5 million, $0.7 million and $0.8 million for the years ended December 31, 2022, 2021 and 2020, respectively.

X

- Definition
The entire disclosure for share-based payment arrangement.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI https://asc.fasb.org/topic&trid=2228938

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (l)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(2)(i)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(2)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 42 R20.htm IDEA: XBRL DOCUMENT v3.22.4

Income Taxes
12 Months Ended

Dec. 31, 2022

Income Tax Disclosure [Abstract]

Income Taxes
12.
Income taxes
The Company recorded an income tax benefit of 0.4 million and zero for the years ended December 31, 2022 and 2021, respectively, which reflects state tax rates applied to the indefinite lived intangibles recorded as part of the Company’s acquisition of Warp Drive Bio in 2018. The Company has incurred net pre-tax losses in the United States only for all periods presented. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the carrying amounts of existing assets and liabilities in the financial statements and their respective tax bases using tax rates expected to be in effect during the years in which the basis differences reverse.
The benefit from income taxes differs from the amount expected by applying the federal statutory rate to the loss before taxes as follows:

Year Ended December 31,

2022

2021

Federal statutory income tax rate

21.0

%

21.0

%

State income tax rate, net of federal benefit

9.4

%

8.9

%

Research tax credits

3.2

%

2.2

%

Change in valuation allowance

-32.4

%

-31.4

%

Non-deductible permanent expenses

-1.0

%

-0.5

%

Other

0.0

%

-0.2

%

Benefit from income taxes

0.2

%

0.0

%

Deferred income tax reflects the tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The categories that give rise to significant components of the deferred tax assets are as follows (in thousands):

December 31,

2022

2021

(in thousands)

Deferred tax assets:

Net operating loss carryforwards

$

132,080

$

123,991

Accruals and reserves

5,494

9,164

Research and development credits

22,558

14,449

Lease liability

18,998

19,979

Stock-based compensation

7,063

3,829

Capitalized research expenses

64,149

—

Other

42

33

Gross deferred tax assets

250,384

171,445

Less: valuation allowance

(224,125

)

(143,474

)

Total deferred tax assets

26,259

27,971

Deferred tax liabilities:

Fixed assets and finite-lived intangible assets

(9,961

)

(10,073

)

Indefinite-lived intangible assets

(7,025

)

(7,444

)

Lease asset

—

—

Right-of-use asset

(16,298

)

(17,898

)

Gross deferred tax liabilities

(33,284

)

(35,415

)

Net deferred tax liability

$

(7,025

)

$

(7,444

)

The realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Due to the lack of earnings history, the net deferred tax assets have been offset by a valuation allowance excluding certain indefinite lived intangibles. The valuation allowance increased by $80.7 million and $58.8 million during the years ended December 31, 2022 and 2021, respectively. The Company had federal and state net operating loss carryforwards of $448.3 million and $445.5 million, respectively, as of December 31, 2022. The federal net operating loss carryforwards, if not utilized, will expire beginning in 2035, with the exception of $354.7 million in federal net operating loss carryforwards, which can be carried forward indefinitely. State net operating loss carryforwards, if not utilized, will expire beginning in 2035. Under the Tax Cuts and Jobs Act (the TCJA), federal net operating losses arising after December 31, 2017 do not expire and cannot be carried back. However, the TCJA limits the amount of federal net operating losses that can be used annually to 80% of taxable income for periods beginning after December 31, 2017. Existing federal net operating losses arising in years ending on or before December 31, 2017 are not affected by these provisions.
The Company also had federal and state research and development credit carryforwards of $20.6 million and $11.6 million, respectively, as of December 31, 2022. The federal credits will expire starting in 2034 if not utilized and the state research credits will expire beginning in 2031, with the exception of $10.7 million in California research credits, which can be carried forward indefinitely. Federal, California, Massachusetts and New Jersey tax laws impose significant restrictions on the utilization of net operating loss carryforwards in the event of a change in ownership of the Company, as defined by Internal Revenue Code Section 382 (Section 382). The Company performed a study in which it determined that it had experienced changes in ownership in 2014, 2018, and 2020 as defined by Section 382. No federal or state net operating losses are expected to expire unutilized as a result of the limitation, with the exception of $5.5 million in California net operating losses. The Company's deferred tax assets have been reduced by the amount of net operating loss carryforwards expected to expire due to the limitation. In addition, in the future the Company may experience ownership changes, which may limit the utilization of net operating loss carryforwards or other tax attributes.
The TCJA amended Internal Revenue Code Section 174 requiring capitalization of specified research and experimental expenditures paid or incurred in tax years beginning after December 31, 2021 and amortizing over a period of 5 or 15 years. This resulted in a deferred tax asset for capitalized research expenses in 2022. Also on August 16, 2022, the United States enacted the Inflation Reduction Act (the IRA), which contains among other things, numerous income tax provisions. At this time, the Company does not anticipate the IRA to have a material impact on its financial statements.
A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:

December 31,

2022

2021

(in thousands)

Beginning balance

$

5,143

$

3,593

Changes related to tax positions taken in the prior year

(7

)

(21

)

Changes related to tax positions taken in the current year

2,466

1,571

Ending balance

$

7,602

$

5,143

The Company has unrecognized tax benefits of $7.1 million and $4.7 million as of December 31, 2022 and 2021, which would affect the effective tax rate if recognized; however, recognition would be in the form of a deferred tax attribute which would likely be offset by a valuation allowance. The Company does not anticipate any significant changes to unrecognized tax benefits over the next 12 months. The Company has recognized no interest or penalties related to uncertain tax positions for the periods presented.
Income tax returns are filed in the United States. The years 2010 through 2022 remain open to examination by the domestic taxing jurisdictions to which the Company is subject. Net operating losses generated on a tax return basis by the Company for 2010 through 2022 remain open to examination by the domestic taxing jurisdictions.

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R21.htm IDEA: XBRL DOCUMENT v3.22.4

Net Loss Per Share Attributable to Common Stockholders
12 Months Ended

Dec. 31, 2022

Earnings Per Share [Abstract]

Net Loss Per Share Attributable to Common Stockholders
13.
Net loss per share attributable to common stockholders
The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders:

Years Ended December 31,

2022

2021

2020

(in thousands, except share and per share data)

Numerator:

Net loss

$

(248,705

)

$

(187,091

)

$

(108,159

)

Redeemable convertible preferred stock dividends-undeclared and cumulative

—

—

(2,219

)

Net loss attributable to common stockholders

$

(248,705

)

$

(187,091

)

$

(110,378

)

Denominator:

Weighted-average shares outstanding

80,636,570

72,866,022

55,109,929

Less: Weighted-average unvested restricted shares and
 shares subject to repurchase

(10,045

)

(59,943

)

(235,810

)

Weighted-average shares used to compute net loss per share
 attributable to common stockholders, basic and diluted

80,626,525

72,806,079

54,874,119

Net loss per share attributable to common stockholders, basic
 and diluted

$

(3.08

)

$

(2.57

)

$

(2.01

)

The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect:

As of December 31,

2022

2021

2020

Options to purchase common stock

8,164,375

6,050,938

5,118,979

Options early exercised subject to future vesting

6,918

30,378

130,793

Unvested restricted stock units of common stock

1,175,032

423,621

85,639

Expected shares to be purchased under ESPP

378,429

176,131

91,210

Total

9,724,754

6,681,068

5,426,621

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-URI https://asc.fasb.org/topic&trid=2144383

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257
+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R22.htm IDEA: XBRL DOCUMENT v3.22.4

Summary of Significant Accounting Policies (Policies)
12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

Basis of Presentation
Basis of presentation
The consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (GAAP) and applicable rules of the Securities and Exchange Commission (SEC) regarding financial reporting and, in the opinion of management, include all normal and recurring adjustments which are necessary to state fairly the Company’s financial position and results of operations for the reported periods. The consolidated financial statements for the years ended December 31, 2022, 2021 and 2020 include the accounts of the Company and its wholly owned subsidiary, Warp Drive Bio, Inc. (Warp Drive). All intercompany balances and transactions have been eliminated in consolidation. The functional and reporting currency of the Company and its subsidiary is the U.S. dollar.

Reverse Stock Split
Reverse stock split
On February 7, 2020, the Company amended and restated its amended and restated certificate of incorporation to effect a 1-for-4.8661 reverse stock split of the Company’s common stock and redeemable convertible preferred stock. The par value and authorized shares of the common stock and redeemable convertible preferred stock were not adjusted as a result of the reverse stock split. All issued and outstanding common stock, options to purchase common stock and per share amounts contained in the financial statements have been retroactively adjusted to give effect to the reverse stock split for all periods presented.

Use of Estimates
Use of estimates
The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, clinical accruals, valuation of in-process research and development and developed technologies, income taxes, useful lives of property and equipment and intangible assets, impairment of goodwill and intangibles, the incremental borrowing rate for determining operating lease assets and liabilities, and stock-based compensation. The extent to which the COVID-19 pandemic may directly or indirectly impact the Company’s business, financial condition and results of operations is highly uncertain and subject to change. The Company considered the potential impact of the COVID-19 pandemic on its estimates and assumptions and there was not a material impact to the Company’s consolidated financial statements as of and for the twelve months ended December 31, 2022. Actual results could materially differ from the Company’s estimates, and there may be changes to the estimates in future periods.

Cash and Cash Equivalents
Cash and cash equivalents
The Company considers all highly liquid investments purchased with original maturities of three months or less at the date of purchase to be cash equivalents. As of December 31, 2022 and 2021, cash equivalents consist of amounts invested in money market funds, commercial paper and corporate bonds with original maturities of three months or less at the date of purchase.

Marketable Securities
Marketable securities
Investments in marketable securities primarily consist of U.S. government debt securities, U.S. government agency bonds, commercial paper, Canadian government securities and corporate bonds. The Company has classified its marketable securities as available-for-sale and may sell these securities prior to their stated maturities. The Company views these marketable securities as available to support current operations and classifies marketable securities with maturities beyond 12 months as current assets. The Company’s investments in marketable securities are carried at estimated fair value, which is derived from independent pricing sources based on quoted prices in active markets for similar securities. Unrealized gains and losses are reported as a component of accumulated other comprehensive loss. The amortized cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the consolidated statements of operations. Realized gains and losses are included in interest income on the consolidated statements of operations.
The Company periodically evaluates its investments to assess whether those with unrealized loss positions are other than temporarily impaired. The Company considers various factors in determining whether to recognize an impairment charge. If the Company determines that the decline in an investment’s fair value is other-than-temporary, the difference is recognized as an impairment loss in the consolidated statements of operations. As of December 31, 2022, no other-than-temporary-impairment has been recorded.

Restricted Cash
Restricted cash
As of December 31, 2022 and 2021, the Company had $1.7 million and $1.7 million, respectively, of noncurrent restricted cash related to Company issued letters of credit in connection with leases. These amounts are held in separate bank accounts to support letter of credit agreements for the leases.

Concentration of Credit Risk and Other Risks and Uncertainties
Concentration of credit risk and other risks and uncertainties
Financial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents and marketable securities. The Company’s cash is held by two financial institutions in the United States, which management believes to be of high credit quality. The Company invests in money market funds, U.S. government debt securities, U.S. government agency bonds, commercial paper and corporate bonds. The Company has not experienced any losses on its deposits of cash and cash equivalents.
The Company is subject to credit risk as its receivable and collaboration revenue are entirely related to its collaboration agreement with Sanofi. For more information, see Note 8, “Sanofi collaboration agreement.”
The Company’s clinical trial sites may be affected by the COVID-19 outbreak due to prioritization of hospital resources toward the COVID-19 outbreak, travel or quarantine restrictions imposed by governments, and the inability to access sites for initiation and patient monitoring and enrollment. As a result, patient screening, new patient enrollment, monitoring and data collection may be affected or delayed. The Company is aware that several clinical sites involved in its clinical studies temporarily stopped or delayed enrolling new patients, with exemptions if appropriate, and it is possible that these or other clinical sites may be similarly affected in the future. These developments may delay the Company’s clinical trial timelines. Some of the Company’s third-party manufacturers which it uses for the supply of materials for product candidates or other materials necessary to manufacture product to conduct preclinical tests and clinical trials and contract research organizations may be impacted by COVID-19, and should they experience disruptions, such as temporary closures or suspension of services, the Company would likely experience delays in advancing clinical trials.

Fair Value Measurement
Fair value measurement
The carrying amounts of the Company’s certain financial instruments, including cash equivalents, accounts payable and accrued expenses and other current liabilities approximate fair value due to their relatively short maturities and market interest rates, if applicable. For more information, refer to Note 4 regarding the fair value of the Company’s available-for-sale securities.
Assets and liabilities recorded at fair value on a recurring basis in the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:
Level 1—Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;
Level 2—Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active; and
Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Property and Equipment, Net
Property and equipment, net
Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed on a straight-line basis over the estimated useful lives of the related assets, which is generally three to five years. Leasehold improvements are amortized using the straight-line method over the shorter of the assets’ estimated useful lives or the remaining term of the lease. Maintenance and repairs are charged to operations as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is reflected in the consolidated statement of operations.
Useful lives of property and equipment are as follows:

Property and equipment

Estimated useful life

Laboratory equipment

4-5 years

Leasehold improvements

Lesser of estimated useful life or remaining lease term

Computer equipment and software

3 years

Furniture and fixtures

5 years

Leases
Leases
The Company determines if an arrangement is, or contains, a lease at inception and then classifies the lease as operating or financing based on the underlying terms and conditions of the contract. Leases with terms greater than one year are initially recognized on the balance sheet as right-of-use assets and lease liabilities based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the rate incurred to borrow, on a collateralized basis, an amount equal to the lease payments over a similar term and in a similar economic environment of the applicable country or region. Variable lease payments are excluded from the right-of-use assets and operating lease liabilities and are recognized in the period in which the obligation for those payments is incurred. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets.

Impairment of Long-Lived Assets
Impairment of long-lived assets
Long-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Recoverability is measured by comparison of the carrying amounts of the asset group to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable, and the carrying amount exceeds the projected discounted future cash flows arising from these assets. There were no impairments of long-lived assets for any of the periods presented.

Acquired Intangible Assets
Acquired intangible assets
Indefinite-lived intangible assets represent the estimated fair value assigned to in-process research and development (IPR&D) acquired in a business combination. The Company reviews indefinite-lived intangible assets for impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying value of the assets might not be recoverable. If the carrying value of an indefinite-lived intangible asset exceeds its fair value, then it is written down to its adjusted fair value. As of December 31, 2022, there have been no such impairments. For IPR&D, if a product candidate derived from the indefinite-lived intangible asset is developed and commercialized, the useful life will be determined, and the carrying value will be amortized prospectively over that estimated useful life. Alternatively, if a product candidate is abandoned, the carrying value of the intangible asset will be charged to research and development expenses in the consolidated statements of operations.
Finite-lived intangible assets acquired in a business combination are recognized separately from goodwill and are initially recognized at their fair value at the acquisition date and are carried at cost less accumulated amortization and impairment. Amortization is computed using the straight-line method over the estimated useful lives of the respective finite-lived intangible assets and is included in research and development expenses in the consolidated statement of operations. Intangible assets are reviewed for impairment at least annually or more frequently if indicators of potential impairment exist. As of December 31, 2022, no such impairment has been recorded.

Goodwill
Goodwill
Goodwill represents the excess of the purchase price over the estimated fair value of the net tangible and intangible assets acquired in a business combination. The Company reviews goodwill for impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying value of goodwill may not be recoverable. Goodwill is tested for impairment at the reporting unit level by first assessing the qualitative factors to determine whether it is more likely than not that the fair value of the Company’s single reporting unit is less than its carrying amount. Qualitative indicators assessed include consideration of macroeconomic, industry and market conditions, the Company’s overall financial performance and personnel or strategy changes. Based on the qualitative assessment, if it is determined that it is more likely than not that its fair value is less than its carrying amount, the fair value of the Company’s single reporting unit is compared to its carrying value. Any excess of the goodwill carrying amount over the fair value is recognized as an impairment loss, and the carrying value of goodwill is written down to fair value. As of December 31, 2022, no goodwill impairment has been identified.

Redeemable Convertible Preferred Stock
Redeemable convertible preferred stock
The Company records all shares of redeemable convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. The redeemable convertible preferred stock is recorded outside of permanent equity because while it is not mandatorily redeemable, in the event of certain events considered not solely within the Company’s control, such as a merger, acquisition or sale of all or substantially all of the Company’s assets (each, a deemed liquidation event), the redeemable convertible preferred stock would have become redeemable at the option of the holders of at least a majority of the then outstanding such shares. The Company did not adjust the carrying values of the redeemable convertible preferred stock to the liquidation preferences of such shares because it was uncertain whether or when a deemed liquidation event would occur that would obligate the Company to pay the liquidation preferences to holders of shares of redeemable convertible preferred stock.

Revenue Recognition
Revenue recognition
The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.
The Company enters into collaboration agreements under which it may obtain upfront license fees, research and development funding, and development, regulatory and commercial milestone payments and royalty payments. The Company’s performance obligations under these arrangements may include licenses of intellectual property, sales and distribution rights, research and development services, delivery of manufactured product and/or participation on joint steering committees.
Licenses of intellectual property: If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from upfront license fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring proportional performance for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of proportional performance each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.
Research, development and regulatory milestone payments: At the inception of each arrangement that includes research, development, or regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. The Company uses the most likely amount method for research, development and regulatory milestone payments. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.
Sales-based milestones and royalties: For arrangements that include sales-based milestone or royalty payments based on the level of sales, and in which the license is deemed to be the predominant item to which the sales-based milestone or royalties relate to, the Company recognizes revenue in the period in which the sales-based milestone is achieved and in the period in which the sales associated with the royalty occur. To date, the Company has not recognized any sales-based milestone or royalty revenue resulting from its collaboration arrangements.
Deferred revenue represents amounts received by the Company for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. The current portion of deferred revenue represents the amount to be recognized within one year from the balance sheet date based on the estimated performance period of the underlying performance obligation. The noncurrent portion of deferred revenue represents amounts to be recognized after one year through the end of the performance period of the performance obligation.

Research and Development Expenditures
Research and development expenditures
Research and development expenses consist of costs incurred for the Company’s own and for collaborative research and development activities. Research and development costs are expensed as incurred. Research and development costs consist of salaries and benefits, including associated stock-based compensation, and laboratory supplies and facility costs, as well as fees paid to other entities that conduct certain research and development activities on the Company’s behalf. The Company estimates preclinical studies and clinical trial expenses based on the services performed pursuant to contracts with research institutions, contract research organizations and clinical manufacturing organizations that conduct and manage preclinical studies and clinical trials on the Company’s behalf based on actual time and expenses incurred by them. Further, the Company accrues expenses related to clinical trials based on the level of patient activity according to the related agreement. The Company monitors patient enrollment levels and related activity to the extent reasonably possible and adjusts estimates accordingly.

Stock-Based Compensation
Stock-based compensation
The Company measures its stock-based awards granted to employees and directors based on the estimated fair values of the awards and recognizes the compensation on a straight-line basis over the requisite service period. The fair value of options issued under the employee stock purchase plan is calculated using the Black-Scholes option-pricing model. Restricted stock units are valued based on the closing price of the Company’s common stock on the date of grant.

Comprehensive Loss
Comprehensive loss
For the years ended December 31, 2022, 2021 and 2020, other comprehensive loss includes net unrealized gains or losses on marketable securities.

Income Taxes
Income taxes
Income taxes are accounted for under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Management makes an assessment of the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company’s historical operating performance and the recorded cumulative net losses in prior fiscal periods, the net deferred tax assets have been fully offset by a valuation allowance.
The Company recognizes uncertain income tax positions at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Changes in recognition or measurement are reflected in the period in which judgment occurs. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of interest expense.

Net Loss per Share Attributable to Common Stockholders
Net loss per share attributable to common stockholders
Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock, stock options, common stock subject to repurchase related to unvested restricted stock awards and early exercise of stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities as the redeemable convertible preferred stock is considered a participating security because it participates in dividends with common stock. The Company also considers the shares issued upon the early exercise of stock options subject to repurchase to be participating securities because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. The holders of all series of redeemable convertible preferred stock and the holders of early exercised shares subject to repurchase do not have a contractual obligation to share in the Company’s losses. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for all periods presented, diluted net loss per share is the same as basic net loss per share for those periods.

Deferred Offering Costs
Deferred offering costs
The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders’ deficit (equity) as a reduction of additional paid-in capital generated as a result of the equity financing. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations. As of December 31, 2022 and 2021, $0.6 million and $0.5 million of deferred offering costs, respectively, were capitalized in other noncurrent assets on the consolidated balance sheets.

Segment Reporting
Segment reporting
The Company has one operating and reportable segment. The Company’s chief operating decision maker, its Chief Executive Officer, manages the Company’s operations on a consolidated basis for the purposes of allocating resources and evaluating financial performance. All of the Company’s long-lived assets are located in the United States.

401(k) Retirement Plans
401(k) retirement plans
The Company maintains a 401(k) retirement plan for its employees. The Company is responsible for administrative costs of the 401(k) plan. The Company may, at its discretion, make matching or profit-sharing contributions to the 401(k) plan. For the years ended December 31, 2022, 2021 and 2020, the Company made $1.3 million, $0.9 million and $0.2 million matching contributions, respectively, under the plan.

Recent Accounting Pronouncements
Recent accounting pronouncements
From time to time, new accounting pronouncements are issued by the FASB, under its ASC or other standard setting bodies, and adopted by the Company as of the specified effective date, unless otherwise discussed below.
Recently adopted accounting pronouncements
In October 2020, the FASB issued ASU 2020-08, Codification Improvements to Subtopic 310-20, Receivables-Nonrefundable Fees and Other Costs (ASU 2020-08). ASU 2020-08 clarifies that an entity should reevaluate whether a callable debt security is within the scope of ASC paragraph 310-20-35-33 for each reporting period. The guidance is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021. Early application is not permitted. All entities should apply ASU 2020-08 on a prospective basis as of the beginning of the period of adoption for existing or newly purchased callable debt securities. The Company adopted the standard for the fiscal year beginning on January 1, 2022 and concluded that adoption of the standard did not have a material impact on its consolidated financial statements.
In October 2020, FASB issued ASU 2020-10, Codification Improvements (ASU 2020-10). ASU 2020-10 updates various codification topics by clarifying or improving disclosure requirements to align with the SEC’s regulations. The amendments are effective for the Company for fiscal years beginning after December 15, 2021, including interim period within those fiscal years. Early
adoption is permitted. Adoption shall be applied retrospectively. The Company adopted the standard for the fiscal year beginning on January 1, 2022 and concluded that adoption of the standard did not have a material impact on its consolidated financial statements.

X

- Definition
Concentration of credit risk and other risks and uncertainties.
+ References
No definition available.
+ Details

Name: rvmd_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock

Namespace Prefix: rvmd_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Intangible assets acquired from business combination policy,
+ References
No definition available.
+ Details

Name: rvmd_IntangibleAssetsAcquiredFromBusinessCombinationPolicyPolicyTextBlock

Namespace Prefix: rvmd_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Restricted cash.
+ References
No definition available.
+ Details

Name: rvmd_RestrictedCashPolicyTextBlock

Namespace Prefix: rvmd_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Reverse stock split policy.
+ References
No definition available.
+ Details

Name: rvmd_ReverseStockSplitPolicyPolicyTextBlock

Namespace Prefix: rvmd_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586
+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for comprehensive income.
+ References
No definition available.
+ Details

Name: us-gaap_ComprehensiveIncomePolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for deferral and amortization of significant deferred charges.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_DeferredChargesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257
+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-URI https://asc.fasb.org/subtopic&trid=2144439

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 55
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 05
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.CC)
-URI https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742
+ Details

Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 25
-URI https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 20
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 19
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319
+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for leasing arrangement entered into by lessee.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980
+ Details

Name: us-gaap_LesseeLeasesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for investment classified as marketable security.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803
+ Details

Name: us-gaap_MarketableSecuritiesPolicy

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for pension plans. This accounting policy may address (1) the types of plans sponsored by the entity (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 30
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6412939&loc=d3e15145-114933

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 70
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 80
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=65877416&loc=d3e29149-114947
+ Details

Name: us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 360
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790
+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for segment reporting.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599
+ Details

Name: us-gaap_SegmentReportingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(1)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI https://asc.fasb.org/topic&trid=2228938

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2.Q6)
-URI https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 05
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=126960819&loc=d3e20905-112640

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27)(b))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27)(c))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 12
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 11
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592
+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R23.htm IDEA: XBRL DOCUMENT v3.22.4

Summary of Significant Accounting Policies (Tables)
12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

Schedule of Useful Lives of Property and Equipment
Useful lives of property and equipment are as follows:

Property and equipment

Estimated useful life

Laboratory equipment

4-5 years

Leasehold improvements

Lesser of estimated useful life or remaining lease term

Computer equipment and software

3 years

Furniture and fixtures

5 years

X

- Definition
Property and equipment estimated useful lives.
+ References
No definition available.
+ Details

Name: rvmd_PropertyAndEquipmentEstimatedUsefulLivesTableTextBlock

Namespace Prefix: rvmd_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 46 R24.htm IDEA: XBRL DOCUMENT v3.22.4

Fair Value Measurements (Tables)
12 Months Ended

Dec. 31, 2022

Fair Value Disclosures [Abstract]

Schedule of Financial Assets Measured at Fair Value
The following table presents information about the Company’s financial assets that are measured at fair value and indicates the fair value hierarchy of the valuation:

December 31, 2022

Total

Level 1

Level 2

Level 3

(in thousands)

Assets:

Money market funds(1)

$

48,522

$

48,522

$

—

$

—

Commercial paper(1, 2)

313,928

—

313,928

—

U.S. and Canadian government and agency securities(2)

251,830

—

251,830

—

Corporate bonds(1, 2)

31,405

—

31,405

—

Total

$

645,685

$

48,522

$

597,163

$

—

December 31, 2021

Total

Level 1

Level 2

Level 3

(in thousands)

Assets:

Money market funds(1)

$

57,134

$

57,134

$

—

$

—

Commercial paper(1, 2)

291,369

—

291,369

—

U.S. and Canadian government and agency securities(2)

87,745

—

87,745

—

Corporate bonds(2)

141,698

—

141,698

—

Total

$

577,946

$

57,134

$

520,812

$

—

(1)
Included in cash and cash equivalents on the consolidated balance sheets.
(2)
Included in marketable securities on the consolidated balance sheets.

X

- Definition
Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 47 R25.htm IDEA: XBRL DOCUMENT v3.22.4

Available-for-sale Securities (Tables)
12 Months Ended

Dec. 31, 2022

Investments, Debt and Equity Securities [Abstract]

Summary of Estimated Value of Available-for-sale Securities and Cash Equivalents and Gross Unrealized Gains and Losses
The following tables summarize the estimated value of the Company’s available-for-sale marketable securities and cash equivalents and the gross unrealized gains and losses:

December 31, 2022

Gross

Gross

Amortized

unrealized

unrealized

Estimated

cost

gain

loss

fair value

(in thousands)

Marketable securities:

Commercial paper

$

216,765

$

—

$

(328

)

$

216,437

U.S. and Canadian government and agency securities

236,916

43

(1,270

)

235,689

Corporate bonds

31,599

—

(194

)

31,405

Total marketable securities

485,280

43

(1,792

)

483,531

Cash equivalents:

Money market funds

48,522

—

—

48,522

Commercial paper

97,526

—

(35

)

97,491

Corporate bonds

16,137

4

—

16,141

Total cash equivalents

162,185

4

(35

)

—

162,154

Total available-for-sale investments

$

647,465

$

47

$

(1,827

)

$

645,685

December 31, 2021

Gross

Gross

Amortized

unrealized

unrealized

Estimated

cost

gain

loss

fair value

(in thousands)

Marketable securities:

Commercial paper

$

239,176

$

1

$

(63

)

$

239,114

U.S. and Canadian government and agency securities

87,926

—

(181

)

87,745

Corporate bonds

141,829

—

(131

)

141,698

Total marketable securities

468,931

1

(375

)

468,557

Cash equivalents:

Money market funds

57,134

—

—

57,134

Commercial paper

52,257

—

(2

)

52,255

Total cash equivalents

109,391

—

(2

)

109,389

Total available-for-sale investments

$

578,322

$

1

$

(377

)

$

577,946

Summary of Amortized Cost and Estimated Fair Value of Available-for-sale Securities and Cash Equivalents by Contractual Maturity
The amortized cost and estimated fair value of the Company’s available-for-sale marketable securities and cash equivalents by contractual maturity are summarized below as of December 31, 2022:

December 31, 2022

Gross

Gross

Amortized

unrealized

unrealized

Estimated

cost

gain

loss

fair value

(in thousands)

Mature in one year or less

$

618,025

$

48

$

(1,752

)

$

616,321

Mature after one year through two years

29,440

(1

)

(75

)

29,364

Total marketable securities

$

647,465

$

47

$

(1,827

)

$

645,685

X

- Definition
Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-URI https://asc.fasb.org/topic&trid=2196928
+ Details

Name: us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 30
-Section 55
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 30
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455
+ Details

Name: us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 48 R26.htm IDEA: XBRL DOCUMENT v3.22.4

Balance Sheet Components (Tables)
12 Months Ended

Dec. 31, 2022

Balance Sheet Related Disclosures [Abstract]

Schedule of Property and Equipment, Net
Property and equipment, net consists of the following:

December 31,

2022

2021

(in thousands)

Laboratory equipment

$

17,163

$

12,727

Leasehold improvements

11,404

7,245

Computer equipment and software

3,965

2,186

Furniture and fixtures

616

69

Construction in progress

—

129

33,148

22,356

Less: accumulated depreciation and amortization

(14,489

)

(10,812

)

Property and equipment, net

$

18,659

$

11,544

Schedule of Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities consist of the following:

December 31,

2022

2021

(in thousands)

Accrued compensation

$

13,281

$

9,852

Accrued research and development

15,161

17,018

Accrued professional services

499

540

Other

505

311

Total accrued expenses and other current liabilities

$

29,446

$

27,721

X

- Definition
Schedule of accrued expenses and other current liabilities.
+ References
No definition available.
+ Details

Name: rvmd_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock

Namespace Prefix: rvmd_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_BalanceSheetRelatedDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 49 R27.htm IDEA: XBRL DOCUMENT v3.22.4

Intangible Assets and Goodwill (Tables)
12 Months Ended

Dec. 31, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets, Net
Intangible assets, net consist of the following as of December 31, 2022:

Gross value

Accumulated
amortization

Net book
value

Weighted-
average
remaining
useful life

(in thousands)

(in years)

In-process research and development — RAS
 Programs

$

55,800

$

—

$

55,800

n/a

Developed technology — tri-complex platform

7,480

(4,473

)

3,007

2.9

Total

$

63,280

$

(4,473

)

$

58,807

Intangible assets, net consist of the following as of December 31, 2021:

Gross value

Accumulated
amortization

Net book
value

Weighted-
average
remaining
useful life

(in thousands)

(in years)

In-process research and development — RAS
 Programs

$

55,800

$

—

$

55,800

n/a

Developed technology — tri-complex platform

7,480

(3,404

)

4,076

3.9

Total

$

63,280

$

(3,404

)

$

59,876

Schedule of Future Amortization Expense
As of December 31, 2022, future amortization expense is as follows:

Amount

(in thousands)

2023

$

1,069

2024

1,068

2025

870

Total

$

3,007

Schedule of Goodwill
Goodwill consists of the following:

Amount

(in thousands)

Balance at December 31, 2021

$

14,608

Adjustment

—

Balance at December 31, 2022

$

14,608

X

- Definition
Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1A
-URI https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 55
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267
+ Details

Name: us-gaap_ScheduleOfGoodwillTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 50 R28.htm IDEA: XBRL DOCUMENT v3.22.4

Commitments and Contingencies (Tables)
12 Months Ended

Dec. 31, 2022

Commitments and Contingencies Disclosure [Abstract]

Summary of Balance Sheet Classification of Operating Lease Liabilities
The balance sheet classification of the Company’s operating lease liabilities was as follows:

December 31,

2022

(in thousands)

Operating lease liabilities:

Operating lease liability – current

$

6,773

Operating lease liability – noncurrent

57,432

Total operating lease liabilities

$

64,205

Schedule of Maturities of Operating Lease Liabilities
As of December 31, 2022, the maturities of the Company’s operating lease liabilities were as follows (in thousands):

2023

$

6,961

2024

7,100

2025

7,349

2026

7,606

2027

7,872

Thereafter

52,550

Total undiscounted lease payments

$

89,438

Less: Imputed interest

(25,233

)

Less: Tenant improvement allowance

—

Total operating lease liabilities

$

64,205

X

- Definition
Summary of balance sheet classification of operating lease liabilities.
+ References
No definition available.
+ Details

Name: rvmd_SummaryOfBalanceSheetClassificationOfOperatingLeaseLiabilitiesTableTextBlock

Namespace Prefix: rvmd_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 51 R29.htm IDEA: XBRL DOCUMENT v3.22.4

Common Stock (Tables)
12 Months Ended

Dec. 31, 2022

Stockholders' Equity Note [Abstract]

Schedule of Common Stock for Future Issuance
The Company has reserved shares of common stock for future issuance as follows:

December 31,

December 31,

2022

2021

Outstanding options to purchase common stock

8,164,375

6,050,938

Unvested restricted stock units of common stock

1,175,032

423,621

Available for future issuance under the 2020 Incentive Award Plan

6,726,307

6,403,548

Available for issuance under the 2020 Employee Stock Purchase Plan

1,700,887

1,089,728

Total

17,766,601

13,967,835

X

- Definition
Schedule of common stock reserved for future issuance table text block.
+ References
No definition available.
+ Details

Name: rvmd_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock

Namespace Prefix: rvmd_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 52 R30.htm IDEA: XBRL DOCUMENT v3.22.4

Stock-Based Compensation (Tables)
12 Months Ended

Dec. 31, 2022

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Summary of Fair Value of Stock Option Awards Estimated at Date of Grant
The fair value of employee and director stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:

Year Ended December 31,

2022

2021

2020

Expected term (years)

6

6

6

Expected volatility

70-73%

70-75%

74-80%

Risk-free interest rate

1.5%-4.2%

0.5%-1.3%

0.2%-1.5%

Dividend yield

0%

0%

0%

Non-employee stock option awards were measured at fair value at each reporting period using a Black-Scholes option-pricing model with the following assumptions:

Year Ended December 31,

2022

2021

2020

Expected term (years)

6

6

6-10

Expected volatility

70-71%

70-75%

74-80%

Risk-free interest rate

1.6%-3.4%

0.9%-1.3%

1.2%-1.5%

Dividend yield

0%

0%

0%

Summary of Total Stock-Based Compensation Expense Related to Stock Options, RSUs and Employee Stock Purchase Plan
Total stock-based compensation expense related to stock options, RSUs and the ESPP by function was as follows:

Year Ended December 31,

2022

2021

2020

(in thousands)

Research and development

$

18,113

$

11,847

$

4,848

General and administrative

13,083

8,877

4,038

Total

$

31,196

$

20,724

$

8,886

2020 Plan and 2014 Plan

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Summary of Option Activity Under the Plan
The following summarizes option activity under both the 2020 Plan and the 2014 Plan:

Number of
Shares
underlying
options

Weighted-
average
exercise price

Weighted-
average
remaining
contractual
term

Aggregate
intrinsic
value

(in years)

(in thousands)

Balance, December 31, 2021

6,050,938

$

14.88

7.74

$

83,953

Options granted

2,758,710

19.37

Options exercised

(249,544

)

6.12

Options cancelled

(395,729

)

26.78

Balance, December 31, 2022

8,164,375

$

16.09

7.53

$

85,181

Options vested and expected to vest as of December 31, 2022

8,164,375

$

16.09

7.53

$

85,181

Options vested and exercisable as of December 31, 2022

4,555,124

$

11.43

6.65

$

66,783

2020 Equity Incentive Plan

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Summary of RSUs Activity Under the Plan
Activity under the 2020 Plan with respect to the Company’s RSUs during the year ended December 31, 2022 was as follows:

Number of
Shares

Weighted-
average
grant date fair value per share

Weighted-
average
remaining contractual term

Aggregate intrinsic value

(in years)

(in thousands)

Balance, December 31, 2021

423,621

$

37.16

3.16

$

10,663

Restricted stock units granted

1,142,366

19.43

Restricted stock units vested

(278,848

)

28.23

Restricted stock units forfeited

(112,107

)

24.58

Balance, December 31, 2022

1,175,032

$

23.25

1.62

27,989

Expected to vest as of December 31, 2022

1,175,032

$

23.25

1.62

27,989

X

- Definition
Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=rvmd_TwoThousandTwentyAndTwoThousandFourteenEquityIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=rvmd_TwoThousandTwentyEquityIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 53 R31.htm IDEA: XBRL DOCUMENT v3.22.4

Income Taxes (Tables)
12 Months Ended

Dec. 31, 2022

Income Tax Disclosure [Abstract]

Summary of Benefit from Income Taxes to Amount Computed by Applying Federal Statutory Rate to Loss Before Taxes
The benefit from income taxes differs from the amount expected by applying the federal statutory rate to the loss before taxes as follows:

Year Ended December 31,

2022

2021

Federal statutory income tax rate

21.0

%

21.0

%

State income tax rate, net of federal benefit

9.4

%

8.9

%

Research tax credits

3.2

%

2.2

%

Change in valuation allowance

-32.4

%

-31.4

%

Non-deductible permanent expenses

-1.0

%

-0.5

%

Other

0.0

%

-0.2

%

Benefit from income taxes

0.2

%

0.0

%

Summary of Categories that Give Rise to Significant Components of Deferred Tax Assets The categories that give rise to significant components of the deferred tax assets are as follows (in thousands):

December 31,

2022

2021

(in thousands)

Deferred tax assets:

Net operating loss carryforwards

$

132,080

$

123,991

Accruals and reserves

5,494

9,164

Research and development credits

22,558

14,449

Lease liability

18,998

19,979

Stock-based compensation

7,063

3,829

Capitalized research expenses

64,149

—

Other

42

33

Gross deferred tax assets

250,384

171,445

Less: valuation allowance

(224,125

)

(143,474

)

Total deferred tax assets

26,259

27,971

Deferred tax liabilities:

Fixed assets and finite-lived intangible assets

(9,961

)

(10,073

)

Indefinite-lived intangible assets

(7,025

)

(7,444

)

Lease asset

—

—

Right-of-use asset

(16,298

)

(17,898

)

Gross deferred tax liabilities

(33,284

)

(35,415

)

Net deferred tax liability

$

(7,025

)

$

(7,444

)

Reconciliation of Gross Unrecognized Tax Benefits
A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:

December 31,

2022

2021

(in thousands)

Beginning balance

$

5,143

$

3,593

Changes related to tax positions taken in the prior year

(7

)

(21

)

Changes related to tax positions taken in the current year

2,466

1,571

Ending balance

$

7,602

$

5,143

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319
+ Details

Name: us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319
+ Details

Name: us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the change in unrecognized tax benefits.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 55
-Paragraph 217
-URI https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-URI https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319
+ Details

Name: us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 54 R32.htm IDEA: XBRL DOCUMENT v3.22.4

Net Loss Per Share Attributable to Common Stockholders (Tables)
12 Months Ended

Dec. 31, 2022

Earnings Per Share [Abstract]

Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders
The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders:

Years Ended December 31,

2022

2021

2020

(in thousands, except share and per share data)

Numerator:

Net loss

$

(248,705

)

$

(187,091

)

$

(108,159

)

Redeemable convertible preferred stock dividends-undeclared and cumulative

—

—

(2,219

)

Net loss attributable to common stockholders

$

(248,705

)

$

(187,091

)

$

(110,378

)

Denominator:

Weighted-average shares outstanding

80,636,570

72,866,022

55,109,929

Less: Weighted-average unvested restricted shares and
 shares subject to repurchase

(10,045

)

(59,943

)

(235,810

)

Weighted-average shares used to compute net loss per share
 attributable to common stockholders, basic and diluted

80,626,525

72,806,079

54,874,119

Net loss per share attributable to common stockholders, basic
 and diluted

$

(3.08

)

$

(2.57

)

$

(2.01

)

Schedule of Outstanding Potentially Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share
The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect:

As of December 31,

2022

2021

2020

Options to purchase common stock

8,164,375

6,050,938

5,118,979

Options early exercised subject to future vesting

6,918

30,378

130,793

Unvested restricted stock units of common stock

1,175,032

423,621

85,639

Expected shares to be purchased under ESPP

378,429

176,131

91,210

Total

9,724,754

6,681,068

5,426,621

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257
+ Details

Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257
+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 55 R33.htm IDEA: XBRL DOCUMENT v3.22.4

Organization - Additional Information (Details) - USD ($)
1 Months Ended 12 Months Ended

Jul. 31, 2022

Nov. 30, 2021

Feb. 28, 2021

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Class Of Stock [Line Items]

Accumulated deficit $ 701,341,000 $ 452,636,000

Common stock, shares, issued 90,411,912 74,142,619

Net proceeds from issuance $ 248,126,000 $ 281,145,000 $ 420,067,000

Initial Public Offering | Common Stock

Class Of Stock [Line Items]

Shares issued 16,100,000

Underwriter's Option to Purchase Additional Shares

Class Of Stock [Line Items]

Common stock, shares, issued 1,725,000 869,565

Underwritten Public Offering

Class Of Stock [Line Items]

Common stock, shares, issued 13,225,000 6,666,666

Common stock, price per share $ 20.00 $ 45.00

Net proceeds from issuance $ 248,100,000 $ 281,100,000

Underwriting discounts and commissions 15,900,000 18,000,000.0

Stock issuance expenses $ 500,000 $ 900,000

ATM | Common Stock

Class Of Stock [Line Items]

Net proceeds from issuance $ 49,900,000 $ 10,100,000

Shares issued 2,385,846 339,302

Aggregate gross proceeds through equity issuance maximum potential amount $ 250,000,000

Commissions and expenses $ 1,400,000 $ 300,000

Proceeds from issuance of common stock gross $ 51,300,000 $ 10,400,000

X

- Definition
Aggregate gross proceeds through equity issuance maximum potential amount.
+ References
No definition available.
+ Details

Name: rvmd_AggregateGrossProceedsThroughEquityIssuanceMaximumPotentialAmount

Namespace Prefix: rvmd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Commissions and expenses.
+ References
No definition available.
+ Details

Name: rvmd_CommissionsAndExpenses

Namespace Prefix: rvmd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Proceeds from issuance of common stock gross.
+ References
No definition available.
+ Details

Name: rvmd_ProceedsFromIssuanceOfCommonStockGross

Namespace Prefix: rvmd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585
+ Details

Name: us-gaap_PaymentsForUnderwritingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for cost incurred directly with the issuance of an equity security.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsOfStockIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Per share or per unit amount of equity securities issued.
+ References
No definition available.
+ Details

Name: us-gaap_SharesIssuedPricePerShare

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=rvmd_UnderwrittenPublicOfferingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=rvmd_AtTheMarketEquityOfferingProgramMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 56 R34.htm IDEA: XBRL DOCUMENT v3.22.4

Summary of Significant Accounting Policies - Additional Information (Details)
12 Months Ended

Feb. 07, 2020

Dec. 31, 2022

USD ($)

Segment

Dec. 31, 2021

USD ($)

Dec. 31, 2020

USD ($)

Sep. 30, 2021

Summary Of Significant Accounting Policies [Line Items]

Reverse stock split 0.2055

Reverse stock split, description 1-for-4.8661

Other-than-temporary impairment $ 0

Restricted cash 1,737,000 $ 1,737,000

Operating lease liability 64,205,000

Operating lease right-of-use asset 55,077,000 59,692,000

Adjustment to accumulated deficit (701,341,000) (452,636,000)

Impairments of long-lived assets 0 0 $ 0

Impairment of intangible assets, indefinite-lived 0

Impairment of intangible assets, finite-lived 0

Goodwill impairment 0

Deferred offering costs $ 600,000 500,000

Number of operating segment | Segment 1

Number of reportable segment | Segment 1

Retirement plan name description 401(k) retirement plan

Retirement plan, matching contributions $ 1,300,000 900,000 $ 200,000

ASU 2019-12

Summary Of Significant Accounting Policies [Line Items]

Change in accounting principle, accounting standards update, early adoption true

Change in accounting principle, accounting standards update, adopted true

Change in accounting principle, accounting standards update, immaterial effect true

Minimum

Summary Of Significant Accounting Policies [Line Items]

Property and equipment, estimated useful lives 3 years

Maximum

Summary Of Significant Accounting Policies [Line Items]

Property and equipment, estimated useful lives 5 years

Letter Of Credit

Summary Of Significant Accounting Policies [Line Items]

Restricted cash $ 1,700,000 $ 1,700,000

X

- Definition
Summary of significant accounting policies.
+ References
No definition available.
+ Details

Name: rvmd_SummaryOfSignificantAccountingPoliciesLineItems

Namespace Prefix: rvmd_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates (true false) whether accounting standards update was adopted.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 20
-Section 65
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 7
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=128293352&loc=SL120154346-209984

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 65
-Paragraph 3
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 65
-Paragraph 3
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (a)(1)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 3
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 3
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (a)(2)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 832
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232
+ Details

Name: us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted

Namespace Prefix: us-gaap_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicates (true false) whether accounting standards update was early adopted.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (c)(1)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 65
-Paragraph 3
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 7
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (c)(2)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (a)(3)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 832
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 20
-Section 65
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=128293352&loc=SL120154346-209984
+ Details

Name: us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption

Namespace Prefix: us-gaap_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=122038215&loc=d3e31010-122693

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (d)(1)
-URI https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(3)
-URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794
+ Details

Name: us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect

Namespace Prefix: us-gaap_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: instant

X

- Definition
Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 5.A)
-URI https://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735
+ Details

Name: us-gaap_DeferredOfferingCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of discretionary contributions made by an employer to a defined contribution plan.
+ References
No definition available.
+ Details

Name: us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Description of defined contribution pension and other postretirement plans.
+ References
No definition available.
+ Details

Name: us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 55
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267
+ Details

Name: us-gaap_GoodwillImpairmentLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275
+ Details

Name: us-gaap_ImpairmentOfIntangibleAssetsFinitelived

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585
+ Details

Name: us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228
+ Details

Name: us-gaap_ImpairmentOfLongLivedAssetsHeldForUse

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 18
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599
+ Details

Name: us-gaap_NumberOfOperatingSegments

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 18
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599
+ Details

Name: us-gaap_NumberOfReportableSegments

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's right to use underlying asset under operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 8A
-URI https://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562
+ Details

Name: us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 210
-Section 45
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580
+ Details

Name: us-gaap_RestrictedCashNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770
+ Details

Name: us-gaap_StockholdersEquityNoteStockSplitConversionRatio1

Namespace Prefix: us-gaap_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: duration

X

- Definition
Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770
+ Details

Name: us-gaap_StockholdersEquityReverseStockSplit

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 57 R35.htm IDEA: XBRL DOCUMENT v3.22.4

Summary of Significant Accounting Policies - Schedule of Useful Lives of Property and Equipment (Details)
12 Months Ended

Dec. 31, 2022

Minimum

Property Plant And Equipment [Line Items]

Estimated useful life 3 years

Maximum

Property Plant And Equipment [Line Items]

Estimated useful life 5 years

Laboratory Equipment | Minimum

Property Plant And Equipment [Line Items]

Estimated useful life 4 years

Laboratory Equipment | Maximum

Property Plant And Equipment [Line Items]

Estimated useful life 5 years

Leasehold Improvements

Property Plant And Equipment [Line Items]

Estimated useful life, description Lesser of estimated useful life or remaining lease term

Computer Equipment and Software

Property Plant And Equipment [Line Items]

Estimated useful life 3 years

Furniture and Fixtures

Property Plant And Equipment [Line Items]

Estimated useful life 5 years

X

- Definition
Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 35
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=126905813&loc=d3e1205-110223
+ Details

Name: us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=rvmd_LaboratoryEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=rvmd_ComputerEquipmentAndSoftwareMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 58 R36.htm IDEA: XBRL DOCUMENT v3.22.4

Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value (Details) - Fair Value, Recurring - USD ($)
$ in Thousands

Dec. 31, 2022

Dec. 31, 2021

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]

Assets fair value $ 645,685 $ 577,946

Money Market Funds

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]

Assets fair value ^[1] 48,522 57,134

Commercial Paper

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]

Assets fair value ^[1],[2] 313,928 291,369

U.S. and Canadian Government And Agency Securities

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]

Assets fair value ^[2] 251,830 87,745 ^[1]

Corporate Bonds

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]

Assets fair value ^[2] 31,405 ^[1] 141,698

Level 1

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]

Assets fair value 48,522 57,134

Level 1 | Money Market Funds

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]

Assets fair value ^[1] 48,522 57,134

Level 1 | Commercial Paper

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]

Assets fair value ^[1],[2] 0

Level 1 | U.S. and Canadian Government And Agency Securities

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]

Assets fair value ^[1],[2] 0

Level 1 | Corporate Bonds

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]

Assets fair value ^[2] 0

Level 2

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]

Assets fair value 597,163 520,812

Level 2 | Commercial Paper

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]

Assets fair value ^[1],[2] 313,928 291,369

Level 2 | U.S. and Canadian Government And Agency Securities

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]

Assets fair value ^[2] 251,830 87,745 ^[1]

Level 2 | Corporate Bonds

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]

Assets fair value ^[2] $ 31,405 ^[1] $ 141,698

[1] Included in cash and cash equivalents on the consolidated balance sheets.

[2] Included in marketable securities on the consolidated balance sheets.

X

- Definition
Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258
+ Details

Name: us-gaap_AssetsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=rvmd_UsAndCanadianGovernmentAgenciesDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 59 R37.htm IDEA: XBRL DOCUMENT v3.22.4

Fair Value Measurements - Additional Information (Details) - USD ($)

Dec. 31, 2022

Dec. 31, 2021

Fair Value Disclosures [Abstract]

Fair value, transfers between Levels 1, 2 or 3, amount $ 0 $ 0

X

- Definition
Fair value level1 level2 level 3 transfers amount.
+ References
No definition available.
+ Details

Name: rvmd_FairValueLevel1Level2Level3TransfersAmount

Namespace Prefix: rvmd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 60 R38.htm IDEA: XBRL DOCUMENT v3.22.4

Available-for-sale Securities - Summary of Estimated Value of Available-for-sale Securities and Cash Equivalents and Gross Unrealized Gains and Losses (Details) - USD ($)
$ in Thousands

Dec. 31, 2022

Dec. 31, 2021

Schedule Of Available For Sale Securities [Line Items]

Amortized Cost $ 647,465 $ 578,322

Gross Unrealized Gain 47 1

Gross Unrealized Loss (1,827) (377)

Estimated Fair Value 645,685 577,946

Marketable Securities

Schedule Of Available For Sale Securities [Line Items]

Amortized Cost 485,280 468,931

Gross Unrealized Gain 43 1

Gross Unrealized Loss (1,792) (375)

Estimated Fair Value 483,531 468,557

Marketable Securities | Corporate Bonds

Schedule Of Available For Sale Securities [Line Items]

Amortized Cost 31,599 141,829

Gross Unrealized Gain 0 0

Gross Unrealized Loss (194) (131)

Estimated Fair Value 31,405 141,698

Marketable Securities | Commercial Paper

Schedule Of Available For Sale Securities [Line Items]

Amortized Cost 216,765 239,176

Gross Unrealized Gain 0 1

Gross Unrealized Loss (328) (63)

Estimated Fair Value 216,437 239,114

Marketable Securities | U.S. and Canadian Government And Agency Securities

Schedule Of Available For Sale Securities [Line Items]

Amortized Cost 236,916 87,926

Gross Unrealized Gain 43 0

Gross Unrealized Loss (1,270) (181)

Estimated Fair Value 235,689 87,745

Cash Equivalents

Schedule Of Available For Sale Securities [Line Items]

Amortized Cost 162,185 109,391

Gross Unrealized Gain 4 0

Gross Unrealized Loss (35) (2)

Estimated Fair Value 162,154 109,389

Cash Equivalents | Corporate Bonds

Schedule Of Available For Sale Securities [Line Items]

Amortized Cost 16,137

Gross Unrealized Gain 4

Gross Unrealized Loss 0

Estimated Fair Value 16,141

Cash Equivalents | Money Market Funds

Schedule Of Available For Sale Securities [Line Items]

Amortized Cost 48,522 57,134

Gross Unrealized Gain 0 0

Gross Unrealized Loss 0 0

Estimated Fair Value 48,522 57,134

Cash Equivalents | Commercial Paper

Schedule Of Available For Sale Securities [Line Items]

Amortized Cost 97,526 52,257

Gross Unrealized Gain 0 0

Gross Unrealized Loss (35) (2)

Estimated Fair Value $ 97,491 $ 52,255

X

- Definition
Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 30
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(6))
-URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 30
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (aa)
-URI https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DebtInstrumentAxis=rvmd_MarketableSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=rvmd_UsAndCanadianGovernmentAgenciesDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=us-gaap_CashEquivalentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 61 R39.htm IDEA: XBRL DOCUMENT v3.22.4

Available-for-sale Securities - Summary of Amortized Cost and Estimated Fair Value of Available-for-sale Securities and Cash Equivalents by Contractual Maturity (Details) - USD ($)
$ in Thousands

Dec. 31, 2022

Dec. 31, 2021

Schedule Of Available For Sale Securities [Line Items]

Amortized Cost $ 647,465 $ 578,322

Gross Unrealized Gain 47 1

Gross Unrealized Loss (1,827) (377)

Estimated Fair Value 645,685 $ 577,946

Mature in One Year or Less

Schedule Of Available For Sale Securities [Line Items]

Amortized Cost 618,025

Gross Unrealized Gain 48

Gross Unrealized Loss (1,752)

Estimated Fair Value 616,321

Mature after One Year through Two Years

Schedule Of Available For Sale Securities [Line Items]

Amortized Cost 29,440

Gross Unrealized Gain 1

Gross Unrealized Loss (75)

Estimated Fair Value $ 29,364

X

- Definition
Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 30
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(6))
-URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 30
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (aa)
-URI https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FinancingReceivablesPeriodPastDueAxis=rvmd_MatureInOneYearOrLessMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancingReceivablesPeriodPastDueAxis=rvmd_MatureAfterOneYearThroughTwoYearsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 62 R40.htm IDEA: XBRL DOCUMENT v3.22.4

Balance Sheet Components - Schedule of Property and Equipment, Net (Details) - USD ($)
$ in Thousands

Dec. 31, 2022

Dec. 31, 2021

Property Plant And Equipment [Line Items]

Property and equipment, gross $ 33,148 $ 22,356

Less: accumulated depreciation and amortization (14,489) (10,812)

Property and equipment, net 18,659 11,544

Laboratory Equipment

Property Plant And Equipment [Line Items]

Property and equipment, gross 17,163 12,727

Leasehold Improvements

Property Plant And Equipment [Line Items]

Property and equipment, gross 11,404 7,245

Computer Equipment and Software

Property Plant And Equipment [Line Items]

Property and equipment, gross 3,965 2,186

Furniture and Fixtures

Property Plant And Equipment [Line Items]

Property and equipment, gross 616 69

Construction in Progress

Property Plant And Equipment [Line Items]

Property and equipment, gross $ 0 $ 129

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 360
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=rvmd_LaboratoryEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=rvmd_ComputerEquipmentAndSoftwareMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 63 R41.htm IDEA: XBRL DOCUMENT v3.22.4

Balance Sheet Components - Additional Information (Details) - USD ($)
$ in Millions
12 Months Ended

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Depreciation and amortization expense $ 4.0 $ 3.1 $ 2.6

X

- Definition
The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 64 R42.htm IDEA: XBRL DOCUMENT v3.22.4

Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)
$ in Thousands

Dec. 31, 2022

Dec. 31, 2021

Accrued Expenses And Other Current Liabilities [Abstract]

Accrued compensation $ 13,281 $ 9,852

Accrued research and development 15,161 17,018

Accrued professional services 499 540

Other 505 311

Total accrued expenses and other current liabilities $ 29,446 $ 27,721

X

- Definition
Accrued expenses and other current liabilities.
+ References
No definition available.
+ Details

Name: rvmd_AccruedExpensesAndOtherCurrentLiabilities

Namespace Prefix: rvmd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accrued expenses and other current liabilities.
+ References
No definition available.
+ Details

Name: rvmd_AccruedExpensesAndOtherCurrentLiabilitiesAbstract

Namespace Prefix: rvmd_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Accrued research and development expense current.
+ References
No definition available.
+ Details

Name: rvmd_AccruedResearchAndDevelopmentExpenseCurrent

Namespace Prefix: rvmd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedEmployeeBenefitsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedProfessionalFeesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 65 R43.htm IDEA: XBRL DOCUMENT v3.22.4

Intangible Assets and Goodwill - Schedule of Intangibles Assets, Net (Details) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2022

Dec. 31, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

In-process research and development - RAS Programs $ 55,800 $ 55,800

Developed technology - tri-complex platform, Gross value 7,480 7,480

Developed technology - tri-complex platform, Accumulated amortization (4,473) (3,404)

Developed technology - tri-complex platform, Net book value $ 3,007 $ 4,076

Developed technology - tri-complex platform, Weighted-average remaining useful life 2 years 10 months 24 days 3 years 10 months 24 days

Intangible assets, Gross value $ 63,280 $ 63,280

Intangible assets, Net book value $ 58,807 $ 59,876

X

- Definition
Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(16))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 928
-SubTopic 340
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before accumulated amortization of intangible assets, excluding goodwill.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(15))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_IntangibleAssetsGrossExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph ((a)(1),(b))
-URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274
+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 66 R44.htm IDEA: XBRL DOCUMENT v3.22.4

Intangible Assets and Goodwill - Additional Information (Details) - USD ($)
12 Months Ended

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Amortization of intangible assets $ 1,069,000 $ 1,069,000 $ 1,068,000

Goodwill impairment $ 0

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 55
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267
+ Details

Name: us-gaap_GoodwillImpairmentLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 67 R45.htm IDEA: XBRL DOCUMENT v3.22.4

Intangible Assets and Goodwill - Schedule of Future Amortization Expense (Details) - USD ($)
$ in Thousands

Dec. 31, 2022

Dec. 31, 2021

Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]

2023 $ 1,069

2024 1,068

2025 870

Developed technology - tri-complex platform, Net book value $ 3,007 $ 4,076

X

- Definition
Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 68 R46.htm IDEA: XBRL DOCUMENT v3.22.4

Intangible Assets and Goodwill - Schedule of Goodwill (Details)
$ in Thousands
12 Months Ended

Dec. 31, 2022

USD ($)

Goodwill and Intangible Assets Disclosure [Abstract]

Balance at December 31, 2021 $ 14,608

Adjustment 0

Balance at December 31, 2022 $ 14,608

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10)(1))
-URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 55
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(15))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) from foreign currency translation adjustments and purchase accounting adjustments of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 25
-Paragraph 16
-URI https://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460
+ Details

Name: us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 69 R47.htm IDEA: XBRL DOCUMENT v3.22.4

Commitment and Contingencies - Additional Information (Details)
$ in Thousands
1 Months Ended 12 Months Ended

Nov. 30, 2021

USD ($)

ft²

Apr. 30, 2020

USD ($)

ft²

Dec. 31, 2022

USD ($)

Dec. 31, 2021

USD ($)

Oct. 31, 2018

ft²

Jan. 31, 2015

ft²

Lessee Lease Description [Line Items]

Operating lease right-of-use asset $ 55,077 $ 59,692

Operating lease liability 64,205

Operating lease cost 6,400 3,400

Sublease income 2,500 2,100

Operating cash flows for operating leases $ 2,400 $ 1,500

Operating lease, weighted average discount rate 6.10%

Operating lease, weighted average remaining lease term 10 years 10 months 24 days 11 years 7 months 6 days

Redwood City Lease

Lessee Lease Description [Line Items]

Lessee operating lease expiration month and year 2033-11

Area of space leased | ft² 41,000

Lessee, operating lease option to extend lease term 10 years

Redwood City Lease | ASC 842

Lessee Lease Description [Line Items]

Operating lease right-of-use asset $ 26,800

Redwood City Lease | Restricted Cash

Lessee Lease Description [Line Items]

Letter of credit $ 1,500 $ 1,500

Redwood City Lease | The 700 Building and 300 Building | ASC 842

Lessee Lease Description [Line Items]

Increase in operating lease right-of-use asset $ 8,600

Redwood City Lease | The 300 Building

Lessee Lease Description [Line Items]

Lessee operating lease expiration month and year 2030-12

Area of space leased | ft² 19,000

Tenant improvement allowance $ 4,600

Redwood City Lease | The 300 Building | ASC 842

Lessee Lease Description [Line Items]

Operating lease right-of-use asset $ 6,400

Operating lease liability 9,000

Redwood City Lease | The 700 Building

Lessee Lease Description [Line Items]

Lessee operating lease expiration month and year 2023-04

Area of space leased | ft² 42,000

Tenant improvement allowance $ 3,400

Redwood City Lease | The 700 Building | ASC 842

Lessee Lease Description [Line Items]

Increase in operating lease right-of-use asset $ 14,800

Redwood City Lease | The 800 Building

Lessee Lease Description [Line Items]

Lessee, operating lease, option to extend The Company has the option to extend the lease for an additional ten years after November 30, 2033.

Cambridge, Massachusetts

Lessee Lease Description [Line Items]

Lessee operating lease expiration month and year 2023-02

Area of space leased | ft² 22,000

Lessee, operating lease, option to extend option to extend the term through February 2028

Cambridge, Massachusetts | Restricted Cash

Lessee Lease Description [Line Items]

Letter of credit $ 200 $ 200

X

- Definition
Area of office space leased.
+ References
No definition available.
+ Details

Name: rvmd_AreaOfOfficeSpaceLeased

Namespace Prefix: rvmd_

Data Type: dtr-types:areaItemType

Balance Type: na

Period Type: instant

X

- Definition
Increase (decrease) in operating lease right-of-use asset.
+ References
No definition available.
+ Details

Name: rvmd_IncreaseDecreaseInOperatingLeaseRightOfUseAsset

Namespace Prefix: rvmd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Lessee operating lease expiration month and year.
+ References
No definition available.
+ Details

Name: rvmd_LesseeOperatingLeaseExpirationMonthAndYear

Namespace Prefix: rvmd_

Data Type: xbrli:gYearMonthItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_LesseeLeaseDescriptionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (a)(3)
-URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseOptionToExtend

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (a)(3)
-URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseRenewalTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Definition
The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.
+ References
No definition available.
+ Details

Name: us-gaap_LettersOfCreditOutstandingAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980
+ Details

Name: us-gaap_OperatingLeaseCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 5
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(1)
-URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980
+ Details

Name: us-gaap_OperatingLeasePayments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of lessee's right to use underlying asset under operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average discount rate for operating lease calculated at point in time.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(4)
-URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971
+ Details

Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(3)
-URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980
+ Details

Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Definition
Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585
+ Details

Name: us-gaap_PaymentsForProceedsFromTenantAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of sublease income excluding finance and operating lease expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971
+ Details

Name: us-gaap_SubleaseIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: srt_StatementGeographicalAxis=rvmd_RedwoodCityCaliforniaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=rvmd_RestrictedCashMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=rvmd_SevenHundredAndThreeHundredSaginawDriveRedwoodCityCaliforniaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=rvmd_ThreeHundredSaginawDriveRedwoodCityCaliforniaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=rvmd_SevenHundredSaginawDriveRedwoodCityCaliforniaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=rvmd_EightHundredSaginawDriveRedwoodCityCaliforniaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=stpr_MA

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 70 R48.htm IDEA: XBRL DOCUMENT v3.22.4

Commitments and Contingencies - Summary of Balance Sheet Classification of Operating Lease Liabilities (Details) - USD ($)
$ in Thousands

Dec. 31, 2022

Dec. 31, 2021

Commitments and Contingencies Disclosure [Abstract]

Operating lease liability – current $ 6,773 $ 6,214

Operating lease liability – noncurrent 57,432 $ 60,419

Total operating lease liabilities $ 64,205

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 71 R49.htm IDEA: XBRL DOCUMENT v3.22.4

Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details)
$ in Thousands

Dec. 31, 2022

USD ($)

Commitments and Contingencies Disclosure [Abstract]

2023 $ 6,961

2024 7,100

2025 7,349

2026 7,606

2027 7,872

Thereafter 52,550

Total undiscounted lease payments 89,438

Less: Imputed interest (25,233)

Less: Tenant improvement allowance 0

Total operating lease liabilities $ 64,205

X

- Definition
Lessee operating lease liability tenant improvement allowance.
+ References
No definition available.
+ Details

Name: rvmd_LesseeOperatingLeaseLiabilityTenantImprovementAllowance

Namespace Prefix: rvmd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 72 R50.htm IDEA: XBRL DOCUMENT v3.22.4

Sanofi Collaboration Agreement - Additional Information (Details) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Jul. 31, 2018

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Deferred revenue, current $ 4,459 $ 12,358

Deferred revenue, noncurrent 0 6,573

Sanofi Agreement

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Upfront cash payment received $ 50,000 $ 50,000

Percentage of reimbursement of internal and external research costs and expenses under research plan 50.00%

Transaction price $ 186,900

Estimated variable consideration for expense reimbursements upon research and development services 136,900

Collaboration revenue recognized 35,400 29,400 $ 43,000

Deferred revenue, current 4,500 12,400

Deferred revenue, noncurrent $ 6,600

Sanofi Agreement | Letter Agreement for the RMC

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]

Reduction in Collaboration Revenue $ 8,500

X

- Definition
Estimated variable consideration for expense reimbursements upon research and development services.
+ References
No definition available.
+ Details

Name: rvmd_EstimatedVariableConsiderationForExpenseReimbursementsUponResearchAndDevelopmentServices

Namespace Prefix: rvmd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Percentage of reimbursement of internal and external research costs and expenses under research plan.
+ References
No definition available.
+ Details

Name: rvmd_PercentageOfReimbursementOfInternalAndExternalResearchCostsAndExpensesUnderResearchPlan

Namespace Prefix: rvmd_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Reduction in Collaboration Revenue
+ References
No definition available.
+ Details

Name: rvmd_ReductionInCollaborationRevenue

Namespace Prefix: rvmd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Transaction price.
+ References
No definition available.
+ Details

Name: rvmd_TransactionPrice

Namespace Prefix: rvmd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Upfront cash payment received.
+ References
No definition available.
+ Details

Name: rvmd_UpfrontCashPaymentReceived

Namespace Prefix: rvmd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 808
-SubTopic 10
-Section 45
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=126928961&loc=SL5834089-161433

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 808
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434
+ Details

Name: us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_TypeOfArrangementAxis=rvmd_SanofiAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=rvmd_LetterAgreementForRmcMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 73 R51.htm IDEA: XBRL DOCUMENT v3.22.4

Redeemable Convertible Preferred Stock - Additional Information (Details) - shares

Dec. 31, 2022

Dec. 31, 2021

Feb. 29, 2020

Temporary Equity [Line Items]

Temporary equity, shares outstanding 0 0

Initial Public Offering

Temporary Equity [Line Items]

Temporary equity, shares outstanding 39,600,423

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_TemporaryEquityLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27)(b))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_TemporaryEquitySharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 74 R52.htm IDEA: XBRL DOCUMENT v3.22.4

Common Stock - Additional Information (Details)
12 Months Ended

Dec. 31, 2022

USD ($)

Vote

$ / shares

shares

Dec. 31, 2021

$ / shares

shares

Stockholders' Equity Note [Abstract]

Common stock, shares authorized | shares 300,000,000 300,000,000

Common stock, par or stated value per share | $ / shares $ 0.0001 $ 0.0001

Common stock, voting rights Each share of common stock is entitled to one vote

Number of voting rights per common share | Vote 1

Common stock, dividends declared | $ $ 0

X

- Definition
Number of voting rights per common share.
+ References
No definition available.
+ Details

Name: rvmd_NumberOfVotingRightsPerCommonShare

Namespace Prefix: rvmd_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644
+ Details

Name: us-gaap_CommonStockVotingRights

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 405
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817
+ Details

Name: us-gaap_DividendsCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 75 R53.htm IDEA: XBRL DOCUMENT v3.22.4

Common Stock - Schedule of Common Stock for Future Issuance (Details) - shares

Dec. 31, 2022

Dec. 31, 2021

Class Of Stock [Line Items]

Common stock reserved for future issuance, Total 17,766,601 13,967,835

Outstanding Options to Purchase Common Stock

Class Of Stock [Line Items]

Common stock reserved for future issuance, Total 8,164,375 6,050,938

Unvested Restricted Stock Units Of Common Stock

Class Of Stock [Line Items]

Common stock reserved for future issuance, Total 1,175,032 423,621

Available for Future Issuance under the 2020 Incentive Award Plan

Class Of Stock [Line Items]

Common stock reserved for future issuance, Total 6,726,307 6,403,548

Available for issuance under the 2020 Employee Stock Purchase Plan

Class Of Stock [Line Items]

Common stock reserved for future issuance, Total 1,700,887 1,089,728

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate number of common shares reserved for future issuance.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_AwardTypeAxis=rvmd_OutstandingOptionsToPurchaseCommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=rvmd_UnvestedRestrictedStockUnitsOfCommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=rvmd_AvailableForFutureIssuanceUnderTheTwoZeroTwoZeroIncentiveAwardPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=rvmd_AvailableForFutureIssuanceUnderTheTwoZeroTwoZeroEmployeeStockPurchasePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 76 R54.htm IDEA: XBRL DOCUMENT v3.22.4

Stock-Based Compensation - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended

Feb. 29, 2020

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Common stock reserved for future issuance, Total 17,766,601 13,967,835

Intrinsic value of the options exercised $ 3,800 $ 13,100 $ 21,700

Weighted-average grant-date fair value of options granted $ 25.13 $ 15.59

Unrecognized stock-based compensation expense related to unvested stock options $ 48,800

Unrecognized stock-based compensation expense, weighted-average period of recognition 2 years 6 months 25 days

Stock-based compensation expense $ 31,196 $ 20,724 $ 8,886

Consultant

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Stock-based compensation expense 500 700 800

Restricted Stock Units (RSUs)

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Unrecognized stock-based compensation expense related to unvested stock options $ 25,800

Unrecognized stock-based compensation expense, weighted-average period of recognition 3 years 25 days

RSU vested, fair value $ 7,900 $ 3,100 $ 100

2020 Equity Incentive Plan

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Award vesting period 4 years

2020 Employee Stock Purchase Plan

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Common stock reserved for future issuance, Total 1,700,887

Purchase price rate 85.00%

Shares purchases 235,555

Unrecognized compensation cost related to ESPP $ 3,200

X

- Definition
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Aggregate number of common shares reserved for future issuance.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of cost not yet recognized for nonvested award under share-based payment arrangement.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cost to be recognized for option under share-based payment arrangement.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares purchased for issuance under share-based payment arrangement.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (l)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_TitleOfIndividualAxis=rvmd_ConsultantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=rvmd_TwoThousandTwentyEquityIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=rvmd_TwoThousandTwentyEmployeeStockPurchasePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 77 R55.htm IDEA: XBRL DOCUMENT v3.22.4

Stock-Based Compensation - Summary of Option Activity Under the Plan (Details) - 2020 Plan and 2014 Plan - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended

Dec. 31, 2022

Dec. 31, 2021

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Number of Shares underlying options, Beginning balance 6,050,938

Number of Shares underlying options, Options granted 2,758,710

Number of Shares underlying options, Options exercised (249,544)

Number of Shares underlying options, Options cancelled (395,729)

Number of Shares underlying options, Ending balance 8,164,375 6,050,938

Number of Shares underlying options, Options vested and expected to vest 8,164,375

Number of Shares underlying options, Options vested and exercisable 4,555,124

Weighted-average exercise price, Beginning balance $ 14.88

Weighted-average exercise price, Options granted 19.37

Weighted-average exercise price, Options exercised 6.12

Weighted-average exercise price, Options cancelled 26.78

Weighted-average exercise price, Ending balance 16.09 $ 14.88

Weighted-average exercise price, Options vested and expected to vest 16.09

Weighted-average exercise price, Options vested and exercisable $ 11.43

Weighted-average remaining contractual term (in years) 7 years 6 months 10 days 7 years 8 months 26 days

Weighted-average remaining contractual term, Options vested and expected to vest 7 years 6 months 10 days

Weighted-average remaining contractual term, Options vested and exercisable 6 years 7 months 24 days

Aggregate intrinsic value $ 85,181 $ 83,953

Aggregate intrinsic value, Options vested and expected to vest 85,181

Aggregate intrinsic value, Options vested and exercisable $ 66,783

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=rvmd_TwoThousandTwentyAndTwoThousandFourteenEquityIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 78 R56.htm IDEA: XBRL DOCUMENT v3.22.4

Summary of Fair Value of Stock Option Awards Estimated at Date of Grant (Details)
12 Months Ended

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Expected volatility, minimum 70.00%

Expected volatility, maximum 73.00%

Risk-free interest rate, minimum 1.50%

Risk-free interest rate, maximum 4.20%

Dividend yield 0.00%

Employee And Director

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Expected term (years) 6 years 6 years 6 years

Expected volatility, minimum 70.00% 74.00%

Expected volatility, maximum 75.00% 80.00%

Risk-free interest rate, minimum 0.50% 0.20%

Risk-free interest rate, maximum 1.30% 1.50%

Dividend yield 0.00% 0.00%

Consultant

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Expected term (years) 6 years 6 years

Expected volatility, minimum 70.00% 70.00% 74.00%

Expected volatility, maximum 71.00% 75.00% 80.00%

Risk-free interest rate, minimum 1.60% 0.90% 1.20%

Risk-free interest rate, maximum 3.40% 1.30% 1.50%

Dividend yield 0.00% 0.00% 0.00%

Consultant | Minimum

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Expected term (years) 6 years

Consultant | Maximum

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Expected term (years) 10 years

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_TitleOfIndividualAxis=rvmd_EmployeeAndDirectorMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=rvmd_ConsultantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 79 R57.htm IDEA: XBRL DOCUMENT v3.22.4

Stock-Based Compensation - Summary of RSUs Activity Under the Plan (Details) - 2020 Equity Incentive Plan - Restricted Stock Units (RSUs) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended

Dec. 31, 2022

Dec. 31, 2021

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Number of Shares, Beginning balance 423,621

Number of Shares, Restricted stock units granted 1,142,366

Number of Shares, Restricted stock units vested (278,848)

Number of Shares, Restricted stock units forfeited (112,107)

Number of Shares, Ending balance 1,175,032 423,621

Number of Shares, Expected to vest 1,175,032

Weighted-average grant date fair value per share, Beginning balance $ 37.16

Weighted-average grant date fair value per share, Restricted stock units granted 19.43

Weighted-average grant date fair value per share, Restricted stock units vested 28.23

Weighted-average grant date fair value per share, Restricted stock units forfeited 24.58

Weighted-average grant date fair value per share, Ending balance 23.25 $ 37.16

Weighted-average grant date fair value per share, Expected to vest $ 23.25

Weighted-average remaining contractual term (in years) 1 year 7 months 13 days 3 years 1 month 28 days

Weighted-average remaining contractual term, Expected to vest 1 year 7 months 13 days

Aggregate intrinsic value $ 27,989 $ 10,663

Aggregate intrinsic value, Expected to vest $ 27,989

X

- Definition
Share based compensation arrangement by share based payment award equity instruments other than options aggregate intrinsic value expected to vest.
+ References
No definition available.
+ Details

Name: rvmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExpectedToVest

Namespace Prefix: rvmd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Share based compensation arrangement by share based payment award equity instruments other than options expected to vest outstanding number.
+ References
No definition available.
+ Details

Name: rvmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestOutstandingNumber

Namespace Prefix: rvmd_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Share based compensation arrangement by share based payment award equity instruments other than options expected to vest weighted average grant date fair value.
+ References
No definition available.
+ Details

Name: rvmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue

Namespace Prefix: rvmd_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Share based compensation arrangement by share based payment awards equity instruments other than options expected to vest weighted average remaining contractual term.
+ References
No definition available.
+ Details

Name: rvmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardsEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageRemainingContractualTerm

Namespace Prefix: rvmd_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PlanNameAxis=rvmd_TwoThousandTwentyEquityIncentivePlansMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 80 R58.htm IDEA: XBRL DOCUMENT v3.22.4

Stock-Based Compensation - Summary of Total Stock-Based Compensation Expense Related to Stock Options, RSUs and Employee Stock Purchase Plan (Details) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Stock-based compensation expense $ 31,196 $ 20,724 $ 8,886

Research and Development

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Stock-based compensation expense 18,113 11,847 4,848

General and Administrative

Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]

Stock-based compensation expense $ 13,083 $ 8,877 $ 4,038

X

- Definition
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 81 R59.htm IDEA: XBRL DOCUMENT v3.22.4

Income Taxes - Additional Information (Details) - USD ($)
12 Months Ended

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Income Taxes [Line Items]

Benefit from income taxes $ 420,000 $ 0 $ 371,000

Increase in valuation allowance $ 80,700,000 58,800,000

Tax cut and jobs act net operating loss deduction limitation percentage 80.00%

Research and development credit carryforwards $ 22,558,000 14,449,000

Net operating losses, limitations on use Federal, California, Massachusetts and New Jersey tax laws impose significant restrictions on the utilization of net operating loss carryforwards in the event of a change in ownership of the Company, as defined by Internal Revenue Code Section 382 (Section 382). The Company performed a study in which it determined that it had experienced changes in ownership in 2014, 2018, and 2020 as defined by Section 382. No federal or state net operating losses are expected to expire unutilized as a result of the limitation, with the exception of $5.5 million in California net operating losses. The Company's deferred tax assets have been reduced by the amount of net operating loss carryforwards expected to expire due to the limitation. In addition, in the future the Company may experience ownership changes, which may limit the utilization of net operating loss carryforwards or other tax attributes.The TCJA amended Internal Revenue Code Section 174 requiring capitalization of specified research and experimental expenditures paid or incurred in tax years beginning after December 31, 2021 and amortizing over a period of 5 or 15 years. This resulted in a deferred tax asset for capitalized research expenses in 2022. Also on August 16, 2022, the United States enacted the Inflation Reduction Act (the IRA), which contains among other things, numerous income tax provisions. At this time, the Company does not anticipate the IRA to have a material impact on its financial statements.

Unrecognized tax benefits that would affect effective tax rate if recognized $ 7,100,000 4,700,000

Interest or penalties related to uncertain tax positions $ 0 $ 0

Years remain open to examination 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022

Federal

Income Taxes [Line Items]

Net operating loss carryforwards subject to expire $ 448,300,000

Net operating loss carryforwards expiration beginning year 2035

Net operating loss carryforwards which can be carried forward indefinitely $ 354,700,000

Research and development credit carryforwards $ 20,600,000

Research and development credit carryforwards expiration starting year 2034

State and Local Net

Income Taxes [Line Items]

Net operating loss carryforwards subject to expire $ 445,500,000

Net operating loss carryforwards expiration beginning year 2035

Research and development credit carryforwards $ 11,600,000

Research and development credit carryforwards expiration starting year 2031

Research and development credit carryforwards which can be carried forward indefinitely $ 10,700,000

Net operating losses expected to expire unutilized as a result of the limitation $ 5,500,000

X

- Definition
Deferred tax assets tax credit carryforwards research not subject to expiration.
+ References
No definition available.
+ Details

Name: rvmd_DeferredTaxAssetsTaxCreditCarryforwardsResearchNotSubjectToExpiration

Namespace Prefix: rvmd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Income taxes.
+ References
No definition available.
+ Details

Name: rvmd_IncomeTaxesLineItems

Namespace Prefix: rvmd_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Net operating loss carryforwards expected to expiration unutilized due to limitations on use.
+ References
No definition available.
+ Details

Name: rvmd_NetOperatingLossCarryforwardsExpectedToExpirationUnutilizedDueToLimitationsOnUse

Namespace Prefix: rvmd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Net operating loss carryforwards expiration starting year.
+ References
No definition available.
+ Details

Name: rvmd_NetOperatingLossCarryforwardsExpirationStartingYear

Namespace Prefix: rvmd_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
Research and development credit carryforwards expiration starting year.
+ References
No definition available.
+ Details

Name: rvmd_ResearchAndDevelopmentTaxCreditCarryforwardsExpirationStartingYear

Namespace Prefix: rvmd_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
Tax cuts and jobs act of 2017 net operating losses limitation percentage.
+ References
No definition available.
+ Details

Name: rvmd_TaxCutsAndJobsActOf2017NetOperatingLossesLimitationPercentage

Namespace Prefix: rvmd_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Tax year being audited in the income tax examination, in YYYY format.
+ References
No definition available.
+ Details

Name: us-gaap_IncomeTaxExaminationYearUnderExamination

Namespace Prefix: us-gaap_

Data Type: dtr-types:gYearListItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingLossCarryforwardsLimitationsOnUse

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319
+ Details

Name: us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 82 R60.htm IDEA: XBRL DOCUMENT v3.22.4

Income Taxes - Summary of Benefit from Income Taxes to Amount Computed by Applying Federal Statutory Rate to Loss Before Taxes (Details)
12 Months Ended

Dec. 31, 2022

Dec. 31, 2021

Effective Income Tax Rate Reconciliation, Percent [Abstract]

Federal statutory income tax rate 21.00% 21.00%

State income tax rate, net of federal benefit 9.40% 8.90%

Research tax credits 3.20% 2.20%

Change in valuation allowance (32.40%) (31.40%)

Non-deductible permanent expenses (1.00%) (0.50%)

Other 0.00% (0.20%)

Benefit from income taxes 0.20% 0.00%

X

- Definition
Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of domestic federal statutory tax rate applicable to pretax income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.4)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.4)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.4)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.4)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.4)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.4)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

XML 83 R61.htm IDEA: XBRL DOCUMENT v3.22.4

Income Taxes - Summary of Categories that Give Rise to Significant Components of Deferred Tax Assets (Details) - USD ($)
$ in Thousands

Dec. 31, 2022

Dec. 31, 2021

Deferred tax assets:

Net operating loss carryforwards $ 132,080 $ 123,991

Accruals and reserves 5,494 9,164

Research and development credits 22,558 14,449

Lease liability 18,998 19,979

Stock-based compensation 7,063 3,829

Capitalized research expenses 64,149

Other 42 33

Gross deferred tax assets 250,384 171,445

Less: valuation allowance (224,125) (143,474)

Total deferred tax assets 26,259 27,971

Deferred tax liabilities:

Fixed assets and finite-lived intangible assets (9,961) (10,073)

Indefinite-lived intangible assets (7,025) (7,444)

Lease asset 0

Right-of-use asset (16,298) (17,898)

Gross deferred tax liabilities (33,284) (35,415)

Net deferred tax liability $ (7,025) $ (7,444)

X

- Definition
Deferred tax assets, lease liability.
+ References
No definition available.
+ Details

Name: rvmd_DeferredTaxAssetsLeaseLiability

Namespace Prefix: rvmd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Deferred Tax Assets Tax Credit Capitalized Research Expenses
+ References
No definition available.
+ Details

Name: rvmd_DeferredTaxAssetsTaxCreditCapitalizedResearchExpenses

Namespace Prefix: rvmd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Deferred tax liabilities fixed assets and finite-lived intangible assets.
+ References
No definition available.
+ Details

Name: rvmd_DeferredTaxLiabilitiesFixedAssetsAndFiniteLivedIntangibleAssets

Namespace Prefix: rvmd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Deferred tax liabilities indefinite-lived intangible assets.
+ References
No definition available.
+ Details

Name: rvmd_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets

Namespace Prefix: rvmd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Deferred tax liabilities, right-of-use asset.
+ References
No definition available.
+ Details

Name: rvmd_DeferredTaxLiabilitiesRightOfUseAsset

Namespace Prefix: rvmd_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred tax liability attributable to taxable temporary differences.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(26)(b))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(15)(b)(2))
-URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(15)(2))
-URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(26)(a))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_DeferredIncomeTaxLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_DeferredTaxAssetsNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsOperatingLossCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319
+ Details

Name: us-gaap_DeferredTaxAssetsOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxLiabilitiesLeasingArrangements

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_DeferredTaxLiabilitiesNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 84 R62.htm IDEA: XBRL DOCUMENT v3.22.4

Income Taxes - Reconciliation of Gross Unrecognized Tax Benefits (Details) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2022

Dec. 31, 2021

Income Tax Disclosure [Abstract]

Beginning balance $ 5,143 $ 3,593

Changes related to tax positions taken in the prior year (7) (21)

Changes related to tax positions taken in current year 2,466 1,571

Ending balance $ 7,602 $ 5,143

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of unrecognized tax benefits.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 10B
-URI https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (a)(1)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (a)(2)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 85 R63.htm IDEA: XBRL DOCUMENT v3.22.4

Net Loss Per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Numerator:

Net loss $ (248,705) $ (187,091) $ (108,159)

Redeemable convertible preferred stock dividends - undeclared and cumulative 0 0 (2,219)

Net loss attributable to common stockholders $ (248,705) $ (187,091) $ (110,378)

Denominator:

Weighted-average shares outstanding 80,636,570 72,866,022 55,109,929

Less: Weighted-average unvested restricted shares and shares subject to repurchase (10,045) (59,943) (235,810)

Weighted-average shares used to compute net loss per share attributable to common stockholders, basic 80,626,525 72,806,079 54,874,119

Weighted-average shares used to compute net loss per share attributable to common stockholders, diluted 80,626,525 72,806,079 54,874,119

Net loss per share attributable to common stockholders, basic $ (3.08) $ (2.57) $ (2.01)

Net loss per share attributable to common stockholders, diluted $ (3.08) $ (2.57) $ (2.01)

X

- Definition
Redeemable convertible preferred stock dividends - undeclared and cumulative.
+ References
No definition available.
+ Details

Name: rvmd_RedeemableConvertiblePreferredStockDividendsUndeclaredAndCumulative

Namespace Prefix: rvmd_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Weighted average number of shares issued basic and diluted.
+ References
No definition available.
+ Details

Name: rvmd_WeightedAverageNumberOfSharesIssuedBasicAndDiluted

Namespace Prefix: rvmd_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetIncomeLossAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e2646-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 86 R64.htm IDEA: XBRL DOCUMENT v3.22.4

Net Loss Per Share Attributable to Common Stockholders - Schedule of Outstanding Potentially Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares
12 Months Ended

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]

Potentially dilutive shares 9,724,754 6,681,068 5,426,621

Option to Purchase Common Stock

Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]

Potentially dilutive shares 8,164,375 6,050,938 5,118,979

Options Early Exercised Subject to Future Vesting

Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]

Potentially dilutive shares 6,918 30,378 130,793

Unvested Restricted Stock Units Of Common Stock

Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]

Potentially dilutive shares 1,175,032 423,621 85,639

Expected Shares To Be Purchased Under ESPP

Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]

Potentially dilutive shares 378,429 176,131 91,210

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=rvmd_OptionsToPurchaseCommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=rvmd_OptionsEarlyExercisedSubjectToFutureVestingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=rvmd_UnvestedRestrictedStockUnitsOfCommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=rvmd_ExpectedSharesToBePurchasedUnderESPPMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 87 rvmd-20221231_htm.xml IDEA: XBRL DOCUMENT 0001628171 us-gaap:DomesticCountryMember 2022-12-31 0001628171 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001628171 rvmd:UnderwrittenPublicOfferingMember 2021-02-28 0001628171 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001628171 rvmd:UnderwrittenPublicOfferingMember 2021-02-01 2021-02-28 0001628171 rvmd:LaboratoryEquipmentMember 2022-12-31 0001628171 us-gaap:CommonStockMember rvmd:AtTheMarketEquityOfferingMember 2021-01-01 2021-12-31 0001628171 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0001628171 us-gaap:StateAndLocalJurisdictionMember 2022-01-01 2022-12-31 0001628171 us-gaap:StateAndLocalJurisdictionMember 2022-12-31 0001628171 rvmd:TwoThousandTwentyEmployeeStockPurchasePlanMember 2022-12-31 0001628171 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001628171 us-gaap:OverAllotmentOptionMember 2022-07-31 0001628171 rvmd:SevenHundredSaginawDriveRedwoodCityCaliforniaMember rvmd:RedwoodCityCaliforniaMember us-gaap:AccountingStandardsUpdate201602Member 2020-04-01 2020-04-30 0001628171 us-gaap:FurnitureAndFixturesMember 2022-01-01 2022-12-31 0001628171 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001628171 rvmd:ThreeHundredSaginawDriveRedwoodCityCaliforniaMember rvmd:RedwoodCityCaliforniaMember us-gaap:AccountingStandardsUpdate201602Member 2020-04-30 0001628171 rvmd:LaboratoryEquipmentMember 2021-12-31 0001628171 us-gaap:AccountingStandardsUpdate201912Member 2021-09-30 0001628171 rvmd:SanofiAgreementMember 2018-07-31 0001628171 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001628171 rvmd:LetterAgreementForRmcMember rvmd:SanofiAgreementMember 2022-01-01 2022-12-31 0001628171 us-gaap:CashEquivalentsMember us-gaap:MoneyMarketFundsMember 2022-12-31 0001628171 srt:MaximumMember rvmd:LaboratoryEquipmentMember 2022-01-01 2022-12-31 0001628171 rvmd:MarketableSecuritiesMember 2022-12-31 0001628171 us-gaap:AdditionalPaidInCapitalMember rvmd:FollowOnOfferingMember 2022-01-01 2022-12-31 0001628171 us-gaap:CommonStockMember us-gaap:IPOMember 2020-01-01 2020-12-31 0001628171 rvmd:UnvestedRestrictedStockUnitsOfCommonStockMember 2021-12-31 0001628171 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001628171 rvmd:ExpectedSharesToBePurchasedUnderESPPMember 2022-01-01 2022-12-31 0001628171 us-gaap:RetainedEarningsMember 2020-12-31 0001628171 rvmd:EmployeeAndDirectorMember 2022-01-01 2022-12-31 0001628171 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001628171 rvmd:ComputerEquipmentAndSoftwareMember 2022-12-31 0001628171 stpr:MA 2022-01-01 2022-12-31 0001628171 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001628171 us-gaap:RestrictedStockUnitsRSUMember rvmd:TwoThousandTwentyEquityIncentivePlansMember 2022-01-01 2022-12-31 0001628171 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001628171 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001628171 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001628171 rvmd:SevenHundredAndThreeHundredSaginawDriveRedwoodCityCaliforniaMember rvmd:RedwoodCityCaliforniaMember us-gaap:AccountingStandardsUpdate201602Member 2021-11-01 2021-11-30 0001628171 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0001628171 rvmd:MarketableSecuritiesMember rvmd:UsAndCanadianGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001628171 us-gaap:LeaseholdImprovementsMember 2022-01-01 2022-12-31 0001628171 us-gaap:CommonStockMember rvmd:FollowOnOfferingMember 2022-01-01 2022-12-31 0001628171 rvmd:TwoThousandTwentyAndTwoThousandFourteenEquityIncentivePlanMember 2021-12-31 0001628171 rvmd:EightHundredSaginawDriveRedwoodCityCaliforniaMember rvmd:RedwoodCityCaliforniaMember 2022-01-01 2022-12-31 0001628171 us-gaap:CashEquivalentsMember 2021-12-31 0001628171 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001628171 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001628171 us-gaap:CommonStockMember rvmd:AtTheMarketEquityOfferingProgramMember 2021-01-01 2021-12-31 0001628171 us-gaap:AdditionalPaidInCapitalMember us-gaap:IPOMember 2020-01-01 2020-12-31 0001628171 us-gaap:RetainedEarningsMember 2019-12-31 0001628171 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001628171 rvmd:EmployeeAndDirectorMember 2021-01-01 2021-12-31 0001628171 rvmd:TwoThousandTwentyEmployeeStockPurchasePlanMember 2020-02-29 0001628171 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001628171 rvmd:OptionsToPurchaseCommonStockMember 2022-01-01 2022-12-31 0001628171 us-gaap:RetainedEarningsMember 2022-12-31 0001628171 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001628171 2020-02-07 2020-02-07 0001628171 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0001628171 rvmd:ExpectedSharesToBePurchasedUnderESPPMember 2020-01-01 2020-12-31 0001628171 us-gaap:CommonStockMember rvmd:AtTheMarketEquityOfferingProgramMember 2021-11-01 2021-11-30 0001628171 2022-12-31 0001628171 rvmd:AvailableForFutureIssuanceUnderTheTwoZeroTwoZeroEmployeeStockPurchasePlanMember 2022-12-31 0001628171 rvmd:UsAndCanadianGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001628171 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001628171 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001628171 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001628171 rvmd:UsAndCanadianGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001628171 rvmd:MatureInOneYearOrLessMember 2022-12-31 0001628171 2020-01-01 2020-12-31 0001628171 us-gaap:AdditionalPaidInCapitalMember rvmd:AtTheMarketEquityOfferingMember 2022-01-01 2022-12-31 0001628171 rvmd:UnvestedRestrictedStockUnitsOfCommonStockMember 2022-01-01 2022-12-31 0001628171 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001628171 us-gaap:LetterOfCreditMember 2022-12-31 0001628171 rvmd:SevenHundredSaginawDriveRedwoodCityCaliforniaMember rvmd:RedwoodCityCaliforniaMember 2022-01-01 2022-12-31 0001628171 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001628171 rvmd:TwoThousandTwentyAndTwoThousandFourteenEquityIncentivePlanMember 2022-12-31 0001628171 rvmd:TwoThousandTwentyEquityIncentivePlanMember 2022-01-01 2022-12-31 0001628171 rvmd:ComputerEquipmentAndSoftwareMember 2022-01-01 2022-12-31 0001628171 rvmd:ThreeHundredSaginawDriveRedwoodCityCaliforniaMember rvmd:RedwoodCityCaliforniaMember 2020-04-30 0001628171 rvmd:AvailableForFutureIssuanceUnderTheTwoZeroTwoZeroIncentiveAwardPlanMember 2021-12-31 0001628171 2019-12-31 0001628171 rvmd:SanofiAgreementMember 2021-12-31 0001628171 us-gaap:RetainedEarningsMember 2021-12-31 0001628171 us-gaap:AdditionalPaidInCapitalMember rvmd:FollowOnOfferingMember 2020-01-01 2020-12-31 0001628171 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001628171 us-gaap:CommonStockMember rvmd:AtTheMarketEquityOfferingMember 2022-01-01 2022-12-31 0001628171 rvmd:MarketableSecuritiesMember rvmd:UsAndCanadianGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0001628171 us-gaap:RestrictedStockUnitsRSUMember rvmd:TwoThousandTwentyEquityIncentivePlansMember 2021-01-01 2021-12-31 0001628171 rvmd:SanofiAgreementMember 2022-12-31 0001628171 rvmd:CollaborationRevenueMember 2020-01-01 2020-12-31 0001628171 rvmd:AvailableForFutureIssuanceUnderTheTwoZeroTwoZeroEmployeeStockPurchasePlanMember 2021-12-31 0001628171 rvmd:UsAndCanadianGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001628171 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001628171 rvmd:OutstandingOptionsToPurchaseCommonStockMember 2022-12-31 0001628171 rvmd:SanofiAgreementMember 2021-01-01 2021-12-31 0001628171 rvmd:AtTheMarketEquityOfferingMember 2021-01-01 2021-12-31 0001628171 rvmd:MatureAfterOneYearThroughTwoYearsMember 2022-12-31 0001628171 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001628171 us-gaap:RedeemableConvertiblePreferredStockMember 2020-01-01 2020-12-31 0001628171 us-gaap:LetterOfCreditMember 2021-12-31 0001628171 us-gaap:CommonStockMember rvmd:AtTheMarketEquityOfferingProgramMember 2022-01-01 2022-12-31 0001628171 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001628171 2022-06-30 0001628171 rvmd:EmployeeAndDirectorMember 2020-01-01 2020-12-31 0001628171 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001628171 rvmd:TwoThousandTwentyAndTwoThousandFourteenEquityIncentivePlanMember 2022-01-01 2022-12-31 0001628171 rvmd:UsAndCanadianGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001628171 us-gaap:RestrictedStockUnitsRSUMember rvmd:TwoThousandTwentyEquityIncentivePlansMember 2022-12-31 0001628171 rvmd:OptionsEarlyExercisedSubjectToFutureVestingMember 2021-01-01 2021-12-31 0001628171 us-gaap:RedeemableConvertiblePreferredStockMember 2019-12-31 0001628171 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001628171 rvmd:OptionsToPurchaseCommonStockMember 2020-01-01 2020-12-31 0001628171 rvmd:ConsultantMember 2021-01-01 2021-12-31 0001628171 rvmd:MarketableSecuritiesMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001628171 rvmd:UnvestedRestrictedStockUnitsOfCommonStockMember 2020-01-01 2020-12-31 0001628171 rvmd:MarketableSecuritiesMember us-gaap:CommercialPaperMember 2022-12-31 0001628171 rvmd:OptionsEarlyExercisedSubjectToFutureVestingMember 2022-01-01 2022-12-31 0001628171 rvmd:UnvestedRestrictedStockUnitsOfCommonStockMember 2021-01-01 2021-12-31 0001628171 us-gaap:CashEquivalentsMember us-gaap:CommercialPaperMember 2022-12-31 0001628171 rvmd:MarketableSecuritiesMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001628171 us-gaap:IPOMember 2020-01-01 2020-12-31 0001628171 us-gaap:CommonStockMember 2020-12-31 0001628171 us-gaap:CommonStockMember 2019-12-31 0001628171 rvmd:CollaborationRevenueMember 2021-01-01 2021-12-31 0001628171 2020-12-31 0001628171 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001628171 rvmd:SanofiAgreementMember 2022-01-01 2022-12-31 0001628171 rvmd:SevenHundredSaginawDriveRedwoodCityCaliforniaMember rvmd:RedwoodCityCaliforniaMember 2015-01-31 0001628171 rvmd:AvailableForFutureIssuanceUnderTheTwoZeroTwoZeroIncentiveAwardPlanMember 2022-12-31 0001628171 rvmd:TwoThousandTwentyEmployeeStockPurchasePlanMember 2022-01-01 2022-12-31 0001628171 rvmd:ConsultantMember 2020-01-01 2020-12-31 0001628171 rvmd:OptionsToPurchaseCommonStockMember 2021-01-01 2021-12-31 0001628171 srt:MinimumMember rvmd:LaboratoryEquipmentMember 2022-01-01 2022-12-31 0001628171 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001628171 2022-01-01 2022-12-31 0001628171 us-gaap:CommonStockMember rvmd:FollowOnOfferingMember 2020-01-01 2020-12-31 0001628171 rvmd:UnderwrittenPublicOfferingMember 2022-07-01 2022-07-31 0001628171 rvmd:UnvestedRestrictedStockUnitsOfCommonStockMember 2022-12-31 0001628171 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001628171 rvmd:TwoThousandTwentyEquityIncentivePlanMember 2020-02-29 2020-02-29 0001628171 stpr:MA rvmd:RestrictedCashMember 2021-12-31 0001628171 us-gaap:CashEquivalentsMember 2022-12-31 0001628171 rvmd:MarketableSecuritiesMember 2021-12-31 0001628171 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001628171 rvmd:FollowOnOfferingMember 2022-01-01 2022-12-31 0001628171 rvmd:CollaborationRevenueMember 2022-01-01 2022-12-31 0001628171 rvmd:ThreeHundredSaginawDriveRedwoodCityCaliforniaMember rvmd:RedwoodCityCaliforniaMember 2022-01-01 2022-12-31 0001628171 rvmd:UsAndCanadianGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001628171 stpr:MA rvmd:RestrictedCashMember 2022-12-31 0001628171 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001628171 srt:MinimumMember 2022-01-01 2022-12-31 0001628171 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001628171 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001628171 rvmd:OptionsEarlyExercisedSubjectToFutureVestingMember 2020-01-01 2020-12-31 0001628171 rvmd:ConsultantMember 2022-01-01 2022-12-31 0001628171 2023-02-23 0001628171 us-gaap:CashEquivalentsMember us-gaap:CommercialPaperMember 2021-12-31 0001628171 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001628171 rvmd:RedwoodCityCaliforniaMember 2022-01-01 2022-12-31 0001628171 us-gaap:ConstructionInProgressMember 2021-12-31 0001628171 rvmd:RedwoodCityCaliforniaMember us-gaap:AccountingStandardsUpdate201602Member 2021-11-30 0001628171 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001628171 us-gaap:AdditionalPaidInCapitalMember rvmd:FollowOnOfferingMember 2021-01-01 2021-12-31 0001628171 us-gaap:AdditionalPaidInCapitalMember rvmd:AtTheMarketEquityOfferingMember 2021-01-01 2021-12-31 0001628171 rvmd:TwoThousandTwentyAndTwoThousandFourteenEquityIncentivePlanMember 2021-01-01 2021-12-31 0001628171 us-gaap:CommonStockMember rvmd:FollowOnOfferingMember 2021-01-01 2021-12-31 0001628171 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001628171 us-gaap:RestrictedStockUnitsRSUMember rvmd:TwoThousandTwentyEquityIncentivePlansMember 2021-12-31 0001628171 us-gaap:IPOMember 2020-02-29 0001628171 2021-01-01 2021-12-31 0001628171 us-gaap:CashEquivalentsMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001628171 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001628171 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001628171 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0001628171 rvmd:SanofiAgreementMember 2020-01-01 2020-12-31 0001628171 rvmd:OutstandingOptionsToPurchaseCommonStockMember 2021-12-31 0001628171 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001628171 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001628171 stpr:MA 2018-10-31 0001628171 us-gaap:CommonStockMember 2022-12-31 0001628171 rvmd:FollowOnOfferingMember 2021-01-01 2021-12-31 0001628171 srt:MaximumMember rvmd:ConsultantMember 2020-01-01 2020-12-31 0001628171 srt:MinimumMember rvmd:ConsultantMember 2020-01-01 2020-12-31 0001628171 rvmd:MarketableSecuritiesMember us-gaap:CommercialPaperMember 2021-12-31 0001628171 2021-12-31 0001628171 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001628171 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-12-31 0001628171 rvmd:RedwoodCityCaliforniaMember 2021-11-30 0001628171 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0001628171 rvmd:RedwoodCityCaliforniaMember rvmd:RestrictedCashMember 2021-12-31 0001628171 rvmd:UnderwrittenPublicOfferingMember 2022-07-31 0001628171 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001628171 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001628171 rvmd:FollowOnOfferingMember 2020-01-01 2020-12-31 0001628171 rvmd:ExpectedSharesToBePurchasedUnderESPPMember 2021-01-01 2021-12-31 0001628171 us-gaap:CashEquivalentsMember us-gaap:MoneyMarketFundsMember 2021-12-31 0001628171 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001628171 rvmd:ComputerEquipmentAndSoftwareMember 2021-12-31 0001628171 us-gaap:ConstructionInProgressMember 2022-12-31 0001628171 srt:MaximumMember 2022-01-01 2022-12-31 0001628171 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001628171 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001628171 rvmd:RedwoodCityCaliforniaMember rvmd:RestrictedCashMember 2022-12-31 0001628171 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001628171 us-gaap:DomesticCountryMember 2022-01-01 2022-12-31 0001628171 us-gaap:OverAllotmentOptionMember 2021-02-28 0001628171 us-gaap:CommonStockMember 2021-12-31 pure rvmd:Segment rvmd:Vote utr:sqft shares iso4217:USD shares iso4217:USD 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 FY false P3Y 0001628171 --12-31 0.2055 10-K true 2022-12-31 2022 false 001-39219 Revolution Medicines, Inc. DE 47-2029180 700 Saginaw Drive Redwood City CA 94063 650 481-6801 Common Stock $0.0001 Par Value per Share RVMD NASDAQ Yes No Yes Yes Large Accelerated Filer false false true false 1231000000 90491696 Portions of the Registrant’s definitive Proxy Statement relating to the Registrant’s 2023 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. The proxy statement will be filed with the Securities and Exchange Commission within 120 days of the Registrant’s fiscal year ended December 31, 2022. 238 PricewaterhouseCoopers LLP San Jose, California 161412000 108497000 483531000 468557000 4673000 5929000 10569000 6790000 660185000 589773000 18659000 11544000 55077000 59692000 58807000 59876000 14608000 14608000 1737000 1737000 2857000 758000 811930000 737988000 21306000 14057000 29446000 27721000 6773000 6214000 4459000 12358000 61984000 60350000 0 6573000 7025000 7444000 57432000 60419000 301000 634000 126742000 135420000 0.0001 0.0001 10000000 10000000 0 0 0 0 0 0 0.0001 0.0001 300000000 300000000 90411912 90411912 74142619 74142619 9000 8000 1388300000 1055572000 -1780000 -376000 -701341000 -452636000 685188000 602568000 811930000 737988000 35380000 29390000 42983000 35380000 29390000 42983000 253073000 186948000 132252000 40586000 30450000 21428000 293659000 217398000 153680000 -258279000 -188008000 -110697000 9154000 929000 2238000 0 12000 71000 9154000 917000 2167000 -249125000 -187091000 -108530000 -420000 -0 -371000 -248705000 -187091000 -108159000 0 0 2219000 -248705000 -187091000 -110378000 -3.08 -3.08 -2.57 -2.57 -2.01 -2.01 80626525 80626525 72806079 72806079 54874119 54874119 -248705000 -187091000 -108159000 -1404000 -492000 42000 -250109000 -187583000 -108117000 39600423 305109000 3292124 4738000 74000 -157386000 -152574000 -39600423 -305109000 39600423 4000 305105000 305109000 23003000 16100000 2000 250695000 250697000 11633000 6900000 1000 167766000 167767000 694441 1877000 1877000 29237 832000 832000 1681 199000 199000 18158 8886000 8886000 42000 42000 -108159000 -108159000 66599748 7000 740098000 116000 -265545000 474676000 388695 1487000 1487000 75991 1875000 1875000 78010 148000 148000 5793 18855000 6666666 1000 281144000 281145000 339302 10096000 10096000 20724000 20724000 -492000 -492000 -187091000 -187091000 74142619 8000 1055572000 -376000 -452636000 602568000 249544 1481000 1481000 16374000 13225000 1000 248125000 248126000 278848 130327 1864000 1864000 2385846 49919000 49919000 272 143000 143000 31196000 -1404000 -1404000 -248705000 -248705000 90411912 9000 1388300000 -1780000 -701341000 685188000 -248705000 -187091000 -108159000 -19000 -119000 -0 1069000 1069000 1068000 31196000 20724000 8886000 3972000 3083000 2611000 3078000 -3012000 -968000 4615000 3180000 2866000 -1256000 -464000 -2344000 3779000 -198000 1924000 7288000 2239000 305000 1502000 8720000 4855000 -14472000 -1661000 -11259000 -2428000 -1468000 -2565000 419000 0 375000 2247000 -81000 -139000 -190000 151000 176000 -224401000 -147180000 -100064000 612769000 671335000 544133000 599469000 526754000 309828000 0 8992000 3005000 10816000 6528000 2933000 -24116000 -142117000 -234233000 248126000 281145000 420067000 49919000 10096000 0 1481000 1487000 1877000 1864000 1875000 832000 -42000 424000 0 301432000 294179000 422776000 52915000 4882000 88479000 110234000 105352000 16873000 163149000 110234000 105352000 161412000 108497000 104268000 1737000 1737000 1084000 163149000 110234000 105352000 143000 149000 199000 1419000 1129000 1813000 82000 0 0 0 35437000 21188000 2000 110000 0 <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.<div style="display:inline;">Organization</div></div>Revolution Medicines, Inc. (the Company) is a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers. The Company was founded in October 2014 and is headquartered in Redwood City, California.LiquidityThe Company has incurred net operating losses in each year since inception. As of December 31, 2022, the Company had an accumulated deficit of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">701.3 million. Management believes that its existing cash, cash equivalents and marketable securities will enable the Company to fund its planned operations for at least 12 months following the issuance date of these consolidated financial statements. The Company has been able to fund its operations through the issuance and sale of common stock and redeemable convertible preferred stock in addition to upfront payments and research and development cost reimbursement received under the Company’s collaboration agreement with Genzyme Corporation, an affiliate of Sanofi. Future capital requirements will depend on many factors, including the timing and extent of spending on research and development. There can be no assurance that, in the event the Company requires additional financing, such financing will be available at terms acceptable to the Company, if at all. Failure to generate sufficient cash flows from operations, raise additional capital and reduce discretionary spending should additional capital not become available could have a material adverse effect on the Company’s ability to achieve its business objectives.Public offeringsIn February 2021, the Company issued and sold <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">6,666,666 shares of its common stock in an underwritten public offering at a price of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">45.00 per share (including the exercise in full by the underwriters of their option to purchase an additional <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">869,565 shares of its common stock) for net proceeds of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">281.1 million, after deducting underwriting discounts and commissions of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">18.0 million and expenses of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.9 million.In November 2021, the Company entered into a sales agreement with Cowen and Company, LLC (Cowen) to sell shares of its common stock, from time to time, with aggregate gross proceeds of up to $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">250 million, through an at-the-market equity offering program (ATM). During the year ended December 31, 2021, the Company sold an aggregate of <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">339,302 shares of common stock under the ATM resulting in gross proceeds of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">10.4 million. After deducting commissions and expenses of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.3 million, net proceeds to the Company for the year ended December 31, 2021 were $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">10.1 million. During the year ended December 31, 2022, the Company sold an aggregate of <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2,385,846 shares of common stock under the ATM resulting in gross proceeds of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">51.3 million. After deducting commissions and expenses of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.4 million, net proceeds to the Company for the year ended December 31, 2022 were $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">49.9 million.In July 2022, the Company issued and sold <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">13,225,000 shares of its common stock in an underwritten public offering (including the exercise in full by the underwriters of their option to purchase an additional <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,725,000 shares of the Company’s common stock) at a price to the public of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">20.00 per share, for net proceeds of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">248.1 million, after deducting underwriting discounts and commissions of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">15.9 million and expenses of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.5 million. -701300000 6666666 45.00 869565 281100000 18000000.0 900000 250000000 339302 10400000 300000 10100000 2385846 51300000 1400000 49900000 13225000 1725000 20.00 248100000 15900000 500000 <div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.<div style="display:inline;">Summary of significant accounting policies</div></div><div style="font-size:12.0pt;font-family:"Times New Roman", serif;">Basis of presentationThe consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (GAAP) and applicable rules of the Securities and Exchange Commission (SEC) regarding financial reporting and, in the opinion of management, include all normal and recurring adjustments which are necessary to state fairly the Company’s financial position and results of operations for the reported periods. The consolidated financial statements for the years ended December 31, 2022, 2021 and 2020 include the accounts of the Company and its wholly owned subsidiary, Warp Drive Bio, Inc. (Warp Drive). All intercompany balances and transactions have been eliminated in consolidation. The functional and reporting currency of the Company and its subsidiary is the U.S. dollar.</div><div style="font-size:10.0pt;font-family:"Times New Roman", serif;">Reverse stock splitOn February 7, 2020, the Company amended and restated its amended and restated certificate of incorporation to effect a 1-for-4.8661 reverse stock split of the Company’s common stock and redeemable convertible preferred stock. The par value and authorized shares of the common stock and redeemable convertible preferred stock were not adjusted as a result of the reverse stock split. All issued and outstanding common stock, options to purchase common stock and per share amounts contained in the financial statements have been retroactively adjusted to give effect to the reverse stock split for all periods presented.</div><div style="font-size:10.0pt;font-family:"Times New Roman", serif;">Use of estimatesThe preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, clinical accruals, valuation of in-process research and development and developed technologies, income taxes, useful lives of property and equipment and intangible assets, impairment of goodwill and intangibles, the incremental borrowing rate for determining operating lease assets and liabilities, and stock-based compensation. The extent to which the COVID-19 pandemic may directly or indirectly impact the Company’s business, financial condition and results of operations is highly uncertain and subject to change. The Company considered the potential impact of the COVID-19 pandemic on its estimates and assumptions and there was not a material impact to the Company’s consolidated financial statements as of and for the twelve months ended December 31, 2022. Actual results could materially differ from the Company’s estimates, and there may be changes to the estimates in future periods.</div><div style="font-size:10.0pt;font-family:"Times New Roman", serif;">Cash and cash equivalentsThe Company considers all highly liquid investments purchased with original maturities of three months or less at the date of purchase to be cash equivalents. As of December 31, 2022 and 2021, cash equivalents consist of amounts invested in money market funds, commercial paper and corporate bonds with original maturities of three months or less at the date of purchase.</div><div style="font-size:10.0pt;font-family:"Times New Roman", serif;">Marketable securitiesInvestments in marketable securities primarily consist of U.S. government debt securities, U.S. government agency bonds, commercial paper, Canadian government securities and corporate bonds. The Company has classified its marketable securities as available-for-sale and may sell these securities prior to their stated maturities. The Company views these marketable securities as available to support current operations and classifies marketable securities with maturities beyond 12 months as current assets. The Company’s investments in marketable securities are carried at estimated fair value, which is derived from independent pricing sources based on quoted prices in active markets for similar securities. Unrealized gains and losses are reported as a component of accumulated other comprehensive loss. The amortized cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the consolidated statements of operations. Realized gains and losses are included in interest income on the consolidated statements of operations.The Company periodically evaluates its investments to assess whether those with unrealized loss positions are other than temporarily impaired. The Company considers various factors in determining whether to recognize an impairment charge. If the Company determines that the decline in an investment’s fair value is other-than-temporary, the difference is recognized as an impairment loss in the consolidated statements of operations. As of December 31, 2022, <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">no other-than-temporary-impairment has been recorded.</div><div style="font-size:10.0pt;font-family:"Times New Roman", serif;">Restricted cash As of December 31, 2022 and 2021, the Company had $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.7 million and $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.7 million, respectively, of noncurrent restricted cash related to Company issued letters of credit in connection with leases. These amounts are held in separate bank accounts to support letter of credit agreements for the leases.</div><div style="font-size:10.0pt;font-family:"Times New Roman", serif;">Concentration of credit risk and other risks and uncertaintiesFinancial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents and marketable securities. The Company’s cash is held by two financial institutions in the United States, which management believes to be of high credit quality. The Company invests in money market funds, U.S. government debt securities, U.S. government agency bonds, commercial paper and corporate bonds. The Company has not experienced any losses on its deposits of cash and cash equivalents.The Company is subject to credit risk as its receivable and collaboration revenue are entirely related to its collaboration agreement with Sanofi. For more information, see Note 8, “Sanofi collaboration agreement.”The Company’s clinical trial sites may be affected by the COVID-19 outbreak due to prioritization of hospital resources toward the COVID-19 outbreak, travel or quarantine restrictions imposed by governments, and the inability to access sites for initiation and patient monitoring and enrollment. As a result, patient screening, new patient enrollment, monitoring and data collection may be affected or delayed. The Company is aware that several clinical sites involved in its clinical studies temporarily stopped or delayed enrolling new patients, with exemptions if appropriate, and it is possible that these or other clinical sites may be similarly affected in the future. These developments may delay the Company’s clinical trial timelines. Some of the Company’s third-party manufacturers which it uses for the supply of materials for product candidates or other materials necessary to manufacture product to conduct preclinical tests and clinical trials and contract research organizations may be impacted by COVID-19, and should they experience disruptions, such as temporary closures or suspension of services, the Company would likely experience delays in advancing clinical trials.</div><div style="font-size:10.0pt;font-family:"Times New Roman", serif;">Fair value measurementThe carrying amounts of the Company’s certain financial instruments, including cash equivalents, accounts payable and accrued expenses and other current liabilities approximate fair value due to their relatively short maturities and market interest rates, if applicable. For more information, refer to Note 4 regarding the fair value of the Company’s available-for-sale securities.Assets and liabilities recorded at fair value on a recurring basis in the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:Level 1—Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;Level 2—Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active; andLevel 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</div><div style="font-size:10.0pt;font-family:"Times New Roman", serif;">Property and equipment, netProperty and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed on a straight-line basis over the estimated useful lives of the related assets, which is generally three to five years. Leasehold improvements are amortized using the straight-line method over the shorter of the assets’ estimated useful lives or the remaining term of the lease. Maintenance and repairs are charged to operations as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is reflected in the consolidated statement of operations.<div style="font-size:12.0pt;font-family:"Times New Roman", serif;">Useful lives of property and equipment are as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:37.787%;"/> <td style="width:1.176%;"/> <td style="width:61.037%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;">Property and equipment</td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;">Estimated useful life</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Laboratory equipment</td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">4-5 years</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Leasehold improvements</td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Lesser of estimated useful life or remaining lease term</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Computer equipment and software</td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">3 years</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Furniture and fixtures</td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">5 years</td> </tr> </table> </div></div><div style="font-size:10.0pt;font-family:"Times New Roman", serif;">LeasesThe Company determines if an arrangement is, or contains, a lease at inception and then classifies the lease as operating or financing based on the underlying terms and conditions of the contract. Leases with terms greater than one year are initially recognized on the balance sheet as right-of-use assets and lease liabilities based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the rate incurred to borrow, on a collateralized basis, an amount equal to the lease payments over a similar term and in a similar economic environment of the applicable country or region. Variable lease payments are excluded from the right-of-use assets and operating lease liabilities and are recognized in the period in which the obligation for those payments is incurred. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets.</div><div style="font-size:10.0pt;font-family:"Times New Roman", serif;">Impairment of long-lived assetsLong-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Recoverability is measured by comparison of the carrying amounts of the asset group to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable, and the carrying amount exceeds the projected discounted future cash flows arising from these assets. There were <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">no impairments of long-lived assets for any of the periods presented.</div><div style="font-size:10.0pt;font-family:"Times New Roman", serif;">Acquired intangible assetsIndefinite-lived intangible assets represent the estimated fair value assigned to in-process research and development (IPR&D) acquired in a business combination. The Company reviews indefinite-lived intangible assets for impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying value of the assets might not be recoverable. If the carrying value of an indefinite-lived intangible asset exceeds its fair value, then it is written down to its adjusted fair value. As of December 31, 2022, there have been <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">no such impairments. For IPR&D, if a product candidate derived from the indefinite-lived intangible asset is developed and commercialized, the useful life will be determined, and the carrying value will be amortized prospectively over that estimated useful life. Alternatively, if a product candidate is abandoned, the carrying value of the intangible asset will be charged to research and development expenses in the consolidated statements of operations.Finite-lived intangible assets acquired in a business combination are recognized separately from goodwill and are initially recognized at their fair value at the acquisition date and are carried at cost less accumulated amortization and impairment. Amortization is computed using the straight-line method over the estimated useful lives of the respective finite-lived intangible assets and is included in research and development expenses in the consolidated statement of operations. Intangible assets are reviewed for impairment at least annually or more frequently if indicators of potential impairment exist. As of December 31, 2022, <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">no such impairment has been recorded.</div><div style="font-size:10.0pt;font-family:"Times New Roman", serif;">Goodwill Goodwill represents the excess of the purchase price over the estimated fair value of the net tangible and intangible assets acquired in a business combination. The Company reviews goodwill for impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying value of goodwill may not be recoverable. Goodwill is tested for impairment at the reporting unit level by first assessing the qualitative factors to determine whether it is more likely than not that the fair value of the Company’s single reporting unit is less than its carrying amount. Qualitative indicators assessed include consideration of macroeconomic, industry and market conditions, the Company’s overall financial performance and personnel or strategy changes. Based on the qualitative assessment, if it is determined that it is more likely than not that its fair value is less than its carrying amount, the fair value of the Company’s single reporting unit is compared to its carrying value. Any excess of the goodwill carrying amount over the fair value is recognized as an impairment loss, and the carrying value of goodwill is written down to fair value. As of December 31, 2022, <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">no goodwill impairment has been identified.</div><div style="font-size:10.0pt;font-family:"Times New Roman", serif;">Redeemable convertible preferred stockThe Company records all shares of redeemable convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. The redeemable convertible preferred stock is recorded outside of permanent equity because while it is not mandatorily redeemable, in the event of certain events considered not solely within the Company’s control, such as a merger, acquisition or sale of all or substantially all of the Company’s assets (each, a deemed liquidation event), the redeemable convertible preferred stock would have become redeemable at the option of the holders of at least a majority of the then outstanding such shares. The Company did not adjust the carrying values of the redeemable convertible preferred stock to the liquidation preferences of such shares because it was uncertain whether or when a deemed liquidation event would occur that would obligate the Company to pay the liquidation preferences to holders of shares of redeemable convertible preferred stock.</div><div style="font-size:10.0pt;font-family:"Times New Roman", serif;">Revenue recognitionThe Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.The Company enters into collaboration agreements under which it may obtain upfront license fees, research and development funding, and development, regulatory and commercial milestone payments and royalty payments. The Company’s performance obligations under these arrangements may include licenses of intellectual property, sales and distribution rights, research and development services, delivery of manufactured product and/or participation on joint steering committees.Licenses of intellectual property: If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from upfront license fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring proportional performance for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of proportional performance each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.Research, development and regulatory milestone payments: At the inception of each arrangement that includes research, development, or regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. The Company uses the most likely amount method for research, development and regulatory milestone payments. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.Sales-based milestones and royalties: For arrangements that include sales-based milestone or royalty payments based on the level of sales, and in which the license is deemed to be the predominant item to which the sales-based milestone or royalties relate to, the Company recognizes revenue in the period in which the sales-based milestone is achieved and in the period in which the sales associated with the royalty occur. To date, the Company has not recognized any sales-based milestone or royalty revenue resulting from its collaboration arrangements.Deferred revenue represents amounts received by the Company for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. The current portion of deferred revenue represents the amount to be recognized within one year from the balance sheet date based on the estimated performance period of the underlying performance obligation. The noncurrent portion of deferred revenue represents amounts to be recognized after one year through the end of the performance period of the performance obligation.</div><div style="font-size:10.0pt;font-family:"Times New Roman", serif;">Research and development expendituresResearch and development expenses consist of costs incurred for the Company’s own and for collaborative research and development activities. Research and development costs are expensed as incurred. Research and development costs consist of salaries and benefits, including associated stock-based compensation, and laboratory supplies and facility costs, as well as fees paid to other entities that conduct certain research and development activities on the Company’s behalf. The Company estimates preclinical studies and clinical trial expenses based on the services performed pursuant to contracts with research institutions, contract research organizations and clinical manufacturing organizations that conduct and manage preclinical studies and clinical trials on the Company’s behalf based on actual time and expenses incurred by them. Further, the Company accrues expenses related to clinical trials based on the level of patient activity according to the related agreement. The Company monitors patient enrollment levels and related activity to the extent reasonably possible and adjusts estimates accordingly.</div><div style="font-size:10.0pt;font-family:"Times New Roman", serif;">Stock-based compensationThe Company measures its stock-based awards granted to employees and directors based on the estimated fair values of the awards and recognizes the compensation on a straight-line basis over the requisite service period. The fair value of options issued under the employee stock purchase plan is calculated using the Black-Scholes option-pricing model. Restricted stock units are valued based on the closing price of the Company’s common stock on the date of grant.</div><div style="font-size:10.0pt;font-family:"Times New Roman", serif;">Comprehensive lossFor the years ended December 31, 2022, 2021 and 2020, other comprehensive loss includes net unrealized gains or losses on marketable securities.</div><div style="font-size:10.0pt;font-family:"Times New Roman", serif;">Income taxesIncome taxes are accounted for under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Management makes an assessment of the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company’s historical operating performance and the recorded cumulative net losses in prior fiscal periods, the net deferred tax assets have been fully offset by a valuation allowance.The Company recognizes uncertain income tax positions at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Changes in recognition or measurement are reflected in the period in which judgment occurs. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of interest expense.</div><div style="font-size:10.0pt;font-family:"Times New Roman", serif;">Net loss per share attributable to common stockholdersBasic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock, stock options, common stock subject to repurchase related to unvested restricted stock awards and early exercise of stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities as the redeemable convertible preferred stock is considered a participating security because it participates in dividends with common stock. The Company also considers the shares issued upon the early exercise of stock options subject to repurchase to be participating securities because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. The holders of all series of redeemable convertible preferred stock and the holders of early exercised shares subject to repurchase do not have a contractual obligation to share in the Company’s losses. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for all periods presented, diluted net loss per share is the same as basic net loss per share for those periods.</div><div style="font-size:10.0pt;font-family:"Times New Roman", serif;">Deferred offering costsThe Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders’ deficit (equity) as a reduction of additional paid-in capital generated as a result of the equity financing. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations. As of December 31, 2022 and 2021, $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.6 million and $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.5 million of deferred offering costs, respectively, were capitalized in other noncurrent assets on the consolidated balance sheets.</div><div style="font-size:10.0pt;font-family:"Times New Roman", serif;">Segment reportingThe Company has <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">one operating and reportable segment. The Company’s chief operating decision maker, its Chief Executive Officer, manages the Company’s operations on a consolidated basis for the purposes of allocating resources and evaluating financial performance. All of the Company’s long-lived assets are located in the United States.</div><div style="font-size:10.0pt;font-family:"Times New Roman", serif;">401(k) retirement plansThe Company maintains a 401(k) retirement plan for its employees. The Company is responsible for administrative costs of the 401(k) plan. The Company may, at its discretion, make matching or profit-sharing contributions to the 401(k) plan. For the years ended December 31, 2022, 2021 and 2020, the Company made $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.3 million, $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.9 million and $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.2 million matching contributions, respectively, under the plan.</div><div style="font-size:10.0pt;font-family:"Times New Roman", serif;">Recent accounting pronouncementsFrom time to time, new accounting pronouncements are issued by the FASB, under its ASC or other standard setting bodies, and adopted by the Company as of the specified effective date, unless otherwise discussed below.Recently adopted accounting pronouncementsIn October 2020, the FASB issued ASU 2020-08, Codification Improvements to Subtopic 310-20, Receivables-Nonrefundable Fees and Other Costs (ASU 2020-08). ASU 2020-08 clarifies that an entity should reevaluate whether a callable debt security is within the scope of ASC paragraph 310-20-35-33 for each reporting period. The guidance is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021. Early application is not permitted. All entities should apply ASU 2020-08 on a prospective basis as of the beginning of the period of adoption for existing or newly purchased callable debt securities. The Company adopted the standard for the fiscal year beginning on January 1, 2022 and concluded that adoption of the standard did not have a material impact on its consolidated financial statements.In October 2020, FASB issued ASU 2020-10, Codification Improvements (ASU 2020-10). ASU 2020-10 updates various codification topics by clarifying or improving disclosure requirements to align with the SEC’s regulations. The amendments are effective for the Company for fiscal years beginning after December 15, 2021, including interim period within those fiscal years. Early adoption is permitted. Adoption shall be applied retrospectively. The Company adopted the standard for the fiscal year beginning on January 1, 2022 and concluded that adoption of the standard did not have a material impact on its consolidated financial statements.</div> Basis of presentationThe consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (GAAP) and applicable rules of the Securities and Exchange Commission (SEC) regarding financial reporting and, in the opinion of management, include all normal and recurring adjustments which are necessary to state fairly the Company’s financial position and results of operations for the reported periods. The consolidated financial statements for the years ended December 31, 2022, 2021 and 2020 include the accounts of the Company and its wholly owned subsidiary, Warp Drive Bio, Inc. (Warp Drive). All intercompany balances and transactions have been eliminated in consolidation. The functional and reporting currency of the Company and its subsidiary is the U.S. dollar. Reverse stock splitOn February 7, 2020, the Company amended and restated its amended and restated certificate of incorporation to effect a 1-for-4.8661 reverse stock split of the Company’s common stock and redeemable convertible preferred stock. The par value and authorized shares of the common stock and redeemable convertible preferred stock were not adjusted as a result of the reverse stock split. All issued and outstanding common stock, options to purchase common stock and per share amounts contained in the financial statements have been retroactively adjusted to give effect to the reverse stock split for all periods presented. 1-for-4.8661 Use of estimatesThe preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, clinical accruals, valuation of in-process research and development and developed technologies, income taxes, useful lives of property and equipment and intangible assets, impairment of goodwill and intangibles, the incremental borrowing rate for determining operating lease assets and liabilities, and stock-based compensation. The extent to which the COVID-19 pandemic may directly or indirectly impact the Company’s business, financial condition and results of operations is highly uncertain and subject to change. The Company considered the potential impact of the COVID-19 pandemic on its estimates and assumptions and there was not a material impact to the Company’s consolidated financial statements as of and for the twelve months ended December 31, 2022. Actual results could materially differ from the Company’s estimates, and there may be changes to the estimates in future periods. Cash and cash equivalentsThe Company considers all highly liquid investments purchased with original maturities of three months or less at the date of purchase to be cash equivalents. As of December 31, 2022 and 2021, cash equivalents consist of amounts invested in money market funds, commercial paper and corporate bonds with original maturities of three months or less at the date of purchase. Marketable securitiesInvestments in marketable securities primarily consist of U.S. government debt securities, U.S. government agency bonds, commercial paper, Canadian government securities and corporate bonds. The Company has classified its marketable securities as available-for-sale and may sell these securities prior to their stated maturities. The Company views these marketable securities as available to support current operations and classifies marketable securities with maturities beyond 12 months as current assets. The Company’s investments in marketable securities are carried at estimated fair value, which is derived from independent pricing sources based on quoted prices in active markets for similar securities. Unrealized gains and losses are reported as a component of accumulated other comprehensive loss. The amortized cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the consolidated statements of operations. Realized gains and losses are included in interest income on the consolidated statements of operations.The Company periodically evaluates its investments to assess whether those with unrealized loss positions are other than temporarily impaired. The Company considers various factors in determining whether to recognize an impairment charge. If the Company determines that the decline in an investment’s fair value is other-than-temporary, the difference is recognized as an impairment loss in the consolidated statements of operations. As of December 31, 2022, <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">no other-than-temporary-impairment has been recorded. 0 Restricted cash As of December 31, 2022 and 2021, the Company had $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.7 million and $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.7 million, respectively, of noncurrent restricted cash related to Company issued letters of credit in connection with leases. These amounts are held in separate bank accounts to support letter of credit agreements for the leases. 1700000 1700000 Concentration of credit risk and other risks and uncertaintiesFinancial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents and marketable securities. The Company’s cash is held by two financial institutions in the United States, which management believes to be of high credit quality. The Company invests in money market funds, U.S. government debt securities, U.S. government agency bonds, commercial paper and corporate bonds. The Company has not experienced any losses on its deposits of cash and cash equivalents.The Company is subject to credit risk as its receivable and collaboration revenue are entirely related to its collaboration agreement with Sanofi. For more information, see Note 8, “Sanofi collaboration agreement.”The Company’s clinical trial sites may be affected by the COVID-19 outbreak due to prioritization of hospital resources toward the COVID-19 outbreak, travel or quarantine restrictions imposed by governments, and the inability to access sites for initiation and patient monitoring and enrollment. As a result, patient screening, new patient enrollment, monitoring and data collection may be affected or delayed. The Company is aware that several clinical sites involved in its clinical studies temporarily stopped or delayed enrolling new patients, with exemptions if appropriate, and it is possible that these or other clinical sites may be similarly affected in the future. These developments may delay the Company’s clinical trial timelines. Some of the Company’s third-party manufacturers which it uses for the supply of materials for product candidates or other materials necessary to manufacture product to conduct preclinical tests and clinical trials and contract research organizations may be impacted by COVID-19, and should they experience disruptions, such as temporary closures or suspension of services, the Company would likely experience delays in advancing clinical trials. Fair value measurementThe carrying amounts of the Company’s certain financial instruments, including cash equivalents, accounts payable and accrued expenses and other current liabilities approximate fair value due to their relatively short maturities and market interest rates, if applicable. For more information, refer to Note 4 regarding the fair value of the Company’s available-for-sale securities.Assets and liabilities recorded at fair value on a recurring basis in the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:Level 1—Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;Level 2—Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active; andLevel 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Property and equipment, netProperty and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed on a straight-line basis over the estimated useful lives of the related assets, which is generally three to five years. Leasehold improvements are amortized using the straight-line method over the shorter of the assets’ estimated useful lives or the remaining term of the lease. Maintenance and repairs are charged to operations as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is reflected in the consolidated statement of operations.<div style="font-size:12.0pt;font-family:"Times New Roman", serif;">Useful lives of property and equipment are as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:37.787%;"/> <td style="width:1.176%;"/> <td style="width:61.037%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;">Property and equipment</td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;">Estimated useful life</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Laboratory equipment</td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">4-5 years</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Leasehold improvements</td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Lesser of estimated useful life or remaining lease term</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Computer equipment and software</td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">3 years</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Furniture and fixtures</td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">5 years</td> </tr> </table> </div> P5Y Useful lives of property and equipment are as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:37.787%;"/> <td style="width:1.176%;"/> <td style="width:61.037%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;">Property and equipment</td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;">Estimated useful life</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Laboratory equipment</td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">4-5 years</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Leasehold improvements</td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Lesser of estimated useful life or remaining lease term</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Computer equipment and software</td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">3 years</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Furniture and fixtures</td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">5 years</td> </tr> </table> P4Y P5Y Lesser of estimated useful life or remaining lease term P3Y P5Y LeasesThe Company determines if an arrangement is, or contains, a lease at inception and then classifies the lease as operating or financing based on the underlying terms and conditions of the contract. Leases with terms greater than one year are initially recognized on the balance sheet as right-of-use assets and lease liabilities based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the rate incurred to borrow, on a collateralized basis, an amount equal to the lease payments over a similar term and in a similar economic environment of the applicable country or region. Variable lease payments are excluded from the right-of-use assets and operating lease liabilities and are recognized in the period in which the obligation for those payments is incurred. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets. Impairment of long-lived assetsLong-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Recoverability is measured by comparison of the carrying amounts of the asset group to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable, and the carrying amount exceeds the projected discounted future cash flows arising from these assets. There were <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">no impairments of long-lived assets for any of the periods presented. 0 0 0 Acquired intangible assetsIndefinite-lived intangible assets represent the estimated fair value assigned to in-process research and development (IPR&D) acquired in a business combination. The Company reviews indefinite-lived intangible assets for impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying value of the assets might not be recoverable. If the carrying value of an indefinite-lived intangible asset exceeds its fair value, then it is written down to its adjusted fair value. As of December 31, 2022, there have been <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">no such impairments. For IPR&D, if a product candidate derived from the indefinite-lived intangible asset is developed and commercialized, the useful life will be determined, and the carrying value will be amortized prospectively over that estimated useful life. Alternatively, if a product candidate is abandoned, the carrying value of the intangible asset will be charged to research and development expenses in the consolidated statements of operations.Finite-lived intangible assets acquired in a business combination are recognized separately from goodwill and are initially recognized at their fair value at the acquisition date and are carried at cost less accumulated amortization and impairment. Amortization is computed using the straight-line method over the estimated useful lives of the respective finite-lived intangible assets and is included in research and development expenses in the consolidated statement of operations. Intangible assets are reviewed for impairment at least annually or more frequently if indicators of potential impairment exist. As of December 31, 2022, <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">no such impairment has been recorded. 0 0 Goodwill Goodwill represents the excess of the purchase price over the estimated fair value of the net tangible and intangible assets acquired in a business combination. The Company reviews goodwill for impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying value of goodwill may not be recoverable. Goodwill is tested for impairment at the reporting unit level by first assessing the qualitative factors to determine whether it is more likely than not that the fair value of the Company’s single reporting unit is less than its carrying amount. Qualitative indicators assessed include consideration of macroeconomic, industry and market conditions, the Company’s overall financial performance and personnel or strategy changes. Based on the qualitative assessment, if it is determined that it is more likely than not that its fair value is less than its carrying amount, the fair value of the Company’s single reporting unit is compared to its carrying value. Any excess of the goodwill carrying amount over the fair value is recognized as an impairment loss, and the carrying value of goodwill is written down to fair value. As of December 31, 2022, <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">no goodwill impairment has been identified. 0 Redeemable convertible preferred stockThe Company records all shares of redeemable convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. The redeemable convertible preferred stock is recorded outside of permanent equity because while it is not mandatorily redeemable, in the event of certain events considered not solely within the Company’s control, such as a merger, acquisition or sale of all or substantially all of the Company’s assets (each, a deemed liquidation event), the redeemable convertible preferred stock would have become redeemable at the option of the holders of at least a majority of the then outstanding such shares. The Company did not adjust the carrying values of the redeemable convertible preferred stock to the liquidation preferences of such shares because it was uncertain whether or when a deemed liquidation event would occur that would obligate the Company to pay the liquidation preferences to holders of shares of redeemable convertible preferred stock. Revenue recognitionThe Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.The Company enters into collaboration agreements under which it may obtain upfront license fees, research and development funding, and development, regulatory and commercial milestone payments and royalty payments. The Company’s performance obligations under these arrangements may include licenses of intellectual property, sales and distribution rights, research and development services, delivery of manufactured product and/or participation on joint steering committees.Licenses of intellectual property: If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from upfront license fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring proportional performance for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of proportional performance each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.Research, development and regulatory milestone payments: At the inception of each arrangement that includes research, development, or regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. The Company uses the most likely amount method for research, development and regulatory milestone payments. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.Sales-based milestones and royalties: For arrangements that include sales-based milestone or royalty payments based on the level of sales, and in which the license is deemed to be the predominant item to which the sales-based milestone or royalties relate to, the Company recognizes revenue in the period in which the sales-based milestone is achieved and in the period in which the sales associated with the royalty occur. To date, the Company has not recognized any sales-based milestone or royalty revenue resulting from its collaboration arrangements.Deferred revenue represents amounts received by the Company for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. The current portion of deferred revenue represents the amount to be recognized within one year from the balance sheet date based on the estimated performance period of the underlying performance obligation. The noncurrent portion of deferred revenue represents amounts to be recognized after one year through the end of the performance period of the performance obligation. Research and development expendituresResearch and development expenses consist of costs incurred for the Company’s own and for collaborative research and development activities. Research and development costs are expensed as incurred. Research and development costs consist of salaries and benefits, including associated stock-based compensation, and laboratory supplies and facility costs, as well as fees paid to other entities that conduct certain research and development activities on the Company’s behalf. The Company estimates preclinical studies and clinical trial expenses based on the services performed pursuant to contracts with research institutions, contract research organizations and clinical manufacturing organizations that conduct and manage preclinical studies and clinical trials on the Company’s behalf based on actual time and expenses incurred by them. Further, the Company accrues expenses related to clinical trials based on the level of patient activity according to the related agreement. The Company monitors patient enrollment levels and related activity to the extent reasonably possible and adjusts estimates accordingly. Stock-based compensationThe Company measures its stock-based awards granted to employees and directors based on the estimated fair values of the awards and recognizes the compensation on a straight-line basis over the requisite service period. The fair value of options issued under the employee stock purchase plan is calculated using the Black-Scholes option-pricing model. Restricted stock units are valued based on the closing price of the Company’s common stock on the date of grant. Comprehensive lossFor the years ended December 31, 2022, 2021 and 2020, other comprehensive loss includes net unrealized gains or losses on marketable securities. Income taxesIncome taxes are accounted for under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Management makes an assessment of the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company’s historical operating performance and the recorded cumulative net losses in prior fiscal periods, the net deferred tax assets have been fully offset by a valuation allowance.The Company recognizes uncertain income tax positions at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Changes in recognition or measurement are reflected in the period in which judgment occurs. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of interest expense. Net loss per share attributable to common stockholdersBasic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock, stock options, common stock subject to repurchase related to unvested restricted stock awards and early exercise of stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities as the redeemable convertible preferred stock is considered a participating security because it participates in dividends with common stock. The Company also considers the shares issued upon the early exercise of stock options subject to repurchase to be participating securities because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. The holders of all series of redeemable convertible preferred stock and the holders of early exercised shares subject to repurchase do not have a contractual obligation to share in the Company’s losses. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for all periods presented, diluted net loss per share is the same as basic net loss per share for those periods. Deferred offering costsThe Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders’ deficit (equity) as a reduction of additional paid-in capital generated as a result of the equity financing. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations. As of December 31, 2022 and 2021, $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.6 million and $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.5 million of deferred offering costs, respectively, were capitalized in other noncurrent assets on the consolidated balance sheets. 600000 500000 Segment reportingThe Company has <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">one operating and reportable segment. The Company’s chief operating decision maker, its Chief Executive Officer, manages the Company’s operations on a consolidated basis for the purposes of allocating resources and evaluating financial performance. All of the Company’s long-lived assets are located in the United States. 1 1 401(k) retirement plansThe Company maintains a 401(k) retirement plan for its employees. The Company is responsible for administrative costs of the 401(k) plan. The Company may, at its discretion, make matching or profit-sharing contributions to the 401(k) plan. For the years ended December 31, 2022, 2021 and 2020, the Company made $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.3 million, $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.9 million and $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.2 million matching contributions, respectively, under the plan. 401(k) retirement plan 1300000 900000 200000 Recent accounting pronouncementsFrom time to time, new accounting pronouncements are issued by the FASB, under its ASC or other standard setting bodies, and adopted by the Company as of the specified effective date, unless otherwise discussed below.Recently adopted accounting pronouncementsIn October 2020, the FASB issued ASU 2020-08, Codification Improvements to Subtopic 310-20, Receivables-Nonrefundable Fees and Other Costs (ASU 2020-08). ASU 2020-08 clarifies that an entity should reevaluate whether a callable debt security is within the scope of ASC paragraph 310-20-35-33 for each reporting period. The guidance is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021. Early application is not permitted. All entities should apply ASU 2020-08 on a prospective basis as of the beginning of the period of adoption for existing or newly purchased callable debt securities. The Company adopted the standard for the fiscal year beginning on January 1, 2022 and concluded that adoption of the standard did not have a material impact on its consolidated financial statements.In October 2020, FASB issued ASU 2020-10, Codification Improvements (ASU 2020-10). ASU 2020-10 updates various codification topics by clarifying or improving disclosure requirements to align with the SEC’s regulations. The amendments are effective for the Company for fiscal years beginning after December 15, 2021, including interim period within those fiscal years. Early adoption is permitted. Adoption shall be applied retrospectively. The Company adopted the standard for the fiscal year beginning on January 1, 2022 and concluded that adoption of the standard did not have a material impact on its consolidated financial statements. true true true <div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.<div style="display:inline;">Fair value measurements</div></div><div style="font-size:12.0pt;font-family:"Times New Roman", serif;">The following table presents information about the Company’s financial assets that are measured at fair value and indicates the fair value hierarchy of the valuation: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.334%;"/> <td style="width:1.223%;"/> <td style="width:1.0%;"/> <td style="width:9.110999999999999%;"/> <td style="width:1.0%;"/> <td style="width:1.223%;"/> <td style="width:1.0%;"/> <td style="width:9.110999999999999%;"/> <td style="width:1.0%;"/> <td style="width:1.223%;"/> <td style="width:1.0%;"/> <td style="width:9.110999999999999%;"/> <td style="width:1.0%;"/> <td style="width:1.223%;"/> <td style="width:1.0%;"/> <td style="width:9.44%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">December 31, 2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Total</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Level 1</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Level 2</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Level 3</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in thousands)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Assets:</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Money market funds<span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:"Times New Roman", serif;position:relative;min-width:fit-content;">(1)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">48,522</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">48,522</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">—</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">—</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Commercial paper<span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:"Times New Roman", serif;position:relative;min-width:fit-content;">(1, 2)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">313,928</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">313,928</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">U.S. and Canadian government and agency securities<span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:"Times New Roman", serif;position:relative;min-width:fit-content;">(2)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">251,830</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">—</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">251,830</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">—</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Corporate bonds<span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:"Times New Roman", serif;position:relative;min-width:fit-content;">(1, 2)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">31,405</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">31,405</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">645,685</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">48,522</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">597,163</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;">—</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> </tr> <tr> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">December 31, 2021</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Total</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Level 1</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Level 2</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Level 3</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in thousands)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Assets:</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Money market funds<span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:"Times New Roman", serif;position:relative;min-width:fit-content;">(1)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">57,134</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">57,134</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">—</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">—</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Commercial paper<span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:"Times New Roman", serif;position:relative;min-width:fit-content;">(1, 2)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">291,369</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">291,369</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">U.S. and Canadian government and agency securities<span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:"Times New Roman", serif;position:relative;min-width:fit-content;">(2)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">87,745</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">87,745</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">—</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Corporate bonds<span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:"Times New Roman", serif;position:relative;min-width:fit-content;">(2)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">141,698</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">141,698</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">577,946</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">57,134</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">520,812</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;">—</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> </tr> </table> <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:7.5pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(1)<div style="display:inline;">Included in cash and cash equivalents on the consolidated balance sheets.</div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:7.5pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(2)<div style="display:inline;">Included in marketable securities on the consolidated balance sheets.</div></div></div>Money market funds are measured at fair value on a recurring basis using quoted prices. U.S. and Canadian government debt securities, government agency bonds, commercial paper and corporate bonds are measured at fair value, which is derived from independent pricing sources based on quoted prices in active markets for similar securities.There were <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">no transfers between Levels 1, 2 or 3 for any of the periods presented. The following table presents information about the Company’s financial assets that are measured at fair value and indicates the fair value hierarchy of the valuation: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.334%;"/> <td style="width:1.223%;"/> <td style="width:1.0%;"/> <td style="width:9.110999999999999%;"/> <td style="width:1.0%;"/> <td style="width:1.223%;"/> <td style="width:1.0%;"/> <td style="width:9.110999999999999%;"/> <td style="width:1.0%;"/> <td style="width:1.223%;"/> <td style="width:1.0%;"/> <td style="width:9.110999999999999%;"/> <td style="width:1.0%;"/> <td style="width:1.223%;"/> <td style="width:1.0%;"/> <td style="width:9.44%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">December 31, 2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Total</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Level 1</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Level 2</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Level 3</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in thousands)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Assets:</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Money market funds<span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:"Times New Roman", serif;position:relative;min-width:fit-content;">(1)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">48,522</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">48,522</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">—</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">—</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Commercial paper<span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:"Times New Roman", serif;position:relative;min-width:fit-content;">(1, 2)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">313,928</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">313,928</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">U.S. and Canadian government and agency securities<span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:"Times New Roman", serif;position:relative;min-width:fit-content;">(2)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">251,830</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">—</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">251,830</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">—</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Corporate bonds<span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:"Times New Roman", serif;position:relative;min-width:fit-content;">(1, 2)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">31,405</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">31,405</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">645,685</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">48,522</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">597,163</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;">—</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> </tr> <tr> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">December 31, 2021</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Total</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Level 1</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Level 2</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Level 3</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in thousands)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Assets:</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Money market funds<span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:"Times New Roman", serif;position:relative;min-width:fit-content;">(1)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">57,134</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">57,134</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">—</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">—</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Commercial paper<span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:"Times New Roman", serif;position:relative;min-width:fit-content;">(1, 2)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">291,369</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">291,369</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">U.S. and Canadian government and agency securities<span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:"Times New Roman", serif;position:relative;min-width:fit-content;">(2)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">87,745</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">87,745</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">—</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Corporate bonds<span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:"Times New Roman", serif;position:relative;min-width:fit-content;">(2)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">141,698</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">141,698</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">577,946</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">57,134</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">520,812</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;">—</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> </tr> </table> <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:7.5pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(1)<div style="display:inline;">Included in cash and cash equivalents on the consolidated balance sheets.</div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:7.5pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(2)<div style="display:inline;">Included in marketable securities on the consolidated balance sheets.</div></div> 48522000 48522000 313928000 313928000 251830000 251830000 31405000 31405000 645685000 48522000 597163000 57134000 57134000 291369000 0 291369000 87745000 0 87745000 141698000 0 141698000 577946000 57134000 520812000 0 0 <div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">4.<div style="display:inline;">Available-for-sale securities</div></div><div style="font-size:14.0pt;font-family:"Times New Roman", serif;">The following tables summarize the estimated value of the Company’s available-for-sale marketable securities and cash equivalents and the gross unrealized gains and losses: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.303%;"/> <td style="width:1.162%;"/> <td style="width:1.0%;"/> <td style="width:9.026%;"/> <td style="width:1.0%;"/> <td style="width:1.162%;"/> <td style="width:1.0%;"/> <td style="width:9.005%;"/> <td style="width:1.0%;"/> <td style="width:1.162%;"/> <td style="width:1.0%;"/> <td style="width:7.462000000000001%;"/> <td style="width:1.0%;"/> <td style="width:1.0%;"/> <td style="width:1.395%;"/> <td style="width:1.0%;"/> <td style="width:1.0%;"/> <td style="width:9.322999999999999%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="16" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">December 31, 2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">Gross</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">Gross</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">Amortized</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">unrealized</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">unrealized</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">Estimated</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">cost</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">gain</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">loss</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">fair value</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="16" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in thousands)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Marketable securities:</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Commercial paper</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">216,765</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">328</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">216,437</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">U.S. and Canadian government and agency securities</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">236,916</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">43</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,270</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">235,689</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Corporate bonds</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">31,599</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">194</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">31,405</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total marketable securities</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">485,280</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">43</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,792</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">483,531</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Cash equivalents:</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Money market funds</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">48,522</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">48,522</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Commercial paper</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">97,526</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">35</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">97,491</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Corporate bonds</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">16,137</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">4</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">16,141</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total cash equivalents</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">162,185</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">4</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">35</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">—</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">162,154</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total available-for-sale investments</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">647,465</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">47</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,827</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);">)</td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">645,685</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> </tr> </table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.22%;"/> <td style="width:1.22%;"/> <td style="width:1.0%;"/> <td style="width:9.086%;"/> <td style="width:1.0%;"/> <td style="width:1.22%;"/> <td style="width:1.0%;"/> <td style="width:9.086%;"/> <td style="width:1.0%;"/> <td style="width:1.22%;"/> <td style="width:1.0%;"/> <td style="width:9.311%;"/> <td style="width:1.0%;"/> <td style="width:1.22%;"/> <td style="width:1.0%;"/> <td style="width:9.414%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">December 31, 2021</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">Gross</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">Gross</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">Amortized</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">unrealized</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">unrealized</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">Estimated</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">cost</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">gain</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">loss</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">fair value</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in thousands)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Marketable securities:</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Commercial paper</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">239,176</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">63</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">239,114</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">U.S. and Canadian government and agency securities</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">87,926</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">181</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">87,745</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Corporate bonds</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">141,829</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">131</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">141,698</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total marketable securities</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">468,931</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">375</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">468,557</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Cash equivalents:</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Money market funds</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">57,134</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">57,134</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Commercial paper</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">52,257</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">52,255</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total cash equivalents</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">109,391</td> <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2</td> <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">109,389</td> <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total available-for-sale investments</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">578,322</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">377</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">577,946</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> </tr> </table></div> <div style="font-size:12.0pt;font-family:"Times New Roman", serif;">The amortized cost and estimated fair value of the Company’s available-for-sale marketable securities and cash equivalents by contractual maturity are summarized below as of December 31, 2022: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.247%;"/> <td style="width:1.152%;"/> <td style="width:1.0%;"/> <td style="width:9.065000000000001%;"/> <td style="width:1.0%;"/> <td style="width:1.162%;"/> <td style="width:1.0%;"/> <td style="width:9.292%;"/> <td style="width:1.0%;"/> <td style="width:1.162%;"/> <td style="width:1.0%;"/> <td style="width:9.292%;"/> <td style="width:1.0%;"/> <td style="width:1.183%;"/> <td style="width:1.0%;"/> <td style="width:9.446000000000002%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">December 31, 2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">Gross</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">Gross</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">Amortized</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">unrealized</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">unrealized</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">Estimated</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">cost</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">gain</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">loss</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">fair value</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in thousands)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Mature in one year or less</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">618,025</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">48</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,752</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">616,321</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Mature after one year through two years</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">29,440</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">75</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">29,364</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total marketable securities</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">647,465</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">47</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,827</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">645,685</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> </tr> </table></div> The following tables summarize the estimated value of the Company’s available-for-sale marketable securities and cash equivalents and the gross unrealized gains and losses: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.303%;"/> <td style="width:1.162%;"/> <td style="width:1.0%;"/> <td style="width:9.026%;"/> <td style="width:1.0%;"/> <td style="width:1.162%;"/> <td style="width:1.0%;"/> <td style="width:9.005%;"/> <td style="width:1.0%;"/> <td style="width:1.162%;"/> <td style="width:1.0%;"/> <td style="width:7.462000000000001%;"/> <td style="width:1.0%;"/> <td style="width:1.0%;"/> <td style="width:1.395%;"/> <td style="width:1.0%;"/> <td style="width:1.0%;"/> <td style="width:9.322999999999999%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="16" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">December 31, 2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">Gross</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">Gross</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">Amortized</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">unrealized</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">unrealized</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">Estimated</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">cost</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">gain</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">loss</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">fair value</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="16" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in thousands)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Marketable securities:</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Commercial paper</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">216,765</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">328</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">216,437</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">U.S. and Canadian government and agency securities</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">236,916</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">43</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,270</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">235,689</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Corporate bonds</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">31,599</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">194</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">31,405</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total marketable securities</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">485,280</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">43</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,792</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">483,531</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Cash equivalents:</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Money market funds</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">48,522</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">48,522</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Commercial paper</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">97,526</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">35</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">97,491</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Corporate bonds</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">16,137</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">4</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">16,141</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total cash equivalents</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">162,185</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">4</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">35</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">—</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">162,154</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total available-for-sale investments</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">647,465</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">47</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,827</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);">)</td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">645,685</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> </tr> </table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.22%;"/> <td style="width:1.22%;"/> <td style="width:1.0%;"/> <td style="width:9.086%;"/> <td style="width:1.0%;"/> <td style="width:1.22%;"/> <td style="width:1.0%;"/> <td style="width:9.086%;"/> <td style="width:1.0%;"/> <td style="width:1.22%;"/> <td style="width:1.0%;"/> <td style="width:9.311%;"/> <td style="width:1.0%;"/> <td style="width:1.22%;"/> <td style="width:1.0%;"/> <td style="width:9.414%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">December 31, 2021</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">Gross</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">Gross</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">Amortized</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">unrealized</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">unrealized</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">Estimated</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">cost</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">gain</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">loss</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">fair value</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in thousands)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Marketable securities:</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Commercial paper</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">239,176</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">63</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">239,114</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">U.S. and Canadian government and agency securities</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">87,926</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">181</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">87,745</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Corporate bonds</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">141,829</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">131</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">141,698</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total marketable securities</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">468,931</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">375</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">468,557</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Cash equivalents:</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Money market funds</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">57,134</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">57,134</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Commercial paper</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">52,257</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">52,255</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total cash equivalents</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">109,391</td> <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2</td> <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">109,389</td> <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total available-for-sale investments</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">578,322</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">377</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">577,946</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> </tr> </table> 216765000 0 328000 216437000 236916000 43000 1270000 235689000 31599000 0 194000 31405000 485280000 43000 1792000 483531000 48522000 0 0 48522000 97526000 0 35000 97491000 16137000 4000 0 16141000 162185000 4000 35000 162154000 647465000 47000 1827000 645685000 239176000 1000 63000 239114000 87926000 0 181000 87745000 141829000 0 131000 141698000 468931000 1000 375000 468557000 57134000 0 0 57134000 52257000 0 2000 52255000 109391000 0 2000 109389000 578322000 1000 377000 577946000 The amortized cost and estimated fair value of the Company’s available-for-sale marketable securities and cash equivalents by contractual maturity are summarized below as of December 31, 2022: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.247%;"/> <td style="width:1.152%;"/> <td style="width:1.0%;"/> <td style="width:9.065000000000001%;"/> <td style="width:1.0%;"/> <td style="width:1.162%;"/> <td style="width:1.0%;"/> <td style="width:9.292%;"/> <td style="width:1.0%;"/> <td style="width:1.162%;"/> <td style="width:1.0%;"/> <td style="width:9.292%;"/> <td style="width:1.0%;"/> <td style="width:1.183%;"/> <td style="width:1.0%;"/> <td style="width:9.446000000000002%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">December 31, 2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">Gross</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">Gross</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">Amortized</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">unrealized</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">unrealized</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">Estimated</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">cost</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">gain</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">loss</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">fair value</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in thousands)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Mature in one year or less</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">618,025</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">48</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,752</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">616,321</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Mature after one year through two years</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">29,440</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">75</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">29,364</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total marketable securities</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">647,465</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">47</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,827</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">645,685</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> </tr> </table> 618025000 48000 1752000 616321000 29440000 1000 75000 29364000 647465000 47000 1827000 645685000 <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.<div style="display:inline;">Balance sheet components</div></div>Property and equipment, net <div style="font-size:12.0pt;font-family:"Times New Roman", serif;">Property and equipment, net consists of the following: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.368%;"/> <td style="width:1.368%;"/> <td style="width:1.0%;"/> <td style="width:13.435%;"/> <td style="width:1.0%;"/> <td style="width:1.368%;"/> <td style="width:1.0%;"/> <td style="width:13.461%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">December 31,</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2021</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in thousands)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Laboratory equipment</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">17,163</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">12,727</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Leasehold improvements</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">11,404</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7,245</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Computer equipment and software</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3,965</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2,186</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Furniture and fixtures</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">616</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">69</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Construction in progress</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">129</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">33,148</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">22,356</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Less: accumulated depreciation and amortization</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">14,489</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">10,812</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Property and equipment, net</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">18,659</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">11,544</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> </tr> </table></div> Depreciation and amortization expense for property and equipment amounted to $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">4.0 million, $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3.1 million and $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2.6 million for the years ended December 31, 2022, 2021 and 2020, respectively.Accrued expenses and other current liabilities<div style="font-size:12.0pt;font-family:"Times New Roman", serif;">Accrued expenses and other current liabilities consist of the following: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.143%;"/> <td style="width:1.43%;"/> <td style="width:1.0%;"/> <td style="width:12.926%;"/> <td style="width:1.0%;"/> <td style="width:1.43%;"/> <td style="width:1.0%;"/> <td style="width:13.072000000000001%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">December 31,</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2021</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in thousands)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Accrued compensation</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">13,281</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">9,852</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Accrued research and development</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">15,161</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">17,018</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Accrued professional services</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">499</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">540</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Other</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">505</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">311</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total accrued expenses and other current liabilities</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">29,446</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">27,721</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> </tr> </table></div> Property and equipment, net consists of the following: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.368%;"/> <td style="width:1.368%;"/> <td style="width:1.0%;"/> <td style="width:13.435%;"/> <td style="width:1.0%;"/> <td style="width:1.368%;"/> <td style="width:1.0%;"/> <td style="width:13.461%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">December 31,</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2021</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in thousands)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Laboratory equipment</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">17,163</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">12,727</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Leasehold improvements</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">11,404</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7,245</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Computer equipment and software</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3,965</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2,186</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Furniture and fixtures</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">616</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">69</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Construction in progress</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">129</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">33,148</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">22,356</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Less: accumulated depreciation and amortization</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">14,489</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">10,812</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Property and equipment, net</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">18,659</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">11,544</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> </tr> </table> 17163000 12727000 11404000 7245000 3965000 2186000 616000 69000 0 129000 33148000 22356000 14489000 10812000 18659000 11544000 4000000.0 3100000 2600000 Accrued expenses and other current liabilities consist of the following: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.143%;"/> <td style="width:1.43%;"/> <td style="width:1.0%;"/> <td style="width:12.926%;"/> <td style="width:1.0%;"/> <td style="width:1.43%;"/> <td style="width:1.0%;"/> <td style="width:13.072000000000001%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">December 31,</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2021</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in thousands)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Accrued compensation</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">13,281</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">9,852</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Accrued research and development</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">15,161</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">17,018</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Accrued professional services</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">499</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">540</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Other</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">505</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">311</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total accrued expenses and other current liabilities</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">29,446</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">27,721</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> </tr> </table> 13281000 9852000 15161000 17018000 499000 540000 505000 311000 29446000 27721000 <div style="text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">6.<div style="display:inline;">Intangible assets and goodwill</div></div>Intangible assets, net<div style="font-size:12.0pt;font-family:"Times New Roman", serif;">Intangible assets, net consist of the following as of December 31, 2022: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:52.704%;"/> <td style="width:0.788%;"/> <td style="width:1.0%;"/> <td style="width:9.203999999999999%;"/> <td style="width:1.0%;"/> <td style="width:0.788%;"/> <td style="width:1.0%;"/> <td style="width:9.439%;"/> <td style="width:1.0%;"/> <td style="width:0.553%;"/> <td style="width:1.0%;"/> <td style="width:8.956999999999999%;"/> <td style="width:1.0%;"/> <td style="width:0.553%;"/> <td style="width:1.0%;"/> <td style="width:9.016%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Gross value</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Accumulated amortization</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Net book value</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Weighted- average remaining useful life</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in thousands)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in years)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">In-process research and development — RAS Programs</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">55,800</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">55,800</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">n/a</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Developed technology — tri-complex platform</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7,480</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">4,473</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3,007</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">2.9</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">63,280</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">4,473</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">58,807</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> </table></div> Amortization expense for the years ended December 31, 2022, 2021 and 2020 were $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.1 million, $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.1 million and $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.1 million, respectively. <div style="font-size:12.0pt;font-family:"Times New Roman", serif;">As of December 31, 2022, future amortization expense is as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:79.387%;"/> <td style="width:1.923%;"/> <td style="width:1.0%;"/> <td style="width:16.689999999999998%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Amount</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in thousands)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">2023</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,069</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">2024</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,068</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">2025</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">870</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3,007</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> </tr> <tr> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> </table></div> <div style="font-size:12.0pt;font-family:"Times New Roman", serif;">Intangible assets, net consist of the following as of December 31, 2021: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:52.835%;"/> <td style="width:0.753%;"/> <td style="width:1.0%;"/> <td style="width:9.209%;"/> <td style="width:1.0%;"/> <td style="width:0.753%;"/> <td style="width:1.0%;"/> <td style="width:9.456%;"/> <td style="width:1.0%;"/> <td style="width:0.506%;"/> <td style="width:1.0%;"/> <td style="width:9.256%;"/> <td style="width:1.0%;"/> <td style="width:0.741%;"/> <td style="width:1.0%;"/> <td style="width:8.491999999999999%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Gross value</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Accumulated amortization</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Net book value</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Weighted- average remaining useful life</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in thousands)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in years)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">In-process research and development — RAS Programs</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">55,800</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">55,800</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">n/a</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Developed technology — tri-complex platform</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7,480</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3,404</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">4,076</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">3.9</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">63,280</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3,404</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">59,876</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> </table></div> Goodwill <div style="font-size:12.0pt;font-family:"Times New Roman", serif;">Goodwill consists of the following: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:79.328%;"/> <td style="width:1.907%;"/> <td style="width:1.0%;"/> <td style="width:16.766%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Amount</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in thousands)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Balance at December 31, 2021</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">14,608</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Adjustment</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Balance at December 31, 2022</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">14,608</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> </tr> </table></div> <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">No impairment has been recognized as of December 31, 2022. Goodwill is not deductible for income tax purposes. Intangible assets, net consist of the following as of December 31, 2022: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:52.704%;"/> <td style="width:0.788%;"/> <td style="width:1.0%;"/> <td style="width:9.203999999999999%;"/> <td style="width:1.0%;"/> <td style="width:0.788%;"/> <td style="width:1.0%;"/> <td style="width:9.439%;"/> <td style="width:1.0%;"/> <td style="width:0.553%;"/> <td style="width:1.0%;"/> <td style="width:8.956999999999999%;"/> <td style="width:1.0%;"/> <td style="width:0.553%;"/> <td style="width:1.0%;"/> <td style="width:9.016%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Gross value</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Accumulated amortization</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Net book value</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Weighted- average remaining useful life</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in thousands)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in years)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">In-process research and development — RAS Programs</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">55,800</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">55,800</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">n/a</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Developed technology — tri-complex platform</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7,480</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">4,473</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3,007</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">2.9</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">63,280</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">4,473</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">58,807</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> </table>Intangible assets, net consist of the following as of December 31, 2021: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:52.835%;"/> <td style="width:0.753%;"/> <td style="width:1.0%;"/> <td style="width:9.209%;"/> <td style="width:1.0%;"/> <td style="width:0.753%;"/> <td style="width:1.0%;"/> <td style="width:9.456%;"/> <td style="width:1.0%;"/> <td style="width:0.506%;"/> <td style="width:1.0%;"/> <td style="width:9.256%;"/> <td style="width:1.0%;"/> <td style="width:0.741%;"/> <td style="width:1.0%;"/> <td style="width:8.491999999999999%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Gross value</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Accumulated amortization</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Net book value</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Weighted- average remaining useful life</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in thousands)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in years)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">In-process research and development — RAS Programs</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">55,800</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">55,800</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">n/a</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Developed technology — tri-complex platform</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7,480</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3,404</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">4,076</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">3.9</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">63,280</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3,404</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">59,876</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> </table> 55800000 55800000 7480000 4473000 3007000 P2Y10M24D 63280000 4473000 58807000 1100000 1100000 1100000 As of December 31, 2022, future amortization expense is as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:79.387%;"/> <td style="width:1.923%;"/> <td style="width:1.0%;"/> <td style="width:16.689999999999998%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Amount</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in thousands)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">2023</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,069</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">2024</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,068</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">2025</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">870</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3,007</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> </tr> <tr> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> </table> 1069000 1068000 870000 3007000 55800000 55800000 7480000 3404000 4076000 P3Y10M24D 63280000 3404000 59876000 Goodwill consists of the following: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:79.328%;"/> <td style="width:1.907%;"/> <td style="width:1.0%;"/> <td style="width:16.766%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Amount</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in thousands)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Balance at December 31, 2021</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">14,608</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Adjustment</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Balance at December 31, 2022</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">14,608</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> </tr> </table> 14608000 0 14608000 0 <div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">7.<div style="display:inline;">Commitments and contingencies</div></div>LeasesIn January 2015, as amended in September 2016, the Company entered into an operating lease for approximately <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">42,000 square feet of office and laboratory space located at 700 Saginaw Drive, Redwood City, California (the 700 Building), with a term through April 2023. In April 2020, the Company amended the lease to lease an additional <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">19,000 square feet of office, laboratory and research and development space located at 300 Saginaw Drive, Redwood City, California (the 300 Building), and to extend the lease term through December 2030. In November 2021, the Company amended the lease to lease an additional <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">41,000 square feet of office, laboratory and research and development space located at 800 Saginaw Drive, Redwood City, California (the 800 Building), and to extend the lease term through November 2033. The Company has the option to extend the lease for an additional ten years after November 30, 2033.The Company maintains letters of credit for the benefit of the landlord which is disclosed as restricted cash in the consolidated balance sheets. Restricted cash related to letters of credit due to the landlord was $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.5 million and $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.5 million as of December 31, 2022 and December 31, 2021, respectively.Through December 31, 2022, the landlord had provided the Company with $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3.4 million in tenant improvement allowances for the 700 Building, and $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">4.6 million for the 300 building, which were recognized as lease incentives. The lease incentives are being amortized as an offset to rent expense over the lease term in the consolidated statements of operations.Upon the execution of the lease in April 2020, which was deemed to be a lease modification, the Company re-evaluated the assumptions used during the adoption of ASC 842 for the lease. The Company determined the amendment consists of two separate contracts under ASC 842. One contract is related to a new right-of-use asset for the 300 Building, which is being accounted for as an operating lease, and the other is related to the modification of the original lease term for the 700 Building. As a result, the Company recorded a right-of-use asset of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">6.4 million and a lease liability of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">9.0 million for the 300 Building and an increase of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">14.8 million to the right-of-use asset and lease liability for the 700 Building upon execution of the lease amendment. The Company is recognizing rent expense for both buildings on a straight-line basis through the remaining extended term of the lease.Upon the execution of the lease amendment in November 2021, which was deemed to be a lease modification, the Company re-evaluated the assumptions used during the lease amendment in April 2020. The Company determined the amendment consists of two separate contracts under ASC 842. One contract is related to a new right-of-use asset for the 800 Building, which is being accounted for as an operating lease, and the other is related to the modification of the lease term, as amended in April 2020, for the 700 Building and 300 Building. As a result, the Company recorded a right-of-use asset and a lease liability of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">26.8 million for the 800 Building and an aggregate increase of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">8.6 million to the right-of-use assets and lease liabilities for the 700 Building and 300 Building upon execution of the lease amendment. The Company is recognizing rent expense for the buildings on a straight-line basis through the remaining extended term of the lease.As part of the Warp Drive acquisition in October 2018, the Company assumed an operating lease for approximately <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">22,000 square feet of office and laboratory space located in Cambridge, Massachusetts (Cambridge Lease), which expires in February 2023, with an option to extend the term through February 2028, subject to certain conditions. In March 2019, the Company fully subleased the Cambridge Lease to Casma Therapeutics, Inc. (Casma), a related party, on financial terms substantially the same as the original lease. The sublease term with Casma is through the remainder of the Cambridge Lease term. The sublease by Casma and related sublease payments by Casma to the Company are fully guaranteed by Third Rock Ventures, LLC, a related party. In conjunction with the Cambridge Lease, the Company issued a letter of credit for $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.2 million, which is included in restricted cash on the consolidated balance sheets as of December 31, 2022 and 2021.<div style="font-size:12.0pt;font-family:"Times New Roman", serif;">The balance sheet classification of the Company’s operating lease liabilities was as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:79.31%;"/> <td style="width:1.906%;"/> <td style="width:1.0%;"/> <td style="width:16.784%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">December 31,</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">(in thousands)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Operating lease liabilities:</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Operating lease liability – current</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">6,773</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Operating lease liability – noncurrent</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">57,432</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total operating lease liabilities</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">64,205</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> </tr> </table></div>For the years ended December 31, 2022 and 2021, operating lease cost was $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">6.4 million and $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3.4 million, respectively, net of sublease income of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2.5 million and $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2.1 million, respectively. The operating cash flows for operating leases were $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2.4 million and $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.5 million year ended December 31, 2022 and 2021, respectively. Short-term lease costs were immaterial for the years ended December 31, 2022 and 2021.<div style="font-size:12.0pt;font-family:"Times New Roman", serif;">As of December 31, 2022, the maturities of the Company’s operating lease liabilities were as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:77.711%;"/> <td style="width:1.874%;"/> <td style="width:1.0%;"/> <td style="width:16.541%;"/> <td style="width:1.0%;"/> <td style="width:1.874%;"/> </tr> <tr> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="4" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">2023</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">6,961</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">2024</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7,100</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">2025</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7,349</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">2026</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7,606</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">2027</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7,872</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Thereafter</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">52,550</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total undiscounted lease payments</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">89,438</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Less: Imputed interest</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">25,233</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Less: Tenant improvement allowance</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total operating lease liabilities</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">64,205</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> </table></div>The amounts reflected in the table above include the Company’s lease payments for the Cambridge lease, but do not reflect any offset for the sublease payments the Company is entitled to receive from Casma.Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company uses its incremental borrowing rate. The weighted-average discount rate used to determine the operating lease liability was <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">6.1%. As of December 31, 2022 and 2021, the weighted-average remaining lease term is 10.9 years and 11.6 years, respectively.Legal mattersFrom time to time, the Company may be involved in litigation related to claims that arise in the ordinary course of its business activities. The Company accrues for these matters when it is probable that losses will be incurred and these losses can be reasonably estimated. As of December 31, 2022 and 2021, the Company does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company’s financial position, results of operations or cash flows.IndemnificationThe Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these arrangements is not determinable. The Company has not incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the Company believes the fair value of these agreements is minimal. OtherThe Company enters into agreements in the ordinary course of business with contract research organizations for clinical trials, contract manufacturing organizations to provide clinical trial materials and with vendors for preclinical studies and other services and products for operating purposes which are generally cancelable at any time by us upon 30 to 90 days prior written notice. 42000 2023-04 19000 2030-12 41000 2033-11 The Company has the option to extend the lease for an additional ten years after November 30, 2033. P10Y 1500000 1500000 3400000 4600000 6400000 9000000.0 14800000 26800000 8600000 22000 2023-02 option to extend the term through February 2028 200000 200000 The balance sheet classification of the Company’s operating lease liabilities was as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:79.31%;"/> <td style="width:1.906%;"/> <td style="width:1.0%;"/> <td style="width:16.784%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">December 31,</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">(in thousands)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Operating lease liabilities:</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Operating lease liability – current</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">6,773</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Operating lease liability – noncurrent</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">57,432</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total operating lease liabilities</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">64,205</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> </tr> </table> 6773000 57432000 64205000 6400000 3400000 2500000 2100000 2400000 1500000 As of December 31, 2022, the maturities of the Company’s operating lease liabilities were as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:77.711%;"/> <td style="width:1.874%;"/> <td style="width:1.0%;"/> <td style="width:16.541%;"/> <td style="width:1.0%;"/> <td style="width:1.874%;"/> </tr> <tr> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="4" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">2023</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">6,961</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">2024</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7,100</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">2025</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7,349</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">2026</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7,606</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">2027</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7,872</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Thereafter</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">52,550</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total undiscounted lease payments</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">89,438</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;">Less: Imputed interest</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">25,233</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Less: Tenant improvement allowance</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total operating lease liabilities</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">64,205</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> </table> 6961000 7100000 7349000 7606000 7872000 52550000 89438000 25233000 0 64205000 0.061 P10Y10M24D P11Y7M6D <div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">8.<div style="display:inline;">Sanofi collaboration agreement</div></div>In June 2018, the Company entered into a collaborative research, development and commercialization agreement (the Sanofi Agreement) with Aventis, Inc. (an affiliate of Sanofi) to research and develop SHP2 inhibitors, including RMC-4630, for any indications. The Sanofi Agreement was assigned to Genzyme Corporation, a Sanofi affiliate, in December 2018. For the purposes of this discussion, we refer to Genzyme Corporation as Sanofi. Pursuant to the Sanofi Agreement, the Company granted Sanofi a worldwide, exclusive, sublicensable (subject to the Company’s consent in certain circumstances) license under certain of the Company’s patents and know-how to research, develop, manufacture, use, sell, offer for sale, import and otherwise commercialize SHP2 inhibitors, including RMC-4630, for any and all uses, subject to the Company’s exercise of rights and performance of obligations under the Sanofi Agreement. In December 2022, the Company received notice of Sanofi’s decision to terminate for convenience under the Sanofi Agreement, with a termination date in June 2023. Upon effectiveness of the termination of the Sanofi Agreement (the termination date), the licenses granted to Sanofi thereunder shall become fully paid-up, royalty-free, perpetual and irrevocable and all rights and obligations of Sanofi under the Sanofi Agreement will revert to the Company.In October 2018, the Company acquired Warp Drive in exchange for issuance of shares of the Company’s Series B redeemable convertible preferred stock and payment of cash. Sanofi was a stockholder of Warp Drive and received the Company’s Series B redeemable convertible preferred stock during the transaction and accordingly became an investor and related party of the Company. As a result of the Company’s underwritten offering of common stock in February 2021, Sanofi’s ownership percentage in the Company decreased and Sanofi is no longer considered a related party.Under the Sanofi Agreement, the Company received a non-refundable, upfront cash payment of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">50 million in July 2018.Prior to the termination date, the Company has primary responsibility for early clinical development of RMC-4630 and is responsible for the manufacture of SHP2 inhibitors for Phase 1 and non-registrational Phase 2 clinical trials pursuant to an approved development plan. In August 2021, the Company entered into a letter agreement with Sanofi (the Letter Agreement) to include an additional clinical study, RMC-4630-03, as part of the Company’s responsibilities under the development plan. Sanofi is responsible to reimburse the Company all internal and external costs and expenses to perform the Company’s activities under approved development plans up to the termination date, except for the RMC-4630-03 study, for which Sanofi will reimburse the Company for <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">50% of the costs and expenses up to the termination date.In addition to the ongoing development plan, the Company was also primarily responsible for performing preclinical research on SHP2 inhibitors pursuant to a research plan through 2021. Sanofi was responsible to reimburse the Company for all internal and external costs and expenses incurred to perform activities under approved research plan for 2021.The Company identified the following promises in the agreement (1) the license related to SHP2 inhibitors, (2) the performance of research and development services for Phase 1 clinical studies and Phase 2 clinical trials that are non-registrational clinical trials and (3) the performance of manufacturing services for the non-registrational clinical trials. The Company determined that the license is not distinct from the services within the context of the agreement because the research, development and manufacturing significantly increase the utility of the intellectual property. The intellectual property (IP) related to SHP2 inhibitors, which is proprietary to the Company, is the foundation for the research and development activities. The manufacturing services are a necessary and integral part of the research and development services as they could only be conducted utilizing the outcomes of these services. Given the research and development services under the Sanofi Agreement are expected to involve significant further development of the initial IP, the Company has concluded that the research, development and manufacturing services are not distinct from the license, and thus the license, research and development services and manufacturing services are combined into a single performance obligation.For revenue recognition purposes, the Company determined that the duration of the contract begins on the effective date of the Sanofi Agreement in July 2018 and ends on the termination date in June 2023.The Company determined that the transaction price of the Sanofi Agreement was $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">186.9 million as of December 31, 2022. In order to determine the transaction price, the Company evaluated all the payments to be received during the duration of the contract. The Company determined that the $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">50.0 million upfront payment and $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">136.9 million of estimated variable consideration for expense reimbursements from Sanofi for agreed upon research and development services as of December 31, 2022 constituted consideration to be included in the transaction price, which is to be allocated to the combined performance obligation. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur.The license, research, development and manufacturing services are combined as one performance obligation that will be performed over the duration of the contract, which is from the effective date of the Sanofi Agreement through the termination date. The Company concluded that it would utilize a cost-based input method to measure proportional performance and to calculate the corresponding amount of revenue to recognize. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to estimated costs to fulfill the combined performance obligation. These costs consist primarily of internal full-time equivalent efforts and third-party costs. As noted above, a percentage of the actual costs incurred under approved research and development plans are reimbursed by Sanofi under the collaboration agreement. The research and development plans are determined by a joint research and development committee, over which Sanofi has final decision-making subject to certain exceptions. Revenue is recognized under the collaboration agreement with Sanofi, based on actual costs incurred as a percentage of total estimated costs to be incurred over the performance obligation as the Company completes its performance obligation. The cumulative effect of revisions to estimated costs to complete the Company’s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated.Pursuant to the termination noticed provided by Sanofi in December 2022, effective as of the termination date, Sanofi will have no further reimbursement obligations post termination. As a result of the termination and development plan adjustments during the year, the Company updated the accounting transaction price for the estimated consideration to be received and updated the estimated costs to fulfill the performance obligation, which increased the Company’s percentage of completion under the agreement with Sanofi, and resulted in total cumulative catch-up adjustments that increased collaboration revenue by $3.0 million for the year ended December 31, 2022.As a result of entering into the Letter Agreement for the RMC-4630-03 study in August 2021, the Company updated the transaction price for the estimated consideration to be received, and updated the estimated costs to fulfill the performance obligation, which decreased the estimated percentage of completion to date and resulted in a cumulative catch-up adjustment that reduced collaboration revenue by $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">8.5 million for the year ended December 31, 2021.During the years ended December 31, 2022, 2021 and 2020, the Company recognized $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">35.4 million, $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">29.4 million and $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">43.0 million of collaboration revenue associated with this agreement, respectively.As of December 31, 2022 and 2021, $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">4.5 million and $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">12.4 million of deferred revenue is classified as current and zero and $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">6.6 million is classified as noncurrent, respectively. 50000000 0.50 186900000 50000000.0 136900000 8500000 35400000 29400000 43000000.0 4500000 12400000 6600000 <div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">9.<div style="display:inline;">Redeemable convertible preferred stock</div></div>Upon the closing of the Company’s initial public offering in February 2020, all shares of redeemable convertible preferred stock then outstanding converted into <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">39,600,423 shares of common stock. There were <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">no shares of redeemable convertible preferred stock outstanding as of December 31, 2022 and 2021. 39600423 0 0 <div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">10.<div style="display:inline;">Common stock</div></div>As of December 31, 2022 and 2021, the Company’s certificate of incorporation authorized the Company to issue <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">300,000,000 shares of common stock, at a par value of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.0001 per share. Each share of common stock is entitled to <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to prior rights of the redeemable convertible preferred stockholders. As of December 31, 2022, <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">no dividends have been declared to date.<div style="font-size:12.0pt;font-family:"Times New Roman", serif;">The Company has reserved shares of common stock for future issuance as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.696%;"/> <td style="width:0.132%;"/> <td style="width:1.0%;"/> <td style="width:14.028%;"/> <td style="width:1.0%;"/> <td style="width:0.116%;"/> <td style="width:1.0%;"/> <td style="width:14.028%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">December 31,</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">December 31,</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2021</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Outstanding options to purchase common stock</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">8,164,375</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">6,050,938</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Unvested restricted stock units of common stock</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,175,032</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">423,621</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Available for future issuance under the 2020 Incentive Award Plan</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">6,726,307</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">6,403,548</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Available for issuance under the 2020 Employee Stock Purchase Plan</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,700,887</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,089,728</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">17,766,601</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">13,967,835</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> </tr> </table></div> 300000000 300000000 0.0001 0.0001 Each share of common stock is entitled to one vote 1 0 The Company has reserved shares of common stock for future issuance as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.696%;"/> <td style="width:0.132%;"/> <td style="width:1.0%;"/> <td style="width:14.028%;"/> <td style="width:1.0%;"/> <td style="width:0.116%;"/> <td style="width:1.0%;"/> <td style="width:14.028%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">December 31,</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">December 31,</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2021</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Outstanding options to purchase common stock</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">8,164,375</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">6,050,938</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Unvested restricted stock units of common stock</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,175,032</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">423,621</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Available for future issuance under the 2020 Incentive Award Plan</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">6,726,307</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">6,403,548</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Available for issuance under the 2020 Employee Stock Purchase Plan</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,700,887</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,089,728</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">17,766,601</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">13,967,835</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> </tr> </table> 8164375 6050938 1175032 423621 6726307 6403548 1700887 1089728 17766601 13967835 <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">11.<div style="display:inline;">Stock-based compensation</div></div>2020 Incentive Award PlanIn February 2020, the Company adopted the 2020 Equity Incentive Plan (the 2020 Plan). The 2020 Plan became effective on February 11, 2020. The 2020 Plan provides for a variety of stock-based compensation awards, including stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance bonus awards, performance stock unit awards, dividend equivalents, or other stock or cash based awards. Under the 2020 Plan, the Company generally grants stock-based awards with service-based vesting conditions only. Options and restricted stock unit awards granted typically vest over a four-year period, but may be granted with different vesting terms.Following the effectiveness of the 2020 Plan, the Company will not make any further grants under the 2014 Equity Incentive Plan (the 2014 Plan). However, the 2014 Plan will continue to govern the terms and conditions of the outstanding awards granted under it. Shares of common stock subject to awards granted under the 2014 Plan that are forfeited or lapse unexercised and which following the effective date of the 2020 Plan were not issued under the 2014 Plan are available for issuance under the 2020 Plan.2020 Employee Stock Purchase PlanIn February 2020, the Company adopted the 2020 Employee Stock Purchase Plan (the ESPP). Under the ESPP, employees have the ability to purchase shares of the Company’s common stock through payroll deductions at a discount during a series of offering periods of 24 months, each comprised of four six-month purchase periods. The purchase price will be the lower of <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">85% of the closing trading price per share of the Company’s common stock on the first day of an offering period in which an employee is enrolled or 85% of the closing trading price per share on the purchase date, which will occur on the last trading day of each purchase period.As of December 31, 2022, there have been <span style="font-size:10.0pt;font-family:"Times New Roman", serif;white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">235,555 shares of common stock purchased under the ESPP. As of December 31, 2022, a total of <span style="font-size:10.0pt;font-family:"Times New Roman", serif;white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,700,887 shares of common stock were available for future issuance under the ESPP. As of December 31, 2022, there was $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3.2 million of unrecognized compensation cost related to the ESPP.Stock options<div style="font-size:12.0pt;font-family:"Times New Roman", serif;">The following summarizes option activity under both the 2020 Plan and the 2014 Plan: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:55.963%;"/> <td style="width:0.074%;"/> <td style="width:1.0%;"/> <td style="width:9.543%;"/> <td style="width:1.0%;"/> <td style="width:0.074%;"/> <td style="width:1.0%;"/> <td style="width:8.186%;"/> <td style="width:1.0%;"/> <td style="width:0.074%;"/> <td style="width:1.0%;"/> <td style="width:8.779%;"/> <td style="width:1.0%;"/> <td style="width:0.271%;"/> <td style="width:1.0%;"/> <td style="width:9.036999999999999%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Number of Shares underlying options</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Weighted- average exercise price</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Weighted- average remaining contractual term</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Aggregate intrinsic value</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in years)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in thousands)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Balance, December 31, 2021</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">6,050,938</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">14.88</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">7.74</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">83,953</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Options granted</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2,758,710</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">19.37</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Options exercised</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">249,544</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">6.12</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Options cancelled</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">395,729</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">26.78</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Balance, December 31, 2022</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">8,164,375</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">16.09</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">7.53</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">85,181</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Options vested and expected to vest as of December 31, 2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">8,164,375</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">16.09</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">7.53</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">85,181</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Options vested and exercisable as of December 31, 2022</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">4,555,124</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">11.43</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">6.65</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">66,783</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table></div> The aggregate intrinsic values of options outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the options and the estimated fair value of the Company’s common stock by the Board of Directors. The intrinsic value of the options exercised for the years December 31, 2022, 2021 and 2020 was $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3.8 million, $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">13.1 million and $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">21.7 million, respectively.During the years ended December 31, 2022, 2021 and 2020, the weighted-average grant-date fair value of options granted was $12.33, $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">25.13 and $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">15.59 per share, respectively. As of December 31, 2022, there was $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">48.8 million of unrecognized stock-based compensation expense related to unvested stock options that is expected to be recognized over a weighted-average period of 2.57 years.<div style="font-size:12.0pt;font-family:"Times New Roman", serif;">The fair value of employee and director stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.5%;"/> <td style="width:1.4%;"/> <td style="width:12.778%;"/> <td style="width:1.4%;"/> <td style="width:12.778%;"/> <td style="width:1.4%;"/> <td style="width:12.743%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Year Ended December 31,</td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2021</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2020</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Expected term (years)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">6</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">6</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">6</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Expected volatility</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">70-<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">73%</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">70-<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">75%</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">74-<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">80%</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Risk-free interest rate</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.5%-<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">4.2%</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.5%-<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.3%</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.2%-<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.5%</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Dividend yield</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0%</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0%</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0%</td> </tr> </table> Non-employee stock option awards were measured at fair value at each reporting period using a Black-Scholes option-pricing model with the following assumptions: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.5%;"/> <td style="width:1.4%;"/> <td style="width:12.778%;"/> <td style="width:1.4%;"/> <td style="width:12.778%;"/> <td style="width:1.4%;"/> <td style="width:12.743%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Year Ended December 31,</td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2021</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2020</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Expected term (years)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">6</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">6</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">6-10</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Expected volatility</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">70-<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">71%</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">70-<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">75%</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">74-<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">80%</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Risk-free interest rate</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.6%-<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3.4%</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.9%-<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.3%</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.2%-<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.5%</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Dividend yield</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0%</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0%</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0%</td> </tr> </table></div> The Black-Scholes model assumptions that determine the fair value of stock-based awards include:Expected term—The expected term is calculated using the simplified method, which is available where there is insufficient historical data about exercise patterns and post-vesting employment termination behavior. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting-tranche for awards with graded vesting. The mid-point between the vesting date and the maximum contractual expiration date is used as the expected term under this method.Expected volatility—Given the Company does not have sufficient trading history for its common stock, the expected volatility was estimated based on the average volatility of the Company and comparable publicly traded biotechnology companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on their similar size, stage in the life cycle or area of specialty.Risk-free interest rate—The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.Expected dividend—The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.Restricted stock unitsRestricted stock units (RSUs) have been granted to employees and directors. The fair value of an RSU award is based on the Company’s stock price on the date of grant. The shares underlying the RSU awards are not issued until the RSUs vest. Upon vesting, each RSU converts into one share of the Company’s common stock. The Company has granted RSUs pursuant to the 2020 plan.<div style="font-size:12.0pt;font-family:"Times New Roman", serif;">Activity under the 2020 Plan with respect to the Company’s RSUs during the year ended December 31, 2022 was as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:58.798%;"/> <td style="width:0.074%;"/> <td style="width:1.0%;"/> <td style="width:10.155%;"/> <td style="width:1.0%;"/> <td style="width:0.074%;"/> <td style="width:1.0%;"/> <td style="width:5.246%;"/> <td style="width:1.0%;"/> <td style="width:0.074%;"/> <td style="width:1.0%;"/> <td style="width:7.571%;"/> <td style="width:1.0%;"/> <td style="width:0.346%;"/> <td style="width:1.0%;"/> <td style="width:9.661%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Number of Shares</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Weighted- average grant date fair value per share</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Weighted- average remaining contractual term</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Aggregate intrinsic value</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in years)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in thousands)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Balance, December 31, 2021</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">423,621</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">37.16</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">3.16</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">10,663</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Restricted stock units granted</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,142,366</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">19.43</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Restricted stock units vested</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">278,848</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">28.23</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Restricted stock units forfeited</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">112,107</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">24.58</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Balance, December 31, 2022</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,175,032</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">23.25</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">1.62</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">27,989</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Expected to vest as of December 31, 2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,175,032</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">23.25</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">1.62</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">27,989</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> </div>The number of RSUs vested includes shares of common stock that the Company withheld to satisfy the minimum statutory tax withholding requirements. As of December 31, 2022, there was $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">25.8 million of total unrecognized compensation cost related to RSUs that is expected to be recognized over a weighted average period of 3.07 years.The total fair value of RSUs vested for the years ended December 31, 2022, 2021 and 2020 was $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7.9 million, $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3.1 million and $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.1 million, respectively.Stock-based compensation expense<div style="font-size:12.0pt;font-family:"Times New Roman", serif;">Total stock-based compensation expense related to stock options, RSUs and the ESPP by function was as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.373%;"/> <td style="width:1.273%;"/> <td style="width:1.0%;"/> <td style="width:10.812999999999999%;"/> <td style="width:1.0%;"/> <td style="width:1.285%;"/> <td style="width:1.0%;"/> <td style="width:10.836%;"/> <td style="width:1.0%;"/> <td style="width:1.285%;"/> <td style="width:1.0%;"/> <td style="width:11.137%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">Year Ended December 31,</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2021</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2020</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in thousands)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Research and development</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">18,113</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">11,847</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">4,848</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">General and administrative</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">13,083</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">8,877</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">4,038</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">31,196</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">20,724</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">8,886</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> </tr> </table></div> Stock-based compensation related to options and RSUs granted to non-employees was $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.5 million, $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.7 million and $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.8 million for the years ended December 31, 2022, 2021 and 2020, respectively. P4Y 0.85 235555 1700887 3200000 The following summarizes option activity under both the 2020 Plan and the 2014 Plan: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:55.963%;"/> <td style="width:0.074%;"/> <td style="width:1.0%;"/> <td style="width:9.543%;"/> <td style="width:1.0%;"/> <td style="width:0.074%;"/> <td style="width:1.0%;"/> <td style="width:8.186%;"/> <td style="width:1.0%;"/> <td style="width:0.074%;"/> <td style="width:1.0%;"/> <td style="width:8.779%;"/> <td style="width:1.0%;"/> <td style="width:0.271%;"/> <td style="width:1.0%;"/> <td style="width:9.036999999999999%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Number of Shares underlying options</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Weighted- average exercise price</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Weighted- average remaining contractual term</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Aggregate intrinsic value</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in years)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in thousands)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Balance, December 31, 2021</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">6,050,938</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">14.88</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">7.74</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">83,953</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Options granted</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2,758,710</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">19.37</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Options exercised</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">249,544</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">6.12</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Options cancelled</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">395,729</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">26.78</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Balance, December 31, 2022</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">8,164,375</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">16.09</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">7.53</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">85,181</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Options vested and expected to vest as of December 31, 2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">8,164,375</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">16.09</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">7.53</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">85,181</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Options vested and exercisable as of December 31, 2022</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">4,555,124</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">11.43</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">6.65</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">66,783</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> 6050938 14.88 P7Y8M26D 83953000 2758710 19.37 249544 6.12 395729 26.78 8164375 16.09 P7Y6M10D 85181000 8164375 16.09 P7Y6M10D 85181000 4555124 11.43 P6Y7M24D 66783000 3800000 13100000 21700000 25.13 15.59 48800000 P2Y6M25D The fair value of employee and director stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.5%;"/> <td style="width:1.4%;"/> <td style="width:12.778%;"/> <td style="width:1.4%;"/> <td style="width:12.778%;"/> <td style="width:1.4%;"/> <td style="width:12.743%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Year Ended December 31,</td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2021</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2020</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Expected term (years)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">6</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">6</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">6</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Expected volatility</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">70-<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">73%</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">70-<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">75%</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">74-<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">80%</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Risk-free interest rate</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.5%-<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">4.2%</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.5%-<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.3%</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.2%-<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.5%</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Dividend yield</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0%</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0%</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0%</td> </tr> </table> Non-employee stock option awards were measured at fair value at each reporting period using a Black-Scholes option-pricing model with the following assumptions: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.5%;"/> <td style="width:1.4%;"/> <td style="width:12.778%;"/> <td style="width:1.4%;"/> <td style="width:12.778%;"/> <td style="width:1.4%;"/> <td style="width:12.743%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Year Ended December 31,</td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2021</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2020</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Expected term (years)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">6</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">6</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">6-10</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Expected volatility</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">70-<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">71%</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">70-<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">75%</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">74-<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">80%</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Risk-free interest rate</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.6%-<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3.4%</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.9%-<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.3%</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.2%-<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.5%</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Dividend yield</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0%</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0%</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0%</td> </tr> </table> P6Y P6Y P6Y 0.70 0.73 0.70 0.75 0.74 0.80 0.015 0.042 0.005 0.013 0.002 0.015 0 0 0 P6Y P6Y P6Y P10Y 0.70 0.71 0.70 0.75 0.74 0.80 0.016 0.034 0.009 0.013 0.012 0.015 0 0 0 Activity under the 2020 Plan with respect to the Company’s RSUs during the year ended December 31, 2022 was as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:58.798%;"/> <td style="width:0.074%;"/> <td style="width:1.0%;"/> <td style="width:10.155%;"/> <td style="width:1.0%;"/> <td style="width:0.074%;"/> <td style="width:1.0%;"/> <td style="width:5.246%;"/> <td style="width:1.0%;"/> <td style="width:0.074%;"/> <td style="width:1.0%;"/> <td style="width:7.571%;"/> <td style="width:1.0%;"/> <td style="width:0.346%;"/> <td style="width:1.0%;"/> <td style="width:9.661%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Number of Shares</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Weighted- average grant date fair value per share</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Weighted- average remaining contractual term</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Aggregate intrinsic value</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in years)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in thousands)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Balance, December 31, 2021</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">423,621</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">37.16</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">3.16</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">10,663</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Restricted stock units granted</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,142,366</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">19.43</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Restricted stock units vested</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">278,848</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">28.23</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Restricted stock units forfeited</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">112,107</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">24.58</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Balance, December 31, 2022</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,175,032</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">23.25</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">1.62</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">27,989</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Expected to vest as of December 31, 2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,175,032</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">23.25</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">1.62</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">27,989</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> 423621 37.16 P3Y1M28D 10663000 1142366 19.43 278848 28.23 112107 24.58 1175032 23.25 P1Y7M13D 27989000 1175032 23.25 P1Y7M13D 27989000 25800000 P3Y25D 7900000 3100000 100000 Total stock-based compensation expense related to stock options, RSUs and the ESPP by function was as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.373%;"/> <td style="width:1.273%;"/> <td style="width:1.0%;"/> <td style="width:10.812999999999999%;"/> <td style="width:1.0%;"/> <td style="width:1.285%;"/> <td style="width:1.0%;"/> <td style="width:10.836%;"/> <td style="width:1.0%;"/> <td style="width:1.285%;"/> <td style="width:1.0%;"/> <td style="width:11.137%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">Year Ended December 31,</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2021</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2020</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in thousands)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Research and development</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">18,113</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">11,847</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">4,848</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">General and administrative</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">13,083</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">8,877</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">4,038</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">31,196</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">20,724</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">8,886</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> </tr> </table> 18113000 11847000 4848000 13083000 8877000 4038000 31196000 20724000 8886000 500000 700000 800000 <div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">12.<div style="display:inline;">Income taxes</div></div>The Company recorded an income tax benefit of <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.4 million and <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">zero for the years ended December 31, 2022 and 2021, respectively, which reflects state tax rates applied to the indefinite lived intangibles recorded as part of the Company’s acquisition of Warp Drive Bio in 2018. The Company has incurred net pre-tax losses in the United States only for all periods presented. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the carrying amounts of existing assets and liabilities in the financial statements and their respective tax bases using tax rates expected to be in effect during the years in which the basis differences reverse.<div style="font-size:12.0pt;font-family:"Times New Roman", serif;">The benefit from income taxes differs from the amount expected by applying the federal statutory rate to the loss before taxes as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:65.517%;"/> <td style="width:1.122%;"/> <td style="width:1.0%;"/> <td style="width:14.21%;"/> <td style="width:1.0%;"/> <td style="width:1.136%;"/> <td style="width:1.0%;"/> <td style="width:14.016%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Year Ended December 31,</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2021</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Federal statutory income tax rate</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">21.0</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">%</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">21.0</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">%</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">State income tax rate, net of federal benefit</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">9.4</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">%</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">8.9</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">%</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Research tax credits</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3.2</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">%</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2.2</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">%</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Change in valuation allowance</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">-<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">32.4</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">%</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">-<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">31.4</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">%</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Non-deductible permanent expenses</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">-<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.0</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">%</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">-<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.5</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">%</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Other</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.0</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">%</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">-<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.2</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">%</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Benefit from income taxes</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.2</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);">%</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.0</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);">%</td> </tr> </table></div> Deferred income tax reflects the tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The categories that give rise to significant components of the deferred tax assets are as follows (in thousands): <div style="font-size:12.0pt;font-family:"Times New Roman", serif;"> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.191%;"/> <td style="width:1.505%;"/> <td style="width:1.0%;"/> <td style="width:13.433%;"/> <td style="width:1.0%;"/> <td style="width:1.518%;"/> <td style="width:1.0%;"/> <td style="width:13.354000000000001%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">December 31,</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2021</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in thousands)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Deferred tax assets:</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Net operating loss carryforwards</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">132,080</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">123,991</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Accruals and reserves</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">5,494</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">9,164</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Research and development credits</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">22,558</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">14,449</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Lease liability</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">18,998</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">19,979</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Stock-based compensation</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7,063</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3,829</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Capitalized research expenses</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">64,149</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Other</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">42</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">33</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Gross deferred tax assets</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">250,384</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">171,445</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Less: valuation allowance</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">224,125</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">143,474</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total deferred tax assets</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">26,259</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">27,971</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Deferred tax liabilities:</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Fixed assets and finite-lived intangible assets</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">9,961</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">10,073</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Indefinite-lived intangible assets</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7,025</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7,444</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Lease asset</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Right-of-use asset</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">16,298</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">17,898</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Gross deferred tax liabilities</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">33,284</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">35,415</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Net deferred tax liability</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7,025</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7,444</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);">)</td> </tr> </table></div> The realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Due to the lack of earnings history, the net deferred tax assets have been offset by a valuation allowance excluding certain indefinite lived intangibles. The valuation allowance increased by $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">80.7 million and $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">58.8 million during the years ended December 31, 2022 and 2021, respectively. The Company had federal and state net operating loss carryforwards of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">448.3 million and $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">445.5 million, respectively, as of December 31, 2022. The federal net operating loss carryforwards, if not utilized, will expire beginning in 2035, with the exception of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">354.7 million in federal net operating loss carryforwards, which can be carried forward indefinitely. State net operating loss carryforwards, if not utilized, will expire beginning in 2035. Under the Tax Cuts and Jobs Act (the TCJA), federal net operating losses arising after December 31, 2017 do not expire and cannot be carried back. However, the TCJA limits the amount of federal net operating losses that can be used annually to <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">80% of taxable income for periods beginning after December 31, 2017. Existing federal net operating losses arising in years ending on or before December 31, 2017 are not affected by these provisions.The Company also had federal and state research and development credit carryforwards of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">20.6 million and $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">11.6 million, respectively, as of December 31, 2022. The federal credits will expire starting in 2034 if not utilized and the state research credits will expire beginning in 2031, with the exception of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">10.7 million in California research credits, which can be carried forward indefinitely. Federal, California, Massachusetts and New Jersey tax laws impose significant restrictions on the utilization of net operating loss carryforwards in the event of a change in ownership of the Company, as defined by Internal Revenue Code Section 382 (Section 382). The Company performed a study in which it determined that it had experienced changes in ownership in 2014, 2018, and 2020 as defined by Section 382. No federal or state net operating losses are expected to expire unutilized as a result of the limitation, with the exception of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">5.5 million in California net operating losses. The Company's deferred tax assets have been reduced by the amount of net operating loss carryforwards expected to expire due to the limitation. In addition, in the future the Company may experience ownership changes, which may limit the utilization of net operating loss carryforwards or other tax attributes.<div>The TCJA amended Internal Revenue Code Section 174 requiring capitalization of specified research and experimental expenditures paid or incurred in tax years beginning after December 31, 2021 and amortizing over a period of 5 or 15 years. This resulted in a deferred tax asset for capitalized research expenses in 2022. Also on August 16, 2022, the United States enacted the Inflation Reduction Act (the IRA), which contains among other things, numerous income tax provisions. At this time, the Company does not anticipate the IRA to have a material impact on its financial statements.</div><div style="font-size:12.0pt;font-family:"Times New Roman", serif;">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.368%;"/> <td style="width:1.368%;"/> <td style="width:1.0%;"/> <td style="width:13.435%;"/> <td style="width:1.0%;"/> <td style="width:1.368%;"/> <td style="width:1.0%;"/> <td style="width:13.461%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">December 31,</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2021</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in thousands)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Beginning balance</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">5,143</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3,593</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Changes related to tax positions taken in the prior year</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">21</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Changes related to tax positions taken in the current year</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2,466</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,571</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Ending balance</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7,602</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">5,143</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> </tr> </table></div> The Company has unrecognized tax benefits of $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7.1 million and $<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">4.7 million as of December 31, 2022 and 2021, which would affect the effective tax rate if recognized; however, recognition would be in the form of a deferred tax attribute which would likely be offset by a valuation allowance. The Company does not anticipate any significant changes to unrecognized tax benefits over the next 12 months. The Company has recognized <span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">no interest or penalties related to uncertain tax positions for the periods presented.Income tax returns are filed in the United States. The years 2010 through 2022 remain open to examination by the domestic taxing jurisdictions to which the Company is subject. Net operating losses generated on a tax return basis by the Company for 2010 through 2022 remain open to examination by the domestic taxing jurisdictions. -400000 0 The benefit from income taxes differs from the amount expected by applying the federal statutory rate to the loss before taxes as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:65.517%;"/> <td style="width:1.122%;"/> <td style="width:1.0%;"/> <td style="width:14.21%;"/> <td style="width:1.0%;"/> <td style="width:1.136%;"/> <td style="width:1.0%;"/> <td style="width:14.016%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Year Ended December 31,</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2021</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Federal statutory income tax rate</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">21.0</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">%</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">21.0</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">%</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">State income tax rate, net of federal benefit</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">9.4</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">%</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">8.9</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">%</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Research tax credits</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3.2</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">%</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2.2</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">%</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Change in valuation allowance</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">-<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">32.4</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">%</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">-<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">31.4</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">%</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Non-deductible permanent expenses</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">-<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1.0</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">%</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">-<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.5</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">%</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Other</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.0</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">%</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">-<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.2</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">%</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Benefit from income taxes</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.2</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);">%</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">0.0</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);">%</td> </tr> </table> 0.210 0.210 0.094 0.089 0.032 0.022 -0.324 -0.314 -0.010 -0.005 0.000 -0.002 0.002 0.000 The categories that give rise to significant components of the deferred tax assets are as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.191%;"/> <td style="width:1.505%;"/> <td style="width:1.0%;"/> <td style="width:13.433%;"/> <td style="width:1.0%;"/> <td style="width:1.518%;"/> <td style="width:1.0%;"/> <td style="width:13.354000000000001%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">December 31,</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2021</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in thousands)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Deferred tax assets:</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Net operating loss carryforwards</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">132,080</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">123,991</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Accruals and reserves</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">5,494</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">9,164</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Research and development credits</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">22,558</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">14,449</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Lease liability</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">18,998</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">19,979</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Stock-based compensation</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7,063</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3,829</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Capitalized research expenses</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">64,149</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Other</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">42</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">33</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Gross deferred tax assets</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">250,384</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">171,445</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Less: valuation allowance</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">224,125</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">143,474</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total deferred tax assets</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">26,259</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">27,971</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Deferred tax liabilities:</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Fixed assets and finite-lived intangible assets</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">9,961</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">10,073</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Indefinite-lived intangible assets</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7,025</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7,444</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Lease asset</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Right-of-use asset</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">16,298</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">17,898</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Gross deferred tax liabilities</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">33,284</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">35,415</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Net deferred tax liability</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7,025</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7,444</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);">)</td> </tr> </table> 132080000 123991000 5494000 9164000 22558000 14449000 18998000 19979000 7063000 3829000 64149000 42000 33000 250384000 171445000 224125000 143474000 26259000 27971000 9961000 10073000 7025000 7444000 0 16298000 17898000 33284000 35415000 7025000 7444000 80700000 58800000 448300000 445500000 2035 354700000 2035 0.80 20600000 11600000 2034 2031 10700000 Federal, California, Massachusetts and New Jersey tax laws impose significant restrictions on the utilization of net operating loss carryforwards in the event of a change in ownership of the Company, as defined by Internal Revenue Code Section 382 (Section 382). The Company performed a study in which it determined that it had experienced changes in ownership in 2014, 2018, and 2020 as defined by Section 382. No federal or state net operating losses are expected to expire unutilized as a result of the limitation, with the exception of $5.5 million in California net operating losses. The Company's deferred tax assets have been reduced by the amount of net operating loss carryforwards expected to expire due to the limitation. In addition, in the future the Company may experience ownership changes, which may limit the utilization of net operating loss carryforwards or other tax attributes.The TCJA amended Internal Revenue Code Section 174 requiring capitalization of specified research and experimental expenditures paid or incurred in tax years beginning after December 31, 2021 and amortizing over a period of 5 or 15 years. This resulted in a deferred tax asset for capitalized research expenses in 2022. Also on August 16, 2022, the United States enacted the Inflation Reduction Act (the IRA), which contains among other things, numerous income tax provisions. At this time, the Company does not anticipate the IRA to have a material impact on its financial statements. 5500000 A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.368%;"/> <td style="width:1.368%;"/> <td style="width:1.0%;"/> <td style="width:13.435%;"/> <td style="width:1.0%;"/> <td style="width:1.368%;"/> <td style="width:1.0%;"/> <td style="width:13.461%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">December 31,</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2021</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in thousands)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Beginning balance</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">5,143</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3,593</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Changes related to tax positions taken in the prior year</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">21</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;">Changes related to tax positions taken in the current year</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2,466</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,571</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Ending balance</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">7,602</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">5,143</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> </tr> </table> 5143000 3593000 7000 21000 2466000 1571000 7602000 5143000 7100000 4700000 0 0 <div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">13.<div style="display:inline;">Net loss per share attributable to common stockholders</div></div><div style="font-size:12.0pt;font-family:"Times New Roman", serif;">The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:54.527%;"/> <td style="width:1.259%;"/> <td style="width:1.0%;"/> <td style="width:11.834%;"/> <td style="width:1.0%;"/> <td style="width:1.259%;"/> <td style="width:1.0%;"/> <td style="width:11.834%;"/> <td style="width:1.0%;"/> <td style="width:1.259%;"/> <td style="width:1.0%;"/> <td style="width:12.030000000000001%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Years Ended December 31,</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2021</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2020</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in thousands, except share and per share data)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Numerator:</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Net loss</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">248,705</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">187,091</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">108,159</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Redeemable convertible preferred stock dividends-undeclared and cumulative</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2,219</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Net loss attributable to common stockholders</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">248,705</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">187,091</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">110,378</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Denominator:</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Weighted-average shares outstanding</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">80,636,570</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">72,866,022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">55,109,929</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Less: Weighted-average unvested restricted shares and shares subject to repurchase</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">10,045</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">59,943</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">235,810</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Weighted-average shares used to compute net loss per share attributable to common stockholders, basic and diluted</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">80,626,525</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">72,806,079</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">54,874,119</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Net loss per share attributable to common stockholders, basic and diluted</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;">(<span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3.08</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;">(<span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2.57</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;">(<span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2.01</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);">)</td> </tr> </table></div> <div style="font-size:12.0pt;font-family:"Times New Roman", serif;">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:56.105%;"/> <td style="width:1.019%;"/> <td style="width:1.0%;"/> <td style="width:11.440999999999999%;"/> <td style="width:1.0%;"/> <td style="width:1.008%;"/> <td style="width:1.0%;"/> <td style="width:11.546%;"/> <td style="width:1.0%;"/> <td style="width:1.008%;"/> <td style="width:1.0%;"/> <td style="width:11.875%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">As of December 31,</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2021</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2020</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Options to purchase common stock</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">8,164,375</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">6,050,938</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">5,118,979</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Options early exercised subject to future vesting</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">6,918</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">30,378</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">130,793</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Unvested restricted stock units of common stock</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,175,032</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">423,621</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">85,639</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Expected shares to be purchased under ESPP</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">378,429</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">176,131</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">91,210</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">9,724,754</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">6,681,068</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">5,426,621</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> </tr> </table></div> The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:54.527%;"/> <td style="width:1.259%;"/> <td style="width:1.0%;"/> <td style="width:11.834%;"/> <td style="width:1.0%;"/> <td style="width:1.259%;"/> <td style="width:1.0%;"/> <td style="width:11.834%;"/> <td style="width:1.0%;"/> <td style="width:1.259%;"/> <td style="width:1.0%;"/> <td style="width:12.030000000000001%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">Years Ended December 31,</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2021</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2020</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;">(in thousands, except share and per share data)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Numerator:</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Net loss</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">248,705</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">187,091</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">108,159</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Redeemable convertible preferred stock dividends-undeclared and cumulative</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">—</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2,219</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Net loss attributable to common stockholders</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">248,705</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">187,091</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">$</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;">(<span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">110,378</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;">)</td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Denominator:</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Weighted-average shares outstanding</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">80,636,570</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">72,866,022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">55,109,929</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Less: Weighted-average unvested restricted shares and shares subject to repurchase</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">10,045</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">59,943</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;">(<span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">235,810</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);">)</td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Weighted-average shares used to compute net loss per share attributable to common stockholders, basic and diluted</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">80,626,525</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">72,806,079</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">54,874,119</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Net loss per share attributable to common stockholders, basic and diluted</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;">(<span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3.08</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;">(<span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2.57</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);">)</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);">$</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;">(<span style="font-size:8.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">2.01</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);">)</td> </tr> </table> -248705000 -187091000 -108159000 0 0 2219000 -248705000 -187091000 -110378000 80636570 72866022 55109929 10045 59943 235810 80626525 80626525 72806079 72806079 54874119 54874119 -3.08 -3.08 -2.57 -2.57 -2.01 -2.01 The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:56.105%;"/> <td style="width:1.019%;"/> <td style="width:1.0%;"/> <td style="width:11.440999999999999%;"/> <td style="width:1.0%;"/> <td style="width:1.008%;"/> <td style="width:1.0%;"/> <td style="width:11.546%;"/> <td style="width:1.0%;"/> <td style="width:1.008%;"/> <td style="width:1.0%;"/> <td style="width:11.875%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">As of December 31,</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2022</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2021</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;">2020</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Options to purchase common stock</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">8,164,375</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">6,050,938</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">5,118,979</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Options early exercised subject to future vesting</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">6,918</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">30,378</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">130,793</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Unvested restricted stock units of common stock</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,175,032</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">423,621</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">85,639</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Expected shares to be purchased under ESPP</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">378,429</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">176,131</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"> </td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">91,210</td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"> </td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;">Total</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">9,724,754</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">6,681,068</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"> </td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">5,426,621</td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"> </td> </tr> </table> 8164375 6050938 5118979 6918 30378 130793 1175032 423621 85639 378429 176131 91210 9724754 6681068 5426621 Included in cash and cash equivalents on the consolidated balance sheets. Included in marketable securities on the consolidated balance sheets. EXCEL 88 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 90 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 91 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 211 371 1 true 65 0 false 7 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 100040 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 100050 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 100060 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Statements 5 false false R6.htm 100070 - Statement - CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) Statements 6 false false R7.htm 100080 - Statement - CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical) Statements 7 false false R8.htm 100090 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 8 false false R9.htm 100100 - Disclosure - Organization Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureOrganization Organization Notes 9 false false R10.htm 100110 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 100120 - Disclosure - Fair Value Measurements Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements Fair Value Measurements Notes 11 false false R12.htm 100130 - Disclosure - Available-for-sale Securities Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecurities Available-for-sale Securities Notes 12 false false R13.htm 100140 - Disclosure - Balance Sheet Components Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponents Balance Sheet Components Notes 13 false false R14.htm 100160 - Disclosure - Intangible Assets and Goodwill Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwill Intangible Assets and Goodwill Notes 14 false false R15.htm 100170 - Disclosure - Commitments and Contingencies Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 100180 - Disclosure - Sanofi Collaboration Agreement Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSanofiCollaborationAgreement Sanofi Collaboration Agreement Notes 16 false false R17.htm 100190 - Disclosure - Redeemable Convertible Preferred Stock Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStock Redeemable Convertible Preferred Stock Notes 17 false false R18.htm 100200 - Disclosure - Common Stock Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommonStock Common Stock Notes 18 false false R19.htm 100210 - Disclosure - Stock-Based Compensation Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation Stock-Based Compensation Notes 19 false false R20.htm 100220 - Disclosure - Income Taxes Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes Income Taxes Notes 20 false false R21.htm 100230 - Disclosure - Net Loss Per Share Attributable to Common Stockholders Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders Net Loss Per Share Attributable to Common Stockholders Notes 21 false false R22.htm 100250 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies 22 false false R23.htm 100260 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies 23 false false R24.htm 100270 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements 24 false false R25.htm 100280 - Disclosure - Available-for-sale Securities (Tables) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesTables Available-for-sale Securities (Tables) Tables http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecurities 25 false false R26.htm 100290 - Disclosure - Balance Sheet Components (Tables) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables Balance Sheet Components (Tables) Tables http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponents 26 false false R27.htm 100310 - Disclosure - Intangible Assets and Goodwill (Tables) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwillTables Intangible Assets and Goodwill (Tables) Tables http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwill 27 false false R28.htm 100320 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies 28 false false R29.htm 100340 - Disclosure - Common Stock (Tables) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommonStockTables Common Stock (Tables) Tables http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommonStock 29 false false R30.htm 100350 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation 30 false false R31.htm 100360 - Disclosure - Income Taxes (Tables) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables Income Taxes (Tables) Tables http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes 31 false false R32.htm 100370 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables Net Loss Per Share Attributable to Common Stockholders (Tables) Tables http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders 32 false false R33.htm 100390 - Disclosure - Organization - Additional Information (Details) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails Organization - Additional Information (Details) Details 33 false false R34.htm 100400 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails Summary of Significant Accounting Policies - Additional Information (Details) Details 34 false false R35.htm 100410 - Disclosure - Summary of Significant Accounting Policies - Schedule of Useful Lives of Property and Equipment (Details) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails Summary of Significant Accounting Policies - Schedule of Useful Lives of Property and Equipment (Details) Details 35 false false R36.htm 100420 - Disclosure - Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value (Details) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetails Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value (Details) Details 36 false false R37.htm 100430 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 37 false false R38.htm 100440 - Disclosure - Available-for-sale Securities - Summary of Estimated Value of Available-for-sale Securities and Cash Equivalents and Gross Unrealized Gains and Losses (Details) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfEstimatedValueOfAvailableForSaleSecuritiesAndCashEquivalentsAndGrossUnrealizedGainsAndLossesDetails Available-for-sale Securities - Summary of Estimated Value of Available-for-sale Securities and Cash Equivalents and Gross Unrealized Gains and Losses (Details) Details 38 false false R39.htm 100450 - Disclosure - Available-for-sale Securities - Summary of Amortized Cost and Estimated Fair Value of Available-for-sale Securities and Cash Equivalents by Contractual Maturity (Details) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAmortizedCostAndEstimatedFairValueOfAvailableForSaleSecuritiesAndCashEquivalentsByContractualMaturityDetails Available-for-sale Securities - Summary of Amortized Cost and Estimated Fair Value of Available-for-sale Securities and Cash Equivalents by Contractual Maturity (Details) Details 39 false false R40.htm 100460 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails Balance Sheet Components - Schedule of Property and Equipment, Net (Details) Details 40 false false R41.htm 100470 - Disclosure - Balance Sheet Components - Additional Information (Details) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails Balance Sheet Components - Additional Information (Details) Details 41 false false R42.htm 100480 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details) Details 42 false false R43.htm 100530 - Disclosure - Intangible Assets and Goodwill - Schedule of Intangibles Assets, Net (Details) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwillScheduleOfIntangiblesAssetsNetDetails Intangible Assets and Goodwill - Schedule of Intangibles Assets, Net (Details) Details 43 false false R44.htm 100540 - Disclosure - Intangible Assets and Goodwill - Additional Information (Details) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwillAdditionalInformationDetails Intangible Assets and Goodwill - Additional Information (Details) Details 44 false false R45.htm 100550 - Disclosure - Intangible Assets and Goodwill - Schedule of Future Amortization Expense (Details) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwillScheduleOfFutureAmortizationExpenseDetails Intangible Assets and Goodwill - Schedule of Future Amortization Expense (Details) Details 45 false false R46.htm 100560 - Disclosure - Intangible Assets and Goodwill - Schedule of Goodwill (Details) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwillScheduleOfGoodwillDetails Intangible Assets and Goodwill - Schedule of Goodwill (Details) Details 46 false false R47.htm 100570 - Disclosure - Commitment and Contingencies - Additional Information (Details) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails Commitment and Contingencies - Additional Information (Details) Details 47 false false R48.htm 100580 - Disclosure - Commitments and Contingencies - Summary of Balance Sheet Classification of Operating Lease Liabilities (Details) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfBalanceSheetClassificationOfOperatingLeaseLiabilitiesDetails Commitments and Contingencies - Summary of Balance Sheet Classification of Operating Lease Liabilities (Details) Details 48 false false R49.htm 100590 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details) Details 49 false false R50.htm 100600 - Disclosure - Sanofi Collaboration Agreement - Additional Information (Details) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSanofiCollaborationAgreementAdditionalInformationDetails Sanofi Collaboration Agreement - Additional Information (Details) Details 50 false false R51.htm 100610 - Disclosure - Redeemable Convertible Preferred Stock - Additional Information (Details) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails Redeemable Convertible Preferred Stock - Additional Information (Details) Details 51 false false R52.htm 100620 - Disclosure - Common Stock - Additional Information (Details) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails Common Stock - Additional Information (Details) Details 52 false false R53.htm 100630 - Disclosure - Common Stock - Schedule of Common Stock for Future Issuance (Details) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockForFutureIssuanceDetails Common Stock - Schedule of Common Stock for Future Issuance (Details) Details 53 false false R54.htm 100640 - Disclosure - Stock-Based Compensation - Additional Information (Details) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails Stock-Based Compensation - Additional Information (Details) Details 54 false false R55.htm 100650 - Disclosure - Stock-Based Compensation - Summary of Option Activity Under the Plan (Details) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityUnderPlanDetails Stock-Based Compensation - Summary of Option Activity Under the Plan (Details) Details 55 false false R56.htm 100660 - Disclosure - Summary of Fair Value of Stock Option Awards Estimated at Date of Grant (Details) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfFairValueOfStockOptionAwardsEstimatedAtDateOfGrantDetails Summary of Fair Value of Stock Option Awards Estimated at Date of Grant (Details) Details 56 false false R57.htm 100670 - Disclosure - Stock-Based Compensation - Summary of RSUs Activity Under the Plan (Details) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRsusActivityUnderPlanDetails Stock-Based Compensation - Summary of RSUs Activity Under the Plan (Details) Details 57 false false R58.htm 100680 - Disclosure - Stock-Based Compensation - Summary of Total Stock-Based Compensation Expense Related to Stock Options, RSUs and Employee Stock Purchase Plan (Details) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseRelatedToStockOptionsRsusAndEmployeeStockPurchasePlanDetails Stock-Based Compensation - Summary of Total Stock-Based Compensation Expense Related to Stock Options, RSUs and Employee Stock Purchase Plan (Details) Details 58 false false R59.htm 100690 - Disclosure - Income Taxes - Additional Information (Details) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails Income Taxes - Additional Information (Details) Details 59 false false R60.htm 100700 - Disclosure - Income Taxes - Summary of Benefit from Income Taxes to Amount Computed by Applying Federal Statutory Rate to Loss Before Taxes (Details) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfBenefitFromIncomeTaxesToAmountComputedByApplyingFederalStatutoryRateToLossBeforeTaxesDetails Income Taxes - Summary of Benefit from Income Taxes to Amount Computed by Applying Federal Statutory Rate to Loss Before Taxes (Details) Details 60 false false R61.htm 100710 - Disclosure - Income Taxes - Summary of Categories that Give Rise to Significant Components of Deferred Tax Assets (Details) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfCategoriesThatGiveRiseToSignificantComponentsOfDeferredTaxAssetsDetails Income Taxes - Summary of Categories that Give Rise to Significant Components of Deferred Tax Assets (Details) Details 61 false false R62.htm 100720 - Disclosure - Income Taxes - Reconciliation of Gross Unrecognized Tax Benefits (Details) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfGrossUnrecognizedTaxBenefitsDetails Income Taxes - Reconciliation of Gross Unrecognized Tax Benefits (Details) Details 62 false false R63.htm 100730 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails Net Loss Per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details) Details 63 false false R64.htm 100740 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Outstanding Potentially Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details) Sheet http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails Net Loss Per Share Attributable to Common Stockholders - Schedule of Outstanding Potentially Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details) Details 64 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, us-gaap:PropertyPlantAndEquipmentUsefulLife, us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 - rvmd-20221231.htm 8 rvmd-20221231.htm rvmd-20221231.xsd rvmd-20221231_cal.xml rvmd-20221231_def.xml rvmd-20221231_lab.xml rvmd-20221231_pre.xml rvmd-ex23_1.htm rvmd-ex31_1.htm rvmd-ex31_2.htm rvmd-ex32_1.htm rvmd-ex32_2.htm img27442415_0.jpg img27442415_1.jpg img27442415_10.jpg img27442415_2.jpg img27442415_3.jpg img27442415_4.jpg img27442415_5.jpg img27442415_6.jpg img27442415_7.jpg img27442415_8.jpg img27442415_9.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 94 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "rvmd-20221231.htm": { "axisCustom": 0, "axisStandard": 23, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 830, "http://xbrl.sec.gov/dei/2022": 37 }, "contextCount": 211, "dts": { "calculationLink": { "local": [ "rvmd-20221231_cal.xml" ] }, "definitionLink": { "local": [ "rvmd-20221231_def.xml" ] }, "inline": { "local": [ "rvmd-20221231.htm" ] }, "labelLink": { "local": [ "rvmd-20221231_lab.xml" ] }, "presentationLink": { "local": [ "rvmd-20221231_pre.xml" ] }, "schema": { "local": [ "rvmd-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 648, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 5, "http://xbrl.sec.gov/dei/2022": 4, "total": 9 }, "keyCustom": 51, "keyStandard": 320, "memberCustom": 32, "memberStandard": 29, "nsprefix": "rvmd", "nsuri": "http://www.revolutionmedicines.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "10", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Fair Value Measurements", "menuCat": "Notes", "order": "11", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Available-for-sale Securities", "menuCat": "Notes", "order": "12", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecurities", "shortName": "Available-for-sale Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Balance Sheet Components", "menuCat": "Notes", "order": "13", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponents", "shortName": "Balance Sheet Components", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Intangible Assets and Goodwill", "menuCat": "Notes", "order": "14", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwill", "shortName": "Intangible Assets and Goodwill", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "15", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Sanofi Collaboration Agreement", "menuCat": "Notes", "order": "16", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSanofiCollaborationAgreement", "shortName": "Sanofi Collaboration Agreement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "rvmd:RedeemableConvertiblePreferredStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Redeemable Convertible Preferred Stock", "menuCat": "Notes", "order": "17", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStock", "shortName": "Redeemable Convertible Preferred Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "rvmd:RedeemableConvertiblePreferredStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Common Stock", "menuCat": "Notes", "order": "18", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommonStock", "shortName": "Common Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Stock-Based Compensation", "menuCat": "Notes", "order": "19", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_bb62c355-4d7b-446b-8b8b-6d4c2b6901c9", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - CONSOLIDATED BALANCE SHEETS", "menuCat": "Statements", "order": "2", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_bb62c355-4d7b-446b-8b8b-6d4c2b6901c9", "decimals": "-3", "lang": null, "name": "us-gaap:MarketableSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "20", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Net Loss Per Share Attributable to Common Stockholders", "menuCat": "Notes", "order": "21", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders", "shortName": "Net Loss Per Share Attributable to Common Stockholders", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "22", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "rvmd:PropertyAndEquipmentEstimatedUsefulLivesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Summary of Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "23", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "rvmd:PropertyAndEquipmentEstimatedUsefulLivesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Fair Value Measurements (Tables)", "menuCat": "Tables", "order": "24", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Available-for-sale Securities (Tables)", "menuCat": "Tables", "order": "25", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesTables", "shortName": "Available-for-sale Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Balance Sheet Components (Tables)", "menuCat": "Tables", "order": "26", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables", "shortName": "Balance Sheet Components (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Intangible Assets and Goodwill (Tables)", "menuCat": "Tables", "order": "27", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwillTables", "shortName": "Intangible Assets and Goodwill (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "rvmd:SummaryOfBalanceSheetClassificationOfOperatingLeaseLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Commitments and Contingencies (Tables)", "menuCat": "Tables", "order": "28", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "rvmd:SummaryOfBalanceSheetClassificationOfOperatingLeaseLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "rvmd:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Common Stock (Tables)", "menuCat": "Tables", "order": "29", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommonStockTables", "shortName": "Common Stock (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "rvmd:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_bb62c355-4d7b-446b-8b8b-6d4c2b6901c9", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_bb62c355-4d7b-446b-8b8b-6d4c2b6901c9", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Stock-Based Compensation (Tables)", "menuCat": "Tables", "order": "30", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Income Taxes (Tables)", "menuCat": "Tables", "order": "31", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)", "menuCat": "Tables", "order": "32", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables", "shortName": "Net Loss Per Share Attributable to Common Stockholders (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_bb62c355-4d7b-446b-8b8b-6d4c2b6901c9", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Organization - Additional Information (Details)", "menuCat": "Details", "order": "33", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails", "shortName": "Organization - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_bbad6f7b-751a-4b1c-85da-b9d803881836", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "p", "rvmd:ReverseStockSplitPolicyPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_3f0ce3d4-ca7e-4e3a-a5ae-b17edc0b0855", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityReverseStockSplit", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)", "menuCat": "Details", "order": "34", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "rvmd:ReverseStockSplitPolicyPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_3f0ce3d4-ca7e-4e3a-a5ae-b17edc0b0855", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityReverseStockSplit", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_26ebd08c-a8e7-415c-80b9-a09169653d4f", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Summary of Significant Accounting Policies - Schedule of Useful Lives of Property and Equipment (Details)", "menuCat": "Details", "order": "35", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails", "shortName": "Summary of Significant Accounting Policies - Schedule of Useful Lives of Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "rvmd:PropertyAndEquipmentEstimatedUsefulLivesTableTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_c0dc1bfe-d585-4f28-b355-9196e51aa821", "decimals": null, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_e16c4bd7-6c40-418f-b8a4-d28b6df2eb32", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value (Details)", "menuCat": "Details", "order": "36", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetails", "shortName": "Fair Value Measurements - Schedule of Financial Assets Measured at Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_e16c4bd7-6c40-418f-b8a4-d28b6df2eb32", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "rvmd:FairValueLevel1Level2Level3TransfersAmount", "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_bb62c355-4d7b-446b-8b8b-6d4c2b6901c9", "decimals": "INF", "first": true, "lang": null, "name": "rvmd:FairValueLevel1Level2Level3TransfersAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Fair Value Measurements - Additional Information (Details)", "menuCat": "Details", "order": "37", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "shortName": "Fair Value Measurements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "rvmd:FairValueLevel1Level2Level3TransfersAmount", "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_bb62c355-4d7b-446b-8b8b-6d4c2b6901c9", "decimals": "INF", "first": true, "lang": null, "name": "rvmd:FairValueLevel1Level2Level3TransfersAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_bb62c355-4d7b-446b-8b8b-6d4c2b6901c9", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Available-for-sale Securities - Summary of Estimated Value of Available-for-sale Securities and Cash Equivalents and Gross Unrealized Gains and Losses (Details)", "menuCat": "Details", "order": "38", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfEstimatedValueOfAvailableForSaleSecuritiesAndCashEquivalentsAndGrossUnrealizedGainsAndLossesDetails", "shortName": "Available-for-sale Securities - Summary of Estimated Value of Available-for-sale Securities and Cash Equivalents and Gross Unrealized Gains and Losses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_9d5b2423-2e35-4f84-8f7a-0d71259f32eb", "decimals": "-3", "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_bb62c355-4d7b-446b-8b8b-6d4c2b6901c9", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Available-for-sale Securities - Summary of Amortized Cost and Estimated Fair Value of Available-for-sale Securities and Cash Equivalents by Contractual Maturity (Details)", "menuCat": "Details", "order": "39", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAmortizedCostAndEstimatedFairValueOfAvailableForSaleSecuritiesAndCashEquivalentsByContractualMaturityDetails", "shortName": "Available-for-sale Securities - Summary of Amortized Cost and Estimated Fair Value of Available-for-sale Securities and Cash Equivalents by Contractual Maturity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_34ddb47f-b6bd-4100-90ad-6423246e5a65", "decimals": "-3", "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "menuCat": "Statements", "order": "4", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_bb62c355-4d7b-446b-8b8b-6d4c2b6901c9", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)", "menuCat": "Details", "order": "40", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails", "shortName": "Balance Sheet Components - Schedule of Property and Equipment, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_bb62c355-4d7b-446b-8b8b-6d4c2b6901c9", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Balance Sheet Components - Additional Information (Details)", "menuCat": "Details", "order": "41", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails", "shortName": "Balance Sheet Components - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "rvmd:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_bb62c355-4d7b-446b-8b8b-6d4c2b6901c9", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedEmployeeBenefitsCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)", "menuCat": "Details", "order": "42", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails", "shortName": "Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "rvmd:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_bb62c355-4d7b-446b-8b8b-6d4c2b6901c9", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedEmployeeBenefitsCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_bb62c355-4d7b-446b-8b8b-6d4c2b6901c9", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100530 - Disclosure - Intangible Assets and Goodwill - Schedule of Intangibles Assets, Net (Details)", "menuCat": "Details", "order": "43", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwillScheduleOfIntangiblesAssetsNetDetails", "shortName": "Intangible Assets and Goodwill - Schedule of Intangibles Assets, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_bb62c355-4d7b-446b-8b8b-6d4c2b6901c9", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100540 - Disclosure - Intangible Assets and Goodwill - Additional Information (Details)", "menuCat": "Details", "order": "44", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwillAdditionalInformationDetails", "shortName": "Intangible Assets and Goodwill - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R45": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_bb62c355-4d7b-446b-8b8b-6d4c2b6901c9", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100550 - Disclosure - Intangible Assets and Goodwill - Schedule of Future Amortization Expense (Details)", "menuCat": "Details", "order": "45", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwillScheduleOfFutureAmortizationExpenseDetails", "shortName": "Intangible Assets and Goodwill - Schedule of Future Amortization Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_bb62c355-4d7b-446b-8b8b-6d4c2b6901c9", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_955a1704-d86a-4f16-8df1-4cb4f584d429", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100560 - Disclosure - Intangible Assets and Goodwill - Schedule of Goodwill (Details)", "menuCat": "Details", "order": "46", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwillScheduleOfGoodwillDetails", "shortName": "Intangible Assets and Goodwill - Schedule of Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": "-3", "lang": null, "name": "us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_bb62c355-4d7b-446b-8b8b-6d4c2b6901c9", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100570 - Disclosure - Commitment and Contingencies - Additional Information (Details)", "menuCat": "Details", "order": "47", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails", "shortName": "Commitment and Contingencies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": "-5", "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_bb62c355-4d7b-446b-8b8b-6d4c2b6901c9", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLiabilityCurrent", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100580 - Disclosure - Commitments and Contingencies - Summary of Balance Sheet Classification of Operating Lease Liabilities (Details)", "menuCat": "Details", "order": "48", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfBalanceSheetClassificationOfOperatingLeaseLiabilitiesDetails", "shortName": "Commitments and Contingencies - Summary of Balance Sheet Classification of Operating Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R49": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_bb62c355-4d7b-446b-8b8b-6d4c2b6901c9", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100590 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details)", "menuCat": "Details", "order": "49", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails", "shortName": "Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_bb62c355-4d7b-446b-8b8b-6d4c2b6901c9", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS", "menuCat": "Statements", "order": "5", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": "-3", "lang": null, "name": "us-gaap:ComprehensiveIncomeNetOfTax", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_bb62c355-4d7b-446b-8b8b-6d4c2b6901c9", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityCurrent", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100600 - Disclosure - Sanofi Collaboration Agreement - Additional Information (Details)", "menuCat": "Details", "order": "50", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSanofiCollaborationAgreementAdditionalInformationDetails", "shortName": "Sanofi Collaboration Agreement - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_30c9de69-0d58-4d45-82b1-192ff98b96e4", "decimals": "-5", "lang": null, "name": "rvmd:UpfrontCashPaymentReceived", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "us-gaap:TemporaryEquitySharesOutstanding", "span", "p", "rvmd:RedeemableConvertiblePreferredStockTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_bb62c355-4d7b-446b-8b8b-6d4c2b6901c9", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:TemporaryEquitySharesOutstanding", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100610 - Disclosure - Redeemable Convertible Preferred Stock - Additional Information (Details)", "menuCat": "Details", "order": "51", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails", "shortName": "Redeemable Convertible Preferred Stock - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "rvmd:RedeemableConvertiblePreferredStockTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_ffcd5db4-cc31-4429-a165-2d98b38ababb", "decimals": "INF", "lang": null, "name": "us-gaap:TemporaryEquitySharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockSharesAuthorized", "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_bb62c355-4d7b-446b-8b8b-6d4c2b6901c9", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100620 - Disclosure - Common Stock - Additional Information (Details)", "menuCat": "Details", "order": "52", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails", "shortName": "Common Stock - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "lang": "en-US", "name": "us-gaap:CommonStockVotingRights", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "rvmd:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_bb62c355-4d7b-446b-8b8b-6d4c2b6901c9", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100630 - Disclosure - Common Stock - Schedule of Common Stock for Future Issuance (Details)", "menuCat": "Details", "order": "53", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockForFutureIssuanceDetails", "shortName": "Common Stock - Schedule of Common Stock for Future Issuance (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "rvmd:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_eec6616c-467a-4e2c-a9b6-bcd4c88922bd", "decimals": "0", "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "rvmd:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_bb62c355-4d7b-446b-8b8b-6d4c2b6901c9", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100640 - Disclosure - Stock-Based Compensation - Additional Information (Details)", "menuCat": "Details", "order": "54", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "shortName": "Stock-Based Compensation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": "-5", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_c2836085-855f-43c6-b492-94ab482ce4ca", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100650 - Disclosure - Stock-Based Compensation - Summary of Option Activity Under the Plan (Details)", "menuCat": "Details", "order": "55", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityUnderPlanDetails", "shortName": "Stock-Based Compensation - Summary of Option Activity Under the Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_c279ffe5-6755-4ef5-9afd-20fed82cb257", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100660 - Disclosure - Summary of Fair Value of Stock Option Awards Estimated at Date of Grant (Details)", "menuCat": "Details", "order": "56", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfFairValueOfStockOptionAwardsEstimatedAtDateOfGrantDetails", "shortName": "Summary of Fair Value of Stock Option Awards Estimated at Date of Grant (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_50872ca8-3527-477f-9c97-c356155c1ee2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100670 - Disclosure - Stock-Based Compensation - Summary of RSUs Activity Under the Plan (Details)", "menuCat": "Details", "order": "57", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRsusActivityUnderPlanDetails", "shortName": "Stock-Based Compensation - Summary of RSUs Activity Under the Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_18254944-6c56-491f-95e0-4d6b8c9db56a", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100680 - Disclosure - Stock-Based Compensation - Summary of Total Stock-Based Compensation Expense Related to Stock Options, RSUs and Employee Stock Purchase Plan (Details)", "menuCat": "Details", "order": "58", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseRelatedToStockOptionsRsusAndEmployeeStockPurchasePlanDetails", "shortName": "Stock-Based Compensation - Summary of Total Stock-Based Compensation Expense Related to Stock Options, RSUs and Employee Stock Purchase Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_c0ecdafb-7c52-4ad8-863e-bc88932f4a07", "decimals": "-3", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100690 - Disclosure - Income Taxes - Additional Information (Details)", "menuCat": "Details", "order": "59", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails", "shortName": "Income Taxes - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": "-5", "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_316b60af-37e7-4043-a19a-e363318c4dfd", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100070 - Statement - CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)", "menuCat": "Statements", "order": "6", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT", "shortName": "CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_316b60af-37e7-4043-a19a-e363318c4dfd", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100700 - Disclosure - Income Taxes - Summary of Benefit from Income Taxes to Amount Computed by Applying Federal Statutory Rate to Loss Before Taxes (Details)", "menuCat": "Details", "order": "60", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfBenefitFromIncomeTaxesToAmountComputedByApplyingFederalStatutoryRateToLossBeforeTaxesDetails", "shortName": "Income Taxes - Summary of Benefit from Income Taxes to Amount Computed by Applying Federal Statutory Rate to Loss Before Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_bb62c355-4d7b-446b-8b8b-6d4c2b6901c9", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100710 - Disclosure - Income Taxes - Summary of Categories that Give Rise to Significant Components of Deferred Tax Assets (Details)", "menuCat": "Details", "order": "61", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfCategoriesThatGiveRiseToSignificantComponentsOfDeferredTaxAssetsDetails", "shortName": "Income Taxes - Summary of Categories that Give Rise to Significant Components of Deferred Tax Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_bb62c355-4d7b-446b-8b8b-6d4c2b6901c9", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_955a1704-d86a-4f16-8df1-4cb4f584d429", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100720 - Disclosure - Income Taxes - Reconciliation of Gross Unrecognized Tax Benefits (Details)", "menuCat": "Details", "order": "62", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfGrossUnrecognizedTaxBenefitsDetails", "shortName": "Income Taxes - Reconciliation of Gross Unrecognized Tax Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_8f57e848-f217-4e98-9949-4c55d6ed0ac1", "decimals": "-3", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100730 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details)", "menuCat": "Details", "order": "63", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails", "shortName": "Net Loss Per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": "0", "lang": null, "name": "rvmd:WeightedAverageNumberOfSharesIssuedBasicAndDiluted", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100740 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Outstanding Potentially Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details)", "menuCat": "Details", "order": "64", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails", "shortName": "Net Loss Per Share Attributable to Common Stockholders - Schedule of Outstanding Potentially Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_4a86c4a4-9de2-4bc5-b7f1-f7ea2b742bb8", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100080 - Statement - CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)", "menuCat": "Statements", "order": "7", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical", "shortName": "CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_4a86c4a4-9de2-4bc5-b7f1-f7ea2b742bb8", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100090 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "menuCat": "Statements", "order": "8", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Organization", "menuCat": "Notes", "order": "9", "role": "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureOrganization", "shortName": "Organization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rvmd-20221231.htm", "contextRef": "C_6214fbe5-48d7-484e-be93-65c83d6be925", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 65, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r687", "r688", "r689" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r687", "r688", "r689" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r687", "r688", "r689" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r687", "r688", "r689" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r690" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r685" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r684" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r684" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r684" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r691" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r684" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r684" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r684" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r684" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r692" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r687", "r688", "r689" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r683" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r686" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "rvmd_AccruedExpensesAndOtherCurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued expenses and other current liabilities.", "label": "Accrued Expenses And Other Current Liabilities", "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Total accrued expenses and other current liabilities" } } }, "localname": "AccruedExpensesAndOtherCurrentLiabilities", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "rvmd_AccruedExpensesAndOtherCurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accrued expenses and other current liabilities.", "label": "Accrued Expenses And Other Current Liabilities [Abstract]" } } }, "localname": "AccruedExpensesAndOtherCurrentLiabilitiesAbstract", "nsuri": "http://www.revolutionmedicines.com/20221231", "xbrltype": "stringItemType" }, "rvmd_AccruedResearchAndDevelopmentExpenseCurrent": { "auth_ref": [], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 1.0, "parentTag": "rvmd_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued research and development expense current.", "label": "Accrued Research And Development Expense Current", "terseLabel": "Accrued research and development" } } }, "localname": "AccruedResearchAndDevelopmentExpenseCurrent", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "rvmd_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExerciseOfStockOptionAndRestrictedStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments to additional paid in capital vesting of early exercise of stock option and restricted stock.", "label": "Adjustments To Additional Paid In Capital Vesting Of Early Exercise Of Stock Option And Restricted Stock", "terseLabel": "Vesting of early exercised stock options and restricted stock" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExerciseOfStockOptionAndRestrictedStock", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "monetaryItemType" }, "rvmd_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExerciseOfStockOptions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments to additional paid in capital vesting of early exercise of stock options.", "label": "Adjustments To Additional Paid In Capital Vesting Of Early Exercise Of Stock Options", "terseLabel": "Vesting of early exercised stock options" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExerciseOfStockOptions", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "monetaryItemType" }, "rvmd_AdvancePaymentsForPropertyAndEquipment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Advance Payments For Property And Equipment", "label": "Advance Payments For Property And Equipment", "terseLabel": "Advance payments for property and equipment" } } }, "localname": "AdvancePaymentsForPropertyAndEquipment", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "rvmd_AggregateGrossProceedsThroughEquityIssuanceMaximumPotentialAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate gross proceeds through equity issuance maximum potential amount.", "label": "Aggregate Gross Proceeds Through Equity Issuance Maximum Potential Amount", "terseLabel": "Aggregate gross proceeds through equity issuance maximum potential amount" } } }, "localname": "AggregateGrossProceedsThroughEquityIssuanceMaximumPotentialAmount", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rvmd_AreaOfOfficeSpaceLeased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of office space leased.", "label": "Area Of Office Space Leased", "terseLabel": "Area of space leased" } } }, "localname": "AreaOfOfficeSpaceLeased", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails" ], "xbrltype": "areaItemType" }, "rvmd_AtTheMarketEquityOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "At the market equity offering.", "label": "At The Market Equity Offering [Member]", "terseLabel": "At The Market Equity Offering" } } }, "localname": "AtTheMarketEquityOfferingMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "domainItemType" }, "rvmd_AtTheMarketEquityOfferingProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "At-the-market equity offering program.", "label": "At-the-market Equity Offering Program [Member]", "terseLabel": "ATM" } } }, "localname": "AtTheMarketEquityOfferingProgramMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rvmd_AvailableForFutureIssuanceUnderTheTwoZeroTwoZeroEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Available for future issuance under the two zero two zero employee stock purchase plan.", "label": "Available For Future Issuance Under The Two Zero Two Zero Employee Stock Purchase Plan [Member]", "terseLabel": "Available for issuance under the 2020 Employee Stock Purchase Plan" } } }, "localname": "AvailableForFutureIssuanceUnderTheTwoZeroTwoZeroEmployeeStockPurchasePlanMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockForFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "rvmd_AvailableForFutureIssuanceUnderTheTwoZeroTwoZeroIncentiveAwardPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Available for future issuance under the two zero two zero incentive award plan.", "label": "Available For Future Issuance Under The Two Zero Two Zero Incentive Award Plan [Member]", "terseLabel": "Available for Future Issuance under the 2020 Incentive Award Plan" } } }, "localname": "AvailableForFutureIssuanceUnderTheTwoZeroTwoZeroIncentiveAwardPlanMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockForFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "rvmd_BusinessCombinationContingentlyReturnableConsiderationAsset": { "auth_ref": [], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveSummaryOfPurchasePriceConsiderationForAcquisitionDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business combination, contingently returnable consideration asset.", "label": "Business Combination Contingently Returnable Consideration Asset", "negatedLabel": "Contingently returnable consideration asset", "terseLabel": "Contingently returnable consideration asset" } } }, "localname": "BusinessCombinationContingentlyReturnableConsiderationAsset", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveSummaryOfPurchasePriceConsiderationForAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "rvmd_CollaborationAgreementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration agreement.", "label": "Collaboration Agreement [Abstract]" } } }, "localname": "CollaborationAgreementAbstract", "nsuri": "http://www.revolutionmedicines.com/20221231", "xbrltype": "stringItemType" }, "rvmd_CollaborationRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration revenue member.", "label": "Collaboration Revenue Member", "terseLabel": "Collaboration Revenue" } } }, "localname": "CollaborationRevenueMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "domainItemType" }, "rvmd_CommissionsAndExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Commissions and expenses.", "label": "Commissions And Expenses", "terseLabel": "Commissions and expenses" } } }, "localname": "CommissionsAndExpenses", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rvmd_ComputerEquipmentAndSoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Computer equipment and software.", "label": "Computer Equipment And Software [Member]", "terseLabel": "Computer Equipment and Software" } } }, "localname": "ComputerEquipmentAndSoftwareMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "rvmd_ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Concentration of credit risk and other risks and uncertainties.", "label": "Concentration Of Credit Risk And Other Risks And Uncertainties Policy [Text Block]", "terseLabel": "Concentration of Credit Risk and Other Risks and Uncertainties" } } }, "localname": "ConcentrationOfCreditRiskAndOtherRisksAndUncertaintiesPolicyTextBlock", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "rvmd_ConsultantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consultant.", "label": "Consultant [Member]", "terseLabel": "Consultant" } } }, "localname": "ConsultantMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfFairValueOfStockOptionAwardsEstimatedAtDateOfGrantDetails" ], "xbrltype": "domainItemType" }, "rvmd_DeferredRentDerecognized": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred rent derecognized.", "label": "Deferred Rent Derecognized", "terseLabel": "Deferred rent derecognized" } } }, "localname": "DeferredRentDerecognized", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rvmd_DeferredTaxAssetsLeaseLiability": { "auth_ref": [], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfCategoriesThatGiveRiseToSignificantComponentsOfDeferredTaxAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets, lease liability.", "label": "Deferred Tax Assets Lease Liability", "terseLabel": "Lease liability" } } }, "localname": "DeferredTaxAssetsLeaseLiability", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfCategoriesThatGiveRiseToSignificantComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "rvmd_DeferredTaxAssetsTaxCreditCapitalizedResearchExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets Tax Credit Capitalized Research Expenses", "label": "Deferred Tax Assets Tax Credit Capitalized Research Expenses", "terseLabel": "Capitalized research expenses" } } }, "localname": "DeferredTaxAssetsTaxCreditCapitalizedResearchExpenses", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfCategoriesThatGiveRiseToSignificantComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "rvmd_DeferredTaxAssetsTaxCreditCarryforwardsResearchNotSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets tax credit carryforwards research not subject to expiration.", "label": "Deferred Tax Assets Tax Credit Carryforwards Research Not Subject To Expiration", "terseLabel": "Research and development credit carryforwards which can be carried forward indefinitely" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearchNotSubjectToExpiration", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rvmd_DeferredTaxLiabilitiesFixedAssetsAndFiniteLivedIntangibleAssets": { "auth_ref": [], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfCategoriesThatGiveRiseToSignificantComponentsOfDeferredTaxAssetsDetails": { "order": 0.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred tax liabilities fixed assets and finite-lived intangible assets.", "label": "Deferred Tax Liabilities Fixed Assets And Finite Lived Intangible Assets", "negatedLabel": "Fixed assets and finite-lived intangible assets" } } }, "localname": "DeferredTaxLiabilitiesFixedAssetsAndFiniteLivedIntangibleAssets", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfCategoriesThatGiveRiseToSignificantComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "rvmd_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets": { "auth_ref": [], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfCategoriesThatGiveRiseToSignificantComponentsOfDeferredTaxAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred tax liabilities indefinite-lived intangible assets.", "label": "Deferred Tax Liabilities Indefinite Lived Intangible Assets", "negatedLabel": "Indefinite-lived intangible assets" } } }, "localname": "DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfCategoriesThatGiveRiseToSignificantComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "rvmd_DeferredTaxLiabilitiesRightOfUseAsset": { "auth_ref": [], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfCategoriesThatGiveRiseToSignificantComponentsOfDeferredTaxAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred tax liabilities, right-of-use asset.", "label": "Deferred Tax Liabilities Right Of Use Asset", "negatedLabel": "Right-of-use asset" } } }, "localname": "DeferredTaxLiabilitiesRightOfUseAsset", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfCategoriesThatGiveRiseToSignificantComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "rvmd_DevelopedTechnologyGenomeMiningPlatformMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Developed technology - genome mining platform.", "label": "Developed Technology Genome Mining Platform [Member]", "terseLabel": "Developed Technology - Genome Mining Platform" } } }, "localname": "DevelopedTechnologyGenomeMiningPlatformMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedAtAcquisitionDateDetails" ], "xbrltype": "domainItemType" }, "rvmd_DevelopedTechnologyTriComplexPlatformMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Developed technology - tri-complex platform.", "label": "Developed Technology Tri Complex Platform [Member]", "terseLabel": "Developed Technology - Tri-complex Platform" } } }, "localname": "DevelopedTechnologyTriComplexPlatformMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedAtAcquisitionDateDetails" ], "xbrltype": "domainItemType" }, "rvmd_EightHundredSaginawDriveRedwoodCityCaliforniaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Eight hundred saginaw drive redwood city, california.", "label": "Eight Hundred Saginaw Drive Redwood City, California [Member]", "terseLabel": "The 800 Building" } } }, "localname": "EightHundredSaginawDriveRedwoodCityCaliforniaMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rvmd_EmployeeAndDirectorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee and director.", "label": "Employee And Director [Member]", "terseLabel": "Employee And Director" } } }, "localname": "EmployeeAndDirectorMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfFairValueOfStockOptionAwardsEstimatedAtDateOfGrantDetails" ], "xbrltype": "domainItemType" }, "rvmd_EstimatedVariableConsiderationForExpenseReimbursementsUponResearchAndDevelopmentServices": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Estimated variable consideration for expense reimbursements upon research and development services.", "label": "Estimated Variable Consideration For Expense Reimbursements Upon Research And Development Services", "terseLabel": "Estimated variable consideration for expense reimbursements upon research and development services" } } }, "localname": "EstimatedVariableConsiderationForExpenseReimbursementsUponResearchAndDevelopmentServices", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSanofiCollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rvmd_ExercisePriceOfEarlyExercisedSharesOfCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Exercise price of early exercised shares of common stock.", "label": "Exercise Price Of Early Exercised Shares Of Common Stock", "terseLabel": "Exercise price of early exercised shares" } } }, "localname": "ExercisePriceOfEarlyExercisedSharesOfCommonStock", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rvmd_ExpectedSharesToBePurchasedUnderESPPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expected shares to be purchased under ESPP.", "label": "Expected Shares To Be Purchased Under E S P P [Member]", "terseLabel": "Expected Shares To Be Purchased Under ESPP" } } }, "localname": "ExpectedSharesToBePurchasedUnderESPPMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "rvmd_FairValueLevel1Level2Level3TransfersAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value level1 level2 level 3 transfers amount.", "label": "Fair Value Level1 Level2 Level3 Transfers Amount", "terseLabel": "Fair value, transfers between Levels 1, 2 or 3, amount" } } }, "localname": "FairValueLevel1Level2Level3TransfersAmount", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rvmd_FollowOnOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Follow-on offering.", "label": "Follow On Offering [Member]", "terseLabel": "Follow-on Offering" } } }, "localname": "FollowOnOfferingMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical" ], "xbrltype": "domainItemType" }, "rvmd_GingkoBioworksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gingko Bioworks.", "label": "Gingko Bioworks [Member]", "terseLabel": "Gingko Bioworks" } } }, "localname": "GingkoBioworksMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rvmd_HoldbackProvisionAssociatedWithWarpDriveAgreementWithRocheMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Holdback provision associated with Warp Drive agreement with Roche.", "label": "Holdback Provision Associated With Warp Drive Agreement With Roche [Member]", "terseLabel": "Holdback Provision Associated with Warp Drive\u2019s Agreement with Roche" } } }, "localname": "HoldbackProvisionAssociatedWithWarpDriveAgreementWithRocheMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rvmd_InProcessResearchAndDevelopmentRelatedToKRASG12CProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In-process research and development related to KRASG12C program.", "label": "In Process Research And Development Related To K R A S G12 C Program [Member]", "terseLabel": "In-process Research and Development - KRASG12C Program" } } }, "localname": "InProcessResearchAndDevelopmentRelatedToKRASG12CProgramMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rvmd_InProcessResearchAndDevelopmentRelatedToKRASG12DProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In-process research and development related to KRASG12D program.", "label": "In Process Research And Development Related To K R A S G12 D Program [Member]", "terseLabel": "In-process Research and Development - KRASG12D Program" } } }, "localname": "InProcessResearchAndDevelopmentRelatedToKRASG12DProgramMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rvmd_InProcessResearchAndDevelopmentRelatedToRASProgramsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In-process research and development related to RAS programs.", "label": "In Process Research And Development Related To R A S Programs [Member]", "terseLabel": "In-process Research and Development - RAS Programs" } } }, "localname": "InProcessResearchAndDevelopmentRelatedToRASProgramsMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedAtAcquisitionDateDetails" ], "xbrltype": "domainItemType" }, "rvmd_IncomeTaxesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income taxes.", "label": "Income Taxes [Line Items]", "terseLabel": "Income Taxes [Line Items]" } } }, "localname": "IncomeTaxesLineItems", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "rvmd_IncomeTaxesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income taxes.", "label": "Income Taxes [Table]", "terseLabel": "Income Taxes [Table]" } } }, "localname": "IncomeTaxesTable", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "rvmd_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in operating lease right-of-use asset.", "label": "Increase Decrease In Operating Lease Right Of Use Asset", "terseLabel": "Increase in operating lease right-of-use asset" } } }, "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rvmd_IntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible asset, useful life.", "label": "Intangible Asset, Useful Life", "terseLabel": "In-process research and development - RAS Programs, Weighted-average remaining useful life" } } }, "localname": "IntangibleAssetUsefulLife", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwillScheduleOfIntangiblesAssetsNetDetails" ], "xbrltype": "durationItemType" }, "rvmd_IntangibleAssetsAcquiredFromBusinessCombinationPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible assets acquired from business combination policy,", "label": "Intangible Assets Acquired From Business Combination Policy Policy [Text Block]", "terseLabel": "Acquired Intangible Assets" } } }, "localname": "IntangibleAssetsAcquiredFromBusinessCombinationPolicyPolicyTextBlock", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "rvmd_IntangibleAssetsMeasurementInput": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible assets measurement input.", "label": "Intangible Assets Measurement Input", "terseLabel": "Intangible assets, measurement input" } } }, "localname": "IntangibleAssetsMeasurementInput", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "rvmd_LaboratoryEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Laboratory equipment.", "label": "Laboratory Equipment [Member]", "terseLabel": "Laboratory Equipment" } } }, "localname": "LaboratoryEquipmentMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "rvmd_LeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfBalanceSheetClassificationOfOperatingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease liabilities.", "label": "Lease Liabilities", "totalLabel": "Total lease liabilities" } } }, "localname": "LeaseLiabilities", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfBalanceSheetClassificationOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "rvmd_LesseeOperatingLeaseExpirationMonthAndYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee operating lease expiration month and year.", "label": "Lessee Operating Lease Expiration Month And Year", "terseLabel": "Lessee operating lease expiration month and year" } } }, "localname": "LesseeOperatingLeaseExpirationMonthAndYear", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails" ], "xbrltype": "gYearMonthItemType" }, "rvmd_LesseeOperatingLeaseLiabilityTenantImprovementAllowance": { "auth_ref": [], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee operating lease liability tenant improvement allowance.", "label": "Lessee Operating Lease Liability Tenant Improvement Allowance", "negatedLabel": "Less: Tenant improvement allowance" } } }, "localname": "LesseeOperatingLeaseLiabilityTenantImprovementAllowance", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "rvmd_LetterAgreementForRmcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Letter agreement for RMC Member.", "label": "Letter Agreement for RMC [Member]", "terseLabel": "Letter Agreement for the RMC" } } }, "localname": "LetterAgreementForRmcMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSanofiCollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rvmd_MarketableSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Marketable securities.", "label": "Marketable Securities [Member]", "terseLabel": "Marketable Securities" } } }, "localname": "MarketableSecuritiesMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfEstimatedValueOfAvailableForSaleSecuritiesAndCashEquivalentsAndGrossUnrealizedGainsAndLossesDetails" ], "xbrltype": "domainItemType" }, "rvmd_MatureAfterOneYearThroughTwoYearsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mature after one year through two years.", "label": "Mature After One Year Through Two Years [Member]", "terseLabel": "Mature after One Year through Two Years" } } }, "localname": "MatureAfterOneYearThroughTwoYearsMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAmortizedCostAndEstimatedFairValueOfAvailableForSaleSecuritiesAndCashEquivalentsByContractualMaturityDetails" ], "xbrltype": "domainItemType" }, "rvmd_MatureInOneYearOrLessMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mature in one year or less.", "label": "Mature In One Year Or Less [Member]", "terseLabel": "Mature in One Year or Less" } } }, "localname": "MatureInOneYearOrLessMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAmortizedCostAndEstimatedFairValueOfAvailableForSaleSecuritiesAndCashEquivalentsByContractualMaturityDetails" ], "xbrltype": "domainItemType" }, "rvmd_MaximumDevelopmentAndRegulatoryMilestonePaymentsToBeReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Maximum development and regulatory milestone payments to be received.", "label": "Maximum Development And Regulatory Milestone Payments To Be Received", "terseLabel": "Maximum development and regulatory milestone payments to be received" } } }, "localname": "MaximumDevelopmentAndRegulatoryMilestonePaymentsToBeReceived", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSanofiCollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rvmd_MaximumMilestonePaymentsReceivableUponAchievementOfCertainMarketingApprovalMilestones": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Maximum milestone payments receivable upon achievement of certain marketing approval milestones.", "label": "Maximum Milestone Payments Receivable Upon Achievement Of Certain Marketing Approval Milestones", "terseLabel": "Maximum milestone payments receivable upon achievement of certain marketing approval milestones" } } }, "localname": "MaximumMilestonePaymentsReceivableUponAchievementOfCertainMarketingApprovalMilestones", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSanofiCollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rvmd_MaximumMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentMilestones": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Maximum milestone payments receivable upon achievement of specified development milestones.", "label": "Maximum Milestone Payments Receivable Upon Achievement Of Specified Development Milestones", "terseLabel": "Maximum milestone payments receivable upon achievement of specified development milestones" } } }, "localname": "MaximumMilestonePaymentsReceivableUponAchievementOfSpecifiedDevelopmentMilestones", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSanofiCollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rvmd_NetOperatingLossCarryforwardsExpectedToExpirationUnutilizedDueToLimitationsOnUse": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net operating loss carryforwards expected to expiration unutilized due to limitations on use.", "label": "Net Operating Loss Carryforwards Expected To Expiration Unutilized Due To Limitations On Use", "terseLabel": "Net operating losses expected to expire unutilized as a result of the limitation" } } }, "localname": "NetOperatingLossCarryforwardsExpectedToExpirationUnutilizedDueToLimitationsOnUse", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rvmd_NetOperatingLossCarryforwardsExpirationStartingYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net operating loss carryforwards expiration starting year.", "label": "Net Operating Loss Carryforwards Expiration Starting Year", "terseLabel": "Net operating loss carryforwards expiration beginning year" } } }, "localname": "NetOperatingLossCarryforwardsExpirationStartingYear", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "gYearItemType" }, "rvmd_NumberOfVotingRightsPerCommonShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of voting rights per common share.", "label": "Number Of Voting Rights Per Common Share", "terseLabel": "Number of voting rights per common share" } } }, "localname": "NumberOfVotingRightsPerCommonShare", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "rvmd_OptionsEarlyExercisedSubjectToFutureVestingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options early exercised subject to future vesting member.", "label": "Options Early Exercised Subject To Future Vesting [Member]", "terseLabel": "Options Early Exercised Subject to Future Vesting" } } }, "localname": "OptionsEarlyExercisedSubjectToFutureVestingMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "rvmd_OptionsToPurchaseCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options to purchase common stock.", "label": "Options To Purchase Common Stock [Member]", "terseLabel": "Option to Purchase Common Stock" } } }, "localname": "OptionsToPurchaseCommonStockMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "rvmd_OutstandingOptionsToPurchaseCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding options to purchase common stock.", "label": "Outstanding Options To Purchase Common Stock [Member]", "terseLabel": "Outstanding Options to Purchase Common Stock" } } }, "localname": "OutstandingOptionsToPurchaseCommonStockMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockForFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "rvmd_PaymentsOfDeferredOfferingCosts": { "auth_ref": [], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments of deferred offering costs.", "label": "Payments Of Deferred Offering Costs", "negatedLabel": "Payments of deferred offering costs" } } }, "localname": "PaymentsOfDeferredOfferingCosts", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "rvmd_PercentageOfMaximumMilestonePaymentsReceivable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of maximum milestone payments receivable.", "label": "Percentage Of Maximum Milestone Payments Receivable", "terseLabel": "Percentage of future milestones payments receivable" } } }, "localname": "PercentageOfMaximumMilestonePaymentsReceivable", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "rvmd_PercentageOfOtherInternalAndExternalCostsAndExpensesIncurredUnderResearchAndDevelopmentPlans": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of other internal and external costs and expenses incurred under research and development plans.", "label": "Percentage Of Other Internal And External Costs And Expenses Incurred Under Research And Development Plans", "terseLabel": "Percentage of other internal and external costs and expenses incurred under research and development plans" } } }, "localname": "PercentageOfOtherInternalAndExternalCostsAndExpensesIncurredUnderResearchAndDevelopmentPlans", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSanofiCollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "rvmd_PercentageOfReimbursementOfInternalAndExternalResearchCostsAndExpensesUnderResearchPlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of reimbursement of internal and external research costs and expenses under research plan.", "label": "Percentage Of Reimbursement Of Internal And External Research Costs And Expenses Under Research Plan", "terseLabel": "Percentage of reimbursement of internal and external research costs and expenses under research plan" } } }, "localname": "PercentageOfReimbursementOfInternalAndExternalResearchCostsAndExpensesUnderResearchPlan", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSanofiCollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "rvmd_ProceedsFromIssuanceOfCommonStockFromAtTheMarketOffering": { "auth_ref": [], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of common stock from at the market offering.", "label": "Proceeds From Issuance Of Common Stock From At The Market Offering", "terseLabel": "Proceeds from issuance of common stock from at-the-market offering" } } }, "localname": "ProceedsFromIssuanceOfCommonStockFromAtTheMarketOffering", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "rvmd_ProceedsFromIssuanceOfCommonStockGross": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of common stock gross.", "label": "Proceeds From Issuance Of Common Stock Gross", "terseLabel": "Proceeds from issuance of common stock gross" } } }, "localname": "ProceedsFromIssuanceOfCommonStockGross", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rvmd_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan": { "auth_ref": [], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of common stock under employee stock purchase plan.", "label": "Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan", "terseLabel": "Proceeds from issuance of common stock under employee stock purchase plan" } } }, "localname": "ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "rvmd_ProceedsFromMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from maturity of marketable securities.", "label": "Proceeds From Maturity Of Marketable Securities", "terseLabel": "Maturities of marketable securities" } } }, "localname": "ProceedsFromMaturityOfMarketableSecurities", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "rvmd_ProceedsFromSaleOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from sale of marketable securities.", "label": "Proceeds From Sale Of Marketable Securities", "terseLabel": "Sales of marketable securities" } } }, "localname": "ProceedsFromSaleOfMarketableSecurities", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "rvmd_PropertyAndEquipmentEstimatedUsefulLivesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Property and equipment estimated useful lives.", "label": "Property And Equipment Estimated Useful Lives Table [Text Block]", "terseLabel": "Schedule of Useful Lives of Property and Equipment" } } }, "localname": "PropertyAndEquipmentEstimatedUsefulLivesTableTextBlock", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "rvmd_RedeemableConvertiblePreferredStockDividendsUndeclaredAndCumulative": { "auth_ref": [], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 }, "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Redeemable convertible preferred stock dividends - undeclared and cumulative.", "label": "Redeemable Convertible Preferred Stock Dividends Undeclared And Cumulative", "negatedLabel": "Redeemable convertible preferred stock dividends - undeclared and cumulative" } } }, "localname": "RedeemableConvertiblePreferredStockDividendsUndeclaredAndCumulative", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "rvmd_RedeemableConvertiblePreferredStockLiabilityPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redeemable convertible preferred stock liability policy.", "label": "Redeemable Convertible Preferred Stock Liability Policy Policy [Text Block]", "terseLabel": "Redeemable Convertible Preferred Stock Liability" } } }, "localname": "RedeemableConvertiblePreferredStockLiabilityPolicyPolicyTextBlock", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "rvmd_RedeemableConvertiblePreferredStockTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redeemable convertible preferred stock.", "label": "Redeemable Convertible Preferred Stock [Text Block]", "terseLabel": "Redeemable Convertible Preferred Stock" } } }, "localname": "RedeemableConvertiblePreferredStockTextBlock", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStock" ], "xbrltype": "textBlockItemType" }, "rvmd_RedeemableConvertiblePreferredStockTrancheLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Redeemable convertible preferred stock tranche liability.", "label": "Redeemable Convertible Preferred Stock Tranche Liability", "terseLabel": "Redeemable convertible preferred stock tranche liability" } } }, "localname": "RedeemableConvertiblePreferredStockTrancheLiability", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rvmd_RedeemableConvertiblePreferredStockTrancheObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Redeemable convertible preferred stock tranche obligation.", "label": "Redeemable Convertible Preferred Stock Tranche Obligation", "terseLabel": "Redeemable convertible preferred stock tranche obligation" } } }, "localname": "RedeemableConvertiblePreferredStockTrancheObligation", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rvmd_ReductionInCollaborationRevenue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reduction in Collaboration Revenue", "label": "Reduction in Collaboration Revenue", "terseLabel": "Reduction in collaboration revenue" } } }, "localname": "ReductionInCollaborationRevenue", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSanofiCollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rvmd_RedwoodCityCaliforniaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redwood City, California.", "label": "Redwood City California [Member]", "terseLabel": "Redwood City Lease" } } }, "localname": "RedwoodCityCaliforniaMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rvmd_ResearchAndDevelopmentTaxCreditCarryforwardsExpirationStartingYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research and development credit carryforwards expiration starting year.", "label": "Research And Development Tax Credit Carryforwards Expiration Starting Year", "terseLabel": "Research and development credit carryforwards expiration starting year" } } }, "localname": "ResearchAndDevelopmentTaxCreditCarryforwardsExpirationStartingYear", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "gYearItemType" }, "rvmd_RestrictedCashMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted cash.", "label": "Restricted Cash [Member]", "terseLabel": "Restricted Cash" } } }, "localname": "RestrictedCashMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rvmd_RestrictedCashPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted cash.", "label": "Restricted Cash Policy [Text Block]", "terseLabel": "Restricted Cash" } } }, "localname": "RestrictedCashPolicyTextBlock", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "rvmd_ReverseStockSplitPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reverse stock split policy.", "label": "Reverse Stock Split Policy Policy [Text Block]", "terseLabel": "Reverse Stock Split" } } }, "localname": "ReverseStockSplitPolicyPolicyTextBlock", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "rvmd_SanofiAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sanofi agreement.", "label": "Sanofi Agreement [Member]", "terseLabel": "Sanofi Agreement" } } }, "localname": "SanofiAgreementMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSanofiCollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rvmd_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of accrued expenses and other current liabilities.", "label": "Schedule Of Accrued Expenses And Other Current Liabilities Table [Text Block]", "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities" } } }, "localname": "ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "rvmd_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of common stock reserved for future issuance table text block.", "label": "Schedule Of Common Stock Reserved For Future Issuance Table [Text Block]", "terseLabel": "Schedule of Common Stock for Future Issuance" } } }, "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommonStockTables" ], "xbrltype": "textBlockItemType" }, "rvmd_SeriesARedeemableConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A redeemable convertible preferred stock.", "label": "Series A Redeemable Convertible Preferred Stock [Member]", "terseLabel": "Series A Redeemable Convertible Preferred Stock", "verboseLabel": "Series A" } } }, "localname": "SeriesARedeemableConvertiblePreferredStockMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rvmd_SeriesBRedeemableConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B redeemable convertible preferred stock.", "label": "Series B Redeemable Convertible Preferred Stock [Member]", "terseLabel": "Series B Redeemable Convertible Preferred Stock", "verboseLabel": "Series B" } } }, "localname": "SeriesBRedeemableConvertiblePreferredStockMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveSummaryOfPurchasePriceConsiderationForAcquisitionDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rvmd_SeriesCRedeemableConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series C redeemable convertible preferred stock.", "label": "Series C Redeemable Convertible Preferred Stock [Member]", "terseLabel": "Series C Redeemable Convertible Preferred Stock", "verboseLabel": "Series C" } } }, "localname": "SeriesCRedeemableConvertiblePreferredStockMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rvmd_SevenHundredAndThreeHundredSaginawDriveRedwoodCityCaliforniaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Seven hundred and three hundred saginaw drive redwood city california.", "label": "Seven Hundred and Three Hundred Saginaw Drive Redwood City California [Member]", "terseLabel": "The 700 Building and 300 Building" } } }, "localname": "SevenHundredAndThreeHundredSaginawDriveRedwoodCityCaliforniaMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rvmd_SevenHundredSaginawDriveRedwoodCityCaliforniaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "700 Saginaw Drive, Redwood City, California.", "label": "Seven Hundred Saginaw Drive Redwood City California [Member]", "terseLabel": "The 700 Building" } } }, "localname": "SevenHundredSaginawDriveRedwoodCityCaliforniaMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rvmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExpectedToVest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options aggregate intrinsic value expected to vest.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Expected To Vest", "terseLabel": "Aggregate intrinsic value, Expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExpectedToVest", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRsusActivityUnderPlanDetails" ], "xbrltype": "monetaryItemType" }, "rvmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestOutstandingNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options expected to vest outstanding number.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expected To Vest Outstanding Number", "terseLabel": "Number of Shares, Expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestOutstandingNumber", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRsusActivityUnderPlanDetails" ], "xbrltype": "sharesItemType" }, "rvmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options expected to vest weighted average grant date fair value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expected To Vest Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant date fair value per share, Expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRsusActivityUnderPlanDetails" ], "xbrltype": "perShareItemType" }, "rvmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardsEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment awards equity instruments other than options expected to vest weighted average remaining contractual term.", "label": "Share Based Compensation Arrangement By Share Based Payment Awards Equity Instruments Other Than Options Expected To Vest Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-average remaining contractual term, Expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardsEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageRemainingContractualTerm", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRsusActivityUnderPlanDetails" ], "xbrltype": "durationItemType" }, "rvmd_SharesOfCommonStockSubjectToRepurchase": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares of common stock subject to repurchase.", "label": "Shares Of Common Stock Subject To Repurchase", "terseLabel": "Shares subject to repurchase" } } }, "localname": "SharesOfCommonStockSubjectToRepurchase", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "rvmd_StockIssuedDuringPeriodSharesStockOptionsEarlyExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares stock options early exercised.", "label": "Stock Issued During Period Shares Stock Options Early Exercised", "terseLabel": "Issuance of common stock pursuant to early exercised stock options, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsEarlyExercised", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "sharesItemType" }, "rvmd_StockIssuedDuringPeriodSharesVestingOfRestrictedStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares vesting of restricted stock.", "label": "Stock Issued During Period Shares Vesting Of Restricted Stock", "terseLabel": "Issuance of common stock related to vesting of restricted stock units, shares" } } }, "localname": "StockIssuedDuringPeriodSharesVestingOfRestrictedStock", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "sharesItemType" }, "rvmd_StockIssuedDuringPeriodValueStockOptionsEarlyExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value stock options early exercised.", "label": "Stock Issued During Period Value Stock Options Early Exercised", "terseLabel": "Issuance of common stock pursuant to early exercised stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsEarlyExercised", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "monetaryItemType" }, "rvmd_StockIssuedDuringPeriodValueVestingOfRestrictedStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value vesting of restricted stock.", "label": "Stock Issued During Period Value Vesting Of Restricted Stock", "terseLabel": "Issuance of common stock related to vesting of restricted stock units" } } }, "localname": "StockIssuedDuringPeriodValueVestingOfRestrictedStock", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "monetaryItemType" }, "rvmd_StockVotingRightsDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock voting rights description.", "label": "Stock Voting Rights Description", "terseLabel": "Stock voting rights description" } } }, "localname": "StockVotingRightsDescription", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "rvmd_SummaryOfBalanceSheetClassificationOfLeaseLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of balance sheet classification of lease liabilities.", "label": "Summary Of Balance Sheet Classification Of Lease Liabilities Table [Text Block]", "terseLabel": "Summary of Balance Sheet Classification of Operating Lease Liabilities" } } }, "localname": "SummaryOfBalanceSheetClassificationOfLeaseLiabilitiesTableTextBlock", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "rvmd_SummaryOfBalanceSheetClassificationOfOperatingLeaseLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of balance sheet classification of operating lease liabilities.", "label": "Summary Of Balance Sheet Classification Of Operating Lease Liabilities [Table Text Block]", "terseLabel": "Summary of Balance Sheet Classification of Operating Lease Liabilities" } } }, "localname": "SummaryOfBalanceSheetClassificationOfOperatingLeaseLiabilitiesTableTextBlock", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "rvmd_SummaryOfSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "Summary Of Significant Accounting Policies [Line Items]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "rvmd_SummaryOfSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Table]", "terseLabel": "Summary Of Significant Accounting Policies [Table]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesTable", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "rvmd_TaxCutsAndJobsActOf2017NetOperatingLossesLimitationPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax cuts and jobs act of 2017 net operating losses limitation percentage.", "label": "Tax Cuts And Jobs Act Of2017 Net Operating Losses Limitation Percentage", "terseLabel": "Tax cut and jobs act net operating loss deduction limitation percentage" } } }, "localname": "TaxCutsAndJobsActOf2017NetOperatingLossesLimitationPercentage", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "rvmd_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary equity, stock issued during period, shares, new issues.", "label": "Temporary Equity Stock Issued During Period Shares New Issues", "terseLabel": "Issuance of redeemable convertible preferred stock, net of issuance costs, shares", "verboseLabel": "Redeemable convertible preferred stock, shares issued" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "sharesItemType" }, "rvmd_ThreeHundredSaginawDriveRedwoodCityCaliforniaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "300 Saginaw Drive, Redwood City, California.", "label": "Three Hundred Saginaw Drive Redwood City California [Member]", "terseLabel": "The 300 Building" } } }, "localname": "ThreeHundredSaginawDriveRedwoodCityCaliforniaMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rvmd_TransactionPrice": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Transaction price.", "label": "Transaction Price", "terseLabel": "Transaction price" } } }, "localname": "TransactionPrice", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSanofiCollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rvmd_TwoThousandFourteenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand fourteen equity incentive plan.", "label": "Two Thousand Fourteen Equity Incentive Plan [Member]", "terseLabel": "2014 Equity Incentive Plan" } } }, "localname": "TwoThousandFourteenEquityIncentivePlanMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rvmd_TwoThousandTwentyAndTwoThousandFourteenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty and two thousand fourteen equity incentive plan.", "label": "Two Thousand Twenty And Two Thousand Fourteen Equity Incentive Plan [Member]", "terseLabel": "2020 Plan and 2014 Plan" } } }, "localname": "TwoThousandTwentyAndTwoThousandFourteenEquityIncentivePlanMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityUnderPlanDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "domainItemType" }, "rvmd_TwoThousandTwentyEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty employee stock purchase plan.", "label": "Two Thousand Twenty Employee Stock Purchase Plan [Member]", "terseLabel": "2020 Employee Stock Purchase Plan" } } }, "localname": "TwoThousandTwentyEmployeeStockPurchasePlanMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rvmd_TwoThousandTwentyEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty equity incentive plan.", "label": "Two Thousand Twenty Equity Incentive Plan [Member]", "terseLabel": "2020 Equity Incentive Plan" } } }, "localname": "TwoThousandTwentyEquityIncentivePlanMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "domainItemType" }, "rvmd_TwoThousandTwentyEquityIncentivePlansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty equity incentive plan.", "label": "Two Thousand Twenty Equity Incentive Plans [Member]", "terseLabel": "2020 Equity Incentive Plan" } } }, "localname": "TwoThousandTwentyEquityIncentivePlansMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRsusActivityUnderPlanDetails" ], "xbrltype": "domainItemType" }, "rvmd_UnderwrittenPublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Underwritten public offering.", "label": "Underwritten Public Offering [Member]", "terseLabel": "Underwritten Public Offering" } } }, "localname": "UnderwrittenPublicOfferingMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rvmd_UnpaidDeferredOfferingCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Unpaid deferred offering costs.", "label": "Unpaid Deferred Offering Costs", "terseLabel": "Unpaid deferred offering costs" } } }, "localname": "UnpaidDeferredOfferingCosts", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "rvmd_UnvestedRestrictedStockUnitsOfCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unvested restricted stock units of common stock.", "label": "Unvested Restricted Stock Units Of Common Stock [Member]", "terseLabel": "Unvested Restricted Stock Units Of Common Stock" } } }, "localname": "UnvestedRestrictedStockUnitsOfCommonStockMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockForFutureIssuanceDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "rvmd_UpfrontCashPaymentReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Upfront cash payment received.", "label": "Upfront Cash Payment Received", "terseLabel": "Upfront cash payment received" } } }, "localname": "UpfrontCashPaymentReceived", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSanofiCollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rvmd_UsAndCanadianGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "US and Canadian government agencies debt securities.", "label": "US and Canadian Government Agencies Debt Securities [Member]", "terseLabel": "U.S. and Canadian Government And Agency Securities" } } }, "localname": "UsAndCanadianGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfEstimatedValueOfAvailableForSaleSecuritiesAndCashEquivalentsAndGrossUnrealizedGainsAndLossesDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "rvmd_VestingOfEarlyExercisedOptionsAndRestrictedStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Vesting of early exercised options and restricted stock.", "label": "Vesting Of Early Exercised Options And Restricted Stock", "terseLabel": "Vesting of early exercised options and restricted stock" } } }, "localname": "VestingOfEarlyExercisedOptionsAndRestrictedStock", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "rvmd_WarpDriveBioIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warp Drive Bio, Inc.", "label": "Warp Drive Bio Inc [Member]", "terseLabel": "Warp Drive", "verboseLabel": "Warp Drive" } } }, "localname": "WarpDriveBioIncMember", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedAtAcquisitionDateDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveSummaryOfProformaFinancialInformationOfAcquisitionDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveSummaryOfPurchasePriceConsiderationForAcquisitionDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rvmd_WeightedAverageNumberOfSharesIssuedBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average number of shares issued basic and diluted.", "label": "Weighted Average Number Of Shares Issued Basic And Diluted", "terseLabel": "Weighted-average shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesIssuedBasicAndDiluted", "nsuri": "http://www.revolutionmedicines.com/20221231", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" ], "xbrltype": "sharesItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r183", "r226", "r234", "r241", "r313", "r441", "r442", "r443", "r470", "r471", "r506", "r509", "r511", "r512", "r566" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative Effect Period of Adoption Adjustment" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r183", "r226", "r234", "r241", "r313", "r441", "r442", "r443", "r470", "r471", "r506", "r509", "r511", "r512", "r566" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r183", "r226", "r234", "r241", "r313", "r441", "r442", "r443", "r470", "r471", "r506", "r509", "r511", "r512", "r566" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r343", "r344", "r345", "r346", "r402", "r599", "r617", "r645", "r646", "r665", "r673", "r682", "r744", "r796", "r797", "r798", "r799", "r800", "r801" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfFairValueOfStockOptionAwardsEstimatedAtDateOfGrantDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r343", "r344", "r345", "r346", "r402", "r599", "r617", "r645", "r646", "r665", "r673", "r682", "r744", "r796", "r797", "r798", "r799", "r800", "r801" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfFairValueOfStockOptionAwardsEstimatedAtDateOfGrantDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r287", "r601", "r666", "r680", "r739", "r740", "r746", "r806" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSanofiCollaborationAgreementAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r287", "r601", "r666", "r680", "r739", "r740", "r746", "r806" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSanofiCollaborationAgreementAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r343", "r344", "r345", "r346", "r395", "r402", "r432", "r433", "r434", "r575", "r599", "r617", "r645", "r646", "r665", "r673", "r682", "r738", "r744", "r797", "r798", "r799", "r800", "r801" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfFairValueOfStockOptionAwardsEstimatedAtDateOfGrantDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r343", "r344", "r345", "r346", "r395", "r402", "r432", "r433", "r434", "r575", "r599", "r617", "r645", "r646", "r665", "r673", "r682", "r738", "r744", "r797", "r798", "r799", "r800", "r801" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfFairValueOfStockOptionAwardsEstimatedAtDateOfGrantDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "auth_ref": [ "r644", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815" ], "lang": { "en-us": { "role": { "label": "Name of Property [Axis]", "terseLabel": "Name of Property" } } }, "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "auth_ref": [ "r644", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815" ], "lang": { "en-us": { "role": { "label": "Name of Property [Domain]", "terseLabel": "Name of Property" } } }, "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r288", "r289", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r667", "r681", "r746" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r288", "r289", "r630", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r667", "r681", "r746" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r718", "r793" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfFairValueOfStockOptionAwardsEstimatedAtDateOfGrantDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfFairValueOfStockOptionAwardsEstimatedAtDateOfGrantDetails" ], "xbrltype": "domainItemType" }, "stpr_MA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MASSACHUSETTS", "terseLabel": "Cambridge, Massachusetts", "verboseLabel": "Massachusetts" } } }, "localname": "MA", "nsuri": "http://xbrl.sec.gov/stpr/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "stpr_NJ": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NEW JERSEY", "terseLabel": "New Jersey" } } }, "localname": "NJ", "nsuri": "http://xbrl.sec.gov/stpr/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "ASU 2016-02", "verboseLabel": "ASC 842" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201613Member": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.", "label": "Accounting Standards Update 2016-13 [Member]", "terseLabel": "ASU 2016-13" } } }, "localname": "AccountingStandardsUpdate201613Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201815Member": { "auth_ref": [ "r337", "r338" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2018-15 Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (a consensus of the FASB Emerging Issues Task Force).", "label": "Accounting Standards Update 2018-15 [Member]", "terseLabel": "ASU 2018-15" } } }, "localname": "AccountingStandardsUpdate201815Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201912Member": { "auth_ref": [ "r468", "r469", "r470", "r471" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2019-12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.", "label": "Accounting Standards Update 2019-12 [Member]", "terseLabel": "ASU 2019-12" } } }, "localname": "AccountingStandardsUpdate201912Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "auth_ref": [ "r181", "r182", "r183", "r184", "r185", "r228", "r229", "r230", "r294", "r295", "r310", "r311", "r312", "r313", "r315", "r316", "r441", "r442", "r443", "r470", "r471", "r485", "r486", "r487", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r524", "r525", "r527", "r528", "r529", "r530", "r531", "r532", "r539", "r540", "r545", "r546", "r547", "r563", "r564", "r565", "r566", "r567", "r568", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r713" ], "lang": { "en-us": { "role": { "documentation": "Indicates amendment to accounting standards.", "label": "Accounting Standards Update [Extensible Enumeration]" } } }, "localname": "AccountingStandardsUpdateExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r16", "r679" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "totalLabel": "Accounts Payable, Current, Total" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableGrossCurrent": { "auth_ref": [ "r199", "r291", "r292", "r650" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, before Allowance for Credit Loss, Current", "terseLabel": "Account receivable" } } }, "localname": "AccountsReceivableGrossCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r49" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "Net amortization of premium (discount) on marketable securities" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "auth_ref": [ "r18" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 0.0, "parentTag": "rvmd_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Employee Benefits, Current", "terseLabel": "Accrued compensation" } } }, "localname": "AccruedEmployeeBenefitsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r18" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 3.0, "parentTag": "rvmd_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional services" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r86", "r191" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: accumulated depreciation and amortization", "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r27", "r28", "r29", "r200", "r613", "r625", "r629" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r26", "r29", "r142", "r568", "r620", "r621", "r701", "r702", "r703", "r710", "r711", "r712" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r11" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance", "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r441", "r442", "r443", "r710", "r711", "r712", "r785" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r181", "r182", "r183", "r184", "r185", "r228", "r229", "r230", "r231", "r241", "r294", "r295", "r310", "r311", "r312", "r313", "r315", "r316", "r441", "r442", "r443", "r468", "r469", "r470", "r471", "r485", "r486", "r487", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r524", "r525", "r527", "r528", "r529", "r530", "r531", "r532", "r539", "r540", "r545", "r546", "r547", "r548", "r563", "r564", "r565", "r566", "r567", "r568", "r603", "r604", "r605", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]", "terseLabel": "Accounting Standards Update" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r120", "r121", "r404" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense", "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r97", "r104" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "terseLabel": "Stock issuance cost" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash (used in) provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r436" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseRelatedToStockOptionsRsusAndEmployeeStockPurchasePlanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r48", "r71", "r77" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets", "totalLabel": "Amortization of Intangible Assets, Total", "verboseLabel": "Amortization expenses" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwillAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Potentially dilutive shares" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSanofiCollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r155", "r169", "r195", "r219", "r272", "r281", "r285", "r304", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r494", "r498", "r523", "r679", "r742", "r743", "r794" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r187", "r201", "r219", "r304", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r494", "r498", "r523", "r679", "r742", "r743", "r794" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r146" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Assets fair value", "totalLabel": "Assets, Fair Value Disclosure, Total" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r67" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfEstimatedValueOfAvailableForSaleSecuritiesAndCashEquivalentsAndGrossUnrealizedGainsAndLossesDetails": { "order": 0.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gain" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAmortizedCostAndEstimatedFairValueOfAvailableForSaleSecuritiesAndCashEquivalentsByContractualMaturityDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfEstimatedValueOfAvailableForSaleSecuritiesAndCashEquivalentsAndGrossUnrealizedGainsAndLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r68" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfEstimatedValueOfAvailableForSaleSecuritiesAndCashEquivalentsAndGrossUnrealizedGainsAndLossesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Gross Unrealized Loss" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAmortizedCostAndEstimatedFairValueOfAvailableForSaleSecuritiesAndCashEquivalentsByContractualMaturityDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfEstimatedValueOfAvailableForSaleSecuritiesAndCashEquivalentsAndGrossUnrealizedGainsAndLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r299", "r322" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfEstimatedValueOfAvailableForSaleSecuritiesAndCashEquivalentsAndGrossUnrealizedGainsAndLossesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "terseLabel": "Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAmortizedCostAndEstimatedFairValueOfAvailableForSaleSecuritiesAndCashEquivalentsByContractualMaturityDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfEstimatedValueOfAvailableForSaleSecuritiesAndCashEquivalentsAndGrossUnrealizedGainsAndLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Abstract]" } } }, "localname": "AvailableForSaleSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r66", "r297", "r322", "r608" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfEstimatedValueOfAvailableForSaleSecuritiesAndCashEquivalentsAndGrossUnrealizedGainsAndLossesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "terseLabel": "Estimated Fair Value", "totalLabel": "Estimated Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAmortizedCostAndEstimatedFairValueOfAvailableForSaleSecuritiesAndCashEquivalentsByContractualMaturityDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfEstimatedValueOfAvailableForSaleSecuritiesAndCashEquivalentsAndGrossUnrealizedGainsAndLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r407", "r408", "r409", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r431", "r432", "r433", "r434", "r435" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockForFutureIssuanceDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRsusActivityUnderPlanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r144", "r145" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Balance Sheet Related Disclosures [Abstract]" } } }, "localname": "BalanceSheetRelatedDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r483", "r671", "r672" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedAtAcquisitionDateDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveSummaryOfProformaFinancialInformationOfAcquisitionDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveSummaryOfPurchasePriceConsiderationForAcquisitionDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r132", "r133", "r483", "r671", "r672" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedAtAcquisitionDateDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveSummaryOfProformaFinancialInformationOfAcquisitionDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveSummaryOfPurchasePriceConsiderationForAcquisitionDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.", "label": "Business Acquisition, Transaction Costs", "terseLabel": "Transaction costs" } } }, "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of equity interests issued or issuable to acquire entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares", "terseLabel": "Business acquisition, shares issued" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedAtAcquisitionDateDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveSummaryOfProformaFinancialInformationOfAcquisitionDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveSummaryOfPurchasePriceConsiderationForAcquisitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "auth_ref": [ "r781", "r782" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "terseLabel": "Summary of Proforma Financial Information of Acquisition" } } }, "localname": "BusinessAcquisitionProFormaInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "auth_ref": [ "r481", "r482" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "terseLabel": "Net loss" } } }, "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveSummaryOfProformaFinancialInformationOfAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r481", "r482" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "Business Acquisition, Pro Forma Revenue", "terseLabel": "Revenue" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveSummaryOfProformaFinancialInformationOfAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r130" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "terseLabel": "Acquisition-related costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r136", "r137", "r138" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveSummaryOfPurchasePriceConsiderationForAcquisitionDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Business acquisition, total consideration", "totalLabel": "Total consideration" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveSummaryOfPurchasePriceConsiderationForAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "auth_ref": [ "r136", "r137" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveSummaryOfPurchasePriceConsiderationForAcquisitionDetails": { "order": 0.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable", "terseLabel": "Series B redeemable convertible preferred stock" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveSummaryOfPurchasePriceConsiderationForAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredOther1": { "auth_ref": [ "r139" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tangible or intangible assets, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash.", "label": "Business Combination, Consideration Transferred, Other", "terseLabel": "Business acquisition, other consideration" } } }, "localname": "BusinessCombinationConsiderationTransferredOther1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r141", "r484" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Acquisition of Warp Drive" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDrive" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": { "auth_ref": [ "r131" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.", "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual", "negatedLabel": "Net loss of acquiree since acquisition date" } } }, "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": { "auth_ref": [ "r131" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.", "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual", "terseLabel": "Revenue of acquiree since acquisition date" } } }, "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": { "auth_ref": [ "r134" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets", "terseLabel": "In-process research and development - RAS programs" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r52", "r53", "r54" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Purchases of property and equipment in accounts payable and accrued expenses and other current liabilities" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r50", "r189", "r649" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r44", "r50", "r55" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash - end of year", "periodStartLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance", "totalLabel": "Cash, cash equivalents and restricted cash - end of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]", "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash to consolidated balance sheets" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r44", "r50", "r55" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash, cash equivalents and restricted cash - end of year", "periodStartLabel": "Cash, cash equivalents and restricted cash - beginning of year", "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r44", "r151" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsMember": { "auth_ref": [ "r189" ], "lang": { "en-us": { "role": { "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Equivalents [Member]", "terseLabel": "Cash Equivalents" } } }, "localname": "CashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfEstimatedValueOfAvailableForSaleSecuritiesAndCashEquivalentsAndGrossUnrealizedGainsAndLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosure of non-cash investing and financing activities" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": { "auth_ref": [ "r181", "r182", "r227", "r294", "r295", "r306", "r307", "r308", "r310", "r311", "r468", "r485", "r486", "r500", "r503", "r504", "r514", "r524", "r526", "r527", "r528", "r531", "r532", "r539", "r544", "r545", "r546", "r547", "r563", "r564", "r603", "r604", "r618", "r619" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether accounting standards update was adopted.", "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]", "terseLabel": "Change in accounting principle, accounting standards update, adopted" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": { "auth_ref": [ "r181", "r182", "r294", "r295", "r306", "r307", "r308", "r310", "r311", "r468", "r485", "r486", "r487", "r500", "r503", "r504", "r505", "r508", "r514", "r524", "r526", "r527", "r528", "r531", "r532", "r539", "r544", "r545", "r546", "r547", "r563", "r564", "r603", "r604", "r618", "r619", "r714" ], "lang": { "en-us": { "role": { "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.", "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date", "terseLabel": "Change in accounting principle, accounting standards update, adoption date" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption": { "auth_ref": [ "r185", "r227", "r295", "r306", "r309", "r312", "r469", "r487", "r500", "r505", "r508", "r514", "r525", "r526", "r529", "r530", "r532", "r540", "r544", "r546", "r547", "r605", "r618", "r619" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether accounting standards update was early adopted.", "label": "Change in Accounting Principle, Accounting Standards Update, Early Adoption [true false]", "terseLabel": "Change in accounting principle, accounting standards update, early adoption" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": { "auth_ref": [ "r228", "r240", "r296", "r314", "r472" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.", "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]", "terseLabel": "Change in accounting principle, accounting standards update, immaterial effect" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r196", "r197", "r198", "r219", "r245", "r246", "r249", "r251", "r260", "r261", "r304", "r347", "r349", "r350", "r351", "r354", "r355", "r373", "r374", "r377", "r381", "r388", "r523", "r647", "r693", "r707", "r715" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockForFutureIssuanceDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveSummaryOfPurchasePriceConsiderationForAcquisitionDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class Of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockForFutureIssuanceDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r490", "r491", "r492" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Sanofi Collaboration Agreement" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSanofiCollaborationAgreement" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSanofiCollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r91" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfEstimatedValueOfAvailableForSaleSecuritiesAndCashEquivalentsAndGrossUnrealizedGainsAndLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": { "auth_ref": [ "r747", "r787" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.", "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]", "terseLabel": "Commercial Paper" } } }, "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r22", "r160", "r174" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 7)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r90", "r341", "r342", "r632", "r741" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common stock reserved for future issuance, Total" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockForFutureIssuanceDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r710", "r711", "r785" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par or stated value per share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares, issued", "totalLabel": "Common Stock, Shares, Issued, Total" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r10", "r97" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "terseLabel": "Common stock, shares, outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r10", "r679" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "terseLabel": "Common stock, $0.0001 par value; 300,000,000 shares authorized at December 31, 2022 and December 31, 2021, respectively; 90,411,912 and 74,142,619 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively", "totalLabel": "Common Stock, Value, Issued, Total" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockVotingRights": { "auth_ref": [ "r98" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Common Stock, Voting Rights", "terseLabel": "Common stock, voting rights" } } }, "localname": "CommonStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r30", "r205", "r207", "r213", "r609", "r614" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Loss" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in Progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r390", "r391", "r394" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue, current" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSanofiCollaborationAgreementAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r390", "r391", "r394" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Deferred revenue, noncurrent" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSanofiCollaborationAgreementAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayable": { "auth_ref": [ "r4", "r158", "r170", "r177" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable", "terseLabel": "Convertible notes payable", "totalLabel": "Convertible Notes Payable, Total" } } }, "localname": "ConvertibleNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r668", "r670", "r807" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate Bonds" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfEstimatedValueOfAvailableForSaleSecuritiesAndCashEquivalentsAndGrossUnrealizedGainsAndLossesDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r2", "r3", "r4", "r156", "r158", "r168", "r222", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r542", "r660", "r661", "r662", "r663", "r664", "r708" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfEstimatedValueOfAvailableForSaleSecuritiesAndCashEquivalentsAndGrossUnrealizedGainsAndLossesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r20", "r222", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r542", "r660", "r661", "r662", "r663", "r664", "r708" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfEstimatedValueOfAvailableForSaleSecuritiesAndCashEquivalentsAndGrossUnrealizedGainsAndLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table]", "terseLabel": "Debt Securities Available For Sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAmortizedCostAndEstimatedFairValueOfAvailableForSaleSecuritiesAndCashEquivalentsByContractualMaturityDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfEstimatedValueOfAvailableForSaleSecuritiesAndCashEquivalentsAndGrossUnrealizedGainsAndLossesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r719" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "terseLabel": "Summary of Estimated Value of Available-for-sale Securities and Cash Equivalents and Gross Unrealized Gains and Losses" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": { "auth_ref": [ "r302", "r658", "r724" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]", "terseLabel": "Summary of Amortized Cost and Estimated Fair Value of Available-for-sale Securities and Cash Equivalents by Contractual Maturity" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredChargesPolicyTextBlock": { "auth_ref": [ "r194" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.", "label": "Deferred Charges, Policy [Policy Text Block]", "terseLabel": "Deferred Offering Costs" } } }, "localname": "DeferredChargesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r5", "r6", "r157", "r167", "r461" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfCategoriesThatGiveRiseToSignificantComponentsOfDeferredTaxAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "Gross deferred tax liabilities", "totalLabel": "Deferred Tax Liabilities, Gross, Total" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfCategoriesThatGiveRiseToSignificantComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r449", "r450" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liability", "totalLabel": "Deferred Income Tax Liabilities, Net, Total" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredOfferingCosts": { "auth_ref": [ "r725" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.", "label": "Deferred Offering Costs", "terseLabel": "Deferred offering costs" } } }, "localname": "DeferredOfferingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRentCreditNoncurrent": { "auth_ref": [ "r180", "r696", "r792" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of rental payment required by lease over rental income recognized, classified as noncurrent.", "label": "Deferred Rent Credit, Noncurrent", "terseLabel": "Deferred rent, noncurrent" } } }, "localname": "DeferredRentCreditNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r462" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfCategoriesThatGiveRiseToSignificantComponentsOfDeferredTaxAssetsDetails": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Gross deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfCategoriesThatGiveRiseToSignificantComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r778" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfCategoriesThatGiveRiseToSignificantComponentsOfDeferredTaxAssetsDetails": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfCategoriesThatGiveRiseToSignificantComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfCategoriesThatGiveRiseToSignificantComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r128", "r779" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfCategoriesThatGiveRiseToSignificantComponentsOfDeferredTaxAssetsDetails": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards", "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfCategoriesThatGiveRiseToSignificantComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration", "terseLabel": "Net operating loss carryforwards which can be carried forward indefinitely" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration", "terseLabel": "Net operating loss carryforwards subject to expire" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r128", "r779" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfCategoriesThatGiveRiseToSignificantComponentsOfDeferredTaxAssetsDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfCategoriesThatGiveRiseToSignificantComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "auth_ref": [ "r127", "r128", "r779" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfCategoriesThatGiveRiseToSignificantComponentsOfDeferredTaxAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research", "terseLabel": "Research and development credits", "verboseLabel": "Research and development credit carryforwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfCategoriesThatGiveRiseToSignificantComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r128", "r779" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfCategoriesThatGiveRiseToSignificantComponentsOfDeferredTaxAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost", "terseLabel": "Stock-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfCategoriesThatGiveRiseToSignificantComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": { "auth_ref": [ "r128", "r779" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfCategoriesThatGiveRiseToSignificantComponentsOfDeferredTaxAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals", "terseLabel": "Accruals and reserves", "totalLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfCategoriesThatGiveRiseToSignificantComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r463" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfCategoriesThatGiveRiseToSignificantComponentsOfDeferredTaxAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Less: valuation allowance", "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfCategoriesThatGiveRiseToSignificantComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r123", "r778" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfCategoriesThatGiveRiseToSignificantComponentsOfDeferredTaxAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "negatedTotalLabel": "Net deferred tax liability", "totalLabel": "Deferred Tax Liabilities, Net, Total" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfCategoriesThatGiveRiseToSignificantComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": { "auth_ref": [ "r128", "r779" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfCategoriesThatGiveRiseToSignificantComponentsOfDeferredTaxAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.", "label": "Deferred Tax Liabilities, Leasing Arrangements", "negatedLabel": "Lease asset" } } }, "localname": "DeferredTaxLiabilitiesLeasingArrangements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfCategoriesThatGiveRiseToSignificantComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Net [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "localname": "DeferredTaxLiabilitiesNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfCategoriesThatGiveRiseToSignificantComponentsOfDeferredTaxAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount", "terseLabel": "Retirement plan, matching contributions" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r48", "r84" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization expense", "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r48", "r270" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization", "totalLabel": "Depreciation, Depletion and Amortization, Total" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of defined contribution pension and other postretirement plans.", "label": "Defined Contribution Plan, Description", "terseLabel": "Retirement plan name description" } } }, "localname": "DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r406", "r437", "r438", "r440", "r445", "r674" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r671", "r672" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Dividends": { "auth_ref": [ "r104", "r166" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.", "label": "Dividends", "terseLabel": "Dividends declared", "totalLabel": "Dividends, Total" } } }, "localname": "Dividends", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsCommonStock": { "auth_ref": [ "r104", "r166" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "Dividends, Common Stock", "terseLabel": "Common stock, dividends declared", "totalLabel": "Dividends, Common Stock, Total" } } }, "localname": "DividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Federal" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r214", "r232", "r233", "r234", "r235", "r236", "r242", "r245", "r249", "r250", "r251", "r255", "r512", "r513", "r610", "r615", "r654" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share attributable to common stockholders, basic", "totalLabel": "Earnings Per Share, Basic, Total" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r214", "r232", "r233", "r234", "r235", "r236", "r245", "r249", "r250", "r251", "r255", "r512", "r513", "r610", "r615", "r654" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share attributable to common stockholders, diluted", "totalLabel": "Earnings Per Share, Diluted, Total" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r58", "r59" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss per Share Attributable to Common Stockholders" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r252", "r253", "r254", "r256" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share Attributable to Common Stockholders" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r452" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfBenefitFromIncomeTaxesToAmountComputedByApplyingFederalStatutoryRateToLossBeforeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Benefit from income taxes" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfBenefitFromIncomeTaxesToAmountComputedByApplyingFederalStatutoryRateToLossBeforeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r220", "r452", "r475" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfBenefitFromIncomeTaxesToAmountComputedByApplyingFederalStatutoryRateToLossBeforeTaxesDetails": { "order": 0.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Federal statutory income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfBenefitFromIncomeTaxesToAmountComputedByApplyingFederalStatutoryRateToLossBeforeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r776", "r780" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfBenefitFromIncomeTaxesToAmountComputedByApplyingFederalStatutoryRateToLossBeforeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Change in valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfBenefitFromIncomeTaxesToAmountComputedByApplyingFederalStatutoryRateToLossBeforeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": { "auth_ref": [ "r776", "r780" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfBenefitFromIncomeTaxesToAmountComputedByApplyingFederalStatutoryRateToLossBeforeTaxesDetails": { "order": 4.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent", "terseLabel": "Non-deductible permanent expenses", "totalLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent, Total" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfBenefitFromIncomeTaxesToAmountComputedByApplyingFederalStatutoryRateToLossBeforeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r776", "r780" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfBenefitFromIncomeTaxesToAmountComputedByApplyingFederalStatutoryRateToLossBeforeTaxesDetails": { "order": 5.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "terseLabel": "Other" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfBenefitFromIncomeTaxesToAmountComputedByApplyingFederalStatutoryRateToLossBeforeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r776", "r780" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfBenefitFromIncomeTaxesToAmountComputedByApplyingFederalStatutoryRateToLossBeforeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State income tax rate, net of federal benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfBenefitFromIncomeTaxesToAmountComputedByApplyingFederalStatutoryRateToLossBeforeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "auth_ref": [ "r776", "r780" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfBenefitFromIncomeTaxesToAmountComputedByApplyingFederalStatutoryRateToLossBeforeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent", "negatedLabel": "Research tax credits", "terseLabel": "Research tax credits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfBenefitFromIncomeTaxesToAmountComputedByApplyingFederalStatutoryRateToLossBeforeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseRelatedToStockOptionsRsusAndEmployeeStockPurchasePlanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r439" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation cost related to ESPP", "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized stock-based compensation expense, weighted-average period of recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r774" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r774" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock-based compensation expense related to unvested stock options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r97", "r183", "r209", "r210", "r211", "r223", "r224", "r225", "r229", "r237", "r239", "r259", "r313", "r389", "r441", "r442", "r443", "r470", "r471", "r511", "r533", "r534", "r535", "r536", "r537", "r538", "r568", "r620", "r621", "r622" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r515", "r516", "r521" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r146", "r147" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Financial Assets Measured at Fair Value" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r149" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]", "terseLabel": "Asset Class" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r146", "r150" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]", "terseLabel": "Asset Class" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r364", "r396", "r397", "r398", "r399", "r400", "r401", "r516", "r572", "r573", "r574", "r661", "r662", "r668", "r669", "r670" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r515", "r516", "r518", "r519", "r522" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r520" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r364", "r396", "r401", "r516", "r572", "r668", "r669", "r670" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r364", "r396", "r401", "r516", "r573", "r661", "r662", "r668", "r669", "r670" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r364", "r396", "r397", "r398", "r399", "r400", "r401", "r516", "r574", "r661", "r662", "r668", "r669", "r670" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurement" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r364", "r396", "r397", "r398", "r399", "r400", "r401", "r572", "r573", "r574", "r661", "r662", "r668", "r669", "r670" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r520", "r522" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r550", "r562" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfBalanceSheetClassificationOfOperatingLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "rvmd_LeaseLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "totalLabel": "Total financing lease liabilities" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfBalanceSheetClassificationOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r550" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfBalanceSheetClassificationOfOperatingLeaseLiabilitiesDetails": { "order": 0.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfBalanceSheetClassificationOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r551" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.", "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]" } } }, "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfBalanceSheetClassificationOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r300", "r301", "r317", "r318", "r319", "r320", "r321", "r323", "r324", "r325", "r372", "r386", "r501", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r658", "r720", "r721", "r722", "r816", "r817", "r818", "r819", "r820", "r821", "r822" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfEstimatedValueOfAvailableForSaleSecuritiesAndCashEquivalentsAndGrossUnrealizedGainsAndLossesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancingReceivablesPeriodPastDueAxis": { "auth_ref": [ "r293", "r319", "r657" ], "lang": { "en-us": { "role": { "documentation": "Information by period in which financial asset is past due or not past due.", "label": "Financial Asset, Aging [Axis]", "terseLabel": "Financial Asset, Period Past Due" } } }, "localname": "FinancingReceivablesPeriodPastDueAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAmortizedCostAndEstimatedFairValueOfAvailableForSaleSecuritiesAndCashEquivalentsByContractualMaturityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancingReceivablesPeriodPastDueDomain": { "auth_ref": [ "r293", "r319", "r657" ], "lang": { "en-us": { "role": { "documentation": "Period in which financial asset is past due or not past due. For past due, element name and standard label in Financial Asset, [numeric lower end] to [numeric higher end] [date measure] Past Due [Member] or Financial Asset, Greater than [low end numeric value] [date measure] Past Due [Member] or Financial Asset, Less than [high end numeric value] [date measure] Past Due [Member] formats.", "label": "Financial Asset, Aging [Domain]", "terseLabel": "Financial Asset, Period Past Due" } } }, "localname": "FinancingReceivablesPeriodPastDueDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAmortizedCostAndEstimatedFairValueOfAvailableForSaleSecuritiesAndCashEquivalentsByContractualMaturityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination.", "label": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]", "terseLabel": "Schedule of Intangible Assets, Net" } } }, "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwillTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Developed technology - tri-complex platform, Weighted-average remaining useful life", "verboseLabel": "Useful life of intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwillScheduleOfIntangiblesAssetsNetDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r193", "r334" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillScheduleOfIntangiblesAssetsNetDetails2": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0 }, "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwillScheduleOfIntangiblesAssetsNetDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Developed technology - tri-complex platform, Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwillScheduleOfIntangiblesAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r78" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwillScheduleOfFutureAmortizationExpenseDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwillScheduleOfFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r78" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwillScheduleOfFutureAmortizationExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwillScheduleOfFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r78" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwillScheduleOfFutureAmortizationExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwillScheduleOfFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r331", "r333", "r334", "r336", "r602", "r606" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedAtAcquisitionDateDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]" } } }, "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r76", "r606" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwillScheduleOfIntangiblesAssetsNetDetails": { "order": 0.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Developed technology - tri-complex platform, Gross value", "totalLabel": "Finite-Lived Intangible Assets, Gross, Total" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwillScheduleOfIntangiblesAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r72", "r75" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedAtAcquisitionDateDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r76", "r602" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwillScheduleOfFutureAmortizationExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwillScheduleOfIntangiblesAssetsNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "periodEndLabel": "Finite-Lived Intangible Assets, Net, Ending Balance", "periodStartLabel": "Finite-Lived Intangible Assets, Net, Beginning Balance", "totalLabel": "Developed technology - tri-complex platform, Net book value" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwillScheduleOfFutureAmortizationExpenseDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwillScheduleOfIntangiblesAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and Fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r48" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedLabel": "Loss on disposal of fixed assets", "totalLabel": "Gain (Loss) on Disposition of Property Plant Equipment, Total" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r34" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative", "totalLabel": "General and Administrative Expense, Total" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and Administrative Expenses", "verboseLabel": "General and Administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseRelatedToStockOptionsRsusAndEmployeeStockPurchasePlanDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r192", "r326", "r607", "r659", "r679", "r726", "r733" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Balance at December 31, 2022", "periodStartLabel": "Balance at December 31, 2021", "terseLabel": "Goodwill", "totalLabel": "Goodwill, Total", "verboseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwillScheduleOfGoodwillDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r80" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Assets and Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwill" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r329", "r330", "r659" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r48", "r327", "r328", "r329", "r659" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "terseLabel": "Goodwill impairment" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwillAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments": { "auth_ref": [ "r129", "r734" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from foreign currency translation adjustments and purchase accounting adjustments of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Translation and Purchase Accounting Adjustments", "terseLabel": "Adjustment" } } }, "localname": "GoodwillTranslationAndPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwillScheduleOfGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]", "terseLabel": "Initial Public Offering" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "auth_ref": [ "r705", "r737" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.", "label": "Impairment of Intangible Assets, Finite-Lived", "terseLabel": "Impairment of intangible assets, finite-lived" } } }, "localname": "ImpairmentOfIntangibleAssetsFinitelived", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "auth_ref": [ "r705", "r737" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)", "terseLabel": "Impairment of intangible assets, indefinite-lived" } } }, "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "auth_ref": [ "r48", "r83", "r88" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).", "label": "Impairment, Long-Lived Asset, Held-for-Use", "terseLabel": "Impairments of long-lived assets", "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total" } } }, "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r81", "r89" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeApproachValuationTechniqueMember": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Valuation approach converting future amounts to single current discounted amount.", "label": "Valuation, Income Approach [Member]", "terseLabel": "Income Approach" } } }, "localname": "IncomeApproachValuationTechniqueMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r31", "r153", "r161", "r176", "r272", "r280", "r284", "r286", "r611", "r656" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r671", "r672" ], "lang": { "en-us": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r339", "r340" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseRelatedToStockOptionsRsusAndEmployeeStockPurchasePlanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseRelatedToStockOptionsRsusAndEmployeeStockPurchasePlanDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r220", "r453", "r459", "r466", "r473", "r476", "r478", "r479", "r480" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationYearUnderExamination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax year being audited in the income tax examination, in YYYY format.", "label": "Income Tax Examination, Year under Examination", "terseLabel": "Years remain open to examination" } } }, "localname": "IncomeTaxExaminationYearUnderExamination", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "gYearListItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r221", "r238", "r239", "r271", "r451", "r474", "r477", "r616" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Benefit from income taxes", "terseLabel": "Benefit from income taxes", "totalLabel": "Income Tax Expense (Benefit), Total" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r208", "r447", "r448", "r459", "r460", "r465", "r467" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r47" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "totalLabel": "Increase (Decrease) in Accounts Payable, Total" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r47" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable", "terseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r704" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r600", "r704" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "auth_ref": [ "r47" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.", "label": "Increase (Decrease) in Deferred Income Taxes", "negatedLabel": "Deferred tax liability" } } }, "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r704", "r790" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease liability", "verboseLabel": "Increase in operating lease liability" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r704" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedLabel": "Other noncurrent assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.", "label": "Increase (Decrease) in Other Noncurrent Liabilities", "terseLabel": "Other noncurrent liabilities" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r47" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets", "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r332", "r335" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedAtAcquisitionDateDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r79" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "periodEndLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill), Ending Balance", "periodStartLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill), Beginning Balance", "terseLabel": "In-process research and development - RAS Programs", "totalLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill), Total" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwillScheduleOfIntangiblesAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r73", "r79" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedAtAcquisitionDateDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [ "r192" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillScheduleOfIntangiblesAssetsNetDetails2": { "order": 0.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "terseLabel": "Intangible assets, Gross value", "totalLabel": "Intangible Assets, Gross (Excluding Goodwill), Total" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwillScheduleOfIntangiblesAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r70", "r74" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureIntangibleAssetsAndGoodwillScheduleOfIntangiblesAssetsNetDetails2": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net", "totalLabel": "Intangible assets, Net book value" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwillScheduleOfIntangiblesAssetsNetDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r152", "r163", "r212", "r269", "r541" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense", "totalLabel": "Interest Expense, Total" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r35", "r268" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 0.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r69", "r154", "r165", "r178", "r648" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Available-for-sale securities" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r85" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee Lease Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r555" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee Lease Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r553" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r791" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Maturities of Operating Lease Liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r562" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total undiscounted lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r562" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r562" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r562" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r562" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r562" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r562" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r562" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: Imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "auth_ref": [ "r554" ], "lang": { "en-us": { "role": { "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.", "label": "Lessee, Operating Lease, Option to Extend", "terseLabel": "Lessee, operating lease, option to extend" } } }, "localname": "LesseeOperatingLeaseOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r789" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Lessee, operating lease option to extend lease term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letter Of Credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Letter of credit" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r17", "r219", "r304", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r495", "r498", "r499", "r523", "r655", "r742", "r794", "r795" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r15", "r159", "r172", "r679", "r709", "r723", "r788" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r19", "r188", "r219", "r304", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r495", "r498", "r499", "r523", "r679", "r742", "r794", "r795" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Marketable securities", "totalLabel": "Marketable Securities, Current, Total" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r164" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities, Policy [Policy Text Block]", "terseLabel": "Marketable Securities" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r786" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input, Discount Rate [Member]", "terseLabel": "Discount Rates" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r747" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfEstimatedValueOfAvailableForSaleSecuritiesAndCashEquivalentsAndGrossUnrealizedGainsAndLossesDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r216" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r216" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r44", "r46", "r49" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r32", "r49", "r162", "r175", "r186", "r204", "r206", "r211", "r219", "r228", "r232", "r233", "r234", "r235", "r238", "r239", "r247", "r272", "r280", "r284", "r286", "r304", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r513", "r523", "r656", "r742" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 }, "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r232", "r233", "r234", "r235", "r242", "r243", "r248", "r251", "r272", "r280", "r284", "r286", "r656" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net loss attributable to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r36" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense), net:" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r717" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segment" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r717" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segment" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r272", "r280", "r284", "r286", "r656" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r556", "r678" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r550" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfBalanceSheetClassificationOfOperatingLeaseLiabilitiesDetails": { "order": 0.0, "parentTag": "rvmd_LeaseLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating lease liability", "totalLabel": "Total operating lease liabilities", "verboseLabel": "Total operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfBalanceSheetClassificationOfOperatingLeaseLiabilitiesDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r550" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfBalanceSheetClassificationOfOperatingLeaseLiabilitiesDetails": { "order": 0.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liability, current", "verboseLabel": "Operating lease liability \u2013 current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfBalanceSheetClassificationOfOperatingLeaseLiabilitiesDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r550" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfBalanceSheetClassificationOfOperatingLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liability, noncurrent", "verboseLabel": "Operating lease liability \u2013 noncurrent" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfBalanceSheetClassificationOfOperatingLeaseLiabilitiesDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r552", "r558" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows for operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r549" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r705" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Operating Lease, Right-of-Use Asset, Amortization Expense", "terseLabel": "Amortization of operating lease right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r561", "r678" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating lease, weighted average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r560", "r678" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating lease, weighted average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.", "label": "Operating Loss Carryforwards, Limitations on Use", "terseLabel": "Net operating losses, limitations on use" } } }, "localname": "OperatingLossCarryforwardsLimitationsOnUse", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r0", "r143" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureOrganization" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r194" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other noncurrent assets", "totalLabel": "Other Assets, Noncurrent, Total" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Alternative [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r202", "r203" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Net unrealized gains (loss) on marketable securities", "terseLabel": "Unrealized gain (loss) on investments, net", "verboseLabel": "Net unrealized gains on marketable securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r18", "r679" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 4.0, "parentTag": "rvmd_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other", "totalLabel": "Other Liabilities, Current, Total" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r21" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other noncurrent liabilities", "totalLabel": "Other Liabilities, Noncurrent, Total" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other Noncurrent Assets" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings": { "auth_ref": [ "r298" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings.", "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-Sale, Recognized in Earnings", "terseLabel": "Other-than-temporary impairment" } } }, "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]", "terseLabel": "Underwriter's Option to Purchase Additional Shares" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForProceedsFromTenantAllowance": { "auth_ref": [ "r37", "r40" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.", "label": "Payments for (Proceeds from) Tenant Allowance", "terseLabel": "Tenant improvement allowance" } } }, "localname": "PaymentsForProceedsFromTenantAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForUnderwritingExpense": { "auth_ref": [ "r45" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies.", "label": "Payments for Underwriting Expense", "terseLabel": "Underwriting discounts and commissions" } } }, "localname": "PaymentsForUnderwritingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r42" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Payments of Dividends", "terseLabel": "Dividends paid", "totalLabel": "Payments of Dividends, Total" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r43" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "terseLabel": "Stock issuance expenses" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r38", "r488" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveSummaryOfPurchasePriceConsiderationForAcquisitionDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Cash", "verboseLabel": "Cash consideration" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveSummaryOfPurchasePriceConsiderationForAcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r65" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities", "totalLabel": "Payments to Acquire Marketable Securities, Total" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r39" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy": { "auth_ref": [ "r108", "r109", "r110", "r111" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for pension plans. This accounting policy may address (1) the types of plans sponsored by the entity (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.", "label": "Pension and Other Postretirement Plans, Pensions, Policy [Policy Text Block]", "terseLabel": "401(k) Retirement Plans" } } }, "localname": "PensionAndOtherPostretirementPlansPensionsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityUnderPlanDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRsusActivityUnderPlanDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityUnderPlanDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRsusActivityUnderPlanDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r9", "r373" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par or stated value per share" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r9", "r373" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "totalLabel": "Preferred Stock, Shares Issued, Total" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r9", "r679" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance", "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance", "terseLabel": "Preferred stock, $0.0001 par value; 10,000,000 shares authorized at December 31, 2022 and December 31, 2021, respectively; zero shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively", "totalLabel": "Preferred Stock, Value, Issued, Total" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r699" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r41" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Gross cash proceeds from issuance of common stock", "terseLabel": "Proceeds from issuance of common stock, net of issuance costs", "verboseLabel": "Net proceeds from issuance" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": { "auth_ref": [ "r41" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.", "label": "Proceeds from Issuance of Redeemable Convertible Preferred Stock", "terseLabel": "Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockPlans": { "auth_ref": [ "r41" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the stock plan during the period.", "label": "Proceeds from Stock Plans", "terseLabel": "Proceeds from issuance of common stock under equity incentive plans" } } }, "localname": "ProceedsFromStockPlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r186", "r204", "r206", "r215", "r219", "r228", "r238", "r239", "r272", "r280", "r284", "r286", "r304", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r493", "r496", "r497", "r513", "r523", "r611", "r656", "r676", "r677", "r703", "r742" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r87" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": { "auth_ref": [ "r82" ], "lang": { "en-us": { "role": { "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).", "label": "Property, Plant and Equipment, Estimated Useful Lives", "terseLabel": "Estimated useful life, description" } } }, "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r85", "r190" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "terseLabel": "Property and equipment, gross", "totalLabel": "Property, Plant and Equipment, Gross, Total" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property Plant And Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r87", "r173", "r612", "r679" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r87", "r633", "r634" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r87" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r85" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated useful life", "verboseLabel": "Property and equipment, estimated useful lives" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_QuarterlyFinancialInformationTextBlock": { "auth_ref": [ "r60", "r258" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.", "label": "Quarterly Financial Information [Text Block]", "terseLabel": "Selected Quarterly Financial Data (Unaudited)" } } }, "localname": "QuarterlyFinancialInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSelectedQuarterlyFinancialDataUnaudited" ], "xbrltype": "textBlockItemType" }, "us-gaap_RedeemableConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.", "label": "Redeemable Convertible Preferred Stock [Member]", "terseLabel": "Redeemable Convertible Preferred Stock" } } }, "localname": "RedeemableConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockForFutureIssuanceDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r122", "r179", "r802" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 0.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development", "totalLabel": "Research and Development Expense, Total" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseRelatedToStockOptionsRsusAndEmployeeStockPurchasePlanDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r122" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Expenditures" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r694", "r706", "r803", "r805" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash", "totalLabel": "Restricted Cash, Total" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r631", "r695", "r706" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock Awards" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRsusActivityUnderPlanDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r12", "r104", "r171", "r624", "r629", "r679" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "terseLabel": "Accumulated deficit", "totalLabel": "Retained Earnings (Accumulated Deficit), Total", "verboseLabel": "Adjustment to accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r183", "r223", "r224", "r225", "r229", "r237", "r239", "r313", "r441", "r442", "r443", "r470", "r471", "r511", "r620", "r622" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": { "auth_ref": [ "r489", "r783" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.", "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer", "terseLabel": "Collaboration revenue recognized" } } }, "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSanofiCollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r266", "r267", "r279", "r282", "r283", "r287", "r288", "r290", "r392", "r393", "r601" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Total revenue", "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total", "verboseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r651", "r652" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenue:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r559", "r678" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Outstanding Potentially Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-Sale [Line Items]", "terseLabel": "Schedule Of Available For Sale Securities [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfAmortizedCostAndEstimatedFairValueOfAvailableForSaleSecuritiesAndCashEquivalentsByContractualMaturityDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfEstimatedValueOfAvailableForSaleSecuritiesAndCashEquivalentsAndGrossUnrealizedGainsAndLossesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r132", "r133", "r483" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule Of Business Acquisitions By Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveSummaryOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedAtAcquisitionDateDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveSummaryOfProformaFinancialInformationOfAcquisitionDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveSummaryOfPurchasePriceConsiderationForAcquisitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r132", "r133" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "terseLabel": "Summary of Purchase Price Consideration For Acquisition" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r784" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSanofiCollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r126" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Summary of Categories that Give Rise to Significant Components of Deferred Tax Assets" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r716" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Summary of Benefit from Income Taxes to Amount Computed by Applying Federal Statutory Rate to Loss Before Taxes" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r117", "r119" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfTotalStockBasedCompensationExpenseRelatedToStockOptionsRsusAndEmployeeStockPurchasePlanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of Total Stock-Based Compensation Expense Related to Stock Options, RSUs and Employee Stock Purchase Plan" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r659", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of Goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwillTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r87" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.", "label": "Quarterly Financial Information [Table Text Block]", "terseLabel": "Summary of Quarterly Financial Data (Unaudited)" } } }, "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSelectedQuarterlyFinancialDataUnauditedTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Summary of Fair Values of Assets Acquired and Liabilities Assumed at Acquisition Date" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r403", "r405", "r407", "r408", "r409", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r431", "r432", "r433", "r434", "r435" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityUnderPlanDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRsusActivityUnderPlanDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfFairValueOfStockOptionAwardsEstimatedAtDateOfGrantDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Summary of RSUs Activity Under the Plan" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r112", "r113", "r114" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Option Activity Under the Plan" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r116" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Summary of Fair Value of Stock Option Awards Estimated at Date of Grant" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r92", "r95", "r96", "r98", "r99", "r100", "r101", "r102", "r103", "r104", "r196", "r197", "r198", "r260", "r373", "r374", "r375", "r377", "r381", "r386", "r388", "r665", "r693", "r707" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule Of Stock By Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockForFutureIssuanceDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r675", "r777" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "terseLabel": "Reconciliation of Gross Unrecognized Tax Benefits" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r75" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of Future Amortization Expense" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIntangibleAssetsAndGoodwillTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r273", "r274", "r275", "r276", "r277", "r278", "r288" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SelectedQuarterlyFinancialInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Selected Quarterly Financial Information [Abstract]" } } }, "localname": "SelectedQuarterlyFinancialInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SeriesCPreferredStockMember": { "auth_ref": [ "r697", "r698", "r745" ], "lang": { "en-us": { "role": { "documentation": "Series C preferred stock.", "label": "Series C Preferred Stock [Member]", "terseLabel": "Series C Preferred Stock" } } }, "localname": "SeriesCPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_SeveranceCosts1": { "auth_ref": [ "r48" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Severance Costs", "terseLabel": "Severance costs" } } }, "localname": "SeveranceCosts1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r47" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense", "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r674" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Award vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Number of Shares, Restricted stock units forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRsusActivityUnderPlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant date fair value per share, Restricted stock units forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRsusActivityUnderPlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Number of Shares, Restricted stock units granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRsusActivityUnderPlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant date fair value per share, Restricted stock units granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRsusActivityUnderPlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r419", "r420" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Number of Shares, Ending balance", "periodStartLabel": "Number of Shares, Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRsusActivityUnderPlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r419", "r420" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted-average grant date fair value per share, Ending balance", "periodStartLabel": "Weighted-average grant date fair value per share, Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRsusActivityUnderPlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r115" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "terseLabel": "Weighted-average remaining contractual term (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRsusActivityUnderPlanDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Number of Shares, Restricted stock units vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRsusActivityUnderPlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r426" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "RSU vested, fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant date fair value per share, Restricted stock units vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRsusActivityUnderPlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfFairValueOfStockOptionAwardsEstimatedAtDateOfGrantDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfFairValueOfStockOptionAwardsEstimatedAtDateOfGrantDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Expected volatility, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfFairValueOfStockOptionAwardsEstimatedAtDateOfGrantDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Expected volatility, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfFairValueOfStockOptionAwardsEstimatedAtDateOfGrantDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk-free interest rate, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfFairValueOfStockOptionAwardsEstimatedAtDateOfGrantDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk-free interest rate, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfFairValueOfStockOptionAwardsEstimatedAtDateOfGrantDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityUnderPlanDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRsusActivityUnderPlanDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfFairValueOfStockOptionAwardsEstimatedAtDateOfGrantDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate", "terseLabel": "Purchase price rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r413" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted-average exercise price, Options vested and exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityUnderPlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r426" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "negatedLabel": "Options exercised", "terseLabel": "Intrinsic value of the options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Number of Shares underlying options, Options cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityUnderPlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Number of Shares underlying options, Options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityUnderPlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant-date fair value of options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r118" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityUnderPlanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r411", "r412" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of Shares underlying options, Ending balance", "periodStartLabel": "Number of Shares underlying options, Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityUnderPlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r411", "r412" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted-average exercise price, Ending balance", "periodStartLabel": "Weighted-average exercise price, Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityUnderPlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Number of Shares underlying options, Options vested and exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityUnderPlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r427" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Aggregate intrinsic value, Options vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityUnderPlanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Number of Shares underlying options, Options vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityUnderPlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Weighted-average exercise price, Options vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityUnderPlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": { "auth_ref": [ "r775" ], "lang": { "en-us": { "role": { "documentation": "Number of shares purchased for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award", "terseLabel": "Shares purchases" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r407", "r408", "r409", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r431", "r432", "r433", "r434", "r435" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockForFutureIssuanceDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRsusActivityUnderPlanDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Weighted-average exercise price, Options exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityUnderPlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Weighted-average exercise price, Options cancelled" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityUnderPlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted-average exercise price, Options granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityUnderPlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r410", "r429", "r430", "r431", "r432", "r435", "r444", "r445" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share Price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding", "terseLabel": "Aggregate intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRsusActivityUnderPlanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r431" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfFairValueOfStockOptionAwardsEstimatedAtDateOfGrantDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r118" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate intrinsic value, Options vested and exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityUnderPlanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-average remaining contractual term, Options vested and exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityUnderPlanDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r115" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-average remaining contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityUnderPlanDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-average remaining contractual term, Options vested and expected to vest" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityUnderPlanDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Stock issued, price per share", "verboseLabel": "Common stock, price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r56", "r217" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "California State", "verboseLabel": "State and Local Net" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r196", "r197", "r198", "r219", "r245", "r246", "r249", "r251", "r260", "r261", "r304", "r347", "r349", "r350", "r351", "r354", "r355", "r373", "r374", "r377", "r381", "r388", "r523", "r647", "r693", "r707", "r715" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/DisclosureCommonStockScheduleOfCommonStockForFutureIssuanceDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveSummaryOfPurchasePriceConsiderationForAcquisitionDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r25", "r97", "r183", "r209", "r210", "r211", "r223", "r224", "r225", "r229", "r237", "r239", "r259", "r313", "r389", "r441", "r442", "r443", "r470", "r471", "r511", "r533", "r534", "r535", "r536", "r537", "r538", "r568", "r620", "r621", "r622" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r223", "r224", "r225", "r259", "r601" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r24", "r97", "r98", "r104", "r366" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Conversion of redeemable convertible preferred stock into common stock, shares", "verboseLabel": "Conversion of shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r9", "r10", "r97", "r104" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock related to employee stock purchase plan, shares" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r9", "r10", "r97", "r104" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock from offering, net of offering costs, shares", "verboseLabel": "Shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r9", "r10", "r97", "r104", "r416" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Number of Shares underlying options, Options exercised", "terseLabel": "Issuance of common stock pursuant to stock option exercises, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionActivityUnderPlanDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r25", "r97", "r104" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Conversion of redeemable convertible preferred stock into common stock" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r9", "r10", "r97", "r104" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock related to employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r9", "r10", "r97", "r104" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock from offering, net of offering costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r25", "r97", "r104" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of common stock pursuant to stock option exercises" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r9", "r10", "r97", "r104" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "negatedLabel": "Repurchases of early exercised stock, shares" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r9", "r10", "r97", "r104" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "terseLabel": "Repurchases of early exercised stock" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r10", "r13", "r14", "r64", "r679", "r709", "r723", "r788" ], "calculation": { "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r107", "r218", "r374", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r387", "r389", "r502" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Common Stock" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommonStock" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy": { "auth_ref": [ "r7", "r8", "r94" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.", "label": "Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]", "terseLabel": "Redeemable Convertible Preferred Stock" } } }, "localname": "StockholdersEquityNoteRedeemablePreferredStockIssuePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "auth_ref": [ "r105" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Reverse stock split" } } }, "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "pureItemType" }, "us-gaap_StockholdersEquityReverseStockSplit": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.", "label": "Stockholders' Equity, Reverse Stock Split", "terseLabel": "Reverse stock split, description" } } }, "localname": "StockholdersEquityReverseStockSplit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r557", "r678" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "terseLabel": "Sublease income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r700" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Balance Sheet Components" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponents" ], "xbrltype": "textBlockItemType" }, "us-gaap_TemporaryEquityByClassOfStockTable": { "auth_ref": [ "r1", "r93" ], "lang": { "en-us": { "role": { "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.", "label": "Temporary Equity, by Class of Stock [Table]", "terseLabel": "Temporary Equity By Class Of Stock [Table]" } } }, "localname": "TemporaryEquityByClassOfStockTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r347", "r349", "r350", "r351", "r354", "r355" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "periodEndLabel": "Redeemable convertible preferred stock, ending balance", "periodStartLabel": "Redeemable convertible preferred stock, beginning balance", "terseLabel": "Redeemable convertible preferred stock, $0.0001 par value; zero shares authorized at December 31, 2021 and 2020, respectively; zero and 39,600,423 shares issued and outstanding at December 31, 2021 and 2020, respectively; aggregate liquidation preference of zero at December 31, 2021 and 2020, respectively" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Temporary Equity Disclosure [Abstract]" } } }, "localname": "TemporaryEquityDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Temporary Equity [Line Items]", "terseLabel": "Temporary Equity [Line Items]" } } }, "localname": "TemporaryEquityLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityRedemptionPricePerShare": { "auth_ref": [ "r1", "r93" ], "lang": { "en-us": { "role": { "documentation": "Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Redemption Price Per Share", "terseLabel": "Shares issued price per share", "verboseLabel": "Redeemable convertible preferred stock, issued price per share" } } }, "localname": "TemporaryEquityRedemptionPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICITParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Outstanding", "periodEndLabel": "Redeemable convertible preferred stock, ending balance, shares", "periodStartLabel": "Redeemable convertible preferred stock, beginning balance, shares", "terseLabel": "Temporary equity, shares outstanding", "verboseLabel": "Shares outstanding" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of new stock classified as temporary equity issued during the period.", "label": "Temporary Equity, Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of redeemable convertible preferred stock, net of issuance costs, value" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityTableTextBlock": { "auth_ref": [ "r1", "r93" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity [Table Text Block]", "terseLabel": "Schedule of Redeemable Convertible Preferred Stock" } } }, "localname": "TemporaryEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r300", "r301", "r372", "r386", "r501", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r720", "r721", "r722", "r816", "r817", "r818", "r819", "r820", "r821", "r822" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfEstimatedValueOfAvailableForSaleSecuritiesAndCashEquivalentsAndGrossUnrealizedGainsAndLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r181", "r182", "r183", "r184", "r185", "r228", "r229", "r230", "r231", "r241", "r294", "r295", "r310", "r311", "r312", "r313", "r315", "r316", "r441", "r442", "r443", "r468", "r469", "r470", "r471", "r485", "r486", "r487", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r524", "r525", "r527", "r528", "r529", "r530", "r531", "r532", "r539", "r540", "r545", "r546", "r547", "r548", "r563", "r564", "r565", "r566", "r567", "r568", "r603", "r604", "r605", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]", "terseLabel": "Accounting Standards Update" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r784" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSanofiCollaborationAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r653", "r668", "r804" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "U.s. Government And Agency Securities" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": { "auth_ref": [ "r804" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).", "label": "US Government Corporations and Agencies Securities [Member]", "terseLabel": "U.S. Government and Agency Securities" } } }, "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAvailableForSaleSecuritiesSummaryOfEstimatedValueOfAvailableForSaleSecuritiesAndCashEquivalentsAndGrossUnrealizedGainsAndLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r446", "r455" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfGrossUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r456" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "negatedLabel": "Changes related to tax positions taken in the prior year" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfGrossUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "auth_ref": [ "r454" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense", "terseLabel": "Interest or penalties related to uncertain tax positions", "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r457" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Changes related to tax positions taken in current year" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfGrossUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r458" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefits that would affect effective tax rate if recognized" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r61", "r62", "r63", "r262", "r263", "r264", "r265" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r464" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "terseLabel": "Increase in valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationTechniqueAxis": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation approach and technique.", "label": "Valuation Approach and Technique [Axis]", "terseLabel": "Valuation Approach and Technique" } } }, "localname": "ValuationTechniqueAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationTechniqueDomain": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Valuation approach and technique.", "label": "Valuation Approach and Technique [Domain]", "terseLabel": "Valuation Approach and Technique" } } }, "localname": "ValuationTechniqueDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureAcquisitionOfWarpDriveAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r244", "r251" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average shares used to compute net loss per share attributable to common stockholders, diluted", "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).", "label": "Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation", "negatedLabel": "Less: Weighted-average unvested restricted shares and shares subject to repurchase" } } }, "localname": "WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r242", "r251" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average shares used to compute net loss per share attributable to common stockholders, basic", "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails", "http://www.revolutionmedicines.com/20221231/taxonomy/role/Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "sharesItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.C)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=6412939&loc=d3e15145-114933", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=d3e29149-114947", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(2)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(4)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org/topic&trid=2303972", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r154": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "https://asc.fasb.org/subtopic&trid=2176304", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r165": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/subtopic&trid=2209399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r178": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "https://asc.fasb.org/subtopic&trid=2324412", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123415192&loc=d3e39927-112707", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31010-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900988&loc=d3e1280-108306", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900988&loc=SL124452896-108306", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "8A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL82887624-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/subtopic&trid=2144439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=120431994&loc=SL118172731-207502", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=120431994&loc=SL118172731-207502", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=126928961&loc=SL5834089-161433", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "https://asc.fasb.org/topic&trid=5833765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL77916155-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL120154346-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2646-109256", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "270", "URI": "https://asc.fasb.org/topic&trid=2126967", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 5))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r647": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r648": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "80", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82922355-210448", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r683": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r684": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r685": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r686": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r687": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r688": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r689": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r69": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r691": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r692": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "https://asc.fasb.org/topic&trid=2122208", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r719": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.A)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r741": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r772": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r773": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r774": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r775": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r776": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r777": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r778": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r779": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r780": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r781": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r782": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r783": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r784": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r785": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r786": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r787": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r788": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r789": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r790": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r791": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r792": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123408481&loc=SL77919140-209958", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r793": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r794": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r795": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r796": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r797": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r798": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r799": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "https://asc.fasb.org/topic&trid=2144416", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r800": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r801": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r802": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r803": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r804": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r805": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r806": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r807": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r808": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r809": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r810": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r811": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r812": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r813": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r814": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r815": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r816": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r817": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r818": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r819": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905813&loc=d3e1205-110223", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r820": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r821": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r822": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126960819&loc=d3e20905-112640", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 95 0000950170-23-004645-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-004645-xbrl.zip M4$L#!!0 ( /: 6U9-!W)&_JD -[7 1 :6UG,C$8 M/4=S[CPM;7Q F2XP2TU=?9:&^NS9&AKXU2C\.J"A-UM_V?IM*UNW.7;W]29[2_'5JQ\=AOE^9I&9LL7&2ZPW.6S^T=%EAZN; M^T\[=WD=..CM<^BP[_%?3IP,# H."3L;?BZ"WX'V/4"*5??ST M>6!P:!C^\G5R2CZ-?)OY[I<:H/Y/U_^K?NGA?LW2T%#7T/SNE]JLB.\#]#1F M+UL_1W_;/LVC9PPL-ER<:[C]VMTG=?.6;]P/&1W[K5W+>(6=9"7\W;7_R[/_ M-L.IZ !E0/NVE320I'L*2CH96K/$M2:9L0S M+1?NHIXUBS/ J:$R-[CBWTB%(!=Z%;BMP#2_(R[EI]VUYN1]#N'X]DERK B!7;H]E[?NIZ369_]TC@EZ%SS"=% M8!V=Y!"4Z7ZES(F+6*;,>$BH[RMJ1=#>CY>H0DY=H@;G*9B4=:"BLZSOV&=B MG,/&8+)A:6_+AGTYZ,:.T6H76E'/M@=](:P-4*F\/-TT@XL>Q'?O91_B.RVC M)F'ZV"O6!N05I"GW@DSJ* G4,O?&,)A2;SX+)D;;<5-8<]I9JP\-B1;4+!H6 MNA59-J8$UHD6E"F=&@)^J*";(.:OW\G&'$FWP0=]C8M;IZZ6J0"-5\J;X2.V MAL'3, /M17ARO3:R^+8O+U7Z4A:F<&*<]C\9NLGI)/:*;MFL-M4K(R>^9'R: MHVM7]N7MA".2@D_ 5%XGK:0)9M)S"IAAD""^.E#,N\P"$ G46\M9B+I+B'&B MTHPXEF90)3VN9K$0/0S MWE7&-_99O.N7@V;H,DC42(\705>8J[/JVI%4[V?=.8*F-*X+Z7E^+^-DA\+J MD(FP09C6GW*?=0"LVP.*'Q%UP4!Z[\C6-M82]#P2*>9>I#XQO@EM;."43=2- M!?KC<RL)THSN&(AR' MV;I^6<=_D7:$BS^TQ$N:(!^@'F&A4PVP /L4R4 M"G%BP=,3L;PGT_5.$PM#.$\%HZDYJ!]R5['K/7,O%!^_'"$7HB&03Q+J"H&' MD"BQ)YUO;A$CE1T:]-7H=Q;DA=+XY<:F1FD-Y_08\0=I.LOW?^/(&_'9N:P. M;^H3P9AG'JM%-#]FK2AU8$+28Z(9FT N034 M0)=U.R\K]$-4 .5)N[-KJ$-*VKE%HP'=6CR3U@ M,#ZU_BO2++_1=M;?2QX!18SR8(O6>NKB,O;\1KA"$LCW7#7MBARFPU>WV'K& M$1?1>#JEO1TG)"]^;OQYNO*47E"V=4R#<'Y%Y<&^B2MDR(W:8R!S0L9[?04L M,N+!!XUK%J'KD.-P*@XD"VHVT )T(4K38LJE;/,.U ;*:>3H56\)/F%?7B6S M51_,=+L6F$=MZK[@.CQTSK-H\$)!POB<6Z=+V_T&H/Z9XG=/7Y3[]WP=Q2') MBZS/M$ J%'L9^J(Z%:"'D9A[.\FTB9Y N3O0EZ(B4:4XB'R7)+92.6] M$7-UY&(N(T31 I'8]W82F_Q-O#*V0?3D:O"\I)<<'V%*B3TU,1Z^Q6=8E,"# M/*@]H/2(R,3>,X"2Y$A,KK%& Q%7Q?9\-DJ4*7CS$9DDHXE^$9OU%*%!T\V< M>5-CI$9JO; \2[)X9^G(LXFEW8_""6-;]A6'+EJW?W-P, AY$'MD.^+ED2_> M586S6]\;PPT7.^F$A- A/S&EP5:HD&+DUU=EA?Z2;0L;ZOOZ,S@^ M(Q9XQ+\/H>J?Y<5-\TI,1A.YZ/$J>&!T'VPI;^\LG5C(/ %-U$U#I!B(*JTI M@B*EW.BI;^/5BV0[*@5V!)/!"W$I]X8=UX;H(O'>&7OB/'2(+MF*A@N![_:# M=4MY)WH)ZLPE$#O:V5_A@BZ!";7/6!N'6!I(%03*C//%Y.1""9&M G2G)I+( M!NAL+B/'L\.\F0JQGLC,6 /[.TJ5[B[7O_*O]Q[^P #W=="[A^4CG=7S<"AO M5=ZH,1$AYT8DHMCJ;1)MHA:K&;-5)IS=HKD+7MF0N85;1S5#7OOZ].F3/"<\2?T3$[Y@^Y\EKS"N=+.D( M:W&>I_!G>BIS63I#1#-,V\,A^BS1:$CT6)!22I[%B*_K9OT .Z$_(A)0PM%G M;N==^OSVRVLGCQ?N%!BO,OQOSJ[6I.5MI2Y0?F-E>FJN2T&(I4\[E@I1&EM3 M'/,;NB!73KT(.435*6)M8(9"$2DD1W>9K3;B*Y*,QTJX\QD132!!&E][_7U> M(3RO&*5(;_N)0Z=:X_*2HM0/(!&@E&CH$;;ETSOV7D0'6BP1C'Z"N)**>F+< MS"D("<,AA#J;N0KZ7/!H9^@#QL.1.BIA]+2ULTT^K1(]EUYARI7_UA_B\$/B M\JO]5GU>7L\KRB]YC' V1-'$O/@R:@)5"UMV"(EI#M!/E;A.-/3M:JTSGP>? MF(YEF3(&]B'<7[JQY9VD-8S%'C^5@N;][X@D&[R5I&.YS!?Y?>?A\<8"S#BD?/ZK!&6%=\R81@"Y7 M."/Q$KM^XPX?V3HN3)-:-K"UF%LA[*KH\0VK!Q2(MQ5B\WG&2$2#[RW6DE#O M\;>BAOZET(M2X4?'J%N"'WHH9Z+H4#H/ZI]NZK=#0-D)93QI,=;OS=$DBR]S M( HUP93+YYDS]\%T/D^7<7QW!72R4%DH9<=[9QM V!-01M;/O>*PP9]Q3L=C M:_>Z1X]ZF%O"P&+/P/P_3-Z5(%&.$>KN>)TT!HSQ9+:4:3 M2(@'H*@T(#X*+I1?AJ='7T *J683(5$F_QGQDK9X-7IG&W8X&\UW(#F6ORLE M)LW@XU5 3+I)_XKD/35M8L3KX:&1;D>W'/JJV[1.F@I8R)'WXR@1@M61Y]9L M9/K@2%0AOXW8*O9266^_UX%9F)"T&'DCH5\DEQ(;6WL$M1<^729K\X)#_>K/ M^9XK@R:.P.[19;::S#WM-FCDF3P_&E'W8S745Q-?%)(^(@=^M'LQ6>5'^SA6 M,Y3?NV=@:J*0T5HWHR./S:-E6T'=*06,.R$IDB*RM^#L"T=%@\?=H3!:9F^0 M=T;&W@\A,O=VFW'[E+U#\ <=LL>ET.VC_&"#/RI*";I!).NV2;8!XN?WSME# MPM4-[K[0%",E$H:]?=_&%PTY7IX7?O1AL&GY;?N6N-Q\JM].L\;;4VD-W8(? M?DK=9M7TNOF;A3(;KV2>Q_'J=*7&@<47S:[6$9-[7I$6L'IK2%G2C*11EL.( MJ)1<)[H;N PB-(#Q@@#+:(:FA)M, MLAJZ_B$$W_:4.X^?8H68KI"114$.0K(],.>R\S(QP7BH?R[4E"6EJ*/DFE"/ M6I9!]UFEZ=LW>]N<#:)6WU! MN;Z+_I/XU\5+UIR@&>Z=XR,/%RDUPZF*KW=5P)=,]N@(;V;!,&]ZP$4%?+(/ M:=^#<7[#*EE1[XM&IGDC^0-]-ZD] G#2K N<>!NO EZ'D$N*5<"@TT,5(+I- M4 $WN@I=3285&5,=7\?K^WF1W^_M25/>CE !V_I\,'001/-R%(X36$PE5_FM M305\\_0MW0=2GH/^9-*HS=]&_C;RMY&_C?RO,<)I(:)&-$PK2N'#:B:6Z>37 MDV.$$S&@1#]+ EY&C^!R)XUAZ]D]11D+#3P V^2.VQZ+VF+<\>I=J/,#5NOO MO2W'ET^HL1[C==&9U4LE\DX3YC%_ZZ[9-%)ITLLB,I+K'*GXZB6ZT-NT.RYR M?] 3GMVG GJO!X5O#+/-RO,[OZ!(-X79N/93';6!@FPVP2C->U3 4SUH&A>1 M-9NY9:!85#BBM)5'*9]-;5DW_*79JX-37R$,'[]]-X2TNM-ZHLC90#:2[%1( MG#^D-5.1P+497W[5SU_;P[LS_'R[G6*E@X.>.OSLR,EU1W9ZZ5B['C[:=637 M@2.]>3>"WNX[PO5PO?^N/(7XAKFE\\*YK[5ZKYR+_,]Q@'_(Y$%;"F M$)9A\SSSF63(N$#&CB5JEM%[1#)"M!WU(KDD^WD1UJX"@!IC!WZH"Q6)'H*U M^3-L/N6*(+\)(],7,CW:S[ZPZ)#.GI"_K3@JF]#B-9BY$8B#WA6^6.*#85Y) MFMSGWXZ_==C[T,.](2:[AOJ_EIU@*F MA0V\I;6>%_<)VU1KP]KX'"+':3/]R\R)]'G)],0Q90:'Z,?6*F'\XB(M*71S M)C6[]2IO>3ZAS$--$;+8[)BH@30;\8)ZZUA+RR"'N)J%OB,X$[2-17]\Y,>T M@WR?,IPD'TVSV;D]_7PQ?5Y.)8-6O^]MY9Q+Q6]RA^1W$YQ'R:7QM7XI@3)Z M_,](E7A-F0KHJ=C]M+MFR^ 3))D2ZB4Q9S] ?IMH[#;-OSJZ@Q?<9J=HG?^> M2CLGB'ARW^#]X3Y/PRM+;]A>1G?@@9J.U9+GV59;Y:&>2BY)@V&L IK-YT 5 M#:US>QE9S4)2FF4"BXCTMT^@RV4ZMF,;ESYO.[R6F?R[T7TWX;P[ MY^@YH !=/\Y9P#O)Z6D68S786F2G@HSB-$N::(?S;>V=4DH\6:MZGCB%19D? M4F.1VF2:'T\\!+V-R0NQN3,<8)-)-PPQ=3EB1OK:L/]-T0>_5P55_J8!ZY3I MY),48C"+W.Y\1N&(SH?CKL%4:H>S#^SB"=O6@VHCYT"]ZH/W>E*;&ZIS.,%=)Z5$!C\:GLGFY V5^/KO MKH@0_.JW/!OLT9O1K("V[20L'67K(M0+DZK2T M.5[0:$[,V(G0X/T3GE!_$K8H/B_^_>S$E8CL M.9V<)I(6'!A'>FG/)81T>]\Y+ ?#/B@V)"&6^W #MS'^!0I?:2!]>Q>6N<5( MZ(E3]!1?S5C6V_D+$BN9F,](?\,7.'KSN*VTG!$3$6'2 M<]WG$2^D[.C]81^.=BCSZ.P;XYS?ADQOF7:GYHYL>BSJ[0T1AJ?GT^D/ARIF M-A5HF,C;_5T6Y-X/*9=?R$L##7][&!!BL)*JU'A$AC:(5,#5@YR27A70.A>< M> ?"=E'9(HR!4VI6J@I(O./[+4H$18&Y1?0Q?UOLDC<1643'TW(UUO4.!]F5 M1U7 Q705@/[V2/F?WY8S*EQ_S3IVM:> M,14P<)D\/41&,DFM^-^2$RAZ3J M'ZZ\Q%:TZ74E598_R;>R6L.W6O-,8\,_#EQ26UBWR) #I3-\L#@Z3LW% [BD M^)BI C:I .$M-<4>K+T6 )"O,!.8 Q"AQ]4NT9JGP%L^,8*FUN0CEINCMI%V MOG:8Z>*^'HN,\A?*+_@+%54TM#!Y9O>!>BE\B#JUP6"FW*)L 3AU:=^ W/X$ MA9.A,#Y2_:'BT^5Q_Z5GKK)@'X2MT^.0[(NCTXKS;D$*>Y[^MNRX7SN#/2:0O]"U- MJK1,YF^8]]I$ZZ?Y/DOUU9JV/&H@PK0F(8#$ZOW%02;FL2C9#A+ M&E=6/"+\U)=W^_Z@<%.:A*HA"O$M+BB@.F]*-SW'"9POB*C(\'(-I=$-4STM MW*[PI]@-8&G^Z(!X"CF-$]CGD(S_"H[<[Y-O_ M^VGS+97K[H)2NL[0NQ\8/#P3E=M\TC\]\L@)ZZ^]7Y0G M-W*GJ($L"MVS.:,WTK7E54ND8O77<^Y=$!%X]";Q5W-;,$2Q*+ 3OEDB40$/ M%#]) D)CN/%R;?N9CV9@H>(T2%/>]A!^^:)PC/@<(/@?YA7#.N F)& ME#8T,&0(G-3'M6KM&Q#[<;\K>-SYTFK;T%5I%RTV%Q^]OAU8\8^$3PF _J^; M@=3: M:?PK'>N)]RW,RT[A4L6N@<35B>I$ZUK<((W,FRZTFK[P3",8KC MZ#SE/>8BQ0ZP[J0*",5%R@0_X ?8G"?I.]9J+T^.1RU90P6< MINBB^YYTJX!?MARO9\U![HI%R#+VZ)QRUB+D!;1Q)Q*#;V52S=)VYH^/M'FQ MFTQ;4];9G*4 2.U/3UW-/M_-09(^A#@8.](3)E\XX5&XOQQ[L_I.A5/NO?:5 M%2>,N%$\X@IPH7&V288\6GD#SQI<$$)XXO00Y<%(!MPKL>2+=) 1>:FRB*2% MGH=O4=7*V!4,EV:6)?21/!>S0+=WHIKG))4 MUZ];TUY:VF9[K&NT?+3:57J(_+.HY[B8/99X0D'Y_NRY&4^=?3QXN+IB"Y>^MM>V@E6\U<3/%=FD&5PL_P! M<@;6EG(OUJQ ',0#C>088AFW21DH)H\UWF4U4:%BIJW"?XBX$-,9"E!'LN"L M9O"I(*%L(AZF,NY%CB0;Y"&BG[K/FIE^;D.5E*32%Y%#>)R) M(#0-SAG$81D?FC5 4D]!/@J(%DUAJD4B2.K,_0@KY&EE M/,@V@2 ;J- M=B?$W(+C]L[N)O/'!ZPBY%SOD:<0%ALHC?+E4V&;/':>'R/>_]WD>6>G/)KO M1^.]KH4APHCXSUWA/6>==-R4ZVQM[,Z'MYSTW- ?-,HYV.FK?GY3H^%L%4!M M6'VO\$.+W?JXN&Z/\G6&S8;_<'M]?_TZSX8GR[2V[E/5C[@5 M5#S7C2=4P*Q2$;8[9TR@ B9G5^%)6X0#7NIJ(R5K0!F.*C9Z)[U6A*L I=II M/$ZM/'&$?TWJ U7 5C\>JM4!?ML0S>-^4 '%/,[)D/;#U-,X)M^Q$6&S@WGH M3?=>+EYSM"/PFN.+9_FJO293"LZ4X.MHBZ^5U5\M_M7*+(P7AE5B43<+74]$ M5:H ++H"1(SR5,"7$\0_6=E*%8R# FIKB7W0OW1+>T;9.C/R37ZRR"A-/J(" M9F;AE4[LG:4"7MWXBQ$UD/IX0[T9)9Z M^_S%Y7U_M3+[[XW]/V!C?V4YP!\"U*# Y.KPXB#?TDS;2^AZ+E+A<[7>?U7D M]#O4X7[?B.FEP]O6Y=(-!:'!@1MZ76T:]%ZMWW'^GO:_&W(9]WRQ9?K-S_RO'#V2,>O7N<^[[POG RE=GX;_9K,H,7EQ^=S M C=;/\Q;9V09%[^J5D%W::7W;WFKYW[I.9CS@UHF0A##Y"A5PUT!^ M%0=\JUHB.OD A\YX\C'*C!XY: *UJ%;#J_RNY[SRWW@S"W N( 8A9Q5 ^@/B M2=<@^,:XLG!G8W&^]X__OAG98[>X6 Q."Q B2B"WEA"0)!;N6SLU%93@1.(C MH7^M%12!62Q1)I('=RAS>% 2I*D"MJPE2Y>UOD_%+E.$3BI@+A< O[[+401: MX:JM7T?YF 4G'IST^2A"]JJ ;^K?-B@?DC\.\((F%+9DO"I-'64D M59OR+J!X?&GX*!_S@CC&C!SY16A5(72RHQ8OC,ZN1P[0?ADS[;OGFYN;E/O#MI5I#O53_AL0SEOBJ=&=8 M?9S))0CN:+QZ(Q&=*!2O_?3CC>$#MWXX^&G>V]^NW#A[X\0J:7>578<*B N$ M24[\/5L:94]^?^2@]7GJ,7++>[G>]M(?ANJ+3+OR]Z?]1 H]NGG/AN3AVPI. M'@BYX_>8FR+X66@\0$K$MH;(1E=8F5X >TG+WF9)_,'=3[OMWJ@ @V"6/K0G M5[*3X]F9DTIY5M51[1J:-^SHY]\$"T/2RR,*/K6&&CZ9 1LXT1RS4R1MI$/2 MEU_',T6J&JBE^:B^GY@Z>EBRIO2G4K^BC1)",T5S$-\9.[I>14.6(N7T:XHF MX[0/,B*AZ/4AY>UT:PWB//O"0\7$AC.(^RX!*1^GX[ZLUSQC%7"LM2=[6CS= MR'!V>(CJ:!FM*("_K=*D9M.CKJW/.FP9> MM7-+J]6Q6AL;O'"!^H^S$Y;,:EBP=M>_ (LJ]N/_>[C87Q<>8?WP^E"&\4N7 MD\&63\-WS]IJI?/'=;.&V8OWBF_=6O>3)CC<.H-5W[SK:KA7\RM!<1"L.PX& MTV-XI1EC0U 5GVJ",S(5,'^2W&.NJ'^,VB-^"I<@D2FAF2LT*N/&.&HV%$R2 MU9PUR>K,PK3J%"ZM5 M-(M\'#1&396W2D/#9!--W$N9\6-TQ594%XDQ23@]1;S$*Z'6\V(OD!N(['U_ M5.XID9AY[(3?ICYBI'I"8,P46=>O]>BJHMR1+I=>%_'Z6)5AGP3)F M'O\NNJ*'R;K5X5NP'$4((I($-K2J(1EN$-.1>)5W L]]CB9K25#_?(B2XJPF MVUSM$?8PI%*>Q1WT#K R\=XIKMN2TX_LG[*UZU6\>8[@@!!&CB;9HT>Z6?9@ MW5;,>H18[IZ"@P*Z#%$7/[>CD1,Y)6X<"<[3M/B^&5+CHH=^J TR%$%.+B-? MP7[H/@%G))[BCC\J-3.?W!*7=;_E%/0JQ(01_*ER8KR1%4''YOVA NIV\,3Y M_8[(+,[3.1607R-5@V7"5%,^8!IPD1EJ+U$>@]#@5"FW[C9 2I9XADDR+BYV M1S8^''3 B +2RF!L1>K!,M@V>>K-%JW>GSJXKKDO/O6]^)!._9$9H.21Q7?[ M+1%087&(N;2K9GXP9Q&N)%ICB/K.&Z&* \CR,V(1FS.K>@LL$ULVBK0958TU MSE!STD"Y8%57]8^PE?PH/<%G4X AO(E;8'F)Z2$)MO,3]UN\"]?QV#\37T>& M=HF$7N+X>NY%'@$,G$!6QR=56UG678&877858#U=S95N&)NB-64+Y/F4=)*6,TU@>G)S$M-+*HK6Z^OK&ZELG"IAD!N^ MN 3FO@\A'N.58DD/GQX^W%0^9);[*/CDJ#SA'SL*0T:ON[6>?AB]=6Q)AUN+ M[O[]APVO%]?VW/$4Y?*X7SJP):O_%_6),< QG"*LZE5L!WL(R!-6J\ DO;C6V;V0.^?'.9-ZII MKP(ZKRS5'&J_,@0V>8/]0CU0]I#+O+4)>P$TG+^M$SW4R]7"1$QO>EUX\4>?"O(:3A;NK"XA>2 M*O9")JE&X&L6T4@3WR:_.LONB:XS"VNP52&0>OU#$.,"X^F[(61U>,.':7=:JTR+S\ L-T4[1 MGVD_C6X)*T! ?F9VZC!5!]>C]$5,)V5.=02,LTV3S_G2^_#X7;E3JS:#(VF. M#3?SV88$YATJRX_!" SWYJ]];[@(M99D7.41%3799ZY-1796[Q=RDYA[["FZ M(Q$SJ:QF%\00'.DB*RTL9^ZF]BJ66PEQF?Z>A)- '3?1%K2*4'4G7!%B/$M:JT5QN7 FY%""I(,"3\P.(?A M4'E, ;H$\0*E4:LV44U#,FHV7/\\[57VK//S\PE;'HW YE6H -3 03Y+4#.? MZ1,W+6M4 8T%V.+O+]^7\.+((8NI/0ZRC#'_1Z@F%)%PEIN(:2('X[\[;3F7F%01^:LX?!IZ?W3.SJ6NJ_#:] O3L2WVN M/-!.?>5S&5VNV($)>$]]\. .)/;T*^1/WX$A$]$JH&R@(67=1".QC-V88DY, M!!^+XKC8@@\ACLUU0S7.#%H#:P5,;R;,0G^&*A).UQ@PU!LHH84TTTAD?*#9 M=/+"%C:?,*?O"$@A V='_)>+(^K-+-Y(HO 29.5O*:F(L7M&(H1D"+T+'J _ ML/= RMC?H97C17>'?9O8A1\8U)>.SIDU60^'-UTH] 6#MD7^EF'AK=%5F<]M M[>[C3.5F3;U>?>_B;)_G<3O;5OA$&)]:LCZ])_3P>X#_QN*+<-CF\C\:'AW] M4ABO==BWT5#M7W6J>/'R/_"*.9QS5A>4$S-#WZ9/_JN^/%85U/X,F,]@84UF8?Q^T\YPSTT> M58O.GC'KJ_3OW='A]W+[[NB<)0;49@Y*IF!:EKC()N*:% E!C53 :R'VG">^ MP_MRG%PF4F9Q&UN5V\.35,"/%Y"WJYJ.0>^OV/V*)'4>7[OAMP/YJ]?8.ZWJ M]/7L]1@'URJ7,O(3-\S_NO3N]<";>0?=:@X&%%TX-#^4:;>V\^JZO2F[KN5N M+O# MA;)([=2-RJ*;^!ZQ6^+L#BH(05+ M(E_$U547@@].*_VOV>$V"U=CW3A+'R3C'L?D8T=5@-YR-F_PB92,.ATG?PM6 M'!93$6O+L1:XJJE_ 6(KFR R=DW7\DR8!R43<>;V)3B90UQV\ZJ@#'99)$6+ M<57X9G]YAVL3YSR)71C@&AIY>D=WJB-%3]^M3($KZ07?FTZBP+8*&%?7"T[C M)_LR#:6S6LA?SO \F@Y@_(E)\IY]X9J[+NQ=>];\Q%> M0_^2&+[O'P':U$4AN$YG[I0BSN?)]>P%'I,H*3V08F!=9WWJP=M;P1[Z:8&> MGCM?;7N+/MRS/M1F%'1AK'3+2%BX!-^0IDE)8_B7#P%SKE+]R$DMEI=R$W(# MPHGS40'7\&7'SP?K2+Q!/R0'_]D!S\:/NY19]]BC MCRJPZ!\XB 5'!2S_]&T:CQ5=430X>%72BMKA_./;/N35?_6 ;X#\.+*80YVT M0?>I '[60QP/5K):VMWEWGZXXE](0?4HN.4O.!;@(I9>2YYT_W4 ,_T51!]( MG!>)K0@ 0JYGS8;ZN45^C(BZ -.V:LL[O1\V78MP-K6-MZOR)WK$119,QF5^ M#GIT2KSS],J3Z8'>U[>_;1!X_KD,%_E:M7DG[5QQ'?]ZNNO5RKQ7*Y6;HM(< M?\V=NS_?2.NL9*'791_KHW-7+FQ:[[NZ:?W.E?=V-?VW-LSW>$\I1-_[%?_@ M_GD(\<^-KEWWDF>BWGS'KJ-TZ@L5\+U?]?5?@.[ X\,?7-:^6E4(GHW>=#1[ MB\VQ4Y?4CH?F]>[62GT6FK9MZ>D/S[WNNN)Y[8VCX?#HN?^LIY&XR1][22PY M=P>/+7X(56LRRI-\RH^F31;N$>$RQ?5!#W-?^3M4G[>@%"E;K#UV,M)FOB_# MKKPCG,OD)[:C?,CR,$YY8R09_+F344=0(X@S.K3R M;^VV2MADBF<,*U+>MPI\VI_N%%9>JYKQ:DV(]6 MNJ:EI?#NAH"E@;6>QL0K$:;-392X2D_>*&QVF6=VVIZ\<-#;&!>?7@?;I/"F M=)'>JLH7<60M, AA,>R3]1YMN5O5,1 G55OQ6Y-? Y.& R-1>9&U^ ,C1" U M&4M6.#+,!YI8>FW541(/T!CU@>+C/\.$B^B>"GU&6*-PAV]Q08::_27 MMU5]O+S);[(&%2Q9CYW%/A15Z2OHG8 M^[#&F4+:FP*/#/(.)$.>A&B*)V)BY/&P>Q,8.V-9Z_UNTO.T[96*_A^AC^#\ MTW9T_1!C4TI\F1]U<8IKM5-X_@A.S'&8].PKOVMM&OMI*O?%H^MOG$/^0)XH MW)@:B $D)%P!%['6HYN1$]!3:&AG/J)HRK9M/TO4'BZAE;=&WO,+$A9-??06 M-GY^KH@XD+L_8U'A'QKW3<6:A,.7>5CW6,BNA^VBC J4*S!6E7 M4^+%,D(\M83'+R3&9YMT5WL4,%H;=E4V)SI[20E&#-ZAI&X=2J/Y.C@CQ9ZK MA_ ;,Z<^O4B[_2@S/Z&L;P\<:F,3NBS=B<8X1KE;*%-2Y-/*ZS:LA0P3&2$> MVS"("V24 +LWF@3,0X(=:J,,&CFE)HFLI0A_3T>X3> A2!##U(8\ML(35YU= M'B&1/[5/>7HUR'WI\8$9]<)SG(@HJ>WHFZ" O:(%+!'Y:> 5>S"VTC*69474 MHS*/MGDU]!.BB+4<_2D=!TI[K@#UDJQ>QUHQXMVOD^J&V&X17'$FR*AS#@^) M%G+1>04!C-8Z;"V44G2_?SDT_B3OL%JAP.=S5*PKTP;$H]96&7>6-VN(:&BK M H(H\[=!'0V^\4TOEO-!W0Q7^';K1=3S$:OUDA);'=1O"OMSX_+;F"Y%A_V& M?(LF8B9#3;'I TA^?K!O7BY4W-&4;AH^UD \%3236_S\_M"%KB2J^XG"H6[? MW%L7LC,*!B]<]QTV;N_KSN+3J75FDM@V%\DS?E]K3Z\^W M7JW5^B1G[Q%_/]^EUX>EVD$]EZPS#-RU-O[C#UV[*P\//2R9K7'=Z.H/>?GW MEYK?(3[0_-8VAR[O3L$Q-72C"E ? Y$Q8J^O@W)V:2M**%,!LK*<)^1*WO1+ M%:"UR7+:!_M&E&PM^Z+@B?$JXW%D8JQH,79)&(AIXAH=%I++2^DSVL$$\?XT- @3MO,&;?) <117!9@5F24J MNU1 C3NR[Y_6_]F^\/;/8W,4-#<<:LMQ%G51SD//E9[[MV6Z-6##*D"T'%VM MPZR90$B\=P*GOXQE_WGY[>\Y?53%1S!VL8$"1VXF&[IC_[>K?[OZOX^KV9W. M5,F658;/NIC[)'T;YJW0;2;=+1HJW[=SC?<9_9UA8?IVLN M*-D..XTC!9R^Y9+!XW)" OQPSNJ&/!&0W#F$/A MYY(]2]/]D],7'34ZL7 [<[PD3^3XXGG4#;EP&J>($%&W^G11[0G>WA77/_3Y']GUQE!WVY+K M+.M:L6!:#;VD<&_FQ6=E: M:0;>&1,T42^GDS;!/OQD40))MQ1NONBL28-=FK EE=W6=W@0R.\=*=KUMK41 ML_SZRR$[G07CH41OA?WG ON'GG.RP/"%-+^=G_<8;3NS:^:/W"G+6&6S!?70 MP.>R/:=/#GX1COTF])]H0V8.;Y_941#8-5)CP'3&B^'QV%P/1?"Q-%#>G) 6 MW&IU]L@1):?DP,/\T_0@[FM>BR6F1S &V[A26U0_A(JFN*,6YM8X/:' MG;_+R-C=7O;,CJ<[&-'M*XHKR^]HNB;U-/VLX[.]IM/NF[%X9OR?$:,"#BS' M0?V+"J@_@4M()9A;S(.M-X,SUB.@Y!(1G2:_F?B7:^LT^&O\LZ>VDR>)MN@J M*LH3S/AR_CEEW/=+4[:O/AIG MNR2(8OWTM7SX6K.IE?-UI]FNLW^/GL>=/)A:A].S$_!<^%2-"4*W3&K\<"$: MMLNTC",V6&"ZR3J#W;Z=P]O'5^[0^Y!\S>ZHKE5TCCG[ORA, 9^];CQZ:"0M MK,2$>]/ZR(%O7MXOH@<[B3*5-J?S1[)-&73"@E][BDVSSUCWG4R#RCX,7#QD MZ2HIZ,I_?>,,@QO\]F'_&#\C(YBZV\.I=?Y06U8H:6+[DPH'DXB3_6^C2-T& MX0_\6T'PMV,7WVW<,C75TC+VH9'Y)JLJC"P%#EO_65%D?\=]==VJ=IL&X*2W\N^M/0TG]I]C\UH@[\>6R[ MLBP';//;K0)J%53,R=?IWR$RY]]/?DX--0(E4H=HM_\\U/TOJP\:_;<02?EW MY-MK^O^XIV76CME981;\T >'/NSNL3)T./?E99W;Y[6)R]<+[SRI_=X'69CU M[R[D:N7\XPYQ+W#G @[T./!.5;:[&JJAAS !+LK'UL.:\F9<(A2CYZ%RCF:C M;4^'_&=E'GB<*B1(XT?]'S+"?&BVO83=$*%6I!9B;MDQ49857&31-3D1'S"_ MHVPLDI^]X+JHH9*0B![1N""*#W=Z8>G:07_Q5;:"7!HX1E&#0 M>^]9;=2G[JA^%3;OE6(94QWA*'8R+2%Z7'68PA?KYFF2K!AO=B &TM+X.A8) M)EWBS*M9AO "V@BQJ/,J90X3E/8==C8S3K3J1[QJ,<-G;6/K2IV>A3/.W8.S M<\XHU+'7(*ZE3F6U"DWD@Z%;TU.<%^Y,*P.9]@F@RAS$*),./R)ADQ-R*4*$( M*;MV0BB391="7O)W$'LTM8!!EK#'(O.9)Y#U]QG:TL FLBZK)< 2)E^24HV+ M/@KII1PML&LE./2VTX!,\GB5E0OIX%(P-:BEDB+=(*- M&<#D!J(.HW*ZD6A2[744.B:CP+8-R6] 8;S\LC)WOTPR7DQ:WGP<\MB-Y$8H M=C"XM;PE3-U,S0;Z B15@I[KUV\;M[MG:S_F,7TA2>W52*C!4+YG)8#&_RZ3=0WIKBF(0(8P4Q!FY/2Y#GCPX/.I@V3L2>W>+XE7\A M?X027S35ZZGN4@J[%>;3:E:6M4^^ ?5H%T@IY/BS*>>2U,W[RK0">C;XW6UF4^0=^NCEZ)#IK5:)0F;_' HB=PRM+-00\23W7R M!A>H ,0L6 4T[IU3]/?U_T]=9^UD=1 A7$)RY0<1D0R,!O582]#?NIQ/B(VA M+S2'?KUV9_4'R#DQDE&?:7+%FES"M:!P71T);80_"HL)H\]*L1B'D1]^?XL MZ?=.NV]T) DS ]O]O[>'O^:A#W*^4U\5\.H>ND0%E%QM)T\=9N[ARL[Q'G*% M9-ET'#[L.:;?3CY)[K'=#A.BJR,A7L,^)D,P166/Y#)\ZC-8NNV3+>Z2J6[. M?1%#W0O)>M@J->EF601E_.#K/UCN&SE4+KS5^M ]7*Q:WG:2!^=1#K M'0A16A.)':\Q-\Q/IHZ?] M%*8+3QWM-/=86+0,#5?^#HKCR.7$.HK00>S31#!D\.5@I_./$%_:&ET=4?Q^ MD+01[GM;$7&?X=,@/%<"AM[O'2;.M^M=5#:OZ-3'J^^<6K:_[AKXY7#QG2LW M?69J%2=Q4K\U J<4(Q1L[8M^T_ICO_Y^:L=ZNT WKZ)%KIXK/D3=.MB5-9)? MH"!$'W'@_/K6(UOR=91KE"9H^%QJM3G*PW=7]77#DJ[D,@J*?1YV$1=C M;R]8-H &*(A,*[8C'1+;)$QSL(:$>"KL4 MH(MHYO QQ=/ 8%@T)YS"[K>& M(Y)7)4M$R4R:I#?4?'A"EGU3G&(AF;K1&7X4FOEZP,,04@KBN66$"IK56&:& M4DV$\Y@B,O*0U%, MIFI ,@1/]TD[GUR)%;SB?[*]'N3K;WMC#H/T_0%X0-1 M)?MQ?>>$!U=XO@HPVOI_V/6#=B8.3W?IA_Y8)%LZ?J//[[5A]$^+EZ^\*KO8 MO/LCO-5D\%X2@&[[_E+#[%O0=#V80BUS&!6<@()14+$#W8AT0&%BXF@5=)QO M[EA.6-B2>E,.LP(AQW_^#$1,0CNHR!$T7+F-+VR>+UH>.?[H9 MOL6#TCYN@^*8=^D&JXNHHP*"W_-.V&IC+9R2326P-I_W5,07"6VEWB7PK^R$Q^\J@SLS;M_FB#T&9 MNW_]G7(;#<&'6 X1E["LP3HWS'&DBTW@?QDHIE(:"PF)H(E M$2DL#88F_USF@AQ2[CH.T#Y61DVH,7G\ M8(T'M6_;R[>I4HL+*2O?_IN^YF MGV8.Y#["Z=6649*Q=6#=UK,X5A/UZ,Z@0H/IJ+PYY22*GV$]"9=2U)@7H/P4 M9S^I3I@LOM[,I]'!BKJ(QX M6MDU_$[8$EH\1NNXVX%P,.WE&B"T>^*BJ((>#0:2=1DETOPQHJR/++&L)_1$ M8 :;R67,PS")3$0JZLU7OCO+)0:S3#N7=3'M\X-X!.791GZ>]!V/ MW_F.=^S NM(]%G#E\?CN5#"HDHI14+&$U4G69BX7L_5\,6'_,L@DMGI1$?-G M))]03[A$G1=N:\*P]85//SD#YTM?0JU)RZ&/+*-J""N2^"5O/FOKM!>>G8): M?&ZR(4E:+P=QH%VVPBK9G$*%<9"HK'EL&TV"HSN+#VK6+&7X20:ND(^WZB/Q M$O=&ZD+4#YY3DL^@U(OT[<]UHAJ5)I=_?H>I#_W H/H\;1L/]QMAFX2PEG?: MC;S98G6D*KJBC@IY4'L)\B@E)YS24R5V;R;@FT_29IC(;\&"!FXL9S8YI%7S M"',W$@H'RB\@=W/MIQ-(FEA;/^7BJLZS450<]?7IX=P$\_DPF]_K[]:[MZLL MLAF>"QS!6!RD]I)3J+I9:5N-QC"1 MP NR18)Y\]#]R,-W: 2>2(0]I(SH('FBP6# 8N1,[ #WY&04K.8$;83=J^+ M2&T65C0%>+%#\R'9'S886LUWB"%R^#L$2)DNB*');0$[M],N[)R:,1W;;5 M+LID28?96,N+;';.4'GE;SO#9NAWT?G(&LEM0BUK(22J)\:1B/BWE^&18!S+ MO)VI*8FRVH%$:B;8W:9L$TB@/6G'<^N.2AAE+02_[K-1_G8>D2L[2UO\O)Z\ M,.BE]KFNMCS-@38I,(JGXCWJW486WR663R1CJQH5Y/^L^ M?Z,-^% ?FXS:@!(N@;%)!J>$KCU,!&J,J0R07[,4WNV[ MDI=H7V3@7@65"EDW']*Z:Q9!?=G_@;WWCFIJV_J&8T6E29>:8T%42BP4!23' M B@($1!0$'(0I1Z,'D BA&P5 0$AQP(<08A21*1$ND(@0BC'!E(CH$#"0>GL M"(0-V=GY-G>,>U^]]X[[O-_XOOG9\ H9J"O M;T#IV*.J&]N./8[9=IJ7Z"SG? JSOB)06Q3**AAKU_48?_U_I2J@$BP-U/N* M,2/:K'*6* RR%6.>Z7*C 4K%OV^@L)2!/^MB13%'Q)@3KOC,NKOT;T=&\ +G M(=:\0R8V];Z#)94*R&.9+)#46O!TE%C^M64JT!KL*1C6=S\FN@_[YOM3Y3X4 ME^MJDIK4HE,;\3$JQI[8#AR%4#"JI5[659%P:[ASLIAYJ'BTSZCV?>-OX^&Y MT7?M0E6FGS"$5REAP#7B"DK8!9!A]8&JC>Z6$:$5;,87)#^B&*((PP;RYM*B MJ2O(C&$@&H=[W&ZQ&KH"W++0ZV)4L&('-GQP=;/3.=I>[,-?6U$L;=PP,-!I M3>-C$>EV,>;>*X@EQOCT\K B-^R&@J5 0N_V@ZOJZY1!1L,,C:AI(>=)=FH9 M5*=<)?%PZP+J5G7E](Q B\-BC ILS<^,YC'609Q7%CNA8-Y!G#5?Y;:!@;E$ M9#[9F"@/'1TS]>T-G;@UPW25C6,=X](7E9S$&$8W:RX'"!=AB\28C5\E@"4U M']929/C29-M5R'HX0C8.V("HPTH6 "EW2S M;AV, V4;L"OZ!_I1IMX2;4A<1[YJI-L;>M#1P^QH:7RK+KH]'ZZOT/<494=, MN9[\0Z^J+['I_:=XM7,269P/V(KH[S-"_ZN/$IR*=*%^SIG5=X^;.G5/&$)M M093X7TJ&(K$G1;FL\R@"UU(4Y5-<(8QJF3)X@O8[D(G;]AB2#C-NXP7MU<43C6M_U699@ZL8HT%<%/$ 2*RNM^ M@M7Y+5,OA;]13"!IT$Q@ &WFKQ6V$%< OJR;1+7Y0)2XH#@S@>+-38QH8:E7 MZ!.'D'PN:ZW_P(YTNXX;9U_CK\,:2UUQ.6.VN8>V71E7>C,WW=W1(^@LG1U; M=!-CNBN4X!8X7%3-"J*O .KWLG[!KX:MH,]@S=\25&.H_74ZY1^V0[V\*6LN M(9:I.82+\93O,F+=0A]NMKMH^_HBHO!Q7*VE(8(04VU5F]O[M+VSB:BHT\D\ MJ)P>J?6P,H.4"%RD][4)"E%Y%Y!&>KGU9$487PN0@X:;JXEHU C2-!%X/8>. M\XA]21TMW"]1/)HLQ:M2E EOYIL>/%*_U,PP:?18R?%,ZK3KK,!MU+D^?W"K M-S MHBFZ?,DS_+9$PW["S0EPFC-<7)!7%5V1,+6AI='4%]:S30SV>*C@,@'A>UK% M&-V "OR5'8R1B0934DO3W;Y^WF L:RBO;ILH9A+!43M,PA4]%4G]UL=$>3.A MM:0AUF13L!#O/[ 5_,RX=5&,"0P$UI#-FO=0.ZJ52QCCR+8>"ZD)NM;Y*)[= M[3H-Z-!32,$*3)V+!$,"O%$L-M)39!Z9-[&*R[D14^#%=S_Y(904;^QV"QQ( MPP59; O(5,Z<8)NFTO2GCSZ'6"?!^>[6N*N\U5T&AB^_E-Y5W;2V2!0T,O$Y MY*!6P2?V-O[-I&G>^ZB8O?WZ9<=>K5V[UZ"H./OC<2F;9NRN%Y=JHDYG75?NU_Q?<[-#]TYB#)"Q9A#[UT1T>@@_+3(;;G& LR02P%F:LT.AC&=#^LSMG!EA.2MS+^K$_Q7^:H:Y+_,KO:ME]WUWV M#Q-T*S^I_%TVT??=87^<87?6M?^-%8I7P0^5TBNJIE8(U6!MZ!!O\+J6J=TJ M-S[0Z$%@5_^UU!(-8WG'\CJFF$9A^4V*QDMUUR\KE=^85@PVM"E56K.^[QA# M7G0/^(75.XAL."+$4RQ$Y:P D4ICIB$DQO!SS0FX1ED%/XN=74R%G''2$%:5 MC(:B&+N\&'.]D,^2MLJ9TJ!U[.1V9>.3"6_3SY"FS=_6%,1M^XH?&F8M_H0M M:Q.E:**.^V31X0K6>5=(#@?+$P2&G=3E*L1?8PW?VS8-JO) I9862TZZX%(M ME"B;!/BIAMCBDS[TCM=I@<7YW#_*N87CF9L^,,-X^MCC774_^=&#S.P-5>R6/JN'C'5M*<%GWYCW/$R>_"S& MK#O%;?0TO*PB[=M^IDUVZ(7K^@=#WTZ\C@S39?OLNJJOE/3X>F/$B8/FQ-+F M7X"L1\4>G6T! MH!#86XQY/2^0A15F3O?,MWW,$_@Q^8IU/S%[]!%%,NDHL\?<]ME@8/7RL1*N M>CQ!IA]J[73OUBN?3C;L/YFGM.[) J7DN,?\ M=*2R>_*%!\;*^S7R5MQ\>^GRPW%KR>OLC@;NL&.V8[Z1S6VO-3LKKMJF?(OX M]%^:O:Y3W7]O^O^/>5&[-1F->POO!J0NV*SR4>VT.YW^T[73_?X]WT:.?ZJY MX/#["JE'4=1_=//1P5)1"@IL'/Q;P1!&SN$L)&4BG%W/W-2AXE#=&EDE?X';R/W* M67=+^4X(G=+J26@-R&ZD_L2W'%EHQ"6HI2:P+LRL05J0/83;GELZF/[^/!1L MU:U.]S0U3N8ED&&S'!1F39BXA=UBA'B$G6%=]>&$--X<=R \K?WR.&PA45%F MI@8I0FRG/6AOQ9B;>/ 8O7<5UZH*+'#JFFM3HY#:D34PED]X-1-%E1 ]KB#) M4-Q!/)NVDES3,L&7<"#(CJ;-W+SS%T=OFH?BG41&H$K:D^P*FF)JA?&"H&\D5'@T@5N"N&:'#!39N@4C%E+50/0^W MX0P9UQR>5R^9J')(N6XCN) $X_-Z^\@U]6F)J;?,]?,--[Y63@[H$0P0QBL4 M)?9-+V>R>HK"+$Z*[N&]:='X$DX,,RR'N#-3E="^]Q;:9Q-QUS&ON/MY?VG-8M"1J57C"RU- M?DO4_+<@(UO0D*C@5UW\:XCMGR&? ^8B8P24/G^UZ/>U,?G!R).&;^2@BP.J M(\?ZLSLK-/&G.R=#@[8@;T]U5-B:>5B?Z)J;>(HK%UD3:J,-?ITIQ 7EI/1- MMT[W'?M:^;(JY9A.S-$4G9#0[9?57@<;7MK\F^H- MB>1DVV277Q[]%>U]>U7"W\J"3Z.^^U"&KABSUI@.A].F/BL@4::NB%00'IH/ M:"<0\"Q$@C%7\?=2AL7_U1-6F0 RQ+' O[Q?DU M4!"XY)+A<]>F?DOB-,. >]W3=?-6ETNMC;MND(M=$978>N+2;( M3MTS3BF?T@<9*:PH*'G8>.NU_3$IUK:QHU_NY*=XE4G$97J;;[O7Z-+D&%)[ M_Q+Y9A>U."=ORF!QZLU+E-%T$O^U^RZ@ 5P^M&()<,,0#=GU8LRW/M:[K/AO M8DS/F!CS834>7,[%IZ,J6A1CX!/3^Y!;DR:(UK@8,_MSK7#SB[H!*9P\Q1$KH5 :A2^8Z8LS; #%F;_P.,<8=5>W/&\68AN7T?%2# M^6*,@MEM,2;+3!J%0]4L>!+_?V:0^'\:8@#0V#J,'TUB ]QIAAAC)CN'>L]H M+NB*Q*-]SL#[M130B%2!!9D6&Y;+R\4L&@"XDC&[(XLV7PW,K9"%=P!P MWM\RJ/:]:%O:^GP0BD C;BM["36NJ&OFAQY1'"%-$'L"NE TAI6KT-_'JRN) MS/='5G<5PL2(O-[C7,F)$&9=.0CWW12DT,QRUE^^K'&IO/6.A,&;O#D)9!V< MLJ0#*T0)@C^8VS\?4TLNQ"HV"1(9>E=4>I"P%MDXDTN2M68G-[;)9I#T5';' M/2;N53V7MMNAG<:CP>KHWM&16#YRK=Z!GS?NF%@Z"UI/ :!ZRQ)^2I67J-#T M7B(*N$#7(D=QOS;1U )Z]ITF^W#.@O3K\)[A-H7/9"KT0)N_-BYKK&Y71<>7 M;KTI9OKG,/ON7\NCNWZ)Z?BVP'FS=;[O6^O@],BM;/-];,952Z=\N^!GQ>^K M)J\( CZUN08!)\"WLDBE#\10_JIS@Y$Y$OIM_?F3M)Z=7H^O-_^2KW.V8 M?2&**7RVCYEK&TF<8?@;6+;-X?_CQK\$K*XS@%R'9QIP,6*,&BPM4T4:$F/B MJ3(?F)>Y!8"\?V(6^8:T>J/QG@#E/8%NYG?;MJ?FMZQ^DUHI_^:;6RM#*C9\ M-\.!\;BS;?G5^81('_CU'QFAO[%^L#\XN^ZL1'-$ MC(&T6!U=_SV;_[=G8[>V(/>SS?/^ !>5?;O/E1RZ2C(L5%0.*FG9:K;FY)GG M,IAMX"Z18CE"_UO\FD=2T<@R\5O\CD>RO'N"]Q!#>-*/7L&!E0!VSQ4Q9F,Y MXZ.$I2@/?ZZ?T=_&RV/+;GKKS[_7 *Q@'@)]N5^N%Y-UN<9)^6'/_-VTLK7R MGD*IO.8*;H%S%\!5K A<4XW"%$T?VX%TP1>0=4.?=1&?:,I@XSX.3 @^BS*I MJU%M[ 5\@5N(+'05G!640 F@_-M78HRL:R-]H]H@CW"]F(HU+GH&.]R=:> ? M>7J6[:\]4/-TK))1=,:N8+Q*#@6_/1\A2="U#6KZC:H$27\5/0[BED.CWR!? MFU1$>227%2-[XU$%=*.TWY3\9 "_KHP_+QCU8\&]>;+HB$ MJ,OF$J7\JRTGL=*PT5/B>)TFN,U5^7E./M=. M]F2WD7J1SA$7-2I=^]/@A1O:08]P#_R?O#;@=)AT&R[A[WG01O8-,YJ"4/<] M] <1M"5\U#DCRK7810GO @+<)6GQ@*:%!?+>8A-4Q6?PM.F3M2CN-TU-*BI_ MKV#U@6D6RO<9%N*;W68:!J.4PUFW* =SQT_BKL&6_KQ:G6-ITH[-[,)N9#^9 M(8#_=DW/*[H,TX[O_2ISDRB7LEYH-4A9";T6&E$[/+= '-"W'J@@-C)Z^^O5 M>AX4479 NL^LP;^I9V)'_;Y,)<1W%R=7'?]F;^K6F)& M[7U\9U@#T*LB\(04>/LI'J#O$+:!'J.UO0(L+AIRUP^LUY)JIQP$\LBZGOR0 M 8L>IO83NSRW5R%MTN,#^U^\X%]\G/51,LATIM')KN#]Q84.\Q;=%GJ)]60" M_X@5=($7ZA*XQ+50A"68%Q,2:+G3/X<,L*N#*N]D M^Z<\/:Y+\LH[T^_6D'-W:]PA':4/[3^; !/@W.2-^%VU;S_E_-+7G]L8?>/^ M7:#LZ0GCL_ADXV._9/NT_][[R7CHAI[#&:)_MQ@SJA*$.DL\PLV>,F6)5DZQ M0%\QYI/AAN^+Z^6YHD[5HPJ1$F.$,;1R%!;.2:*]%_/C8 M]\7JB/>QE218B37$F3S$]R5 !_DF7'J3K#PYU@%TH0T_#95=15OOZ3>1.^'V MI#:GW_VXP4N>_EJ0:'V9*WRYW;*4K*P:].;LL:DMEM^(\%%?H2[0+B]Z!( * MW#8QQB3YJ_/[TG$C'9MB@_N[G.[='EIDJ.IZF%D6X099/A0++QYQY873G^P] M_N ;K%J?5-^=+&6O]JPQPL;(^Z(?(>5F=FAHA#%SSG=.QQ(X2.?+T2>+Q)BC MMH+K*)D@Q.+A@>7D-U7DS>#<498?%EX-!8LQ[T=\157)P(<@+(SJY,XL+-R7 M@&P9C,7.N8S0KZ#1YP&\G!"'W!QE?"U#MNP3);-&XZ@?\*A=?A5CTM_@>5OQ MO>[(K=2I56+,-;H,L,C,%I)VH>KKPR_BQ9BM7Q<%RT?)26S:DNYO;34H['Z' M '0?X'"(ZVSOOQL/]M\-_)_&N!OU'57<%I'22]_/*';^ N#;RO"/3747)]$& M%+!?("UM(9;+(BLI!]#6;S3H5IO !<7QVL*?T6V@PZ8CI!U(_QO6J#$-01'\ MGXM(Y!] HSLXC,1_*IMN F;Q]*^]] \92K :+0"2JM$Q(AGJ)!;4)0\B2B*3F4"#KHZ\@$B3>IFI2;/D52,:PG4D3 M=I/[D4ZF;% >Q?2%&'.3[EI9^Q+TR1O6#R61](K.1Q%.&^K>TAJ[<]&GZM8# MZQ8B7Z9J*@'MVU6 CJ"!QD/'9;9A\=>OLN[&384N'O:GJS?+#STZ'JIW^DZ0OA*4?CO!:4S:GMNH(7VCJ/&!D5Z!9$K7N]T:F0V;)HTH M'N&0[]2(%;4C0\]%Z[>% T$NQD&?<:_<=!,;D,$J2L(TTY(HBT&@Z6(D3*1%[42*Z 1^'A2=W M((WO@=$-5;UU;\MX_\O9/G"&PGU52PY\P@AD2QASZ?'UVD,DCL%%U^" M%54TBO1E+_]AO(0M@YS4>4)K*YC[)=_KF;_ U[3,7RX7E9:P8R3N2 MYK:T?E(L )Y@W;)0)21H;>H28P(8FOZ>J[H0/+P!J@%+V0U::R&)E2TY%$D4 M>*G!NF!EPC!KG0=%J@ITJL\FLU[U&;Q\/&IZD9[O)T@ &5S7>.],3N,LN5IR M1AT%&*> ^CT6!Y%ZE@*B PWSB/%41:C&GM]R;9*R,\\-4O'@GUJHK*K,W%S6 M/<";#T4!J]])_8)#%_GY-ZY^F7W@G+4^%?OR1X_-8/[Y?/YY;] NH[$WR<=: M"RXE%]]_=KQIM*_;< %?RM1X7>:I-72B1J]UMW,I'*GG5OIS+GPOO=*8-"18H^4&!I33\PA*[2"S^A/KL;B9(;B/[H)&J( /V$"J0[(T MJCE(8DOBKO6]7V#3I>##=3TA[\T.\96:&?R60R4LOLN#IZ-AU=0"?ZX[8Z-_ M4&2I/LZUB[=E" F&P]!MO!\^#Y4)G5%U6 )!A/4$ !1C!.E5T!UP%6\05DC@ MK820-P1)7+R%$D47#*JZC?)=1?+>MXZ!NNKX6TL+-[VA()XD7>.,HL=*]Z## M/1T>FD8[0NT+>!Q87C@\./55: E[06-\X1$^:S*/AWI!D# 3A6Y$51XQ>E!K M>NL]+F,*SQV4ASB._!A:@3]6RCPDA:Y 5?_X^MEI\TM0=3/*:7O@/<"6L1F4 M'*A<+1OSNI*4-N"7[:U%ZA$6Z&T>$X;? 2IT"3S ,5IBH)X(.-7:ZO-CX M.GG*L6Y#O!0DRYV.XV88X&_7:?-[BH:+;+GS*"[1,]?-)\>T6:4V9:IQ*'A> M2\_43WRCIH2/9();3;N1M->:V/Z:MD0LZ(B/8DE2)9!W1%7*9J[L+:+&M!CS M:ZUMO:G.9"\XR+VMI4!K8FTT(FI"QL,MX>=-3%,3S9VYA+60#\<.G"\O#:PR MY<3]-T">#%!1QQ7._&+.SG/!15B""ON8"]?OK% (1.N)KF[XJU?Z)%6?^+RJZC^(US6I'L.M1&0P_O@K@-5K%V&:OC!7.678)Z@K&=P2/DZV# Q9,).;XO'*\*! MP]A;=0H@I[GF8-@K@85R+(&T/A"0-L2I]T)U8HQ+_(K@[$,Y4/R,]1B\0HQ9 MLZD;V3R M/1H:4+KS(^3A(YC>+6>B>:!%5 WV-]"W, T&F9%:6V"*IYYPB8@ M,6ENK$B=9U%3.,%:-Y^XU\-J]A"X/8Y[T,2QL]C\S-5<\A^>9-/.+V(,I+-< MYJZ@63"X$ME,5A$T@C0:4WKH+;$/[P0QA%B*%K:"T$C0A'U%O\/*YBI!W$TA M@ RU:U#:W(,[J#ZZT/>ZEG\Z]0CHFC0]%T&0F:CJ\\Q^%JC/DPZ7$.E^8*%X MI[>,K;4>\@*7RQS),@S1S:J>RDODL&^6\!<:_S :E!UGJ94#:J. (GP$E]#9 M--S4]S6>Z1O(5VBN2F,DF%L6!PQL(VXDWYAM4Q@9BQ@<@2S2 M_)\-3!^#Y\$%6$E6$,^O2@@AQFBM$]'J%"98\M.AK#X"H=L6X80S@?4,%$;[ MT%8C;9D[^4_HX 2O[H%P]X0#--N41HJCFA+A+7S+=,B57;<>Y#3AHY%]'[A0 M5/'I^NVY%Y9R08EA;"S>CW8=6(M8D ^W.7;"NGP&-^Q:W2XHS+['.UZ?:-]> M]Q.9:,NWS\@;+ZG?UC/Q]&/?^!VW04G_O$KAB;WI5[_\_CCA.O MX<'#C,5C-':;4,YBIQ@SK@D0N[L9DW)#AF>PIZ#W0FMR@L,'ID(H.#&$TBDC M^JT^ JR-QS WAPVWK:(<3S^!!H)(W08US]KB3V?)9=PP]H$*?>]AJ\?\0'?. M'''E**+(WYY="+DM-(8;OUS"H@K\LS)/%(V&R\Y3A&EB=B*K2\,#11DY[_#S MDKI(E63,$02<,_W.05XQ90]B1[ MR,-G\&>P+>Y7YDX>/090J-.F./.U*\OPL11"%KFRI5$9T4W]F8^+ICAQW[L> MJ10JOHZ(G#[ATE:?'GMG\B43V_*E'M16>I MW N9JS3X+5L DR7&9+\03\8+ND2Q+!_"1^NC+[JH^Y!W=6:=YB2A,R7LPY,7 M[V.OSP76&A"4_ #YT)KU,;1\K;#@U[I1O&O)Y_$7WP_%3MY5,%;NTVW;4ORE\^/#<8XDKR2/8V[SB MK>\@:N5I\.5%6?6;S>= \H%GO3>?^FQB>IJH'Y&44G:ZD1?#T+/?GJ*52VDH MG[!)TMI$,>P:/VS1480=4V_$*M:ID@F-:OB;L#-?Y56F*M_UUHDCJ#'<0OVR M2+U1C9OFM'KKL?8*SM3\Y*^=NL9,/W(1ELSZ3[S4/ MZ( S4;#9^7;]+[6\C$ [$$GPZ]R?)!?Z+(!CG&+\Q777G?6^AR&:^VGBQ"]]S: MNMM3#+^4/JVXM35YD"G;\J[M^8ZBHM")^AR_,B!@7,>R\\+UQ;;X'D1)E"7& M^..AK6&3O<,X=4O^PI!++H@[!5WG20=,VSGJ*PQCX\UW@F6N28.- UL[26F# MCB]>H%SYE;QZA@GQ4,%IZ3!B1R@YY8O0.>9BP,OD .? DRE:] I'=O,-04=Y MIH[\\SE1=DA*W/[NA_F[[MQ(+;W_LH-4W\+_$ICJ[U\STM'8P[)]_\ M5*9Q.,^#+Q->>E:QI#,_M9-2SC55C=E5?$8C4LKT6>EXQ>/;\<'([3E]X##? M_HX73U9J(IQP:T[3945H[D2:^?ZS9\]X_NRA>;1G]KCJ MA0N?D[>4PE[#K-44\PZ@"@:&L1O(ZH=-]IQ)#&S6VM)AOB\G_65WG[K#TPG7 M%!>?+U[J?SR:9?:NONAP>F?+, #+6SJ]PJH#0[FLLK 8:KLOF#W$F-+QO0IR MV(S@RZ$7N!%8]0"LW*^,6&+Y[O^TW#_OS-=4O,R\& M"C) 8C3@3X/T7%^AWD^UW!90@S5!V.&.H&_U39"9L]W_.3';??)>A/K7UY@ILC48\]%;.G"GC*\H8C!R+V]SA_ M/1ST_LB#SH2\ T\>O^/=+279SS?_D?8)=__K)DJ-K"@__6L(]%N*3*5!SB7# M8*.'YW[[U=GMCQ=>N9ZG=QE=.EUH::*QJ\CMH;_37WFF20ZB=Y4]YXIHT4*4.>H4LUJ;YP]Y7P@+?CQ(/!04 M\O2($;--XPVSU#N/O\C#Q=49@BJP/ H5"T29L!EC0GE "N3 BL8+0Q*Q>1'" M?-\.JO*XKR/?F1/]N,:?TI[S*=!3[N[$R:AWDI2ZK=U!Q7!_X.(YTH>$&0G( M1( RKQOYY(A78DP9$/,8)%Q#?D+JM?;Q\?%,E3S"58O$ C*=VTUOLO.VY*^9 MSVBRX/-,0[UU.MUF17E Z./"U MV8EB6@E%#5U%?NH_S#&Q6!W;E"95M[>JZC2U8_8]]];\VAY>=-"?&;EWF[PW MT@TKV])J#ER(']CIFWF:>V/3@/^3!SW['\<;X;:5_CGBN#_;4F_ZG=(IY7.8 M[:P$=UILG3IH#PR][/9F9>5?F7;'PM>OPWJJE"L1EI@_\TO0-D$[5.A^R"\Q^]6 M[(7X\^T7_]BZ O:^TH$97U=QS36'_XHG][DU5.?K[).K>< MR(?W.YBA9XO&(U4D+J?HQN4/:^'TLZ\5$';^.0MOVW%N_%RVTRZ>AH5QW^.Q/%TV%.DAGO0K!6? M$Q4*K.JWC#C8=KN]0E?*7>R^NC)L6^6NSQ?:_-R"UJV MM'KO>$7%H3Q5\Q@6M+'[]2Y&!2A?L>TA9B7Q[O%)S)>ZK1!.:$KQ$ST!AF(! M28HL>+A'=B,YX6=HGD?4FAB4*:Z@3ZJ3XNODP,$DYJ]IL==SNMS$&)MKJJ%F M(FSC[OK@9V.O+^-CO6UM7U00)[^HZK46/N6.'Y&=VG5N[]+';AOY>_@FY?*+>A.]HVO M)V@GFM?%ZF](UCV<)R@[=(?QQYL'GUYI M8B&W01E"W*^PEKE75E4<;GKZUZ"0\A[/=FD*W/^:RY,=Z M?K81 M=!W&#_4#DKWNIV$LU)T_WN:57<\%E,;=%J)#1(Y+;(^[O&%V2G5,U!/SL E> M; F'Z:';DD-T1Z;\!U=1=WP<[[/()0V3UE0F#R42>#Y5R^][8NNK!Q@7\B%V MD\5N*(I!#FNI'HP+0>GR;Q&)ASF6_)@'N0/^U?3H^0@/G NM*>W+W=+QM,JX M@M%JKSW=)0[W;N^T.?GLLV!*.Q+RH MVLO3, JX__Q!9/@?)\(;>!>N%224^^__)1!?^$MPP!G["RD\;UNYN/CL!+:] MLW9,M(U<@3UK&KGV',I U\&YIP(G,S:@UUX\7Z3CEI??XY2?!TL,%M\S, ME,R+RJIG ZJW,Q[_"=IN.PG%GJ@#YSJLB_IM?ZD=H3054F3X5KG#1;;-J52# MSGG5T-HP;FE%Q9.HX,?ILE*P&93OSW=ID [PIQPI[(-NB#$$I"V]'M&D'VUG M;AXY$\A92HUS:@QK(@75910O_?;T4_>Q';D770H95VUM@VV=E=;V7;EHISU= M-KE[_^U(MQ=IY$^['F^P-X@^W;?K6<99F[\N.1<4!X3LY#YKO?R4VW8K>=O] MI_8C2C =J#\BQER43<"OQU]LZ[=M0'1$SX"+V!OXU19K*$JBA^9V0T=%R762 ML"Z4/$20(K?Q+D;SUAE,UQF1HW@J;!%@!U*C>3B%,Z/&X=(]+!Y+TC\M8ZJ9 M<:XZ1^N4CTRGH&/Y)!$M!GC.@A5FAAAQ>#_\37J9#JRH*W@$^L99;*82LQB/630@,JJ*1.A"[6)#A((?4X" M0@W419>F&AXJ"ERN#Q\MQGCCH5-I>5-1Y\U-N)*)ZJ?1Q7U%EZ5XE?:4%T78 M@<3F(#./3DJH5ER.!_E9D!;;,M"UM&.FPI_S#E[/KQG&3:T0[H>5.$9M*$NK M($U9@A'+9A0QBN'LF[489D=N/E( K>.Q;-;Y1#3XO+ROHPKI\8N,(1CSYED MY(M^;B=& ;)Z^,!].=060![9X8'T#VP""X$2TE0$"AL3Z.OFU#^[\[ T8LS@);S[?I=.1P^W3546 M9B_Y$J_I,E.(:8"G#$BX97$ BD V/ )\IL);!#D](:0H0%I;5(/GYB"2E"M= MV=!**H9BSD]-JMC!-.-/\#SC\B ##B_VEB$0-[ U]90H90Z7-*#/3XK.#QBN M1S:"SO-/MS%$GJ*I(#'&8,H?&/>,'Z&L%\Q A\W517DD7H2'+2)'E 7\^J"^ MKT>9_(R*!8$EO6\*]@CC/IBFF(3RR!?-_YQ'6=:G3W[WQ@O"#.Z95TJ3MH:> M6J?[#8]([A,Z4$BBNV*,#VX%; E)#J]C*O%$@<-5,4R5_("[4 3;4]N=)A.@ MA8$>%'M\E,0JCJFUTN52G4#!GS$,!7DFA-R)NC8@N,5[-0/NSD1,, M;ICHX?*]&_/.%!^&F4F^Z9F+>W,/O,DXYLCT7;^_%9=FVNS@GS?:%LW?IYKP M%I*,W_-"RF7KFMOLD;+\V":OP%-LWHY3SOX&X<[Y-D8[6]\7^QTW,V;D0P=1 M5EV,HAQTO.W4,C&&30##Q)@_3/'<^4'0D;B$ZP$@?T1&C)F5("8;NGX9[+N: M*I(8QH-/JL28[+; 7XQY;SU> M!5O4(!MLQ1C+I;;E&G[U@\@OHV),+ >H/PZ,LLZ(,=P\R$R,>:=)/=5N+$E63<>\5D)*9P&K&1H1%L,=667Q4]G MCW 3L4VLC7,BXPFVL=I(EZM)FG[1O" O5XSQ#7"IK!Y('M-2$3UB^>/CM-;Q M"3?GQ9BD3 O(>IC6.SB$FZK@ZWK6QKSE1@_&3UMLA=5%CXQF)& ]L*JIR!?9 M.$5X-6!>#AT'W]J![ZL:W](P?6.9,E!J,53+/*(]ES)LLR<2<;_1<.[2)C?H MMH%6;7BYMVE%@4.>8]'QVI$#K7OOYRR]-.X5%;PZNY-] %W92]/!&:# ]J'/ M8M*9(PI_^%S-=(UJ\=GTR'S+3;\.*VY9G>8.<"Q^"4U""L);JJ26+, MT$/BG#437=%87QYJ:T:&P+_[UFCI,OBV<0$QADB@L#F\^*%AI%/3P#J0'C>O MKWWT6;4'PGKT,: J[;TE')/=0'S4]#=3('S!9%I/P[VA?FB@NV\\:I9%3Q1B9ML89),#O MWWX;.%\7CR_;.[B$J4<-S@B+_/S?,O]9I@!:+\:LKA$EX7V(<6IA38PH+10/ M1IM'Y'P,Z/.(*3-IE%6=X+,O%/4>SPMPT#1I-&W.?W+LHKXVN?%N+_/WE$') MK=?8,X3)UZS1/MNY:YV:HJ7^)<>VV1L.G!@O^--_Z;7.0]?GKM; MR L-AN2N4H:>,3$Z.^KQKL[;6TV+4[04QZKO M)II>OO_I:NXF2^,.*U?!^<&Y3=W 3 TZD6SA7M*25 !KX3--C/G)I4@I?_2[ MPSK;Q9A'S05B3.1',>;;&FSO/>"#M[,84S<)+*[\\531]RVT?YK ]T=UOF^Q M_GX@/QXG^@\C_/[,T_;/?SKQ]'V3(N!CA[K21%=$6"+&_+7AQZ-9/[;A_TE5/YYY^K]9C6TZT BW M+8YJ .'Y"@UT">:9)Y *CW0+UL_WH\KPBTLT/_5D*G6''D,:*3_G>RERB*2. M*=\7S [/_3FGYX\5YJ081V]S@B:$FD"]&4":Z5TKQEBWFZL+[2BK$KBM17QU M:WYL4\%^"Z5$VQ;\QO+Z0G<"3U=W1B,P4^TE?_4"QPTGB,G(MKU9^ZV^VF_N=R\2Q'8A$%9]STZ MCBT6]D?O???5\.WL;>>S'4EXW5S'I W%JXQ:AK;:9 3\_Z%^-B@&!#O%QT$C?(Y 2_02MN;1^G39Q+5 X)3,W]Z(Y9D^M# "6YIK M9%7($\W8#89TA;Z!L0$<.-,@^=H@5-J"PPY/RL@?-U:[DB!@2)_Q6SI:Z>:2 MH9G[Y8%,K7%J$Q8E3[<,<1)(\Q)]\C'?S!K$-;,^9MMUA>!7032>/2VXD.S. M6YO(E(ML3X@BLDJO M^LC;9U]^^MGV3'6W>V[ VXW)RG^)[CIGJ\59#1FFW5$^&7HB+:OVN\OS#@ZZY&_; %SXL M(U8:4!([&2WTA&W P:;1T)E^VV'Z;5K3S$;*83",KCN('2_^\<8L]PJ#NRMBLT2RDLP(:%JI2.^@; MF6'"O0@'6(OL(&_E+DQ%@F^'FF+9A%M\BBT(IS&NF?O[%XZ&W2/?T(4HV@'# M!%:'N2V/H/C9W?+)6+!_%>WJN9Y2_\M^/1-A2V\M\9/C&O&I1LXVNW/R&XP" M=#:43]BS>A079Z9R#^3MBN](3DN_[^9 NEX:&Y-WS3EXW847%..5F_3T]=B: M]N03[%4/>&7.&8Z->D?R-7KJL)VMQ!PG%+RZ;Q/F+,1^)P.;[\8I'P%+4/E82E>$#W M+H ^^&MU:]HM-"' J8.">P+M];]XOJ?B?4"D&\>NIIJO7%D=4YEJ7-FSTTLQ M4YN3:QL;8[>W\X3((^O6R!_[;6YGV]M^;'[HC?6W.!ZA%6;C[/T^X-Z3<7N' M^YVIAOU!-6?:APPVL7E[F78:2@&DG8]O/([-*GE1%5-$O3N-BEYF=;";*)JJWY^>S0@OJG?\YZCKN& MCX_>FL@;,P5F/GUH"I;JF6V^6V_N>,30?M6V$ILBC9+JAS%65KM>@4:XPD!$$U2L?E>')6T*,+5[6(4JV..G,M00;C.XU4@\X]/++Z[EE+""\T .I_0S8OE^? 4M7A-2 P>=7; MNX \TRCW,4"MD:[.P&T&6;&_GDMUX!/B9H)4N-HEF;*R?B[A,5F_]HVW,Z;U MASK/O8CG?5,N5/PV^21GQX%3>4[*W T.]R\K+28;YW?FKM_1==N+D-D>S=F5 M/##&4MN4N1HL1=/:KELM[S/\Y6)]JH?KG(-WQ^;RESE6Z#:[34A5V; M*(HEU#;9&X+G KFFX#?FR=XZ?5 8LKY*& %CP-3&MEZAP$546*<\"I3A&@^Z M-RZXF)(:26L#5.CRYM*YY-9^(=[]^8=077W),Y4OFWPMP6YJFPNJ)I54@-W?QE]::ECH&KTK4?QMLK1N2Y+!$]E=B2=LKX;B"[E@=_Y; M*:[+?? C<,%1+GL=HRF=^%%'T 4M\FE#N"3615*?"=?ZMKF$T)3 ;A;C(5 MP.!ZUS1]3@*%F//YM.<89V!'-VZ.)&M U^"$>V8NW7?9'6#<=BZUVB?U0L[K M?-O\>J&=I5)G;$,'.\):PM&I0'M7\JZN#+=[E^-O7LTS_IRMF*U8>+3G/?F>%UM56QQU9\6,'V7\)61\90UI%?%O! ZB$1Y >()>YB(JI*M#6H87F M&6ERBB@4NX8<^\IS13O%EBO2.5;QH>ZMY$?US[I-:4UU)9>JRHY?.7_C-/7M MM@TM]504W-7O ,Z3HK0V@[2XBW-X1?AB'10&ZAX3I==I]%/;39_$\DFVH&R# MM&RS&R/)L$V:3+3O@8VD:W,JJXN?_;JYQR!EUB667>U#XXZ2MG:4?]0OF'L6 M+Q'VF9YL6@7+<036J<\.DHK[V MZ]7EZDP&@Q-N4"B8CLB++"G$X4%YV!F*&Z;=&C#H9D;PM_+"EI/LU97X)C08 MX(E\K)@<<[O"0[EC5U)-;)5R7U1T%FV-[]B;U!%I8KDBK )NB-_QZ)"EXLD5 MQ)MX\%),0B$Y5G \GA"!HYWS;\_AG0@"DRDK7W2H,)LV)\$U@RO=E4AGB^- MCZ"5U6LWE0<31A8=#C:NFR[2\V*%%61V,0_XYT\,J/-7=WZR#N;&= ^T;KI] M>""X\#3@^RGRJ7G0UG59B]QO.0GRP9M#%P-IN]EO5:**8F[>USYC13<[^T8N MF&:^>/7Q^[)Q=K,/]F=OXR23MKXV,>=>T#S'RI^D^SY@'#W!R MQGM.9=C8%.39[$O+F_)J[:#MK6V;-1)CHIWY1Y X5.<@C2\KQN@^_=>O"D2F MHXQD,<8)=FK_E<)^FJ&K.,L7UNJ CQW3:0J4#L*AFJW:!($\7S9^"U@6..4R]L& MTS?&J=S!Z.K8&'/W[$,% Z-+@M3('"C*4@C$FCME'_<% M);H+EEO"I$L[S4ABDD#ZB3-@$N!F?CG MW3FQGDE?&_L(C4&_]?6?A6@YY,Q(;ULHNJC??1S95\XQVK3E):'&C_&DP>OR M_A-&&H:7%7V>UA\ZSO5Y>'>\HZDW%#8+%*UBGUF+CRG5*-B<_8![V;"T4-M< MV]SR;&F%:;*W_9C]R9B 857#OG)WS^K!-[$M^!L;,-A-=4H8#$;VEH4<9L4K MC#3QFIE,%PNLI:X38]J](5>4\$DVX.$JQJFLZ@.7B;-"5*$WN_&+!9PE-R&U M;1\*W9D2B'H)%IZ;1U+J3HHQ6A821VO^@MZ#64:?U2X"MS(W6@[JWAKV>%^X MHOJXJH.*V8,WSVZ\6P' ..(-_-QI1 FUDP80I2CZ$Z5\ZUA]<]?<[?NR2WG)&#,@E6XLQ*?/C M]YU&FH"V23RB< HU;@9Q+/!?M8!*D.0,T43*^&@ NL3<*L:\#<=SPV$Y,2:K M!62@O%GE)K!(\LRWU'C!6!2A)M@00(>[)T3Z!-_E.^X\5Z% ]",-"5\^9D?4 M12UZ K1&$K -+'B_)RIDI!;[;UV?,$=;@7*PB?1 MT1\\".0N;\^&>6CK\KUY7"*B@4.E?!N@09ZLUL15>L4;15OE5IO M ^3,?QK;LE\J*:F:K;LU7ZHP)V;33[_[H^/Z%Q44OVVP4"\'23?A/5QIBXCT M=-D-4)@E^#GY/3>N>%K?\* QQ[8R<[1>8V/Z Z^*XSJ[V8I6+L$:EXL50TX] M*DG:$UP0>_O3N1&EV'QM5<.7=^\V;9N<9ER(U*QIVN'3D6?O?'G3AE#M=3:Y M1M<:[0X'Z>S8*<;XMSRP'-CE9N=W_Z/\KXTJJEL MWY-R0D0(B(*"$!41E2&E@)0,.:6HJ(A141 04EX*&6),64(1)"0J C*7$U1! M240$9(Q 0@1" B3 K4*,3$&"D*D4F>0]VWNON^^[K?ZB^]>O6' M_24KYR3[O___W[#/WOO(>>-*M!8)*FB? QAS+-[_[\/^+ZJO%-.5<_/5]WI0 M@=+Z88#<]O;&KJV''I[YUN76:76C]<]V%QN.YF15/5ULN=9DFS+C[.#= MT?20N;"W1X$R/B#WF?NM\V\-S4E\*PNPHNV2=?:^X&OAL@SW%!-FGZ8BXN5._G$ECI*%=?V/(#%'^X^A;CF33OFG6B?] M7PGKOP:UT]WI2SKT-S3UCO(EG9Y07M^ ,IZN62D%P-$[2SKC9=H<_2]G]\Y_ M LCH! \A<@M$PU<$M,_]6M[X"_\?>_3A7V3[]9+U/_Y3H7@61BSI'""CU*Y_ M _Z:T :1HNU/5^NLT^_:ZWO XIXWWW_BR?Y&]GKY9O49%=#@>GGMMPZ9W]_\ M3_#B)?SC:[@&,-OTD2I!IY: TH:7^._WW8\^-4GS#^'TL1QBO\<(;RHN8>[1)#7*PLT)1X %IG,]U/ MB>*QM/1O=C"U"VN22?'H9=63Y)@T4].7L8?8Y]4XQ=/@:NQ8SSI+-'_QTJ/2 M@VWAC5Z+HX?#_0S.5'T8*/=P'D\M*#^.,S@#%F0D$32,^NON)3:;**=/?+XZ M;/&R-C#4U?S3RR.V.SH&.M^Q(G+EFY^_27\1_2+P%0!67GJTNR]Z[YGTRC4; M[BF9N_[ _M=)EO#/R3W4]U_);E%A%D20!=QAN7N::-'5A(HF-(D>]Y6DW"TF M"_GYI>77P>">>+? -X'1?J-OF?MR%\S.5'W=F"W6*_NA]M T-^G"QT99L^_U MA?:A(;^W?-MD#R]M(MO<^[9WQ8MF-\-FK=[<]N'8YMLCB7GXI@(CYAG-DXVH M@G=IUC\3UC?BF44N/8:1%1NVO-W\I'2@<$>4BU6476= E)U>EW-&AA(V+S]; M(O3]KK+W0;G;S^V7_M@469\Y]/?L.'IJ?OK$EZO6;GDQO_4U-[ M:RJI=I2P^@&>M!BP4+M""7),TA7:=P9.,H?9-BUEC&T4/>ZGHN$_$G"WL2A8 MI:B%K-MGPCP (S]Y'=S+7;]>]&IKJ*'9W$%RAM@0!:R_$(T51^4S!A# M<5)7?LX&M0D8_Z(9?)]7H5X.7[0Y19*V+I'B7P2<7SO1?I%7P MPF?P M\UD!HILN.5F7U&:U"4X.5QTB?/V6;/*M*7=-7UY;D#XYPJNOQ/SE8EY?H8$F MB1>!60[W\3L60Y/D+; M0T0D#EJ6(30]#]=W-)V]-70B@:CK!9'2.8#,@H:*#-TNFIOZ6"#UGDX$PY2Q MHE)(]\96Z%51!5]:;2NCI3A2MU".03S!3W B6': F^AS!+X(PF1AL B0K0=# M'DZP\WTL/3)FSL7P4"-3U[/+B#*Z(;]DY3X>"B:.L)@C/9<3#VLM[='3A]?K M_*-]Y74.&7 +?>KL]%W3T!L,4&=Q+CBUK_,9\1TB=+LW7!?"NM'\R59/=N^B6LVIO"!>\I'.K1+U>\^ IW"S#& 22 M]TIDXWQZ9G[9=%$17-,M Y)C+21FP;"C@;6V$HT\0HK4[GGG!CUPE1-4:U', M[ 9"$.,.Y<0">VA)IVG#Y^P6U4ZU,81)HCJ137Q'*I"OAB-G92CX*.>QR\5% ]4: M\E0G=P_LKK"TZ.+:#E)BJRE;-$]X4:0;2JS[$%&RKA M7 6.^;QNP,./*'/ '.GU.%=U((*@:91[6I\576+?>H]$AMU'-OI( ?765/Y* M9 =ZG6M',OR1NI>>SMT/6 *RJ[:W 5F(;4YJ!V8F!SZ:\IBW=DE'_L9@\W$/ MK9I=\Y9]4Y@J3!EF*N90[3@<5)QHZE,[%/E4XP\UY=96PAE! M@RR>R928GJX.E-/6D>\+S)IR6^2X]3"[X_H82TY;3\X(&L#$AES##\Y;^IUJ MS)^<]-[B[L(F\=\E7F=PQY_V_M,&!/7H:TZPRNL##3R-N<,U@X0"(J =L;4U M2SK?TXTIAV$\2&HW7P,'' $5$VBS.1YJ8B@?8=<0Q+<+'>$,N9T!.%FXO9EF M0 [S8KYHZ(TAKGEE1PP36&U3O^Q']B&#]+J%-O=':.7-05[D[ ID"-C("]=@ M@D%:.N8:32"8%O@1B)(Q.F=-8$*;N6569S+XN9.W.E:8-68%N=Z: M2SR(,X==SX();P7(ED'S[L ^NT6=062-^ILAQ!I/\1.I :MJ>8^?S+\$#/ C M'GS_?O;( '4SP7R2G'$6U"AO.C.>AG@GEF]Q-7,*\GS94&US_P_B]^2<5UA3 M;1G\A'0C%J_5AV4%6@*#1[H02Q%B%"VI_YA7K#X-5T)HN27[!G75U(]1]=%X M?<3<5XY?-R8AFWW;1#\(#O1/7M\PRLNPO=\>:N!J9?V [,Y??FQ-T^?AF.F\ M_-'912<3970C1-*"6IDR7_,+ [M-?0@N^K*22*++"Y_-MEHCTD)//FTSN9OO MQNM\1%-F@[:9ZJU7%08'UXM8OJ8^]!MN0.9<@D/HY"+1:K:C:2:[P(&>FG>D MC[FDPZML0_2HK^@H[G(@,Q:E'TH>%XS9P4D)3T+)(UU:!E4GR'/20CVA[52S M/EZMAUV)!"[N:,HNIEFERK(<:K;TQOB81)4&AT2[B5@V3/&7S1@S 7X+Z7JT M=W]1B[[,I_U[P]_CL8_"147DT6+83W64XD]7%L"_FB7%,-Z,*Z_ I*NKTF2H M-:-PA!^3E(;>@-W_X?2QBBB)$=;(>]]31V0GS).?*Z3+9@W(_B/>()K?'$G= M":<>;H(P4^-$CW!U 1J"$(6_1+%VU@^1.Z0)BE4L+H\%G)".G4+=MI<!"VQBM'74'CZ:LD!A2=C<8'9:N@L_P4-7( M^KM/?*,]3I?"*>.GH ^0;<:9K@LLC;Z6_3'P>NP>K0"=1'J@5.60VMX$2D*, M[D/ZG1$RE-K13T:'M2I&=H767NXF5&_%@X7:+P.JNQ6T\,2?"0!T/LN#/(+L M=L.E +6T5L9MFG$1G"+E(2[#-/]O?A36=H=6F=\[ C9[\L9QJ]5H+_,+0EA*#UR".X M^R(-L:9JL>G?YUG_T70%2SH-G/Q5J3*\C%[6C= MIX-,7#K-@A,O/^JLL98%W/+8)*?KA:#OQ)ESKC<3T,/ 6BXZRI6[!7XD#_'F MBWX8Z5.AJ]:DDG M,NLDXVR%;H M"G"WQ=DWR^$A'^9KEN;L!5@7_[JD>>#]ZYGPWJIY_8;\6=\^5LAU/BY_;"AT M4,Z1J0.7=%8@L+&"0+3Q.%"M_JEQ0 I?NP8F='!WI2IOPVU1"B #K>=(\:J! M?U.[P2UR%**)S%%#>A:SN-+UG!H> F::A* YX M>"RI,G RP+QLED6YR4#:EW3JR^Y0$BXJ&BG[Y0[;-F*XIM&+0CYC+7F\@[L) M]E1XDJ0DY7EX?S59(O//J R$,8*F/'[R:P\7PYLVR@<7"_O;J8;]\V]3K)QK2T;[P,G2-Z18AN&D[73?)-=RT/1H<0N+ M&>58Y7)TBTG)@WOT?C+NE(B_$FV$UJ(D>3 M9PO[*#!O,I2/>ZE??;C.! QY$21]V*EK>9=Y#,#4;0_Q"6UZ#GDXE'Q8-]ET MZ7&,(HSA\B!7*?[YWMSN7>ZCXC^FSM9\?,CZ1/K\"2AMT>]<-&5?E+FGO2O@ M7^=EQA@ @J"(),[YYQ^L]K$;N,_3D6!+7/O"_:SC_>?ZH-K#]\: MXL<-Y7%W'R!%VG,MX8/]'==/C+G :=$DRI['=Y\=L)E>< N?^YJ&!5CXZ5C5 M&3)/^;&7%H5/ NJ\!8 1N;DSGS<=HC!P[%8F@:3I=UI]77H7S1\U:VO VK@" M3!>V0*B+]*'K7-.X1N??3 Z%VH%"?H^7G);*=8 7.Y=T FHS@NL@&XZH?X(' MXA@9B!%<#15\"P+3Q$KR):4"T6]3V2%OS$D=H[HX.+P4!CJ 6F6JO$3@>O?H<*6)&Z_)'4+G/B< MM'*^>^>MOHOOWGJ0/O63/$[+'@$G:T4N*.-(?[>3I:+?2R?S\KET8EDT*@%= M<"G7M?^"#6LDI'-M;C?)/B7&0FY8[*)^1G'3RH2C<(8?M##=+)]-!^IL4^<3 MC\\B:Z)45\A+.LIL$>=PF+0Z:/:")H]S[2KD>A8.*(,GHUP(Y9S38*7 O*4K MQ64U=O-+%U\;ADOB\<0(OC&6)3=MAM!FM#8 ($PLZ80+AQ>41$AW^H!M%L=5 MJM4BM#:O.1N&O!;[ZS6/$:-) MM!6+/IS;W;DO#K#PV ]*CL$L!GFW>S"$?2@-H05S065JQ=M)7'2^U]OH_-Q? M*U8[%Q"FLOPMW/5<]$?L@BTR]#-XIUC0JJ3$4F'5,.'ZX?>#; MJ(;VUA=<)\EA)W&[?>:/^O7;*Y5A%FD-Q,LTJT6>VB1.V=!X"^(XJ/:2\[PU MC[E?]F$8U@+8S7YXE!N4D8?>2O;H0CT;H(2,M!K5![0L' M%D725C(9YA,_3 5=JBV-;C+(+6<$DJ_Y#,8:;/4 M \KBFKH5WBB3=1]%1[ M*?Y@'+_ER^E9N^2D.^A:$>LQY2O8I!3I'=.%=>6;7+0P:0X&\'.2EW36<7QE M=@;7!&YKQ3_E,,B,#JI=[Q7L-T!*3.5?TB;1=UDVJ^1-QZ[DX1SB>@FP^T2Y MQE>]2U-&-55'P&S502WAN(@8"?+9X8( .**8XMWTXGD*!G7A B40CB^CG 1O M(QM$6UH:?7_Z@Z0?G7LO-,1^7SF)W$/:^&C9JS&)%:_(-]'P5U/6T^[R"PZ* MD0EHTI^4Z!;5=\=E54KO)==UU9DOGX^MSTJNJJI]=?KO&V"M4%]!USRB!(-A M"K9Z?; X:V4'E*\4[PE?^6JV'A?'/:=R=K6P^/L]8IJCZ-/P\ZOJ&]0.-'@< M)4;[P3>U#JM?*U3/:6G>C37>CA])D,7-G(,^ 884@SXU2N7%5WG1KDQ0309C M,6F()7Q3CLKD,8FC[\LJ/M W4'9=50CUX(,+TE>-LLB82#'&[1N[E"^O_UGQ M6HL)^6HO2-@>0E+>!<^)(WDL809B2C'3M,P%4OQD4RV8=J!>.&T3JW*-!E9Y M?)M!JGJ++8J'(,1(?8X]:-W7!PTB-L71/YG^/'JAZQOL.0:'B3"'0C#CL03" M-97[0*ROTU&6J[BF.*PTT/[G0R07_>8$N],.+\M7,H_(WQ\M6GDZ.K>CG6I #%*MJ+RJ$=]!,//\;M3_5H'T?=]M@$ %(=8IV1'%_:0+ M FMM]F%M0=H-3EP4R._ B^^-3N2_8FUN(O+2) %L=NZ8"#D/. 1N#> (KX@\\Y=9A=YA%V[#3P$^O#C$>_YA M&3GIP*!(,_>(='30Q.=%KM"/Z'ZFOB7$[:/."1%[ANC\Y)7<2"_7(L?Q:*O- M@$ZT.\F$?$4Y3+JL/O D9)CC7U\RVE!YT;.^+6%_0]VO$>DR>63-QW/5,]\; MGI''[CD4^JT_+S7$6[E-\XQJ0?E*PU('+>FLE&NRJ&C*H2_FDK(*Q*?K9CA@ MER%_T-:X,-*7=%"T*-HJ MV$:^8;+P72N5\WW^KOPJ.TI*3&@ N=I)PQQT:H M*YLXKPE:Z.3NK -'D4+^C\!-'Y7_Y)(.>/:_[;NO7=*93HT"\8>TWE(";W_7 MF0$NERUD(JC1PT_.1]*8%,0-JGE*XJ+(BF X4#KJKS4-A9:0:_;WO1QWQ2H1 MQGX;WC3ZAR"X6Y"?_]SYD1C03W,HB.\_J>^!/- MS_O?<6XA2C'2E^"S:^X3_U3*I_>[0BVB+A__AI,=X=VPNSWV8)F1:QKEFZ8M MD!TYZ1#><*/_G^2;K."OGEC\].!0?=;95_9K'789VW.I_*VK-_(VJ)LH\=KX M$"A7P"YM3*2/L2::0N 2F;BD\SW>F#JH[:AO3E8NOMZ,_RBXC6=(V:KR5:-@ M/_#]41X!DSRV\G5>R&O*_N+)PNV0AYN-UKC&S!H!R=6&(IN<"' M/#UMY=[JC^\980?'_S7U03A%G<*_OESEX!(\2CK*[,>,]=E9'IDZ4\]^WG+_ M5-<;:Q8G]WMV8\(H?SIM;?:5.-1V[&$W54BO/.VZ E66'XXEL$A)W=*I. M,9F<0=O,7?CVHJOJS]E[#FG)!7B[QD M($(K>:R0/;"7TE/S&W7]Q!!M(\5.]372IW7DL;R-:F?(M*0R9QEYJHNZ'4X" M&?+QZ4HY0[>[(IC6'@*QI7%9K!X3>4A)>5/FVVC3O%NP>3H2#@=3V=&2P9J: M(:73M?BH2]L(S96$*3OR^=<7N>P:7 M6V:C/@)'<(N(1Z(SP"V?+_CMA.F@]IF5*YNX]R&"PX**J.^8#=]C:Z<(MH M.I:1ZA9PQ^-PPI/SXF"XK<:1LR>B@J!%I?#-;ND7)H=R]\G?1_(<."0M],]K M*M0'I!(36"B;G2Y2H)-YM:)R;=F;]R,>40"("Z;K4XP@81J3=/LGVK)BT& A M6Z*,'^3:B-5K14R5,.,J+Z.K=9@38_\W-CDVPV&O? A7FWOJN.L4\7+#I\^\ M4(F32I>C55=E?(,>A/WT_,C;@WFF"V;Y#Q\Q34:Z'3C&N+7U+^]VK[T?(CYX MKWBO!WL?5&F6[T+H_-1[I:^MICIY[F?/OL!-"C/2Y6SKA-MLAW%G/6M[XDZ< M0\BMW+7? MV,Z1EM/QHA]AWN-EJ;4XQ0[*6D0K89U&5J2SA>%3-EM0-$=R;D MI ;UY+3K"],D1AR4G':3AO(X(*/IPO>#0.GS_K"Z@5C>"K+/L2;H9!XX?]DY MQ$J.#)T!.U*'D4QM;4]&CSG#EF;3S:I@ZJLF=JJ?L@XL2U?35'O@Y:WLT"VU MO>ICD+?6;+*$MV:1C8%O/N3C\YMXZ?.H5/1&"UF$(-'Z!#/EJ'VPS^#'TL;G M*0EIO^GOZ,,%),Y\_W&F>DRIODYO*1-0K?Q*ES,B6Z?B3((B6R=SMTPN^+\3 M*,7?N:(G%HPV_FGB%?7^]TW>8Y6L6ONFCVFKJHF/<543IZ;8N7VA09%UD_ON M3@[YWR5]OE+-'/\E%$,4\]@[[GN+8'17W@Q.&ZD,&)+BS,EFLHB; M5)26YQ3L=M_E2EO86 6H5T ,/MJ LG[(A9=$-Z=8R$>] ^%ZA3MIG?H[.$G: MXJ>,A3!9E)!R1L<$U@5&>0^19C]>*N '7 QCW6N]CIO15VVDON%Z:EH\,- ) MZN_BW[C;X&!5#-)!,WJB>:(VEN&2AH;HZW@1.2D_4#QZ.8F*)9T-ZCB(T>'# MR,Q%;.XZS$\9^"FI\&EPH96Z/,FK'V"Y5.*-0^+]\%_]P5QHPA,;ZB2)GD7<^W%QH_G[8+M@57#&B^K<2<*.%_?$NT*_OQ$Z\C;(N>K6 MGM@5HG><-X_,7B*;*5&@1$"F)+I%ANX#=U, N%@A20Y(DM-2KE#6C-D,8*U^ M-Y\<V#_SD;%5;ZTA_S,-T7-2F00C/51S M^"_(20ZT$5U;:4S7#IPX3ED\,(_:-&D\$8#L':(:P'3%%;:C4-Y7B9;^$*;@&]H;0>6=*(PEA-6N^ZW7^]*CL4/S\K+^+[^0AD]@^-=U%UUH:L: M]N[D;O,%?.E\LUS7/#-1OT^8W'=E3&7&BZ?+NO$))-]$%X23,Y&*AW)ORF97 M3A4"C9Q@+?)]L-HT2 F.37SJ['9O-+()^^O5RK=OHWK6<@]/'8L@6HOOC!N_ MZECV]PUL5,[<++R3-#U?07'4"@-,$"]+JY2,-$WJ1"DO1;+L)7=3FLL^R#;' MPU..,8FT[C3U.AL.SM_L]\!4)-9-[F=9DZXIR8?.V'?TC]/A'0O3+,A6ICOM M";&5T9#P]B4XT+ ,:E;^TP!Q=U\"7,E/8D3!W6=TN1SOE(=F^2MI!R[J#6'LXH&>M4DU1PP4#M M)X]MC#9O64AW#L'SKY\LVI%&E,T$^/=CBFM%$:R&W GJ*,R'%EKQ*UB8)+%9 M^JM:FAS(EIAR #!"QDY1[P];55)-P.X2,35AH0.Q>@X1+;4^^+5DUW:L)626 MR0FO]GC9A$ME^K#9;-Z@HW./XY+.7R4@>YJEBH9=E66@?Z,*0'Z7,#'321!7 MZ_@[\)NH?=C],$YU(#* !IY 9VB%@F8V9]X2UV7EIM46&=SM<)G@$[F_"[OR MWDO;FTS<2C+I;*\ZX%I\Q9M'ZQ;^>-['"Z9=[M8?M4;6.&@S. N^6UG9!7X^ M";%G4L&*J3._&)=&T3=P[:E"NSBP>>;,YJZ52G8)>;D<2'&.H#@/-;UYGL8> MF_[!/,!?+*P@':;FL99TGN8\]M .QDH#S7VNC?JBIIBK#UO+LQ_*/2.4)T'' M L5L-M>QKY3)@Z]*>_9!G(/BW(>83'N&HP-&>[7>"$PX]0+*2GY@[ME"\WS=:D>Q# >@70H>HAR'/X#'W*.CA6BL]TZZ%W +>Y7X- M&H4 YL@;BG9D@/?E^'8)*GH?B::0K%:?AI;Q9;.K0J-6DQSG*S6.W:=K^RW. M]HL5XT(+:AO5?8@6A8)WS:9RS=5.K[&F%+2FA"?-']NH^0U91\X[5 ?.IE , M)>LI!X@0(A3D0I%<])[1B4]18GK.7'5<*"_1='U+GE_AQ_VS)"L%.I>Z\\N; M@:BC>":OG;09KE$HPR!\&V\S9;GV\UBDE59GEJ3]%2^(QC_OR 4H9S7W@4B) MH3H>+HJ3]GBU(WNA' MO$_SQX?>\7SC$APUPACRBDAC?U(E MG4TG E&IFB*7J=6Q+;JRP^SV32:JD^."?$G*#JO=_8[;N,0UXP=2/OY)T+\6 M'A^A.RCYBA9-ND5CQK7A5ZH3X6OR#T_@!$5!%LZG/QQ*YG#UAYR%)A_J\8E_K,8..8"0]?YZW[R,HZ@S>:*%S5!,TS%ZZ?+/"@BWL]>](:_V++\]0F[LKB1DTA M=ADYIP-=GRH8#9-?J54 (PQY80FH\@;-IGFJ +*U+%8RXPX=1UN0?62I@MF; M^$WJ$)FEHQ OHKB611D#7:0DNO$TQP=L/GL_J/<]AH<;,-+=.,&H;$IT',R+ MJ)^BW=6<($\I.5J^^RQ'=:*2"[?CU@7"4S+=UFJT\D[!$:+;2TP.8CD5)$RC M.*S@&5XY6>H7(K*GA,L$(+7V:6CI_=B+-7!>N_%=!_J=*@PZ#\+/)"SIK%D0 M(/:OJ5O4.R#7%'L/6U#2N:1C5C,O@8]2]E1N4SO#I^6SR^!@>5SFO"4:QTD, M.]+KX$")2-02575"E*8(0O/']"!"\(38L)(05H)'3D;1ER,[*1" GPU3V*6=%+C7$.W@NSV'KP2I-2L>)GP%D^/NHFR!5064\6E M18_5CB ZF8O^,"0NZ*S=5QQ? N..]UV^PA!O/YK_D6PE[:Q(.5BAL_,QZL2_ MGY%7 &&2.-:*G7/G*7B9]C_58 SA'&^(EBJ'=J26$FH_A#J ,:1<8?>?E@AK%4C8:UT%=]F*PHV*R'L8(@DH?Q5:1@XB^ER_GG*1LZ_G,\YEG.J+M2!C+CLZ M?/Q;]KF=CPT6_[$XZ6M[RBX940L="QE,B4&D.2U=?2[J211B"WEF9Y4%D5,% M/UEM"CE,<0UG$$X%>Y<33 O1(7C_D'4CIQI?I!X/\3MMJG<%<^50\]Q__O)C M]-+POP%02P,$% @ ]H!;5F@2?Z$_MP XA,! !$ !I;60G$$E2A DYP:1+%EH)*J@) ')0: )"I(E*UDR MDB1G4++DC.0,DI,T#33=K]5[[Z__-^'>F3=OYLU,^Q7?.=8Y:^^UJD[M7=6G M&OD%N0A<45544030T $ #?4/0,X \@ N-C8.-A8N#@X.'AXN/B$%$2$! 2$M M&3D)!2,=,Q,C'0/#5=:;'%>O\[ P,'"*WN#AOR4D),3,(2XM)B!U4U!(X#L( M&AX>'B$!(0T1$8W -89K O_P!_D1(,5%E\7"PD"[#J"3HF&0HB'; 6:4GUAH M/S[ 7SYHZ!B86-@XN'CX!*@+JJX Z&@8&.B8&%A8F)BH6A]4/8!)BD5V[98< M-KGV0YSKCA0"_M'O<%ENEWVBU!D^8!5\Y!2 AT]%34-+Q\;.P7F#2TA81%1, M7$+^CH*BDK**JNX]/7VPP7U#6 M5U;7UC>^;FX='AU_.X&>PL[.O_-" S#0_OKY)WF1HGBA8V)B8.)\YX6&[O[] M E),K&NWL,GDM'$>.I)?%_#'I;@=_:[L$QZ+H,X!Y2.G87PJ5J$EML/OU'XP M^_N(!?R;F/V-V!^\I@%"##14XV&0 B#@E(LSTP__/ZKH7;1MJZBV>/A8H7%F MA@(_2A$OQ*AY].:W&6E)]2#H^KD*J;YM%GK^'1Z-VZ)Y.=I,_&E$@NUD9IN\ M=OE?$X+VC!Z*>:S=CNS646\B26B+QS3/ 5Q=P-PX(2=6?"Y?JU*QN=5\;LL1 MBE+5M%@17-/Y*,;Y IWB2+#_ND=8NVC-=+BA9?".94U%O:V#B,_=]H&/-SBL M7GZ0>3CO)U'/G3HNI29=74P5D6L=D6\3@9MF %^BT/^J@>:)*_89!T#7P.M@ MZWHE+"TJ'X,$](:S:M[:+]889#:2%8:P*9\&?2&A/P[ =KM8]Y.0X!9L-VR! MD@0+,QIU'R.Z[(\]C:#[TX+ABRM'17//.Z]X0-H-]=^ZVG3.GS&F[8"H8!8* ML[47.:F*SI]8)OPD#+G95XR.I/3,,WW2W:>+G]0>UZPX)'3?JF'8@!A#BXY7 M)*T:;U#5.-IR6F_8>O!>D[&(55L7X.*[&ULC,WNNA:.N\'"S/NI5"9^YNE+; MP?T9,=9>I@PVBQ6_W@\^8NSOS*@^SHO(,%#M^I,B =6YH[././PKC-[5)"GG MAQV RSU]J_&*9%3#DQI3>T2=4X-CU-,-X1Q9+ IM62QA)# .&DE5AYQH M?LO C]-6 "BT[[D6*UTPRXVY@K@'+AB+:IA,=QN@-YY:XM!V&6MA;7&_'6]\ M3!Q1;$T%%BGB/<$-:QKRY3U3,&EC=JEXOS>(&64X7#OA'45QWZK%<@Y:>+]$ M:A>/9,B7#$NI4>X5Z.T9:FM2IQ.3<>1P-*U M^I'*8KJ)_9T/\D(Q@]X/D("!,0!$5""*3O>UMDWY8]N*LR)T-7!K&ZYS:.# P.*H 5R%]/6@ES\D!N9OZ-W M2Y-R.T:WZ)Y5+RT<;04!6JFO+(DT\^_*-J.-?1:B1GK;?)DGUD:-V][;6>N( MN]-;'/6%(P'W#7R*V%$_=<#-15\QIR0G8CV,T!%O]%XM?U$8.SH);PK_XMY% M[>Y$P:Q'PI&/_K;&4&7Z+A[/%[:^HUG<:Q'= Q]G#"H>!,@:$X8G 5^_OCD>8FUO:M9!2Q8%I@&?C'&QJ[4WGK4CG=:_# MR+,,(B[NE(/]L'>35>I@]>=/JNK+:A.$]'U:/6(4H_IT_>&J6&G MFT=S/L'TPJ4[J3*3V&H\S=*R9':!:O)M,8=&\0RQQ AS* MTKGH,[_T5FQF'R%:JGPN/B+/4#TBLAZ^*+#A/TYK=-CU=+R)Y!YB>N1ZRY%W M^JULD^0:<]ORDX_;-: (P&KXOBG+^.K0M_M\[ZJ,"NY\:']=V6SP)$8O_/&' M9]CP;])5SZ.S\>3[HD-;O/*V_YI:?%*ZH=WJ=-PPMI/^2^3L*M$^:@N+V0Q M%QD(TZ0Y,7Q#/X[ M8GV7W),WMS-KA0)N]50S?'\]K"EUS?:S>C1JZ'JS :3 MPK2\.75#UZO*:M6W.9O))-#KZ&,?,!R(F:/&)WSNA.!VF:LMM4UT;OZ/>9NJ MQA):5:H$Z<7E ]Q>:8 $383*<3,]\2LP==JOQVA( UM6:-_TJ8/A\C=K/-\; MJ>>I/((**":SO19\_96!"N.E&$MX^J91):";#H/,44P[(P&2BTP_>@5*)8/Q M8B%>]A6=IB<&5XU?9_&TIV!IS\;(8HP-H0:5] _CW@JNSFAU![-NU4YI)J5M M:C0G5JWF!X0VB.CW$)N<%4\9\%3)6O7%3,U3L;DAF3R2\FU,O;<2D3(@& TJ]Y2DK/!/TCU6DDYOIQ!_I& HX M=K&42%QQ[ =<7/0E;!M.I)D&=[X@ABL2MGV1P,ESJ=)$F@T9!U.)YX>IS*&N MO#I&00>(H)KJ9ZI#R85A+15%)7F$+/0T'S#-.3"N#N'H*CRR-?Q6SQ<,UD[X ME-T$N2FVHR]7M^X$1#W#?*;)BO&1/6:[_8/2(A* *1=G'B_9NJ2R\%:^_K*8 MPL#D(ZF%O4:A3UQ3O$5%UYR::YUD05TQKR"4W>_VX)Y!WX,CTG+--](26M@G ME+V0UH>L7OHYPA,)T--IET,YZ;(W NG\N1-@C/BVC0RI!_Z&:2P3D ]"]X69 M*\XNV() ?+ZS9S%%G@,DZE-P3@S]T$^'9B&QK>>/3)+!#0DJ(MFDU;1Q-]P? M?KK(+_(YP*$MJ"J]HI!CK7_Z6G8RRIWGF6$'_4NRQG3W=2FT!2&T,H5',S9> M]8:F@^^M#J9]TEBN>XJF.7WV4Z']DNW"V#!N1W[_$#L_ 2Q*1QE?%=%GRY>4 M%!T]?M])1I/3XDAR"$=)06=LK]3.;NB+]3K4W><=82N;=H"[(,.B8R2:5"17 M0DB)>O[\@O7D!.C1&,\+.QYKOJ3P&'2]^ /!4P,G[%NR]/<*3X,G8N)]#\Z' M "3@TUP95WHZLZTBBT4956J[F1FF;%Z=<(2 RE,69]_!?NV?P)I&*;L:.Y)5 M,^Y:&;1GHGLG8$+L@;7VN^;CP->"E?!0N=-/%&AU"GJC?*!*EV3)?;[>B[MX M(GT;]FLXM/L3=0W[#/1\>-;U2 !J'$M0%T\W+^[4W7+K"8-W.R8'PQ,_B2UN M:NU#"BJW>H7Q%L=(H/2!_*TL>!1M(X,7#!^5O$]>38#Q?7URN1SW! MQA&;2^],+X&5$!& 1WE8:ZQ])Q::XXW0YPBXN&L8 O8*9U!QE)&(,CG?IN7! MV+ 8SP1#U" ^41?5=4)1^@/WAWBW;\VFJT\ MKS@F5<#*2Z9R]"X\,BK2P&57WTY*EP@V9%%3'=LS/CYU-]A6H8K@0:FXE'GI MABS]-WT]1 64][G*"&*PY4)^X'(=[NEK&+09Z9SB2JEY[]"8SC+DVRYM\;1F MU0,UL:<$3E.D%N:I.T59>2S-5ACO,C^XVOGN3=X/5!KY-M[<'(-=Y\C;%2O)S^/BKV MF;Q]8F-N0)9_/2H(-=?%("= >[N'O7ER*.Y+XK@XJUS') M#.4$_J-*CEFC3&7<]V[K1Q;*F8&.*L3R'=4UU&FL!^TB]2\FR-Z6X*91*#V^ M_+Q"7-1XR<7XO.W :A[ST+5KVMZ!K^3;Y_Z.N=X;GB*M2XH46(#%(B"1M&N5 M02(A C;4? 47=RVUJ3',?281VM[^PIUU#WVK(,0O6I-2\;70NVZ K/ M))Z4V=D_:.:Z:W48A"WZL'65_V$*L5'*:*-)Z:9$NC_[V-,J7([R8*UR,F,6 M[[#J+3+/33\2P]VO&<3D'?.<0U4+ "R!B!M:_O,MB333ZKWSO-MLY!ZTY""AG[GW,T:%<9> M$ABLQC*XUPG2U,;]_)UTAXC83?)/OO3C2S4QZ]+<^@GKRS1C%33AL2P"^:OQ M"PT80Y-YP[(,0X=(X.5:55W:C$%UK[3BC%%E7<*=S8'+%PX$ MN>5'F\6N1,.33%-V9KO8\@E6C?T7ODNW+N?]2+Q.O#@Q I,[#"D3(Z^-.0BK M&1FIS9%QU,18H^.AQ;\QE^ELD 9I5XP7F3>-[F765R5*LH<$\F)GO,]NW[H,8FX R*%?!'80 (*PO8H3^W&(ZKS MEN=$.H_8$J8A)+-=UT45==EJA:.SI'=+VR,$%<92UVI'*[>S(]>"X=ZRIGR\ MGQ&G6$9S*ONFL0J )Q((DC+/L):@J'8WC#.SBSP_%8E^HA(B*O :_:8**^E, MD\G!WMME21#!3)A2>5E]VO+REI6#W;1.P'W:<5^P\17ZM,9+[@J4] O@Y-O! M7>?I4&C#S3>=K8.]1ZZTO)C!+C/-VT1?5DH[99VBXFHEI@![2B3N6$\N<1V M#-6I!2>J4NG!8]XL[VV\PNM-KE"K=55;Q/(_$>B1Z[[FSS0_COX9[6 C MBEPE3:V?9M-)A7$GNT'E5JCL]GJ:!8"Y&AN^(K;HE4J!YI_I4=%VGCY5]-0U MF3LYZTK[K;NTD:CT*<=IFHXGB:3MCBMA$0TER]6H,O4.+P4*M+7C&?5-:5LC M" 4FH^P6?JX=?/O;RM/S@0'<39E^XGP8-HE>;R:D=K5/U SX,-T2[<@XWC(G MO(@NNT=:6R-64OUS:$!;..I%8*GG07KY8)0B?M<:7LQ.#0*/<@VF,(BG:/H= M3:D/3:/?>3BU*4SL98X*\\I05B7,>[]S"K1?'5P@\I.CW3:9HT#KM*&#QF9Y MRQY722O.#XA7QI%6'F$2>D](/6\_&5=SY6KA^Z$'I/IA27.IFFA N"HI%U]D!=151CQ$-%O_KZ( M;&9>3,; 0CV"7E1!"IMV<4]HD'QK"):G6CE<23!C/:.7TGG\H-&6\(%0MI_B M&HCK&22JV)U""X?@LCK$+G>P:$K)!QJ2=2%Y%V-/4 9;6D-IPV2< JW/6U8IME6 U:E2 M8S)!SD(+[[9]YBHZ;OU!'26Y2*C3'LV!!B5Z!HD;&\%7\JUE*[7N$ MN[1B'*&SF7YB)#@P_9'35B^?WBVZ,;OK5-S$A5)6,N;#>A\Q-@VF91O&&[$6 M]XFM1V1CC6_7)!))4"L$4>$09@3(B\N-.2:=A')B!)0G;+?YLH^].Z28<+J_ M3;7KVCP]-W*+U89*@>O^9S:1M,9=*==\H7YYC:K);PV:.-MD"U/]M]2:I)0M M@R88P]T+&=Y\^"2K\\S] ?XW5524J[QH(3"RJ6^S:69/:CT4-@JZ$!O/]G=L M"3 GQ %IH)X85&?+MJ&%)4L-EY('#TQR 8_QJB[RD"\03FB+4LCX1X.EWP_VV9K M^5Z>;;:)-_).5OCK;D4PT_*';WQ4'A#EQ/N58Z@'RT3H7="0@JK[I$F6^Z_-O*0VH%MC)=+J+S H'.H MQXGS)A/-4X(ON*#^-,K&3&R8&*)%$)P@;8L M+9UE:"71DZ_3FTD=\;-+:F^6W@C:,6K@V"N8>\2,;)UV,3&'CNJD:\;NN'<- M!(G-E=4OA$M\Z%I*X_Z \@)"YN$[HWJ@_SY$>NQX7A-C=DZ=8]_"04 8APN@ M = J"1\5P&;:J.K=@UCK(Y& 0?Q*?66KL8US3[ H::3VF\#)VNU^+S8*M#:3 MCD)88&Z);8#G-FD(!&3JA2MMV\W IERM[EIHRP MS6[TW>ISQZ!)Q.BC?^;YF7%0:!!C#F8@G\V6%_*D=BQIG'K'H5"%:^$\7"- MBB72HXNF5#[3C]\;O%P(PK<.<73J?I(*+_28EZ-K0 *572^UQV+/4_!S%F>: MKJ_M/ZF>V!4V,5Q+L)WB726D#N?*9R15PI!9/5)W==%"^[X4:'T#O$]2#)!\ MS\Q5?V;I:)\]4I-5#Q6#E_$RW4=W5](F-H<)WF FXW_V$PS/Q=N-!C.W)XDT M9&U9Y]CHGT8P9E6<$=5R&,A&Y,]LB.@OTRED7$G<) M]DC#P[W"F7O*A0[3<3PXF<]QN^ YI7=08:W%L#*QK7XO+/-]#51]H IKW!]8 MQI[U[O8),O*ZL&=\:3S^;;M8?[*KNEH[Q-YWSI;'D3R*OPNK80<)^-MUK9B& M* #.TY!(*=:PV/5!K=V*4&SCAD@2\Q^!NJ^9[>5N(_U[6U%20Q4['^FF8]49 M??&8>:L9\#B8)5XOF'J63(<"BR651G;47O&]\M;+WJHOSIE/Q93H*Y3^D#8U;1')\,EYHDD&A7+3=1]_ M.^E)O$_1EI+R.%'SMW@.*[:7(=S7<;X^^_JQ8%!#06O,%<^AD=12IN8YEZ%2 M<1>#5^"3J;6:^_SE,?SWHF?-G\2)D7S ,8WS M,C/2H$>>8:3+RI"47+K6B>6)+#:>,5.@]/-)%04*0!L5QCEF=B$;I0@)2&M4 MS302#NZ!RPD?:QO/32B03>5/T$ ?4B)76 MM$ O@R"[9(0!IR.(J@#%%@ MFI8[*8 J+OPS $K5KWUL?*)KH!=F9ZB(%)E^D+4+;3F>1 *,H"6#..W=;&;# M= N[R^9)A!<26,F#*Y-<[_6O]?Z_]^ZSET+_,?>,\C M@3F4>9?_8>3_8ZU'[^^&/\5,B;X<-:C\"[C5Y7OF?4105)7$1(8FG#]"R@= MR";X @F\R]K50@*0;\*I?P6+FGZ'0(W15A?W0 N71)9_I9 %S8>TG-/)C).< M(@'Y^V/_/Z'G06M%S"'B@_+J_XU(_=O0\X1G<9A!;J\RO_'I/[OH"O\M7^] MUE:@C.[S?.Y]?\QB[(1>D@1G=H$ +TGAPIR1-L<2N'\3Q&&CK]'*I MH8K^3#C$KY(1B_4Z+9@E7TSJ@NZ($:-#%$%QR!&VM_/MOC"%*/%C5Z="@$R& MX*$FCLP<=QU,/NNS0_8"+&C=PU3=5%/0@F,MXEZU\U>GKL@O3"=%RS$2-KJA M86XW/1:6#3WD]<(TPU3M;NOBI-\@/_,UC/5/CV\")1:[44T7YW2&4)6P$3R! M+B_6?2VH<=,< K^<]HAJF^X*]3;*WY[V\^>SFQ_IO:6,!*XM\D_GT>#FI:U. MFA^D0?E(X5)-0_9OTEGZJI^1R-SS6SFKA7/&\;R44%&$SCB"ET\Z1C_+O%V\ MU#B^&Q%:-6T9[MJ-*[L+UQNS10C5#'FS8=?QIG2JO4Y32'Y=+BC6K1N^@L%Z MLFGJXP *DR%M?UA7%:Q[L)^<+B*#;R_3="]-3)QVD6[X$)4I+VO2PG!Z'DU0 M$T&K=&?7E#&](FKA7QW!HP]K%;=ZY:LFO4ULEZ*(VPJVM6DXXF6IHD7?=-X6 MN,@H2:+KGR_4R?1GG!>_> M1Q%>+FRBH4"NX,%%+"_1,)8 31S;&\\HVJ W5 ;E7K#Z5A;%@(U>Q^F P75F MNH=V.7D!.8?2H00SCU^IT05/-5(1A"\N!GBN5%G"R+N@\R*A.P2:97-&K^]B MFPDZ,843#R^PT*Q$&1X/DC0.7H!L,XUWU()((0UOHA O# MY!&$2,ZUI8A]> M)5OOCLPC6+_.FH,.V)A/1P+GTZ]7*%QP3I74#)WX"'8L3)N*C#>*\7BW[,#: MTZV.*]8M'>C=#D^;-%7-"#TJ;4^GQ-(1/L(FU*-K+K%OGT[ M*5'[-*DU#S<_Y!VO#%!FKXA4GO,2B*;%SG.$DD0=GH$X6T:=^7'V'S!8(BZ+ M.2AKHHD)]-:<:P^)2R\#ERYVP=W'B%[2V)Z%&O?J9XYG8! 2P#N%&X%@=R$5 MH-W10220.P]>F(%]@YX6MEQI64W?AISL+(PT7B#LTN&H$+_&V2%\C"LGEGN1 M.N@OY6FW8JN6:&16-CLC1H*6".GQXA=C>N&RPG1BKGCH &T)^I^]J6B)P:+^@P3_.G>ANFX#]+4,W MEM/#\OPGE',,YA@UY&]\PO2EU.#6#XT7*ZPJ&_;0[5PXB-WVFDB]3(3XYH($^N^22!/4XO9A!W!2%7S>;0@)'O7T7X%1$)_SI M#,RUR,YLV>XR,8RODDBR==1&UW QEN@S86\EF=L+L8LOV_QK.1?/=U1=CKM>LCM,X'P8K%]>'S"Q_7'R@[&&;- -2U=//#$TN3". M-+&2%H7#%S6FS,WC)[O75^1"AU]9U,VJW42;%7COE?( H]\1"9"!5O-@'(CF M1TA@N-'4,HN?/'"BP[RXGI- M\*=Z+L.75RY#K]?NQV&F%[#&[ILZ'U3B^K)XU,^/RY:3=5/PR86\X?BJSAZK MT?O(,$RC9X*C O8Y?\&PU]UNL:&@^(%8DH&]VBO8H%A4I+1MU;"W7?:V*56Z M6<0\O>V#SB569J''BLHKI32=$NN-FI],!<8:;RS9&4Q;1;@3QA!-/EU5(B#U MH[';.*;\BD [T.%K4RND+\R&[,8))+ZLP1V/P^HJH/E\NE)U;X7"Q/!9E-H5 MI4.OK27UN9I 5Y7*C':?,CP6C%(T?%3>.[Z9<.W.OA>6JDK4-RC_?%JT/_PPL 1""=]_LXVC:5^S'3D MN8G^;1VQJ3>[/*M!6+)?YRKN"0UBP)+;/MB>/XGV>32M?@3Z,F%MK&+?=ROM M"K1[>P!M)>G;>ZZZJ;S*^ 'F3TB V*6)NNW#M"W=DT0(I"GM?A)6G),'4+\! MF(^F3-BEM_4;J1XJ-CEGST\;;";%D3"HX3V.P;E*^>"=++V16)N+\.8][8&. M73:WBS3=YXL.KPS'WXVX0BCOJ^6(FUP\Z@M'/=.KF$=H%W/YAQ.1S>3!K1(= M,0W35K$\Y.2]-)\9TDMH? S A?? (D.F1DU-8Z2#F($D#/FT!EY7/(3&YGKT M3,:AXJ6T'C*]71)"^#>]"U8N=XM'B#Y:D/1K,K\N4=WXF'ZERI9O)Q7$GZGE>@+S MPO'5262NP_H+;4F))@SO,9NK*"G&OF-"C:FCWTY*[V[QVU0EI)KGWG[XH:*F M\E7U\NL[904RM1C%8.F]*8TL=P)FZ)1^EN]4>(\_?W+4:B:%@]D:' MJ*XA@27L,=0?+4@KR\8TQ HRJ+Z[!NGJ>CMI[_7<%;X]Q%F@8Q4O$I]8T,?Q M(F9[:96)=BQ)Y'&ELJ'R&?X6-JT3SFVT36,DT&8&;"%(QOA*A+F3Q1.6*2.D M0AA??=JO4Z(I5B2M1](*>+Y:Z,.Q!K]Q+ED/%4_>8ANQ53&)K>CF ;?]0\+A(OA[]T M+WXF91%"K A@)%4M\6%O29"$>RL4F:C;0,_C!EFYR6^Y8M]N>\8%+$+9&T(Y MG9]J9*<.,'Y,O$458NQ2P="84Y1]1] M.JQ:7BNKCUH"\;<;218+S;"M8V[')(?U!M M+Y:(D@ZA?2%,[YO451 5Z>** MB2G;0&#"((X9'NYZ(\*=E76AEW4&C*]F:G!8\S_E5Y)@P=(5#Q"%&245#HQ9 MU9<2ZQP0"8Q&!E(_?MD-G,"TNE*%S$@W41V-C;AY#X*NM&LA0OM7/#('U'G$ MGESI>DLL 4'?.#2'3>9]F6K+VX1.Z"^^LELVR,)8L$\$%_.YK(C'I\Y7^-_8\T1G=OU;]9QF<0IE_%=;ET\O-&EO]J7OY7,2:? M>YSS#W"=7;_K397S0H]B+SV=),AT_A>%-7N8:._.8>PJE/X3?^@O[T,S]5P[L:+P_6%-Z*5PC'MG4QF?7^EG]:4?EHIU58J?^5CB,7\TQKS3_ FA?]BL')E<>;K&HI> M24T:D"4DX/*S,OT_OUG^8V&QXEZL.*'4U"F=9S;\"4U/*\?BY+CW5^S3B]V3 M[/]VO/]IV+_V";=0SF*BP1L'S8'.RPW[%'.F'NGM";NVI7/3;8RYV9MTBCFJ M?GDL$5V1;[HHWV5LTQ7"-#OUP5[AB;%?1XQG9K8P\/7MC6CKK5J-L-AI! MBV>-2M213RHGJR)D]B]\$9PZ$R>9?C4]LF'HJ9C@Z^*>;XUW=X:6;C[W++1UOJ^U&>.>#T6;R;%#K>N MVG?LFH2;9B3>QEV/\Z"/FY/S6[(%[N30G&.A4N5\FX2C_H,EX8ML;O>2[>K) M/OKW[1;H;.>XK8@G?I(0FFW#LHG*4@(/7XOJ,>$K1_T>/]<81SQIMZ/%K:1]3H"Y4K3$-8XC!ZXKC]2&I4^P^%Q[QP.AQ(MMT'KH^6 M[*R-AN^V*EQ[L%T+'=3\.)FQ9_*NAI#AP<:$'U7C\JF!.L1H'%0II>'"3+)9 MP]XA59A3';.W)"M ?FV5:P_ ZO1:KQ=+[&R9:>_G"QZ(V!"A9$G>9=+7F%>S MFPNW#'_M:?I40VE3)R1@K;5SU8D1/S"%VR)-(JT)"W ] ML-:0NOG4)<)MV\7OC2M>]H6Q'WE*D/FQXVO!T2C5%;AFG@T3SH>J2:%]TFUP M#8$[H<#TPISG\!QWK0XZZ4M[)_R5',,#A?G43(YP5I65FH.3A-QU:MZ+_&8% M :X+' [_V4/]RE[N%CI;JN;KXP^>VUT?;NSG:I4+BFXP5I5D\!G?31G"'JA9 M:BBV1X@Z7-E*T%>AP9YHE<.S_'P6[F??R<]/8O/Q(&)NO"92. *;Z-$&>(2W M."M.TYDO!7I,)O?J,]R8:4_-)""#G,7*XN7JB@LKH^:;1/@#=[IK7P!@?W:]\]GZ_H326%#LOE MT]55RQO#E;TAV6%J9=4M1HH)0DYIYB+R94]P 82KV_/"5PK1W=W1SQ+R,1: MBRJ4+=P!UR<@CXO)%#C/D! VS+?,],NT^G/R7H<"GQS**4;&H$Z.#()PXC?B M>[:62T;DBZ_&&>?[;^Z1?4[9$%G6QPN<-???X<2H^NM;PR4.G>?K[S*L7AM; MASV=U)W_9--BK6C!9/[R,[[*IFV]7J)K\Q']NQF[Z#%=^*>U6D)=E@H/';/@2N,DG?099\7Z70N M3%'K=$:SBM)<&XZFN/$HF$LS"ZU?WISD%5QEF=&VW?#NM-B'-]5O[>M?D*G5 MTX00@\WSVY3-2C,RB!LZF-C4,5I';$4.>>>]<_S==Y4$!-['S"6NX\C$,R5( M6=2_,)L>S/AL\?$LW4(EYHZ86.>RO+,_7*9Y?-!#QY93BLUG"42E_J1+Y8V! M.C2(@*&,?P[O+,KU*O&9IF$DGE*0-_C=9A)VT\VLASXL2B)OA9979SJO1%\' MW7R/BX'YVEF66LB,TN;*ID396(Y1X9>IW#)Z=,_$R%MI4XTF4>[)V>)TC9F M)+9TC1]@;MS;^Y7JTAW?1'4\E9L=X@;>/P,P]B+?%+L>!+VYZ5(88&DM-,7F M$?(,XRS8D1@X\WO*_XV+2+R1VTKH"^_5^H::A.EUM<+GM6^]OZ0IN3U]K/K: MO7PI+IQ9BPAXO&VXGF7M6I)-34\UN<.D_"7/X>T-$9X]\GF#"6DLQABMV2G MIC-Z8E1(N\.S4:M-Z"C0W?/2S_&Z*"UCV=B%;GJK_K&U>W7L%O7(K.EGAE@S M2:4-JMOX#S"_ --B!)'9X3'JP4-TV_)C+L7RX);FT'-J_]6W#\$1)JJIS<8V MDANOK= #/N=O)J4%6K.7NGHE5JAM"/<]"^*Z]@1?JE(+>)ANYNUH(JV=KA:P M?*Q9[_Y:.E#P#AJ-Y.MW8>N@B%0DT8,R)HO,*T@R] YM5Y(^C@X=>6JYFAW/(/ M?GTU/P]T@ 3J;U1N()A/%0"1O[R=_Z^6[[M/1G[D!P#S?LU$3#SBPL?Z']H4 M@+Z+\IM"J(E:<[AYYC+=8?6R>G/_IHR;W;&,J"CKBA@#(8F-O[=@-MM X;.$ M9(OQV,=[4\9XBB,M[F(XF$> <+$"\-C$PU:YZ6 $YK;^V6(D@<+/J*(&]\VT MJ*4[O9+X("5[5L9F4DDJ<;JG#6NE_TJ,6/Q;]#AQ8SN67 G]" HTL-9H494M M+4\5@4&)73:-1XY6#P3#>"VXC0]GLV;(U/#KTI.:UVK$VR$FYL^<O6Y!N(!(?T0%S*KRA#I?1/*-!>NB\.DIC" M'*5 (F^OC+P.,K)ZFP4$IJPI2WMN]UM 6O,.+"_1-Y# IXA!),!0,A(*; CS MH7LX@.M"UX\UV)EUE5,;]V4<,#]"(+CTBU45P<, M3'/;6NG07->*[J)[J:<]!$C@)_QECS*J<-$G2QI]F9!LL+*\XQJM?X^0,FZ5 M'Z=6*E!76Y9R;\>.;T2HL2I@C>6U:IC0P];:KVW2N#O6$]4)$U1ETU,S'0X. M-*T*^)@*3'[$6.H*@$[M\+>&FM0]EQGQ-%>]M]G^!MW4DO(63M@:@J-"")2& G_[>SPMK, M#^=5-[N8H;[,9Q!JA"4):CZWC\AL.>-# E/:OYZ '168]7.^@"I03T$OK.58 M# (#0TXHD M0M:?(8&#$B2PQ8T$8I# 93SS;V?N%-HG-B:!%R 2>$L8$A ,_I<%B"K4V6&> M@D'6X&9G*2 X=\MY*!)8;4$"CY5^/3'IH/ Q3'R &$3QX5M& GTH7Y9,D, 8 M& FP(8$++M!O9WN<65MC#3C_3EVCFYGL=!:F4W'@%S_D&OVQ3^0W>3]!6G%0 M=/C@_C^1<9DO[[0Y/]80'\^$_N+L!0:%LHSJ]!WS7XPT!A^>_2.L"O0D[(D$ W M\_<&^P->;^KW3B"*N (Z#X&LDGSO5K]@[^3_IBC]KU25?L%VN_=[\T?\2C3K M#_ &KM^%[$3UT_]4)?=ALKXF"],^AX@L%%#V;ZBC/W=5__=MS\?27&T7@NI! M@_W'WDT+,G-UGSER-8N-,T.G6..CQVGR$!)*:7MN9JA]ETI4&NZGH\>0$;:L"$P#A,\1492M>Z(#<89$@S3NAG/ZK3ZIGZV,WU,9*K-$+**XUT M3*B7\]N*C_#*$UGV(_BKTTP5^ M,RYE)&0XEG0S.+NW<(L_LZF;G(=_)NBB857\D_1M/PWQ#.*TT$ZZZBR[I2EA M1OD[;QW,!YX^S:$FG%VT>WK3^=/76S!]BF;1\#ET_00*4:KDVT.F;B3F?WV^=DM)VU/>4L3IB1.QM MB-$N/G-60[4G17-A@V*1868/=/!JM*F(& E]5&/=X@&_1P9Q9.@* MG\SU+UW+#8SXK1-J2\(+4S?MAZL['-A'9@0#FP[RKIHS#MKL?/TEAHEN0*>E=L?6[2D=HTU_EYG_6H>/F>I2=] M06L^!^ JC>/$??UB&2>H;[\P&!K49CSJJK9]P6CD*?JFR%$4>NT4CR8KGF;@/\U<,82X(M?>%'.'4Y,KPC9DHU M8[ML,4? M_EWO7"4/@W-J\[VH449BB? G;ZV7:1S@,L+/;>DW*1H4J^1=PK/-+3@I% W&[CT!VRN%$ MR692_/A%;>TPW[<3/4SAT8_RSTEN*HF?^\O2"?WX\8]_IORQ^QI=V]01"> A M"I& #-3LM URB!J$(.^1P&!3XN7! ES/VG91^5RRSGG\_Q(T;>;9PR12EX=L$YSDOA%U.0!2(D MT*'])QL^]F\@UEK'%U%*F8TKOX.@1DLDH(<$TI_S72RUP-[+U-P%5>9[7G9E M#?\KKC(;Y3)/WY-"K Q_+17[,PQH"30.V9CO1< <$%Q1Q:,DNUQ,$,>OW\ I M?P(Y2-]J.=Y_C 2\15%/A=+$9C TG@14^\V+>^!WC#])L>W2=J$:G#[K)4VY M\6>0W[4XJ7_X#POZ8S=JJ<2?69%$5>ED^Z0-XES^=CWC..5'5-!T+$#Q(M#\ M"W^Q,22P\3+O=ZF:,VN981K"H+,EZS^@7ZS]2=R?VW._?P2G-]M_9G;W[0\^4_5,DKV+U]7 M?.>U]=QQU=!UR;$#23W(K%Y$OYI9+H3",3.>RJ' 6;B4FCY$>:9"]9&2PQ M[1DE([G4S3X>]2Y*<[0E&;^^]B%IJK=/-8CT X\'3HR3;Z[?U7'T_L.&VVI^ MM-=&+!-F^1=5C;%9%NS8K&ZLZ[,^_$JK P2:Y8RDDEN M:F2P6Q$JCCP0+;@:L29R@I.R7+N//>419E![J-"16R+DD6Q_>L3-T2$ :;4N MDE_BE<+CY;5GJ1W?"YY[Q8)M(+>W(WN.AM+WA6Y[O?N+$X-OQ?I]L$2]6L'9 M!=5B!BL--%(_FHCW@''@[+@)N=(A$@BNK*WAMO?6)287]> @8D$O8'W?J/&AVF(>5NV5 [)M.\4 M3^C[6?,GX^+,STLD]1R(84Y;;5J-$U7)W?NNR1T&<\NWH^7)5HL< U0Z55C3 M5#((6^CD*206 O4Y1_BGYX](97MILEDO5=8;O#;@2N],;.D2@_?L5E_J:K10 MZ^+A826:WZ0&5M>"C<%R?V3XSU!IY*I'HZ YJS9MMKIA?P+;5>KKVGYXBY9Y MPK/Z?"&5)##E(CN[YE$HY/H10?&\Z>6\4=!,>+@ES: -L"%%Q+)@6]\QT)SC MK8=QIO.QZP96G7BX_-8+)Z."!\[3Y;QP5&C$[0KU=GUV?K/ !]U$22CV?F=X MM#_ZAJ,EIM6,K0P=75!%GJT(V.SAV$ZR]1NE1G6\BV&Q[FYI)2DF!9#* MP=%F4G6#]R2ZZ[BE2KBB%&YK)[F]D[LE[5>)(1SQ=X,H Y9M3;HFC?RBT^SI MNLIV"]ZV&R+F(W^MGBAKDU66CU M3B4 1VZ)DZ^(\2DC&-YB=?FH1I'%<%$57XV+<&RKK8VD3XW?N!^-PT&QX<,PEUL7KE&I?QYM;RM:A'GV\F/ M6IKN^R<^3^ LY/''Q@\GRHJ,VQ8:K]3$-R;PN55R@N;JS*K?RT74JA;\F+4" M+:*(GG;0OFID6)9!9>2$?H[J29AJ?'46*Q?XUEU)US'G-$A,O_^5!^<<*K^KW93=9)GH% M>T@K.$;-KJ)CO\?1*8S6M#WZ/R;.^7I1RVU,J5&9\RS?1+ M/ :M09[YF-8<@>K>N.AO_,;B=V>8>B ]B,7S)H=5B#/_U^+!WWG\[HQT'!*( MO_QTXK70C5A_.&R4_CN17[UY?@,)<%\$_GME#5R\=$%7C\) )/\3]"T1I.JV M".^6(RY(!/-!J*W9\1K*%5VXU:^ $0I/40G/C6+(8")"0?,PZY=[?J5^*[\X M':8@7'IVA*)>@!""_'++KPTD3%F!TB2W"J6)V1DEJ#/JUYM^(]V960U9HIAH MV>A% M?S8,._W_9K XWI#\*O)TW"SR"K]Y '>C7NW[M2'2A4]\#BR&J[?C@ MH>DK2K_>]5O;F&L;@7X5Y/?;?E71YC])1902N&DUX9=A4>=;Z2LJ_Q/$D>3# MAW17H;)I5+8\-%UM*]@&C?WRU0UZBE=^;Z[.B5B@'0H5SC.M$K9BO6!6EQ-6 MO0$U^[X9[MF6+!-Y#'_Z]9Z_V\F? MK(>3.YMISXQ^!8_GK7ZZ,[_G/&]1 M4[M"ON74-ELFME!AUFDKW6GN!XOT;]=T842UZKLYU K< MRW! M^:.,6;I@!W.S,;!-@3#J+>K8XD-@D6I^:VP^"[ODG4*;[9C:@8GYL,H M':]C6::W"IZN$?--?/Z-#S,VW2OFMI*DVZNKW;&.N;O\>@C(GQ3!(VJ I >[C])HM&.UI(,P_6 M,Q[[4'5I7#R%;JU1+8-]\IDQR3+0';<5H^R87_BRE 970EV&3QBE2]Y563XQ M8%="J[9(X;XQ(*T N'\#A\$L%6">1;R7DZ_257T,M^\U^"12!XBKODUV^%SK MY07^8& PO5GOTQ0?=YO;X(H2A8T*?E;&NA_/'YF)$XB4KT3HDKC5]GF!7F\./YC0C]^5C>6_ SB^M#E;[T740PVT5OZ8.<9F/V _I5*LCB[VWIB/([= M(>][98 M2@5C_HL""QEOZ*WKMS;?W*=G>C^&]K42G+PU>>/Y(3824#W$;LFW@MI2<*A& MSN],LPV 3U]TWZH+=*R1EM3/+7N0('*.'0W)GS>Q!E.74HY-.C_.[1&/O$&# M%L];];8]#9>IDND%5W&YF46=IA:B)95 @$@ A@3,L M) !+ BWQ#T$VOEN[VH*:KIOJ*3 ;IULP3\U1\^M5X%.RN$//9]ZN[^9! ^V2\MM(DQQ0. M-,>^%S4E%1R'_&Y\@6M>Y7^JZI3^#CYO/Z_HKG2 M8= +\P=\=2P(CQ^:@W_37 UENE0!97H!_@()+"G!V;SXX B47ZC4%/]8]3>O MS7ZK!"UQ#T,V3I' -1 ,G/2[UB,HJ#]JOR_/(;PXG_EX; M!5/]9G9VB1)2$T&Y'O>KRM]:?JFC@+2",U$J["-N0PY*A7[K&3DHG#\J"T4D MYE,+-(:FC3UCN/98S(D%DG>M"[PCHY,-/'MFD*;@0D=<5%M2Z+P5I**$I2<%00D*SDV0;(D07)0,X]1\_[[LR=>?.^N3-O_MB_7Z]> M>U75JK5WI56K=D4 -0JY16-%27G)06.W!5I3$J,<:Q21PA.)\_[)C4X4FGVS MI"E-YR1'T"2SQV;Y37NZB+I,13:4>(]6LI>#&#&S?4AK>/6MQ[5EMGS]D2W+ M;>O*4+GR(:KN(\BY%$5F[D8E>_->:8]2@T[566.%=?9,F!A-X[O[*GF:.8WX)6YAHL^F$.'F,^78=Y&*L MHM=V^!4Q,)>)!_P]W%-@E=_)UO6,(^4;HE2JIEK9#.TP+&?NZ:CH,NU]6T$+ MT!VA,9LU\'N^?3/\TP*#MRO-<8')TRABFA<.K_Q5B5%5=:K\Z@6-'%@*.,A9 M,#\XWTPM"]&FU'X3"Z01O%_BF CYEL@2+0?J-R%Q'5D$[M/=7+E6]^9-8KVJ M1$V:BXG<*.<=N0LEYQ2.7IK&P.%+?0U*E(BW=XF"[:IIZVK[8EHA3&?AHYE# MAZ>L[U%G&DJ)70#L3\%[P"[$6Z 4DW$6A6!AHTH999/@Z[:.+@Q9X@1D_5F4?#A1RG>#.RCZC0EEOT%-=81>QNS!G:(^1]HC1RA?52OP.;7B*?A\[?8@!C7SXJ 0G:8Y M7V\X!+(!$=5RW6=3'U_A9E(L63!27Z:+5RXH3(82ML-V#M=5EP:D1B@>%>J_ M[%Z56L;UX:&AIUFJ=@L7TNW-;6ECO@8>E'PJ@F!^=[\8F\LQ/S0H>[?D.S MXGLG'HT M&SQ>\8=:P^^\D!S)'./ )#5%VHC*N9KE)302"K/OT9>^8-<%KU;^J)87/5)8 M3[F4XIZA*= Q;O\EX07X[:$-GXT%N1>E6>)#*&7PO-;P)\[V MEH<9RQTO?$X9N"44,.X<$>.OCRIB?.YW[--JCFZ\6S-B5;!K5*?SY'B)U$G= MJ[>^OFL2@C]H2;$E+KM$>:TR)KTS=ZVJ=FPE+9U/1U-+6T^:3ZCU@$HL48.; MOE-@(FU(F,RI:$F.;X.7B1-TB=7-.%19JBPL&!9>?#"3C,J90'_ES.R M8SANDL+85E=YXHIQ57%=6R:FL74$7;_(E^W("?R)(6'B,RO?M+4^:C,WN9 @ M&> #9#I="SK"+SR@_%S;C,1R-DA]9OTX4J..T,+UOFK(I\HEF?#@'9K5B=@: M<<"P?=$:6\3$U@3+-Z/3PKYJX W3\DV6D:B9Y%?%KL3KJN7;U')#BRX.?4+# M7^DL>Z,'\V7Z1FCHB05>?/V'"PT+< 4B5:38(>6/(,S WX(POK\%89!:*O? M*TMH;0]4NNF,U D4+\21*O+^&?95-,7D;^$=D=_".TC]^()2.JQZN8T95Z#(!+@.$,83D#M=A;M;,3RW#)*"7=O+^@ M!2UB(VV"JP@.Z"H4,[HZBW&L8[6)U&'47[.+7OP5[5[ &NA':"CI*C2T8;_C M>\Y2Y8@T%\*_JZA=V2,_8_YUOD>\)R*7,5JU%^"N_5Q&I#'R"^)?)GL6?YX, M[RF8]0)]0YI?2$/D%ZR_S-53WG,0;#2^TT2Y+Y#[K_%8",GB_Q .ARUH&G3C^"&WH7I MSUS-P%\'_]QW%2T1_RU:@@"6?WD,^AA_M1-J]7XBFM.X\^E(^13$0A;,(J&3 MOFO0(;+CZ6>F@,G3)UUN&="3.Y*;"2F%UY$@Y9,S1==?([J[IT8(X'KF2-/W MF(M;734&IJU"A]7E3[ MT)JE"HH4]Q479X_G;BW>%IO9D$8 M:N7!42L0#;4XV7E5&ZJ:\(U4^F:%S^&TM_M*+?-U2"<<7[XH3W.NVU.HP,S6 MU='Q@9_)QPXQEJ$6OX['TWC7TO:F.[@360=78E1\,#UE9D?Z @'13]_$([B! M"(D7#>XD.S=:85J03SY<,:VSIF0KXS4.DC7JRF@ AN_B5IYHD"_G*XB M_\EK44%N\NW=<&&*J*4!_#"L@JB"@L@-DL:T^X%?NTFM]M$U/C?YJ=@I((!\ MY8K(I2>S6@W?A(C=C1WOMF/*ETJD[XN1^5./H'#**AL%+7N]-5E\.$PG:S=[ M^TWS2\'C"7=A-%OL)=9[%K7]69:+%IZ/F,J[^_(G^,(^S3DL7.]Z<^.+MK?T M@&">/"M!-TN]0Q%,HEXXD-;4"W*H/+= M51>BF?!Z +.0XC[!7M1X'W4_\$9R]3Q':/,+-19TUXLW!:S7(N9HH'4YO7J0 MCW.G/W3"-G=.+_YGAC,FQN53<8"=06P((T@ MM9$+_M1I#=F"&2W2O/8EU ?Z1.NO*X"3#:?FU(\&)UO(Q0B@]YIR-=, M5UW:('[=X\J-$PV1NO/U@\T-FJ-X"V\>]P'<\E#"8 $%(ZZBY&G3XO46#>K*P,.N$7G Q5^%?A,=^:O4_+Q0MI#BP>L/W@NJMKG>5BWT9!-^QX MQ[[U+.N8XG.NE+&O5 ]>@K-=_\(*-2TO[C'G/(Q0N6),@,YTO-9E)'JF(F_* M-QRE0Z;4=\;0<3=)$UA;^_VE821L@R 5&G4E5Q7(^%PRR16M<)[=>/YQRTX_ MEFW\S+][HU,2\U>FN ZGZI8-JE=7X@WUV[]4P/HG<'$6:<]W'M MNBC]'B?I:>8LS,+Q)XH\F'.;XIR=J><@YO)L$)]$==[=!PZ=)[9OV@U%YYB" MVN#\<:V2S^S)>U^_JO.#2),)5]\0 T XKLE8)ZVZ5 %ML4KUH7-:9OJ?MW>8 M5SI@1F+^RJ'8@IT%2GNKP=L7X@7FL0Y.?3?*]5]^;!0??07A&*[ZN.]-$W'FW-Q%=CU?7O)EU*>>0I=G+A9*=7N7 M%?Y):?2E=35ABO?8FUG&C(TF&R@M5NF(A,JO3>FY%"E9>AU(#CK3/'OH\?,FM:,JI$X=/>1RW61EOTZ!IXCD&,BL,0&B*X M&GQH6!LKM<690*D4BU_]YMF'^O#O1-LT!"&^.!(BAU3>IM=GYJ@;]BY./ECL M6M@\*(Y3"ESJIWW+)U[.1S0U?YO[$88S?^V=^D+?)=(^$=9G^\WVCF377?*9 MMS*J]+%L"#0^,7V5ND6CF#?O+2Z"$7!T1Q,!J"O@H<7+F1YS'4#H ^]94Z'M M94R-B[9&V%6K-&]JQAJ'@+$R:_WSUH'O55(RV!_3$U WJ-7L#$ './*0E8C%]F7R"O7+J MNG\QSCPBL"R4)C3FA@!DSYVR,G1=IX6:V7O*K#SZA@1<^EW.3W>'O3G^)97\ MDTK%)H5#QL!K=.X( #Q]8?ISPSP$?\E>MF9?:-ASROW< FGW)B?L7B( :VC: M+ZU<#J4^EL5MNMF8ILH*O;.;O.1:7THVYK&9ZIE.MO$J;;32";L)>R.> EB$ B88P2>; MSS?@MWP5]Q(3%L^UDDI%#![6I9VZ[S^@6@@.E>>;4!8'7KFDM53J/BI_0Q?M M;I&G(; IVV,\S82]D74:V%]R]36[^BJ+>3+.L?SGC/6R&>VD,LFK%D(*&"E4 M*#J.>( :M>?"I82@\8'2WNX[4DGN;X+?F$VK;E*_"7LL0FU@4*1HVU58&PAT M[JT&%-2SIP5A:M!$34',=FB_KT:%:DS/) W>"FA))$'Z4Q8*-:%:395S0!(L"DPEI)F&SW73W+6<-V8DZ6N4+&QO&K",;R=S(D7.== M:S;$+AC9S>O/!@5H(589KGGFM4'FD(H9?<)JEZ?FX5A/3;T_Y"4JT-'6:M*C MO"O?DZA(TVI,2H:5RC+3V1,5?"^1GINY*ZWRH7@YD1LE<.V"/QGB8O'45[;, MC(*GM(^FH.:;$TW9XQUIFO&,/QVQ%\P*TB7C5(&8,(&UI<]T(@TQ6 $,+M0I MV\.%0\)XG(*D"N-HQ8U5!W?*>P1NDX>GA;NQ&5&%;* ON0B.1;IHBMYZ)0JM,C[(.EEPL><#[3;-P88 Z\N]<#/K>&T#12!*V<9[+[G7 %)R308RKEVJ'0D\^HR3FQ@5V 9CG-'#>[%U+1;^?O6 MQL\H#MWHSS+8X'TIJR>)MK]"X0"W7+O*7V^/N3R>OY!S$\3S?/X);#QX<#[ M\Z\0*I3S#%1FZGJY&O\K#,H];_.F RC2R_:LNMK["!.G5,FDG"H7@!_T_P(C M#";,J7<*N\I>G[[::9),#_T?G#_?WS[FDXCJ<"W!WR)UPA MI(06W ;]1D+CG].ZRIC&OLJ8=E?XG:485QG,#5D_&.<\^@=,'DJ8R!'H=-?L MS_F?)5V94Q?9ST8U[S2G_P:@'\"S[*/=\-\,'< MR(_%J-OXXQF)Q_X56P$8R\7N0&J4IKHZ EWB73)N"1TO1C5%U,C0"S*.!SM! M6=YI\C)*LVAX2EH);_Z2ZX'R6YA%_O$B!XEQ2^O4)'DIB$0B=3V:4O1ZOP0VN2F*1&#OH(=(!BSN MF8ZL9!VA:G [ZAMBKU>C.%]P3U4T5P,=].YT&U$4N#$G'BLPS'I4V6UW4M+S M;/ *V N3XKUPG]Z4X^J7[=G\5%"02NQJ9).;-A.[8BE$Y\)WML\HQ1GUI'?Q MP2QJ=F&G-\H3/YI+4Y3"U,#5(VM2F//31@O2;4G+87J30"+#SVD8=:C*Y9ZV MPN1H^!(#FB.LAV_R-.=%6!(5FR#X'5_2P3HT+,H/=:8B8^0)KSBC[S M;_FE^TLM1S7@3XF6G)$ ZVOY5$T^MN#/YI!>M\/&*YYM&J]^&K MD,*[S/-R;<81RSK#V^5-VX]8%[@,O2,ZYEY^2 R,L]-XOT#?3>=-CR(:V%C$L2*9Z"+T,;2+N9>\+FE!N M_6^\SQC>U+Q_Y0WP;L<"HZFE!1>2Z3/J.KJ7VW==>^W(1373L>%\VM0 M<%GD"PV4(8 -I'D>"+OTH?VY0 MC).WGNMA7" 7P1 /6A:)(0 _)(0@"+XXC,"V*+_M75&LHH:)7"5*>(K>Z6/D(@W]TOAIQ?AS&?V0 MZ,.0Z(LN/B'1F_[:^HD-Y&/X+4@%UXE<)37X,_ QTK;X\_=/"Q:Z$;@(7D22 M-,J(G#/HG 3T<^,7!CB*VS3ME2"7"!^Y1)27(;I#]1:717DB!I=)WUWK&L'\ M3FSIAQ!!^AXO94;6VKKSD MJW9N^[^(L-\2V9_8XZS)6^>K*&JUOF%^9OEVWR(6K2$_R.P[Y>/1MI(>@AE# M,@H)]OT1QZ3;>I,>S$.'D]M9M:-"\Y;VKM\E=()#6$[5EXMI#M;H423;"89@ M 4NA;Y+GL=GE*LMCGKO;G]!^8'LZP_]F@N)HGBB-/MO@>:Z(HB0*^>/#0NX. M3:$"@KIT6)E(I5;/K* N:="3Q3N]V*./0&W8U!>^@F&A$/C^W)@'W9*+8;1X MR-Q2:T\HE3PF>W0'AB[[MC"YHZNLR_N+.TN[][0TU]7X]F>['(E)%9[O0TH4 M!6JJO^@^P9)&$5 S(O3V8$6O=^PJ?Q>CS,[97(UU>D 4H47<29,XUK^F5N5U MLWX\GY,N'G,N[VA8 M]8!;E=+8,HUIVDM[^XN@G"GH;46!L7(_M[%]_0W&=+(L7E!VH B MS#//Q:ES,=ZI-F,VH3[<-2=7Q/E!P($LU]Z&*PT\[7JY%^XLYX W\\C==P4[ M=#[8W/QO+>Y#L#PQ*/TD\\U5R\S+*C\O:.7->O&2T%M;.;0'=?7&T-Y6Z?='LXZ6%@ODCDUK2E]2X#[^.29$3WERU5;WZ9,'O)-+$H<%X.G MT+ 0A7?4=^*J/\NJ"RQ;?_C3Z1'H6MY MYG%_X8ZLTNA+"WZB'9:B@@*BX&:K7DV>/7;?;?B8O2[66'D?=9LFQV;!I,XL M+)!01YZ>)4)"-K5#O?N6/# 'A6/JX'G='D\2+]G[_GTV_8PY,[G4VL2 J=+L M0!*S<.8N$3T=R-'3PJ0-CELQ+@"RM\B:AFB:H[RNC,'$T6,P?-DUA4)E>/O< MV)NM@O^1 ROI1NQQ2K)T_GH55#1' )=I>.JU3GZCQK<4$)>:("PO0C936WV- M9#6 ^?FF5&EMA 952<#ME*&A! .4AU&?(I*MFE]?=^'>(>V4Y3UG$B*/('C1 M&<>TUF7#C87G3]POM$N4IXNW=Y%(,;P:N+1HQ;*SD]%0$\$QZ:]!RH1GN"@I MT@<\']K)&*N8E2?6>UX[K(OJ$/1\1*Z6.L:S*VY)] N0X.QI=B;;&+/([^M( M?GC;FI6WJL+,2/CD;I1C,..]9E2/])<^$HQ92%F\H+Y!R,47-=M0 4\A<_/+ M6&K8;IK:L7XJ+EO8<4-(,1#!JRUS,.-Y\!FCV#F&.@)(ECN!HX!@ M2I>^^>!!VG,$<"WI@KX,VT#Y5&_&9$CS%QQA6^0&\#?<\[#;"&!1_),[2=)7 M^+)0X""\>1RT=@]I\WD/P/%^QVB^X MC2DZLO:;J@?^I?D%L1US@J(N.SSQ4WXA]1?<&@$E.1=%.^QK!=@_DRKY,^K4 MWO]#-EU+VHK; D_4_7P7 ](&I2U XJB;O\"XFMX]5>08G5TX2M,?TTL1UX.W MC36M$;HCB=U%,DK??/X0LP&)W?E/1N'1YR$-KMBJR^N[X#WR'SR7TX*_<6Z" M8?W)\R4_?/ O&"[?YX$'64Z0')G_8_$44XL0P"\H0"6]@@.MTV;C?PRA'/HHEEK_3-/MN&N,J]%4EY MK"CQ=YDS>FVUKHEQXGAJ9BBS1,*RIE4U','_NP3!U=4BO];VY#G)M,GRJ2I$!HKP)MX00_SC:-$=' M/%6ES..$N&^8F[$' ]=,SSAAT/2SPH17ME5M55V&M7ZDF/NVT>2\H 1CTZH2 M,Q"V@*U]EM:T[II3U0@Y'VGYDR_K^SN*H$#!J0[L L#MPHZF)#^\V-"&6)W, M!UM,OI"]K9%A]%!V_H[Z>JQCPVAL200K\Z=D"5R?=-PA$8$]>0RR4;V]")<8 MD8G#'M"]Z74[]8U(SUC,!E"O'H/=315'._LZ(E2#=6'R=K7&AJH1A_.XS1J! M.@O36#,],WXE$28;7@&4X9JX71R+V)AW11QZMT5>8L7G'$_WB;E+%"[;=02^ M)>!IIJ.Z/:ZS^VZG(@S%9?[9&'-JY3A'WLVE6BFR\M<4Z(8. U1L6ZY+WORT M$QQM 0I1N_I/1V6"Y%;-/A7/ !CQX9!R1A]+L2U-4"NLL=W$]CB'>6G>EN X MX)(L82C^HJ"#?4U.SGT)C-.WG"#6RB<8Y4MDJ5\MFU>P^.#.AVF?^!(ZJT$N M!$ @!S@=JCU]Z:>+^J5/;%*5&XOW!>)]ZY=PWX^O/FPW?(O+@_^FZ5Y'-EDLP^D_(XUH]96 MS_N_$EKF#C?:J!\K7J-;%R8]5'O @4W\Y*961VX,^3/9C+:7&",8JYV-6V.[ M^ I%(AE10VCU=JY6![I] Q_P[:/"8)^.N[_LK@GSW6+$%*X?=01=6W=.-8U3 MKAVY']<7)23&^!1+0XW,2A!=,"]IC X*\C,:WK7R$*[-=W;>F^HQ/+9M [G8 M?OIZ,45N(VMS!W N5[N3-U!D#KHK[Y<%\[%DZ1>\SWHC$$(L*V7L(% ;.8C] MM1"FH#KV<(+S$N-%3>"QSJ.%1ZYDHNP,7_V\C)*Q2@,9 RI'!<26 M,3=/ACEY#CU)AA>W#1(LQ\UV=+#(_1% E"(%!FH\Q<=K,TH:) _]2UZRW%,9 M]\_-5VGI,R^N=>RRC.=RV6)$D1GSD$$ ..,]:A;N[KR'W87ZQ6\Q]@-[2/(X M/O4\OFV'CN=^=%6AJ76<8]L+#I5(*J*-,2X)/E5]S]1[RMOMD:UM +.?B/V6 M 65]3[T77>-0=5-P/L!1,%(.CP%MN]Y=4UC%![^RI'_F91&J(D;ZD'93L(<8 M5](" J@TW6?4,T=G].0MOF%F1$4-B& T6MN:M)6$>*6>/8RQE&*C%W":%UD M\5CH;E#ANTK:NT$>(HYI[:^,,IK)SAJS0%/;=Y7?:E_OHUY.R$VCP5+ 5Q7$ M:/\*[9WCF*=ZJ7LO4_Q;^,SM5YT3ME?L^B[@"EYB!HG4)XD2'&]:FPB.3I0N M]GII[MP(#_?I"\WROK8 U5P[\]OU3XD87B(J6JF4T,@,]G*W M[&,DML!Y/%+/'S=R"]M67\>2)"IL_-^/(A:Q('5P9#YXH"+L\OQ'IJH&7^?% M.=+4F*]" $MYK);WNN&0%F>P[0:'6@RXI7LG MKS)!W4T#CL?OU9V'*:76U\$)Y)&VCM XZ&3[M]Q:PTW*@VT#!. U?Y6X.OT4 M5%F<,#_C%H+_?7ZOU#'L]!AY>Y/U;YFJF'1(_$D6E.?'5^FG%)#[EQ5O=^#+ MHZ;_"K79QT/8V_ETSB<4:>*NSK]0]V(.9O\\3FW0LJB0@#-:9_KM2[_%=\LT M9R\D4B-+^=BF_&X_FWDT=UR3(X[W(J'YYY?_1Y&B+.4?I1"O9_P;TB.Q?C!=NB/9#O$O2&]V=:1\SZJO%D-WX]:'Q_&.!M,- MCB!K-ZO,]23URH M%?6;I/N PJ;4W1(Q209MY]:>R/=P+(19R^YM^1^]/I)R).WY^.[4:9U 2E4? MG?C]%W*+C(GRN,UY4A<%Q2I?SX*W,7+VM$<4ZBXR1:C?OD$[++*2LL_7@P?JU_G6DCH0 M8\1$(R,0(\3H 2$UFO=L2&?XIFZ4..!:F8( J';]]8Z.D(]>>I]FK3#E7N6% MC.W L6?2042=##U*D,(IPOM:"O#,Z>CU()?1E9C-5[FU4:E6Z/Q MRZAW.2QI-SWW:+3?U>)0Q&!<[).?$(>II6ZH#1-M6Y:[N]*\O$EU(Z9X4[LP M;%GOCH5;&\E.0Y&ZN(!A"+_&;;+H)5C:E*V3J9%MZG:6? $%7)H0H.Q:9>L^AWT#$>^+*9 W-N"V-)NE:7:,&X7_!= M#B]?75^8K3#C'=5R);ON1P V#"$D8^NP-[#V7(XT[BRS'@%N9J4EJP]697S M<_G4Y\/6MP:VJW@*7)N^%4Z!)]&7$8!DJXX1WK5FEXG.Z%C5',J 5V/,Y9O= M:0V^62P=GP1]BO!AV% O1:E&&:)R*1LGM',]R5BM3CN[$1T$)M(^" M=*A*N![MWW#"NP:^: F M 14)6"N;XE#Y#((R\L9I"W[&SRG&'GLD]WVT$I<:K *!9FCGQ3L*&@10K#,! M#S2/OB,S(;47E7"T6>XTI"76,,[E67.+W0]UF2YRTLZE()8>I:MLD7.LW'=O MTW2,Y.R^C<,>7&VJ['R '^:TG.G:_UC+I.V,+D#H(2SRW."Y3\] >_L^@%Q\ET!K>,G%U]EBDF]^V]0"S)L7E?QEHG@"QT3$QLJ\ "E M:IIQ:<$'+"G:GY"5.3.U&=!$2)]P7$OYB]3S./T776D;C:3$?]Y0P>;D56K4 M \^ RW($,!2BJ_7S$,:Q>G)KSB*_URG5@5(9.N<1X@RMJP9=G!5XIV$FU%D\ M2S3?8D_ *E9*XOC#GK_6#+M26X]&)Q" "@*0 7+^#4'^_YJ.,TJOP[UE;'P] MEU!3#R.6)+30"GN#VS>S1*ANO,4_#5Q-,TB2V;K?I'=[4EW+)4#+HBXN+^P! M?PWS6WU)?9F<2:XBLMO+/$>%*,V-]^2>W#NO XL?,7Z;D;^HUO:5,\KQ454%;%57\<< M6O$4Z%T7LT -Y-"LU[H521(XP[84D;?@A//GBIBZ*19Q)J\XSAJ'+;6KZND MLX(-B*V)?*,T4,^#4K'GK=,[X^Q+I6;+4=(7W,Z6I.YV#]M"WM1->YS['4** MG2&=F8Q"JQ)05O^C!F6UO0V-#:?:X-2E584: [R4%C\A[?I083*VI3(/L2)- M6%RK$/:8)74$_0J4_,-C*;:AVJ\O/H8IBB1C#6A!)4(6F[&/"_:%#^+%<20B MI$&SXFAA"X_.Z-Z5A^%"&CHB/&0N,O"-*&/US)LH90M M3D-,87G7;WKDV\A2TTLPM$>I1)%&^4L!RX'S(XZ,S 8*2.],OB9T9?S5I^_! MW[AY0$7XG1YT9?[S+1.1'=[2]CFS @6AZN\U)-=2,V!F),VOEDA=_"=?0=&V M;)/7 BF]!=$ I]&_G9T<<&G2JQYTF#8J]N$]XC]/+RL+%15U#4OZ#.T? R(/ M3PK]:U@I)N>ZS=(WQ@F&=7K2S6^Z' _=KB\!OBYB.+4:8L$ZW0"?96EH>TCD MW#0L4U!TGW/^^)$#;)C8MK^=\:#0[;ITYIS+MSD7$]&ZH8MWA4>M[TC6X#N3 M#-%1\^$?WB@0$_-LR]?"DA8'2ME&K!(1@++C@SM"1&2]^P9^CX*+&FT#5U;V MONS-!WCUEM_4O'3BU]/3>OJNI$ MQ"PJG!V.@C[B76-IRM-S<=5^S*'0:O=2;MX9QPXQN>S)@8VUB+KH<86-9Q#R4"+.RLK32-AS0Q[CS MIMNPHS74!:,!<,;OF7-9&KXCNC$\(#-VI%#2%./([%?LLNAAF//0?P4E6SNI MHY:1O]IZ*[F^2G_PZO.Z^ PRQ5T\5+C-:ZZ%&*UPZN$+LMK"\*+>URP32C75 M8;TA89"T"-&-H06/U3O!MS](T*,HM.GRA2GL] MQ1$QNO^."8"?:+\<,+I<[8E&W]V+4+Y6[7X(U*VUY7# MZ H\Z]K;_4FN!GNYX_L[XQ:..F:/"6I8Y&]OI?5D;));(M3"1LDY]\:3C M!MK'/#8>&D,3ZN$\79>=CG'W"E^Y,>N"_(2(G9WA&0'%TLL%Z9?J19XI)2\< MP:>,NDAU7>RY>A!:O?W00S"U !ZUE*"E-EP4<6Q'3>+7RS;3L<_.V(%;^4'L MY7*\;Z(IRF"% JDI1$53NU2:"6K^;L#X&+I[8',-P$JO7/3&^*X)T3G?4&6T M.R9T8FH+>[#]PI"(I_M6F_U1X>,MCFD]7 \A7SG)%S&M5_#7] MV&)=A?#_*1WT[RH=I.29.P]W;T%J6 M+FV^P;GX6[C6$U>EA/P;#*TTR]3!\?H-C-NJ".!@CO5\2P6')<&"9EBK()^5 M_S22XY5*UV3'"G7.%Q2ZX2"V%9W>!O;F6*Z8E+EUQMLQ./.[W*4S7;I:$:VW M=1ILUX.=\OUA>AD*&94QKGD6SI77:0-)+8**NP$J/X;KP5%P\NF2-SHQ?]"? M]@=2)6.RGIIH.$F9I[+XZ.VRTUJ!)ZU6*'?R:5XH-X7*XQD0[2J;:^(7YN2L MJQUT/^G)[!T1Q?'.[_7#VO(-]YW&=_\3T'$>^'27\/*8O@S+:&;UB/(&5XJ[ MX!CXR-;W!IX:Q2L$[ASFR";0LY!AV&'LN[(H#[.V YNU*Z[V2WV08S%M1D] M?5" \=7B.HO5_8B-C;.ML'+=.=D5.1:^ZRX MC!08/UWP-J%^J9HPISEN @B MGD&)T^/8<;3L:^P'L9[(/^+0N34A*GM4$6%"6%4ZU[WRP6:?K)@(Y?OAAN<& M OA[[&3&)_R/[4HHV],;X]2C*O0@")4/"\?M@?LQ;_9,_RK5Q%[^]U58AI#EL> MS5*LRM:ZJLY]=Y+^CD-4Z$I,=;1^R&GQ=];9[4%'X+N4%\( EK=R+NO?8[ F MPW_3KBOQK'CYAP1Z45LU P(3ZNT&,K5^=J9)33U_T71Q$@0_Q_M32EWU//Q_ MI^>W<]D_B6;.G8*+2@H/3U#CCP?(/S!L( CNEG5Y2'^ [$_,08Z\]1OWTO[\ M0P#6M)H+GA>]DH/=]-D7OS?#A%A/-Y).!G\LA@P#Z/=FVM\@7B&(^*^#P/KW M.@ >,(]ZUQRD%^VB[/'/0-=_&H+? @G9?V-"_$B+TY+*^N7BE;A:SOXG(_;_ M.H*K'>Y170^]@S'0;HH,78#-Y88C?._'$,FK$VN9Y7O1H ;YICF\^7\*>O\Y M$/RXM2,UD'%0H#BU_GAWF3!@JZBPP+!D3*,@PS3=P>^6#ZF5?5.FN&,B!93E M\U*(P-RZ_6=JU,Q0PT,JU0]F,,OLH/U2CDL M2<8Q)=K%#U5=A&\#W=^E4:#M9%^/J^VD\Z;%2E)K].YYB"'M(CMF:^-HBWPK M-BTJ8Z5I7BKL3'/0G0NIO9/W.^T)Z64B3E-3=[ZBF72FH/H>]INNA&S;?(LJ M,BA,K0'A7X@.>U!ZHF6F6+LS18JOY%0]?8DNM MIF!-M(2CL;Q)\_SQX?+G3\2(%46H>>=''L0(6+I';7UW5S]D8*1KG7LX(J"4 M%3?+8D]C/DVNX53*G4+Y397UG1?-FA?)!'JD._ET7X7&'-[SI;]'GUH9<:%K%.&<_(TZI?+-J2W&3(5=]6<#D>K$'W?(L9<>3 MF=:L@EYEX918?K\7QLH=$D3?4((OQ?GS)F68\Q+$\=\C@)MR81B*L: MI>6^P.6Y6L_T>OPJR$\\RZ558?1"PW.QZU6M5@\-*W5M=K"WBHV8"2S@U5RH M(5G^&GVA6ML\SB'VK9D@K:F,V$W28((NXH]._5(HZ[%AK>"[ H)+[B4F9DR# M.I5.8G9O-*!K(E27[+':0PV%0M*:QWP;C)%0M39FNN:3/8T-@I-2:0XO\S@' M5< PU*YUN'+G*(]? ;NG8,:92? '/O>1%='O;D(K(?A)*9L$ M9_ 0RUS-]!RTEFCQCT K:JB-U/:F!@0!!',@ "SS6.,DUSLC/=F-7<$,&2H[ MF =&_KRO1CAT-!=2ITL&A[23 AOOFPEA-_D,*%8U1$BG':A,IQ:CT-A'4T15 M.1=H0%R\=*SMY4S(FR#7 E!K#00,WXQ<3;U(:'KXOF@3AQA M!_6-1A/FJLPMQY,"3_X7OLI#ED?JS\5]7)Y^+01>IIM\P&*'#3DTMZ<>X?>9 M"G&/>(BGZ)D??]#):(C>?6PDCN54N.Q-%)JX%,+=<6:5LRC;A-N,!IF"[,Z% M!M+P"],!C\DOS>SO[\N6# _IVB21U'--8TZ9#W5T7I=\PP4/M;@5DCGRG3P75Z,DA1Y5F.L^.BUF=3J/K$EXY#,-1+C,LZ*50>O.9DIH'\'3=WM5>28(&M51-6%BM[/<^_A*]\O!F4FY) MY^A27+QRF;YBI)K4[EJ^WCV7Q,Z66M$-YY(!ICL/.M"J55]_D!+X\+BSP%Z5 MDDB W=65O+['TU#;NU1'-,5U/2+?1O!,\3O>UB2]=%ZZ\Z$J][L+Y0P7U6:6 M(][ _(#79B0[KMC%\ 9&TE;P/0Y*/'/9K*E.=_P>'R63MZ^\B05R7H+(%+]% M%B-'3VYEIP:F_O7<]7_G"QMU;S[XM^9QR2E0H;TPBZ&'F13EPD^78SY M*J?KJ6LX::_HCMMUJ<4 ;142@K!EREOKD)T "_V)Z( >+D9W/ M*2N3$AI>?MF/YQ%2OL<.&]6D>^LAN0B^Y^+/C#7U:GAGP;JD_X"100I];?\F MD_##F ^F@1%F%=4R2F;M@L$)F%JC7L1?((3ORYG/M$M+M*HE%J8VMUI14II1 M*MS)H]HK9D,:VN,8M61)ZI_Y CED!GM%3.-,7K2P)%E/3*7AP^H"(\;&+:EK M_.IL KR"DD9%TH,.&8.'F.2/#0^\^FYUZ!'-2"J'SHPI-\[>WIC*.Q+H'R8Z M:@JK:E4,EHE67+DQ8\@RILAS5F*=4Z3!M1?WQN95<&^NBG2Y%7!$O!EX,$\ MX]92(!!?&KA5#[*^16#A*H_ZB=1E (/16X0ZTUXSD:0.NKV23]JFZ91D\#)[ M2IV(T'A[:/I,B9Q4#O7R6ZPGENRB-JYY(SM4J,#-1W8RDT(C,B)NZB#LF27* M>CLEL7Z8W)@'*!]")7L4U6BXT-B27W-V%\S7E T#M<%)H#IS#0L(H&Q&W$U6 MSH0?C9B.+@<(WK]!%;STV7H1&]^EJFUQ,E=PU*ZL-OJ!WKO9;M.N?)6*$?QT^D9AP09\ZXV ,CV, M\EA8X3C@\V7$/5A9XB<$4.CA:9$+I0QP1+J<[Q,IQK8+/'HPG[;MGP9RD57I MV[F%^A2GP-QSL]I1G ;![0)5F9=:?=JN<<[7RGC/+QS6'I7O0#9N*7V7/AS- MV=N4"Y.$E>29E>"(5\8^T.K OD_.W4#!"M>9;;1_7U!@%\BB2 MMTF=8M 89!>NMLZ1C&UY,6[&SO9E]O%M8$@9'^#L/$RC_HY![2F_-B:E .W?L>;R[0FU-.G.(&MY,;BLMOFZU1996([8>>3%B2/#2S+-NMFO#KDOJKTG"NJ#=N_"B M+".9BUG9D!"WW]00WU2_8=B1'81/PZVXR+WM.]W9#R0P.B"%GW0XS=L,) MKZY/\VC(T-Q;%Y6:=$:S M8\"^B0"Z':#3U2F.S@;_T8:TGSB9"B'8_RJ%,*[19DXQ%/7OH9 M$>C60M +:-+[(XO1N[KM;/N]\1_G!N+=#$PIY>EA/7AN5GF+E\9#U_7R"P[H MT([QC08&(T_'+B6;X71[$X$[1[L8EXE+C,.:%KR3]-V\@E*H)A]$4$WP>L W M7/+:&VE+QSST*\>C*R4=G&S8^-]1+?M,HKZ)C-_#&-+8WY]6FK6WGQ=M:I/C MFE>')2U>\JU1TJZ,I=(X/G?V;ITAHVPI*[?4797?"PBLQ\_C8N4XUPBIH=NE MQ1(>L!+#-CXN;&WS(A^SAM.ZN*M55APP,=^[U[-"/VDW^[Y[@^_6 "QA04=, MNZ9RK)Q(;-[/POTM5K;NDW03)N&%NUFCN.MR[;/=J(;YJ?T!BT47D0V4\!IN MN/]8]X4R @@?:6XZ.D %=2%\U_.+.?"%OJX%9H"NFO]N>[2+DSRO]^X27[' M?DYH;[RH );4JA;KF95@;21T'G" ZW1GS>WNS06*S[D1'N_=< D:TKPR6?]S M)OA\:>=;4'#41XWP;.3#4Z=Y>0\!2 ZO>0E.Y%_0&1E@OZE@_/2@0GU\_7:< MCNBR3=M3@R;-R8:]P@K6YCC/:TQEN50Z@ZXY'0]GO%YOK^_J. >4G^=1HJV? M>?9JL:26JB<*?EGT62;&P!O5.3>EHY_6<1187G2^B*2\YVF, (8>A&& NS$G M&F- 9]?'![PO& M,&]$F.&9%>[KK:I^JBP?*4HR!!(LVZH!\[ MU,IC956JON>J>)KM;*6(T8N%05V3'EEZ2)9>>+012B<#I2VQWBOTI*7$'+#7 MA_869!N6TAOS6J: P3MFXD+ ^E[K%/6,M/QWQA&FO8&4O-^D0U=A%F[8US9(%%HL)85]C<:S MG.;L'_!@UG]<(.@45YH@7Q<'?;&S;>J=@UD@ )I=2:2XE4.^A15V8$S0-P=H MS*4' MB69JS:$XIS3H.QRXWL+NY;I82\?5_-A;7DYB,IIGWB[<&9MY9(!V5> M23'[-CTWT#A[T6:Y[)[H'<%#7B_0HQ@A"B,6J\<22@Y7=-EMUO0OR-5P M"1"NEG)T9P/4>.X"TF2' S3VS>C%%7+42Y+!V\O#CD$ZH&?%!_B9$72HU1B# M_/&N@.W">5Y80*4;NN]K*Q*( M^G%.N$J4XI<2)N%^>3!)0+O0K5'6"_Y4/3/I[RY!,O[XPN0BKZ]%S=% !-7YZ_=;R4$YS*JG9/"$T'0 7@# MY>3\(10!A(*/UI"C*5JR#!@"Q^ ="" K[,(> 11)'G-?"H"7DR[=KHY%%^=, M?OV[Z*\.S_\/]O_!_A^ 789#^X/0T"\WT/X3D?=?&WM(VO;S.;#",?+G54V$ M5\HE,>)Z\#X$D-D$V[T:M#5_AE28H0C@;P3H7QW_XX;'(H#EIDLW4!EXO0C. M_R?U@7@O$,!/@WZ&]1L!]$IJ2-?JCV%_POI]!BG_#Q"@23F5Q.*Q SM' E#X M;SG#?RH",OB,'Y_OI(&:W-RM_[>>SNDEA MK7 ,1LHYI$,QHG?QTQ+\.&T\U70X@0#(?\BJ. 0@!X;.PQNN:M],JFS].$3\ MT[!CZ\NKSW6!_Y!5HH%-?PZB_ G4]JL903_Y]EM7)Z/_&/3_ 5XO_]9)8ZG MAKN&AO]=B'#0RD/-+&*VP/&\3MV@?#2!6FHT1Q'OFVTU=(1HZ7^U M]]5Q4;7MN@M14"E)Z9!4! 7I#A%&))5.I<$!Z2$'04"01KJDI!F%H;M+NF2& M[AJZ\^ ;?J_O/I_?M\_>^YS]GOW]L7Z_66O6\]S/?=UKGEAS/=<-YZ(R4(%> M.VAO7U<*VW(CEXUS<1-[KC,@56:C=C L%(H2HPZ45.^)7O?725,C-)7[ZI&GED@!2>T7K<-@\2 MRLZBF-SB82T6;@*G@WZ3 MT# :BTG^//:\M:=-9TQAZF.:4K$[(,H/U,^2M0&W!S]@MR>]J;G9^66<#KN@X[E9UEV.YMJ%CAM9;4H]:VVB M@8#S%>+7>0>6*UHU@V\-6=J#R?N&^*M[[9GC][8);/'#,.%)G>G76A< &=E()GL"4PGCQO:Y9?*T.IGG#D*TR'3\44,8H+*8V3]4JW M6R8;OL4_!]"<2/&@YL#.=59? 7!$L>^,A-WM%AZO=Q M2L-L'NA$Q >SO2=XS$'?G-M 6DE.$V[40W\UW; &MUUFD8F3KD47]3[!L!JJ'HO5Z=;JN784V< MCZ9 "(T8$%JY=;S]!SSIE+)3>2LB;9U;BZ"T!M,7:L=R^S%T#J+U]!*EM2V, M%3OI&Y$UUC#U\=-BA* +$FODKJ4J$QN%@/Z:A!-"$KV;"ZWFW[EMCI%X&HHL MKSF]8E6S0?@DY+?TDO\4'#U$'H?:BYYJ(%ZK^9W#E@NGP,[Q-\VF/A^$_W]H=S(UIG^ MV8#O5B&2!49X-C9X#BRRNETL=/'.N*!_*EAAQK?63J]#-U!]+)=V;QT/)0%F%"_PW1?\(B_2/A43TOM @ M0LY478Q^AJ7T-RA%_YU _K:'95/OCS6!3LMR0H-16JO0X88?T/S* J/^5=7: MZ8\2U[^??/>[00JROS=T@8FX8/>O"L@_G'QO)SEKRV_2S= _BD#_=O(],I]Z M=85/B[(O();?/KMP[ *Z'\^^ ^GCO[F.RE,[\W1,VC^MN<#G#Y^_>[W*I18, M!9O7[!!6_J:]_,/)]S _3ZG\77YZX0?YZ=_/OL<%AWAF JD).[V\+KI^#+U M^P^?_P:>Z?\3\#Z? [^0CG_QI5D4O@[];]?$?\7W?PO>K^3O2MM_TT;1;<*J MOYHS__23 )X"*RB6;C*F/9W0[J"P:A?*K3T)_!J[$SL'D^J+8C4QIKF1TQ+# M>H5(23WAOV:K-NG&.> UOTFIRQ_;KSO$=5R#.CY(EM4:\K\T0Y3**("[..Q\7 +!*K)NLC6% IE94K,&\KV'^9?SG53*\B'MW3 M"2 'MM-BA!ZDNPIOVE)%)HU$'EFFG(6T$;PW6"1NT7-.SM;JX&UX,[P6DC=> MD8_4NV^9@Q]R-6J1'NLP=E<+AF-VLYI<#W=TY&ZL S.5U&H[&MM_" M5RKX[68$7X7*J NL"1?V;W O"D:9@ALP2?EWLQ$^"48YZFU&F9I-MF#:AJ8[ M/D\/R!?NBI!!1.6J/;>&I;&X*SW5';4?KU!XA4@4$E^FCE>\$AW57(-L[+SG MVQ6XP$-,'X>B5I4?EP6/!9@$V.<_E101[(-Q4TFLU+W275;;6HN<7,'_H-YR MC3R_P5MIO8UA'Z:0XB%$TGULH'2:R% <_L3"A54]-98B.E^RJ)ZM>4$0N,+C MH<"P0#P"F0%M5-74=^148%GPI09=B5,H\P#.+,4#(XXBF2D7F)DJ\NX]ZM_1 MN47%5#\J97#]O8SL38 1/8"M.P\Q 9KJ+DV8HZOBUSLO?N9/XR14U":PG[T M<^37C,4K@$Y%K]TZH6GQGL!I/&\@>5I8 _.&;"'9Y(:[\@F69SZ\02AYL* M#.QBJQJD!")%5@\WQH.G6AE\9?JGBS1P#8W:'(5+.#IXITW1$P\,W+"A."^5 MY_JN<0V&(5#:,VV0$2^,G4GT@T$K[Z.7:KI8A0/L=*\,:TJKBQ@BC'#7T"9W M[BA@>N* S=V!C>+/6:!,/3..-EMVH2$-'1)MN_'L.JU-C'*^&9D7,BE2,CU7 M5)0\/M@!#D1H.*B(ZE33O1*EPQ 1WH_3O/I>7EZM,Z$]0;CB.;^+,!A PI#B M-9]T1!OQS&D3:AP*V^D96R1\:7VH4V-'LDN.C).R:VD'7H)AMS!O";Z-E.KN M??T!EU6\*NG)YH#SE: *]J)TD/%V*W.H<63;^TQ%(\J0$3Z<;BH+YJGA-VR[ M"N@CXR*?85KP<.UY5AUY]51M!=HIHDF[[F&F*F:%/CCJ%B%N7 9BY&$+(UNR M^D"2-@LQ6WI"GG,L3Q Q8MS&M)H05!H:9E MDOTN25.:$RN)U0*X 'H18"O"N*E84!4LWI=>?#8.R.ZU;L]< [8 M"Y1\FH>[*IZN)03 !K*_N1:-,A-WSSZ59_]N> M)_3:S/R:,^*ABVFF*(_H/O+7K+?E%_/=A?F6LV/H&5/5>F[?F<&\>Y;>H4:K MD@[TA#5/[\S])72]Y%?=<6_[BXZ^NS/X=.^71,(:Z2=UNQ==;GN7A/_*.3"E M8WX.;&\;7/3!OZ8"_J'T4>?%@)ZM=J9J0Z2F=PY<7[F8%2?%T1RC?DUA_*>R M0V;0^V[*-5N%(2GE%S>H:=:]-?#&[ M_<&GX#\5WHV]&!2?P4YR9UG^ 1K!%V#H'Z5#YTSHI.S/@8W\(NCAX<74JGKB M%QGZ'XNZ&5\,CX.LYP K_W56V+^!ZD^%5[AJHD7^4U"6<:=:G@(=RP5A'O_) M/=/\G+,;5-]4[L^![\+QF+_H_8O^(D[_!]CRB >A]>B_:/PG_:[QOURSO6GR MNSS]]WA$I)3##L3L]0X/"O\FR/^#E;\%&JYV8>TJ[B\:_-#?DA'\8.1OKJGZ M+]=,H7U+'=#]>^J 'VQ\!ZR]5T?MA%;@F\S_141_U^/_HXT_1$*3-?M//HO^ M8.1[@%FE[/7^Y/&?C'S'=>Z_"ZX8.26BI@4KP=7_"M=?(5S_1[AZ3>(\,SB] MU1&:5/T_(0#O7>G. 7JYJ!.\H?FZC*Y;I&5D]!0)Z5+ 7YTXK.@ M96$+..P!&5]7BK5CSQ[GD6T&*"O'XDQ0\@-,GYR"LD-OFG8SL#*37::N.AIJCIJ1X=;#7H[-UE"XTA4U MGSX8,,O:B-/_1([R+<7(Y'[UAG&X3]S5-$#M7#39[E@EN#90K_+3LA2&] MY3-I>&0ML.'4Q9K2"U]GG>I^:U]F15=1/LR641,I0_1VV.[A'7:G6G3*[?@> MC 6/$Q.:0#CS@$CCT(,6YBC&0E!E_C/.XE>4)SFHCRVJ/EPJC4LB/?"TNK&,,/:=DMDEA8\0 MW&:G>:K.^<7_'+!+7HJW1VDJ0;8;PE=:'@8=/-"[G6"0[:=_,8H)C3QB"0R. ML^QZA6NMR#:WWXB';G$D%+GTT0(?'NM6_R RT!"@]$%GE*$O<3^='+!/(CL0 ME-61?5;4:[7S3O'=J\A+Z@M^G!ASHX^+^79.!(&7D+@F@:#@/+-8^? 4]APG M-\J^58LZ2WP#Y&@6IF!5NR9E_U'6*@) X55:JAO5SO20YF_?B8SO>=$.N^>WT2#.T,!/&@W M+W"L:O =AX\A-K$/182^S SSH>$EBF!22."+V+V)VOW@# GUPDZ'4/E6@8(& M3P5Y--K8);B;9K].+\I>%O.>A3UI&.#W]+(%^DP/PG0L4#X M1Z^B7B\E8L,6WPV$#Y/FX6$M6A]8-) [!%(FZL/?T+G'Q>70-(:9HNM^_ZFS MAFWN-J?B)+ZCCG%B3-LGKZK$N4/]%NEE:"=DZQ4:PH*>EUT>E Q.5Y=U<>CZ M]!#-)A3^QC:(6)P9]ER;)/GC,KETH)T.>7>C9EW!4$H9KZY;6T1/(WZ=7]P: M86E6"V '3 ;2X)SF@#;'\Z;6410K2*+/GFOWBKN,PWB,[?4IM\1K^1BF/9AI M"$^8C$VE4%,18L;B'W4,T7M"YX[)O]9L/GJ7OL2#2#_=TM(<];X?HQ(Q.\H) M/+%DIOJ<9-[>?P[,9ELD[6%=C&0]\]F1O8S[S<+B:[4._3NE[HVY? H<2)?, M74&Q[@PBM*(T2(O8L!5.@O>!Q8>*$[\4B"'K,O$ @7#M1_-QGAXNX2=+)?NV M;)-O'[_P[S)[*R%S^;V$@)>&*"$^71]7I_Q]DK/N9\4\?7B56#+$[YT]TV8= M+@3[IP;1-LW"VK#*TW*EH7?N MJQ0CD(.;7;N5\75;O40/O_*VF>U=O)QKY"1(5O'+A0PFI292=T0)M>6:!J<. M[&?TR$:(2\@1#,4;C5.QI(.JM[Y(HW5_D1? '^9>%N!),$A;'(H4> FB2N.X MTWQ#'S^H>G:WV[7GLK/O6ZZ$>U+D3:@=Q:4YXB%CH?O/0SWX&?8 XWS$:(.+ M&=E2E0P3,]'G4^7SM*5]S2NG.WNA(%NSC-%W3J0F'6-D79AB M$,K=DV6W2_,4HNA+CFJX]#Y4/+<9;'N?/;HF&O(!:\.\6$T@?3P.^W@-14P- MJ4\:\VW3CC=@N&0=?V:/=> EJW!#^D,1XAPP:[L6 Z[_+(BI+$-*(V&KK1J3 MG^'CBL/K7T3\<(#[N 8N1;EU6:?/^M(#:F)5;F70(KJJ2$*FJ0"T\1Z>Z E# MK-%NX]"^C9XNXZB186EX._ *0JJ87>U_!7#4] VNY$]?+A$P&IQK0;(5'_8V M&0A5\+(8M3VD#Q%?>:I]T"U1V,O&_>Y=5FI!15SKZ\ TY-B9I5!57,NH96I) M:?[CYF,=^$'4C%+J8O&1/[S8_7GD\>HQWL@P*04%_T(?[ "Q\NP8[XWEHYB; M>TE[ ]*K4/-#7J<'KM7&XXG'IN@NCS=AOKLYA4^TL;23D*=Q.:A1Q=5%\17L7-9]A/R.*W3D- MOB/,-,X:0](Y&:_M9TG.F<+C>EOLT31&?Q@F/3%.4(EUNJOL9J[#$4E&5F6! M1@B81#A3JGRC:H=$2\),^;VU=R-,_T*L/$!+-1D(\VRG-$6]* M^K[FK,M(1C0:!N&-79[Q!"W?/L,(O%6^:6B=DL)4=BL[LQ80QP6(T(;_CG88 MI>_)71WZ,S=8S?J;7U/9>[]+@W87[9]N))VH. 42KYX^#MT^!Q#<)\'R/WY) ML_'9+OAPK_IB,DIX#OC#.%*"LY3Q4.1GTAG0^J8^T07$\=F!PC?14?5RZ9-C M/>C$M7.@22VZ5WH@"W,O$$K?7S/U8HEF&^5V#K@R_ZJ/^H>FY'PQ35U^YG7\ MJ"9T:>)'4ZEG).P70Z?(\,1^/71399Y+:?>.^&FJ7NO.^@^VODFCWI3Y)HVZ M?CPE>I"]3 2*=;F&BI=]:F/"]A3?/"%&L9V[K MHNO>OWKRYOAB[9#DTGT\!;UP.?N[R_=.F!%J)\?CT FL7[&YMGVS [UO#\0/U<,$OON<<@[4NZ5#NZL63C=JOH'S M0_6Z]M]1E/J3FZ)_K+]R^7M QM)2UH<>R[C9<<7 M#6YZ"OTK>_///A,C=LB#(MFK,%HU]=DN= ^\RT&-1RK9#1N^)_Y#>ANBIS@Y M-I6QH4IQ_HO=-@'Q6,$WL-IH0\PU.SM/)&[)TX=;HAOBQ7F%< JOB((VW--3ET08>SXD#BS= M]'R:GFR,8S5_>S2 9Y+6(-1309>U.,6#3\>DCO?(MT&'_F%QN2>.Q6/_P;S\ M$I[&1,;K,GQ=5T<%'"F?Q=:\GHNJ=5;PY2JCE7S.71@5'8%-KZ^^@< RKG M,*"(^6!ZXKKH6YS 7>]MLZ.N.+JPKE5:?<[[K1UC,LNBIX^J_$\>\D:N9(KZ MD P:Z@G(6@O*+.+1J7PB"AT-#W9>R?QPJ4RPZ, CJN2VX1E%9&^:P>4H:AL0 M.6&MD;8/K75\P+"&%& 3J^9CKX/9@/#\NLRS;;$_S+3E4A&M\+XOK(P"K54G MU;1N!E9D8BZ &5"I8FR7Y[XB5="7SKJ7G$&FJ_&>61"]T-:<]SH/,1]K4YG0?-]^]+6Q;)@C;FX=P=P?@KCI%/S<\! M0Y[B$"W6O,KK\C-MA]&1Z,SHKW7LB=#FR9E]W6\M[CM&K0FQN63I5IM4EB9. MENE-2=4#F8)H.F(>_VYRV1RB)=.S "\5_+!7O4"T=M>_P@ :E8DT'R)_4VX,>^G#4!Z([AL0 M'STKV<#NM"H^2[[(\@%7&5FOMJ^9GK[_=K<_^]3O!&D!0:F.$X7#O<5??.%O MEL=,-ZW[X"3"4;&)B;#=>\>'<@V^M[9J#$86=CG:M9@C4CSXD7C7Q VL\^J- M->!NSV)HY"%GZF,^#'=&CF$#^7Q"7ITFFA#91DVY+YW?Y ZE0_>$CJJ'X?4RWIL+:?B(JC<=KM2WYUDW&YB*D%N? M%:FI9/<7P:T^"+,WKFWD*%Q@E&<-",H@6]?!(4*[7*Q:6!LB!\8.9>))_6!$ M2DJ*B?B4[TKQ7-0?/F9&7^QW=RJ2WK*XPP\+U6#RF<(-3W>P3TF,\N4XP;#^ MILCG7-,SAI("';ED,]HHN>WBZ)FK]\=?'!'V5ZD/GCS(-3\2"2>*W;F=;;:? MLHU*:;A-AW7K]9S5C"]-H_MZ#94*$5IKRQ25\K%J_[JKU#0-BA1^6-UK!;X2 MAF2.14-#SK_XVE;;FB=W3^RL_#7'B?1>\#Z4Y@#M-.+TF^K,M4FX M6DGOGR].$_U_>+'T-^Y-,(IF[4QT _V8]?AB+#HA;&2!6:7\W[B(5T^SQ:H! MK3T'=GCRVEE@(C;SX5&V QFX,BQ[WP;*R/\^&L/_97NX_I6[(9 Z[8A0?2M2:%;O/1<%MEZY>>3[-C@Z\-)@[@JZR+*LLM]%L8/7\]1R':\'T B%@81F MPX<\R#:"U0>,^YGZN.-&UM;I/%K M:BPY>P^F5T?O=4.&^@J;8N3X#JU(<9)N+FZJWV)=17=<9!L.B>57>MEZ6W<'W/ND$',XXAHH, M\LQT239.VL"9YG1SL9OO14?TY7.)=E] :&9]$0>X%K(Y+N\WH7YID;RJH<95 M!-(LF!$L:@"-943KQ4ALY(1P89\HV_1-VP-2HQZ35,?+1" MTI*4KZX[#V!S*OKH)^I_HC<=8RDD"=,4-W.AJL17-\?#-K_,HC5':<*\S52N M_A/:3";LC 8BJ5Y97EW91YLX[5U@T[W%*YU.*-G'3DUV%-_G[=\G8V7*Y#0R>0ZUCA#(U0F4M M15WIC.N66C*(#1IUL7I/<*:RA%2FCLON[KJ0GDP4@VZ'Z$;2W[X5[G6Q('"D M#/4'=FCP5WH@MH_"C@S-#%O]Q\=$3K9*KI$?AY\JF,^)4,OFX^$?Y'?K#C"4 ME_MHJ=VNC$XVNS7>1BI,1-)"]0I',@OV;DW(Q"J7V7MFX"68+7R50R0EY.J< M'8:TT1V0Y6/<:.!H4 '#W)TN:EK-_\JP+WV)QES1\7-RSYH1#DN>F;G3^2FO M9HY8 .KCRL_KC[+'T=QN'&=XTY&E<]<:86Y%:4'>7B\&P\W%!R.7MY?9^.H"')\ M)&$CR[HV$Z:04?1@"BF;#Z&7KAIDC%QS,4OG&58F4;-7M5,3VGXO?+3?K0FT M%8L0#7"= S>Z4W3,7DGN88BHI+4:&9#=93<$%EZ])#8^K @/?[TX9"-4K AB M:0PF+\0VN!QD5E*L>A28BAB3GA<[&(][.^:)BXM''R0MP<>/D?M;U@M84%'' M&$F'7%#[-,4#J&MDF)Y\7-^(.L>$IU@W@+W9::_R;AJL)=[/M4GS-I&XH)R) MD_E-&X4+[V6\9H];?;G<@7PECO*MOQ"!, MMJ0Q3$93K%HSF52W[*[M,.!(560#)3@'9I/,D_8ZSH%'Z?;_'/_P#V,H->-/ M2.C<25)N-QE<:&ZCF,=B:?XN%5QC1ZF-NNY?]_P[[PD_ME6CIT&4?#T'8-_V M!B1+48:N4O>YC?R,69O-]5M=47^?X)KZ/ZZBO& L))OZ>37\J=\- > Z5,^S+K@!+2B7ADN=? M]C_J*SCWI/IWK(K/ 1/DH2BXW*4C."'.M3NPLXVO"Q,='?%!#WOIFFWV*./' M$6[#$9=BM4M*<-A8%UJ=D >.A9(8F9HN>=\]5ZYJJK("#:YT;UJ2550]$T_@ MR%AS;Y=M$RAS4< X)T,R8US3CXT6,AO$:"R6CJM&(;,4%)$J!:@,<*VP:3;+ MLDD,L<:985#??L:95#O,_WRCH^X(O',SLIQ/(V^6H*%\6DU]E-*3.#J3=F>Z M',$"Y*MN3]6\65_/J"SML^5NB&':6F,,-'QA(WOGDS)H);33_IGB%19X( \. M\_$=5@J[_I-"FI$W!AUWG .K^',%%7Q%" O*?"!VWFSH5GZ,L2#ZP"H5,O^L MH^O+IA\N96DN\?!H1IPE6V%TY&P%VC+MB3R70E02OG[=0IH#5\2D%;D)N0\J M-3XF)W$MPI5U$ M\FF"Y)?M>_^ 1[F#8#E"*9YU)<\[1?V;8D=1@!XD'A.VA8])Y#N^5(SESP]\M\^FS M-#^6_: D1=SNX/W73-57)*6_K*\P@W-]W/*YC*6EBLSDET1-V#0)"&\*I:XW M$JE:CAET=YA#J^&5D0951X' 2.VTQ!?075*K41#_[+88U1AQ*^2SW7$-WE*X MA=J15';NN]N^:L@]"]^MKZ0C&KY"87B",IB8I/E6*IO@IH2/D;&26HOUK'QK M5WR3B*SET[^"O;&Q^S*O@A OZLOC Q(^4&=(6;\X!]3(<_?STH"(83O7D9YF3#3K)7SS>-7F1GA :JLJK:8XV >KQL+4,1TDG):-@^$ M8O?4Y4$MS3;,-:U]%;](L_?G'Y0\S/8UO0HA.YW',5@^8ZKNA4->]!<1P4N] MV=$]CJUCEEJ6RN9X75V(5DS2_MP6WONSB]JY?Q! MC,?8MVL,2['F<5491U=5*D<]T+0!1SNU6.V5\KR2-T*B0F=TID4XJD3EO(0= M5F;7SY9 ?J"2*(;(*VIF!CZ''J0?VW+'1A&CHQ,KV&$Z$$W65O@( 2'V5O1' MSBDRK/O:=+34YP#/(P#80;!ZE&]>616AO8]CTEXIBS1E@RNPT[*#1Z6KE2*V M*=#2P=^:64?#:MP5FFF^[O)Q7'NYKQMG+\OIQ9 /:21?WX-72N^]\4J= ,K/ MF,S^ "HSG[ I]G0^(6L\S;GM\[0P(3UBAB)\]2;/_@ =*J2Q C.5QY=D(Z]D@0;GB[)\_ MA5T"61&VD@:Y?OI"7.&D[[4U7X%S:T4"7A@ D7T"K_@4:U,(2BGZY,]/N><;[+LK>SO_A/XTNN!AAWODU$OCA->'3*KO_=(4LUONA9?AHI%] MP)-+J4P9X2+=.;TEB@\U2<*A';ALHP#7Z."/> (F#[GD11;7H13/+F8\%?3E M1ENN::]4KB[(N-SA+<'\LB-B0UN.A&S$C\)09@O4>@YH0P'<(_^M@R(LCBDD MBEZLGRMKMK(TJ+]K8[F%4NUQ^Y-TI^M!GWTFR^H,#PN^7F.)>]JS@T.]\+"D MHKQ_U[$(+*@:*E' EHO"=U )!6VU4WK4?A+:![[E27V4PS9]PNTBZ\:Y-EW/ MREIF*04/R4:T\H:^G)I5O8;/1R?>&OCH_N.$X!O+Y'!$XI\.:^_]0AK$6\?Q.D3=:^LP MB"/L64)+V#*-]TU.I*Z.1C1JSL5IYAQ0#\%\X;N 25..U4:&GHC'A894TK5R MFV93$9(R,C.8%N;2<') 60GOKG+@R+K<:)*H?9@1$+W"0$G/W$ZVWS!D=$@ MPH*S>6OY'-#W4[WJWT"#.*D,R)=%,1B&\5&:,'@X#*CA&UCG:9D[S,_HEE9X MVZM],C7T)":0GBO$>)&)NV'='E(*@+M Z3CS,&LP@ZISSM(FTJQ@+!NI)>D3 M(LL"^$CP3#T2JQ-)C?=P9B1>X!V_6V-%\K4!#*7D\ /3E7X.F[[?Y^= $GIK MZTF APS&.<#]:(X>D]3JY+ M<3YO,J5':7L/9I:2KA[,8C@PY:Y DE_>W3>Q#SHN1X*)/IN'4]6F%#+I =); MS?A^[V>'$/;#?O96.)U9%B%CG!JZG43%&./S-)S\*>ISJI!71FC-ZG<\VK:\ MK[QN*BH?<.6=@N'592R7N\=0[266;(TO$XJ;1MW$SHIP.!;$I-5/JJ#'=8PG M (2#_*<9!]G7=COEZZWPBQ.@E$8O[3J@]+QWP V'[0R/' \[9LP )PB]3Y=; M/LRF7#L^61&/O+NH7I[#(L"HVT_PD/ F=73MQG/9DCUE;DUR#T04O(I4WF3 M=$CN]3 -77L >L#D+EEF$&P:AU?*)0E%9L\:ET=E%6'DPZW.T([QE?X)JO'- ME%?H)_L%6FIO*9NSZP.P>_"*+"O[!-ZG,O/UVAKCZ5V]<(+$2+9$'F(4AU9 MM^9LGQ7.V(A%_X'F@D*@7&+;A_XUXGSV%QJ8,4*O<:<=(J^WS OZ,<\3H2V_ M5XOC7O!<@M:88$F M9C9IVNUGRE3 .!(WB?"_== M7H[%;ZX@"MF%Q*?&#.0K?99!9QTW A= >1F^=D8;>>V>O6'\SR.:;:QCP]6@ MA9#"A^6A6 _URTO$KI+%5):(/7@=]ED&0V9E7=WQIEJ8:>SI7D6RGJ:"M6'/ MG4[&BD?/Y@P\1=E5&6.2PL1&%?2)Q3 MK)VNY$9N=C(-E4:UO]5/Z"Z*H[2; M4M]>4F$3$D^?4*]S 3L4(+MY0RFR2S@-\_LX0FP$!RVJ1-:D-C:PJO+8565] M1ODN7;N1Z'SR152@MF2C*UV_G%X3&1C,6&&N:*54(#. QK)P&:43@ &J-UB+ M!2:\FLJYCGR_1KJ\>=^UU[ZMT4FI<(=#52HBA)Y'Q0>=(SV?&&;U.+B;Z&Y6\UQ59H\8?]7#F>(*8 ZAPM"2J!A?ZGP]*128; M4:?T@PBTH@>?;S&I$&"$5G;'A% "N.YK+.@9*95'>%CC#3-91?QLZ^-ZPK/% M%;ZK+T:E"K$H \1*$0)@BBAOT2=C#^J=&QT$VG3N:*E6P0,4+*>[\*WO5"_A M2U5C#"FWDDMHS?.W**,M?=:IX_ZRMUEMY)$9^LI=IX%^I25=3M<2X;(HX)Z: MCSB F&&9V>,T)00MOK8N; ^]U-Q$5#U?[^79I*!L/0QQ97N#E1+A4%94$F01 MXX%&K:'1,5,MBV'0LGD=0'R$AZ;>JLB&!Q:A\=U])8^95>2O49UD;XTSRJF3K9GV1.M4ENZM4Q=&CT*L#>Y]809J4KB+,(G4!I%B4>!& MV/)8*ISM_GT!,K0)GX;HMKN25&7-8D1HBS>^%";;$0!4X0N!(7/J65,>?*V3 M._27#6^8/YZT='V0P+MI+GV/05%U2"LCPJC+^>U(+7J($24V :'\ M1EYG2;">!W80#2&X-1?;]Q2 M5/!2V;@ORS7!5Z^ M*3ZD@>N$E%/*XL'3 +7"&1=T^/7:%Z68*LRU@F^56Y9JA6VZ%X38LX;750;ZL.< M,*%T('E,S6/Q3F8.]Z1Z;HSA^0T_C&L*T6!^'JYU;#TMT[U(A)VFMQ\H/\$= M 0Y!WGP=\3BOIC6GTLN;K.V%<\^WB4!@LQ];T+LL6:NIB54+6S-L BT_ [TB M>48:$0-C5&C5IQ9'>O^>XHVRLB 97U]"N3ZC ;J0):M9[Z^9#X/:*#B?^P&9 MS'1.E+' >F8^C>R&\Y(CPFTL,>9*4:-SQ' ,UW-'MM2[9YJX[I-,E+23^J_N M6V"!-N13+=+,5;+8X^[Z>9X1,J3@^@/!$@XH%/1E> MX7DT8LF6Y/I$!L?S@:?XRAJ.6'E>JCDJ/2LF/XR#'N4I2>[50\:SBG/6QM_" M!^,?$*+(TEY"/%1S('\3N;?7)[VGA5D8IN7TY(TOCLW5XPR*7J]+F##RV&[/ MV5@J9PNLJWW+J+S".PR77#+?IS[VCGD<@.5=-8\KS,/><3TM)>5 M946C9N$E)!.F)OA>M(:T6:W2AZ!6OK:+"I^1.(:8DRB.:[;-BPM:LF80O@*%K_?!W)NJ;U,F!XEE=UQ5P:)%DY>.JUT):JG? MXR6W\K;+H8"/6%N942JSN!WH?\"OJ!GRX,[\!^\\[T2,1YBY.9G9VQ141@;H M,A(*?%Q7%7/X3/4.W:NU2><_^,+N+W*(GH_\+U!+ P04 " #V@%M6G+HR MJ>X 0!C1P$ $@ &EM9S(W-#0R-#$U7S$P+FIP9^R[!5!W:]>O?>F86 M=G9V4FH> 6Y6?D8V=M:_0&"0D)!0D%'P4%'Q6-\1O6/]GQ[/+0#&*UAD^$8X M&'( %@,&#@/FN0,@?;E/!)B_#>#O P86#AX!$?0*Z37RRP55;P!8&#@X6'@X M! 1X^)>S[B_G 7@,!,QW+"*(6 K?0.36V*S>D/17%!_+6G$41T\HV;[;^""] MQGV+AT] ]9Z:Y@,M.P45U165=?4UM6WM7=T M=G7W]/:-C4],3DW/S,ZMKJUO;&YM[^SNG9Z=7UQ>7=_'@X>])==,+".?UV 8_PC@414T0!],T:BYS5^Q7V1TAZ62L2!9OB M".(56R*[:T2V_WC'7G1\[ #EY%1>OC NR3,-5>< M;>W0SD2KQ2^%?D_SDX94WGCDD(./6%S1_^[*M<>64$.:4?#H%5TW/KSM?NNQ M,&&4$O44>\_14\]=:,;"-HEDLNCVX\)6D:;F_!QX:V$8FV6;<,,J4^B+,.:H MDFRV+A,8TEC]UB@+46GY&7#;9G^?K7N=T\MDGK#KTD*EN/X$ES2"4$"+Q,3P M/:Z=:N #C>(]@3"A\9[UCH ) P.PM&!Q=.D,=,[ MH]!7\9@*]M\;HSLKYPPI[;MFLE5%OK-7N.2DIH;_;9F:JJS:2?!X/,CJS'L(@[!,%;K M=E'>2/3B%B*"]7ZJ%/1]178GMF)OOEJ6+9'8(:_7-O?*=HHQ["$V' 0R%D\_ M*H(ES?Z+R)1UZ @532&N5#2$)!JET?Y46)>_/'Q^+V2F[N56=3I^^9OU+\J M0TFT/LZHQD:7M,9_]"EPR#QO69P@:9 'F8&_[[B0Q.<,"AQ%L[DGG"!BB),9 M@^IAQH74!Z?M14W.P+6IT\PJ?=U1P4U$8P<2A MU1++B?Y%.\.EC.#YP#W'9=&3"JOS%[H?=RNGGWB+DVWAQUL]S>B9?0PB>*)C MF!%EU]")^480ZFFCU(=B!2IKF/>4;430[WH5[6E3%=% ZY);:F8N;H7F3A7" MMZ(,18_H]STN3^PP+D'K3_AUE@C"1QV1]#\C/.O5NYGY;\HN3=SIYF%L?7RB;1 M2'>PIF.E!BA9.!1D8?Y>N$$=]2.4S9.Y]:F*S4&P@1!1 MS-_3R2&AP@Y ML>[6@%[*W_ (!NZDL%1G=E&CJK-Q 4NX[KWJ!DHFL3.1/$(07=(8OUZ.Z1UT MLT@EI@\B4=9:+TQ@ZUN;1PU)0:13-C>3JJF[9[]+3OJR3?)EZ*\<2D.>4*$[ MQ<2@]CG>7*;EE\J6DNCCL0>1$9$(V&K,R3UX%WGN+PD]PLLC]-'YW_RNF#6I MGO-+?KRL'+2!DP9NLC#JX_BPCBE0!U9QW9?8C*"N]]8/Y:IG]\+14>1#$V>OCIV*/76N M=I1?Z$ZR]!=>%XS'AA' 5A!&^.\JSMMAK56GJ7Z72(GF!4,8<1>*1%BI+4_1 M._;B*F/TEX.\TH0[-6T/)U9?K\BN7O*LM$$K7SKG1DW_.-F:( ^8*:IH8F;AT7+;@C M8J6R#F^;"";,2_OJ+$ MLH6SKVNACFW47T<.[5SI>@Y^0/M^\X>S_-)..B(-)QI!% JO=$4FYI+]4UFM MRA@K'^)\>OIN2++_DIJ,*#+!,; MNU3UJ>D&COS]*]R8BGW<4V=,)*V(GJ?35FYN5BMF%Y- M(86\4>74=EXGSI&Y-?O"^ 3^D7JVI^IX5-7AO8DRK(-X>)@U<0O5O!>DFJ_E M#F;8F8(2;$P@R*ZN]R8H)UW,28@\<&D;3+?LAV)+9Y9!ZBZ=3K\7BZ+8[I%C:M,.,SN(8YNH[<2_:0QD/>V?II)^I>4D<)$T#V3 MW=7P-^HFN)&F;VI2.3HWCM)QA>OX-/!M:M?A3@MX'R2%VAHQU[XJU^J\4U:$ ML2=F1K7CU$9*Z9=N&-.;?D^@OR;\._ KJP5>J]M&N 7;38+_?DM-C2!Q]6AS M31D*E:1A5>^MQXX\$QT]L&>[W.0R MS;/ZR+FNM7],=3V2J_2 MM^NCY\;IZXY)$7H$V-7U9_7<*(0ZSH;KS<(C[W7:ZP3# M"M3IP .H?>.'BT%3;'NO$+P<1>:/-;GX>Z%.M]T57P@2:DT4%X;/8,R/U!P$<5)_P_%+US^/ MA/(:X :^W)H8=$[69V!)D_6W\R4[S*#Q5!N^V[=T?FG&1+-Z58QIFPXUU16C M7,N^Q.R=!/ON-C6+SF:KM#R\ UYTEURS57.QZ39%)W>.0)3/T#=QL\1MG(NU>@-= MSBM7VR7R,)FK'[0M7^TR4>#:_O"*G%CY7E9U'U[Y\'&$/3&) Q)ZA&)^K?\; M<3Y54X]B7V.)=.R(W9R<6-"U]B@& 8FPZ#U;S?($_?Z',;L>=^PGWCDD<.7N^F&OJ^89 MH.)J)[WLVWX&P%5FXNERUGESRZ;3^8Y4.9^1L$D4Z3!\.G"_:X1KHDOEYM\8 M*3:?4N54D)3!,QC5BKR=Z4?A@F%286<-Y*3"0-N4M8*!M< MT-RH[4U0"=3D*M)-=HS""4O_JCS^8VB3$>IUV?3=Y)]CA"73TEE4\0ZL88&B M-C!$]RL>G-=;[B'GWD$YU]5DJ>T.AX0!EP%)J@R\-4GZ:_TW(@NB(9&1(Z^! M[H91NXF;9",3XBR%N849-AEXO1\V;[H)HZS$X<*27E?DJ,_/N"DWU53X<[^+ M_(S);DVCQ- H9L7]#%Q.10_[7^(_J.#6UU>^'DD/XD:-)Q.37$EEQG3>OU,@ M];_$/K4UVU;VJN@B,T:(!SI_6Z>R\:R7E/RP%L9VPR)X7[66I02#F.8ASWTL M?3(#D[8,,".F+.;1Y>AE4)0*O.?S$RQ%!1)39-"SGR"" ZWRGN M-.'4CK#/SYLQJ#7TQQ. 3ME6J .#XC@PX6@0]\VH39/V/WATVA^(TE9;9/U MNXW&IO#YR]W"VM"_JCB\Q#0L8I1R7&@_ )M.U3,/O89THK M9@W38K;]D(3Q"3>)%XGCC 4<4$1,]DF2(C/-=DMVZ0E# Z*8/8=0>2M=I+59;$]OSIV6C MZY:P*9/2@[SZH*%1I4.%('#F1(UZUGP!$'%HEVAY!I;I;CB,]Q+<>(MC;;\) MW=6MT\CR&J4_H+,/DGX.%AMCL-N1U/?F/*) "%?TQ)1\,(8+.ZE\NT1^,CFQ MM2\W>% >G)W0F>4^'X[0T,)-:,7,TFFWA#>F\W$T5L9=]+!)]#>IQ9C7>0V^ M -O=%'L30LJR4FW#*,=\,B-?S#([$IX]]3PD[#&,34LL]1MNHF',*%L3J[HD MH6U/=\2 :X0Q[*15$]PS GN? :N,"P?T:0.<]420+AGXD19;E#RM_+N+11" M<<5F[4NX$^P,LE<'>R<+T(LF\S9"@:QJR;[?#S;=96FOIRH>F]=2TA%&T.K= M,]RC"3-BYM2\+F_+$OQ5PR)/E0?I V(1#U6GB&\W0+ ^FH27>1PR5TLG8 M^Q62U0>]@?1+K-BLB6&V]0T80W*WCG] RZ^@'<^@NZG MQO5G8 2LJ^4D=K;>9KU#H<['26\C=37_ZU/7I#P> BF3@.0E])%V:JU;QG]J M:XTOX-=')$PF)C(4E-#NU/,@8-.#)N3F^XP1Z6[9F6"H6LJ[:E[/8'KT7Q9& M$W8?PMZ9!"KYZUQ-PN:3!H@>V([>E+2_;:(.XOM6T&UB1N0C'VRJ%0R(,S18 M]ZZ3)NLTC1*JCAB.VSMG)&?AG7__V5UYI8O,178_@N@8;IDU_D!%)[S&$2.Q M:@0\Y,D)"-0^F%:7K&HTJK>-"!;FJHL;MJE25Y72Z $.[Q5AKQ\0U$M/H&/& M$3OUU04<# )K9Y,RS;'DNC[,]V'68:Q\:$Z=2N-N&(Z&%%5UISB+4['X:P,Y M(^(&AKU4[K780&S=,^!7DJWOXUF1RGU713F:X:938R"/O N."]MV1=] ,#5= M(HIY!K0JIA@X<"OJ:D(ZY"(H40+X=5/0J5-,!53:SK7VKER@_H4,T8<-@J(2 MHTAN'1LK/N+\*<9P?)^#N&Y2UU[-8F?.?<*76"U_RX,CVJ9-.E:%G(K9[JB' M7=I9($UD7;K&C'ZRGBLR/J*\F?LSIWSZJ"JPRGENR^F3T6"H*@M@LY1)P:U5 M2P3[X8GX9/+*S]V5/Z'246&I;WR0=-:!>#O)MV&]Y+,$D-Q>*[,J:ABC2NW M3/TL98J$YKL?)53BH-/C0;63#HP9I_N.*\X\\BI8)'@I0.E[/#=QTRD4V1)U MC]FIV-R^RI@X1P3[-S(K*(:E1=!09+U$2(I]&'6/DX2R8 M=3<#L87UB3&NH!*M*OWJ4930G&K*19M"2(TC$8GU_"4VS(2"9I]3N;@YK>=! MMQ:?(H0\:&6 "Z0KT:>7"V\D4*\4?WD?SUB2/G:QZD)O55&6VM^_SO?&G"^0 MI):X0IBP4H7YB35,6HM\JZ]+.JZ*^FSZ.LB/-"D?U"1R07)I.-SA]PQ48\E7 M<$;L2E#%*\JQ8].JOK'B^[#FQ957+.]4J'BO'$EH/$*IGC: R;%[*[8XHTO! MS7W1<2=FN-,8I MR^MO]V](G,P?CNF&6!Z/32]DY+1D<*=Z&><6M#7=,H?B1$E66#O*=D"EU)!. MP%Q!\]OI?&^6*5=,_0\5UMTAA %K;42M@,Q,/[X 4&D7J@4GU/XJE)$;2A9M M2<$JM;:R1@5@MF_K;V:=V M^3G5921Q^J/1?8E^<;SQ^8#(K;60A_4V.(@GM*;,4)$,\@"5-KR!#V(L!^TD9/IW?2]PT MIJZ'XY[/K.2-I+5NM<[LD\:"U.N81+IH:N)3+QX!:RDW:6LSZ]Q0N<_W#%7W M@:OQ1N>;.;\CY F.40,5XL$+)@&I&PVG@R7$X(P?WI-[XD<54VRJV^=?W>,F$ MX5?QY1Y-54P=LUEU(\6'WVS(JR2V:RGJ3& S2!^P:"ZWV;Q,MV6W%) G7==LI?%CI M?H]OU+_4N&"'\]W1>5GV-"E1&NL/YQY7!TSCD#GH;A-5%0FI_Q8JB_F2:W6U MS]![A7J9#A)AP(XR=5N8F*^^*^2H54&$?L *N&2'R.!T?&!GI81P+Q2'O/JV M]VI?-4"U\HJ12#-4,]X$^<359@M+/0>E!C#;C)DE]IYYXL/KW)P+?;A1K M,'E>8"FW0LLP<(?N NP9%[LL=$037Z;9!#L?)],,+!J<"XJ)D+FZSV,UZE< M?EK5.%1BI$<[!^.$'G4U7<@C1G0($;Z5O*)T'0$I@6WOC */.'CHLV4$$$+7 M>;MY%RST:8NL=FLVJ2T_)ZF("..5.WV1B%7BS6RWLK1-Y=8:>'6%9P$J7:LN M##BUB/TF%.+&?J[64-=@C^6-^81[<&]=2;R9" +TBOG":)\B M\Q9UW'/X!GFE>: ;,S;2E+ZDSGC>M1[8,)E@G.&;?LGR27X!*XLT\0BJ 46] MK9 (UJ]7AY>=@!VV"FF&5FV$#I(3A"+%3FY!DM:GQBHL(*6(Y8U[G;:>UVP#]Y4W-?"&*\^>? M!SKY,EGW5<9.G49AVS(-"7T:C^2(MHYF>,.4J,4J-RW;OIV ?93*A[39'9?0 MSLFE6,JW!#].Z!75.=7T="6? >4%&@HB5V4=[P>AS.4;EY5%D^KRFKE-D7P^L62< :$IY>H$T] M:4DVJ3<%50M+S=2DQ\H(HUQB>?<,>/GX[LEE XY1*ESKQ#;F3.WDVW+V;(N\ MHO"-'X^?F'H(8I_>/%(<"$J+)$(;EO5O[T^OK[=YAKF'!/+@/(*V^3$*M4R? M2-!=YH_,MUR=*9]N-=V6(3CBC@^42QS-XTF!(L:A/COZ\*>D\6\^_&_!&Z&M8O(.85RPXH(_)S^X:=&:0(O$<_#9 M#6QR5@U)OLG/2P>>7ML^35D/T<#E9M3=NHFS3$U_KAB7:9?Y79AD?A@ADFI=D?'M%+\)_NDN_/'N2_4FQWQQFI,&-HC1N0 MQ1&U>B78U.7%ZT+W&OV--$EEO7*^/@-U#!8[*G;.U]],2\ AR(JX3&$WA:)N M0KU/(2>MHD'9."=L@P=/\6/Y(< "ER/G80SG0!C(R#_\WGCS;*'K'H]SBOCK M>CI)-)6U2OW#[JK<&VV3>CM.%=P:15&F(58-Y'JY*)MEYOW=I"LH?H.47;^ M(.&H ?'A@*M7PK6^B# IFT0?FJPXC.3^[DOGIRFR1',*0G\S-W2:T3<&% MT=[5U1V[Y\YB*M*]+\^ 5D, G?MPN([X@!2+0U6#,!@J)<2*IR[C_16E MS+"U!;\;V*X"?G3;PH_U8W_I.OLD#,%I_9 23US_M:IMIS[(1#TWN.08BCOX MSCJAV62=Q;&@.)Z(DU5S$%G2PORX(V\ 48H'^8S( MJ(Q('J0"MN$D86J>H.(L,QYE3(M%19F".HA^2M/OD8L-;5A?IL"9EHSZS_+=J !]XE2#T]%TQTAY"EF-%+.)=1S]VC^Q7VU1%=H+?!B6&A M:]Z&O^^AK_ M[%3)./IISFSHQK 87??(]EDQDZP6[M,2*DN:.44'!KOKU'>%;=V6:ITG=<36 M_03@PH7.?Y(]F=?R5X*I]#RPW+]61EB[X9$+^IN:PO@OZ6K/[*L9_ M:DZAGCM3YTH.(^'2"@"/?\F#^WC":C%["'SSDL)U&9G?)#C.C MH)G;H2'M_(#OSEXJ=M96\-U!7@W)'@2J-DN<7A;SE2K3(N^]>/PN%BAJ>Z5< M">;!IS\H>$4A6 FS:VD-;]N)$BE6WI_*@.]EU-+;X M0E)FT]#"@C9*./;ODQW;UZ4UG.DM,V/TE]G>19K:_?C00EAO&\'3]8%#B$1] M1F!<+*8";/8A2(FK()(%A*+([]9"JL@61@-7G)?UPIKQ:HQ3A)HLA9@5AT4WY"/3?#UDIOOQ/E2^D:,[=Y!B43VF[,T0<2]WF>!NA9+\^1B&$JW;J MQ%VB23ZVRRNN;+>TS,_131Q&$S5?]$FS0M=+S<.&&?O*JJ71SB[?;XTI_:'# M> B.YXIX_[4GUO"5ZWX_,=NA Z=L+WV&57&GQRVX=0%4AW^8D%ZDJ;Y'L/S3 MGE"^*')HH-R\'8=E&_32ELLSZO;#,36CFU/EQL&+4-]*6\GMGX8&^%;!E4?= M=?@";'*1':4$?KPS3PE_._=\"'Z*( QG$O0!E;G7.'N7?;8 M#LO;<0,6&:"1Z@:?7LC1A^5X_V:7V&9/6H9$PXS..6M";N'MIU?3%H M<"D@2C3;E\6_@J9XR$4_83BFD_56I=^<:P51]F]#,*#+E7F>)DCI(UQ/PVV=67+P96UK"_O?" __?%EQ\7]@3/LFNL,+ZUJ"881"079 M#C#G'T$\6VB99OA1T64$7A@%$7I=4A33JJ]6WE=7G [5..:I=QIM[.Y39E O M%<%AJA+!VA[!%#H\\?JXBPU-]U>07],A^=\:Z+M9E=.&1PJP:@C _S^0F[ MR M$I$DIM=O-@CXELW-[IS)KSJ1B=:26M]#N9#2-S5G?\Q/GX1&2&U!EAAHS@#I;_,MJW*1&08;Y?!7X"6_E>)Z\G&VJIFY:CUM2T&N9VWB9D\XT MIS?+2@%^1\I:O<:]VS,LZU]?0 /G8XENJJY5$F!N7D39<(_3^Z<^X@.%0@PU M;?H,IIA[ (ZAB*M1_DW&T[G4!P/''\&$P_0&>!FLJSYE/UAT$1'-*O,L#AF. M#RFKZOT,?40"Q/#AY4%(.>"\7;EOUH7&";[M^ADT6L?O(+J+?E1*PGJ[O92O M#ZHRK>R"XPZA^G4)$G,U/P9GN>P^5.Z,VRI^'> MR2XYJK23??64\?TY!Z@2@(1O!$9VF"IM!7WCZ<"%CPB]4O&-ETCJVMJ:F6\N6AE+4XAWVIZF6 MM&=7,+F@1M>S'*L98X-TP$V*J)^H*+69\+[G/D_?WI@='N[6?(0YGLX\67#D?"(N MK6ZH/6R$\^!C3!4C$4?W M:AW<(T9)E./.LE1Q:8ZN'MMB8[*L'W&OTOR!:B)#=8*"[AT0\RTU6GA= .GN MNE(>1)?7#@V5[>X@<$BN]WP'+:Z\S0&;)Y:_LI+:IIA.)[D)5QZO.ORXU*VD MX:0B7UY_OEYV+D*BS1G%U++@LIW+75P?!&R:KTV1=@X7#6:QRQ.SBVP^IN/W M@QB\?4-2DJW'4VJ[*TZ>JIN(J^?U-DS5/=*F(6#Z/$6#[Y*:^=S< J?:?B]5 MJ9^SPC5+AW].S6\.,8B.(YYX,3&TLQP;YO+R"L?[,17*Z+U:R)*AR5YO/V$K M]VMUQ]L?--S+5]CXPE]P(Y;"9-6@L^'X5G7E! /NJV(2B1[ESRO1*+)(5\/% M="KBM:?L6\CN7\J>;TGF.QBJ&]M)OUGVS#PE)X[L00UA>ZU%&]6Q_=T)E"@LOVVXAUYQ M'T+4[7K2@UYU6'5!TC9H:>#.L&'ZG<+FO]:=,@;;FF0-6UOF]AQ3!M-+-]MX M^Z&LG!X',61.FC_H%.P9@>O-G%U5A$2$,:[_N#BZUB,RKIU:-_?4LC-P??Y\ -'ST[C0>WM1L#FWE*UA )3D$F MQ&? M]3$K?V&C&>?FG5@>[ MB"PP^>)7 MH)HW7<^ '+.)2KT&N$B6$TPGD3$[3^HD:#M]8YTR.3OI.D\H(S8+/39?J_6K MSPK"<_=HNH 1;7@UT_0U'.M^?(H]'KXSYCE13/68/&N\JY# MK'61HT..<&CTSHX<,8CL&=#F*BK2'8<^!.ONO^%Y?<:V/F-!#3>?K9:&,N%Z M*%(M;4(57?W*FBY3\KT8,VP,8)NTS6]7;(A*JN';5G&C5O0ST%$4YR::O_E# M7/) W6(MW B*Z[0U&+"1GUF>N6E:^VV[V*6\X/#+>VO^1^4A,+D-5_2[H)7H%=I" M$MLA"9VN/P0T<#]E2%7_G!S_.L@:UUXRN\]G-'_HS7SG:]Z67&3EH?U@.U6L MI;8_.IR]K\SK0IA'QCD^T\OK^Q%.<77B( MV5E]*!50M:>>#TNY]"Z8WRMW6OX\H3MZ]+ZR(DQBL:,,]KZ+-:V6F^2FN#H( M6*>HF9Q6.!5H'65T,,7(F%\S=J8C&?+P8$MZ9%L.RM?+W*]WXT5+1TM0WVM# MK*RK=,Y$&'D&,)F_-WN3_]E[:66)(I.7DFZ2V^K9<1,>0U='XZ"Y4YH6,E?O MU&ZHV8S.38QQN\[.Z'SY,R+/\G]K.9F4[U;">+ MV1\YEB^#>+>VM5["_"N7:Z4ZXE/C4J<,!3OK#IGOF.E5,%9@TQPIO'UW7'1) M,IM?8F66X=)AHH'%BETZ.<'-H@8_@SO'(^ZX\PN!8+/1:N.7=NO= MMBW0N4>_'2.&B#)5:9^L2*_@PN6QUB4VC-QGR9710[T4L@KQUX5B182_64). MZ/C$-.K"0EQ7DYOUU6HG$+$HGYC MV3UO,(U;)THS&Q:):A@,3^^!R9U00--HCAQGB;DGSN5 V#4+PWE!CYPN1:0% MBQ_^=IA9XZ*JW03(C-@3$U?>IBNIA27S1W9);1 7S*O^MK&%=+\O[;Q+C)FN-,.+A^$CJD*#K5$!.'-1VL3, MXB1&\AM"[\Y7?!"I)JFI_55\_DVJ8OF]>UKI6-$65IP^1%MMP7WAD)+F04Y] M[Z66::-R;BN?$B]N%>JYFQ!9!Q;-\0WZ&MK,GJ4ZJ*ZLG'KQ31(2,WT9:3"S M%TS-7I3.TB;_E2"=97@..@T]4@TOX4\U/7SI;8Q4=2?XS9YE@\X9,BRU7RQ] MJ>H$1!3%5+R'G/(O7B5VJ/O6SW0"VUL;K<I[:;!FW\)@@8/(5"KS)7"Y/YY,HBMLQ^OZ7=*8C3M7%D MOGC9"Q6+%IEI$SUU^8K&O(_&Y$K9,ZX6]^&!(?[%[Z*B]T*,8X)')F+=:DG% MC(R]>0Y%UO@O"LVC<$-A>J3N+]WC'*@Q\47&4[S%$%3O/S5U$>)5M5CD!4B\ M ?#;X;JV6M'8,-U-WNY9PZN^WRRO.L:_)WSP=,KO+PA=N.H18'4/98AN#JPD M[.^G$^!$[L<_(C%F)%BACFS8"""6 (T_ Y/3+UE25*T^!5F3K**C4YI8;?+A M/OHJ4<;;B]=BX=0*?R+@7B"@/:]>.\E.&'XP77M/62+0+DJORWC@%5P7%8'( MTS)H/R$/0K4V@DH*!>/;2?MP2"CSV6ZW3XAO;C9Y\&XE[J:F$]\Y7,B#" URS @XP@JS1'4M#H_T(8<6\#T%/K+IK3SK M,T3CC';2C[QR*!IJJC+.B#'2,JR]!!O1K2V&()[>BRZ>XJD@8(/^XE%'E*#* MKRG%TMQB*\+5)$9?A[Y9R:J#"%T>5:%QS**RT!+=1/T'@Z.K'E%$12MK)RV< MEU0L@D.,WF^1(5"C8U5BW@ZO!93=5ELC)H&EBDJ2@ MNW.:WM3!^"IX>G.;N M-:_68/9$?%WTT7O)D,TP9%Q9MGD\HJ\D6&."W>YYW$G]!N;L,5?( M+4TZ-PAFTJM0-+LNR8.7@Y>-@[[J I7>XL>?O"?.T,1%0X@<>HHLL>9-8UVV0CE2HCDZ M.-ENQR3*._YX$V.SP:46T^4'X:7)_.Z"%$O.!0&]=U]VX")]!!29\)?V L#U MG&-S]#2?2C?*(UPLUP5 %T7!Q.C:5:-V)GKC0:8$X(&2#4EVIQ0>9-S7K8$@ M$-%:(UH0L)8U:B^CIS;Y_D_I/7'54Q*#M\ED/&&25=TP]]7UH)'L\DP^7"J-?RG[ 1(CQ%">\J',@H]JLM*\AN_/:3;]+[9?^PJXA M.#S:R7H])&QN+JC'4SPT&9QITURU=Q]'_R34$5 <>U M>5=S,6GC@Z-B' AK<)E.4\*_T&+=NN.;/6#8J \_ZAOU67[TW!7&\Z!-'"H[.3C($6)3 MKK2!3MI(MF9V8KA7:(S].,SE5(>H&=0T/NT L'%/#+/X)#XUQ^Q0/@5]LWUD MC1P1/[:V8I5=2"?ONFQ90XT$XP_HMA]+-<]W9:7N- I8+^YY9*^Q&\,U"=Q7 MT*-B0UH3>+GQPU*D-?=ODQ MY56N Q$O=K]>WEV^ M.'X&PA6>DI\!V6?@YE(MPXO.,]=SO/E)0/S.\9'O&5B??-FM0/_M M*_JR@E MT,#6_/V*B;]K*!O_"_)?D/^"_!?DOR#_"R$ET5//G9=TJ@>> ?68?[RXE##6 M54[_8X_XO$IRLVP:UHL8C"T/\]]:]RD +H5S?[??3^Y<#NPM$4YP MT$6DSA709ZDI3:XNDM-[P1;,=O&N4X1OP)"&?/^UW'XMI5HZ"8V6JIO[6NUB M!$K;2EZC"[Y?_#[_J>QSIO T%YGL-T:O0Z0&6&%JGI9A"]JEBC2YO-9<$1-7 MG")E-G%>D%>?6N9])M]TN,X6K=DAN6OPOI;8U"E#R6I(Q] W)J) *PFZ6I), MBA2!';C$FMK*B>:RRL ?"'Y%L8Y(KH:UK4ZQ?)*D3I@B@K709O1G(&.?8"H6 M%YQ=!.%'FF,AU\^[P(?WGF<_OA&+9B [LPC:>[-0-?-'?VB7D.\L+3S*1PR& M2"^A,=O$<_89,(E1&^Q'Q6-"N,T_>,@O-ISO*K[\;Z071[!\N_S MS'_@[ W^"_3_#&BY!!!A!7+Q)RQT]6E#6HLJD0\C)(W&A4G]\0SDFH7?7XO/ M"^W.K3\]3OY5Y_X^'[T:OG.H?0::[?^J7_\XL'.O>$HN%CI>_*O0_6-.^@^< MO]7$_PC:.=WP)>?&@^DBGFL!(\J'+59(1^3(-!-)YJQ3*TA10<50_->#70)1 MOAE"IJ2=V!;F0X%OS<0$P=L.5[Y-ITN:J3&E#69+2,#ZR+T*DMM=28C]2XJX M"RR6LI;FOQ/&PQ>L*DE_X)[@@'?F>&L&3VJMQL7G@;^B4G RXZ18)6YTDR0% M59,]F3D:#JW$V7=+]0;=C:.'/0@V6GI2#>J6M!7JK$V^%Y+P>JJB?: ?#UB: M8 P?H7F*'CPX21UZ!DH@-1R>FV!+##>)5XK$Z&;Z!EL07E>81]-AWP=;VT(M M#O]TM-N@F# )%?QN>?$;9<,_)Z.'YH*C60O\F]CQY'&A'6@>FNACA6[,/G,R M#FMJ1,&!Z0.2,SY6W2?KYQPCNZM+Q+5FE@V=4@4%4?4IZ?_$SPV1M?][[O\O MX'2B7 Z%$LD@%&FWSFN0)QD#N8)&GE4UY8,6VH#O?PB_@:93PVB#:"S" -+V M5\/[8W7]P_BF;SM:]7Z0H_]F1JZ[\[PKC"GF#!5@ M>M\X>FL2:9H9+UNH2P?EI_BUC'*/@N;?95FQ*)V#6Z0AKDA0( MLSH?./TXNO ,1)CY-[%0'^RZCIWM.(ZTP@0;C!O1[PYZA[/ML).-N:O/ + =ZH9IRF-A2Z@-"7I7I[,/AU$(ZX M,"+"MX#6[XHFP[&G7!WKI6,F743+WMNY"J<&([>*!Q^>-@C%MX-*!*/7I'N& MYQ2/P$2'D-Y'-NU8L!U_H_1Z4NK MEIP>*LLW8;3Q&\9I(XRWC?6YQ^(IK-V MZB^AEU'6;9'L960JGV'%$-DNH*[!3A8KQM2A^J'^KTN+D55.'K>\K:\>><69 M/_08W(\^NHLW;ZN*^7W&V@YO)&DI6_*_",N)$KJ;-F,:H6L_RSW1@;^K\OH?X'^KX!* MHBPY'"]*Q#W=K7,P_-M:WU;-,_1JNO&F]Z8L\TX>?/1TTO9D76(.!6<2#U9"6*H) MI.TW'#JOLR?&>E$O;IT2"_P.7EWOWP1=,4^^DT-IS!F<68$B297\&;F8R0YS MBE#55Z.PCK;G@7;(YV$NNU7U="9\N)_.WR48#*LQ M9"PR1$O&ET,)& F;;-5!I=4^FV+*GY0M2$ED?<16T.Q*_VN#H##(KSS2,-X# MZ?"E/[("KCFVA=XT**Y)5"ZR7OQH-?/WOATVZ'D$6W-2R$\Q0B\JZZ-_G@'Y ME"'RI(IT33$P0T1G#N+LI[2LFU+;UFM"@0,'4RZ8$9)S%FK.0D?H>YZTA6D/ M0HV35/<>C91EF\[+IX\I?8;>%8&^825HO+J&KO9:N]S'R'SM].2 M4JIQXYI1. UW/XWKFDR;K1&2HZM3?U1/_:9D+ODDXOT,[.?O9-0F6BK;'6 K M@,E>GQ[*$+8V"6G$303K42>D.8;6&CSPD'J5?"NF6Y.%7"VB,JUK]AO._G 4 M;7T(0]_6[%VS,F MY]G42.GO#IZP'KI7M>R_*2?FTX%43Y5R(JVO/!ERXU!*OW@U M?]E7O@BU&5?]64FO".8V3@IM?P#;%(&IA0RS\T=.+K\*9(;Y)V,K:.#Y87_1 MAY!_/./-0"OJ!N3A\HIMY4]3DDVB:A;MR9ZVD6^? 7^SE$CUZ?1U#&&7 MZ0;KP:*&.5<\N"M6;50]@NOORPA;U6N5R#YVUGM3TUV^^$[Y*GFED 8:>WB? MDW0VK^E'TE:;SV^7L[3TAW@R!I9];'G<.L+IK,>SL++6\KHZ?,^T*$70\M8H M%^9H;/M.1834G]VXZ="']#H^\3:ABB0RI_.:GB'J+C!6J*^^,8;EF+U)YP1- MSLQ'XXOEY%_MJ/CNROSCF73\3$7= W JC(V29#-+V[#Y F?3><3B1&M,&0\:'CNA _62E!^N4+C<61S,>IHE1O# MU98K@6> :#IMTFR>T/WC8GK=+RT);DK]_$N2Z'9^=+KMM%N=%<=VTH$Z%HPM MG5\]@^O3Y\^ M7X.QN/5;?CF^&4!E\M4R9KD(#3I,X2DK,O5LW+Y*5V)T8VA M4,1N)+M0JJZM)]4^H*1F76L[X*(BRT02WN_S@'2/RL35 UU$E+7J+VXE<\;F M#0?E&"Q4!%Y)'KNI9X"-6OS$H+%ZM@J6.C8OQ+WS[FY:L0#G8QX XP4R5:>; MROZ8C&-,1P(VO:233K!8!6,KY[S[?S\JD! F\V%%ES>VTM2VVO2(2(_G!^MKG[O'BL-I5H1N2-SQGWQWZ*:$CWJ767 M^_Y AX*3ZW3&X:*=4:%_41EG^[3*P5UF>= :TOG&(%']H^5)H/06&B MK*6 TIZ"-2/F.XZXHBR+FHKV^S$&5H)3XH"3SA<6&.E"3YD"N\HVVW]0A2TZ MZ]X0#NMUVJATC67CCO\YV831P*AW3<_ZIG+^O8C\0L>V]F1_$#V2Q=]B.'/?> M78;J3%6]'3^0FQV1="2C@R6)AZ,*OR>S\61<*^>7-,J7,/]Y/F'1E:[2VD5+++RA5=1!A? M.6$JW3GCQ@&A%MF]X .KYH%F1D',][=XO2MH+(-FQC73F-JFO.8+*793K#18 MNG#DO$>*PBW#\E; 6IG=(>C+^(4YH@UERK4LM7M%I>Z!W5Q/$3/W2DBJMIG1 MI[*ZL&/%B1+R-\/NY!"TE2YV\%P:I,LE,N0R#36!)L.+_/XSZ?FRQ(:(CZ;]@RDL#P#R^1>Z)6MSX! YC/0Y$=JXOOD*OX, MN+\6' 0]G(8_W6*[)Z#?KI,^GM$ _X+[%]Q_5SB M,?5*D6;CEQ[X=0&>%0A027I@&9TRL;A4&V$M.?J^P!;AK/?0S*8-N3(6V@[Q MO.XI;O@1$9%-G/$M0":7:R*S8,9$?3*^JNDL2[; T:O'7>3 K-\>E4GI1"R+ MR>Z^C*J,6TU^ ^-Q6N?\4+OU'Q@YC;U4E?0AS$J_WX"-1+%HU07T9NJC MHBYGXT@(3[/]_Z#UJC%88ANL.;18VE/G7>T)J2^&*Y3%.L8Z6]R['$;+"JF? ME1#?*"Y_C*'KQVR;6^V+"Q?4T.,&C9S?JE"AL/7R6W45DWRG4!AWD&71,@-) M%6S_+$H51;?D=BU7*3L@F Z_"*6S),:1>JP>VM8:Y9LV]'$' ]= M&7#86.G&F,4C/639OTEMJX=BK6:'YLS:2\HL9*8RV)2%[WG*93LHS*JUO@FC M4Z4(%7]=YH5@<&BL\(2YY3[K%DWK9M%?MEWOV:XA5!Z9MYJ%_*!^@%!8?SA M2^82&^5)=B',;WWYKT\P\8O@9(N/J?[ M$BBC+X'RL5Q#^^3,OM;W)"1U@Q;Q5"@@-I/.G4QH0H6O8U1CT'VK$%7M$'3- MYOC/=&L9'#OVK?9Q8S)HO/J%8N!8+JZP!TD[WX^[F#('Q_7TE8(7T"]Q!A\S M1>=L/ 304@_ZGH93YJ[V7$#_CA'^[W%J8]258&3.,3Q!DT-*,',U5G%)*Y1M M6P#%M45IHTV,*!TT09L$"$Z" M- X-2? P1V"6W#7)A!<&@D0/'B0;H(T+L'=I7'7QMV:YN7.3.Z=]]\[]<_[ MWWLU[W\U57VJ>MGT:&D@4HK_13ZY^;QLYK1H97%QB6$'ONMEYO'F&,H86 M&3XOD!Z(F+2Y\FH'\WQJ:C E[],+/#Y-EEU!7D(FK3,CR]KM##CD44,(9O4+ M85M05I"EV6TYR%KLN-ZJ&,AF7RP-@ZS\Z,&2MJ3K_]N!_L((3:AIJR>AY:KQ M53:CIVWH.976=TOWE$/_ZDJ[TO 0;F +WM'F ZT99WUK5!JM3'+_LR:8Q3;2 MYMZ$A4/P:.*LMGX(3L %3+,BVXQ$4_D.[W"/,Y\Y+2 &>Z/*,'XTUF96H+WN ME'_EZV X:(99!EG.\4?YI/63KQX)8VC1JU4<*,LU@'_=,'J(Z!YA4Q _4R0@ M]T]HN^0"';9!+I?5"N3"^:4'5 5#D&@5EZ1*KQS@^3;HZHCA-_2I/KH&!#E. M,>=\8KW5BD?Z!8!S=%IPDA@1XV9=4J"5XYZ5I/+I0C5'[!KP3R#X63C9'9QW M09SK7VH=BG.!(P+\&Z06DE\#\,W+761O:+*TROTK@VP; K."&QW/IY>A!?@/ M87D;%P-W=O\RQ\@9K?PXSC8 *>05@GNMY>#=%,L6-4SP1F==/M$0N$ZA0CHL MQ*/[ 'BY#/4'F&F[]L;-![&JI./Z;HGJ7S&GEXRRVL )'*.4>51, 'E'""HH MGD5DGP%)+W4_7G(>QL,;+)AXISCG$Q=S0U@:[4Y[,>4U0!.PXSV,BSF!82^( M?LN(.;QL7T!D5N$_(H.<5QNEM[\6WT\Z*<19NBO-.\^8.!O MSYS#,4'SVJ M-_(5R/])*FC AD-:C#!MT;\)FP*1'O]-6^&W)Q;6%\G$Q\=J#: VP55552E7 M!7W1V5X$:%D@_->VNPH3KF/QU8Q>D1 M5;=BF:5;N@IN9 ? 6#BCBFEEK]31T3O7BJ++11J950?D0(Z"'YC?JZA)T#CC M_;B*5&J^*,]HW&5;DG?;X0%UF%0+"326J_)8VM$6V;Y?4?EY'YAW#+\&_"4O MP\#NY:7+DRLVJ^">C.S+SW4?[57K'P['W-E4.)3/,F+ (O.N 7=/ [%]^OAO M<; 0GE7,H1;D[W@U]Y#N+C-#9G\J1^W,]-RR[>1N .LV:VM?@O UX&5\6"7K M,7'!0AHA?-F@[T*DXKZPQM-Y24C[.4KJS]$#9RL5^<$#"TUWJ_B+_3>Z_ MR?TFQ[A!:V]J6&"(&$XT_0O&4J/:J9R?(]RWGW[#_7]]G<573[E1,H]-'2H" MK6ZJCR$"50L2*-)?_2X86DL5L'0SC2UO)WCBL [H+*+;*R-P36M7M%![\'7) MP7[^9&U9KQGV4\WZ/B./JI:8-[WPL_(O3Y2&,$+9X>2ORXH!-N&3[E'PA MC?6!1M4\/ N[@1VFV),B_1S84<$7<>RJ??L>!0K_15719LG3PL%!?N(*;4/T MW)6=ZI;G(\'[ZQ]S&;\9DQ!]EV]WBW'*_$45CO"BNCIO$5Y MPO:"*7AV+%QSC&^T6:]N)1M7!\$[" "H-W9KJAVJ9G>EFFM8I]&G6 MOBSZ69YQD##I ML"B(/>2.^8L"75FO251U MN4TTI2W$NL-:3 ^(-PZU&ZTYN0;;(%,?("EN:B%6#[W9=)3$XWBF50U4*C5P MUC:3;YXE'NT-AW[.DYV ],S#2;)RJ0+A"KI.!9;Q9+%]*RXAC^^,-[8).6SV MZ@QZOAMC+^.I_SAX_)K/^)@B-;;%D;*5.!@4RO.!VY?,',="7"I+?<#)A)>XQT+WI5B/N[N-D""*POLFQI*;$J*V_S##?":.K9_^/N[E M\VHKGN8Q?F<*^J17OY0:P0G[MBU"05ONXA,8-_O!Z/P3@_?'L5;89P1B^^VP M-&NWH_B[9/=45\1J"&!)WC=WVXWT(CT'='O6N:]&W2#A MZO]60:S )5=C#L%F-?3F:DL_<&FLJO=-(_K[P82<]WOY>.H^[\]J6F( -TYV MPSC:-$5+^_Y63?^L>X0L]AEA=R(IQR]6J\TQG#G:VJ2)+Q3;6;Z/W[IBEJ4. MX54E"G]K\>H)!8X(1:$W&'(PU@)RBKDP@+BO'PQ\X##LT@M;T9%% M]J@Y;PBRD5(808\W^Z\!"Y2CWH/+5['52][B3 M-FZ=X88F\W,@P4;\DQO$L5^*FTH1.)"U,>3Z/TXR?PL+H_JB($(!"L) 7B1 M3E*3J@P>5<7RMWA)5!S =_%<_<&N@GE!,BT@CA,[-*2I0N,-HRH@[RGU$7BU MGGZ84'Q4!4X:S:?F[F/WXX@:)+]?Q%:F2Z [F=9T*@%_;=/Z9?) MJ&UXNW^[+=:53(HV;J(R6G!MGW3=$A':5OTVS;7_R>7^'^^]+'@OP,3+6Y@> MYI71O*Y![>Z.]>^%WVNE,GM/;19!NRO0KT05J<^'MC(TJ';X>!P?_["',FV< M',&]C6V4XL=5ZJITKAY),P4D%$Y8=+2-:9=X+>L'@/SU"L(RP;U/'-\N, AK M,+_*"&$*_M<="HK ^]RE#DX%L@1R3;,DXR'A/G8CR4ZK5<7J7Q<6>D;["E^0 MJ _Z=G_#6AQ#K%H&P7^"M%KF&MDZ:A%*\ MK\,H3&LSL-U2M*56\]JV>STROS7&W(E6ZN9)Y/,//TXZ MJ:G.ON$%_,NG)O 3R(7;'RL!OGC!L*G6D-T5@$9&P>__H%\93FX2[/)]@.&P9%ORN^ MN/ &+;KBR\,H-M7YN%=_-N>1K&&,)_'D-."[(?WK6-EB8K-$M6*]8^QU,=Y8R ME@ZURA[O=G-YT6% :HCQ.46\[E^TCK=S_]%K)53[;IR0_1;0^>8WS":DC:PN M(G>A\5%VZW1I6;YG+JZ/0.H" MT]"YKJ9L/J68L,![C,P9O<1:6]"C0[MK )3A]VG?"+5% LZL. M%!)*M"CMSM;2LJTV-$G2BZIE!,JTE)YAA'%EC'4[!5 M)[M7^81/4,RE^W:%RSJG^NA.K91]'A&Y?B"=FA!N 95O^B"7!IA5FO=K6W'> M]+E^-.Y[7/=1U//AHTW''\.K)N<5[WA,Z MBT?EM(BI'-V\\>VW%H5_Y6WR/*#3 Q_JZH&CJ9X$J_?L6%IR^0WU"MT'8KX;8JGJYYY&^,$ZWJ$<*T7 M[:QPERM*\CSJR9#-C%BM2>J],X9Y.4EERCP8>@"19CDBUP+,F;I%5J@".Z\8 M;J:%-E9$4_0[$)@BIHNQ7ZIS/X)?#O#AGJXO^QIVQ M=6):5D?]\.4=B2=!LKWPD6W*$6CMZV_Z,>E/3W@QF[45>^4)1%3:D0E)>S JR$O!5JP,\V2=W6F6@^C+^[/DSH3OKH2RIX?7IW T^YMA-IQQ:L]Q@T6IV'C>.#AQ?P] M1C9"98JVE/?(I/\HES5(Y7[%$P">CQ! \W]7#/Z?D@T0WU &VD?%]_IA[+N=]A6=M']XI)71 M#7[NW#N9QJ#X%\9B-\2$1-LUZ0997ZAI\/R UD7S73''CAR%UMU9VW:VE_RP M_3Q5;>+[S9J,JIDGBH$J\JP[IA'+>$H]"W7M9ZK]_U5:*74*)T%I?#),LZ^F MR H=A5Z,FOY-D@E-G#"6V,'WR>ET##6@U8%L MU9\[V#:DQSBX3?5]Y:T++\LA[&]D27B1&ITN]2)EY/CA!*BK:M-XQ!1DIY%" MY, _$%^_ V,? C.6A2[71@C-WPC+]6D>AL2Z<\<4J:/7;W%8)9&^:G@HG)J1 MQA9N":ZJB.P8N ;81L&ZB;LMZA^ECM8/9TON/$EC2>:_ D+7C@O3I>OQ/5*/ MW#/-QYJ70 T[W9D;AP+YS/UE_82]MQI,1W77 //5Y:3>WXX171/4M9],*NH3 MU:*KC[='YHO\\T0O-^6N'AQ3G#Z>;!J6?]Y.%A9GZ,-,HUI? M-K@P)S33&1782=!YR',&=%\:=+(AUOE\N^?NC$9$![8^)Q,_5'F.EGAE?!CH M%ZO2S]--C,*$5K>'L"'-_2/BHFFMG5;SK\^^53$]LXA)J78IU$B M_1A-J,2P#.U7L,J%YQ$!-B+U1YOU;AB6YODX@X61Y22_(?L\&O&C'M9VHZ?[,V*T'B>\SV M7]^ @OP:>&9MO4V#CT!U:U_5+N=JWWFYM6^\K><9-9HJ_@"[F9*7G-:"='V./OR+.ORE%\/;U-" M\X#XA^ VG?2($,=\>#"20LTC652D'5Q MC]7+V6N XRDBF8WI)%M-ZOR8S\Y51A=.^>'2D5_Z'PP^=M9MY7_-OT1M6>&$ M7FWIM#+H0YQ_^RR,C$B-SF,QG&/ZE2_Z8.'2ZB.;=T[EQK' 9JB?8+P2*6?D MFU3AU-AF/?9L&\BJ)]@3K 4HG9,Y*:/EN/=*9K2%.) MGI.N9==H\(!Z61AK*/M];;DE[Y);*1XN>PL"Q_)EB\SQKP%Y,A/7 M@-D'3R$%JOM-8W&#)M9(<(T0MSS1!N/00MK5^-1%R-K:OM>E-LDG0\G2@TPV MUU-PD\PB2[+6!-,:UKU#[_QV7@;**I':"*\H0ODA5L6^436D+E@]Q&K'/38M MQ'%C_HU@_=LLSP[E2""*.)T*GBMS^O(#_4 'SI5E^%Y?N UBW0#K''>'@Q]Q MMU%A+NH8DU^?:YHUOBR1GY %:J30:M!>K&*6YM)2H2QT5/R?I[QC*\- MS]V@-%>56&5^1T>:,VM;07UF!*/GXD4_X?@]]54[CD]/^!%E0PI$9N]CZ:NJ MT6P&X(M7<^P7J:./&OR/#=)'25B;!>N!2R')KA %A_C4:2^-8*Q*SP_MPS4X MFPU;H%:[_9OHSVZ>IZ:*)1O5LDDL5@_9Q>]-?C:Z!@0CH%A"B4L)C%M13&I2 M_40,B!(%*23VH';+7FYM6+,1S)Z(Z47S2IH_/0$4T6QJQ.L2!;1UR=3 M%0Q#Z*:WE_<@^SN6T8/&E2BD@K&IA;,I*S/W#?K3H/:-5&2A&7^45=N^5B3Z MDKMPJRONGILK&VTTT2<:9,Y'[;9E$DM'MMR[%>2+?\*!P0=D: MV.Y]O"1L>C8#9.U+ NBT_QJ@6>7U1GS.\5"&HKR4O7.R!D>XLAWD#PZ LU*Z MF2./K\3W'5U.'JSDKCMEML_56$UZ@RCP7Y)B"JC66JOK>N1)4PS5YL\M?7&+ M-V5]/5R&=/LN;IF/>*-W&&+U(CY=>2.36>-KR!:+WI"M=.4ZS9@Y#;1\4'9+ M9KD4D@4]U-H8SFY+SP,=F>EUAP,Q2._P^ MU;(C\9WP!8_0%G%;JVUW7XF>F3/06(TE)3]*+K"[/.AE 95&?4X=DS+CH&I. MH5ML,3&S3&+F*\>B>Q(D="-WHR[?YJZ E&8KK,IJR/D>QIT,MJV=^:S"!S6_ M^O\GBJ)0T2PE"13H$<]*V8:7.\\1IH954@JG0.Z[^&*DG@2"&757>3S *GF,W)%Q6^*]SR#^V_K^&E!VYJ\*/\R^#VTQ)VUL4=F?B]C^]W8VG& M4;D4'^ED%?,HN?FHJ*2U]TW"(]+-\Z98>V.;Y FA!%2I+<[";84HF.ZZ[K,] ML2G=\9Y=JUFS &68A.Y<]VSU'![F=?'(B1;ZV<<=&$[PU52:(08"6U-7;N*J MVA V2WQ=W=MC,W.Z M@/15KT2)Z6B\MZ;U$KERL5-J+^UR>Y\X.S03)1<>2< '%;2F&UUNR-LPR1"& M%:1W@%G=PM6W_M,[G(JK.#'])*:YA=^8G>'#NVW9;*_)5S?L\E&ILBUW5=YN M6XWK)2%=AY;EZ@.(6.0>:'/=,AO!V5IMA2P0<[K_T4T]\.9.S.;Q-[R^D$,A MB&KU\$ZTA2&@0G%#X,J8O);PT6?)I-&Z=R[XL MQ3Y+%'\UC[A2I!G.D8(8@.C?'<;HR4<1B,^]5!/%GSALFS?1S/U@9BTXWH76 M,_OQG[1MTH&4)V<,H5EDQ"CIP3T=NL2[H?[7R$657E%KD>VO"AI M;22HYIR"RO]#=5LQ95T+[(=OCP2M#[\ITMT)64ABRT*RSV+W4DQ!H_IEH!67 MXH%X+TO?*R/OY@&\T6*53\W\KVI1M9WMB[%ND\"97]%8S>[G[_YQ2PZI3_+A MZSS]4/#0ESET#$,Q6%P]Y- XK=]/\:,H,%>3.Y$G/3COM9H?;_B3 M-@*1IF'5:1$!ST5AXVN J\O%,6*(T3"1+HY>+3Q YW-C+\T@*SI[DL/,'+5V@&#WP4E$(*YH$J\.F M^&58B]W%V-,0WJX-W>Y.3D\A3Q+*>JT&[M!!BWJZ40-U>*KS>^ZX8.XU]&Q# MN'I@8Z)_(Z?%$X4F_F*3V3F8S5B.'B$86>CLKI/83!9VH]V!$ M) 3O6N6A\ M.&5]GK[&2?G-Z\DU *[5_%)1:BPFYGA@+=60H?Q[JYB[Q2/CA116N7/:AF3H M70@;].%#[Q<_GC*:/",6Y?M)<7^[$ ,R)R%#JZ4T5 NK7 - 8W%07(U./M?5 M:(;.OD8_6#IXXCY1^EXK381K"%*8D=O66TE\DY:M8W[YL1TL'9$DO>\T4S^. M).)L'^[5JQ>N1PZ#@.;BQ&$3Z??9*PGN740IF^YY?4Y@E^*20#_U;EC2D+AW M5R8QR7+8IG),O;-/$$D0C[@&N!69?Y^8_6;I$30':4Y^=1&1D7!5G.N5V7%I MI&MB%SYSQ3E4F:+57.&NF1#PHIS22/?^E9B1VNMH=XJA4,U4I)BIF6+9!656 M1.O7' Z/^:4+U7!%%[H"LS\LDCC<93'\1?=[;@>Y68.U7L?PA.<_<=<^O*J# MMA.7:I-4V;SPAW,7?>AT,V=(M:QAO,M\D!]\/TT;3_3H&U[]J?KPT6:HI4?- MEQ#+O%NVZ;?B#6QQJ=;@PI=*9<.JG$XTC%'E&;0?=];RFK[38E7\%O.B%_N; MA]M3HBW&(JHV?1U4?UETM)_-JJ'-B5&J'+1NE6W+8\EF083,WN($?Z/S.[@K M28.]>(1D5EX$L)SV@5-Q0D\+38+U*DP:ME.*95()?"_:>,N=;*%LUFD&PGOY MY*3W&A!SU3LE-^V\N6IXA A\>PV(2FOQUA5,X\=+$>QGL,9X[YC=_/;'FXSO MJZGDKIC.;,D8WNDM(F_DDS2G:X P])Q(#;CXRU*1+A&V"H;O\3DC<0 QY]> MEQ: ;39P./<0:EMI3BN+\N:YCZ_7'?ZT;#O^]I8SPQF2* MCZU1'S,OY.OFE MD+6BC\_KE37NOF[M0SZ1]#,_<6ZW^7HT/ MX]J9,R0+R72."%I=&JK56&(DT9@2!3M5:Q@!MB$1PL22U+"MB\2$ MAI7][N55=3XYI'0C>_9ASL-:[_&*,]#*B+R3ECB#53)0):J;GI^ M+_6:=5F39.M5Y/GJ^[:@_HWG0G8HC M3$'6'BQH;>Q(V1"8X'"'YNNY#X$'SR)$>]0@NN"VKC!L1%F/-H7G@#^$J>*W MJ!369J#]:5@QXI^.O]*B62\4YI>DEA4D?I]_?TNS+0\O/%M;K__40-N_?]:Z M>1^\&+7A@&8[=>@H)OU:?V,MKU^NJ09(.BL/UY/(39O1F.(V:C;U3+O2;Q]) MS&'9(6$8U^HN#NQPIL#?UK$M7'\S[7TXU]&D?)55MQUUPWSRG>H]<\K 27J( M]ZKB&P(/IKR?H!2K#5W\ZM@GCI;FN)=O5B&!9V/] 4>724_)W#Z*1K^^'T?- M 6N/TL+^[JZZ7.':OD!B&WY$QZI-/6A2IT4%3-[1QV_L''/4!M4\?%!'KC:\ M,]LEHQ5%_5&?. AJ%Y%1UXNP5I !YQ ]C#:FN+^\MK_E.W].(JF/>Y;\:[#J M#TZ4N -7,E&V/U],V[D@.@(%C,%RQ801ID_DNU]'W/B^!23M7]*AJ_"M%; , M3S22\S*FNP8D@$.=ECI3G"4@\+9[><@A?QZ2$O>M*OY5'/W-H.T!TXV#" C9(?GX=I&- M:15WL;BQ?>O[#\!LI['4>U\?HY*^0IWI;QY#%MZE-?*(+X0])"%PQ1.EAFHN M%+%XB?62MP]N'@K8;K[,FHQ9/;24C^J>Z#YLS,I>BZ& ^4=(D7^@KSI"H)M_ MCA7K%^6:3UT&'Q2MC6!C>\\:&K?Q$BB/4PH8R]]I$RR$%NF,GV#UI*?VY$-6 M1PO%OG30U57H2MD^#![@$;H$8>O<7W7E53/CTQL]C&*<2I$[\E_/)!X5%;[=%';LSYA4X?7DV73HIRC0)/KE,M3K6C:M4@] M5'*H0NB[U_5A@"M8\NWW.9H^R(&4/+XCK MBA7,_I&^LEH[F.=3L1#N,:*[O_H:D ;!A#"_DU6.+\[=*VJ-$G^$/= JZ276 M^GV.X4]G7N1_P!46@E89X4AM,5*!"F]B/:\!!PR9?UYY,VH?$6^3J_4";IT# M5KO')2FL",0I'O>+2''0]JQ&)ML](0CD75#+*]*H)-#1ZKQUX=Y)%(HJ*GF MK@Y\.4=M8-Y.]1\ WHR/!A&52I M_=V _:;U[<'_EPD_?OI8A'I/%,'WA:0\Y=?7DHGIA(%J'(ZPH&:8Q:;G MW_C"&4=3Z%TYZ._V:DH$EU%%V]!^>1I*'*/ MA94-\8*IRH;A%N\UP#P HJ0C$>SY0+@T#WSUC>2@$XND_*0JG#F$%&1]C.6A=X1JY% M1V%VO+/V()I;7/VWUS5UR03H$A6N :QLP@[G5+CSS'I_E\!\7FB!DK-C4QA- M";.>*U1R)$?#ANN,+DH$)V1^WI'"B3@![@J2&-UN:K\QT1.*I/LD\O.(>> : M '&?_KO@2L,MHLQSB^7P/3([C2KVZ7UL'D85JSK6O 270]+5-K1*N8?'![@]%Y \Y2O-N>83,(W<#PVU[[;*T MSO'IF: S0O4IPK$3VWD&7/EPMFO JGXGOV:SROA1(O/:5+B2LK,ZXB4B MV&]9Q5R^,V)T8&,.'QGZ2(A5XUF5T8)QFMU'=PK\1(=N"SK7FL]V=C8JAN-F M1;37@,^7K3S0_5V;Q_V8_0I63&<6?P5L%V>*\DSI:DHD#3&H<'P_=-'NI?$/NDF9(%YI4TIB&VB]2S'/I9<)J0U)- MS[2+]6;J^2FBX.U^&_R;1K/9'NW)-Q-V!J8IKZ3A/3!2N^I[D<#8RA-!Z;7R1T:; 66[)ZH)0#PX*_Y= E)"H8G6G-36 MQ'^ .9K_ $G :N^'YT?@[PC]PI9?H7-'%,]_1R2JWU%(A)3$FZ"D/*DG87(> M+ZCYYOYQ'ILG?4Y_#%GG3>B/"5!4K_D_W$0!;_>SSA2 6V?&4/C\S,,B4[S! M->2&MY=C@BBV5TX93_J/$+N_^\Y$GA5],/.M\@>0W.F.@@B5DR6XA>?N&&*3 M_5PY?7D-:544"$XZ ;J\F'/+FH:^&YN)"WWD_S.552A1]%2F!V\NV^+/'@ ^ M3+ERS+RRMC:*O*"^#X'K)#5-&L7-*MMQR28'$P=#X&;_T-FGEO/=H@\*M+N, M($Y[KR!XQS"Z\J*%O+"HXEM6'XZB! M2'-V.V*)Y)"*#\+L!3P;.[9WCP^0[>30U+Q*N2SZ>C^M&6GR(K?0C,6*MN/I MN:I")0XZ%Q,"V%U'<#2W$6;&UHE% <45?)D5!-6,KEY!9@T@V0";08U[15.= MIYIS^Y4*&/2#74(QP[*GJN+ZD31?J(0ZOCU",S^0WZ=U_V0L>8,_+-9-9&D* M;(4TDJ^EUH-WW0<,911/M9!TCG[#L!%= YBZ1C!:SQ<%Z$3-1KU+ZQ@? MEN;[D(OCG5.U=9;T"VO3(G,W'F-CT[RR+$@^/FK!X)8=W7_(G/A;\K83F"J5Z08%*FW"UQAZ >+K9\RYKSNCW\F"?G9Z=>F8> M?WR/ZZ;A4D\]O,7VD*"CE_JR\8F -[(;]FA3X:H'>&K2:J0SI:VI7:O&T,W MQ[C$3VY!@3/S3OV\WCO7GY5&!82M_ M757+OCAT,\L8&L=PLQ+AH+CG%'NUI)U5=).O.]]'5*@?J0AK*P$>ETO.[71( M'(%U-]N>E$@_*C-_:%A,'HRQY"_35]&T6"TK4,[:Q34L'.;J]F+JT=)BG$HN MI2KTDE4>$930UX\E1%M9MU-[VI#8FTP@QW6:!,P+QK *':EB?3 MX"N/CH?MEZ'4*AB/Q,I6,?MV SKZ%ROT>7)>AFHHRF_(\#C.1LDZR*3-->!] M?K2KBTJ$WLNML)8C)E%0BLNK\_+]NPO#8UR4Q#HB>7\&H00Z64))68Y.XB%. M>S>7FVDYEHH%;G^W:I)_S&AN_P,\$.'0]=:Z. ]I]7!2A*@$(NVN 7M^\B=A M4#-@Z=IE [>0$'/AWV-A29XX,>4*5GRDH"^Q#,H(L;#XR1OWKXESK6E MD"8RV;X[F2H-YCG62X23DF?F[EVT_*!C1?\F;ACM@3AQX!M__8XM]Y#H0^G2 MAA"&'1KG ^AH=1=ZLPV/XO%T1.WA+&)0A"A-\D>,7,3/*:8I"3^R9TSO_2)% M*?Q2YU>S2XK+_]CU0KVV\I1$,(ZE/8_V0+ZJX-_J,FA MN<,E!/&UFP;ER3K);54"1!'N9497:/M2C/!23JQK^TP>E?'9U5KB1G4X1H*$ MLS.J,UP.NC][G(-E&^FZU<*P5'!K&>OTHFB^\YFA758Q+]^!U'G@96Z= X=V MUS!D\O1\XKP[PF%W5UVI59I@N859^(JT[ATM/<@\P$6G.K-\^+A;QZ3-@U*Y M)4",04I I?'B"-RX?FI_QMPF;R6P.CK5'14H'G:%PO!"OL*O@%)^6KX?XF4I M6XP\PQ)NRWLCJ> +'DDR;B^J AB_A1EG*:5DHE+%W,??O7/3/,NDZ6EY'QU7 M+445<9?ZL3WP-:-E_U$1\?3$9.N-( 1U^&N$/#6>']CZL(V'PXHDBH4&Q&[S M-48=::(IP&@<\3112D>!R*B4 D?;NFJQ/%:7_,7!MYNK7_?DAP=4..WR7>-6 M6$]O$!E].LBX3%P^YDU2V2=RYTYZ%GLK517;U[S+,^!P]G!LA(&_I+S3VE0U M]_DA_R[NQK[%@8P'BP?\N574S@;-*43T(BW;\726;NAH"E8J0T/Z)$ =]0M$ MR&?-4PF'6+=.H?FRQ2T-;OWV7ASV#KJ67'"N ^DYM_'BBYC$ P<*^TPV30@* MPX=>&Z':':- "4^+J,?8.Q MR VL90 +V"!G!8M;Y#OR 6Q"]AYJQH89&Y/.CY"%%DMG'=-S"87S^ZY!N4Y$ MV$.I=MS F/#DR67^$K$$7LG EM]DH3)LERQ"+W;=N 0J 4*_J MR+&6$%4GHLA$?4DWM= +L&/9A12RU-@?RR@G>54R&=#5E.L#J5W#7"J\><14 M7?>\VE\ZG\RZNYYE/ZMZJ1R6V=9O\^QNWQ-6]GXQRD"TA7]#<[B[:9ADY.LP M'!-SG(DSO.-UJJ=[_O&!!@3[0H=L5 ;\'@Q;O_(/2D=!@ZPJ!E:!4PYEBBMT M4BQ7]]VC.H[9-@(-:I%/,"6TQ0R1VDVKFM)L9C/?$(:L5_]/51CY==R,&!.F MW*A&?#N-ZF5M0=6$UT^3QS*>053<3>':@KZ<5,"=Z$HS!:P= M(U[GMV],[;4ZJI[L34ZUW$OM!.O42#Z@*/C5'IK/I:5U%^0-=MM2]\\]=Y M65UAG(&;!*:L\KQ_9<#[1C7@A@\ @ <@*E-+XNNR/G#A7R*F)+C/D/$M$U=I MSSHP?R6G1#T;3 M__*^B"/*]V['\VJS1?2PI1:BC3/]'API;*MJ9(MNU9 3Q;U%=ISR9%$XP8'H M/?JYC$:3S]"KZ3 O>SY0$,;R6V#3!7'MJME1P?NU40[< :K;1N@&()?.FY?6 MX<:,N\ 9C/+^N4$U>O''\59.XB&[/UG9<2A_J&6!1\?;L6$)+HG,ML9/&#$9 M70F[^3E"5V=#N^R>0P:L@.JSH%/=:X"HRJD&7(@ E.;'')/S6_5;Y2[SK*'0F9$&[01A4V M,\G?ER'MX@]00@/!_IZ"ZU-)>=G\Q7E[L(P0YIO_0V6<-4^UQ4I/L,UC?+=3 M)5,CMY\ )]K1)H+D*L,JCNB0&GXFYL"]]A:<0K2,OL?''S+T%[EAT85>=X68 M*W-5OVS(Q)F]3S8I>EP(>;QNDY]E_[.+/LSPT:"_M8)&G%VUS6"6G:-/@>M [XZ JH:8K2S5?KAU>6(.6][=DD9(!I MT#6 C''^,N3HUR5]1W- 7;3H5^ +=HSB#$_Q0RKLT_0H35MWYT\E?RXTX2[9CT/&(A.W+' MGA^HK_GE/[&_!G&3*$\NU;"ZD4NZ[3F&T'O=WO2'9'EY,Y7MNT M]Q_U)#JZS(5B-&'8NQ5%T>,[)[ +R[H#-=00_W^YRV8!CI\T? MJQT^E]3(19O(/Q-UTIF_6KQ_HWEN4[.:N*4SSV)2N52*0T,R@)36H+\89:LH M3X]+0Y]LX,/S+[6V\^;X&M N?_8OP\"_F@I7Z9;7 M "'H_C"6",>D$D3@:GV%E+*&ZYLO?MTYY\_;N8M 7;Y&8=VO 4NY& ;L /)7 M &LXV[@&W&_&#PQW/>A8;S8P#4SCDA>$O465?1^[>)H57M417O+3 R8]/NQI M$?URXMA,_*D5Q_-E?.S0-2!P14?O+_:JPGG9Z]4(G?Y8OFM 7''>K2O7U2KA M7,6 2C?/A(GC296C%HG5"HG$_A57M=90+G(VQS6!+[9-DC 5X:7S3SI]Z0N9 MSIUN664V5AR!*GV 6TY4HSWH68[]^&A^N;@XD@/& M"&XZ4I0# !JXD8QU0FEQ?YZOJ]4V:0!M7I@\[LKM=2=0],,(R5)JI#61W6KI MPLOVNOP:"YS6W;[ &JFQ+W0N#[Y%L;<)3SW?"A\W[=)=!BI=>(.]T1X-C]'% MW0QJ:69B/YLR(G*G9FLH"<6'CNI*91E2UQTJTR<;1&%CI1?'FD=7$:3VK;OT MYR\W=UZB'6V'3[[&]]*5J6U>>:VJQBYHU2GJE5O GM.DC!M>=D)^JIF3)!G? MNO?0^4?0$ZOS])H)20$)R MSAY-W)EVG4T9N0:P7P-0",CK,S]HYL:^AI05Y0C[PV>><9!=OYM@/M!*,UN8.-TS4>:#&41R#6 MXGX%7+5!DF')0?C'6PMAC,BOSP"I64?'+\H@9:S0M2(L/[2IBOUIH,)!NR0\ MJHY)FK^NFTO%9ON!WOGF-2 B;2_S+Y=@_C)>*J;Z[_WB+QI_S.(V_-F"_77_ MOTSD_B.Y?YG,_0\<#O#?C/Z;T?\>C,#ABQ"\*5<_V6A<99DP$\837V68=^4Q M'/B/[)DRZ>]D4[;29A7V4];OD308VK!L?XQN!]%WVK; WO.CE!9 (%':]^;5 MB'$CE7N4[6\_\.+4 1ODLUT@?P&-MDV()WV.)?DN"YV6Y981HHE :;<==^X0 M<1SB[]2IXPX>6#WAR-U5NHS8>BQ"O4QUI!9Y!FV]B/??N9.4+T8;%V1K:-/P M^%AIVL/QJ$BV%,4U=6E<65Y%(#YS5ZF]>,E/>W3O(.MXU 6]CL^\@%QFL"HES7)]TLB3OVKLS[$;$#IZMM4F96TR:)#'R*(;) M/%]VD_8 .ES5.]D/SSJ-B&TX"/PF*O$#&])4;-E+[)P@!TT'96E_L M0OJEX+4M,-9J/+>828SIB-TH= M8O\,UPI9%*NF>L)B%!X5/8CC@DI -?)NT_Q5B7U;FJ M?9L33X7Q;O?R;]Z[YC_;BX7R&\OVRZX![N@SH$"NF]/LG W)-L=2V MGN_97_W?W&R>^W@)F4PC+S^OUYA(*\IMD#X\K^5;U/C@G+BP MC"/%@+H=ZJ'&7HSI?VEITS=3N2;\%?Y]WESZ-.7J(=K !+XS?L&GH?.&\6&6 MT6/[N]F%H$<]Y;H4/\JK(X.7/M]1S%TYP?"K]O#@R]=T64VY[XFY1:O&2&[) MH9?+%-Y%FV6T)SQ_X6[]@5.1_8\E>0[5QQ&E+H+F5L2QO7D)>D9;:MWGDGP_ M!>*3+P[/U4*;728=-7G&5WW7Q[5J"<3L>X*I/QKYWORP'Q$8@O[^#4]WKIF' M6Y7[I17+C9.^5:DE&.UKDG<[0;:2VE1X_&&+2"XO;@\I&YN75-RU=9&"OBQ? MQ%3NY]]KY+V)N",%SOL_KPC\?1 OD:V,(N.#G!XHD$M0.#S.+#JG2AW=.NYV M#?Q9[5WG=M+/+6/I^VK+YS%VV7WXY*G[9@R^AYNC<3.^IM]:9D-"X![Z0"!% M]5R5YJ"ITN%XV5O06V4="5O8?33A:C^ZB)P^D'2@+3I-&O# T2+B=\R[_*)6 M'1RK&:LGI%;P*Q./]/VOWO;N?W(\A#LT3T*#6#T+.AI<,T\=7N*EO=G8UM5Q MLD%X"H^J+'Q]FMV'NLG>A6M0]RL%/28[L5BKU5MH7A1B-0@1I>QAK7\^Y[C? M =';T/FJ+4&SG-;4PZRXJCTXO>0(";H(M8ALS;N;71[;1!",C*$GIDHM6'XRS7]#.UB$*:WJVX*67%T#%'3 M>R/HF@&+JS#ST2^08 >4&<)#;#\'!M^.X,.$QEP#6$S.I83;T['>HP.H!%YI MO"%5_B4Z.D?B/M>&EOTS%[FK"=7ZK_CWJ>:V0?H7B8,H<($.[CN/[LSASV%4 M1M8_U;Z:N:NL17B^ 6._]9ZH?.QJ_A0Q6'0^[X&2(PN)12N?J2T::V;J+KL8 M7P-NN1KHZ!YM5G_G>%-;:R#WKC^MUNL3IG^H3CKAH4+C_3<$3.(AQ"KB@)O? M9(N#9FIN:GG%JYM4\ZQ+*0D&G!2.J4I4U&9.R&JD\ M1-6YS7/X1)&DK&G?UTMSOQ_I7W@QCSG.2*-4BR,.^D1I.?"$1'?N;ED\)^9FE7)2L'>I&SVY\#!NM[L]F:5@8N0$@LW4]9-Y0@Y_ MT4"8I(G7OP#]M/5%C75AE]+\XGAM')-;7DG#@! %HG&.$3F5%DJQ/-U@$T=Q M:>G]/R:.OOUKZO_'_*.)E)'D@)/I!P#&#.=(53QOT8I&JIQP6E=\*D#A^;,) MK ]4.';-/2WLN)]@^LI/PE>=QOO&FYXPH:D?%X:;.ERV2";+DIV>7,U7PWG3 MEK-<0V6L@UQI9C6@@R::#L@VE=_YI5KD7+<+7&_&XO7D:[K(4C<+#>54/_"L M&>@1L?2TI;V-=8-)>.4UX!,/M/FP2*2\W+?OMN\D40CM4V6QG\3#9$>VDTJG M:0Y/Y+)M8&]=<^)!P;7"#9.JJO$*8M3-[('V/ZB^1>#6.4[:M'(_E97["=)@ M[8/\BB7@#978/%=+B=$2&Y9G+I"#0?%?0X_Z@$?OBAWS&V:;5T.438&^;_EM M0LN$E![%KUW M#6;]9CMW%JX!7GAI444\E5+ZE:XOZ#W?MHD*O;(+R7>5!J=L="2HYW! ON3G!W MEQ L0'!H++B[0^.:X&Z-->Y.@A,LD_SF_N^],W.?JJFIJ;G//)47NZI75_5G MG7W.Z;77.OOL_B0:#GM[2Z!YPS.VO"X0V^MZI\G-QIUS MJ245UZL&GETXV:](%WVYGW*+?Y?9QKY?<4_XA!&LP:U$O)^FL-B0M9&E$OV- M=J7IT#93I62-,;(E/T.U8SPTHMRT5.>0Y[6OK<"0PU;80:QI5FA>MOZT??W> MH8=SME2J^$.]VA (UN<*TN^2=&TBY_^QT\P/31H\(>:T/">LPK_8M*BE/1+. M$\=K%J6Q2P^G.*%X7P3R\1*8Y=&\XLCTDBX]G/=,ON8Y<7;G>(-ZYO"Q7\<*W?YM_:T47^,2G!WGB3@L+0+\_:V:XRF/H,]^-PQ\1/ MN@X"L1_)J1N7&.@?[>=$;,.?Z?VXI'BWMCC5\PMXN9KB$/IAEO%!@&6/*/># M< ?4_-ZAC2D>E-E/M9CT"UBE+[ZXT[(3HMSX8?H+"%=H&F03,>QZ_[Z_<;_* MYTM9 ]EWQS?:*I\TOS&6,6C J:,#SP! M:/5*R];7R7T*Y"8IH&@%&\5+B9&D9M<%^9,#?V:GLU.T.B.6%(/X*QRJKYZ_ MZV%B_! BAL;IMZD'>%#3Q"2YRD"+VM*NQT],]49>P\N8(E*78PQWX\@,"G,X MB>=@O/N_NSS@?^96[6UJ6Z+WA95Y*XOZ@8/%_U'#),(:>-GU.$K33*>_+:H1B!_".-2:\NGHL M>WUT^W"#!+_H?9#L/-B*^]@UW5:R^3,MQ%XK=4P _Z9T?X*A<\[Q0:%4MZK0 M#?X[=BE:2-3+H>Y?@)!6XT&:?6-\<9^Y53I5E.E*K(O?F'=GV(\M50/5U^Z< MN)I3?"[8-YSKVW#[(.C!5MG7\V_I4QX+VE:RAFK+#'D1%^/_!--JX=N4/,/5 M= .).?HTOK@!JIPA0Q=,8=&[V7UU38A-JYK:6_6@#&^==7P5FS2[VL,:7<6\ ME9[GNM0U%*Z&*3D?)&N@[\1+0NI:A!SH;^P^=O7S6YW0-# MNK<3J07_!F7,3@E[Z.+MVFF3Z>6#I(=F%PX7OUW[P>BD/!^;'9,_/!_U>86- MT:&TMN_(X#3WYF5RU#%#E?4'WXW=6MOJ1FS(UC##AV]^85<'^A_+SUZJS]+> MTT7:32+SJ1)\J+PD0][(KE00HM5ITUW-3_*2='2=NZH^6MT0*&F6-=4)= MW]*8?)XZR!+'CS#GO%'=NY_T-SORY:>9N'P=J;XM4K[??/5A[%1)3=FJDVS& M#67%SIAQVN\GZ:G%@Q](L^7,*T77\+0_D>&>NVI#$E>+LOF?K>F$RVY9)>=8 M,59Z,>MYUZRR'7X!)4\-DU,:SX8";82NR9V([_F_@[+05)=5OUR-8$VF^L4K%\[;?J[>ED\K%O MLX1^ERD]#Z Z.52)MV3'JAY6(YHH!ZSUR?X_1MU3MVE93S.K[B%/@1B"P]' M=3'&JJ+D)=^\M+O"WO1?OD>P)5Z)6)$R#EJ)';8T0?,-@-MLRKE58__:/!OO ME_^IZ5"F6AX $*$!CS.41#OZ;ZZ$V1Z7BTD>,,AL>OHNR.-Z'&2RD.T:U,V M^M7G[[J"TD%Z)FLT,?\*<_S68)774DA/MWUC,413\3OI+27\KT1I!KQ&CN<=':U]BPT: MET+8EO5Z#3XS>DDA[-A=BP1 /6IL>'C3I$HK=!7<]I1XYI\Q1%7CI@<_8\Q) MB/]*W>$!44;&,"\PL [J49?C__1B;5GN6E+"+.*YU#-8'=VE5&LA',*.')^0A<77Y_"_RWWC==6?^.^E/ GY]\<>W[__ MN?,+B*4X^TOFKYN_;OZZ^:_=J*;+U+2$YZ4MFD6WEN.(5U.?=85I2;-V6$)$DZ M%(??ONG!V!263';D9LHC2GY+=L] W^$SGKU122T?:5Z85DS("M;I+.8NQF7_ M2AC#,,U%AH<+B*+Z"4DQ:F2;+ZB7]*==@/PM8;^ "=8'KU] -,7B==?%R"^ M7'1+TZI*S:3IVJ_ZX?P7,!![._68;?L[,^PZVWKB_J/Y]A\FUW\F_"/N_#\B MYJ"N_8BK M$I<$@!V*6,TD)0MS0BZT:BRT29.!;KLD=\JDNT:]*#!S/CH1P]^O"-P$\4P= M7^'%>.BMY*T"^:/QL6+/G#/@?;9B&AP5H;G0O/A\K1B9 O81] #DZ##3(&D) M3/%7NP$L_Q_H[_VOT.#Z;LO&80JJ)(\B/YG=O6C?QJ=V2K3)L7XI+KDY23A0 M]'MWKS=M]]U\JBIKJO+#>4V[N'PSWZ"G6H-/#*8L=8^65D>'RWFT.?/7D[*'A.?..^QY7BI3& M1(W^,D!1;!S35^M-;K9@[T?*UL^G3=:YX?INEC+==GXTW8QCBC%6Y4_WF7HW+;P']B[TD"UYO@ M_<7/7T!MH"N(7V9)C+'',I4\#ZB4E:6?;>8H.=3;EG'*C M*M;IL#Y<]C&]['%''7-DRX,S\=FP/F28 MMO019X=)Y7HT8=OP)G\:K*;ZUH,N!HJ/\VCD&RR;S\)L: D=1^%F5NQ'XT)# MUTSXA 9U&)^6W;Y( T:;9LQFEK[I2BX\8V]4M&BU'$,IL,F,*X=4"RY&N6!\@ 4H O!RU1Y7=Y]"_!>I'%7X#B M/,7-Z9_*J/-?1NR_Z7__4Q7]G[7 #_]41/\R]O\%JO\+_0O]"_T+_0O];X26 M4J:/K]R7OJ18T[MX:'+JKM-98NX)(]EDP4WZ M#LGBG*ET(2?_L;,<;R@4[ED@[N[P>00]E\X:+YS#.:Z8\+W:&.#)I4%&+_\T M5,_S"W#H:!])OF"EO:#(<,[ Y"N'_O,(@^"_6U;K+^XO[B_N+^XO[B_N+^XO M[B_N+^[_!5P66)K.0Z!1X(2_Z-]UH0](G?=,&/>JIB( ]_]R>76L;Y7UN9)S M@=ZA,EW)5)TT^9/&=<9'D=EQ'5V6TB*6_!SVF:LET945O9M(9A-*2\ M/P&R%3RE=UW$14F./M164:7)T:WY;M0_7D6T_"8&^U4KCF/6E M\LQ)-14BS1E3!)8RRCA6AW8.?,3NE;#'A/I, YHP\35)^6V"9_S+AW'P"E#R7HJB_UF%N>7';%# MO\^#Q6 \.78 #JQD ^B"OLRZWY,I2;<]#;9&/,EIREHVA==-OR4E4#E$0?2\ M_*YSLG,P-W6;WJ.:RM5/\ITI<0?5_R7#$[[ANL]'([(.W( @.,07/M@RI_%2 MTS+#GW/J.4D!9%4%0"!B^RH6V[H)9K.BHX"?:VWM5.V/[L_.%M<-[NBFU9O9 M*0&+'A.=N"N0KT_D&+167-^/, F.(Y;XHF]1/P1@]D?\LP$;ZI62@BD:5K .\ M#RA^CKN#\<3M_L:KVHWC7&^YYFDK56Q;R;F M0U*P[W>>::,:N+9\HZV9GP'NZBH:U=4G7".:K1W-,2@$0:=.(G\$/+:N[+7> MM;?-G%:ED8RA'I"OC8^K$M6A,!_$H4PX]E<<.*_N$R_[Z"?(NA<:A/*X#"YE MX2MK]RLY!\B(0.%FIB35H=R"S'1+)P0W[$M]F;D96_23/I-(K:#HKHYI=S(+ M)"BZ)[%A/GQATJ0=DTLYSPZZR!%IM9#?LD?Y';4-L6$Y79@_YXKX3FI%58$H MYZM7'.RG(\VNR\3 _GY>B4W:7&;>MP0;7FN'&*>V.CD*(_X>^-*C M(@P5RN9:Z*;43#7GMQI",\W#RBQ_4LVB %AHMK]SGLU+X)6UD__XC[@00UYB$=+Z3<209/'D:/,<"* C_X&)U@)5'<[&932. MUR=-Q.;G&9PLW3SY,2$R]&07,_.F/?4V+^0\"VQ'ZEH(:=#@C-QFF#&2K#S##T9A])6[O8EP]@N3B&BWQOV A?4A)IW66)W^#" M-4GB9?I6'PBX;WNDI'UZH2\;77(2/($@DAT-6$WI5]YXIY>,A#W=B3K@Y0R<3"8N?,CDE_",>-JNH]W%2P>OBY> MMGDA[7&[]))7Z/+.+81<4H6 QS+R(L83WTPEJQ#I0YKG'9NU(UPPGD4XH7*&D M"[N^P:W @1&4A;9URO*#M#<]J]W>[?M'L _Y"JA24Y-(%47X:PY27L2(GZM< MUI,!';,B7M>K$DF[ND91IMAW #2O14ZN+1O5H*_H,*']3KVR;OSI30+1"6GQ M3]Z?9-K\![]CH*;T=7]2A:Q[ ,O+EX$$: ,MKJ615;YO^OC5Y-<0[_*#SGAQ_Q[]U%8RE^ N8*$2F MIOX-4>5DI/0T*LNG20A ,I;S+KJMZ]\<4)AC&Q;W;'#,=')!N1XD?2+;1_") MV(,8V.RP^M=RUY26YNV^%OMFD/-$>W.ENR\^./BG+T/F,2B&.@:J7$BI"^L, M9++<(<["L9&0 \II][Q8],"')8N?2:'OMLD7O][T 6ZXFICA56/%T M*.4<%>7#8X60EU?KIN!E0Z6GMQ!25&HGL:S'?K7.D77H2^$_8?,;6%18IGV MWV7=U2)#.:@\MGP'\-/5.N;Y^:#9N_; BBP#E>):'J'M#X-;U7P(2_ ! KH@ M^K?S.7/,"W@\-_&\**G(-W?O)C2"NL[+C21?+?DLWI[U47: MV!K2M 'HJQ;HAUAL+Y]?P'@2]3[.T=I7S++A-V,3)NO-1\V^2TV9QD M'-,D[8+&#3$E[!N(%-I Z![FYAJQ^/+O&"^$-HYS7_:[J M.Z2[L\"3[8Z^S22#B\<(-Z"_1YUEA5">5U_1H&VA($*TK='>VOCR\\4"TLHO M(-=?8.KW(#@!;5AAE;::5^X,72FX#UQ*^'YY4X&VAH$6Z3MFM*ST6%8G*UQQ MQ XK*?@"9>"#:1%=#>5@=D84/RNV%X9ZY'8W^SH[[^S%?=H232U/!%1TYN^> M$@J7I1W]_!%?R@[G-SXGXSP6:0ATWNAO@J3K6^\^P8*DFR\>MAJFM#/379NL MQ:.4D8TEM>2.+*&TM3KJRWW$@P=9$K6O_%EW-!F O'I']T?&_BLF!VX2+X=M M!#.'Y>W+B9]X801AHG4)2K.JUOTEM)\-V\:UY6F,JE#H"4GJV/<9$*KRRK_Z MV;NZNCJBYQ8V&M65/.%(2?X9\@>AW"G9U2;(M7B4?M(>"D'?[K>;D6, M-/TXMW(]N(NN2('?R*3JO+!DW4/>8DZ("GUU)D9F@&<(NUL]E_NRGF10N7-> M^/6^,L#Y+J+V]\T<5GJ4K)I>236A%LCM$9[,>6+:WKO"V+M&>)-D_)8, MD?- UZ+\I;ZCY)4B>;:GJ5#J(5? H A^@: &6]LQ?!@ M%:0^<_DH2Q=N\>R,>0?6S\0+_'#26?O9BIZD,YI#A#IFE& 0!P93W0 B*U-5*3'\Z+$3+F9! M&N"'-ZK@6G [EMO8T*E7SF?&[ G/2>D,.9F0T.([^+HU75 3,_^MM$S"_'61 M7G^*2GGGAYRE0/$LY\1!\DHQ,C)QF_KK5/G]E=3Q.+-M[^0<#?!_>J*QC MH=>TE^7%W/V[<#)YQN,&>*[G36#/XNN6 MWEM+7O&MQ>9-(HO_5W/<.BFPZ<4A#FES3R\C#>N0NG)<9+[U&IJS#,"&3$VU MZUZR(RL:#S*/$TY6T.Q"%:T<(+XT9%=#2"8X1SQ14;EVO=,0;OME8I%;081G M_+&](CX!NA%(/H +)Z"[/Y^%EK7;+[,C$]6DLHS4&_[*9+W)KR? S\9K??JJ M"WMES"*AQ]FFG#3ENKI&9GF7PX<',!RX++F\!\D]JM[9TK1$#*@TF+>';U@U MCL1Q(&"UJS[#7<^=Z>H5O*A:F#1" MW[L0'K.T$5CVL'6-!"U]6:>D!R]JM->I\RI\C4% Z!:V(9-3AQ:T1TR\"9VV M1I>R3-N82";@ ^RWP>)W)K4YK;-&;4]KC;5@[;W'\=+B?D\A%^GS[['WRW # MSK'=\%#-5OX?XTF>IC08HT+9VQN2057.IF4O2;(+=7-]W9:ELH*QERW?0I#032#2SLT M"@)I4P>AS/'E*Y=$L.%B?@O )S1M"N*C,JCMS\7V PCA:[FC'58%00NKK3!#*Q<=^(6/F:Z:O2[]R"A%655,EJ1& B=&NO'/3.U2W:4"_A M"X49-T&T!6Y!+EF]MZU>Q3%T4E'(*RVSXL#)P1RD-YJ;ZE+HD8 R@( *'.^(5USVI$R"W:I/4C3"+ZF08_/T@B':S)Z(2[H MW"?P"]"8-VMO,<#OG_;U5BLZ2RLR&YO2K\F&+>&&?=CNB!U2-NY)VD#E]#&R7,Y> M+,Q4\>\"NVF=I#R>T5]5Y:;Q43'UF483_,YX=$Z 5I1NA"$$YWZ? $$M69IP'(+X65QW"SY4-"J[6O3;$:>0;RX*FG7H)XUOH))+EO1&KT5 M2:25#(Y-8V.:XI'H^CB/K(R+F$R^@FD((0O7&)<-B+9'6Y9^,:H[2,L9913+ M+]=G7N*V3-9XN?(7]:LL+=S MXV*^3/ =1012)X\/O\?TBIFSK>2+3IX_ZS=#S_Y& 20Y+VPU[<*YJB7(3;$V M$#E0?Q;WM"H\N393>&62@W2JYT01<%G>*A)B;8T$J2V$J@30QHQ;1]*V80\" ME_TROZ-;)C9-T_1W=QKKZN,-]O[S&+$)=.F;&N3FHID%. MR*X!7CG/5O3[+*V91T\:&>+:*(SUKW;SC5VK#N;N,BO'$J<&QQQ8IN35V%79 M*BIZG :/)O8TTE5FW4FTI8J+E^@BRV)IY55?M%$^5S*QLMT9?L[MY MR>+]']9][Q1V;HY8;L XA$ M 6K/^D'.F6RG'&:3;:'=.<&'T;33QKUV*GV]?;)?GL//5NC]%? M30R[>3JB;V.(*?FL<^65#.X+^TWFYDYI1@(/N(F:JK(!Q3 E56KO @\X^81W MT^P(?$3"H4I[LK:%BXN&!BM?4?0BF["X,N6,C+"*&]Y4V*@NZN'5Q_!7&VS% M\*W4E!G4$)T-&F+-$^8\=_P^EB^.KOSSAK,6NZ^=Q8E#44E1---T_\:#.+2Z M3-S5[OHNJB1O9U.\ MUL1(6$/T82M5@KG;5@K85K)LCNC497)259E8780#<4[J55Y">^27<(BVA6M5 MV1N+S-&7R1.,D @96_7H5(TFA"2:L@#.M,.*"N-:*>Q4LHR@\W<[*S5L' H\ M _*0&86O#9^H]>5GAE=6%L"RHM&:LU>O3TQBF$48JEB+ODC$MVTH)S&G#+RR M5_7;A^\[N86 ^<"KMJG;FNX19&T151P?39 U5>8[3 [>2,['5!51S2S+/B4Y MNI(OYOV$#WEU_5,6T7E,M9GX.I=G"Z^=^#3QF_8GAP_I)6:#H EJ0?8)"20% MW/ RVU:/0D=S3_/2_G[0H'E("CL>/_I"#^"D'OP+F .:\FV=1MU.Z)CG.9G3 M&D8C^#Z' XWIEFBA3;6/I+)L0X_%B6HM3P\^(AHP/XL7@B!4BD%.E;78TB) MXGC+;;4[F;&J2C[5Y8=:RH3,;H.Y6=?>\J9C+M21:,TI \+L VII0-:].C[X MBRFDN>V+]"[$X]Z3<8_HYQ=+&O)G2GB113"K3LII;NY@NZ)#2^L/@]IY?+YQ"DV==D_O4C(A$7Z,C[['=!4>.1D,X:?]=G!?S)9KE1LF)I- MGW)"5=PTUF9ZAFM$@?R;((CO6B+XS/10R56VT%K3AR6;+"E*@D_MC,D7[)N@ MP6WP[J=%4_W49F/6H2)M(. M+P)>D8_I.;WUNMF9MLJ2U5WV)];=.K-T9NZ!-"T<:9;-+0]O]&*$'R5")W:_ MRVR[KV9%3]#'!-6:Z-M4Y-%J(N$?/XFNJ"H7]'37CCQY-57TOSKZV1SXH<=! M],R1)#*P;W[HD_I8'L+EDA=;5B^O63M+639H2XSPZ1?MCJO%C\ %GZQ"[)B8 M(2,,%2=4V#TX)\JBJ<)C=-G%L --=IW%WEIQPF\E3Y;0^SF/XM)##'>,Y'"\ MBIE6KFKNGG@0Q_C]:S6 MM'Z:_H=1:TWRZ^1Y7A7]LHW@?,>A[VU1%)7B9./59&O75PV1;0G7]EJ*T75+ M"8$T'XL1G9>QK\IU';*M_7S+_*+I8^6AE;6N+]].V2?N*$YV&R71\YTB5P)6 MD6VL+S&4Y+&Y&F7R")H!7$_^Y3(EU2Y6D6)8@WUE;GUC#&R5.X:P?U;C^#4S M,_.Q/55#0[A)$"WLN5=K= 8[&C)%H.4)5ME9A1%&%>6[I, N9@. MH)GE;K9?;U.S]!-NUXGP/M'0&Z85%W)8Z39R@>M3T3.@OT>3[JCU0M65 T)W M:5%1F&IKA'^\(?T]N*H'':DVM!I\'.^WKG ,(+A^?2&'.'2.+_[PWA,1LWE, MJ=AJCF!+HS&$[JF_X[SH7(?X59T#[;<@..!$?FO^'.@B;11AFZFV7T7VQ>(= MD:T-^8*.,_RQA>AZ?0[*-N"(^@:542H8M8P-R./;; PTC<;GR]=G+.E6%BTT M>G\(@\[7]^7"=";PZD"#-SC8N\DD00,Q IY"KF)H5;::/?*=$7*^,Q9OEA2\ MX4$5-$&$\6T>SWRV&G@VA5D8(/::,\=3?>@1I5S:J*;FC%)^_,A9GS3].F97 M,T6O&QH*YGWHBA!GEO).D^=414P(;A-O$#K]B2['X+]=S]U-C,1?ZK"H;J[2 MJP;P:BJC(%LX#[3@PN5BUYV%QCWYU:>+0BSHC&.YE8/(? .\R6(XC_1D(HD9 MJ4(D@=^'CS"I^I+TQ79B#,/\ F/)DT3+_:.> :]6=*'U=;WNXHNZYP7F8%,( M.W8 ^U08?;4-$&DP=VPY;1%ZB#9X>90Y^=BBHDLY+F+';E00Y0)PV]PQ\PS? MR\^JY 0^NTU3[Y;ZW#LQ1-8I)FD&4^"),S"#)-_WZ 9<;)I%#>: M/#T4J6) UOCH]1UUMTS;:BAVI6B7DC6NNC0LY$I%INCCS3'S/*592?*UX$989")M':^-5E0 M7M"HDA&#I\R\:UT)#8OV%M@)>5,&;\3@2+=%+K*G:$DD%-S.$>IQ,6K31W8V M"8CS":TK(S0HF"JU^0DPOX/M3L-DM]*(3K'E.;*<"D(%73.B%PXT62UFVODK M%$K>C2!J\10,?NXZ(B.26/*,>"8>X]E>UUO:(W.HV=88"%/;QZ' MGD0=Q5M3:4#_-D).F-%/DMPW4^A=\G>VKS ]U#ZE,WN-HQGZ#D#70&!>TYY7 MH[..?:6'?"=&C).$#3'X*/9B['U;2\3PN&]+.+8XB)ZG9G9]MTM/,7)7]>DM7;=U3;Q<57;1.^_Y6PHZFZ\QMJ-A!M@V0_ O0 M#'>W9^9^[T>EZ]N0'^G*$QQ^XE^3$.AT#6 M6I9 6M;=.;/(L%YI?1WW$$+I)47X9K:S*QG$=UND3=W=!,X.;GF=8KA%LVV. M=3U(V&)\Y)Y:_3T(_[A?FS5DTS.\U-NOJX-ZAG3.:;MVE2=OHJH MM_'O1MD#>DZ;BJ2K*YE7<^TWVDXD*94X-K\/IZ')#'",+B6N^QXCII5N&V9R MO,>Z#>W?/,=HL_]^DL_:C-6JC:DQ0'IY)2R[.G/Y95K.0.J<[:YL<<"1IG<[ MRJQ1I"#+"MY]^O@7T*"GSL:Z1$R)?_Y,0\K?T/\=^.F*R?Y316%JIFDT7/^> M"9[4QZ($Y:Y()4B:MXA%#'V2*?*N7SX-EL]NU;P>%)MKS(>$S[X!T'Q=L=BT M-)KOQQ0NH6@ M_C#-3HK6]MJ&3R.NSA\JD0I,P40O6L@#/HPJB:<5>Y(7EEAC%=H*N.VI!CC6 M=S4J#)ZS+OOUG))N\0_X'!I/GU!"BZ"?WCG224JG=$XM^* "E-,5Z]!3;MP0 MR>7#LG/3#+CN7X#HI-IW1].Z<*+X;6]2:5+KZ/&!FB&$''JP@!JWL"37TO-3 MU%1#OL4Y/#[+?F3R1>JLQ2J;*_<5F:+4T@%;:U>&>\F0V?QZ)E=ZP?JB6BPUA,^Q1"^K#HV)G!'D] M@$J;IBM.&@0[I/C"8*?7/^O(%?'$ !],40&@<.,[9E^>A*&LPMA17OZRJ'+D MM[P[!K*V*^Y<;Y]&$]KS@C2=+P7.4EJN<6BD#J_M"8W.](1L M?T7E+*OW16>\ORZ;5H1US&4Z,X?,AG98"ADG]BX9S/"^3*K,U@(%2C=^ 5@]>3"7ICQ$H#A]I:[5C^@ \*X M;O!5JVN5Z7TX/+Z'IOV,B41L6VJ+M\JBML7!;U/M5%"$8NTLCDAV?# MR5DBM04&*'6"X _<5Z342..7]&S3;-$B+4*^]+B2F'%DG'-&D=[T ?K3Z5+S M+ WV/RQV+51<;3WQ%TV4 R7B'UPSO0225-/TPKQ5S&[KZE>$7X6#+2S-S_%]'FTS9WABF2F M>JTZ_BK++9HIRMO2Q!5L!9S^0K3T*;A!UK.MEEU MN" .DRC4M:&92$B=N+'8$S?YVD=>\V)5\;@E=3#F50Z.'NE>_$"'$:1U.R4; M5@.3?BPW^CCF9Q9[KO_MH[D9?1=-U'VL"9P%;$EJKIV[E+M45KY. =1&MVB2 M".[F\48O"! )*LBZ?\+Q,I^VL_1:,0FU=C0AE=B8;<2ZKN$\64TWQNOX!7PF M?OJ&EN[6VN1UA6(>DM>#;D]/3?+3N-^K\I%3'C+-1%57]UD:T31 (&$Y83E; M%^!:X9F7K8T9'Q>.I]_4OJ&YH9\K7[.5LZ09(DM:V0C4*,(?KE FW0KJ3NAW M@BMQ5Y!6)L"_]N'B^7V-:3S &X,1W!*XP4U@SQ=L JYI/3I726U/RXVUS*Y$ M]W2EQ?V+:TU)8 Z?##;JACD#XHNOKLL+0Z2EV,F'@@'-\33H^OC?FYVP M*K6[W,[49PZ2U4;0-<&YX'/*KXY?A&S\V^%(8U*O2R#_#Q[/ [6UC3,5FQ#( M[U2;,D3RY!J7C MB%05@I319_Q2EKOW$]USH[(V'[!&YY>*+U7N,BQ:O3S)'&,8@^<-S,*8!]1@ M#C4?S&U3PE/@ 6"2M,W/1C_0\N!X0Z/ITCVUW-\L)%"^U_6J4;I#UHGZ+,,> M W+QQMS6@].5 G[C0Z.6NDBJR?/+ ^4%:QZ!*%B%Y@''_LU9 ?CMU.^":6@% M\@)E$($;^A51LT;Z'T&37!5<(P:R$("V <+C,;6D][;V#7'(6Y4 )%-;XI5V M#ZW:CLK+Y/+6YZ?V4]IOWYT[MWD2;0.8%E>00FK*ND3\[I6"%;7W;0RY1 M[8ZZ05A-4)@\9C6"'D_1VN,<;&;QI1*S47CL:2 B-#%FIY*5E\"#O,3@J".X MU]&1-! NX0-0\F)05!GB5;G@-/YT$< ;/VI=R3_X7:+IK19^VI3SZ(S&RW\# M_I3!L\X9GV&2[5]V5&>H7Q5I:BW<431%K43]+#4B;(F<[[Z"7\ALSCYS;#SY MQ(EII_W':9'()#[?PT"#)9&Y&6DB/WU,QN2SRF5=@\K^^#()HU#"Q3@%0CAY M!1)2'$&SUP^,:0MOMHA.&OC;MV<2?% ([0G>$>*:KED2#7Q\#=,*.ZZ"E%;0 MR=).;W5<5.(H:VW#,)>Q,W,C_?RSY;^3M:.?CI"JE-)DP9=0Y.0@ W@2)0!< M ++-]E6F"TDFO?M*U%'^,G8ZE$HLA^VK&VD(C>\/&]\3K=YGOHN0)1!O79U? M+&G?IQDC^"7V[J-^U[1RBZ8TIAA*2(+*CYT?%Z8R\Q^2EWZ"ZF_C]IKDGXR( M=1-A[M&GF97M9Y+8TB%%%.YY#/HN E$Y _,1U?9%TIN";?8.=Z_SPXS.CPL) MT366!ZAC?@$@,X09KD?ZGNO*PCY[5X2.PH8C?1U)OE=Y%Y 7WMW+"\BPUN>T M,;AKH#(6L1%2](3 NW@Q3 MUB6,Q#2*::[RA0]A.^]RUFHW'2_'"$2:U/L]X M*G?T3I,8=>PK8&NZH'V.^_)>,Q6XVWH@[#(A[#P#P,A>K=$TDR=GRP? "YND@Y!J;EGY5SEQ&,63\8J MV;RV=*.FI3\'*73-BT);LPH=JP[9!\%?3,WK$DY[7B$S^2D)618+'RI0B#?) MD?&MO#T7#AZY5A+]+A4R/AJKG/LQ6W<9K+T)#!X&?F%@<@8K @_[<"ST,7,P MO7!%ZG"TEDO ;)Z]Y(@MO9*](9*(F5GH*@TMF4HF$L^H[/:^>'=P@H@<&J8U M5Q3"6E51$1/F3)]X%O3D(S5@Y'$2LPT7AR'M:.]=N#22, MCQ>DB>#?JH=;^ C@7Y$4Q2L_;YRHU8C-=4Q$OU?=OR.5M2W27Y.:7EW\9A*^PV^FZC5Q MKPU8'NE!_B\;C&@*[X5#[IE5[&@)D&[R9!G?RJMP/DZ>3+Z,_SG3T&%]Z>M5 MI3JL5^ZT=\)*(/(.$\VT$Y/ON87H*=AEB='A"%FNRV8!SMF5FK/<"LJ&E5F1YDBC>=A"8"46*&IO M"!!3<.(X_+OX%CVY8TH;U=*M3)-E\%U"(673U($?%GMUSE/[.[EQQR])%FB? MZQ.3[5%P6-@V>SH3Y2!Y0O0#,0V4&=Y&G(ZO8!1E8RQ[XBP'C@Z,1'U2.8CS MI/B6(%U_<7IA7[ZRMC!09[67&5PG!T8-[1YDE*%N]#LJI4>@+P3PI-:T:UMF M'2"#Q6J>=G!@SGE$A/BC>>3I>G<#5Y6&YJ0*-VA+78/RC1K75UE$!T'D#Z\1 M]^82E&>.A:0=4GPT'M#\;/HJOS-GOC[_4N46%T/33LFBKZU[W!GE!5F8L9-\ M);0*1+8>0GYEA@UF5[$1.,VU+)$QG8F_'-'!9G$@-ZK@1:)-]&$P4O1[!#&B MS4Z?.J0\+[VUN)9VYFZDPQ\=8(DB$*6DR1*P"."]-,7%X([ I6*K>T.U_C.N M:7FODTUK'[G2W,N'6?/T\'7Q&\OB!4BM)#[;/"*8%WM1VE&54\W+5BYFY7E3 MFB:DL=G98BS+V%U5+:N,@D_T>%[FG[W75: )4DW@]L^Y /-%4N9'Y]6'X9A'ZSSI7GCF9<3D(Q<(9T"=A@#[WTLLAS0UX/_0W4KE,YCFS1E^R)\Y&D].8IO=:IC#@%P[3.&R M#T6U9I#[!8YCD=T3SS+AFG]&>.4JAG):FR]8HZ$"5A(#H6[UZMH5"3)+H$5: ML2;8J8X'2#(83[+1(P9/KD-YB4^F5_FZ9C;"WH"U&FQ3Z>$"21+K,0-E$=TG M7LUI_#Y313PA5=5+;N$$]EF%+RZHW9Y>C+; 1B8I'$<1\AHM_,C/IS4P7.'; M5=?]*P1=*,ANX+&@\; R+W-NO8ZTK!P,B-2*<=!$YU3P[U0/)AQF9#,15F$> M.KSJ&U[HG4P7F-J/7E+UH='(>WSM$65NR%S?+# A, $Z"2]SA&M/7:.NK!-^ MC&3QU=UTT_[%D+7(O@4A)I_5L@N'($<&Q;=ZXS.R[BQ^;EN0+QG5B5*\,_.W M.[/G<.L.1*\^XHYICBLP>@O)Y2:ZFZ_YVA#:M8J/7PDC!*YU70 =7">N&PIO M;AA9\)^#M9.\+L0$F[\G3#13SZ6\55#<]+Y2D.;Y!5AI:-MU[47 RS#Y=[JX M'LP<>/2S4W?<1EAA3)=:T0(OI,1,GCG)=#\@Z::9!?%X\@$O3YTX!]8Q )[= M34$YG2ISOA@:#O[?@7L6BV>I5X!JPMBIH@Z.!B=VW9V?B+S7122OOE)(THD% MU[8QN=4]L_>C/:1NN9H/=-[HA/"A^VS?C[$SWYHWS"';8"IEK#XUV' A=U/^ M;%?Z:5Y8K6CW)BO,Z"^ G/,AFD MOIEPD=&PUP "G/BITS.E2KVZ &H%%QR9SNFWT6A;.W9&68)QSSXFT:Y,Z\!& M!+<_;UGS5*\:Y=/C @8KTI8.Y@GTN^H:AA6C8H O6-)$J5S/9EJVF$K.MES\ M?O]5JW+AX.6KN&$I]?6LYV4$-S>>U_4'L,,EJWKY=8M>$2,WR> !(O-D\YP?(K,&V B"I/S5&S";A+! MW4!U36IFNZ,5AS NX*UM2XMP6)/:,8;X!^I9KI)J.QT65!,OU(SP9[\#QO"[ M)Y%9B?E>'-A*1TJX8K:YH+VM2X*Y.49\;#HR-:%P"YY!A:,0>UG^P0N2:)YK M@SKMX%@ZB>>K83F&_&1MRD@G-N<[ERLB][*-O.#4V4W%@% I(OJ:GRW"9:?1 MYJ[&Q9^_LT2/C;3)@;90B6)D5!:E;6JM;9+C6Z5DM#P2K/E1M;<#3S*R^_.@ MU6GCTYI!W%D[$I^"O53[TFWV)BV[:G.0W[]'8T>M4."ZX)?)TP1J@=KMK $ M;=4CS;O$J"Z+M#7UF0NF9+62%1KI,+2H4$07]F5F%6C5J:/:/:]&:^T,]Y)W M\N8WF=W'Y3!$=(<]Y%U51D_;:$/;YU5N;>5D#L.;HIDFIB241C3P8CR)H.;U MC%^ ,@;SQ\V+XSO[\7B[)M>.?FKZ4T:(TD7M<7[P]^Y*#+IA>U&%F-7-@],B MI#19;5-7=B8G0?2$6)NTZ3E!D#.B9'L#DSK[?0[823C42;BLL=2?&T(E2)C? MW.&I/4WGERL[M+S2#:=]OQGP4FON&,*7FWR5:9HL3KZC_VGBC#?OTTT)?Z2F[<-T@D;DJ')+X M'B)Y6!:&>EU]UX^GHC2%=KI[J59T$RT'>_;H8=G#C+.U!D!O/EO#0*K/[0M> M4?+K/,[FG\SGIH(3U<"Z)U^EOGD'UT/NGDR=JM2R#>HG3'+DW7 /'59P=Z&UIH5C MUGC;F]3NE#%4*YPQ>TW&MQ%ARF\A4/L&^)S^WCW 1FPP.T:P"".+EO;@6_0:Z^$,K#4## @=*MSA+I2 MB?T1H=+W8X%1V:Z*H9RXV/W37%$1N&WN)LAJWW72^HO=[>:N6\TAGKQ-Z%_? MQC:\8$"*Q)YP'N@ %/S+:6._X,]M'N3%CB;9?P-'3M [$^U[$0FYE9!M1JHT M0)6?-;:C1O7ZS5/?.)[$O?L(TN;46;5-;KJADQOCU&Y\@]3749%3<*LZ!'5! M</F,28SB?7O'OJ-,0:5P)GTHN/XSFE6 ME]B\X'IAS>-LL#Q,%@XV^!SQ"2%A>2=@8'XZ@$FN0OMKA62A')]<2_X%M=26 MTSB?2#NYKK)E$KA\%1W,8_9K_"8;\C!F*5(S7: MSY!6,TU"8:OF$3K?:X<#LY.$M=?]D-S=-%DJRVQ4Y..L8!\\ZU >#HAE/5[I MKP.^M5\''!C@#=X8!BM=I%8Z[$4LAV3)4&-2T3S;MA1&$4+XBH>9ZFYU"AHA0CAJ*B;+E<$6Z)7,+1_$[E8(\[ MT74-A>"5W\G4+O\':7)JI0_5]#6;K1&@[-FK,:DY;]%Z-VA;4V.4@BNU/ &C MBU-P2_?$CABQBBT^I\W%@1S?O1UJU5G6%5+! MRA!?VQ41EVHN,\)MXZ\PGSAQ_LN["*#N$J[GBS_ M,?O+]LW!$O>L*LZ_%OUT0W\?[O2I9L.,ZN__;C6LV#JH$07]'>:&>I"KV,O5 MV^3Q'@XEI/E%Q%"Z-NV>MQ68F$Z> *:4I;^78O=FNK]F(O^NJMMXYU]_/TZ>K37U'RS4KMKIN- M.Z#\?9,G@@(*?B&B._.T)F&Y8T"MP,Z E+\7!J2Y4[%'O1B #M^0I!;MQ.^: MZ-:O])>Z%LDT$RFE";[->@!@SC%/SA[1)]'%\QM4R*8V8T@CZA,MK2A(L6D= ME8 V/@MO";^[U 0,=?1/ZO_&5:QT+#J M*NZ>_RGG)*%\3AEBX7 ]C8,#5<^7&M5IK=Q_!#,ZK+#@*F3(%JQZXFB@SK1GYH[,:LPD)@D<74K8O8P)KF>J&0+5W^I^&$(,1]+B,5'TB- \Z*HJTOBDIBI\12D@C1>)*M8@6/]Q\"L#Z7;87]QHTL9G((I]?? MF.?[94=O%),=L29]9P]$RE# U\?LFV#02=L)^JK[U1AOZ1M%UIB.B-D,R[IZ MF*] E2#W-+DH&DO:& /)T]W\H0GT-5;RMEN4V])OH9U3NB==4LT8Z3&ION3^ MOI+[51E/# 002F)K8T&"!S\X6]1S!&;?]/U *'6T,Z1%Q0SDH5WI^.^%9Z0]6C59?.\G0:G;7X6M/E%E5IETERUKZDLL9S67WF;":\]U^^.@) MWV-3V^&>90V!Q,&9F$,QZ"PD TF%0^.C\?:29J M<%#6I>2)PZN+0PY*Q<94B>=HN,@$&2 C!I96E2V[&MI=E+*:Q15A\)$8(+A M=IGR=1RB6NA3S'FV![D"U\=SB\G%G]2YGD:%QG<3HSC]T8\Y7+<3@9WL-(7& M,Z<.A\4HFBA,HH>X(UV41/_H"N%V)W>\]+:Q/.E)>/5[ FN G-FX=U\6W::. M@^A=W;OM*MOKNZ3.\9S#1[!EL"/5PNI9+I*@+#1"NYK2*9@%U6#D6VR](=DT M$0X7#NH,SMR9IR7'C=X ,PW %4ET(6VLBL,8\= M9R=2A1A)*POC 3?7MC_J/UM4., %C/[=S_LJ,5'2V'K1SF[WB.8Z!69,*-\1 MW84@P*BMU7E_=;'HBKEBO[DFCJ< HXU\#A2OO?W>QP\HL-:Y?-!EE'YY097G7]CE70GE,F_J\+<66^IC\[U^_ 63@IS$D+T9&X M-YDUQJJ,JB\U/^I*_\Z]R241+BZ9V;Y0.+Q^Q_VL+[\R ]S] +S;QN?.]K^@ M%+/63_'5P(_+1DD/_QWKF!@UJ9I199EB+-VI,3UC[&(>7:AK,!I,R[U/Y$,7 M>YR%.UMFOMHG,>=I,$NP6&3$"^.7LKK$RUM;(H$8MZ9S>2XD&5TQ('/!C7"*(>Q=_D,#>6X-F.]Z?5-M?!@5:9I>!D6HM+J6Z,SL\Q? M,NH&_97I"O!M&/<7&7U6Q$7.P=B' .,L5&L5DSQ3VN15*[WKO4 MWD(^#+R9*,$02?GM:>$F'2"ZZQ]K&*J'3%6K7D*7MFWT5LKY[#5?3867T?%# M:N(CP\\I[D%8"=/8N83.*?20DZ6O!=J^"Y+ID4*B9(.0>KJPV747I4BT*G7B M'C1T@L\]6U^M\!]A3'1/]1@#D8MQ'CP&U_7_GJ"ODWJH\+2C,39K[NJL/%"E M+H%<\EMM.KA6]'"&I;+1=+0G3*XA:>Y2.6'NL_N5GJN-(^C1)B@FO* MV>P*C^!W$'G!+-BB8&YVT.V2_W6PH1X9ISU(4;]RS'#:9*@B,EPRSWHGS1OT MV?$FPJDT$)3?!(^N6C#NIXL0[3_0Z"3MIVD#5#5JD%Q"I;X>K?:42K4$*2_+ M4G3,.T*3J+WB0PBN-#!:58EF3Y8TV?'L7[]=]]#ZH/L !%7>H@EI3:TCQW6J M(L%UN@T-(;;1';$)*$T"C:VN0UCN5Q,.Z*UC/(J?RW.2-<>=&)VK5>,,11%H M3(W[*,N7._OB$%O5UAJ-[S1R%!B+=Q"TXLLLS!E(J@2EO_7W33Z%(LO EBNR MWI+KL)(Z3DW.P\-UG:>]CL'?M=-0W12SE]W;5[,GA212U1F6U.M54N?"<1B: M#U[_/F2.':]_&Z]?MV7\"TESB.)L53)GOG@X:6Z"G;L1CXR1_9M*&PV8U"/+ MG)VX:E-%B"!O?L\&](=%J+TB(J +Z5*_6:N5@S\ ]H-EM6'?GZG7&9:H>'5L M!,M)J3>_[T8[/G@S7J/X&8)<:?",YSD@@E22L>=H'?+_3'/=.]F">Q*6,BE% M;*[)=CA%6@<3%>*9?L52E1;04LA.HAK1[@IN)WRTPL]F MZ@<-(FNBEG(;3_A:)\_;6^M0NB71G*&<'[R7%L?WYT [U,Z$>QP_?RF1^H@< MAO[]S>382T9)MR=B[0\ !=#*SPRK)VG7W#"^/PBG==.0TKV8;WQ[IFG@U^*7 MO]@LE5J(,(W8G61T#8@]MZ>0>77=2(8V\H&XR7U71-K^Z ).E="/4VS\BA/# M:C?*=U5&9FT.Q%%(+;X9] P/P&:=ORSKOW.CQ/P6 #M<,06&)K=I^WMZ>H;4 MJ8[PY4OM_:*TNJ"YTUV^$HQ*"+ 70Y$HPC_!YQ;?[''[>E(2'%)TYZ;+Z6-O MU-7"Y'VSZ%Q69&\Z))0N;H.$!>?ZQ3PQ&JIA8F5_.L#HI;?\>,[O'(,H:4HF ME/\7UZY(/^-/Z9.EGMRP$Y9,494$=*O7(C@+VKS+23<=MP[E6:B5YP2$D!V$ M@K]*+W1%PKHAA&Z'?-=]R.=/D*O&KE]=Z<6:78Y^N\?H[VH5II-](S[Z5VO% M$NH@]D]1XJV3=W+@E%D.53D>4/ZN !G+S8]Z:M^W<3[#!;9H;U529IR_05K< M(";TC;5)OCVLW%EW:ON!-0$\)WT303%2L43^0? )C%Q M2;3XO41.?CZ\*Z'O7@>68S+1OLX]P?GK377Q=%OOC@R&9OTDIY,G!,[_ M$KDP!UA&G;<#ZW[G[6=E"WI&2*@3LP.U$+>*Q#.&XB4;/P?"N$Q1'@O@>@ M33\SR\S S]$/?E@BQV&P,RF2^(B0QF+>"- SS/5+:>7:/*/Y/;XNKO,T6#), M@%^B&(/)+,FTL/CM]3.)B 7K?TK$LBP31S10)ZF'(SBYA$$#>GPS$M^Z5F3, M>D370Y3(T2V#V$&*QDC.I[PX,S(,= R1ARWE5L?)XV,._\BUG%Q4+ MA 9KLH6D\1::R6K=[6;"6@>4CO/YT8Z660IP0SEC!$P2R"I"D 3VN[E,7,\H 2 M2B_.$;$8_3PC(@EA AVS'E"7S<)>4Q)\;@%L!Z4))[Y_70U^2?34ZSNP4R-" MT[K3%/V1 NFREX*QCULD\R1B51B#67-2I%OSM@A-7>D!4#2HN7P #!S;,$$F M_%(*4H5H=E)%#AP=PM?P[AEGYPY#66='KN4:-(P&XZ$'0"L7K0).S;R!7*F= M<((S537R$?.18KFET?BQ]*F-30(% @PM9L03V0>9PA-5DLS_&>'_1 M(RYFU8Q!!(=Y_KP@-]X7AS)94/N6W0G-SK;71/9[3[1(BW+8^3H6O&>]I.)6 MI_[V='$>\" M/[6]]!HK],[+)F:.,#,"N5_IG$IF/6P4"_[:0%H1/5<3.$BRA?-#";4$.8HM_I*, MT/GEV*+";:_K1! BMT2JMSSD4\W;I'KY(4S_^@&WP-]Y(XY6M15A*LEQ"Y*$ M97/-261X@;,(E&L"Y8G_L?]EQ3D!Z8XA]&]-^B8S3KBETO??.;X(-U]#*>^/L?X]Z2'F3#624I:EFSJ_J&!AR"I!H*)XN9RVD8 MOPG^4#GC[S0U[0(QN#YP]N< W14^@< MM05KTC^ +BWSNPH:6,LC-!>IXB$,(ZU'V)4_V327D3*,55-37]&R\TN\BKA> M=-!QKII!Y"T2WE=I\1[':H:X^3\37VWR SAH"(AVO W;QW*29M]7A9T,P_9_ M^S7:-ER%P+;D!;(GMYAC99NB,,*X4;S>]392KLY.)LRITD].Y5?3W%IX.%Z-#I6:5B6MC( M7Q.'8L<&DPYTO&6;(^(4_+!<(L1U:F5+O1V#;__G%TIJRTO[RV?4C=1['X)P M>L;/.0()YTQ*(#V.WF2Z-F0&"-XN_V4: C\X=[ M?]\$,;1\0&9FF/*N[JC Q=#KX_)+M$8+G&7Q.:Q&@I\ MW!;HZYM2(Z_S;L>U6J/Z&GUN)^OH>Y60\K=4F AL6HT7)\-^ MU3*$1D:*#FBJ+%[EF,26"6H 6B-3L(';?+HAQQ>S$(> 5[V3VH]N6X39%SVD M#.TEW:60OU:%JO)O%;T$I5 2JP3&, 5=O#*"(CJ*U<4^",AM%_9O MD-DU6PC, M9Z2U'!2"Z)J;8X9H^64.$FLU7[B+/5I7Q?H$O#;@>$Y1T"\__/13?J<_DQ7B M2?LN.9BH" &5F=?A0HV7T65;VW"MBHTMYYC^:&]TOAVAZR6: MF\S%D/I:S 179S1^354>E(.!]$FK?O!(@"VJ1'-GC5*O8@*8UM)5,7IHFA6- MZ6E0AM*.OIN#<%,N7QW8 GEV<4HQYC'#R*I =OA$DC ^3<>[.;'+4$[17C6L MN7"@ZB_1>81.3_NY GK4-07VAT7Z"+:W]L;D:5\YG@*?MS*F77UF:\BZU? M]D"H]L1^C8//UL]O\L0)9;(]RWQ# MNBDDCQ CI>^^*0"E=AL05<"]='SQQ' M>2152Y-:-.V3K!X'=D*/_.8$9WV7P0+2^5SXRZ^_.N:RP_"KH6@$Y(YESZ5V M_45]M[;CN;K<7#Y@ZW !-L(C_19Y+#- M39!CS,&P >D'3W[_#V++G FG0\Z:'9N::O_>*4HZN9#;ZXLUEB"ZB=I^*'U. M]$IC8T,J,UWMEUYZM%)3+W+:=&V*Z-H^@[T+)\.9!\!=2@&G6!0]IHLR=)N\ M9"C1MW#/'&0RDLFK8.KI1"Z&7OJTD_!Z\O74'FEA8/:TX5W.YN:^9*4(83<+#B9+#YO7Y$,+3'* WX=,?O< M&4K,HAB'"/;^I=NV&[!K"!3ZELSH&\]"C(TXM18J]>4"":FKKV*'LAI0^_7" M]M!ZFSKY'X!JUB.1M81?$-D[K?J(N3?2LT1J];2.2H$39L&< M8P$HE/YG"([< D1Y)4//S3P;WC1B;7ZM5CR(S].9V*Y):#C>Q<87]4^<+"YX M@^.*QAK](HOB,C8W8^HT.3E'6 MJ? "V3?V#V'G;SN:/!Q[[9A*75UGD8P5D33P)"VLK"Q<\?J+M.L[1&J!@MF- M3IDJZ)CJ57,>%DVY D ;[;%L"H"EMEK9=H8-V= 8_G3.6L%*:=(%RUFM=:P) M$^*K T8&1Y['Q\+!STC%Q[N"Z%L&XC,/^["&?AW1H07HE*@+A!^_:YR4KB/!=)^IUYF5EA_P"7*>))$;0 M,VMJX1S>\X-I&A!^4XKRQ"C) 3\,=F;A^9\F MKP9'I(P&I+T;G@DG3J>-6N8,:S14,!+VX1T1=O>I#_T*I;JC\M/A(>ZF34(; M-+T\5OIA#QUUTV_ \+VG_8XU.">DWG$M7.M ]UDG?9.WQAVR@.W]D6QV9/ET M7%KD?2A2 Z,9*H60)GPMN, Y2\FKZ__I)&/X;@F,J^EN:GI1@(8=$P4=$U&P^C5(EC D2;P2 M*;'8G.*^UO16;+X*,O<]J/'30*OIEY"?VLI4'U?]RMLY>=+PN<]@SJ5=+Y%NBJSIZYQG3Q]+^# MED[&GE^Z[[6Q!WAE&K9-'EA4'E.-VU<.V50C"$IKZ8EP8&,R:HN?FAUE#_$HG>7I(WN3AY0SS6ZQ_3:U<\ \A*(X'%OSBL5%=3T=M*^/N'2 E( Q@]5,H^ MBMAB+PXSH)TX)28AL-(LI W%U9Q4YU0 $9XA9I=-3-B\.A]GTHZS012V3?8G\S/_K^$W8)&R<'Z()Y M=)X73@2N $W0T[/=F-4GA_#\^J_68AJYL1H*^(!UY%Z +EBP%^Z4\[QMC%$Y M^'5X'+86=CMELGLIQ1[\8"NM$])+%'95KN-U(H-67B1T=;=6E]WGG--1,]W M>%8;_7[K_E3GZQG3LZ?B$S!_+CD%2/JK7BO2]BC8_;OO5?+HO+A#2EM4WI=E M^#;@*:=;:?'=>E).1\)RKD-3_,V6+]BO9 &>G]CE5;/(#G<0XN"7[9/A9]M4 M>*18\U#:(T(9XEN0/9)L&[H-!RW]%O9@67# M]\Z,,D"/724R51.DL;?(-$QPD%NAY#CW67$9?8L[+;S9)>55].D,15UQ/W)H#[ MM\-< 0: MX]NVJ(/3JA#EF,W?VDEAK'5QM%\KMJ4^6JE7"I',SP8L)M/DC^2NM98O*13%:YO&-:P'=WYOP&?2W$*?2F\O9)^]^ M)VM/<)U%:H+:DBX;8D177OUAS(C(\I2D[8,KWVOST"FXE4#LHQ)C.A8K!=/5 MEDSB,2::#>U3WG_LMU\GC8Y(ZI'NS!-!]]= Q5>@]E9WZ']2 .DG=X-NQ5H& M!_V-?V3 OF"T71![@-+.)2GVAUD#Y.VZ=C01(2-_/>,/'!"XA )1TB15[08; MD9R-/J]Q<"8B^+EK22X5A,JO;@9)\2PU--PW1['F)\9B_]1H]48P"P;8JH#$AW&8Z\1:OPI5;; $;H7Z+'K04?%YR?9?QG4G*:C+. MD_P0"$:5;VV./PT$=MWC#29+?5?\KVIRB>NOY4=?VD4)QE$163B>OT$+\?,N MA_7-[>NZSOE&,R"$BYV:W4]BVTQM?K*A..; <"E]K!,'8*))Q@] 2YMIYE") M_?5&1B25PM:@]]=X*@V$\1*U"Y:9H8YQV2KTE<28= "5ZC.I >W,.W0-3-E? MU:TQPT:U9LREA/AM9B&YWGU*(!SI=5P*U0^[]W-O*XWY1]0])05>1RVY,1@* M-,9>RF#MNK G+>:29&07V5YX_;)K;6W4NY$^\G7\PF0-^HP_7/S'&)3'XVQ' MS*]L98M\&1^&:]%XF85I=W$R:W=Q<3HOU%FI0%)@%K+^M%9=__AI9O9?\^-U M[N4*I5SN=D5=.@_-/<-:POK8 P)1S MQ?@T[0$H#1QX-*)@ N5\N%V=UD(7,84=5-GW=;]/Q0-0PJXX-.;5MBTP_,:\ M9,ZVN'!)+K\ [NV/W\E%W55V\ODDCN=I[A4@"@36@#A*/M&(,H*93JFU,=]; MN':S4A>AG*>6.>C.4NF>FG"&8!<0DFM;*L:I0>9B:O,-3.AF:%+J>9XKPT[* MHBD*3GK4ILC^G%2[RF#3Q>/;-+#'8.+X=8AJ=[D'@ MVVU44XR8.@4@[(99_=(:+?X!0-7,+*$U'$Y5K:(XS_.BL O;Q98:Y5KMJ($Z M'F(\ %'UA2 W/VU=<:N2!9,=V(LJ4(T#56G36Y$9:SP7%*:,MB36^E9/8D!' MMX5VULZR%'825>Y^J> B+9#9!]=C7FVV@Y]S0-_V9T!!N3?"V<3D2QN'\V5\ M0RA#KM,IP&PM:K=.RD 00Z;'Q=9(XDW7;8_S%>%9":'=)-]5Q(S@'<_^'YN& M0;>*?3W=5\).]P()97YKSD83U)1J50&RJ:];O,85^C^16S]3?HI3[HL25\%8 M;[+:C/,8=J]UD8XZ@,V(U07!=!&[.X$3;0>_7X)Z16EF2)H-NN6K[OL:QV%< M%4:"43<^$NF11*!V23]3/PUT/S>NF&QWBQI ,17-HLPR[<L'2W6F83VD( =R$L01!'OFY5[4B)">@,$)"AQH@B9#>VK7]" M(=K=4WBU[ 1<(G "@$>GHII?LJ E,&G']MN^ M_R&$K#/B,0O!=!&XPI&4?'\NL47384)H>3LG\K;[^1&IKLKX(!1L@ M4@(\62ILCKE3WA?Q9&?@JDS,$9]F/>LC:;^ ML:XQ\<[H(/8[*%;2YL=I5S0$7)_43OB3U#2U5LTCVM@7F7 MH.AJQ9W^R-]F1?6>-K=T4>7&+S%BW2T'L(,PT8D6%F4+6S^UMJM6B*.;]\<9 M%=WDK>-Y_I4%V650523@4MI9I>@E,"4L&"/P*K$)8 ,$+JW2BU*US3)/E'0X M.P%,,*B4?_)2[5@JFM%P<%.6C4UI)?YSO?E3@G7[%AJZ&%6W )K[B0/C\)N7 MR4F-LNV,2V)KXY@E#H96B&1OGB\>IJ7BY7O]6B[);.*9-FC96?AL%!QWG-&O M9EA@,U]2>'B\+#61/.]#&P);7F;0UA'*>[K H!;X XN67@/9ROA91-HN>?%I M@5KVB+241SUE? 9P@;+;N]>P3O#(X#A)P\SSQ=GQ+/SL0&N[8H;CMS!>-69TS(A$@J8+R!;UK1#\ M,*X^&4;C/Q=&X%3I&U5%D!3RPSTM>#]@YQJCN&93>^S M[+?L@LV0*!>S U]O;?V\?_E"\?'/'C4EHP>@MMY4^G 2#A _QC7_D+24KPPK!!\J0C DK?+&4<>SXY*B;.L\"\6P1;5*1[[GP9W]#X#DTH3ZSF3=P>UC0%\X^\;:\?V] MOH3[04;@L'U"!/!/&]>M\T&*Y87NLNU.^1*$#AEMHRLY'4GBSA1(02JI^<4W M!G71[$1:/MG@3,?Q[?\\]%-WK5&G@]HOM5"\/#T!T9A#U@= AS\P(&B[ ^FY M ZF8D\=+>%.9E>)(;JG3[H:)&8B3\J^17O(*I.%EG-7\Z[T_C;G9=MLJKA8P M68)"TD5LR[X;^)*EX+_TNPF;')OMHV69?+(2RUR'R%90?]NE^M^>C] HTJG:!B-IZAO\ 8QXKH!89^('EG"87Z0TW9$.-B?%D&:>':K_BP8G> M>[;LNK2TT^WLU_I/OBQ:9%07WFN=#TAGL"_]Z+!'5U$:4G'K']E\K MH8L96N1H+$\@?CX )+QQ:_,@+][^UQ?ZB+%9[,T,-D9P 5T_0Q'>.AY>QKG0 M?_OP(KKN1=U%_+>#K AB3OTR6V(BOPP)9,U_\,SYOXG0J&5T/$(G&-TOXA&> M([*UV8.(\0!Q'$.V+)P46*I=Z338RO]9 CD68P/H"^C+>8D4;?W$ 72C#ED( M7OTTX'42?S/SS,-FB_S@SV2=[7]6*;P[&X7:R7W5VAY3V27B(I=CT>T^?T+- M;8Y2EK32TM[G0WDE5=SDR.=A3B[89*+4TK#\?S523H7;UEU/Y'0S"HH0"M_X M?[OR>5>)]3?F;) ==RY=?.*\!YYQPD+$W7E3AH+R:[$=)&Y=:_L_-ZG_+__7 M!"\@L!-&0Q7VDN=UF143P^NL2H0 ,E937_JHQD/][SE2^L]LX+'G^&Z*<";\ M5;P]:;\X?=]&1%S %[I)O5LZ*?('(,OF7C'Q 8@H+]'J*+H_EO@VJ/.K:2)& ML3.0-D\.=UM9/GI58@ MS*%\\@/ECK=NEITR9SGQ%N?^[MK(>MH'$A6Y*RNJY]\]O^-"7\ I)H^W]VHWW/#[7X].X.J:(0-B1ZN M)E@_B69GT^H.$K70E5Y!.1J^0Y,^DNK2+"Z>Y0NZ493:]%+);M]VE!?2*!X22&,[L;;)TO-,5QS]PKL^%[R M6@WNZUW:RV1]@N9Q6@AS;^DAB_MVRS%R3MR0J)XA\3I\RX,]1(^MY;@7R,A8 M2C;94?55J%LXH%ZU3'7S^QB61L,^.3,P?TX2?O,1LU[-RG' M-K21,]%;^\WB7/L7==>. M%28Y]L+P<.XGL^347KU!6"8?_8.'_8 XGQCAF"6G3#\G)S1!W2S%36(CJ_O[ MD98H(M\#?2DV)-0S&@=QN#2D$*D=\2+Z))KR1;\3%LFOR<'_'?2=71;:?WHB''4:>J!C<Z%C02^4ISR^".I;C#0"7@6PLS!PM/5U>H/^5L7Z6ZDSFF4G_ F(O2 MK#_5:M79 X"S>^$7\)UH)O\N>CV9T%S!=MV GUS_ -W%-0X?7.ICHX,L$]+% M[.7Q?$F'%Z9[LAK#&!\V V.Z>?IS/LAYQD'3Q%Y@6JAVL+53LZS=1D,DEP@- M[_F\!1;6;.,PL9&)[3U=_02\G%NUAB_SU[!&B.>Y MG0G%G)5@0M]Q=^O7>0Y1HW,618Q8$TSU>N4^YR>[+CZZ:\HA#@Z1X0MZPQFZ M&O&,:!1!Q%O!XS'Z)_8'D\FK2N<6)7;N.Z,J[D3,"[7MWE$D0^1D@#K6;!#7 M_-YLP%W57 ?)Q+JW\&\[J?[V&);M 6]4@6&T# *2SRO]"^*@%[_C3-HED]TP MA :%5.;EL$\ZC$7H'O/H8+$]F%LNAMESJ<#7-3[Q)^Z M#H'L/."4G8:J_08=@9:STFEC'.)\Z<1UJZ%7_O&)&;6O3G]?;PR&-3KFJKTM M-F'^7=D0&*\3W'ZWQ+I!^_UL'2U;G<@@_ =#4\3J(-ST!?[%)S0/16G>=A"" MU\5]MACBLZ?8Z)"_N#UY1!DB@KB)\R.V)E]W<;''5^R8A?TH6>QWXS*M:QJ? M'/=X6RW.:[Y2H8$J0F7!&)QI#\.7[A(A?4':!-],IN/]-MX?GCK 2M7;8%'@ M WAFX9?B@YT7]>^')8E>EPPE8CP:C6DQW=F^__76TPF&YW;>;";:=S/T.?&Y MIHJ,>'F$8XW-J@+:1XOI16!KQYQ3"NEJ0[!DPNMO0P>-P*%3GT1P;WG"F;%J M?E_=L?S%=\99(@.<(M90&'"V52]Z($,U&5XNE^?S[G7"V>Z+M[L0A1,3!_+W('CTD;:Q/$#/HD M9=C#,+#0\8Y\+K.>?GXSL8;,;PK=OR2=(BTKY10HPA/!"TUB>J:8#:?HJ(WM M0E-//RP8F[W]I&\1;?2*UY?SPS&3GVN7T[_3JQ?U<=,&O9YB#&P(,+7?:N,# M<*5V]NOOBN\#\)[G 2 QICJ2=T?KX,>*1I"K^_4^ !]5Y!Z 3-K;B =@S6AB MDKYV/T5E8#>;DU]]CF4I/C%@K=2ZQK,RS+-!DD.YM,;_2-4==L\\ 3]\C3@Q M$.L%4[('5,X=E4\&8FV?M.V0-(:]DC) C_+*S!85"G=>%NOJN5&=-Y&1_&MZ MR'B\8^+I)SJC*G'77?@9'A1%4=OJ+:CX2)]RA2]-+U&T'X!]Y*^C])W T]^G M]U?O[MG+'X#?S-D/P'#LO7S@<>X](1?!_?O $XX'(-K3S>)7BO14S]I66R#G M+X)303AW-M)1:Y74@CAK^4SJ\[9#?*1FTQ&BWB?9?=@U&]3WFR5#-_[ "!$E MPK=EMA#C9W&ZGQ7"84M$IL%DRULBH:N:_FG]3W%7J:$!):1[J4HL14V8'4J7 MSF,=]G),4*$AP12-R1)#UYS?X/KF M6KNC2W=C/;C,6>N8526PJB)*S%IK+_27DW"QV,)L4?M*NHK:T=U]NED1]8DQ M-EV"GNG[N"+)JC9+ESQ+KZZW4D^;15[XUHRE#&TJY3OH)JB51/'2.LGVVP2^ MO#[A"V8U_'-+:B"^IOD';^@?S:C#\>3 0B1\4A=@K!:C@#6-S\[7ZAO M[A')HM/Z:77BO>3T"WH*!C4A+WY23>Q3OFF.V*6,;);E=";I+-?NW*)_G:IB MY0(PN6^_C%Q9\*1+EQJW[I7*F7)K2P _BR=S^]3&Y!X#7(]@MGQ@K4I4%S%1 M[>OA5OTQ$T$@." =!+AF_!WB6RS;:1HP3!IW#(7&[ZF6-@G@@2\7IQ3$'G25W5@Z<3?XL$HE)U5 U_]1>B[1]%_ M']EH8=X>Z.73BR8=EX6Y^T)//#,R439B$^*@#_TP[G)4-\/$7%%"643=2S6Q M424NO_9..-_U[CM)38:CWG/!5$IV[S#'RA5(,> MC#GB_<<4R7541;K0)6+,6Y1^:8FDH]4,RQ6*7UISU#=[H-TOGI=YZ>UC?;6A:FE/9 MC3/^'FP6,[[PXWB&"N6IQ^!%,@J2SQ3K$JID6::VKT-$]X=N5^VSU->#N4Q M=R#7?;G"A^G)B?+V)*&![GS0X!V1(=?ZY)3+O(&@"V7<% YJBT4IWO/QD>4; M/:Y5N+1F[)]W$VW*Y&<1C>!6SN'HQ.PF!-"LTO[H8=(D@-<5TX>W& MHEI>'C<]9L[?R$[=3P[!JO?_:$'F+,P7G#0+[IT7%97*TG& 4FHW-(ZE:CO( MI#@9&"Y,?\]T&E%B%XZB6GX^J#7^GJ=H9UR54]KB.9(W^G6B[\=QQAD ]S?FK[@[QVO3,SQ63[^S&HDH"?3:HC94/ M;[+6;437]G0YSYP)=Y*KY@SL2:5GB-3&0MGY,N@&&Y,"/Q=+IHV@WXOHO7O: M.B BHJ%*7(EAR^IS94>HYA6?@;TW5B;5"#4K#C27LRLRFN]VWF+3>.<6@K7D MM7Z*S)@>\LGM$O^076J'B6B'NC/F2@QS<"_$E/&BIFTY25@LECX -@ZL779E MWSA1<3%K^0+R>^?5;K?Z=QI0SK:HBU#[?%*&_"DI(VV=G)A^HGL(M@VX["&,(FKZ_@!R(VFNITLJU=.@5N\O MZ"YHAX-PWQUEV,$+6\]TZQ/EB']J;_)P?62-(J4_KMGZ@ZJ()0J/%M%5U5*) M99E$LWUK8)RE%?TJ2OB\XRN87M=B>#"7RWZZPRUL6/H#(.GT MZT_2 [!:RJIW_'K*L=A\K/T956)0YSTUAL>[HZCM!^!TZP&(?W=K'Y:_0L:" M,XDNTQ%2#L8Z7H\ !L8D-85R^=$5GZDP!>#B_NAQ>J"UZ\OU?%;YT]>V#)AH5#''F5T3JD[Y.KK*UG7 MU.DDHZ,:QYX.L2?!$EW="W>%Q2?@V2&[NG&< H)I?$-/-5T4R1C/N@"=JH90 MN4B-!IC*38+SAT$\59=3/E:G"8V#X%[)-/^4N@RV&G^[/.$IL*0(PP3\&UWB M@&C;T$&#V%XS2>:+ST(0+I2:&X<5CLAV>E\K2P'9[IZAK"11P-+/?\+G/:,O M%<6GRL]O'%1*DS)[)"+BGJ$V(K37 U:&Q2[H*.&KE%;UBJ27JI*)@H2S'VD< MFNZ6443;MA)<_QA=?C[G"&!7];,)VR,HRG-M^^"K4E6$W8MP4W_O/Y$:B+=; MY[)SVNZ.NV!@I'PL*UE^7*8F_/>#&64#6FCL[_@6T ^THE[JP13*_IY#&J:$ MU_-!0(\E&J,H5?!?&V(4.&WX?L;8IAU#8YB*;U?U7!,:?=R:?9&6[) "KSU4 M&O+(/C0RVF87(,:R%#W'0Z5MYC(;^J'CM>Z55W(:P4ZJS?JOY,_T)D?+5U.3 M9&;G+9^V1"6F'>MYP-);O(M3OX:SW.!1)K!RYVXZ?0Q27V=#_5FZWK%F&;&Z MIBMGGVC*K-[R>/RW(F* MEY:7YOL6.1R22NUP3Y1=,@?9^8-J6%N5EZP6U58![2:,$[>@NK,O\?%^ZUZ^ MI#89Z(R$=S7)/:\(?^$T#YM+\#T[B+D%;"%[7KK7'U+Q/Z4C-_WE4W#U0Y*5 M7D61PU=@QA)6(L0]LEUW]2!(@[G73.40]@'I\(/ MN%CC#1=WE1B^FZ9L"F**SJ^%#JEKIJ%%#*O2=M91)$U=.&6;7> VOAG>ZD0H MI?\\EA&5/$$1O2^/53@F"8/[WZ4'F@O.]$M3Y7)P# ^-" M2A[4[[H$P,[>0BW>2F.2@=*P9E^F:E0%]<OZ8M#2R,?=$$9+I%!J]@ \M\;D=Z*]M*#TO5LJ%!*D8&DDA7N^ M'[5[ 'Z.3XYJ&$OCM9YNG.W)4/PZ2C#LQT\U:'?W99ZGM8TA(_'^E?HNJG4DQIJ8[X" M[G;,?+.6 0@YOU=WL)Y2O8 T'AQ06@UVLI7%4Z'*]J.Z/!D:<5U,]UV%2!C, MLJTT-L\ C4GP"7U%PNUN)IOL9_BK;Y]\Y:_S)G2Q"?G,8S"Y>LU&5$_2SG(.^M),Q@GS)@)W58U#9 M=71TGFYR67W/L+/+*'IT$+FT3]@#T.U+QLB8TERPJU)<=@@;[XQ7'L5,=F)B M5V+VJNSIZ;;?\.1(=?B!NQ/7OK%SW2]Y2&><*XQTI"[6QG^$7=OL>C2K- =F((UFJ#W]&?RD# MD5U^Z3\+K1Q'( O?5Z;T=J2_^N(S4/Z)'+WS]T, S-$7&[E0N[ M-[,R[O1T@T"5#<*CJ7GAK-U#E7Q66--Q3Z5Q -C_ Y>C_T=2TEY@=S'E9CPW M/2?OSOV^-S=<9XF5E1-335W(_E]IEW\DY+!O[)X0?Z-,A ^MV7+TL]'U,C)> MGHJ029.AFX)-^S49#A: ,OUV^W]S#HKY.\PL5>,POBO[.'_#8J4^K_ MX\0:B?*6TCB/]7-CN\G$/G')"@[>6Z72&@UT6O,:$;#GA?Z'40I'\/O*5KT1 MFBPWGW_+9/SOBO3#S'\"4$L#!!0 ( /: 6U9UV ZM8^0 S^ 1 M:6UG,C/?-)_[[5LU;/3-]:^Z_[ MZKTZ[YRS[][WU;O[=;<*/'JEI*H$8& " ,;]![A; !0 /%Q<$"X.'@@$>O M[R$!.2$!/CX!#2D9,3D#+1,C RT]_6-6'O;'S%PL]/0 2%!/YQ$HP'#QX0X!-0$Q)2"SRA?R+P3X^['H $#V,%*PL+@QG ),' M(L&X&P"8[G\G#L:_#."_# Q,+&P<7!#>@X?X]P]G M ^[G 6P2'-(G_/*X9%H6(&974E)1T]"R M/67G>/9<2%A$5$Q<0N&EHI*RBNHKG;>Z>OH&AD:65M8VMG;V#NX>GE[>$!_? ML/"(R*CHF-B4U$]IZ1F?OV3F%Q06%9>4EI5_KV]H;&IN:6WKZQ\8'!H>&?TQ M/3,[-P_[]1N^AEC?V-S:_K.SBSH^.3T[OT#_O?Q'7!@ %L9_'?]J7"3W<6%B M8V-A@_X1%P:F]S\.(,'&><*/2RJO!;)P)6,6",$C?Y&<5]?[@$50&TGQWFWJ M(26KT!H;ZA^A_4MD_V.!A?ZG(OL_ _MO<<$! BR,^^1AD0"RP,4E1W[PP_^- M_XW_3Z+:>.A69KH#RQKL7;ZPK,[P,U*(LK12'DOJT!H1+)')2=QGQC4C99\[ M7+&CSIXR,=7@%LR:$&4#?"3B\SUE+K,WDYEN3*)W,"-K;NXPOI$123%D523A MP\& *Y#E?//$Z@0\A?2ST 7K&N$=W.5CQ6]@&1D?FD93)M@LZ+RQZSF@,V)5 M1R#(R4O4>.')'^B'P(FWZO23GSB,Q;8/LZ/RA#!FM$Q L8$"$.6^C",+5U=7 M/V^:!2X1K2C^G!>J^#F.&WI1H;>L?Q@E?1#3ZM,:F* 4SFBO-.SU4K8@@DF0 MN:+K+0XZJ>!:[BKH7+WQ5-;B^!K:F,_C?3@D4A_TX6S88:\P1>R]C[6GRI2: M8%V/ID2*WT/ DV(37C)\A&,/JW(BT,P__%9DJR^-?LN!L4"Q'C05S_> M(^E FEG5;%'%4L9*$>\=!DMVIS(+<[#(G_Q8@..?18TH2F.HFQ"M/.#MRW"3 M7L$V5SU^A*WU23+9Y-T7C#_]C>;(J,$:?,@$VL! W=7%O^>[\=(0R3>B=A56 MLA4:J/DKX-"N1A)E.^1"A)8<(+-K2T@OX_[Y*G[NG@T3)/WTN,B&?TJ"SDZ"\*46?^5142=\E-*X N=D@$=R2 M[AW"PR@VP#7V[9%":EBBV*&$)BA_2N6PKD"R5E&*V:8P27UQKH.;.:U1X1[CP,GLARWM MQXS2>DN"21)JUL_^<&#-E5:S#ZV0>VA@+!DN[*:WQ8][TZ0(.I$^ L2V MW9_A?O>035PFF#_#VQ];_J7*B:W4&:'[0!IWTP9K]P,'U@Q'N6]QA46^_8P# M;=:L5]/'^([O]!BW[+_6_F-*ZZQ,RDTU[]7NA5]TH.'#F^[PX MHPR^)V%:7?3^@*WJYWN#K(]EUM)$>-BZ;?]\=?PKX!P(LM?X2WFJ<7D5=(/9 MV=:A?/[I#DAV>7D'U#3? 9,<6+S]9*K(*,09-/)P*3*DD@)L^_Y#*_N8B M5M+DZ: #A.[VC\D!'?4FZ2Z)M?5MC %!N MBSUA"F[+FJA'Z;SM[@BX$-CAWI+U?K)J.KRXSKXXB>T%\V8"W;(Z7,@P3ZJ? M9Y7^N-5%Y%K6UCGF2=F"MK3EUVMJJI01YD1W0%\SK$-Y]:Q1T=BGV!6;^2E9 M^+KOJO^2Q!G]B8GU'3 L2?QT3P6E',9SC3 2=/Q!P[8O4(U!??QT<*'U5K0-V 5:R432#WW1\Y%3(0%(23W(-4U6^UV MVH:?))G+0U78\]@2-6IKK.JG3IV MD_#0%?IH=L_2/S*L4SS6,YLYX[$0)0Q'G,7PZTKJYQ?8EL=G*\"U@@NCB;F0 M!-M20EK;DUC$ZAU0S?TM)"018'BP)\?H="5P!_R+^HG.Y4TX\W(>5)EUHWO$';Y"?S<3\V:WOMP<<7 M[J/K\]4K!H:[08WQZ=[G'TWAHPE(*'4R'>7C^++5U>"@AQ?CLJ]F&CZ_EG"* MJ/JDG)(^6>D0A(,9+,5IH)AZ7OE=6?/'"RN^$=D_6TVWLFA+M2!*FW^&^?ZF$UZ(?*"-UG__("UG76U'B/#:P6%SH3 MPT#H!W2HS^>5SN#FQ!>!-I]2'[FX#QWUP#Z90UX$8*VN1':8.D1*OV*06ZI? M3U-F&6/_1;W.9"6EQ\M=G#Q@/&LL#9R0 MX/)UFDV7J"YB@_=M87\<;OR&U4#/X_I-$Q!O81M?Z? ^K[>\=+NHP>'3R']@E$;/!KO^/AG:JI\H,%. MA>@PI(X!TE>E0&O&ALP()+::M2M+2S.N4_)59D_-$Q5-=L=P#3J0:A M63N## :U77T_)D$-NA;#?9]SH0@Y'R%<*/+=;IX0&YNZX$KBO0"1O)G8->>H M#"_:UF1&RKH(?0?TGR=YS7^5F2&W,RA[H?(>Q/8JJX2!_TC/*!]DG K70":I.XD=I[(,P;*/.NCQ1EBM MF"YW&[T16W&>JRMD]CDD'GAI! )<^E.Y?*L.%26F*EJ=C3$.=D<.]MTRUD^M3B&FNS-%'3Q)5*,)0H<8L*7ZI M9N8H#<54A'ZHASDEVM!LU]C:]MARZT5"0@_1?GQ+S\7>H*+EE0*SH;)]*<3F MYJQ!,T6!!,.P9V/U>BSG-;W?)*AIH9>BJD$/J5373XJ=0/[N>4@PJ.GYJZ*" MY?$R.]^ F\$*HW%W)_IIXRYW,H%0S0VLCV\DB-*\_A<0L/\OP/I9=ZP9(7*K M3B:U BQKVQ7F\H7JMTU ^R>^39^A0O5U*($QQ&UA@&P7.5AL:CN2J6@M\.ZC5QY=D@(\ MHS];"CD<9YW"0*P?NVL'L*_C0*=C8P^JQO=RZ0HR.A [+$I(91O7--S=3 MIO GJ3GE29W>KEGWK-5_<\U$= CI:*&A4O#YKW< WE =6UB_=?$P-2#.]?C#%Z++Y%&T@R;5BK1,>VG&HG_CG+S6+HS&SP*WJNZ]"8SBU ,,?A[_RH9Q*(-W)[5DK2QV:92C32 M[PO+ L-&*MDFJ].U#RN1!*:&P\S4M05"%CO(&7J380V9UY%W1W#&+'7\96N1 M?:XDWQ<^L4@?'WI_-Z:$1_>"R*3HUL;.Z^:$?S&W*43%L/B\8E+Z50+:,[[( ML+TB19S/'KK4"]71V[([*\,:?=A[3(F59Z7H?,J7C1;,'42IOK,--)/$T!,\ M6TC-;ET,<)=CK"L 9YI'"YUU3?/F=319)@D\G2#.8Y _EX*Q$P\E1__A:50ZT;I+4'_U^JDLE*Q\"^C=QK3HBJ60 MI'Z:'>W&.=/#1FGQ#EX7=_L _\D[P'&BWZDA/EIDW?YQL"A6,JRD%#3;!HWS MX,9Z&6Y*Y<_*= M/0%A>Q1!5,"^8V:-XE5([0^J/T\H5'/+$#!>'&PSF-"->T"W*3UK"UQB&,Z' M'@W= 112PI8R(> UOP0:O;/9%H&EQQS]V!R$%Q"&$,L)?CFFE_/<)7$>=+-S MK&%:\?U%K8G'-GH&"(M9E\?/AOW)8LVI' 1V& GG&ZD?D!D;C'-9>;T+K]F+ M/6Y7EU2JO_G<4?7FX.!=1Q@T!3+CUS'.847G)DH?8580,NN92_QB*I#MWIA( MY,YX=+K1U#QX\MYN67K#2_L'EL=!YCSL6JT08O:#L_/]T?[DV/->&I*.B,6- MB(>YJ9/G-3FG8>4:"%D,]@2/@ZH-RVAL[QP*QPOKH34>DG]>*)K@@U? MW/;[^)*&;EA>,LGDK(T$-?!$64J^R\\I.81.-@+>@2PHYX@U3I5#SR4E3K$- MI[I(@I_;O]]2BAVZ#LH:H)02V4K9"_RBGPZR5KPW-35D7QT')082 MS3B=$FH,NW&%ZY"3%B<@A MV*&D$IVLAYOLQ$3T8*\>JX(L&)3%UNGG$@CO@._==N:/=I"DW(W<(I*C+ S8 MY6]MSRS/'( SB?^ F 3.5DC^W-)\I_*=*,#YQ.55EM9J^2?736/RK0P=RB8& ML??,18ASI;&7/%NG^Q-JK9:(;Y4Q7#\9TGZE880^G1?Q-%WJJZW>.+@PV"^S(Q/K+1F3R@Q%?Q]:37\=TR9Z2R[U M4>FGF\KC)%XQ/VB8]#MY(9KV:(DA5I*U[B %A6+2'3'&M=-YNXE-@']V8.4;0-S/(U&4R<6*FX8+ M=G_JRL2EXMZK2H^RIAZ"00.^C'7%#K[C:1-Q7LRI Y;&M_#CX52&VF55WDF^ MI8O @8,X&(L(>AU(ZQ*2-S9MD3[V-# K]F1^?XUJ-0O-R'@F4DH>Q3OLFUZ/+9H9T7B4 M@=<2+YK^=<,,XQ2O8A_4*7$\L="_TC"1@!N#[37E0(E3\R08*$SF<2L(N:VB MVQ5<#I9,4$; 0DZSM-?5NV#8HE['U$7Q\)]>M6(L3_C1VQ1M_CIY]^Y,E#U: M1RO2]*F0@/!/PX^ F!0'.\L,34W.@GE.?YK^'(AP)Z'L[KVZ5F;4E \F(;MKD]N>&52RP_T\6- M)M/M3)R&#?#]G7Y4^C12)80]=W$7M&=:Y5]\O 0IZ#;K&B@!BFJLCTJ@J$+@UGV=(2NF(L;GRTE0(SCS-FVMBO^,X?TYI]K;QU3^*1JY6&Q)M=BS M<+TRVRI[K\OT'-$L>[>OB%1[T[&]4 RFZ!HI=/?J@:@6\K8,8=SMVAJ@#+3_LM-7ZCK62Y1-G0@4RFO MQMPNO3G0N>!=.8P?;X4D3!!Y6(102R(V='!==$C?-3.P MU'LB]Y@IA\[M 1"_U9(4<4N;\1:)6U6VJZ/A$H3X8MV2:4=?&!W^\:N&JQ=F.[0F2I+& 8]Q%G_;L"JID2VFJ.82OT81#\@^A.BA',^J M;#C!Z1@=N4DL@"_I(X;NQ.=^.;1HMYD733"V.>;;L99DR\1=8=LD5S&ZV+#F MY%!C@+%QO8OYZ]M&=#/"N 9[IVX/IF%'IAV+F)4P%IGDBS=PEN5=.AKI':8S M(YQN4(/^/M*?.>#9:,/%CVHC':[+:\%O=UY>>)6W!S6[!OSX'@?+CTCC%56+ MKBF5B%0AN^7;L[X4'M.2_G332#^@9D<:[9?^.[M&L;M;^)RJU8=6!KFA(BFJ M=/GE\2F!P9JX&C%2IGF0%]-T6=Z:QBK%03P"6M_JAB"ZV+=BPQI&OPRU$*21 MC(:FO4GTOK Q61+/=@W:':KL9SDZ3:3XC0W3IW5NQ0950P?''>\V*!][TA-K MQ9ZNT$%6U&?W/7(>V/O>1'S?KKMN9#Y:L8A\. MI(%QG=&-2^K%@DTE;V6V.$:2X\F^U0*)Q"S,1F7CY"-T0G2K/"61(K+^M"MV2?_8PM9H$_QTX]$8PWKMTG\H;4R MT@T/I.CH#!"8\/"Z4GC%?S6\;;\\/DEL+I]]M(ZS-)[1E^4+UK?^-$AO56-: M\YPS:+W2#N-"EDH*9!_H6(1BZ/Y&]$!EPP-T7A;72;9IO;U=#D"/'=+4OC&Q5+PUTV>_H8#:[9#?-V%$-W\DY:QBG!A2%3JG8 8@^!] M]G8F^(W=H115'$5G7,"733U.? MH19]>^*SSL.'*Z,S 7KL.N@IRR#\S.,.B("5X0LT+DXMU/->J(XR16O+T@([ M=\":./(7\@QEG.K'M$3$/P06*5]YCZ"'-$BLH#]0' F+RWX[>697O1'M M##EO< 95PX#U%>H::71_L3W<)SZ TO<4ZO9]"+&3R'2@R#! WR?%_ MMU6&)E*KJ(G/\ [D;E2G&U"W(IW1" 62U1EE;(FH#Z48;Y)D>0!0E8,,Z[10 ME?F;Z1KGZ_8#Q2].%B3M7_"& O\\499^ ]K4;32GA7@KSN][&-^\$6ODW#98 M;7XX\=,PM-HKK($4PAT"FX21K 6A*V4$P5TL+IG#+Y*N!$;.!=RW^.Z X3L M1/$#LMU[Z1(1R )Y:"S2DKFM"2. B5()?&$-6I%O=/^3^Y$#Z_>U(F(U3K!2^US#DA9/Y<&CSMY845[:X#>O M(2N3C$L54!G>=$91Y+0.&0FG,"OY6?W&_9&:;)_*G2_%Q+)P]XL LSQ4AYKN7@C9+[;E51%'Y/&&4<3A[Y M%TWR!PNGBZ8K9RU+5!DY',-[JO?=GGKQ,2G-;U0J\Z;\SG"18'\0_L)KU-O MI[ .!>\:A\DARU#5 I)*N5 QD^S!]O44U\R]@PZ%@J4_Y@L?'42.BL(%Z')7 M'VO!V)OX1X0S>#^-^WC/T,[E"Q:I>!>Y>*0%%%\]:LPYP=*ST5 M'LSNIU!8N&Y:.M-_*]%0&/=806:CC6])@]!*=T#3N]OYI?J1_H"CP\.AI97] M;>$"WFBA$7\%W- +691@-F768X/?2>D2]8_X"J3=*F\/-VI*T9[1KU8%\:**)6S!= M D39E:"*(-:)O>]>8$GRSWI.<&!NAW0Q[2R#FMOL>-@[9WG- ^8.>L=^^,@& MC[*WLAZK6T/,UW2S(U8)=?KT+U;@>K 3J7'>Y$UR-A(EW*T-<@(B7YA+L4,3 M[7BX-]QI4=3K>\!OBP\_ KJZYJ!@:#.*:2%C[O5_.< M+E*N4J$O))*25:E[]W;4UHZB&2E0IF/&=FT_144!RN-7#K+ M['?*_\!\G<9L)-N]0[4+Z 72Q)@2?'(B_-E<$<215&8X*/6J@\(VQRWR5CQ= M*\W-]101%C!119+\A*!9]<_2HB^A]TOU&X#B:SXD2@W%^ V>F.9Y'L>WG^V= M/E)8 \()'KF@UP3ANR#S;_>T9NZ-<+R+9P6#@&+Z_'C5/ 5!M[8VD)N%P2/KVHNN@Z62']=H=0&:V M#+=K^^2=:OB(_7BJJ5H5BT!IGI[Q;>9 ][V44Q?4:JWM@/FW5QB:T:3NIV95 M%T;2/ @+)7X%3*$NPF77Q) -F;P+78-=;U,GCOU_.HD/+?7_G0;?4LX*JV-I MU,Y(*7H7FAHZ+7@Z?UD)7X@TB0^#T1R8$G8>=$[D4)QJAX&Y7EA]#,5X(4 L M+796>< ^:/2T-4^FV2(PJ?C).YA P,,31X+6XGD$.#=&_Y M23NLTP 1$XP86969$GG1HV+QT& M(E)-W1KF=':67-(VH / M1QF4(JF)JY>U:E[KKSG787]3L!5D9\3=_.LZW@="0KAPX7Y;43QUT=G:OL[T ML#ENG]OCM\MXTS<>;>,1/>FA'?+ML:46)^PS,>GRZAR4;*]O=6V;;DXT=V&' M[:^XQCG3=APWS#KIVC<.\Q7K*_AVOAL2/$65O2ZE:@EU?);QIXL]3B9W0(,B M8 F96:M%R13@YI6 !?YIKL"U%46!K_A2O39Y/08B]\P M%N?3 )^5:!D*_!72<00O$3KTI/^RJ&>PO^?K>L9LVH_C#X(3 H+Q?6JJA/_K[8$EG5O45,A&(',PGY0L M\I:;:J"+?)R(E4S:?QLF2+8OP.WS(0[GQ/9_@+]U&$/1,H[_G] MZC123'P?GPNA.H)UGB7@.0VV]IOD=D?W>,P\;ZP3HJ4_6'3::%.GLFN)&7]N MGOQ1S^)PD;98A.=3Z8J&&>[# X]VL-]>KX\GO05;*XE/H#W3 M8#,[]@WXZU07!YIS@#;MU'WQZJY@J?6UR(Q2 MB/:%.;)J*>W';WDOF%' [X2.LB?^_B&HA'XL%O%1F;2Z2@C=E3'B:0P">L#$ M>27P-&F_2^E(5+)UI<7RR)>B];$ VT/+8;*L8CG/KC^%^>N MMA:@K'BE_+OK]X.XB=_=-GX'(]!MD_D"Y"YX)9(R^V&<,9\RZ5"J*;[C%ZTW M^S@KQQOKK3M'IJ#H#LNUHX=*2=4.M89_PS@2TKT8\\@I658HP"]@#5#2'7Z' M3$4HW+&(BU2#.Y7M#3$!QJXT!^9F4:6(B*:1<:[*XX3W"2!D>3S&WX>;5=>$ M&_Z:[:B2\\2C!B-\E[J_U O!!5XWBS?+GX^,)31B/!+<3K0:9URP3^R__Q65 M4_K!$@A9E".\T'CA0$@U9,:(HBSQ*;&G_>:=(>(_P:P'[UB/&IK?GLP$-L]X M(T7'$.IJ1DAH',_I,T\!VF/A9L.Y7[;)*?RSV>C1P;>SUURWF&C=LC_+3,VS MPDX:;VUBB@S&.E)^B#0D))*\V$X=EWHLZ9A$TO7(V:6+ MIEI(?R[_V.F':'#V-\V%BZ1M._"'SWUFBR^OG/HYG$N$H?D&,DIS($>(] J[ M%QS#8:=5U&FVC;&>P++@*MRJ2 UK_!M[JBTR:&8V#W4G5L$>F1NGB M*\JH'R>NAFG#1!'FC&C;WHM'\M6[YE8IGKRT?^\-"%9HH*+8M1U6-LJ[%TJ$ MCE*D-#(M2HS[P*9_]9;RU<^W6&D]G+TC1_#FC#58N P46QOMKI8Z*A=K]-O7 M*O5T(Q4]MW+O.A10GI]@F0P7\*JUU!_)UR5)X'?T%CW2>)5#Z)S5WFJ% IY. M[.:3UTVH80(7YB_4$?B=;VNT049 WFI0)&U0Z%F"OK;JX];TP_?G&T;1XY56 MWX9*7$>?>4 M9V_V)$Z^:_Y=E,['TD>USO@>!#U.VFYBK)Z,C04!-3N9SA4E.][ZDKR-N-:- M$9:VMG"!X4T00+2-&2P6P+M&0.L2/DVMPACG_[P4:+QH:*>(W8=-MA&0#M,K1^PE; M2:7R?H"D8;[C@4RX)VC/T.PQ.F:-%]_T)M5@/K>Y=9VO7*JZ=-L]KT0LXE1SA+BU:6WGD'VKLYQ-5G6;9]OE7G M;:QMDV]V#(PL#VR?NU_<*AQ?G549)]T372,2#HE4-Q,LDNIZM:A,U[("'8O0 MEE]O*?7@O2]H%/?QKQVC#4%3&:^7J([7-\B\6:L;#LS.X>!8?Z6H(5J]LG,: M1MGGM[#]J^F#@(FUAE6B#SZ: >ZR S4$8X@5# (0&&N!=I]OG ZD&;%:&\:$J6/TAVJJE9V/#_7 M%S#FLG=J55ED(9P091003-W+W/%8N?>$!BC"^; 2!]?%7;UHJTR._T)RT_+O M^(B"6'0]5Z*[2)$3A4(WYD:1R_NKGT,ETZ#J"_(+:$0P*Y(W_ E2.9)Y"M$J MJOV T;#ZE:- .V.AU7H\44F1#BHJ)&B-$T4<*>QRP/3]#K!8NBGY<2SZ]PZ0 M)^;7>[B0_5E^''MN MRG-F&_O#)A2A'A^;V)&<#M#[QL<"O:B@_G4$M^_P *USHWL!V$N+VK(MEO_Y M)_'5/!99G_:+R[>,C$@5I--\#2)+3:<;=E9V,))B@8\1!U,S5#U(T6LR2/I1 M2?SX3$PJX9?PRKPT+-;#F'.<9][OU%!8)X[RX3C],+ J1N?FQI\BF"UH_&]3 MV+]*:U1-%7Z6KG;':J3C=$I6$3\D0OG3+"83ATKR@Z68E)!#66M,<&+%:8^Y MH&<>)=XI2HO'K88"/P/4[?^D>\&A!W2(F@,U2+5B52P7R41(FKQ!I)S,O9U; M49YO!R=A^=P!Y-Q2][JL>?\\ MS=/ 8)AWS)Z)=Q&CL^AL]@&8" IW'00@ 1LG!M<"J.(,&P/[*70,BYPXG=MU MT(;87B?J\(OEO;XG\>=KF3K(:VJ]>NNU/JI)4+?U)"S1^(CD#L"2:5RPOP,> M>DC* F:0-X;L+;%G/V%4CG)I1:M1C)_A?+)2&]NR\F@UMJAHH0-]$Y3T5O/- MIW8/]-.X]_T[.9\/61(A&\2O-4'?'. R-?GFID9F?YJ3^\$(&YC5?$?=QLTG MHI!+%^D79U#J"A%&'I1,5LUNYE)UFJ5(34")2+T7KR'T=^4CA)@E7(G.F3H5 MYK;A:C9VKV,?Y%#UE_PV,?>1L!+EE-XLC?.&]QV7&G^ MVX@W8=?Z_$FR-#< MZP"="L)7P\9?5;/56$J6\%8-];%WN ),P3W)N^.,IF9$-J=JO#;1A M)5RV<1,ER03ZD.0U:T<4_FHS'DJRO\]=1Z7;L%K?IWF_P_B;A 9.JX)"LAFF M7/P!>-I<0M7!V>9 _I9Q=+K2ZKH]=S9_&!KFO@K%W)'!FR[^7DNJSC;FTMK2 M\B3;YN(@)#7DT"\%G,($"S(EO9'@XM',Q:I/L4TY\Q>ZVGHC1*RV> M2Y"3F%YK[RL:7K7/97GL=/;H24,\CC9 +?_+ML@6HLLC98UJDE8R99SIU['3 M#+SM-19\;< 'BM!4HK=:+Y;8T/>[]Z?38+AHE",;K$3 [@)?T@1*]95ME,&; MH1_[\D3O6GY5L!P"?872RR@/LG'0L[3:D-_BG@U:M&CUL[+-+IC4Q):E%G[F MT1V1N3C);\B6P-W+$)Y8NH+>$99N#N,2UHBXM(TLS-Q:_@F78P4;2C4%8HD$ M?-YF66ZX=ED[0=3@[+8]_\C:&D5"N;/UC.#+^6)^Q;5T9W<'4BFSK2IA+CL/ M_*BQ)7'KJ9)-O-.R@#@!($[O%L"!!;U]],MHQYS4W\_"^E'L/-P.$ MV^UDBT_'7-0/?F?-%B;^4>H)<'8;6J'2X4^3T=$ H;[F-!8N6 %/SY\^8<)@ M&T6.H8\X+R/HPD,VQ^][%\Y?-%UXC4]UM)*YZISU;>^8=9M9H[#DVV!GQ _1 MDF]F2DR9'TSO'J^^[*/.BW8RN#CE4E):W,ZK4<_%C.7X-T%,A^XR@*STN?VI MB[L#R%[\G+2OP4L19Y$=V$ANP*R"-D&&P/A]<.OY3A<4T;SG%7%$QZ-]72X MV6O7$JOH1(LS5)I&1I 6F90O9# M4L&+K]U!1:/!5"\ M9)V#W7U^##S;/1=&ZEL9SQ\(2T9WY$)39+T^X*=/:%C$GU,TKC,10^(.LCF: M4N7:.X(>#5MR2<3F\AO[R-%(#?$*]VNK5%H1.MZ^I0;F:';!S.6GZB)8]<: M=3!3*Q!%?")K/[T8F?#MIH8$K@_*,'Q5BM)VDI%,UVU)>[\,I0RTHH]WWLF& M0.DG0?'&Z*]FLU+@DCT)W;2JY8*R8>[L:&',91.]VFJK3^4?O544WJ'B24:$ M]QDQ40:HDK#]QGK,7J[V%(.T[Q1ST6+G8M!UPV4.M"=E/5$L7*3PDF$K/H'B MVV0?V]N$3\^T"^.1$MOS3=CWT)?UR9N)B_0C-Z:?TRT3%U,' 9_J M!+"+]]4;=+7D9^8ON!ET.,E8@)>Q>YCFSGGZ,L--45=OWD#ZN7>;C]\81.G7 M5!/E54'(CWN#%L)DM R3H=B%+4O.=N@6H(=,&1&70C$IG(\WF/.?T37';PP1 MRQN;X:/=2] OCH]T_!:J= P[J+-O]S=')E08@S\*IFA@90)K720[3;1W0)R_ M?>4N4L&OK#C7DLDN7C8EO%O.UY;Z'#\6CAXK^F4OBR=L(+0GQOW$+]K*;C6> M.5V YPV(1AALB'XSC<[<'F"D1K%M1]6X"#B'\\>P?,Q676CUS?9ASX942$3U M^W7JK&W"(HXZ-+R]7=TE)BXC9LTL"02R\KP]_OK:QD^"4E\Z=]@C9''0;DZ8 M,_VI1OT4TTLC/6/>M*7B+\C=7J2 I"X079$HBJL=,YJY1NK;FZ)O,S4TFYJU MM[ICZ(RU!M_SB-P%^7+AR(I\O*ZQ,F7<+3IRK.-#>M+<=2F2Y;:_E>-;R6P) M>Y7%=@2";3P]?TWXL=AI1M?O5>=VSL-3/!<9_%X'&%G_T_+Z45=WK+0,=TF> MU>5<'*8(]WMO=YNS%@0GO5"91O##%W8 GJTQ?F8!@^R-%'4O\P=.C:94_C6P,,42#T[]G8N48]?%@GM"X6[[6Z5-3 MP;>SCH4&[P)T8R+APC_6WI*D.Q(PKHA6>=$2#U(?!I+OR;#D:$0.G;RV?Y*" M%\GB,T+WZHKR ['9#5AA0);@:1=*&!HM)8TP'L>\16&:_N6/(=7D$TP8"^O9 M9O^[57%-5VO^8.>6OFEV,_&'Y%E7MX!"YY&!:\/'_G?##%>,&IK82.5@RQ;T MB\PW1:[>.$/UMU_]N$C)/V4\J=6X"I$'+=?)4-JG9XH.0FEWFAY%.W$7)(I] M)/V P0 U.@\& (Q@"0R3Q)#5H'U9>O MZ^W4R1W0V'0'%/RE\Z\,:FPYO(X M(%T53RN(NE$ 6E+-%/RJPYLV8G8^)!/^PA@2??@7U5HWG#>$JZ%1L7,IE%,O M9/Z;ZON2_+LR5YRQZF'#COUNICYY;X8W(/?YMF>W9.;PY5VG-2B-N=TY[;RHH $2Q-UZ]_5([65YFUO@,,O:T)#LX\"(*R''3]\,4:#B3FAS"B MG?)5-(.^YV)??0'>/'0%3KHB )TE-S,Z=BO2BZX+*]F4/*W#!#G M$.2=LK1RLTR%B7EL!UT-V*BE>ZK#/B ?BW3H'-6_-?2+?0OK0^]V32/@L[D] M0+<'C604J>P*.+TOD5MJ/P"D54@=SK6Z:? M:Z]_^'?LQ*Q=X.C$L#[^8U%P[Q P4O,:>4^YXRS*R-NZXF6310=W ML/A5P.(&Z.-)J#2?JK.;FWMF;S.: \J6D%V%&+M1DZ_]I.I4K/I(L^4/OK,X M->L'$'9(++!^[;FVY,QM/D2)I=":*6US##](U.5_ A7K"^0)JZR?VE9?R7SQDNZ[@, M8R[KV"GZ=[L?>OHET>YFLTY=VXHD\^12F(E5-G_,>VOI_5GPPGU2$Y M26XNJ*NS,*=W"CC.^_?3[?=NQ*74C*OO8'[_^J,;UWLWLC[GL?*@.:KQ*VAV*A?;*/GA=<@LOA MC0;SKQ0--U76JTS;8*%.6;/Y6W:3/4KDXFOGC?"&'P\2!'E?WRR'W?YE3/OC MZQT2V(M2T+OGXJ0O-WEV32N6Q_R;JR]%79:@E]5?E9?/MXG-T2J7D>UE#D;L M,35"BG.1PG20]\NIE^M;U.SLL'29EEPBM5X9KIS^H/JLP]S#EY-JPHWI01T; M3L-37Y)6P0WW'=&/ #6'Z :!:@KBGQL,E,T%3A^^&D>DDWYHS M3@C7E,6'&0)-MCIAO;&_['(XJ%D][RE M&(/T7N8=$"'I9^GB5VQG)M0UX\$)L\GL,>:*(N![T;4JUS/\)LM=CB9;I'ZZ M>RUKW_D4_)OG\0Q.P[F^E5, 0IY&=C^YLV5?N=%W.0D"3XRQ\.\G='>B'_#[ M'G8#'O=W75-=1?+$((_ZO?3=C)?>Q B/QG]7(&W^?,02TD#Z2VQ=:KVV1KNI M.7%ZGLY.Z5>^/"VQ'"X.H*9(KHGQ_W>8O"E;3U!604DWILT'6TY7NZ0/<3:U M8*HR9'B=Q=$/29!E'E1 MY#ZT>SHR&76'+V9[2;0C\AE/UN;YC!TN.V'A_N" MZ;W7+;D/?8,&!S.7$>=W@)(?F')F>]:1U;"_</[#\KL8<9=9*C* MS$5X0G&-!6.:W_M:E9WS$&;J+=,1A7?NLR1[)IM1?>+3\WZ$R@:JE?DSMC,> M*'(Z,Z&TBR,W58+^D"%<'">T2X^Z'3QK.*:H;NZ0=WY95*/^/86*OH-_Y1OC M,G98$>!5NL,,2DA+CE1X-B*TNWE+#W03G?(!@#$ 7&;N_B=>V/OO@96.8JSR M+H"$J7SA?>JG%D- ]JL0\W5IHKX AZX Y5^@AY7I=>;O:<\*;N=G&]_M[X"I MS6,;U8/"D*GSBM7"V*H+4XTW9_?MM.T=;&O8D MWQ'DQ764E.$=8&%P!YS&S@>+LF=+0OI_++QMRQ5CW[)Y"-I25#6$PZXABG> MN=?*I32G4I&L3\U>V7.S$[.<4BU%"L5_[[GE?P@*ZN2$_@&+C\SYM9_2X .I M:?3;+,"W8!F+4)^!3__41MM_#'<9*13A2J2_ .Q<#2^Y))$R>\TPOUG/D8:> MEY5XEP.K.+_%/#);H L5D;#1_'Y9,>3=@JMS?/D$"C>9*"C&6'R8/O;P7_XX MAY6!=K\#6$\4[H :B^MQ3XJQ:_$[(,7GWK[ :F]MVOXGO+&8\W])3-O#[6OI M.^ )E#+HEY[L#7-C+O[E?Y>5%FX%!%&JMV/RL(OO0RA!E!O[R^3[KU+E9RY/ M7IN7[%W4@,&$/U22OSQ(>TN ";*1R6]9BRN02(]O;MYUG1F6T4=?).7CW6:C*N4W-1.SU_>1O_#._&5[92;)J(P8_!1_KI*6UL\P)KS#> M >_W1&F#SEVR-IUNMG.:Q3671'*,A'CO)YS (I?W$ZE;A_<3[=3:2R))K];] M[S/.DG8'W-3?-QE8.:1[PZWV#FC*N>0NE^DTWS.#?GT#=FQJ93(?"'#Y?6(_ M[I0..Y5.B>6HR96)_NG!QI,Q[CV\ M)>--%B81!9$WN!.<+>BL(@T6F1*VIJ2;S/11AL&AO-)%X[0GHP!>RZYRZP0' MELY:6Z&7_M30,ONOZL^FOA@D9L27M< Z;(5B 99U_;0IE%!2R\]SAL(*\I52 M=&;14[W?.^L'LB?><]R7#:# .5CT$M$Q??6]P?69#8G2-#_CC]R4@."R/[E$ MQFOMN&C//+X)PE*I>&_A61@O!G M^X5.NH+8F_C%7 =1;#09V1UD,%CL[O^M#X.E;-IY(W..^1>#8 5!?^Q-G,#V M3,<@E,9-L//] 23FS](5X);/^MM5T(OX37@E6-JY/!-^,H=H,H#=NMB MJ"D(!.Z D9B ^Y.*RYZ^U;VL=NV_ [3[RI=GOF:H&2TT775MS\U4C',:G!EQ MY'>]7?S/,TG%BOGOG70W,_.E7GLPH^BX5*B0R4=< Z2 "E,"X%-]3UBLMGVR M9WNV=T#A5DO;@3#Q7Q89DGM:,Y:]81<>A/VTZ3XBGF+B_!K4T?W2P^R>Y9)_ MW &WO^^ /XT%/2O'X@9!"QHWE+.0[5MESCO@ZOX\^?-)6$$CFQ;W?21[:JP7 M=,)P![C<%@;]#+KIOLP>5237G\LQ(M?3RRAUH,K(^+AD:"R77LUL$[M3R/:# M)1Z+%A6UEUU0XCN7JY62TO:0(S\DXG]T+7&_E;QG83^$^16.:="?XNK0UCO@ M_N*CTBC>F]#J[E,=39#\?^T7]8\V[-2@32G&3[M*5R4U;V8QUNX D]QTA.E MF94!GG JG:(LH-2,>I\*VQ:KE'7CM.8%.HGBTS)]LW%[ZP';E0?NM-T3TD\Y MWC]>,=(HLX;]HEWW(!35N]>E4)5,Z!M45F>#CJ1I4UVI2_!P77!?I+AD[&I0 M\IR_+I]HV/RRDXSD?&M')%ZZ(9PBX7<\:2*W#U'[%W@ M'7DZUN*&:%9RQ19NO@H;%9?>FP7_E"%:4?"CK+7\/G-@$O IK?[+YL,N/0KJ MNK^O(A::ZZ#5X)D__\NL4,0T54XLMW*WS^ZIF7#E-I3S:6-#TE\L=,EMCVC0 M)5[-Y]$[8.7/'1 3:#NTVKW,#'$*H$.";E^J'5T]N)_*SZ_Y5O%G)5CVF-D\ MZ-<;C1L*BL"]0?-CGL#22R,FFMT&+<7 ]U[_P]7QKX#1N#1HE :9=.-[7] [ MXM4\[>H*MRK0\*"]>>A]MXZ[>I[0U%SUGRK_V%HYXIUBH$H,VG#KOF?]H$MN M.Z3H=:(>T_G,':#8R/AO-<9FM^P1S:".57O@(_I[?>+^=A](R+GJUA?BOSM_GE_GZW_'ZE^0_A67 GX M\FTZ;55=:\-[A@*B'ZHZR3\^^LXGN =*I+Z*ZVLF!=-F;7UUJ XW-93D*KV* M7&J7%V>/?Q\L];5G:N<#NK[_\IN$66S=KONK]*;SC/K.I62\88$*<9V>QT@^ ME>I41$F\IRF97LK$\-N9_?RF&1QDY"%YZD$*C1!X,L[HO=^(/$:]E28P*JP>IA-XT5W6P M[*NY"M8SI3UZI&&"DJ-FPG>AJ?97+"'4ANK%PA'/*&_AU.LGF087(D>\H0I6 MME6"!F%:C6AH[L3E-QB)"=R,FELD(O%170T6$R3EWED3S4VB1:Z4.T/W=Q@9 M6J=T#5_&R62=:PBMKH8D?64J!N?YJ=D[Y[>E++.WA L,/*#8E1+/C+MK9][T91 MY$3V[:9K]EMP\4/]%["_OWS=\C&J5XI4.H!SQJG!B6<"_*7*8T_%NDV\!;*F M*W '=,C][:;URBG:N51O#5.O:ZH/K[-DZ%"C3?%;)6K "$,NIB+W7G#Q!?X0 MP)@0_Y^_+&(EH+@KIR'#2BW3#?.I;Z.XV6:4I@;>_>9A]NG[B.'6S1%C> M =.<1@ JV7VAL] MX=$PG;QO7# E\C+Z"P,-@Z9LN[O M2()9Y@R;&$( L-6G32!\I&==<7-?_FJ*0>+C@'L<%YAWJR -T]3?;] %/V]L MQ^5^/W^/-GR>1&2M7SW7V)BZ[2R"^(1/' M>(BW(?DW?EDQ"EF-1BIA&QU "$R?N&,JF H.'^2I?PD4>XRY/?0OPZ+F2M8E M(QP'[&5AHPRDR?Y0RW!,!=@D* BH?5Y@I$S 8(X %2WV[Z.N4S3"U.$'E*? M+&K3.X>^/7WREK*:(3[SNV32Z'BC3^Y@.ZQ"PYK_7&^AO,^J:UJXGFLKKKYK M87#)F#HNUGWKD>B8Q]USPL"1(]]X2#O(^+U'2 M.+H(8VT:RTG2GDZ:>YB0=4^^]JD@7^ !8^'- )[:DDGQ!6/-,1671/\2%-:2 MQJLJ->:'\3?H?4^U:V^'?CH[*Q'$*RUIC[,$XX#5IX<7F!!>Q*G6^)JM M 3$UQ_6A"IN,WR!B?OI?$AA_!SS]QT8X(!8L-Q.9@FW1-[UZ\!T_]D@_K,'8 MMZX]U6$Z25E(';IB_"S'\B"JEX$D%-\IK856!J7CV827HOQSV.#D<>6XQ3S< M(V_:H(7*)0%/;H8CQ5YVY41<>O&6.%SW6Y!0@XB55[ZW:^?P9;D+E;=9O6=+ MTKO!@&R23&2Q 6C09^["NQS4D>AF@7U)[2T&SY&*H,D5V0J\-J3VLF[*^^LQ M&7,?SS(+97671!,O5=HX(XA7:.G6$UFJBNFD].KU M4KM=$'9Z^>G3+9$P^;+ MQ7(U3YA0A"K54.O;MEW/&/\Q2N.. F;#73!G:V"_E< DJ6<,BQQB/(U3E+W\3_BXS _XAGH!2+ MWXB"[/*P8!,,)OX,9CAB56)Y$$7BDAQ#JR;I0-RC@(TXIV.Y8A_7M=LV/7Y^!]O&A@.>IA95(W' ?:MW MR-S-@?OU"\S^ID<$H6C;[S;CHKZ6R>/S)IV9#T@RA@H9XQ<]+*9KN*T[62ZY M4PRNS L/S@)XFBPYK$=G"+&'P+Y/;(I"C)^F- Y/>:C>)W+O6S6Z.RW]^8:& MM*L<6D&6[ZL\652T;8G.<$#ENI?,38]=S 94W]!3;/,[%,X+MQ RF)67?KW' M2QD&7%D&**B9_&5;F%W\: Q$$JK.__*4T"#R *M\$ ';I?8 .S?U#ZT%HQ/[ M13OBG+@.[ ,U.:;_[J.B&F<:$U\WG6U'>XS9HE,\Y+Q[7Q"\\^<;]BG'E9,^WJCGJIQOOHY%IW4S:D*(^,H;,TT9,*^&7J;CA^2 M:3^"MH NJ?H)%B*3E"L;!?>"[YT'^QB57FK>(&)/]/Z"W^)K&E8QHQJ'5.(; M=_^0K4YS6>+)Z"STG1[8?J)^2T)^)Z0%;>?+A9^,="0$%?E?,^\KZ<1W M>HH+Y]ZTJ<4$^M/\E%*W$B1\O8Y^,]"O>.O(FEP_=,.-,OMOU86-C\/G* M EQE9-P#([JB%F%>\T;(N+40E4_'PTTYZJOWP8).3=%04"8&9?C=B952KB.; M/4@EX8H^M6RDW4 G4Z\W6=9Q+ZLVT/-L3W??7_--@N+YEUDGI:1KDOZ%Z9GZ MDUT&1B:.J#!F;6[$OM%B9D;MECPR_+FB\P0I\;-[3K,( M4KI9Y^?C% MK( M>1QQP&QMYWY&[5>T?&ZG)9ES6Z\+ _A5B_2;F9U!8&^U+3,)"&H[3[WR3T*E MH+ 9$),/_._=.ZTTG:=L_1/^<4GFZO0+F20/'^36EBMML)'@B=&WP+7.EQ8R M-=O_T:Y(\)J7 Z8W>F]G)O+_;M8['N=VR4=1J)0U?0D9F1C\=H-70%18R_M? M$##&N%MSYI>N% -VFJ^LVPU>7L-\_7F/(FL6,2=SY7>Z(^\=I?IB=5:40B0! MX8KFL2#(K_E"IL+#BU;([>3@=6[[16QZP=_LF%'[#:S>Q:=^G];G.0C&KAO7 M3O?^8[08VB7-A0N-!!YPA8(E" XRR<3)<#&SCI!<1\E;]H(TLP"&V!HYVY*C M=]^D68I(E*? KEV:1<=FKJ1F]NJ7C=*2O'K50]HF6':8@S]*KBEW MQS[E,+2A*C4\\G7JN=_4'=WG@^)R!VE2%MT*NBOY@/O9>EWDRFFCE]*(].,5 M0OB9(8,RVRA;QK#?N^BB-\-C^/$:Q"]#!Y^G>WPA?_!W%5U1<;E4]1O]XJ27 M\9F[Z@?272H:Z(_LS+7W@!<[\=](]/O_!Q+]%LE0:%OG%22BU#3*RZM%)M?0 M+_TK6,0]YD65!MZG6T3;C_]">"S#+^] = )XR://-/8"A/<@;[!#%2<7EX'Z MF?75U@PNZ1O2YB43O#[+@V0SR%A^2#N]CNF;,&_.!3_Z2ZT[<813$![_F):- M-=FP2J4(=YH:/X_QTQ%)(]["3KXDU[[VT.CH50GN9G[MBBO]M=_0JBSY'V15 M(YMVVI8N5%"V&W]KS.R?%STV5BPU13S^S(.FQ?=G#5.T0E94_H$^N4'X-/&5FM0LME MVH8) 43@C/JCZ*RV>=[LE_2Z-"H]XZP(=R:%154F)[4ZG[EAZN MQN[NK^E\ MY!PZP7*;A/=SJB?<_1"EF#3=TK2]&6S/VBQ;0+;UPE3("?0@>J7QU9M0ZBRG MDLT+F 5*M-!";*8:D]1;HXA2'$24$ZS/+-!U^98T/3RCH%*3Q(4Z4YK>TP?W,/[ZN"1764M&CFFX-;MJIK3Y-ZTB8[ MNQ<<)Z0/\WU?GTJEC+Z8?W@X[9/6\#B7_R.%QGTG"P:V@'JCD]:,K9#?^Z:: M?^P/Z*S/G@XHWY,LCH:839TCA);N[**P&Y^3CO?WTJTK[]#OQ]F>#U9L5PE@ MPJVGT;WO3,L/4)EO-'KKJUPR1T$3K&?MZV3R9V1'?DRVG3-EV9_PW0X<1.S[ M?(;P[4]U^NGZ-+Q:JH=5^&!9A[^A'GTCNICO;-()][Q=%JAWR1 R^"N #'#0 M?&717D=B)%.WXVN;P4#O;)*"A;+QL3:'I3=!F..)IXN8>^KE,2$N*R)@GIT66- ME_R+Z \4RBX8#^UCN\ZA>IU.U4XHSA3GF/.8+-@;\O[J)N'84\.=.IF%26S_ MC\G^]T9#+ ^)W>/\H[,?=9Z=BU]K>M=XOUT2P]]B4KWK3!-R]< M,.G(G^KQ$%(_RA-B?;ONEDA &%2Z,^DRD?N,,[2$>N!]R5$8P\>7\3FQ M7RB*\ XJKG0^X*W5_?\AM]TJ"PM@/0*F*-(X#(4]=Z4'_^5]$E N@-_XIJ9G MB(8E";7Z:YU:4SY'MN$ #FVPA"J6JWN2 <(KY.B/:M;82=CF^YW3?6(<$)B% M9-F@'&M!"UT&?CWTPZKDQ8#V@+8__3BL+_;W"PG+&J@SEL/ HHU^65I_'""/ M.,R/>)1%@A0UW'MSL#L^;'>#&L:[P&>A=8.*AFZZ&U91YRO%)\1[$;T*%@ M;>=5Y;P7##67D35A##P6,6^(C25G";>#+\VI,,R)SLH6,*VMM);]2EN9HV.U MA+X0P).YW"CVAU?&03A-$^;V+ 9[)E8=AA2HOW[_=SD5?<@*XI*SB0.,/KH3 MV$B[39ZLHP5TT@(%:"7W#JAP1 #W_\Z\N_V51T283%N'#+94%NQ1 879/YR. MSW_EU)HL^:Y,UUTI9F-M M:9ZE31@@7WKAKVD%4B-UKM"T.:/^@&MZA=0+4SG*4?[1B:^#'I^MT)6XM0R*U KMD6I\7QV/7.UGV> MM$_0[E%VP1::]69/LV[\45 )=&RK)J>&R-)+P=%5?!O!G M1#9/ 4V=R@"MF:=#!R*JG3Q06Q*UNYI)0<+-9T4P8N].%BJ97;+\.=N+*G/1 MY/G5 F@BW^8D-?OKN%]!W$@&K+)G"@XPX;R:&+RQ;"Y@%8\#FF,"R!>=+CGJ MK#'>63NFDOJ3SF5&E8&F!3V1FUX0XKR/:#\[>B6S-=46<]B[B?KMFXBI"7GG MP40,)L:;OS7NDJ48LO,!<867CTSR0K-/YYLBKY)PP!.1]:.GM2Y1:)Z3-_RW M=VU-)NIEYEM&4+*3CG3'28B?!7PE>[M?A(U^E2H27O]TE'H((0<9Y;NDY^ P MLVCB@,TG3<'PK'P1WJ&F.[?WOLT5F\=DEN;;"='N'MS+:&9_YW!XD\RD"$$. MRG-.[#PG.#D'#3Y6ONP4=HF3SW4 '>2-P/_V^M[?4I#5/B5M9L536RDT$]S\ MLB\=@[1O)Y'ZEY\XDKWCW%]9D-;5((=UNW5DG5/'X8!GQ3;XG7]/4?;\C8NM M"\$NKB#+II^/:O@OWF*L]D!M.GUZ%P?;?^#Z2V)LOA^Y=S=G="W%)N&$;X6#3^%-*0)A]N<*SO D6^10Z(C[VP M3:V)E<_$'J6! QH>5]F]O?;J(ISW#ZRNLDOC]$;"2ETW7E1.0I?P&M9:[N9T M[^Q#)">4E-GT%4FC\?2TXQ_O\W04-HQ*@Z-$.![^#0=\Q>3OT;1A#79G*K4G M-P[TQ]ZX/UAZ\*,L.2TPO%B)L=:*.Y7CJMQ/ 8S]1+"=_0T$L)._S]6A"&HO=LHG>YQK0Y!U8EH!C MZL'T^']C\] UJ3F$+N M]^^-?SSE36:TYF1E3)35#)(8\/C7V9@?:.WJY)%EQ>)K$^7SW4WJUNFL7GU< M/H0_&MP7;V8VC/WXYUS,UBPU%@,YA QP%H8@K8XQSV1I#'N]CMB4@QFF=G.< MI"B;;]69WY$FT#/Q=24W-;$O+'%:O !#% -V!IR.$3PY<+;VK(MMR"+FU6"J MO\ E]IV)2$Q<:YKMT^%KQDZV[Z]/MS<[=T6OOGX;3-#G2DY[''F&H,,!/7?# ML6V]8-OI&Q*;)M[B@%4UC;&,&MABV^^+ T9P^J[!<,"?"&TP!*(08Q%D+Q\; M92?]+_=/%!ZQ7,;B@&HGZ+% M3Z$"YT]QJC-OWGN#&<=[ON89)'X9HI=+A9Z4'=W+&'SMF2CW][OQE'10>'JFE\OQ M1T:]4"J\+)H,#Z;E@>G^TX0(R_CFK1N=>@ W!1M9I6#"P'Z@>5MD['_18'70 MDN3_LM$%D'_=V@JN+Z0>0_")WL&(2KTIRLZIV(D-B_J;+N3SQFVTK>BH^$"' MF&S3ZL]QE':%3>PQ+DSP[C9'HS6U3D/[#JO"H!U1[ZQDG=Y M57D N_DK=@')QS\+ 6JBVV'3G[HWO"""9ATN.(!*F@=3N+1GH8^=GWB([KI^>O)YYS-G$.( 7!,3LP?;7&4&2VB69 @?%G>_O!>+&V*Y=LVR1)%1CZ" M(QY\XXOV-'O4($D7-']&2;C?A]15>*IX(C'TI^7MGZPK;)G-22::ARC0]]]A M.VG/BGEGC>A,UDFVV),O&_+U+@FQTF$26^61IW$1*?2KYU73ZDDY=M6W>Q]J M#+C!R7K7BX@NT2F4:,%!#GWLPK;K(4N?%:-'H^0$O8;F8"AG76I<9 MRW%;9*W^:=GM^"*E:RAKZE](I^;J1-7".629E#('0O5EX*"U\*[N6]&PN>/T M1.4NNU-Z+OP^:?+#D];IN.!':?6-@CF9-OA2 7F:24F3HCQ.6&K^M[!-O#L8 M' "2E"'SVZYGYOV13+G1Y(@Q2,58]5/A/3AAUY3&H^\Q1? M.BQLD<^+), T].. CC$9^27.<#X#89O$J=!K J_6H MI$WX*SY?SBGH^Z'S\ MO':(OC=LE;D,J9PEYVC=Z$M*_PY9N"CPB MG9AH^M5&9[K[ :ZWH7']A6+"% MV#+&Y*-A=BQG8[!3@[$ /XTTS9\O7\\T/&-8%U\A0-L/M@\EMFE,F:89VJ&N MTCUL110#!]#39P&#''\V+"OB@*Q7D,/[H-W%"]["C^.:#:J^);N2U!#LKZ%T M:DWKL>-2J7\>3D8[*GW FH^I.OY_3^$;:V]@'NHVJTX-^61*7D-/Q%2P.0" G @[; MV@ST&MU^E.235O.0$@^%U7Z 2LA&\PAIA&=R1[XT#^ (Z>NP8';PCR>"=&R2 M^9*W04CL39BS]))TRD2W'N*]2-'KN;;Q5>1JWNF,O$!CRM7-4-4 =5JZI7V> M/CV[#/GI?G"YQH^]U@/VMMY$J#_GMVW)4]$)S[)>$AZ*O'7-] 9XI*M?2;Y@(=)>I6J328RD+BO8 5>#I:#=!A*X@!T-'TXQA^"?6>; M*H8.VX7L+$,PA%K>D4W3LX.!!S49=DWCX!OL&_U8:9%<6UGVQ/%.(K,@Q7>L MM1^.E60,:EOR#*VQAK#%IUEH72]3"MBJ4PJVEO.X1,Z#^K0LJ7YT$Z[WK9 ] MYV+?TX3[T#$TWW +:FO-KFBC^DQA--^E]:JZML0>1: .ZG8M'/"/4GSO@))N M90(<:[@;.KGFZE#P;+OK-@?=HXIM%)NTE5T"G#WGRN.8:7F0V.8*UE9(ICX\ M_Q)N54-X'/59F6UCY7KII'Z:S_\8OE+O%:PR'SAK3.UQ0"5/M_U9TYTVS<+D M5@_6'%1%VA1S5'JM!?RI%S/SX7R*SV&7T9CCW635'5O"2 LW/ATS*<[R/C!.WT8B9? MIL$V%C);W[/Q[ZGI0K-% @31(GW9MCT;8=0@+7IC"!MQ0A.")4:6S"Q.H -W M3,^V$7T37+X372Y4;*I,7"-Z!M#\IV[+/]2>T#@5%"XBR+9\X1%[>_QFR39, M1F4,GQ6=0]9-1N%[-3C &%3SL\ZZ;8*'97P3;?10DVSD74O!(SMCAK8;-D"6]*?*D,- MW46R(_RL\>1'>EE1_FS?;.M6#*<->J@>4^W=$N$XYM$2Y]BO^@GDS?(5NZ=FQXM@5K>*.62>/\7 M]X!KEG3:C!N-R4=I/C>O&EA-E>QP7!"G68E\>N[J\_0U(_?K; M'BNX\SGI 5)W'M3365(+:/HYV-&TK[_P884M-T?5E\)';Q[H>MC_9"+7A32N M,B].&"NHO#/?3\[A=C;(B27'4@T&P39!DHMD 6-E%_=>=1L_\=1DCY6]/>QZ M3DSC8I1>_57 R_ +U3\*TTVH+ NU!(5YPW M48(?J9=Y!S0Y0!X'W)B H3VS(&WPF\9*%$;W\X6>"M+W%)D(/.["%SKZ':@[ MIJDONE[,J]3#8-#%A .(ZUM-3S;\<$"((1PK9701Y9X[(O+R:_GH6?>*#7X" MIM+39[:MH:FU4:7LS)CS6;U3Y;9F?O=7Z:X/7_"EO? +,/8.#+DJN6L,\*<6 M!DG.=EEUV)5>]]Y7CB*&XE9CE9VQRD.T,(2,(5V5KDU\ MH'#X=H+% R4CK^]I8ZB1:F1H4>:6E])U#7OU<.'D@_K=7X%,(_W81BC4[8=] M',G^+&)&S$)<2^F>AN9+7\3TGD2RD4$N'\D.:[YF,1?,=@^3J)0B] MJ9WD>JW(0)KY_0K8GOW'XX7>#QLDK 0?3&JWC C0'%@N4%%F&8%N\F$!A-DL MXC];/9!1..!U"Z@B\N'<\.^M5DAE\Z/;[M^&7:KK*B[TIIG*TFOU\HOL)@P^ M5K>HD;0+[*0N;U?K]Y..X ![HXQNTC:&YVE*LR8AE?N'8D9D6E.AIH,S1%UG3L?H<2.%2.*C"-Y(ZSF-Y:GAM@P/JR]S_YJ(, MB=^6FK9CL-30@-+(XCQOG!@L,R[L^OSV[28W(NL[[+?3'ZL;0=AC+)2$H1,1 MA+"9#6RL^+Z*)*PVS^6:,M@ 9PAJX)+!RA@!I3W^OR+B$OF/[/?3,H)0U^) MNJ'_MG60,U1Y)"HI='^X<6^^JYJN5\V/N7JYAG/$7]7+UK9P)Z&%N;\ 4^KN M\D'+1\BZX)&W%M$9/\6T@?'VU6J\,L(5YF!,ND0;^_3S]G6-?YDB-8U ^2*, MUM8]U_=1F6+C/ %>*1DS:?9-&RG(K/9 UI&&5T63T\@XH]CIZ2MO.-U\'=W#%(BI5]Y6!3MI*[UE[UL^)4U/?$@G)R6@(=5AA;KT8(< MP2HA;N& 2?4-'*!8Z04!8*M^?U:K++.N1+DQ"(%F,[./*CFV"JH?[:T",QS\ MXC_4[KD._O/@%,_=GS;,(D+FG4,-C>RC&&A2YT!MZ1C61727X*_GS#H>@RK- M)5E/P%E)V;EP3@K#4/,&\B;I%6BSJ% FV3:F_3XL0RO8+K/1J57"]:4"% M!8N$;%I/0 ZMQ/Z _]?%_'KATZVNF#B=J+&@1)<,E%G_6 (J\ " M>0'.K?E:$,+\LK 2)BE+&F33=B;T%?7U31/LF6JH+)3KH?7-9F>.+CF>OL(I M?W P[D'_8S!B3!.L='^HEVLG^7H$VBS^LA\K>%704^D([V2:+] +BV>$GA_7*%V M9"_W&9OJB](LKM?XJS3-UV*597-&<.C338Y'GP.U?,1T%LTTJ2*N] / \]+&Y_$.9LIY]H/(=,,TKT$:P]LA,. M A8?QP9I6AP.D(D>2]5K4-HG##)[-O&J"Q%*TPK^3MVWR9[46E]?TS]]_.,Y-W=KXRD;780DR'5FD*388M!43#A(S_2)-PQ>=Y@*'Y^YV*H*[::K[ M"MS.*CUL84U(ZQNY/AQS"Q&5/9Q)#%DTV>+ S6NTF]=I(*2+(TYL]15'HK6, M1QOVRZ,KK"$M(4Q$)>N1R^=4M;6UNIC;+/K9_?W=\/GN0P12Q=\0!\BK'6#_ MFL8!1ZG2CY?A-%LFU^*,0CK$BMVG/Y4_X"@N4,O4]%]\+OI-3L]'$ VHC'"EJ:3+*/)E_$Z M?(/0PG+I,4EHK3KB=.^I;S[WL%CZO+LG6[K%4^/*+U*Z;'E;[ M!X#F,(#$F0F! QC@ZD?WXLX)Y!Y+&,9FL@]]4Q%%/\UNH%1*-WWEM]$&?(_+_TT1<46+!VZ?V^@_C;C M5?VM].7VF>W0>E1Y'?HS?]@9C-*>'E,9VA4E0AUIC(KV''];H^7=QSG )+ 4$J[S=-84K/R;*L*H_1",Y ES5KSX"CV+$!6.O>1 $O^T3WWD=EVX)3E@@1&*7- M%:8_%!$E0A/)F_8\>3RT]H5/.]MX'-DV]OZX",J>)([&CH>J_H)VKQC?.>?H MDT:NPK\&\K Q^KQ2XF*]>I?&W%GH! S6@51'?R0]G?+ZB#_*PU:/9N%]1/A M@%HPT$(++Z1--(+"R]=R*A--V29CE.V_#R(-FV3!V \JHL.;"Z"/3RBM##(C M!UNQCT8?V;-0SBE#H6N[MGM0U3_[S1)N,;T\AW.6K/RG=;3-3(V@ES6/M?1< MDB[S20(=J)5=J]V^'++$^5LOQ]';7HD<1.Q;5-6>B%705'WMG)P*(WH?^T-* MKQK-(5?LAPW/1C[A]3(=MJJK.PHL261?%[@7W$=Z77L>?]L>U@4[ MUO!7!:E+(1Q#-99V.()5Z(V[0CEA\'A4__G>VA+G@]_1.6>EVXL;?][L3S\P M1F);>[63?ZE):=U[0 J5S DTO?F^_^+B-1UEE<\B(WVA_4JQO&:MJ)X!1TT3 MRB%Y7FWL*,KNA_"^P].^G%!IZB[G=KVSKE!WPP++9'O>P;OF7?TNB7VQOBP' MBN&'%R+ZV%NFY-P)U,5]9.N?0UH"I-6+@P7HC&[5F(N&5%@>&7,J%WS;CBBV M.9]^YU)AKBN5;9$8340JO'#M=N99X->*BNJ?Y6'#XQR1A"_8;1JIB%.#B-<" M[]UPNF'\P]L+2W'CC=Q#B(9ZT^,MW+MDI.V$%FZ>RN%=+>]QSWPJ*UUQV%V^&37)>/:%%!). M(^8\ZQVB*6DU_S'/[HZ]2$;,5/M[3^S1K]6]V=F5Z?JZ%30!'!EE$KQO[*5F MJ&/ZL.5>\Q#!0R(KO$_[)%T#XA++]<0 U[K@)3&5S>/"E-C/&@(9XM8E7L-:[ M&37KM3%?UL3P$Q9N0/F@6_1+"#(5+()/2L;,O_BJ@;?:$_UJ)= 7=H<68V,H M\YKPPNZPE! DN;^/:F.= R]H5V*1Q2I<^ ]?[= :;1\FLG'#?E\AQ)T:?[MT M5;)8C O EIUN^A$CC G7W8BS]VN$T24F(_?E8XDNZUW.BGUYONERL"?YW;%TO3//4O=L M6/Q;Y1AL3;KD&28A(;[W?(1";PQ*PWF\ M*LRJSU/SH+NER_>L485'?&^-WZZ8/7*2!\]57>9MSHAY6>+TO>0?98H_:"NN M$XI?_-5@_1$!#0RLED;L;NPY]:_[\+>S?Y9^Q96JF]!0L7I_8>FTIT3'@_I MU/^X]>#;\8\'K&KEGM,C,0 M(&C24%#UJS@X_8=HZFC;D8.^2TL>0UI.A@&%!0E-?PA)R^K&3H<;]8R_O$+$ MZ>1O,SVQ%S+ C)&:_X %]@R2LAH'87^:U<:B<,D3*7/F*_7/Z>*-M=P0 <<"QFZHVUSQ1QWF"CUF>_L*]3U MI]@4 2\-UNV,&0=DN(47>\!N(%8N#' 7!?[IE9^O(DS K&PMHE@=S/'$OH/ MQ#4/S?8N%UI6U!CZ1#:QVZ";9;5GV"['YKQOPTUO2)A)K:[027P/!+5^]X8M M=C7K"J\ _1@,8S>_X@#CA/#H[$W+K&1_GJ_3O=Y-E/IFTT&*B9&=!X MG'"097?4PDXH"[)F&J1QIK5QF?-3H@"3(N5T;3H"8Z"OI9 M6IHI^%U1,[_!.TKY7/6%SEM*,\_5_1Z)%1L6$4_J0:0?5C[S(4BHBV!7"O8F MEWO)]!OM(7TSN;9*M^_&2::'N(<[KD%JEA1-R7JD]-<88J=(KRZF]FEMZYPR M"VZ_A52PV)?B]Y'.J^L\&!C&=]RGK,JEPLMR$?V)<$")Q$2GB08D]36XG[A= MH/N>^C=X=J(O9A3:IULQY;OCHD(.4^<:0D.E% &R_E[_ M?)M%_]ET!TTY.D^WG8%#DCTQM5"2FD\MWZ5SJ;@F=6CU77CC'\\$X5TO?QM: M9%NNP>@EELI1VU03:RI37)*?]LO*2.$G89 _NG:NG&5/WT+!5B6GH#?U862\ M=LSG/IOIQV'&DF>/#%5MR3^?!_-;6Y"_J*=>,;X\J+DOW+E]//>Z;WH.9:3$ MZ);VF32"(447VL4J""1D(NE.J0]$?NT$4@W1J4V58= 3SI=QZPBI]1>SUHQA MD R?VF+NFN_Y ?7E WT"CL7L!5.&)EVI6WEFN=[Q"HP.X4\;*))=<_5[M[,) M7.8J7J\$JWNW'-%?86'7;2%3!AFY[R"6R5<#AO*B&TEV=2M2JFZQY(X9]AO] M\DNBB'Q3WJ+8)-F]DO-Q_<3.$%OH3/)?A)NR1NF92M?B:A?M*GZ^M/O H^QF M@O%$A:@WG["F4QEI#/=2)&:S46UG< !>^&MG!![1 M/IIS0+,"Q]3%K*=&/C^=\SF +,DAS:3?R[:=;\AZI?L/"@<,]I8[BJYD@! O M>@$7@NM.(%9GI05Q@!FHNW^7V/\J=,A?+ 0!C!,'Y!+G[0PQ(W)E5OS%#G_U M7R.R0]BAI",$K9,NNCS7N/]Z?=HFZGLT_%GO% =<<@3>P@'5@QAFN]Q LO:% M8_%VD']FR7R"-:BN7;*1+T]]VDFE318?NQ'A<(][+8J_OY>4+-]SZ6TF(+&! MGW*8\-G?^JM(@TN/^"AOGRW;!STG06<2X!G=04B_RGG0+HR-J\M:^#G3:BS'(AR21P!7H'GB:^2\/ ME2)9_MNITN7_=JI::D7CDADM_R.LS_?,O9M%X8&7[*&Q+(FQSLO *7PC\*(UH1L@OA!\1 M[3BI)VEIW$!6.A3SWG];<7&'7*;WZ1 \A9/KF^A-ETPBDY!,[_:_YU?($D M[XPK.+ET0O4%PI)D_>&6A_CS_"U[FF;!!)50M:8AMC[=EQKMR,Q&^I::^EU.R3A[^O<-"=IKJW@GI)0#[-_^S6[% M@+NG7?R+-1YA2)\E6/G"RZX8;AFL55J3VZWCT@A%T:/Z$C2CPR!#TF.X$-Z- MW+QL3(9.RLA<>$:-HS]1>+<^*^>+9U*Q K9(2JSR1AABEQH,RM^2ZXB!P62F MU_/""@'FR4T.5A9^8M:W@_P[>->#7J:;52WY4CM^B61Z;<*C&F!^WN00FJTJ MIB\8+UU)MAY/R[A6M51WW23_2230&T;F\R+BC%=D87?W2U[FMO1>E_UB7Z!< MS77)1*)9X2!:D8/R6:[1B@69Q+OX.,"Z:?0UP:=7_KL_+3*^4,_,(@) 7@KI M&8=L7'5A94'0[@(U71<"?8(##+'EV%1W'&!>6%P=09!2KSL<>\_E_J.>&ULW M]XH@L-;H//U$S^H^,;)Z$+ZE#+WC+],\C+G>L-_>>!Z_%P^=[;I %[0M>;.Y MHKMLYUA#3%#RY78&MD&S//?(9-H(7;WN.DE=[YX);\8G6)-8T8H$NB)GVH,Y M*+;KM'M0_7VIEI$W=0@/I4^B194WUAG)\M>%U&XT=%^C3TZ-._?0,M7P9/9< MJCV\SW+7*"CC,>N^> O(F877PE^*10^9OLR%I]&]G.^?:G_-(JCJ\X6&DQ9: M8Q)J^/U>^,L[D<,++QOA:7=MAOO'^BS)>>5]?=2B(G. MO0!5-2^4%->#_+HX*9=II#!+/!^>>DZP%^GB#3*_W0MB$5ZQ0V&S77/"_X%L"D;8+>1WD^2TLB;L1%U$^GJYZA*6BNM[);5TY/S M6B7/VC^ZX DYD@U=)A+96JNILI]B)YX/^)A=!#U^V[KO6M,I\/)T$(@\VPY; M'Y@^%V0::Q#NO+E8]N4U>0GYZ(2L9%1'ZTA2;4]4:Y&"K%IE[6H3U9#'^#BT MI.@KBN]V!E])\:ME8IWH12'' >\VKT%6^LOSIMFJ\JJRZ"Y[)]+;235%SZ@H M=]Z>4D?!I^WU)?,^BJ;9YO>21:\OQ?2OM ]T/C"?"8UHIHUGW*@2G&_<_- M*L(& 'Q/Q9NN$K0;D?":PD^' U]2),>;KE=]O5738/@^=;W5F_JW80N=5 8P ML&86VV!-N]X40M)Q4[" 0_'JQ-]X6@^IMB8/U9 ]BO_LK^U>3:'$OG2/0MI& M\U5#;@^Q,JMUE;J,&C,II5A4Q=&UA.P#<]6O9M6VLP*$JR5R,A$$!+3"WOMB M&K0FPFQ<+@QWV1C".NB8&X(A^$IOV;R.0M.XA:]1",<+5SB8)6WUX!]1(S&( M&<3>P>AE/:P:!_R!UQ.,IQ0_9$G-Z60118YFISWV3UKWR;)&S5Q8.(K/5$ML M>-FM%-;@@%205+N)86?T3QVEL"!RQ3#O^J;+>$*HAH\A$?1E"X/7+N1[%MAO M?4I N'YJ3387[SIB,9'49S+N^L_[N8:T,5=92,[+D>N'B)U:TR5S$^4C-F5# MHL7@S-*0$!S H?'G#YMPP-4]E2V>8S@% M;.$[#@@YL_[XCPU=X7G^DJJ=PV+RTD1VU:X!W\3>E?>@*F8J0X!/,J[%F>D> MA::WS<996NI04PLO.\P?%<9)TA7-*[-<.-7;1^CP*0*_JLBE3_/0H*!,<%W! M-H&=(JOLSC^)AIYO#'"I9SWOEMYT)JU./5^0J/I)4IC?+. M9-/ (2MU@MRX MJ]WI[ J&@J/':WPO'_9BMF'\/2S"H-#P3ND]%D6[@($M1164194X8/KCJLC. MO#@.2%3-Q0$3TSA@3^68'I/V#@>LZI/O?).Y<]@U%*B4[ZV/?381 =LIA&T^ M,+$PR5@RO60SX< !)<4XX$NN3XRO!.P(#"-QIPJCT[+A^6AZ\/V[AA?[:U#"$+U#@<_6.]"W+C/T_]5:^PM_*7#$!T8P M/9!3?&UD"%:121Y;CS@1.:K-/[38N6(<@\VE%*+?5\1=DKT$S6^'7=TJSOJC MV+IQP%D/[*.%+!)8+6U]X M3_IO5-N.R8(5#F"F60!_&P^_Q>(=8#^SBUAIG<'6\A]3;UHBJ+"F!5,?T-J7 ME!/\2R0D,L(OCM0R0G-HDDNW"\IHV6Y_6Q^83.=:M$R$T?_/S^QI/)F1_)?_ MZSLPMMA8&\Q5S/;VZ)%K::K6I\GM15(>:ZEG>W&^0]_R--?5*,5/%-H=K/KL M+'5?$3)\-'0FJ"' A\3G:RIH/KU3Y6PG>H=&3/,R>4+PD5#>L]EH0C:VA!89 MG@$^66HDK_2K_)@6 MK9UUJQ%=N9@I.#""AKQ_WP'(#2^FG3/5#2UE_S6[1Y]#'C.W>?Z9JSO7AYVN=Z'WQ+NV92O\[ MHSL8MZP4=7MTB;>I%OQL(-!8 GY<>Y(2 UGU.R+'O-N'G=KKNQT28)7J#U W ME'% MGD)0V?6L0PR'-OJ!;D2*:S]\T *MKD+3 @[B.&E^OM3*>B(->SU*^8B MR'L-8]E0''"/,P:Q2PM"-+?!.D_^;\3JTZ-J3 @+:+FJ:8@E[%@P>]L?:X@] M8F^"N+K$-.=-(@&6R2 M>P*T@M>=N@MYYU4E,]XA^@W/WI!-_//VE^J/=>1R'DR%.82$TKVA9;WU6"K< MM)SF@O)2,KF;@M,%D^92$P'P5'I:=0_V45$@.J)?W,BESL*4@U@D#4>L'.S" MCI8@"V>HK&T@XQNK(XZ,NV^(;U 3+23]"E@4>@90:JD63;=YCQ=3 M'R58Q5)HM7JJ#1!I,=X?SF:L\H0KLJ8"O[^5+X]#WS08ZD8BGPWW$/*;2>:M M J5\VC;:F0Q2AM\2%91N(JPE[SSS8+U>;X2^@K8R178\:V.5.A;7:% DO';K M'Z=G)3&?JFO^&"J7(!4'&MK^#,^XL)Q/,?#UEX_8A^8YV"D043/U%XXNSB'( MPZR#*\S@&>QT9!]6*4=/I?=R8K>_L0&KGEOF_O$W[,VLXU\"JH[&GY^X'(A3A60^ZG.6]8"+P0^*Z.SM0^P$N4 U+_'$E=&X>:-=CK M12*[R[J('IA)W=^X5G"3TE8SUE!*/_N6FN(5)E7J:[C6+^GO+GFSMS]-N+U^ MUW(M8%CZ]Q#B(J> M/&WB^!EV/Z'X3*MP;?5^DGO7AE9O$%M/,R,.<#^N*J0^ M3,A-O&72ZJ'6C6=NE/<[7UK4LUJ!/3*6*7# G2]^6X[$L_;R=.:=%'5D0AC( M:IVSO*-O$;+^!NU(]D ).KE D@H]_ANC:'3+8Q[TRP[E M?^E<*GTOQ\T!FJEEL\7[#]-;/77B?/U@N]6UDCQ7-:&K!),RU_B]\@ MF7!CSC%0371IH//U%[,7&9?2^?/X[$%XCP",!V>:0GUU556BCW7HLJZB9O O M1?5E<4S C[F*8PTZ6]XW5:PKEKE$LCB Y_;5^8^R'=&?\R*%"OZ6KRS>??B9 MD>06K!-.5/&]BS>C<.C]_?>5::_@-&/F312/RIZ03*H7U (/53],4VV$#8QO MYB1H]QZX&<5J^*5NR!2@A0_/LSVN'<[(O[Z[JF!K9EN:1BHTLV0^*_;$I5F\ MN]\5PE#1"%%&^EG?2+. 6I/8?=]CJN"A3S[.H6L-$@Z2.(>K@A,N@R1',OZO MN9+ -&EFQWF.6;Q3)>,G/-LU_XB?,04V&8V M4P!)GJ%-G+OF7B]KE1?!JA$;E#^IXI3Z[(-W%KDA'=T GZ"F M'1;:@2YV7+\9I?G[!!:" XYU3IU03J#B92])K$,0(TG:YBE''3PVZ ]'6:O% M9%4,^]UN*0O3TAE:FB/]/S1;K28$J;E^//3WBLN.Z= J4+*B:?+" <'>4Q5& M%M?0.$!^3)8>UET+DBI3*,B%.&R]_^FY#3_]\0M:S+X\2U+R[%2-2/>A2>P# MG@W%JCP 5KZ(/_0VRN0Q[!PL,$;ZZ0Z=8HBOKE3W9&VTO*VJ7P[-TDZ MBG,2>\L,4G>\Q0%>X5]W7T/FOFZ^ =V5;,(H1"L.]5S.*=%C[APZ(ST147X1 MYK)F4>4V0W49>&2$BX)' MAA49N4:*\N_=BJT2A=Z9IZ4^K1!^;Q.\F:20:-VK__Q0FX'_B[VW"HJSZ[I% MF^ >W"U8<'>'8"%X< NNC;M+K4]^^S MO^]FW^V+KGKJN9AKK;G&''..KC6?M7Q7"83]XO/8=F$6J&O@W4#S]K;? MKYZ4:AA87%\^O6 B)<+(:+PDYEI^YAX)M^4)=CN-R]U_+HD3M*8:1/VKM O@7QNOB) M]3=[%^M9:_&&[9,W#[?GDB?X2.\QFY\BQMJ[?URMS?C[*],GCYW/-_3NTB^_ M D[DEUX!5Q_>TEGTKJF=>APR5O_VS6L.K1 MY:9U;[+U*/@NXI7GCJ@>L-TB,6L%J-*$B8&"" M7JR6N:+7PF$)7T0Q87-+>W4IQ.L2Y$C. [I0JM_>HRX0^@NZGVW5O0DJ4AO! MXEJ0W1-9Y3CF#XC]377X5(Q&.">445KW%? ]3^\54$"O]0KHBS9Z$1(GKLW7 MEC^Z>#2Z).0R@1J/G<:(D?FX%0,1AB>3H5U=P>K1X^%37 M'.RYS3N?ZSZVQ M=R2=G9/:OF253L]HHRZ7]Y6_>GQ>/)7 MO.^]K,G=%"DS0!A&P8)V%86I9HW'3SFM'!TXS4'.]5\!3_3$@4LR&:\ )/=: MZ" B2+A7=/W9\+Q]-BNNV?8%V\_AY7N.T2O@'4O PSG IB3$F"*U]3R@DS:= MKY%<6?_PSY.W2B9\,-+ <^V]S<1_;Z?ST]WE0O,W \]MU<;VQM:\?E"'@A=5 M%/Q-=1P413_^KLNW0EDT]7\:KPGZ5B#^:#1)(L/EP[%S+#8Z?G"SZ(_[MJ&F M%*LBU? MI_?W\=EA()]/]G/C;:=LPA@B'A-A-Y,BW CO&'2/3/\ M_\KEI>)U5$&/1M.$;QJF9/I>AN/)SY/T[KZ@"141&Q;:FZ-!0M"(04 X.MN_ MXRP@*\D_)J*?8! FK]+&$W^P-X?$(]ES6 M7I]M(=(D0LSP0P< >X*,Z;,ZW_"QWOEF+8D 88+0F3 MF99QI$]UZ(A:@.R)@NCS]C>;_/BK(GS?A9G0<3*;76DZRA'>KLWRO$E09-'6 M5X"D4NTK( B_]\F]8OUA6[6CJZLIO!_4J6PQD5R;8\>+KS+XHGO3CQAU6!E< MJ.9[K9N]Q)Y2H9"IH!8?TX7*>&Z'OE];11 BF/@]W_NM_=\1P: M704^Y$VM/2>ZK!"M.CU5K@?\CZ6H[_M]LJDLH4"T>0786J'WQ<^VO (T"1D$ M;IP6H_Z2]@I4!A7^MA[F_UD<'ET_KO<@>CFXCIIFPG9-LX5GC(R1J:SKYT/ENZ-VY]- MOB.VD&PPF/"GPQZJ^;C6/"$$$+,Z5Y.T"YV>I*O9J'17005FO[L[&6R>*;!E MQ#? /+;KO,G8!MG\&M>5.FTP@:")7?V#6X ]RG=1=1 #I3O]]#&DRL 9S*3 MV]EQQ5ML;A<3-4);+\;A2/ 0>9# -#3MQ$02Z?:S*N\/H=; 9Z?V0WFGW-@62U$69R75.$/X';'I@^=?1S\478U#RP3@$-1#^!:J+3SC,'%L!>L[PP>(HZBD]46& M6SS_RNMS39ZI#[:QZ%F?F#.C:ZLXZK8LCR#]H^7'BZQ;H&DMU]+']M?U-[/4 M\5EP5T-Q@Z?KY;5$"[^?I,K[5O!S";N3:%-WZ6<#?4^&M9V?(SYT.T@L\9"4 M*.C-8AI9CY-2WR],HC*Q]X'>"9'>B7 ,.Z0:@W\Y0Q.;?P/3YLKE)W/T3-W; MGMF4.CHAB#'D9!9_Q_54XM@3:."H414TM_A&1ITHV&AJ,+_<:+F=>Q]++#%R[*(>@YZ3ST'M MZ??:M)"T#:3C0]2OKX!=H:N 9W1OBA>TMRILK^R-=2[[7P&W/"K4X^&9?.GN>M=:NVA9J21\OTJFT):&RN M45H"12/PK-'54JCSV(;X5^+L5; M)EIZ?'X%0,_$7G!Z$5\!3.S_U M4IM@A>X\;U;?D'N;]#[1^V.^L7RMU"N@/T;L28/B*N=!["6L^^TE OLK /(5 MQGGVS)['#>QLM$SYW\UPA1UJT?'A@(L- @MQZ2)*S7!^VWNF*RG/\U+)# MZ>.;<.":DD,$>;C>\(YPM+9,]SQ6_B>+:%VH*7BDR*C:5H;ZO5C^2,!LNC@] M L:8.@"S_.Z_FOZ['LK2-[[>?JNI3VSGW@C4]&WV>++_NC2 M@'QLV_7FS. MB<+ '^?^[D)UQ^^?#S@&82$ZR?@4,>.R\ OX2WXH]$0Z^ H95_^>PXL04:RM&MT0]_WP&IO%Y M[,TA3V_;K/72N'X14*_CL*O0VAT&Z=*J)OEAXJFFS+I I5]@'$]-^F.AU<%% M+>#?#Z K652^G5Z;A*/%JEAL^#E(?8@XA4:O2BA)R%DA#&[RYI/,-0+28QL] M"@92;),M](9C#ZCA,9180]W\AQ X&3-XGV4]X]PK] TS'>_?([=J1%]0XWCM MXL-_M01C,GXJ_Z%4LQB?<7B9,;#8[MS M':B5)=.;_O9>L6+X:()&,1&41^OOD.B"/'$M"CWZ(ROB8O3O\57/&QO !N+U MS-*(GDZ1RZ)N%OW\M/WA""?UP.]\^CK.^V@4ZK;RC.#P)KS/*9PQV]]$N-A; M*JZ\?WP%G/\G2SC<8GH@J0![WQV5EMA E:'K&34T<8?$;$P^]@"\S<[R8]0Y M;TCKU>/N/XV/;MQ+]K[B:@L#V4\N6#1 RE:O)R!/UW];^Z#.'#.P5&$R V>J/=J^+)6N; MU+J[NN(3S]:$81R8\Q";Y>>AGH71ZL K2LED\V^P3HS:IF4@K6WJJ#=&1KG9 M97O&M/[GL+_1"UT+N3*LI_HNM+CPI(>IKA-GIO$\7358'A4_YCWO?@R=M_?* MMA.OU_>1P^:/OQPR_I!H%--^]H^_%K"Y,T(Z7=$2)5HXCM;I:8J1YO;_Q C M.7P "N)/-2!Y0K5G7?'NRB8Z5L;@N)8KB..+. MB*TS"C788)^EMQHS)Q)R;/E8X9V6@5!I7Z[\I5N_D<@9"1*LH:;HE@ :ZG M&KYB/T\RNSJ^0U\^]/:V> WJLO1&U!(51$_$X#G2PO']H.$7X#>^!9 =X@V= M:8H27CU$/TJ^ H8^FZ--?%AR(XK0&#FBHA'Z:F:6C6&#B63E3MP:=DY^<3_$ M4M9/+.5W!+Z'\.5B*9"52 2ZM#GR4P?-!PJ!F";N?.(QU\'N3NM&GD420 _Z M]36'9CK94.I$TDH'RN\I0]HA(X(W(0M@;XS0HM-:/Q>W/5CLN@QQAV:V?Q4T^^4',0*( FG"9H&N*=H(>ZR M( Q^O3HOZ.R!P()5/B5L_\GL?F*F1RI^T4QT1!8@A0GFT/[;/1I^?B?$?U[; MI4;9TIE\_KL5E$P]D#@6I]&:(/G9A%EBG\RK'W#WF2EET5>LP-K;9VO3T'8/ M#R3F46W4R6'R+E0C)4F>$H#H/7QUD5,*UFTIMO7@BP+F'-Y4?>M<;$;2UHO8 MTSP8@Z7@\@++80BZ LBCI1W_#M>&-J%V:O.(*!BT$J!,-?*V^AU2JN6G._ A M<0XF!UVJ>P8,I!&04RR CG46+R^&NVR=7(![J"-Q.I*QOXL^(R"/GX@&!PHQ M,DVX95VB@<#+R\L=Z5$959=#@C$"U [_D7W,_IRM156]]SQ."1T1".-2]Q2R!T? ME/Q='O6;!W_?6#[&1-1N%T.^=69IV.^B=,WEFEJ3R ]=";9\$ J1KPX3W%&3 MR3,H<4@[FDJE?*$?ELZ!WR!TM5A-76:+)H(]/X=*4W8H![,IV( M?G@3-J(4&_$I/_[WQ#%U^ZZ:6Y)K; 2SU0P>,D46 M,I@+VA&@U1 M.R''+H.8H]PP:ZJ&1A6O -/!YH\7\AQAW3R\VK-N)KV?-6L__OX0@4/$TU>9I P%T^1DW4C1&JGK7@ M46'Y,.UV9.&F0-($28[2RX>ZGS)QG&: Q(\)B4DRN]FNF!"_FNBBT_L67E!Z MQ/XR39.IE>EB,T.:@#9>1+W6-\Y] )^^*S?,R=W>_ .?49B1.=YUR#?\EK2T=]@&Y[,"0'P&3='ED9N#!-=58)N/>RS<9@W;!X M:Z\264O19I;FU,4D,(9E9][$=^9?9NTFLI=.,R[-)*V(T40A<;1,MR^=7-$D M;T\RSV(U4R>^F$5;)W^9E^^O_G V#_(;@+=9EXAV\J0T_#^+&F5[6K2DJ,5F$ < MV1%MPW.. @S475F&M9AE?L2B=?.%-*'V$:(9RIYM1R[FV7- M<@L49>(O EY0CS-[.RLI/VA6XP*T,/GR%$*DPE4:&ENBKH\X1V=3 M41,,<4=65L5IS$@3HRZ8)GT]:&_)69!=]H3T6+ ]=Y/V*,ZE@(Z))<^'"%QA M%E]2!80XQ,E*0WS%MQBNFFOJ?C$'6'F):\SP5L7DW\S(J=C$1[\IQU./OX89 MQ:?+Z"\XOOV-3GY/K9\3D2<'B7 M;2IP6\@0'8@DN, 56A\UL M,0GY?6'JQV- I8HD=0IDW(Y^DG#;/>==MF7" M[6QK[XQ;PM?YXE1NM],(<$2&D273UL!\MWYVU=/,%L%:?5&<=NZ; 2Q")_DY M%-W&ZO\E0=Y(S4?-]W/:-2:*%[0C2D<6;X!GG"]XJ2@Z^^=GB=6A\_,9CJU MG 'R#XN7=S[/].KS+-Q_*,.$"L@JTZY]YT"M:KXNZ#J,# M48+9WV7?3KN+LMH.7<55_/7[K:FE8#0,OL+@.N0]L.R7, MAG:V9X "71]. B]K.6T@X/D182".3 M[09XQ:;'WZV7SM_I^ H8P\<>#FE&TX.(+FBP!4C>VU%P^VAWY/+SUZK44LZY M&N'8B#+/.^Q!W+;J=Q\.TC1Z6]HB6#F&',@W#K*#93S%!FQ73F GFFLCB5,$ M:PHL'8I/ST035O@P5O8T-M',-7P;<)\NNVX6;FJ5FW)JJO+;K#+ITGA<2)X/ M:"P1-[2B'G(O5>*'.DHR O8FM8.;AT"N'+8RR-C61,+%*5@#9;,3\J2/*\TZ M5>/F]JV#G;#.GN:B;[4A. M&]AA>=Q<*J#H4#]NXA_=#I 7$NF?:1K/;;K=P+83VZZK3^E)#WR*22_73.,@ M3M^'0VP$Q5$+?0!A* @9-@D=H+W2I5#@Z\ZAIBE'\Z^% M%] $7P+-V2L*)DSEX!T)( C<&Y2U>Y1H6:P-EAF577(MJV'MFFVTH44V2I0= M;\I+ #@(/&? 7.0THBCJYZ@YP+X+K7.+PF7.6LFWSE&,ZA4Y%2W8=NJC& > M)H !JET+NBQT7X.IQ$"W7@8[&U/.L>U:F$_ZEL++>4.('?&#HN8]%1UF"BY8 M'6U\J+!>0G7]!D$P[63M(T++B(,E;#4V")/#J-6G R Q7BGG&L.#>MIEJI=R MIQ%!\LV/L*TK=S*_A,7*;"+M[EFL[6^0U"O/B8:=B>FCF]N[Y$OU; 3)"BSH05H+,/,FYB=8;2YAY0:S0MKO?8="#' MH=Q ;V@MRQ7M\^%LK!U5N)9C,$'2$5/\^Y(": JCTV&^44K8H.4_%:7(CRL, M!+_*[PO"EA7@CN]A%.^VF20$&G,]V@.YM2E;)(!#SB1QF'8KKOZGQ^0OJ7L2 MS82BE"?0?)0=D)+GWJ40 H^%KL_9-F9]T* M6]6*POSBJB);VGVC',4!'+!/*CP!IQ'NP)+G+'6/_&.Z:KS.TOD=)I[.*!KG M-&VP=/4?3EDG:H90W(H+ ML^6IK)L^9$A8OV31JDW3IO:9BE:)L.:0YMW7?6KJ KSH_5F"V=VTNI8P%A'\ M6_F.2_7$>9!(ON_WBB2=5E(,0>+Y*XY.491Y$/1::#R39G@]H+&I1FG9@1REU-4]50G!:**LDYUBY[!(S-F;-,<<[G%YZTHQ& M2[)#[Q4AJ=\OWVOH(=X >RP35[]5.CI@9);CO\)0=<3O/T>BKVO^87%#=OEJ M,1)=&ZT.YO>GZ273TQLRUMCF4.6">S8'5%"V?H\M. MM;!@:1(-=/_8)GDQGJ7X.SMC=CMHX>RBTVLM"$OXLO*L-2O@-\904X!3T-#;^VM @1^5"[7UP5DS)_+9$)!HV M^AD%V'D"[JW,@VR9\E"W#*4P)LM8T:=4I:B'!C3Z69$9QS#FD/E/9 U!\]:L MS+N9VL3(-.+3..\_8PMB(R.2C[3'&FDU+/.X[$8"'32Y7(A%5E*J8GTEJ=-B_67",@YZFX M_I>>[BA*NS?OQ/EK/V'^"-FY;N^KI5]^DJW1,0!?R5:<)AO*"[?L?\JI3I(L M,B$R)F*A&MFHRJ!/ /35:BEN2>Z@KWMCQ3F)D[L (02*B[[R14W>KIB^O[+< M*4 ?+8(L4MX%4]VO$JIF.ZI@/*W\-/BR#&U4JE,0D@G]K@HPN.(*'8>EWXBZ M!@H9+E,O,P_8"&I 2[V<$PW7V=8TK\>J0J90WB=!\-!76&$019S F5F;LL4& MW1&Q-Z.MP._4$AC9 M&M)%S:#;7ZI^TN3[95 <526.@>*%IIVS2C'$KJ1DVP8Q&#XL#7.PK.>H&@M, M3Z!"RB!9QY!,(J!!H#1S$2>]#.HRMJXRG"[1M5Z&0BA$S]QZ\EN-!-(Y\6$O MPKQ0J<;1N@*[F0*&1:G(219,VM\/4D]S#N19M>MYIB0H&4HBJ8X6C%-ZU 3T M=X0N'4?8:_!L"NFTX/=-\T3U4<>&F/"0(-NEHFGSBO.#G(9M'L!'X'7I[\,^ M9+%5Z0QDA^M5+ =#$B3U'&NQZR[9D&RT.3A#A!7@'2H#=Y:/@I#K_%X4KAZ+ MN*$D-4B2+2/0 ] 5S#5W<%0$B:LE:\(ZF2V;Y"AYBG"SWT9 MD;FY' HT=>5!=GW$OJ!K:]5S3Q%%Z(,[8,6M0K8> M3GC""5/E@ MN7=YBUM.Y4T8 Z?Y18*D$UU_DZ/%3(Y@+YTJHQN7OW '.;\\6 M%YLF]4Y^_6(UUM'0-P[\AH2XG?E6Z.\+5#=W^NCX4ONQ#*>">:H:#*2(VWT' MNV$2"/Z8&\>\YT/;+[MD\7T%-$A!TR./5X5'0S\7\@HP(M-@#JW !E2!;SQ_ M'LMU+#_A80\[QIK#;UC(;PO7CA\'TU!\9JDVT-H;-?5HI\UWWL1WL0BVU:3XNM"3*_)W9% MVJ).C?V8A(?;L3S5=T_>1RJ!2!<1=+"MW@$U^??E33MO=G/7\'6P]AW?M:"R M4P.>]I,X# Z==[Y MZ,^F:B^C\_9NL)9NGI0&1ZB?T)DP'B4H2=W.0 W"7)7#Y1L;&WH//AIU<8_ M]4T#PA@7WB%QF7&C!RQ! /^=\"9$<>DN/:S6WO58^^*#ROK,;*(S'_N6Y &K MW(;X#)=^Z> ESN9#N'K'>_"]8&X.KE%7$@2(MY].;:5JOQ',9^GXF]U[#E%^ M;Q9/]T%6*>KE6F1.J('+ ;4I8BWM%K4Y^K0 MG-..V)ZY60;:B6#")#U[CC#"G:C6O<<SR;P4G\U/2D.',W8P!8 MER%_6B,,OWC_Y+)MU'+?5%Y;(J3CBS!6,((WIOJH_M<>XD2,2/@F01%HJH-5 MM -Z\Z[D+IZX/I['V"@1O;"F5JR;@<(7/V$0>)E8L2J6,NWB?O)Z,!"%VL%M M("\K==(,8ZU2%+6G>Y';JZ1CD4 U0K]#SQ"3B6N$G<__['#D?'4$ S V#3!] M.![!SQ3Y36RP%-H\D4=WXE>HHF>TQ9P_\I5<1V..*_'^JUG8J8%8N%MB[8FC MC21>^!1KL9KJAT/MXPH^"*GY3"9 MEB0-/R(S@,ASVB*Y:_>-P 3+F5KU8XBHMIU+J_#^ C?, %B4BQV<3OS3TW42 M/VU!)VN-;9Z]S%",P]TEDBA)I*(/GPQI!A-8MCU:8JVE^_V?TULL7(SQ/T*) M*'T@AK9[0!_#1@@]5,TS3U)9%(H%W^4^=E/&R8;-D,(K>8_BC*BQU\VD9MMV MF]7:@-6\UW>$18]BA$@$G08X&9)"DFQR/V[RIIJCM6Z?*+A85Z#FO'QNR@>" M"JVP6W1<@OO(ET[P#LEA(:0=\1'GMX_H2K9CQK*/^CB#QL3B'-FC4/?-G(?_ M3C5+_WT;),FPO.L6>9LMT]?V]LC"-/X-A'XMS0T8<[@8LW=]V(!I%T.D[JXE MGLFL<=,H,!6R5F^R(CB/2M4ON$=A?"+![PCU^H$D;R M)8C'?A^NF(1^TVA8ER'\=IPY>@4-LBWPK$_3N=]6,/&MI1L@L MH33;Y0BS7YZ/FLMEH+;)?*?(XNK .?VC$IZGJA)9O<$T",!;Z:F:'K];T']3 ),MY8PDCE0<_ M_W'<-Y2^2O.6&/;^66Z8T-W9AM"> M4P(LPN!/$Z[ I)?QEH+/Y-0L+%SA]U-JJ &7DA5*SEKT@>QW=AJ8. @-&'U#\^*FD%>/!P$&D-1)7WG+TYQQLW$X"!ZX33)F)X.1^L]F[?/ZW?&]S>,* M+.VNB4R[G9RK[1,8QYO]]RA1<&OF.58$A(_:8C5'![#/!%.[>J@BX=+M5E3) M& 7HY)''WYD2&:\$.XL+D_\ W++A#G-OD>9^=%UM)AN&:XG#P9;M5"O9 M&+U)D=!M0\R=TOP!-B6$3TF/ M,_*;P-R1S0**?UV=Z1M*6Y*F$W".B4Z:L009##$P$AXD(+[A55F=(MHU2]%6 M\]=Y3%7ZSI>KBZ:X/5IQ A?!,79V=X ,AI(@COH#Z\#LE_I%YO-<*6:/&E:- MZGEX'=[:C4\PDJD@&<%C^NPY1/J]10C:"VU+:_(CBA1T3'="KFKM DMXB3_Y MOC]PGQ[EZSFX%&_]H8*H].H (ELR7'Y8>,-BAAQ)O<6W[P,_II^8)/"N+59A M4%!QD7BF$AK9VX@/E6D76TN[5FP3NR2B-=]N5MK-U0:XY\*[^[.%3;RA7F6K MZ>53&(\1+;ZL)6LG0!->CZ7). S#*Q_#LD_0%&1S!!8R$)IH:]#,^+T3BS__ M)4:\V*!QQ,/IB='91=/72V2II[ZP)4.TD+P$HE1?G+[6*D^X.@/(?C\]D% Y MWE_>)9*O>V+(;)[F=S^_FL,.LDU/$#Q"GJ]K=*X9/]MD?5R[3+ Q\D#6YK* M"?=;N;0&BE8H-9E$56>W\A $?+^'!&2NI38^Z#^4O+8QG?J6(6JO@<=[D(V5 MQK^/MVI%G YMCC9X!5CHKW*)$K'"^60'BCIL-KX3 9?YEJ30+VOP(\QYE8GRL\T*[[8)NN/L*V0.RT",CQNZ*V!E#7=+YZ MX92YC>RF]9N/JZ;!.E\C?FB_1%C=U+6UZ^3VB98[1S,Y5@K\,/ I RN,=6JX MQ_*;-ZFSK<__GB9X$G?/WZU(0DR9&R][TH;^&"I^Y_W%;;SB^+PZR9F3Y[D# M.ZHN3O"D!WWT-E6XA<1PD26S@_RWC+/ME'\]V (II;BR< MI'>J*K)XY.S:]TG-#*;M^"%.X$/CDUX1R%:W)=[.W*SWG66X6Y$'%B.@,V-9 M(BBD[AV[L]-?'OM;BX57EBF\O*T\:QK5Y_1)OI8.9X,O2GM?@!FX%<\+<\?T MB5NMP2Q-6#73+J:5TEY>4%/R23\>X'O9=B6E19(X<5B:_;J#13%LNRZAX^%R M6Q!-5=TG/#>5M.LB4YK?G@=V=7\9A*\D\C%*^W]*[ IA M8?BK;_=>??5V%46?WY_W:M!^5_B<47V?N-3R'FE\_'[&V7L%MF+U0=+ 4JTU M?8B#,ND\$TQ=+$LS3B5 ^<646?!*20XQ9 % WB*( 8#B-H60R B:I/VO>Z+^ M^5UOD^NO/C@,7=9N>WK[+'H6R!4_?@$0)=1+$?-=HL8.?3,CO:U5J^6$M(;4 M-@?@EU1;_V193)0LQUN!;J3%Y3CC:2@)WB%F L"^\#8LP@2ELE"A29EOU]Q: M;3* )/D^6*)AEU< CO%\+=LMJM LYGB58:19>_#'@UCD./:23W\> M_/KB$YR=$F.T)':$5MTP$59G4?1_'GTR:V_GPZAIX*R[P63EQ, L8D , F-B%,/G'7NX UD_"BT\"9>LVD;LYC"2H M3#ZI,M?[:T<"L=I);23:EM:('?.^BCY(PGP.7O[W$%2]L<,P'R:WG()D."9. MO@FM)($+::'=#:B'KMOS4DLW1B/S"DP-*W6#@C/%M]W@H+;]]J/6YFEUQ046 M*@-%W[%+>@6YW>NN0:;V/H/NQ^3?Z !G,4SN:=$%E8[,Y=$A_!M4[5W+)>8A ME'V?=J9 3@4AG!-V!'@W3Z>L_3WBP'?9%]B> ME=RS!4FQ/U",FMH3KO90G-QREZ&J>3:RY3[M+WDAT,.8I/ANRF68MBKI!_0B M@.WP1EDY'4*J53O;M#[92>5.NF.VCWBG?5A=W3HBOBYN%@QBD5S1 MCF2EGX27XNFR0S7;IPP6G['=/!O?7WXB>P6@PGY:JJIZ*NH*2C579&;L'.<= M.[3F9TJ*@1D5^KM2I8(8:0/-I)V-O%MG:WRH\4O^KCO\5 WA_JX&<3B7=Y[9@>4"6,-FZB.B M,-Z3-#_5GO$A-EU)C>I^N:]DZY ML3[+]O-NQFSF']] Q"EG1T2B8:* MLD!(TO0O%[!MT57W47J9I_/,I73HM[I4!5GL(>I5#[*^LA,/^[&[:. J,J\]P: G#.]2NGVI)Z?/9$.\T M%VFM((L,.9WKA[L"*+*]BN+-+WFANR5"(W?]-PYFM23QGMQ02MU8F, M(#"\("VXGE&@Z\V6GDP7H0[C3%K]GOK5#OAV<4S]ILK1+B-'-CPM5A7(!C>: MG]Z-]3/*:/KF?&\*S"?SO_I0YT]NJ*?O.?]7X&CQ@J?L]JI5Y@]U9'4] [GF MV"+L#(F_D@1A3>GHC:[4;M76F:KU^XPYDD@@_J[\0>AJ7URAP'G4D2@>^*QV MYF_.<<3NXETD\Z*R/3-UZ([!QCMP?AV4&V;-J+QL B! M0H^$^V$#H(^J^Y$?-#X%=.7#!/J=33]]PY&#_ 3'[BI,RU^ MK:VG(1AX,>V M#U,Q;Y@ VB[7N7>GB9^3!Y*&^@O=T*H$WWLA=,WN&:2'T_'A3%<7>=\RD:8M MJ]O2K<'"#MIMM?'3YWZ$K;\RS 9I?;=CWIK?6_ZDQ88W%7&-P#HESW!]+2_L MR!5UU$,_3-NZRE/VH2M*@? 0X>_6$8@G5,]>(\V?A)]P5-AGQ7CWH"Y>HDF1 M]:[6+CB/<;<&[7!$R=]9Z<)9$%JCM2<6:@EA[C"5+APM0S7YC0J.MSZL7P]^ M5[[A>;8.R4?T91P>#:^YPS$O[V>Y&\\X7)1DVO"-@JW(![ "8..<>$]W>WTYH/;AR/Y)6FW'R.6VN&7GS( M3F7=)YOUVKB)[2-(^["(/ Y["*'T$5T\SWGDN>F[I9I6Y'?57P,Q:5-(H?L4 M$X'L_H3;)QTI]PLG6QC$PG(_>7NDXR?;**\KQ@=-:V2DO46\1@./=.2N7*(ZQ9;[1KD1N=%WSTQ2'3]JN['1I:$M=\\_GY;E-KW-86 M311A"HW3SU -U3X 1G"@: MN\Q$/-\XVE=2LP,*]?%:E663YBRIWJC;,1;R+>D?0\4_J-2S [. MSO@F:>"AY.SQ5'&2,-K%-Z0Q,J=$<7*O70%7H)3!0DFXT:(;%9)%@^9<;)5O M@7[33SS$0WI82G)^82W+O4D?A3ST35G?%07$L?5JX-0U$P*\7 R3_0%:<)%I MM:/A.TCW4?L>;7V(UM6^M5@7 RGOFSQH;_.79R#('$([2.K#F24[ZX3XIB5Z MZMYNVWADFG?"RW0TPDUE_0#@H(S2)/ 3'04*.,!N6?-M,72N56W;$%=7M\?N MY\D_O@_C-1=CQZK13A#,T\=HGO,$D#B;45;< MCI W%@O77%!=BZ.ZT^V:6?EKA:F2$&#@QCE).G?9>UZ?CN_NO]UX8VK('\&J075K]P MSQ)M/>U5L&!:,XZ %W7]?/734>=Z3+AB#$I,?'?H<29@[L%+--DK7]FK M"$Q _-V#@/E&?]J&Y7X\%-$&3@4!<")X3).](K O%$LAM^QP8>]6K?PESB_/ MCEKJ\0NS>RB)N94V6@R:60QTQK;L"BW=Q1-(F^/P'9O=1\H'ZGB$G5\["4 I MK"7-.]1WB%573!ZANQ"1'6KU+FX<1M'5T1VF[2YL@Q'U*KS^E46=L][C\!EP MVXTMI.U*)LI$S="D8+6,PYCJ'"3#]PX&D7R@:_ _BAIEA4=EJ$;I^J?@LW$C M;KF)*1+2@S(4)9] >"_>DK3J?>O:-T@.$Z?5\@REC8T[ %J#5FA_RI?&VP3B M'E#1[&=G J#,;.DQ9&WW,TQCO\VN[GJZBZVNS[P'!J$IMB1$MVRT.8D-A=/7 M4GB(1 *(B]>V*YR?O$R^[B>?&@KMWK88$4HY[3Z^91V;1L/>')[S17R(- UC M'S^V F%B@CT%LZ_+B. <8H-6VFF=@@-$%)GFJB79AK6TS:PS:D;*4?)/8*-\ M0F4V SUI)(#HS+#84!E7-S8]WM"6O\DG5FY+R2@@0L>R+3)HG42Z+A#WVPX& M;UQV$LRV9\/6_/&@A^HVSWS_->^9GHMP5'^0&C7*>CLL93GAF7YIT"5WUB7N MYN]EAV9TS>6-$%]_?G*UT6,;" MC;5W%HI3 .10TR2EMPAJ9PNKXRD^7RK)(^_@KG3\U6GCN"Z1T:.):)*?4J\Y MSJVT.^^)#BA7L'G5Q M)M^;I=%1OV3?S-3W:]"-!A2PAH=R,1"*5$A-+S!^NA#5#4%FIK\"@VP$:\I+ MAUT$AWK7G!JGA;[E,<-KTI"2;U:D#QKQ6[>BX@H6>>MBD56 L=8_2:A-[,BB M!+=1/[1#R?KH(?,ZA:N&"AYE( -)&BQ%Z^*L)13W"XP>O:"YMZS;M<_#-CA^ MFS7]SF>:7J5MD;JMW3+SR%;5H>?+1R&5#X'LB!(K C1'C?\^@I;^M[ 7)]P2 M3%9>N%,MFRP'Z[KN+3(W2A5FC?GF3\EHC_0CT=P:KU-"# B"7P&-\=]_Y\FW MY>Y-B%_3+ P>=/G&RCX>=A1:U,;C?V!,HX\K&C]OOOD1=(,7*?K6"_ M0WCFVB Q:7_O4H\*BF3%4J%M;(+V" 1QE_, M^TE"&J%P\A\:&DKXX?BF,$2\:G"&.\PW9R,_I*U+042&),7M:1J6NGX4*S,' M8@G?@:2 LQ."%*/="^D663:Y7Z_V:,D-AG+-(D=E[')&%P^>%0%>6A$T5W=Q MI6ZF/M5G^.Y\Z?8->BVA;?+4+3JFV0/RXS-(-'_)X;W#JN&;1\)]X.=^@,;M M3RE#=8I6OX8T >3YST,,UM;RUM6@$\T3-0''&=T:Y$5D5KCA,/+#&P5ED>0@A6D%E1O(AQYB?EG7 M,0%GW&P,#/YU2'7KNC"#%TRS7HI)KAG0X7B7K^8(:^>2REF\?QPV9+Y.F-Y\ M=_5)BW8T]';U0\,CD4*D6G_!&ATD%..K_=B,5C:0C&L,/H_"4-8>R+MFJ,#- M/NVZ@I]> I(S5NRQF(?94CH<(,<0#(:W>1 E^O!KLVC!OLIW+5.:H%74;R@_ M*#SE8#?^WMD10.I*E,O7.&_/0_8!&* )'-,F5=]" M%;ZQ[$M+2^LPOUJH*FQ9R(5LS567MW+*2%ZK!'H*J#ARXI)[)V"H79CZU"HZ MV.:#%V0]G#C"0&3:Q4WGN%FT7LE%UIV(J)W^7OI)F"Y[XR;1@RZ159F7TU:[ M%_:$LT3#84$C-\ !YDP=&Y& M]L=&R;9CJA6WO]M73__4I[I^&ILB]\?QOC FQ[BN3$+ D",E3X&)W7'AF2ET M:C8=%:G8HZL%JEVR!\G!,S9&??\_HW_M.\RHG/=P4HI].3K#P M+6KRMSDKK0)"N%G6"*Z :B>U@*%3D^LL[Y.#9=&&C> GT$L>^DCR^ZSI- 4N MI^8Q@PI'C&'AI*T*!*\#6.7^JW'\-P&?Y69Z-#7_L;O]YH(6#DVXE!XMH#,Y M$+"?/] !@5N6TFI%D.N2YQG'KZ?+//@)*D_<;:RV8J%9AQN$!U[,G5'A8G$ MA'&$4#@U$>DR9M#4BF#L\,)I1V9$XGE1UV(SIA@VTV[A=X\O(>E4\GT[^[&U M1.M^C0-:CGX)^H5>_F8.B+F2#@93U,<^C =!(4F("'6^_Q>]_T?1NZ\P#&*9 M*:6MNCJ]LE&5Q9U3L&;>4OV@@MO!BX0&H&Y%\[H;_P_ *W('<.EY_XOF%S/K M4)I["X5-.Q^JN!@@#,+[>M@.3Y-\\8C#EX'9:?>Y*IFMU<4''OBY5 MB=N2\S/9K);3-9;OVZZ'PRQ3DL2=[K6(EOS5F7QE\7*DW19=VMW6,E<15R3" M*R#Y:#U,D[3Q.'8T,0X@ CN<-$P0=HRCP[.=^6L@@68$V\Q#XXNK="3?7DXNQ+SO6YT_9$.Z*OX+?XC%QIY*DX/U#S4*\:BG==+F4,YT[.(0 MJ0;%?132LLW$[%I^D*!E JJH:%?G*EU.ZL%.^9%/[3R-W%)N][V.D!"PFP_@@Q<7!#H#_A$OXW\;_ MT6P0"PN+Z^1NJ8XLL%1DO[M 3]W>+";TH !PY9R_8_91^(Z2E/;A90J"=U%0 MK=])TM\'6@S:DT2N M(/SZ*5>$]B[4I%# 8$WUGX"=Y8&\ ]%#<#T2-O16MW5U&?1.=MLS=_G:OTK+ MK:E&FEY7XB3GLG/IDB,H6C[*N"\;0XA39./6'R7E?%/" \9$99FO]XD\QG=N MSI8-K'05H<4.99O6RXV&ZP'E;4F4AF(%8,%,0.6N4(9]%X\U\]\84,PVY[B3 M2%FK(OC>RPB+#W]G4 M^W_"C2+:EE:SB*3S\VR;I%BC M_DU-__]W:^<\3/GRO *^![X"!M1)@>4_TFD+LY^RSQ]#R)M/4E00V:ZNS]E\ M,8VY-:_Z,4Z3"'>C)U6))\ _#+<_(D(JR>F6';CK'?!*0ETJ2&+'?]!%HI Z MBKH3T9A!3FSS:T4?PMTS>3MWGSW.B14F+>BU?S>3] ./'%#0$NOA[/5-$W_% M NP>$/3R'F0HF]H;NEIMQ3:068_B=.C6ER)EC+,/2+,/--@BN73T3D&?6G6C MK5U8B\)65 926M)-<^81*'$I.1,O&-G"3(BJ[G(DF6+9GSN>9I8S@7V93&JJ M$@:#P:,D<0 B'MO1:[V17 HVY!N2X4N!.UQ_ ;DA9[S3L&V U2$[_]T)$) MN [ ,'CX@$EF!7U!:VIA")#@$B 0W)W@P8.[^^ Z# 08" X9-N^[>W5[6U>[=_?A/NV' M?W55]Y>NKE\__>^N[J=?M4YA^:5"5<5'B%WFV]4/;181OT'N@2:.YCJQ2IIO M5BDHW5(-WY\M.T,*+!L WA/AL1&E/;DFFMO+5-/;MHP+ZHGBNB>[;Z<4V#[4 M+IO0 P25_*Q\K#^7P^T@>*B47.R8@J_\CBP- A4?$+%BL)ID\9L"\R_?+T4. MW#&VFA)MK\1NC[.D/6SR['[;4W%Y6?B0/]LTCEUZK4LYS/-[EO[]0LV2BA-1 M6+WA1[KWGPU9BX%O,:GE7H/2G^7:6>9YCQ@T3+NGT?;H9=ZW(A5\5-]:\:K> MN(UWG5>KUV0ZUM]!/T;W)_96E2CCAV#TRY1@CK;I^%C"MMLU8??&-IN'_4V- M=^H'+_IX0=0KEMX]+UAF.AV5O&1)ZF8<_'DLG0K6*_]\)>P^,A7+Z/OL.;B= MPC?]G>Y7TOVK4T(NB[<+>$5=0 W_FW6.B=TP4^=@&S=B5R7':R&0IE>WIV0D M6,EN+QR;6E4@',2MGC"GAA6Z;XN9>1U!-&*?KC_F5+)F5^[D13Y_:[RSTPQO9G"< N#RR8H_X83S9?8_!PCR-IHI_+H8DLL??[F>.V["MF2H]Z]YAXL1Z)X^9D.&BTCN8%T2TK,TW MGXT/7^]Q9IVU/LMIYE8[2VNU*3D.X.@/J@ -I=P?0SY:IV6F;6LHX!"XN2;2'Z6G"0OJ.M,"?S%+O M8NVLJP$XI-D#UEYQ!+.,Y/ 22!94:_CLB9>PB'_H'\!> <%88&MK\HNRJG=C M4[W3B':?<*JT-CEP0:ZQH.;29H3=_I0Z;A;6,K?I\?H-022B@Y5]SS@Q&QQ^ MB=.(;_@N?#:&-M;:MR?")@9VNE3G@0E:;,MQ#)<4LW2A2=W&_* ! M,PO%]J@ T4/#]M-H7B=ICV([':TJH=5\FLK3/?*GX>70 CM!.B+= MS?O6)85$L\HT#;).+NE?3.J \U;QC>%* MN7YX!H0C"]X]=GYN)FOL?I$Z&G^\LCF<44L*T,HXKU:NS71T@"%41^UXU0\^ MOBT!BO?YR/4NM^NAR83KIDWZWJCNAYN,&"0?,3.6T]MK=#;*(\< 7EF8Z6?; M7;2F32A>,2(:=L,GQ+LKGHU=W2FF HQ%=6W>TB1[1MG4>4(6Z+%F=D?Q570U M&G.^L8T5%U49#*U\B0QAF#D0^(IP^[%3FZ7R7:;&1!^CYUZD=?J8KZ'$G<>6 M9>KHI!%,G6M[%4I&:;TZPM 7KIU3:4X;1YB)%[3)8P"3&C?%-L;]_<+E2N*B M*C82\-L)8_7:$OV4[E .%[Q<].T2*\4N$8\"[O0BIC [\='&=K$(4OC?/C/^ M*T;N!5G*CM.^V?2&RZ@"4QI'+)!DP%1]2XCJ[J+T/$FCLO-HH!4R8 5I3.46T:Z1I)8U MU:9D5_RJ8PP)>F*>A0NI-(?Z\M82&.38R,*';%7VO.#1RU@2CF+UKPJDL&XV MG%G.,O M9&CS2$UX>NNFLH 2;?(8=J>U\O2GQ$4.,54WY$7'*554UO3>B>K, MXQ8\N3I@B((;"\L'9;N7+WB"M1;O8EW,5&*KMNI0R3,3E-EL6J>OUN&."DAX53KC/\A\CZV>E)2I\\*34;'Q*316>:74]K1LL.W5R-/A<@'#?J) M .P*PWL#WS\)/%KV%'L^ZGF$ Z0K_ZZ:'[T+ M-)#M(=]38G3%-KCZONROF[%>=1Z\DC;08B7TGE!,0[;D05 M-J?W]&LG)0?WP3& &YHP[E64DNV]7%EC[MM:"R&?RP0*MO_3_H M 7#]&U -V[)$/U -)Y^F]\P4E:_A2&YCO0-TM5[D3Y@)C+CC>>)OS< M:B_*)WU%Y_P9XP*?$Z/)R]G(6-O'C3D6%VC'YG;/C:UV7_ZY?E)8PYQBOZ6- MS P^X8<8_739Y8\(.&E4!G++)XS/1!_1W#7 UY9Z2HQ6C$U+;3EB\A(4^O6C M&:$D6JCVN8Y<)[>2PRMXNC'B5X(FO2J07?WX721!X[2R-GV6T!B 4;(U;+%WO!QPG705:\J_MW7&F MVE8)='YCU2BQ]X68?_MZQ/96#9\ZQ331%>_(K([U1T^)Q;ZR'9EPG-03D(RS M@#RCRRGDLINZ(J_;1/TG<:960[;X'$M 4O2"_&G!U[7(161"NH&2PLO@/E)B" GYK L8QS!7YLW M#!.!\1,9/'M/:GME+>4W>]9C\VMWT;_PV_&5;H"2;[N Q6NI_OK']CZ)(WM*4W#:8K.+CB_2IT/D;9BG?5%#GO\ *>XN?%-JU#S6, M!.R=E\/ A[TJ!K/"^_6]&GJP714O!$WLA@(S)X"?6#([X_SD'\]X*7H@MG!D MTVS]I_I#G]S.%I_^HH4^,-\H?HUF\\I7#'EQ*16@M)?PFT<888",#8_"O$@ MYW\BGKC3JXA[E2T>'C]-?'3_D*Q3?=O^Z^AB:OVWQ"N_$R60H69AY!BCUTP] M5[*T4W3:/^JG82%#7VB=DPA?2+CNI#A$T[Y=I/&2D!'%[*-Y@N.TDKU?\UK2$A@CGD-&0!+]E5% M6%'F_NC,J $H,A80!]]%KO_MV<].E$JXB*:I?1.".+7[6@L^)2= '#VPHLQ4$ M[XN)&BY4;3\UZ]OC?B[!_2+0\>N@S"')YC]RKS_'%QGLC%"USE1(/%X>@W[> MF7BF'+C6 _ %N2D!1%6G;;.X="!BNA71@M2,.;%;-<).V-Y./0N)9DA:D<+, MWN!R-3*WT$5?$@N3^C<82N1O,(RHUG!1_<7E,> KQ=JL:](UMWZ\=Y)DDD\O M*F__C_*4_[?^6_\_](A@.;FV-FOW2VUOV""#%D_8 R"LU.8!((]\ )SDFL6V M/@"8Z4YN-]:'.P*JQ1@^EZJK*61T(R3 M"@&,[GQGK)I#5G+2;;?YG3\L$@U,VE3Z%/=5JMQQF*+,4(WIR-S.^ K2Z+:( MMP#\B"X>IFB/2A6STZ<"\^EA!]&L"%_JS$UJC0G.:\<- M1UZ!R%]M'%YBH;+4]K>[2Z2+@RK MDSE(=E8QF]TFG-7GUR.%IT>19KN*(E] M32P1'V>RD_*> &^<\S%IS]^+!.&$\5=99HWH1)[)".GHAD\MH(WI=\(LLGSV M&MEF//Y ^\".>2U*Z$2+-,B96@.6;8%\@<,K98DAYIT/T\&2?&+]GK15U65& M)LNKEMH?K'T@@GGR&G'QC-JK;6)/!LJ0"^#W;B9#;DYLN]II]'Y> M[S&3Y011 ?;FO_XHS_2WC-<096<2IIL^,?G &B>H;_<9HLWDXR/M9EH9^Z$* M.G40A$JP77 ^: EK??F.$+/4%R:]0S,#%]'40$%17\]4RBB&+Y."['/G,VSQ]?8O7ML7 MNW!@EE!7+3?\<_G6F;L0GA9&/F<43=!CXL[RJ3)'4_(UW5^// "\.=/B^^C MQ)@,T!Z[%%M[XO!9[I(97Z,S@>NR^K*S+J3E9.?FN^6@B8^=5Y-5_6L6+C#Z M85SBW&"9.@BU9%REGW7:W]G0:GZ[TSE-3X MF7_O;Y=6Z\U6QA_G1>US;6ZX$.\4W=80*HR:PSCU,W.:PZL.QNOZ)EK'--'\ M /[(TRXLQ9CEKA$_ )$)*B L-G_C"-27M"::7P4Q>9TJ-/@"-JCWU2 H&/]B MXLVY1072JC%&?4(VR_MWRQ(P%]]?0#_Y?NU4S&#>11O6.]UK M>>>U-&>9,/)";X^2^O8.Y.(25')-LA$M8"_&+2+1U=BTSNS"]'7 ]OD*]WL$ M/%A&BV;KAR9J.)'?I9GZ279WWC>=FL:OBC)';;I9G\[*L@?3S[+#0;_>X%1"LUB:IE@;L;D$VY\?=5"CUJHWH5=SXTEL'6"SQH$4 M,7';(1D:9\!$(63J/,9Z>T 'RJ'=,?V+4B)PBFCW; 0A94FG0P# )F&+K<>H M*_)>FS"HF:LZ^N7DWRZIPS@?12+ C MD$40V#@G]>$GHJ:XSZYJ?VRK]9!!V'35S+0B12=-'T_.DXHMZ2<68\.H7,3% M8371.EX]P=4"_[-POZAOGS?^H.?O/C^L>4@Y$MC3$>A6/> M)$M9:F2OOGQ(;/V20>\I,K- . ]>_^ROF#?AE]^1:E'8_#4-$;.3/'P$P&+# M6$\R&_LGS7JS%]3GK=KUZM&'/_BI*BV#NNW^!F?9&72R6-0#8 ?O 0##N:@B M8&TW921+!OM/@[.LGS_5S=0RJFL)[;M,&D_@:_O9^AAKJX7[;$P*_=)P_6(2 M5#I/?4":SY8[NXP#]M!SI:Y[==:FP2K\.6:0FJP9F0#/AR[K^SPYM@!][/S4(8[NG[%I;4\A,/QM(,9>RZOH]OUDX<,Z1?7?G25E M$+9(NV$WZ@ D&5.S?-M1W\>9:G*5 M)EZJDZVU91B)O1L8YC('0M=F]P(614H;L)?+H(XPUKK6%/8/A(O4%BQ!_:TD M=.83N=>8"JCQPI(\\P-6*9-OQ?& $L!OZJ0;ZV 970G+=)%$#I R#6$Q,UK$ MK('G\8\[*<@RWN\XWN'6NO-QZ%@'G;WG5%^UMV2/7OC[[^R_^"WCQ<],72;N MGC6;_]+@(U#)&NE;(^[TB1(2^\1+-S'$P:JKL/+C/(?DW7R;V">_3P:V#%KW=#V?:8PRAX, M@>"M#&II6*@9,+1,8B>GQN3/NC^>XSW_A@1KI#3&+ML2&WE);ZHL%!I\V\)7 M<7PB')4ZJYS3XK;D4X*O/M3FOW,$I$:(9,&DC?.\7QXLJ\[XCRDCWB37LL<) MO!J0ZM\#9+C3E#EMXC7P4:G,:'WP<2*4K#5=%UD=M3;NGU_E>N\VKKI!/XD# M*O2NJ?:XG'I^WEQ_]P 'N'&<*M7I75)Q6>X'9JQNS RH1H&PJ0MW'GYL&Y% M[BWN$?'"C;7$HE:QZHSY#,30IIQ'.6UMD?TK$P(L./2$LQ=Q6TXWCX;0J H! M$09NP0POM3IZ)16M+\4,TS0/ #RM;W]NY$Y"5>[9P4Y7.P^ #B+G>M#0 Z"" MNFKD^ $0XG]RV0$<.991ITGTUC4:U^E75I(M19J?$30^ )Q!V?[RIZ\"J4[7 M(QQ/^(MC>TU6:%BB.,:<4FWADNEW^*ZN(4D'<87%')Q%2?'6D";_V(CZK1=Y(Q?LFF)OM-?Y&R:^4@$C6YSVUFYU\,TOP(=Z4VC7^I:Q59?WOLNWMT$R4 M8TTE,I!CQH//]=BKYE2W.9)+K:^^S#52"J _B5.K3]74"/?(:$I-8A-%E=JQ MN07G@)*NI[=L_3T$3E_?KC9%8!%<2KBOHHV"M@2_[/CI59POQT"[)-L[PK9$ M3HDB)XCZ,EQ57X_4]-1K:9&,-6$*8ZS K[=5FUN;FKB"'/E-')Z:+@V1NV;] M %F$@K[UMJB>DOOBMJG,9HDF#6E_+:L2^A&+ [GHL8=?EI;;T]IF#5J15AJ[T6&)T4[&,+O388[)*=,^M@MM5P'FI!+5>L*4(( MU(A:.EQ"GXE>5!F.&&J3>9>M7O P* ^/#R/0[)<=(\9 MTKQM*1@J]M=8. M>$KY0LR7;Q*!%-T^H9XNRS35T0,Z,82OD8KO?WGJ)7W1L_%1\I'-K-(^!?62 M+1L?/+6#8Z^;W@F&C*LSQX 8BL MK&P[NX7(-<6O@6)WG?#X^-DI944+)+_$GI'B26E3L?!\8E-2Y><8E5=4W:LP80\_:UK>L^HNF M;:=[X:GW0$<-\Z'"1];(LW.$4Q6/7#>TV)ZV<$66ZM1_P5,(K$9_Z_&[.9V# M.7BD[;UE.\!3\/H!H!@]N'U4"^_O8SSCD6!\S+RQ)R_09VN?Q355'U1#,+(_ M5_U>]6@JT#J^YB*8Z9O*I)Y_*-D*M-S)1R.6$[,O-DVRWPD:!IN M.B)[_3)M39QA&J"LX(E)<#VW*F0V<^'CQ%K_M6YI:'>41GUCFSGZ LL+: ZW?,;;B_J*[BQMM)5K,D#83KF>@5T>A?$[159Z<%'I4?5P?C]1[K, MNRF'3,MH]&[-1T^F[D=9:CG$5ZKSO!+W,C:_2B+VAPTCOU MW6'\#%1*=3-O'P @&-E ]@FI!,=*1G9_];]N^?\?A.76PS!*IL!]'*O$W3-+ MB^C "DDMS[+V@HO2KM#B+[D:&W2K]PSPQA> !D_ZV?/XJ)ZD6JJG,YQ+KU!E(%^(%1Z)PF*.ZT(]@U7&;-&D0][OW' MOJIN8XB_#62SI8L+A@HF2L(K)ICE<=<4Y7R7W@ MWA:[M65L(G!$[7;EDF0Z&H1_3(9[GE09@3KW_=2N016<@B]QUN1XUXPH]#4C MQQB\+OX)]FS/#TCOE@H0O930A?K]R*&)F0TAQA9"ZN^BK-LM*DP/.IA."0WK MS+GI%OEAT35JK-%..C\H.*9;RS@QOZ*RP]@G^3WXE!\ ;^X"2TLE17JW!&@W M%?#+VH.'3LQD_M=1>^RWS"E"8-C8K'DJII-AJ'W/TL)T?_, V-YK*JE *&>L M(LA'_U'LDH\R72NZR]W\?@ ,C#FJT/:1]8?BYP!D'DM&LJAGRH5P87&]9'JD MBM .-[K^XZ]Y6;C(JUF\=.F6V-7D.-'TVM "19^2!9P].<]4@#F(F'C&7O;V M-8-U<GUMXT71'T594\E?6+0_(01>;N\@P/XIOU.S6O_>_002HP1P0;.B**J*70HA M=L_67W?,'/O/)3-C23Z)>(G!H+*KS]=&L16 NP*^]NI%=15I %7CS> ^8QB6 MB11-A-%)P=#.O. 7;1R;)?X\>7P?W=I[8X!CTL< 0=4!7F=Q)O75_W""&+XW M3S#85OZII\@M5/\!\%VX\^9W;'U)>8Q:G[$4*;)?ZX@&F8NL:6D!YUA)X$S7 M<^9]*>;RU]J.MF0*,T((3Q#0D5 ?WAZN5-0%'$%K5RVA[#/,<^#QT?!)BR-<*HLL]H!7FA[7K!XN^7F M4>7))]X&&5E5!TKQ]XVMX>+._*R!^2$O5"S';'HV@BB-D+#O&)P4P@0'$ MDE.6^ 3J>#5TP)5GBC.'<)UDOQ'-,.EP'J5L'3XO$SDQ>\6&9IM/_G=4&7@0 MD,_RT:XNEB42*X'SBIRCM[;YTH1",DRMZB0FKA6/@A![YH.Z0=U,T > G"#Z M98LZ3\0=#\Y?*SXU]"A&:LQ-L#& T,*2-^:9* MJO),/%FNI/A:Y6<(2<39M5^OH;-$NG%4&,OWBB4LQOY6.%?TF9TTR[94'&XV MSJJT$'(+S78'U1)KCY>*3%AP9E'IL#_YU$&Z/_#2$[7[M6F>;UC#!JB^2%Q M3W\I@OSR!B?K6Q"377J4N9(3K!R\VAL.Q3M^^5P&![CQW>% M>>DPJ1SI$31Y5:*:'!SD\P!P_SMFR=-R^^Q>-_CG!SS3Z*6!!\#$P'500FI- M\6(?:B#\Z/YY84 (W(Y=LZ])#@)]OO4\XKFT]N8^+^]6I#)5O ;KX.)CBBZG M2=K#DFK90C6#;QFKR\)J[.^=LWA0L3DB?B1/O0W>11DW+)-/"F'%'C#N#Q2I M6&JC)L)._KKAK0 -_?K07_",3U-<;Q%TS@I56Y$?LFR<-IW(O75/3&M1TXJB M,7Z8(S;T=8_OV+L8 '+=VKO:,[*$U]9R1%U6)<9I3J\!IEKLCN^!>Q;CD@L% M4_*,)H7[ !<)/59GN0R6E_YA:# MB4;M5/[,5$AA6[<:/]ZO7D(8Q?[Y_]4"@?.P]"]02P,$% @ ]H!;5DXX M+"P"_@ 3G ! !$ !I;6\@!E"X!!Z[J?N^_F\[^&S_SES6'NOM;[[N^+L@YW +@!7'RJJ* (XN " <_D'8*8"8D)"(D("8B(B(A(28E/S:%7(R,G)&:AK*:ZQ,(#96)A:6ZQQ\G-=OWF5G M8>$2O7/WWGTA(2$0I[BTF( 4GZ"0P$\A."0D).1DY Q7KC (W&"Y(? ?OK!? M "IBG'0"3CR%0ZV P!=KI, YV\7\"\7#BX>/@$A$3$)*=GE ]57 M 5POIF M+\TM+*VL;5S=W#T\(5[>KUX'AX2&A4?$)[Q]EYCT/CGE0W9.;EY^0>''RD]5 MU36UG^OJV]H[.KNZ>WJ_#@V/C(Z-3TQ.+2[!EU=6U]8W-I'[!X='QR>HT[.? M>N$ >#C_>OT_ZD5UJ1/M%/O7!P/7\^0(5/<.,^(;6<%I&I,\U-@4#B M:P_BLBI:2=@%M1&T+UP&2>DXA!9O(7^J]C?-_C[%@OY3FOV;8O^NUQ1 CH=S MZ3P\*@ ,[+F)23U> N^H5B/?S:8YVR1Y#,JQ1G_"5UXQUTI\E %LZ<,04:A\ M3.@Y%D#3ZT.1]3)L6*"'_QD6*%_-P@*YE$;N@ OX=\^ %QF1&A>4)U@ Q5>% M!>#NXUJR++%H=ID[6" +@P6P ,$8#.T0BU+T?8P%Y"^P (:L!(R:=1_1)&+' M L0#$=!U: L6:'7/QP+,V1@JV#4L\ ,+0+% T)8&1M3(_1I.#Q9H$UR"G8'V ML #"R!H+=*UC@=>6G>!#\#P66*@?Q@+1XT8*_Q]8')LC+2PR!UDR]MK7%7(S M5"-B6^4"9OOY4^]-*DQ9?@]88NH/L@?ML< M'^U+)['68F(SZC>!9>CO)+M! M?[?"K=(/ >*@WVL-^MT"MPHR*93^H+/2'\Q7O\F%%_?'=?W!?@7NT ACIB%? M [/%A+OCWM$S&PX*'XMR*+:OD3"4=W-F]C)L#(LVFL*;F%OO&8CD.=S*V(AH MM;5E.WW)7DHHNRN1<8AC\GX1]Z9G0.GZ>X S+&P')P#2=VM=2 M?IFH.<94E<]O-(C.MJR'7U:<-E4L!9U@@$ O(_ISE&8:Z$ND8ULB99TL#6=V_PW]=3U]H>$=9VX>\VS@" M"S@WA]29A(#W'S5*8@%C%=DK?P?62NLC_OO<7-1?31G#1E/1G#%K.LJ759O0 ME[$[-WZO8[*;XXWW&64N8/]WV&CX:"\L@Q6!!4+MJALBDSEK6KHGJ2=%5604 M_9^*H5VCW+;4$=".*_1=>9N\4D8&LU-Q:_K&"BM? P[%\*/\*%G73@%4P.P&N;WW;+K:?GNS)CM]AW9UFZO[3QQMQ55.0B M%F!2$6Y.O3MH_$54U=(=E,0=D]RE+";%0A-SH>!ZTL)<1<9KIC4,K3@Z71XN M92,+Y]W1&GQ8H>W:(G:JLDQ! #C^7NX?+3P&"T8;9$.Z5<_](STXPPWLPA3' MHYL8-326?71F_WN#0^J\'JI^O'-*,:I9O-&JK&37PIH"9OONOA<$[\3O!/:U MIN7W9K$%[3_QY;W$KT3H0= _A:1CO):J:Q.7O.C$7CS8EV0AT!10D0G0).+Y M.WA Z;4_NY6_8/7(;A72]4I-FE(Z[Q#W'6V2F7O=47>DEBJ*940AJIJC695: M!>WD^Z?WYC4<:^84O]]C%F>M#XQ!95Z!_>.A6X%678IF;Y-0M='O_Q$$M%[# MJ8C@V2@LT+>AURA(NLK[UF;YW71K'T5#U_T4X/?B_N#:S?Q0F;L0QP[O M^@U2_JH=!2PP.FUSSTN-L[R576:RMW3U?SPZC_%'%*.-%B\(JHE]7;UX(B,A M'LTP&T*.9';."Y/G'1C:#=H>]$,L$'<)V:VS;BSP\$,FWG^K?_X^?L[KV;AF MSQ%%>XW.@A/ F0L0!_^57=JQ0/#BH@981K'D(GWU%#P%-<,"BK,;#>)8H-O6 MLQ-&5<5/E"JV)S/LZ0II6*BIB%)A+SNI>',?=3"="W#^]?XW1B1%5<4R;<3Z MY?3>O@GEL[)0B_]E+DH5N!<"SNIR-B%XWVF>AQKZJIC.MUP4']9-'5BKW;KP[E,EF?[4A>^T/ M7/4'-R35HBX64\/4VM8Q-^@^>C1U3U[M"IT)IY"(_=Y$+S_N-D^U<6_36VW( M<$KUQ C2NDLL%21]!3#]:\K^KV3M%8Z7"+9=VF%7-&&9$](=.Q$4"M6H_OJ^ ML1'GO/E\8,4XSC"FXC(W5FJ;/X(70,6X@']PWM"R-,"XWDPVU']^5N]Z"NU(4ZL*N@9 WW8X*WDBQM&-L:\68+)$CX;N+1MC[EC%>R.\HD_7TE M]@>3)&2CK1#-9<7Z&W/J^2_'HZC'?/J>QSU2^4(J3]/+7L!J,Q".X86XMDU] MJW^"M*&O=;H>OVCWG)J8GK$OOIWE*F1 'VCX.XC?X(ROVG2)]>;\TV$^.A_) MX%GF2SJ_'M-Q58YMU/^_%>HO*[OQ^86^5W0R)7J:!62ZJ,B\Q?GZ=P ([(R< M;W,V?%1S/-6T4L5;H]IG*VMJXJ**%]M6OX+,B 2_LD0^3=OQRFLE^]9%=;"H M^'#'SK0IA@OW[XCTKHGS;+Z\ IV\7>FEDU/*3K6>=+8K_C;;&@N2NKEZA!:CN,:8:%PQM=O:XEO;E;PF1]G'-'.L2LY ^!57(Q%IW 3X$%QN-U M]?XYQ:ZA.J'&PP-[>3@T^.X1R0ZOZ:CP?4=,O0^9*8?*[K-R^,Q+9UEFZ%\A MO&@11FN%X1]2S,TV(EF8K1B)+F.&NK\]!"_K]/_C*WV5)2C+I>ZB2_,45B:3 M\U:8R;?=:Z?G4FFTC--5N^=SV;FWT^%EM6C-T4;ZB_05+& YQ3LP+84^3:9B M;1!!8FI+X2=^*,#SG]-[NGZYEXBWOHH*/817DVR59N)&=8GB;0H:88%7:+)L MR.VY1:'J#)7=]]*=H]]25]Y&P3D!3VE@2QVI%%0U3V=L3:][,*MX]K1[ZOE5 MB8#^=V)VA3VG2H\TB:)M9(BK!YN%K8UIAJIYU:?5QN[Z;NW4JC5K2HT]-YC_ M"DHN@>$\4UV,C?3G1SC$N4M,*.5'1KY,?- F3ASVZNAB8VVZR=MH+ZAJ>H_- M>NY>HD]%P3.#5$BVK@E7(35Y^70:!EE/]<-?7'_@]? OH[XJ\'1&/H>C\Q+Q M+ ,5TJJ[3S7)N30[,!N0V0&91@"BUA)BCM1]'3\VWE[?A 4B[5]E[WNN($9E+?(9? MEO%:H,BO=$QJ42Z*<=\U9DEI@GNW)S%/#V'!]$],2#942^+=[]L$+6I_G[KG^Z#IF*VS@4MYLM!M5Y& MHG:, \V^C>?GJ_4MU&AVQ%K8D9ZP>?SYHY$ M[]R /1XAD8CJR52PB'+9N0'J@LKX.1OG&C\E^J)!.=48Z[A$2?-@*'U(R#.N MT'73&22M!CQ'Q -E4# B\?A"_GUJ1JBNO1)SVB,YE17'RZX1@4 (+D!_[1S\E=[G3JC@QP;YNFX3D#[J!F.^DO++!)%/R<;JT)D3Z@:M;ETJ( M4T=M(2/:=E+*=*%$M&O,PZ/^[8G6K=PO=?)VFSGE^,]W'W<+V;*1#5>7T5JS MW:Q+V> [+#XE82Z(_G2Q\"0!127+9K]PP0W&1T.:$*M)SJX7[USSO>9^J4S$ M0>1SCBR+@G=T<2[9]&@@3.B*S5>X[.A1&0/KHXZ4CKM#4P&YGG<2/+[<;P@" MAWN;XL[4_=KQ3GQ]G2#)CA#H.4. M>77C:%53.(F^M7I5*5S\!;_Y):(-69 RRD0AM+V9?KCJO6D,E3VQ MKG(O3^/^,LW W6<8X9468BD82L\??.Z(#FZ>\/""0?L..&9KIR4%IW?'/Z!P MW*L1M]](_?)2HBSA_(#/\P)>Z^$U6^O@.B^U9=XQ"0O$C,)>@_8U M,9S0B2?0]>F(A$7'P&HH'BI?]Y7F(+R^-@WV::M((,E\J^)-S6)&/E[!&CN^ ME3'Z*N)BMZ)@4TEW/,M/<7&7[T70!K7HW?\X[YFXE3WV>W;E;?J>.(3D3WZT-'H@W8Y!EO9M#-Z?3PN_NB1?>7L<"- MJ9J"?X\/8^#E I0!IM&=I(H@]7_&V3/A[UN0:?$>PY>'N^H^JP&2;H(@BCN?!V#'&G.6I3MIF.H# MC5#?&[9%OM2CO@I>7M[C^B_C_8*$T\(6IJO#R39566"Y?BIW7U@9W^;@*7P< MTSA^(\]7>+"J#'<>HDB6>CR\1U85+Q5FSER1=C432KPCR\9;AG)1=7R= HY- MU1W)1=)(J1WGUYE5DW!_;'Z/XW4L4SWF*V\Q(N6\2.*>*CEK(%=?SG>F]HK^ M71[.^Y:W.71X=P;..=?]\#11KCDVQG@U"-]QT;[\Z=QZB/%'QP%/&ZX,"GH;!R0XTS76.%EH>XOY/\H MK>ZW@2NDJM&[5GG[>OYRBIRFFZWN@JRG>WU-R446]5YF)=-?P%-ZF-YSZX,3 M:!$6T*/S].@"/QJY3'GI-=EXQM13H<5S*"G9#V-^NAYKJ3Q?7U+<;Q'#0[D: MOUO2(+=FXQTR4!NS)^BLL^_KU5%D951>9@*6,)+,(-13T3;XUX.H\HL$3R/, MBS7'YGXL$&(;B12=\IT/ MO-'L>*L)[7K[F7F7C#.D $NX=&CDHC;F36:-7\ M:97S"W[M!JTJ"L4Q25W'BEU">5S90R@#6GH([5W_9.KMV;NH1.8,*FMN]AM^ MKY=W3./*S8C&2P!G$-NWV_"V2(O'YY[GLGZICO/3<1O?1;>[FVVG>$(1\VVQ M5R"V.D9Z,M,%-BHG?-4DZ'$-YP!"/V2<4>??&/YO+/_[!DMI?1THW&3_5LL% M]!D6V'CR!&=<2^$:\',\Y7VQ.=3W2TM#"_YDJSU'0H" ;[6VP2%AZ8BN"&)V MJL_>F:D/O\M]K MWR3J,6#L)#$.-9=.W]NY\F'V " *WDK' B5/4>VVE\IV..+J*7A*9]4E M*NM;@>PBHGI*JHXE54#1WN#7OO39*!ZU^#Z5&(VYEF2A89G36P[)9MW+ *N? M=?UEHC-_%16I,+:[5J^:?E/^5GW')E7X=?270L[=F->7Z53G@H&D1M0!1*!/ M>6^">G >!T:Q3IU+G"&(8=HJK,K:W\"3 M>]J ,W_.$';L:IQ]&2F,+]=*LH:^A7$?/PZ=;.Y?V3/A<2P560-'N\ZQ(PH1 MG;&1C8\SY5VAQ9M.ICNWR3A>OB2<"I03TU8G$>_BPNNRD^*\%. 9*L3EA@7( M;8:V*HT_V3!U=L%MA0S>4]_BK6X)S0?SN ^ -;JMV6 YM]Z]?L!5LD!ET-72 M1NN4:3F,VVP:04G9NNCS$E$6[JLK&HFK5*M6HT?+_C:N\?GU+XP.45"F,U=% M^KZLC:W"=Q(!-5&&[];-IT3AR'[ 2VE[Z]@$I2#L>QG2-I&*H&1 .G_" M F_ QTEG;!)0.F='RA9+B=MTAX MUD8SZU#6L%#J+S558;X5I1K2O9SQ&H695_XUJR)==H\]Y9:APP)EK/*GK9?U MA40W^AV(##H>DX5>R*2H_Y?2@H)L"1I2Y=-";JM_T1FE;>-1_P0I+^FB]3#A MRT:&.J6Q&HB,H! EGATY2%(M,N359FU"^%"#6_1#X9/,G MP':WU6$(WM'()6E2,+7_C[V<&2/#5DN9MRW6!M:/[+EQTE_'3 _RYT.N[LS3ARP5MC+D9$3KR*<_*?; H!T!Z&)+,L@#9USUQI'A$'; M5[@7+C+Z^92-5MX32L?@#D%LL(#AYPM8HY:M8V&]1M[<>WCZVL0O['UW([KS M_.W(#QIH=YCH+[6\YX.@K>1K;@ M&)(2DI[9ZN5G^=&&]"SR>Z1@*Q5+/7?!^E,G=2>H+(7E P1O;%BC[J)/M&CK M66Y(NB.0\#3UL5(TI^]+VEN5DU++SUEB[AO7(0T&L$"PT1+HD\.!S%?7VM+^ M=L_%6O'C,I8@7FEW(RH91DAJQUEIUO'GL44^T8L4+J6Y^;>:1.KB# /5?NQW MM0;(.KEYNC:?#H;(X[7B:Q)1(3(W8(C"*E?'Y8O4[9WC*#CSOF__?(SW<1DO M@A-,*G/K(A4CEYRZ/7'>XK1VF7!;7I:M)A'-^-:NUMZO4,:[QVV;6DUWH[OL M<]A1RNSLTCB<>!M&_*]]!3DN282YG:GKM1L[![^]E,=PU_D).2-MH+\Z-)(# MI!4!="$^6?>=BW6X/P9-M'RRI'9<][?LDCZ(\EDJ01/3LR\:Q4Z)VAVL[@M> M]*]A 8M930-? D3Q3:Y=QZ.&Z6]X;RKR+ MLG&=3(M:2@".+,W/ /389%?TQW!AV0GSNA7>.Y09%N#H:V\Y6GXWILN)Z,:H M)(5"MWIYBO^MFB=WI+_(QEPM\=E.Q0Q?I#LO;Y]/HVNF8WV7/L,"0KHQM'XM MDXTM4H9JQXUFDB(=L>TV-_W'./3=)OJ0:=/_+E1 M]HN. +N$C:N-8MNVV?NEUT$"E)DOPP(!=?@'([!&*[R^1D>" MW1+D0Q"QP?KPYIEZR*01O(#8]$J84'"P1XH3 MI!-?#[F.T\.92=NIA!!MZS5S?G'B_:W&Y64G?E)RS&0LLJO!N:&,-Z,*IQ]2 MOVIPF?[?JD^O[1=3X7#4<>1*.$WY@3A!IU-&@K=I09A7MD:Y>^T[M[& )F)V MNY;^@P;EQY),W4*&TQ@+.T+\F09<#IV<:VFL\TK)-9(\%LM<^1#J>\DPE703LM!SZ M'FKB_+9)512'\L$"UYO,,.TIH9BWTNXCP*]$_;^-WTUQF90Q_VJ2HW%-'(5K MOQF$#BVE$RA;^88QX3ND^M.WUZ8$^B>X6'LY<(Y*S3J@UPYCR:ST%4L*-Z8^ M*GV\ S%]EBUP'0"ET0-.[5G"T/*%^-2A)_[A7%H$GE!X;SH#GI5D!8AR61"/CWU-&9S#X M""P0B6'9U/ZDK\+0,+CJ>O*C)Z=L'(!]K"THA3V[+$YOS)&<\Z,YF:$5O >7 MY#_G8=FG$?+I'2,UW<"MME MAVD&YE75<>>1U.QKWK/;[9:*# MXN"G0-2VQM>FH']KPOSGFC%_2]6_ML(ON'?YJ37L"99KFD&ZHKJDD96*"G=[ M&6<3KU,L4*0=&*3T?ZOQILMR)[[]S#XG#MA\=H?]5/+(1H<(_0,[(:H<25SFKGW.$;#PUP7?ZPG.O&]]]Y[ H M@Q49 ENR5S6HJ S9%'?SR;9VLGA*^IV,/(]AV3>_5%(WV.KXA(W@A]0-)+-& M=,K0L^B\"E(H$SUW2:PA(/.Q.:\63>E6.X8%KNUN45?1Q0!G'BO-IK!^\F^C-UQ+9H13;[1H5,>,*RZ^2!>C"TG$+74J(NY/7^D M!T:>[37?A=@JR^"/-?YRS#U57AZ!X\RG^C'4>!;/14[:1Y/(P!GN=W.@]2JJ M9MFP.Z^?W)7[U" '!UEUM0Y8#AQG.XK,]#5&[#:5MF;[I3X>+N,#C_!EV;%3 M'YWGW-]Z%04'ZP\BZ-_[TUGA7I*PA)VQ=N^)ZG;/0(UMO[!DD\WT4DNP@\S- MJ:FHNEA53*_C+(DJUVW9CCJ@$GIT>@UG2Q\<>5I#[!?=C[_9 MR43LQ=!>+43M!603])WTDC]^TY_X WO@#.BCNM6;D7R%65.=KD+UA@]4&X*? M[FO%*A\TW/HL9<;"9LO3"KI61Y%T%E/0NYI%6'D&J1K*^+D#"LH M=5QH=O E6[JB;7YS_UR[+M%EUK4:@B8!)Y<)(5;?^7Q RPS*W+0J4-M-\+SK M6?$J4+C.'PNH=="L3V*H9$$/-C+N#1\YTMG,L00QYS8.C3)YQCU1G Y@MR97 MV9HA7>=I\^4LFMZ:$T-%?MRH-&ZDU]=6(:G K$Q+UB4+N7@+$"K>)C_U5^D'FM7+T122E.0=W+87\[T+)*"=AI[@('?R.1:RAE%5J3FVU9YADEA7 M9CQ(U?K3G .=V<39K9]+O#Q:(V)DI^W:-&9!>J3"[=F[C-F&"4M:5&/&?&Q/ MQ^[ )155$]E7-^(%7#^_*/*]H3K=$F8L7M]H\( #,K9B[Q7:?RO\*;@S]CW- M?)DW<%1"HU>)I(BT+K+>9^3ERZ965&YERXSI8'FURWWA9?FEU@HM7+(!!UM6 MCG%&D*?M/+K3O9: &B_\\1MR-HSM*#NEGL>T%$,//W+_C ?OL,!- RPP?A2+ M>:<@R^I^34N6X%># <.)Y$M?Y"7T,WML28=\;A^%NW]?C#0S+MZ_>@#R:2DC M=J''K7;T\$++0"OL:UPWB_D'/ =Y-)QHE55PKL+_[NI6)Y2RJNY)=7I7V>I7 M2>K@>Y0CDO[5JDMYZ?9%:#6$2+H7*-G>_?B]N"U(HJC#,@J4 M$H;:NG&K1*S8+F^$1[#HS;6H-Y(Q1[6V3DD>3H9=#!R#Q1',!?@O+9K-D!3Y MGHLP7$C"8O.G&];%EA'V(CI8(+&<\ M9^,9AFCO'W>7#AP:I9>LV+^+]IDS19V][%5JVZO! O9S?D48FB:8!1Q#+3VG M[DE9!UO")'_,N M&P'Q-AAHYBE:M]:^?^V?/&B%$LM CT"_30P&2TU#&C7W4 M1TJ*/D=/>R]7*[Z=%#?-A-L"3Y5?>/*+XU.$U'/OMT0J;?MS(BCR29NC0D(;O -,:%O_$1P6^*O,OPS&J&>1@;W++5K8EQTB0R^C4 GAP9:0\K M#)562Y[^HE,SF,P!E966UJ@V+.-''=S-7CRD"_^LY%4HA]_IP_]MOE\G0/@( M&N$M$[IP(=@Q/N7Q,3$E(3CHQC5_*WPZJ['@@;0CM'9; MJ;&-+R!ZCQN;[)SF@$\5=<1J&X*:Q;^_CJ&I51YY4/^-F+U+\4>.&=O[4DF= M. P3M,UH(37/](/-F*#A!O7]'B5N5S8_9.S'LI,"O+FJ*S;3'?I7$BNLXG.; M9EXHCSW'"_"3Y;!$EC ADF7&L0!I^Q\WO,Y@!F;4%P MPUK'3R1TZJ=BUS+CF)5)H?OKM]B&L';0Z6UCULLRGZ.T\M]#>2N2 M/](-"Y"ERT@6[/+Q59,%VMO:VWT<4N[^C!\8&)>0(<#CW?A)IW]OASG+X'M. MIWF.BC-I1NI$?2*Z E4"V&_-TS9*+Y;1MRXV/927K#$$Y0V8Z7,5G&C;0,X46;(FN?#5K> M>#1%?*\'NI(6^+;(W\^ODN=]/?+I]Q++!2Q N<6<8/3C:+W$06O@VSH#@=W) M1I!?X)XL2%U'-PPM;[IH3^UG\MA:9XR%<#^;;Y(3>.X=3ZA.X*41"ZV"+@J/ M2,6B]/QU=Y$7D0W;L,WQ"V.PR?$G(U"[22TKORXU?T2*R^->DVMKB>U4GZ0_ M1<&G GBM0/2-DF6VY5;S%B.'6WVQ1V0%!L0=3?X;Y-X+<+&!L5((;,DS%,U? M6)ITK[%EI*>W&E(UZW_<_KBFO/G]@_Z[W"4VJK2$I@TKC*R*4/TM M.7Q<"KEU!L>_[36"VT6)ZQ+H(D;I*>=(^-U9!BOAWU:JAA(%3WL3%: M''%X$/]2Y/X=SL(O75 632*-WX3OWQZ%C^!M62ZS,3G&N^2MP8-!6:+V^5." M+= QRPCX,&NKM.P^(J-BB4RLNN GB%0*#*(=T)'!S1'7-3).F0TR>+(NMUID M9\OA334L\$H9W!4@,<43_[M[L2CEQLMX\H!C'B7T"FV%5_*ACO^WM_Y_+P3G M-UX8-S+6(ZQ;TD**8)P73M5ZAW@'2UJJ3+]F)FJ#/)Q<5!BVNIO1@8*+R:_O#/Y\9Q )7?\E%0L0OH%& ^Y5NK=^=P_TWRT"'THC M=<=Y:8^HU_9YJ[NDGO9N;SC>26$:>48R?FPA[:V]8#.DKS'CJ/MZ:;$P+_>3 M1KH??8Q:][@?5K03&I:]$,O&4//388$?X:*8*]>Q !-X\2;2\8(X ;HP1(G, MQ.L&451I@.2M4HH,VV\5T;",%7]$23])U($'>'N4AJH,FPY6V;+RS>98W2V! MUT;G7*]XHIF9!@@&KO-D_(4/LT>*KX^Z-31);*@:S+8A'EY;>&O.[>3CI.:U MZ7L%T:?!;&PCL7)495]GSUE.*T3I^/!_N+P44N\!6P#T-*==UVEYHF\+2_!G5;2S0F@."*_U.RMB@8=)O M;_WV>5E6^W^ B-&?$:CT5P'H,7.',>_$//)!_S FZ!(7KC#*HP'J:12>?,AX MZ]"L0>X'XC6FJ#NKE$8YR_Y".)M/_N?!2*1[\VY%E4-67* .T6?A-6-2A$5V M#LJSPY]L],4;J\K&P8FY3FX'R&UM1N=>'<.$GBZ5+8,_G]*P F'QSGPAE/HP\]-R0Z33/)NZQVT^.3V M3X]R_HI"BLNHK>B:N1 7JY$^'(/31ERZ5LH4P'6$,GMMKJM$:#1:*:_?E'8@ MZ+9.\V>Z'UB@XSM-W==/9K$OI9VX?X^S6WL!53]7/(%Z85VFD!X6)2?DBI_\ M$)>V%B=J(6/T79;O#<1J>(E<4:]SX6923;<;9<%,N&_V1, UMTW!-#9;I3_= MA.07/.W>)2>=T:J=*4WE-=75-71,+RT4/-R^ZS^N2L^,GR!*$[W^HF%JN>77 M__;[C0UL696J_ND\%#41_U41^+]]<[Z2DE>WI(,*7MR M>[GMNG-A2U@!E\G MX]S;E?P4&$71Y+IC)/J_&?DS8;"0")YY"_SR0TBR6!=]&> ;M M5)W77('R5/=/X\'F6K0R4 #Y2:?[Z/\*ZG0!4[[+YS:OS@WSSI0SR;;YV.__IQE7Y9MLA_P3O_?$ !H_6^C]"]9 MQILU_7O4M2T)M1G/&IMOUR3OK A &!>.6 +[K8Q1VN,=^MVA:(6"DMF\K-S" M>$GS.-(B,>9W"(IM,Y1R ?1/-V]H-XC<#032L)8I.''2L,NE,U!2L-!VK:[E M>8D7+Y,_5C]MX%;U*6A*H/-&M)GVK#(>GG ?C I5A:L1>!N.^7 )8NTA*<M*U\>+)Z]2IZ"O<7EJL"+C& M$O#Y<3R1?$SUW/C_?!#[:Q'5OST2E/0[O5;=U5P[2I!D[ M9),(X)K.>%KB,;!ZKTT%2*O_E[GV[Z!KVZ1+[GT,YRMCW;?1E#DBV>C,/(X4"@84SA530G M@F"+A<]*S WH"'8?>TGUY-68Z]&SXYN_C6(3N#_A_03\IQ,X6#'QUH:Z,?.R M#:[X^"AW.%=UT%_W?@,,+.J39[TM IY$7?5F6HX-0^OC<'Y)<,8"6I=L5&C- M)HJ\79NCO^EA3)R\4VI&K3@_Y13U:ML)>E^6J9D/P1<+Y[UF[=EF /FEB.]< M+>P4B'I9"(<][$#.!PN#:&90GNW'-8%"9#[OZEOJ+&6)91]TT4N&VZ6EF<7I MP_[IN3R1P=^:#8;YOV6*,21]I(9G,O_[VT1T(<:ESU?P3_K9#A=N\B5'M[!N^/DN#1U?0;M?4U M![3D-7MOG)X%OIN9H9F?J@+_*3CK,RB'A[L%()_5W"\RCUM>WD\TX;&0^RZR M)N4])M* R&Z?P@)1O&@-J:1RDS:DLL[LH+9BU(HJ;D["%R)\)P+#O\SO3*Y! M7K1WUBL/5Y/PF46;Z\6K6DO5*@$!UV9?>#D MJ2SH:]W>_\(R>E!OCK5IQ+'YCDV\C;>J=<(5IME?>)T2S'TWRB>-Q3FB?+1D MF<"4T&7Z8NB$J^9EM []>;@LM&6?; R\+5X W9 ?-_I;-_6:.Z_MPT$S%6$C M]>]=XA0CMH5CU[M_T+'?3E ;%XI^*3YT9,"\ /.=FN%H\&]0Z?12VB$^1FXT M,_E4S]K5QY@;6MZ)45I)^8+X:*T_WN7'\QA!^,[=_,.T;!]4-+&7AD648< W ML[O@NU@_X$>F D-1:LBV3O/=IMRK27>O6MJ3BWLX6CZ'"QZUR!,6>O!58@B MQQL-]KC9# %4;H$2O%])KA8I7!MBYX:@W^'/KYZ>40E0[AHC)?2K]QP V,:] MO.SS)_N]/ 7D[$GIX_4H:*^YG[]P$AC]5TP M49-2YMVR1%)4-8S5EV(\+W%WDG.X%%_7I9-DVI-.UUK3N3Q>3LIC7; SDM7U M&/XT=_LLPJ ]GW-B"/R)4/$%2REY&JZ+ADE7@/1J!$*#PE=W) L9 M$YD_L-2G0:UOX\K;V,>6,E9BL_V@=$C+D[RV!3@L(8/2^"H@0=&-CQ?[B30K M@R29VROW5SFP@&(4'?9P?@9RBRD M^QJ$:(/&! RUK<&.XA4OMQ+I(S);E'UT;<9'PJ=O F/TE#2,J[^A(C51@4N4 MKSPQ[*-'1C)&3*?9_1'3P1!-]2R]9^07"X0,&90E@!^-J9]CX<;8^+&+5V*M M%L>/YB%1=N#)PKX \98.#PS!B4X8N *=X![' @J\;O^!M^Q/CGA-'@UFZAVI M*0YUT=M'WAK9HD[L"WJ2R'A-RH6=4%=;@)@]B'A/H^P& MRFC):P6E4*2?^U4D*U-!BN"\ITYHN<[:KX@;U5R4\9^;0 MNQ)4F.*S'T0Y_W8( 66"4=)@AHX?M6#B.XW<763HL4#<<-?\T84C%LBIT+W< MOD]&A(TD55ZK%9I,3?X"H705Z,I'ON">]3W/GMC "")A,5)J2SVC=CSF['J3[F_H>Q4*:I>GL-% M$KW*8;L5V\9TY3C:YTI9NA/?AZ=%E)=,V&)=$UE270C7*3=I5EZU: .,9(^15MI#073SEVL(J *Q/O M62>>F:;5_!"(5ZEZ;;?LCJXG.[L$\X4;6@)1LII VR@Q'W;K*D_E"OMSCWB< MGI6P+M< #7W@L%^^DTDDJ?2956U2ADY6@>5V^:GZG(4$^LM5,#6/<2/1XVJD M0E*7!MXT*ENK:L2"($I7!.EE'OA=G@MP\@F0&$8K(8\E$$252@N9Y MC^P7#X16ZVT+K[VS>U-2]1*D3KS5#_C,TG:@>9#IW3%23,+,(]&.US_[6$?) M!GMH%C/@#=\(A:?L%.#\/ %E^^L#4*/@W_6+-(GT?F)7[]A[-[; 1,W,_./$ MS)P<3&*.^;47>VOK3.;R<^2 =]'2CC>8'*+Z>.PE3^HSQFQRB#4E<4OD53#3 MZ7Q;K;[CJVHP 211^L7WU0--+].Q%S$;;,IC.J>J!>(,1)S28P$R'SXTYG=C M>) 6Z4A!.<1)J$/)H##S"W)/*D+9Y<\')%U[;\D76%C<"M#\2_P,T[X*(XU4 M2]+&9+W&'0.V?E?JV=FOWGL0W-JE04[)LR?+5JT B4E%RAN4HVR7NL=V!]&J MV;/,PM [.#-K-B(_<-/NN0[C\WL?41+45'"^JJJKWDK\/'H[0%7R_>@]@U6R M8,")&!0,./Y?Y(YC'F1<6J)\";HA]?/3,;C)*2E$$M,>?@G<@Y]Q1WO$/9U? M*?KER!&/)(=#M*M$!^52Q].IT_&V&F^3"%BGOQ0R.G>LRFZW,::QDB,M\&W2O[5G-'Z?1 I*K6=;&& N7_! M[^:)8OUPRC?;?&<)*@9,$X7Q:H3C26<#8/=0-1+4LBU;ES-I[ZEAVL @O3CWS3!:8? M"63?W@:&[:^+2* G.)P-YGA0D4LD51H$4R@O^QUA*,W-^RD*%.4O;\N2$V]> M*$M1) OAK(^SW1DLD=*R7BS<$[$Y<6;,K-U/VY-E2/A$7M7]/'TA@'MPAL# M5,3P<32BBNU6EX23/&C2YEHA\CNG<0\$X7U$"KB'[G-Q7: M8;H8\UA)S\)6=NE8(M9/1D; G[U U?V_:0&!96_I!I5-8:[*QXF\#ZAIJW'B MVW914;==(&NY1HE/0C@3=4F8[EA8B $4*L+[N9ALZR*Y$E]Y(YWOO!Z\#G>V M[9;KM.[71BT R3/^^Y8Q<2G 67W$?DMX,WCD,)80XMK!QO295)CL_?MLQ;+5 MKL'$"1<*P2]BK2?%IXTJ\'EBR$F[CO^M43O^8O>-1MA-LN>1>-1%P<]%6>B- M5<1!Z8#/+=J5>MUH=WN:)=&(0S"-R>FQ2$UTP83D+V$ZM*<109D.D@8L:Q=Z M)>#7W@-AOBJ+*M7]_GO]Y^9]JDY;;='RG;L/D@1U26;/4957)N5?#8L#(FJM\BV]F'8'!LN M#O#G5H/HQ)KEHP:Z_,60HI'784]J?N1:E52APLW*!0-PERU?+UCBQZNYR_P% MT\JR?5* K+5+^RQQ1MN[]6NO:5:&*M/5@4=A? M,RU Z5(<_6<\^NT("X2?;:#<%PWZ;_- W%NN/KRN:_Y5\2QBM>,1N MT,/'-F5V]8;16QY"X+#'%+4:(&FS['\+VI.(!8XN+MDV5TO7Z+?G.8"M@DO/ M<9=F%4Y8B[38C)25%)><$!PXF#\;YLSLNRJH4]3ES[/)9%&+Q&N7H1K9*]EQ M^YPV;T.M(='QOG4B.!R@QJ,T2=,D*I^:-9B;ZG:UEGH\_;4A.Y&3/$9:CH5* M>SP.33?6AC(P0"S-*3CS!3MSMPJIL[X,CJ0U9[\>W=I4KN#*1!\IPP6)7=RY M-)W]T30/Q TFG,-KR9BX]6+/#MWPA. Z.4X:RP^B'VZZD;:PJ^B'+12-G/!( MYN"8R36JS;&*MJC*@!45@D!S_&P*2B3EH[%##._H46PTG0SK('^;U7'B@SVM M26K1Y,\.6G6!UUD'#]GWF(##^O_ &39#CJ49OV &[W_'<11\/PDO_ .W]R:V+Y%8S1()E6EWT;IIBI3+W-1-GG1 MG1[VB?& *Y27V590(VVV(22RW3NDVOFC7LG(26+/2V)E';#(T82,':X$_'8M MV@3>4$+4FD$ZX@NB:37S%'*^];8B;\-4$PA+:'!PCGJ5X?V#J$++D%P0U2Z/ M,R$@."G4AC5K"[PK? M\4WVV,@;[^%8N&9?U) PGO$69T\X+@N2K8CDGP97\LL,'XM'T6 VALUBYN\Q MGL7P? =U-(LA'3O\')40WW/-L7G/ K )4UFJ<0WHX<.7=NH"C4L?%@7 ' M*%::;_X\GIJJ-/_9*ZJ1*QT69;J!O@]259#YG:KI-(]'B[?= M+D"/WFFK%KT-9]I5@!.$?2>[T7TA*(2S%[9UDR>;4(>1G$+N6O6R# 4R?73@ M"_/TN4% 2EZT)6]+_JGXF9(Y7:>M M1N4=Z_%O^^ANL87$[<\,75QXZZ0\7X7WF+>\+?1A\)?T?V3\5V5>-VGXP,6!(>CK>JB,A\FDQW7*) M,VJ;#RWG<=*%8X^;3$J9],$!#W5&$Y#Y(D FN'+D;C6/L[.IEZ,[R08'=5$A M6JY3KXQM$/TTT^ RG5,[":@Z;V*8$%36617F>"2[C#N007C/VUNGK+U$H]OX M9J0&DJ+:QXPPY#C5_VM8L]TW0JE527_#-]U Z+)E&>EHDT)&')H2E'Q=W/ M%+XCJ&WE<*_>OB91_W94!9Z@?9=S+W/SZY,M7S,XC&K6QI_FLB[CH*,_VZF? ME?[6PT%UA_$+.?$"X0!19B?@38F^Q22*O@5"1%]\PMS&:,".H7M&EH>OC]J9C]P<2+9)(A[*DUC!Z>D>JN)9D09I M5B+.(([=9463_<4S-L,J'_6[G4KN!1E3:++$X&7X]/",^=]&M734@R*E[N2C M;);P+@J&%%^D"%LMOWBJ%6GFA.?AKRVA250X:*R2!8GMDN#OM))B7O(SGM>. MU?QDO;,6,OGB_AL69##HH#^T/V/^8>$'M.+8831>M\[^!>T-=,7%%[:0FQGZ>.ZDQ"12563@+=IK' U=G4] =(F1_/NL*K&58(K^&< M.'E[EGX,(/W+@%-( E"K YMJO%[\W:KG\+QU&5!UO4CYEF@;6?@U^)W]*)!= MC<90@#2)E-YBKZ-,+RA,*+_NN]2[QJAFZ.QWVQ>-G!UW$+6+1V@F+Y+R1=N81@0K$&V;()#Q<)YR:]/#@R(J&\_ M6Q)KBRHG()H].NHW18NAPHMLC(5'I, %6U2VB5IZJ06.8SU3S8HSI6U%W=]\ M/%@.9-EJH7Z.>=;CHB?Q7AXU%5+#,D,>'X*>+;@XX6P\/51S5$>RQ1*6Y,SX M?>CRFS-L8!2U?Y$? L3(L40@UM$*2*)N&2*D4MC2B-"Y'\GSNE?G]Q?PW[^V M]*(@W&DU"%(G807RK3/$&A!*VQ>+R6Y(TCGC&0U<-8%$9=V!MY_>2,"'YYOO MR[)A@) M[L%43TH)LBY =OMAZ9J874'K:>BCT2LF7_QO#3FH.6&[-9B5P7F'P\6DHSB*@OAZC1Q1 ME"8A1;LY!TD0IO?Y6;.C'$XRYO6MPJSO/3+%->/4;97C0A MLM40B5EN<<;/VNF3G.GTZ%YJU[6V'@?#GKSRB M U>9-&5/']1XOTK=(ZOT0'MSV5Z,?D3X:M9+$>#=.?+[>396S=USB>]^NQ=^REQB-J*X@1[EI!P\!)Y]VAVVH*W+;> W.#3#Z M]P$0?; F& =ZS&0U'\7NA5)E$6I2>Y(U^&)NOH_R[1TTZF<=&6XQR?WG\'H% M1%G?)S#;7BXJ BP1CEH9"@AH(F% M"T(@Z937(L="5BG<$>2)"80"TACV?TO>_TUT!*HT?Z5V7G@->";I](/QCZ(0 M@S2P[ZJ0FX//5>6:"4CR:=.4HU\_!4V6A29XPR!;[H(#>OR]&X;YUI6GXFQ8 M9,)MXO[A6FS;/3=C[6&*SUQ"I 658H.-#ZPM]A4!WOYIG=]_X/7(L&0H^,LL MR\T(;=6:R!_2WE>ST!1)K/,\_$&-U'?/"6^L">_PS<$<L:51]GT2(RS3"_*1F^./78" ?J!*C%VGJ#)%LD5 M8*AP>'#A3(67\'F->(,7I%G;BBV@31#27O8)B15\*0W/*).,=7JL/L#]U5MR ML1/JDEG,)/IPBC99 ]B^1J@^OSG/3+>-:!_9\WIXJKN&C!A6 ;-O=5< M]03E M=@[Z6Z8D;PUMA8740N>MGXO.H>SDS"QBH9V$E0W<*BV'77QGJ#4E@] MBA!J4>YN;&TJ,32UEYANB$W]8JA4'C*B0N=^8-*&[\<.66G#5,S?%9A7=TY6 MO>O@^>(Q?_]&H&RAIY V5O1.&TZS4<&<0S9CU:Q0]5B-DJ=W.KOO.^SV)XG5 MM\38V4N8T]O\$?E/FE&@U44&:278,G!L0_"A4[!;3A_:C79'_4H4CRU3C+K MU5A[3%3DO,W0"5ERDN#F[VJ1H_5<:B/"*M?\*8>4)QW+0>4:$T,^DY*85L @ MN2?) U)K"5RB/[HP\G7@K]>!PJ\A7+&5?AE@))1=)"S'9)NZF/73H*\ZCUKNDAA0AQ0HV>Q^D;N:KV.AL#A]HIIL!$ MG74!M"@OZ]5A)5L@G.4M2]*7N8I1YH\P%:Q\PD6'#^\"I92Z5AEC7OK=+T5I M2CLI:]#N9.LE6D!D#-IA4)5.7CU7I;48>*U'6^A%RU%H\[U&ST('!S@CH5+P M?1.7T'Z\;,^MTF 9G+( M #Q5%@WZUDF6@2AM0))K#"GT?_[V();FZ6'S77ZS7+6:V9%R.7$C% M0]*?88GG^2Y7N1SZE@;N2R66Y/93='1$V:F.'-TO(GIFK6D(ATX$6(E Y,81 M5V4\^)@P/UDHW2'W2L9(MML_UL0YI$.YX>#4 JMAQ,]UB>.R56+7U8\S- M^!0-GG3)@;2>[2JGZO(2A:F;VJ4GUJO>GDAY\"RKX?BD7E"4NI=_V.-*\L:7 MP>,IP))//V5/B F93+JX5DEB>BR363PH((L8U96(.N+()<)!(:U!)0Y !C.V M8\$*4Y4+-P6RX(,[R+ ^.;P'6]_[)EIR'DWDCIU*TG/.!6Q.W [5@H['_- R M[FQ +(8V^T;,GK-:C^GI;6#FK]'NY$S7JT@[J=5/5WYKW MU%\ODV>H'9J;$F-?*@),?VJ?_)E0\7A8:[4O4BB'VAP5W]XXG96\R^ZQF+5+ M1B;BJL+$4,3^_B%[)MW35F*4+YS@AL#P5D!W]:EHXVH<+:UK]4G*GITD8=%+ M&A3=[)]7%R/.,HJO(]'V(J9V8H%E0L5X\6TROJOX,Z(=4Z4,1$9/ND98P^KW MFW.@@??4QN;M.Z]&IA@,\3MRS,&N/DGB%;8%+ !5,?02(;3UK\NXPI*C84OT MXVM3H/*S \(G0E2X1GG=&MX_I MU"2).I(OOP4\=W757 IN(9SOAF$<',V5>PR+^+9F/S)PJ<[YVB]>;@PXP?JP@TN(YVN >8SLA=Z%#^YWV]"IG\5!FCN MTT3I"S/>085W,_"':$[IGDT9=L8<;2@)8.Z7GE0SK4GO-4U)*>?9"6)[\#AH M?GI]JIY1$!N_TJVWY_N&C\GHH"@.;)*2Q(Y?M'WCKEO"NR1SB/R4,XP0VQ]K MQJ#[QK#-L:8P?&6,I_>I!_/6O]I#7@4P[,*P.OUM.NL,*+7\_>D'^U@T-YFL MXI^OIV!5F**C9@MUY!ALB$(/_,01$EIXX'=7O0*I=7I43U0X!23A/ M8CPHTK[+VCYYN!K=1KR4ZI"E.L/Q]N(;/T'TQ;H_N<$[5'0G+5$TY;3'L+03 MY?10)ZVR=L&:U'V:;3'Q@O&::P#1@KU7 -W$BX=NA9P%,Y7M_1\KY- XR>/S MA- :;L 5_6>=]RS7/TJZ2_^2*5'QCPJ,7,)/GYI5U\-K)>9*L&MXV7=+8BN7KD8 M-VYU$>B?= 80C7\X>OGE5/)5DC<;=[ BXR) ](9RE_XTV>Y1C.&U-NPL-M@! M#Y34(YLM69+F-4E8GU@7(U .:GHIB8PKJD"9&\ZF=1OK!(:>,F -]A/>*$56AACPL MK$ I&T\>@&J>$ZP;)%)Q+ X&/EA8CTFQ[0)-5QE>8GFN;; MR%$^G4?[:>GG:4YNF=Z"0*7X'(V"S1KF1-98J]CI\3"]U^LD^[;H ^4!E/:P MQTO"E1/O)]^-G&H%8OHZ=U<+E8"=^E MY4LWN\R,[ [/:FHD.CRK4+OQ>3EPWA2+HDO"<*49OG++MLF7H.;@3ZZ3O7D! M60GCC5ZAYCT3O_#!6:JM_L>OU8^$:T"XGJ^N0-W-)LMI& MLIL*2ZTL5/3V>-ETS\ZH-G3$^8FD29)/B+X0(YEM*[-)S3BTI_U36G\F=I:( MV,$)6DY7%&#N!D7_U)LX0R4E(K5C24C8E0 BH,3OZO:L^W;UT,#C(N7?2XY9V^:J M&&OFDD[K,I3B\9? :6T_=QUV5$5W35!+0CLZ,-,@1UM%^C$CBRZ99F6(DXW' MD]4-!!]N/+JR&FUR)N5GY-S*1I-"FVAD)+T4FZF@ZH2]#RDQ-G:XH/]DG=OYT?'P/65:@L^'[1@,!=DI"EI(RO RS3&[QI$< M;P'7\7DSEI@V[8)TP,JE[ HC&I-^:&M.&&;F,!2?_O@UH!*Z)?B!]K6K4U $^@8GX2& +F>5SJ/"\%T@ MIYT+L*/0N*?$E'7XN/N==Z)(6:LXDR=-&=_-0MM-S7Z//15"^^=;O#VNY']. MD+HQ:9ON(_R] #Y$M&TZ3T\F@52_(\/.EX>QWNVPHJP.K54SOY,N!_11%V[G M[A >EAB*I[[)$U7[4NJYNVF8!+(FDXZ;])9U3:K4 8!D.3I@$\*ABRJ K'&R MNH5M9%E79)7G<)XI$O.!84RVRE9(A[#"%<5L)!3:C.[F[_V^NI7^F^,7ZX1O MI32>KP==/8M'7(9]6LC1.G9;<:H;$,8Q5!IN5]NJ"EA8M$.U0!+>K,J0PE]4UBWRT?09V7_DLD?07OF#V>I M?B2NF(=1SDI\G8-/ZAK@\,Q\>>%7N2US M"RZ %XZO0F*B7VYND ]'3&T,:> ME(JQQ6TNB<-!X_UYXY4QP0($JG(8O^;/ED%_\U0 C^D!/WF$<%N\$$:E;VIU M4_!#X?)!J*<8];H/(T*ZK/SFT#T!HIR07#T7UK6Q<$:2[4^&)I_9C/)C+S>? MX09W/0_I8CB;_?>_F.$X"G R&K&$/MVL5;9MO!3N;4.95]!O=J\5_SGDK2%9 M-=VSBB*9? JL\$NT"IB?%,LMZ)A*8 M8G21VI2_/2];(VQRY\9#>!T8X% >O8<+RC$\L4"4]?J(9'P .Z@C65\%T+:2 MII ^&G86A8J D'+CT 3\!EP45"OODJFP,=SYA#=,2RJU2'9B)+2SBN6:2'1 M2;@NK21USNB;['4R]/A\!.?!X6YV\3 ^R\,%^,3IT #TS9>X@P[($B$Z=-9B*^ MAMD3WQQ-%YHX.,EC"$J]-P,YP;U;ZBC5E>@#]:YTQ?*6GN[*[M)23RKQK@>C M8G?*7HVU\MBG+K&-\VPA0441Y34T$WAE[I/&7\KQ$M#T.9H"V9>+--V 36L5 MV":HY] \9PBJEI LOU:N;*^MFA+-P-03F\9A- MNC>]I_"?'6KG9@LH ER'X9 (XZUN63*4>=?7&><^!\YJ+P,=7AYF]!1M\D-N M0__]-;NSDK,<$M1.*R?[*R%__1E9T$F:V(#+-E$MS9PN M!KPI=_.()78DQ>>9"KO2@V-24#+K3"^B9/FU,("<^DBOL9) M&94OCMJ?PYH[U3TBYQH#/P<\>XKV-5S>%F6^4J[>(0$L<2C1O&/S M DTM**1!64H;R^M?% TV[OYZL?@S7\&-D<0CN@5K];RFQ+!UJ!B$)(LK_BQ_ MR+ F?LE55"HQDN( W9Y-U]M-K6V*?)= F$LRY1MWER%8AX3#-)C@( M77L6>O8F&^X;03SX_(HYL_&@7=HGB4BX!>[$P!:"\.WRV0JV3-.:A/T )>&L MR6^2DX8IC5Q:YX^LN!W-1+3272I/N.-5X.T 62?8Q]CC5 #-L:F&:WYAZ+B^ M_$>G/8:S :3V7W.PWP,VI\5A$A0PZA!4L<*49MFZC?5XY3N@W= M>.;<[BEVU5(6G+::%BNL#L&/-= ?;X,K>."$P:;IM3OK%WJBUMOZ<_'19M,! M566HC-X 9E21_ZHYGKU(HQXT!7=(ZD3NTUM57)=@(AIGL3YYMS$#<<2R21/B MH*\'9*,;=9_OP^'MJCZ<>R)OI'OED_O-E@L]:9<#I;1 2,*UGFRBZ7T>J[;( MY\UAWVC2 O,Y >+?2UWZQ+%<]\43J@02 M0\43B-&8;]"P #5: ?LRO\<''Y8Y7RW ! 'LXJD?L2=4@78Q92/.CN("$FOJ MU9M4'"U'!G1NF!Y)(M R#ZP%MPGGYKF)#R'R(+:%@RBX(=T"M_?(K36G30V? MK+_>/OZ'Q"W3^-!KP+H[LNX'Q.0:L,.M][=D-Z 7DI" 2ZLUVAQ"J[Y:;BQV M6R?%Y9X&]0LF(7JK#LN)%M+F:T O Q7R)I*)+C^K((*!S9:X'KW2*%/F^AP# M/3@&W48[(506'ZT!**SX0XR1(VG%=DNL8T&35J'Y9G)*8WW@HI"(Y4TZNG67 MTPIN9&S\JY&20EMCMG"/58<,WQ_E'W9QQ^\^ZFDA)!N M5D_=FZ[A(YH?1#P?<MZ1KH.:F=S:@@5H:H_R11+T?YW>R.6=/K2^A M!;3DMS>'@1*#2%GR.2(&/Z_PSHOF8WHJC2HJ66L#3M;GN=E9(RLR42XQL[4& M6:CYUX>6[B??;&T"7II"YQ+%URXE \6L YAZ$B!D5 M:5=DNT0Z=5IN;[@1==\F4"GC5JIE_(,S;#E0P\&>GM RF9\*TCRJ62]WVS@E MI=G8L9 S>OZ-]IOGA+N)G*\D(^>\GVG1^WN>:@%0O6MPI8PU(HK=QJ>?YN01 M+/H*A_.6 ),6ZAHAS"J[0R.ZYEY 2( M);BSY^7B5T1DWV^>.-M^^>'2UR*O^!55':UWG:7>PT [ M[5Z<_"1&673^G5<26NA(NYBC 3,+X31A/"(,/M\.9$74YA5W[Q4O942;O.G@ MS@5QF*G0;7BC,R>'R#%X(;G!N^9A/C)Y<'_]P8O!BUVN5W%B%"QUGI&#T*> M]I*79QWHZ8=7K)>JK>-^UJ#5)ND7RP_K*.&^66HF"J[MF0>*Q&N#NECX5;/U\"%@!$#U)-H-$-^-\,$-U MCO9<44R!7IY%6!RSQB'5%03<9@&)L_22A&_6;\5W.D50M7(VSPAE?-\69O_( MB;!_T&Y!15*K9(1]1X7)D][_D[]\PQ'N/.H3-=2\QPOF?B)NSB8M(V*XABZ^ M$B*RX#)6ZL3.+[AOVY;UWP[YZVX[)$5X_PLFN :I;T,:_J@J< MR$8P/QX7?@+M68N4DBX3LG]_ZQ%R@6.G<3G)7Y0P92=E*X %T1;-BDS>RZ:O M14#72#D7[%T&9W'E]N7N*D^2 XZP=WV*NOGP=VDAT7YBH/WUA[0+%OGJ->+? M4NX0OFEG^A[C7L$SE8>H68Z]%+3,LTV3(4V"(:32&I.J&>S+>"G$0=V)'2P! M-7N>,[*DAT+^:O0*>F,\3G./7MI4QBEC*VQTA0,?ZL1):[A)I'55T(,G=GN) M:/;2E<_-"N!.?)JQ7_M]++GSZ:QLV"O4 &<7?U-+$/\UR^OWZ/.&XD#6GG[U MR:Y;9<0NG# ^!L,''Y .$5M5\=*76GI/ @:TK=R:?RA4C:!M.1 M'>8EJ6""CWLY'QFJJC.\U.) M\*[1B%:.Y@F#;MAY-.O[+->J?)/>*\L$99U*)6=IWUF]GX*$^=< O/@KTFN MQ.QWV7W9%\=?ZS*:Z%WJJ"]M;X5'UV0Y= ')QU?:D+5O"W>'$[V\>"K2)P&$ MCW4PMK"<$%\O"46[1B,E"L\+X1JR>E/,,SRG34HWKH-'HZJ_%//A8WR/TWV? MF>6X2XSR/1G^\6:]U;UY[*/3[-K$[[@*YE?1\7-*B202M MZ8K*C!%JC;3$ Q :IG4HO;4,6;Q=(&E(=_JS,6M2:K3(YDV6=2[ZMGO)4\%] MR4'#(/-+[I96!%\8M^641342*QS)6CYQ"^G4S^**UJNGZ3)?"+!$H<-!9U_C MRR]%W>!<$!(84/Z(8M^3QQZI4OI9NT3O-NC)")'.J YPTC0\#.07D/XVK8#0Q[(4S?QR8H69V[,_=9/Q,#=V"$*],5'_?KOF*+&BEGKR;KA_ZSM8+2-E0UP:#C>26DY(_#M:KX_?+?& 9EU5E_C@D,7&B&?)O?9S/ M.G%A,TD7]5UF[>CD;$![+LY?-*M_$QLR\_@U^BM&AWXPI[9WVVXEF*F1-/5_ M-S-H])P]@>Y^Q]>.\M(*?VNG$KNO(J(ZD3R'SVT+%2[5NFX'* 7*!"!F8E=Y MN%:G?""J'.:IPUW_/K#/--% L!8_,JJ'H&2I6J+%E?\$WIDKQ9TI.&5D>[^?#FS&RS:9&\:;R1(HC(8J5.E1"/ M7HJ&K5F:+71AX;Y.D%$ 83R6B?D75?_S2N<7R3[*L5^8 [5VY.B)PG@O+5AO M?E^$E$Z)7:J$1T]1EIU]+NC3;2NA&#GV&)O-OHGF04A4-M-X#8',JI^-!?QV MZL;SQLJ0Q_R/ L^^\#]L.KGDFFM67#5 $G4-7 K-WL.QKHGC$W>5F 5/;<1-J%\!]4=3O:\CH[O0ZUX$@@?M"-/.-:RM81'P5@ZK>,!3'Z*4S4= M^'6>(F&^.56W2+6X2=6VWLN-KIDY135CP.]+>5-%7]XM-3(V;VG[8JRG*Y(A\4=+S_'$T%>R$QD5,9+.IFZ?6WT&J4XU8\M8:O,V[DH M4-.5'+(]I-#2IE= NYA-MVW%0R6N2A+M\V"9CRTKQRYT\"SP;75_4&7BP-!B MR=;2=9C.QZ]D\EQ8 0S'6%V, ?Y+$G9@C\-J/XR =$CPI>'%U^$:/VDA$/BI M%PZWY?WXPYP^X3EP^JS*C!_[>U1\SQ51V7:795V3FIG(FEI M0<-&]E 95I3CY#Y,2@;C4S2 D5,RT(1Q"=1@>:@*#7DR><6F;E&D7N1 2T<; MW#WDB]>]B>7?AQ]N9Q':W@-P,D9*G:.)B.1?$^Y&%S)V8U5B# MD^6JD ^EP"6QMD6/C*XHMK0(_,O?&# MB@6LZM?O>0Y4Z>Y^>^@(OF(^.^JTE243+O;S>F<7"V^"D!K:ZWX3.)C4J$A0 M;>>8-_!BKY#FFI!A _,ZT:,>[8C,VH&OA(HEHN=\_\XG;+I3EOX%==$ MLV^)PQ7)3/5W$Y!AB#?%NN*@J&LNOJ@X,XO'O;>K.:_J*(%D2*WPFGD4].[T MH=_<(1-+?<=@TRT 03UZ4.*1'!U%7:^_C>;5R#2OE(EU&4Z!5JWMWGLAMD4B MGEJS$!=ZB6Q_17]FH,WJ$:&?QKC%Y&G8K#O5^/Z@$AMQ0[WMT_CDVR!&CC[S MWA:!_X(4),5&@%2R)F*FP:U\#KQQ"GJ^99&FY7+^!HJMI_<9G;L@%-VYXFF% MR(P?SQK'):C8(9NN%A&%%T)CDH':=,AF?BK^#!M]8X7OI4WF&$;6K8(,:+N(,#,H)ON'PV=06I=/?(\6;BR62D[GO0DG@2?% M><'JK08O;1N8DD]X5==EQQCUHOK@>KVA7O1+9;FPW7>&L!D3E:RU.<$64XFO M:PEI?_[E'BD#_WS=RX'>TWK7I"TF0! %Z4B;Y6.(XHE=^)B?(O"1 ME.R"B:&]DOR Z"G*Y?VEXL=)H1N&9F\<4$EW;&)BVGS7D@53]XL ?7O,Y1Q[ M^JZ?/^)\KSN]-@-.C_>$]D5;$4&EYD #O:N*_H5U$TD84XAA;0 :LK=D+?9. M-Y!K1L@;\[56&GV2C"G=EKA>1R[^.5*VF\<-SAAYR;?Z?4_,LB;%6+*L.(TR M,6BP&->+DEOFW*7Z8F:VFXC4GI8;9IT$WM,<9Q-960BQ/"]9_\FY<)V+-OJ\5@!3P>YS<*T,S MY=Z="L<(-CPC]SQNUR[(U7;KC%LK.YU)NV06!%U6BHYK4UCLV_%,4C MB3!U[)9MWP\/W MAT*( MA?EN$^$M@:-5'+@$VUO0>@NE5H0"]FTB+.X M0LPX7G?4(:^'>'EL7](KXCQM]"0UAK[BG8&R:P#NU3T@*KX[/2>\PL-0.*4V MT'3>7AN6 1%VS0NYBWZ;BKZ)H:8([A2>7GAP%00G0->IJT(2)KZL72W2'?L< MI,+I+(#U>4UL>[$>&M)9NR009?+6SP!2^)CFZ4/"K#L8\H))1H'L4BX'^KG^MGHUR(PM>!+;3EB_& P^+_X@Y!1U MH??.V&ZK?29UX.OSX/OCRBN4-<('HG"[Z:V,KHNEB%J!5UP8^X_Q6>Z%P?0( M'S[3DJE&BT60SE!+W?7G:3D5Z''QF2C/U$T3"0QZ]7+E<.V48G>ZZU(40;Z$ M6SNUU=9FLJCU-%/+@\6A!HV&B>.BB@XY6T2Q\*=DRZ@#B)$Y8=4._B]&=6=? M\O :F+19DD^6?L3T8EJ95;P)@I@[S$^%[,Q1I&UK>GYHMP7LTKND=*H@CO9T MGT*N 7Q$9C9?>-JVEOB^KVAC2?[Z_\J7W/$8D+'Q0LB*VC4@UMW"V MHR#E_YGSWV5.QCSJJ#,:*7.%0H5K4L;GSW=6^>=YII$]5MN:PL1"0C.N*)6# MV[9M)]H0K)#>TGF3AS2U2)MH M*!N2,(M.5#1!BG 6]W843[[NPZ-@[$NN]]> T,25B@M:H8I+''-D:2M5;2!J MM#>WB^;6Q3*@>.T')>>>S, -&L@@( O/R;A[:G_$68Q K, M=146RW4-N&5PZ?#N.VO=Y?>>:X ?[O\IT_I0\2N?8F17.28:(:.#-WOA!B'R M\UK5D%T]#[7QAM.+X+T!D;!$J8?BAX]%G=I4U\XM;R/=9=NY4E V('0_0<2) M$'_2RV26XEP\6<0G*8IK@(+2S=.#N'X*!?4C#'X0T!IJSM]^QI] MA2+W3YJ_\H=? UHQ &YM_WO-\6Z+OED\]1;ESE$G.+V$7MT,I5V4Z?WCR8$W MCC(AW%AK9J*_6KX>LK :KQ0L2]PK".40T^D_9H-6[:4\V/[ZE:#1 M?W_V_SES'-Y.2WFMJ@;< WL>RQ+O#(,PLG;5.>K-BC];P' .LHH8%8")?U@Y MQ<#N^1A1Y!65#KZO1NR5TOCH VV,BO\."/?_\;1-/\A:&ZX] YFO[\T:3WYV MXEZV\L+5G&Z(?;,V=PN">QK_A_E#M> :U7@K?5SXSWXT#B7D7P6\R\4S__\O MV/V_-B<>R=AA30WIU"ETOV$)?UG4*X8;BI8.Z3K '3GIEGA)]0!V3Y4\#9>& M*(]B>]0.5-DV#M^&!!IP(49@F"B;U4U;2Y8O;*HZ8PK:B^V^?*FRRFE5-@!CM^CS6J_KI<=*[QK8_4#:7T.L7^A'_^PYOM_[] M\?'_32=I10"M3,^ MZC'37%.;XJFPH.5II J6:W^0KJO,D!&^R5%6ZU( H1)FC:50/J>O[(R!#'D7 MYV+Y_58>FX-DUI\2DD7;I0U+ WXN)EW#2@DTI-YP'L-"*-]9Q4[ 8LIZ6#5*%IP4U$F/MK;M,)2BB%\915,1+-C1E@)=RLPD\+)W3,.3PU:3QI<-"+W M-TIS.3?-L5\7)J!<[I#AFQ >FB\[4%9._D'R?@J:O5K];>XRJ<35L\S&0OJ3 M^/H$$-6XJP$QJIQJ5A4)8BT<"!OLG!E@S=Y]D!M)]5EYN3X)H-/+@?XAI_=" MWC;=L<3A/&-]FI [MR;:O2J3DNE^[P/R+1:TJ!ZD5R3O8< =<-SA4I_!./0 M--);KT,6LAL3\_ BQ%"&40/]BH(J+*V'*LGND]*Q%)5+D_SY"9:SB@?UDP%J M*4:U\M(]45A:5\6=>9$"6&^R@VWPD![XT8OG[6GRH)<#O-#AF-EU ME-D!&64FQ!9ZX47C\TH%0=G@2 M=P!V+#&&7MLG &'7J-JNQY"WDQ"!&NS6HTGC(3HK#_RG01=C6/1V:^K?G0"+ MJ-8S_&N 8XZ$?C:% ?9G4G)V&M8XZB1-49<):%<>>!.LO[G5JV-B]G%AIO;B MI99C^/<&IZSPUE5#_KD%5/@*,! FI"Y\$-M2V/U@B\$J=<.+S9=4)WRF$<\\ M2H:L7F4&I%C.=P?M Y0IT4;IL%!D2U8-T(^4C1;.PH([Y@ :&1'QA>5U\WG\ M?(,O4@U?-576 SJE8M;HR]S@A V0 EN=^>V)B!K?';\R&P[&(5R\ ;;)#MRH M1=]$H_361,PV))'IA"-DV@SU@CKRL"'[)=:MPQ379"E=QI)&?6CI,'! M^E4E34R)N*D?:D.]%YAI,A5$DC<":/RVVN1@7\VDY1:W,X5X++6;F&$UPI"))O-F=+Q:XW M?9@'!NV7PUTWYIY14=\AMTF:ZP&83/GI2:FO0DB,1LSEIQFX?"/HJ>YO!6VH M9UH1S^D*QF?,"T>N'5';IXOD%3UT*3*=?TA9D(8C77A\#2B8S_UVV=//D2,0 MMIBRDY[<8_S$=AGGE(^@*9+/>$VK,G*V^=U3EHJ56)2!B_?J =O5L6]3&75A M??;XAX+$JM2@.#5_G%RL[3J?T/-L]JGJC8]9F7",>J-68)]KC-LL19XVS+C# MTH:@L/HYQ]V'=+8M%'+MZ(B2XK^VXK[!CZ26$L@.%2'Y0@2Q9D:KUQ#8CV$WP' ^<\G8&WU/+A3 FM MVD8D]#%S)I/%OWG-3?194TZ:JQ@)311I6 MNH>4R5KCPU!8-7LPQ%93[)^]Y,!,QIT:*/#V<6Y0-8?^5AOU,,"GY9^: ='] MAUQ* ^95R#=Z*=#/MPO7@ MUBG_T[4+K?.@!EZ6T3Y]*UVQL5(S+ )\_> =3 MYL]^A.ZK8O+N4%+.E(%(N&EET=.)!/QBZ>*0)>H,J.Y;/"FI;[B0OR8=:1K_ MG"ME0O@'5[M/6J300<#J!]C:TPSM:ANE>YOB@2_9L#YWU/$N-1,9SZ-<+#RL M5\E3SQ-LL;3SDE/,:P !CW00#[G&GL]M0?]?0RPC>^HBBD;5\LYT+KI[;" M;XIO_\BMSOEB!B[K*2FQ;U1JHLQPP)B:F1%ILU+5A7"D\'")?D9_('6?FJ%F M$J5E=@UXE='9Z/GQ^3%PDWN ZBL=*;0MY!97-.(:$'E:@69H[T-9QYT G%\V M'0+AQ$8#E9G?$O<$A;%[+A"^V>Q%SII0(DV\+ MNPP@1YL<_T-3\;?^\K]W#_Y[N[\GTQ[J&E2/ZZ><"H\/5LP^NR3Y ^@'Q !> M; V,MQT:KTK@\22PO1AF8D4[(9&'Y/X):BR2>&BIH-*W+-EN<9Q?HX4(? VF MW9O*>4\T3'PI!?W3KZ@2&1RCUIEYU6+6V &99^ATRR')W?GPOJB 99>">A(C M_Z;^8,4%J1*I-CY>SY4?!U]&7VIC%?_1;,[@7S6F^^O[L[^T*?Q3!KXXF[%# M>Y6R(JW>G>[9YCP#EKA(1PY=2 M8__-%#ACI+%^X:HE>:UGJ@')KH$^$A3[E?PXGR>0)@A_;@M]3XXA]F_F^Z=J M(?^ 12VJO;XN!O(IX= (#=9FR\'8./3^;D[T?:-0MS0OF?N(U^G _-*]RMU4 M U$7XZ7Y#*&(AYM9>6O66[CK5B*NTGOF<+9DMW(4GE[EIY@A=QVV*.$]9J4] M)IVS+_$W_)@$G*.&G(:FY&Z[MDPO]ORHKM/!GKNCDN_"_-951E?DH&-7$P/@ M _JOM4C#=&PI-]FF?9HV6=;_A:3KME_S<65G;WX#>_Q,PQ' 'K94R!YQ=];1 M,GUS5/M8OH^VM!-?9?.!W!#&"R:R)!=-)&$0W&29PMC^POHP>=U87A_/%\62 MH,QE)11B63%7[ !B M)G?"0M0:-[/9Z\*Z'PVSSIC%@*C1-_%IO.G%1_C-9H.KWU;SW=Z&F?7?@L,F MA%ZC9\H(=)VP!8K:WICV_8H_6QGW$PSYUQQ&B6&VDZW!/+G'!QO9#CL1EMB* M_7B,2$%/]J"03,3]K>X0-90'5<09Z:20\4LO@0.TQW':=(3MJ6*7]D=1-XY. MZ\:E[75"?E!.#]M?Z,W4(-0D\3@^UPG8Z1_0/5MIT%."$97,!QW:WC(G6MP5 M;>PVA\D(?_27\SO9]E1',T2)RVM:LUBY)4X6>IZMP]X7K98'="E,^+$[T3H0 MFYNHTI$8OT[MT.M(&&B?NQ6&)>T6YP:L^IM!_9E7^#\AR$V&?\:I>GWB]. ^ M/%YGN@+CPQ.UIAD*F-GZ_.4CSDPB7"Z%YK:%MI>FP"SC*KY*EF%FER^NE(XLG=2Z1_!^P\ANW M4:3\)V:SG8N^>G09?!;_G=">\4+[IUSIKTV$_T*/_ACH@LIC!^Z"/K5.'&&[ M&U"_,*8"S65?&QI 9JV -SMUN<3?RL4J:Y8)C/8FOIBJ"O<4GKW.MJ[9R,=( ME3WB56$J(\1->%B>SH'.>_*PIFVF^D!S5[4@69/P643B1KA%R%WJCS[C*2L(@KWDRQV((-N[Z_8 M>8;$=A-2(<488ZWGZZ+@B-!4F6$OZ,*S499U98K:R^3C&[;M/R:1B9_]/E#" MA^LM"E)B3UL1PL-[9E)1 WP+M4QRXK%<_N1-3%_Z0$S'%!(FG'$-(%$@G[A4 MCYHY]]Z8?\^B;SU]^P.)9\KR8.C>J!#:[I0.$()D[&E,37MO3]G*\$;1W]K> MB?-"%]9&;;2_1&3@="0TW],WNZC9Z*44OD+T5$$?AQ M(KR^E+)=<@RABJZM_+.\U1IL0]WZHJIL&2 )X7TUBE0';VS=W;E^KOH''1V M+>G&7%?*E]T; M$?WX1K5!EYQ$2/VZV$MEKR)CU2);:+Z>KSHIP ;Q\Z0 6?-/F0Z/E<( M;5;'\(JLM7[J\D[>\I+JIIF9W?G)X^]R"P>TJ6)T^$D^3V789J#<]^HFJVM4 MA;,>QGA&='%1,_K8,"X\'#@3H]< ..D 70K!^89M*+O5^0Y(EI9!D[J"SU@N M!ZWRT*MVLWGR%4N:/LPB)XI="<_0TB]:7A0CE4XE(F_MW.Y]>"YOJ?KH$UHH M&LF0R ,9A?:;< "#8GC9S&P9S&:20[#G#%Q6($1!UXXWU,,UU6K'JS$[L!SY ML_F-@8PS=Y%8X=4_@!CS].LX#W3=JA,'K["8$;D$G+_SP%]6_F]B$;^/!L9( M\V/6MA\0PYM#]/1GV('DNGI4=_,9>XP_.*-^*L9"S76FCZ!2WN]1$*V,@2@N MSREA')$P'DI/9>I^L84O+&>=R)E B2BN8:M9X5AY".G" +Q?B&\_^NWSN*%] MY .2XD'U^PF4=_N8[71"%B;/ELEWEQ$1*+5=T$,I<:_2A5X^FT3F^5O> I*0 M\MM\G"W>!W(,\8IN 60GUG&^.:C'!MV>!Z%*C^KP:&A&^=$ROU_HQ]45[4K$ M5KOL-$[!GD9]3S?,C=-=8_0BO8\^&P?.)9#@&GW9MLI:AXJVR;\&=!JYE1AW MO)SUB5*W=@QZ>EG)Q!$8QM/0>*KE(R1+LB<(M/7).LQ-LKM8_\J/IT#*">-V M8,[GBE.=)R&HS]:B[@'X4% ,@I]TC^_5U7T:*#5YOEHW9S<_II:Z\DQM4,8I MYP@?0>74(BLW?=2VRC$K)5WRF3UUJG"QX+M\6FVRF"X G6-P*'N-_D2.7O#W M@,A#Z[?*_]=H,_]9,_=_RYI-^V)JHO>H3X?Y5%\KENQ^?0ZC40L[UKYUK!J2 MH/8N$[U7)9GMDB?=4NU9ZVHZ#'E N)+;_RB>>N"P+U"P M0S@?#B$>7KT&8*B7*=*.>F]T)^0C&(QH=-SBYM^0[1, W-T-L%S!OPUZ?+/O,64Y7.ZF@!AHUCETKR7"O 6-V,-9E-:Q; 4MW.6 M+PYTPRX/%&WXVM[%MELX^]RLQS#%EFF9N'9<$9^J+%^'(6 3B,Z7K\KS)GL#2@N& 7P>IF&6POBJOBM-K M@M('1'<6E17D&"(57:\XIP\/+ADNK@'A1\\;3)AXYY1T50Y7MQ&9(4UAGQA->B$VQ)@8[]B MM9Z<8]^'*(HX6S3HDPBM+7,BV /GCN0HS^@ MV)(ED[(HM?/1SR<*9S=T=-_&Z#G82OV$C<:D3(V/S;N^E=@9[),(C)7#H.A! M?>_^V@C,\K#.ZR\KZ;/AV3]Y37WZ.GHT2<28D/:@PI!E[0QV&"!8 CQ_U59^#3A-Y?R5J/TQ_HQ( MR&U9BM4D2)C$6*PZ]83X6V5W59TYR#*G S38]A"TEDU)1%Y,3^UUVXK6Z'D< M&$BC Q0G+RO##\,*)M =.XUPIV=85J]-]P8==*CX;>+WO_WVA(F0_!G^2:" M!L#M&D!@R![XS"V39QHI1B.+/!-V W+/7A)4@,UU)]V+04XU&6_H03R@_5$8 MI:N,4N^8=AA3DDO4F3$'>D[=S!/-'&7$QOXGF1HW*U.9SOYAVMCUNIGFM1X@ M(S(L%#'??=\#DF?:(>6JY?N@YHVIYF4MV% !>(?0^K3,U MO2*BYHF%[_OY@;NM$Q"/6C:=!KEDB'99]C=M)3$H<$BA"O$92#-3D^%17>.; M:C<3H#O([[@#NI,\:+/> M H#.$%= ]-C]8)?218A2!-$PU$=;1K80%%589BO2.#V2Q;,V.#YGBOUL"!S+K*G MV3[_^9:B_TNI]L9=0 4$/XW68XI$Y M+Z+A6'E,0T.F=G4]XY!6>+:UGH@?( MOH,YZH!7)ZJ_,M7HWK,"DE13!F4:^KTI+D'5L7)WAUAY==$4R]9Z43XT9BM7 MDA-RZOX%;V;V;/ PP'MX@>%!-#P^S+*^84QJHZJ!Q)NRBMN!F/^(6H LTY)Z MQ0OS@WTK(S(UK0#\#F%/B[_G3WZ\H,[SH=>26@F/VH))FP*,3CVBQ9)Y$4N. MMG5%/)O3U48HQ<<>P1J:>@;BX0[H0T=4D'Y[_CCYQ-FU"[V(0A(%Z159XI@Z MBZ97D$]83$B\,V^4M1H:L/_L0Q1@1'4MR?L@;C,*<#P:>L$S4H=(?EP]S1[) M$V#TDJ4*/[E]@.O!\\\JW-3XSRSIB!T$G B[O%87+8%:-< O/%//EU1'OO%: M4)'43'^?RG;&[>_*9!@:/(1N(QPNI"[,IB9[ M0,ZWAM^?-#:+*+JO2F1#VOKX3G]5_DYQGO M2F1GE$@.42QE[X^KD@!2+,*4^L6?]"H7WR:Y6<].*=9BT]UDU/G&P:4J_4(D MX5:2N$4LW3?9%WA3EEB4B_5%^=)T6X?\'5@ M;V"ST+FJ0 ^C "X5H MKC)=7K@3';G)U$1G81 (T-,&T >>#>02L/^N\[V;\VL4R8'^X3\YT?]6#Z\L M$FE^(=NMA0Y4\>"V"M,#YK$Q3(-NR#>V)>9KP$>_Y0N3E-V64@.E)H%(MI2ULE@LI3%VAP%(]4I3T_P= MHBH%DJ6E%\J#W8&Y#*[V9J)F$Y=8%>#T(?,&$57_XMI\.Z&('D=*E3&!$O14 M?7F1LW6#?!TY!K?5"H+RKZ]8IVI$FR9X>875R^UIM",VJTD%GV6U![T990KI MC8(T<;!@KL,4"9X6+-E'7)&&:S$Q/V#G$ASH(R_Y M>$#-&&L:>O)9]^R.V*O:.U5)(A]R]2DEJ"A#]T_2=YNI'(33@JKQ3 (?C>W, M;*^S5_ M3E+K3Y.YI\LDH!?-*#OAT M=8M6CP]5&+1:0 8^2.EZXK/ZR%3'[LH%GZ?:S$H&ILJN# M>Q266=&!,CK)@:[*CV=2 ."TF%,BRFU&W+-^WJ-JR6@C67\O3I/'O.R>B:K/ M>\ZWQ X",0$ W-.YLZT)J) 9NWDJU8RPR%M+$6VQ5Z^_Q2^Q5 P:E*QO-N)R MH _4+!.A^I01X=$VR=IC4.:6FL;LXQ\=RWYJ'5[(*ZZPL6S&Y6MX%2GG.R]?\ M7]R]=50=6[8WNG$2W%T2W-T=@FP(&H)#<'=W#>X0(+@$M^#NLK'@EN#NLM$0 M]''Z?7T[2=\^.>?T[?'N]_ZH,:K&WE4U:ZZYIJW?FG/BW NC1W6,7X6A6)RN M;$1M7ATZ=9#5I#%./&%@9W1TL/JQ1/Z=Y'%)X+"\WU/ M1]2BC>%:W8V,]MT?A_M9G?^W3/P9-/V;OA8F0N-S2(KZULW%?> 7MR>XW%)O/+@>U1CAI+Q6TR"7T6-*VL*)-8!R1A:\='?.0CR^$M9] &3']Y)< M<<5%?W]1R_X 0%??6\+"OXLR\BN;TWV[&D#-%]N*BRKR%?.0JP>[WAMKLG:_ M+Z@+H5FJ7'/D/4RT.^R&T3%&_HAD N1R.3]ZX]%#2AEKPY3"P=/XI)VK_!NS;^0 0HPH3 MM0D'Q_X?2;67T P".2 MG+.Z?G@ P)XJ_G"EJBG^N[=;[Q-:'M@6/Z&::[1!I2 6W" M)R''IMF$7&NQQH \J5*]1-H@VVF(:Z@K9:3W.0B:Q$X8U^??(PUI!1>2ZU8Y M@WKW 2#B1I=VY;/28-,"D;W(V;J&BU@7 N+SDGL1Z94@"?!0+?PG4P?YNXS_ MJV.FJ7B2WYCW9;1X\4K0M<;"5D==YU*HAA9JR(T4;3+-9H2N.LCTB#3*--71 MGMK)1D%"Y-&H?B?G'[X[+Z\+ VRT_PM5M6^:A4)_8A+PO';*DS% YP0QP[N\ M$H.Q@ SS[E.!_?91/>YHMF#MY ^$9ORXLC_U"]G[JRQ ZHMTXBEW@AV[Y: L M*-B=Y,?!>7ZH;^)XLX^.ZG*X.Z 5ZY>R>YZN-*LYP<#!A[-LX80^1( 6X,_6 M?^!5")7Q;ZH5#GE8<9(>)A0-'QO7P+B5Y!@!ZPK1^ M;G-=YNYC3F=^%J!W.FL-L&&#@?U)+TR5/\^-A^J"V")C= MM:YA8Z@O52;4\B"&UG1WU2L@NQ&!!>BF]G],I#+]SW-$V\J>RYMI*G_:YN!6 M:'5KVF R3=R%38<> *QAB6(66>I 2SO$XQ[^EZ_63/G72D6#_<]0I34:[8F' M%1U(;/?1-4B?B0''\#HMJIVCQR*->)T'KA(P6S3[4^8?YR].5F29?W%C69F- M8OMDV1JO3*7"(V91D] MYY D2-?-8.>)P15D,5U4X?TE7])_3T1B; =:.UKN2>2\M<( UK;W0\ F&ZO M%23DW=ICU ZC&@F6^3U[W4IFSN[OAF!:.YK5P_J[J>,*H?2L V"" M7+.>"/V%-_X3J5M.OU(B%[P_+BL)(_P;_L8O;)U*027^WGK^&^:7P\6V")63/;] MA'&7__]G9)5LB/=0;#R*S3+P4AX HM5Q+^).&!,,8R2D8C^$1*=!$EP%V=K2 M558W!RA4UK?6Q@!M[/"',*(B(EA1UI #D)_@B.O-#N8H6VNBO@5)^_]3U7? M_"T<%B9^ WXDQ';9%4JLR737("$4M6ZF+[G-34WI#&4,^J3L M$_4B\1VXT''N //$V+74@8O.'(L4EHG:)[H6X5Y)SUT+Q$DY9R&\]6)C),52 M %_E2BH[B9>TW;,"S['MBDFB/&RY4]MC69IQF82$ (-NT=>IF7?M\0^5X#X M 9@B']I^^GSA<0HM)CV&Y3(__+93*\ XJEYA07?EN>_L:)\:MAG;7=1/"AY$ M614FQ E!:T$K>3,20$QR MGTLA5[XN)=H(]1O*\7 5S$Y/FAQL1R)S'T^+*D MK,:-PF26AZ:9<\CLH!\"'QLD+!2R;X8KUN)>BE%B;;Z665-DTX+ZPC.@ON5J M\)2]X(=8]=D,Y#&;FE8AV8;*X;:TL$0CREARO]>BOE5T<(0 %/ZO6<@$+V]> MN9[U5@SGS9G-HILJ)EL=''ENN'QZK^],->P/RS))>*9B=?0L_-*&E;^PT)/W MY&B4(()"^/J(U,NB>H*?)L=45=XI_S,]#@IJ$-"EFJU0?YE%WX4P?F#@:^G6 MES-'?BNO&F5P MJ%4]35@V-M"YN3^*3+4\RS$?LF0LRQ^NT:=.(2C2,Y(_.I* CBXJ.KSER)G; MB3,=-WL,1[],'+%V[+=( 0<8TA*IIC;&X#A,5A8-74N ,T=,[-SB8?T1*=89 M8/;QIG4###K(K-5@0C0UXN?3.2=P?IYBQ;M+Z!5>E*;6+LO:6N2L@PJL>%@O M+(&(!=9K*%!Y+OB2?K<"V6\HMC(-GLOCTN'%[:F_T(T@*CX0/>D#V"D,@(^[ MJA9DZ79INXQ-7%].N%&DEKAIUD$MDYKPC\$F!9&[>5)] ))ANU3Z)8<.D(-8 M+52R:VJ#0",(,HY?H-%*%=@J??"NV.6M<-,ZY_,O_4:9?F9,P#/=7H4MP6."; M.V)Y[/E/*[(D(8QY3E0QT;5CF?JYWCI3[0CM;JM/K!6VEK856S*6(Z (Y&ZD M+@5\\*=F/#%6#[W/E\QY?9)M^\EGV$ZJG[N=MT ?REKMC"E/]2OJPM] MYH_YA-"T05F!&4 4")#YT^A0&B*Q#V1>,[C\:[[8 SURH,\T>C\:=OIR(KRO.XS_4D5EJA]<4K>C4<\.4&<=0;E+@.T=7 M53>SP$I(PXZ!1>W$[\,U810M[!A"!W(3 2E]*?]KF>P/UCM]/+A]@B;ZC%9E M)>B*7I-731VK[%2"NBB,!ZCNXI"]D&3!^5S1JXF1K=+'ZD;"$LS1=%5V][M8 M/J_!5$&U9:(R^W?,0#MJ2*5X(/YP%-S[XLXW48*ZKN5!W!/4,]SC2NP0KY5U MJ8D F("]/UJ*]._KQ0A]B1^=UHYA0#;&E8%'Y61<:+K,#D_FLC*@F)$A]ECM M1FAEL!H?[6R/IBSZO&)[:T7KY&9C"L%\8H,I'IYH4S5Z!^<:2YJAG;9Q2:[9 M]5;&)6]ZJ0OGB CU>C81/%F,I#X/UBLQ<%WD*BCYO%F(5KV"/!&HHXZ+[-L< M]YDXN1=@^6?QU[V>@@\ R?C>NC-N#,DUA")MX ;9H2/5YR*2I%KGVM%]P2?@ MRW9W&PXBH4\-AFC-?>RQ;F&\= =Z+?:NEF.P;[J.EUQ%-=_QU#=.V5#5KP- MDVT3 M%O0,W287-S"'QJ964Y4KJ!D)+XC%B8B X/:7_4PDO^@^F;/&N9VJ- MLLSBWBSWJU \>ZWHPA_EO?<\2CUT!4)MB7#"IF#&NN55:=_&\J(HPV$9Q.@7 MA@!K^!Y;[>A/BWX Y(3LCU>O)$ZX:^]GZ^(,S#=7:>S(Q7$C,-[INBOC2_K7 M,#R]U?DLXA@?2(M8?S;(['Y;ON']#F+L[SR<_>.+0U 15Q\QXV[99_@KY!.? M)9_<]20_RO')- =)3Y%!(W@I"1J=3M:M1)VA2,>%A$.3[![RR;6J!;D9O15A MR$<"_])25ESBK+#MFG9(5PN)*8/VRDEH%S3(9R8I0&C2"!(&]1 Y[F_":[Z\ MO'^'&/Q!!!@\4_L&B<,#0"OU&_[V/:'/ "=X^RY@]0$P)NY8'DYN11!1 @E_ M 5NRV^14'IL_;S;#XJ:2.!Z2$VUG50P+&"#/!/DR_!5VC/)#\/.Z=!;V'H2T MZP;MT;7V'?'RIW:.7ER4C08SRUJ!U[LKM2#)L='0<75]54F]7[PZOH5:C917 MBKL_DP92)G0/MEF&$Y:R#(%PR3+@%-Q5)0 #.<,#7$GT8QPTK^B$,F"=H. MF^^X?G$V&"M&G([0$O7YM2(N>9S[T^GFVJ#K$0^9M\O0)S5*C%(+I(5@Q#"AZM&6MEQ_B*G&[(+T@]-L3G#0RD@U*=T\_FW..+\P- M EQS\>#@R'9$M@6*@X)7!3"ZXX89DXT-4G2Q@;G)6[&^.US-&-&6:]_U5?P? M:5_ZJ^-GPZSU(Y*X$%"J^1$5OD7=:/7&PJ9&GA[)R?[F,MQ49*[4E8=^ :)/ MU*'72A5CM-VX!6[L(< HD"Q;V<,M,^ZX1A9B 8D#U0C-#?LAE[A+Y$+@I!\'ZS MR@414-">IW=UW#U7_B'?/,EBS21:5@VQ0#812]/EM7PR\8MYRIG.T>'EAK7: MFF^,M\ 5+\9MV:9XT<2M&;RDP5!R%AH%9\!*A/,(KP)4"]^:V865C,)$+0/# M^:)2KT&=/6R"=)Y2 EF5L-#_/,:P$/0$0C0"H\_]X!A; M5E[::=))J&J ]G[O" OH?#8%"R-?(%@#$?[!M?QH7R=5;.;<(<_\B<5ES[Q] M=2_Y,_\X0IA.Z A_.(WH[GOV>(W6JB@OBD,&)SZ7QDF3L^[D#Z*-2PW$FJB# M'48-HSRXI=JT@]LOKI+O,HMU'@!6"^9-EA%,>=KQG?C;F[#)!!Z^C#Z&!F3 M<%245@CYRMO/==!(\*DE^CNG0%-Y%723"X6\LLN.LKY]=9N93 N^FW=90JS)*(^E;^ MW->4HQ02DE1IV_S6.U?RX1G44G)*,@@T5,1QWF"46T>4"5\^C?\T> M.QL/- MID!-2V=1BJR^/C(O853\-1[5*58 3GC=E=RD5NO$44[<>735YR[$:F S)4L' MA%KY$[C ;:J(:91PQEUPM\9G*<1*\K?.D7G"V_??&+3C:'/-"P'" 5>"&'< M)?39C1.AH,,+,\NV7O*/]%8V6Z&!>:[MO?B+#:V3+13F MERCLL7WL*0T2NG&LV/.;A/:YZQPFJ[%]?@P#NY?-RW>TB96/P3,U/]DJD8S* MN*=(F9I@I@W%<(N5YZA-@Y$_;BJM&!<1VS# 7=;^GNLD31!Y0G9PCF ?)!G' M)QZO1QW N%GA7$AT,D#J4A:.]&(T[_.0?0G186_5)ZMZP'R=?P?40"?W1\(3 MSH+"@951S#<6@MBS^M,<",Z1Y<34+>%2$-_(7FU9S_'&UU.$KOOYHBA.WP*= M3 13#?+-PGT*ET6_(D MA+PF$VX.]2I(:_)E&1"00&*[Q\!E9$]'/NJ:WFZ8 MT<9>FI$X_2+!)35B:XLFAM&Y ;&@8A-;8FZ[LT0QP8 ]>#TW8Z'.X.3, AMZ M2=33UXYK.AU<2,5]V.?J(]G8E-E-:26]Q\?7SCHXH^G"#*1H4>1+4E%ZZE:% M=.M0B>H^!E?@&M #U3UA-K&@:5/1V*AI=B2V?G!P*]%K-YC8%1\;$=5:5S)4 MF]K(@>*7\FW*FMBY]D:[2:N=@2F>CUY.CO=,VO@D^*(E* MK?H0WQ P&7&TAT*O8305@_BIHIGT 6 *%3W3DN+J>Y=>(U\]M-D;3D.99+T2 M,"KAK+< %??H*>W@,]9^W$MB =JM?CRXXWU-7[6@@\*/:&@=0@/%;]=.)D K M(-;+9:*1*CGFZ%"L/0_#92_0X8]@OU!!;X,\V4\D1KIGY=$^'J&7R MHDSE5.9.CH#O/>/1I_%1@J"%511X9:1E4JB WE?@V6#0QS+73NO:2*4YJ8MD M^2\'1QH+A8:B<2Q:;$9VOG(+3'(U$#LS]EHR1HA)SOLV]OV(%;D9NA)'4+J& M'BLJV'G%5U7+"BD,0ETS+LYADDG\*16A:09-;I*$VXW%2U SVVW@7 ?SI'"Z M/C>.-%4EK%?V173/N;+UX:QSE>]Y9Q@=VU&\,N4ZIVMI5+IZW&6H"$:KRK=& M;]@AD@M<[T^/NR?WV'9DL :FVJOI5Z+.I9)8CQ!B*3L#D9JIX-Z2&]<8G*39 M73DH3MF4IBR=R:?-R1I6P3$(#56B57#9++WG)O&(H:GW1KL1"F0OHQ-W_9 J ME8AW^++GK7/$*6&4MZXFN4GB"(KTV9WHI&KJC?&E1?\:]EP- WOBV_A[(POP)@0@GEKT6CJM8L]Q"@IVKQC;=\,VZ)X#)7WQOL" M8CO)Z'.GFH(C=:.EQJW/2VB<""(M"ROJEYXOOF.4J;S)HN99R30/[N%-'VEU M<%C5ANE/3S+^X(W#\D6B.P&N)9<8I\[>#N3 _Z9 L]0;"VS]/M,@1=6F\HVU MU8P,M %] VEU I\P%1P5SZXPP1Q7Z%%YBPBG7\FN@=S4Q/QA;*GJ<]>\8.$O(IU&M^_+:,V7\0KG#A4MN0=R#Q7WH1V[:(:_%=0Z @*?KMP)6;JO' M(?:[3;6?IX\Y^#@SB&1G+0<(+>'>]2-/:[6)*+ ZQ&:8/0#0U=Z8W>-[6#R& M4BB'^W84"WQ:XJ?]V)4: UV9K376M368=3_#L:(\&7J)"] V=&1#1H2B/\XOD MRF3O7-8[&PPV-<@^6V><]#[1PB-78BY!5!(2=4%-9PL#G#.0:-Y_:9YZ@;VB MKB%_Z7KD^>G;*=/U)T1;S-O&47*N I8=;U+\VON2 GE+*YOS+SWVO>VNII^M MH\2Y\1#;%E E+6=AORG8-F M#[GBCSM\67HL(CP_];" ) ##5K-8*^U+KNU]Z$,/ !*2.44)+\]:/T[OMV-0 M-K)6(\@5?NDDQ75R_'S MD%J9= F:?$B9T>IB<@^>$="(2[1<0GJI]))@0VKWM1N9:)!"4]ZEH'I=C&R+ M9&-_=[TP]T8&I]/H$[/KB\.RJ7K5RR3.2G[% 3W',69)6JG!LXBLVT+(K5"7 MDB5-J6M0 G(ZLR>YG?9=%NMZN7,YSRAN<1O9"=XX,6ABIO?X0E94(FIBW! M M:(Z+CXVDJ9@WC?A#E 5.EZJJ,S'-";$?9X%=H=F8P4N^"W\;;_E(-3I\U MT)B$&^ LA:- _DK]'J7E3+',I+8UB ;*2"9! D"<5ISFOC(&&Y2T=IFXK5 Y MRSXSX82 H.="KF.;3(SL[6@+*TPKTH_+GD%RXCA7N^%\'?3.<=W!D -!U!K: M7XH58K'C\[J[D1L)URMUC;Q>'W<;P;=\=W.KPK5C12*Y?5M>[SHT-?% M9H^<#IE$VIMKSN12+'/C!M(JJA"#U+4J"'3$".T"\4!:&VN^ @@B,YDZ$\N* M85/B5N11#'BYHYFXW.HH)-26Z'#\NE][V;H%2=^@F<7)S1Q:N-CPS2W.55LS M?PI&;*Y@Y46UZW_>\!%62T>S_2VC7+:+T.5FVJB3%7U>3DAQ25$DKP3.D:ZN M;L3&S&B@;28:OQ.FY%=BI[2WR/XJOC9WD"2@OR:>?P,U%KSZ+=,W!O==JJ\H M43F(*E'U"3Z-L3$W !G(,>3YC^?&K[V(%P?/]\C#NMSY*_9E:W'MI@"LDL(N M&%YUJ\R!TE<'CF0W/C'HW8CFZVU;5F%#Z>JR^>*>MK7P29Z\ON@+\:FH;47= M31JUG%7 /0KL4 )>;(R5&S#(#KPQGPO%4Z&KE.B+DC>#(XNR$\35^ M%;+MEQ[EM%75M_B%B_%;T!M&&*D9>@;R>;); O%NMZJK MQ'JOZ(RL/]5P[C//M^:OA*IBJZTZRXK@D7!7_:C^I3E)\RS4E )2ZYIJH:#'ZM MC3/O6LM:)N$A"T6/M"L^@U@Z^&,O"JX^=#>!ZJKNPGNY\*U*NFOF<^$5HWDH M0.2 E+&54]B?92^]8GM^/,B%#,T#E-<2CM M6F.PWT[2E%RMNY7JJEQ:VS(/8M3X_=1&"#\4Z2)#8MIKP@52?G1-ZB$!1ZJ) M%(Z:&U5BY+K8EZS,?R!J,V8Y _28Y$-0I>FWM,M.,ED+51HE*298;DWG3JYF M3*<\7[W=/3**]!L,3GAA+LF'$W"F*DM?Y@3N ZEH1'ZJ1U6[:YMFI-0_&L^) MRXT?8MVV=B/_Z"!,'((L(2G]4[9"I2]P(\7FB>G$P@/@HPZL4)G! M?V KCX[!*M>)?W<9$O&RF(?08?-=_JE;XLMOQVF!HBQ7LV);MR\> )GRCR'< MRNO'=Q)D(=>%;;0LAV2>[:[ZW#YM> "L.[JUHPEM3S[&=%=8=@\ T Y464XC M$]<:U>VUZYL' &2YT-4BL4V/_+=S3_W&2T(? " :=?! $>ZH+HY 6: M=D)KMDX-PQ'!O7MC+% 9-C'#3Y:]/PQECFTY"NEFU\(V $7[ '!AJ4JSFZCV M_ 6O5:7!=:$Y&EJ:9M>>MGWV+'S8)FZN?2,',EQX>Q[3ZIX(JXV.%D3DN[V6 M!U (KZ/67ICZ[0>K((UZNQ5G_# H_#^^"*(HQ_75"_!!W%"^6NFKEY #?/T3 M@RN., N)9/,<;NQ#W!?J3AS!=YQJB;#O*JGTXT1]Y0!#Z'817T=@'-I^]\$E M9JM6V$/J\2KU54]<-^==WF\J-PXEB#H766\ Y-W+5B,AMV4:IR\$I*5RIRXT M/_(:/*$@BY3X_ ':5^HUD2T/9=&WGWCPDYB,P6F*V^O\'@F C)\7NG345W?Y M;?E5UR9MK%;7;6U(;X3CUG2SVT:).5&3R:S9TAQ2=G\2-(B9<:VD'TA M!SC5J%+\+$H??A(282(KK(&?1_5/?]$?(<;FYSV\H*0U2M!P0>"US^CT;Z25 M.ZS>9G 3 \9 F5:K6S4WS]TDUM:<8CY:=3P#W"$!W!D_YLU;N'-L);GFE1VM MFAI"E>,:D"UE@0_+/QADJ7_9JQ83V&S1ITQY;D>M@S4BW(T*099%OI("^O4T M#I";L'1,YS:[5( O$Y-:4M=?:,:Q!E(EZOO@=P6LMK\]/")+=DR_UX25RFM( ME'H7]5;BDX)!/>$K_E],#F0C<;W8AR5^2DKZE GF3\WN0K5[P^2 MD#8X9,K1BZG[DL[&(KN75V!#G2^#>F0S4@+9A9L@E*=# %A>_ OE*O_3'K_3 M46S@>D#AU9M#YR5B9 ZG&Z$$.Q98>4H= IJN=9>7:6M--O^KY?:/$//DQ^31 M$ >0_Y$@!(1ND*8-"L)HY=*W9]:4IX-;1#=1GP*^VOGM:W/]D[W9:N%831QG M'Q83:]"TB,3*C_G2\T6_8B#1-%T*!,4&,=#/OX[UYAR=-(-O M/10R52I//B&S"35%ZOR,>WVSC_!5;2;,E<^;%IR4J,RV;6M0(DUN8+H'':9> M@P?A-,GOCNI,,[@MU$.OX+-\08\5^^Z'AII UG",?.<8S*AD?L>MTH6=2QSW MLL0".[AD%T-"S4;G'@\0;N (JS!(:ECWU^.D'GOE(1TNYH5E.;9["HN"4&EU M$VI,'A\')-](VT[I_>6,0,!IP^74P9IB_X@86, M,$E5@0=9QQ[)NBP^?G#>+$YG8_:T&U? ]@/AS:S0'Y"T'U8'\WXB9I:M&+@> M?:6F0\PZ[^JJXQ7U=0#!CBM1E?EXP=F0I#D"10-PP?M_GV?SXR9SY1]MZI:G M!U442B#AFWE7-ZO[+V;Q,#V]]5XY BV84 25F99C<$6S H4[."CK2&P]O)ZQ M].,O+EU"GY'*6/?9@B"^)8 D#>)8:3-_?^)QW6,%OVWYDJM)4&.6:V9X>D'W M#O' 7@[:U]Y";KT+'VLFW"IW02VYC$'3D]AP@CVV#KA0A;V$0I6V5?TK-FI* M@MNBLX;9K[VR-4-]U:E23%)4H&(0^C]]OARAJ?/&&"OUY%XB#I!]:T:/2Z Z M5+0P'[U$?L%S>:CN_;O:)#OGBD\$?#>_:#9#P:C-B9>7 DQCTLY.#U4\8*:3 MVDVT*F$L'-NZT.74#@.4RF*ZFX>4!LFKDYQ'N894Q1X14 0^-F0N\YQZ+HN)2,\^ENVUPGW- M^PT,&*\7]7$/O_KUL)?]A.5]/W'[XO.7&G"[_+?KW[[1:<13*+X/J@,?=_*P MA7\FTU">>D%+K@KKL &:E"0["T7I?Y'K_0=FB\4/:7ZF'PEI3%>2)_3IZ@*? M),YW=YT=N+1):8:V5#4&>Z]7D]XMZ+K_)N9<#P#XA8JKP6.5>M>V[F(-> Y< M]62U)DBR6&;>0PIY,E_XW=>_H!.2VAOK2G0)*PB!H#]',?#%-.,[E"QTE8R" ME3(H5>QER^J$C#DT:"5))WIK,B+,*F9C$B7SZ-^?.Q8:KIHO*L<9'3VT>:E+ M&6,GUCBH6(,)-!U,[,CMXAR 0H&.,IDH\SNOU,AV9P;#H<7G62QQE(Z(9["R@,,P5PPD#!8: M-/K3D)/20_ )#VQL98$3_>QRU'5D"V4(Y_(_.'Y-BD:C@*H#B)-#U2K31OA- M"NS]Q]W0A/]%?@>1%DJ9)363-2J3^]7(!$ M11F;E?FG^0<]V8*%>8]3.>XI4>1UE_;2.0E-EMQ:GX06?:BFY+"#F]QN-F5J MG)\BV]7=C&K2$MH%G7$V TAL)OT867K$/>I9.K:_&*[.-XVQ-R]*RDXQ,J = MU0P_ QLI;]I3M'I0@7$P"FX_\K%%=Q>[0NT/C+*L.(82$[>B+3>4DNK'#)F MOD$&\JPUD1SO1@FL?U MQS>K%?6>YG1C6@YL6M[DJ4O12G"3!JA='[^%V0[, 8_$/:^>-'Z/T*4=$40T MO_'4C?[(E2+Z!"/.[/>GQG0.O5WQ\T!Q #41H%S^AW6?G]56)O' >L"J),[C M0&KZU&D8=MJQ6"V;1MO $ ')O/L$'N._]>YUS_URQL![UO(GLB_NE\(EX_: MOL%?-JV,7>3\-K'.-T6X[;(K#C#]&3U3?Y%NW-U]K3R74<#C/X*>O8%6':/N M_W$P*SZNPY9O!N[[XC:[@H_6M3_GZ^788R MOC@O8[/%LH/97_SD$JO6K3!5Y@9!T<"%NSDV9AC1XT/ 4TU6PMNL=:B%:29< M-75S;^3IPUKX\8OA-[*(?E%,!Y&-T(O[I7]H!;4?LMA<:MRQB-(O;[LQ:5.)@5UJY M]XB8;WONK]5KK5RT)MJ(.-J*&-)G2LLN&_4 UB3&Q@;U^:[DAKJ":;DH8M# M\F8T\R!ND6<4K!1NAT AU(1I.:048PO#"5RWLW-36X&32:E7,=][IO(46WSN MEEY'AL$T?WA"W?-\TVNKXTBAFEJ+11_5ZM?M#775]9-'$31/7VQ"D**DARKU M.4N2&F!"["BKOENXZM.R";[6=XL?*%ZPH)+(6!M&E;[!EQW%M<=DHW?%6\&^ M+$-!86PW6;O!K*L\836=[*-=1K+>HNFQQF%I8H[]C"ZBQ&O/G84BD=.2"G(' MQ=OHE>ZYVX0[;4TSO(T3N53)T%3+%H5JP6X_BDC>G-1!Y MVA7'R6M82/D/(-_?*@O_5,BH\7OD_G<0 TAT+!D6 #)0H"2]XN0XB$- 6D!P M]#60*B&LYZ5U$0V1J)0R7>978*$W^2A'>[<-ZH"UFA2](9Y.%EK -<:CYXU: MMEIU):HS0R$Y.3&A*=! K)D;>S"_NWLU!I1,>C.)TZ9U24$CGZ7-;L$6)]F--8ET#IKXQ"&/)%58D5 MGJSP><-Q<,FV4+@UE;!)4@^.8C/S1HZ5,HEPEL'^L=R5EK2KJ(P1R:B4V:8$Q1?LOD'CI[LDD%KA8GLSRD:])6GJ1R__ZH[WZ='./ZH&_7$X-,_B MJSYO_/%:G(JV:6R^D).MP-!%O5%YE@3I@EOXL!VT";49J2_:N+ JKV)$=D3* MJ59K6!:O7BEZ%"9LM$X=RX[9I6\,#HI!W?=#$?OG7[VBC[ME&V\!,6SFQCZC MXHFD<)+S67R=A3SX]VS][RY__@,9!97V6]^;,N)K&;KAEP@AE=ODS -<"1G> M]F&B=J/#473.$T=+]Q-TS<#UC"5#%,+*"B,G ?CG5;K]*@*E;K.=SM8*(+Q30O6HH\MZ9-;> MM]&U^= QO,T3F"GK3SS4J:_AQJAQKV_&X QL[) 6:U0Y)W+'I/W68PEH]R1$ MH)V@E6M[;QDI^)]15$6?>VA+G")XNZ*5'M>@Z(UYT=7\X6J,_^_0DC4T!$TL MR80GQ^$^5SHFC\!21LZ-'WLM@*$UZ2F>3YF7NQ">*FDL'D/&*!V'@@BQAP0L M,E/![VW2W..L7.B(H\_AD5"U3_.7]/8@IDN[LND+*F\_H/-Z .2Q*L"]^0OB M#3M ;MMS.K@7FY-H8N";Y41^B36ZJ\,+GJDMI(@,RJ_2DGX2JD-#A@%@?6DY M"'4R.BB/E7ZBO2$?Y-X047_,_SZ39,$M]M%Z$C$HW@(C&3QY\A8T024"&66& M,]G"!/(I)7X'RK'1TH##G?\#"*7[W>I9_V 4*T<[QLX2T6E0D6?% *=G80(^ MD(1(.@>R!T6!5AOGS<2MF.E7WM=K6A+15<*8)1++BT:Z>/*5D*5OM#[OSDR8 MD+%9'P' H[Q.?QOP".3FT[^1IXOB@M@]"JP;T=VF-?G[C%_?X!@-"/HY\A M"1VV"]'?OZOC!KZ?(S@.8 G?26A;A)E*\NA;=G'C2ASU^9AG[E@IH@O"Q0]WI/]K(SPW:W/"C OG] M?%I4./3A&K$:==17*M>:TZE>39\7GCLF'BLVQ4FVJA/+Y%15T1XI\=8-4A(A)#&0+XU&V!]WS>S&]ZY%E"!O#@%NQL<%9^,= M^\,/6_S)/0!8' )*?1*3F^U3UA_J:D.,-F)6$,%PC501KXE0>MV90I9,SX>6 M.=6$6<7(Y3'#4$05.RP]UK&"UVV-3YC\RPRU9T9+V*-R;;6?.;^\0Q$*)'Y& M+-DK!"O[U(^A1W7FC'FE1I3#%J40&>9%Q M#7;U#\@MIZ@>NR\U^K1 M!+[0@9ZRPE&LK#RAFS?]^A5]E*&A^A5O\A/&(AI+@,,BD+C601[\YK,N..+- M',$#8)581>L;]XV$GFE[Z^G=P=?=:/>]G2S$2 .Q^YFI&LW1FF]OOB09;QL/ M+QD;.,ZG17C=;F>\LT@AN9RZYF\W/?6I=H)I!3W^B#9IHQC=GG8VF696-LM"R/ST 5!%['S:TO*MS=!8L/&;7=HYSV5I/=B[R,#+ARJX1<)Q M2.9;RIJ%&?W,BB2=UW9((H'#+#3SB!S=QT?K!6R!RA<*./040/S*C !4V5HZ M4<.+6V'QX2+7K=0'7L?V:HZ??T376 IU>H,AZ6-=+!PDP*.[X(%M]4E.H%(; M!A-B.QP\KQC==7:E08+)KX$@2:XH6D>W35M)3@=LW@)DV&;%@BQ:*NMNB )K MR^_N7\H0'QAP TQ( N5_*F#\8P>1\I^J/_ZC+0?,14+;!ST[ Q?HW<;H,*Z1_C::;K# MAEJL#B// JL9]>J5N/KM1WKB/O4UT@.%-";^49[RCW;Q4*[5UA@2K_ X%/6A M7%17=9[HJ4;%A%&009<" &0!VCF-99)];<03'SH>BJ@0+T!63.S&)Z3&2O.0 M0*C:\P&P:#F:O$6JT[B..RJ6,EONHWI2'IC])I7NVU&<;79(6)>;!(I\,FKT M3&J!ZWYW2EE=GIU5(7.XK+@'*&-)C3^K(S:3197GJ;O)!2;$N*)ZDUQ[OH5S MW**:UG$4-@UU'&?H.JD)8CD4$S2Q\,I6"K]8/@ERNJ<6SR1_O%#:,X=']=M: M3Q#2Q],GYZX FX?9;QRV!;\=)!Y'@\G+FQ;TZ$0*OB\8^^-UL>V2=!"FGS=. MJ8J=T.TZXT=\%.AM_X*M B34FZ.BY[3>[[?$B W;K8FDG12;8&!OQJ2QL$#O MQ8^/]^7+V&XLJ?G#L%Y%<4.9M4ATZ*G<5,4PZII9M,4ARM=D]A (#1'8&[9/ M^/V6?#EV2I%(0!DDLS:1D8'?+,KR>MA$R.GW>!.02QH\(J8TDJ);6'*794Q< MBB'XJ3#@L^,4GSP K&*EY*_0,"'B[5;:T;C"CCGVWV#.Y4ZB,,(T3+2L6^'< MGHEM12!O^#X1L"B=8+B@TX3 +BD4]W%JB.=761(FJYAO;$]7KVOT/YVC2S6+ M,Z50.!D@@%5]U4\:E5/IY$/@ZB'6RJDZ%\3X#M95-PBXQ.P&TV/>*_*U%V S MKBZ_)HO'CC4K5//,BZ6#QHY82U!N#),12-'0@3>*.\P[W\/[>BNG:%;>16BQQG,"F-7D3A MAF$,RS)6[F_@E3_L53S=^.A)5M1;_&;)U:.'"B@K_C;)MC9E!#%5-!DUD0#7 MEVW*$"ILWS0+<1'J12UX*]@B]TL2\WP1P0:/B3[0V& AD3RSS.SOF^U^AK<^ MAET_+E+\YI4JM4V7.NZ'TWD47* M\E2OMCWV,_PG>G%XG"8$=5+%4J.>^KE5)RKAA7NGN\[U0Q0;1IVR$5AAA-P2 M9!8)_*BYZVW44/IA139%7Q:7%[^(<"7;&2O+9\Y6<>FH4I-)B$A&B?+P5Z'9BOF)0;6R=3=4[H]A)Y+8<$6BMJU&3Z M/\!/-!BT?-2!C#C33O\3=;F5\Z9+=:'HM][V?3[3P0;\R M3]*'H+,,A62/?@:24E90;SC'A A?.WYBGD$^57,3;F5/(&-!MH4 // >)QC* M(-=KM9?4M8?8+C,W320FK4Y1F7&:]Y+F5""3*A4<4?A*?FQYGV A,OW.5_F4FY38=(:CE4NX\L:XR#$1; V?Z]_[.- *3PP. M(-@ALL6-3-LHQF_%H"?-DDJ8??U8J]AMT,C([+D16]S#K"/7(@EZT(>(D]VI M7-_QP'+)]MM#E:]P97=V,XI<9"&YTZ8GEA@5]ME?QB7'S9GX2RA;VKQI@2/A M1"$T28O*B612KIJI^>R$Q&LG4-KQSA9^QU8$#AI5!!HM1AR@\2?ZJG![1$/L MT<$<)>>[IF@B(5\"B64X:E3C6)Y1BH0L##0;3K+G+0:#!9;F*^LJ:"$D; M&_1>=.2P8F:X#5KWWP=-EI;+?U_I6Q@&*].HW"PE,N+KS*SI3 R0W%ZN(P K0A!,2.R:.\YQR-;C[M8^81TX_?']N%M8:595&J$AXMVC58FTJW)E M>UW3T"8+US.:;_9UHN5T+I7C/>CXZR1JF&@+Y2?J!#%;Z:A^@ M-U:0<[]2E6F7JZRO<05961L]1A570(QWMDW:DX@! ?YDG==1M)^\N<$'34AM MM40WK9$]98CT=1-)L5,QKPWF6V)KFYB$Y:4!.Z:E YXB>>+9^36SA7,.Q54O M?=ON>F "!Y##.L0Z^L3\GG71O3^NIO0A;O-;O4"2RD1)X!H9[*<8^PNNX+ MXUC\\>Y))#WNT-[/*L)(:@;,G*QXM>867T"8&NE$!G3BDJ.Z^UL(28'+#GA/ M]U..JN]*?#"1;*RJ/FOV0K+ A @/)W+CD9_CEO_+G8/_G^U/_.\ XW]+YX#; M;Z,R.'^+\'WN*'ZK .S)] @*XALW[]>?@ ]?]%-?$_YJHE]%QE/CJ.:)Y$ M>0-GFB!K)SBQ\0QV!+SK@&="ON5SC22XG[7%BZ]\>A(59!PH$VQW^5&S33S< MWI$'*MOW2JETW.]F(=E@[A>MMB,MF5L& \4.CJ9PL M!-BC!*Q2N/O1TI5K1)PW*N/&U9-.9HXE!89T+IAZ7P"Z4IUDA;BWII!6)J]K MQVHLAE4N+C4U7DST>ZP@!RR<$V\UO 8?%5%UTPUL^>7-$[1FW<]_EE5H^O@,\K:U/VARJ##AFM=4^_>N4^6RB4DX!=R04[1*AL M ES[0CF&0O-.V&/,OE9H+,U3] YJ2@!8*YUY:)57W&64QVV169$0"]!21_$6BI/^^HQ6EE1+NCB_,KI31JNV&"1 M7-MZ,LHL&_AL3H5[RG"%6B@'TS MEGU?6?MV)/H/#X! A]PAWM*J9:KY[4O6$KGF):=>=:.PT_&PK MAW02B8KT=14PL7VB?8E]=4"HN8)9CC*A[D36-UKE1@G^XHC2B/6LCLHBT^_/ M259H<^<86QWRS, R:V\83Y=.J!H:ZZO1PD/\>,*-UVM0)7D$>)U+T^4[4RZ6 MPS=.8#Z&EN48B1#E'LWJ(>(BZ+.">" 1B+K0[+2( EDLAGHAFF M\+OV9A-5.OH5-52,7T =8R(BPRFE(2>,FFNDG^^7=B.G/]=8,*\TQ^ATS'^N M(H:(?2+5JLP?9FC$?Z!%TJI3FS.W5Y=H0UQ9+%:X@(= 7ZEQEP;3T76X\(5G M8,3C1D48;&GO:O\ D&MHCE?ULBOUQ8A6DI.TP _<-!XKWK*U9CP 5D&A# ,,K,*Z MSCP;(!#_V?VA)$=4WFHZBM:TV$"IQ=<;Y[N4*1!>5\B:@F_=%!&0?)T>6&8# MOV/0K8,^<6[5F3*QJ/C9T62OQP.;TI>SY(\ZWM\?O]P97Q(6@!\-D@$E)4PX MOI_ $NHZX\/1.WJ-J6JA%7D1N91\0CFDZ?_$N&K*2JCZZ#:78:.ITC77T@>% M,?<<#Q-"IG=.+M.@W-7Z35BQP.)I-@')0N9PA8F6F,/@+J"\_Y5+2:>^& ]/7Z;0U1/BH.UA!N-&?%.!2;@7;P(<%/4QHN^YR M108,U9IJXOJ5B^1!7K&#$U:DMQOHZB&CY/$Z\=Z3>>^JYN;ZG)SP$X-PXG5- M^J"[/8"'"Y=W"/[>I$8;3!V]_,6 M:M/ N[&:_511!J0YE,P<(@UOW85[YD#?TO\S7]S:(K>LYG(#KC'A^36_UI MAAS<8*6)YRTQR!F6]KC55T5OR@6*>[P1G&:4C*>^FBGNH13E17\!K=K.AU+* M+I1O&2/4\QQ'T33!1$Y_C:I=1M>>E[&!CQ)@[346C3@!R?"MG-6F1PF(;C=D M(=?^B4CC^^.7P>5:"U6D6)\WZS3YEI3UL\F<4>4H[FY4@7 >CKE9$CT]EP^W MHC.,Z]OD77X#.VXAI1# M_[CS_OET&?FDDPUNS;76T.8H(;Z[&'O1XDN_$$ 4,J8WUH?2J]='1Z5,YQ8/ M@(-T"1!E?9@B( $?&V1@2&YHI!PE 9^%>$CJE;FV'/K,3SC,2W!B39?7+:L_ MZT[:[]M3CA7CJY)57".M;J+:@QT4>69ZB\Q"1._4XJ.D5;YTP4GU%%EC]8MA M=1;&O(W TQ#1RH-H[J?)CW%2G+U;SDV7"U>32H1079ZVC32@NQA7#$<_]8T[ MAG\I;\2U0R] ?S\Q3LM3+F-DX*V#N0Y>0Y02LJ!1K H7]Q%"Q6BK7OF'8H;[ M<*2@!!>]PDBR&WP6)X@(^H/Q:M;MXUP@1MUJ H\""L?BCB!NPV2M1:N)RC1R M4?'"B[HU/4#@\U @'QH$]P />7R\JOZXT%I!IF9#PUGN*4QMJ28SPR2/)^'I MIP[#DZ["PSB(_BL<];:Z:O#FN[J9T-R]NBH!WQ">1 9?;O1*1'UA'9&5 M;0Z?SNX#0=:3_'CD7 ^7XQ;!3I71 GT>NP%9*. M&/."?\1B9<,>TM':X/L/N8/S2J=+4@@^+O:QF=T\CS+!U8VO"#9.REY4[Q5( M:$&]WP6]3F:VE_1Y;[C]T?T#& PS>=&K ,"_SP(0M7M/?UB9#__6PF"$763! MT)9MGFG4H([J.Y))XT1U3&=@2Q9E[H-BZO.9^4WO9;30H7M@[Y&SU?Q6HU>K MG%V:27M6%HH0^&4&O2!ZX\SYCJ.114EJ>)'W#+F9#<$GZ])<^ XH\PVNI[R. M'\7!E]4H(2U\!?NH$N-];I"?T**D-^Q1QDZTUJ_(7M7B)+HSA>9.UH0WDL?) MR%?F?D2+B5NC>4( 01X#;XG1:T$53%&=)!PL/;59.:[I1I8S(F*2KC-BS M807RV&:'@(NJ]8CD$\9.<3!0F:;0)"!T4B?Q?P"\T/XD7VN\QRMZI=Y"Q9&0 M,#V2^J&T[E32 D&&-CC<-%[_M(\,[O]I[ZOCJMJV_1>M4H* -"@IW9TJY9:4 M;@0D-BG=+=T"2J=T2;?2B'1)=]=&4FK_\)Q[WCW@N7K.>>?>=^][O\^']<=: MFS77F&.,.>8<76X\3F\3BT<+>G#C9&PP\XJW56LS18H\^ZE] MRO-I4C5@=4$=L6!W(OG@J<>"C=>^?$()+AL&*]TZ2IL-]<_?G@O@O_].O7F) MSGLWY4O? )^[1? TWIJE:L_,8&!3M5F"KG.OIM$A[!;M*-DNP9G@NYA85-\XMQQP!::8I741MHB1_ZZ>-@L&-@M ]38HPA N MOY]J"^6Q43S:W1E;6_U- FE[=R_Q;-NMW&8WSK70:4+=?/=TCRK4D@ M;]E(OBSF08&9Q/6OB,PK13/APB\,:G@R%.BA-X "\(=:IV:A1RKXZ*>?A]T@ MTC90H'6]X&MFD,O/5KYYJ7KML:=X>_OZU\21=,%(YPY@P2.JZJ]@(K?&]EZW MY>@2*.#I5'C.J6&#!=,.!2X_%+O\CLW(UX+A_WGM+(;9;XMJ^5<FHNV=VAS9*P).U2S)55- <>W$_-4:33<1:HWM M@-=/PNRYYA.C^K\1R#<)!?]->_?[FD+=(1&F;OHPS./62_S30VX(%&ASY$B: M047KMB][0,?A%_2T?XM<_80E!=[)2S/YF_E."/6O&K?4?YT)^)U-\96T)/+V M%>R3(-?*&KNKK:VS;O=O86U^UB>AOK=+6#2CM[]7$'..(^H%!?C*DDYO37Y% M*%XI./8O)_HO[;_\SE0P8S,CNB:=:F840L(:%X_&.Y-B7URYUV2+W*26K8X! MJVZS>H:"NYTJ4. ]_\A7<.5E\-%_MOY?;6J$/>?"Y^0 MB&&&0[DIZ-[C\,_Q85SS_"*."9>3_<%=T1#!*PPKJ X %K[AXI67UK.2T<3^ M1QLJ +?5\_:5H=_@K\4P]NA:3#O?!54*^U0&A]*Y&P S=GQHX,'UJR 1I/^\ MN;&=L]D%/@V=5GD5"@A]??A3=GJBE3$W=S9>[KDAE**QN\R!H,IPJXT/WAA; MJ(Y>WRSH.?^W2/S'P_^;I/3_7^+_GA(7/0I-?JFS""827$'_R;X7_EQ?#9WQ MR&V^CD :@NAKP*>:$DWP4)39R Z3P>6UC"?_^X+(*\W8_2KH]_;?=-JZVM1Z M[,YVR)[I@\90,3+>3%.\=%U$/7.R%'E\I^ CS/SW7 M_/FF+(B)1NCVIP,<$[IB)^G :6HI)R)Y8?'^&?Q$PFT?N8^/\6FO .@ YRO1 MMK2C;!L;?V7JFK)K;S1+IR2(!P M35&Q/%(#1!?]Z05N9PF,)9X9$A\@<8#HSKCJBE;17X9;^$1E9 N?;XZV3DXE MU<130$_7:X1L&C'+N)YYF(W4O$P0!==:/^%IQ")CU**(P;6"I\C!561';UG[ M\X5G@M&;5JW<9KLP/XPHJ#G@3(FH.[?8(R5ZS]4.*)<.[23Z>\LB=ZP!V MF5^?U!Q_]MH*;))2$![-W?!RKU MZHMEO WW02%7;\'(H_(^AEH5W7E$-1):DVIO60*02L &^F<25CA+H'Z.=5T# M?T+=7JGMG*RNJI\=E,NO8YI1D=@X5 8SG\>Q:7^D @#O].C"GPB9BOSE=S! M27$R@[Q/G2I+,S'=9+Y. )L&AQ#D(;2<>#IDO?,BTR!KM7=]BLB48T3NE=IX M=TP@LXHR9C:-.T>D)Q<=:RLX6@L=[$H&H0K>I.R?ZCZ& LJ-)DN,2,/01.USQ[ SO1>'Z!YJH3%:GPGK*>V2]]^GJ FQ6+-=X)\N!GCY1?*@:!VZQI]Q273'?(,=>L GGG$[@ M[A C(_U'S+6;$Q/F%8F<^BJPK:[*.Y51M$&Z=;93M'VA?LY4.:O7WI/7E-N' MQR4_%9!S*0F88P_;3*1TB:]T%5..@Q"B+=QVQ )D%!>VPOEZGL:Z)O8+#>%AT(E11DE5N!#, M%)4>O<< *5RH8U-Q;35$(+-053)EK6+X<,P[UB=^S*5$BO #C-Y3@5DT='H/ M3^[\!AC#PUA.G[NALL&Z#56QX$Z_P06R3C*!B<-WI*Y8, -_)K>T[^#YT)PY MB?H*R9C=,(]M@BY14RWV" F!)S/%QJ1I]91W)''6WZT^5 M9SZS"A'Y_)<4+D=CGPM$T0TBLWOE;5BTS= 'O@H2GUT,/&F*H%6IA[" M7IZ96N%;!EZZ'3EA]%EE'._I:_*G:WGSWJ3%3VJ(6%@U&#U*N4^Y9^I8034T M9JE!I2<\#B$MG]"/;N$#*X:_ !J^ETG\UV=,7+0:6X^7MF7J=@3*P#>"=S+R MIT?GRF5JXZD)JCHZEP?,3JP/2SUX7B-Q0K_G!='*/]H MA'Y.TM9%J]EJE2?1?PYF=ET,5GS3.CL#/] K44,)EE1,R-7LU,)IDT N4'Y M;@Z9MY/K/771Y#@;&C"_Q02/_@CH_;WI]WY)6$W;8WT":B T=CQ;&%O*U4$( M2:%,,D!+>JXC_]D=90-IFJ)C]BT3@B.VPW[PXHC'/K]CORFZ0GU%_2#Y(-W2 MP&:LQ9(,,AG&X34+!Q,4C"[ S/Z6S,$ R,#JKCMW2&KI(,E?KRW@Y[!>.(1/'ICM?'?8D._%QX# M&U*151":O,:3QK!84A8]4Y@E0A_:7[NT-* VP =#$NSK9\-=YK?Y1#9Q0H2?$:GA!DV707&&F4&+%$+K>V1W MT[,V9T!@P^30K8<>MU<0:1[]U WPU26JC?35<\DPP[]H>_?1NGHE9-FSC%^N MEW$L540<.T!DTX%7!#^*I]52L_%0#!VU"B8+NW$KR7HA@G'Y8%U0:8N "L/,IY:Q&H& MHE^,!(R#3PSLU\WS@V0?$#XFS"F>NZ]R/[AJ_^O!N3^H//E9X](.F3WFI@X4 M\?T,@Y7!"K&L:W"P@LSJE"FZ=K-:F$=&;%UV2G5QLO6?&4P9"SZND\-R&(3! M'=X(RZ3UZ*8MWD'+9?!/GEQC,AI1#>HE91Y3;=644 X# %C+R C+=_ '!02- MQQ\HL\\R\HR([U:/;%LBJY<'\CPPQ3.[&TK[N?5ZAV['FHL[/\LO!V\:KF22 M5I+_=C.,2/]OIHA8*WUT;8H1$C3%$-JLFO\FQ6JY2Q>U]L1T5N091J[(Q2PB M.C<1'[OE3)^7=/-(Z='0*"S_8M[SZD*1IP+:_!Y=%L<:6]DS4."Z]"SU*6_. MY/2X ^03R-Q,=4K/5I> K<&&"==LLGW,<<1\5H.H5G"6GU;<5BFB?Y@K(29% M6^ I?TDL\.D/0>N^TNV0U%SG)ILD,KQIS5NU^;3?-&ADI'Q+MKGRHP49FF]8 M5TB@QZG"JE1&FKXBC3@IT^:VIN2<.0 >,VCJTFR3WN%(<\/PG_B4[TUWB-(5 MW4EC3AXA914+[(,XZ'7-/DKHXD=(/VF15JE&R%@,\3U>&+X44!A?:F+8"'' =FH=,0_9"U9@R[_?]K@O M):&VZ_[$NUU)&F\8V7H3!!2)U6YJN)K?%RF!NWP@18GL2BCDYW-!#3=7PHX" M[U?V+T>+*VH$O6T+;E]YW_?"GDL?":F 5NYBXF"HIZH]K5^!ZOU0$4&8FD4-K].@*!EM*6!WJ;0&TA-R*JB3"5;-V',,33H8 M5SMY4XF,2?DPN>+>BS&NF:U66B55R+N$[3+>;>QUV_!DHUL;AZX/%=N1#N6! M3PN+NQ=6 KO'_K;,8)D6G.'(<67+Z<&'SQ$U=@9INN6BZ/.20[5T8V6G%4H" M=X9-9P 'Q0,EK6?B1=SDR0AO';[X8\'T]6EJZ>0;'_NZLT4ER58*F@V+N _* M;$2K:;%[5NH3WE:X@:N[#S(D5)E9EA M[ND,:UI"W5;5O#6"Y.],E;%^1T%U:U+/1C/@#!<]#98:[MD_*_GT;RC#'S/# MEZ[OX?!DD#1$L-M7#V,<1YI=Y)%?ZPZ4BNM6*&.TJQ10:&Q\1)H:JQ%"2KG@ ME8:(?;U'EN&3\18JOUJ5.2=Z.;77C_TI%B=N4NJ;^E=ZX'ZQ#3+ '@6_G037 M\Y9!:E6#)X-?JEH9,1V:W/:W)D%1G597;G&EJJQ) M'#T +3;?OI9_ROOZA?@R<-R+I"OB,#>U1GQS!S$SC?YL*>TB#4<4-NJ@2I#>9#]<3\LB)IEZIO$P+]'@S/[ZPO M4U-@'+[BB)B2\Z$FK:0BXGG#U%CZ_$XK->P9=OM*N2:9 %PY\YK1694CSIQ3 M7%%_'N5]/$]*"]A[C86//1+?1,X.3";O#TYC.G/1+1=.ZU355+WB13=(UY<;;WW5,3I,2V^/.V!6< MN]^@]=AQ7!\^O]O'B%;4:]25IZ;68F#TF4XOYFG6&(OKAP\\K[5KH\/+(!ENC>O(G.^O\8JOL;X,Y/T]\_H3P$#,)^PSC;29S)YFZJX>YJF(@#%'CA+&*5 MYDQ05%G6;_:U%(U@$7MPKP?8VVE7?O8@I!;D M8+&?JQ,- );U=W@+(C,U1U=X2CMM[*/?()89IGM(D+:O--%X$;FT/#]G&F'8 M)[D)2E9?Q3\VO.EQ4&52.JK/N1#TQ7B-Z4(M[+TBVV?TDAY=^+,GV/W."K-M M)2[$GT>D16\&@FN4RO1'RUXF'12D= J\8B5J(UJ 2G#,1\+IM5PI,&@>DQNS3$UG'>?ZKF&07,B:Y)870!E:0@RP3VR<2N6AT0=HT,@5AWA MY1#'OMRZO9AZG)UT5?9=ET0\W;HBY4/U%L+VS#N\+_7QX.)OM6%/]@D1B@94 M:-[=V:@GBWE<6SR0;SVO:Q+3^RK]]613S0:?#XR"PWJDPB;?[4S&8%F3O6QZ MZSIN.0,'T-L)Z0Y_LBEQC-;K)@RWK1AMV*?[A(B-9FD)=NQF)7DT.#Z/G@H: M\2E%=B&3F[4H8(FV^:(&?\%K[8O''X98N=2TNK(/I2V-@=KITG3B685Q"*' M]&-1E^*Q&E&8E]G=U]J0$'.,'!6B S-%,E%V=-_%#1MJ/NBB/7NA&OZ-:A%^8T;;J+Y!!HI^C M!;T^-9A9G:N(%C?=*E UPKBN_+X\7%BW%U:<\) ]-\MX8!3,H^#MJ#'YT:Z+ M-&*-XJ/MN!)INY/9BD!4]H5-/6?NQ;!MOT=BRFF?ISZ(3PP MZZJNI/VEDTJ/=;+'NBRQRPV$S;K?YB+PI03Y3@B3W7AN%;*?*P(XN%2\>-97 M:DJ@9DHI;!$;?V$1;?OPR"O*,22P+&F"HC\W!XCC450D2F1O+<=('&G-;3Y: M&U-SV\0S6RPK?WVC?S[/YQ?C(T@:XWS@Z)?W36KZQN?9N?2?/Q/T, M/UG2;EQWBT_=HE9>/;)"&$>N+7L]J*NVF&YY9:4!.,M\.8##*2WRGUK2_B#; M 3<4N'Y$UA2[H#ITD/&&HJ43;+>FQ\+5?JN2$!;!F@22QT< !83$H<#V7M*I M @FZV\+M/+=/5C(7YL4W-Y%Z9*N6WR[U,9E/Z7CN8FFM[9-Z028, KAXF 9@ M@1C=&,B$ C>:WC?LP8>>7\R74*!%]NH#A8;;ZX>.=/CZ]7&$+&NJ47N*870? M5.1OO29T%VY,UATIH)'4;:TG[BVL;W'+,JV^093Z H]2[TEOD0BO6%4+<$&( MC\[,]#&L&!1P2X<"%Q<:[R"QGE''Z:-;&LY:S_YQO15)ERY-UYQ MI>WC$Z';,8IYHY(,=&*%URR# ]FRJ58@^RP-.T/FQ1O30@+I#X^V,5] M%D#KH&^M#<.M(&?Y@H13VA'(_:$L%'MW*(.4Q>G/0P&T-?QF5/Q9KQI (.;WXQ3+X+;D2(Q*A1( M)G<[/)8^IPF]?/M+ /8'POHY OO7-,3W%MUW"L?*!<:Q(;2=)'!5: M_X?KW1M[LE^40-_PXVH=X:_!Y0A>OOTY5([MZ^6VXVLV 3+33_L,[/KJJQW6)9.)>$O8J# MH[I5HY]!&6Q%3LO&L20MT*5_1^'UJTUG')EW,"-!<^YL_P(*+QI!IX,<-EWX MDT>%+>4#1M20L2FAL,(XJG;46A.QJ7WR70W&JQK\FU#&'^B?TL^1[.\/M[\% MLG_0E#QCH7V)\"2@64M9IKGQ!G6*RZ[><$Y=)1(D<\EX0A?98C2K"<>Z?,=XK+!1/YU!)-.HSCC8X0>D+L(+I=> M/+-*0C\GL5>3@R#Z.CFDIU?<4B5K7U)!G'."?"J4^6;CZH*QC440\S.8BWXW M]+OMR+M=NE7X&:KR?1/R"^;E>^U0A?")Y=J[B57&B?6[CO IEFCP[<:K-887 MS%=Z1>OV4J_WD-Y8L5[WK1F@9]"[06PH)XKZB0FSW8XJDE8W>O\W!^V50Y-_#2=^#T<5;C=KT@XO#!;R<1ME M$'&TSH'T0#VL7;6&1\^#TFE0WV612X_>S(BN(I:>7%Y94N?PI"MRB49GS*J&STPPP;KA MRDOXE[Y7RA0NS*(MU9*M9#TC+ #FX4 M("6^!RD+*3FP,AF!\6I4LVT3HWY'/$]CX4(-Q_H7V+&KQK +'_D,FOH>L?> M\0,_!4)92\+ZAT23).8G: ,)H_.6I^N#ZY?307RS(OI3UNGWR76HI;YNSA2L M,/04,L@CI[(:&:<4*8.)4_E:GC5G@TR;P+VCAWL^ (C[+E_RS9'7.^:TT,;6 M J][+$Q$"K51WI,-J%ZNQY/F;T4U^=/46FGR7W#.E+'4OJ]>9) M/0#]3A/#V42"Z*U[YD\B_67SZ\.?@($7"Y+!6IB4J2FC>_3-PWZ?N:.%*Q-/ M.6@'2:Y (F"NCMA_HJ:9VH>J>S6Y$M4/,V"DAPS?/5>UL5W)X>\@=67OJO!S M5DB96(T\BAB7X+$Y^VA;>$!&&M$OP279XH]64Y0>7-EM"#OR3S*YZL/9D)/& MWM/[D/V7CH^0P8&\(U%\HP)/WQ!E\I:TSG\9N="S2]LD@O_\U=#@#F5NME'T M([8$^L)"RHF;-:8O"%%BHJI]B+W($Y'R&;WWC?:WKZWRE/6+1DZIMK$%WKSS M@*GC'7F\*QM,U/^U%45L/V; M1^6]PIN17;:QBAGF>48XC@DIE%-;6(DLCIO:UWH:V&"Z_P29XE<88[/W\U;_ M(A3XAQPJB+RL!IF_JI^W_I?Y+7/GI$?]\XW'>IWI[Q&ZLZ*WK3NY*+ETI J. M2#];Y+"P2">SP7#^B.F2I2_ ROK:<#R(7*OMV89_DK:J0N)3 4AYPJQ856F_ MW#V?Q50SS'9[L-^0+_T$)NUO0?'_-6LJI5.%P@G#Z'*93VIB5MG&G" C(\(\ M!;B;$@9D"3DY$FU\3[-68P^J].><7)":BU6&VL,I &39]ILBG^U/V4U_6Z;._B(YRH3[/R?YU8 M>4\&YE*L?7A'T:^>#%*>D?5X8FN^3FM9LA>98=?+%>LKVE MP3IIIM*/BNL,&X;BXJS#,@W)ZHZLLL+B2N.VL=-&[Y'0JI4-ZM(( M5JLY$+=60P&"!UB)K!!2^Z'R-99Y,JYF.K$UF%,$VRDP4 \].A(18G M1\:/3^86!9M'R&CIW)!* _UQR9GL S]&?9JY&WS_<3&_C^/AIWQ)2/T)FZ ) M!JY(6S3?>SSN\9J""7?+ ;;W;XS6,^L\/XTC4TU63SRL5S,C+U?"Y2:/7)-( M1M-J9FVRG'>#JV5)]S_H+*["Q8 "Q&\=Y>QQIBB&^8R>W[RN-T+,8?)<0F MJ%4=4-Z^ZF5\M0"H% _.P$2N4,.US0=1-08;KP@TO3GR=*J4;ZM#%K.I4G!? M>;WFA)(X-&#ON":(:=\]K5P]7,M//Q05'_; (-V8Q(B.Z&5)U1TIQ%Z@S7FI MU%EIMH.R=$ J_(UJ#T)!VL%X/K=M8X4#:OQ.:?D2^JZ%^,(0^@9HTZJ9AV+Z ME.SF"I-1#.7B4OBLT>(7O(?&=^E@$T;)DV8)99!\\&?S?ST0C]/+_=XQWTQA6V,Y9CVL Z;34U MU28L]W:5A.OMA,')S-RK(> !,,^T4%\^^^U!T]*X:^;IW2>O-L/U3/8[82*% M\-G^++ #"6;F['Y3TZ$K?=$0HW9I(O^SN2/_A>NO]&%%+"/;UUC7WA2<,@5# M@5FT$]VT5./;%9S%M$$8A!$E=]JJ9\[9^XSQ<4)S);'&HJ-T'>BTUJ:6)LGO M37N^FRMTQ[Z?!: !1%DPOR D_Q#6K>=H^UQBV=]M ]L&"J3&EEI+?P&,IO?7 M;Y][TDQ 'MB8T]0Q!>?SXZY]GDUWR))CC^Y$2#H=6.RKI?-]-$6;\TF9>/:$N.^E;1)R.K> M4Q9:T;\#0+\'LJ M^/MV,E6S .5YWQ EI#4TZX$137#UB_3^G$ 1P7>O3_K# MCQB>.[PKB+E?.F!]AC/<)LY,0+.M@AJOM%)(YG#-QQ-EX6,&B/FEO+I8X MITA/_O93\\<-QXA'"[%] WOCJ)2#JJO#BL.V,]$8:LW%R539C>[4L$._%V'Q M2Y *R6L?&1U]\JB\2;[.L]]^/RYPCBJ,4N?E=>Q6:;*LGIS8[75!F=Y2%U7# M-X.EN00=3Z& XB''ZAVI4QPD+)CN[RG6J!SP-P7*-ORC.!.4)"QE4,X12&4@ M&0IHV.CR71BHVKZWH8,C<#E'@9+51X318>IM%/O#<<1)V*\LEPE>R)+$E!3, MC+8?L*]%Q<CS0X&F!$U:^S$),N4M#M(.':SL.X#C+*J^_;+J )]PZDJU M690+PF1K9K8J&S*\1]S3]K>\83P("N21_75H)7FEJ 22-1%;;1)%954Q9WJ] M:G=YSY118H&^/PK-]#PY%SX4W.]H""]PFVT[C31'<_LD0'(&K_3X ]ZC(@3Q M]T@I69OYR27E(6/#UV8\*:X3RI(JB! !JHOJGXN\.H5[[7:Q-)#VC>:&^@GVL03/KN.N%::V=K^G#T]6MFS#"5=E^$L1/\,B![*]!5T.X M7T==AY6H?@69_!E_5*5#@ 7S"LY=B@7)%%AZX3&>4\4H0C;CU+5:>YRR M"M[@>7KY*(1VGN0PP6[MP;Y:A#F64[>=%5]CNJ*M]X.C :B2!9&Z97[@^F[":4 M#GVD8EQ_:[B D"(J)+-\[D%C\UO1=KQ0_0GY6]NRQG;18R,MC,@/,M7%K,[B M4">'!N[/1K-;8R0_Y>H@WSGOLKOU +N9$66'O)AK;&4-3]GQIN.0!J=H_YYA M(CVC9$EQ<+<*O;:R%XD<%DHOPM@O]NG22NO*3GT ($!\83@9+S2L:"D%"F2@ M?XV$7XI5_0.DQM6+^W*E#*5O9M)_##+Y!AI218)\0=3JO/GQ><4%"DV*?;C6;IG&1&Q8SSY9 M>%= ]3X2A;QEA\#0I]7JUH3<4?:E) ?LEK!%CU3=8.^0.)LLB-(E#I=JP^59>V5;#[+!)A ME)EEP#R?Q&SGI,!!=]/CX6LGMAGTW4EZY3/LM=VXG:P2B7),6[.VH:^R>AYU MADH,E*I0@3$J5(MV4#."HY?/5BH$Q)GW2;)IA2BS0?)M_"$%EJH%I*/3@U]19)Z#MR.-T=1YRU M12]XD-1=HWJA49>S >1^4S/D-_7IAP4\"D#B.SAEA2O5T;D9HRJ=R!IL/*H@ M,K&EUN#B#-MESPS#-ZI^98,7^V?-9FYE6EF\:%Y#*2F7E^ M.C;WCVR>V\'"+.BN*K'C\5E2+'8:6:S(C#W\Y,,0JT)>B=O]O.:APVI?+J^0 MX7Z7(PG&.J=BL08-FZK9*P:,KAS!J6?OEQ0!N! LRQ[*N#ET3(:J;/4CK4># M.B7!@G;9:\_TM4CM NC.5L5G$OV3-*GA4B!OZA.I+YS;_#8X(8:YJ:>Z";[D M&(GSI+L*98H[WM5!X2M]*^4'EC[C[*L12J_">S[XV +VW6H"44\)SN":8AD2 MS(DF\^N3ZGD)'G/1]/3)8 Q"W,B4SREV5'CB[,$BM>6^\709/I9!DKIF>FKNXS/*"*^FT Y62Y,X_?$YX/2OA[:/RF4D%4#2QD&(. M'WXCC:LY;N\F!^XTI!C.VVXHT0V8M@A9FHW"YT^.D,>X&W&=5\C,/CL-4O!: MT#MO+P'G[,G&K?2#0V/%YR5IY@RGIRW^O"]$[8BCWFFM?)XP&ILJM,R2L *; M9Y&;6@(72DSRMZ-1]Z)B^E@RBB:8'(44R5*BD77LN50[5_7^/]!;AOV!_!B@MLV-=S>PBE4U5$ MKI<.;"JJK<833>DEK:6I$W,A^)/N>$Q5T\SQX:_?#G2VKD"!7\]J(XMLOA2A H\R%L_9X>O)/@]V:DE2I>1L*,OZ>-9EF*[M@P1V^E MH>'VL)^/SWHAXGQJ;DF%<2Z\D?TW]7"%2H%!G?OT]W+2:\"S8R(O; MX27'FY7G %+X-9WX"]^6:SZR;HZ(\_W8XE"MX_%JS*UTD5DU?WD2>K\%E,_7 M97O* *,5_P**4B_-.*GHB\GA3K'_O$SE%M&K9>YME7/*D<+2DTE&L;Z9BAB% MP2GI>P4@!YDV_"T[T]IX?2$X/#KN KOW=CRN405';_E9(&Z-M-IA[2'/&%%K M4_#>R#^5P@+2W2W0,Z3SC7% \VZ(1V$:HM9Q?@RFT2OQHO@BBJ%TCF:?WCG- M#[LS?#K*E1W8)Y)^M$/'X?FY^]T:6RN;4[8@ M<_2"%Y>L>@ M&WE\2Q;>6)[ON1D5A7,S[PN898^ ]-:>Y@9L?34'S+76S@<1 M8YMSIAWU1EA^'40'N20?WL8UVG$24Q=!SKJ+QH(XAFF).FY>JXTCG3@F*Q%NLR,*8IAF-[6_UF1X34L%P>ZWK(4-/175XG)RAP37VT MZ+Q_T&1+2_G.VWZF&R")'H68&RQ<'=A]1_*^1X'SV7=[PI=54O98_ 2<71&0 M!F60GOVU*=VL1^QD/HU*VUG,DGIR1(L)-N:P2"_0OO[5(I.JV?OU.?Y1D' " M%-!^&>]FS=AU_,R=(.,H5*D2HJZZ-\8[H3Z%09'AD]7D%W^^[L3\CNO.ZTHX MJA#NN/>J4QD%J[>MC'O'FAQ,W2P-5\$UVI\G"A%"I*5J#7H5ZT,@':G*$F;" M'OEIS.$#1K*A_573OM,[LP50X)/;Q:JK;U,(8\*^4%6+:)5';I76-'UR0MID MY#;YEQ(VB]JX-!F+6S2(:MP]@$U!=Q7ZA0O"$*=[H*%1QT-33'%GE/J4?N M+ ('3D^SCG;/]9-.T,>@P,90QAP]IH;$AOG&=G\C%)"VBR#POX.9K'B_(*\F MAM0K,0W^!M 1VGH[)I&H?VIX&&%XGR"F5)S JH6@A8R\GU#[I4:0DP$-3VS_ MCFN%PVP='KN]3H 3R$BVL#=[>N'6"[WW:U6H7O'N8D3@+KH]9(<\:W[1KH71*#["B(:>T.R\?CY?FV@YJE[YO_RRD MC2WEB$B7MH)D#.R]M G'[GVAB =OA]WA?-GCS ]%3N\[$A,!!7U9UP$BR4@X MHZO.P"27_-2O6>U_ WS\ZPHI*ZD_..1?O3:;=WIO+IA&;;'_5,D (;]KX_#I M/>LDII3PSO":+KQ6%P35\_:=MC,T'K?SZX(G-H#-GM*=L_#YT&-":RAPBNEV ML";X]FLE\@=58=NA!*Z]- HP2+J:ZMDWMFT^'Z?()=DPCWE:PC3? MO1[#[O:_FQ=7C[T/O1NU%VL9Q@_)<$$*HG/>O"\?[3+&(;HH(NRQ;-D8T'"Y M.6!]I>#!%;(N=\R=YY@V[!)55[N5C%8?L'"%+K$KW8(K3*U"O\PBV3].R3<[ M.$$KYURD7O-$@DG'GA=MI*4>@5K&<(*-,D;M&YO55%O)0ET#(TL=DWC<>=<" MEL8(.E7RS^TC5FE]GZK!OEI>XJ19OU+D+T^>E/JC4#/< M0;(F/?6;B2! ]DAD#8DJSZUCKD_Q$H>C3[6C MQODZ9@['QM8'#Z_X^..E-Q45+_K':,&&NB^NO22W%$U1P$(!@!F 5^G>#Y11 MMJP"7%;#]-!,%@7,+%Q[AS0*=03>W7*#!K'?>F1PX(F+P%!AGRU%G\_CG'J/ MG3!!_.4?24M)''(T4):@I519=:*PE79W\< $X[X71FL:U1L)JBKR&>O\G!]) M'.:JK^8QZ$PVMRGG(J"6A*N\551U6V:SKWC76W_Y<"*(.Q<*_(]IU5^AWS!7 M#C]::WN3Y)) B:*0X2E9-B;ZM_ A0L^)E'!1(Z3$^(; /=>.P+(U M$5LG36.20Q]]&=D.9&LJ:R\+] M*/C\=8VO/HV-Y_B("G(IX,+XM?>8+".6Y>5M[JTC.]$J-]L>[.3)DJ[DI &N M]ZO_F^/3YNVL894_:OSVZSRD: G">F@XS3#*L=6^6W42*$2T M_^\R:?R>Z>ORYJ?TY=\54'4O9MP1MGE=AWGD6]>C[[E*$B ]YZG>77;,2D8[ M_@\:N'#Y5YWCK.[0><]K LP#7Z! UM=F]FP=7_V_3C=W#TOZF].@V^9%# .[^L_9G\;8X&_?IRPT/Z#YZ/;O4@ M/&]*:>?*Z_G^]QLN_$,J+RBP(M][\4T-="AP2ZG0F3?56.8!PD%PYJ0(K'< M]Z;L,#L1K"<7R:/&'_ DEI_G P&<#G9"M0H6(Q 19_'PF(B%S\X/JUJ^#Z!J]9G+$T2Y2<<<;JF!HAV#HI]=. D M=6K8C NKA[>42'U7(I.T\VXRZATXH'C;'5@N>][PH\':I[;*XY(PU#69X)-1 M-]G#*DUXH_#.AGH0SJFD'*3'=Z2IVJ2(_7UU356E4VY-:MSC >X.$[T970 E M'J"E_6>NAOYMUG3'/_GP"PV7OR5N[49X4W@G)*GG3/BK39/X^VY6=C3ULL]L M%/9\^*/JHG9M>]*1Z_^PHX57%F3N''SLJ8*^UN*EA65E'W$V.DU4F#K07!]2 M4=GVM=JWPP7T5926EZK@C$U1*TK@*V$D:W2WT;412?!%3E69?[^K:_JEY8GV M5-%3]R@K*%+">W&"PN2C^(5)P]MT)=B#,UJZZCX>%($L393?T[;BI=(QV49^ M6+"P5&_XOBGGQ(D>T50:HY^+^Q &(GGE4)"E.MSS&M]-,>,%*/ #F656#FP4;$@&=V74#@>EH&"*XK.D)8^),JO@'_J8 M[N?CC(L$SY?T1QB..2GK "!,HL8[GK#W2 V\WI'5@P5_($H($Q//E2W+R,NO M##U0AH0&EG5Q?9JZD%2C?H!6I.C[B9""VB]3.=3_4<94[=?!-_E8]!?[8$;, MR77'^@K$-+Z#\#&?@+:-606B5R3UHXOC>ZGN@M#1_P=02P,$% @ ]H!; M5G&1KC9^B@ W, !$ !I;6GN'$) 20$116! 0!I$Z1II$.DN2>D8>H!A MYK_1)_1YX_^=[_G.M\Y9Z\5UR][WGOO:5U^_:]^;P0YCIX#3BG(*<@ .+@#@ M@/\ [!@@ Q 1$! 2G"(B)"0D)B8B(:,F)R,E)6,XN\@L*"D(X1,5%!,1XKPD*G!#!(28F)B,EHR MX/_Q#_830$6$RX3/CH=S <"EPL&CPL$V A"0SU,XWW^ WWYP'BXYTZA8\/7O4!KP/X5*?.G.>7(CBK9DQXP8%:P#\ZE8A- MNJB.1KT'R7[MH6, ,0DM'3T#X\5+')Q=\^%A<4EI67E%9W]#8U-S2VO:YMZ]_8'!H>&1T>F9V[MO\PN+2\N;6]L[N MWC[JX/!$+AP #^?WGW\J%Q4H%RX^/AX^X8E<.+AN)Q^@PC]UGI_@C)0:H;'# MV0L"_D34TM&I177$;-?4D30/'7M(:-D%IR]NGHCV7;+_FF !_RW)_A#L3[E& M 3(\'-!X>%0 %-@_Y'SK1_*?\9_Q7QRB55B <14D*>]\7VK4+ MG;HX#'?\@\Z'>-L[2;+PYL\Z%U>%#BGVVNX^BTBI>:X;ARNB,F%=Q,!!2"(J MDG_,K5$Z6/S&0+$C3,_@UH?FVW5U+"TFABXF]KX0*Z+1DOSQ]^/FI2\WV^WP ME%ZGDC%"7S"?+:=*YLY#LL8Y9: (%?LVU&;*M8FCKP5+-Y8*W*"J@@0!SL5: M' 4HRZ\0RF7'@K0\6R4%;3/U5^%/H&N:>U';YB_Q8Q3*HCB@JZ% C>PEPAIZ MUAV@6/V!5X__AB3I?R;^^42)X2&FZ\['F"W,.JF2]F:MQ1S5VSD_@1;_&$FT MI3>EY[0O/R6JI++LV+D4"_0^S3KKJG4="TS?1,*.R3TA&#)C+#"3A06>;-1A M@1VA11B*/P0+A!;&+F8MB/A6'4\V'C9@SB((L4#W4"H6F&J&8"ZG!S8GTU26 MAWZ=;*P4[/L\S19Y$_4ZZ=DG@*"-?3/T@+=$C!\+L$6!=%:Y+;! 6F_0A=3P M^9@HWH6A%UJB,UB 88F5M$]S13UNU.*9GI5V\)(M4R2U+QM'2E=Y#BOAYBBJ MI6Z(];P-KYX:?LSYTE"9FZ5-A-_J"Q0Z@2:=4==[6C$*FP7SG=P^*JK(N[D6 MTP=S1 E/8LC'=R0,OR;"O))'\KNHT&L9IX+-XMZOX'%?NF0Z]SS2V5QIM+RY>RJIW*X28P84>K$ MNES5*F];+C +B*,E ]=)-;\X-0E5JC!G(2M#=&C\-=4%B,3Y(W=P+M)\L]D, M7;E76ZE"["ZL-I2WIIT7[]#V+97M",%M-FRODN'\E0(5^ [5KE!=41QL9=7. MG#_P JUP]@$F!-]L&,F)5_"VVDT)-51@66FR/(@%*.T>]\X\_#"N9^CQYJJ MK]$5,P::)5::S;NO9UE(>(P4HQ,(+[(P&\\Z#&B[LK$AS^VGD.=P-E$#:K+_ MHP/GS0S? :V+W>'V&RP@*70I @N<$X=B:M) +Y.5__5:.&Q&/G,7"T29@_Y) M)4F7E=Y5E";1[$<;>N>(\=JJ.8[Y?R;^^42Y4;C1EA*HR24K+)!!I>4$-]'G M:[Y.BORHQ3Y%6,J>/+E$I7JGEM9[0%9FK\KN !6&.:+V*1C#^%[ K5-)B9- M<_$/+?N1+>A("0@6>)^?B8E2;#HR*$.C9;& 3^@@LJ215F9B7_ YBH> M+FPH0Z@B@[,]^8:+Q/N!O"OK:^BC,.U'"2,L4]'=M!&ASQ5C^T*W5?RN-=D@ M2ST6XBX$WQQ)FG.MSPF25N!(*=1VT6$SGU#0Q*=:)C>VP) @]^*G2ZOP)+L%FZ/E0%,\U>T37&Z!S/?>Y06Y>BA#0?[E)6&K:N9,CM99^85;CD: MM4*#<,X%S6VC=C]E+I71)LBO<>=U>(G1[@UY2OM$S-EG-5BS?>.(.GA\+$[N M/(E,Q[#"NFNP0&P9!.U8)@0'W/4:KU]W]7P73=.HJ?8TO\U-*P+X9+ L8Q(Y M[R>B$I#'BY:=/;X[$F@QI%M@\]IWZ>";[4V?(97>'.][O6LE\+!:HKY"U9J\ MZ9?W\"-6JB[>O'3KE;<'CG^'(GM])MS*I#I(!GC&?LND?.84C0 MCHV&_OO!PBOH"1F5KI''VP;>U;L'4@#F7#=AF*X[I*$7TQU_R-"7QGA'D]MA M[ZK*RXXB0C:)/)7!^+I#9\UX*"T::N-\Q1G5TVC;%#I6<)%A-A&G;L./>V06 M61M!%WIQ\[+.K%8"Y/RZV- WD5E;5RQ M#9:@:!UEU:&-GR]B$ :9,;.L-SC M5CX7]RQ^OMV&0C%[U(@>K[#73RRVP9>^?-,W9/HFD2 +:SWW37^QP]3*H+FJ M8@'GPBPCNE#Z8:J:LFMK#^P].5>BEXSDEY#*-N]&ZQR$D\14 MWRKP[0\#I+X<"<"6G;_A^1YK-.ZAR\!N?MQNQI=W\]S/-*_/!3#A1_+[P_QVJAXC;Q]/J>^5RZ9:ISS]C4T9%H]R@/-B4S6(4XB^9"1H4J=S0-QC,S M/ODL655VD9X?(X!#TG(\98$@1_/DNVLT."[>Z-K3'^RI\DFVXOGTKV=/]5S+/*3A=*YQA:(5& MN.X-=NOHR=M8D=E+G0F*Y.R_G,4"X/EQXNK^OP RKWF#L7JA$ZQ/ADZP18+T M'L0<8298K(IAAT19Z']]+86T7TT6H/[_S-#?B'09ZR)'26_<>Z_-N,QU[M;9 M5-.#^5OL?E)B_.N<9RVX/[Y]6WT30UL6+BX(1>. Q2.J!PN0ZC6S)D P0 <6 M:%D63_=*A(ZZ&RV@(0>LL[+N;F@>.WI/<>]$!7N1^=E-V^J,;(<+[-Z67$ MM:5PB.X"VH4U@\^_)*Z7-ZAD?^15$]=S^3)F^"MD)@-#:TM607 %[&DR<_6F MF7\)"Y-*N3:O&9%JQ7D]*X+1VZL.H2L2W4C*4TJ9RZQM55>BS,/#6)5]N*Y4:XJRE> M?R[:;]UIN@$C0/4UIC5XWA\*VNG )6?4'EY6U4^KNNQ"1!TCX&O-BEK(M[;T M9=PL?(+VR%_Y2MF7MWO3Q@(GANN=]BBQ_*9W(P%#V^S1\%H,#FS*M0J6YW[! MRD;1K;R\SXZU6W%5^P.0;II\5T"^FR2J$7;:6^71)C_Z?.K2=;I"GH1VV\>/ MI:/Z/Y;:JW+: H3L3L-KWCQ(FZX [W-7[#(4A$B??9W_]GP=YQ4 B".I?=D' M8>@+AUUH/AA*0:(%"YR)6MU@6V.U]$$[CR5-1O)+,F.B-_EF",J\M*=S53K;-Y][Z-9,7.![UI+U"EPIW&AXG%2')[I5SE&# MO/.V4:)#U[G0;B1'T&X2TPQ'A)"!=%?;A_X"FK6+VVK5=16=]L1L 3?\]04L M;L#],53N:2I#Y_1NKIFH\0_?DM;W:*J?,E; .Z\7VQ>X),GT ;4]0U/VM%HH M8UQVVN&X.D!;5S"INJ39?A*JSYH6/I2&:M=YT_"5?RH55^I7P@1O+='U759AUS*!5)\._S37,Y+GPJ<2(*;H?O*;K?+ MAG:8CB\L1I//D9,*[.J'FWI%(H( ]X5 ">IAU%"]*X9]DS<[1W_Y\*F%YJ/R MEACATU7N8IOPNY_([MN1KQQF;-1//C5D';!CW;.AX'J@])KX2JM,%G[R73(S MAE6'T7=*A<_@)&+GG3+?16'I\V+ IUXKU0K!6=-J#M"^7)<-?-M/36B_@\2RU ?_ /72+CNSL83# ?HZ@U'/#*J-OM%'^L$7[6\ MNH><5"?JJK7R[RTN#*-R9X002$T?D5^?;/-RZ[]4+?\@7,$:WR1PFRH1TEFC M42=!$UB7?/9#S_D77XQ/9;P(]XCA;V=V91!A_:1**"5+K8KS/SP([)XBYG0& M$"N==L= ?P(_9-@3!MU:@V "+D-_2<]V!SA+6&#WY HG[KI\/@-K<;$JKJEG M3_2*DBQPZ3\3_VIBD".L&&\FBFQ\B=B]-.):XXP)W2OJ]#".B?&*SG$7%BO' MW$FCD:67CH9&$W465JS"'6(!@OK/";21 K#(0"RQ:=6,!I DE%J"11W/X@K]3"V6P M0%TX%'U?A=V+&:': +L@PH?2T TY)K\.1W';8: :P][GJDL&KO#.;_)4%XU. M-#B:* NFPGAE?:K"6QC&PJ>&;/Z1NKK4K K)A+ZLG=V, :/%-_OH%A;TG<[& M*0#/-,:]B3EZ563J_::E(LGB6.MN&MO@R]"TK#M1N@+B%N8I^+_- .!$TZ9\ M4#&*@9U"Z_!. I MV10.+;H'>YT+"F&-AZRI!08-K-5"7N6[FM5OK)KHM8C*38*B;/DC17=3*%.D M\'$II!9E>>SA)-IEP86R58JCTLO7(C@_*UP:8[.]UGFMBG5@HOO?Q*NP][O8.";/P)TESKQ2*VK!.#YS^]??SL:G4',W89C$-:P MG0+&%=&] J493=@T$3P3[3N,!9;TA>+LII5Z7LU Z'R!\P7J=6,$N&QIV3X MT#Y+1GLT[T%(E)5C&6R$.NH]>1QH D(B-2U-TN-Y."I^WO71Y,8+1!.D@W52 MED-BH .U;=#O?7.:M/WX4KW>A RNR(50@;EK#N7^;7B%TT8I\.Q7-UJ:O'B$ M9R3@4RMZD%(EL6SRIE:XY:=5W_7K28VXQ',N+04,,T:A,1:^ERJ[G?G()U:& M7JIY#"7?J:*E^23FG5\^%2F^.5C]4%F][_8F84"&P=E&W.7>I?7"Y/56]OV^ MF^5#XPC1Q8-,0;L-Z!A[&*Q6J61S9E4DW(\0ZS$44:(=Y^V)1D39JF MI-%V[VIX;W7#W252^OYL[(;<; Y\NSL4X9!OH1EO9^&4/2+CQ&SHU<"^7%"T MP-3*<=[G4.L5ILOAMAA-]C@^_YB^98P8B9R$P5,!PKN@*OT&C4)WE""G,3V' MFO#L>HZ/-E?%GL=(MQ7?EA19>TXY+7# VJ?-5)_];2?_9T0\OSS:=,SWG-B[2Y X-]":?/I:9P0)A.^WY-[@$ MQYCI>>CA/#I/%QA6!0C?64$;KK^I)?>6[CVU/\*3;_BP25W.6O7#TT_G6$JD]/PS9RQA/,UZ9B/)),0H5XUUMP[I'%6'T2 MNS:M4*V5@Q*8Q5!-,"E\Z%T;6#>P-7Z]T4P=WEPA_G%[2QBNN,?'/*H_Z4YJ M5%(LO7]F^,[3L(%G,I\.=U(H+D##XP^+X\^BS#Z-OBMZ)_E-=]-T:]^D8 MT:'S6O)KW$IQR,S=^$(4W;U-WB2R\$.;Z@]=C_B'EQ>#2F.[")F%H7<"N!-1 MUV8B<">G?>**1^/BTO?&!F[+]:@-@? )SW8(PESW9,A\Q0,%]!F9BATOV'JBG\FB+#(OBL M"GBA.\>D^N\W6<-LORK_D&A5"I]JS=!@BO*,N2?')VZY ;Y\ M&DW2#"NWYW;/7S^J/[6LT'7'+9_/SU7K)8SLK5?<([TWV8_]1%K6.[NAN/>C M9B594V69]_]>BX]K?\U0V8;R:;7W!RL'"T,:)3N)VP_H]H(]2M-HVEE;V#(\ M;>;37VII:JZ=^A+A=CY"ES/L\NEK\=!Z\97FKRRL[:JUUSWN6?C^%4@^YPUA3^NK"8'J15]Q#NE6U%^$D!HP1H"EK*DFU@ -Q9M M-/8C:U8U"HV&.OR[HO5228;"L>XMV-.E%W_5R/E[\;=[M?P%,3,6C(+*T9H#VCXKJADRMN_#>6>D'C>,B#&EV9U MHS8I9YG6UV4]X1O8$1EX?WSNY"?%X]7[PQJC.9LRE ML#L)D^U>]LY[+F?JIX(IMPJ88K]>)PS=?FT6"J7B?8(X*R8CM.D:_C0_S53K_I5[Y7=L/RTE#A52 M18D*_O;7G_;A8'DFU9.!Z9YZH;46TYE?2* MU82?54US_88?=Y]Y"J6([& U4_YQJ<%E+*!W]#C.SGIKY)PK';\M1(3=6,_5 MS8MQJ9KNK?);=S;E7KM['IMUSUY^HSWQ3B$]%GB2V509-Q"9:D(9 MLIHOU#Z2=UY@[%K;EBWI_'NQ]6'W-4D66/U89@7R^+#%0:CS#4&&H*[U-O]C M+WNYR5=;GU@^0:0,.APA%"X\,JK(XR^ZN7JD1]QM-I<"1JF8[:F;J227KTIU MU;CL_+M]SW"5/59X"[KJ>WF*:C3:NK(\N?N]<"G_4KBJ8I?D5#)XP*9,XH7I MH7J/)/%_)OX7)WS_[O;%(U1@HZY9L&!#EF49ZQVF $X2G:0HV?O,L6N&&K L M%,/.N])>)L/RY'7D\M4QBYZ7<)4XRB_+$5%73),I]1.UU#8%U@37-.IU@YI* M.IHRWKWM_7(N*(/[Z /.J'B'DZY1E& 8].GH7OGAX_>E0X.E/;=6WK65?["= MB([:AUT&UC$L8XL][O=MG?7:WPP77O)8J*B$UL8\M#]J)J WH=\K^%"N$J3. ML*.L.R*$@<^].8W<-T@%Y+;Y'6\AJXLE48DC"A?< M.S$"]NA#+85?;L-0^Z]+]%_*]]V>=*-5)H(%W%&)R=50H/OMJT>J_@=U>QD6 M-*X+8CLS?BRR@N449Q/AEG@!W^0'/0TNL'D;WZ M.2SC [*,KU_S7Y!.J MA+>C,@")4)/;.=2)VWVAZE,B&B!YP(6Z>ZKB+G@''9HR$S&7DSM?5%5W(I 8.N3(^V9]\UEX[\C>)[UM/L=[8E(Q6M*W[+O&U#M4W%2V] MP='W_)RZ[G+B[&C<\;MJZ+23ODWG0"_*V@_22+9\?KNMI83UX9.)3HD7X$3$ MA2S\!<)N]7C5NKN./B=D\4.-;"E\7Q!3QUQUO#&GBK?X[DKHY]N$>/VJIJ 1 MOM^(/_W^V&]:,ORQ2";;,7'.2_U*Z%A1,LC2=Q4$'8""?$[%8YXZ.J'R^H>6 M(F9].YUV3JQ!P1 :#JXAIGGQOI/0\(1=L8$11*(/IP7-O;.)K(DGBQBH3Q.) M2O1[A%79B1Z>3!#3?)!S7VG"E>74 S_Y? 9. M []:8F3UR03Q_1]\;6L]QCCLG%C$@D:2 Y3@13D%]0+'*.@*PNZ\&HG'G#HT M83@G4E.\?751/2C87CQ+($L2_4-JP= JIV1/!T5]0N).E1+@1JBYO7Y6IWS) MA=8\^O#-H5# A[I+R-5N :)(EI/SFW,(MN9\8I[[655G"!X2.-[8O,VNJ=X@ M\MV0-(%^R4'80&B2QT:F+-UC[WE]RIJAX[?@3U99!U-WE*WMH'=.=E3+8D97BS#--GZPO6%PA@JKWRX.>;SD??DB)%Y)Q;X M,&>]TGFMBF$M=-W\E\Y'^%\"I7\#H4YZ?T*VV4)ZE6D1L+6Y-#J>/Y[/-#'1 MVF9GYP]/>G'F6K>F'FK!H)(54M:W4W-SK3(K$2Z K#XG/V& TPI57$0KI2PS M5HVJO%NAS.RRU>/@8G#WQW%=E* NOC'=QO+$%+>1K+_:%*:^4 M&D=_];8=]?>[3S]% BQ5<\R(>DN9N9>]?-BE^K["2B^+9C_+(3#.FBR Z$(E M23T2$0*=9OE8H6/'NK>W-5U@6Z"#ZQ$C_#;2#P!HJOY,DC1AA&'5XB[YUZ,( MBBPNO4T/M/U /L(B7\$:=RHJTILOVS)0^>/@VL6:*ZK2$/SWRP2>"<"B^??G M,G\._M^?083R=YJ_]2-3-\$]@>(.H?P)NG\VF>DMHAG@1:<$3O#_A[',#\'/ M\#=S_H76/QTMHN#_=W>*U20)1/[N[L%_<^!$"=Y>8OH8[IM)SA5^MP\G(O+2,9PI)E6>(B]O;>325 MKZGU/;+@63]S\85QO!5N?EUK@5:#(>'F8%PZT^/-!%VXA(Y8<5&D\;:H];JM M1Z?#F$@*Q8K4 ,= \4:QOH6PIUX()\]Z0,BGC:T8?MVXUZDZEJZ,'B&: XCB M=;?8A0-2RO9A&T,H8]__S L>9%B 45FH+, E>^KU3-R5.=,8@?LOUI:)%JT: M9-?3_+' 61\M+( '(K.9W#&T&TB(M@HDI(X%%B]57W&&*$XWWU7[]K%H?O[L M"WT/@[*+1[9I(&S[8U'67\YS+G.'C'8=P+]Z?!TMW(96QZ]51AV?VC5"4X)] M3>@[%9]LGNJ\RMH<(KESQ[6VY5C \XV:/A9H2<<"NQV(Z'O+@] 7Q\O M]-S CU&>[N#58>=C&[WUI:/MH:IIK"Z]!"+C,8!_A=<[2\=/XH:7&]0*]ZTB:B%IRT[G!I(L IC6KF7 M,(C_4$F%O [(=7J.LRZKU;=6Z$)).N+^D)Q2/4PS3%<8:I70DQ:)3W>J_2#D M.%ED;KZ*#Z5<@@4.\2VP (IV$BT+0;ZQ H$P$8A7D#P(5&C7D=8I+ "EFY'? M"V8ZZ)G<7I&C+%S2)T1?&L4"Q[B"6 !-:H>Y4(P6G:DZUC.(5:[M6UMK+14F M07XQ$GE0?LY_15>]93I763JQ[U%?LVHVK[;BZLI5'YCBR=#E?K]TEG!H)PT< M8)1^/R1?^=ZU!.^"1R=;JDR#X<+?7VZQT[WZ]61OU;C&O.%D2^]_[B,_W?WO M'9*OR#%]W^44SJ>WT]7EQ 'O95QSLO_9X-D3O/L_T'!?EIM;7$[')W@B/>^SX@9786S\(;J.::D=V\'G>Q0;" M=UO1,M-OR!^<>ZI?S_(\<=4V_-JJ5![YP[%&1N&P@MU\.D5E=1[ISIMN45W: MX>K->E;,N^I,B4Y-UB@E&1N\>D;7*'MUG7,AUHV.>8TQPUW6L9+DFP2YF=#@ M75F](_7FS@? :\>[#1O*O6+RJ>_"'D;D+7UNMZ,_-W%):E1\F0?64,GNRSS M(F@C;F!S\7Q0#BY%0Y=B1;J%KI-Y*=D@;?H;][9+-)C%O10R.R;W0%GXI\-Q M-;;7$MYHDC/'?@^]_@]7' M'W'?Q0)P4J.C+<2T_NZBEYZ5%7-YN$"A597V0=F1=#L&9H/8V,("$9!16J/M M(QLL /M!(_\FQIL'MO$9"P1!1G3=T"A=+# 9AP5(&I:Y#R+M5@?0+1V(G]98 M7.5@;C_GB;D,7BHQ9A.XP]<&07-#F/)CI M$F*'LA@+(+@QU#^?T(Q[RK]&A>GV&C7OJU_*-NUY(R)I;/_D; 6JT[)PKQ-D M5NHF'YI(9;-0$]/6!UN$@+G,5PO-^?,)=T.S:73CH$OB&HR/FU63@SO"LR M MKG#.0^5G FE'9HH@Y$J*Q^!SH(9R?S!1\C-'/TYH.C %,AA?:!6&.&3O"@R. M%,O\>>7 !LF*YQW#ZQ:F U0M6'E"/&7RH?>Y=TZD(5X[NZH0L%K[& C[R1 M" JLP%V9^^!",96U$"P@,3F)!8!=%92",]\A^1("10V?E4>S)] =$^Q,HDE M&W!O[U >K+R#3:KU+)A#MH>4L$!M6MKQ ]CVTC%87O".C$&*92<4Q34P9Y1) M,8&>=K]O$/&".%PJ7_C'!E&;[7RW;Y/#,\$O!\KA@K[!-=?J#PT3,=2]#'D\ MVF]$GEVB69AC'5AZ=! R1%W3J:=W.+Q>-ROQ$>8ZR/=#3=_E!2MX5&JXN=^$KA!Q%K!O1?I!O4XAX7VFU?;QS??F4B#(8T@ MI@WI#ML@!_NH$T7"UTK0\"@T7B]TFKT;]H<=(,@8\S^BH7KR2*(=X[V&!39Z MOX?F3W2Q@ X;: DL $'A')Q@)_G[T;8.#%"&N:, >'OBATZ-9TDT5;M M=$8HJ<+H_6W[A_H^NWN%LC^BP^)'=$S4S=!>"K>Z" ;+ZQ7CW"-/Q8Q\1P2: MO9(6-B?TS_C+=H]@QC>]LH!0$(?_<>81_UIG\GD\\^F ,S$<9 M8#X"D]?@;=!U$"T8G+I_$'OR-['_]*)*?G&D/M8E??=8:3:,C.Z/'4PP[N1/(*#5W=](;B+"KVL^ M1]77F93X4R\=U#<#6$#;)]?O2!"R7<]W-'5/T=65/\E0RPJB]CUF?UY[XBP@ MZ+V6"3LQAG?%GCETX8G1_J>TU6Y8%Q%BPU]C3>S9'D:^WP@9O0C;8>Q#G-@I M<$:X? C$?,ZB(=XSHOU MU7N6VS>U][I^A+<% D4'^1&8/[F]9W9,]@".5DV*C,XJ)R^0+$9+3(U65 M34^G(L$"]D?WW]#"0.W]XMM_9OKJVN;Z+TM[C2-C,0]5#DQK T?S8']:JC#! M6YYZ;?7$NPF#MXOA=29#J1W#'X'AX8H% M]I? ROA'W-'MC6)40.=9^H69J)\SF:'=+VNK^/"7$KR3"7M85FUT(A)-8TGF MT C%G:W5-A/]?";=";N*B8"6*UI":5:,DS_3C ?]D @+?/G#=O C#M"K4GPR MCP] >E1;286E,^*,R('\0DZVDCI(L,SX7>!&BV3U!CR[^/9#% M08_^X4]#[?#'@1AWL)GR)I'H($0CPS H&GCQ%O^)U6&@U8U^MWH4ZO;.B?U^ ML[K/;U;G_-W/U-;$ L<.(&J0,^;N6.#Y8-+/U>4[UR=ILUIF^GY2'N(TFP+/ M YK8-^37#C5^*3K2;UO4G%7$@?@ U8%#R/7G/@B(;@2Q ?V?A3O]. MOJAS;OT5'JG3$E!'Q(3$P%9'1C7!9]P'81(@X !V,K@<8T6W(/?^E=L+_4NW M!V4)/T9$[T+ 3 #Y76_@RB=1,J#*?Q--:&MC!*RZR52P2=RHCV!%%3OY.[%3 MK'VMXN!2NA])I'CR'W+G(*1A3:!>)63T;$W$1_Z/=V))8MP/M11^T4"FE-$_ MU+&?G?/9YLNDA\F\?0/6^7'*3QK]S\Q*F/H.O/G%TZKOV#HQ\Y@IU.]M@QG) MPSVOPWBYTKOLX&^Y?@7TCX39\7/"K*3\*6$:_(N$F;TC+M&*&E+4,+.]UR0A M_Z(U!&SMIYBFM^_KYF2V67WGDO#?^DNOSDOPJ"?_JO\+#N6-*-_C?N"EL:L?0[-":KI9/; M:Y3'1Y!I?3[&V#*N>;$V#ENCQD.V'W;0_>.%DTO?\<1O+YPLP#Z,P;J*H?NK ML"#(HU*PS)C#-H;!RF)D:/29;^TB&@'6Y,5?;JWP!XW?M+W@;V4#1^V%8(ZC MD(7F*+=WV@I3Y.>_-H^\:G34O"OQ7-U8^?"HFMTDSLI?*)4?L<;?\:K MPN_Q>A(J!Y-_*D9^Q :Q, HYVH/6EV.J$2] MRJ.W\) D91O3R(*\7M _<)0 MK=L13QGZ"(P;WQ:4VIZ>W<$/2=-6V@]DCA1@?&!@ []JN1?,&6!@_0E)-V&X M.KJ(J)UT+VT&197G)O30JD.M\E\D'5+,+([BGY N+ D1S^-)SLZT)&M_!+-R M;!6H9XAK944)V:8$= [VQ]K9D,F67Q*I7]C*7I%Y\'<>JHF+K!ARO%6>FJ1H MR!I&]4G+#CVJ>OW-H[CO:@797/:S@.B(='O^#B_CI28/7W_*4+2>G4M6QZS" M3K;FLO9=N)T%U9&(_&4\._P% -+L)YI/U[!A*L9[I9@KKT1!Z#5O_KA4Z6W! MXQ;NF_[=@?5E8OZ&*SJ>%'"O=TO-I,@TZP!TT6D(NM$1CP78>OZ!X;*#[X3Q C?C_4LZO.K+/&TR MPURX,N/>C/W";ODK1HA^+#A#%*W&6.-N]@8:F-IEDK<3K-H)M,L\Z M-2YARKI\U1E8G,WV(N="MRINKT!NJKSJ9SDBMG.AO[$-W[L.WEYR#'J$!/%, MPD1+4+6H>?R-XNO7>UIG1+:M&9)J:.XK<"QR@WSK&S4J2UB-&0CQ/6M7MW1P58>6^=M[5,+?DWG/Y M5)K\M+)@;ZG,?$SBM'0[Y$US?IE0 M\J7N0EG4FMQ$6KU@SA/>+2>X]>,J(]QAHQ:7&7+#K68E_ &[:A3/13;/7TWR8NWZ?D7G3EH+CXN<#1"%A3##@X'H$BA1; #<4LS@U@- M7,,"1H4&=A(!U4R*Y47O-VN2=MR*EC4,K"@IYBIB>*0O?)%K,V8/?N8;&-J^ MW ^+]FGM&E;'W-]GZR-LJ*%/)*W1P )XAE$H+5TH^M@2CF+<_79#?7%OE#PX M]9V!G)CAZ%*$.E/,XVBR.1KGKO&1Q#GGPA30!WQTH[;X*@C?9Z!SU^4HHJ:. MK]WJ)]_].-%F;\)/D.P:2W+W-G#,[1O[78CBLN]K$H&6H(%P]XU:XJ MJ=(1.G-[C'8JP)3-,S#\;)>)CH\\*5BS9_?9H#FJ&-E]MAI0VYY88(??$K*_ M#L5@!W4 MRX+=-VX<-/5A)!W&IV5=:E<1TEH[=[]W![63?WE()>AU6MDS$TW?=)Q(RPD. MB8!(GU,N+(3$L[ 01U25=FG_A0'9U\&3K9S&D_!7I9Y1NO.(:84),!O>>Y\31?3,O&(<=R M7UZEHK^C6HOVZYV],ZD/7:G(ZS*T+\K TQ+EESDTEP3YRV#R\CB&2G2R#@-=7@>W5(;>*8.Y(Y_SY"? MQ0(&7#CSIB)VR$T$&N//YE?S/Z,5XIT0OFF?%OFN6OZY,5/-]V8NZ$,I2_'/SCF/:$@RB\D=X%*\IJ42;5!;'-<2-"W,3&-)3?8T_1#Q9QV !L.F/"OE^0$A:!?IA M"D$1".PFCSTWT! ;<7A@L9?5JV2&F>((TXB6RPZM$KLEW].\P;!8;23EFY%) M0XR\)A.A"KFOTLJX[A9?F"=K838J\$YY7W%N56O,0,\H/GE)&5Y@A^?"=P=Q M+7$QR5%ZK0,7 +$Y]XS=(>TNB.).,)JL-UCTI;^"&=M7'C74IW](,L/C>R%L M\DQ'QNABO,:8E,<>5X%)',.L]ZQ#R,U&#XS$J_G,D30^D[,MT&F:3>%C4D^P M(8+,RJ,OU%X"@\H.1/\(-K358$CCDNK$5WUWUWGQ,[W'JQS]FM/T^/1736>!"HEK!V$1<]FX&3>T/QA]VG>C6*O,267CW%DL2EJY1\>N.P)K;U( M_![1"CK:O?QJFK(&&A@I8<3NR3?%G#7B&L$"+1&(8T>C;T::EJ\Q;36S&&TH M)L#JVTTH:K,,"Q18H7,N.PL4?KCT-I3[[*N3G<%#ONE)=&P-'J:Z[T!+6;^E MX0NHCZINZ$H'-,X9=*AE<7Q[5D&PO#6 >.R]]^2AP(WV?"BC&>8L^4U,W39L ML77E6@+*>OMXSS!L2T(#K*V>,+Y6SK0$T<)SVP&9W8@Y]U[82EP+)N RA:4/ M*48^@@-3H0];O%!S)>UX#[[;DU3A=M0/+0AY-^"U<4 XC@6&+F'D,A>Z[]&- M8+HJ9C$ZPEM"^RU#<,%A6.OU(4QYYA;-PUSM/XX?5W/9=KV*;ZP/Y4R_35&R MAJ" SB6#F7VW#;%SO? ,B]68!+,9AF8=Q!?Z(.*0L5ROLV/K:_?E8KGOP=>$ M.*!Q*V ^&+++LP#\[4'L3(*.R;FSJ5"7W)[B 4"V0)!=;5(N)_H M:U$,#PM<) 4AM",(&V6'JK2>H$@QBK2QF&\MF+!"EX5NK=PG8'L[3HC4^J++ MR; AZYSD_W?>2CS;H;)\HG6?;67+P&<)\DR^VS% M.'N7=+G-]Q 6T;Z?MQGHKXH\'!'5B.X^U'JD']^P=EV)Y0)F?E;M0TUE/]^W MZG(KN@DRVV$FZD. <,' YK_]ZMG/UR3ILOYON]5Y23(-I3?B>LJ3?929_?AM M H<;"BS/;C=)_L8_YE$E;/E &VB(,@X H< MF\2(2S)!;4J.'(J.[D"MJ)[=86H^?O*>C3@ MP)"!0XML7-<];2\SP8HBH+*-^/OUNDU^=9JCFS&L[0J%0=M5^4T JV M.,)*8&N6[X0%",L0:,\HE(PSXN!P"(KT\@*#-@OO[J1<[QJO7 MVJ8Z; YQSJ)DXE+4A]_$2*=N0G ME,W,/#R<>Q^T]GUV-:L=QBR#I-6M8HZF*'([0_DV/56^&T>2;I>'6V7P2L>[#+-3$Q6B M_%_\@WT\-G2V4="&^!O>C-ZC%\-&QF)ZI(V95)/3*374_FH7^;\:LS!S:5#W M?H+.TM[[T3&.B5!JDC0D]6*AC5EE>6GP/ ,O3^O96P6D .77_@NB7\3EK,:;SA**&S#INV]+:V*?PV['\PB# MNK-&OA$:VCX]%&SM0K1QH2@Z/=)$S()]?3/]28SV^9M2;6(S^;!Z\1Q8]T(! M;/(-'T8^#4.UIH$)$7?"H$=@6^* ,S4N$3YS8'?H MA)_](M#-U$-GSR7 @$ M4R[?_4WFH:=:I _@@J>Q0.4785\\\Y5!/W&2DY<30('I%@\C/V8T4;P1>N7\ M0NSE_GOB!Q5W'2-O1.E'.EZVRC^K6EX98UZMD3N:EOC4.+3[K1G?#RW6:\DNHMM0N\ _>[."K8^[' 7RB"WNX%%KW4+C R$=>-T%&2+,"Y M!<),7>X.YXT0W_,EJ C8#,&FS_+PEQX()[Z _EK$O8-0*A-Z;C_I!;RB^9K+ M?B2<[]HNR#(IL.5NE;VUQZPUPE((DL.H' . &R:=_^ JVM+\2][M!POT"&=)H M1.$^>L5"ZU45:<7J M-%%<,;5.O$- /=IY3_=7F&;Q&!/E] "2*=A /%+U'O MQ[:@ WPPR\Y,&9*C"YY< N+R"W+R6>B5LZ]T_SA9Q%OL"H%MW=VA/-Q6^68@ MY 2EP )S28N0W7GXYTI+L%A[8($(Z)Q]'V(5(HP)C_RPHM$,WQ*QF-P[>1%$ M3E['!3FR<+1:0S?G_JXF2S/':G_OD X=Q:AR[%A^TJ-+:2P:;8E9 M0'<_SY[\E>[B-\A&,7_A+G?[I M^/]:IWV986WB8+.\$@M;M#$8YIGS]+!K8LLNO(@"DES6 M!Z8E<+! 3% Z%J@ ^YNW*Q.Y _4P8M9U/!3W/%C,_EZ-)H ^]9:WFFYW?UQ9 M6IOTZ&'HE;6$AQ376EFX6[UY/*:5;G)G[6X0+6N5=;A=B?#B?;[%%/3XHE[T M95O]'4\,([I'TL:-UUC M6^JP&^*;,O ],N@IT+@?*3@@N%)QQ?:+D4/Z'>^&X0!REW_[U6_AA'NLH&(- M05,L7DC;I$.'W2@[]N@ _90Q5@X+//_SHA_OE)K_R1LII^BIBU5Q'_S_Z\0$ M!:NOA 3E8=K3++I'ST.NG6M'''WQ@#[+]R;1Y<0I9+P='ID:YX_/.C4D(L&* MDB2CI!@&G4@_R+E8E?"BUU07[E)IE(M/NH7FX-)^QNO[-+[IF_B08I-[) M9BO9I5P,S_]P\Z4S5973)^NI9,IO*JA4JU-#(:L1'35'3>0[CL=O/_.SZ3ZG M8#=OO=EOAO]@M_#FUYZE&P83Z_"J.X%-7**587?3,)YI^>):0%89FXPETT? ]F'#O1TT1O;0[C8)K M]JU^*^[>>!2X^A1)+U.9>N;V:3])#N8I,YJOW?BT+UT'::-U=:6?C]6GLD40 MT-QS!NX-4Y^(!O8?R[JEA6:P3/U1^;FQ-M*,^J+.> 8#6RJ9 MDY8*ZBE_O,F'&B"-HD,EM#1'V67K-V4.EZ;PK,TF-"6,NBL 5/85C2%'Z3C) MEPDWM<)XBO.=&EONE[UL4!S(*/$17:.F"V(G;?1;<&7:R4-\L#?:WMB$S9L= M)P5A5+X,GB"LQLGM_738Y!DP!1ITHR_FZ:!"A]00E47F^;/1TGIIP1?]6!3V M"@;H;W!'AN-D:K[X,,[#E5U/:]5?Z7Y%7)2K_KI5_QV2 !3EZA'\<&ZR=2"T MT <+G/MQ,F31[]T')J#_2FZ#4X#9)\@K[:27 5/6:/4=ET(;%)AWV/?EP30* MZB*UQ.U!6?32-P1U9!IN]9N982SP;"\"C*L^,*X4#$L,E3;M,#*'PL=>(&Q. MO>CR$/JD<]4(:6H/ A?WA:Z3]TY9"/T0&@:;;)'H9R%L2^_R^]*/HOQGSUH^GV&L?1SQN*E9%#VGT<1[*)'\)311K8 M9I/R*"BGM8W&$&S;'T6__W0-I0(]7FF"X1;RH@\N1?XN_*],2S(^]*/LJO951OP/'*FV3 MBD6+?E4\FC;\5>,HM<&H:W,318B)#96W?O2F]8%%D5XXK1E\P7A6S/LLV?T/ M_9@0"V,EM359E#%R@_3K7GU9*02$%TFMC2-;LM.^' A;V^T[=$B$ B82P$WZ MA;X2+N^K3-H+Y8ML[VYEVKDNA$=+/Y]*;% 4.G5%ML=AJO^I?Q= MQH-)H?JN*00?U[B_Q.,[PCZ;Q$/-[ \70'98YCW M?E,J?%0^'X!2=>7O>B!*?#A7J::)+E6^]71!I8N M3ZE+]Y+"^83!"9\WJ8N_:T7[:"]%0K]@D'YC-$D6 MX#<2/: W&:K!V0+9W/NN$_TGY$51I:(IM201X4Y+HW!90!C656;EXZ4*N:)E M1>8F3GXCW G,IL_O-M.O>O7,^VZX-F,!-^:^S24Y3IP@9,JJ2?(G1RZEZ8 U MD^39E!/^)K?71B<-^[GGHHM^4POAY]BBX)NL[[X; PM,M B"H@5MELV9P*5Z M7]0R\PZ*@OR!]%*WOKF6L1RI%E9!V<@\]T%J9%]=:8%FB[ M]VLJ32>>\N!Z49=#]^]+A].8Y_T8"\NC2T!6>W^8[Z&H(%J39R@0S>_CN,^D1P0FP>X0S%!RB#./-5]\F0WS@*964^;S/'&4/GR6?LO M$60X- _*+J<\8E,E4&!HZ^(04R4TA?PP*JM9JY[),?^)MQK'$C&9,.^Q6.@@ M)<%8:;&,7"O0')0K#N8J (['G11-Y"16:9ZB(QX>?VR&[.">?,^.DS 6N-!- M8(V@*+9P,4MLRPK3X0U:?>T=%T6UYPXT@.4O.2E1RSDDEB4A0;5[<>="L-5BZ(W1A&^,7H M58G\.7%]2U![5P[88"5/5#@F$CQ&,16/R68O8M]>R]#E["6#$9@3^NRX@J*"EL=]\, MY\V-C/\5SUXM2(,S <:[!@ST3H&5_^K":HGBUOICR-B8CP03_*LKRZO6F.B" MRZ^9?;V %@;P2MYU!8^E M87_4?I*O,9%0B4\@9ON7L[0TU=+])KG3J.#5^DVOT3A[O'@VMWS4C3&YT$:< MYU@%R%T#=#LAT_K3*W"Z3'8Y'O(V$[$-KT%"6?8$WL@+9>^256>F]-( VM6B M0!OJ1DH?T0?Y=U4L4O,^;*2F#I4 V,A@4_&7_+=[!;> M;#[Y'[+Q'X8N.C$^*C<"E#-PG-XK ME>;+MS)U2CK7.]]L5[0HXNMX-I]*]OJ_:&CKF)1P?%-$K7L)43&-AM-EO?,BVQ=^^0 MTBLCF#\X0*9&V HM552J5EJQJL9]55K;]TZB:0YW&-9OITI%K:[HYB,Y<2%1 MUSQ=ZZ^!7Y9"YKA2WI+VBJI'['8_B%(/<-L7\LSQ,PEG_@UN).G-.Q)>"%HK M,/?R\H('%!NEO^6BPY"5L]@0%RV\6#B5L%F>9HWX=SS4@>W'#7*[8:*-KD'? M_^(P9M% ?QR/NR*%D,?RU;*)J!>LW,))[EUKT]0^E)<4!P9= M^O'RE#F:@+;WIS(U]'Q/?*P-+045Z/2(:9WC(FJ4!;S*DP6\/!E[9Y4.)HB? MCQ&.E MWM5;78L#-=EF2[#? V&XKA?4T@Z*BI6!S>.1K6FS5PEE?8I'F>%T[9F?Q.]OX [BV/T,?//5[RA)H,M4XRF_B MSIT0_=&[\X>#%]^"7ILC[HQC#?7O37,,04SIE(>EQ];)G)R_,;LCA"9I69MG MKV69<#%BG-7=?)5JWMH2[9I391&A91?FL:2!DW$WFNTC?K#@_TM'M;CJ0%[B M6Y-OO_M4& &?,L2URH(W;^2//_-QM_J?\O MKO[]$_^;#4:SJ%A_Q>(59DMMRVF!?0#IZY8VB#3@2.8UF>&_3RKY!0 MV9I94TO<(GPC1CR64'ZVG=[?K*?1]^9!$C^%)!E>F;S.U&\;U1N(G 3"/@, M FW>'N??_O<=^>UQ+0^V*0@94!0TWW@-^$UM)).($,^COV!D8:71MY+]U?-' MJ*+J.ON_=EUX.V^W]:%>8]ZID/*1I5\-8L>JY@Y6\_0M>X^UJ&,^I>,_R;>( MND=J.1KGB[LP+KD%KQ![=$LZ\T(U DJ37(]7+/",1D49<+0L;%)CCUFM3:<; M6>6T+XWV^Q;W::1DVXP 0BTHO_?$M(&9@VA MIL7-:>%"1.$'*RHCKCYEK+*G3Y]++>DT3PO9UC=#H>RM6G=82NOQV =;6[]? MX-B4F&+-[GODJ$'Y#KB 'VOS#G3YV3]&[[J)0A8&_NI(PDFK!H,T,,3]K=!P MX]T$=4_<_DSM7<$>?6FNSZ#$)1[;0GQZ3:N<0!C;Z;% ]RK5K82]&J?L*'*][_Z.K^_^[7VO^5'Z'^!Q3^D4#!:\!P MT U7JW6ZN6VN6K._U][Z_B"B;.P_\GY:W?I;[R?PK]Y/ BS?S66VY/^9'-@4 M,MB2@%(G>$:XD*>WX?3K&;@6K-R.(:$I17X]\X<'B U+UX<$17LFPLP'G#R! MKDE?ZD1(^[P_3KR[D#VN!8*G5' +Z]A7&3_],9T7Q7YYR(<;@=7V=/')=YY> M% 'RSNZ;+8>$U"6I$[A"UZ8-:?&I'B:JB#[[AV&:E\JH?YQB:#6@;!.>'@MX M]F?]3]:5(YV"#N=^_U93>?Z=IA)K*/W!3)0Q M\UM*>?,O\'ON1L06:$4WJ? 8W5E=.N0V<8M3X"MQ6/P1Y\0+PR@%EJ<[ST^2 MWNZ#V2@*B@@FYFNLP<*(U0_#L)/6@(*@5B%A)L6UIUV2K//A@RZ M,MM0OT!/0-;Z&1O&%#/6O]A )V^Z/ASZLS]2IRBHM8M#C(>6QMA%:89J+MM9 M\K@Q^(8R)6*-E8A^723NQ@7)NUX#A,<#EMSC4=Y/3XNVA<_"SJ6LO_J,!_>P M4S9F)Z[_=7B&CF\%$J)7X\JX3_)*AFY/W:KD\.*Z)>*;:HYE"VWCFSYY^UV1 M5)'W"4O"LAG? &UYW?_!M7_^;KIN[-.\)V(!?[R2D:,BWJD_WM:?!_Z+#RB, M#IE9_JC&<#X*'9M^UNQ>:K'AK/?Q+KO8KY +J[P$=^E5DEF/-2HG)J&1&:#?.!SCP1]0T'C6P'C;61 /81+M#F:XG#Y0G-T;4J[?)&"_M^+3F M/.])Z/X)O'=AV4J7MIW8\&E*L^'M:#TQ\$:2TJ=@ 7U-9@ZJ4(J'9(Q*[P&- M!N[:_UQVH_^@_'](1?1W9G[[?\#:@O^P5)8YH;>-/JUZMSSF8EFR&,'%7,V\ MJ<;:5^NKL/S#&4Z6MVEPQO_X[/8W1TW9^+!.I=BP/IB;*M_EQ5R4&8[YYE<*MQAE7_8I,+;;5*"6^1$LRTYE ML7-R)8?^ X9:/S^& M5Y]D@? 3@1Z5=KSI3W_ARW\X):9YZ;%CJ1OJF94 [(;;E_MD-(.5?0U]O Q> M)!'4+*-6RYR52-JU?]9#RFJI2VFC((&!DY,(1E\ *HUB5RSJ#8@JL(S%[(@:W[:9(.I8' M5PMRFDS3J]49S;C@T&%"%8ZO?IY6?]+[8AC\0)U0<4?Y'/>FG^2K15WA\F+U M<*\!38U=OXENH/7:\1_QAG^SYW""?V/D5>(H+O!UT45_"OXI^*?@GX)_"OXI M^*?@GX)_"OY?(G@[*^#AV-X7<\L><9R4^F&&$*QA;"7PDXFIIFUC?5/(<(]C MH2&7KRTQ]%\H]@OIMR/O@%RB%J/.^R(\X7<]3IEG,W[A!_,4WA#*OPVR/OK; M^(9\\M!0%;S48+G4/X)Q..&EE^2^FY=GGZ\!&[[C\^V.L^0FC=P&BYF][GOGT$+#RX=85MK #P,9&Z$^Q@I(@RN7M*4JIXK#[ M%)]3?U$=RYS0%B!=I$[U8Y=-EWP&2.C8EZ3E L4AZ/O"1XKRGOEDV_R\?7/& M4DRO(O?9>71%FM;V9&N;45=F3W$#&;HO@,&-YX HW':'0:WF38ZX-87- ?):$YZZ+..*[73&<@%-B2_GG"B- M8-9KEBZV^H??O2Z*/48&W%>9&J69CM_#6O<3G) ,M;; +%"]V-I7G)A4++I9.'SF?N^7@'S)T%&@3;QM^9RRK9RJ3&ZC=F@06J M#Z*B]8778880D/#>P7>!D+=+3QU(\A *[U38VM1\($4(16(JU".VCZXQ0/O/ M\,%H6L'B0].X_J+HA20BNYYU0T6/(,?MGYY[S]7KH%G:,.!]*% ]S3MI]57$ MQ081'[>O73WLYB7/5;19F_,4T>5.A7@*Z,IIA*5$&YK\?FL9I&QC85@:)2 ) MHM,E;ZIW_K&F.CTQHN!C:C'B0=I&Q"$ZJ+J1,$20V8W>=G);PY(8S1=]]N&9 M\&^N.3 D\DM",P1[70/2/ZP:9Q\N'*BPM?RG8^O4D'DQJQR3_J9(/LA9L=;^H\$J0\(W=",R9WZQQW!$U07.'7]-#$6,)%!1[ 2.-0^(UJ9, MT323Z:T_RR!)D;^CP@CKE,18%2 O^1^C+VN274$>,L?&ECK< O%?59\6D=I M5J%!S[#Q/&BIMFIG*2 PH&!4LGJEM7-#?*B;>*6/&G!ZL:U,A;4>T,4P4=!@ MO728B4HN0U+U?,!*-K(OJ7RVY2'':=[H2H-F]&?'A(J^NS/0Q#U!M\T?\5^( M1C3?WY(+B4KN+\#2^((@*[GX;DRW>NSYLJ1&4R@V .AU[-" MH*. YT_]6-4\F3^E(SYL\-_G#P6@\.)MCRL#J28N7! #]9.NPA+:U?CCHE4( M.WI=2@+GM/-@B.S(NN\O%=:5FV&%I:M?E]H*K-&=F=[RBH7:TNS,G-J3FWQ+ MGUR%X\AFM7E)-P:.?(24]RN>.'!M_,:U+6KI5'4 RIT<)K&5ED6T$N]VW@.[ M_AI8Q9MIE"?B@&SO?%GX54\H]07BIL);F#NSHMLS5]K=^BFL<-'IY,[J8J-L M[%T:NR\H=Q>+*QF>8-D._J%I.^%[9E$8U;S3BR5+WWI1.U%.&ORU7G4*R-_$V M]O.7S4?S1^B+CB;,VS1BG^@$CJESRZ;)IS M*;L8M+%G4#N%W-K?W$?5^D_8.2JK+FDW+8B5:,$;U&ZV M>JM16^U)^Q5\#>C+R'V +FXUC$_2D!\G#2E]34]TKW[CEB_%$\!F]16WQ>J6 M%5TSK D&V;X&&%D*/X>EF63Y .1[?_4,XSDH4*G'H$!4X*A![]^>^1,NN[O" M<#B0OYR+_AMU-N,+BO=A2_%^OX=J_"6Z6K#)I=@HK;:FJ&?GMM*PD\\-MZ8U MDCL !F*&$!^6WR=>Y>N)U-BP ;AK0;E2& A4:BWXU;A)?UC8+D:+_TZ*U/HF M05X?%*##'GMAC=2Q,4[L]3+CF_:H_-3@ ^7-\.RO3$!(!4R(SVS*LD=VIB'] MSM>B?Z]%\<0NF"V8J4JXQBZ-RN!MI,;[ON6_QTZ,[>HS&ZQ;I6F;9->9=84? M(V?2]4X..Z7?+/;A0J)8"9!66."@E#+E,8@*Z__30#4(1,HC?V9O9!E,BJ"! M=![AV!A@C&,DE1FVV5C1"37OGV70@/R\RR4B<(>)3&:?9Z.ZYJ=SI[I7I?)< M/6]'"#]U=C AXF-GB>!-$=^Q4)R/:#[!DQ&.M!NZ@)^Y-K M< >'Q;%4R[\QRXLD!:]L[D%)XS$M>#:[H2U?D#WVW M9W,)[BU@ J[- F2PK"2VH'H ,4[_C4M.,DM',']>+TL^1V)8 4;,_"9V(U=UFPP(;NBI=[8"S%S( MYILM..UY!*M7,L1R++U/>2BGS8<\GJPUBI?EI>$8-]$++3L"-VASG>51W> M=CZI1>9166&_[/0IW8%.D\[1;4GNS16/V<1W\84\QTL1<;_2%5C#ER3I(EZ+ M^Q;X$QQYB-0>,@&QF#*.?C>I6W:!18_U^!R$=EZ MV^FP3H>4J<)@-FG5MJ4DF4O S?.M266Y>DK M%$,O^:64QD"S[4VVC14SB%S/C3V4P _U"[!D:WGTDYNET7CZ!OU*:@429T MKU@[+G\GA?-NG4E0V[)QW3Q9,?@6G[\?4I=R>\[7;L/[T'SDI=5=KCJ:APP7 MHXEDBEM!S%@4R@[I@ M[G-A057@E.U)EUJ/TO0YY$+GQOF3E[<)XLL%\G+$S=%=<<^1CW/OHW=;A18] M>EZ.EDFT6*^"!&CI<\.ZJNV7_>]W9?29!89=5B60_JYT]IW]DDJ3*KO'%*RR MR:HY.!%0A@OLO9)M;4;/M7DC@6!!259BK=N[1ML]7GBK504Q"A"Y8YI.ZCG_ M=[4)RL;M]1-['O(;OXQH?"@O-9P\:DQGBW91@5 FE+$*SL@W#"Z:.X\P[RS4?UB2.F1:9J,\D5 MR0P<%\%A,(5<@EH)G*5)-1J<,>R!=2NZ*]13T?F+C&T+-,&4[N43:I,;HW)Z M7,.L@\VK@9VL0)&.WC Z7]+,=FDF&_F'\97)-/GU=QOF\=X=HUHPJR&>R$2\ M;5_!]TE#[IY,%1+]X7@B"DE$>UN&W]&>56RX,XV*#X9T/[=U3!=#'2+O,BE4 M4^E\-713U[6XH\+2E('!':!+SV6>5="R*U9*KAVEH=(J/8OA;D\A_73LILK" MLGZBG-#%XJ_6A9Z/*?QX8?DSG:SR'F?@'-\?8W58_E(?DYCCB!O5?\<_F8X1R$(FD2Z:Z%2O=\VXZ MOGL;/0 9TH>'B[*X!+#ODXX.IG)F0:#JV&WF#\H+VA^BQ_%<-Y/AS3+M%,@V M+O2/!H> DJ!>C9*%'+GO#F*2'5\!%RTO"_K(*9Z5_CKPT*],$%+>F_LL%R)@ M>TX(XB-%X^_K,FQ,X$>X70,HVQ^5@:U[Q;=]7QA-K0I,##!9A-IP+PO+<,[/ MM<;^4 A"C([3@@TL'PQJ67I4&O"9>>G MS),X$"B,X:FO'$+("](XM1I.F[;#4T=;D8:#Z"REGXS;[MF)?=9/,(J7!_T! MH+Y4M3>";P0Y,J757+YGWW+3&E24H4VFB/"W1E3;F("(+7\F?MJ&N?ABG+7Y M_'RLF9O>($*&'D'",,+^DBAF]FA?6/2%DL=]CBY8Y!W6BP9^H6[\M[$:UKZ M^G)P97]F7KPG!3E6??X)KW:L=$?;3.;#D V\*N?RL7=K.UOC3B]!S+HPN=#> MC$^2XE5X[RD@#U-'&(]KV'9Z5Q],71C[(85)EQVOO"I)^"Y;S+N M4(A_74PGKA!?V\(&>UA37@24@YV!\@'X4W.'[D"A H^&R+N"-KA<+T.)N-:S M(62.X*+!:9/%GZ+@0#C)BK;U6P$Z;WX&G1"X^A 7P#ADQ]0[B+1T7L&F"LC4 M5.T-=)&@6EQ4*UEI?"K8?9;R")9DGM,.@3Y;0HQ'5[<+(K#/#>J8#J*$;%V4 MO%-FW6A@(&!$:2L&L:U&)T5??1#!\4U<37/TZI3XAC*(S41LLYW,# MMN"@*VKAST_\-3UZW&POX5NKK]2>DI><\Z9@8L7^!GYDWP*B@40[?@K5:GYA M(231%T.FX2%A>W8/\,7$LW^I,*3Z/\0(E4N'[C7**XK-H?JE&IZA]+58;41K M]HE%9#A8WBT;G49>O!.<8;L;UB\UL>C,QB;;>2Z?$9-4[NG!FTU9&J8'[NM= MO=N) 45Y7@/(I=Y_=J(:RS4\'R[S[U\0H=(%.#3OF4KGD4%W\LB Z*9*>_A: M]'Z!BSK"L"A6AO)R>)!(P=8]/M0M0$7X0@ES4H+DZ8KKEVIJ>JX!)"\ ;>#C M[-D:/&+MWXAW4R>0." %9PWF"M*UKJ1%QKD@1N-"RUG[OKAF4@X\#4Y\ST9. MDS@TUP'K(VH$T6^9U6146%HNEC0V2:.W,USXF;W8'SSVR@:X>643-R"LR<#C MO=K @B6KGS EUJ8/[]/MWEM&:]/=#SETR,;-ZPU6_,O40F'&'6,E5K1K9949 ME^X[)YP4R0_4X8EZA#(7P"CT>'^.ZS7@1>JS&?K';=Z32\\A+H++57@XYRV& M,3V_V77-]A4<"I>Q<3VM-8F.&.Z!97P9^.N'MP(T\5#H,HE$HL6?J]1R=FD) M$=4;Z0^)OL.B.=)UA9WL.6[Y;'+9!\L$\",UXCC0/Q*1.;Y#ZAD/9WA,K'>5 M7NN"6F(C[XZ0BLGA9LYAK@']BAJ]OS?H?"US.F:DFGJO 89B_.+<+6F"9P6Y#B]]<*VF50, M8A1HWF%NO(KN&$TF%;VW,;SDPSE!WJP,^1'LB2IMQC!M]1X]>9BCT)4^$A)V MH]B;$#]C$OK@=GU0$=;HD.12TE\;@V/W2RVZ^H4IM]GHT?&_<]-H&V%Q$J+J&1P? M1KQ)Q@B/CVL*6Q+9L6Z_!JQH,I[4IQ!N^B"2)'8?(KB,%()U5;=46(Z[^BNS M5OA[Y^E.YC KUMNC)=M>AY5W0!P$8"NP+"!^,Y1O^L(%*0@:,H,DOI1@!@8H MG>\>FEF-<+2GWTV85B?XHDZN,C03FVB!=0IRQW#J8LA3O5W(O=3IW.2P<'O):Z-[NJ,3 MZ]FHX'5=P]08)T\#])CV3$-1*W- M#6M)C&F-BK2[82WF3I,K K'5/^CM :'N\>Y;F<-1O9W"Z+GZ*ND(H2.-:4_S MI@XPE/N]8GMMPI+4VVY4P9 JMNT%>CQNK_/>*CBK;Z^@W5A*'_[AF,C.0"H[ M-?SYUHX*G600#3;V=-#8BA&=4_/!O@ZF5>L*Y7%GL3M[3/R!*SDL[]"/[#_& MP4B0OR"RDIUF% FBL'#L/=5KC&5],G?ZE;(Q6H1-2K\-D@W)*P65QLU.[PT6 M3D@>I"NG6[Y2? M&=:N4V/YB25M/^:)R4?2/JS_@E"8E91]N,]SP;PL MUG[+\I)"P7 W$*M:FURB7%5U=DT>6$,X4M6 3NNWG&'HVA4?\U01@ MSLO+F[E^E!>I))#:*^<=!FV[9%*\-0>2LK'G3O$+^2&11?3RI@/IB7=?J$C? M,*QKP'-T4PG(H5I/0Q\H!XAH4Y]Y&/!M@9QR5YHWN15EC=*,E T F[3#M]::YB:T, M%X9S$0O:C ?BJ2-6&KRIF95.Z-,!.CGI2"&78U81<%S?CF"[#L\)K!D6>*N3 M1N3N6QF"T@V<-4<"*SF_1*J:;.''Q?>G1\_>?&"0"50= V]"G>?LPR7'=P_] M'WI< YH^$MWJ"THO'\2W3O']9>;Q7SG%\&^*\7TDB$DIH=KTIYQ1JE!M]F"0,6UIQ7]72RA:H>%O.?9F0 M$6F_TF+:?*( R3T#,%\#T*G;=%9, ;JFZ./9ZI]9(XFZ34F6"E7/Z$GS 43[ M[R#'VIJ8@?TV],EH_V_O*(?6EC:OQ]/(9HL:+MN1Y&" ?PLOBP.FXAI W"X9 MA,@A>!%ZKJ,CO>=;-?_6M*K7FH?G!7%$"$=R8V+O9PE%Z<'5.UC^4B>Y9_&? MP3%,)G">YCBZ[WFAFW^Q0)\TE & .@I=C)IC[ZW$SWD[.(Z?8[ MY@%/&,0JI3*B#\7YO7MGKM5)0?\:0'MD11?Z]4M@+\A5R/\KH;'7K&7S1NJ^ MS'&-3=\J?6LG6@J&^*;;U["EXT,E[.WN1_LU([59ON1U^'HDL<\QP];S"V'T MCY9/?67;5_>#U:JM/KSD_U'U(9)AEN:[%B"U.8D/=^*/E:8*JH%TOO@)WA7; MU Q[+C9BFMVVJ GRC6R2:&'3Y0O8\5AC'ZH _]8ENT'D&L3F(V*K MXQ\N>B%4H06,_"GJNQ!55(=1,^:JI!1X(I59&B%4U3BZ]^A<#GZ\GYQ3PA7! M=B8K^%HPAV]5.1*>G/3V;3-Y$:3#ZR6FO'1[:7LHX-X8W$7^OB#"Z_6 MP;;U$8?059#P,\.9ZGXC_=3(]S5(JX>RXZ^Z:7#<0#'PSVL[R*5>:LNM5M:^ M/F]/LM\^(<8IO3SZN?AOR;SA1J7 JBVCUISX7+OJ&6T!G7CJ8EM;+\GOVH78 MU=[3P2:FH$AD"EG@OE&47NYO20B7)W]S/OD-<)@R6N7W?)5& MNDOQ59U<=.+2Z?=!0LW-GS! 71ZIM%U-I$B[ES[LU15^G>YR6 :GX>-53I+\ M!H[J->LHC?57]79!#/MK%((CY=V][4%T*\AT]E:W?CNMS;#YK6_7 JPKLG4 MU6U=1%R3%7B"GV2CZU "C\RT\O;J4\77NY ;!G8*E M.AD&CGH]9M;?1E:U+B@7><1XY)$RQ9:!XN;"*]B,7>PVWT83$1/_ [HW=,HB MI&+XXLM&5D4(:TI@(.U$N^@KQ!QZ-8_VZOP3\(.0EWHLHT7PFJR#S9#")UW\ M8/FNV]C**^H5-F#Y&YV([]"9] RC!-X/KY(I=!88U\.F.SP\-SLI;EBU@CBJ MVJZV)NO%],W--_M=)C^*2Y-_B#% 5= >;,M3K>WNPO@PD MTA?,&6^WX?:VHF@FX&*_!B-TG)-4 E6*+/Q*%N(F4A5\JTIU/#"R'!N$O 6.&IB']M>+ZS_MI$E\Q&Z7)K1!OZ4, MYW[S*OAY-PK>RC5Y+*/T8%ON<#&C/H!6$/GN7L)A#,F;03>9?77%G[!TT1H;3\LPSTSS 3P M)\PIO/.FB"E!'T0U,DI6/X%SIQ]<F/=%_TO4:P444'YSF-A>LM)H#XUKJC2!C-IWREY8J<"\OE(%JIZF% MB^V/#O?E;^5 LQ#")-NMTCTAB*5F&N?78]O*]VT-I#6G:)D;$I&LF!_XN M1?["$QZ6N%H.L[<;O4Y3N+\^.:F@P5\P;4I7"%;EL%%Z#SA/C#V@#QNKR\3- MPD)!NS&[;+M\6N=(E6*1K;';+HYL$KDW8%P,[&<^:3<)#2& OXX>:QB2,.UY ML$W <8Q'C/(,(MV!!9&_D>@0[CDTL3!QKEL6+,X,%U/8;K%/+EY)Z,]U<]^+ M_=FH0]_/U-5_&^/:4?JH>,CE]9N]-^D;NG<%%H5VNX2;"(XV<#L+8_ENY5:6 MPQU;=>9* W@S@, [VOPV,CWRXI@_L^2G!+#TD)_@A5VO MRY>&Q_@J2OW'M/7(2]PKZD3";5^^]X_GW])HO$&85Z1"%F^UP\=[.WEF%"P1 M 1H&Z&PZ:;/G#ZR<8P)3!/L=LXS?O-SP/71GENJ6Q:_?@A[ M+[OP]IG[--1B1L+R85"LKU0#:^>>TI)N+J/]:A&P_K:Z>.IT7%ET[HP5SW1MEYAL'H"F<]R5K'U*GO:3C6)"&4&/AGPL M_/BXVHE0(\G#GBN=ZHFL]=$G!;CJNF[HD)XM,>X*% M,1]L.>P)W/V"0LHO=%$Q"H((L*1\-?FA^5F!DTZ\QMLXY_T@,3WB,OVU[!/\ M%K*@GM:5FA*DN5\0V2,D*[-EFNNDVO92![3;0&PI>EE\G'9"#9%@1!%*@:B] M:VUX->KWCGBX68SRK30U06#+ !H#_R;>O%O-?INQK?OZ5T!3GAV=K(L/H9 M8-,IF):PX@\G%91+M#FA56^WQ?N\:0RZ*V(9.846EGV8(]\EEM@!E5CG2]%= MX:C)"Z8W68_G[K5Q&]#ACSD/>8 MCYRD+ UUS%I<],^94'SHACKMR\@H8@=/7C^M:2:O.'>\YWK#68=\=(<[48 ME[ ;L?65X"M%^<%64-2]*==/YR^01"!VT8$[M,NW-@+1J-1XG.1QYU\_T,JQ MKD7HP2P_A+F-9\&*2ESU4& 6VYST&)[M_@C#WA*Z5@WC%5?FG'L/G3:;TY5U M.S)_VJ+IV%J0F"J;FFAS6@+'>"!0859!4'#E:^Z=EKS'GT7C$A[MO2LE"_F MDA4.[?9DF?$M382"_5\I1QWID@0YM],Y@0\#.EZZ)/RL:N9-7OWL;PI"D=D, M?$G%JEMJ]WD)<<&:$O5#N5O?NW&]%[/^T*5!X6HEG%9OX%-UU M$BZ=:6O4+7FA3UB,=R<[.TD40J!8AMN$AL6\:3 ULU@5=YJ@(LY.%4?AC[>+T>RW@J0TC;J;H*]MU(HBJ=9 MD!V1Z<%EV80X1X:A*CO\>LT@#011KH&S#I[<9=,I=DZL22$C'#CSR6,BOK/L M$9T,G>@-7]2*XTA1CY\7=]-G>A+1F%NHV^^3YU>+)HX.:+#6/9WWSLDA&7(# M@]7N[QQ<3ZDB;),CYWF]1/"?3:FB6/1P[;%Y90L+.VMP-MJ4M1>3A;$_S$7] M/_/W;C*'QS8/,W+9P,Q^@A1>L01RHT\2;8 G?94#W",?M!M5B,[:Y[ MU/AU9[)]$H":"U.#G9&KJ.1C MH@K! M/]M-'GH".-(Q'\)LK4I.^\O2I7I*PTLIM<%G$+X/->OTG*=1+-DO22%^+Y3X M,3_*$4ZN^[;HG*^_N9/C+9S9@0DR;TB'&$?\Z7#+?E2#V]1F)'6IP$^VQ]:^ MA?;I.=68^]:F1Q".$>']VLK\=#02*ABU((9AC0.)^/K@X_RSW;)BPA*?1%7 MG%CE?KF3$IN O,S-VS[F(4//@> PR*)X.J:DY9F890<$)+DKU M>O6PPHIXG#-B0&8L7SZYL"%F=AN;OJ."7HLJGCNH2K8Z3IA:&L!'I%GNDIM M%JXT*#"\$'OT4,3+66$)YJ$9GH@2*2HI#-WL\OEW0$6P_.DNF=L5!SJRP:D6 MG%Q](7V#7BS]!\27+J$N&[!,T1[NZ.7B7SU7%ML+V.?&C5AZWDBV%7,C.8^) M:".U'B\!E>5G\A#W6,!R)T:J3L+RWJDZ^BN\^'[!\YFN!J4!P87$T2SNP*LIPN'!MS=M@!%@DX2A M[2,*P4%/TC6 )H@9A\A]OI(00QHQ=).:OVN]3]Y]F'CKB?T?/Q>29S( G!YUH9FG/5]TQ79W^8 M&B)Y<2;G(QF[?\I=OILU)D($D%BT8F:O ?&>YWP>B_:?S4F #)MWQ-099!U> M2J5H,@QUH58F/NI1I#D$9 WXQJ@2"HS MMC8D>4,Z*3EUHWV](^Y-U7QTS72$_[88#$$E?K534;=.R,\E^"J:N9[:8\77 MT8GVD%ZE:8K=46EM3#@N.YA,-]=D2"I4V,?;5)1+#)2_!E Y9B:<]@?=WIZ; M.]_U6(,%U%AN*W2)49;WR,IRLN!"CG",K3$GI8@5U=5?O1F/'L5N">;I2^M' MX3'SW^;4^?])P?EJB3UX4H]9*0VWC]VU7GG,!7D9MW'($"'8QI$3!>52 M4IQR5?"3#BN$;$$);7ZQZ<5M)+X7M5QJR!;9LQ"&' F^WAEJA=26;IVZ=>9] M@J^:MCX]9J +;N@[=;B4UZ^F61E+EZ,O/OC(Y8T>F3 M3LOP0=X=UND5$>1EE !\BYE^I'J6C92:;Z<_MU;+$X/+ASL]9W7+WWA^IU^. M*S,\T]]W,/>T/M069OY>C(,EN\9-U$H0<0T@=];TOULT@##?805JS09.ESN/ M TQ*PL7I;X'.G-HI1?=B%]!-:7ZE_IJ43IF*YS^]Q99'P9X! NIS\=V_:+!G M?;DBXD-6Q<$4ZNC-> EE6L'Q$YV+Y]#V6N9!5F^$.?-)6$YIO:+S4>N/U-N+ MT(P7GR$;3Y(8K!"X,2QV=QC'?K"$S)S4W$'!$3T?J@W]L\*9.E9Z90U/^*[!@0[*)<06$[AETDT5"PD/#YJ/'_H4WJ% MDWV5AE1B0T<6D<. -E6/:M5\7*J9^U/6M&/6W;O>OE^Q>6= P=$44%F*9LV? M]#S_)F^$3CC?/G2&T1-5!40KJ+%S*>?Z^KYW!.V+9%P19 .,&:A6%1PBBXYA"."<80CE%P^%F.- MCWUD )V5\&.U%_05?*0[ U]O-[-07QE#:F=5N=K9R7#4*QRMO^9!!^P&44B2 M?+B0=Y/LPFKY_\PV%6T^#(L7P[39BP^CJ@%^#[#CJB#:$43M'B&] 40R2+!8 MO^5#7K*;FS4N%\Y$[.0,-$=8/89[5I)?GF$98;7M&2UZ=#OZVUNZ.>HM:Q9) M_I$C_I9J27E'->@&71LR5HU=U/L*MV>SO!A;_TER!FYWF5-3S5/MP#(XN^%ZC> -RSS)+$4WN?I5VFR9#Y^5>%40T6M>ZHEHQPA==!O MQAJF LL=#)V-=^_RC*OH+9^=LQ,A3AN\&-5 M^FHA6#)V.43EH0_[?K(%KP"?+/4SS9X4E?8ASA>JS#43/+Y#IPK?M_"G0TQ- MV/F=AN'%;#*;C( 3DA5WS6F+DJM*&V>DL$S5*6&X1D[;F;(W%^G12&D0<"N2 M6:NKT46A1X^[XUV<4M]H;GJ%G!TM0RKBC53\;+,S-L7;4B)IJ M;0V6C;J4Y*%!.[T$02:XNGK5\+%R3SI&3=C&S:;M-?%ES1 MX.Q(W" VV@@D.R,XJ/<3[1R4J\FGX?L@5;$7;CEQ<),B)G:E5F#64UN8T-^V M;>Y"TXI5[O0IA(3Y1T3./3M0KD*9#&_ZA2-N123- M*![$5G\&\2*)H+E<4CF:C7Y*8D59KWWVA9FS[#E7\B.N0@L;F85B2,=.-J8T MWL/'@U\4B%R4H&AZ:!_Y[E/C)S!$?8(QT$"3@$7Z":*K<7WR2#C"^'=UK&/3 MW+PT&1?8_\$U((A \)>#=U"'"MMB(3A+#<.6>_K[61'9MT;;&%:MYXRX,B_? M&B?JW9<0ON-XQ1/[PY+I3)BSZ4,/?V&=WCINL"9.).&&K=\\ 8)$WIH6/#TH M-V72!@:]B"2Q%>^=K$88]M49X'"NK>V8L9-RQ"[I88HI'R<_8FM[P.78;*@7 M#0!XT.#\?''3?(^\O4&OG 17EC$](&+Z%%.&!X60XE2+U1P,;Z]):7:[*T2B],-U([2CC6%-!U/G48 WC^T!< MY0BM5QCF'CCDH]MO3PSEXA+^!^[W>3^WDO)IEQ:2#^/1-V!30PMS#8@X'A:V MGX8:?GSS6GSY?NQCCWC2=/@7AGAOP(R<<'\>(3;RBI]5VE1+R(XQ5O9NRAW> M\[89UPO^KT>6JE!!]X%Y46?>_J2NJ!*C>;("V&$TP2F ]"[!P5NR 3J(>N&B1I)POD7 M[2.1"[>^JN!MK%,6 8X'WPT YS.QM4_JZK%%ZY5MYIJ%+>V=+7XQ^F^GDO%Q M>!>,2_X:-FW?@B3C[3/SZ9H3+FQL6FF4WT@'J>%RY5( C)0O!/*(6(F@!16I M+V'W9HOIIO:IDY,BI%S'%"MQD?I,H+AV5J3@P_O<$QY;F^>O3.*J2'_BN8D MLF^)9[]+](T:-#N-4#!&)"@_C^H_^&1N"J3ZAE_8)'SOLE""BU1L/5YD ZTY M=-.4%:!H)09=,EBTM;['U!R(X^M< VX71(IF9=D]WC"/ CO4=W7?*4-]IJ@E MA@^#7UGMS][1.B>DLRSU>UD?[DP&W BHN/WR<9:\ M]T_^RNF#/04'3)#NW!%>2H#0D$XZ<]O!W119TQ@2!@%\I'C>$\#!#?RC<6RM M@?H5FSA3+5N;!+MRQE-SC@Q*VSC);N,,'Y@=_[BBGQ;P"(K[?0S) =)65_D: M-@T76O"-BBI7^ZH!:$8^Q<*)>',?QS+,M+5E/RACY,KM)@YPL[[3N/?(" NJ M7G1Z!3_4Q'D<;Y>-;V2'V_E"Y,+QEHXX4CG<,RXKSH_,7M:*T,J'(NU>;7J> M3Q@M3O )3\G$10 BB-I"!U3B7*XP,;2I8,^;T!0$QM=O]HN?4X[LO(M5VE&/ MA7^Q5Z^O^\4+-9>5-K\'8-1=%@\'=, M@Q2RVS:989 6]FY)Z?(&]4T%\H'%+3I"Q_K,U7/=FVC3&5]1LWTPV,91ZI[K M+$$FT&O.OI%HVWO(5WNPK.$""AW;0,L UAU:ND]K<::.Y94I+V@F%>B+?6"! M7.=6WR%\#)<9EW?7OCH,TK@HNJ_M6&5@2+3KFC"ZX9(,+G>UEZI]5QRRA<$)_P=U.4!];?OL9!H_)@U_SUX^ 0W%=^:>WUNO MBIP0RO$Q2 HJ4*)6\Y1:=R53Q >9#HI9I0S3J)\MGLW:-=['+&D*VMMPWNTC M*Q 3"5!SP(X/8+J"7V7T?684EIRGDW,8GDPYI"Y!JZOCHU(4%8%9F&PFXQ!0 M(%./P"BHU"F#NO++BQ.U44KY%"UE,\#1RIU^N'#TT6G7E">#JTL1E^;VDP_# MC'VXH>V^(5H%X"P-C(2QV,_Y$1_6QD$B2]K0* #++152$0U.SM5F94)3.+9R M,%=T+F5@J<^W6,3\;BY= HBXAC4TB8CMZAI@-H%]A6<$CTK@".6*93A>U.=4 MZZT(5P'@YN=3/"R,Y[QDCKEIL/D4"1ZI-;1YO7WY)+!N^ -+W MY"J@J\?B;#Z9:F*L3$U<,X?-AMF6U4Q+>DJ9CJL=(-L=^]\ZZXRH1SAE,")#2&/E%BCFP^)17M05/[+E\ MU#.7/!* )&D[4XB3R7?@_QA";L[\ D A>]6([U:_5+ MW5*_JD-R3'>WWC,Q#=Z0';/C[VO4$N;:EO)]QH?F_?#2DZ8<%\&YY;:*>I32 MQY%:_;_F]A*FQ([V7=&*U$#+N1N^Y0F))'#6L6J^N%U_$&\4L-:_1K@PY,0% M+\X26J>GE/!R'V83&U"]T:8'8 6,Q5AEA2GX$8I[%89\B-Z:;[5]:[(F(;!U MA]\?\UVU1P&&,KN2PKRFP'EXQ>YVFKDCF/[QL-&V,8H9K6Y,DCI\E$^2ZJ^/ M]NS\6+HMYKQW8OGX2U--4ZIHTJ!*T'L>=2)6E9/J;\S]OLK1'M-E6V;ATD:Q MFCXTJ%5!O&KLPPH6.VT1R\HD]Q': U/^)"AV!E5D"]O< MCOX,V;?JOB7YN"PWI<<&^9N@IWZ7SET#B52F5GWN)?"=0Y((D_Y<]JMQ+^F] M9A&VESC!'(FM*QV.N%WS2G>QYGV92=-02[T>C]=W=LU];-E,N? %*E18V([+ M%-2*<@C.WSH;K2WZ*8Q#?<+LE3I;4*SN0V:'HXG46[F,V(F,WSMDG1@#&@W>V"WC J)M3=HCA-)\,N MQH4.I!D7&UQW4;EI_#>OI +KB(T[_W\6*>TEU!%5TN6FK?A/J+&<^<2#OJ^3 MUX!V8&S?)S;IM_]'S)WX7OKW68 O,.(; D.F*2KVX5>-=2OM, M)8V+)Q9?6=QPX_M1W^4_%KM>+5U]5^EP0-^C7T>8"V42)LKY&>Z6]CP?P.=> M]>#+[]_^DG_B+W_=RZ@RWWOCY=2V=[]/I/2%)3D=XV;]OTH?2@@>[%K;99R79I 9:;T MKD[. TX/O=K.2ZCM*N>YN,'MQA$!:BBSNCVJ;P>V/[;G=]2)^ O(\G[MN!X@7#O_=,8= M_=F7T_[N+J].6WAEGUJ%L\Y5G_\S MR%2TW0[[Z#<_?]FK]ZM/YJ]R!;8G+FY(X7KEM:7-@;F@Z,ZD/=]%)OY8[/+A M^Q'[3K-;FS>?KM-=O'V+1U383B5Q5@>&_PP5I8]G,7R=&WQDEU[WHM[D@"L+ MVOVU)-/O[K"PZ=UQ,J?OL&G=I5?2KRWTWMZO$3ZVZ=@-Y:(-)RQL^G@K%3YL MOU&?OM2W[*ATZ.4ONY=WG)M976]<>."\\Y85=C/6>WU8_J?SE_K?"L?_#(NN M-9B")IF>[W%^/)^W(NJ1=6UZ2-^]2O&J(QOW]&__?31 B)U]\G%1MN4?A0_M MX[-^>[XP]$_UJI=AM^[-?Z1K?W33BUV+,QZ_":A/ MDVP]XW=T:L'I!D^&Y!6/ES*41ZT_(L^3,2%SM==^JDU\=B;I4!9&;TSO].Z MY3OJQ*]LO?\FVM?-,__/\^;3OU4.EB\KYWUJ]K'YWD[[UG]:%TS.\[V4$]S) MG[K^T%F>:_PY#__,MO%U">>[-;VO\>;/U%__8[7_QC_:C2-/9VF?=PO== MCOWO_38[L.O2W=M9AJS=\[^%.JI_$'TT[9_2I=R2]9W[ M9&=X%J_.BCKZ*2KB,+/7)^/4T :&QC;)\]LO;=^G\*/(FK\A4VUIIG"VF57N MW)5SVY[W5&[,"ZA;+,+X9@O2>>:CF#Q<__\F %!+ P04 " #V@%M6**B5 MS3(; @ R*P( $0 &EM9S(W-#0R-#$U7S4N:G!GW+QU5-3]VC[ZA4&&'E&Z M!FFEI)M!D!(I13J4D!*0;H80D"X!05)2NCNE11I!Z>X8T@$&YLSSO'OO]]W/ M.K]GO^><_\Z7]5FLF4_=UW4W,POT3_02+BX M8-Q;>& P&!\?CX"(C)B(D)"(^LY="!D]#92!GH:.CI&%AYV1B8N9CHY#Y#[7 M0SY!04$HNYB4*+\DCX @_Q^'8.'CXQ,1$E$1$U/QWZ.[Q___^$%W *1XV#:W M!$%83 V*1:(% O=#4 Q,RRE9WDS\80+ *F3H'X M!!245-0TK&SL'/\<'9^@/:'\B^]\!"_Q_A>Q?P/X;UPQ !,+"* ]$"L" WY<< MG_T)_H^C' ?Y9;F=W,-$?;)%T^$(I/=0Q>NI&^D E^V=_K5@(E9F A+IK>T9 M?ZF#\&,8R%J\/$200])Q!4)KTY21SO.AGE_W>U4_TT+1!75LX72>VH MT#XH@;&-\%3"[$X=H5N=;E([8@G/<1(50>C[*"%&7E[63^C-^9U%]8EU77V\%-/QZ MBUE#6>PWZ&(4["[O^::=WH7#LC88);'BR+I!7/2)#'?IKK\&-7_'>8\#,F'% M+6CYE07YJTHBEKAEY+CK, :K^W' (03U%'+X_G9<] M&#OXG*PNQ_HC=Y14T@;VDWI^@N[NT-NV.\AYMISRG8H=\==?'.VX5_I>UB6% M^XU0L_B='N PO#O;L@+-;'UN@2^I51?9H %$ AJPWM%);E,=YS*Q3L_]*>U' MZ2A*1_(!:X],V^2]CWP>TD Q6>O'@7QKB3G1*NO'TQ>@>-_BN-$;?J29_H_] MFJF(9Q/YS8SZK=<-4>SL^5-$7N?#XN' Z0/.D"-8CP,$::)OQZ#K2BRG*4_, MVI9ISV+524U;);/U:'52VSVLQ6BYG0(%_7&F%UU.$=?*F-D?]FQ)Y&,0 =4^ M,Q?6)M6<^"@X3]-0+71%G01IN_PZL6C TYDDAKZ*B]<#*^7JP;)SDNB6A#?! MT.B-"%+1X$?V1/O$GGEZ8"?KWCWFV(2 $"+'3!\-<*ZFH4.8'QO2^ZLT2^CC M*9H-:HL:$=,E!:)'"FC@0]K!W)/; )@E1K]@.2:2@>I(NT70UJ*MIM7G0L43 M[Q$/KM\SJO/-- VPK_P]49Q5Z:]M=LB@55[H4)'U[^K2PU"7% ?]A:DIL4BG M@4K_U[%?!L P]:=GC%#E,7E/]VC7*$4=9,+R(HZUSK2VILBE?8Y02>G=CR%O M/WT(Y">[X6K[@+4CJ!/C$:3W@_$Z1Q*6U_-EH:] Q89&1;[!\6YZU?%S4?: M23?R77<=?&M+J>\!X7*T2IU>L;AJ'-@VG!\1\.B:$5HK2O'A3[?FM,]/!'GJ M.8K6$U]$8U=2=9&<*2HA,S_;2N--MN@YV!9RAV0R*W(Y*01J/RCJLR)15*17 M.I2A+R5?GX9!)>D=R&LB& K$OX4?>PKO^ 0N?EVKH*;O&'*M;Y- '&0NX[4\ M%T+>?$MY%"+_3%_6.9APVAT<_5.LEQAP^:"3K'PT\3C\>&8,);(2X.B"5?_^ M9Y9UP);FTY27WJ:MXM226\S)9GVM=%?SBL5HG6_* UQ#Y6CL@%*6NAT@J$/Y2.+_X)+F'_*# 6D]G\+F_;AJ) MZJ,KF5W]LH@LJV-K_?3UR'@C_F;]X3$*6O$[N>8:X J,CMP"BG>D&9 C11[J M&I,\]J?7:M!ZZW:;E%RK&);/22S[*VJPGPSY_E(*X1Q9V/\V$.61F42"*D80 MXZ,B(QOP,WYY]@_C[ E)<;>/JMUEX1&E^LA7B"O%41^Q H]+W!\\M:P5\B(O8 1)%J:3<^#Z;!K965BGT*_NNTJ+]DA-J)Z<[;F8.7I*G,>X*ZE\_&7 MCWE]PN,IH2'%KM^7;BF6ZX3*;,-7$VQ[MYYE09H30IAQJX4@D9^]I<*"5_R43UZB'0RXE2A(>_Y'>:*1V&R M5^PIY_DX^E$L-@G>JUC8NXQ;["%^[,2V6FUC0E+8OY6G[5Y:][R+I/N>98GW MTS C[;;XV:X_R4TX D:"4CM*GXYJ>3IU0]7V0Y-5MS?]O)*J8D;/\;<2RVJ: M.V[KL3\!9[^:&!?SW:RQ61E2*33#YJL,SGX,3%0D8;[T ?6%!W!(>/YZYF9(HEOAH;[=&'6UE*"YZAO/6=N2P1=>U/43Z7MMT M"[NW)7V1X//MW\\^?I_#=FL 5N-.3(N1EKT+](B^3E\1$QJ?5+=/*6;UE;QU(V]N+X=8./IGWN%UK%^'VKJS(48QVDX]$J6KK;AW-L.ZG4SRSZFPRHT0GUJ%ZZ MSJL+*_5(-CFR+W8M-%#D.C]I+BHR8R4+Q&=)@WPH'.@@_XFBFCPS,E@NC1HN MYZI^PA(OFO]A/3=*#8OEK+-_I!;PND6^!BT /N2Z9 BIE>@*"XIX+-'2@!\I/!3=\5[)SIVX+ZC/O%[.WV MA9_"FU1;MAGJ,7>-MN2T)GPH"Q<4L9/:73Y<:+=D2':$NG\#,>!B94',/SXVB U>4]0L/@:UL^(FC . @-/$IM37@^8><: MQ;.KUOI>Q=;YKOP#AAT%&,P+J)?W=.A45=L7G+?]ZO4NWR 38ES;) "Y,%>Y MQ8#D0)XSM3[Y:QF4[L>]N\!9B?ST-I6BM+"'.#'2/<:.>/#]>3G7$U"@1(8X M2 8JKVG\8@4-T-0U(NZ<=#<)S4VY\\3BVGH^D;SC>51<^-))/.X TNJB#X]P M00,D*.Y1UY';)@TZ$Z41 _=X6<8%G[R5J&90WU!WEJ%/)]_4!_>VX]M>MHB; M7C?U>@=2X+:^8WJBW &$2'E;DN>LP,*EZ1 %[Z,CBFN_"Q":U'I^?6C&G,:Q MZ;9:LV3&<(HUHVD(#9;F\;#MF?DUMD]Q/HX,- L_OYUACZLVQ[=)M[2TTDRL M/VRGJ-!65=\31-!CWJYH]#@%K/E M0P@:^-HSS=->QZ;4@@;$S8_=E>Y*^$PTEWF%GV[QAGZ%DB2LQ-S>6;@7?[Q+ M+'W? ]XS4Y.J6N,^I1]^_Y4M'"_J)XG: M0Z7M88&T%W;JJY!@%SM%O8IVVP9[P3HM"[XO)S_/8X@3#M,(@,.M,I+#E<50 M.\%TMM/.PD''8L6-&6N$#$NCQ0"02!P0+[J9V;$"A?@8C[>HK/!E_]HR9HQ& M\.FU[#Y^4=_WG(TND7HU#B-(MJ:Q9RGJ-:(WJMAP>X BKW#02JG1F]"125;1 MZ+NNRV'DJ9"9"3(]5]]',J'[\FF\,=>WL5G/MY6SPB0X04@9*6>D)9._1!/G M]QLJE"J_J<)F5RAM*S7/_'LU_][ <5TA_IQ8,,,LD.[6O00(C7_'SB M]ZEIONX\MA#9Z *O:"HG#E#%YP:,]R37ZX=V2=TY.-^P_93"9'JB>L_=K#64 MRU.(/>*&R4J:,'5A5L,V[+ ,U[2Z.N9[8HACFCD@,,&>1N>215(5OBYY[P@B M>Y2;_-!ZW_'6?L6\4/J:GV&A0.0J"VF&J*1CQN?&V5Q$DBOMYSP M8/RK=)&UK@O\R-!E- !B8=9.U6E,NTM>VN20V%?&#U"OQ@M@"NT7\HX+$.2G MY46:N4'+@@%'!]_;7%/)<>\2K'84\,$(L9)/(U$99)4M/THV8S0IO5PG]&E= M@_4VW^K>I2+^%A6:-#OI-0K.&3.L#[QAW#*6K,LPNK>AQ]U_\K)!IHI1K',I M]E'GEJKR*AJX"\5#,C^;NHN[PO%5!J^?GX^@Q1U(RWQI!>2T5V"HLTX=#K;71P&V[%HKSWZ'/&B+[X]^9L "1J/39ZF!8 MUS39;CF]=5(&K KQ)M8H7>'@KJ!3$6\\&6<]NYOS.ZE6#E#!YY8K+63?LB]4 M^X=+\X\VE59I^BF+J/VQX6&*3/&^I/$P<'#VSPLTUU^5J+Z)LYTJEC+U) M&X*/8SEZ%)=1@S4]9FQ7Z&.'^/&A/O-UY90KIX'P+ZGUJ$*/VYMTS0\/1T^E MB@L0[I'=N%$V_ZT CZW>"_EUQ;M-*&!*+-)5XG! M_OV#S[H4*VZQCPF'8K/#.I9<3LF+CR:T)@5C0@><\TWF]0Q]ZX1.[/*M9JVU M^[_%.G9D09Y^KD()<24@=113K1F4S:N"T^?#7IOZQROOV 8V_CCC)?!QJ*MH M:&_,?'Q$)A;.&98RM> Z@H=_\8CQK>A%7U861/-S. ?PGT8A3_8)4!LO_#(-^ 06%KR8;PZ4G8);F7J\7N#?UX MBV9>74K)S'7^4(IAWP:_DSC=%_!9%D1LNL7,?2DS0)IFDLMN)75CY=OP#Y_U MN; FXI[WAU_CSIA:)E;2%RK=EU4I-O6.\D+*N2?")M1KZ\)\_)\?.IA\C'8, MQ'7>-U$R]+!5:$:L^4$;*Z+M'H@^PZF/32)X#VC&.\<%##L?ZI*BV!!<^EHS M-AY>6'8"Q>V'YCQ*VU=#L_YK"!(.T+ TUZQ<(4H1Z6GK$6AE;TRUH;CI5=-/ M!2UD:RJ/%A?.9/^Z/9)"'O]KA Y1I!CL#F0]Y3B@6ZU8S2J;>(ZP#RBQ27U= M '^U:6P=66K)GLYT(:_[<.DA.%8\R!#6AR_T*&>;5)%XL@T:OP=_$Z$US_Z! M(%8J1.1DM\Y?S-OC+"9,F@7ATU1P+IQHEY/X@4I(U#)I#17U[K&IC@08G*]N MG"C7;5MDX#>FT^/SB"3(T1';-_IR8YY5-I^55L:/4O15IH:B5_\10_(2]+:> M@:Z/\)@09Y3=ALE"WR99E/W!^=?KE\[1YNES2ML!6/W%YS M(K4;R5EBG?JZ=I73^UIV:MQ:B+22/=&,]T1)=(!Z+:"OL/P98C&@16B9,O%4 MZH&$,JM1.=MO-V:QW@V65:FB].DN*.Z"[>*L\Y9&NLS@)C6%,AGEL#L9$5G: MR;B_^ P"$N#'.%:C?22[T]0:'*3B%L+GZA1'"?)S;(@\(S\\ZQA &"R?5K7$ M+*.:X[_[_7(<@"'$@14_V()\B8?BXTG!YI^\@C5M%DFVUA1:D/KUM3LDTJ^0 M5Y/B?<&'J!>6N4-%/B_&RI:4GZG6@@W(=YE998I/LV&R\W#[O\5E"9%W;6VRYPF;R%#8-@ MZU'[WNZ*Q+SL E59Z<&K0,5@MY*"X>!ZL\J+QG)-3,O@(=+ME9::5/R9Y7?\ MRY9BP;BD#E!Z"=82P=BGS@R&3U\/E_/'5U3ICYJFF,:"0HA(M(+2.^@V,TZQ MEMHD0MR0M$OWOS7_?-QA^. RUNTFH&_5 $9W5DZRZW<7<9T?[&KMZ37]Q"ZG MYN5>'!FS/9@S7L-L=J:U"$IBA4!Z"F*]NKNM#/U0-[XA/[OE;I[YI<27=CDY MR ?VA5A.=?1E^+[:6MS\VD]?+8G;!=OAP F4>L8W!Y,8 O;/R/32= U2Y)P( M2Q+HKE!=0@XK_"5P*(KT 5 E^EZ ]U9H:E=F1^J9Q"&>E7YRV!N4O+O9ADV= MU1W"&+'>GEOO:>7L)*M=P:4\>ZZ#NU"19Q5]O_)/TMU>'D Y7A8D MS-$ L^6DU]GM&\\Q1>D [/S)^4[W$>4[05[RZX0K^[Y]$W-G%FB;R\\^:A@G MT2FF;;!O"1DENRXX;%D0V09]FU]\MWTALFO<:NRZFDFPL[]J0H(<[*K+M&VM MA#,=_'P2EV(W[/3(%%?&DBYSA>$#5I]'[_F$VG5>"\S=UYFXM,;-QMAZ#2_B M^+N86@JO'0%&LIP M]^AU;E-T?>YUT9X"$^0\[#D!/N,K*I*-].7V4#]R1'0.ZTUHGF_\CE(D%QJP M2GJ:S1@7:BI>B"H$#=P0(@OD1_W(=W<+;;0KU,DG)SSO/"&??\I!:;7CI!40 M>:+E T8#;+.KT,O+3VA 7LZX0YH2R6)K,H,&$#'ZU]7PE+2ZH5_#/BU[N_LZ M7"C"Y59,#ITA+DME&C_,M>;A[AY_]^&MB'N^(D7M[AVOQMUXJQ47&$Z>Y+(>= MKBZT^=\SJ$=])'*L MFWSG_ @-ZNRT.66/18UVYJKO=$#3SG:W>X 7M3&ZR*C5<&*MI*F4;VH!G6K>BG@4[X<0V";P9K<5YYMJU.G(YQ@ M?\7:$AGAF9R\]H;TEQ(U.&G?N "A?RB7O)S74Y8"U+?7DPA1_:K:,,H%B^W) M++E0,5>6G<@@0H*7(SY=13'T[8WOD#"LMVS"^0),(=_[H+Y-9J6*9DLQ)-NI MZ^?5%@6>E+\[@[^'"0:8SSG]4IWUE%PCJ<%::P+J$B? FY3#R$=-1Y-P'M)>/8F"9AGK&G6ZV[+.?6(+?,0D3!840D=W6W'9 MJ!YUGS0$@\]2314IRAQG.3F4JME?6 MS,(0Q(HAG*TL4Q6IN&3'_+QN\HT+[,'!S".N9[YE;C-=V9U.D%6]&WI$7:7G MT7/=H^A6ZW.EU9@]+T/%R^7_VI6G:QQKMKG-E47>7UX7P]A (ZQ][6=.BSA.I,0 MXSK<9VRN3:!=SN!C$L9C?N AR@C]^K[FBM/[5D7(^(*$D#J70>Y+! MJ4+0NCKEXL\=.*2$YU-OZD)]Z5.SU(->Y8^S!HXAK'S!]]YK. ][T$WK'3T3 M3%9#OJ +IV=@+"GAQV.:99QNZ%MV@,B927W0)TFFS^O$M:(8YJ/[*$:;3"7* MR&!C4 I2:#.0;QY_PW,KD^*S@3F03,- M#G>L31"IVYI;"S3(Y](1;L?W[&0/>KAQ'D!@PE@.\#550/Y(^KMU.TV)J]WS MYY,UK6SG\]I2*NJFY?AX6OY=4@@U"2$78X)Q27K>;F^#:Y'>R[KVDDX'9E)G M]M1\J>:WAN5V%P!#[8[;)6L!BOD\51[U<%$.A_3K5X^@XGT-?JTUMX+M)I*8 M'/N;P?&2-^Z^AU6SN7J7^]C^DA*=QEQC/M1'ZBM@%(M(YBM*RG%)^56W.9PJ M$42@)Q'>67F6+?])5RI#CE=]_0Q/NJM+0_?)3$Y#G_K'R*ETP&<=<=CK!T7 M8U .;*WP<_G&UE>DQ^8)CGKF(W//HW-*;5%FDWLH3\3"HCYB:'#QI_5,@,'G MBJ8WUXL+]_Q%:9/3X)25Y7J?.HW)&E*5\Q&]$2Q5?.[N%>^K^<18XEL2]&G\ M8O*MAGDK0/>A9HK2@$7S-B*VE@B0)^9%@GIU/2 *98,DV-Z2Z_8XR? M(EE,F_+]>SST W&>$HYYY.GO'I?,.Z>'(!L_-C/WE107"-G/KYG;]W3!M$ZY M2X"ZE%;0V4JK&H0 Z39ULI]TB9M,/.6\V6=)TP9? FQY2P/$>I\4/FRU>2Z MY_]2:JA(27&E8Q3\?DN:?5I2&0'KE=-KM)VLEB-O7>4ARJ%F9L%V[!S8W-BH MJ"UE.T8#Y]:(UODBR3C=^1&6G:ST0HL/]M(=2WY"IRGC-1L3:JEON%6#>+IL M7IEPE.=_-X,&BX^H5TWL:?=^&UZ8&<,BQ.%[H-#(DL9!M18/IP$0O.$94J.2 MSDOSM(\1V]ZM3U8.V"D&"'%#\0;KXR+7_5>E=J:[541JD&&(MMZU,//@TEN.X+2]./G@[F-U6,U>RJA%Z-S\[DVB\^P[4Q:*5\,LG+?]A9_IL#J\A3<*.F=&8226QZ"*T 1$K"6$=ZK-J._)#"QI@),-XZROU/4]^QQF3N/OC1S=ID4#[QV^5?IQ[PBG M*O;&@&U$QB^TD\;ZN*KLN&L?ER;XX\."O< Q/N3P\AU]AN9L=3N'4FL1K-&Y M:BZG7C4]JD+V^@+G72.V[.7YN_KQ8K5VE*JMZ7>MO#^9?RC<]=>UI!X"S)#P M%9UW/L^+B$44?K3]<--HB-D;+_@FGE85<#D=A:([J@M;DN+M%H>_MXP?/^,1 M*<%EX[ZGH975K_90'QZ,DLJ=)RP5D9W@.@ >L-;51(MT[O!GT6G% M([WE,Y\9/3&"JL=?J\E/S-[[ /U]E#GE+\F\[*V$!O!NF 4'JI[?&G!EIE6/ M_44E-.;#)0^M/B^2#6CB')]SE<#;1&"WFG+?50ZD[7\UOI<3?EK9]+A>ICII M.<)?^LW:IMBP]5230HI905VF=8&^P2_1EU.C'5^HB:DC87;9#KOX-BW&U3'RC%;Q2\([7I(O&M3S8Q>J36GTK)>6,47@)]KKH M7L/(4]) 3W"M$P/+>/NRT'C.6(L0(M^78G]-=B9X/EP?3XO![PWV AKH3P4N M\6[+,*XQO-,9;B,X"@E:0@,1QA*91NU7+,Z+:G'U\N[&SQ.NP M) Q;@8;;.)#5CX_<.UM-3V1;KPQ)#3OOMG\X6J[/[J4#C88G=)I02A+G>C _ MGBBO'<&DUF'1O)B]A+HI BQJO$U(P(]8#?!JA T<&L4#1P)8JT92T]Q"4)F>.5^"(FA(CB]6?D' M*C]9,6F(:BBO10>VZG3!224Y5_855(@A+ZZ,)AVI4Z1'N#QD9-AYLEQ?74QE MY"Q'@70:*<4S0O.-A\D8DS;&Q6BMMO@[TIQLOB!^A,18>L*"3U5I^K0]:$0M M#"R"G;QPS0WW^W$BG<.!)3^*BD9DSA'- 3F#XBR%5%?VRV-0C/&[&Z'=VGX? M482!!WN7PO"&2^.D_6O;B('1^/)[I^QI #C?4VJW_-\_4FHQ/A?\=)Y5'Z*E M$ZW*ES@6(@>ZNT:Z;3RF.[2L2HK2RF"SY=K%AWZH9[!%-##3.M=G8Q+^1CM5 MERMB]^9..4[=^;B0:_A.9[32LZIB.*NY=)[6:5GHBODS2$@F45F!MB\/I]6M M\>AW'TTYT4!T26:ZMT-8"_GR(15WT^Z,S8+OQ\KW%^741C]'.!YU=JS.E+6' MGJ8(XM7*@AA-^(A89QG-+.RH M.G]RM&2J?D#J+VW2G#0;L+^O[:/Y)AE64Q]RK^5Q,D5<-38_(4=B !IH\Q?: M]H)VF8 ]G#4I+XU#<41LE/6,%F1#?[@GU"-Z3!HQU:7G2H3#G1&S=ITZU=@Y MSV'A,KS>T5GU!?N<5L#3).J%Z74>BN7(/XHUU^(;0O?PHS,2X"R_Z4*FH %\ MAYGV9:Z*FZ]7[BGGL*I\-%#MF7+\V]-S>%@@LZ_5I7[A]F@M[YU?R/"#ON\_ MWHRR4#(X1X43WA8.F?%\O0/1G\N"D")KT0!KZ/+AM6\7&LC#UT<#=U#NI=;2 MPJ,HSIPYW>U]GPC.'\?I>Z7L0.FMY+RVP5[UXG?[YZE;W(#895N\A7T5$[!ZNNH:H6*E)* U/MO3\!D3D)NP>YKB.K9-LS@(?%+I8UMY\BJLW^=D>Y8<'%ACQ'.U[ %1::]&[.<2GS>'H3KI2EZ$D#6R M;')V2H5U] "O?!Z$&A&6;)_["=4@]G<,X7GZ"WH]G-\4'DGD[@8UD,X>E7V= M^(KP,%E*CBQ]<[9K]!I?I#'IQ]O"92U^1+<+*,^+IQDQW7G#VFH[KR,78IM_ M-9[3\A0-')*]RNRM=5DDVFI2>'\I%/T)1]PEX%W2E3MG")7=KV$GT0U_,4B0 MUW"R2%A=-SHZ^<&Q2_9N\IX'64. ,$+@-PS+0[XTS*[<6H3$N &=:O,4>9#@W MZKCM]07'"2PGP^"-J.Y9H)FXH=Y*2FYC&K)BF]T]-:F857*X5K)Y9??T8N&1_H6#@,=+>ZF7R[]U068P^PB&T1:Z@ MTZS86L/HD7WSO<78L4@S@J4#>K 7<')(B%3=OV%5*=OQ$YUP+94O23,RZ,16 MV*<@=[\=Y8^K$R]6QG,Y\WO9+KVW>2F&WAW2%(B2!)7/VZ0&RH*OQ5AXC@7N,28.QCO&BIZ7U""EEG!:*.6Z M8JFQYFOS/Q1<(PSLI2IE&&R/#%Z(K_CP_'C*\*B%S?GVUJ>HQH[SC3*/5&\[ M]O./XPYGVW>XI4J3]R;49*(%UIL"E9=>G9RRT)RE.W>V08_H9ER:RC+8[80B M].T25TGOUF<]P[J*F)9ZX'#;PT#NZ,7GF5VO-R)Q]UA%UO@MRZ9P2)$TP-&^ M[,&(_G5^C1Y*0E 'F_;5^<#^3_X[%*K=%4NH8,K=@&'.C%U,G&]AL]1DFW/]QYZ(NR&F8)8,( O"A30OAO29T,O?QF>PD* ,R!1U M0ZEO&L!K[O0O$H4]W3?X&;$Z022&4BK;5,7$O%S;WS/K43&)7TPV]P4\AV>/ MW:$?*C7[]VZQ1TJ*449(LA=NQ5>HU_2\GT,#H*!&6L1+#E XLK=_$6?3JI]# M>[),W,S+M!P)[C6FK$;"LPR,/!(4 SU*3)69DBY9S5_F, ;^PBU ](64U6:& M)+71'O7&RQG<"EB]4F(RCPRB#8FJ$@5>QCI!2N71 ('*\N8UX>*%A",:Z,/< M$56VZ#*Z_N'@*[GXL>U5? MYT%4*6K!Q9@2C;>TZB9ZP#DEJ;R42>+1_$W\()E\5A8OZC>_>(SJMT=]=3:T MD- ;\O$S*=BSBK'LNN:)5:O]W+!TMV)<,+.HJ9P(=\(0X!D3N+^<>?[QZ/D@ M3;.< U=>K18PYA1=9/H?B][GC*UYZ7T\6Z2#G9 M"1\5SQ5.%2COBQ;9!$P&4T('D9B1R=.X$@52!_4(_'I2 M.6SAW'I.G/-*PJOH?/\L"T* 6#_(*T!:]D@3C(7$>1;,&ROC39;5XNV'8V,)0I&;P*$*HEZ M2.;/2$G+O)W?#%SN<64YG.+?CBE8[ AD3_L,G5//8 &I#*792 ;S'XP9O^QY M%FQM/4_:1+\5KC&D,*;Y26V!4I%=DL+M%#X@1T>NMYWDW]59XA^^D+^;S9+0 M 6#V-T/(/=Q?-!NH2IB,'_+HWJF875!DCA43?<'R@_<.DK!+^F%#H*^[ZI5A M['VEV9%XJ:RTN..'(ZLO7* ATA#$<"G#EUQKZ.O62/[<3.L4!%[G;G'WLW9^M=]E/T\!AH#A*#I[N$NV2^[E_]4T*^-*]+40X%B:':Y8SH MVSLS ?VY'D>2@#K=-'&167;1ETX0WA>P98HIU\7(B!4I_8F]&>D8<&+!_42J M.;%A$YN$&I_NDZ"O5Z/@'$UY,N#_R]!6J%^)@G15"J;6%3C8O)"[>#.;^T!M M5):HDOJ4/B:[U L!C48A,Q9O.H_0P-8O#M 8&EAV\*"\"F%[Z<%?.A]&V4( VQ";A1UM_S&C MB.(^Q$8#H\Z8 HD=#:QPKF>>H_OJVXX_#O"#3_*O:%>89Z*< /V\EV53)/_!7BN3'6O%]N1SO^93[E2 MWH(R#M".^A\3O?#Z_['L7Z_:]-BS4==%-Y_0 #<,@ND$5?X\% /ZX_] !?\W M5 L8.IEO*'[_.YN+"#:!Z^9_LGG22H9U^JO[V!V8HQC$5/Z;XG\:4A0Y+K/KCS@>\>/!TEE)KYIG+GU)\;0E<, M1:-_V=:F%P=HZR^D/_OS9)%_JJ3-[1\2-2[9PU<\1'=O(D0P0AAHW_ CAH9J MGO>M$(N8%]*[SWT6QNO_5HD#-<4B/U[GAYZ1GL(XMD^S($6TO0Q4DV)!L@546S&F-_9"?_2]?6BLQTF-501 KR/ZUV7UI)D$1UM0MBG5/^%9\Z M\BF*&PW(\41AW'<,?O3B&/QFL_SIZ/Q[E!5H#X)\VO+G;,Q_S6K!OUHN.UQ2 MN\!1)!%H(+P\YB2))=HWY; MWYZV[-BY_T46I/0/6BO00,K?R.;,DU%@SV86[>ZHI#_HB$T:T#$X"IZ"_X6Q M+_]4D,@-&%/.].@,WB86UI:/9X]J7L*%#I=*I<<370A4,L2^A>L#E]XW=V&$ M\-'!'#2PY&*">L'^3XH4_FD"AFT9(A3U'[%%OYO&JN0P%/.OF4F D:/@'R88 M\G71P/=_[87^19+B=>IG78!,^0AK#-6US5WZ_''?T7F %;*:.9D&^8%(&%V+QFHA& MYP:W[T80_E5ON?V22K <11R#LET/Q\0A^%^/@"*2/!QN0H@Q#3\(X[$T%Z:8 MR))Y$&!-_._/@2V_@JXHHU@Q:#-J@)QBT/]% ;YLNQJ<*,%94W04_?6AM M@J2%(C&6BF\9@G'@E^/M"&'847D2Q_\?)(K[AT3._Y"(^7]*1 +_4R#S_Q*( M[I\"]?\AD 0F(<>DP!=AP\&BQAXX[IADM:>..5GL[TY&GD22P PGWF(='LI M33&!3&]YY$_AB&)05G^BR_P3'344.=T7RK)FAK*&T+>+ U=W_Y,T(U!]OGY, M8*J$8>!O_A=\Q?^"_Z\;;%>KG,3R+RTQ*<@,_K=7FSN!6QD*,-F_^]]G_J0\ M%/8GX_P8QF-?UJ5NR,;VZEZ>@A:%'/:$W0;;SO<-T< (!XGZI@Q4[^\A?K/U M)2^1+RU-PND%B?#T%M'KKV=ZIZUF$5F!=N'_B9)F MPQ:R*G<'V/RE6_]>YG@*9FR5XY.^I^9B#S"7!9_A]V/O55-:?UB<_]K5/X[J@:VR+6 MLKK0_A3KK.^O*V/^"MLGJHWGT^KJU .-T82T;D@%D[]TP]\#_,!]L/I^_SY9 MD*3#&S0@7D&KWK!<:BKC526,)SV)=0;[SU<67H)DGR3Y"A,[<^45E= X(8T(]?R]MM(>4M:*# MYG]V!\5XQXGZ\8#T_/]\9).ON@T)K!N3&MO_8C3_YAU"1],5NT_>OE67;CO% M.F?_S[RXJ=T"Y]\"?,/^E@-Z;Y*:G+1KCO]-/-CR6D5DN0R(8AP7_F^BO1XT M&'>]'RE,DY_;NOG_W=(%^"T:.!-3X<[B'7F[2[X4U9L!BB(G@JF!8WZPO(8 M;EHTL(^4I/,C,YSE 5YZ1Z3F=H:CFP:^ M] ]'QA!6WOOST2VN* [;WI?:\]J,XH 8+ K@X^(QA,SO@R=74Y^;WDUAER_4 MUH-Z"_"9BHKE46N&Z2EX\V7A)Q&JA2PWW#"*%@AJVR@M(*6NM#1G!]A>D.8^ MGU=0U5.1N/YVKZK1M1=/5S=F7>9V3&5F1G.2NB/^3"%E$,1S^^($PD_;ILX+W9'4T'-._ MS,5*J7GR8M_8OH?>-,F H-U:=UIW[M]GP7(B,05H *73,&IWUN;$7J>+CANM MV0AO;U,*\V>.F7%-?K7/Y)SO$3/WK]'=;19/[948" M3X[82R;U&JH MT6J?^*1&VA^GJTAM%+N_3BXCU70B0[F_)\E7@@Q9[:)H$JQSI\T+64 #^VI[ MYD^7FJ#)8.MA*3C-$J65*P^^X3%6)_.N<7/^@LTE*VKF]WM!5?8G2G'S&TJ! M(^YL).0*JP/VRH#YZY89&,1$Y?.C8MZ$<^N#GE00(_$&:88ON#&+I+AK%&G9 MG=ID_=!#?X6#ZJ'MLC>S\AW_MWO22]O;X4OK+Z+=Y1V9BF]3N;R$Z)_1XX[T M"?/_^K6+3^/AQL7Z;4&0&_#W/?!+Z6N3T/EDDM>\\YMO^]O0FXF*>LWX)_82 MBE]$>P#7KJ_:^E?;EV6QMS)B'L05VL=65)I3)R0-=-*5.4_7.J5V3U'2U':G M&F775LZ_-^/Y[A;-K\RR=G8^Y/YP8;N-5,F''4XS1+^SJ9] U_T=M^JTWZ\!%1)(TC;;PO?F() MEGOL] RL,>7C2@D,\91F;UW"HGEKF@>W5R?L/F;RB_[N[[)Z&51WX+9VE%$[ MBG3O;"I+SIG=/9\QV*')^XK/94KK4^S*S*0SU-+BCI?J3\WLJ@=N?K,FC#6\.\"^K=OD M(IRP<[L'[C)55[+8DF+&HV56%=V6&>7@L7CM%H2)+RKJU]A5M:T$)UV_W\X: M7QB;5W#MKKC! MY,&YU@FVXK5UG^S'2J9)F!5B8[,R#;'A3Q:/'% 1"W.51M:'O_V@"O+"!=#%@SS'A0EKU,^XF;S>X) MO>+3]D#<%YE[.@QF<@W+*MA@G*->6^].M9%55=^?\;W#B(3#U.^(WZCW#'QH MP&T$#2AJ@$P1]"==%EP8U[%*KLB=0@/6#1SF\RA&NV$%!6_GR8D5I&=1[4!U MZLG3^DG\>USYC=WC9I*%0+1CK]*(OF74Q[CE#N6.,>X**>DSE]105/(:1N(& M^*G^*#AE@+:'69$IT8553ZD3QY6<#+;#O/U;43W/QA832?EV,L]^\]Z$V#Z M('_'7(^A"K'_"-U0PF%IDZ.B=V:HTV*O$.G1QINEU>F$%UYFQ#&E )L5=&U\ M:96=C.X4YN%7 ]SFVX%L68M2#8SDT<7RB[OG 7&_/<\/9? [=OMSP/Z^HM(U MCOYJCJ/CJ^5BITS^-(Y]#G)/X +1B8(4^XYL/Y:]*_=UF"P"4,56/MMA':SN M=WS]LP@J]88>;%K+2\U&3@Y8$$0.BH#*9@Y=>(/%;VHH5K6<"_038EFO^K8^ MMPH\1GHN1U&;S9KROJ:[2#9Y")[D?0(@AB2Z9D**9@73:;QC2=SW3&'2B9,S M*(XCUTGX-J^M>6A!"LM3J,P\'6_[!!+$P! &'Q>BO7#R>E"$29I>.K]R\;NYG&=" F45 MF"U0XAI@$.57=;SR[X-P J6$F7?V\R<2O4#5]!^/B+2 M[?. J ^WOC?H-PJ(S#3^ ?NI+)L;J,X\XR_)J8D4XTG,GUN,LL&_5:+*)_/. MGB"O\E+GKMV:;Q%OK6>FY8+D(B?M^69ZXZKH67D.ZKG-&/*Y[KU'V+T^<3>K M.D,N6#^1S5<\#D0>7B,D*V MC:?FKM2=O;ZP!G/\:0 M4D%XFT6&;;"#:(. M321^6G0,'M?$QC^6)WSD5VB)A82*E>Y-U#3L9UP^?[\>_]"Y)EX@_JUT8GKV MUN^JGQ'-T#O;J9[)3$IYD](CC)V,YHZ9FM.E &]TZ=Y^[2>+NOJZN@9;T=3S MA9\;HF5B"UG8,GUT(#7$)$7J38KS\F8@SN3'E-.K='^)!KKNH;F'PP*CDVWB MDW8.M,IU*OUGA+,2C\CG3\TK$D\ZYCS?0%8.4R,>-=4B#D(=2TN[U4N>ZB_T MLKIRV^-=;+R:I'O;>#;"Y,]\)*YK+7R^ *T)7U#Y]+SM\DB&ZR3NN\W/X9[M MZ$U)1[TFUJED"X]IFKRTY @:^Y!;;PL/,T"_9R>/MB2TV\,VJZ9K=DU(Y81: MO-Z%#DQRN_MOR(@FZGS1IG<PKF^'\Z"5_QQ M,@VK8VU:?9D7LCWU<,BA2+_'L=AP^WC>4X#QE>UMDP]+IVXL4 WPFREHN*NM MT@W+4-'CNLO@&B%6_E5)6P M6GQ(JA*4_?M;@5&S?$PIRE.NUS0A9."M*B;(2V1%$]ST4];8FGO)DR7A)==; M73Y4L7_&U]Z3)ZU3C(VU5???,D<\/2$V8;W;;R, #]K2Z M:L+^S(24.\TKN&KDMH%"8@#,XS8$.%.T3#2MV8'/ESZYB9@\P!J*]0:C]5WJX/O[%*.&EI-0.O9%_@J^P!O8W!]1,)LG&V:,X0J\&8 ME!2UATYJ.H!9VGFIKX-&5?(J?>VIN]OA:UZNCW-<_KW8)=[1>ZL@L/1'(>(? MUSG6&>+RS?ZU4]F$'9\?I6BIW&.%MSQ\M#JI@?/<0^1)^%=B760J;,_Z8R^/ M=.^-0RHLZ-M(UK"S'@/S**S"LI;/J'0]?;UISF .[YO#\YV"[-6"\9IR7NY/ MR_;IK^L??LJ=S'5[)[I0I!.H4R:U=12\7CL5L^Q2WQBB$ZJJE6CVME=X1*%/ M;L\*E/ YG -$L'HC;8$&?#!-']:%K^CG_WZIUB7] 2!).X8EM(YW$5S0#" Z=F!%Y8,GB^RU,"6UMLJ:>,BK'^N$FO2>SROM2S-?7C%-A'J M#N6RG/LMI':PX[W=2-2%E*'3P#G9=5:FE;_#\C8#('C0\DQ5;*8B-^KG?E[X MY..V-_O'9@?1SD^3CM9HF1FTY*I&<7J'/AXTI2M6B,'4;33/'\(GXW.0U:DE MBSYK^R] I;K5-:G;*=S9&4;SLKT&[(@L,$N2E1,_;3D0GF:H)_DI7213HR6U M%1+8HND$COL\M[]#.\ ,"RM5NJ'R&/90F*>/&]&V)E>0<,\B"DX:B\4KTS2_ MV0W,]7,E&N$7X)1C]BX&]2W99L/?M?%;W*KI'W2[OLSL0.+C^U0?+105;D",2U?P!V_. \IH*.OE[;-B/L24RKE2%+\FY6%L M".XS$>9OD$Z;6$TYW!^J.<9-%PN4>0N?Q_3BNML[RK>H\?9;:&RMKYZSR5). MAK\;7J]32WGYUK.3C/-K04BZ^K0@@"F2-AG5&22TBG.&.TP?7UNWVQY_^/AY ML%W6$17,K.[QW#W-J0"I3@9$Y:N]B^I7VB-6/*=&//2'&%Y-#G@WF%K5G_=+ M_GB_K"C3SY/,T @ZR2* 63:'515=0.?%"KCGU]@/A25"C&L]7UHX("\^^HI] M>71O^$(OQ/&$ ,AC*&>"IO)EGJL)/$M7PU?X9=X_HJ=OA ;ADPV1*R;.6A=V.2>JY5^K'[ L H6,M_6%)6P>'-U$J J M;C0)%7P6="J:172N+1?R#&\5]U.&NE"616M$V-(=WJ;-L\+W-0V2K^>O+S5N MJ>OSJZN%%&0,6WDR\I]^.]&PC+X%T+=#>J-;QB*]T\9&G:?\R4[IJT1S]_N> MB <3:: TL1#,ZX%C N11#> M*'++W73NHX$;9& =HR^9O_PO)WPP$) :*:9LW M;P+^_)B/M\ V5'QJL>#RV&DOE;WNPA-W>LO;1LA:MYSZ-&T4#2_>XGOA"W+ C- M1(V=@7ZCKN GPHC2UE59G1WU1T8'"0@=[<;NU/3U5O\=L^<;HJB&:]N9_7A: M ]>Z^D )#YD+LV#9PM.EY^'G'8"+= W6UU\^S(B>C[B;^^[EJ,?M29 E3K_I MSAN:"81=#2'Y*3_;,?RNP5@7,VFM;A"2()U+=].1^GS#GZ/+@8X1SVX_^Y2T M.P<:6TR;9WB[.VX_0#LD#4P[3*Q6Y\@4$!0WYRA#O6#>^C@TQDOA8GH##W5; MCD/LFM-@0):O/KS8L4G@0^3JY.7_1=I[ #7QO0^_2PU2@DJ1'A"DJR @-1! M""!5Z2 B(%5Z[P$$!$-H@HKT7@2D]XX4%0@=Z1!Z[R5 >/G^?[]_>>^==^Z= M>S-SDMG=F9W-S'G.^7SV>4WEVQC&UTA43,TUYFN&XYD[^?4RBO\ MCI6!&;6\HY(DNC^=WNE@#$&QP=-!TYA&-"BM;Z^[;9CI&K"@B[YZDA)^7!AW M\T=>!4U\R0GX.MW?[OV29-F M-H:F@I3YF>5HP7@'Y[1Z11]2X#PW$LOD]W@/A0XLUU^RNAF]5Z\!EER9]CDR MYYKGJP7XWH%GA<#Y3N3IZ=G;A="EM2W0E=_S:^"GMN/>9OL'F(2ZT#6@F MYT5K@H*U3/;FP(W\V4$YP<[=V& O4>HW1 MX:G4.I)'R3M,9BN:+9N+Y@G=AE=I1AI,C;.2H-U@(PAI HC/6HR[7", M=0?N1@;W(>T7LHHLZ2C>]WJ!AX,HR@ Q+)IHDA=9ZA+.Q\HSDDP0O9\?,.[< M;P%@32T1(MS?L[R=P%(#:*V3AF2"%;"Z8!",H5)7J[%VO66_]1H@E1YW'AC8 M3LE$B%A_3ZLVMMJ]!C"9*2<-T>?K:7ZDP$BN/"Y3YA1^\'VW2B-.M=&'"/)9 M93#\ZEG@3O0RC%H$[^)X]0Q^***]RH1[I6#4\D^VKF>@=W/']LL\1HRE+AV@ M5!>:&OL,JEE61C7QJ)- ?@\AP"'"YE)(2V3:"^LNI=6C= !B$IY?L% ],,#N M;2V)V7WY?5[/[,"5 >MYHS1G&NV?383&WVN51?ZBJK?QV/NXO:%A"T2W-U.- M7.JY+NDK+!GR=([S2VM#1IM"?:/#&ADSO70?T-Z.*/EPOK.BV1^0-D-3G+M^ MDF221A.%).93@I$6BIM?K9R>%DOZOF0E[W"4ND 3*I,IG?>ZN";?6(_AGY/J4]L5?@NR!"(:FSK$;_D*5I!5O#& M^()KD_6[^AR'LX@"/V03O;&P4K6AP[N'Q0''+I0;4G"7E8M(S%EAR0[%+9 M\?ZF+M2);>7]Y7MG;O][OA1T8>F<$^WVW=/<"@+"G:=3)EF7YH-"_239 6%F M+BN7A^R]UT"WK<;9L\LGZ6E;S'P$!4]C;\0+\*M1\)>'A$H)+$=:&QH=7@/2 ML?M8[?!V$T8,CH/!)'"S7V8OG3(QO[2@98%J;]61N"$ M-JD6MUU(N0Z#/-9ZK:RQ 7CRZ*/5EYK6:4RB*I]+-31Q'TVD57SC[AG5\U55'V6NJR-K M LO(KL,5(&#_JMD7S#;XW_VKM\#:267@/^#*\EC*^!XO\XP4\:PY^_ MVSLK1/M&DD]H+!$")3*8E=>G X?9(, U;?VY\S4 >7(-- >F<&\?I>,IK0]# M5,"W.)S/--5W]W. D/58&$4KQYXUD_OJ7E;+F:;$X2:,&*0:J>J^>C]9G'U\ M_<64X7-/K@2Z>9<_/MRGZ2"#B=_>[(!<9]9J;#@IG^$#U.S3Y]H'@Y\IA)(E M*==X7MTE>QM!N:/Y]AN3X/'W @?R/YVTD\34FH0'SQWO$. K2UR0AF^_>,[] MTE/K2/*_<1AN_N"=M M[?2>F 37?ZF>BGXTRYT1'?1!\]%-IYZC5-QS( WQ5![!R>>>S"%K&U-_APL+XF MP* H,_1YRZ,5E7VT":,_Q'.F-\"@O+!/E(+"E^P21P-8O(QTS=EM6LQJN>[; M/?T;LEF3XYEF_OZ?C&9S_4N3?LXE"P$I5"4>AJ&T;36V,]'SQZO \1=F,5<: MK..B[GNE^B$R^X\:KP$?3@-MG,X1NWZ9V,L82OK\I4@E=:76 ;J;R,&<^2\J MIF2%*]7'@F8LH]\,8(R2--KF[O3\?KC],R62:4ERETNZO6F>/VY!YTLP6'8Q M^Q6TIX.&_G@%(36L=B:392@0MZI9^[5;/ B?LC5Y7-9Q/II<]K=-JC?DIRN? MS#5@6+_\0T[2D++0)%;%$D>XD=2ACTZW.X% WJZ&,^<% MR4[V"VDCXR.!7TZ4)6"[[Z9P>E;4# \).V-80%,^P1_' +!LY37PUJZ4ZIC, M^1X]-A)S'(WGU2*OEVBD,&*OZ/J@;.X,DU\:\)91S%1C+/[QG1[^XG'6XYOP M-\$IM8PI_DI?"!,(2!Y&3\X6G"O"+1>;W^^#0MPT[G:M[,RP-;!__/*9\";L M) ]-'BX^!C9P#(FR(@T:%M,1BX1(GY"I_71R#?8>\W(YQ#%5-YK0]5]G'?.]G"2QNO#) J M>:$U?DD$VG6G;A+J73]'X^L57>+?T.UO3<@QI>,57<(RS<8<$+CD,A*XQ3*' M%;P!6)__[P#[OR=^?*^\0-V!Y_0WK+P%@>"BXA!2[U,EK<:B%Z'YJ^(#AA+D MF@ 1P;HB]-9E/OT !D;L?%RDB^8Q/2 O$:H9RPR>[I&_K;*TOZG+'*3705$T M&B[G3P10J3UH:[O(3E#00D W*_=>=Q2U4/?4>+XM%K80.P3.\]C+ Z.,SYSW MCC9EW?UU6* \8/,/>^.@J:NT@.,=P:[(LFYRZ]C,4"7T&\T;&Z5QFWG4\6P8 M4S9LCZFN,OF0\GHF^H7M9$:7UPE+@K!S176G)MQ%X578@)U#3+"O)I&^O6KV MG5:HZQ7ODD=LEXOB5B"5=K_N@X>1RXVRF"A(QT; G$^J\SJ^W\ Y*;#^IRR] MS/UI29,@$[(%HS>%27/.$&,9AUS9 B>V?#W% >(& MSQ\]GA^5?*M%O._!9$V%@8\TR']]T(X(%S#W.A MU[(R]9VV(Z@=&*H.5>\7-TWA"-U[%OM4MF#;@>&^HB?>).*I ![76&)^E(*+ M&!T[ZU$V#LTN#O,7A-VK)4 1Z<:Q"6>'',2&Z.0U')H!#L;[!TE&-I=?NA1W M7TAJ$@=G9A)I(7A&28T[,6S=JH<_Q=08GZ);TXH!9;7)QB6P+6V=,2+'>^"E M%K2-,%[8U$>3<-N>BN" \G57475JEB3=85N?O'O!I!%LR'A6GMJNUU,2EO=W MP^/>WGGUO;W^\$878FH\0R.;-R[/G7PQD1$Z^O@DI%YYT_T2_[ MG7\L/[=NTOE+;BOV%LO,QOV2TD86N/PPY,H'.(<:^BH;T!LX.?5,W]D>D%?W M??N5_,<\BTOZ4:G7_GA'PVOJSM-J?$G_-XJ>*%K,!%8THY0X:6Q3K25N;=>_T 1:70(;CH]I-(O8:=X%-\%S ,; MSPZ?0E)=T0':#@\WAZ-M5BPX!8SG)TIEL?O["1 M8:BS862]D+ _FJI] R14PO)I>#2,]R#!M6>Y=LP]+:+R2I-V. ^UH+T060.,?[*59MF'1QT[._O-ZL2U[(R>D:3^ MWC2)7H@F-SCSU:"M5FD5_?,JG-]?#7!S%D:)2M]#!6>#1DQ/J7\:@W%7:G.O=IS5#\RZR.W&AQ#PA\TLDC$0$YS>[=38#A6PQ%5N*9K)_ MY\;O0WJ_=E8B&*X%HT_5E$(6;-U:W2MYW=5,5K4?D%:9*5_X3)"B%>)[E7@, M^=4043SF7$>B-R"KS4Q/]SW-=PPAK5-7TS1817\TM98D_L:,GF3-7T$GE6+C MP7N*O&3P-7 5:(LEZ,:1:5"OYY[\U;8]*3I@,N]7W_"_XEL]%C+LV?_$J[TP M6KL4: @42JR*8]%*4CH-W]PMJ.0Y]WR0IJ3YE/ZM5SZ:>*D2%Y;Q>U<\2ES) M(;N18-=-& C:Q^DMUG9"C%RMS:KA.DZG>"B)@TY=[:[QSF@/WYCE3,LL+K@8 M34S3?>GW&W>.<_O8+[:]^3]0F76-&Z\SY,;O2Q!XJ^>!J3S<4^>X2L!=ZAK M%GA)I\DK$5-JG3&X"50.\RO_+FNEQGN04S3;M]Q="3SYHS'#DELUFAGVM*:2 M='#[=X]$LV2:;>1+XC2'DS+FI635*]$[E^R3&7+M3^B6DT\VTU2 2+NL1[(/ MS-1;CT]*OK4%$(XTOA(47)G\ YF=$5N IQ^+C'@)+1A_UH+GGR&_L)HR2#ZC M\V0IOII;-6EP9-(=&_S[=RJ;=I"<0Q"I2>P1LA!UK]VCG9ES4&KKSY/(ICI>CCN*F&00W?"NO-,;,PM"6F, M(?7I+,<>9*_>2V5QE4+S\4GLL[]E)C#W,A=N3'6#)/$<_EC;])Z;21V!(+^* M/G,7?XE8+4@G^\@7)\@"5?31QL0BY[&ZS ,1PE-O#W);JD.[-2W(U*([&=X. M$X;HE-L(ME(AT<0+R!.//C@;VP\#V2/IJO>S;&61L, J_LBCUCH3C=67AG:& M[A>%\ *CQLCG8G<)@F ,5EP13.PLQ!1/Z.F,WUL2BIIHIF!#/R@X2[ M]L&?;HLWO.].=KA+'B@!#&K+!U,16E$K155^Z9F;J!'Y1OGAZ.O*@6ECL++0 MZ0L%#AQ]T> ,?_EM 6IR- $F*IAB.WZ.>H&. *A95;4+U21SHF!-488)':XZ M,EOCZQA[RD0+FYYTV3:8=&7C,TI&SE.JN)@H=G Y82.!V$%]OS62T\+RB8+> MB!_^E"J5Y7QNIC.U.6Q&I710:P+F!>MO*R^ XW6MD$H+9 AZ;(K55)ZB SU* M]DVNSCKDSHPU_D=3E%#M41Y'\=V3MU*WO8F_51:02Y_ZJ/KPT*\@Q%]3^4FB M+U\2QAG),H?EIW]9^O"&"2M0RCG>S'SVL>/D5H&Q4Y?:N_W=I;%U3Y M;1);NA0JOY0X7^W]RF'6: +\ @SI4;UXBI@PINCN2]M;IG%@V -_YZ$F MR<5['<^C:&E'W-Q$DWQUGCZ5E#0<.0F'2BMFV3HG_= MD$V^!CJ;6H[,]#X%Z&Q"@)8;GI798IEI6<_4_/]3VP3YC]JFFO^J;<+>("Y& MFNN_=@ '_#=AO0Y2#Z%NV796%)!P3R<4WTWKRJVIL9DX4: WO^(I>S9<^XPI MM3ED-J_VJS:9E\;.R)L/.*%=&.&PX]6(P10Z=NZ2K_[,=YYV_\&OV;F"5_?_ MEE]%=5P#[OY-=GRM.(K:?=WBY;N#?Q7"ZM,& ^NA??XT=HYV;VTHBI/O,^K? MLW!&A5P#I;"['*;\SHH?F93P,UE;=9@117=@0P*:$\S/296R;.CL-WR2AE&" M=U$@%4 ?$&I!\B=51>_ZB8N@=1U-SK=)##+V5*\[%KO/29M]E]:4RO]N= M!\59?L5.'7=EAM$!E7C#?O"S6-JXZ.SUN_SU'Z-*[R=_)\#6')22)MEP)2I; MQ^[+#*!GQ.'F'JUABA6?;89:^S> E/6C:$L$^VV#D1.B;^FEQ M51Q*:6(3'NP;JXM!B0[EQ91P&&AI!O6#E6\0!O]RN:Y_,-G7]T4WY[1$;3]) M&TU@Q]AKQ]')$?(&HS_:/C'OHY>U%SV4F)]%3Q,9'VP((#S,\]F2?H7Q+ M2TE$Z^5/269*@&KL>X<=:"*[[FN7)V&D@+?C"W^ &F_\4G+DD5N?@H6].MW# MM](&U;$13]+>,DM7[:B 'C>16<6(E=X[7AA3^$SN%AX/W&+W67P2A/N&EG8 < M,5T^2R]Q;4&A_G6;/TTR$4*OU6-0]!KK6M#LWOZ.8Z:Q)FJ\H.#O/L$^%B]( M]G\_4GS"9ZM/J[46D*"S]5<[1ASJ<0AC6JG+SJW)ZC/K+'"7U#"U:W,8U]S# M%; JOZU,%9U@X"\)?%1U5!#TWDS5KRE:/2!AI85&2D9D)QY<8 /IL^[NUY0V MRVM9N)E_[YTU^)KS&GA%*(S6:%2F7RU&.U_J;"59YMCEZ\/=WTI,&_X28LP8 M6-A^S>U@5!,E"J?3Z=+'L ;*J*SYT6-\6T ;Y%2BM'=K=HM[NV0F7\O#(*K/ M'6L_2DG8L0VG3]^:0PM'4AE^%-U/ZDZ74G_:T:%W9V0SW(0LV M-_RM"9BB&O.G0:HG)3+=J:"0GXER&Z.T4+,[!S(:4I3STKBP!ILW!W5FRJ#A M8H4?-(3@9(QX.F7<:G5M65TB3Y9U]ON8MMJV/FBL(SMY[5T\M)O(SC5PIQ$$ MB7P(>3F,T1Y=,$XP^4PJ&=@HJ1*8HW0") 9TT)M#$!\C=KQ]]L(519+% M2 P7/Z(&LECOPOJA$OYV)O^";HDK/LC?'\ 6G\E_U>(DW(P ^UT!)G-1VE)N ME_NZ_]Q_GG>["$%=J6FOCAS>(#?3T0FUD^\B@OB)-]:=VO4G(,W]9XBDRSE5 MH\I-@B56](.?@E66$3G(E,,T8 .EC\,OST!.=0'L?\SC7-%Z%7Y,Z.:!7./- M@Q*+!G.*NC=#@J??]F5^(:!":N5ALW3V#X?MJ^I),"9ML-9+-;L@I+/FU#/S MCROSJ4X@%;=X."&Q8N44^RSG:T0KH$>1T^:Z M&*6Y47Z8Q_;0,GN^YD+QAY3:_EVHR[9;L:AIN=!W#2'D>9W4_H1>[OJ@/$6R M4SN-#C4W63=!#J!,4ZL4Y&#,8MN%!RU3RBJ955HM%<[R//4^YD0P])5IL$,+ MS'1O?7;\UD3&,L[%E)JRH>$0R #_&+,- MR4! P*?&"U) G.53"/3P><^JL,<\S@T(@LNV8H?FM]NDAKU?QO;DA71+:1)P MJ T^6:5GMOTN(*6>OI0QCQ#[:=SZ""S.S%/ D,]ZUYLK'D;OL$E1V3^AEE$M M" I!6^V72@SZ417#%U\6SM@J6.@]*J^1C/YQ5/HR3I IIT>2Z0UB>U?1Y=W(=(@\.,RTU$KC?/\1-Z;=Y@:5YT]UV E M1_FI2VM\T1?29G4/!U@^]76Z .P3P8&\7]$)Y-W66[!N$;R_#0_"96:/L9H$ M<9;(?>2=81!QM-!IW0?[-Q-@GO<'3^,DL2],6429+I* OS6Q5M$<0$<^\3=7 MAW*$%[D$DR[MU^^*20L_W%@EXN*LD*C,^G>10+OI.J>3/,%DH^?B7(A41. " M>YE:F2JL(0I.^,ZZ[J/,+P5CVTWQZRFCZ[X"-.YT7YTNF?&\Z8;P# MO[M?M-\TOYC>'_KF>NOE"C<=-+#3EV%JWS%L=6^LP37W=Z+"U=(3ECBV-?CQ M*7Y6_:UH20%YI$9E[,@;QBT(H72L$\ B23/IZYOIIX TPXZB^]\VYY M@.NK MYVABS8!DK?\&[?NH- U#@')X3[AV_F7YT_E5]H/L[31YV"WDJG2*LQ'M8%7H MAT^\'R/*/47WN$IXF[]:QDO%&Q,L/VL,NH3_*!*-8JSYYN1!3+ $$C_!:A*) ML8O>(\!YL\WK57F!6@4F^"7Z2TE\XT2-C.KW$-< (WAU*/_RZ=Z+_EB[^F2\ M-_WV]ONGU\"4].A&]J[E(=T.5!!'#?2__2QNIN'B?#Z:A^3WEKM7QM4$>_(D M'V"RP*+Q7&A$J:;0:'R9Q[%QXW9YQM\C)TF3P8;A>Y=JCK2Y$)9D3NN9^"T*.]= M9 !/MHEERD+!D[Z#7K_ $XW]4HXDFP=)RIRQJ5;BC_KBNJ>3@*-M/0QGCE#+ MB7H*1?DU0-!W^..T6V6IBI+!ZZ->5-1LL23;.VKYR@"YNF4]2WW,BU?C= ,^ MEG2"\@>Q;?1'Z61XE^N,S@_YDBFZ):.$>R)A$':>#N?AL0QR[:*,R5^RH*$4 MO@A+3]:458[X?G]K?*](Y1774&91<.7HUU8S2L)Y#(K'X:WRFR"S.UVQ)=-X MAX([&L7RP:X5F$D^<08C J,$)0:KFO8M%)/8U13^Y M$Y6IKT9!XJ4*9QE%MC[^.TD/=[B"A]YR5#ZLX0<[:0S5:X"\Y(;;L5[/KI:7 M"LD/8T>PE+*&V+"O5D43(CE;9/S@%K=KX-9J[#H,(IWWP=WYT='(SFA*.=T? M'[#MHM=N)_K^^[$2DGX]9Q D16&QA=3$R^B%];+\@ZP4M#J('$J9\=-"'T[X MV5G!:T7,0M)@/R7U""_#>Y'"$+? LJO;X,'%$:%$L$==G@T; MHH446Z@Q=CAS6$3MU[T\8_C %#; Q>H?\ EO=,I/;E^5BOC5FZ7NO5^(8I][ M8/;N $VS+9 <@86E=EH<$]0ZGU4 0JJG'O+E=[XD>MX$^!OD[LY MJ5B(6,;>K]Y BC[4"G[KUGEV5O7'S8.4!=.*X63R_#N7$+W MK8R'/. !BGDVR0&'$<")PS40!?C^_)G_*3$:KP$+P35ILM54.H!WZHX*9R'[ M ?&+7_QFGCIQ$#PQZD5L^'-#3&&T(9#3$B?=NIHZ:];X>Z'%, M")-AB%0RY'E:V^5[D@.WGKC38P*[&>U#GA@_74@0US6V@+0W6BWJ=>14W]WT MH999V_(<>)=U9;#S&S=P4/KVT]O3(@O(%XB&[<>8;"0X/00=[0.D="#R[(@4HR$-CKY2S)H9R1J8$ MK:&1D4Y:V\ODGC5^:6N0?K G*^GC&[)F>Q\L""/VO@882+"#1U(^@SM"Q^F$ MJU4^+:V/SYFJ(!>@&AQ2Y2!MTZ1TC_P:^/DV_Z:/Q/C>?)5$P"#R_^]7A2NX MNQ,E9(_KO)XAT1)WH:/'PCC5?WGPP1-\/;G M('OQ4ZMTN('HTBOWN"9<(PC3&(M<4_?--4>KVT!Y-D)G MM-TY2('R]#;35P&7V8!S#\NH%6SPT?&V(1D9]VD?6^L1R^J$]CW3QDU22*+ MO1S?U8Y $DJ*M=_>4EXCI;>I4LO@$[Y4(VB00H:U;BKS4.;0UIZ.>)*<>,)% M6;&%XILJD#2NLHT%+#2ROZM;'!R&X? )- 0:J,TX5D',3GRBG2:ZL_+7I;Y MJK!=-:8;&DAJ=YO1Z1>6%*CPM9ATR'KX32E.RMR.1IR^F]6?ER8VCC;*D\C\ M$$\KU$I\J6Q5Q&5G\9;]._.PJ=Y$DJ]6?JO]9EXRB'0"E<9OJB/VQR2?J,BL M0+52=\ZUWTR2[3ZEJNRZ0!]WBU///:B)>](C^)D9-)9;]Z.VIKRL/NX^6SWY M8._5?!XQXMYCH=W/:2(5M4=<4+OLO9J01WXO"\A\7B/V6_:?*N-2LGW *\W)>]WAQ7[BV0I6#@@!@C\.6R- O4>H7?;$E'[[EYI0 MCUR0JB.M ,?"06@M&]#_:[49QE\N:"XY];4?A!5?R M,I4GJ!QU?Y(NOA>1P+G13Q:Z^KV=NH?9';? M1T6T6>9"#SKA(7_#G?RC_.GGT^C:%ONHML7T=UG;IY]1:LA!H_SZ'C8.3BF( MOY[N4=(%!<,-Q_;&FGP7BDWF7E;.JGO44QW\2AE#2.=9* _G3RMHQ='V,KJD MC.R?#5="#0>,ADQ'MBPH"3=C) MV*&N+XDN_L6C'M)X(XR7*MDZE="2C*OBS<$28CASIA[=DVRHLZ1Z91;7OG:Y^]4#F9?36U%;\,%V,+T[@&]#6)9);\O7)6Q;8DHW%-:LZ4?Y>FD#P7C=> D.8N M5[-_!0R/B^Z1V&F_=$(9)?;#-3 #^54.=A)*/AXX(QW_K^H6QVM@/+_M(NL\ MJ6@\F'?TC'C!Q>EIX$L=,6@O\QI ,.$[6J3_J2Y1_J)R%=I[5+@6Q1%$;1$? MI+?J%J%+AUI2-T(G 16Y-N,28Z5VN:VW:AMC[F-2(@-SQ4L+*U.D*:2'9OO_ MPFJJD,]"\F3']TO9S_@6F@;<%XT2F.>K>KJ4+_[()/AJ\Y4+B-%#HP"-2ZE] M$YY]T:XG=J(:"U?W5?^V*S"[V/RH3PI2#2Q5U\G6$,.'!YS8C?R[RI5[+\D0=6[ZR8)=-L ML2J_A)CP2"Z:I!/:_$3WR-8$J@L*2K%NO]]_Q'D_/AO/! 1C45Z+"(;!,-,) MMG#Y81&V>5-WG/:W\)9B;JD]L=T^0')S,JQ+G#H$\(=R8YH -H[X8%<5P:F6 M8OJ!9A_S*H#I0 U@!HY/&-_ .4DRXH 91H32IQ:() M7$/B2 B:R!+:EW#"\\1BZ4B46#I1-CM48U.I.!F35_QXN H@#PIGETZ0TQ-0 M$;V[X=_2;WL.!7:W=?+>"S"B5))#MF%WOK^/:JW ZQ=$V"H0;EO2<95!*9OD MXMX91QT*#?#6I-OZ5J^H/#;?:[-PGB77Q;MQ9I=_"Z)()064/-7F<1"P_04O*"[XF&=V5KJ[D0X6?Q M>^E@ 9IZ1'"@5V.JY"@,K,2+!R+^_FR%*SH5+$_N3EUC4S;:2F24FJ(&Z.XH M48/A]X,U7*-M):UN ,E&WZKGW;_DI.@-+J/^GW3 */#&.+#[3\MNVJK<*@%] M]SCU?V["+I*328&7X\B1ZNIM5Z=85AG!F]D19GX3BZ^($NJGB"(?'U)GR0PJ7=+?O< MD6.ZR@ONC]/JC%YB)_.\LS)!2DJ]58XWQ]-/GA().EZ#J@;(PAB#J:Z ( M]B&2YC:8&BQ68,Y!D4W1R:)ARRYN Q RN3/GD] AQ/J?6./UA,G7,!&X.^O]ACII^6Z.&-IE/? /K,W M^-$O:$!N7<9R!6^#/2&3 'TZ'H+1DYW7YT0XSOL!(OH/@/+$CH39W*=P&"*. M^##=I C/V-8\-BO\+MO+W >(2JK\$'\S4"M\JCA93G5:SZ"@R&UA3$,WLYTD M\%.6PWX[\2<@_I5:O09,JZL_Q/UE MWXI=?/<)6@,>?:DVO#+J3L)?_*OHS\*3:4!H?"^=9-L>-RR:F+?,U)!*:#YR MH:V*9TGB&327NYOCF2K]BE%^:,M/,./A9L^[H1>-*S[+ANS=&;3\^X6"A-9SJQ< M5HZX/UD_2N_S[I7]HGDKQGI,C+C/J!*G3+?>QR.%";KYR-_B( RJ+?WCQ/?. M^H8V]T*9WW ^=*L)M$JDQ9 JRI,"/Q<4O0;213CN>)=62F1T]Q@AU)Z5E8&L M.<#9XA?,1%DW4P%B4(KV[K>O:*"3GPB$_U%33>C,@V#?"[JF-D>4N,=Y#1F MRBY+(&,1\$!SG>6/OUWP'FC(&\T^W%O"T8RO_DB%KH'/+)A \N@Q\VAI$79( M(ST][AX$ Z-NL#I.MSHZ2D>Z]RO0K4?_0E!%:[0WO9ZGOP8B?VO^:XUD9RF/ MC!=8<*C):!YRB3)$201:_:,I );A__9BNO]#JRW]Z#'N&4AZ?/9=)\GQ@7'H MAM8K@VM@OW5T=T">D\XT?N+0*%=S6S*V6C.K1':J:* MCB'"*'@>O@*3CQZDX*QF/K0_[\&?U#LC.3'5GE-Y"8P0S>"WD+.U4H,S>TP@ MQ5EYU\;O#D/[_C2[7)*V2/T7(GBGYM:*,C/B Z4^P(YU9B3 ?=/X_EU+[QB- M!=V8399%:6 IWMGN-< .;0Y<^W=U4GC-_>+)_)D5%@')XVM@GY9J/, MD\*';-U.24$_)P #UEA[-EO XZ $R$5N"@:T5+3 MJ#BVKXP+M>CBWO/B:@AP[_ZJK]AS9MW;#S<>GN3D_9XFO7](OK3:]&Q0"?$Y MHHN2W1X0*$'AFRT^D^-_'$0_H: M1N7$WQ&841*M7!5YVNZ3E\;B(-7>!==J@A$ =WU8? @,]*AL[-+7XPV>"QM. MNY0;\]#K:@;HTG 6E6P:C@Y?E2OUD@@8ZKG6=A; #8E96PE,.YFS7--OH MKP%M+F=42^506V/]I^P+0._/(N+=C\ M*2UFT_-YTC*]Z/!7,16FH/L^0BH41?7&TOK (]?'%YT-W!.?=($[ML=^C:V+ M!C%9#<4\6ND*]\J06;NM?SEYIK_$]QOS?+G MOR43$B<5?M6<[[[F%.;DTW_ G]<_$Y36$!*Y$\!X]K,2"K]XNOS;9EP5U'<- M\"^5\_AU1:I%[.8R.K$GBB_@XPN16NB+Y' MHEE,.; M,!J'XNU=>\Z*QF@_JI+>VVDFF-EFE_WN]SN-#TN]GU@^-_CFW]B15=I26YJC M'WKN?)"*U%#IV;\7OMVHD]&7\XI)T@^M!!?LG;CB)E@1^VH5M>!$/+UMQIO% MSC/YE] )MC06M9W0'U_\V]R3'N65+5B??"7#6^3Q33\1Q+KU+A57B6=&?MT (^,/HB[\$CL!Q:YM'Z:02"!:?^.B&S>%XG5NK,5Y%/D$L/H&I?%4QD2,S1L6GD42N@FN)9N)DSJ%.TF+FMF8O +I M5FVA)W+X;+IW]L!>?3Z[;:449,]O7:IYLKRM_?.T#D>-X[STT0056&-?-4]B[VL:Y]-[1 M[_*IF]<$A9_MOK!W[*KY1J!:]J.J"B7EBI)A2A[/O)0^\ZB_FUM46%B=_OO+ MPL8/@FN@0D.$\BP+C:G'F4 M]>FZ@0+7D@*!P0V/ :U,9:7&8YC "Q(%X M#IK'>I:0D9"0U@'J\!(T#,M@XI&\Q #DW2^,^R5J58_$)=SG)B66)4A.M7UG MX=(Q+!R)8*+H2W4R1# U8E>2:]E+A1&F$ T5#Z$Q!+D_+X\SBI%EE ?:+5VE MN]!&,1@FH4E$S"Y58045NN(3,AK)'#PZ?Y3K6'L+.' ^*H;^45>'9TR9O-U_ MKO5D*B?Y!?Z?*0,"\Z#>=$KAD:JG(\<%CI_&#NTR#G#R-9%YUF:X8>'>;NO'F:X1C3RL+]W! SV$46/#\B;MRU? MQO;=-C,"G88,[Q67$IQ]\3(WB5S_VOS[\ VSW3 MJ8$2P#FM?I+X24^.A>[DFD\1F$2$P[P_:'':DTUL]ZA4X:QA(>''./N8?=;/ MZBQ-2QQ7Q;\904"^T+63 (;* M) #6_Y%M@+M!>NB)M=>B+58LDI-_03,JP0=(,"W>HH2]VDE M/X@QD9\6EH7%A]*):TJ>;!KF9\CE,Q,!CWF_PPT/'G_$/1 T[%[8])1^-Y&T M%3(8&!K(4K4^N5)*')X]O:$'OSVE:'P-5/IRGW(V&XZ)&*7H:=>-[*A;U<8T M$%Q*SZF::A(!6S35JZD2;KGR6DQ?OR"M/#[RZC< MUHV)_&/PRFRBQ",^KJEB$P;^].-+91;A,;40+_=$<9ND?JH2M.!;16Q-_&#% M4#PH5Y0 !O2\J&,5W507++_+9!Y=[Q,I1SSX^4%0U[0;Q-!CF7?JU)'CMD8. M8+LVR]XTR'_,R*W%,J[Y\7^1A M5Z#*&YT[E%\2>W]A#H3QV)F7+G_^#7.!^]@J#E6/ME<+Q4U0;UI/6AV,QCB( MD_=54G8.>]ASW/:FFT?CAZ4N/C/^^H#C/G@52N3//A\-,CKSA*/$VD3O1HW? M_7'^)75.UN3M7G1[GO98?ZD[!"N2)KC#))QV97NZIF>+H:,&UA:5/I,">2\& M820!"50_"/8*E$#%\,IS! MLS1K0KS%M>:VAXI-9*MLG$0DH:K8&"R7MO_XH M3?Q&YCAYK"+?>ED.23) J GJB?TU^'1- M)TD.)H_#_W;2&Y5]LLM7\Z6U&I.J8+(/3L9RUGF;WOK9^!Z^B1I--#>]Y[2$ M1!-G^Z0@ R 2-I6?!Y)>/_']]":9LC[=1]?NQP%^%R74H$PC<(/=-64"3 "YH3QO,X6)G8CFPGKJF9#%8T3_0DB#\:L"V,ZR7Q0A<1LTN& MN:+"O@4M(VDY#K?5NB1M)\9#R/XQ>;[J&),?1+>12QK,]D]# !+=9DGVR,_/.ZOH@?OMOIWJ FV!JR^?7[0CIY"01 M*W(Q]EJ<8J$Q:_P*E]UC$(WEK4334#HIAX:$\1C9)0;73HX7=&_"?8#>UEA? MARZP3?%O?*\^_:3;G:G(K+3^3!=#$?/@WVU831 ;9IOI.KJV":$P$X=,WZ)FW918XURL\[TGJ)ZM[#?A>5 MX*!D\BQE%)N8-?NTK.AMVHBB +Q7@QKE]X(?$Z_'V%;[//-!:A;.^%=H'%K8 M"!X^70QG385+N96J[9GDS$?);\_MA77GY@X\WGYM5GE[5;+:H1UY],['==/$ MX"I^CQ(7V'UU#=257 ,+*7D(^\ JF050\O.&7Q=6 ^SFNUL7-R(K_0EO;O#? M?*B'\/.\!F+_ZWF]_RSD#9 ,[!FT_T_W2*?DJ?CH%SKPC)Y#K^B2!=T\F/_J M+,P+]]QYN2UU)[ U4.*0.X.'VN,:.!AZF0@::OZT%X82EB&UF0P0?#3P]-TU MX']^0UFV J*.#LYHSR(!^17@#ZB92*[N(H3PPJU8Y%59$(QFU4H/SXN9[V>S MX(:EO.TLD'F0L[N!-R+Y2!GTM7:-?^#2.C\^T\N USC.B?["6!(Q$J M65[[V"RGT!_@)[>.TQ(RPA MZP:$Y+Q;0*GNP$MU=[.=N4VPBX%W;\:P.5ZMJ!S)ZE[Z+0?SL-D%6KZJ>B)9 M#P56GB/ZS>.\&9)4Y1+V6HIZ8P3U$9==^!;6K1"<9 M[YK37*%NF,S']?&#[TL8VF^6+S^9=1S#%=R^_F!6^ MVTOV\<-)I0HR/P_I-J-3_%!ZO):O>N&2S35HP[]0H>(&+%KC1#X^4':M) ^4 M2*#+:\[F;GONK_P1OOK3B_-];E^.7CZK^5EV7\*=?,FP -._.)UG M4X355!$T./]0&&8LKZ8B9=1 R\#8Z=82^"OVA5-HE>GZ<'6I/:7)GDA8ANM" MQ"/3>QSO*=_IRA%? T+)X#1/FLWC;B\KS:&C5Z3MOYY/F/\EX; ZE$EQ?^HY M5K/WU9[30)/I;E.4,35M[-MA353LVTCNS$J1_UQ[0R5<^3]R,]ZONP&9'VXG MT#R97TTO&L,Q*:T7M)\=E(%??^!H31 R>R>VD?^7UB<$L^LY0UE.KSESAW0. M8Z_CLA@CY1^F$NKHKNRA(Z-B1\.:87[$X0XC64LF-GX[\O.KP6^RXWE#EO7* M#\))#Q2?U'59XT?VW:Z^T_C.0K9*?0MO0,90^<%=I>(J.KJ13TITN\TU::'*'F+0\,_A1LZ8;+?U\T%>S27D,[QD<"!#'*6_G [8U^D M$")($K;%W2HSX[ANHG@--/5V8Y<)65H$ME_KO-:7+UP_E?!OI:"9MGS:L[X6 M2/#ZD2V#6WU GF_.0.?4.A 63?R&;B%HP'G=<"^PN_$?2S$H-[,XI"9Z MTX$\/BT6^P]3P6GCW9R<_ ^L4&G+#3CZ9K[<5 I/LNBU!,)<#JT8S0$:2_J4 NI*G9XU+:W-$!V-C_MBI=?BO/Y3 MAGIV-5ZY=LEY(-<:KYLLSH=4*#6/JX2(%1/WQ+_ BTMJ'P;>5@*9N*IU#48' M%HNY+R((<&H V'D6B9]]&W::O>&UM5-^:<@R-;9&_ M>'6X%Q?'86H[ L+_?D]BE'[%?2%A6?AU*J)=JURQ5 M%[-E%%[[:>_-13X%X//SI,S1SGJ8HU>(NXNF'#Y.LXSM"O%?+)8MO4N?*5=+ M6-!V^M-M%M@;O6I[9:7]%7.(1^885!DM)SF>PZ'%2Z.4\+)Y=!$A[=ZR9Y*1 M8W25Z\Q4AF'_3?_PS&>,?$"HG;3[/O>[DE&QTOP'9>5UL83H"'HP3+KRK]NV MV/V0O-8I(U9><"7>079=0JTJI G!?? %[XN3MFM0$E:^,X!R6$HYE_%U17'R MX%+7?OX+RF9)O0'LV,? A1G#YY+SO:PR[%0(S(@FJ,GOZ=@WO3W[;[]D$Z>> M'E"-+Z\%\NMI>-6R6*_2]>Z:Z.RE:==5Q6T^;XA_)Q1P@-]*4.N.'2_FST#H MGI=+H$&"BU'@QU1G+KNJ[QR^>K;.>*@T%N#2HOS:G*EC_NS7?TJB94NH90WI MN:3P?]?Q*Q8!/8 6M38_7,M2V7=N#J4Q;=&0,@V$P"%I,E& TU!ATP]W3:%# M)Q^?R((1=Q&7Z6T/)&5LV,)5H$K1_7<>+T,J,4,(87Z9D:*'_72GF8.-Q7AX!ZU#W%E_+NL15A?_W(3==]<%U+=4)7=;[B281 MTR&PV[9ZZG/W*1HB)FL);$]H-N=(CCB&+\4F*R.E!_T\X+$W>!0>V#F.I)O% M[G5%AWE(VJUO?>:\YI73#ZO7[6IQ=541;'*6 Z [A0B'JAYB:\>4""/!:S MY\4NPFZ/YSM=%?7@/Z 948:-9;AS>VJKQ6W M(95M@((#QPWKBE1\_&XO)<)<%&[FY55)5:V+GGVS%V)B"BM<86:G3+^<]3">/2-8]% J@.B8 MUMR;VTC$0[F3RFP,4_1 L ?@:6IT72W1F6$R0=6MG/I"CGO/'*;J&* MPM*9:V.64@/8]NH]:>" J*$4X+'4*\Z+8-II*/:CHX_CPKUS)R#.P(FR 6]& MMYXPRNG$$EAQ.0C1GMZW$'U+*6>P[V MSE>FH[-DZ)[_OA0AWSG["XC9873>N%] UJ0P)_UT,C4T45"063;$BA_0_?[[ M1'\:7FWP)IP@@O]?AZ3TF\J:KIW=VP&3UR)<:O2D#?OS-QE^5?^D#B;SW&V< MO6BM@(8R)"#TCWB']78'N!VR0F%M%S_[%EL[WK4X L+'4$60LF#'!MQH0D%% M#QS:2EQRE[/\E<>)K'IG813!0:8W8;C'FEG@3Z;%[B?;ZJR%2I':C#4L@WF"A*VC_5CI@)('OX+\!J,ZTIG 1>'T MP5?#JQWJSOSWIO8F\9?F2<7T4-/$SC$3$2PGPHQ-+B;RK4 )H61Z7M8O\SB$ MNT3'&3%T9LG#3B%K#3RTQ/B"DTN='Y)QB='I Y\;/'(@#G>"FP['KV@^8^W? MZLY'_4/5FX*_0'T[^AE=2-RVAG.#WBA-3CF'ZAFUD/!WB;=PIR;(*OBL\D=9 M9>XTHTE3>&B?XHJWJ3F[P4AZ]:7T15LO_ANQK2C8X>) MG;T-T8%[$XTI>XY7UH<*S0I9M'1;TUAA#S/\:9&]S+AQGB;/-G-"['>^ EPO M;QIB(=DURR;3KL*I^-OUF**.7F%&S! !1>0/E_^YW"!\BN$+>PY:^@M(4'NY M]A=WIJ;-FWWV3NT0OH?^?[+H.7NT\U@/*0J[%L1Z)9K0I1QOVA3UT2.%OC,) M5/,&D0_]%OVRM#(H^Y5M.4US\P0.J:?B %6LGR.^*F:"0KH(N<\-;.'V!4;[ M5"E\EW&E$%+U)!3[J/'R6CI+[E[8=IEFZ_3H+Z )?O03)I_INK/X?,>ZN8;[ M#4/Z;.6_#W8)#.$B'T8-M5QJ7U&$WOB#ZS]KWK$M'"^8:WY(D$C[Z;H"_Q2\ M1?JUZ%$]$:<)>I,<$?6L6+AL0W&P;T6FK.;YF:LAY'6&3V?/D#-B-[/XFF=)\(>1E21*HJ M*XVOL1JCA48T<#[F]7)AYPYHDW_3R\V^J&ZA>= M5H149_QJ0SY*X?DKQ"SBN[9CJT#L>>%FNCRV1?V=S(*O=*ZN7A\?I5[OX'Z# MD(Y72/^#B][)MR)2AJ_[D:&$*F@B(%+'B,9GAETRRN[%BLB2C\4+,DIYPAP? M@]U.4&\K"Z_(K*>Z203;\\PW\I)%&58@;D*;"<'JOZ-Y^DRME,3QS4+PE-T> M%!$MXO?EDKJ[MJ;)71UZX?,PCF#W0\]*.XDO"E? @\XC M5!X5/'6=/Z/.,<>\4N#EV\L6CC9 '2H!XVLHUNUTVCCFH]L*5H#&[@YDKPK? M2O#3X4=2$J,G7D(-+7Z2T0$7^1=/8\E)V]"LE^EA%GKT!C(,9IX;FJ#I5_E1 M>^1U9ADZ7R8PLXQ[T;HH6JYR4!A*2CC$4\2WJXY$-]M3S[!J!40WEGQN'-;> M>;'%WO2IW)T;L.7QN+M?,?@=\+X75-\YN[ MUT7DX?1G^20%43Q0!BW &:-/\6CYGPQINOX!*HN M[NC;T89G4X=3%HF*X'PK)=<)44JPV8M&8:_PE:QW5"V;&^&WH(I#LQ,4O0Q;*=LFYR-@+XA!$_66X) MD/N]YZ6D+6=& 7( S*T 2=$H1;XKXISK$U@!\(:V<%-3:=DTRN>ZX&8;)L-W MA0=,9%YH_)+1OQ.T\C!UM$+?-L0"EP.DEN!,)TD#6V5#>_ O:\!#("#J<:)_ M_UY1DDC@<1+14?,E"<@+2/#.W R(*;K.!P#>0^F6-R9O6R( =TF3^,\6Z&BT M .:4;I4RR([G6#>F="L;LG]K/'FI&N2=R5;,%'0B*0/\,6VQNJC:IM7=*V?I MS0-J[ ]TBG>_%:6=Y#S*.4N<\PSRU7_\4%SZYJ,'Z3U.*5PF K:NJ\;"@;5W,__M,86V./'_OM,9ZE?J8(6X[W*TUOI MOHM*TI@#Z;R@X>3!/4O^&-9_Q,>/S&0S$J,X*/5M8$HG90%5UHC&1:P;IF.DV[$[IN"$,6CD)%X0IGR=OUFZ-8$NT M^J:-S3:]DNS]+G+N5Z(39I3)D0F[+HU*\7)#W8DW,SP,5*G8.%2SVTS1FE!R M/!S'GLL 4DY5FJ9/B(92/EX<2720)R_Y"IP9MD_CO)RCQ0BY7X\UX>MT9>$D MW.SRFE.\%4"_P2#]-&6;@CJ.TJ>6@_%KY5.'" M8#CW#9SIT5<,8_YW8Z&K@ M5WL"\672-Y=1_JYW=EOSX]+UXH+29)*Y> BOI2SJ&M(=)W9,H_O(FC,RYLNB MOQW_=YX#P7XI"C)7F0U9SNZ[!1$A.%UP.M"/,3F"<4)N%$ M+"OQ_0:]< %:O30K(9K)+-YT$A1)QU^_/9ZZ+BIS4;5,D)TRS10*?)^W;))G M.*TFH:R!YL1H_133&G5W,E<'0OA3]E]/.=#+6,<#@IZ*$4<&(1^<='$S-UM_ M;>$'KMQ)+!X%[6HM'U-E;SC%[B)[E^6T*H.RB@J<_ 5JN=M!L\;*FF7DQGM9 MJD$B%!PGV/W1HZJ@/N$06=>O?P'O5D-$O\X_UJ1P@95.3WHL]7QI=H!W+$4F M67!Z'/F;\/-'V#]&HU-R$W^O5!WSM5HH#=_X?QDTE4L-C;QJ1>]X.76A."DN M:XF]NT]]OGPZV(F,I?<\DTMX(]XQYI0!G+[@6IJHS66][("T%SZD]Z\WG,5> M[NMO9:^6XO@I"!YFG4D$"_!N\-MXB.N$3\L*2;Z)[WAB^/ZQ)GN3/ @/>.[; M1H#S$N_WZ-:+%>RLM$3GQ*O>I+A,$?>#,Z9#T#^5\$/DKX ^0\(LOMOCB(U6 MCV*_L$Z2J/6GD^]$'8)+07IUG<]+]OP?'2%RZ!<44=J!DC:%5JP-C"/\ ?OC M,&W@(C26%5X&PF+-;J5O KO/(DL)[$7$T1,J&EB"$\2UIC^\ZJ(2J4Q$_7T, ML/LD+H\C*[^FQU=?YG$7A(PK2PV]910Z%Z"_P6/NZJI"%Z4$%3!*7?#(O^9& MCA41_(,H>4&E8[F!$XKV> (,F5[=]-)7J33^!7!!#40C6#E2(K9;N620R6ST MEL9YU+@SKH=Q1"^YC^0AWD$*G8X5VS!7B)Q*D2A^=WQ4RL>H+.>5_>*6-,H$ M0& &D8>"^J6^VSC7VU0'? M2Z$MQY+?I,6NN<"[*ZH,8)@W62VME\P9K9?;SV:N'=-*QF2:D^D7^\\ HAM0 M8FP?OOK8>DK>3H!+B78>><'K*@J9JS%,2\<[&_DP.;C_,0+UF(;) V<^RC!T&, M3B+D&.=9X@YX2T>.HU5&J0WC_+Z9&.9R0)FG0 M 5?XH_R@QWIFKLP*;W0@S))V!^K'-_/EA";0+(5;V5'%BGBKD7(R+#E*B;Z' MA*@38=KHJU#A=S<>=?KE\\;;'!3<./= A+VE?5%&PB'*J.W+U:37[TP=46GI M?2(^OG4*<^OO93V>A+]V6@.#RWFEEA(/1^E[4E*+K676C.I\$E=4$OOJ)&9O MT1AT6MG0\"[2[L,V1!#S\.]3P5#0T^'J"XFU'6S]T%9H%U[7FGX"5AB?"S2J MJ1<9U"!6/]1//8M4NW C^RAML6GTZGGG,+;K7A'\8.\1./MH M4KPHV<89D;P,C#J)$#\4II(WY.M;J=!=G"@6\XS.'L'X[OUW)_4^*&6,FKZS M-#6-5\CAO#:!D@V->[OHN(+P^0=;"H-5:J^05G/99*E,8M(0 P/K:X, S[] UGW9OH'K:-VW>YML]2D^AK\R():FJ/AN MKML*+W[>.B/ET^_VI=*B]6IN<\_LZHT--%YESN!8-MY1 TTE!-"'&X MN&;L)"J&QL#W'+,KH5WO*C-E61O0-TX4S8IRMIL[1&&;D+4$I=S&+VG?F2C]Z M30-0'2.G?XGW^.Y1=R6;J:&6.0,4LVU3F[K?82AZ%J>4GR3W_@)SE:\:-2?0 M0]?&HS)-IA61U5496H;OZ_>0/ IQV$20+-KD$&U'1?D;]>\*I523%874!(SA M),:+I33KG0$"[D)7RX[.14XGUC?9A:O6'L:3@V\9*V\UW-E5#*P(2:@[(C7J M4E;=B36AOB.GV7+CR#SV)V6DP_7I&_%AJQ^#(B9;SFGJRK3(^"Z.%.SGWPP" M772'+;,ULY2N2SNB4,-CQCR>K8 (9U*KK21IQ]F)=X'Q]"F74*<[U88)G)6K M3Q_H@U]_3-$GI?+MK.KO/U9\CS * (Y>^^JV9=$3\2]3#O9*LA#.F] ^HU/U M4U]A'ZO\)1NPZ:+?>$<63;_D2?0?JP*C N,OO9M=V?(=*BONM9K^4,/XI4/% MI,7PNBX<]B@3_"('$Q/F$"K0K:F6+;^E"-3J4[^ M-LERMQ?$\ZAVG!D@.=*J 1.YV\_=FZ?"0CZ%E#=#MKCU3_Z7O'?MJ&.^#]-K M?YR+96%< EF?HDC@0J6!GA7E6UEH!%+YBH.#SJB^!$>&OO9WOK(QFCL3M5KM-^HV MP8)@Q_:7*P25/@-<\?/62=NCC:PA(8.LY\^_;@8B+\-/X[RK\NB9,).!%C6?PC'YZ"P2U+]:(W/(H:/;;[7 MYD&B#EYK6PDL8P&N;XN?JC7K)?@W,S&E+X.MB-S6IH2F@6!"Q98@^BNAI !5 MG.%U+N\/WE06J1\Z'QP)SPI_&#"^RI=2 -?3(7XR3%LBZO6_G"MX(OO5&-3# M35 "[V&D&@@(9/&>R_)R7M)>E*42(7!YEPI]S?-4VG8GV?2DYO:6TF-A8"N' M.@3P6;TV(Y7BY<%CZ3^$B[/E4HN0!+TL@&Q MQ2"8"^6R[_4RFV^]^BDOT9\U5QC?QC4B4M5>I?8-16#*6XYC T6S7?48_+XB M1EA:#D15XO[.]A@4"RO0N]08U'4_T(&_4H0.U":P#OS#97(5FJA)"%DH_XGF MHST7>Y"%H8OA)5)-E6Q[ Y]I?T?3Z F+9%V8(S\EK.H MTLR3TL<=H'T]#SC5ROHWSMA;30O>%TH1,CJ0X C1]L2HR]1BT-S#@R)"_R@= M6.#A.M<+^A=X^,/[H AX0Z]R0'/"V=KR4F2B@NPR'=A1) "&RQR>GY^+2"_/ MTSXA@L0DUSABEBB41!YU[ZH 7(07-KZ%!R#RT"1A3P?TL"=#7:]IVSYR=BM^ M,DU1#9=D/G$$GBP1U?G;G)Y*4@I*-/?5"SW#NM;^_J[0Q M-J^=X-*3!^/^O$>XN:ZDFG$K?78_KW C3:?US00+TSU@!<+Y%8B>E-MF5HXX MU&WX$=UKDL0U/>]XW/:P4NV>@. M/6M=CSP=]^7I&X:0W/X7MX4AMD^ADH8 -,%;$1SQ9#BCO=6MGB&'!*DN2NLC M'A)VZ$>_?)2._]X8N-Y#0D^HIY5Y('W>Y*Q<'^!GY[&CMR1-8;@?INCGS&^>$TT=Z!XCHBV7S) Y16P^ MJBLG\[Q++>.&":$(<5O%G4R0_;Z#M;.]VWCW?8FG5]7^=P*[?N7ZKQJ^=S7% MC61.G0\^D\V$;/S\I*A,QS-;>OG7B]X4!=K+\FHQJ"_[^[(D=O<('5?OBF)F M2,,#>H74CZ\*6>OG)%[C54AX!\U6Z-T[:TO_ROL!;"%!U5V=-:5_"'TC6^2< M%B%^(Q 'D9E(W'NKI8J]MC0)9W>UT3KBD/71^;K&I[8^D&F1A:S]B1#S4PF! M\@)IF*X'/D=<*!"")-E_1-_Z6I=I/6VX$,((A'B-5;B($.Q8;KW59^N.VI%P MT1*B:VH)^I3.V!&J1?B*P37::>!A=K$7OR$@TV_UNO-)_&6\L>Z"2N"ZSQJX*/^H\KK;]NIF>2C1R;DK'9(S9GU]&HJ[++ON(S9YZGR!F2WB MV5?@295KK$( T\D[-C[7[,M*=8,[ *4_(5RQ!VU8!%R:T)3OR M?B5T:T-Q.$WZ4:R9$>,S1ES:WX[KV;>7!\@A-6IT]EEHW'2ZY"622(HH(27' M7^#.3?<*=0I*HE3*N98F%W,"E89^)=K [_]*9FSCWB ,P56?'JWTC+(]ZE\L MRAM8;!W\7[$(#R8;UZWN_@@32*QPF@9<*:?;M%L.A(G42[+TED?5H%S>7F#/ M :HB' 8D*)CT"&(1.CV0TR%V@]C>O/'>1F]]"L3RMZ)C):QCF M!8/F_I5FXCE'>Q1\1V3?O?,/BMPO/*V+?7;5C.BLRU@P99L_0P5N(9FNH][^ M:I>2T6^C!4Q*DP8H+$WNSD6@N[,;WEEU]/<8(,*UW6T\AJE]*8&>/4M%0<>F5D,A<*G^7L$>R,[QAOPF M']8T,#/(QJIL,J;,-[YMBX2(1M4@^%X67_P5C:+IUOTDWCUW"&7C5AWP'DCN M(J"RB)GQ_DW3V-X0/H^<)2ZF\,9TLYA@,$$G12!J'=W77FEBT[FL->KF'5RP M3^..W<:EJ"S#;BW>ES#9*&WY+R#3X&56 M7=,ZA*AS\QN6X!&A8H"8 O8!;)&\MWD9\^2_:5&)4"+H$+F-<^RN=W/CBQR2 M-4!-I3P%.>C"1A[&6AUCBO26QT\_):21;DOQ%)%L2"K%0:O9LE)@/&!2'HMO M,H2LCZ.QAPG #]D\-A<$=WEH3$+Q]8K99V)%=8(#]*G/L_5LOLG,B8>*488C M31H^[PJ"]T7(=2]KI_JW<49[8EWD/XMM#5[(@D58ZZ:A$ >9<&A A^[UMNGT MS<72TL">K@Y&:-]#@^];P?#_B$%+.F7]3P4N8ZUU\90)/M9&;9'MG](/!XKE M&CB-3L2\K^Y5 F%MG9)/ P.F5OT7FY\NQD&QF^1%JPFKFW1D*9H$IKXHX.+3 MBZS>K_1\MD@_,%MZ!?=G721M:#-OSG6QHW_0#5X?1@#64OMT*6BF7Q+$DIRQ M!/L++@NLD*(I3\FP3B2W%%J;N5-C'0U#7^T)J3+4@4'B9EK445ULK//Z@[?(:/ZVJ"N$FH2A.)KLWO]^Y9Z 3 MJ@B>(?%;U@Z)(E3D4E;%"JM$J7LW &1!?!_FB,_R!;)0JU/$I/3ZTX\0.!=- M<+GEL..O<] )Z=XE(OF6.?.K(I5B@8GZMK03X57L)DY*'8@UB)EX;RJ\]JJ. M1;!Y.CMID5PTA5@FP%\$J(OW.Q'254:#0-\.QRB4,O[HD5KU#7;L19AO?B5S M:2G.@21,UW+3'W!)XUZ03I-<*P15K?#@G[;H5>G^&4IFWL+X\ M1E(K$L?-QM>HFY7.$-O;'-%Q7OGE+["!<^9>5($ZJU'WA6BB)M3=L 2+W]XH M S@?0[CC[\EZ5]V=8JUT.=@!ZTZQB'JI>R@VM[;99K:P5_P?3]Q M+:N X[FF\6NJZ&>8RC12RL0(L=@@B?I*T-'6^8C73&7D"_O!0WG=MV_;-BX^ MAIS\/FZATR![>1#B4*\?VHBW0N>(0P_?37:I[EVV>NB)ICUR]>(795X[/0PP M#K+X87(?;>[^".!M]C\/^#UA/8<*#;YBDW:PO;I:M/OAZQ/\;7V!V)&[GHUN M2MX(R']B'+WQ @A42# 9#>G(X""\/R*.W;&I9,@B@..%-B)#H$?='B7 M!Z8:AAFZC ()VD.8"23"EU%0>=_UPAM&'R3O+1V O?_DUX MFLXG-CT4>>D3V._Z%XJU0VW.;H);+BO.Y"U&PYX!,/%*MOWU'VD?NSR#Y?E! M@?[MYVVZR,;+&:?K%S?<;$J-^5$W/!('DUTECKBH[A%HIM'T>L1^A:^!7ZEE MW/[#09>KH:VX0! N7!+ZX#-GMYD-V8_$2Z0-6Z3Q3Z!/7500F^.LH N"/:;(0"OX\.<*&I(K8T[E_]..'D?VR1Y>>U)SXNZT)])_B: M_+/K@\<7CG+VWX09U*N1^+T%0IO,NI"X\UINIUAK8'OT(O-I:(ZWU'VB5'R/ ML737 7A+OF*=7XGHV]^Z10TR!1UY;S9C5!()+-9G^U@5:BTQ)3=WQQ\M%X2= MQ__K[[#UTJ4/X$]F?*H:;G4YU2], $/=KG+ $U*HE$&R_S;ZY,$O+_A#1I%3 MV7Y]]OFEGP.$IZL?&9!U<;9;\-<-Y)MA./8?DJOAYKYD:C7\3P*:!O+6A_"; M1;Z"_#: M)%Z=G(CB\Q1 %N;(VEMLM-SV9+]@9A^5L%2SW)MZ&6>.L:NVQ](4Z*A ? MWHV#7A\Q)78ALM!AC?"UPINQ6B?I:08TZ[D @+SI!Q=!@PJ);XZQ@EQB9P[Z MGOL)W]Y4^3O\95&E!K)G:QL;+7L'9=1T[+1U_GK@=H3-6&X244(6Q^D?$41 M3\0(?1.?)>$=L5PWQ7A<+E_IW;W(,I)$M@.#W4AZ*T#V"9I#YK[^D+.K;6SW MVCWI@*$_9F1WD^P45KGB3,E&+ XN^):JC0V_=GU24!$ANFU(7!NESE!@A:/G M..)YHU]1!/,8X.A=!MU\['R(6$?!%IZQ6Y8@;?/X"Z"6ZSO@ZMH:HS;P.HA( MY4"LIL22W3N9QLUK\256?92IZ(/QD=R%KHYX[9)FT7F<9^^YQ;T/Q$-7I#>8GPW)I(S[+ &RW"B(]C# M]1XK[(?*-0E@SB3MK MU7_B$<"*$7@IAEB24//R=Z\CCCH=G>F1E"=_*B+"P40#Y?CB:YE8_)MP 8_- MX8E7-A)15>A5_+C[EV[/##X;0C]3^?1F,Z"L#3!6GK[!OJ+[ZS**J!0'AQ_[ M'K*Q-)]<^QZUD/YAR.$[!__Z]O=1?KD(<:C!AG8:2.ZW_[IK$=1 M^V3XMSB EAJXIU#2LNGEU&I0!V\/$)/CZ#,.L&ED;LT&2EB!7C5"01)2C\O> M&<#@G-N2,&1_4G^UGX#C3]O\ \)J*VZ//OMTJXIKSUI_=6S^VT:AO>G9V.Y_ M]1AF>[@YB_BYKE"=I0WMQ"8DF;H!1J-*QX;QY@#RXYH#@;1?C/4%NE>D4/!6 M+=GY@AY@DS38D<<-CD='CC?A71R*\_]>=D!86CQZB]OSJJTK/MZ!Z%,OS[V/ M(A)A!&6KQ)<$3$MY!7W>8@UO1)2-^-"MA@+MVF:N)K>(]Z9F2[L#8ZEC1H>G M>JRFTK<'E,IRPT!CK8!H]:2E:QC6BEJE?KGEV1;&GJ-"C14)LX.K@TBAJWC1V.XEW]<15 1LWB4; MQ5F"MC9##)4A_0H,,:H1TS4SBZ,+1L%O_K&?][%[^CIP[YB\@G^;&]^7FB#> M.:,MZOV.GI2ZYCF\S">V\K*2.Z5C29)4H+3:I)FE,HMU/*NOGIXJ<2*>XULB MTRMQB0XJ9ZR.0:*H+=Y#Z=V0!=PFG]!E[(C,J)^'U[L_EK!!TJQ*-#V,!%(7 M96PHD#V%YGJ6)4GGJGRSI2256Y[^9P9">4*9/?X\^0-N"J9#N>+@EW,J1PD6 M%J>ELTK)LU>_!WP UGZ3:*EH^.\38<_$!XVT+ULL7KEC2.^-&Y&R%0KER?V>I_/5GQL'-LE9L4FNCCO M];-)C^W.,/D44)&,U=&]GB7XS$M43FI3?+*A9>@W*,\:")DB*Q6G:\/E5(ET ME\NRX_O]RNPZ;>J959'^O(ZTK6SBR/Z'_&C.*M$Q(P)Z&))%!:2ZO'[<'8SK7V' M*T-TGQ\V[% *'4=)H7J;687I#9K#!U5IJ6:Q.$LZ14Q]/;'#R+S:HT@VDQKL M9?,_/XT [FLVF1H6!-S*)<"KSA9T& MZ*JO)07R'&:.(S\BRKTZ6O87*U?3 9"0(*DS@K#,8X(?+WZ6H!R O)$>A8?C@HCN-UE[B[PP MNW)OJ'%.7\SV\;&&*992Z"IK'W$.RB+P[@]P -S^>#",'ZOCXEIN:]Z*\ '] MO!#^!O"$+-55Q63.#?OSU*?*G]=78NMC]G0*F&+W_5M-:I27\_*VYQ!&V\KPY@6E=PGY%P1%!!%LL%#XHC \X M?B'J]/@0?92RL"W29$7"]0+Y:""CD>I+,/&]X>SIH92.?5E*D?M[Q#4)0%?F M@'.7JG!6GS+W$!Q,*R[^..J'[%4+(R][6<31P]I@JAD*%S4ZC8)I S?T#,(R MLTR<;7RDST)F&8M&R4;3/MCS,[]-7_Y ;S@0:*U#3O#\UKY.QP3FQO%OLV5: M5+CTO.MN5T(G0N0?1R[N-P7/9BN)R7<4%?^P1$ #S$MJJZ6ZAL# @]IWA$,) M9$"QT2I*2][/SV:@U66=S,+@',GC04Z6OM68]^- C1'9*Q]1((JD,5^JSV5M M*?YLY'*?:"TS5<[=!NWH9C5Q(*1D"#2\O(F5_?FEMKHZ1/>E;LGSM+->".?, MK&ADUT"!3C+N88NF!1:ZBO957#;:0B,:5L<\']=('(ZV?\VY"\-[^N0V1CB$ MI,RNK1E+#6P34'B^P ;A/)9+)K&L2"4("&B][PM4AGQ_G8+%^QS*$9(&4XH5#<6.;*=] M-8T]O^+<:K& K*L20O^YY:I 9Y$25<'E &/S]7P#>DA.\7<1P*^C MGD=WZFVT'I2L>'[P1-"OQ L">*&1\V#R90 /M!L)QW=^15L8"7O9M]'N3-,: M^&.^K3N!G]!1!I6B1L^6)<@D00@ I!Z[*ST ]P;K:];"7U:C[C M/$I"G<;']B2$5/KJ.%Y&GMOB;'Y_^VOGXX]T;D1C)L=J$/H>^^]]^U?O9GKF/I_;RU:YTLZK\_/QXX6;/[WV:<<2,Z?_Z=2JJSSN3"#'G^T&5>I M;S@V:6%)HU**!YVI5!;1@PRYE<#<]5_@BS[7762YY0ODEXVL(-E3-8XH$6.1 M%>/\ '60H6M'SBL*7$_)WE5B [3#+*A4'9F"U%3H5]=XFH^]34L7F01$5.3W MP.QMYQB69ZPL^9O9UL_8@8]:35IR3' )[H1Y*+/LU5_ O/5@3/4N[_S=BQ[! ME#J?WFH8<UH1E$PJ/'=JHN>^^>.?F5956WO7QE3)3UGR< MOW]?- TEVW6@"'>+2A"?]DW#O:/_2^9"&T,Q=#>TT?L7*&2)'=5"]E[Q'.MN M\HV-6*5(Y5DB^_42ZPU<%:(S9T_1E/\..XJ2=Y;0^GP([=FBK *.W6IETFFY'X+J7EB2*'/^P>UQT-2?KH@K2\] MVQ2_NKCTIOV.$@?Z*RDC>\O:WP1:)+=6=YJF:^Z$6'A6:J8JSE!ED'[]8CH[AYL58$VHL6XH.ARKV%PV+K^\U[9;?N2_))^K7Z)DK9[B6/VZV0F$A M(/9TD\@QEM?&7=%,9O M-=YE(3-)>HKSQCV8H8UH_[! '96R2GY)W0Q+'3/[W7?"/CV.K!!. ;EB>$4@ M^/%S#+]-@5F("3/B4.*:8(_GN5)C63HF%B2G5$.#FS";\19G^''(=U1J6<&Z M8CQM(<#,&$M()0/(8B#^=,81RAG5N+S1AY%5F*H2R.-FD[;9*/LE.,SVBZ?3 MW>RWE, PA53U&1JN&Z6*-WJ_.(=NU&[(1HSM'3A>.XU*YN1@>.M-3%TSR+9F M+P\G0'W^09,2.XN8@T7>K3=E7X@U*90,Z!385^0N6MZOC.([@LE"?.:Z!(UE M*\$=B6"+X%H9!<=7@'LJR#HA2C5@L75NDS;\^AOYX(@M;0)UD[E$$E;:\76E M@H[=>FUW BQ, $%)W_*&)"1/1T^[CY'V3LN9#K33=#TB<:'NT[)4E)AC\IZ( M4T]9)Y>=.YTVJ65^NQ[\X^EPW/^=)Y8@BE*Q5J%M-D+J8W3&IEES"!6E0H.- M&9W:0%R5H7?0L0C^]]0A-95Z<4H>\$G&OLELZP<[M_SEKN\#;\-)C^-D:=3R MR2""DMX[,FPYM*129!!.QK/EA6J,%BULJ7ND+R)OKG;A'VAR[7VEGW^XV!'5 M$AIKU$6=_\QN!D]F5^AI6J\RQM<.P8X>2<-0(Y>],]W'"DRIJO)J^*H 9];L M A\(O'8-P;H>M@C!1#QBH2%M"F"-7P8M<2#L*.X[.!6.^%DA=X8SB_\,Z-66 M%(@R;J/X+8QVK1->T'8.';)-^&VB8^DH#ZDTTJ-I.*?XG4'>X% @:4A3@'KQHH5RQ):X]!])P6GTD>MG0G4[6G$:(]3N M&G;3L!-V33ZKZHB#]YQTA0F(?P%6^:[9@EFFV3&MM@B>^7?#\\O.W19OLCMF M:)+3W5&HP3QD?T FW6$R/BO-$@74/>&Z)?U?92CDU-EL_^1ENJR1;Z9UE(8L MA=Q0C.93E>2 X-(KJW!&*GH3GLQ714GV[;UM'NN%69_X*G*G7!CI8"I//9XW M5ZO?R;I?<]L+/K>5KKW@+#VG=HY7=7 S7ZS[.3V% ![!<TO-2Q'\:G;'UXC\L=K?.^@K6/)CW(O)'HPK"OW[AR6'5]KHOT?_083+ M'YD0Y4#([F:\OI:S?U:43,25.LS>M(?'YE3R_0\_#QT#G#J#AKM+)3.GG1ZZ M<)'#"S@#">N7.!]TH, KFV?K,>A^;CP;+;=YY?# M-XT*25']L3/UV]&):SO>+^:AIM\D M8%<5T/IZ6.@/DNEN>^0<(Z'F^ =;+!@,@Y8LUF&VW25B=I"(>7;?C+N)POPB M]J%>I5^H%N&J6QD<;8I$M@Y]F+KPKQNX(]3Y+"L>NBJ]9=-H@O+I58I!N9O7 M5@& 9.9'1TL6WE?DC=;?<1SC(A8'&V47095FF (?=A0\*.\U[CVH>&=&&;IS M +_>#YE0N><$=0I^IA&U;XW5QC,T/./?A6,BBE)!72M4-L'AA%T/H#)GY.9, M/-&L(&C&06$*SQLO:KMB>()"3N4W ;=*[B]UX1\^-BSDPIA>GZEZ/[\"G!.6 MR58M^>=_"+*)7A=;O*K2K:[_"WPE;=J;FPR#K9KZ=3CR.\U/V-G?JA34&FUG MF*.1T(TJ6 .V]%/R5;U1D_V=2I(_2A]&HYG#?!G-,U:]GGX.SXZUOGW9ORU6 MGK2D-NP(QX[X07L7IGW,72[FX'%M$VU#I5*/7@/K&(;F$."9ETP5"4;&0&BTJ)B:.RO;H=-)3Q]T M/1Z=2Q?=]4Q$CP].1[E@DZ0LY">W[BF;_0LL7.K*,@^E#7Z*_TDE!?:]Z:6O M:^ZE:M12V?G#0PMVLXPD?6](T.Z#,?Z8S]/M^8=0,/9NZA;L:># IJ/P>L!N M%W1KVBG@R+)4^N/G7:"=:7J^W/TDL?=6)L(S0XC-)VE--&GL&@;?7Y[%8U?Y MWP@'W5?[T*.C7%\M77]G*\SXF4LO76$P?85Q&JX0NR(9>JP[F[LI:*%,[=%J M]?21ATCH.ORU53EZ[]?\$[1MB'7@KH1T/9A:%3/06[U/E&,P'H7YF J^<\:& M\/ PG<#1'\_Q14R6?-O-*&@,YIU#91HA+RV/UF>RQ$D<=XP^S$U>)( .9!]C MDQ:'_&9?8M@5CPUE6,O651Z=_;XS4LM6WL)Z$3R2V/"3 V9A,% @]+U^=/;] MF^@B"E?6XXQ@1)'U8Q"/P(M^$G"WM8HO,L2[""[TUIAY^%PY7QO)HQ$2L8!K M21[!L/L+;+5[V//PN34(?0Z]VP<+5N!'R;2W$D/ (YI"Y9:#P2[%Q3TTN Z! M%9C_1%$3IVJXE7Y1<_Z33<^Y,G<^4-8F\2+(+=8H,X M"J1 7MZ<5Z3(#!B809=.L3FE:BH*?P'%M=._@*CZG_^#NL,Z,%HZO(FWLORM4M'%\!?@6-'REQ5!T'F]E^?\5%URI%@LE<<* M;\7$FG;E5>KV>P#[U=OS1Y-+QMZA5Q>&GS>3>*9%\0>DT%TSYWB,(\+=VO./[E*U_" M(B@.>/E.# ]7RQ.A]*ZL?GN?93 4A^'2A063J>)#7>X]T0R J[IR8F,N+-(A M0D$#M%DY$:*!G:JF#_&3!99;X1*WEV@O%#+6_??DFHL(!V 9((4E_B=[C4ES M\1XG]!CC)P/N^VN3##6S58]?M W7/W+KXB/&N!/.ZD5I1/\"AYMP^KAV^W<# MX,+3'67Q9M]/N-2BYD9S%!OR:C[\Q=N)5N@=05$_*+2U%!;,XS!+HRYX> Y% M*$1]WS1;/>%4\<$-OXV_9HV?;7G8>B*T;R>[<[!B?#0Q:^#&(5@WO1S;UX7 MVVD_.Y0L+]X%;DK4-2?5LK/V?TF<>EX$_OBSW!FHSEVUR'YCU7:O,]9?$;H$ M+?M$G%FY^LFC(2E;-5@O/$9CF+>7G--D"S5M[)M,GLPRA.F-#Y=W/DF6^RY4 M=%98D21JV;#IE@^ZKE"^[IKQ$P?;W^>/F6G:Q\/SX^J@,8<4)N8RX' M#(-JY%I - ;KG](!X1",QF^Y7DCN.9 *VY/R2B:3UNITFD"UY9BPMR&:E[C\ MTL #R=E?(*B=,FM)W0_12V&A0-T3.W;9:1I2?'RL/_^G8O"(3:-A%DX[0B-9 M[OQP&^5* =$K*'\>HAH%V2G*$U9Q#JT\:8P7?K##T/T=T_@HHKL)%\10G#YF MC$,[93J^=<2L1JYDF14B^Q#.2=@4UOU:EX!W'LHE3*GOLUG.]_"@=C![$BX47'6G>8/S^]U,!H^B;RNO^_K%Q]MO3Z]]B:9 MJXW_I.U76QWRPNFW_&-E;3ZBS"0@J7[&U'!GFZG?-A/A09U\<70$^K(Z4AB! MK.4T& K.)$^FJ_?+[>>7Y*_/5(M,JE?B8:7WLH7C/?919L_FJ2O\Q&/NX.@" MM@K79"JMW%PCU'0TI**03*:S5N@_770:>_PB*GT1;Z9CK/I6 -\#GIK(GJV, M0BEQ"; WC)$:#UL$IA_=VL(?ANU\R.O."L\^;S1MJ"[.SO$L0X191F%\5VF% M#EP2Z?69 M8/B4TT?I=GSII%JRPA4W8V]9G](G@2:LWUA,DT3]F]V^ YI=+@UY2 L')Y.U M_?CEO;Z-E5;^N2<9Z8N&(.^^%M,%LQ31*.OUL0XUFTL"PN&IUE1)_FBKG6"8 M-1 H0(QGP=LO+*<1_T0DDHWME@S ZZOAD**,Y,-X6*684R@/T6TE_9U,@=#[ MP_-JN/*BZM:B:@[$^7L$'?#_Y*G\JO)"(!PLX+,Y]!> W)EO>KJ1B9E?4M=Z MJ(LR)#,$\KPMW:?_QV;6(&/G*EW:NS6E\W?RZ\L'E\05G^KE!XEJN <1B(A- M#O7^ ATK%-T$)*F1'^J>Z3=_VXE9FBLQBH/JS9D:! .,[B-N^/ZW52%WC2\& MW9_)_@(MR$U_@?Y3_0U][/.B6))YBI.%3VM)U23 ]5+(N_.T?PAN7]N)^2V" MO&=9F..J:F2'YT0U6#=B-EHSV-D35 !@)^Y$_P4\'3M(XERR=Y0""9QYAYC] M:R]8G$F7P&T YJI:"SZ%FSRR[^,Y2$-/0U>S?8@194).CEJOK(^7%IQ3Z3I] M,CFZ4)0B'L,951M\U7%HP.]9JM:[KE'(A(.LH% MEPH%O2T0E2FDQ2?]C>&Q]KU!?9A8LRR"*Y"U;S:_=9K9#3G<(OL]HC%G+V)L M@,T6)Q]!I9FVCYGY[>C$B!X=Y:ALT#M="1%F_7=Q[(\_%1F5M5 MA3^0=FH"^GL8HTSY:Z)N>\#4YS\Q'3MFPU[OF['U7YA@RGN03U^,*)O5!9%]X1FSHFOCV'J>G9I$1#4/&>\*92N@.CE1='EH,?K8IAF2\S!\JT)'X+667/)BN\^(M!!/5]A!" M.!L+RVUH:A))(?'VJF[)]!KF16CS.M9WX?Y2,">@05#P0T8\OSHA'N&W6%A MK((VD-WG7=CFM.532IRU]4B=9J/>?* M\-GD=X,Z=CS)D+UODTKQUIMGAIUU?1Y3-6'?8UN73!* XNT[(>VBH6F*MA,K M=2Y6?GI[M-MY\G0!_]J23\I\IZ13 ;VB8]I&RZ^!CE*GOCI OVG:P8&QG*G" MWBR%5,TL7*L:ES:GV#B0EUB=E4'*^UU4@A]0_@HBUSSS(7?J./'9Y_E?65.0 MN?D+O/+$Z>HZ;>=Y.JQN'3X<]Z8[$OP#&KNB"-9NKR11^"'3;%?%>^'4+":< M,%?^1_MS8:H%O#3NQ]^-\7M0__20Y+]W:RNLZ6N-64/51;\N8 M>9-P Q'VXPU$GL2FY^3/[.[4A6SWMW- M$Q]=W.C. Q?NASD+EI<^OM@LW"B M1%*;+P6H1+V#Z]P?@S+].:^XOE;>>?2UOS9O(Y@ ?X2.RW1P?#[.[@ADV#-& MH_([ZRD6%J+,+2+G'5?!&]K^F36@)>+J0^0_>FP M%5-G>L"V7'_?[<*/NQO&+Y=U?UWQ]">+]"[:>$X;(5)N;LM@=8'W=[_?KVZ- M;VM6<]J"1[-\W_+C]!#@4+?. XB3R&N9#0]\<]9V(M,$&(FQ$!56#H,%I: P M>KK$_T7:6T75%;3=F@MW=R?!+6AP#0[!W3U8<'?7;-P2G" ;)P1W9^,0W&WC M!'?O?/W_Y_09IV].C[ZHJW518]4::]9\:M3[SGZ#T!_K8FP M:QB '(VM7F= -\9?OU?-:1T:LD8+@'-'0S/<5%D"8F+BJ^Z5IV+XS]W2W?9K MZ5FA(U(14S_J3 =2RDP_"Q7KAZO1\AZ!5Q,Q_*^V3@1NE'P'!_#S!*TP)L_# M4IXK#GVH*=73J(XF*;>#>=#]$F$A"^\+FS5J<7Q3IK]]88&--$N96K;.+-)(]^!C.;A%+(T<)R#GAM('K@V4,E;9013@H9C(M]J)33NM?> M ,ATV!!+6%Y950+\VDO88";;U.!LNZ:Y"%G"/Q>HO%)SIB8+D.==W%1P\X=* M)[DJ<[BI8@SNSB0U/# 4Z[83@Y@&U[L4 $N-UI' U9!W\QS$T*:1>\FU4A& MR'=K.@FX^Q;H58VS1#I\L!\43+"[@5LYOS+ :0S?W=8$;_TTVB,V$LQ=C]]Q M7EUC&SA$HPABC29C0&HA.)G/4%M?H9U*['ZZ_GAUT%)?'S$^OO<&I!(72C37 M3B)]7+H7&L"5*8U87$G?J9U0*09\^Z!P<"*'*_&^?J@33;.$WL_]8GZY'2K% M1KB1)/!X\9TEP;3# G_]4&7@DX4>,S&)4OZ9XWS.LUC T+,;T@$?;I@"Z=!I M[VRL;>(V'$NB/AUL3Q@,PM?>I9VY=ET]GW[R4X7OPO-W3@XK7#2D"-\V!]4^0"/8-%N%?O*@3=8=\ C?I? M>JB5I[7U_:Y<+@. :O*Z=&H,OY60G@KE8..SF%FQHHN/*-B%554:KAY'1C:+ M)]N4O5AH(+UV8#NK0W2-3JK)#).!YH/X;H*C[]PGAZ^K/G[KZNUR?1& AXE) M%6#2E3ZXH&9[ DU' &'5+5>&M!>^;*^M""]TW(LI)$_V\?9>([4V4_KWOP$! M+6+I]OW"6#\'JNZ[E!OS,)R:)]Z D_!]JIB! &J)5YQ0)'R@/#:60!QP)U / ML%!JR!C)?5UFXLRI842L:Q"BT- &]7X0'<9TBWZ]\L-;_NT02''XI\4O*MDB MH56%*D]#G")4'O\XU3U)[A4O,^9DVW*)&I'#;?C GK"OMU'?L'1^OF_W8&N1 M@\)E@6#J); >9G>#(,,ZXH\DH:1W(4V-9.Q%WKKRNIR[Q,$.HT,+=9[O;1Y( MFRL!0](%^V7$B,E9-!QK=B&JE8L7&M:6C0I3D9#*4P$/XAOFI$G)@? #L\MI MZ<4_[;CUUAUCMWA/^W8L@'A9I ;L0R\O4H?! G2AOR<[FHFG9&E98)+RO]PT M,2B>JSYLV=._"9)$VG7JD./RO2R:8:C8NH>W"YL0MXU^!OR6DYGV1JC+QKL! M+QD9ZAKZ),I="*B7_\GFQ5)E2BXO7:T*_YI&,@SIZE!*]L--5M%DS?LJOZL7 M-OAW0S"W_^:GO.S2,A_,C^B^R$'Q T[YVV&$LH8KN8@5+IC56X';\BO9^G.O MD&['P8HT3RI6/SQY9R,:9?SSB Q0_%(I.%S:^2(F6;TJ[L 5"ZJ6YI+8#<+4 MG*M *V/] '_QDV@'[OTI@!,6[%VB5E'L'4BATT?:L'\;T=&P5LBD:Q50(@VD M)/C/HZOY1'+HZ8@,/W7IK[><3_P4ID&*4>B=5Q^N;>1C=@N6NZOD?*U#!80# M&.%D!F_Q+#Q*3.H'EU7696LG9E/=^:\_&B]+A7Y!2"M,4ACB_*-2S*&KR J[ MS56 ?V)NB*[.C+Q*%*=(\%1T<9./N;\EFKE R9[NJ*!O4.3XZ\Z.1X4FCY-]70[?YH5K91_;F.[ /$D=T0!%0(P;MJA(;H+JO9,W/L>- MRIH!2+GQJWD0XGPL+J_5_OUDWUBB-"N+,R4:!I$7VR%G QH:VQ-Q4E)OV+7: M_TZ8[H*NO@'_*?S-1V?Y[Z+>XR.J**4$>!LQON=6ZAZ1BMWC__'@\ V(&D\ M#L#W@4,_Q@'/'8![Y)5GRK 6#JRQP4/1LMM\/"#,"T-^?9V/O)A0#Q-RQ28G M(^@V"=>@(\-EA"NZQR$/"Q8@1N*_&0>TDV#2Q?O@*#H&?#(&.KCT>"I8#C*^ MV7H.)TUQ'#]L=ZC6G"F3)3=7FN#9@+7.3VY^[)9$1XC&S?[[3ZY8(W!:1K-W M #LDZ+O60;UY*PY\)P*$J.PNJPE4E?4FR<,71W>1VI](X5&Z- MY?]RF;PG%-Q^!G)6R1^7J2#[%.C)[;C%.:LQO=:8TLQ$Z_P*PU4]_<0V'8AGON4N9V_9CJ^KV_J,!2Z(HOT-++[>*=J"908RR71[J_\L/JDB MR5]$&2FQ]&D_$K2E)E^A+KX29SQ[$VR?"ZOI"4^+3S=NAJ@UYC0L>>\;S_A+ M5-AU7;#Z?5OD)"=Z;X[+N%#&LI%B2/*AE!8)QAO: /B:!+^^U_/L+47T2.^=B_Z [J)V^]'7L$ %BSU\YO=R&]6%2\_ MY^WM>Q(M4IWBVB()8L/L'=[TBYH;FQM:=!W-_7QX MPWY++SO+2("-1M%G:'J^_@H\D0S>#6ORW =/5^JMK=3D.GT=/Q[B2!8>(^42 MQ XJR$=U^85;X0,*H^'Z(&'B:SGRQSH'XJ7JNU\ IN>5CT"BMO":KUJQ;8TO MXW%9TE,1@CJ=0FFMUX,_>"L?GCR;%$Y2*GYK,!;:V5R8[=$LFW"V'VV'.:]U MWPO3G8_A&_*2A,U+IUG,TS".__UY4$ZQ^EQ\E1%NOXO0IO7F[-M92>[@(6@F MCUF"Q(KIF5],H3_K4V>H3=5NJ/=N(&R[M!>5N7=-!0YO_C\N/65C.X5>GE+' M:UU[( :+&OYQ^OGGQJ9:WV"(E(2;Z1MY_)'$$88L5.SOFJ1Z@+5DG;T]6A3C MGZ00\F#+BQ41^_;[E$WI/VL-BL@QM8DIS/&UM:^1O_PIMD04^^=)JU(QL.M_ MX'>^ 9N)KB"1IW_B,Q=(:,?;.AE:91FYS&++-ARJ%>&2;OP&1 M4[Y_&J\"U MU*"=>WVK["2K7$8LAI]1=B2>F+I\SP\']CUH-[G@5FB;P@G M_J\K\.CK-XM!TY0^@6[#D76[B7-V;!"(=4%ZKS/ XB(L&I"=/^"<;\T8%.T[ M77=$FS7W75W?H:XAD_[+DX05=7PXU;'J#ZNE'7BK\-8?1"3#%%=&";$E?]Y= M<%6GT+NWB&?MDLOL[&P&*0P%^&XK$A?X%>S*DN6#/J"0\+]:I!SJ^S+;, MQ@P%+_.UR]U6G>&MBE+:H!1Y*PPID3[,,*7U4"SNY_41S LR+7,@[\?/]=I> MF"RSX<\+-^!CO?<4A[H&-0Z]'!_\S;AAAJV3C^#-#WLQ)KCX%Q :%31GWL M75DQ]DG,6C'Z9&]C&<1*JUP)(SV(* _GZ3>S/FJ0C*(OW1RW*K&'7?PCU1$: MBD)M04V:9_^A_\GV#6 Z*([TA&9;GY=[A=%R0>E\,ZOR99TSA<5L?(H2"9>_ M@ HMA&%1Q"8JUQ/U9$E6#, >;@5"%:F;M*OTB@X:N4(Z*<_OOQOZ:US@=UOX MX_&]RBA<=QC?/0E)S+(KB[DY[LH60*BJ?/BZ,["@1M(MK%_)D_U2WFN07!/\ M;]%M_\?#FWWPP3^/:&GXT.P_&1D=1^U(T%I(+%L\]QN >W\O=C.O %QO8*V1 M3:+8-/'OGN QK+H8B52L>XO=IL'* M'#:PAX <&'P#3LJF"DQMZ>Z&4#:D;6.X;O0MTTT4BKW_^(!7$57XN[F*.Z: M% D/U3.2W6#KH]J]1TWI)C5\C"\6BVV@Z?2AHZ?H*V/8,WL#\A,&.]C5F_2J MBN-MPOJ8-Q\#/XY+"#3I&WE>B[0O%SE?0S/4?27U1"^/[QS> '3_WS2V,-VL M+M/?AXZ=NJB8:/$,,E^3E^E;7"S8O]@ M$&$I/?\TH]P^JPFQ1WP#LFCK *1M7XT:=]OK6S0W6C::H%'^8EP^:.SDI$7; M0EAL4XD=@V+\U=\+<(X;44I'!AW^#:0#4$^Q+Y5H!@+]*;'RJT>W)KYYE!US MV6%YWNI;Q9ZVY)!]D;V#N:MFAROAC<]3F/JFWOE-/D!0*(:FWG/]HJS;XA]$ M' K[0>7]M7P=JFB9BE;RUJ1\6ZCZ[;][GU)[&;?K9T?KD8D.$%B4YA*CK[NLTK\.6W1T!69?:8OPEI:7K6656&] MBG_& A5>R(Q6*ND2SY()$X5U+=QG\3)]C!07V7/S,"%(!=LM*T4VBA$]'AK! M0KD;T\'"D&WC%KK3,MX\>W[L17Y<3J?V_9D#EG$P2C-\$ ?!$*T%4M=\GI>; MT"1?YE+BR,2:JV[FK_DO^Y**BU(*?SZ;VDSY_^5L\WG5A,EK3UT&D)"\QA?. MJSO/M@GSUV'#^E0KK3Y3:BX0OPO=V9+=BK=/%'^?)MF5ZC9*L!;KO_/#F1Q[ MHQT)\+C%AZDM]1[5Z_K/M9#C1.=W!,M+5I33+" Z$UQ4#&9 3\[36ND@6*DJ-HZ7[58>V%!/AKI M1I23NT\Z3U#C,J\Q20$))K@326&RH85#X!,!-"5*A@12,&D7T @.^-K2U-8, M.F'V;()QF5DN0]@DA(\\/+6!Z:%-BBURG*;L=@07F9::]@]!$#PW43MLZ<9! MK.?*[PS".1^^+<"5WE:QHQT045(OL+GO:,/DN4^'_/GG5R@@O4ZHBB)CK3>] MQ%!5\Z:AX[QVV()N[6JJLX<*X*&=GM\['Q-M2D8S2R/L:4) MN'\K!Z1/_=#-?@ZM.;E"*_ AM>3W\!5$7Q#0\:I!1R80F7?&+I]XN OLD4AJ;;Q-!W)J&EJ MM9+PVN'?)@RR%)C8=E7VS03,Y%%VJ""9\^'FR) GF@=M7BS)D)/,Q;!7$>A_ MU:)7^$5\%[M *_9%FXT=6OI()"JX9(R)2EV:X"'S2A"&Z3-1]1N?#JZ:<0 M%4F!QR.TA/JJCI& T6A":>J;(<1Z"JG1NMP?&+';HA1VWRJ>16=VV7ZP<3L^ M[)_F=L+/AGBKCF2("+$[ M=O @:INI3/E;YICHJ%9O2IY;=61[UPF?TD FE8N\2VE) MCGO-K5.]=-P0R+FMS7HY6(B"73N(GF9/F%EF"O5Y\I5@:L4>)G48W^J'\K0@ M(-;;7N:OQGWT[DP7+@=B2@PQ%6$^N4MXEXO0I'J,_AFUR/J,X\A@/EB$RXE M*HXC#KU3?)0K>X&]RE^:4^9=*$.\#CDE!\LXPX7T=9Q+'1-YT3XYN79C&E94 M_0F31Q=NQ_@:--GA*W&AC\ MI]UX1LO?=5D,#5681"T7:'G_'#10S.??O0%F>EJ6!KK^:0!,(@J$ID9_$E5; MM:VSV)>T8X6>*8X#&6F C5Z9.^RZ^+^:5W*TFY5\J-DR M>,+:SN3" SV_R!ZQ[,EKA?X6&SH0Y'BE=A:_JRF_(2%^_QXGV6W2[EPE.E-W MNMV"*9IY90-&,)+$"'*&Y1B4 [B@M_$!WD[M^#?@-FZ"";1J BU-V+XFV")6 MJQ2?6"XL!)W=GRA%#3GT<;=*>!4%QU,[,.)$SQ*%Q@=<>LOKO1;IBE99N=Y. MYX=R&9EVAX2ULDY<&S&*1N1AY&4K<+45@?07;!O?&OC9G0KDEAG#WYG#@ZQI M,_<;6[XP*DL,+?-3O=@I&2J9R'Q.=YODKN3DV5(=6U:<<&:1U9I:[_LT M_=&FZ$FZZEG6[P-2&O4KN8:[DI?J-%VZ@7TD2!Y/2EPMDI53RVJ-,MU!N'>% MX0H??3.40ZXH3X;VD8LQN>]O4YZ]7VKKU)E VJ=X_BQ./GRONU(K)86^B M_.?=[+- D/]RD>JHU7L8)W9MF2-I2;>?1X3IWSP=9Y ^J'&L-24,18>'VA\Z6_)M<<(-=%YLK$.0^'BB'9'WS((WF *#*7*;QD MF+/K*B,TR1>_S8T+%W/N%T_CB0L/H=>C\FP3/+ MOB3H>B\8+VG1/.2R .(FG[1"):'\-3K5FGP?'Z8 ' 1I"^H,2JQ(TU#>6VMY MY7Z.^%_/, [/@#=@*.(GNF5 G)#E_G*GV?\LM._,/ .0*2.:=UZ29*:] M1?Q0@9-")RZ"P5/9*IJ=$AA(IQT9'Z)(?C:#1"C2EC91S>CQXA0\' XFHMQ) M?-#CC6"CKCL[ -.Z!@LQD:?UI"6:F("<\@]J.;;KPVYL%'# MB,4\!J4#N*%5\/;KN&V-JNCG"8)X!Z.3ET,U/V(I+AUE/)2)XSE?\6$LGCZ- MC?ZR5?U-M8FYDC"SGL?YYQN*Z+"'0SU@:LN'*&:\H5!F[SH/FNZI5T!"A]*) M#/K-*K$XKO\=6Y.G$;C;"_Y@I$BNUD=07!ISNR?SU+^?CW2HA1XIC2J_RITS M5^Q09&AXT$3:O\!IT.>(E$C';SL1%+9 D&KUM/*]CO](&E#0I&O_^KN0B,%U M/VW G91@;B*J>,U.B(+0ZK+PJ[///F*+9^_+IOB@-_2B1N,^^E$[90L+_6 ^ M_..45"HCA5:4Q@T/S'ZC1I+([*5@@B *=NE1_]S'M5\G$^([%@TL22W!/=2Y M.4HFYSN-B=Z1D"=IL:E,TR;*-A7$8.Y9)EBN1<-]5F_XZ?+JS5+%6GYU_HI. MZJ:ZQ@N*E\8?3,F# G+A21/,L?Z_81>)'^)M8'73N1/X=L7!9#J)?H$==C95 MQ9EFZ'(3D\'E86=4=J&\5B]+1CT)DBOK'4Y;[%%FZ;8W66F8Z>#18)SNKY9- MU_D8-?#^?'73^?%/!I%"WQ8,(8ZC2<203T)YN\:1Z4G1M[3VJ+>ZW00\=H%7 MFRTO(F7;PR M=D"'-#4U*/;K[R(46,N>0IIG[L^ M@[LHB/8=UY 6!05Q2-]SAYA"5E,MGY,%RX!OI6#"MX_V!U .I-0")(3X&="3 M>^6+FV:85JO!8B'VV)_29#JJ#YN<20F&7RKL7-D&FSPU"?0<31S]8 ?+/X-/ MN&2"33F!%Z$9^7=%20>B9!?:8>7>"B;H]\EK#JN6/>X5@Z=+(G$^JUTMN7+A M6>GT[TA\.2;M_,N'X9T&J<1"*.P(J=W-)2ATLC5(:*D^^VRG@MQ-U!@<6L6TWX,8(2)KEQ"KOP$R@-7*:)SKP[O M&O1>#JU&2&3&:"WS,>8W) ;ZJ M<+TIP> C)9;!0HQ@72^>@QC.4\?G:COY_3MA4$ ZL MV!.W-T#\_@VX_IIVEK8I1M&U8]/X!OSR#WKD50"6[MF\]KPM-.JH3R.WK%8. MD"'7-;*@3<[C59T(?]*YUV$HU:^AC=:.Z'Z?(]_8.W<5MA^*EJ<0D5(X90;Y MPDW0W>-"TGWCI1/Y_?P_P';+J]6OQ95KC^L[ZYIRIWP#]*\-FAWI?^<*V>?5 M*5_\+BKV^LK0R4+6+8IC@K%D)'Q&WO3O&[F_XB,%,QA,@!_NBKM0GRMO!F:81F]H) M;%V%[I^%]!QJF:>=%(VRX MS#+C3.6"]5W=UZ%@:]I<[]Y[CZ3HA8QQN;4!H MA!EE=S'&M/36ZTUIR$"'.?YK?QP!1P)/\+Y==MLZ+$NE*T5KIH >!=,Z3N93 MRK/N=;YL6ERQBI#<=C V>M?H,!!?-/]M[&*P39M>"0QGNOGT.'/=X5+?\KPS M4WGZQ5CC!"41O$!Q ">JR]#D+I]8QM0,-_OE1TX>"P%TO<:>3^/H<7:ANKBH MY5UL:6^H'Y9=38!=NOK#>_=TJ>X@]C0D"I@S<>Q2HQU3D4F%K/GRA)W] M Y1OM-'T;/@JI-D.)),+F;)T=1-R#UZ^,XW?Y]"D?!Y"J..Z9S@B/"];=E+$ ML6)E(^ZD=FF!T(!6TMGSB?C'C6@VGO.6N%5A\%-M#7W%AB+!7$\R?QH-J ?10!\=5PD?3A89RP>H$'A<74(/E; V+NB/N< ;L^)XD"ET+MDEQ<' M8?)LBZ;98N@9PVU:6K _>2@BJ'6_1$2TX5HV0?A]+NVT,1UJ$\[KY;IRELD3 M>'%ATG5Y&'W2R3E9]GWG$HW9R*]\5&OBG20(,7Z78(0KV!$1#;/^@2,MVNLW@!0X]->P*BC)*S2QJ4OGXP@JZLE5&^0^%5K@=9:GH=ZG M;_KJP.;T5;2'=9CPYZ5/HM!++V=<^&/F8.ZZ@>U.4XLD^9]&$BRGWF!\&MKO M3FL@?PA)";I3+ZRR-ZTZU)D,S;_+3W@NE=BHTR2[\M,'I#%E/U78'O3+L5_! M@]I.Z9RS*8?&+^=O0&]4GW;I C%?$\[9]QN6 V[=-P#K&8?P>TSY4>*^FLM3 M-%D>(^7^QH-./D^N0KW-2K%8P$7W/Y0]'O[V*U(TP&7U4;-6ZD\$A>[-I)G: M2J\%6=X9Y8^=V'2]9)AT!H8& %K6^AM7TUU>A7&?_J?GX^%N/]\#:G1Z7DSQ7%UP3SXJ*5/\6B M71+&JKI0,%*5;F=[\NVE?4QV^^\6KZ^N_7?EBV*K[X.Q7SWJD)[](*\'KUH) M0^3HVOW_L^\:.+!JG\8MM+DT,8^M\6("[4OEAAL)N:DI]*IOYEC^5:CW33[R1PS!&=U:/_OF=%V#I-SR -D.;_9OUPZ2 M$O.TC9WTNI:C!B/M2,;=CU1JQOPNHL64S7- M_V1R]UIIQLT76LJ=JYW!DYN#*^MV:^2NA5#[@8#VY,)TX[/%YIID[QUU MFH_[G?G[9C40ELSUQS%9FFXY$ AJ[XQI ^M=#?W5CL'#Y$RS/V)QV;5 41Y@ MH96B.8>9?U0DAU_)[/P.L+"A#*W+D6R&H,4C"FD 1T\RP&:*.)&95PL+X4!< MSTB3.$O914U,]8=G ;.MW>QQC-\T2LXG>2*UN9R+.G1X5G?8"DG!+9"/;I]K MOZFVI&\?.7V8GH 3DA&]*OTK1@K$GZXC*V>J;RKL84\SPA-GB8@EE9AL&-IE M(.[=6F="(U@A=!D-\@Y^-F>N[%_UM;[O\<:,",LV"N&<:!5*^] *]5)36T%4 ME!$ R;A+ ;)/V6F?L[?SGL[JPD<)W"YKU WRGVT5Z>K[K>B0Y5?Q-T$Z!<\" MYQI&HY@MI9!HK3I[/*S.C0W1WF 1ACY?YS_/ E8E\>@NL'US%RF/F8=5$^^T M!.#1W0:^]*H5+]$K,FUU3>IWD*Q[@@@T9L]M8#W3\"JP\O F>Y<;;(0UJ$X M?G76F. KAIK?[9@1*Q=Q4RGG6\KZPSWR%CZ MMR.P)[_H7RHB?W-;XW^^$/'77P@<$(O\:OVN./7E(; S;+F!]]VY;!B;,+O# M'H0AQXTY\/:KAVC8HHZT!S>_S?:! ,/'=U]2=E32D#1 %HN:SDQ:+\L(H*=+ M&QBS;Z/AF\%RQ_%IVI[1%NH=5^QG%.*L-!E_?_W/!RD7M,.]J MS'1!_XMU#?]7UNT"DO[#LU&3+#9%EEC3G9;_#^OFGU/>/\,58/_0_JW26LAP ME8^93I2H$)Z^XRHP7$6IZ[$O,+3W.ZV]<7*LW.>A-3#-CN33#N>GFIEL4J 5 MH%9MO(K(B$/QT42@XJ!HR20@O6)KPA5?YST"H$=R><5?;47K3LL>]? M ;>ANYZ:GZ0JH@0J4.T'^;/[!;(+I+XW8&59[%%T=[8J)IWJMGDW"$><$LT: M/!G@7"M9OU_F":/IEZ+CWB;"\J2'6.$];/<;&(8]W9C\_*BEO?H^G9M*XZEO MXU +1_W]I]!*H2DD>6B..9N!$6]Z$BVI4>B#=JTI3,CLBY+K5C""W)!94M+, MH7KK#Q0<&;U)VGB;U,BE)CAD./]F^"D$/<2=93FX?/@%OXM/U@E&,_GJG?J+ M!C@A"V'KS>;)@G5PES5(Q%4=0=I&+E^+$_ESEY?>?8&H=V#M#@!\OJQ_ M\F2>38JD:4F9D!5!;1(._,B= MP%6+]V^D5*RMF1QQ?SP6,DRGK3U6.]11LBU=4:C6K&PWO9I$K,1[*7.$3?RP M30P?-"I--:M1Y>[#V\E+@A"O<$*2@H3:UOS/ /8=KP1@8Z"8AW.!DL] MTN::H.SXJ)8*'A:89N"40%; R1<]5&!MTR)B"%U6;29)TL!L7RO6P*F:Y?N(YBBX%G-"GODEF0!1_\Y M4Q^T^LS6:!#=,773?$^\ MACLV:J^%.!#RN:Y:)>@#(:MU6RHJ5YDYQ/)--E_@R@9T8E6#_UPD!E)\-[NK75Q_P2(H+O^<>^$R'U&1FSLE M*?NNG"_#V?:6^XCOLQ1A;<97+XC$_>Q3S!>$%(8IG31_JXOWDDY840Z6K!#< MU<:_;DLV<",-X_I&]MIMG7D_K-.*A!(^7\,=.]RK))UCS_=W*2"E*V M3ODS[!N0-*IZ_ 90_W_MDO?_ZIH7XN^A_LK8J!;O?O_X!BSHL6S8=[\*) MK M?97H>9U,^#?IL#BE48FQHY^S^8ZB%.Y0LQL@1 ?( MXYL?57O2YGHQ.B1]==@+O.^D%J F7%J_VAQ1VT+#GTB/G _@N$XE_R1>W(P# M>I'7V,)_X@-O1&V27?*,(TN3*XOB ^2.1.LW)\)<.0:#PG<"WP3 M_!2YRE;SL,>_]*DLV$[RK!UTN?=5+U[^O:TJ<"P>L^7$NQ0"N@%EQP(7[&3W MF &HVXH5C#^N]X6R;/;P7J2=,4'9!$AYR@TW+EJY:ZG45CT8: LYWGE;[:0Q M?()V=#G#Y/T2G%V[4U-(,6)C(1)4#)T8TO6NHHY=ZU#*FRG[7*K9>CV@K3:= M6F:Z;^]3@$0Y6LD(P[*N# AI H(/G'"/U5YY,.:Q.;9)4CJ/=P]H-?QJGG7* M_]787S>QH@DSS%!M-\*%QL26S2MYAD#VKB/A&FSKM; .O^WY M(G(B<8#^/*G8"<',_%]AWECJ*_(=0HH@] NMP'%F@^][L10A=Y4C;LV^3 ?2 M?'\=\'L(U7BBRH,-:T6BJGS9PSN)C(_F:U4J?WRM@CLS"(*ZG!UF OO^+%MD M-?@F]+-B9C)CR1:EUP37E'G@ ? *K1V^@VHA!7"-;]MJE)[PI;&1@Y4C?TL; MW&)+N+1,S1^)$Q$&/HGPZ0QU%[S#-&X2WSL-A&C\O#%*@;T*9A) M0$F\UP@+!?I?-91U'VK+/WB3[U7"(@\)Y"//2V52=%OYXL1NMGNE!2G-.'VF9B19B@K#;<2(9NUZ] " M\$%[RG76J699U7G:&G*9+'=ETUUB@>'<>3\WP,V7:=PA)@G M.[CLKCKKTWEG6K[$-Q9-7)S(M$C#5_J&>;>]!PDN67]5>,_S^E-P!HD#(Y\'%S?P3](,X&+C)1RQO_\W^206P*/;.&V0G MHB\N+XDR[UY>PJ6%R*2T3#8I'#[_3\@UY"E-@O;,B!-I696W.5:;3H#1O MDQ21,= .-Z'0CY60^TP@3FTMF)AROT%N&GEB\1;Z-,:E))),/#@^$/,TX/+H MIP&C14UK2MD_!1OIN3^J+IH&)N( J[0*:NNQ"@B\2FD7F1QIO/P1QS:2FLY& M!$P]SL8U;6B1A+$%4Z8KC1KIB+<:7Z K55*5.K1F;7#Q-K UHU22:7$%,C'8,P5QHU'OC8#:;:836$Y8UB>KB[%3>Y.0K7-VCGS=>#S MSF#$L9H;(U^7-INC%=%;,$&"+](^2*!7$L/#;<4.!$H#:X: 9A+WL[0;@K\% MX=UISN+"!!#\K-O;LT6/QRFDD=\RN[T3;7I(8U5]6,I8OK%2JV,X@8;.6(8Z MT_H;$3Q4V,.MMP.DFT&C5@]D*TGSS<>3X8T*GQLSKJ@/:Z=$-XH!'V;]3^^M MT\]9F\>G* 7QH[*RWSG+\HDH_B%A M&\88'U$X%30C84A'I^30-R"B$W%56H'S-S2/1,<.%T)3LJ:C:TD#35@KA'X$P<.S]ZI((2 M9N>Z3!MY&[YE0MGG4(W?72@8SNLB04%6)M,2'07PH/BGG'I7VS0OYM#CS^D\ M+0D[*4AU98=J XY)9M'#4)#:I=2KI;^KY#]-@[5"<2(:>_;ZBE_ M77ZD?2GM*FM+!WZ;CP4@KTW.JB)-+&>$^DO_K NH M4TB:HKI)PN+$VIVN31G!X<%M7'(3_)\ +<[- 1"C/W, 4_INP>>\1"*(U,-O9TV_RUUY"P6#3*_465.G>,,^_5=3]6U2G 09]"D)TONJ!,P3N\=97E_L00JB>J^MO7 MHLJGT!OYD(.W=OO0\I(O9VJQP)-!K/\%G\K-> Y>3>K[)$UG4)6H-%Z_6F*] M(VKC5G;8"F(Q)-!HM/@O5$W![KA&,?=3($-?\=(W=LR#6OWN+H^2KWEE:/&! M10L_;4699AK0##Q>_S2D;_Y\B$TN%?K%?;DO8I^T$$BX_ ;8KQ@>3N".EZ@T M& B9EA.2_<":$0XT3LW80'./R7I!O#S:H-T<&H%>=HM5N4AL%S)X!!T7W!!_ MW]&RE=!(B7BN?@-.3KL\HTJ&W_\D3 &"D!E2-(NSQZGXY9[^O9:]-UJ_K\IS MJ,>F^"M"TC;T@(LQ^7B;/@%OTLWIML([4O$W;2SP3S61KJH":^DN>FKZMUXA MQ1HO&W@HOD\UI]9@#% 5:^7[2&K%.FS8:@':A8DN'&&S-P#%)'JXT>D^8_F+ MD,O)6F=)8[LB=,V@OY7+]GOHQ%K7PDLV^8B( -L^^L1?+UJ"8=:JUE+1>3[ M[ UFW^S%RBRRR+ *=ZX;GXFOW%"C;2.E#Q2FW3 RFW'J;0)C:)0V>5SZ." M0!_R(O$&^#TSCP-FAD&0L:ZSO'WCT?.$P:DLJ?.)$L_2?UPLKZR,\HIW(,(R M^#_"K2K2SZ-B]!FL4C$Y?":;BH$ NX.+WP4D(LVOFJ&R":[L:+EPYNT&,O=5 M-8>^G_0,5XK'DC9E>?K#Z@.1:-8[J'IR.:(&]?U =)W%, _;VMU.SH))XA16 M5=-)D6:3#-ESD>C$@IR+LBQZ8\D/+5:4IB1]./_L8]G/[$*8W6;B P%\F (R M6#2"1;^]"N45>C(R3QG/$'7I]\,D% %>SDS:'S52(1H]^:B(ZG3+9$C".Z8O MS+90(FS$49:P1-GSS'0_%ZY($FW*G*-ZC89O4G/1L1@O)34-F*%.!IU'YZZ<'T\0'-XEWZER8G*KUH$5;--Z M0_DOU'5)S;L_?GM1752(RB7+=9L?Z'@&B$C+$=D')(&V;E MNP5*>\:^B?E MF:T^32%010:B"M*U+-SH>AJ-<#HABF[GO@$:QC_@OH7+4C')[*""79C7S)1U M;$=JU.ZW2YK^X0(9<7 URF17 V"C3@@7&X-&U^I$VRB8J:5>R+!WDGL-G&]F M>Q4+P]KQ,<,,=\,EVYB3PC7O>+T/9JQOPZ=V2LM(BMWQM]\B?E8JK G? M0ZG-NT>YK9Z0>[=,\6LDQ^^50'=5^%WC3]; [T//-G![%_""6G^U[X[I&G9< MJ;CADN+S*MMH>A[ MJS< 1W[S#%UZRX66<]5G6V8X;1"%,BU"@?R&1DTDWJXYT+>V-*?2QO#@-CW# MH:)DL2:%+4&:*R\&H MDD.&BV5_$MMF/-^>+_.K*W.I=J;\G K+@BW<9=5$2A1M=@1#KOR!:"KC%P^R MWE#/4XOIHI7]H6!F)HM0^;+32LNF8-$S3A3FB2YW4J""ZX'58OBKU\W=HS9X MI:#CCU+#K.)^[Y;#&K]ID2M6E92+2W$/>7FHID6C]''3U!\GL*%0>&,$.*GS M:+ XX5 Y],YK;I@XXMO=Z(8FZQ#\#_'D9_QRU M7E8(D@_8"0"/3373'3;.G%.JL.Z/V@YC/_4RTI9% I@5*ZIV("1"OMR8K[WY MTFO-3J/N6L;KUS"""DGEI61UDPHYKGUNYWY^FM@KK%0\R9PB B>?M)C(MCRI.QD07(0>B>SS:KBQ,]H$TV%-('!]JQV@%BUDM*@$H? MF)SSL _"LO$2K!IETLW@K+G;^$52D]$0H S5GCUE/[5<8ZW639G4/WZENX>^ MX@;H_/64BN-=BAW,#[A:JXB-7?KC#Y%LN]<$!?+ 4*4VK[&D33J6=*AL,F3\ M4^'T@CJO?R1-^P]TY8Y'?T@,)YOE%?LF=*L6#O(]R>^K?-U_;945I_KT_X.F MW?<'>#=NL?YO<#9^,D:Z&,/;KG#(3WG)S8;)>["E WS8)\#)*M!,U24:ZE?\ M;F3XL.YK'LO'?Y)@SN"MRZ-\)$L;]NIFU!3Q2G?TB"*7LVSP]3(>Q3! ,*&W MF95BE3*P.1^O-UGE*A^KY)J*_,"86G.%>=UWYD0_UVIJYK)Y#3T;O/I)U M5OGXA /2([S$]GRJ0IT%^$MJ+:9.GIFR-!/' M6SJ>5.%!6S)*6LF[19]B\#!6'?D'=&EHR+>3DEQ&POYMCNK$16+',%J/&F$\ M7 [$/<3P<.JU0B-IQ'!AV5KVR5LS3O NH"GXV^F6=+G=ISYXRG[-)MQ*&RZN M\>[RB;%( =[L"O0$<=_I"6.],-GZ?&*,[!<;V(]8'P?G4^.YZRB8QU"Q---G6&!1MVJSOP0SY%J0PC8/"UNZ*(%^@^IP(;\./[6F M7)8Z^I$&;F*B#'J33P&T+G<9HLUY"/QC'.N]E%[":-*Y8B_TZSVRRWYX3E_R_&P M<.=B0,_]--A#)6'(VW5AH#2#LSU---E\N/^9G^JT1D.K'HMIBB6)]M M37+- YPB H.R55226&:Y1YK=%)#]<5K@9*UBS+JU+FN82[JK>&X=SU_NSUB:!!F\UJ_[H.+0=P?>1MIDM$.*,_9-X<*U=D MC"J8)O!("GPY5^$7CA'+$-7)H41;05EG3]!/ZR8,L(!;C-^ ".]!.5-8D">%[?VB M*T@S_N4 [IA,ONHCBU7'S"E-2TCWN\2=FH7U8ERSEE><670<$QZ;7+8Y'K(: MKGFO3QV>-V+&@QWLC^+4RK3G!2:W -1]=Q7" \KW;A1I,P,>(:\);I=\6\<&U36$\+$^9]=W^6@] M4C&#Q![':J 8/N8*!N*_TNKK0R/:GZKB1FZJHU]%(L]]GM7!))@+ M$7H#VG)_YJ#W6%F[-7EOH0P3YR,]&(LSY[DG]*OM87=;TRGK KX:CHXP,!:F MQ)1>7K?E4P(&/XDCAH55$>J(/:A/NQV1/U+#8\HQ4+R4Y?L7);O$_RA>]8:W MW,<'FH6\!:@4["#U*3GK_>Y@=.OX(%)E1<8>XKMC<<0!)-?&:;_9'S0DU D: MGZU848,%_LYNM"2?PCY^":;UT>9,R:RLX$E[W-)?%ZL1,+ M>/+Q&@V+AI,G%'^,%TJC$#A3_ZXP.#UV#._]D"N9,-_"YK;](2R_\-LG#[)\ M?F878M&35WR86?F=%?UA'Q\N@V49-.%DGO8VD0JT5V-@. M-_IKE55+:E[+_\796T7%$77=HH4V3D* X! @P2%8,1R*Z,TO?6V/[W:F 9+^Z^AW:R33M01)@T3K:3F$=6N%% M$'VV]Y=<,H__] 4IT]^(Z [B-"(6L$D,AJ3X3N="',KF>@**!K?E6 >T/J5( M3,9-HI4QAY(^R[))/M'FMHZSH!!:.DCL$70R8C7E ,XN+/+92*//%38;C!L[ MD,(P?!TOI1?G\F8=+JJN&L8&TGZ8J3-/08\&_K3SYP-0\S>VDQ-VZCYD6-^& M]>?91^9=?,MM&#'O&7V7)J5?++;.?!_7IQV,4\'MVZ)P#PD^SZC;N541FL2O M3#,NE<5W=]IB0V^F[UT%S'*R14=!?]MM,EUD\?:+\'."DY2$Y#H3<5BGH2CQK:SV4%?+Y(IP"F -V%L4,X5*]<1 MN% M;*1RVXXC$]LWU5*DM:T\2J?W20M[GO9%]-Y$"G#FA02L+O5L9K>1BQ39@9O^JKOF,R,'\>L7=C M+!K*"K"U83F.(=J,JT7CTO9^*?,-AV/&,CGHLD@H@U(^>>N8]YU&(Z8P5]R: MRWN EVL[2>IBX+Q2?J9HXT#GK)?]&9-\8\S1#J4YLI2_D4[_VZ5D,)3.41=+ M$^^G6S?ED';2W_>+:F&@ZA-=:M_5%XL!!VEG7G$_6[B<+-A9)O4A7H XL>,CU) WZO7YN^_+.0 MVQ]0'K?X;&*^M3HX&,W)S\JC.$=@5;XL>9''X%A2ZV9\H?-V+*'RBJLO,TX( M %V4EZF&4QT=JO>.2G_B34NR:WP VN0,KDYJWK7'6_C YAF&U2XFT_EL,88X M44_^Q%1"/%ZN$]_8X#N:GE7,#\I-?#:D9_P[+QRQRDX4?K!C/E(K)EELR?-O[3#P&E3 M[Z=>OXS.M[!05 7#,0^SD]7#,FEQS_AE%4@+J)O(.9) M81^^4OY]+(!Y0O[D^I=<&1$8CS%*GRS?,G35V0GJ.T7H;#3ASVL[L:*8] &; ML4$SU=*$;-V9YH#J?N*^'KDPM[-94RMWZZSU[>F?5]"GZY4\0)H2II24[[ M=(88Q0Q>TV2D&).7<%$H-DX?L'%3;17^;1-&;Z"BF)ON*)/U_39&BD-K3KT8E M&?>:LYZ^%TC8.XC8,BK#MM,*EOPR4Z<;A'0;0;[T;#RXS_W//ZU05J%().&Z MBN 1VN5"V .0EHG1&^#"SI$;NE?R=L:$9+KS#2C=9Q3ZCJ MX"Z1M>ZGGX,KI\#DEA^H!2S\F**(,JG3Q*!@ASPSB;8[ MXW;X+5!U)IGI6&X0G^97,??5-PQ>1(^)\/K3;W4:]BO219I%I5W,R(_#Z]X6 M8_@UMN?J>!A&Z71.]=J2J716=\FL\J>.4_U G5LA&?VRK*-]"!6@-Z!#^!C= M94*,L6,WN"S??A.L&RP&"2_*0KY7>/C/%J0 M9W20_F]@6\K27N#+48_/V"-:[]W'7HG)5Z8)QM)?J;!B M' 0]"VK5.N5O)9*^U2C_-S@HW)?'Y3]6@#CY(RI#S*26;/'(=0.)UXPK,L^: M]TBY"ZR2B4^..N]9,>:QQG,4B6'"WVTBW/!#5FAF,(J0VJ<]5^+PU&F9F:P9 M.8?*W><(!T>3Q>0)G\['%\DR*2I]BG[ARZ(.U\/TL89R+L@T[.M MJN:>2F(P>F(L[',/OY,WY4[S^.N/:(K\Q">O83A]7U68,4,0HUO:-22_H*([ M(OF./]]D5;K7YRW0R6/53(1,0[F[Q=]+?HJ';0@*91*_+-!H"R^PY@$Q"O7O MRY>\%8^NY0C @>%;V_))N?#8L(&AFJ:)%$Q@^BPQI_5]50 M5PIR>"=XVF';HL_,%V"&QFKY1MGDC#P 7/B)G8 NB]=CX/-,(M-MS*K4T>I M#G.D3@?R U1#_C@= MZ%O+N!E1.RO,*U8<'W'W<-E!^?Y]&X_ 6:]FF:SDIG9-B.NVZP$"B$N1;T^7 MD_*ITYH3B,AY:P.M&VF=-V2_"_/:>>[9A^01M]YDG/>*6!@'L4PF*0MD$:$A MBS'DU&;@$AI>J=O;.EP#-Y'W#J\3LU(WX4-LGGV<$B+V*J!*R6\PK &,8-Z; M";SJS8W3(@^17K2K]5J!;)#6#/<7JH\Q,WQ>L^GJ< DLP'KU2GPJDTOT0*/1 MT(]#G]O:*9*$G.64EJ,MOB.#/FQ2=8/+7C"Y>.*GRHUJM41) _CI'N=%&\&'6A^;YJ.< WL^:GU]5@PC[UZ5*/]_??"Z%_W7-^6@>5WOC=N=RQ ML(&R)1ZES(M0EDDNES1==U.5B64C)?&^,J47EC<9T"J6$J0M1FT[HF ]NC]& MI^&)GO0#('[$B!L$/S Z4'[93;GMZ6,EMC2[64.G()BJ,,*\,SH=8[J??#\F M17[H+_/3UCUL0A"W/.V$5/9& <[87!S(\@#8RG*UJ/_0MZ^F$^]1Y9:2D*[ MW@U-\;6*8V?T$>YU#4F4HHM^ '!R0UJT\A&6^JB15O/<:M//2.H'8,8H/D*< MJ=S[8_"^)U]7-KGV39XSXLG/7SVN _WB51L9^[7Q$1E7B7CS+0/%>O'MCKYM M%HF[N-M0X64,HGRB_/'+ ?P83\FZW16K4Z'H:VH[T^Z,[^#]?+'R36?+A5M-9%A6M>A5&H.Y"@@BK5 ;%.P^ M>QO )HSYFN)0+% S6U!O;G>;(_#W!?X3R77J)//]-&^;5F16/U":I68BK_C M=Z9;%ABNF3%RTC=(2Q?]5[XQJX%&,W1[>(CV;;$Z_!3DAW6WC>Y%9^0NE>..Q4F]T0HP;:"?CX%#R#6_'Y.?9_#X= MZ9!'YS+=LP@-_H<7)ZH5AKA^;R9G3=8UA]0XK3MW3!MJ\+PB ..MU)_1ASL_ MNS9H8<*$TD**%V6ACX;_PO=A-\FOL^L)Q9*Z M+$RYB@"='=6':Q;*RX*(UV*1#-RJ$GO+ZK8SUY]P138O>Q1H^#Z&H>SXH_'DA0=O )QT=U,*1]2A_QSSN3R-/"G=X62%F): M7;R5KYH,$_?6A2P)]A.?9"Q^:VY.3%, M\M@;V1R8,MP2=])LPX.ZQFB1ZI^M<@.2=.G8,7"H; M((HT$[%S-@31#4[7MM?C)3!$2<3I7*A4/I*R'13ME=/\T[$"E7A=Z8> MY.O* :I;,^(#O7=0,;.K2SB,Z/AB/?57M6!]M(-=W@(1&9<%=34<7B'Y .A, M>K!]2+L-'1H48O%+1DSQJ0:ZKI!V2>T']+*B'Q6*Y\6?N&M.^:E82&8V(D/U M_EM&ZKL]KZLKER4E&U%I ?.-K[V>OVY#]&?HSRYX[G9N9@+61B(#&<8$!AT( MJTSTWF5JX$=THLE]>A2%N81 >$"R8Q1->'4U]P/Q<*OX@0EPQH:A.UXP5A'1 MV5@+?J7:\ 8E.Z#\9PV&QQ&"/=UYJ<:U*JK2((N]Z3H/)_38%&*FV59!T'E MN9[37 RINENZFKN=FL@P/V/R'_O[S1RA]0'!L%4]D84'H'4N_F*5J.* C?F; ME^WRYRT8TV#T]RT_ (\:G?-3,G:(1Z1SF+]7EA5CL05\YM1UR6G0VMS)#9F1 M_0YY#2GPQ4HYJOA.G%LT2#AI!<'W[YX1/ \\&CP/=AT-,2"GVBXJZ*\DG(S0 M3.!3!@(TZ&Q=>&MFX]B&6!E^EE'21O&(5#X9;WN]G_JO+)!\3Y:/F08%*O<5 M"D>]L,U8CT#V5G\]"_]4 C8 #LQ2W[9SSM'%U3F,F&'O9NZW1(UH+[=9^:2H MGN59!7XE^8N7CN %B@7>QJ?]6RT$G3PP?69N52,94:AP7MQ1<\[=WEN MYI%_>CF+%E#.FC\[SND-H_&GQ0.1=+S7G>)-(L6HB3?NG::N(0H[+5$KS1JJ M#0; .& #9/EIZLO*< L1V>/[T)XWSOX5R]HY+1D^5Q#C78BS15.9>Y.JPT3L(BI.S\ \)C;_$7MWK!5B?.]U47'7><%<4PW8-!3H MWK&![LTQ1%:U$MZ9IT0[SLL1'DB1M'-U[(I-/FW;GG^MYT7+_E[V I>/A$^^ MHT?,XB*^%RI^T0MYDJ:47COT_-D^RZ:->JN%Y=[]]B,4@6M)/D4$+CM?[40, M-+4EW)3A9W@">9;\U MEX'J%BW1'J2KN^5**/MQA]=Q#F<3B'X/5N&J]%7UO.,>O(5[G08E2;#-=0SL M2MA'F\@K,*!HE5^/_,::P6A:=,@_4WK[,>6?/9'HYIFBOAH/8XA 0KNHZU)YJ96].( #P^Z8.M9)&@5@NTV(N!R$=\0@$D M5F">W-$#&)CE8SVGEMK\0I-AF_C<];V-4VC49N[?'_+1] EB5AX2[ 57945[ MKDYM;6%/VKOR^0/?0GD$NX4(!N/RL3;O-#5$7FJXUSYRI)![AV%X9?2\3M8V MUYNI"F;ZOA<;YV0[OB=_AMP-7A+VI5&"<(HP MW&&)R$JA,U"O4E-(9_X?+J9=2EG#BP< [WRN*&,KY,/AH<_ T#M#9XX<,#O0 M"OEILN_6DO:<8"%.?F"[YBQ^7=PBV.B2DBZO0.C[#GT*P&8A38GD_0! ?.QN M6!AXMG0^"=P-J1P:ZLTKNXO1-Y%8W=NBEV!>4B!MYSL>(ZA)K,-IZR>NGIUH M03]C1@*; 0(J"\D4&2KY9 K)M;[C:"#\PZ%<4I/&?BW=\ZU.6VZ,\)Z3Z> M1=S>IQ>[C'7Q9LB#/ 2+C[O?AL,>MY-U]@-0LY)N5$W?$C\-E=B/8H6A_]^, M%N*-7&2LSG]](;LQP3J;M.EYTXWZ?O8 [,ZQ8OQM(''=99,#K9!VO(ECO8+A MHO4!%\OY"I1Z?"04;C@LC&5C!U*T]8EG3 831Z@^7XNI0]<09]_?B$O"Z=JV MD=.['G$Y@66:=J<2EA,&EH.%RTJA@_> 9T9#UP/P9/:=TZ>U:,V:NT&)Y$AL M\-*!D7_JA0R3[.Y^=VE5)WU0\>X0P"ILE-#BZV([[#- &[>F$,6*MA!QB603 MLKK(=;-CA6'=&((:X24D^HS,^:%^9KS%H93K4$&NNGN#?]L<E<)4)1P'; M4(ECT]A;Q=YML><7P(VT$_])CPRHCYKGA7)/Q(7KQ2?+6E3*FDPAN]ZJSW.& M"K0^ ;2C7_ZN-2)SA3:T?,KJN1O)N7 J(QF6$LS'.Y[S_)*4/!^[$@&WM&<# MOD8/ '5=V@.@[4Q@=HU#?/$SNC+:A*6Q_[DA&NJ$_F]CC=VKP'/4YX D56T8 M868EE7?PM5=V\5 (:DPPC?N[GVN\Z+KN;3V_^G\F('?OF+/<5Z=D9U[ MA"U^^D+OOG(AJ*2-2/]IO! 0KR@O8(AV'O%IQHYIJ7F&^G]>16^5/,6*1B7K M:>-E8^&F'Z=P/5!(WG][-]G^> (BJOI+(:=,ZNGUOEW^]0"R1C,@[D/ UN/" M:;*C4)_1C#:*>^S>HPK 2V0$Y/;6ZBZ'U3;;O#$-:UEX-:$TC$?J8^Y9Q!]& ML:B3_*\D.OI&M1@2KY65W!\ >D*$EM[..!3KI:^K4N-F\N*.0,YD3EX! /:S MI-P0*6]]UI/#//:D(J5X\3WE7;_+W@/@7\58;1'_[RNW%*W[+KOQVOE12J@W M3NLN^G91L;UO[?;Z23]?CE(/IOHS^.R/XOM4$R)22YI@MG9;,UX*+;KNW.'X M6N6)(7/$* 9J@,/FV.9 ZFK0)>90GB?HUQO$V4>GHC! (W^WNMYW!6 M4-._0KLF+42M7F/YG\&%0"*G,R+,O+0'4%V0YQ)^KK7=!&N M6E!6?"'.P-TA)=J4S:.[WV+IN*C##Y "P,1P@&LL5>2ELTIA^?OUDZ<&Q4H! M;]?)3 =<6WO%IYU-BFK4?@K>OCQ+$K[HS_9>F5+,Q%, IDG1?YL'1S#U&'L MN1&7K@W^IQUTIMI;]@#P]B'-(AZ PSKI%OKUMV"_M7NIUZB7T MXZ3A"URCZ M9$]HE]BSWO6>%L_1Y[!(7>_0#\T7@ NL;.\MXI'2C7QOC7G[&!(XQF M^%]ENCNCFL=WXI:5B/>TK3A5A_'0.C1XHX!]+M0K[]ZYMWT5RC$/ (WMS@6[ M_59##_AY[3[+=+_1N0%.![T1MT/$:FZ+9*VEQ)T:" +9,'UN1,^W8-"HUGUO M<,2^O.\Z,GIAM(CB.6.N>'=;-V8^R=OY\T"IY"@+)W-+0NV7*-$7JI]_I;O1B5L-SC_J+,:4]3%)V <4S#QCSRU2!(;W[MEP +28 M>_O%^A!PLQ.QVN3(KX&L+7N+]ET MKSX UJI8O^DJN%[8/ !MZ0KW#J\-'DT+GG_'')+',R. 9JD](VCLMC$\65G8 MG#PMNQ88 D.R1WC28/0H/_J,V,&;L2L%7JCN!0Q'AFXG7EHAR4T5F%P?NOB/ M-QEXY=YDB][N?RDYV<1$DR.Q#_FE,)=VD&%:W19XOO&(J@P@I9;[4Q8_@OE) MR(0/CJC&A_W74NETPNY)L- MLT6W#?5U$\8:(+XC5WEU@*\XA.007O;QUUE8.%'>DT<4CX/+=_>?;G^B$[9T M/HZX<#1<\'[%ZGN.!P!=5P3YWI)^3QH&>M9Q$[^E&DM09/&D]::X9*PI=JK/ M,@/P(Y#7T!%+BP.8;C4Q+!&9I\)ESZ/X?HJ(!T/2]K054%IHXFS;]61=KU%G M!Y;^\ZIL!7"M!8I?I.:)C6=0B(W8&<+KAYJK.,2@* MIFA'![I84BO([M_3%MBW^6+7I5V'PTBNHQ#@XIHU&/%KI5"P\%(0:D4%: MG6XO.WK0Q!_+9CT &_ U[# ,26MR V5 *UL#X=(E%;@^\H M*\QHQ#] 19 K'2XBJ(EZ+A?N&O_+OGOQ/3T8<>_=6U*BD^^63X ZP==Q8_F<*)T%OYV MX+ZW<&#AJ2PD>320Q]O9F3RC4WBSC^!19'O=X#@1S) #3=P!$0\=R5;B'2FZ MC0< /[=K'^<.NVH3@B]' 3JXF/8XZLI*T'TB 3.9R+Z*1%@0WW\V M0OU(&PSJ7(CMNZM<.8,15>H@\M8EU/@"?O90HLA6 []5*.ZH_6ZQF!AA_I+C M)82=>_42[#'K:V5SH^5HR4IC'EX-P]N@"SDO>A>0'!R5*L+.L/(5 M0N#6+A#%/6?)5_=AD[/>JHHA7A20W:<3$V"DABG0/E*GDAIZ M$@ M)S1X2=L$C?Z3=Q+IX8+X(QP[W%(2X>C0E^>,,N%NJK"#&\V8Z;$L9K-<'1IM M2&/Z(R3'62MGJCYKC0HV)+RT%U+O7[+,$7BO7&#<;&L&VZ_ MY _HR__5605]*S6YQ%[QR+QH:0GS;AM'_^K>1;BT(IXFEB;J[[[\1_-@G,/W MGLLO6GZ/(KG6'(S?'/MII8Y5Y+_N5VN)6U(A%MYESXV/SRW>$PT)O7N/2G%V M=^FP_/R%C.5LGA4C/6-X?YG".F?>]D<6>>02WD^H![NJ:56<'7IO]4C#A?(W*,J8 M0^FTHJYD7Y1Q3[/S2C@_P1[W\Q!S\!O*&YQ9(8*K=:CX>?F"79J7IU!:U3NJ MY7\<*EN3GP@\*S$W-\]Z'0K] O -3N.JB_5V^Y2;)@@(*)URU%D3KYYT-EM6 M4E0D=S>C(KE#R=H*Z,()AW]\$);WS'_[XJM?4&XF]W-:< X@7AK55+I,*Z.9 ML_6][DLUQF"=V:4@3@OUG/&,COVH>SOXW:G.3D,0&ZYFNF8;0<4S/R"8\-;@CE;5)V3Y MWO37$Y!0CPQ(MRK.+-#]P2%-\[K"FNLF*,C8.W+$OIHV[YHAP'<4^WU%;($^ MS-"1O1<0XVI^ -0-<)F@S\6D]FK-M,=LGMS-.=FK4[&M@;:D2,$!R6GNPW:= M'RFXVC&6*XZ=.M 4 ?.#1YP$#&1=Q%P2*C4M,(NQ]96;/(7M_@B&7M&G #;6 M:J_'T<4V;01-E,3T%2XC'F_G"^"_0V1H'-BK+ 1>Z%PC7-3%C M?/66NHG\,#\_?>N8_"'HW_R8D 7&%HVV]#,!QP< )ZQ^5EQ/=:'H>+[-&H9> M,6=[FU,8=T7EL33^O5O@"7^H)()&F_TRFWW:V+!C7IRK_ $PXZH]+U40;S,P M/@Y82"/ Y9A(C'<= GS^52M@5I)6U[J]8._?P)(_E+-OL/RQWYRES!66[N=% M53_MS6 '2'X)FFZ0?#$B@.+)':Y-6LJ+$[Y@I=[&:[S Q0S)5?.U*+>E*OS6 M1N3(O6':/,X-J:7:\'\B'CHQJ(VQQ=3F=T6*-K"L9V(WI)?E K].%.R[7W0K[Z3\PY;U?I?[H$523WSJAD-(Y9-O@9TC)3 M^WGKF>4:$=? M.>"F.Z^35^@#<:YJKKUPW[K_01X?R)MEY3X9Z$%67C!T>(!5T%+S;XDI$I\7 MB?59]#AU?+?Z0*?Y\+;U6^-K>2>FS]Y6'#G2UJM0$5 56=KWQ97W_HX_Z]0+ M[TO\FUCL# 3P9[;-^RGI=P303.Z4)C]W_4!U[8^V+SWK&MO92]3F&!-$5#@& MTD30:U#M.FPE*?477%C6B;G6,!\/P!F( E0?XW[092:AC:F?LH+>0D"JS4N] MX *MA&ZZ;)]UJ$@S1^L$ES]7^>Y\P>YH80UJX%U6Q(G^4+$-455U^;&2[ER MF_VK#(GK$*:9VJ77>[\*OU$13I1:;M8+E-O;]+Q2M&DD.U1A>6NNMO+&=Z- SCP?87W2\YSNJ3&[)1_EFK%RA2$D MG:J:Q>S&-86!^(,:*'OL?R8?H*4HVN8?28&,7*7VEN.ZTL0OI-".;L>]\L0U MX + MUMUI'#>HZ]"/_GFRZV'(D63&'DJ?$PI?1ND=:N=+NG]+,Z\M6FGFL"@1:G+;S>A(F+*#E#^5 F"_Q5LZ/0D1'"$%(Y7*J?N'J;9- M4P61?H\W"V6E=/D@E/7O UN+N@9#!WG+AE!OO1_*I: U*3KI?"3I[P2. ]%\G6Z4]P+/ MMP<@5_&0LXT4(3N&EC2\?A1^ILJ+DD'__<$LQK- >&!C3XJB'O7L=*J,F*7[ MBAWTH:\15>=U1RT+H.7M=<\NL""TE^4/$&JZ9S""F5-4.#OJ^MV$'F3F5_PF M!_?%V@/PA><%^E@]3W.6F MQ?K01(@DH:OH2!?DV9[\A+0SW7?TVV8,U:&@)?JL"- 7HVN %P M0Q')5?!Z!!^]:#OJ/4/\:4GDA-7.WQR,G* &O-L0_=/MV'6*O_L9GYX3QKW$ M<(C/(W(8AIL&I_)M*S-I)V%+,#8K_Y5H(++%Z$?U.3)(*L^.Y,5H/9M313_^ M^!?BXT.V8N1/=?;NW8ULE^M^S='(-CO::7OO*'J)5:BJ<0.>-(Q(]A'/UW)A M*CT ]&ILL^"V;%,,>DP+5/GLPOA4H8^,[8* CN",]"^5!+&:!WCI,1P9 M./9]0'U>&B9P+-RH>Z MQ>"@-@5PQPRHQ(ZJ(M/%L3))+Y_F4QJ[ZH2$+7IE-NF7LM#5C>T]!-W4L_E3 M LCU@$1@>.N[,P7*[A)Z=<6D%A^,% FM2P$T.KRD?+,HR;I/ N[%-$EB]"V2 MX:U29Z1 2)/":A00WTI;3#.V#,5CS3_( $P+*']$ 1R3;9B0_BW(8\3X3S6# MQ)G4*#C/XYLY%S%] &8EVB^M/J/]'Q3)U_&LJ]PSH:U1&K*XI1;S2GCW2]$% M_XD\O1'&C1IV+.D' ";MAON01ZXU]DNW33<(^?D!2"Q=0'7^KRWK@0< C_5$ M3F9/"C0=]U4=62T%LF\ EBS?$#.6NM@/)<>_[G6OZV5%;X!TI1@G-K QW(9$ MZ;Y-XKNET61%[UJ6;WU;=6N1>S61%9$&-BC38)T5Y##2"UP)&IG.?(LL5[PMGH=ROLAZ:\4IXHO M6@]!%Z.VBZJGX"$53Z=M'KJRNR;G_6H-?>'%/9:7@4TP4C ?ZXTO5_VC\%PV MIH(U<'O@YM?\_.T>M*&^,2LG*C%U9)/#A!X3D72!O?*V780F_$OEOL->_OWX MT=OJ8A1%!Q"HE5]]-]S7"O@O2E)[_WD _F&O6DY6(B;=O3%ZWL!JYPGW,+(8 MG1XM(IW&RNEV.PTS,69G=A3T5ZC9Z;OM ["7^EQG9UQ/W_4FJ@ JBU99:6P\ M81D\.%H6VX'R&+'/P3Y=KOE]U"R _^(!2*W?^ OYYP$C3N?5Y8),T5^73<'! MP2[\_'M4@W)[9(L^?4A<2%NA"JQ)?OVC"Z9DIXF$/LRG\85@5J1<^9P]^;Q39H&T@(%3-C6G[&H( M9]P.]U [*B2_Y36_H-%FI9?LXO=QSPF,P5$6' MFD[9=_U>WLE/QBXC"3/%8=^&W;/B57NK=F%$TRL]M_ZZ=$\3OSH\I]"^ M^35W(^D$H=$F)D)$37'#AB.%M;;OA//D8OOVEN)ZJ0#3-DPU@'+(\7._*_,9M5KVE(#@L<0HC:Z MHO#5>+VI/,+2?G[2#WQ<0<>0^4?7JM2Q@O>]2KZ.AT2VQMA,7$?NN.\8533? M*F45XP*LLE( OIK!J8Y_=L#9RH2_%08HT*%,L[PYR]E#JK0U38,D97LZJK?>%W9,%3PN "P[M/V6^@OFZL&+)1 MPW>6I_*J]IKN3,%\>9)?T?Q70W)2Y-\-[]@LC6BJWXPLPJ]+2#Q-?\>VA4%? M&5I@$WS9F=2X$9/5X@XH):X=S'&1#,Z^*F)B('ZTTH^(!-[3P!9#E]Y<8HW#9XWS..D4-O$MTB"RT/> LW>F28BN [4A!7.(RL3J M.=>X#L%.5JJ%6*YT'ZET^8*>MXKCFUX1'=2MZN5"&$#,&C [&I+U;&!OK_\G M%2L&;+INT-A==F)^ZQ5JKLZ44:$*3Q7GKB#.O>7S7O^)\NEQG8VY<[%=\R,> MMFL.9A_:?/(R-F&+UKVSDR7DX&9U[-$#7#7]>)\G_7U/W1ZDZM#IX?5RX'W2 M!\+?6MQ2%",F<+V!-DU]F]'I053A[:5GB9,ZCZD\7K!E;K\A,?6QN4C"FF[:5BD#W M$DT03>PQ?WPP=DB%H9TO>;NEN+M \Q=_X;E M>95\[NO53W-;I+WN69NW@8+A[X'/\[D1Y3S^?MB_:=RC];;JW6+R IFT"'M= MD2PTMUK--I$_?[8QC:RS,3:^<3,R^OM4R^=;@K )?PRR6_QVANT]0*K^/\=' M2-:87"L%#*.2U*:5[BM1&/1Y ZEUY4O&[[&AVS2ER@%S8M1YV[11=> M9QC+))V",?$*RE;04IGS6D)9L5XY-T-%(M2 .Z\,#3%AH"8,5%^1 CVU$1Z# M C6D&D:!GRG:O6&;(^9&Z& MUFKR-^$'VHI9&Q227X'Q;!P)/U]MOSM\"979>?LW54L=D##M80PW*4X)9!6 I7RH;!4N?+V/& 71L* M9&R BE8./*72&Z)TQI4VYV&HSMHWP'?&;#/77@#XMTTG\[QP1^T-*='\> ?A M;R"2D*N7PDW: BE/%Y]=:$\,NA*<9, J1<+\-7E(/BAJ]'A _5 G3[B M0>.-\Q6[G4;)'^F[_#H%;RTYAM4^$I=:E_FJH:O/QXR-N@\!K]ALP8J*@$G= MOBG: [#IUOX 5/E!=OL/!ATFVS >@/^=!HUKJ_Z]B__\-LE4P_1'2G.MG MO(#G.$*'XUM!Z#I]:R2R-;?E)/@?HE>.L?6V<25RF>^1YM!WCML[.)!-_:GA M:GFJ?(V?H&)(*X6G(K91#",63C- G''R4(R9O_TKNRDO;>IZ :\X67T 0N#$ M6 B&V?WO&E?K>\?YD7I"*2G:^(F=PE+>\$J)\%XP=<6:TC=_R3:M4EKP:,?J MN3!7[G"KW-K0 Q %IRB6C9?U!B#Y^]+'E$.78Q+Y-P-J9+V;GY*$^R6G]J9V&G3;7IX51=1QB;V= MDHW.LW,/2%V'O]!_U9@%Z#_SPGO.E-,$A^%#3HM;GCT 4F7Q2(K%!^#L[_[G M6,8^Z?&UB<^[&1SR7CZVXP)?/D;3IT>R)/EFK/.("VU4$B_4Y^4AF@,LY&6O M)^I8GSEVQ956-+(OY\#GO+T,&\Y8PG\*9JKI4/>_"S(LS=D/Z.Q'LF*H_']E M=DR@9,N<_VO7G/7@1+J?7I%7GA4-DO*25 T]*G4!;!M/&^==[*>YYDI3N@,3 MWQB',C=W9C7N=CR!X,7;0_&37K\]XW(T]ZEX M&5!"19 J.0ET[$ONHQVK..2?[D"1TNO!O^8-OI6K&I;%I_ >+:+(=I>)$*IV MA5_:STBXIF:[N;Z)Q/&CQE!,1^.M_)Y;>*2<]J]+\] "@Z'"\<1(CE$!Y:1E MGJN"V1W_[J=L5R8/0*P7X!C#&%LJK*4>BC&+IQ[FY*N>($+;/(K^!0,1/CK1 MQ4]#G#FK5668AI;Y!>7APJH>"@38HO\PJ-XZS9LH_U _QK9I-1G+!YK[O7U9 MB*MRT4BF/CJ*&2P\DQ!]HPFEA1:+=S=N%M,V[:G*C![W[TF1N$L#<& \&.<1 M.+VPM;2\]LQU@N._U5HEN)BN4)6S+$QY%)-6R5 M*:<8Z>L\/E9VW'G?.-C4#>>&Z[E_89G$S\0L* Z,X)$?$]CZ-N?6[[WYQ;O9 M_*JW;\HA<@I%9*=KF*O8EC2M\D.D=PO9Q]C*GYC2"2IXM8@Q<1 %W!3]H<.> M]A?MJ>32D\GB/+B0A:S*%&U$]>B_"O5O6N=Y/B&N.[4EPR3;:2!$8>7QM^H: M5.ZS$XDBG=VW5HHG_BMP4)/D..R?3@Q#G9S#B)\X:">?L]?C,+^1 M%8V:FCSTD !I^$GH3*TURHS-4-+!KLFH<;CS%E6F=ZE'[T:Q/45W"F@NBP:? M=AF(H(@E-\?U5<#&SFV(+ _ ":$2 6 MP.[]@GOAF[D$*YI9B!>SN1R]0=.U%!# EC1 VT+,&5?=&YUJ+0P0P31"- M?P8^KHUCHQ%Z;U3>A=R.@DKM1>O"$M$:)WE>U,=XI70@6QV@9Z!>+O;QY_'O M8RN=>(.8T*OC]QUZ3G@J3@KOWF_]F^&35/#Y5EWL9)FZ^&W[2^_!"!-FR#B4 MY\"@K:A"Q;F.HX3%$\SJ1 II%D73SW,Z28^*+[17X&7VRV.0(W^JUO!/X23N M,I$9W48IW5A=ZXBW8N,WC7,$+6!7#&!Q90+3%'ASQFC=;!Y*]4\.E(AT&DU;-$9J9U+CI2C/Y?*3O=O1$WH/2&2#:Q=#ZD'3H*D MR$B6Z XI2)Q(+I"VU9T5_$R^^:IWW MM#FDDXF&<,HB"B@\;X[SBIL]D&_@+E78]+PN^X(QB:$^@-XH3"'Y \KP/#\7 M#N&IL%L_P^W%O=5V?M'WCN6@AS_!;8/&:T^**BB$("3#8$#?6)YU%F,AQ.#U M\*^@D:&X[%VTI 7LEVEA$O&*A?O]KK5!N\KV6F[OF$U\XR[1OJ$141J2;3X MSR3I.;N^2??7VXJ0B?4[2M.\!_Q2:<<,JRIL M0@57].:;T?MI2B8DQYCD*P3U'9WLC$#QM=W$&YMP2O+C / 0&8\.6LB7S:R7KBS, ,P M60Z+"XY1 QD ;K+CPMH8+#,%'G3DIZW3[27X'"\[\)M]%OVKBTI0(:T?]Z8U M%A<7YJ7I;@HY.O85A-';HD]'PF&GRS&I3QT=PFZ."S#2Z9$@:2F2W0S:^/#: MNJHJU63*) U)'\/')X?;3^#/DKB/IVA9YDCLOWMA&B=$(7WA/%Z;Z#P?BR& MN#>,.2=KJM'QEXP\& \(94BR'A#3G2[/9Z.3IY2\O%I\_C0H9VY/G2_WQK9S MQ(B.5 TS4 M2S8'AQ%QO'&.T(GSZX-AOA_:J"B M!Z!KO96>D^H=)A$D@ W#3&3!Q\K(15 M)=Z$2:97YF1K>Z%.K6C8-U+)(%*_,M7/N+-M( M[SF!R+[KK8[KPC9![* 4O=+0NN,K,1E_C[*7]3P-DK;"/Z,K(Y>?UV=N36FH M@;"%'P&L/[*8B B]1)C>P"&&G/9"BE[.#B5YVENAS3C%2)(3^;I9@*O. M!!>#C1)#I+\RF5*:)JYNRMNPSZ ]])66G- ;EO+:(F'ZPYR^2QAQWO@JOR.3 MPS5V-C,'ZZ;9[8P@S'M"]HR3MT6(ER.WE> G^3O);R<(7>5K=?E/E24P/+ZN ML_NUE*LC===&L^EB]L$X0IV,(?F7H$=2KQZ^IORYZYCFGNV&W<6G!V]VU3TG M&/KB$TTP!@ ^?;FX.(KRX_(3'$ M,LLMA?*A\UN!2E_6IAIA!!>*?*XGJMY6.IUO<8^BZIR=QD3[#RYR&XMN,@#& M*ID_24^65,2T-.?$E5HIY+.OKG[LFV;U%K&+YI[0;:<[NXPJ9"&+3GC* 1F3 M@E.:_YZ*4;[(*(+!LNB:4JF(('X F%(>@/N0_]/_1G6_(7W(XT]7>]SM7%TY MTVRY8C!>B7@V$4#F.CZ"3W2+=/DW1BBD5YWQ1GX.X69W?@: M5[(+*A[8=Q5TADG^NMMCC5=\-\A$.W%4A/;J2!AY,(6B00SO]-'1-4X>UXX< M[C'^=G E/Y]#>]I@%72_#L;;EJ1%7/2@7D[#E_B-)LHY3SC+-6P=ORA3$FRP MTW.JX'"<#'U^ A;[)?%3RNO:E,''/F,Q$G^Q.A+ T^# ])M,2HKV4?ASD^] M-2[^D.>>AMHWC"T>Z'JY&DGUDR6NL,NJ^!*@!/?KAA%RILTSZ],&^$JL_O7 M;WAOI&+ZJ,T5!L!"%:\E0@$+2%? .OTMB^_./3(::7_=32AYIX3P*S*PU_EE M8%RVR-_]2NC5WJ9YEM\3!Y!"6E_.Z_&5/\W.D5R7OPW#O28N^ZH4GO[0>>$_ M1_P/WU+\\\B:<>Z7NHEU4WP]^Q.<8/W12 O0"V8=UE4_;$TI:NU54UKPIOU_ M=;6YGC_EB^ 3&$7/_"A0]+Q9)G M=7\CP)UOZ)[6+E$\IXH)N9ZQ>GR5'R5 %V4YST];B\(>CVHZPW\G$-<:6?ZG MD=I[IQ^A1CF-,&RH7BA&1HK%W*!+ !N9@DCOU%ZN03J3'<5.**T"##O__06R M](]G_Y?G-_%[&C_88U@[[I75ICV6A-[6"HFF;.JW)OHM1_\?RMXR*HZH>_.M1M*XNS6A"4YP M@C06@B=8@@2W! ONWK@$:#P)V@1W">[NK@D0G.!N#4%NWO_ M&UFOP J)GZX$*.0IWN>CV-9/!Z"J%Q#?OC M-E_L6AQ+8UY\[4E_A8QIUPS( WS2[LQ/'I:8/;*BH7(^]2#[YC.^("5 MUR[<92Z^'"J'F:$C\8*((Y[1=R7/25+TQ 7UG;FQKN'LV(SVG3A];%OFBAYP MI'4S=;X0Z-F:3+=VK._PC5V24DSBC MNN1?.V?U")#!% I.7?CW*#;0+>XD)60)K-!WL)_&FJC)+D7EGK18VA)(M;YG MH#IMBU__K+&ILFE8<3O\7G%9,O-[DQG&Y)8BXR42KXOWQ39]E:).Y9Z--=+S MYWFR!+[T$Y?#*3B;[0+!MW4_@0.QUK9+R-X?(P:!/7S?^_5QL T#W@R\X:U3 M@7* BVO.EM..'^U"6YQ?)UIP[[OVRMJ9@V>5[8&6-4FF&_;+JU>2%Z!S=+A: MPF93Y8C=GE2/%CN43W)ZM[^AO+LOD[#Q)"D?O)O?E., M230KC2IU^KI M51$X_V*4)QV^/6[FIPWSKU4[* MMNM\]0B\AQ5DL8LG^*G9W IWJ]5,X#O6L'Y(J)I=X>\%Y1_Z!H+\W0G16>S4 MJQ,8)(>:$;0BU)\NQKVQX@/\F-))X?K9$DY*85]_H.$ZC\8*'*O2PL4E/R'2 MVMA \YII)6$-5MGR29NEOGB/@+*9PC>B"XS !)'Q5@Y& PHCL$;F+,Q)B2M$ MEI87]DEK%.!7#!H:"/>?KG?S\[*TC+:#QA[185RC3" KLFL(T]["*02]%!JPI+B^\LVTF^$XA MQ0^Y4OLGKK)9PT>H-64)52\5T7*+Z#R*VZA/5;^M^_!(J65QY5S'M:'W^?7: M+,DT;QNWKBS#!2RBJ,U2L-=)%H?RF&-N" AM;K;7"8.83S*+MO6#;K6&23&R MEJ26')R,%?A/,UK%8B\SBG>UQ?XD2Z85RC4MF ;OA?] _QD%W)AA7_'GU)%* M.$VE'"W)+YM9Y/@G!_0LTS>?M#4*I[F#%L_E&.D4PW-P"FR%3<_R1%^ZE[\! M-$?IWB6^,DVT)0T>8&V5DZ;\] C,0JZ+>W5JJ"+^49 V&UK.,'GCHKUOWP,[ MUL:.1%&63:*(^/N IG=FV;?^9-[JF-L1!GK!1(.R79E(;RUH9A+J@^?FB,7Y MXER%?6W:$[/BY94-:>H."[>KHJ>A^>*[PC;#2M/KQ69"4Z/O.1A9WL3$ M&DRO=#=D:LGET0)_XCAAB*-+$SCRAE P7UXAX=C ^;YJQ\>!'8[1%EGWJZV( M=3C%\A(CWE+[6=']CU&,54=^/T[*'J-GTRT\^4);=RWUQ#WI+3$[W^$\*WO" MJ5KI7W02\N7P?Q46XN#&/;@GQ/ "W[ZX.BW]-<<*9_B M1*CR[0?1&;UIP$8;4W 632.^>A8Y3*?8ON_)>*^*.B5.7$8EJ7-E&;49^MK%$9UX*(V_337*)C6,L)$>R=WRW'$6>]<04]8IY\#[ M8D1I@[X0[;UY]'M]%=KGJJO=L*-QE%GV>WKBKBHTF=IJL>A'($;T>YQ>9"4& MUY9.I@H@<+-"#4V0> 1P M'+OXV)0T>8>ZL[P;\ZSFEQG;8_O5(H;N?/N_\Y0P=,'9%A>'/6#NZ6SK&.A&3 MA+])-V/LZKFA0[@DT_X#@\EGT99:\-?GV# ?AN^-5E EYAC-M8^;B M1HX=*J(E_DMP!?FN)!ZJP*5 "3^E95RB\D9NS'E':N&2X0)TZ/(R 6\C2^.= M173W4PQSV%^M'7NFQI@/87*N;GBE!++L.]93\L_>E(*0>"<]O/:-&U3K:FNL92OPDGI,LU\[VB;?Z=K M<[;3XJQ:0P5RR5'5>TXA4I *]B9;+5\M]",M,NX1&!8%5A\!66F(( MR%1B@ MW>T5UN]S[-2QE\<>4V6?KQ-XOSQN+?A1/((N-SX3B5 NE.<74T?3U(BUV6K- MW/K-HN5CV0JP,WQ,HHK5J,3WYNE _$].]U7[NFXS#7E^)\/K_^7Z_P\'? // MYP?*&=C;51>"I+SC@W+-,ZHP@:?J'8&9*#.%(JKRJW]2*S)3R &$DJO5M9OR M*6+1]W%-%']1R! MD0#JMP^.0>?:)K%R=IQ?- '6Q3Y-BU!_ J[#!%S]:2<>@37*D[Q\ M!/W*@N0@*<"2\[Q'>91RA>*.]IK#P<4SY']D1(LL5UEA#,(@0)"MRWPS(J[7I MP2\?@0F=4D#?+%9-$*@*,G2?Z1\&3L=;!8F^J3NK84S'\WJ\D$P"=M99"9]V MT&/JO8U/A",MR4D %V@F6-K;S[;WX:FO[!?UAC3E*1:+'YJ:^B$B_+>A$E]N M)L"&&Y#(*QK&A.'75L=N!.%@OE-W M%9UU)-C0WF_6QW-/T09P;VA6JS0DLK,&Q_[__$-"!6N!O3:@*WG2ORHG3^K#!@I3$]F.2G[K.";= M;S#OM=H>5N__E-W'UVA:%?RT*CQM=T=B!_U+[?3'^>.%^>Y4OTX$R$.*N_X^ M?T?TT*ASU2$\Y0$BX^*.V9>W\%)2]Q'X#9EKSA!0JIPLHYA7JXU=?D;5]5S@ M2,U%QPJM>M&9ZA(=+9>(\5!S4IJ(UH)5A)Q6-UM44Z%6_SN42=JB-=X)00BA77\ ^_"Z *(^LD7/:\[23S-#@S?8].^ MB3OI."<-<,W:-VB-6>AF5*GQ^ >+T!,?Z8A&&M(X'M\T$Q9A FD.M5;;C([_=G#BL8>+Y M!;AD X@UU(#WPXL8H&7 XIWH(JG*/.-/]/VI+*SSP,F)ZJ^Q M'W;O\7T,0I1;\"ID]_[-KI3-JB4P3>44FUEKINM^INJU>CNM!>OE\'\$'+R! MT5G!X3>V:FEOVB*4;$6ZT6?5/C*$Z(P9L9ULK01?WG"5@[]AWV0GX6&;'RBT M7U;DUYT/;!=,-3X"U)[:$/(=M8^+VD==04?/= ME?V=@(QWG498C+%]98-X=2^<.]FL\B.CE.B"L^EE"MZ0C$)2@PG (]A[;&C) M#'\"IV+9T/3][4D7I88J9G$_>>VB'@&.=FGR/S?F29E'2'\M_([1X0WJ,:>W M(Y)V9ZNO6L'N0KI'R;^^7@_^"SDF-%QA:>.Y5H4U<&COX5T;MPB%J<,:B>?3RG5480L2(8AUJ1ZU MF0E,U&S&YQ?:CX!HB<8KWY',X,O"LIEM)Y@YH-4A_)^?W.GT/["H$7BZY*?().L\/5 08IWVB]NR_?(LB^DWG) 4P0[J W&0X5C@"4*[.:ZM>'V(I 7S:9;0H?:5 M=MWGNN5EMO"_6)AJ"W"14W#&IP7 T1=*FO];$+ROO#UF\UG.GE2(# M,GJN28#?,K >:VW]+Y*?#M*1:@C*R8LA\G21T:?2Q#W^!MY.FM/N@2K2N/\[ M/OK/4.S@C_.FT6-#[WK@L79^CPI:N&5K=Q$4Q[WEO?P'FOF>/5:DDJ9C=ZY7 MO3Z(/I&OGD;L6I62$\AHM]7YD&0N% ;'-9<5NH[,O$,+7[E*4 MB0$Y/Y5*T&J^CL]"_[+/\%3D)O#OP.\9A-Z-S4[W58%PERQQ)V8X-#9 ;[>% M,)?@%2X'9\D8=#-T(P)9=_TVT".2HUXVDQ/ID[JAE5Z39FV?B%CUM MD(^R^IF33<6A8'.[FD"&ER ]P*B3Y&MXXME0S\!2'RF(BYT5TA<;6S]A!_9R5T M?CP"[P*62\A 7U#J(#.TS<0)G,3!1*K%?[=Q1@J>G6/-CT)M!/ .QYVD\7V4 MN.E?K4+C,$+;V_?XCEE?ZH2>:![]VD4^J.9XN-FU9YMXPDE?/O48OWH4 ^? M@Z)[>&)$X:3B4A 4L%8?F&;<0%-70OPP%-GN'HZ0Z#=]&#@V6FX86L74ZM!" M!RD@\SLQA"OE'.Q(>AUP#F*%J' X/CWG%Z5"8@(FYBFY)AX;;>S#?7)9RW>_1*C)=(XA.TJ0;7!>G#VUT,U7I6J ,<;/#S M?BEE2,ZVN8,C]2\$8$2'"F;F\C!& MJ7%RXS^7XVM364Q4*)$.&$3/A4PW!TO)3(!%GF^= $Q@L86>X9*_\$9CUI9+>1H5>TN[E RZG!3=LC$20 MH:T&Y-/=1M]RJEK,=1@V$(-/RY[ M:MYI70^4/T[&8O"3L/#@3U)5SZ2<;=WA @_#C.# BWP,SAGBQ=3I?)@-:MP& M0.ID@E&S;^2[N!74&BJ;#"?&J>4A>K.\Y)\J)/M2YS8S>BSNK="W#@-D&T^N MJKA#)Q@+;NL/]KR%M*HI.I9HO_I.;F;QD) OW+?5'@:0^K(LC'WE.8Q+6Y16 M77+>7=()JR;_^PM/+%@:XVG>-W,,M -*:PFUN;R9FOV8Y^<']4XP@>(2,9%- M"XMW_+E<'3U3[@,F(' ;W[$A3T2M%4PN_Z?A0/NI8&VT_I(BF 3YM^R2##12 MQ#&D8TM!WXLF#YK +T8-W;,KV*UBFK.G:2$L\H.H_LMQ^E/F0?*RA^"Q: M;/4T3F9 ';=)6/8]\C9NUM$0D%>TWC4)L&9G("EJ(9259 M$%?K$0)"IU2AAV[+F.49R/-%^2V KI/*[X]1S;4-:8L;]&S1$:)O5!7T ,2 MAGC/!(AX.5 MR^=74PH@?YP-8*@%Q[;6'8_7V4Z5#$M*/0*6 5UU:'=CS"^J[N-ZLJN$^Z'N MBC?*X=3;U'0TP'K-2JR1X!OAWQ].XEI,@N^?,B6_"J:C Q0DEW1*[T1//^9M M0 @-;&CRDUQ_;31949!0V:M'++:9$&I#3RIX*N]SUZ.ZL,KO!$?%&'6L[%]F M,[JA.Z OUGIG=:_0]6[\S+%D)#Q^2 +-Z8BN&Z/O M&'&DT,;(+[]J@9O1#EN_?BLO@[>'(Y\4=N^QNNZ+3RY:CY,88D@QNBLRUAO?_0B)('"^I<8 MR4Z;VR=9K+<6NP]Q>UZ1A"<(E[N27@1[I1UX]]ZF=[3G-C:;:UZ 4\UQ:_D] M(2:BW:8DQ>P% QA,-X%1G 5=:$[7Y_4O6?>T'GGF B2 MO!/C[GS&2#OI"1TR)X_+6F.[T<(&+BT>]OTYZ#U:CO=^YXC3CN- '#6*;Q $H3W M27*G]=*L+X6>E97-#P>!)M4TU1H?DN'9L6K,I(/T)84GKS7N"[1GRJ<$[/)W MS\0I@* #X<+;RW+O,6S[HZ?5M<-*KL-45)V#@J =8SP8*4$MU)8FVO1@S:]* MWENQNTBRJ[552^-E<:@Z+T %:-%3*M=/"OH8BOV2CL7 O9087[>Y_V_.3DW2 M?SS\W^,M+\"4_(('XY2K[@Q/B18OV%@*==V%OU9F?D__WG4_UM2^6!B6)9QL1"-D66RK=0?M M![E[WP2ZWVK[5*OQVB/0DV.^9;5P$\!&3$=I-RM!?J^07<&>U \M*947[C\F MHPOZM2?!_FOY&W.FT^ _R5;SS#CYYLMB]JV6M3KK2,CAD7C4.6%HY@M+UPDA MI6O2WO0Q+ZF+D:PMHS*.S/<^ETB+A^,[^;8WXA#=*">$.XGY.4ZD=V]%' M#ZZ@#6,J7RYMSSLE:\@P'[%A<2SBC@<5RSEBES7D%RV#WT%ONV>[CVNGW/6G M[]1#?TG>/(X R;"QY%;QK45E;;\"=__';CWT&<%.[B&3NZDTM6;!%\Z*[(W= MUXTC.1'J >O"B9 2F[C1R,.+9X M7.63T 9VQ09E\7*[*CAL]6*#4U]*4Z=7JC=L)CBRH<\\X*)\)7I7(@H^LP-G MW&=2T?<;* (IFJM7QG<^64[O)>DFS2=@? 6[-KF"?,%/=[\1#,D O-PS"HQL/*I^_I1]-G+8H64DF7M%?BA)A'IKFIOKX3V4 M=WC$#X7R]:,\)"_:P19FQ/G%_):VV)ON'*"^I9GNK%B%GAN/G67U/G,OF>*8SDK MA?ZN=P+;^PE(,R2?_.C-'[J5P#DSOO ROJ?^>E)VO^P#V3::D_)AH#*9'ZR" M1H1,-!+2!C>JC134<>X\ FBHKYYIW>J_VU\X/>QM*5C2G^XH"(**=SI.P :. M/C/\,G0G*@Z.::O?7CM#G;%@-),I0L]_T!4T M#-8G;CH<]WF]O=&VV*F6KNY/H(SVZ/5N[\M@(SQHM2.S"*O]&HO:"G@]GZA? MG\@7P;1BY%H\K3#&AX!':H]_W_<^&,5 AI=+QFO-7SR62DT_!OCZE! 0_O,545 M$):=G5E]?>C3H&>X=(HB&J]KJNNGN9#3!V;$^M+-4*T'RZ79.!DJ:(4@4/P" M?8=]"*SF:UF+@77'%HK/P1 ?F\Y9Z. !^41+' M_A/7? &.WZ;'<& ;BDI;_SAQ!^,Z-,#=/]%0OGSWP/*0%>,A8(?N0H\D^* KLR/*\75& M;GI\!T/;15^,1OA8056_#5"%D4AE&?9L!=MPK%0 +A7!,(O'$?8 MXYX-&?SJ3'7!Z,J4JL9JM>-,Z"2-X[AYE\.\C9XG8?Y\G3\0:URR9K*A3\9$ MWB7V,\BY[D1 M'T_G.U#JV+WD49ZX3A%#&'YG[4+>(F.7+Y?Y;.^))Q2B;IOE%FCVBF#*@#3% MXA-24P1P&R\#7F:_NZL( GM?\H0P,)P?;<\?$=F%\RXBKA#+#KM&'OF[7_0R M6H"C8A0'=\3W#-.$&#JB3AT9.$N'XSW7'WA9"RMDW5G4J/40GT5).G)^K)@ MOQ-)B$6<.S+:PYJ^?92XPT[4%/;9"6;>/ =*RNZ(".,G+;2DUDKC5;WV'[D[6\%6YH<<>753+ (>J,$ MIDWWVAMY!YS^B@5"?O;GOJ&A7OX-X[6 R\:V4\,J0T%E$6/=^=$K%2X;41:% M3QP(O9WO$S6C)+_+6^1$,C<1OZWK$GQ[$5YTCCD_=5XTL7S+M:JB'H." 6\7 M:8*;[TF#M& M9C!ZE(WRSCX3'PD[7MD2D76Q5%2Z6! RW=D*?5?JB6W).@1_ M<0] P!#/UQ0LC0INYW:3VLB*@--F>GQ/1)5QAO#@ZO*8O[F M45?;7%#.('4\&B!,?CN;ZOC-DE0$*/Z>PYP!&YS)SR&,TUT@"$+_H-2O8:1R MZM)5_!(5.\M+%W$,T-.BC'>\:2[GJ*-)1'=;#O6,K!$0F'Q!N%]=B00 D_*SE0\"[^P!>>$-J?&H.CZC2]2 M,3;^$^A#C2>?X@K?)YSV?%" ?KWU9U1_7 67QNY5$4^*Y4H0P0$= M'O%B$4/MMA'["3AZ8\Y7WS;[E]YO:W_6!.IGS2EKZ@L'?OT<7K 4.O3^5I=' MX"1NU%2B/HK;+E&S=O*N@M#3792?Y+T6[WF6NK1(G^39(^ .ETR(;HS!BR(? MH$W69V1891!0+2?LD!2:K?UMKG?R"$241U41.W3IRT]4H8.&ZXE7%H5*BY[[/3F/F8%JAPGI>UM2U,!V$_:!-*M*81V,F\C1_;6A(J M]:2-DI/<@@MKRK@\6S"+G$)??"O(6CTKV5!5-OIBX%8=4X*G@]_&F[Z\Q&F# MD$BXS UMR:^:=KVJA#_XK$_2,/WB2'Q>:97[X['QB6I:X0J_Q$S4+G,$;S69 M^YN-7W5'=[:C?Z;N6-?VOYR,59T*O-4W^>DGJ,HDI[UMSL\S5"#E2DXE$5AA M-GW(S>6Z;ZN"M1$[1C7[5/%A1UJD?TV:PK;C02Q@8-;N$3!!/0(7GY*/DU<# MZ!Z!_\D4")PER2?/$JO\< 3V;);J*(GZ\'M;JNRHAI]V%I\FO$@6^61!K,TM MN>CE1EZ*S_7C=9<@@OF(^80-/1_ELQ: 4H8IT;R.N<_Z"%L,\G[Q_8'UHN*[ M2WP<$@0G'E_)@H>PAN%8:UJ>'ML'G2P/@E<0[L(PA& 2FBY?&ETGI+_>9 M2R*.V"!7_86K%'PIA/161Z.#>VU>5&0]L.W;%7EVV;HF";4&1219QJ!N$/.L MD%"?V,8BA9R=>N_H@JVZT-SMQG[T\XJ4?*_G6RGO#7UO#)I31 99F261='R_)J:OF?TF/J-V7^*C.IUU5%D2].I3;*#CU@:#]$KG%F>$]9'];2BRWU.9HVI0V[ M]-N+:3_KX;:#Q0W)Q%.5V-D-]V4XLG[M&M$/W-IQ[__=IJ)2W 5K]/ X<@Y9_<];TCJ'MNREC%? MQ_+O)VIO_STI0_.O0G."BGY88%[H=U^ZH%)QQ%RA11>ER.!KQ=88!\_ZKG.4 M@LY?NBFN4Q6J%.HD<^<+F'?P>YVY%V(?#E+F-:@V<0CFZ;]:0 8FP$KFID+M M76]4[P%LC\)^NA W8N0CL!Y1THY3LU*/6EA6\KJM8]6*<*?U M'>Q,<87WK,?K^%=X545Z#_R5NB.N1>$1Y_>3B@C:;@;6H%/]>_*3+R UW<7; MV!K01=JKBL7XB=GWI$/C&!OQ;Q?$AC]53.^O-4JY7:Y:ZD&/5M+7G"]_6Q \6B2H=E",'*LG''0UA#\ 42 M=]USF$M1Z1:/[1&@22AE41?,M;>9+;%%T2>4GM MKZD@J7B2J+B\C>: "R3V/_G^N=Q+$NY&;F>"'^0L$0J@,870 M;47N&Y&>PEK[/Q]9BOL6#NFS@3/)2/LWC%#R8.6;1T"?WS:+6+(GKK].Y3#8 MZF^W!W/F/1OZ;U=;J](+?4Y/4@NGCD"=Z4"=HN)L(J98,I.WA4!NSKX+.S6_WWEF(@K%&JCHW+/.09GS06%A2:JF?#)E/K2;8'V-(W M%*#'*PY1F4P\><(&LOJ?*(T]07A&LK7H<@15T'OK$?9]=))?56$0#:_J^NJ_ MJ*R6TR>\&7/ZS*_4,?2F/((:+3,/:]7 MXA]YQEHX*,5VBU,D^$/ISS=E!Y=M"I,7=%=(#*_LAA;+E%EHN EQ+S9'L72? M6@4L-?#(4M^A^MNO5>VEJFW.YGF&6L:/1!>&1]Z)=U)3))4+NN$O8+\YI'0 RXM3)=(I$**QIIEC$-'B_3QTWY9.$R M+6%#K>/HBIO^#]W[[F2GVFM;L(LZ2IH4R0SZ).83;S^VV3N6D=2)T@6$^KDP M*S\"S$V20J\--O^E" RBP3^O_L%&9Q%' M:\%MSL.E+A*O6K'7C_)DHQO:[4\6I933>X\B?>U3_ C@/!B/M=AVT!"=$D:7 M?MK4M)MLV?UQW[N=58'6]J5OW9E7G% 9L(EF8_8GRZEX[:T9/'BHNAA\FPJH MZFX'WNT9* +J,;'?X)Q W!=';^?([ MZY8GBXI5VRX#YY#7 /BR DIT1&)N_EP@;H/S01!$" J$AM'AR#%:;@WV8<+> MS*9]X:Q5,V%/6QGB(!SH3Y] JX*91&],Q[\!,Q8!)"Z):N<@.(MNG%*?]Q3Z M634Y%3.D8 I.WBV])6+70:0 >TNZ9;)J:;U)HWX$Y=N^]AJ3P!?_0QQ?0_13 M5*(0S>I[;5R83Q8;0[$Y,R)?;-[P9-U'W#C"VSIR^54\ _=8FK]9:SO'.CF" M$7T<8[99]%E]*N?7#^R"JO14>$0R TA"(]2H*7;XZQE,["--H26R#]G!\MZ%[FGX;XT91)FWG^84%ZG*%/)-8+C'=4JE?GFQ+,NV1//*RG7J/P!US)GUMF\CYU8U+;.=\\,UE1>HF+3-G PF! MP+[1Z(FJ\X)\$8'_UE#=BK3.G1S@+2[@8->#7[:[\-WI_'[)2=L^";]BSSUK M5SUAB,I[XQ2)M7BO?1!+R/)]N]W!QM&T88;AK0.=(1)F45;IQ4\-0E+2KS+\8WQR9?'+7F]*_C/[E6C@LH1UQ;/ *X ML>\>W,[I1VM27(;M8)]H6#EV?U,YR@&JY.O$F<(]2ZR@ARY&/A:<)3& M,F^8 Z85]P=_/3@/QQ^F7A(&:K9D\K4M]VRH^?KXG_U+4&@M:S!0B?&=F0.5 M[0L*M8*%'O/IPW5WR]=X[";O0-<9#:P)$IR3.T@"G75PD%V+UUKX5'[:P3DT MLFQ[L7DX#DV4OA,C^/*J'/H:]7Z]5:0+M93'1MN_1_L O\91N__2MM0NDOAOW(O MWZGWJ.H4U50XNFHF\HO4@L1X9YBA2A0FA=H)E_10H>9B9LFIV@EJ7,^GTU,P MS LJ7EJA;^]#0O0PYQ$PA;7(VK1"FKXIZH,"=[5E^VB!'WC.R,P>$P\)VVE) MM,$"J>Z,.HKEU_'+2O2_2"A)7I-+.F7"R\? ]+89IX1A,,Q3?0V?#,*>_+EM MY=IWC19U[HA!HY"4!6QT*&,FWZ[1YY,-V8D:0G"G]=K^Q0S7@D+\T6RW5[4E MGN=&- @AS89>6B%XLA(NJ$:DMJ'_YF/7\H:FGY%KQA_IJ5(N$+R$.!G$%\V MG,^;QW39H+?Q<] ,[VHC-M1<'@I@.CL\)ED9^2:]%(%U$Q6-EWFGCHD >7ZP M@X$P\QM-$'[>U2I%N"&8>?$_$]OG@\ 3[[)PF:W]::TQ?O"SI8B\;_J:HJ/[ M")QVU.:MK9#N+G/4-H::)BP?+=WH-+DMF.DJ'0Q/%!W(RT B_E4=0B&=N1;\ M@N76O+Q\/:L47,6[AGCSY,F7Y:HB&M+T$IZ0?D;]7G;NPB<:^2S;_(6-@=IH^9SYF7NE/W NY(*S]TPW(R@^\37ZGSU% MM-R7ADEF<.[%/F*!?4T!3,-^9!XZ.ME@-9-(G]\.^E@;SYZ<+SO]=Q**];5W MB&/0N?][M!:Q5Q9.+41JC,1SK;(;^&-_[SDFTNU"\TR/5,%G0G]V3KYNPON9 M\TZ>FG7ZUHT;>P.E]"EO[H[VL[S]>K=Z>R>;4O]8/_<9.E*ZDV#79+$T[7RW M5>G2L8'0H\+.(W[58HD=.+@=/67W2<76;+-JV*^<2U/1(I;3\[=YPDNB*J." MF2E#+^$ &^)N;%-FK+S(A>;^$86IKZX_6&9)9*"^73KG_&2!0XD'F%JV(G:O M/&.%5R*))X/9Z?FE^AJA6'5)EF<*9.R]M51J*I]:_51+Y&>/8>+>>B-RMO0C M?3\3/+!S?BHRNXL>ZUZK$^<$]6/JNG0B8Y[]^8L?D/5;G4@J#>[A8>'AZ-67 MYC!$A;2M?I=>\PX#4VV;#A-WEVCX1]GYLQ*N6RUOS1G'@03Y\FAJ732LBP+Q M$&IS.!MHYG_S9<3E02#1,JR\82\<:01 MA)U&7U^69>AT0V6C)LLO5:0D/5O^!"H] ]OU> B"@M:%_ 832=W Q30V>.G$ M&3.[.6=IMOR2\JL#SC54J?399Z7R!QX,2: +2-?]FXH[TH_5DMMU'O5F/B9; M 2\Y:^D5*R HOL*'1^#M-%TB+6;#ZROHEM14:X"4"$..($CU4%AR5>Q:S ;.(ROGV(M0TW2GJGXQ[:L5J=.(WU-/84OT(*-5O)"):VB,> MM,YSX!V*.6&'.WZ<^RYG2M/0AGX,G5%_H?]X=B&G_MD%'%E/%T?K13;,G:6> M_YNTNHW[IP&0+9V]F*;U-<_=K"V=0K2*Q&=]R+A7V%Z&&@I%(FAM1975")5I M.RZF!8HYC @\#_34$\)P/:N9!ZCU0#<[+O7/@"9^*0.=2>8CW_@$554K-!\W M?#9J*HVI\MM =;WH(I?TS$N3"R16O@/'G([(C7K])F>7).01*+B3KX\+?2P.B>?G72&>?>ZO_ M6BA/QVUBTM/QZ!@N(RL\NQ4FF!QJ#+@278GZG'\])&_=AO<:VOS1MA4,6Z"[ M*QQNV-B79IBIMG]]^D 6OU0B*K\:''U5(76BUF-\6))U,/K&/.JTDP]F =58$YD.03VU!T/E[[7YKNO]#]*2->8J#6=FL8:'!I^;.! M6E2+BW5^SQ#=&Z=)NXDSPB)!4,4Z@G)QQ]V.J?+C3DXS1.9!:/5V+L>K>(_; MSX?/VI(VC!9J[PAX7U->1[,&5!"Q0S: =N4X15^>;X#&J*SWS!W MW=B=@W/6. >Y'V$IWB\?9(JGFA]:^$&?_NPV9HV$R=K3FYG)T# M9!.GX+RX\=?O2"?LD7+,'?Q#1?.,&;EF]<]A0FX6*J]S,3>)_]61#QY?X<%< MWO_X3VU3 WZZL"H!Q^_DT1Y*QR6 KI=I,'S3T45]X,6:Q>!BETO'59D$ MKK+*M[9)]TZN5>JX:]9*]%; [X4#3P:9"]O:K/$)4WA,\ ^W<9A[L3^D$:$^ MR?U\[>-9;HR[96RZZQWGVW(_*W2^3DV-IDLZG>B[#Y,]WJUAU9&AS=&=[.BH M^>P[A;,*NP9:9KIYXE/Q-P^3)^2GTGAU]O7LA\'!MS3 S=6$&/\%+YX_.*B0J_O"%4NL*95\,N?X9?D9-.Z M-0LCPI=PRS";F6T#H@PX4FVFQ]].\0[%>M'-1CP])Z/<$7N[/!& ;O+O)05! MA*.94GIRZ)D;V0PUU]%%C)4W 7JO,Y';[60@]^G[]Q(_WA*?F7VOHX*[*,XS M":$?2^4!G@5]M-DOH@[+9,9_'4K#+KA<'LBW^V94 ,]-^2^PWJPTAIRY)D(: M8WJ%/N^DO9Z#I.]9']8;M^M=T;X5&6@4U>02XBAU!] H! M?6D4_.T>CH/=#.R+U,&2,HN#7-[GJEX8T^)5J[$B_]EH@C-QZ6*(['=>%,@O MZHM2]?M;1?=11;XP0:SM*RXZ]\H_\41BXU8Z?/."G?=9M_/[-II0.\OL^+&; M.U:7*.?+&2G;]P70U,-2?:\>7+6G]4:P:+4-]QZ!0&HRD'1B)>ARH]8U$U+Y MI2>3;?JB< N-*2IZ &XJ/0RI,++EU$Q4%A,@D>%1@H+;\?Z)?1,\*; MC0U>_\QYG]<1P)WDQK%$YS,!GJ+13C3__C,O([2I&X< [NPW>&1SR"B>1#P1 M/2$-?0*GII"&,I^GSR3]O_J7NC"(/?.%%A+']$GM&PJ[&(Q'EWZ8%<1=M/7U MRA/YC_'M/&I=+4DL7 +]6H@:1.=@(9E-8'TFP\Q?H_E4YZ4L&J^%X MU*50C$QL%\MHSZHKY#?DD 88GM;?G>FN^C%@\W=X;O7V.R$(K$/[6%?CRGV)S11YWJ@A/4X>P\EI^HHC MFA+L0,_! J9FI@%^U9T&1'PZFEKG_GCN:=<_$E==7P4N+&Y**;V-+1+:)/HL M)7)D]=V\7F* _L?<#^/@!)F+@ISGM%MC"@S]1Z2> BO>VD/Y$-ON7Z M#9=A7=GO9KR F@+'>^P*<8W Q'3ME5"'+Z]/)=.\]6UZQ8XDX2=6Z+O#@5]I MZ16$C"&-0X'Q_8+/?C9$9[\F*8!=%?2E(>DF,#6;PY2 "U&RZ ;,=KSIH;M> M I<]ZU+L?C 5$JN+EQ$N3;_?Y\^+LEJP85\7_X>NF:?MY7H-L>9$='TBA(.@LGT+MRGCZW[3B7(P'HC,( MM$,N_]OFU5%5GL&.7NM6APLFD(O/TIF1O/VU);&GY5B=WJEC#.ON[^V;E4RN F$D M+8*[!>EMWP\I\RW++D\K7=C7-N*\7&L@F2* _FIJSWZ=0KT8_YFP7@[URBT_%.XZ49 MJDI1USW[Z[^E.KWIPY*%V^Q(;/^FI<3I]2UZ"$\0W+>%5T!C:Q4ZC:1.Z]K7 M#XT59^U<:3UKG!A;=#6-^2+P*(>?#4 =J<=$8"X&[;T99M.*J+P_ /F=Q&E /P/7M"8W;M?5%[UHS4<@;XP\M$51<1%N0/([ MX'.]FFKB>U3DNH1LWW4FQ8E\_ C^@]=X$= +L\ID_ED.6:M(DIO=C[FPN=O&5CCVQ%WA=TPIKS[[^":Z-6$ MAOT.D3]P":GN+'*C#<53ZE.*+U?<.MT#>D?+3Y:J0?%GE@50>L5-NO-^[L*[ M=ZAPA]4!7W.*^#54C>TWWX:1DZET/M.\B'5A"](AT7^DT&^2[>XZ,4C$G5K9Z#?MS"Y9S9VL_REW!+?S,?^4%OIT+2TWI_+,97.=MM7AIM6J8CJ% M]LV8ZI.EZ-@"\L#<._E3U;2-80BNY[SB]&'NC([P/ 6!^^8V-6::*&/LTD:9 MBS%%;:);'NKEN5)C"P/V%[2U UP6=?[RZ6D,-A-T#_!48T3I!=4#!XK_NNN6 M^S(L1F+&*O'W\2.@'&] \6%9J0,O!X:W'07LW,F4H?XXQ)[H6U\U>2\OZHO] M6A@7$.0FQO-HP[H9V%X$W,M7>HV):K-PK,7(0Q8,:U<^NYE!]74-(LC/GCBK M.B4 U)>;9HV$=+:XJUD(=X9GL]S/]55\>+A4<"R9<\J?.&*#J:G'"&P(/WN[ MH#)\^38\!3_O_Z:2ISB;ME;2YO[;B)O0B!GV?Y'U%DQQ==&V]H;&0I! < \2 M/,'=">[N[I#&71L(+HT$#PT$=PCN$-P)&MPA0'"'!KZ\YU9]I^K>G[!WS;G& M?%;-L8:?BQBY9_(Y:C^)3>S5"X!YMRY3TY"L@?HW31M+WO'Y"'%\/;Y#=AN5 M^Q!_PQ@K8E,[?^N83H@_[T@E,)EEE),K1-#3))V0;M)C@!^5^[3^?]\_20V< MPC6D[TV?YZ1J"I# ;V-<8F%_ :9" OFJ-:KHMXHC6?T%-YIR5/^-OXU3\5#OF$*'U'OW!$'_ZKM919+$!*ZS;A9]XJL%$_[J8& M53AO2,C>7Z@_RAJNK-P!C^_^2&M:PC[;*"':III"J8X6^LB3[X+5]%TYU9BZ M3IWJ&S3)_=#L*W9[Q*7&4,DSR8% :L0&N:#*W'%8PY63H,(;CX"V(B^R4JJS MW@ZW)9E>%31[$<+Z^0\%S;#GK45'R_FXOS%LKAD<**MA@T+N1'NM3A&^*2?5 M&ZQ,-\\6PKWYI=]BB5.,4@P??Y0U;?^?NP+1>Y+*H/]CQ^NX^+^2@<1PX/B_ MOCSTGS116[%L7WP?VAX+[$IX]CAV@'(FQO-7T6PJI?^X\_M\UVNL0#L6(.T) MG=)Q_!8_B ?\!?,/2/OL%44Z-0\3\4\PT2XW?;-TBX8M["7DV ,M:J-CG\7H M$0L*4'>1HH'[RRV/I=6[I0U\\YJ?B578_C8/"V0)N!BQ\KD3*_M[-#55O8-O M,CK?V2=:2O>2L@\[)> 8^E\(Y?#S$0_,;8#45]>9WHV\5@^KWNXRO"1NZBDZ/>Z* MUO,IMKOF1 M 2^ ;81]W=W^&=>]8=%".V/M7>5H:BH!;M3$.5Y*A&T$<@7CT"%,H$SU!0]- MVN<,)1X__WK[:EOQ%%W$]NDUMDJ@ \,O><.%V1$N&F*WU494\W<]N5-L6 MX?2'3+2N2?!#9Y1YC8,#938N]!]<997U(OB=9K",JT(;&"-:BK(*G259@H.% M*S+?9UCV@+WNER^$XL]#_ .,,T39U);0T4#)G9VWOZ$_,VDQ8Y/$N!!8?@EI MM'-L#%4V-'Z+??*;BV(E(2^SC+O@Z*&E9+SBU@*&)YQ5$"NET$4XVSQ] ,O_ M0EX_AL-HP!H*SV.IDC=MW-VT^ZZ>_X 5TU4']KT];;,Z@CL+'. A=VR\-/1S M^''BM4T1JO[UK^[_UT=;OJ:R(R8KRKZA%;OPZAQ;J[-QRC)+A;G.*X6F/&X( MNP'P*8X7DOS05CZ,2_!(UX8?:1'N^-?!:_,T]&I(X5PQ/GA=^P)(<_I;+&$E\]::BN42OIZC(TYI4 ())Z3;; M6J*97;9?J&22BX&FT('#0'*3@- !;?$L>T/KU;H!+ZQ_*#VE&JZ')@1A>U6= M"JZBKVD.V7'4"9O_-/F9;&'FP>K0WE-U34)Z6,V0LF0<,"E##=FPZ.(K+^M+ M17)_LN\86D(8I%BK1U :$.,[Z/>!#@CC[,^P>(QZT%4:##735/T,U+A"O5\H M$='JD-LJ,]'M*=,U/+B5QR#$2?_V8),'Q_XWD:TH)--"W+(+9E/>Y]GP0"O7 M[)*KZ*(U2',,W47C9,3(7X">$I!WG6;S(+N>*:5$7U"8GWXU,>T^>:M.HC^^ MXB')XW4?._;L0C6CHX]9+!8#XG'KL3([U#X+;R@>P?#JMC@3V(?;\:9LDLO5 MR.)L!*_3HMN$N.O6JV#UE2W#-NXG^BSX#QXTX!8?TS9+?W\?JOC#PRM]'X%? M7=R3_XA)$L_%LXG.R M\0 7!3FM4R>JFOJDPSUQ,K785'L@:6^/69?$+EL-S[*.#,%8:9LR2L-(UOT8 M<\PE,:+Y9%U%W' _5LC!;8MY,)[0M@+A)]7S1S?#1$\]W<]+ A2<_8" ''%Q M0ANAM5#M3H[_#%T"!.^$RG,2'Z/*A"S'T??)3MJ2+% O%W,=K7QT6YB<&FGX M)H7^#[]H80!]C071T(&)*)RSB75[53BGP(XF4%"6A3/+O&[HN MI1:"L(]BJ!R]!?5J.] %]>@+ZM[6/V0\/T7.Q"K2:;^6^R(/I";S)1/'\=X=CIWAWV"!1SFL?<6_AARUWR5DQ][ZIT MR\$7,E74UM7#&@-+2W9R.3[$%DR++91L:V*1A7T1]MV>H^MJFO;9:]+B>(/R M4GJD$X1EZ$@9NQQ1BVJ),D]H=CW"W.$:UYSC[L4[4?.PP57)RX0 )="OL4WQ&:0T';. MX'Q$FOF])6;'DQ+-2WE/B4D!H[,WP337I MW&Y#5($L(1UT/)Z-6<'H7.JD5&2@&?W?+\-T6Z#&3X')X$:H)##NJIC;(@:P MNA=X)JM%;^V#V"5)_TJL'U,T/ZB5&'_*8OV+KXX_RB[L1;$NKHE>$SHVM%2 MLI^)%_E]$\%'X.T$,N"W_O, YH2P2$Q**Q0M$CSN"0 [#]&;G6^'9$+RI1^_ M^_ \NAE-$=-UH0.5W@40;_@_*&XB;+5ZRC>MN)FF5[E1^FQX 7LJ"WG:*L!N ME3D0HZ1?"JG%%Y;$T9BM6WZ"V9#!3XZA=\24T]]SL;_#21U9_3'S?HKNSYF< M.P95.GT<&^&?]"TN-G@M_/[G[-O'O2.N*]#<\]"*M4'TW\G/X66[H_1EE2 M$(+V+\\!O!M\_&X1Q8C. -2M@SY[QPQ2(C'4L25U0@H+77S_?[EFRE^4Y[<."?&_+)!D [G2KY%MR" M3>4VV,#&J!$^$FN36>?+\CR3+:0,/H9AKHDQ9[&'VASQ=.(,B.XB8/R7P$AI4R.2#PB/^QH?_W:@%Z$ , MA_.=11U3@6G\7D&RA6#;&Q2V,L9\AE '[ S7WN:BCX98K?-L!;2\.T:!<)7;?QS@#KN12VB3\&FNKS23L%J=GNXT@(84% M2K3?\J];?N%I\O*JZO7OK<@GOA=;&23+[)MOM\O_LQ28YWHKQ[QH*H=+ECUX M4CT/$2!A[JX2X76XF-!?FAYAJ/O)D4ISZ&8$#7W^H'?D&L.JC5?7+NKR=8_W M!0")461(2>&-,H7$8L\TR(XV6]"J(G*6?<-%N"KXV#W 7Q+[R6WVWS#O^G2: M;@XA>[61?%V(M 41?7+?8 #X:+B%?BN>;K]W=[!-..C0:30#O]2 5F"%."]'WMZPHU-:,^YTMKV*M:>, '? M&['EGI/X73(2&<5L_#K#T:318+(2$]9,A_*&]W^FF? )+!GBGJ(@+!]1^08[ MX5C",B?J5 ?%-SW*1"XZ_I)YC3$N8!;*YII"/OS)8 B M]X=13*BI^$!9>Y'I&#Q2^2W:+;+7FF-"L)9H#T(6.N9!#*+'9XR;)Q\;W-MT M&==6%RDJ-OS,!^+_@RT//$C^)#1_ 7J7/$Z\B,$Z+J)K(-1K_*D^=B)0<:$+ M);H-YQW)G.ZW?I;$)[9%RHFVKT1$D_) J5OP!_F-&VZB^W!LW\ZAREL(M_X: MMP65HZ8SIQA^5*_I35$KX(-O;ILAO%!;DHYR=9N+_>YN,O<^8?/YZ^D7)[Q.D3;O=![W!%+R="'3A>_>4&4CDUY?&.PH)6DU>L>96'HC MB-U8YXPQQGL"#NLR]=]^;I41HQ13DW(Y/E?ID2N4*Q7I0%\:%#3 _25+-I2+ MBPA><29R12"[SL4XC7[&FFO7*[)SM=U;4\CF^6OXE+2SQ?\$_?SDS*;"/7&7 M+'\7=?Y6'BH^*\199,O#2LW5I&Y4\!?Q&SSXU>!,EV+T%:O?H#'QV7A'^]) M)7[9"I5W8F+&HDI ]&N+LW)?U*@K$[Q%THZW:N$7^%3LBN&2OSF^X<.E )^ MIB]"9AL?20Y)FB+J'4S>+*[UDLGM&]%R2I3D(K34L _P38B1L^NO$9X%19X^ MTXC&"ZF K8H54_=>^Y'JK*V$\ IBO>H1QA9R'Q3(_"=8D^A$W$8DDWUL'ZI8 MBV2_6'U]Y9F .!S75A=K5I?9U-1"Z*;76MF6D?VA;>4J+:[C2GORCZ@W" M:N3P'V%;T'Q)A>6Y<11]�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�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�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end

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
Document and Entity Information - USD ($) $ in Millions	Dec. 31, 2022	Feb. 23, 2023	Jun. 30, 2022
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Registrant Name	Revolution Medicines, Inc.
Entity Central Index Key	0001628171
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		90,491,696
Entity Shell Company	false
Entity Small Business	false
Title of 12(b) Security	Common Stock $0.0001 Par Value per Share
Trading Symbol	RVMD
Security Exchange Name	NASDAQ
Entity File Number	001-39219
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	47-2029180
Entity Address, Address Line One	700 Saginaw Drive
Entity Address, City or Town	Redwood City
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94063
City Area Code	650
Local Phone Number	481-6801
ICFR Auditor Attestation Flag	true
Document Annual Report	true
Document Transition Report	false
Entity Public Float			$ 1,231
Documents Incorporated by Reference	Portions of the Registrant’s definitive Proxy Statement relating to the Registrant’s 2023 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. The proxy statement will be filed with the Securities and Exchange Commission within 120 days of the Registrant’s fiscal year ended December 31, 2022.
Auditor Name	PricewaterhouseCoopers LLP
Auditor Location	San Jose, California
Auditor Firm ID	238

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 161,412	$ 108,497
Marketable securities	483,531	468,557
Account receivable	4,673	5,929
Prepaid expenses and other current assets	10,569	6,790
Total current assets	660,185	589,773
Property and equipment, net	18,659	11,544
Operating lease right-of-use asset	55,077	59,692
Intangible assets, net	58,807	59,876
Goodwill	14,608	14,608
Restricted cash	1,737	1,737
Other noncurrent assets	2,857	758
Total assets	811,930	737,988
Current liabilities:
Accounts payable	21,306	14,057
Accrued expenses and other current liabilities	29,446	27,721
Operating lease liability, current	6,773	6,214
Deferred revenue, current	4,459	12,358
Total current liabilities	61,984	60,350
Deferred revenue, noncurrent	0	6,573
Deferred tax liability	7,025	7,444
Operating lease liability, noncurrent	57,432	60,419
Other noncurrent liabilities	301	634
Total liabilities	126,742	135,420
Commitments and contingencies (Note 7)
Stockholders' equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at December 31, 2022 and December 31, 2021, respectively; zero shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively	0	0
Common stock, $0.0001 par value; 300,000,000 shares authorized at December 31, 2022 and December 31, 2021, respectively; 90,411,912 and 74,142,619 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively	9	8
Additional paid-in capital	1,388,300	1,055,572
Accumulated other comprehensive loss	(1,780)	(376)
Accumulated deficit	(701,341)	(452,636)
Total stockholders' equity	685,188	602,568
Total liabilities and stockholders' equity	$ 811,930	$ 737,988

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par or stated value per share	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par or stated value per share	$ 0.0001	$ 0.0001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares, issued	90,411,912	74,142,619
Common stock, shares, outstanding	90,411,912	74,142,619

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenue:
Total revenue	$ 35,380,000	$ 29,390,000	$ 42,983,000
Operating expenses:
Research and development	253,073,000	186,948,000	132,252,000
General and administrative	40,586,000	30,450,000	21,428,000
Total operating expenses	293,659,000	217,398,000	153,680,000
Loss from operations	(258,279,000)	(188,008,000)	(110,697,000)
Other income (expense), net:
Interest income	9,154,000	929,000	2,238,000
Interest expense	0	(12,000)	(71,000)
Total other income, net	9,154,000	917,000	2,167,000
Loss before income taxes	(249,125,000)	(187,091,000)	(108,530,000)
Benefit from income taxes	420,000	0	371,000
Net loss	(248,705,000)	(187,091,000)	(108,159,000)
Redeemable convertible preferred stock dividends - undeclared and cumulative	0	0	(2,219,000)
Net loss attributable to common stockholders	$ (248,705,000)	$ (187,091,000)	$ (110,378,000)
Net loss per share attributable to common stockholders, basic	$ (3.08)	$ (2.57)	$ (2.01)
Net loss per share attributable to common stockholders, diluted	$ (3.08)	$ (2.57)	$ (2.01)
Weighted-average shares used to compute net loss per share attributable to common stockholders, basic	80,626,525	72,806,079	54,874,119
Weighted-average shares used to compute net loss per share attributable to common stockholders, diluted	80,626,525	72,806,079	54,874,119
Collaboration Revenue
Revenue:
Total revenue	$ 35,380,000	$ 29,390,000	$ 42,983,000

CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands	Total	Initial Public Offering	Follow-on Offering	At The Market Equity Offering	Common Stock	Common Stock Initial Public Offering	Common Stock Follow-on Offering	Common Stock At The Market Equity Offering	Additional Paid-In Capital	Additional Paid-In Capital Initial Public Offering	Additional Paid-In Capital Follow-on Offering	Additional Paid-In Capital At The Market Equity Offering	Accumulated Other Comprehensive Income	Accumulated Deficit	Redeemable Convertible Preferred Stock
Beginning balance at Dec. 31, 2019	$ (152,574)								$ 4,738				$ 74	$ (157,386)
Redeemable convertible preferred stock, beginning balance, shares at Dec. 31, 2019															39,600,423
Redeemable convertible preferred stock, beginning balance at Dec. 31, 2019															$ 305,109
Beginning balance, shares at Dec. 31, 2019					3,292,124
Conversion of redeemable convertible preferred stock into common stock	305,109				$ 4				305,105						$ (305,109)
Conversion of redeemable convertible preferred stock into common stock, shares					39,600,423										(39,600,423)
Issuance of common stock from offering, net of offering costs		$ 250,697	$ 167,767			$ 2	$ 1			$ 250,695	$ 167,766
Issuance of common stock from offering, net of offering costs, shares						16,100,000	6,900,000
Issuance of common stock pursuant to stock option exercises	1,877								1,877
Issuance of common stock pursuant to stock option exercises, shares					694,441
Issuance of common stock related to employee stock purchase plan	832								832
Issuance of common stock related to employee stock purchase plan, shares					29,237
Issuance of common stock related to vesting of restricted stock units, shares					1,681
Vesting of early exercised stock options	199								199
Repurchases of early exercised stock, shares					(18,158)
Stock-based compensation expense	8,886								8,886
Net unrealized gains (loss) on marketable securities	42												42
Net loss	(108,159)													(108,159)
Ending balance at Dec. 31, 2020	474,676				$ 7				740,098				116	(265,545)
Ending balance, shares at Dec. 31, 2020					66,599,748
Issuance of common stock from offering, net of offering costs			281,145	$ 10,096			$ 1				281,144	$ 10,096
Issuance of common stock from offering, net of offering costs, shares							6,666,666	339,302
Issuance of common stock pursuant to stock option exercises	1,487								1,487
Issuance of common stock pursuant to stock option exercises, shares					388,695
Issuance of common stock related to employee stock purchase plan	1,875								1,875
Issuance of common stock related to employee stock purchase plan, shares					75,991
Issuance of common stock related to vesting of restricted stock units, shares					78,010
Vesting of early exercised stock options	148								148
Repurchases of early exercised stock, shares					(5,793)
Stock-based compensation expense	20,724								20,724
Net unrealized gains (loss) on marketable securities	(492)												(492)
Net loss	(187,091)													(187,091)
Ending balance at Dec. 31, 2021	$ 602,568				$ 8				1,055,572				(376)	(452,636)
Redeemable convertible preferred stock, ending balance, shares at Dec. 31, 2021	0
Ending balance, shares at Dec. 31, 2021					74,142,619
Issuance of common stock from offering, net of offering costs	$ 49,919		$ 248,126				$ 1				$ 248,125	$ 49,919
Issuance of common stock from offering, net of offering costs, shares							13,225,000	2,385,846
Issuance of common stock pursuant to stock option exercises	1,481								1,481
Issuance of common stock pursuant to stock option exercises, shares					249,544
Issuance of common stock related to employee stock purchase plan	1,864								1,864
Issuance of common stock related to employee stock purchase plan, shares					130,327
Issuance of common stock related to vesting of restricted stock units, shares					278,848
Vesting of early exercised stock options	143								143
Repurchases of early exercised stock, shares					(272)
Stock-based compensation expense									31,196
Net unrealized gains (loss) on marketable securities	(1,404)												(1,404)
Net loss	(248,705)													(248,705)
Ending balance at Dec. 31, 2022	$ 685,188				$ 9				$ 1,388,300				$ (1,780)	$ (701,341)
Redeemable convertible preferred stock, ending balance, shares at Dec. 31, 2022	0
Ending balance, shares at Dec. 31, 2022					90,411,912

Redeemable Convertible Preferred Stock	12 Months Ended
Redeemable Convertible Preferred Stock	Dec. 31, 2022
Temporary Equity Disclosure [Abstract]
Redeemable Convertible Preferred Stock	9. Redeemable convertible preferred stock Upon the closing of the Company’s initial public offering in February 2020, all shares of redeemable convertible preferred stock then outstanding converted into 39,600,423 shares of common stock. There were no shares of redeemable convertible preferred stock outstanding as of December 31, 2022 and 2021.

Organization - Additional Information (Details) - USD ($)	1 Months Ended			12 Months Ended
	Jul. 31, 2022	Nov. 30, 2021	Feb. 28, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Class Of Stock [Line Items]
Accumulated deficit				$ 701,341,000	$ 452,636,000
Common stock, shares, issued				90,411,912	74,142,619
Net proceeds from issuance				$ 248,126,000	$ 281,145,000	$ 420,067,000
Initial Public Offering \| Common Stock
Class Of Stock [Line Items]
Shares issued						16,100,000
Underwriter's Option to Purchase Additional Shares
Class Of Stock [Line Items]
Common stock, shares, issued	1,725,000		869,565
Underwritten Public Offering
Class Of Stock [Line Items]
Common stock, shares, issued	13,225,000		6,666,666
Common stock, price per share	$ 20.00		$ 45.00
Net proceeds from issuance	$ 248,100,000		$ 281,100,000
Underwriting discounts and commissions	15,900,000		18,000,000.0
Stock issuance expenses	$ 500,000		$ 900,000
ATM \| Common Stock
Class Of Stock [Line Items]
Net proceeds from issuance				$ 49,900,000	$ 10,100,000
Shares issued				2,385,846	339,302
Aggregate gross proceeds through equity issuance maximum potential amount		$ 250,000,000
Commissions and expenses				$ 1,400,000	$ 300,000
Proceeds from issuance of common stock gross				$ 51,300,000	$ 10,400,000

Summary of Significant Accounting Policies - Additional Information (Details)		12 Months Ended
	Feb. 07, 2020	Dec. 31, 2022 USD ($) Segment	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Sep. 30, 2021
Summary Of Significant Accounting Policies [Line Items]
Reverse stock split	0.2055
Reverse stock split, description	1-for-4.8661
Other-than-temporary impairment		$ 0
Restricted cash		1,737,000	$ 1,737,000
Operating lease liability		64,205,000
Operating lease right-of-use asset		55,077,000	59,692,000
Adjustment to accumulated deficit		(701,341,000)	(452,636,000)
Impairments of long-lived assets		0	0	$ 0
Impairment of intangible assets, indefinite-lived		0
Impairment of intangible assets, finite-lived		0
Goodwill impairment		0
Deferred offering costs		$ 600,000	500,000
Number of operating segment \| Segment		1
Number of reportable segment \| Segment		1
Retirement plan name description		401(k) retirement plan
Retirement plan, matching contributions		$ 1,300,000	900,000	$ 200,000
ASU 2019-12
Summary Of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, early adoption					true
Change in accounting principle, accounting standards update, adopted					true
Change in accounting principle, accounting standards update, immaterial effect					true
Minimum
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives		3 years
Maximum
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives		5 years
Letter Of Credit
Summary Of Significant Accounting Policies [Line Items]
Restricted cash		$ 1,700,000	$ 1,700,000

Summary of Significant Accounting Policies - Schedule of Useful Lives of Property and Equipment (Details)	12 Months Ended
	Dec. 31, 2022
Minimum
Property Plant And Equipment [Line Items]
Estimated useful life	3 years
Maximum
Property Plant And Equipment [Line Items]
Estimated useful life	5 years
Laboratory Equipment \| Minimum
Property Plant And Equipment [Line Items]
Estimated useful life	4 years
Laboratory Equipment \| Maximum
Property Plant And Equipment [Line Items]
Estimated useful life	5 years
Leasehold Improvements
Property Plant And Equipment [Line Items]
Estimated useful life, description	Lesser of estimated useful life or remaining lease term
Computer Equipment and Software
Property Plant And Equipment [Line Items]
Estimated useful life	3 years
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Estimated useful life	5 years

Fair Value Measurements - Additional Information (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Fair value, transfers between Levels 1, 2 or 3, amount	$ 0	$ 0

Available-for-sale Securities - Summary of Estimated Value of Available-for-sale Securities and Cash Equivalents and Gross Unrealized Gains and Losses (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 647,465	$ 578,322
Gross Unrealized Gain	47	1
Gross Unrealized Loss	(1,827)	(377)
Estimated Fair Value	645,685	577,946
Marketable Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	485,280	468,931
Gross Unrealized Gain	43	1
Gross Unrealized Loss	(1,792)	(375)
Estimated Fair Value	483,531	468,557
Marketable Securities \| Corporate Bonds
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	31,599	141,829
Gross Unrealized Gain	0	0
Gross Unrealized Loss	(194)	(131)
Estimated Fair Value	31,405	141,698
Marketable Securities \| Commercial Paper
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	216,765	239,176
Gross Unrealized Gain	0	1
Gross Unrealized Loss	(328)	(63)
Estimated Fair Value	216,437	239,114
Marketable Securities \| U.S. and Canadian Government And Agency Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	236,916	87,926
Gross Unrealized Gain	43	0
Gross Unrealized Loss	(1,270)	(181)
Estimated Fair Value	235,689	87,745
Cash Equivalents
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	162,185	109,391
Gross Unrealized Gain	4	0
Gross Unrealized Loss	(35)	(2)
Estimated Fair Value	162,154	109,389
Cash Equivalents \| Corporate Bonds
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	16,137
Gross Unrealized Gain	4
Gross Unrealized Loss	0
Estimated Fair Value	16,141
Cash Equivalents \| Money Market Funds
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	48,522	57,134
Gross Unrealized Gain	0	0
Gross Unrealized Loss	0	0
Estimated Fair Value	48,522	57,134
Cash Equivalents \| Commercial Paper
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	97,526	52,257
Gross Unrealized Gain	0	0
Gross Unrealized Loss	(35)	(2)
Estimated Fair Value	$ 97,491	$ 52,255

Balance Sheet Components - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 33,148	$ 22,356
Less: accumulated depreciation and amortization	(14,489)	(10,812)
Property and equipment, net	18,659	11,544
Laboratory Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	17,163	12,727
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment, gross	11,404	7,245
Computer Equipment and Software
Property Plant And Equipment [Line Items]
Property and equipment, gross	3,965	2,186
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Property and equipment, gross	616	69
Construction in Progress
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 0	$ 129

Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Accrued Expenses And Other Current Liabilities [Abstract]
Accrued compensation	$ 13,281	$ 9,852
Accrued research and development	15,161	17,018
Accrued professional services	499	540
Other	505	311
Total accrued expenses and other current liabilities	$ 29,446	$ 27,721

Intangible Assets and Goodwill - Schedule of Intangibles Assets, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
In-process research and development - RAS Programs	$ 55,800	$ 55,800
Developed technology - tri-complex platform, Gross value	7,480	7,480
Developed technology - tri-complex platform, Accumulated amortization	(4,473)	(3,404)
Developed technology - tri-complex platform, Net book value	$ 3,007	$ 4,076
Developed technology - tri-complex platform, Weighted-average remaining useful life	2 years 10 months 24 days	3 years 10 months 24 days
Intangible assets, Gross value	$ 63,280	$ 63,280
Intangible assets, Net book value	$ 58,807	$ 59,876

Intangible Assets and Goodwill - Schedule of Future Amortization Expense (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2023	$ 1,069
2024	1,068
2025	870
Developed technology - tri-complex platform, Net book value	$ 3,007	$ 4,076

Intangible Assets and Goodwill - Schedule of Goodwill (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Balance at December 31, 2021	$ 14,608
Adjustment	0
Balance at December 31, 2022	$ 14,608

Commitment and Contingencies - Additional Information (Details) $ in Thousands	1 Months Ended		12 Months Ended
	Nov. 30, 2021 USD ($) ft²	Apr. 30, 2020 USD ($) ft²	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Oct. 31, 2018 ft²	Jan. 31, 2015 ft²
Lessee Lease Description [Line Items]
Operating lease right-of-use asset			$ 55,077	$ 59,692
Operating lease liability			64,205
Operating lease cost			6,400	3,400
Sublease income			2,500	2,100
Operating cash flows for operating leases			$ 2,400	$ 1,500
Operating lease, weighted average discount rate			6.10%
Operating lease, weighted average remaining lease term			10 years 10 months 24 days	11 years 7 months 6 days
Redwood City Lease
Lessee Lease Description [Line Items]
Lessee operating lease expiration month and year			2033-11
Area of space leased \| ft²	41,000
Lessee, operating lease option to extend lease term	10 years
Redwood City Lease \| ASC 842
Lessee Lease Description [Line Items]
Operating lease right-of-use asset	$ 26,800
Redwood City Lease \| Restricted Cash
Lessee Lease Description [Line Items]
Letter of credit			$ 1,500	$ 1,500
Redwood City Lease \| The 700 Building and 300 Building \| ASC 842
Lessee Lease Description [Line Items]
Increase in operating lease right-of-use asset	$ 8,600
Redwood City Lease \| The 300 Building
Lessee Lease Description [Line Items]
Lessee operating lease expiration month and year			2030-12
Area of space leased \| ft²		19,000
Tenant improvement allowance			$ 4,600
Redwood City Lease \| The 300 Building \| ASC 842
Lessee Lease Description [Line Items]
Operating lease right-of-use asset		$ 6,400
Operating lease liability		9,000
Redwood City Lease \| The 700 Building
Lessee Lease Description [Line Items]
Lessee operating lease expiration month and year			2023-04
Area of space leased \| ft²						42,000
Tenant improvement allowance			$ 3,400
Redwood City Lease \| The 700 Building \| ASC 842
Lessee Lease Description [Line Items]
Increase in operating lease right-of-use asset		$ 14,800
Redwood City Lease \| The 800 Building
Lessee Lease Description [Line Items]
Lessee, operating lease, option to extend			The Company has the option to extend the lease for an additional ten years after November 30, 2033.
Cambridge, Massachusetts
Lessee Lease Description [Line Items]
Lessee operating lease expiration month and year			2023-02
Area of space leased \| ft²					22,000
Lessee, operating lease, option to extend			option to extend the term through February 2028
Cambridge, Massachusetts \| Restricted Cash
Lessee Lease Description [Line Items]
Letter of credit			$ 200	$ 200

Commitments and Contingencies - Summary of Balance Sheet Classification of Operating Lease Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Operating lease liability – current	$ 6,773	$ 6,214
Operating lease liability – noncurrent	57,432	$ 60,419
Total operating lease liabilities	$ 64,205

Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2023	$ 6,961
2024	7,100
2025	7,349
2026	7,606
2027	7,872
Thereafter	52,550
Total undiscounted lease payments	89,438
Less: Imputed interest	(25,233)
Less: Tenant improvement allowance	0
Total operating lease liabilities	$ 64,205

Redeemable Convertible Preferred Stock - Additional Information (Details) - shares	Dec. 31, 2022	Dec. 31, 2021	Feb. 29, 2020
Temporary Equity [Line Items]
Temporary equity, shares outstanding	0	0
Initial Public Offering
Temporary Equity [Line Items]
Temporary equity, shares outstanding			39,600,423

Common Stock - Additional Information (Details)	12 Months Ended
Common Stock - Additional Information (Details)	Dec. 31, 2022 USD ($) Vote $ / shares shares	Dec. 31, 2021 $ / shares shares
Stockholders' Equity Note [Abstract]
Common stock, shares authorized \| shares	300,000,000	300,000,000
Common stock, par or stated value per share \| $ / shares	$ 0.0001	$ 0.0001
Common stock, voting rights	Each share of common stock is entitled to one vote
Number of voting rights per common share \| Vote	1
Common stock, dividends declared \| $	$ 0

Common Stock - Schedule of Common Stock for Future Issuance (Details) - shares	Dec. 31, 2022	Dec. 31, 2021
Class Of Stock [Line Items]
Common stock reserved for future issuance, Total	17,766,601	13,967,835
Outstanding Options to Purchase Common Stock
Class Of Stock [Line Items]
Common stock reserved for future issuance, Total	8,164,375	6,050,938
Unvested Restricted Stock Units Of Common Stock
Class Of Stock [Line Items]
Common stock reserved for future issuance, Total	1,175,032	423,621
Available for Future Issuance under the 2020 Incentive Award Plan
Class Of Stock [Line Items]
Common stock reserved for future issuance, Total	6,726,307	6,403,548
Available for issuance under the 2020 Employee Stock Purchase Plan
Class Of Stock [Line Items]
Common stock reserved for future issuance, Total	1,700,887	1,089,728

Stock-Based Compensation - Summary of Option Activity Under the Plan (Details) - 2020 Plan and 2014 Plan - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares underlying options, Beginning balance	6,050,938
Number of Shares underlying options, Options granted	2,758,710
Number of Shares underlying options, Options exercised	(249,544)
Number of Shares underlying options, Options cancelled	(395,729)
Number of Shares underlying options, Ending balance	8,164,375	6,050,938
Number of Shares underlying options, Options vested and expected to vest	8,164,375
Number of Shares underlying options, Options vested and exercisable	4,555,124
Weighted-average exercise price, Beginning balance	$ 14.88
Weighted-average exercise price, Options granted	19.37
Weighted-average exercise price, Options exercised	6.12
Weighted-average exercise price, Options cancelled	26.78
Weighted-average exercise price, Ending balance	16.09	$ 14.88
Weighted-average exercise price, Options vested and expected to vest	16.09
Weighted-average exercise price, Options vested and exercisable	$ 11.43
Weighted-average remaining contractual term (in years)	7 years 6 months 10 days	7 years 8 months 26 days
Weighted-average remaining contractual term, Options vested and expected to vest	7 years 6 months 10 days
Weighted-average remaining contractual term, Options vested and exercisable	6 years 7 months 24 days
Aggregate intrinsic value	$ 85,181	$ 83,953
Aggregate intrinsic value, Options vested and expected to vest	85,181
Aggregate intrinsic value, Options vested and exercisable	$ 66,783

Income Taxes - Summary of Benefit from Income Taxes to Amount Computed by Applying Federal Statutory Rate to Loss Before Taxes (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Federal statutory income tax rate	21.00%	21.00%
State income tax rate, net of federal benefit	9.40%	8.90%
Research tax credits	3.20%	2.20%
Change in valuation allowance	(32.40%)	(31.40%)
Non-deductible permanent expenses	(1.00%)	(0.50%)
Other	0.00%	(0.20%)
Benefit from income taxes	0.20%	0.00%

Income Taxes - Summary of Categories that Give Rise to Significant Components of Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred tax assets:
Net operating loss carryforwards	$ 132,080	$ 123,991
Accruals and reserves	5,494	9,164
Research and development credits	22,558	14,449
Lease liability	18,998	19,979
Stock-based compensation	7,063	3,829
Capitalized research expenses	64,149
Other	42	33
Gross deferred tax assets	250,384	171,445
Less: valuation allowance	(224,125)	(143,474)
Total deferred tax assets	26,259	27,971
Deferred tax liabilities:
Fixed assets and finite-lived intangible assets	(9,961)	(10,073)
Indefinite-lived intangible assets	(7,025)	(7,444)
Lease asset	0
Right-of-use asset	(16,298)	(17,898)
Gross deferred tax liabilities	(33,284)	(35,415)
Net deferred tax liability	$ (7,025)	$ (7,444)

Income Taxes - Reconciliation of Gross Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Beginning balance	$ 5,143	$ 3,593
Changes related to tax positions taken in the prior year	(7)	(21)
Changes related to tax positions taken in current year	2,466	1,571
Ending balance	$ 7,602	$ 5,143